PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Ramaswamy, M; Efimova, EV; Martinez, O; Mulherkar, NU; Singh, SP; Prabhakar, BS				Ramaswamy, M; Efimova, EV; Martinez, O; Mulherkar, NU; Singh, SP; Prabhakar, BS			IG20 (MADD splice variant-5), a proapoptotic protein, interacts with DR4/DR5 and enhances TRAIL-induced apoptosis by increasing recruitment of FADD and caspase-8 to the DISC	ONCOGENE			English	Article						IG20; MADD; TRAIL; DISC; caspase-8; apoptosis; cancer	NUCLEOTIDE EXCHANGE PROTEIN; DEATH DOMAIN; TUMORICIDAL ACTIVITY; NEOPLASTIC-CELLS; RECEPTOR FAMILY; DECOY RECEPTORS; IN-VIVO; DENN-SV; EXPRESSION; LIGAND	Recently, we identified (I) under bar nsulinoma -(G) under bar lucagonoma clone 20 (IG20) that can render cells more susceptible to tumor necrosis factor-alpha (TNF-alpha)-induced apoptosis. In addition, it can slow cell proliferation, and enhance drug- and radiation-induced cell death. TNF-related apoptosis-inducing ligand (TRAIL) can selectively induce apoptosis in some cancer cells and render others susceptible to cotreatment with drugs and irradiation, with little or no effect on most normal cells. In this study, we investigated the potential of IG20 to enhance TRAIL-induced apoptosis and found that it can render cells more susceptible to TRAIL treatment through enhanced activation of caspases. Further, we showed that this effect can be suppressed by caspase inhibitors, p35 and CrmA, and a (d) under bar ominant-(n) under bar egative (F) under bar as- (a) under bar ssociated (d) under bar eath (d) under bar omain-containing protein (DN-FADD). Results from colocalization and immunoprecipitation studies showed that IG20 can interact with TRAIL death receptors (DR), DR4 and DR5 and increase recruitment of FADD and caspase-8 into the TRAIL death-inducing signaling complex (DISC). These results indicate that IG20 is a novel protein that can enhance TRAIL-induced apoptosis by facilitating DISC formation.	Univ Illinois, Dept Microbiol & Immunol, Chicago, IL 60612 USA; Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA; Univ Illinois, Ctr Mol Biol & Oral Dis, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Prabhakar, BS (corresponding author), Univ Illinois, Dept Microbiol & Immunol, M-C 790,Room E-705,Bldg 935,835 S Wolcott Ave, Chicago, IL 60612 USA.	bprabhak@uic.edu		Ramaswamy, Madhu/0000-0001-8870-5328; Martinez, Osvaldo/0000-0001-7335-4342; Singh, Surya/0000-0001-5668-1712				Al-Zoubi AM, 2001, J BIOL CHEM, V276, P47202, DOI 10.1074/jbc.M104835200; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; BEIDLER DR, 1995, J BIOL CHEM, V270, P16526, DOI 10.1074/jbc.270.28.16526; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Brown TL, 1998, CURR BIOL, V8, pR191; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Chow VTK, 1998, GENOME, V41, P543, DOI 10.1139/gen-41-4-543; Chow VTK, 1996, DNA SEQUENCE, V6, P263, DOI 10.3109/10425179609020873; Coppola T, 2002, BIOCHEM J, V362, P273, DOI 10.1042/0264-6021:3620273; Cunningham SJ, 1996, THESIS U TEXAS MED B; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Efimova E, 2003, CANCER RES, V63, P8768; Efimova EV, 2004, ONCOGENE, V23, P1076, DOI 10.1038/sj.onc.1207210; GOTO Y, 1992, J BIOL CHEM, V267, P15252; Griffith TS, 1999, J EXP MED, V189, P1343, DOI 10.1084/jem.189.8.1343; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kim KH, 2000, CLIN CANCER RES, V6, P335; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Kuang AA, 2000, J BIOL CHEM, V275, P25065, DOI 10.1074/jbc.C000284200; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Leverkus M, 2000, CANCER RES, V60, P553; Lim KM, 2004, INT J CANCER, V109, P24, DOI 10.1002/ijc.11660; Lim KM, 2002, MOL CARCINOGEN, V35, P110, DOI 10.1002/mc.10082; Miyazaki T, 2001, NAT IMMUNOL, V2, P493, DOI 10.1038/88684; NEZNANOV N, 2002, MED SCI MONIT, V8, P391; Ozoren N, 2002, NEOPLASIA, V4, P551, DOI 10.1038/sj.neo.7900270; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1998, FEBS LETT, V424, P41, DOI 10.1016/S0014-5793(98)00135-5; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Sarker M, 2002, ONCOGENE, V21, P4323, DOI 10.1038/sj.onc.1205523; Schievella AR, 1997, J BIOL CHEM, V272, P12069, DOI 10.1074/jbc.272.18.12069; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Sprick MR, 2002, EMBO J, V21, P4520, DOI 10.1093/emboj/cdf441; Suliman A, 2001, ONCOGENE, V20, P2122, DOI 10.1038/sj.onc.1204282; Takai Y, 1996, GENES CELLS, V1, P615, DOI 10.1046/j.1365-2443.1996.00257.x; Tanaka M, 2001, MOL BIOL CELL, V12, P1421, DOI 10.1091/mbc.12.5.1421; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Wada M, 1997, J BIOL CHEM, V272, P3875, DOI 10.1074/jbc.272.7.3875; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yamada H, 1999, BIOCHEM BIOPH RES CO, V265, P130, DOI 10.1006/bbrc.1999.1641; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	48	33	35	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6083	6094		10.1038/sj.onc.1207804	http://dx.doi.org/10.1038/sj.onc.1207804			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15208670				2022-12-28	WOS:000223261000008
J	Theodorou, V; Boer, M; Weigelt, B; Jonkers, J; van der Valk, M; Hilkens, J				Theodorou, V; Boer, M; Weigelt, B; Jonkers, J; van der Valk, M; Hilkens, J			Fgf10 is an oncogene activated by MMTV insertional mutagenesis in mouse mammary tumors and overexpressed in a subset of human breast carcinomas	ONCOGENE			English	Article						mammary cancer; Fgf10; Wnt1; MMTV; insertional mutagenesis	KERATINOCYTE GROWTH-FACTOR; PROVIRAL INSERTION; IN-VIVO; EXPRESSION; GENE; CANCER; VIRUS; DIFFERENTIATION; TUMORIGENESIS; RECEPTOR	Mouse mammary tumor virus (MMTV) infection causes a high incidence of murine mammary carcinomas by insertion of its proviral DNA in the genome of mammary epithelial cells. Retroviral insertion can activate flanking proto-oncogenes by a process called insertional mutagenesis. By sequencing the DNA adjacent to MMTV proviral insertions in mammary tumors from BALB/c mice infected with C3H-MMTV, we have found a common MMTV insertion site in the Fgf10 locus. RT-PCR studies showed that Fgf10 is expressed only in those tumors harboring a MMTV proviral insertion in this locus, suggesting that Fgf10 is a proto-oncogene. The oncogenicity of Fgf10 was evaluated in vivo by subcutaneous transplantation of retrovirally transduced HC11 mammary epithelial cells into BALB/c mice. Highly vascularized invasive subcutaneous tumors developed indicating that Fgf10 can act as an oncogene. A survey of primary human breast carcinomas revealed strongly elevated Fgf10 mRNA levels in approximately 10% of the tumors tested, suggesting that Fgf10 may also be involved in oncogenicity of a subset of human breast cancers.	Netherlands Canc Inst, Div Tumor Biol, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Div Expt Oncol, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Div Expt Anim Pathol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute	Hilkens, J (corresponding author), Netherlands Canc Inst, Div Tumor Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	j.hilkens@nki.nl	Theodorou, Vasiliki/GON-4996-2022; Jonkers, Jos/AAG-3246-2019; Theodorou, Vasiliki/H-1576-2016	Jonkers, Jos/0000-0002-9264-9792; Theodorou, Vasiliki/0000-0003-1614-700X; Hilkens, John/0000-0002-0932-7793				Asano K, 1997, J BIOL CHEM, V272, P23477, DOI 10.1074/jbc.272.38.23477; Bansal GS, 1997, BRIT J CANCER, V75, P1567, DOI 10.1038/bjc.1997.269; BANSAL GS, 1995, BRIT J CANCER, V72, P1420, DOI 10.1038/bjc.1995.524; Beer HD, 1997, ONCOGENE, V15, P2211, DOI 10.1038/sj.onc.1201383; Bellusci S, 1997, DEVELOPMENT, V124, P4867; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Bittner J J, 1939, Am J Cancer, V35, P90; Bosma AJ, 2002, CLIN CANCER RES, V8, P1871; Callahan R, 2000, ONCOGENE, V19, P992, DOI 10.1038/sj.onc.1203276; DANIELSON KG, 1984, P NATL ACAD SCI-BIOL, V81, P3756, DOI 10.1073/pnas.81.12.3756; Dickson C, 2000, BREAST CANCER RES, V2, P191, DOI 10.1186/bcr53; GALLAHAN D, 1987, J VIROL, V61, P66, DOI 10.1128/JVI.61.1.66-74.1987; Humphreys RC, 1997, CELL GROWTH DIFFER, V8, P839; Hwang HC, 2002, P NATL ACAD SCI USA, V99, P11293, DOI 10.1073/pnas.162356099; Igarashi M, 1998, J BIOL CHEM, V273, P13230, DOI 10.1074/jbc.273.21.13230; IVANYI D, 1989, J PATHOL, V159, P7, DOI 10.1002/path.1711590105; Jackson D, 1997, J MAMMARY GLAND BIOL, V2, P385, DOI 10.1023/A:1026351414004; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; LEE FS, 1995, P NATL ACAD SCI USA, V92, P2268, DOI 10.1073/pnas.92.6.2268; Lu WQ, 1999, J BIOL CHEM, V274, P12827, DOI 10.1074/jbc.274.18.12827; Lund AH, 2002, NAT GENET, V32, P160, DOI 10.1038/ng956; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; Mailleux AA, 2002, DEVELOPMENT, V129, P53; Marsh SK, 1999, ONCOGENE, V18, P1053, DOI 10.1038/sj.onc.1202392; Martin GR, 1998, GENE DEV, V12, P1571, DOI 10.1101/gad.12.11.1571; MERLO GR, 1993, ANN NY ACAD SCI, V698, P108, DOI 10.1111/j.1749-6632.1993.tb17195.x; Michiels F, 2000, METHOD ENZYMOL, V325, P295; Mikkers H, 2002, NAT GENET, V32, P459, DOI 10.1038/ng1102-459b; Mikkers H, 2002, ONCOGENE, V21, P6559, DOI 10.1038/sj.onc.1205930; Min HS, 1998, GENE DEV, V12, P3156, DOI 10.1101/gad.12.20.3156; MORRIS VL, 1991, ONCOGENE RES, V6, P53; Ngan ESW, 2002, P NATL ACAD SCI USA, V99, P11187, DOI 10.1073/pnas.172366199; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Ornitz DM, 2001, GENOME BIOL, V2; Palmieri C, 2003, J ENDOCRINOL, V177, P65, DOI 10.1677/joe.0.1770065; PENAULTLLORCA F, 1995, INT J CANCER, V61, P170, DOI 10.1002/ijc.2910610205; PETERS G, 1983, CELL, V33, P369, DOI 10.1016/0092-8674(83)90418-X; PETERS G, 1989, P NATL ACAD SCI USA, V86, P5678, DOI 10.1073/pnas.86.15.5678; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; QURESHI SJ, 1994, GENET ANAL-BIOMOL E, V11, P95, DOI 10.1016/1050-3862(94)90046-9; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; Sekine K, 1999, NAT GENET, V21, P138, DOI 10.1038/5096; Spencer-Dene B, 2001, ENDOCR-RELAT CANCER, V8, P211, DOI 10.1677/erc.0.0080211; STAMP G, 1992, CELL GROWTH DIFFER, V3, P929; Suzuki K, 2000, FEBS LETT, V481, P53, DOI 10.1016/S0014-5793(00)01968-2; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Tanaka A, 2002, VIRCHOWS ARCH, V441, P380, DOI 10.1007/s00428-002-0687-9; Taniguchi F, 2003, J CLIN ENDOCR METAB, V88, P773, DOI 10.1210/jc.2002-021062; VANDERVALK MA, 1981, MAMMARY TUMORS MOUSE, P45; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918	51	58	60	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6047	6055		10.1038/sj.onc.1207816	http://dx.doi.org/10.1038/sj.onc.1207816			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15208658				2022-12-28	WOS:000223261000004
J	Yao, R; Natsume, Y; Noda, T				Yao, R; Natsume, Y; Noda, T			MAGI-3 is involved in the regulation of the JNK signaling pathway as a scaffold protein for frizzled and Ltap	ONCOGENE			English	Article						firzzled; MAGI-3; Ltap; JNK; PDZ	CONVERGENT EXTENSION MOVEMENTS; D-ASPARTATE RECEPTORS; TISSUE POLARITY GENE; PDZ DOMAIN; GUANYLATE KINASE; CELL-POLARITY; VERTEBRATE GASTRULATION; PLANAR POLARITY; LOOP-TAIL; DROSOPHILA	A seven-transmembrane protein, frizzled, has been implicated in a planar cell polarity (PCP) pathway as well as the canonical Wnt signaling pathway. Although both pathways require a cytoplasmic protein, dishevelled, the molecular mechanism by which frizzled regulates intracellular signaling remains to be elucidated. In the mouse, nine frizzled family members have been identified and six of them contain a PDZ-binding motif at their carboxyl-termini. In this study, we show that a multi-PDZ containing protein, MAGI-3, specifically binds to frizzled-4 and -7. Furthermore, we also demonstrate that MAGI-3 interacts with Ltap, a mouse homolog of the Drosophila PCP protein, stbm, and that these three molecules can form a ternary complex. In epithelial cells, MAGI-3, frizzled-4, and Ltap colocalized at cell contact sites, indicating that these molecules form a physiologically significant complex. Finally, we found that MAGI-3 strongly activated JNK in conjunction with frizzled-4 and Ltap, and that this activation required the small GTPase, Rac. These results indicate that MAGI-3 functions as a scaffold protein for frizzled-4 and Ltap and regulates the JNK signaling cascade.	Tohoku Univ, Sch Med, Ctr Translat Adv Anim Res Human Dis, Aoba Ku, Sendai, Miyagi 9808575, Japan; JFCR Canc Inst, Dept Cell Biol, Toshima Ku, Tokyo 1708455, Japan; RIKEN, Gen Sci Ctr, Mouse Funct Gen Res Grp, Totsuka Ku, Kanagawa 2440804, Japan	Tohoku University; Japanese Foundation for Cancer Research; RIKEN	Noda, T (corresponding author), Tohoku Univ, Sch Med, Ctr Translat Adv Anim Res Human Dis, Aoba Ku, 2-1 Seiryo Cho, Sendai, Miyagi 9808575, Japan.	tnoda@ims.u-tokyo.ac.jp	Noda, Tetsuo/B-1667-2016					Adamsky K, 2003, J CELL SCI, V116, P1279, DOI 10.1242/jcs.00302; Adler PN, 2002, DEV CELL, V2, P525, DOI 10.1016/S1534-5807(02)00176-4; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Darken RS, 2002, EMBO J, V21, P976, DOI 10.1093/emboj/21.5.976; Dobrosotskaya I, 1997, J BIOL CHEM, V272, P31589, DOI 10.1074/jbc.272.50.31589; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; Goto T, 2002, DEV BIOL, V247, P165, DOI 10.1006/dbio.2002.0673; Habas R, 2003, GENE DEV, V17, P295, DOI 10.1101/gad.1022203; Habas R, 2001, CELL, V107, P843, DOI 10.1016/S0092-8674(01)00614-6; Heisenberg CP, 2000, NATURE, V405, P76, DOI 10.1038/35011068; Hirao K, 2000, J BIOL CHEM, V275, P2966, DOI 10.1074/jbc.275.4.2966; Hirao K, 1998, J BIOL CHEM, V273, P21105, DOI 10.1074/jbc.273.33.21105; Ide N, 1999, ONCOGENE, V18, P7810, DOI 10.1038/sj.onc.1203153; Ishikawa T, 2001, DEVELOPMENT, V128, P25; Jessen JR, 2002, NAT CELL BIOL, V4, P610, DOI 10.1038/ncb828; Kibar Z, 2001, NAT GENET, V28, P251, DOI 10.1038/90081; Korinek V, 1998, MOL CELL BIOL, V18, P1248, DOI 10.1128/MCB.18.3.1248; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Murdoch JN, 2001, HUM MOL GENET, V10, P2593, DOI 10.1093/hmg/10.22.2593; Nishimura W, 2000, J CELL PHYSIOL, V185, P358, DOI 10.1002/1097-4652(200012)185:3<358::AID-JCP6>3.3.CO;2-R; Park M, 2002, NAT CELL BIOL, V4, P20, DOI 10.1038/ncb716; Robitaille J, 2002, NAT GENET, V32, P326, DOI 10.1038/ng957; Shiratsuchi T, 1998, BIOCHEM BIOPH RES CO, V247, P597, DOI 10.1006/bbrc.1998.8603; Shoji H, 2000, J BIOL CHEM, V275, P5485, DOI 10.1074/jbc.275.8.5485; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Taylor J, 1998, GENETICS, V150, P199; Wallingford JB, 2002, DEVELOPMENT, V129, P5815, DOI 10.1242/dev.00123; Wallingford JB, 2000, NATURE, V405, P81, DOI 10.1038/35011077; Wang YS, 2002, J NEUROSCI, V22, P8563; Wang YS, 2001, J NEUROSCI, V21, P4761, DOI 10.1523/JNEUROSCI.21-13-04761.2001; Wang YS, 1996, J BIOL CHEM, V271, P4468; Wolff T, 1998, DEVELOPMENT, V125, P1149; Wood JD, 1998, MOL CELL NEUROSCI, V11, P149, DOI 10.1006/mcne.1998.0677; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199; Yamanaka H, 2002, EMBO REP, V3, P69, DOI 10.1093/embo-reports/kvf008; Yao RJ, 2001, BIOCHEM BIOPH RES CO, V286, P771, DOI 10.1006/bbrc.2001.5430	37	56	63	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6023	6030		10.1038/sj.onc.1207817	http://dx.doi.org/10.1038/sj.onc.1207817			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15195140				2022-12-28	WOS:000223261000001
J	Giampieri, S; Garcia-Escudero, R; Green, J; Storey, A				Giampieri, S; Garcia-Escudero, R; Green, J; Storey, A			Human papillomavirus type 77 E6 protein selectively inhibits p53-dependent transcription of proapoptotic genes following UV-B irradiation	ONCOGENE			English	Article						p53; apoptosis; transcriptional activation; HPV; UV-B	TUMOR-SUPPRESSOR PROTEIN; NONMELANOMA SKIN-CANCER; EPIDERMODYSPLASIA-VERRUCIFORMIS; P53-INDUCED APOPTOSIS; E6 PROTEINS; P53 MUTANTS; HPV TYPES; ACTIVATION; PROMOTERS; DEFINES	DNA damage, such as that elicited by UV-B, can induce either a cell cycle arrest or apoptosis that can be signalled by the p53 protein through the activation of a number of downstream cellular target genes. In contrast to oncogenic anogenital human papillomaviruses (HPVs), which mediate proteolytic degradation of p53, the E6 protein of cutaneous HPVs, such as HPV 77, do not promote p53 degradation. We have previously shown, however, that expression of HPV 77 E6 can effectively block UV-induced apoptosis in cells that have UY-activated p53. Here, we report that expression of the E6 protein from the cutaneous HPV 77 attenuates the UY-induced transactivation of p53-regulated proapoptotic genes Fas, PUMAbeta, Apaf-1, PIG3. This inhibition of p53-activation of proapoptotic genes by HPV77 E6 is exerted selectively, as the increased expression of p53 target genes involved in cell cycle arrest or regulatory functions regulation, such as p21 and Hdm2, is unaffected. Our data suggest that HPV 77 E6 may play an important role in specifically deregulating p53-dependent transactivation of proapoptotic genes upon UV-B irradiation.	Canc Res UK, Skin Tumour Lab, London E1 2AT, England	Cancer Research UK	Storey, A (corresponding author), Canc Res UK, Skin Tumour Lab, 2 Newark St, London E1 2AT, England.	alan.storey@cancer.org.uk	Garcia-Escudero, Ramon/A-2735-2012	Garcia-Escudero, Ramon/0000-0001-5640-6542; Storey, Alan/0000-0003-2001-9772; Giampieri, Silvia/0000-0001-5484-3140; Green, Judith/0000-0001-6825-9404				Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Campomenosi P, 2001, ONCOGENE, V20, P3573, DOI 10.1038/sj.onc.1204468; de Villiers EM, 1999, SEMIN CANCER BIOL, V9, P413, DOI 10.1006/scbi.1999.0145; Delius H, 1998, VIROLOGY, V240, P359, DOI 10.1006/viro.1997.8943; Harwood CA, 2000, J MED VIROL, V61, P289, DOI 10.1002/1096-9071(200007)61:3&lt;289::AID-JMV2&gt;3.0.CO;2-Z; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Jackson S, 2000, GENE DEV, V14, P3065, DOI 10.1101/gad.182100; Jackson S, 2000, ONCOGENE, V19, P592, DOI 10.1038/sj.onc.1203339; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Malanchi I, 2002, ONCOGENE, V21, P5665, DOI 10.1038/sj.onc.1205617; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Orth G, 2001, J VIROL, V75, P4952, DOI 10.1128/JVI.75.10.4952-4953.2001; ORTH G, 1986, CIBA F SYMP, V120, P157; Pluquet O, 2001, CANCER LETT, V174, P1, DOI 10.1016/S0304-3835(01)00698-X; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Purdie KJ, 1999, EMBO J, V18, P5359, DOI 10.1093/emboj/18.19.5359; Rapp B, 1997, J VIROL, V71, P6956, DOI 10.1128/JVI.71.9.6956-6966.1997; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Scolnick DM, 1997, CANCER RES, V57, P3693; Sesto A, 2002, P NATL ACAD SCI USA, V99, P2965, DOI 10.1073/pnas.052678999; STEGER G, 1992, ARCH VIROL, V125, P355, DOI 10.1007/BF01309654; STOREY A, 1995, ONCOGENE, V11, P653; Storey A, 2002, TRENDS MOL MED, V8, P417, DOI 10.1016/S1471-4914(02)02387-0; Surentheran T, 1998, J CLIN PATHOL, V51, P606, DOI 10.1136/jcp.51.8.606; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Wattre P, 1996, ANN BIOL CLIN-PARIS, V54, P189; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1	32	31	33	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2004	23	34					5864	5870		10.1038/sj.onc.1207711	http://dx.doi.org/10.1038/sj.onc.1207711			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KW	15077176				2022-12-28	WOS:000222629800017
J	Munz, M; Kieu, C; Mack, B; Schmitt, B; Zeidler, R; Gires, O				Munz, M; Kieu, C; Mack, B; Schmitt, B; Zeidler, R; Gires, O			The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation	ONCOGENE			English	Article						EpCAM; carcinoma; c-myc; cyclines	EPSTEIN-BARR-VIRUS; MOLECULE EP-CAM; BREAST-CANCER; TARGET; CYCLE; OVEREXPRESSION; EXPRESSION; RECEPTOR; GROWTH; 17-1A	Epithelial cell adhesion molecule (EpCAM) is a membrane glycoprotein expressed on adenomatous and simple epithelia, where it is involved in homophilic adhesion at the basolateral membrane. Carcinomas strongly overexpress EpCAM through an, as yet, unknown mechanism. Interestingly, otherwise EpCAM-negative squamous epithelia are seen to express EpCAM concomitant with their transformation and de-differentiation. The amount of EpCAM and the number of expressing cells both increase with the grade of dysplasia. Despite an important amount of data correlating the expression of EpCAM with cellular proliferation and de-differentiation, such as the coexpression with Ki-67, a marker for proliferation, it is unknown whether EpCAM may directly contribute to carcinogenesis. Here, we show that EpCAM has a direct impact on cell cycle and proliferation, and the ability to rapidly upregulate the proto-oncogene c-myc and cyclin A/E. Human epithelial 293 cells as well as murine NIH3T3 fibroblasts expressing EpCAM had a decreased requirement for growth factors, enhanced metabolic activity and colony formation capacity. Importantly, the inhibition of EpCAM expression with antisense mRNA led to a strong decrease in proliferation and metabolism in human carcinoma cells. Moreover, domain swapping experiments demonstrated that the intracellular part of EpCAM is necessary and sufficient to transduce the effects described. Thus, the data presented here highlight the role of EpCAM, demonstrating for the first time a direct link to cell cycle and proliferation.	Univ Munich, Clin Cooperat Grp Mol Oncol, GSF Natl Res Ctr Environm & Hlth, D-81377 Munich, Germany; Univ Munich, Dept Otorhinolaryngol, D-81377 Munich, Germany; Univ Munich, Head & Neck Res Dept, D-81377 Munich, Germany; Vaecgene Biotech Inc, D-81377 Munich, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; University of Munich; University of Munich	Gires, O (corresponding author), Univ Munich, Clin Cooperat Grp Mol Oncol, GSF Natl Res Ctr Environm & Hlth, Marchioninistr 15, D-81377 Munich, Germany.	ogires@med.uni-muenchen.de	Gires, Olivier/V-2689-2017	Gires, Olivier/0000-0002-2292-7064				Amati B, 1998, FRONT BIOSCI, V3, pd250, DOI [10.2741/a239, DOI 10.2741/A239]; Balzar M, 1999, J MOL MED, V77, P699, DOI 10.1007/s001099900038; Blazar M, 2001, MOL CELL BIOL, V21, P2570, DOI 10.1128/MCB.21.7.2570-2580.2001; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Chaubal S, 1999, ANTICANCER RES, V19, P2237; DAKSIS JI, 1994, ONCOGENE, V9, P3635; Dang CV, 1999, EXP CELL RES, V253, P63, DOI 10.1006/excr.1999.4686; Dang CV, 1999, MOL CELL BIOL, V19, P1; Davies DE, 1996, BIOCHEM PHARMACOL, V51, P1101, DOI 10.1016/0006-2952(95)02232-5; Field J K, 1992, Eur J Cancer B Oral Oncol, V28B, P67, DOI 10.1016/0964-1955(92)90016-T; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Gastl G, 2000, LANCET, V356, P1981, DOI 10.1016/S0140-6736(00)03312-2; Gires O, 1997, EMBO J, V16, P6131, DOI 10.1093/emboj/16.20.6131; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Litvinov SV, 1997, J CELL BIOL, V139, P1337, DOI 10.1083/jcb.139.5.1337; Litvinov SV, 1996, AM J PATHOL, V148, P865; Meden H, 1997, EUR J OBSTET GYN R B, V71, P173, DOI 10.1016/S0301-2115(96)02630-9; Meyaard L, 2001, J EXP MED, V194, P107, DOI 10.1084/jem.194.1.107; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Packeisen J, 1999, HYBRIDOMA, V18, P37, DOI 10.1089/hyb.1999.18.37; Pauli C, 2003, CANCER LETT, V193, P25, DOI 10.1016/S0304-3835(03)00003-X; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; Piyathilake CJ, 2000, HUM PATHOL, V31, P482, DOI 10.1053/hp.2000.6711; RIETHMULLER G, 1994, LANCET, V343, P1177, DOI 10.1016/S0140-6736(94)92398-1; Rodrigo JP, 1996, ARCH OTOLARYNGOL, V122, P504; Roh H, 2000, ONCOGENE, V19, P6138, DOI 10.1038/sj.onc.1204001; Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397; Spizzo G, 2002, INT J CANCER, V98, P883, DOI 10.1002/ijc.10270; SUGDEN B, 1977, J VIROL, V23, P503, DOI 10.1128/JVI.23.3.503-508.1977; TANDON AK, 1990, CANCER RES, V50, P3317; Zornig M, 1996, CURR BIOL, V6, P1553, DOI 10.1016/S0960-9822(02)70769-0	32	283	306	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2004	23	34					5748	5758		10.1038/sj.onc.1207610	http://dx.doi.org/10.1038/sj.onc.1207610			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KW	15195135				2022-12-28	WOS:000222629800004
J	Miller, LD; Lee, KC; Mochly-Rosen, D; Cartwright, CA				Miller, LD; Lee, KC; Mochly-Rosen, D; Cartwright, CA			RACK1 regulates Src-mediated Sam68 and p190RhoGAP signaling	ONCOGENE			English	Article						Src; tyrosine kinase; RACK1; PKC; Sam68; p190RhoGAP	PROTEIN-KINASE-C; TYROSINE PHOSPHORYLATION; BETA-SUBUNIT; ACTIVATION; GROWTH; REGION; P190; MECHANISMS; INHIBITOR; SUBSTRATE	RACK1 is the founding member of a family of receptors for activated C kinase collectively called RACKs. Upon activation of PKC, RACK1 co-localizes with the Src tyrosine kinase at the plasma membrane and functions as a substrate, binding partner and inhibitor of Src (as measured in vitro), and a growth inhibitor in NIH 3T3 cells. To further analyze the function of RACK1 in Src and PKC signaling, we utilized cell-permeable peptides that modulate the interaction of RACK1 and betaIIPKC, thereby affecting betaIIPKC translocation and function. We found that the association of betaIIPKC and RACK1 is necessary for Src phosphorylation of RACK1. Src activity is required for tyrosine phosphorylation of RACK1, and for RACK1 binding to Src, but not to betaIIPKC. Endogenous Src kinase activity, as measured by phosphorylation of Sam68 (a mitotic-specific Src substrate involved in cell cycle regulation and RNA splicing) or p190RhoGAP (a Src substrate and GTPase-activating protein involved in actin reorganization), increases with disruption of the Src-RACK1 complex, and decreases with enhanced complex formation. RACK1 inhibits Src-mediated p190RhoGAP signaling and actin cytoskeleton rearrangement. Thus, RACK1 functions as an endogenous inhibitor of the Src kinase in diverse signaling pathways that regulate distinct cellular functions. Our results demonstrate the potential for using peptide modulators of Src activity as a tool for uncovering the function of Src in cells.	Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Dept Mol Pharmacol, Stanford, CA 94305 USA	Stanford University; Stanford University	Cartwright, CA (corresponding author), Stanford Univ, Dept Med, Sch Med, M211 Alway Bldg,300 Pasteur Dr, Stanford, CA 94305 USA.	chris.cartwright@stanford.edu		Mochly-Rosen, Daria/0000-0002-6691-8733	NHLBI NIH HHS [R01 HL52141] Funding Source: Medline; NIDDK NIH HHS [DK65339, R01 DK43743] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052141] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043743] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aitken A, 2002, BIOCHEM SOC T, V30, P351, DOI 10.1042/bst0300351; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Chang BY, 2002, ONCOGENE, V21, P7619, DOI 10.1038/sj.onc.1206002; Chang BY, 2001, J BIOL CHEM, V276, P20346, DOI 10.1074/jbc.M101375200; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; Donovan S, 2002, BBA-REV CANCER, V1602, P23, DOI 10.1016/S0304-419X(01)00041-5; Dorn GW, 2002, ANNU REV PHYSIOL, V64, P407, DOI 10.1146/annurev.physiol.64.081501.155903; Fincham VJ, 1999, J CELL SCI, V112, P947; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hay JC, 1996, J BIOL CHEM, V271, P5671, DOI 10.1074/jbc.271.10.5671; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; Lukong KE, 2003, BBA-REV CANCER, V1653, P73, DOI 10.1016/j.bbcan.2003.09.001; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; RON D, 1995, P NATL ACAD SCI USA, V92, P492, DOI 10.1073/pnas.92.2.492; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Roof RW, 2000, FEBS LETT, V472, P117, DOI 10.1016/S0014-5793(00)01439-3; Roof RW, 1998, MOL CELL BIOL, V18, P7052, DOI 10.1128/MCB.18.12.7052; Schechtman D, 2001, ONCOGENE, V20, P6339, DOI 10.1038/sj.onc.1204778; Souroujon MC, 1998, NAT BIOTECHNOL, V16, P919, DOI 10.1038/nbt1098-919; Stebbins EG, 2001, J BIOL CHEM, V276, P29644, DOI 10.1074/jbc.M101044200; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513	28	30	32	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5682	5686		10.1038/sj.onc.1207735	http://dx.doi.org/10.1038/sj.onc.1207735			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15184885				2022-12-28	WOS:000222629500013
J	Sansom, OJ; Bishop, SM; Bird, A; Clarke, AR				Sansom, OJ; Bishop, SM; Bird, A; Clarke, AR			MBD4 deficiency does not increase mutation or accelerate tumorigenesis in mice lacking MMR	ONCOGENE			English	Article						MBD4; MMR; DNA methylation; cancer	MSH2; MED1; CARCINOMAS; APOPTOSIS; GENE	Mbd4 (methyl-binding domain 4) has been shown to be mutated in a high percentage of mismatch repair (MMR)deficient colorectal tumours that exhibit microsatellite instability (MSI). However, the significance of these mutations is still unclear as they are predominantly monoallelic and the majority occur at a poly-A tract. Apart from MMR-deficient tumours, no other reports of mutations of Mbd4 in human neoplasia are as yet published. To address the significance of loss of Mbd4 in the absence of MMR, we have crossed Mbd4-deficient mice to mice lacking DNA MMR. We show that, in the context of MMR deficiency, additional loss of Mbd4 does not alter spontaneous mutation frequency at the endogenous DIb-1b locus, nor does it modify tumour onset, tumour spectrum or MSI compared to singly mutant Msh2 or Mlh1 mice. Taken together, these findings show that nullizygosity or heterozygosity for Mbd4 does not affect MMR-dependent tumorigenesis.	Univ Cardiff, Sch Biosci, Cardiff CF10 3US, S Glam, Wales; Univ Edinburgh, Inst Cell & Mol Biol, Wellcome Trust Ctr Cell Biol, Edinburgh EH9 3JR, Midlothian, Scotland	Cardiff University; University of Edinburgh	Clarke, AR (corresponding author), Univ Cardiff, Sch Biosci, Museum Ave,POB 911, Cardiff CF10 3US, S Glam, Wales.	clarkear@cardiff.ac.uk	Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014	Sansom, Owen J./0000-0001-9540-3010; Clarke, Alan/0000-0002-4281-426X; Bird, Adrian/0000-0002-8600-0372				Bacon AL, 2000, HUM MOL GENET, V9, P2707, DOI 10.1093/hmg/9.18.2707; Bader S, 1999, ONCOGENE, V18, P8044, DOI 10.1038/sj.onc.1203229; Bader S, 2000, BRIT J CANCER, V83, P1646, DOI 10.1054/bjoc.2000.1482; Bellacosa A, 1999, P NATL ACAD SCI USA, V96, P3969, DOI 10.1073/pnas.96.7.3969; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; Cortellino S, 2003, P NATL ACAD SCI USA, V100, P15071, DOI 10.1073/pnas.2334585100; Cranston A, 1997, NAT GENET, V17, P114, DOI 10.1038/ng0997-114; Drummond JT, 2001, NUCLEIC ACIDS RES, V29, P2234, DOI 10.1093/nar/29.11.2234; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843; Kongkanuntn R, 1999, ONCOGENE, V18, P7219, DOI 10.1038/sj.onc.1203181; Millar CB, 2002, SCIENCE, V297, P403, DOI 10.1126/science.1073354; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Riccio A, 1999, NAT GENET, V23, P266, DOI 10.1038/15443; Sansom OJ, 2000, MUTAT RES-FUND MOL M, V452, P149, DOI 10.1016/S0027-5107(00)00089-0; Sansom OJ, 2003, ONCOGENE, V22, P7130, DOI 10.1038/sj.onc.1206850; Sansom OJ, 2003, DNA REPAIR, V2, P1029, DOI 10.1016/S1568-7864(03)00111-3; Sansom OJ, 2001, CANCER RES, V61, P7060; Screaton RA, 2003, P NATL ACAD SCI USA, V100, P5211, DOI 10.1073/pnas.0431215100; Toft NJ, 2002, ONCOGENE, V21, P6299, DOI 10.1038/sj.onc.1205727; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; WINTON DJ, 1988, NATURE, V333, P463, DOI 10.1038/333463a0; Wong E, 2002, P NATL ACAD SCI USA, V99, P14937, DOI 10.1073/pnas.232579299	23	14	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5693	5696		10.1038/sj.onc.1207767	http://dx.doi.org/10.1038/sj.onc.1207767			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15184874				2022-12-28	WOS:000222629500015
J	Wang, HM; Radjendirane, V; Wary, KK; Chakrabarty, S				Wang, HM; Radjendirane, V; Wary, KK; Chakrabarty, S			Transforming growth factor beta regulates cell-cell adhesion through extracellular matrix remodeling and activation of focal adhesion kinase in human colon carcinoma Moser cells	ONCOGENE			English	Article						TGFB; cell adhesion; colon cancer	C-ALPHA; CARCINOEMBRYONIC ANTIGEN; RECEPTOR EXPRESSION; CANCER CELLS; FIBRONECTIN; GROWTH-FACTOR-BETA-1; INDUCTION; DIFFERENTIATION; STIMULATION; REQUIREMENT	Transforming growth factor (TGF) beta is a potent regulator of cell-matrix and cell-cell adhesions (collectively termed cellular adhesions). Cellular adhesions play crucial roles in controlling the differentiation of epithelial cells and in maintaining the integrity of the epithelium. Loss of TGF beta-responsiveness is thought to be an important early initiating event in the malignant progression of epithelial cancer. In the TGFbeta-responsive human colon adenocarcinoma Moser cells, TGFbeta promotes cellular adhesions and suppresses their malignant phenotype. TGFbeta promotes cell-matrix adhesion by inducing the synthesis of extracellular matrix (ECM) adhesion molecules and the expression of integrin receptors for these molecules (termed ECM remodeling). TGFbeta promotes cell-cell adhesion through the induction of E-cadherin expression, an epithelial associated homotypic cell-cell adhesion molecule, which also functions as a tumor suppressor in colon cancer. How TGFbeta regulates E-cadherin expression is not known. In this study, we showed that the induction of E-cadherin by TGFbeta was mediated through the activation of focal adhesion kinase (FAK), a major signaling molecule in focal adhesion contacts and that the activation of FAK was due to ECM remodeling and increased cell-matrix interactions. Thus, TGFbeta regulates cell-cell adhesion through its ability to remodel the ECM and to activate FAK through ECM remodeling.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Div Pathol & Lab Med, Houston, TX 77030 USA; Texas A&M Univ Syst, Inst Biossci & Technol, Hlth Sci Ctr, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston	Chakrabarty, S (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Div Pathol & Lab Med, 1515 Holcombe Blvd, Houston, TX 77030 USA.	schakrab@mdanderson.org		Wary, Kishore/0000-0001-8851-8565	NATIONAL CANCER INSTITUTE [R01CA047775] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 47775] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRATTAIN MG, 1984, CANCER METAST REV, V3, P177, DOI 10.1007/BF00048384; Brattain Michael G., 1996, Current Opinion in Oncology, V8, P49, DOI 10.1097/00001622-199601000-00009; BREEN E, 1995, ANN SURG ONCOL, V2, P378, DOI 10.1007/BF02306369; CHAKRABARTY S, 1989, CANCER RES, V49, P2112; Chakrabarty S, 1998, LAB INVEST, V78, P413; CHAKRABARTY S, 1995, J CELL PHYSIOL, V164, P148, DOI 10.1002/jcp.1041640119; CHAKRABARTY S, 1992, INT J CANCER, V50, P968, DOI 10.1002/ijc.2910500624; CHAKRABARTY S, 1988, CANCER RES, V48, P4059; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HUANG S, 1994, INT J CANCER, V57, P742, DOI 10.1002/ijc.2910570522; Ilyas M, 1999, P NATL ACAD SCI USA, V96, P3087, DOI 10.1073/pnas.96.6.3087; Jacks T, 2002, CELL, V111, P923, DOI 10.1016/S0092-8674(02)01229-1; LIN CQ, 1993, FASEB J, V7, P737, DOI 10.1096/fasebj.7.9.8330681; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; Rajagopal S, 1997, J CELL PHYSIOL, V170, P138, DOI 10.1002/(SICI)1097-4652(199702)170:2<138::AID-JCP5>3.0.CO;2-P; ROSKELLEY CD, 1994, P NATL ACAD SCI USA, V91, P12378, DOI 10.1073/pnas.91.26.12378; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; TANG DG, 1995, J CELL PHYSIOL, V165, P291, DOI 10.1002/jcp.1041650210; Thannickal VJ, 2003, J BIOL CHEM, V278, P12384, DOI 10.1074/jbc.M208544200; Varallo VM, 2003, ONCOGENE, V22, P3680, DOI 10.1038/sj.onc.1206415; Wang HM, 2001, J CELL PHYSIOL, V187, P188, DOI 10.1002/jcp.1068; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	27	54	55	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2004	23	32					5558	5561		10.1038/sj.onc.1207701	http://dx.doi.org/10.1038/sj.onc.1207701			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15133493				2022-12-28	WOS:000222588400016
J	Martin-Oliva, D; O'Valle, F; Munoz-Gamez, JA; Valenzuela, MT; Nunez, MI; Aguilar, M; de Almodovar, JMR; del Moral, RG; Oliver, FJ				Martin-Oliva, D; O'Valle, F; Munoz-Gamez, JA; Valenzuela, MT; Nunez, MI; Aguilar, M; de Almodovar, JMR; del Moral, RG; Oliver, FJ			Crosstalk between PARP-1 and NF-kappa B modulates the promotion of skin neoplasia	ONCOGENE			English	Article						skin carcinogenesis; PARP-1; NF-kappa B; inflammation	NITRIC-OXIDE SYNTHASE; POLY(ADP-RIBOSE) POLYMERASE; TRANSCRIPTIONAL ACTIVATION; TRANSGENIC MICE; DEFICIENT MICE; HUMAN CANCER; FACTOR-ALPHA; EXPRESSION; CELLS; CARCINOGENESIS	Poly (ADP-ribose) polymerase-1 (PARP-1)-deficient mice are protected against septic shock, type I diabetes, stroke and inflammation. It is now accepted that inflammation and related events, such as activation of NF-kappaB, are key components in the initiation and progression of epithelial cancer and in particular in the neoplastic transformation of keratinocytes and skin carcinogenesis. Here, we report that PARP-1-deficient mice display a strikingly reduced susceptibility to skin carcinogenesis. In parp-1(-/-) mice, development of papilloma-like premalignant lesions induced with DMBA and TPA, is strongly delayed and the final number of tumor-bearing mice and total tumor number were significantly reduced. In addition, epidermis of parp-1(-/-) mice did not show increased proliferation rates after treatment with carcinogen. Deregulated NF-kappaB is a hallmark for tumorigenesis together with the concomitant release of early inflammatory mediators. In the absence of PARP-1, NF-kappaB activation and induction kappaB-target genes did not take place during the promotion of tumor development. These results suggest that PARP-1 abolition impairs the promotion of skin carcinogenesis interfering with the activation of NF-kappaB and might have an important implication in targeting PARP-1 as a new antineoplastic therapeutic approach.	CSIC, Inst Parasitol & Biomed, Granada 18001, Spain; Univ Hosp, Granada, Spain; Univ Granada, Dept Pathol, E-18071 Granada, Spain; Univ Granada, Dept Radiol & Phys Med, E-18071 Granada, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN); University of Granada; University of Granada	Oliver, FJ (corresponding author), CSIC, Inst Parasitol & Biomed, C Ventanilla 11, Granada 18001, Spain.	joliver@ipb.csic.es	OValle, Francisco/AAA-9151-2019; Oliver, Javier/S-1725-2018; Martín-Oliva, David/L-8472-2014; Núñez, María Isabel/L-9924-2014	Oliver, Javier/0000-0001-8468-1998; Martín-Oliva, David/0000-0002-8095-5442; Núñez, María Isabel/0000-0001-8159-7969; Ruiz De Almodovar Rivera, Jose Mariano/0000-0002-7053-1072				Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; Bargou RC, 1996, BLOOD, V87, P4340, DOI 10.1182/blood.V87.10.4340.bloodjournal87104340; Bauerle PA, 1996, CELL, V87, P13; Bell S, 2003, CELL SIGNAL, V15, P1, DOI 10.1016/S0898-6568(02)00080-3; Benoit V, 2000, ONCOGENE, V19, P4787, DOI 10.1038/sj.onc.1203831; Brantley DM, 2001, MOL BIOL CELL, V12, P1445, DOI 10.1091/mbc.12.5.1445; Budunova IV, 1999, ONCOGENE, V18, P7423, DOI 10.1038/sj.onc.1203104; Conde C, 2001, EMBO J, V20, P3535, DOI 10.1093/emboj/20.13.3535; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; EMURCIA JM, 1997, P NATL ACAD SCI USA, V94, P73037; Gilmore T, 2002, CANCER LETT, V181, P1, DOI 10.1016/S0304-3835(01)00795-9; Greenhalgh DA, 1996, CANCER RES, V56, P4413; Hassa PO, 1999, BIOL CHEM, V380, P953, DOI 10.1515/BC.1999.118; Hassa PO, 2001, J BIOL CHEM, V276, P45588, DOI 10.1074/jbc.M106528200; Hassa PO, 2002, CELL MOL LIFE SCI, V59, P1534, DOI 10.1007/s00018-002-8527-2; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Liu DB, 2000, DIABETES, V49, P1116, DOI 10.2337/diabetes.49.7.1116; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; MAYO MW, 2000, BIOCHIM BIOPHYS ACTA, V1470, P55; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; Musgrave BL, 1999, EXP CELL RES, V252, P96, DOI 10.1006/excr.1999.4631; Noda A, 2000, ONCOGENE, V19, P21, DOI 10.1038/sj.onc.1203230; Nozaki T, 2003, CANCER SCI, V94, P497, DOI 10.1111/j.1349-7006.2003.tb01472.x; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; PANDOLFI F, 1992, CANCER, V69, P1165; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Samper E, 2001, J CELL BIOL, V154, P49, DOI 10.1083/jcb.200103049; Shall S, 2000, MUTAT RES-DNA REPAIR, V460, P1, DOI 10.1016/S0921-8777(00)00016-1; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Slaga T J, 1995, Prog Clin Biol Res, V391, P1; Tong WM, 2002, CANCER RES, V62, P6990; Tsutsumi M, 2001, CARCINOGENESIS, V22, P1, DOI 10.1093/carcin/22.1.1; Tucker PC, 2001, FASEB J, V15, P2241, DOI 10.1096/fj.01-0133com; Velasco M, 1997, J BIOL CHEM, V272, P23025, DOI 10.1074/jbc.272.37.23025; Wang XJ, 1999, P NATL ACAD SCI USA, V96, P8483, DOI 10.1073/pnas.96.15.8483; Weinberg WC, 1999, CANCER RES, V59, P2050; XIE QW, 1994, J BIOL CHEM, V269, P4705; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221	42	51	54	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2004	23	31					5275	5283		10.1038/sj.onc.1207696	http://dx.doi.org/10.1038/sj.onc.1207696			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15077172				2022-12-28	WOS:000222491600003
J	Al-Fageeh, M; Li, QJ; Dashwood, WM; Myzak, MC; Dashwood, RH				Al-Fageeh, M; Li, QJ; Dashwood, WM; Myzak, MC; Dashwood, RH			Phosphorylation and ubiquitination of oncogenic mutants of beta-catenin containing substitutions at Asp32	ONCOGENE			English	Article						beta-catenin; TCF/LEF; APC; Wnt signaling; colorectal cancer; CTNNB1; human beta-catenin gene; Ctnnb1; rat beta-catenin gene	WNT SIGNALING PATHWAY; RAT COLON TUMORS; MUTATIONAL ANALYSIS; ADHESION SYSTEM; LIVER-TUMORS; GENE CTNNB1; CELL-LINES; CANCER; CADHERIN; DEGRADATION	beta-Catenin, a member of the Wnt signaling pathway, is downregulated by glycogen synthase kinase-3beta (GSK-3beta)-dependent phosphorylation of Ser/Thr residues in the N-terminus of the protein, followed by ubiquitination and proteosomal degradation. In human and rodent cancers, mutations that substitute one of the critical Ser/Thr residues in the GSK-3beta region of beta-catenin stabilize the protein and activate beta-catenin/TCF/LEF target genes. This study examined three oncogenic beta-catenin mutants from rat colon tumors containing substitutions adjacent to amino-acid residue Ser33, a key target for phosphorylation by GSK-3beta. Compared with wild-type beta-catenin (WT), the beta-catenin mutants D32G, D32N, and D32Y strongly activated TCF-4-dependent transcription in HEK293 cells, and there was accumulation of beta-catenin in the cell lysates. Immunoblotting with phosphospecific antibodies indicated that there was little if any effect on the phosphorylation of Ser37, Thr41 or Ser45; however, the phosphorylation of Ser33 appeared to be affected in the beta-catenin mutants. Specifically, antiphospho-beta-catenin 33/37/41 antibody identified high, intermediate and low expression levels of phosphorylated beta-catenin in cells transfected with D32G, D32N and D32Y, respectively. Experiments with the proteosome inhibitor N-acetyl-Leu-Leu-norleucinal ( ALLN) revealed ubiquitinated bands on all three mutant beta-catenins, as well as on WT beta-catenin. The relative order of ubiquitination was WT>D32G>D32N>D32Y, in parallel with findings from the phosphorylation studies. These results are discussed in the context of previous studies, which indicated that amino-acid residue D32 lies within the ubiquitination recognition motif of beta-catenin.	Oregon State Univ, Linus Pauling Inst Sci & Med, Corvallis, OR 97331 USA; Oregon State Univ, Dept Environm & Mol Toxicol, Corvallis, OR 97331 USA	Oregon State University; Oregon State University	Dashwood, RH (corresponding author), Oregon State Univ, Linus Pauling Inst Sci & Med, 571 Weniger Hall, Corvallis, OR 97331 USA.	rod.dashwood@oregonstate.edu	Dashwood, Roderick H/E-9090-2011; Dashwood, Roderick/AAF-2025-2020	Li, Qingjie/0000-0003-1405-7000	NCI NIH HHS [R01 CA065525-07, CA65525, R01 CA080176-05, R01 CA065525-09, R01 CA080176-02, R01 CA065525-08, R01 CA080176-04, R01 CA065525-06A1, P01 CA090890-01A29001, R01 CA065525, P01 CA090890-05, R29 CA065525, CA80176, P01 CA090890-05S1, CA90890, R01 CA080176, P01 CA090890-01A20003, P01 CA090890, R01 CA080176-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065525, P01CA090890, R29CA065525, R01CA080176] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Blum CA, 2003, MOL CARCINOGEN, V36, P195, DOI 10.1002/mc.10112; Blum CA, 2001, CARCINOGENESIS, V22, P315, DOI 10.1093/carcin/22.2.315; Clements WM, 2002, CANCER RES, V62, P3503; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; Dashwood RH, 1998, CANCER RES, V58, P1127; Dashwood WM, 2002, BIOCHEM BIOPH RES CO, V296, P584, DOI 10.1016/S0006-291X(02)00914-2; Espinosa L, 2003, J BIOL CHEM, V278, P32227, DOI 10.1074/jbc.M304001200; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Hagen T, 2002, BIOCHEM BIOPH RES CO, V294, P324, DOI 10.1016/S0006-291X(02)00485-0; Hajra KM, 2002, GENE CHROMOSOME CANC, V34, P255, DOI 10.1002/gcc.10083; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Huelsken J, 2002, J CELL SCI, V115, P3977, DOI 10.1242/jcs.00089; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Li QJ, 2004, GENOMICS, V83, P231, DOI 10.1016/j.ygeno.2003.08.004; Li QJ, 2002, GENE, V283, P255, DOI 10.1016/S0378-1119(01)00839-3; Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Oving IM, 2002, EUR J CLIN INVEST, V32, P448, DOI 10.1046/j.1365-2362.2002.01004.x; Polakis P, 2000, GENE DEV, V14, P1837; Porfiri E, 1997, ONCOGENE, V15, P2833, DOI 10.1038/sj.onc.1201462; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sparks AB, 1998, CANCER RES, V58, P1130; Suzui M, 1999, MOL CARCINOGEN, V24, P232, DOI 10.1002/(SICI)1098-2744(199903)24:3<232::AID-MC10>3.0.CO;2-M; Takahashi M, 1998, CANCER RES, V58, P42; Van Gassen G, 2000, MOL MED, V6, P570, DOI 10.1007/BF03401795; Wang ZH, 2003, CANCER RES, V63, P5234	32	29	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 17	2004	23	28					4839	4846		10.1038/sj.onc.1207634	http://dx.doi.org/10.1038/sj.onc.1207634			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	830EK	15064718	Green Accepted			2022-12-28	WOS:000222104200004
J	Menendez, JA; Oza, BP; Atlas, E; Verma, VA; Mehmi, I; Lupu, R				Menendez, JA; Oza, BP; Atlas, E; Verma, VA; Mehmi, I; Lupu, R			Inhibition of tumor-associated fatty acid synthase activity antagonizes estradiol- and tamoxifen-induced agonist transactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cells	ONCOGENE			English	Article						fatty acid synthase; estradiol; tamoxifen; cerulenin; C75; RNA interference; small interfering RNA; estrogen receptor; apoptosis; endometrial cancer	BREAST-CANCER; FOOD-INTAKE; PROGESTERONE-RECEPTOR; ANTIBIOTIC CERULENIN; RIBONUCLEIC-ACID; RNA INTERFERENCE; LIPID-METABOLISM; GENE-EXPRESSION; IN-VITRO; ACTIVATION	Overexpression of the lipogenic enzyme fatty acid synthase (FAS) is a common molecular feature in subsets of sex-steroid-related tumors including endometrium and breast carcinomas that are associated with poor prognosis. Pharmacological inhibition of tumor-associated FAS hyperactivity is under investigation as a chemotherapeutic target. We examined the effects of the mycotoxin cerulenin (a covalent FAS inactivator), and the novel small compound C75 ( a slow-binding FAS inhibitor) on estradiol (E-2)- and tamoxifen (TAM)-stimulated ER-driven molecular responses in Ishikawa cells, an in vitro model of well-differentiated human endometrial carcinoma. We evaluated the effects of FAS inhibition on E-2- and TAM-induced estrogen receptor ( ER) transcriptional activity by using transient cotransfection assays with an estrogen-response element reporter construct (ERE-Luciferase). Antiestrogenic effects of cerulenin and C75 were observed by dose-dependent inhibition of E-2- stimulated ERE-dependent transcription, whereas FAS inhibitors did not significantly increase the levels of ERE transcriptional activity in the absence of E-2. Moreover, pharmacological blockade of FAS activity completely abolished TAM-stimulated ERE activity. To address the reliability of transient transfection assays, the effects of FAS inhibitors on E-2- inducible gene products were evaluated. FAS blockade induced a dose-dependent decrease in E-2- inducible alkaline phosphatase activity. E-2- stimulated accumulation of progesterone receptor (PR) and HER-2/neu oncogene was abolished in the presence of FAS blockers. FAS inhibition also resulted in a marked downregulation of E-2-stimulated ERalpha expression, and noticeably impaired E-2- induced ERalpha nuclear accumulation. A dose-dependent decrease in cell proliferation and cell viability was observed after FAS blockade. A Cell Death ELISA, detecting DNA fragmentation, demonstrated that FAS inhibitors stimulated apoptosis of Ishikawa cells. The analysis of critical E-2- and TAM-related cell cycle proteins revealed an increase of both the expression and the nuclear accumulation of cyclin-dependent kinase inhibitors p21(WAF1/CIP1) and p27(Kip1) following FAS inhibition. To rule out non-FAS cerulenin- and C75-related effects, we finally monitored ER signaling after silencing of FAS gene expression using the highly sequence-specific mechanism of RNA interference (RNAi). The concentrations of E-2 and TAM inducing half-maximal ERE activity (EC50) dramatically increased (4100 times) in FAS RNAi-transfected Ishikawa cells. Moreover, depletion of FAS by RNAi also caused loss of ERalpha expression, downregulation of PR, and accumulation of p21(WAF1/CIP1) and p27(Kip1) in E-2- stimulated Ishikawa cells. If chemically stable FAS inhibitors or cell-selective vector systems able to deliver RNAi targeting FAS gene demonstrate systemic anticancer effects in vivo, our results render FAS as a novel target for the prevention and treatment of endometrial carcinoma.	Evanston NW Healthcare Res Inst, Dept Med, Evanston, IL 60201 USA; Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Lupu, R (corresponding author), Evanston NW Healthcare Res Inst, Dept Med, 1001 Univ Pl, Evanston, IL 60201 USA.	r-lupu@northwestern.edu	MENENDEZ, JAVIER A/C-6148-2016	MENENDEZ, JAVIER A/0000-0001-8733-4561; Verma, Vishal/0000-0001-7600-4372				ALBERT JL, 1990, CANCER RES, V50, P3306; Alo PL, 1999, TUMORI, V85, P35, DOI 10.1177/030089169908500108; Alo PL, 1996, CANCER, V77, P474, DOI 10.1002/(SICI)1097-0142(19960201)77:3<474::AID-CNCR8>3.0.CO;2-K; Atanaskova N, 2002, ONCOGENE, V21, P4000, DOI 10.1038/sj.onc.1205506; Bamberger AM, 1999, VIRCHOWS ARCH, V434, P423, DOI 10.1007/s004280050361; Barsalou A, 1998, J BIOL CHEM, V273, P17138, DOI 10.1074/jbc.273.27.17138; Beato M, 1996, STEROIDS, V61, P240, DOI 10.1016/0039-128X(96)00030-X; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Cariou S, 2000, P NATL ACAD SCI USA, V97, P9042, DOI 10.1073/pnas.160016897; CHALBOS D, 1992, J STEROID BIOCHEM, V43, P223, DOI 10.1016/0960-0760(92)90211-Z; CHRISTIE WW, 1981, BIOCHIM BIOPHYS ACTA, V666, P284, DOI 10.1016/0005-2760(81)90118-1; Colacurci N, 2000, PANMINERVA MED, V42, P45; Cosman F, 1999, ENDOCR REV, V20, P418, DOI 10.1210/er.20.3.418; De Schrijver E, 2003, CANCER RES, V63, P3799; Dils R, 1975, Methods Enzymol, V35, P74, DOI 10.1016/0076-6879(75)35140-9; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; ESCOT C, 1990, J CLIN ENDOCR METAB, V70, P1319, DOI 10.1210/jcem-70-5-1319; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Favoni RE, 1998, TRENDS PHARMACOL SCI, V19, P406, DOI 10.1016/S0165-6147(98)01252-8; Foster JS, 1996, MOL ENDOCRINOL, V10, P488, DOI 10.1210/me.10.5.488; Gallo MA, 1997, SEMIN ONCOL, V24, pS71; Gansler TS, 1997, HUM PATHOL, V28, P686, DOI 10.1016/S0046-8177(97)90177-5; Goldstein SR, 2000, EUR J CANCER, V36, pS54; Harborth J, 2001, J CELL SCI, V114, P4557; Hata H, 1998, ONCOLOGY-BASEL, V55, P35, DOI 10.1159/000055257; Heemers H, 2001, MOL ENDOCRINOL, V15, P1817, DOI 10.1210/me.15.10.1817; HOLINKA CF, 1986, J STEROID BIOCHEM, V25, P781, DOI 10.1016/0022-4731(86)90308-0; JAMIL A, 1991, J MOL ENDOCRINOL, V6, P215, DOI 10.1677/jme.0.0060215; JENSEN V, 1993, BREAST CANC RES TREA, V27, P1; JOYEUX C, 1989, MOL ENDOCRINOL, V3, P681, DOI 10.1210/mend-3-4-681; KALKHOVEN E, 1994, MOL CELL ENDOCRINOL, V102, P45, DOI 10.1016/0303-7207(94)90096-5; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; Kawata M, 2001, ARCH HISTOL CYTOL, V64, P353, DOI 10.1679/aohc.64.353; Kim EK, 2002, AM J PHYSIOL-ENDOC M, V283, pE867, DOI 10.1152/ajpendo.00178.2002; KRISHNA PLB, 2001, CANCER RES, V61, P6137; Kuhajda FP, 2000, P NATL ACAD SCI USA, V97, P3450, DOI 10.1073/pnas.050582897; Kuhajda FP, 2000, NUTRITION, V16, P202, DOI 10.1016/S0899-9007(99)00266-X; Kumar MV, 2002, P NATL ACAD SCI USA, V99, P1921, DOI 10.1073/pnas.042683699; Kusakabe T, 2000, J HISTOCHEM CYTOCHEM, V48, P613, DOI 10.1177/002215540004800505; Lasset C, 2001, LANCET, V357, P66, DOI 10.1016/S0140-6736(05)71563-4; Lessey BA, 1996, J STEROID BIOCHEM, V59, P31, DOI 10.1016/S0960-0760(96)00103-3; Li JN, 2001, CANCER RES, V61, P1493; Loftus TM, 2000, SCIENCE, V288, P2379, DOI 10.1126/science.288.5475.2379; Lupu R, 2003, INT J ONCOL, V23, P1407; Markogiannakis E, 1997, LIFE SCI, V61, P1083, DOI 10.1016/S0024-3205(97)00617-6; Menendez JA, 2004, INT J ONCOL, V24, P591; Milgraum LZ, 1997, CLIN CANCER RES, V3, P2115; Moche M, 1999, J BIOL CHEM, V274, P6031, DOI 10.1074/jbc.274.10.6031; MOELLING K, 1990, FEBS LETT, V261, P373, DOI 10.1016/0014-5793(90)80595-A; Nishida M, 1996, Hum Cell, V9, P109; Nishida Masato, 2002, Hum Cell, V15, P104, DOI 10.1111/j.1749-0774.2002.tb00105.x; OMURA S, 1976, BACTERIOL REV, V40, P681, DOI 10.1128/MMBR.40.3.681-697.1976; PEREZ L, 1991, FEBS LETT, V280, P129, DOI 10.1016/0014-5793(91)80220-W; Perlmann T, 1997, CELL, V90, P391, DOI 10.1016/S0092-8674(00)80498-5; Persson I, 2000, J STEROID BIOCHEM, V74, P357, DOI 10.1016/S0960-0760(00)00113-8; Pisha Emily, 1997, Methods in Cell Science, V19, P37, DOI 10.1023/A:1009746605060; Pizer ES, 1997, INT J GYNECOL PATHOL, V16, P45, DOI 10.1097/00004347-199701000-00008; Pizer ES, 1996, CANCER RES, V56, P1189; Pizer ES, 1998, CANCER-AM CANCER SOC, V83, P528, DOI 10.1002/(SICI)1097-0142(19980801)83:3<528::AID-CNCR22>3.0.CO;2-X; Pizer ES, 2000, CANCER RES, V60, P213; Pizer ES, 1996, CANCER RES, V56, P2745; Pizer ES, 1998, CANCER RES, V58, P4611; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; Price AC, 2001, J BIOL CHEM, V276, P6551, DOI 10.1074/jbc.M007101200; RONCARI DAK, 1974, CAN J BIOCHEM CELL B, V52, P221, DOI 10.1139/o74-035; Sakamoto T, 2002, MOL CELL ENDOCRINOL, V192, P93, DOI 10.1016/S0303-7207(02)00086-2; Schwartz LB, 1997, AM J OBSTET GYNECOL, V176, P129, DOI 10.1016/S0002-9378(97)80025-7; Shimokawa T, 2002, P NATL ACAD SCI USA, V99, P66, DOI 10.1073/pnas.012606199; Shiozawa T, 1998, MOL HUM REPROD, V4, P899, DOI 10.1093/molehr/4.9.899; Shurbaji MS, 1996, HUM PATHOL, V27, P917, DOI 10.1016/S0046-8177(96)90218-X; Simard J, 1997, CANCER RES, V57, P3494; SIMON SM, 1992, J BIOL CHEM, V267, P3922; Smith SMR, 2000, AM J SURG, V180, P249, DOI 10.1016/S0002-9610(00)00453-0; Swinnen JV, 2002, INT J CANCER, V98, P19, DOI 10.1002/ijc.10127; Swinnen JV, 1997, CANCER RES, V57, P1086; Thupari JN, 2002, P NATL ACAD SCI USA, V99, P9498, DOI 10.1073/pnas.132128899; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; VANCE D, 1972, BIOCHEM BIOPH RES CO, V48, P649, DOI 10.1016/0006-291X(72)90397-X; VANLEEUWEN FE, 1994, LANCET, V343, P448, DOI 10.1016/S0140-6736(94)92692-1; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; WEISS L, 1986, BIOL CHEM H-S, V367, P905, DOI 10.1515/bchm3.1986.367.2.905; WITKOWSKI A, 1991, EUR J BIOCHEM, V198, P571, DOI 10.1111/j.1432-1033.1991.tb16052.x; Wortman MD, 2003, NAT MED, V9, P483, DOI 10.1038/nm0503-483; Ye QN, 2000, BBA-GENE STRUCT EXPR, V1493, P373, DOI 10.1016/S0167-4781(00)00202-5; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0	89	39	40	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2004	23	28					4945	4958		10.1038/sj.onc.1207476	http://dx.doi.org/10.1038/sj.onc.1207476			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	830EK	15094777				2022-12-28	WOS:000222104200016
J	Ito, Y				Ito, Y			Oncogenic potential of the RUNX gene family: 'Overview'	ONCOGENE			English	Review						runt-related (RUNX); RUNX1/AML1; RUNX2; RUNX3; PEBP2/CBF; developmental regulator; heterodimeric transcription factor; leukemia, gastric cancer	ACUTE MYELOID-LEUKEMIA; CORE-BINDING-FACTOR; MULTIPLE CHROMOSOMAL TRANSLOCATIONS; DOMAIN TRANSCRIPTION FACTOR; DNA-BINDING; AML1 GENE; FUNCTIONAL COOPERATION; INTESTINAL METAPLASIA; EMBRYONAL CARCINOMA; POINT MUTATIONS	Runt-related (RUNX) gene family is composed of three members, RUNX1/AML1, RUNX2 and RUNX3, and encodes the DNA-binding ( a) subunits of the Runt domain transcription factor polyomavirus enhancer-binding protein 2 ( PEBP2)/core-binding factor (CBF), which is a heterodimeric transcription factor. RUNX1 is most frequently involved in human acute leukemia. RUNX2 shows oncogenic potential in mouse experimental system. RUNX3 is a strong candidate as a gastric cancer tumor suppressor. The beta subunit gene of PEBP2/CBF is also frequently involved in chromosome rearrangements associated with human leukemia. In this Overview, I will summarize how this growing field has been formed and what are the challenging new frontiers for better understanding of the oncogenic potential of this gene family.	Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117609, Singapore; Natl Univ Singapore, Oncol Res Inst, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; National University of Singapore	Ito, Y (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.	itoy@imcb.a-star.edu.sg						ADRIAANSEN HJ, 1993, BLOOD, V81, P3043; Ahn MY, 1998, P NATL ACAD SCI USA, V95, P1812, DOI 10.1073/pnas.95.4.1812; Akagi K, 2004, NUCLEIC ACIDS RES, V32, pD523, DOI 10.1093/nar/gkh013; Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254; AMATI P, 1985, CELL, V43, P561, DOI 10.1016/0092-8674(85)90225-9; BAE SC, 1995, GENE, V159, P245, DOI 10.1016/0378-1119(95)00060-J; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; Bangsow C, 2001, GENE, V279, P221, DOI 10.1016/S0378-1119(01)00760-0; Barnes GL, 2003, CANCER RES, V63, P2631; Berardi MJ, 1999, STRUCT FOLD DES, V7, P1247, DOI 10.1016/S0969-2126(00)80058-1; BISHOP JM, 1983, CELL, V32, P1018; Bruhn L, 1997, GENE DEV, V11, P640, DOI 10.1101/gad.11.5.640; Burns CE, 2002, EXP HEMATOL, V30, P1381, DOI 10.1016/S0301-472X(02)00955-4; Cameron ER, 2003, BLOOD CELL MOL DIS, V30, P194, DOI 10.1016/S1079-9796(03)00031-7; Chakraborty S, 2003, ONCOGENE, V22, P5229, DOI 10.1038/sj.onc.1206600; Coffman JA, 1996, DEV BIOL, V174, P43, DOI 10.1006/dbio.1996.0050; Crosier PS, 2002, INT J DEV BIOL, V46, P493; Daga A, 1996, GENE DEV, V10, P1194, DOI 10.1101/gad.10.10.1194; DePinho RA, 1999, NAT GENET, V23, P253, DOI 10.1038/15423; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Fainaru O, 2004, EMBO J, V23, P969, DOI 10.1038/sj.emboj.7600085; Goger M, 1999, NAT STRUCT BIOL, V6, P620; Golling G, 1996, MOL CELL BIOL, V16, P932; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Helms C, 2003, NAT GENET, V35, P349, DOI 10.1038/ng1268; Hess J, 2001, J BIOL CHEM, V276, P20029, DOI 10.1074/jbc.M010601200; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; Huang G, 2001, EMBO J, V20, P723, DOI 10.1093/emboj/20.4.723; Huang XM, 1999, NAT STRUCT BIOL, V6, P624; Ichikawa M, 2004, NAT MED, V10, P299, DOI 10.1038/nm997; Imai Y, 1998, BIOCHEM BIOPH RES CO, V252, P582, DOI 10.1006/bbrc.1998.9705; Inoue K, 2002, NAT NEUROSCI, V5, P946, DOI 10.1038/nn925; Ito Y, 1999, GENES CELLS, V4, P685, DOI 10.1046/j.1365-2443.1999.00298.x; Ito Y, 2003, CURR OPIN GENET DEV, V13, P43, DOI 10.1016/S0959-437X(03)00007-8; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; Kagoshima H, 1996, J BIOL CHEM, V271, P33074, DOI 10.1074/jbc.271.51.33074; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; Kanno T, 1998, MOL CELL BIOL, V18, P2444, DOI 10.1128/MCB.18.5.2444; Kataoka H, 2000, MECH DEVELOP, V98, P139, DOI 10.1016/S0925-4773(00)00445-7; KATINKA M, 1980, CELL, V20, P393, DOI 10.1016/0092-8674(80)90625-X; Kim S, 2003, GENE DEV, V17, P1979, DOI 10.1101/gad.1119303; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; KITA K, 1992, BLOOD, V80, P470; Kitabayashi I, 2001, EMBO J, V20, P7184, DOI 10.1093/emboj/20.24.7184; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lebestky T, 2000, SCIENCE, V288, P146, DOI 10.1126/science.288.5463.146; Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797-307; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; Li FQ, 2004, J BIOL CHEM, V279, P2873, DOI 10.1074/jbc.M310759200; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Li QL, 2004, BIOCHEM BIOPH RES CO, V314, P223, DOI 10.1016/j.bbrc.2003.12.079; Libermann TA, 1999, J BIOL CHEM, V274, P24671, DOI 10.1074/jbc.274.35.24671; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; LU J, 1995, MOL CELL BIOL, V15, P1651; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; Mao SF, 1999, MOL CELL BIOL, V19, P3635; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Mulloy JC, 2002, BLOOD, V99, P15, DOI 10.1182/blood.V99.1.15; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Mutoh H, 2002, BIOCHEM BIOPH RES CO, V294, P470, DOI 10.1016/S0006-291X(02)00480-1; Nagata T, 1999, NAT STRUCT BIOL, V6, P615; Nam S, 2002, MOL CELL BIOL, V22, P547, DOI 10.1128/MCB.22.2.547-554.2002; Niini T, 2000, HAEMATOLOGICA, V85, P362; Niki M, 1997, P NATL ACAD SCI USA, V94, P5697, DOI 10.1073/pnas.94.11.5697; North T, 1999, DEVELOPMENT, V126, P2563; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okada H, 1998, ONCOGENE, V17, P2287, DOI 10.1038/sj.onc.1202151; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; Prokunina L, 2002, NAT GENET, V32, P666, DOI 10.1038/ng1020; Rennert J, 2003, BMC EVOL BIOL, V3, DOI 10.1186/1471-2148-3-4; Robertson AJ, 2002, MECH DEVELOP, V117, P327, DOI 10.1016/S0925-4773(02)00201-0; SATAKE M, 1992, JPN J CANCER RES, V83, P714, DOI 10.1111/j.1349-7006.1992.tb01971.x; Silberg DG, 2002, GASTROENTEROLOGY, V122, P689, DOI 10.1053/gast.2002.31902; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; SPECK NA, 1990, J VIROL, V64, P543, DOI 10.1128/JVI.64.2.543-550.1990; Speck NA, 2002, NAT REV CANCER, V2, P502, DOI 10.1038/nrc840; Stewart M, 1997, P NATL ACAD SCI USA, V94, P8646, DOI 10.1073/pnas.94.16.8646; Sudol M, 2000, CELL, V103, P1001, DOI 10.1016/S0092-8674(00)00203-8; Tahirov TH, 2001, CELL, V104, P755, DOI 10.1016/S0092-8674(01)00271-9; TANAKA K, 1982, EMBO J, V1, P1521, DOI 10.1002/j.1460-2075.1982.tb01349.x; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; Tanaka T, 1996, MOL CELL BIOL, V16, P3967; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Tokuhiro S, 2003, NAT GENET, V35, P341, DOI 10.1038/ng1267; Tracey WD, 1998, DEVELOPMENT, V125, P1371; VEGAFLORES M, UNPUB; Wada M, 2004, ONCOGENE, V23, P2401, DOI 10.1038/sj.onc.1207395; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; Warren AJ, 2000, EMBO J, V19, P3004, DOI 10.1093/emboj/19.12.3004; Wee HJ, 2002, EMBO REP, V3, P967, DOI 10.1093/embo-reports/kvf193; Weith A, 1996, CYTOGENET CELL GENET, V72, P114; Woolf E, 2003, P NATL ACAD SCI USA, V100, P7731, DOI 10.1073/pnas.1232420100; Wotton S, 2002, CANCER RES, V62, P7181; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551; Yamaguchi Y, 2004, J BIOL CHEM, V279, P15630, DOI 10.1074/jbc.M400355200; Yokomizo T, 2001, GENES CELLS, V6, P13, DOI 10.1046/j.1365-2443.2001.00393.x; Yuasa Y, 2003, NAT REV CANCER, V3, P592, DOI 10.1038/nrc1141; Zaidi SK, 2004, EMBO J, V23, P790, DOI 10.1038/sj.emboj.7600073; Zeng CM, 1997, P NATL ACAD SCI USA, V94, P6746, DOI 10.1073/pnas.94.13.6746; Zhang YW, 2000, P NATL ACAD SCI USA, V97, P10549, DOI 10.1073/pnas.180309597	122	258	267	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2004	23	24					4198	4208		10.1038/sj.onc.1207755	http://dx.doi.org/10.1038/sj.onc.1207755			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823BZ	15156173				2022-12-28	WOS:000221586000002
J	Stein, GS; Lian, JB; van Wijnen, AJ; Stein, JL; Montecino, M; Javed, A; Zaidi, SK; Young, DW; Choi, JY; Pockwinse, SM				Stein, GS; Lian, JB; van Wijnen, AJ; Stein, JL; Montecino, M; Javed, A; Zaidi, SK; Young, DW; Choi, JY; Pockwinse, SM			Runx2 control of organization, assembly and activity of the regulatory machinery for skeletal gene expression	ONCOGENE			English	Review						nuclear architecture; gene expression; Runx/AML/Cbfa; osteoblast; chromatin modifications	BONE MORPHOGENETIC PROTEIN-2; RAT OSTEOCALCIN GENE; GROWTH-FACTOR BETA-1; CORE-BINDING-FACTOR; TRANSCRIPTIONAL UP-REGULATION; MATRIX TARGETING SIGNAL; NUCLEAR-MATRIX; OSTEOBLAST DIFFERENTIATION; DNA-BINDING; COLLAGENASE-3 PROMOTER	We present an overview of Runx involvement in regulatory mechanisms that are requisite for fidelity of bone cell growth and differentiation, as well as for skeletal homeostasis and the structural and functional integrity of skeletal tissue. Runx-mediated control is addressed from the perspective of support for biological parameters of skeletal gene expression. W e review recent findings that are consistent with an active role for Runx proteins as scaffolds for integration, organization and combinatorial assembly of nucleic acids and regulatory factors within the three-dimensional context of nuclear architecture.	Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Ctr Canc, Worcester, MA 01655 USA; Univ Concepcion, Dept Biol Mol, Concepcion, Chile; Kyungpook Natl Univ, Skeletal Dis Genome Res Ctr, Sch Med, Dept Biochem, Taegu, South Korea	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Universidad de Concepcion; Kyungpook National University	Stein, GS (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, Room S3-310,55 Lake Ave N, Worcester, MA 01655 USA.	gary.stein@umassmed.edu	van Wijnen, Andre J./AAG-3578-2019; Zaidi, Sayyed Kaleem/I-5596-2019	van Wijnen, Andre J./0000-0002-4458-0946; Zaidi, Sayyed Kaleem/0000-0001-6664-5168; Javed, Amjad/0000-0002-0847-8266	FOGARTY INTERNATIONAL CENTER [R03TW000990] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA082834] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR048818, R01AR045688, R01AR045689, R01AR039588, R01AR049069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R37DE012528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012528] Funding Source: NIH RePORTER; FIC NIH HHS [R03 TW00990] Funding Source: Medline; NCI NIH HHS [P01CA82834] Funding Source: Medline; NIAMS NIH HHS [R01 AR049069, AR45688, P01AR48818, AR39588, AR45689] Funding Source: Medline; NIDCR NIH HHS [DE12528] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Alvarez M, 1997, ENDOCRINOLOGY, V138, P482, DOI 10.1210/en.138.1.482; BAE SC, 1993, ONCOGENE, V8, P809; Balint E, 2003, J CELL BIOCHEM, V89, P401, DOI 10.1002/jcb.10515; Banerjee C, 2001, ENDOCRINOLOGY, V142, P4026, DOI 10.1210/en.142.9.4026; Banerjee C, 1997, J CELL BIOCHEM, V66, P1, DOI 10.1002/(SICI)1097-4644(19970701)66:1<1::AID-JCB1>3.0.CO;2-V; Bannister AJ, 1995, ONCOGENE, V11, P2509; Berezney R, 1996, J CELL BIOCHEM, V62, P223, DOI 10.1002/(SICI)1097-4644(199608)62:2<223::AID-JCB10>3.3.CO;2-M; BIDWELL JP, 1993, P NATL ACAD SCI USA, V90, P3162, DOI 10.1073/pnas.90.8.3162; BLANCO JCG, 1995, P NATL ACAD SCI USA, V92, P1535, DOI 10.1073/pnas.92.5.1535; BLENCOWE BJ, 1994, J CELL BIOL, V127, P593, DOI 10.1083/jcb.127.3.593; BORTELL R, 1992, P NATL ACAD SCI USA, V89, P6119, DOI 10.1073/pnas.89.13.6119; BREEN EC, 1994, P NATL ACAD SCI USA, V91, P12902, DOI 10.1073/pnas.91.26.12902; Cameron ER, 2003, BLOOD CELL MOL DIS, V30, P194, DOI 10.1016/S1079-9796(03)00031-7; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chen HY, 1996, BIOCHEM J, V320, P257, DOI 10.1042/bj3200257; Chen S, 2002, CONNECT TISSUE RES, V43, P338, DOI 10.1080/03008200290000691; Choi JY, 1999, J BONE MINER RES, V14, pS469; Choi JY, 2001, P NATL ACAD SCI USA, V98, P8650, DOI 10.1073/pnas.151236498; Cohen MM, 2001, AM J MED GENET, V104, P185, DOI 10.1002/ajmg.10064; D'Alonzo RC, 2002, J BIOL CHEM, V277, P816, DOI 10.1074/jbc.M107082200; Davie JR, 1997, MOL BIOL REP, V24, P197, DOI 10.1023/A:1006811817247; de Crombrugghe B, 2000, MATRIX BIOL, V19, P389, DOI 10.1016/S0945-053X(00)00094-9; DeFranco DB, 2002, MOL ENDOCRINOL, V16, P1449, DOI 10.1210/me.16.7.1449; DEMAY MB, 1990, P NATL ACAD SCI USA, V87, P369, DOI 10.1073/pnas.87.1.369; Drissi H, 2000, J CELL PHYSIOL, V184, P341, DOI 10.1002/1097-4652(200009)184:3<341::AID-JCP8>3.0.CO;2-Z; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; DWORETZKY SI, 1992, P NATL ACAD SCI USA, V89, P4178, DOI 10.1073/pnas.89.9.4178; Enomoto H, 2000, J BIOL CHEM, V275, P8695, DOI 10.1074/jbc.275.12.8695; Fang MA, 2001, J CELL BIOCHEM, V80, P550, DOI 10.1002/1097-4644(20010315)80:4<550::AID-JCB1009>3.3.CO;2-T; Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369; Frank R, 1995, ONCOGENE, V11, P2667; Gasser SM, 2002, SCIENCE, V296, P1412, DOI 10.1126/science.1067703; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; Goodman RH, 2000, GENE DEV, V14, P1553; Gori F, 1999, J BONE MINER RES, V14, P1522, DOI 10.1359/jbmr.1999.14.9.1522; Grande MA, 1997, J CELL SCI, V110, P1781; Guo B, 1997, P NATL ACAD SCI USA, V94, P121, DOI 10.1073/pnas.94.1.121; GUO B, 1995, P NATL ACAD SCI USA, V92, P10526, DOI 10.1073/pnas.92.23.10526; Guo WH, 2002, ONCOGENE, V21, P8351, DOI 10.1038/sj.onc.1206037; Gutierrez J, 2000, BIOCHEMISTRY-US, V39, P13565, DOI 10.1021/bi0013896; Gutierrez S, 2002, J BIOL CHEM, V277, P1316, DOI 10.1074/jbc.M106611200; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Harada H, 1999, J BIOL CHEM, V274, P6972, DOI 10.1074/jbc.274.11.6972; Harrington KS, 2002, J CELL SCI, V115, P4167, DOI 10.1242/jcs.00095; HOFFMANN HM, 1994, P NATL ACAD SCI USA, V91, P12887, DOI 10.1073/pnas.91.26.12887; Jackson DA, 1997, MOL BIOL REP, V24, P209, DOI 10.1023/A:1006873614521; Javed A, 1999, MOL CELL BIOL, V19, P7491; Javed A, 2001, MOL CELL BIOL, V21, P2891, DOI 10.1128/MCB.21.8.2891-2905.2001; Javed A, 2000, J CELL SCI, V113, P2221; Ji CH, 1998, J CELL BIOCHEM, V69, P353, DOI 10.1002/(SICI)1097-4644(19980601)69:3<353::AID-JCB12>3.3.CO;2-W; Karsenty G, 2003, NATURE, V423, P316, DOI 10.1038/nature01654; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Komori T, 2002, J CELL BIOCHEM, V87, P1, DOI 10.1002/jcb.10276; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; Kundu M, 2002, NAT GENET, V32, P639, DOI 10.1038/ng1050; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Lee MH, 1999, J CELL BIOCHEM, V73, P114, DOI 10.1002/(SICI)1097-4644(19990401)73:1<114::AID-JCB13>3.3.CO;2-D; Lengner CJ, 2001, J BONE MINER RES, V16, pS366; Levanon D, 2003, EMBO REP, V4, P560, DOI 10.1038/sj.embor.embor868; Levanon D, 2001, MECH DEVELOP, V109, P413, DOI 10.1016/S0925-4773(01)00537-8; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Lian J. B., 2003, Current Pharmaceutical Design, V9, P2677, DOI 10.2174/1381612033453659; Lian JB, 2003, J CELL PHYSIOL, V196, P301, DOI 10.1002/jcp.10316; Lindenmuth DM, 1997, J CELL BIOCHEM, V66, P123; Liu F, 2002, BONE, V31, P212, DOI 10.1016/S8756-3282(02)00806-2; Liu WG, 2001, J CELL BIOL, V155, P157, DOI 10.1083/jcb.200105052; Ma H, 1998, J CELL BIOL, V143, P1415, DOI 10.1083/jcb.143.6.1415; Ma H, 1999, J CELL BIOL, V146, P531, DOI 10.1083/jcb.146.3.531; MACDONALD PN, 1995, J BIOL CHEM, V270, P4748, DOI 10.1074/jbc.270.9.4748; MANCINI MA, 1994, P NATL ACAD SCI USA, V91, P418, DOI 10.1073/pnas.91.1.418; Mao SF, 1999, MOL CELL BIOL, V19, P3635; MARKOSE ER, 1990, P NATL ACAD SCI USA, V87, P1701, DOI 10.1073/pnas.87.5.1701; McNeil S, 1998, J CELL BIOCHEM, V68, P500, DOI 10.1002/(SICI)1097-4644(19980315)68:4<500::AID-JCB9>3.3.CO;2-T; McNeil S, 1999, P NATL ACAD SCI USA, V96, P14882, DOI 10.1073/pnas.96.26.14882; MERRIMAN HL, 1995, BIOCHEMISTRY-US, V34, P13125, DOI 10.1021/bi00040a025; Meyers S, 1996, ONCOGENE, V13, P303; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; Miller J, 2002, NAT GENET, V32, P645, DOI 10.1038/ng1049; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Mody N, 2003, J NUCL CARDIOL, V10, P177, DOI 10.1067/mnc.2003.0012; Montecino M, 1999, BIOCHEMISTRY-US, V38, P1338, DOI 10.1021/bi982171a; Montecino M, 1996, BIOCHEMISTRY-US, V35, P5093, DOI 10.1021/bi952489s; Montecino M, 1994, J BONE MINER RES, V9, pS352; Mueller E, 2002, J BIOL CHEM, V277, P41925, DOI 10.1074/jbc.M206950200; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/s0092-8674(01)00622-5; Nardozza TA, 1996, J CELL BIOCHEM, V61, P467, DOI 10.1002/(SICI)1097-4644(19960601)61:3<467::AID-JCB14>3.3.CO;2-W; North T, 1999, DEVELOPMENT, V126, P2563; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Pardali E, 2000, J BIOL CHEM, V275, P3552, DOI 10.1074/jbc.275.5.3552; Paredes R, 2002, BIOCHEM J, V363, P667, DOI 10.1042/0264-6021:3630667; Pratap J, 2003, CANCER RES, V63, P5357; Puig-Kroger A, 2003, BLOOD, V102, P3252, DOI 10.1182/blood-2003-02-0618; Raisz L.G., 2002, PRINCIPLES BONE BIOL, P59; Ryoo HM, 1997, MOL ENDOCRINOL, V11, P1681, DOI 10.1210/me.11.11.1681; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; Selvamurugan N, 1998, J BIOL CHEM, V273, P10647, DOI 10.1074/jbc.273.17.10647; Selvamurugan N, 2000, J BIOL CHEM, V275, P5037, DOI 10.1074/jbc.275.7.5037; Shen J, 2003, MOL ENDOCRINOL, V17, P743, DOI 10.1210/me.2002-0122; Shen JL, 2002, J BIOL CHEM, V277, P20284, DOI 10.1074/jbc.M112440200; Sierra J, 2003, MOL CELL BIOL, V23, P3339, DOI 10.1128/MCB.23.9.3339-3351.2003; Speck NA, 1999, CANCER RES, V59, p1789S; Speck NA, 1995, CRIT REV EUKAR GENE, V5, P337, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.60; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Spencer VA, 1999, GENE, V240, P1, DOI 10.1016/S0378-1119(99)00405-9; Stein GS, 2000, J CELL SCI, V113, P2527; Stein GS, 2000, CANCER RES, V60, P2067; Stein GS, 1996, J CELL BIOCHEM, V62, P198, DOI 10.1002/(SICI)1097-4644(199608)62:2<198::AID-JCB8>3.3.CO;2-3; Stewart M, 1997, P NATL ACAD SCI USA, V94, P8646, DOI 10.1073/pnas.94.16.8646; Stricker S, 2002, DEV BIOL, V245, P95, DOI 10.1006/dbio.2002.0640; Sun LX, 2001, CANCER RES, V61, P4994; Takeda S, 2001, GENE DEV, V15, P467, DOI 10.1101/gad.845101; TAMURA M, 1994, J CELL BIOL, V126, P773, DOI 10.1083/jcb.126.3.773; Tang L, 1999, J BIOL CHEM, V274, P33580, DOI 10.1074/jbc.274.47.33580; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P850, DOI 10.1073/pnas.0337434100; Thirunavukkarasu K, 2000, J BIOL CHEM, V275, P25163, DOI 10.1074/jbc.M000322200; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Ueta C, 2001, J CELL BIOL, V153, P87, DOI 10.1083/jcb.153.1.87; Vaes BLT, 2002, J BONE MINER RES, V17, P2106, DOI 10.1359/jbmr.2002.17.12.2106; Vaillant F, 2002, J IMMUNOL, V169, P2866, DOI 10.4049/jimmunol.169.6.2866; van Wijnen Andre J., 2003, P31; VANWIJNEN AJ, 1993, BIOCHEMISTRY-US, V32, P8397, DOI 10.1021/bi00084a003; Villagra A, 2002, J CELL BIOCHEM, V85, P112, DOI 10.1002/jcb.10113; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; Wei XY, 1999, J CELL BIOL, V146, P543, DOI 10.1083/jcb.146.3.543; Wei XY, 1998, SCIENCE, V281, P1502, DOI 10.1126/science.281.5382.1502; Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982-7992.2002; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Xie XQ, 1999, EUR J IMMUNOL, V29, P488, DOI 10.1002/(SICI)1521-4141(199902)29:02<488::AID-IMMU488>3.0.CO;2-N; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zaidi SK, 2004, EMBO J, V23, P790, DOI 10.1038/sj.emboj.7600073; Zaidi SK, 2002, P NATL ACAD SCI USA, V99, P8048, DOI 10.1073/pnas.112664499; Zaidi SK, 2003, P NATL ACAD SCI USA, V100, P14852, DOI 10.1073/pnas.2533076100; Zelzer E, 2001, MECH DEVELOP, V106, P97, DOI 10.1016/S0925-4773(01)00428-2; Zeng CM, 1998, P NATL ACAD SCI USA, V95, P1585, DOI 10.1073/pnas.95.4.1585; Zeng CM, 1997, P NATL ACAD SCI USA, V94, P6746, DOI 10.1073/pnas.94.13.6746; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; Zhang X, 2003, CURR OPIN RHEUMATOL, V15, P387, DOI 10.1097/00002281-200307000-00004; Zhang YW, 2000, P NATL ACAD SCI USA, V97, P10549, DOI 10.1073/pnas.180309597	152	410	433	2	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2004	23	24					4315	4329		10.1038/sj.onc.1207676	http://dx.doi.org/10.1038/sj.onc.1207676			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823BZ	15156188				2022-12-28	WOS:000221586000017
J	Ren, Y; Chan, HM; Li, Z; Lin, CL; Nicholls, J; Chen, CF; Lee, PY; Lui, V; Bacher, M; Tam, PKH				Ren, Y; Chan, HM; Li, Z; Lin, CL; Nicholls, J; Chen, CF; Lee, PY; Lui, V; Bacher, M; Tam, PKH			Upregulation of macrophage migration inhibitory factor contributes to induced N-Myc expression by the activation of ERK signaling pathway and increased expression of interleukin-8 and VEGF in neuroblastoma	ONCOGENE			English	Article						MIF; N-myc; neuroblastoma; MAPK; angiogenesis	ENDOTHELIAL GROWTH-FACTOR; HUMAN-MELANOMA CELLS; ANGIOGENIC FACTORS; HEPATOCELLULAR-CARCINOMA; TUMOR-GROWTH; FACTOR MIF; RECEPTORS; CANCER; STAGE; ADENOCARCINOMA	Macrophage migration inhibitory factor (MIF) has been linked to fundamental processes such as control of cell proliferation, cell survival, angiogenesis, and tumor progression. The expression of MIF has been reported in several tumors. However, the precise role of MIF in tumor cells remains unclear. In the present study, we investigated the expression pattern and the function of MIF in neuroblastoma. Our results showed that intracellular MIF was upregulated in neuroblastoma tumor tissues and cell lines. MIF protein expression significantly correlated with the grade of tumor differentiation. In addition, we found that MIF induced a significant dose-dependent increase of vascular endothelial growth factor and interleukin-8 secretion. We also observed that an increased MIF expression level correlated with N-Myc protein ( the N-myc oncogene product) expression in neuroblastoma tissues. MIF increased the expression of N-myc mRNA and N-Myc protein and induced N-Myc translocation from the cytoplasm to nucleus in neuroblastoma cell lines. MIF-induced N-Myc expression was found to be dependent on ERK signaling pathways. The inhibition of ERK activation reduced MIF-mediated N-Myc expression. These results suggest that MIF may contribute to the progression of neuroblastoma by ( a) inducing N-Myc expression and ( b) upregulating the expression of angiogenic factors.	Univ Hong Kong, Med Ctr, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Med Ctr, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Med Ctr, Dept Pediat, Hong Kong, Hong Kong, Peoples R China; Univ Marburg, Inst Immunol, D-35032 Marburg, Germany	University of Hong Kong; University of Hong Kong; University of Hong Kong; Philipps University Marburg	Ren, Y (corresponding author), Univ Hong Kong, Med Ctr, Dept Surg, Room L09-56,Fac Med Bldg,21 Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.	yren@hkucc.hku.hk; paultam@hkucc.hku.hk	Lee, Pui Yue/C-4332-2009; Nicholls, John Malcolm/C-4375-2009; /C-4359-2009; /C-4405-2009	Nicholls, John Malcolm/0000-0001-7217-7444; /0000-0002-1758-8854; /0000-0001-6231-3035				Akbar SMF, 2001, CANCER LETT, V171, P125, DOI 10.1016/S0304-3835(01)00606-1; BERYCKERE F, 1994, BIOTECHNIQUES, V16, P405; Bin Q, 2002, TUMOR BIOL, V23, P123, DOI 10.1159/000064028; Bini L, 1997, ELECTROPHORESIS, V18, P2832, DOI 10.1002/elps.1150181519; Bown N, 2001, J CLIN PATHOL, V54, P897, DOI 10.1136/jcp.54.12.897; Breit S, 2000, CANCER RES, V60, P4596; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1992, AM J PEDIAT HEMATOL, V14, P111; BROWN LF, 1995, HUM PATHOL, V26, P86, DOI 10.1016/0046-8177(95)90119-1; BROWN LF, 1993, CANCER RES, V53, P4727; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chambery D, 1999, CANCER RES, V59, P2898; Chesney J, 1999, MOL MED, V5, P181, DOI 10.1007/BF03402061; DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72; Desbaillets I, 1997, J EXP MED, V186, P1201, DOI 10.1084/jem.186.8.1201; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Eggert A, 2000, CLIN CANCER RES, V6, P1900; Ferrer FA, 2000, J UROLOGY, V164, P1016, DOI 10.1016/S0022-5347(05)67240-0; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; Gille J, 1997, EMBO J, V16, P750, DOI 10.1093/emboj/16.4.750; Hudson JD, 1999, J EXP MED, V190, P1375, DOI 10.1084/jem.190.10.1375; Kamimura A, 2000, CANCER, V89, P334, DOI 10.1002/1097-0142(20000715)89:2<334::AID-CNCR18>3.0.CO;2-N; Karkkainen MJ, 2000, ONCOGENE, V19, P5598, DOI 10.1038/sj.onc.1203855; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; Langer I, 2000, MED PEDIATR ONCOL, V34, P386, DOI 10.1002/(SICI)1096-911X(200006)34:6<386::AID-MPO2>3.0.CO;2-3; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Leng L, 2003, J EXP MED, V197, P1467, DOI 10.1084/jem.20030286; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; Mattern J, 1996, BRIT J CANCER, V73, P931, DOI 10.1038/bjc.1996.166; Meister B, 1999, EUR J CANCER, V35, P445, DOI 10.1016/S0959-8049(98)00387-6; Meitar D, 1996, J CLIN ONCOL, V14, P405, DOI 10.1200/JCO.1996.14.2.405; MeyerSiegler K, 1996, UROLOGY, V48, P448, DOI 10.1016/S0090-4295(96)00207-5; Misawa A, 2000, CANCER RES, V60, P64; Mitchell RA, 2000, SEMIN CANCER BIOL, V10, P359, DOI 10.1006/scbi.2000.0328; Ogawa H, 2000, CYTOKINE, V12, P309, DOI 10.1006/cyto.1999.0562; PRITCHARD J, 1994, LANCET, V344, P869, DOI 10.1016/S0140-6736(94)92834-7; Ren Y, 2003, INT J CANCER, V107, P22, DOI 10.1002/ijc.11287; Rossler J, 1999, INT J CANCER, V81, P113; Seeger R C, 1988, Prog Clin Biol Res, V271, P41; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Shimada H, 1999, CANCER, V86, P364, DOI 10.1002/(SICI)1097-0142(19990715)86:2<364::AID-CNCR21>3.3.CO;2-Z; Shimizu T, 1999, BIOCHEM BIOPH RES CO, V264, P751, DOI 10.1006/bbrc.1999.1584; SINGH RK, 1994, CANCER RES, V54, P3242; SMITH DR, 1994, J EXP MED, V179, P1409, DOI 10.1084/jem.179.5.1409; Tweddle DA, 2001, AM J PATHOL, V158, P2067, DOI 10.1016/S0002-9440(10)64678-0; Wada RK, 1997, CANCER LETT, V121, P181, DOI 10.1016/S0304-3835(97)00351-0; Yang YB, 2000, J CLIN ENDOCR METAB, V85, P4721, DOI 10.1210/jc.85.12.4721	48	78	87	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4146	4154		10.1038/sj.onc.1207490	http://dx.doi.org/10.1038/sj.onc.1207490			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15064733				2022-12-28	WOS:000221520200013
J	Lu, M; Xia, LJ; Luo, D; Waxman, S; Jing, YK				Lu, M; Xia, LJ; Luo, D; Waxman, S; Jing, YK			Dual effects of glutathione-S-transferase pi on As2O3 action in prostate cancer cells: enhancement of growth inhibition and inhibition of apoptosis	ONCOGENE			English	Article						arsenic trioxide; prostate cancer; glutathione-S-transferase pi	ACUTE PROMYELOCYTIC LEUKEMIA; ARSENIC TRIOXIDE AS2O3; ACTIVATION; RESISTANT; EXPRESSION; PROTEIN; ERK; DIFFERENTIATION; TOXICITY; INDUCER	To determine the effects of glutathione-S-transferase pi (GSTpi) on the actions of As2O3, As2O3-induced growth inhibition and apoptosis was studied in three prostate cancer cell lines: DU-145, PC-3 and LNCaP cells. As2O3 inhibited cell proliferation of DU-145 and PC-3 cells ( both cells express GSTpi), but not of LNCaP cells ( which lack GSTpi expression) at concentrations below 1 muM. LNCaP cells stably transfected and expressed GSTpi (LNCaP/GSTpi) became sensitive to As2O3 growth inhibition. As2O3 arrested cell growth of DU-145, PC-3 and LNCaP/GSTpi cells in the G2/M phase of the cell cycle at low concentrations (<2 mu M), but did not induce apoptosis. At higher concentrations (10-20 mu M), As2O3 induced apoptosis in LNCaP cells, but not in DU-145 or PC-3 cells. The apoptosis induction due to As2O3 treatment of LNCaP cell correlated with the activation of JNK and p38 and induction of p53 protein. LNCaP/GSTp cells became insensitive to As2O3-induced apoptosis with reduced JNK activition. These data indicate that GST pi increases growth inhibition due to As2O3 treatment and prevents As2O3-induced apoptosis in prostate cancer cells. Therefore, it appears that As2O3 inhibits cell growth and induces apoptosis through different mechanisms.	CUNY Mt Sinai Sch Med, Dept Med, Div Hematol Oncol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Jing, YK (corresponding author), CUNY Mt Sinai Sch Med, Dept Med, Div Hematol Oncol, Box 1178, New York, NY 10029 USA.	yongkui.jing@mssm.edu			NCI NIH HHS [CA93533, CA85478] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093533] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Blagosklonny MV, 2002, INT J CANCER, V98, P161, DOI 10.1002/ijc.10158; Bode A, 2000, DRUG RESIST UPDATE, V3, P21, DOI 10.1054/drup.2000.0114; Chen GQ, 2003, CANCER RES, V63, P1853; Chen GQ, 1997, BLOOD, V89, P3345; Chen YC, 1998, J CELL PHYSIOL, V177, P324, DOI 10.1002/(SICI)1097-4652(199811)177:2<324::AID-JCP14>3.0.CO;2-9; Cookson MS, 1997, J UROLOGY, V157, P673, DOI 10.1016/S0022-5347(01)65248-0; Dai J, 1999, BLOOD, V93, P268, DOI 10.1182/blood.V93.1.268.401a21_268_277; Gurr JR, 1999, MOL PHARMACOL, V56, P102, DOI 10.1124/mol.56.1.102; Huang CS, 1999, J BIOL CHEM, V274, P14595, DOI 10.1074/jbc.274.21.14595; Huang MJ, 2002, LEUKEMIA LYMPHOMA, V43, P2191, DOI 10.1080/1042819021000032980; Iwama K, 2001, INT J CANCER, V92, P518, DOI 10.1002/ijc.1220; Jing YK, 1997, CANCER RES, V57, P1668; Jing YK, 1999, BLOOD, V94, P2102, DOI 10.1182/blood.V94.6.2102; LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733; Leszczyniecka M, 2002, P NATL ACAD SCI USA, V99, P16636, DOI 10.1073/pnas.252643699; Lin XH, 2001, AM J PATHOL, V159, P1815, DOI 10.1016/S0002-9440(10)63028-3; Liu J, 2001, MOL PHARMACOL, V60, P302, DOI 10.1124/mol.60.2.302; Liu YS, 1996, FREE RADICAL BIO MED, V21, P771, DOI 10.1016/0891-5849(96)00176-1; LO JF, 1992, BIOCHEM J, V288, P977, DOI 10.1042/bj2880977; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; Moskaluk CA, 1997, CANCER-AM CANCER SOC, V79, P1595, DOI 10.1002/(SICI)1097-0142(19970415)79:8<1595::AID-CNCR23>3.0.CO;2-S; Park JW, 2001, BIOCHEM BIOPH RES CO, V286, P726, DOI 10.1006/bbrc.2001.5416; Polek TC, 2003, ENDOCRINOLOGY, V144, P50, DOI 10.1210/en.2001-210109; Samet JM, 1998, AM J PHYSIOL-LUNG C, V275, pL551, DOI 10.1152/ajplung.1998.275.3.L551; Shao WL, 1998, J NATL CANCER I, V90, P124, DOI 10.1093/jnci/90.2.124; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; Styblo M, 2002, ENVIRON HEALTH PERSP, V110, P767, DOI 10.1289/ehp.02110s5767; Styblo M, 2000, ARCH TOXICOL, V74, P289, DOI 10.1007/s002040000134; WANG HF, 1993, BIOCHEM BIOPH RES CO, V192, P1093, DOI 10.1006/bbrc.1993.1529; Wang T, 2001, J BIOL CHEM, V276, P20999, DOI 10.1074/jbc.M101355200; Wang ZL, 1996, TOXICOL APPL PHARM, V137, P112, DOI 10.1006/taap.1996.0062; Wu GS, 1998, ONCOGENE, V16, P2177, DOI 10.1038/sj.onc.1201755; Yang CH, 1999, BRIT J CANCER, V81, P796, DOI 10.1038/sj.bjc.6690766; Yin ZM, 2000, CANCER RES, V60, P4053	36	35	39	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					3945	3952		10.1038/sj.onc.1207500	http://dx.doi.org/10.1038/sj.onc.1207500			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15007384				2022-12-28	WOS:000221382000006
J	Park, J; Song, SH; Kim, TY; Choi, MC; Jong, HS; Kim, TY; Lee, JW; Kim, NK; Kim, WH; Bang, YJ				Park, J; Song, SH; Kim, TY; Choi, MC; Jong, HS; Kim, TY; Lee, JW; Kim, NK; Kim, WH; Bang, YJ			Aberrant methylation of integrin alpha 4 gene in human gastric cancer cells	ONCOGENE			English	Article						integrin alpha 4; methylation; gastric cancer	TUMOR-SUPPRESSOR GENE; DNA METHYLATION; TRANSCRIPTIONAL REPRESSION; PROMOTER HYPERMETHYLATION; METALLOPROTEINASE-3 GENE; ALPHA-4 INTEGRINS; TISSUE INHIBITOR; 5'-CPG ISLAND; EXPRESSION; INACTIVATION	Integrins are adhesion receptors that mediate both cell extracellular matrix and cell-cell interactions. It has also been reported that the loss of integrin alpha4 expression might be associated with metastasis in several cancers. However, the molecular mechanism for loss of their expression in cancers has not been explored. In the present study, we found that the integrin alpha4 expression is lost in human gastric cancer cell lines and that this is recovered by treatment with DNA methyltransferase inhibitor, implying transcriptional silencing by DNA methylation. Methylation-specific PCR (MSP) and bisulfite genomic DNA sequencing demonstrated the CpG methylation-dependent silencing of integrin alpha4 expression in eight of nine (88.8%) gastric cancer cell lines and in 84.7% of 46 primary tumors. We also investigated whether the restoration of integrin alpha4 in integrin alpha4-inactivated cells affects their ability to invade extracellular matrix, using matrigel assays. Interestingly, integrin alpha4-stable transfectants had markedly less invasive ability than the parental cells. Taken together, these results suggest that the transcriptional repression of the integrin alpha4 gene is caused by aberrant DNA methylation, and that this may play an important role in human gastric carcinogenesis.	Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110744, South Korea; Seoul Natl Univ, Coll Med, Canc Res Inst, Natl Res Lab Canc Epigenet, Seoul 110744, South Korea; Seoul Natl Univ, Coll Med, Dept Pathol, Seoul 110744, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU)	Bang, YJ (corresponding author), Seoul Natl Univ, Coll Med, Dept Internal Med, 28 Yongon Dong, Seoul 110744, South Korea.	bangyj@plaza.snu.ac.kr	Bang, Yung Jue/J-2759-2012; Lee, Jung Weon/F-9149-2012; Kim, Tae-You/J-2750-2012; Lee, Jung Weon/AAC-1146-2020	Bang, Yung Jue/0000-0001-6000-4597; Lee, Jung Weon/0000-0003-2722-8200; KIM, TAI YOUNG/0000-0001-8086-2476				Akama TO, 1997, CANCER RES, V57, P3294; Bachman KE, 1999, CANCER RES, V59, P798; Burgers WA, 2002, TRENDS GENET, V18, P275, DOI 10.1016/S0168-9525(02)02667-7; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; Ebert MPA, 2003, J CLIN ONCOL, V21, P1708, DOI 10.1200/JCO.2003.10.017; Felding-Habermann B, 2003, CLIN EXP METASTAS, V20, P203, DOI 10.1023/A:1022983000355; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GAROFALO A, 1995, CANCER RES, V55, P414; Gosslar U, 1996, P NATL ACAD SCI USA, V93, P4821, DOI 10.1073/pnas.93.10.4821; HAMANN A, 1994, J IMMUNOL, V152, P3282; Herman JG, 1996, CANCER RES, V56, P722; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Holzmann B, 1998, CURR TOP MICROBIOL, V231, P125; HUHTALA P, 1995, J CELL BIOL, V129, P867, DOI 10.1083/jcb.129.3.867; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; Jong HS, 1999, CANCER, V86, P559, DOI 10.1002/(SICI)1097-0142(19990815)86:4<559::AID-CNCR3>3.0.CO;2-4; Kang GH, 2003, LAB INVEST, V83, P519, DOI 10.1097/01.LAB.0000064704.53132.65; Kang SH, 1999, ONCOGENE, V18, P7280, DOI 10.1038/sj.onc.1203146; Kang SH, 2000, INT J CANCER, V86, P632, DOI 10.1002/(SICI)1097-0215(20000601)86:5<632::AID-IJC5>3.0.CO;2-5; Kim TY, 2003, ONCOGENE, V22, P3943, DOI 10.1038/sj.onc.1206573; Kuroki T, 2003, CANCER RES, V63, P3352; Leung WK, 2001, CANCER-AM CANCER SOC, V91, P2294; Li H, 2003, P NATL ACAD SCI USA, V100, P8412, DOI 10.1073/pnas.1430846100; LOBB RR, 1994, J CLIN INVEST, V94, P1722, DOI 10.1172/JCI117519; Lu QJ, 2002, BLOOD, V99, P4503, DOI 10.1182/blood.V99.12.4503; Michetti M, 2000, GASTROENTEROLOGY, V119, P109, DOI 10.1053/gast.2000.8548; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; QIAN F, 1994, CELL, V77, P335, DOI 10.1016/0092-8674(94)90149-X; RINCON J, 1992, INT J CANCER, V51, P452, DOI 10.1002/ijc.2910510319; Sato S, 1998, ONCOGENE, V17, P105, DOI 10.1038/sj.onc.1201913; Song SH, 2000, INT J CANCER, V87, P236, DOI 10.1002/1097-0215(20000715)87:2<236::AID-IJC14>3.0.CO;2-M; Song SH, 2001, CANCER RES, V61, P4628; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; Stirzaker C, 1997, CANCER RES, V57, P2229; TAMKUN JW, 1986, CELL, V46, P271, DOI 10.1016/0092-8674(86)90744-0; Toyooka S, 2002, CANCER RES, V62, P3382; Tsuchiya T, 2000, ONCOGENE, V19, P3642, DOI 10.1038/sj.onc.1203704; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416; Zhu ZY, 2001, CANCER RES, V61, P1707	43	41	45	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3474	3480		10.1038/sj.onc.1207470	http://dx.doi.org/10.1038/sj.onc.1207470			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	14990990				2022-12-28	WOS:000220975000022
J	Mamane, Y; Petroulakis, E; Rong, LW; Yoshida, K; Ler, LW; Sonenberg, N				Mamane, Y; Petroulakis, E; Rong, LW; Yoshida, K; Ler, LW; Sonenberg, N			eIF4E - from translation to transformation	ONCOGENE			English	Review						translation initiation; eIF4E; transformation	INITIATION-FACTOR 4E; CAP-BINDING PROTEIN; MESSENGER-RNA TRANSLATION; MYC-DEPENDENT APOPTOSIS; CYCLIN D1 PROTEIN; EUKARYOTIC TRANSLATION; ORNITHINE-DECARBOXYLASE; C-MYC; CELL-CYCLE; ANTI-ANGIOGENESIS	Over the years, studies have focused on the transcriptional regulation of oncogenesis. More recently, a growing emphasis has been placed on translational control. The Ras and Akt signal transduction pathways play a critical role in regulating mRNA translation and cellular transformation. The question arises: How might the Ras and Akt signaling pathways affect translation and mediate transformation? These pathways converge on a crucial effector of translation, the initiation factor eIF4E, which binds the 5' cap of mRNAs. This review focuses on the role of eIF4E in oncogenesis. eIF4E controls the translation of various malignancy-associated mRNAs which are involved in polyamine synthesis, cell cycle progression, activation of proto-oncogenes, angiogenesis, autocrine growth stimulation, cell survival, invasion and communication with the extracellular environment. eIF4E-mediated translational modulation of these mRNAs plays a pivotal role in both tumor formation and metastasis. Interestingly, eIF4E activity is implicated in mitosis, embryogenesis and in apoptosis. Finally, the finding that eIF4E is overexpressed in several human cancers makes it a prime target for anticancer therapies.	McGill Univ, Dept Biochem, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada	McGill University	Sonenberg, N (corresponding author), McGill Univ, Dept Biochem, McGill Canc Ctr, 3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.	nahum.sonenberg@mcgill.ca						Amiri A, 2001, DEVELOPMENT, V128, P3899; Anthony B, 1996, INT J CANCER, V65, P858, DOI 10.1002/(SICI)1097-0215(19960315)65:6<858::AID-IJC25>3.0.CO;2-Z; Auvinen M, 1997, CANCER RES, V57, P3016; Bauer C, 2002, INT J CANCER, V98, P181, DOI 10.1002/ijc.10180; Bauer C, 2001, CANCER, V92, P822, DOI 10.1002/1097-0142(20010815)92:4<822::AID-CNCR1388>3.0.CO;2-A; Bisacchi D, 2003, CANCER DETECT PREV, V27, P229, DOI 10.1016/S0361-090X(03)00030-8; Boudreau N, 2003, BREAST CANCER RES, V5, P140, DOI 10.1186/bcr589; Brass N, 1997, HUM MOL GENET, V6, P33, DOI 10.1093/hmg/6.1.33; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; Carter PS, 1999, ONCOGENE, V18, P4326, DOI 10.1038/sj.onc.1202890; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; Clemens MJ, 1999, INT J BIOCHEM CELL B, V31, P1, DOI 10.1016/S1357-2725(98)00127-7; Clemens MJ, 2001, J CELL MOL MED, V5, P221, DOI 10.1111/j.1582-4934.2001.tb00157.x; Cormier P, 2001, DEV BIOL, V232, P275, DOI 10.1006/dbio.2001.0206; Cruz MC, 1999, MOL CELL BIOL, V19, P4101; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; Dai Y, 2003, CURR OPIN PHARMACOL, V3, P362, DOI 10.1016/S1471-4892(03)00079-1; DARVEAU A, 1985, P NATL ACAD SCI USA, V82, P2315, DOI 10.1073/pnas.82.8.2315; Davidson NE, 1999, ENDOCR-RELAT CANCER, V6, P69, DOI 10.1677/erc.0.0060069; De Benedetti A, 1999, INT J BIOCHEM CELL B, V31, P59, DOI 10.1016/S1357-2725(98)00132-0; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; DeFatta RJ, 2000, LARYNGOSCOPE, V110, P928, DOI 10.1097/00005537-200006000-00007; Detillieux KA, 2003, CARDIOVASC RES, V57, P8, DOI 10.1016/S0008-6363(02)00708-3; Diehl JA, 2002, CANCER BIOL THER, V1, P226, DOI 10.4161/cbt.72; Dobashi Y, 2003, CURR MED CHEM, V10, P2549, DOI 10.2174/0929867033456495; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Dua K, 2001, PROTEOMICS, V1, P1191, DOI 10.1002/1615-9861(200110)1:10<1191::AID-PROT1191>3.0.CO;2-8; DUNCAN R, 1987, J BIOL CHEM, V262, P380; Duncan RF, 2003, BIOCHEM J, V369, P213, DOI 10.1042/BJ20020435; Eberle J, 1997, INT J CANCER, V71, P396, DOI 10.1002/(SICI)1097-0215(19970502)71:3<396::AID-IJC16>3.0.CO;2-E; Fahrenkrug SC, 1999, DIFFERENTIATION, V65, P191, DOI 10.1046/j.1432-0436.1999.6540191.x; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; FREDERICKSON RM, 1991, MOL CELL BIOL, V11, P2896, DOI 10.1128/MCB.11.5.2896; FukuchiShimogori T, 1997, CANCER RES, V57, P5041; Gallego J, 2002, CURR OPIN DRUG DISC, V5, P777; Gartel AL, 2003, EXP CELL RES, V283, P17, DOI 10.1016/S0014-4827(02)00020-4; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; GRAFF JR, 1995, INT J CANCER, V60, P255; Graff JR, 1997, BIOCHEM BIOPH RES CO, V240, P15, DOI 10.1006/bbrc.1997.7592; Graff JR, 2003, CLIN EXP METASTAS, V20, P265, DOI 10.1023/A:1022943419011; GRENS A, 1990, J BIOL CHEM, V265, P11810; Guo SS, 2003, J ENDOCRINOL, V179, P73, DOI 10.1677/joe.0.1790073; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; Hermeking H, 2003, CURR CANCER DRUG TAR, V3, P163, DOI 10.2174/1568009033481949; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Hillary RA, 2003, BBA-PROTEINS PROTEOM, V1647, P161, DOI 10.1016/S1570-9639(03)00088-8; HIREMATH LS, 1985, J BIOL CHEM, V260, P7843; Holcik M, 2000, TRENDS GENET, V16, P469, DOI 10.1016/S0168-9525(00)02106-5; Houghton PJ, 2003, CURR TOP MICROBIOL, V279, P339; Hui P, 2003, LEUKEMIA LYMPHOMA, V44, P1385, DOI 10.1080/1042819031000079168; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Jacinto E, 2003, NAT REV MOL CELL BIO, V4, P117, DOI 10.1038/nrm1018; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; JEFFERIES HBJ, 1996, TRANSLATIONAL CONTRO, P389; Johnson DG, 1999, ANNU REV PHARMACOL, V39, P295, DOI 10.1146/annurev.pharmtox.39.1.295; Keiper BD, 1999, INT J BIOCHEM CELL B, V31, P37, DOI 10.1016/S1357-2725(98)00130-7; KEREKATTE V, 1995, INT J CANCER, V64, P27, DOI 10.1002/ijc.2910640107; Kevil C, 1995, ONCOGENE, V11, P2339; Kevil CG, 1996, INT J CANCER, V65, P785, DOI 10.1002/(SICI)1097-0215(19960315)65:6<785::AID-IJC14>3.0.CO;2-3; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim DH, 2003, CURR TOP MICROBIOL, V279, P259; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; KLEIN PS, 1994, SCIENCE, V265, P803, DOI 10.1126/science.8047887; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; Kwiatkowski DJ, 2003, ANN HUM GENET, V67, P87, DOI 10.1046/j.1469-1809.2003.00012.x; Lachance PED, 2002, MOL CELL BIOL, V22, P1656, DOI 10.1128/MCB.22.6.1656-1663.2002; Lai HK, 2000, ONCOGENE, V19, P1623, DOI 10.1038/sj.onc.1203473; Lasko P, 2003, DEV CELL, V5, P671, DOI 10.1016/S1534-5807(03)00333-2; LAZARISKARATZAS A, 1992, GENE DEV, V6, P1631, DOI 10.1101/gad.6.9.1631; LAZARISKARATZAS A, 1992, MOL CELL BIOL, V12, P1234, DOI 10.1128/MCB.12.3.1234; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Levens DL, 2003, GENE DEV, V17, P1071, DOI 10.1101/gad.1095203; Li BDL, 2002, ANN SURG, V235, P732, DOI 10.1097/00000658-200205000-00016; Li S, 2003, J BIOL CHEM, V278, P3015, DOI 10.1074/jbc.M208821200; Li SN, 2002, MOL CELL BIOL, V22, P2853, DOI 10.1128/MCB.22.8.2853-2861.2002; LODISH HF, 1974, NATURE, V251, P385, DOI 10.1038/251385a0; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Long XM, 2002, CURR BIOL, V12, P1448, DOI 10.1016/S0960-9822(02)01091-6; LORENZ MC, 1995, J BIOL CHEM, V270, P27531, DOI 10.1074/jbc.270.46.27531; Lynch M, 2004, J BIOL CHEM, V279, P3327, DOI 10.1074/jbc.M310872200; Maeshima Y, 2002, SCIENCE, V295, P140, DOI 10.1126/science.1065298; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Manni A, 2002, IN VIVO, V16, P493; Manning BD, 2003, TRENDS BIOCHEM SCI, V28, P573, DOI 10.1016/j.tibs.2003.09.003; MANZELLA JM, 1990, J BIOL CHEM, V265, P11817; Marygold SJ, 2002, CURR BIOL, V12, pR785, DOI 10.1016/S0960-9822(02)01294-0; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; Menand B, 2002, P NATL ACAD SCI USA, V99, P6422, DOI 10.1073/pnas.092141899; Meyuhas O, 2000, EUR J BIOCHEM, V267, P6321, DOI 10.1046/j.1432-1327.2000.01719.x; Meyuhas Oded, 1996, V30, P363; Mita Monica M, 2003, Clin Breast Cancer, V4, P126, DOI 10.3816/CBC.2003.n.018; Miyamoto R, 2003, ORAL ONCOL, V39, P610, DOI 10.1016/S1368-8375(03)00048-4; Morris MJ, 2002, SURG ONCOL, V11, P13, DOI 10.1016/S0960-7404(02)00006-3; Morrish F, 2003, GENE DEV, V17, P240, DOI 10.1101/gad.1032503; MOSHIER JA, 1993, CANCER RES, V53, P2618; Nathan CAO, 1999, LARYNGOSCOPE, V109, P1253, DOI 10.1097/00005537-199908000-00013; Oldham S, 2000, GENE DEV, V14, P2689, DOI 10.1101/gad.845700; Park MT, 2003, J BIOCHEM MOL BIOL, V36, P60; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Pegg AE, 2003, BIOCHEM SOC T, V31, P356, DOI 10.1042/BST0310356; Pelengaris S, 2003, ARCH BIOCHEM BIOPHYS, V416, P129, DOI 10.1016/S0003-9861(03)00294-7; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; Polsky D, 2003, ONCOGENE, V22, P3087, DOI 10.1038/sj.onc.1206449; Polunovsky VA, 1996, MOL CELL BIOL, V16, P6573; Polunovsky VA, 2000, J BIOL CHEM, V275, P24776, DOI 10.1074/jbc.M001938200; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Poulin F, 1998, J BIOL CHEM, V273, P14002, DOI 10.1074/jbc.273.22.14002; Prendergast GC, 2003, CANCER CELL, V4, P244, DOI 10.1016/S1535-6108(03)00247-2; Prevot D, 2003, BIOL CELL, V95, P141, DOI 10.1016/S0248-4900(03)00031-5; Proud CG, 2003, CURR TOP MICROBIOL, V279, P215; Proud CG, 2002, EUR J BIOCHEM, V269, P5337, DOI 10.1046/j.1432-1033.2002.03289.x; Pyronnet S, 2001, CURR OPIN GENET DEV, V11, P13, DOI 10.1016/S0959-437X(00)00150-7; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Pyronnet S, 2000, BIOCHEM PHARMACOL, V60, P1237, DOI 10.1016/S0006-2952(00)00429-9; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; Raught B, 2001, P NATL ACAD SCI USA, V98, P7037, DOI 10.1073/pnas.121145898; RHOADS RE, 1993, PROG NUCLEIC ACID RE, V46, P183, DOI 10.1016/S0079-6603(08)61022-3; Ribatti D, 2003, J HEMATOTH STEM CELL, V12, P11, DOI 10.1089/152581603321210091; Ribatti D, 2002, EUR J CANCER, V38, P750, DOI 10.1016/S0959-8049(01)00337-9; RINKERSCHAEFFER CW, 1992, J BIOL CHEM, V267, P10659; RINKERSCHAEFFER CW, 1993, INT J CANCER, V55, P841, DOI 10.1002/ijc.2910550525; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; Rosenwald IB, 1999, ONCOGENE, V18, P2507, DOI 10.1038/sj.onc.1202563; Rosenwald IB, 2001, CANCER-AM CANCER SOC, V92, P2164, DOI 10.1002/1097-0142(20011015)92:8<2164::AID-CNCR1559>3.0.CO;2-A; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Rousseau D, 1996, ONCOGENE, V13, P2415; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Ruegg C, 2003, CELL MOL LIFE SCI, V60, P1135, DOI 10.1007/s00018-003-2297-3; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SAITO H, 1983, P NATL ACAD SCI-BIOL, V80, P7476, DOI 10.1073/pnas.80.24.7476; Salaun P, 2003, DEV BIOL, V255, P428, DOI 10.1016/S0012-1606(02)00099-4; Schipper RG, 2002, J HISTOCHEM CYTOCHEM, V50, P1143, DOI 10.1177/002215540205000901; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Seiler N, 2003, CURR DRUG TARGETS, V4, P565, DOI 10.2174/1389450033490876; SHANTZ LM, 1994, CANCER RES, V54, P2313; Shantz LM, 1999, INT J BIOCHEM CELL B, V31, P107, DOI 10.1016/S1357-2725(98)00135-6; Shantz LM, 2004, BIOCHEM J, V377, P257, DOI 10.1042/BJ20030778; Shepherd FA, 2001, LUNG CANCER, V34, pS81; Shinkaruk S., 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P95, DOI 10.2174/1568011033353452; Shuda M, 2000, ANTICANCER RES, V20, P2489; SMITH MR, 1991, NEW BIOL, V3, P601; Stacey DW, 2003, CURR OPIN CELL BIOL, V15, P158, DOI 10.1016/S0955-0674(03)00008-5; Streit M, 2003, ONCOGENE, V22, P3172, DOI 10.1038/sj.onc.1206457; Tan A, 2000, ONCOGENE, V19, P1437, DOI 10.1038/sj.onc.1203446; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Thomas T, 2003, J CELL MOL MED, V7, P113, DOI 10.1111/j.1582-4934.2003.tb00210.x; Thomas T, 2002, ONCOL RES, V13, P123; Thornton S, 2003, J MOL MED, V81, P536, DOI 10.1007/s00109-003-0461-8; Tonini T, 2003, ONCOGENE, V22, P6549, DOI 10.1038/sj.onc.1206816; Topisirovic I, 2003, MOL CELL BIOL, V23, P8992, DOI 10.1128/MCB.23.24.8992-9002.2003; Vagner S, 2001, EMBO REP, V2, P893, DOI 10.1093/embo-reports/kve208; Vermeulen K, 2003, CELL PROLIFERAT, V36, P131, DOI 10.1046/j.1365-2184.2003.00266.x; Wallace HM, 2001, EUR J GASTROEN HEPAT, V13, P1033, DOI 10.1097/00042737-200109000-00006; Wang ST, 1999, AM J PATHOL, V155, P247, DOI 10.1016/S0002-9440(10)65118-8; Wang ST, 2001, THYROID, V11, P1101, DOI 10.1089/10507250152740939; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Watkins SJ, 2002, BRIT J CANCER, V86, P1023, DOI 10.1038/sj/bjc/6600222; Willis AE, 1999, INT J BIOCHEM CELL B, V31, P73, DOI 10.1016/S1357-2725(98)00133-2; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Zhang HB, 2000, GENE DEV, V14, P2712, DOI 10.1101/gad.835000; Zimmer SG, 2000, ANTICANCER RES, V20, P1343; Zogakis TG, 2001, EXPERT OPIN BIOL TH, V1, P253, DOI 10.1517/14712598.1.2.253	173	367	382	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2004	23	18					3172	3179		10.1038/sj.onc.1207549	http://dx.doi.org/10.1038/sj.onc.1207549			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	813AJ	15094766	Green Published			2022-12-28	WOS:000220879700005
J	Bedrosian, I; Lu, KH; Verschraegen, C; Keyomarsi, K				Bedrosian, I; Lu, KH; Verschraegen, C; Keyomarsi, K			Cyclin E deregulation alters the biologic properties of ovarian cancer cells	ONCOGENE			English	Article						ovarian cancer; cyclin E; cell cycle; lovastatin	TUMOR BREAST CELLS; POTENTIAL PROGNOSTIC MARKER; E EXPRESSION; LUNG-CANCER; G1 ARREST; SURVIVAL; OVEREXPRESSION; PROLIFERATION; AMPLIFICATION; SENSITIVITY	We have previously shown that the low molecular weight (LMW) forms (trunk 1 and trunk 2) of cyclin E are biochemically hyperactive and induce G1/S progression in normal epithelial cells. Here we investigate the biologic consequences of LMW cyclin E expression in ovarian cancer cells. Using a panel of ovarian carcinoma tumors we find that cyclin E overexpression is invariably due to the presence of LMW forms and that expression of these forms appears to correlate with more advanced grade and stage of disease. Despite similar expression of p21 and p27, cyclin E overexpressing tumors have higher kinase function. Using an isogenic ovarian cancer model, we find that clones that overexpress the trunk 1 (T1) protein have a 10-fold increase in cyclin E kinase function, a 20% increase in S-phase fraction, a 10-15% decrease in doubling time and a 20% increase in colony formation compared to parental cells that express only the FL cyclin E protein. T1 clones were resistant to G1 arrest but more sensitive to cisplatin. Therefore, in ovarian tumors, the presence of LMW cyclin E forms confers altered biologic properties. Our data provides a potential mechanism for the poor prognosis of patients with LMW cyclin E expressing tumors.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA; Univ New Mexico, Canc Res & Treatment Ctr, Dept Expt Therapeut, Albuquerque, NM 87131 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of New Mexico	Keyomarsi, K (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Box 66, Houston, TX 77030 USA.	kkeyomar@mdanderson.org	Verschraegen, Claire/AAE-7620-2020; Keyomarsi, Khandan/H-2716-2016	Verschraegen, Claire/0000-0001-6544-3089; Keyomarsi, Khandan/0000-0002-5440-0849	NCI NIH HHS [T32-CA09599-14, R01-CA87548] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009599, R01CA087548] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKLI S, 2003, CANCER BIOL THER, V2, P16; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Cappella P, 2001, INT J CANCER, V93, P401, DOI 10.1002/ijc.1351.abs; Chen XM, 1999, ONCOGENE, V18, P5691, DOI 10.1038/sj.onc.1202948; Del Pizzo JJ, 1999, AM J PATHOL, V155, P1129, DOI 10.1016/S0002-9440(10)65216-9; Farley J, 2003, CANCER RES, V63, P1235; Fukuse T, 2000, CANCER RES, V60, P242; GrayBablin J, 1997, CANCER RES, V57, P604; Harwell RM, 2000, CANCER RES, V60, P481; Itamochi H, 2002, ONCOLOGY-BASEL, V62, P349, DOI 10.1159/000065067; Jang SJ, 1999, EUR J SURG ONCOL, V25, P157, DOI 10.1053/ejso.1998.0619; Johnson KR, 1997, CLIN CANCER RES, V3, P1739; KEYOMARSI K, 1994, CANCER RES, V54, P380; Keyomarsi K, 2002, NEW ENGL J MED, V347, P1566, DOI 10.1056/NEJMoa021153; Keyomarsi K, 1997, Prog Cell Cycle Res, V3, P171; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KEYOMARSI K, 1995, ONCOGENE, V11, P941; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; Kolfschoten GM, 2000, BRIT J CANCER, V83, P921, DOI 10.1054/bjoc.2000.1373; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; Mishina T, 2000, CLIN CANCER RES, V6, P11; Muller-Tidow C, 2001, CANCER RES, V61, P647; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Pestell KE, 2000, MOL PHARMACOL, V57, P503, DOI 10.1124/mol.57.3.503; Porter DC, 2001, MOL CELL BIOL, V21, P6254, DOI 10.1128/MCB.21.18.6254-6269.2001; Rao S, 1998, ONCOGENE, V17, P2393, DOI 10.1038/sj.onc.1202322; Rao S, 1999, P NATL ACAD SCI USA, V96, P7797, DOI 10.1073/pnas.96.14.7797; Sangfelt O, 1999, ONCOGENE, V18, P2798, DOI 10.1038/sj.onc.1202609; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Smith ML, 2000, ANTICANCER RES, V20, P2537; Sui L, 2001, GYNECOL ONCOL, V83, P56, DOI 10.1006/gyno.2001.6308; Wang XD, 2003, ONCOGENE, V22, P769, DOI 10.1038/sj.onc.1206166; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wingate H, 2003, CELL CYCLE, V2, P461, DOI 10.4161/cc.2.5.464	35	58	61	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2004	23	15					2648	2657		10.1038/sj.onc.1207408	http://dx.doi.org/10.1038/sj.onc.1207408			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	810OZ	15007381				2022-12-28	WOS:000220714900006
J	Simone, C; Stiegler, P; Forcales, SV; Bagella, L; De Luca, A; Sartorelli, V; Giordano, A; Puri, AL				Simone, C; Stiegler, P; Forcales, SV; Bagella, L; De Luca, A; Sartorelli, V; Giordano, A; Puri, AL			Deacetylase recruitment by the C/H3 domain of the acetyltransferase p300	ONCOGENE			English	Article						deacetylases; acetyltransferases; p300; HDAC; transcription	HISTONE DEACETYLASE; TRANSCRIPTIONAL CONTROL; DNA-BINDING; PROTEINS; MUSCLE; MYOD; CBP; ACETYLATION; PCAF; CHROMATIN	The balance between acetylation and deacetylation of histone and nonhistone proteins controls gene expression in a variety of cellular processes, with transcription being activated by acetyltransferases and silenced by deacetylases. W e report here the formation and enzymatic characterization of a complex between the acetyltransferase p300 and histone deacetylases. The C/ H3 region of p300 was found to co- purify deacetylase activity from nuclear cell extracts. A prototype of class I histone deacetylases, HDAC1, interacts with p300 C/ H3 domain in vitro and in vivo. The p300- binding protein E1A competes with HDAC1 for C/ H3 binding; and, like E1A, HDAC1 overexpression interferes with either activation of Gal4p300 fusion protein or p300- dependent co- activation of two C/ H3- binding proteins, MyoD and p53. The exposure to deacetylase inhibitors could reverse the dominant- negative effect of a C/ H3 fragment insulated from the rest of the molecule, on MyoD- and p53-dependent transcription, whereas inhibition by E1A was resistant to trichostatin A. The se data support the hypothesis that association between acetyltransferases and deacetylases can control the expression of genes implicated in cellular growth and differentiation, and suggest that the dominant- negative effect of the p300 C/ H3 fragment relies on deacetylase recruitment.	Univ Roma La Sapienza, Fdn A Cesalpino, DTI, Gene Express Lab, Rome, Italy; Salk Inst Biol Studies, Peptide Biol Lab, La Jolla, CA 92093 USA; Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; IRCCS Neuromed, I-86077 Pozzilli, IS, Italy; NIAMS, Muscle Biol Lab, Muscle Gene Express Grp, NIH, Bethesda, MD 20892 USA	Sapienza University Rome; Salk Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; IRCCS Neuromed; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Puri, AL (corresponding author), Univ Roma La Sapienza, Fdn A Cesalpino, DTI, Gene Express Lab, Rome, Italy.	plorenzo@salk.edu	Simone, Cristiano/K-3452-2018; De Luca, Antonio/AAD-9562-2020; Giordano, Antonio/F-1927-2010; Forcales, Sonia-V./B-2157-2013; Forcales, Sonia/AAU-8996-2020	Simone, Cristiano/0000-0002-2628-7658; De Luca, Antonio/0000-0002-3905-6154; Giordano, Antonio/0000-0002-5959-016X; Forcales, Sonia-V./0000-0002-7111-4959; Forcales, Sonia/0000-0002-7111-4959; Sartorelli, Vittorio/0000-0002-9284-3675; Puri, Pier Lorenzo/0000-0003-4964-0095; BAGELLA, Luigi/0000-0003-2815-037X	Telethon [GFP01009] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041125] Funding Source: NIH RePORTER	Telethon(Fondazione Telethon); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Archer SY, 1999, CURR OPIN GENET DEV, V9, P171, DOI 10.1016/S0959-437X(99)80026-4; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bartl S, 1997, MOL CELL BIOL, V17, P5033, DOI 10.1128/MCB.17.9.5033; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chan HM, 2001, J CELL SCI, V114, P2363; Cho H, 1998, MOL CELL BIOL, V18, P5355, DOI 10.1128/MCB.18.9.5355; COSTANZO A, 2002, MOL CELL, V8, P1243; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; Dallas PB, 1997, J VIROL, V71, P1726, DOI 10.1128/JVI.71.2.1726-1731.1997; Eberharter A, 2002, EMBO REP, V3, P224, DOI 10.1093/embo-reports/kvf053; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; Felzien LK, 1999, MOL CELL BIOL, V19, P4241; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Goodman RH, 2000, GENE DEV, V14, P1553; Grozinger CM, 2002, CHEM BIOL, V9, P3, DOI 10.1016/S1074-5521(02)00092-3; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Howe L, 1999, CRIT REV EUKAR GENE, V9, P231, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.80; Iavarone A, 1999, MOL CELL BIOL, V19, P916; Iezzi S, 2002, P NATL ACAD SCI USA, V99, P7757, DOI 10.1073/pnas.112218599; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; JOHNSTON LA, 1992, MOL CELL BIOL, V12, P5123, DOI 10.1128/MCB.12.11.5123; Khochbin S, 2001, CURR OPIN GENET DEV, V11, P162, DOI 10.1016/S0959-437X(00)00174-X; Kim TK, 1998, P NATL ACAD SCI USA, V95, P12191, DOI 10.1073/pnas.95.21.12191; KOUZARIDES T, 2000, EMBO J, V21, P2383; Kraus WL, 1999, MOL CELL BIOL, V19, P8123; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Mal A, 2001, EMBO J, V20, P1739, DOI 10.1093/emboj/20.7.1739; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; McKinsey TA, 2001, CURR OPIN GENET DEV, V11, P497, DOI 10.1016/S0959-437X(00)00224-0; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Newman BL, 2002, GENETICS, V162, P1675; O'Connor MJ, 1999, J VIROL, V73, P3574; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Polesskaya A, 2000, J BIOL CHEM, V275, P34359, DOI 10.1074/jbc.M003815200; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Puri PL, 2001, MOL CELL, V8, P885, DOI 10.1016/S1097-2765(01)00373-2; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sang NL, 1997, J CELL BIOCHEM, V66, P277, DOI 10.1002/(SICI)1097-4644(19970901)66:3<277::AID-JCB1>3.0.CO;2-M; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; SATORELLI V, 2001, FRONT BIOSCI, V6, pD1024; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Stiegler P, 1998, CANCER RES, V58, P5049; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Wade PA, 2001, ONCOGENE, V20, P3166, DOI 10.1038/sj.onc.1204340; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; Yamagoe S, 2003, MOL CELL BIOL, V23, P1025, DOI 10.1128/MCB.23.3.1025-1033.2003; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; Zeng L, 2002, FEBS LETT, V513, P124, DOI 10.1016/S0014-5793(01)03309-9	64	27	27	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2004	23	12					2177	2187		10.1038/sj.onc.1207327	http://dx.doi.org/10.1038/sj.onc.1207327			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	804EB	14968110				2022-12-28	WOS:000220280900007
J	Busino, L; Chiesa, M; Draetta, GF; Donzelli, M				Busino, L; Chiesa, M; Draetta, GF; Donzelli, M			Cdc25A phosphatase: combinatorial phosphorylation, ubiquitylation and proteolysis	ONCOGENE			English	Review						Cdc25A; APC/C; SCF; checkpoints	ANAPHASE-PROMOTING COMPLEX; F-BOX PROTEINS; UBIQUITIN-LIGASE COMPLEX; S-PHASE CHECKPOINT; CELL-CYCLE; DNA-DAMAGE; MEDIATED DEGRADATION; G(1)/S TRANSITION; BREAST-CANCER; BETA-CATENIN	In eukaryotic cells, control mechanisms of cell-cycle progression have evolved to accurately monitor the integrity of genetic information to be transferred to the progeny. Cdc25A phosphatase is an essential activator of cell-cycle progression and is targeted by checkpoint signals. Ubiquitylation regulates Cdc25A activity through. ne tuning of its protein levels. Two different ubiquitin ligases (APC/C and SCF complex) are involved in Cdc25A turnover. While APC/C is involved in regulating Cdc25A at the exit of mitosis, SCF regulates the abundance of Cdc25A in S phase and G2. In response to DNA damage or to stalled replication, the activation of the ATM and ATR protein kinases leads to Chk1 and Chk2 activation and to Cdc25A hyperphosphorylation. These events stimulate SCF-mediated ubiquitylation of Cdc25A and its proteolysis. This contributes to delaying cell-cycle progression, thereby preventing genomic instability. Based on recent findings, we discuss the role of Cdc25A ubiquitylation and degradation in cell-cycle progression and in response to DNA damage. Moreover, we discuss the role of phosphorylation at multiple sites in triggering ubiquitylation signals.	European Inst Oncol, I-20141 Milan, Italy	IRCCS European Institute of Oncology (IEO)	Donzelli, M (corresponding author), European Inst Oncol, 435 Via Ripamonti, I-20141 Milan, Italy.	mdonzell@ieo.it	Donzelli, Maddalena/ABD-3774-2020	DONZELLI, MADDALENA/0000-0002-4045-0802	Telethon [E.0865] Funding Source: Medline	Telethon(Fondazione Telethon)		Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bendjennat M, 2003, CELL, V114, P599, DOI 10.1016/j.cell.2003.08.001; Bernardi R, 2000, ONCOGENE, V19, P2447, DOI 10.1038/sj.onc.1203564; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; Broggini M, 2000, ANTICANCER RES, V20, P4835; Busino L, 2003, NATURE, V426, P87, DOI 10.1038/nature02082; Cangi MG, 2000, J CLIN INVEST, V106, P753, DOI 10.1172/JCI9174; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Cenciarelli C, 1999, CURR BIOL, V9, P1177, DOI 10.1016/S0960-9822(00)80020-2; Clucas C, 2002, EMBO J, V21, P665, DOI 10.1093/emboj/21.4.665; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Donzelli M, 2003, EMBO REP, V4, P671, DOI 10.1038/sj.embor.embor887; Donzelli M, 2002, EMBO J, V21, P4875, DOI 10.1093/emboj/cdf491; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Goloudina A, 2003, CELL CYCLE, V2, P473, DOI 10.4161/cc.2.5.482; Guardavaccaro D, 2003, DEV CELL, V4, P799, DOI 10.1016/S1534-5807(03)00154-0; Hassepass I, 2003, J BIOL CHEM, V278, P29824, DOI 10.1074/jbc.M302704200; Hernandez S, 2001, LAB INVEST, V81, P465, DOI 10.1038/labinvest.3780254; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; Ito Y, 2002, BRIT J CANCER, V86, P1909, DOI 10.1038/sj.bjc.6600364; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Kaneko Y, 1999, ONCOGENE, V18, P3673, DOI 10.1038/sj.onc.1202706; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Kramer ER, 2000, MOL BIOL CELL, V11, P1555, DOI 10.1091/mbc.11.5.1555; Listovsky T, 2000, EXP CELL RES, V255, P184, DOI 10.1006/excr.1999.4788; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu QH, 2000, GENE DEV, V14, P1448; Lukas C, 1999, NATURE, V401, P815, DOI 10.1038/44611; Lukas C, 2001, CANCER RES, V61, P4990; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Mailand N, 2002, EMBO J, V21, P5911, DOI 10.1093/emboj/cdf567; Margottin-Goguet F, 2003, DEV CELL, V4, P813, DOI 10.1016/S1534-5807(03)00153-9; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Molinari M, 2000, EMBO REP, V1, P71, DOI 10.1093/embo-reports/kvd018; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Parisi T, 2003, EMBO J, V22, P4794, DOI 10.1093/emboj/cdg482; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Peters JM, 2003, MOL CELL, V11, P1420, DOI 10.1016/S1097-2765(03)00233-8; Pfleger CM, 2000, GENE DEV, V14, P655; Pines J, 1999, NAT CELL BIOL, V1, pE73, DOI 10.1038/11041; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Reimann JDR, 2001, CELL, V105, P645, DOI 10.1016/S0092-8674(01)00361-0; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; Sexl V, 1999, ONCOGENE, V18, P573, DOI 10.1038/sj.onc.1202362; Shimuta K, 2002, EMBO J, V21, P3694, DOI 10.1093/emboj/cdf357; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Takai H, 2000, GENE DEV, V14, P1439; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Verma R, 1997, MOL BIOL CELL, V8, P1427, DOI 10.1091/mbc.8.8.1427; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Winston JT, 1999, CURR BIOL, V9, P1180, DOI 10.1016/S0960-9822(00)80021-4; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Xiao Z, 2003, J BIOL CHEM, V278, P21767, DOI 10.1074/jbc.M300229200; Xu XD, 2003, CLIN CANCER RES, V9, P1764; Zachariae W, 1998, SCIENCE, V282, P1721, DOI 10.1126/science.282.5394.1721; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou L, 1998, SCIENCE, V280, P593, DOI 10.1126/science.280.5363.593	71	154	163	3	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2004	23	11					2050	2056		10.1038/sj.onc.1207394	http://dx.doi.org/10.1038/sj.onc.1207394			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	803EC	15021892				2022-12-28	WOS:000220213400009
J	Connor, MK; Seth, A				Connor, MK; Seth, A			A central role for the ring finger protein RNF11 in ubiquitin-mediated proteolysis via interactions with E2s and E3s	ONCOGENE			English	Review						RNF11; ubiquitination; Smurf2; TGF-beta; breast cancer; signaling; EGFR	GROWTH-FACTOR-BETA; KINASE INHIBITOR P27(KIP1); U-BOX PROTEINS; TGF-BETA; BREAST-CANCER; NEGATIVE REGULATION; PROGNOSTIC-FACTOR; LIGASE; BRCA1; PHOSPHORYLATION	The identification of novel tumor-associated genes represents an important area of cancer research. To that end, we have discovered a number of genes whose expression is altered in breast tumors. One of these genes has been identified as the ring finger protein 11 ( RNF11) and its expression is elevated in breast and prostate cancer. The RNF11 gene encodes a 154 amino-acid protein that contains a ring finger and a PY motif. RNF11 is capable of binding numerous proteins, which encompass a wide variety of cellular pathways and mechanisms. This gives RNF11 a corresponding breadth of functions, including involvement in TGF-beta and epidermal growth factor receptor ( EGFR) signaling. In addition, RNF11 has the potential to mediate the ubiquitination and subsequent proteolysis of many cellular proteins. Thus, it may represent an important target of novel cancer therapies.	Sunnybrook & Womens Coll Hlth Sci Ctr, Lab Mol Pathol, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Lab Med & Pathobiol, CIHR Grp Matrix Dynam, Toronto, ON M4N 3M5, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Seth, A (corresponding author), Sunnybrook & Womens Coll Hlth Sci Ctr, Lab Mol Pathol, Rm E-423B,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	arun.seth@utoronto.ca						Aravind L, 2000, CURR BIOL, V10, pR132, DOI 10.1016/S0960-9822(00)00398-5; Asao H, 1997, J BIOL CHEM, V272, P32785, DOI 10.1074/jbc.272.52.32785; Bache KG, 2003, J BIOL CHEM, V278, P12513, DOI 10.1074/jbc.M210843200; Ben-Izhak O, 2003, J UROLOGY, V170, P241, DOI 10.1097/01.ju.0000072113.34524.a7; Boehmer C, 2003, BIOCHEM BIOPH RES CO, V306, P156, DOI 10.1016/S0006-291X(03)00921-5; Bres V, 2003, NAT CELL BIOL, V5, P754, DOI 10.1038/ncb1023; Burger AM, 1998, EUR J CANCER PREV, V7, pS29, DOI 10.1097/00008469-199802001-00007; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Catzavelos C, 1999, CANCER RES, V59, P684; Confalonieri S, 2000, J CELL BIOL, V150, P905, DOI 10.1083/jcb.150.4.905; Coopman PJP, 2000, NATURE, V406, P742, DOI 10.1038/35021086; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Donovan J, 2000, BREAST CANCER RES, V2, P116, DOI 10.1186/bcr43; Fang S, 2003, SEMIN CANCER BIOL, V13, P5, DOI 10.1016/S1044-579X(02)00095-0; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Fukuchi M, 2002, CANCER RES, V62, P7162; Gillessen S, 2002, ONKOLOGIE, V25, P534, DOI 10.1159/000068624; Gilmore PM, 2003, BIOCHEM SOC T, V31, P257, DOI 10.1042/bst0310257; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; Hatakeyama S, 2003, BIOCHEM BIOPH RES CO, V302, P635, DOI 10.1016/S0006-291X(03)00245-6; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Itoh F, 2001, EMBO J, V20, P4132, DOI 10.1093/emboj/20.15.4132; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Jolliffe CN, 2000, BIOCHEM J, V351, P557, DOI 10.1042/0264-6021:3510557; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kitching R, 2003, BBA-MOL BASIS DIS, V1639, P104, DOI 10.1016/j.bbadis.2003.07.001; Kretzschmar M, 2000, BREAST CANCER RES, V2, P107, DOI 10.1186/bcr42; LI HX, 2003, IN PRESS ONCOGENE; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Liu XD, 2001, CYTOKINE GROWTH F R, V12, P1, DOI 10.1016/S1359-6101(00)00031-9; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Medrano EE, 2003, ONCOGENE, V22, P3123, DOI 10.1038/sj.onc.1206452; Mehra A, 2002, BIOCHEM CELL BIOL, V80, P605, DOI 10.1139/O02-161; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Miyazono K, 2003, CANCER SCI, V94, P230, DOI 10.1111/j.1349-7006.2003.tb01425.x; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Monteleone G, 2001, J CLIN INVEST, V108, P601, DOI 10.1172/JCI200112821; Mori N, 2003, INT J CANCER, V105, P661, DOI 10.1002/ijc.11146; Moynahan ME, 2002, ONCOGENE, V21, P8994, DOI 10.1038/sj.onc.1206177; Mustelin T, 2003, BIOCHEM J, V371, P15, DOI 10.1042/BJ20021637; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nalepa G, 2003, CANCER TREAT REV, V29, P49, DOI 10.1016/S0305-7372(03)00083-5; Peng HZ, 2002, CANCER RES, V62, P3773; Pray TR, 2002, DRUG RESIST UPDATE, V5, P249, DOI 10.1016/S1368-7646(02)00121-8; Rosen EM, 2003, J CELL PHYSIOL, V196, P19, DOI 10.1002/jcp.10257; Sakamoto KM, 2002, MOL GENET METAB, V77, P44, DOI 10.1016/S1096-7192(02)00146-4; Seki N, 1999, BBA-GENE STRUCT EXPR, V1489, P421, DOI 10.1016/S0167-4781(99)00190-6; Shigemasa K, 2003, CLIN CANCER RES, V9, P1756; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Subramaniam V, 2003, BRIT J CANCER, V89, P1538, DOI 10.1038/sj.bjc.6601301; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; Tanaka N, 1999, J BIOL CHEM, V274, P19129, DOI 10.1074/jbc.274.27.19129; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Winberg G, 2000, MOL CELL BIOL, V20, P8526, DOI 10.1128/MCB.20.22.8526-8535.2000; Xu J, 2000, P NATL ACAD SCI USA, V97, P4820, DOI 10.1073/pnas.97.9.4820; Yanagi S, 2001, BIOCHEM BIOPH RES CO, V288, P495, DOI 10.1006/bbrc.2001.5788; Zheng L, 2000, MOL CELL, V6, P757, DOI 10.1016/S1097-2765(00)00075-7	60	17	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2004	23	11					2089	2095		10.1038/sj.onc.1207380	http://dx.doi.org/10.1038/sj.onc.1207380			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	803EC	15021896				2022-12-28	WOS:000220213400013
J	Guardavaccaro, D; Pagano, M				Guardavaccaro, D; Pagano, M			Oncogenic aberrations of cullin-dependent ubiquitin ligases	ONCOGENE			English	Review						ubiquitin; cancer; cullin; cell cycle	F-BOX PROTEIN; KAPPA-B-ALPHA; SIGNAL-INDUCED UBIQUITINATION; ANAPHASE-PROMOTING COMPLEX; LINDAU TUMOR-SUPPRESSOR; TARGETS CYCLIN-E; BETA-TRCP; S-PHASE; CELL-CYCLE; MEDIATED PROTEOLYSIS	Accumulating evidence points to a key role of the ubiquitin - proteasome pathway in oncogenesis. Aberrant proteolysis of substrates involved in cellular processes such as the cell division cycle, gene transcription, the DNA damage response and apoptosis has been reported to contribute significantly to neoplastic transformation. Cullin-dependent ubiquitin ligases (CDLs) form a class of structurally related multisubunit enzymes central to the ubiquitin-mediated proteolysis of many important biological substrates. In this review, we describe the role of CDLs in the ubiquitinylation of cancer-related substrates and discuss how altered ubiquitinylation by CDLs may contribute to tumor development.	NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; NYU, Sch Med, Inst Canc, New York, NY 10016 USA	New York University; New York University	Pagano, M (corresponding author), NYU, Sch Med, Dept Pathol, MSB 599,550 1st Ave, New York, NY 10016 USA.	michele.pagano@med.nyu.edu		Guardavaccaro, Daniele/0000-0002-4517-1765; pagano, michele/0000-0003-3210-2442	NATIONAL CANCER INSTITUTE [R01CA076584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057587] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA76584] Funding Source: Medline; NIGMS NIH HHS [R01-GM57587] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersen JS, 2003, NATURE, V426, P570, DOI 10.1038/nature02166; Arai T, 2003, P NATL ACAD SCI USA, V100, P9855, DOI 10.1073/pnas.1733908100; BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Bashir T, 2003, ADV CANCER RES, V88, P101, DOI 10.1016/S0065-230X(03)88305-7; BASHIR T, 2004, IN PRESS NATURE; Ben-Izhak O, 2003, J UROLOGY, V170, P241, DOI 10.1097/01.ju.0000072113.34524.a7; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Bhatia N, 2002, ONCOGENE, V21, P1501, DOI 10.1038/sj.onc.1205311; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Brower CS, 2002, P NATL ACAD SCI USA, V99, P10353, DOI 10.1073/pnas.162424199; Busino L, 2003, NATURE, V426, P87, DOI 10.1038/nature02082; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Carrano AC, 2001, J CELL BIOL, V153, P1381, DOI 10.1083/jcb.153.7.1381; Cenciarelli C, 1999, CURR BIOL, V9, P1177, DOI 10.1016/S0960-9822(00)80020-2; Charrasse S, 2000, ONCOGENE, V19, P2986, DOI 10.1038/sj.onc.1203618; Chen LC, 1998, CANCER RES, V58, P3677; CHEN W, 1995, MOL CELL BIOL, V15, P3424; Chen XA, 2001, J BIOL CHEM, V276, P48175, DOI 10.1074/jbc.M106808200; Chiarle R, 2002, AM J PATHOL, V160, P1457, DOI 10.1016/S0002-9440(10)62571-0; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; Dealy MJ, 1999, NAT GENET, V23, P245, DOI 10.1038/13886; Dias DC, 2002, P NATL ACAD SCI USA, V99, P16601, DOI 10.1073/pnas.252646399; Dow MR, 1998, GENETICS, V150, P119; Dowen SE, 2003, ONCOGENE, V22, P2531, DOI 10.1038/sj.onc.1206296; El-Rifai W, 2001, INT J CANCER, V92, P832, DOI 10.1002/ijc.1264; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Feng H, 1999, NAT CELL BIOL, V1, P486, DOI 10.1038/70272; Fong A, 2002, J BIOL CHEM, V277, P22111, DOI 10.1074/jbc.C200151200; Freed E, 1999, GENE DEV, V13, P2242, DOI 10.1101/gad.13.17.2242; Furukawa M, 2003, NAT CELL BIOL, V5, P1001, DOI 10.1038/ncb1056; Ganiatsas S, 2001, ONCOGENE, V20, P3641, DOI 10.1038/sj.onc.1204501; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; GARD DL, 1990, J CELL BIOL, V110, P2033, DOI 10.1083/jcb.110.6.2033; Garriga J, 2003, MOL CELL BIOL, V23, P5165, DOI 10.1128/MCB.23.15.5165-5173.2003; Gerstein AV, 2002, GENE CHROMOSOME CANC, V34, P9, DOI 10.1002/gcc.10037; Geyer R, 2003, MOL CELL, V12, P783, DOI 10.1016/S1097-2765(03)00341-1; Groisman R, 2003, CELL, V113, P357, DOI 10.1016/S0092-8674(03)00316-7; Gstaiger M, 1999, EXP CELL RES, V247, P554, DOI 10.1006/excr.1999.4386; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; Guardavaccaro D, 2003, DEV CELL, V4, P799, DOI 10.1016/S1534-5807(03)00154-0; Gupta-Rossi N, 2001, J BIOL CHEM, V276, P34371, DOI 10.1074/jbc.M101343200; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hatakeyama S, 1999, P NATL ACAD SCI USA, V96, P3859, DOI 10.1073/pnas.96.7.3859; Hattori K, 1999, J BIOL CHEM, V274, P29641, DOI 10.1074/jbc.274.42.29641; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hershko D, 2001, CANCER, V91, P1745, DOI 10.1002/1097-0142(20010501)91:9<1745::AID-CNCR1193>3.0.CO;2-H; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Hori T, 1999, ONCOGENE, V18, P6829, DOI 10.1038/sj.onc.1203093; Hsu JY, 2002, NAT CELL BIOL, V4, P358, DOI 10.1038/ncb785; Inui N, 2003, BIOCHEM BIOPH RES CO, V303, P978, DOI 10.1016/S0006-291X(03)00469-8; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kamura T, 2003, P NATL ACAD SCI USA, V100, P10231, DOI 10.1073/pnas.1831009100; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kamura T, 2001, J BIOL CHEM, V276, P29748, DOI 10.1074/jbc.M103093200; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Keyomarsi K, 1997, Prog Cell Cycle Res, V3, P171; Kiernan RE, 2001, MOL CELL BIOL, V21, P7956, DOI 10.1128/MCB.21.23.7956-7970.2001; Kile BT, 2002, TRENDS BIOCHEM SCI, V27, P235, DOI 10.1016/S0968-0004(02)02085-6; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Kimura T, 2003, CANCER SCI, V94, P431, DOI 10.1111/j.1349-7006.2003.tb01460.x; Kipreos ET, 2000, GENOME BIOL, V1, DOI 10.1186/gb-2000-1-5-reviews3002; Kipreos ET, 2000, DEVELOPMENT, V127, P5071; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Ko HW, 2002, NATURE, V420, P673, DOI 10.1038/nature01272; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Koike J, 2000, BIOCHEM BIOPH RES CO, V269, P103, DOI 10.1006/bbrc.2000.2241; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Kroll M, 1999, J BIOL CHEM, V274, P7941, DOI 10.1074/jbc.274.12.7941; Kudo Y, 2001, CANCER RES, V61, P7044; Kurz T, 2002, SCIENCE, V295, P1294, DOI 10.1126/science.1067765; Lassot I, 2001, MOL CELL BIOL, V21, P2192, DOI 10.1128/MCB.21.6.2192-2202.2001; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Latres E, 2001, P NATL ACAD SCI USA, V98, P2515, DOI 10.1073/pnas.041475098; Li XH, 2003, J BIOL CHEM, V278, P30854, DOI 10.1074/jbc.C300251200; Luque I, 1997, SEMIN CANCER BIOL, V8, P103, DOI 10.1006/scbi.1997.0061; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Mantovani F, 2003, J BIOL CHEM, V278, P42477, DOI 10.1074/jbc.M302799200; Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2; Margottin-Goguet F, 2003, DEV CELL, V4, P813, DOI 10.1016/S1534-5807(03)00153-9; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Maruyama S, 2001, GENOMICS, V78, P214, DOI 10.1006/geno.2001.6658; Masuda T, 2002, CANCER RES, V62, P3819; Matise MP, 1999, ONCOGENE, V18, P7852, DOI 10.1038/sj.onc.1203243; Mendez J, 2002, MOL CELL, V9, P481, DOI 10.1016/S1097-2765(02)00467-7; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; Nag A, 2001, MOL CELL BIOL, V21, P6738, DOI 10.1128/MCB.21.20.6738-6747.2001; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nayak S, 2002, CURR BIOL, V12, P277, DOI 10.1016/S0960-9822(02)00682-6; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; Oberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Okabe H, 2001, CANCER RES, V61, P2129; Orian A, 2000, EMBO J, V19, P2580, DOI 10.1093/emboj/19.11.2580; Ou CY, 2002, GENE DEV, V16, P2403, DOI 10.1101/gad.1011402; Pagano M, 2003, CANCER CELL, V4, P251, DOI 10.1016/S1535-6108(03)00243-5; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Peters JM, 2003, MOL CELL, V11, P1420, DOI 10.1016/S1097-2765(03)00233-8; Pintard L, 2003, NATURE, V425, P311, DOI 10.1038/nature01959; Piva R, 2002, MOL CELL BIOL, V22, P8375, DOI 10.1128/MCB.22.23.8375-8387.2002; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Polakis P, 2000, GENE DEV, V14, P1837; Pugh CW, 2003, SEMIN CANCER BIOL, V13, P83, DOI 10.1016/S1044-579X(02)00103-7; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Querido E, 2001, J VIROL, V75, P699, DOI 10.1128/JVI.75.2.699-709.2001; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Reimann JDR, 2001, CELL, V105, P645, DOI 10.1016/S0092-8674(01)00361-0; Rui LY, 2002, J BIOL CHEM, V277, P42394, DOI 10.1074/jbc.C200444200; Saitoh T, 2001, INT J ONCOL, V18, P959; Schoenfeld AR, 2000, P NATL ACAD SCI USA, V97, P8507, DOI 10.1073/pnas.97.15.8507; Schwechheimer C, 2001, TRENDS CELL BIOL, V11, P420, DOI 10.1016/S0962-8924(01)02091-8; Shigemasa K, 2003, CLIN CANCER RES, V9, P1756; Shim EH, 2003, CANCER RES, V63, P1583; Shirane M, 1999, J BIOL CHEM, V274, P28169, DOI 10.1074/jbc.274.40.28169; Signoretti S, 2002, J CLIN INVEST, V110, P633, DOI 10.1172/JCI200215795; Singer JD, 1999, GENE DEV, V13, P2375, DOI 10.1101/gad.13.18.2375; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Soldatenkov VA, 1999, CANCER RES, V59, P5085; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Spruck CH, 2002, CANCER RES, V62, P4535; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Unoki M, 2001, ONCOGENE, V20, P4457, DOI 10.1038/sj.onc.1204608; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Wang YS, 1999, CURR BIOL, V9, P1191, DOI 10.1016/S0960-9822(00)80024-X; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Winston JT, 1999, CURR BIOL, V9, P1180, DOI 10.1016/S0960-9822(00)80021-4; Wu C, 1999, J BIOL CHEM, V274, P29591, DOI 10.1074/jbc.274.42.29591; Wu GY, 2001, MOL CELL BIOL, V21, P7403, DOI 10.1128/MCB.21.21.7403-7415.2001; Xu L, 2003, NATURE, V425, P316, DOI 10.1038/nature01985; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Yasui K, 2002, HEPATOLOGY, V35, P1476, DOI 10.1053/jhep.2002.33683; Yokoi S, 2002, AM J PATHOL, V161, P207, DOI 10.1016/S0002-9440(10)64172-7; Yu HT, 1998, SCIENCE, V279, P1219, DOI 10.1126/science.279.5354.1219; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; Zhong WW, 2003, NATURE, V423, P885, DOI 10.1038/nature01747; ZOLLMAN S, 1994, P NATL ACAD SCI USA, V91, P10717, DOI 10.1073/pnas.91.22.10717	146	72	80	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2004	23	11					2037	2049		10.1038/sj.onc.1207413	http://dx.doi.org/10.1038/sj.onc.1207413			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	803EC	15021891				2022-12-28	WOS:000220213400008
J	Marmor, MD; Yarden, Y				Marmor, MD; Yarden, Y			Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases	ONCOGENE			English	Review						E3 ligase; endocytosis; growth factor; oncogene; signal transduction; tyrosine kinase; ubiquitin	EPIDERMAL-GROWTH-FACTOR; UBIQUITIN-INTERACTING MOTIF; LIGAND-INDUCED UBIQUITINATION; ERBB SIGNALING NETWORK; HRS-BINDING-PROTEIN; C-CBL; DOWN-REGULATION; EGF-RECEPTOR; MULTIVESICULAR-BODY; ADAPTER PROTEIN	Growth factors and their transmembrane receptor tyrosine kinases play pivotal roles in morphogenesis, cell fate determination and pathogenesis, including multiple stages of cancer. The amplitude and kinetics of signaling by growth factor receptors are determined by an endocytic process, which sorts activated, autophosphorylated receptors to degradation in lysosomes. Recent studies uncovered the role of protein ubiquitylation in vesicular trafficking of growth factor receptors. Decoration of ligand-activated receptors by multiple monomeric ubiquitins distinguishes this degradative route from the proteasome-mediated pathway, which involves polymeric chains of ubiquitin. Although receptor ubiquitylation occurs at the cell surface, its major role is to sort internalized receptors to the lumen of the multivesicular body, en route to the lysosome. The ubiquitin ligases that control this late sorting event belong to the Cbl family of RING finger adaptors, which bind specific phosphotyrosine residues in the receptors upon activation by ligand. Another group of E3 ubiquitin ligases, the Nedd4 family, regulates the initial sorting event, which targets receptors to clathrin-coated regions of the plasma membrane. This step entails ubiquitin-dependent assembly of a clathrin-binding complex of adaptors such as epsins, which share ubiquitin-interacting motifs. The concerted action of both ubiquitin-binding adaptors of membrane coats and E3 ligases, as well as their regulation by protein phosphorylation and ubiquitylation, ensure robust endocytosis of growth factor receptors. Genetic defects and virus-mediated manipulations of the endocytic pathway divert receptors to a default recycling pathway, thereby enabling unrestrained signaling characteristic to transformed cells.	Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Yarden, Y (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.	yosef.yarden@weizmann.ac.il	高, 雨莉/HGU-8187-2022; YARDEN, YOSEF/K-1467-2012		NATIONAL CANCER INSTITUTE [R01CA072981, R37CA072981] Funding Source: NIH RePORTER; NCI NIH HHS [CA72981] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amerik AY, 2000, MOL BIOL CELL, V11, P3365, DOI 10.1091/mbc.11.10.3365; Asao H, 1997, J BIOL CHEM, V272, P32785, DOI 10.1074/jbc.272.52.32785; Babst M, 2002, DEV CELL, V3, P283, DOI 10.1016/S1534-5807(02)00219-8; Babst M, 2000, TRAFFIC, V1, P248, DOI 10.1034/j.1600-0854.2000.010307.x; Bache KG, 2003, J CELL BIOL, V162, P435, DOI 10.1083/jcb.200302131; Bache KG, 2003, J BIOL CHEM, V278, P12513, DOI 10.1074/jbc.M210843200; Bao J, 2000, J BIOL CHEM, V275, P26178, DOI 10.1074/jbc.M002367200; Bao J, 2003, P NATL ACAD SCI USA, V100, P2438, DOI 10.1073/pnas.0437945100; Bartkiewicz M, 1999, J BIOL CHEM, V274, P30887, DOI 10.1074/jbc.274.43.30887; Baulida J, 1996, J BIOL CHEM, V271, P5251; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; Bilodeau PS, 2002, NAT CELL BIOL, V4, P534, DOI 10.1038/ncb815; Bishop N, 2002, J CELL BIOL, V157, P91, DOI 10.1083/jcb.200112080; Bishop N, 2001, J BIOL CHEM, V276, P11735, DOI 10.1074/jbc.M009863200; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Cadavid ALM, 2000, DEVELOPMENT, V127, P1727; Carbone R, 1997, CANCER RES, V57, P5498; Chen LY, 2002, TRAFFIC, V3, P110, DOI 10.1034/j.1600-0854.2002.030204.x; Chin LS, 2001, J BIOL CHEM, V276, P7069, DOI 10.1074/jbc.M004129200; Citri A, 2002, EMBO J, V21, P2407, DOI 10.1093/emboj/21.10.2407; Confalonieri S, 2000, J CELL BIOL, V150, P905, DOI 10.1083/jcb.150.4.905; Conibear E, 1998, BBA-MOL CELL RES, V1404, P211, DOI 10.1016/S0167-4889(98)00058-5; Courbard JR, 2002, J BIOL CHEM, V277, P45267, DOI 10.1074/jbc.M206460200; de Melker AA, 2001, J CELL SCI, V114, P2167; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; De Sepulveda P, 1999, EMBO J, V18, P904; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Di Fiore PP, 1999, CURR OPIN CELL BIOL, V11, P483, DOI 10.1016/S0955-0674(99)80069-6; Di Fiore PP, 2003, NAT REV MOL CELL BIO, V4, P491, DOI 10.1038/nrm1124; Dikic I, 2003, CURR OPIN CELL BIOL, V15, P128, DOI 10.1016/S0955-0674(03)00004-8; Donaldson KM, 2003, CURR BIOL, V13, P258, DOI 10.1016/S0960-9822(03)00043-5; Duan L, 2003, J BIOL CHEM, V278, P28950, DOI 10.1074/jbc.M304474200; Dunn R, 2001, J BIOL CHEM, V276, P25974, DOI 10.1074/jbc.M104113200; EBNER R, 1991, CELL REGUL, V2, P599, DOI 10.1091/mbc.2.8.599; Esters H, 2001, J MOL BIOL, V310, P141, DOI 10.1006/jmbi.2001.4735; Ettenberg SA, 2001, J BIOL CHEM, V276, P27677, DOI 10.1074/jbc.M102641200; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; Fiorini M, 2001, FEBS LETT, V490, P132, DOI 10.1016/S0014-5793(01)02116-0; Frederick L, 2000, CANCER RES, V60, P1383; Freed EO, 2003, TRENDS MICROBIOL, V11, P56, DOI 10.1016/S0966-842X(02)00013-6; FRENCH AR, 1994, J BIOL CHEM, V269, P15749; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Gayther SA, 1997, ONCOGENE, V15, P2119, DOI 10.1038/sj.onc.1201591; Govers P, 1998, J BIOL CHEM, V273, P16426, DOI 10.1074/jbc.273.26.16426; Govers R, 1999, EMBO J, V18, P28, DOI 10.1093/emboj/18.1.28; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Haglund K, 2002, P NATL ACAD SCI USA, V99, P12191, DOI 10.1073/pnas.192462299; Hall AB, 2003, CURR BIOL, V13, P308, DOI 10.1016/S0960-9822(03)00086-1; Hayakawa A, 2000, J BIOL CHEM, V275, P29636, DOI 10.1074/jbc.M002696200; Heilker R, 1999, BIOESSAYS, V21, P558, DOI 10.1002/(SICI)1521-1878(199907)21:7<558::AID-BIES4>3.0.CO;2-R; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hofmann K, 2001, TRENDS BIOCHEM SCI, V26, P347, DOI 10.1016/S0968-0004(01)01835-7; Jiang XJ, 2003, MOL BIOL CELL, V14, P858, DOI 10.1091/mbc.E02-08-0532; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kang RS, 2003, CELL, V113, P621, DOI 10.1016/S0092-8674(03)00362-3; Kato M, 2000, J BIOL CHEM, V275, P37481, DOI 10.1074/jbc.M007251200; Katz M, 2002, TRAFFIC, V3, P740, DOI 10.1034/j.1600-0854.2002.31006.x; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Katzmann DJ, 2003, J CELL BIOL, V162, P413, DOI 10.1083/jcb.200302136; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Kikonyogo A, 2001, P NATL ACAD SCI USA, V98, P11199, DOI 10.1073/pnas.201268998; Klapisz E, 2002, J BIOL CHEM, V277, P30746, DOI 10.1074/jbc.M203004200; Klapper LN, 1999, P NATL ACAD SCI USA, V96, P4995, DOI 10.1073/pnas.96.9.4995; Klapper LN, 2000, CANCER RES, V60, P3384; Komada M, 2001, BIOCHEM BIOPH RES CO, V281, P1065, DOI 10.1006/bbrc.2001.4441; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Lee MP, 1997, CANCER RES, V57, P3131; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Levkowitz G, 1996, ONCOGENE, V12, P1117; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Lin SY, 1998, J GASTROEN HEPATOL, V13, P1111, DOI 10.1111/j.1440-1746.1998.tb00585.x; Liu RT, 2002, ONCOGENE, V21, P4830, DOI 10.1038/sj.onc.1205612; Lloyd TE, 2002, CELL, V108, P261, DOI 10.1016/S0092-8674(02)00611-6; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Lu Q, 2003, P NATL ACAD SCI USA, V100, P7626, DOI 10.1073/pnas.0932599100; Madura K, 2002, CELL CYCLE, V1, P233, DOI 10.4161/cc.1.4.130; Marchese A, 2001, J BIOL CHEM, V276, P45509, DOI 10.1074/jbc.C100527200; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Meyer HH, 2002, EMBO J, V21, P5645, DOI 10.1093/emboj/cdf579; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Morrione A, 1999, J BIOL CHEM, V274, P24094, DOI 10.1074/jbc.274.34.24094; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; NESTEROV A, 1995, P NATL ACAD SCI USA, V92, P8719, DOI 10.1073/pnas.92.19.8719; Nesterov A, 1999, EMBO J, V18, P2489, DOI 10.1093/emboj/18.9.2489; Oldham CE, 2002, CURR BIOL, V12, P1112, DOI 10.1016/S0960-9822(02)00900-4; Orsini MJ, 1999, J BIOL CHEM, V274, P31076, DOI 10.1074/jbc.274.43.31076; Penengo L, 2003, ONCOGENE, V22, P3669, DOI 10.1038/sj.onc.1206585; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Peschard P, 2003, CANCER CELL, V3, P519, DOI 10.1016/S1535-6108(03)00136-3; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Pornillos O, 2002, EMBO J, V21, P2397, DOI 10.1093/emboj/21.10.2397; Pornillos O, 2003, J CELL BIOL, V162, P425, DOI 10.1083/jcb.200302138; Pornillos O, 2002, TRENDS CELL BIOL, V12, P569, DOI 10.1016/S0962-8924(02)02402-9; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Raiborg C, 2001, EMBO J, V20, P5008, DOI 10.1093/emboj/20.17.5008; Rubin C, 2003, CURR BIOL, V13, P297, DOI 10.1016/S0960-9822(03)00053-8; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; Santolini E, 1999, EXP CELL RES, V253, P186, DOI 10.1006/excr.1999.4694; Schmidt MHH, 2003, P NATL ACAD SCI USA, V100, P6505, DOI 10.1073/pnas.1031790100; Shekhtman A, 2002, BIOCHEM BIOPH RES CO, V296, P1222, DOI 10.1016/S0006-291X(02)02006-5; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Shih SC, 2003, EMBO J, V22, P1273, DOI 10.1093/emboj/cdg140; Shtiegman K, 2003, SEMIN CANCER BIOL, V13, P29, DOI 10.1016/S1044-579X(02)00097-4; SHU HKG, 1991, J VIROL, V65, P6173, DOI 10.1128/JVI.65.11.6173-6180.1991; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Springael JY, 1999, BIOCHEM BIOPH RES CO, V257, P561, DOI 10.1006/bbrc.1999.0505; Stang E, 2000, J BIOL CHEM, V275, P13940, DOI 10.1074/jbc.275.18.13940; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; STRAIGHT SW, 1995, J VIROL, V69, P3185, DOI 10.1128/JVI.69.5.3185-3192.1995; Sun W, 2003, J CELL BIOL, V162, P125, DOI 10.1083/jcb.200302083; Takata H, 2000, GENES CELLS, V5, P57, DOI 10.1046/j.1365-2443.2000.00303.x; Tanaka S, 1996, NATURE, V383, P528, DOI 10.1038/383528a0; Thien CBF, 2001, MOL CELL, V7, P355, DOI 10.1016/S1097-2765(01)00183-6; Thien CBF, 1997, ONCOGENE, V15, P2909, DOI 10.1038/sj.onc.1201468; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Torrisi MR, 1999, MOL BIOL CELL, V10, P417, DOI 10.1091/mbc.10.2.417; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; Tsygankov AY, 2001, ONCOGENE, V20, P6382, DOI 10.1038/sj.onc.1204781; Tzahar E, 1998, EMBO J, V17, P5948, DOI 10.1093/emboj/17.20.5948; Urbe S, 2000, MOL CELL BIOL, V20, P7685, DOI 10.1128/MCB.20.20.7685-7692.2000; vanDelft S, 1997, J CELL BIOL, V136, P811, DOI 10.1083/jcb.136.4.811; Vecchione A, 2003, MOL CELL BIOL, V23, P3363, DOI 10.1128/MCB.23.9.3363-3372.2003; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; Wendland B, 1998, J CELL BIOL, V141, P71, DOI 10.1083/jcb.141.1.71; Wilde A, 1999, CELL, V96, P677, DOI 10.1016/S0092-8674(00)80578-4; Wiley HS, 2001, TRAFFIC, V2, P12, DOI 10.1034/j.1600-0854.2001.020103.x; WILEY HS, 1991, J BIOL CHEM, V266, P11083; Wilhelmsen K, 2002, ONCOGENE, V21, P1079, DOI 10.1038/sj.onc.1205166; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; Wong A, 2002, P NATL ACAD SCI USA, V99, P6684, DOI 10.1073/pnas.052138899; Wong ESM, 2002, EMBO J, V21, P4796, DOI 10.1093/emboj/cdf493; Worthylake R, 1999, J BIOL CHEM, V274, P8865, DOI 10.1074/jbc.274.13.8865; Xu WP, 2002, P NATL ACAD SCI USA, V99, P12847, DOI 10.1073/pnas.202365899; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yokouchi M, 1999, ONCOGENE, V18, P759, DOI 10.1038/sj.onc.1202326; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Yokouchi M, 2001, J BIOL CHEM, V276, P35185, DOI 10.1074/jbc.M102219200; Zheng FF, 2000, CANCER RES, V60, P2090	155	304	317	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2004	23	11					2057	2070		10.1038/sj.onc.1207390	http://dx.doi.org/10.1038/sj.onc.1207390			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	803EC	15021893				2022-12-28	WOS:000220213400010
J	Farhana, L; Dawson, MI; Huang, Y; Zhang, YX; Rishi, AK; Reddy, KB; Freeman, RS; Fontana, JA				Farhana, L; Dawson, MI; Huang, Y; Zhang, YX; Rishi, AK; Reddy, KB; Freeman, RS; Fontana, JA			Apoptosis signaling by the novel compound 3-Cl-AHPC involves increased EGFR proteolysis and accompanying decreased phosphatidylinositol 3-kinase and AKT kinase activities	ONCOGENE			English	Article						3-Cl-AHPC; CD437/AHPN; PI3-K; AKT; EGFR	PROSTATE CARCINOMA-CELLS; GROWTH-FACTOR RECEPTOR; SYNTHETIC RETINOID CD437; INTEGRIN-LINKED KINASE; NF-KAPPA-B; PROTEIN-KINASE; CANCER CELLS; PHOSPHOINOSITIDE 3-KINASE; CELLULAR-SURVIVAL; ACTIVATION	The threonine and serine protein kinase AKT plays a major role in inhibiting apoptosis in a number of malignant cell types including prostate and breast carcinoma. Activation of AKT is a complex process involving translocation to the plasma membrane and phosphorylation of serine and threonine amino-acid residues. We now report that the novel compound 4-[3(1-adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid (3-Cl-AHPC), induces apoptosis in breast and prostate carcinoma cells and inhibits AKT activity in these cells. Overexpression of a constitutively activated AKT inhibits 3-Cl-AHPC-mediated apoptosis. Decrease in AKT activity occurs through 3-Cl-AHPC inhibition of phosphatidylinositol 3 kinase (PI3-K) activity. 3-Cl-AHPC inhibits PI3-K activity by enhancing epidermal growth factor receptor ( EGFR) proteolysis and thus inhibiting EGFR association with the p85 subunit of PI3-K. 3-Cl-AHPC-mediated decrease in PI3-K activity results in the reduced synthesis of phosphatidylinositol 3,4 bisphosphate and phosphatidylinositol 3,4,5 triphosphate with the subsequent inhibition of integrin-linked kinase activity and serine-473 phosphorylation of AKT. Overexpression of EGFR results in increased AKT activity and inhibition of 3-Cl-AHPC-mediated decrease in AKT activation, AKT activity and 3-Cl-AHPC-mediated apoptosis. Inhibition of AKT activity by this compound results in the inability of AKT to phosphorylate and inactivate the proapoptotic forkhead transcription factor.	Wayne State Univ, John D Dingell VA Med Ctr, Karmanos Canc Inst, Dept Internal Med, Detroit, MI 48201 USA; Burnham Inst, La Jolla, CA 92037 USA; SUNY, Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA; Wayne State Univ, Dept Pathol, Detroit, MI 48201 USA; Univ Rochester, Dept Physiol & Pharmacol, Rochester, NY 14642 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Sanford Burnham Prebys Medical Discovery Institute; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; SUNY Maritime College; Wayne State University; University of Rochester	Fontana, JA (corresponding author), Wayne State Univ, John D Dingell VA Med Ctr, Karmanos Canc Inst, Dept Internal Med, Room C3687,4646 John R, Detroit, MI 48201 USA.	Joseph.Fontana@Med.VA.Gov		Fontana, Joseph/0000-0003-3829-3358	NATIONAL CANCER INSTITUTE [P01CA051993] Funding Source: NIH RePORTER; NCI NIH HHS [P0 CA51993] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal R, 2000, BIOCHEM PHARMACOL, V60, P1051, DOI 10.1016/S0006-2952(00)00385-3; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; AUGER KR, 1990, METHODS INOSITIDE RE; Ayllon V, 2000, MOL MEMBR BIOL, V17, P65; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Balmer LA, 2001, MOL CELL BIOL, V21, P2070, DOI 10.1128/MCB.21.6.2070-2084.2001; Brognard J, 2001, CANCER RES, V61, P3986; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Charpentier B, 1995, J MED CHEM, V38, P4993, DOI 10.1021/jm00026a006; Chen RH, 1998, ONCOGENE, V17, P1959, DOI 10.1038/sj.onc.1202111; Crowder RJ, 1998, J NEUROSCI, V18, P2933; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davies MA, 1999, CANCER RES, V59, P2551; de Medina SGD, 1998, HUM PATHOL, V29, P1005, DOI 10.1016/S0046-8177(98)90208-8; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Ettenberg S A, 1999, Mol Cell Biol Res Commun, V2, P111, DOI 10.1006/mcbr.1999.0157; Farhana L, 2002, CANCER RES, V62, P3842; Ghosh AK, 1999, GENE, V235, P85, DOI 10.1016/S0378-1119(99)00206-1; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hausler P, 1998, EUR J IMMUNOL, V28, P57, DOI 10.1002/(SICI)1521-4141(199801)28:01<57::AID-IMMU57>3.0.CO;2-8; Holmes WF, 2000, J CELL PHYSIOL, V185, P61, DOI 10.1002/1097-4652(200010)185:1<61::AID-JCP5>3.0.CO;2-0; Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397; Inukai I, 2001, FEBS LETT, V490, P32, DOI 10.1016/S0014-5793(01)02132-9; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1999, NATURE, V401, P33, DOI 10.1038/43354; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LAZEBNIK Y, 2000, SCIENCE, V287, pA1363; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; LEVYTOLEDANO R, 1994, J BIOL CHEM, V269, P31178; Li XS, 1996, CANCER RES, V56, P5055; Liang JY, 1999, PROSTATE, V38, P228; Lin JQ, 1999, CANCER RES, V59, P2891; Pacold ME, 2000, CELL, V103, P931, DOI 10.1016/S0092-8674(00)00196-3; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Philpott KL, 1997, J CELL BIOL, V139, P809, DOI 10.1083/jcb.139.3.809; Ponzanelli I, 2000, BLOOD, V95, P2672; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Rong R, 2002, ONCOGENE, V21, P1062, DOI 10.1038/sj.onc.1205154; Rubiol I, 1999, EUR J BIOCHEM, V266, P70, DOI 10.1046/j.1432-1327.1999.00815.x; Schwartz S, 1999, INT J ONCOL, V14, P367; SHAO ZM, 1995, ONCOGENE, V11, P493; SJOLANDER A, 1991, P NATL ACAD SCI USA, V88, P7908, DOI 10.1073/pnas.88.18.7908; SOLER C, 1994, J BIOL CHEM, V269, P12320; SOOK E, 2002, EMBO J, V21, P4796; Sun SY, 2000, MOL PHARMACOL, V58, P508, DOI 10.1124/mol.58.3.508; Sun SY, 2000, ONCOGENE, V19, P4513, DOI 10.1038/sj.onc.1203810; Tang D, 2001, J BIOL CHEM, V276, P30461, DOI 10.1074/jbc.M102045200; Tiganis T, 1999, J BIOL CHEM, V274, P27768, DOI 10.1074/jbc.274.39.27768; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; Wan XL, 2001, J MOL MED, V79, P143, DOI 10.1007/s001090100201; YAMAMOTO K, 1992, ENDOCRINOLOGY, V130, P1490, DOI 10.1210/en.130.3.1490; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang YX, 2002, BLOOD, V100, P2917, DOI 10.1182/blood.V100.8.2917; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	70	16	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	2004	23	10					1874	1884		10.1038/sj.onc.1207311	http://dx.doi.org/10.1038/sj.onc.1207311			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	801XV	14981538				2022-12-28	WOS:000220129500009
J	Freund, A; Jolivel, V; Durand, S; Kersual, N; Chalbos, D; Chavey, C; Vignon, F; Lazennec, G				Freund, A; Jolivel, V; Durand, S; Kersual, N; Chalbos, D; Chavey, C; Vignon, F; Lazennec, G			Mechanisms underlying differential expression of interleukin-8 in breast cancer cells	ONCOGENE			English	Article						estrogen receptor; breast; cancer; interleukin-8	NF-KAPPA-B; GENE-EXPRESSION; CONSTITUTIVE ACTIVATION; PROSTATE-CANCER; GROWTH-FACTOR; ANGIOGENESIS; BINDING; BETA; PROLIFERATION; MELANOMA	We have recently reported that interleukin-8 (IL-8) expression was inversely correlated to estrogen receptor (ER) status and was overexpressed in invasive breast cancer cells. In the present study, we show that IL-8 overexpression in breast cancer cells involves a higher transcriptional activity of IL-8 gene promoter. Cloning of IL-8 promoter from MDA-MB-231 and MCF-7 cells expressing high and low levels of IL-8, respectively, shows the integrity of the promoter in both cell lines. Deletion and site-directed mutagenesis of the promoter demonstrate that NF-kappaB and AP-1 and to a lesser extent C/EBP binding sites play a crucial role in the control of IL-8 promoter activity in MDA-MB-231 cells. Knock-down of NF-kappaB and AP-1 activities by adenovirus-mediated expression of an NF-kappaB super-repressor and RNA interference, respectively, decreased IL-8 expression in MDA-MB-231 cells. On the contrary, restoration of Fra-1, Fra-2, c-Jun, p50, p65, C/EBPalpha and C/EBPbeta expression levels in MCF-7 cells led to a promoter activity comparable to that observed in MDA-MB-231 cells. Our data constitute the first extensive study of IL-8 gene overexpression in breast cancer cells and suggest that the high expression of IL-8 in invasive cancer cells requires a complex cooperation between NF-kappaB, AP-1 and C/EBP transcription factors.	INSERM, U540, F-34090 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Lazennec, G (corresponding author), INSERM, U540, 60 Rue Navacelles, F-34090 Montpellier, France.	lazennec@montp.inserm.fr	Jolivel, Valérie/ABB-1136-2021; Jolivel, Valerie/A-6810-2017; Durand, Sebastien/Q-2138-2019	Jolivel, Valérie/0000-0002-4114-4559; Jolivel, Valerie/0000-0002-4114-4559; Durand, Sebastien/0000-0002-9960-9099; Chavey, Carine/0000-0002-5267-5638; Lazennec, Gwendal/0000-0002-8522-1763				Bharti AC, 2002, BIOCHEM PHARMACOL, V64, P883, DOI 10.1016/S0006-2952(02)01154-1; Brew R, 1996, EUR J CANCER, V32A, P2142, DOI 10.1016/S0959-8049(96)00221-3; BROWN PH, 1993, ONCOGENE, V8, P877; Ferrer FA, 1998, UROLOGY, V51, P161, DOI 10.1016/S0090-4295(97)00491-3; Freund A, 2003, ONCOGENE, V22, P256, DOI 10.1038/sj.onc.1206113; Fujioka S, 2003, CLIN CANCER RES, V9, P346; Gilmore T, 2002, CANCER LETT, V181, P1, DOI 10.1016/S0304-3835(01)00795-9; Haller D, 2002, J BIOL CHEM, V277, P38168, DOI 10.1074/jbc.M205737200; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; KUNSCH C, 1994, J IMMUNOL, V153, P153; Lazennec G, 2001, ENDOCRINOLOGY, V142, P4120, DOI 10.1210/en.142.9.4120; Le XD, 2000, J INTERF CYTOK RES, V20, P935, DOI 10.1089/10799900050198372; Lin Y, 2004, INT J CANCER, V109, P507, DOI 10.1002/ijc.11724; Masuya D, 2001, CANCER, V92, P2628, DOI 10.1002/1097-0142(20011115)92:10<2628::AID-CNCR1616>3.0.CO;2-F; Milde-Langosch K, 2003, BREAST CANCER RES TR, V79, P175, DOI 10.1023/A:1023929504884; Milligan L, 2000, ONCOGENE, V19, P5810, DOI 10.1038/sj.onc.1203965; MUKAIDA N, 1989, J IMMUNOL, V143, P1366; MUKAIDA N, 1994, J LEUKOCYTE BIOL, V56, P554, DOI 10.1002/jlb.56.5.554; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Newton TR, 1999, J BIOL CHEM, V274, P18827, DOI 10.1074/jbc.274.26.18827; Nurnberg W, 1999, J PATHOL, V189, P546, DOI 10.1002/(SICI)1096-9896(199912)189:4<546::AID-PATH487>3.0.CO;2-L; Osborne CK, 1998, BREAST CANCER RES TR, V51, P227, DOI 10.1023/A:1006132427948; Patel PS, 2002, J INTERF CYTOK RES, V22, P427, DOI 10.1089/10799900252952217; Philips A, 1998, MOL ENDOCRINOL, V12, P973, DOI 10.1210/me.12.7.973; Roebuck KA, 1999, J INTERF CYTOK RES, V19, P429, DOI 10.1089/107999099313866; SHEIKH MS, 1994, INVAS METAST, V14, P329; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Wardell SE, 2002, MOL CELL BIOL, V22, P5451, DOI 10.1128/MCB.22.15.5451-5466.2002; Xie KP, 2001, CYTOKINE GROWTH F R, V12, P375, DOI 10.1016/S1359-6101(01)00016-8; Xu L, 2000, ONCOL RES, V12, P97, DOI 10.3727/096504001108747567; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506; Zerbini LF, 2003, CANCER RES, V63, P2206	33	86	91	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6105	6114		10.1038/sj.onc.1207815	http://dx.doi.org/10.1038/sj.onc.1207815			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15208657	Green Accepted, Green Submitted			2022-12-28	WOS:000223261000010
J	Flores, I; Murphy, DJ; Swigart, LB; Knies, U; Evan, GI				Flores, I; Murphy, DJ; Swigart, LB; Knies, U; Evan, GI			Defining the temporal requirements for Myc in the progression and maintenance of skin neoplasia	ONCOGENE			English	Article						Myc; epidermis; hyperplasia; differentiation; oncogene inactivation	TERMINALLY DIFFERENTIATING CELLS; B-INDUCED APOPTOSIS; C-MYC; STEM-CELLS; EPIDERMAL DIFFERENTIATION; MOUSE EPIDERMIS; EXPRESSION; P63; KERATINOCYTES; PROLIFERATION	The homeostatic integrity of skin epidermis is maintained by a balance between keratinocyte proliferation, on one hand, and terminal differentiation combined with outward migration and shedding, on the other. Perturbation of this balance in favor of proliferation can result in hyperplasia and, potentially, tumorigenesis. We have previously described a reversible transgenic mouse model of epidermal neoplasia in which expression of an acutely regulatable form of Myc, MycER(TAM), is targeted to epidermis via the involucrin promoter. In this model, sustained activation of MycER(TM) induces a complex neoplastic lesion involving marked hyperplasia of less-differentiated suprabasal cells, angiogenesis and overt papillomatosis. Subsequent deactivation of MycER(TAM) triggers complete papilloma regression. Here, we provide evidence that Myc-induced papillomas are self-limiting because of the eventual differentiation of MycER(TAM)-expressing keratinocytes. Thus, keratinocyte differentiation eventually prevails over Myc-induced proliferation. We also show that regression of Myc-induced papillomas following MycER(TAM) deactivation occurs through a combination of growth arrest and irreversible differentiation. Finally, we demonstrate that transient deactivation of Myc is sufficient to expel keratinocytes irreversibly from the proliferative compartment and render them refractory to the mitogenic influence of subsequent Myc reactivation. Such observations illustrate the potential utility of even short-term inhibition of oncogenic lesions in the treatment of cancer.	Univ Calif San Francisco, Ctr Comprehens Canc, Canc Res Inst, San Francisco, CA 94143 USA; John Radcliffe Hosp, Inst Mol Med, Canc Res United Kingdom, Mol Oncol Labs, Oxford OX3 9DS, England	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Cancer Research UK; University of Oxford	Evan, GI (corresponding author), Univ Calif San Francisco, Ctr Comprehens Canc, Canc Res Inst, 2340 Sutter St,Room S236, San Francisco, CA 94143 USA.	gevan@cc.ucsf.edu	Murphy, Daniel/V-1079-2019; Flores, Ignacio/E-8304-2016	Murphy, Daniel/0000-0002-5538-5468; Flores, Ignacio/0000-0001-8789-6396				Arnold I, 2001, CURR BIOL, V11, P558, DOI 10.1016/S0960-9822(01)00154-3; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Dotto GP, 1999, CRIT REV ORAL BIOL M, V10, P442; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; Gandarillas A, 1999, EXP DERMATOL, V8, P71, DOI 10.1111/j.1600-0625.1999.tb00350.x; HERTLE MD, 1992, J CLIN INVEST, V89, P1892, DOI 10.1172/JCI115794; HUITFELDT HS, 1991, CARCINOGENESIS, V12, P2063, DOI 10.1093/carcin/12.11.2063; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; Koster MI, 2004, GENE DEV, V18, P126, DOI 10.1101/gad.1165104; Li ER, 2000, EXP DERMATOL, V9, P431, DOI 10.1034/j.1600-0625.2000.009006431.x; Liefer KM, 2000, CANCER RES, V60, P4016; MOORE JP, 1987, ONCOGENE RES, V2, P65; Parsa R, 1999, J INVEST DERMATOL, V113, P1099, DOI 10.1046/j.1523-1747.1999.00780.x; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Pellegrini G, 2001, P NATL ACAD SCI USA, V98, P3156, DOI 10.1073/pnas.061032098; POLAKOWSKA RR, 1994, DEV DYNAM, V199, P176, DOI 10.1002/aja.1001990303; REGNIER M, 1986, J INVEST DERMATOL, V87, P472, DOI 10.1111/1523-1747.ep12455517; ROOP DR, 1988, CANCER RES, V48, P3245; SCHWEIZER J, 1984, CELL, V37, P159, DOI 10.1016/0092-8674(84)90311-8; STOLER A, 1988, J CELL BIOL, V107, P427, DOI 10.1083/jcb.107.2.427; Waikel RL, 1999, ONCOGENE, V18, P4870, DOI 10.1038/sj.onc.1203040; WATT FM, 1984, J CELL BIOL, V98, P16, DOI 10.1083/jcb.98.1.16; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539	26	52	54	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2004	23	35					5923	5930		10.1038/sj.onc.1207796	http://dx.doi.org/10.1038/sj.onc.1207796			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15208685				2022-12-28	WOS:000222941100006
J	Duxbury, MS; Ito, H; Benoit, E; Zinner, MJ; Ashley, SW; Whang, EE				Duxbury, MS; Ito, H; Benoit, E; Zinner, MJ; Ashley, SW; Whang, EE			Overexpression of CEACAM6 promotes insulin-like growth factor I-induced pancreatic adenocarcinoma cellular invasiveness	ONCOGENE			English	Article						pancreatic adenocarcinoma; cancer; CEACAM6; insulin-like growth factor I; IGF-I invasion; Akt; Src; MMP-2	PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; TUMOR-NECROSIS-FACTOR; REACTING ANTIGEN NCA; FACTOR RECEPTOR; CANCER CELLS; CARCINOMA-CELLS; IGF-I; MATRIX METALLOPROTEINASE-2; ANTIBODY BY114; FAMILY-MEMBERS	Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) is a glycosylphosphatidylinositol-linked immunoglobulin superfamily member that is overexpressed in a variety of human cancers. We have recently reported that suppression of CEACAM6 expression impairs pancreatic adenocarcinoma progression in vivo. In order to characterize the mechanisms through which CEACAM6 influences the malignant phenotype, CEA-CAM6-overexpressing Capan2 pancreatic adenocarcinoma cells were established by stable transfection. We determined the effect of CEACAM6 overexpression on cellular invasiveness towards insulin-like growth factor I (IGF-I), a peptide of critical importance in pancreatic cancer malignant cellular behavior and tumor progression. IGF-I-induced cellular invasiveness and IGF-IR expression were significantly increased in clones overexpressing CEACAM6. Using inhibitory anti-IGF-IR antibody, a requirement for IGF-IR signaling in the enhanced invasiveness towards IGF-I induced by CEACAM6 overexpression was confirmed. CEACAM6-overexpressing clones exhibited increased Akt and c-Src kinase activities, as well as higher levels of matrix metalloproteinase-2 (MMP-2) expression and activity in the presence of IGF-I. While Akt kinase is both necessary and sufficient to induce IGF-IR upregulation, c-Sre kinase activity is necessary, but alone is insufficient to upregulate IGF-IR expression. CEACAM6 is an important determinant of pancreatic adenocarcinoma malignant cellular behavior and, together with its downstream targets, warrants further investigation as a therapeutic target in this disease.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Whang, EE (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Surg, 75 Francis St, Boston, MA 02115 USA.	ewhang1@partners.org						BASERGA R, 1994, CELL PROLIFERAT, V27, P63, DOI 10.1111/j.1365-2184.1994.tb01406.x; BERGMANN U, 1995, CANCER RES, V55, P2007; BERROZPE G, 1994, INT J CANCER, V58, P185, DOI 10.1002/ijc.2910580207; Brodt P, 2001, J BIOL CHEM, V276, P33608, DOI 10.1074/jbc.M102754200; Burfeind P, 1996, P NATL ACAD SCI USA, V93, P7263, DOI 10.1073/pnas.93.14.7263; Datta K, 2000, J BIOL CHEM, V275, P20700, DOI 10.1074/jbc.M909970199; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Dunn SE, 1998, CANCER RES, V58, P3353; Duxbury MS, 2004, ONCOGENE, V23, P465, DOI 10.1038/sj.onc.1207036; Ellenrieder V, 1999, ANN ONCOL, V10, P46, DOI 10.1023/A:1008380501633; Flossmann-Kast BBM, 1998, CANCER RES, V58, P3551; Gardner-Thorpe J, 2002, BIOCHEM BIOPH RES CO, V293, P391, DOI 10.1016/S0006-291X(02)00237-1; Guirouilh J, 2000, INT J ONCOL, V17, P777; HASEGAWA T, 1993, BRIT J CANCER, V67, P58, DOI 10.1038/bjc.1993.9; Ilantzis C, 2002, NEOPLASIA, V4, P151, DOI 10.1038/sj.neo.7900201; Ito H, 2003, SURGERY, V134, P221, DOI 10.1067/msy.2003.224; Jiang TY, 2003, J BIOL CHEM, V278, P15789, DOI 10.1074/jbc.M212525200; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KALTHOFF H, 1993, ONCOGENE, V8, P289; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; KODERA Y, 1993, BRIT J CANCER, V68, P130, DOI 10.1038/bjc.1993.300; Kuroki M, 2001, J LEUKOCYTE BIOL, V70, P543; Lazar-Molnar E, 2000, CYTOKINE, V12, P547, DOI 10.1006/cyto.1999.0614; Li SL, 2000, CANCER IMMUNOL IMMUN, V49, P243, DOI 10.1007/s002620000115; LOHR M, 1994, BRIT J CANCER, V69, P144, DOI 10.1038/bjc.1994.24; Long L, 1998, CANCER RES, V58, P3243; LONG L, 1994, CANCER RES, V54, P3732; Long L, 1998, EXP CELL RES, V238, P116, DOI 10.1006/excr.1997.3814; MACAULAY VM, 1992, BRIT J CANCER, V65, P311, DOI 10.1038/bjc.1992.65; MAYNE KM, 1993, BRIT J HAEMATOL, V83, P30, DOI 10.1111/j.1365-2141.1993.tb04627.x; Mira E, 1999, ENDOCRINOLOGY, V140, P1657, DOI 10.1210/en.140.4.1657; Murphy LO, 2001, BRIT J CANCER, V84, P926, DOI 10.1054/bjoc.2001.1698; Naumann M, 1996, GASTROENTEROLOGY, V110, P1215, DOI 10.1053/gast.1996.v110.pm8613012; Ordonez C, 2000, CANCER RES, V60, P3419; Ouban A, 2003, HUM PATHOL, V34, P803, DOI 10.1016/S0046-8177(03)00291-0; Park BK, 2001, CANCER RES, V61, P7647; PIETRZKOWSKI Z, 1993, CANCER RES, V53, P1102; Prisco M, 1997, MOL CELL BIOL, V17, P1084, DOI 10.1128/MCB.17.3.1084; RAITANO AB, 1990, PANCREAS, V5, P267, DOI 10.1097/00006676-199005000-00005; RESNICOFF M, 1994, CANCER RES, V54, P2218; Scholzel S, 2000, AM J PATHOL, V156, P595, DOI 10.1016/S0002-9440(10)64764-5; SELL C, 1995, CANCER RES, V55, P303; Shanmugathasan M, 2000, PATHOL INT, V50, P273, DOI 10.1046/j.1440-1827.2000.01047.x; Sipos B, 2003, VIRCHOWS ARCH, V442, P444, DOI 10.1007/s00428-003-0784-4; SKUBITZ KM, 1995, J IMMUNOL, V155, P5382; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; STRACKE ML, 1989, J BIOL CHEM, V264, P21544; Streuli CH, 1999, J MAMMARY GLAND BIOL, V4, P183, DOI 10.1023/A:1018729308878; Tanno S, 2001, CANCER RES, V61, P589; Tooze JA, 1995, EXP HEMATOL, V23, P1484; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Wu YL, 1996, J CELL PHYSIOL, V168, P499, DOI 10.1002/(SICI)1097-4652(199609)168:3<499::AID-JCP2>3.0.CO;2-K; Wu YP, 2002, CANCER RES, V62, P1030; Yawata A, 1998, ONCOGENE, V16, P2681, DOI 10.1038/sj.onc.1201792; Yoon A, 2001, MOL CELL BIOCHEM, V223, P1, DOI 10.1023/A:1017549222677; Zeng HY, 2003, BIOCHEM BIOPH RES CO, V302, P46, DOI 10.1016/S0006-291X(03)00107-4; Zhang DL, 2003, ONCOGENE, V22, P974, DOI 10.1038/sj.onc.1206197	58	31	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2004	23	34					5834	5842		10.1038/sj.onc.1207775	http://dx.doi.org/10.1038/sj.onc.1207775			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KW	15208677				2022-12-28	WOS:000222629800013
J	Cerisano, V; Aalto, Y; Perdichizzi, S; Bernard, G; Manara, MC; Benini, S; Cenacchi, G; Preda, P; Lattanzi, G; Nagy, B; Knuutila, S; Colombo, MP; Bernard, A; Picci, P; Scotlandi, K				Cerisano, V; Aalto, Y; Perdichizzi, S; Bernard, G; Manara, MC; Benini, S; Cenacchi, G; Preda, P; Lattanzi, G; Nagy, B; Knuutila, S; Colombo, MP; Bernard, A; Picci, P; Scotlandi, K			Molecular mechanisms of CD99-induced caspase-independent cell death and cell-cell adhesion in Ewing's sarcoma cells: actin and zyxin as key intracellular mediators	ONCOGENE			English	Article						CD99; Ewing's sarcoma; homotypic aggregation; apoptosis; zyxin; actin	MIC2 GENE-PRODUCT; REED-STERNBERG PHENOTYPE; PSEUDOAUTOSOMAL GENE; CD99 ENGAGEMENT; NEUROECTODERMAL TUMOR; MEMBRANE-PROTEIN; DOWN-REGULATION; T-CELLS; APOPTOSIS; PHOSPHATIDYLSERINE	CD99 is a unique 32-kDa cell surface molecule with broad cellular expression but still poorly understood biological functions. In cancer cells, CD99 is highly expressed in virtually all Ewing's sarcoma (ES). Engagement of CD99 induces fast homotypic aggregation of ES cells and caspase-independent apoptosis. In this study, we analysed signal transduction after CD99 engagement on ES cells. Findings obtained with selective inhibitors indicated that only actin cytoskeleton integrity was essential for cell-cell adhesion and apoptosis of ES cells. Indeed, CD99 stimulation induced actin repolymerization, further supporting the role of cytoskeleton in CD99 signaling. Gene expression profiling of ES cells after CD99 engagement showed modulation in the expression of 32 genes. Among the pool of upregulated genes reported to be involved in cell adhesion, we chose to analyse the role of zyxin, a cytoplasmic adherens junction protein found to play a role in the regulation of the actin cytoskeleton. Overexpression of zyxin after CD99 ligation was confirmed by real-time PCR and Western blot. Treatment of ES cells with zyxin antisense otigonucleotides inhibited CD99-induced cell aggregation and apoptosis, suggesting a functional role for this protein. Therefore, our findings indicate that CD99 functions occur through reorganization of cytoskeleton and identify actin and zyxin as the early signaling events driven by CD99 engagement.	Ist Ortoped Rizzoli, Lab Ric Oncol, I-40136 Bologna, Italy; Haartman Inst, Dept Pathol, FIN-00014 Helsinki, Finland; Haartman Inst, Dept Med Genet, FIN-00014 Helsinki, Finland; Univ Helsinki, FIN-00014 Helsinki, Finland; Hosp Archet, UMR 576, Unite INSERM, Nice 3, France; Univ Bologna, Dipartimento Clin Sci Radiol & Istocitopatol, Bologna, Italy; Ist Ortoped Rizzoli, ITOI CNR, Unit Bologna, I-40136 Bologna, Italy; Ist Nazl Studio & Cura Tumori, Immunotherapy & Gene Therapy Unit, I-20133 Milan, Italy	IRCCS Istituto Ortopedico Rizzoli; University of Helsinki; CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Bologna; IRCCS Istituto Ortopedico Rizzoli; Fondazione IRCCS Istituto Nazionale Tumori Milan	Scotlandi, K (corresponding author), Ist Ortoped Rizzoli, Lab Ric Oncol, I-40136 Bologna, Italy.	katia.scotlandi@ior.it	Scotlandi, Katia/J-9009-2016; Colombo, Mario P./V-7166-2017; Nagy, Balint/F-6943-2012; LATTANZI, GIOVANNA/P-8214-2015; Manara, Maria Cristina/K-3366-2018; Lattanzi, Giovanna/AAY-3186-2020; BENINI, STEFANIA/D-1804-2019; Picci, Piero/J-5979-2016	Scotlandi, Katia/0000-0001-6114-9499; Colombo, Mario P./0000-0003-0042-7955; LATTANZI, GIOVANNA/0000-0002-7103-8722; Manara, Maria Cristina/0000-0001-5686-720X; Lattanzi, Giovanna/0000-0002-7103-8722; BENINI, STEFANIA/0000-0003-0958-9088; Picci, Piero/0000-0002-8519-4101; CENACCHI, GIOVANNA/0000-0001-5824-3118				Alberti I, 2002, FASEB J, V16, P1946, DOI 10.1096/fj.02-0049fje; AMBROS IM, 1991, CANCER, V67, P1886, DOI 10.1002/1097-0142(19910401)67:7<1886::AID-CNCR2820670712>3.0.CO;2-U; AUSSEL C, 1993, BIOCHEMISTRY-US, V32, P10096, DOI 10.1021/bi00089a027; BANTING GS, 1989, MOL IMMUNOL, V26, P181, DOI 10.1016/0161-5890(89)90100-4; Beckerle MC, 1997, BIOESSAYS, V19, P949, DOI 10.1002/bies.950191104; BERNARD A, 1988, J IMMUNOL, V140, P1802; Bernard G, 2000, EUR J IMMUNOL, V30, P3061, DOI 10.1002/1521-4141(200010)30:10<3061::AID-IMMU3061>3.0.CO;2-M; Bernard G, 1997, J IMMUNOL, V158, P2543; BERNARD G, 1995, J IMMUNOL, V154, P26; Choi FY, 1998, J IMMUNOL, V161, P749; CRAWFORD AW, 1991, J BIOL CHEM, V266, P5847; Dworzak MN, 1999, BRIT J HAEMATOL, V105, P690, DOI 10.1046/j.1365-2141.1999.01426.x; Fidler I.J., 1997, CANC PRINCIPLES PRAC; Fisher C, 1998, Ann Diagn Pathol, V2, P401, DOI 10.1016/S1092-9134(98)80042-7; GELIN C, 1989, EMBO J, V8, P3253, DOI 10.1002/j.1460-2075.1989.tb08485.x; GELIN C, 1995, LEUCOCYTE TYPING, V5; GOODFELLOW PJ, 1986, SCIENCE, V234, P740, DOI 10.1126/science.2877492; Granter SR, 1996, HUM PATHOL, V27, P1273, DOI 10.1016/S0046-8177(96)90336-6; Hahn JH, 1997, J IMMUNOL, V159, P2250; Hahn MJ, 2000, FEBS LETT, V470, P350, DOI 10.1016/S0014-5793(00)01330-2; Jung KC, 2002, J KOREAN MED SCI, V17, P483, DOI 10.3346/jkms.2002.17.4.483; Kasinrerk W, 2000, IMMUNOL LETT, V71, P33, DOI 10.1016/S0165-2478(99)00165-0; Kettunen E, 2001, INT J CANCER, V91, P492, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1094>3.0.CO;2-M; Kim MK, 2003, FEBS LETT, V546, P379, DOI 10.1016/S0014-5793(03)00567-2; Kim SH, 1998, BLOOD, V92, P4287, DOI 10.1182/blood.V92.11.4287.423k41_4287_4295; Kim SH, 2000, BLOOD, V95, P294; KOVAR H, 1990, ONCOGENE, V5, P1067; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Mateo W, 2002, BLOOD, V100, P2882, DOI 10.1182/blood-2001-12-0217; Nix DA, 2001, J BIOL CHEM, V276, P34759, DOI 10.1074/jbc.M102820200; Nix DA, 1997, J CELL BIOL, V138, P1139, DOI 10.1083/jcb.138.5.1139; Pettersen RD, 1999, J IMMUNOL, V162, P7031; Pettersen RD, 2001, J IMMUNOL, V166, P4931, DOI 10.4049/jimmunol.166.8.4931; PREDA P, 1995, MICROSC RES TECHNIQ, V32, P75, DOI 10.1002/jemt.1070320108; RAMANI P, 1993, HISTOPATHOLOGY, V23, P557, DOI 10.1111/j.1365-2559.1993.tb01243.x; Schenkel AR, 2002, NAT IMMUNOL, V3, P143, DOI 10.1038/ni749; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Scotlandi K, 2000, CANCER RES, V60, P5134; Scotlandi K, 1996, CANCER RES, V56, P2434; Scotlandi K, 1996, HUM PATHOL, V27, P408, DOI 10.1016/S0046-8177(96)90115-X; Shen JC, 1998, MOL CARCINOGEN, V23, P13, DOI 10.1002/(SICI)1098-2744(199809)23:1<13::AID-MC2>3.0.CO;2-I; Sohn HW, 1998, AM J PATHOL, V153, P1937, DOI 10.1016/S0002-9440(10)65707-0; Sohn HW, 2001, J IMMUNOL, V166, P787, DOI 10.4049/jimmunol.166.2.787; Waclavicek M, 1998, J IMMUNOL, V161, P4671; Wingett D, 1999, CELL IMMUNOL, V193, P17, DOI 10.1006/cimm.1999.1470; Yoon SS, 2003, FEBS LETT, V540, P217, DOI 10.1016/S0014-5793(03)00268-0; Zen K, 1996, IMMUNOBIOLOGY, V195, P323, DOI 10.1016/S0171-2985(96)80049-0	47	83	91	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5664	5674		10.1038/sj.onc.1207741	http://dx.doi.org/10.1038/sj.onc.1207741			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15184883				2022-12-28	WOS:000222629500011
J	Saleem, A; Dutta, J; Malegaonkar, D; Rasheed, F; Rasheed, Z; Rajendra, R; Marshall, H; Luo, MJ; Li, HH; Rubin, EH				Saleem, A; Dutta, J; Malegaonkar, D; Rasheed, F; Rasheed, Z; Rajendra, R; Marshall, H; Luo, MJ; Li, HH; Rubin, EH			The topoisomerase I- and p53-binding protein topors is differentially expressed in normal and malignant human tissues and may function as a tumor suppressor	ONCOGENE			English	Article						topors; tumor suppressor; topoisomerase I; p53; ubiquitin E3 ligase	CHROMOSOME 9P; HUMAN CANCERS; PROSTATE-CANCER; HIGH-FREQUENCY; GENE; DELETION; LUNG; IDENTIFICATION; METHYLATION; REGION	Topors was identified recently as a human protein that binds to topoisomerase I and p53. Topors contains a highly conserved RING domain and localizes in promyelocytic leukemia nuclear bodies. Relatively little is known regarding topors expression patterns or function. We now demonstrate that topors mRNA and protein are widely expressed in normal human tissues. By contrast, topors mRNA and protein levels are decreased or undetectable in colon adenocarcinomas relative to normal colon tissue, and expression of the topors protein is not detectable in several colon cancer cell lines. The human TOPORS gene is located on chromosome 9p21, with loss of heterozygosity in this region frequently observed in several different malignancies. While we were unable to detect loss of heterozygosity of the TOPORS gene in 16 sporadic colon cancer cases, increased methylation of a CpG island in the TOPORS promoter was evident in colon adenocarcinoma specimens relative to matched normal tissues. Additional studies indicate that forced expression of topors inhibits cellular proliferation and is associated with an accumulation of cells in the G(0)/G(1) phase of the cell cycle. This effect is independent of the topors RING domain and maps to a C-terminal region of the protein. These results suggest that topors functions as a negative regulator of cell growth, and possibly as a tumor suppressor.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Dept Pharmacol, New Brunswick, NJ 08903 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Dept Mol Genet & Microbiol, New Brunswick, NJ USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Dept Med, New Brunswick, NJ USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Rubin, EH (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Dept Pharmacol, New Brunswick, NJ 08903 USA.	ehrubin@umdnj.edu			NATIONAL CANCER INSTITUTE [R01CA039662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059170] Funding Source: NIH RePORTER; NCI NIH HHS [CA39662] Funding Source: Medline; NIGMS NIH HHS [GM59170] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boutell C, 2003, J BIOL CHEM, V278, P36596, DOI 10.1074/jbc.M300776200; Boutell C, 2002, J VIROL, V76, P841, DOI 10.1128/JVI.76.2.841-850.2002; CHANG JY, 1992, BIOCHEM PHARMACOL, V43, P2443, DOI 10.1016/0006-2952(92)90325-D; Chu D, 2001, J BIOL CHEM, V276, P14004, DOI 10.1074/jbc.M010262200; Cui XF, 2000, J MOL DIAGN, V2, P29, DOI 10.1016/S1525-1578(10)60612-5; Devlin J, 1996, BRIT J CANCER, V73, P420, DOI 10.1038/bjc.1996.75; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; GIOVANELLA BC, 1989, SCIENCE, V246, P1046, DOI 10.1126/science.2555920; Haluska P, 1999, NUCLEIC ACIDS RES, V27, P2538, DOI 10.1093/nar/27.12.2538; He DL, 2003, CHINESE MED J-PEKING, V116, P1394; HERMAN JG, 1995, CANCER RES, V55, P4525; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; KAMB A, 1994, SCIENCE, V264, P440; Kim SK, 1997, CANCER RES, V57, P400; LI HH, 1995, GENOMICS, V26, P199, DOI 10.1016/0888-7543(95)80201-V; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Nuovo GJ, 1999, P NATL ACAD SCI USA, V96, P12754, DOI 10.1073/pnas.96.22.12754; Perinchery G, 1999, INT J CANCER, V83, P610, DOI 10.1002/(SICI)1097-0215(19991126)83:5<610::AID-IJC7>3.0.CO;2-2; Pollock PM, 2001, CANCER RES, V61, P1154; PUIG S, 1995, AM J HUM GENET, V57, P395; Rasheed ZA, 2002, EXP CELL RES, V277, P152, DOI 10.1006/excr.2002.5550; Schraml P, 2001, AM J PATHOL, V158, P593, DOI 10.1016/S0002-9440(10)64001-1; Waber P, 1997, ONCOGENE, V15, P1699, DOI 10.1038/sj.onc.1201336; Weger S, 2003, EXP CELL RES, V290, P13, DOI 10.1016/S0014-4827(03)00292-1; Wiest JS, 1997, CANCER RES, V57, P1; Zhou R, 1999, GENE, V235, P93, DOI 10.1016/S0378-1119(99)00203-6	30	37	39	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2004	23	31					5293	5300		10.1038/sj.onc.1207700	http://dx.doi.org/10.1038/sj.onc.1207700			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15107820				2022-12-28	WOS:000222491600005
J	Di Stefano, V; Blandino, G; Sacchi, A; Soddu, S; D'Orazi, G				Di Stefano, V; Blandino, G; Sacchi, A; Soddu, S; D'Orazi, G			HIPK2 neutralizes MDM2 inhibition rescuing p53 transcriptional activity and apoptotic function	ONCOGENE			English	Article						HIPK2; p53; ubiquitination; MDM2; nuclear export; apoptosis	INTERACTING PROTEIN KINASE-2; AUTOREGULATORY FEEDBACK LOOP; TUMOR-SUPPRESSOR PROTEIN; DNA-DAMAGE; P53-INDUCED APOPTOSIS; GENE AMPLIFICATION; GROWTH-CONTROL; PHOSPHORYLATION; DEGRADATION; CANCER	The p53 oncosuppressor protein is subject to negative regulation by MDM2, which efficiently inhibits its activity through an autoregulatory loop. In response to stress, however, p53 undergoes post-translational modi. cations that allow the protein to escape MDM2 control, accumulate, and become active. Recent studies have shown that, following DNA damage, the HIPK2 serine/ threonine kinase binds and phosphorylates p53, inducing p53 transcriptional activity and apoptotic function. Here, we investigated the role of HIPK2 in the activation of p53 in the presence of MDM2. We found that HIPK2 rescues p53 transcriptional activity overcoming MDM2 inhibition, and that restoration of this p53 function induces apoptosis. Recovery of p53-dependent apoptosis is achieved by preventing p53 nuclear export and ubiquitination mediated by MDM2 in vitro and in vivo following genotoxic stress. These results shed new light on the mechanisms by which the HIPK2/p53 pathway promotes apoptosis and suppression of tumorigenesis.	Regina Elena Inst Canc Res, Mol Oncogenesis Lab, Dept Expt Oncol, I-00158 Rome, Italy; Univ G DAnnunzio, Dept Oncol & Neurosci, I-66013 Chieti, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; G d'Annunzio University of Chieti-Pescara	D'Orazi, G (corresponding author), Regina Elena Inst Canc Res, Mol Oncogenesis Lab, Dept Expt Oncol, Via Messi Oro 156, I-00158 Rome, Italy.	dorazi@ifo.it	Soddu, Silvia/ABH-6774-2020; Blandino, Giovanni/B-1137-2013; D'Orazi, Gabriella/T-2792-2019; Soddu, Silvia/K-2467-2018	Soddu, Silvia/0000-0001-8526-0044; Blandino, Giovanni/0000-0002-6970-2241; D'Orazi, Gabriella/0000-0001-6876-9105; Soddu, Silvia/0000-0001-8526-0044	Telethon [GP0234Y01] Funding Source: Medline	Telethon(Fondazione Telethon)		Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Chen JD, 1996, MOL CELL BIOL, V16, P2445; Chene P, 2003, NAT REV CANCER, V3, P102, DOI 10.1038/nrc991; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Di Stefano V, 2004, EXP CELL RES, V293, P311, DOI 10.1016/j.yexcr.2003.09.032; Eymin B, 2002, ONCOGENE, V21, P2750, DOI 10.1038/sj.onc.1205359; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kim EJ, 2002, J BIOL CHEM, V277, P32020, DOI 10.1074/jbc.M200153200; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Leite KRM, 2001, MODERN PATHOL, V14, P428, DOI 10.1038/modpathol.3880330; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LUCA RMD, 1995, NATURE, V378, P203; MIYASHITA T, 1995, CELL, V80, P293; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PICKSLEY SM, 1993, BIOESSAYS, V15, P689, DOI 10.1002/bies.950151008; Polsky D, 2001, CANCER RES, V61, P7642; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Prives C, 1999, J PATHOL, V187, P112; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; Velculescu VE, 1996, CLIN CHEM, V42, P858; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wang Y, 2001, BMC Mol Biol, V2, P8, DOI 10.1186/1471-2199-2-8; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126	47	56	56	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2004	23	30					5185	5192		10.1038/sj.onc.1207656	http://dx.doi.org/10.1038/sj.onc.1207656			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	834AE	15122315				2022-12-28	WOS:000222382500008
J	Reagan-Shaw, S; Afaq, F; Aziz, MH; Ahmad, N				Reagan-Shaw, S; Afaq, F; Aziz, MH; Ahmad, N			Modulations of critical cell cycle regulatory events during chemoprevention of ultraviolet B-mediated responses by resveratrol in SKH-1 hairless mouse skin	ONCOGENE			English	Article						resveratrol; cell cycle; ultraviolet (UV); skin cancer	GREEN TEA POLYPHENOL; GENE-EXPRESSION; KAPPA-B; PHOTOCARCINOGENESIS; CANCER; ACTIVATION; PREVENTION; CARCINOMA; LIGHT; MICE	Multiple exposures to solar ultraviolet (UV) radiation cause critical damages that may lead to the development of several cutaneous disorders including skin cancer, the most frequently diagnosed malignancy in the USA. Therefore, efforts are needed to: (i) study the mechanism(s) of UV-mediated cutaneous damages, and (ii) design novel approaches for the management of skin cancer. 'Chemoprevention' via plant-based agents may be a useful approach for the management of neoplasia. Here, we evaluated the involvement of cell cycle regulatory molecules during resveratrol-mediated protection from multiple exposures of UVB ( 180 mJ/cm(2); on alternate days x 7 exposures) radiations in the SKH-1 hairless mouse skin. Resveratrol was topically applied on the skin of SKH-1 hairless mice at a dose of 10 mumol/mouse ( in 0.2 ml acetone; 30 min prior to each UVB exposure). Studies were performed at 24 h following the last UVB exposure. Topical application of resveratrol resulted in significant decrease in UVB-induced bi-fold skin thickness, hyperplasia, and infiltration of leukocytes. The data from immunoblot and/or immunohistochemical analyses revealed that multiple exposure to UVB radiations causes significant upregulation in: ( i) proliferating cell nuclear antigen ( PCNA), a marker of cellular proliferation, and ( ii) cyclin-dependent kinase (cdk)- 2, - 4 and - 6, cyclin-D1, and cyclin-D2. Resveratrol treatment resulted in significant downregulation in UV-mediated increases in these critical cell cycle regulatory proteins. An interesting observation of this study was that resveratrol treatment resulted in a further stimulation of UVB-mediated increases in cyclin kinase inhibitor WAF1/p21 and tumor suppressor p53. Further, resveratrol was also found to cause significant decreases in UVB-mediated upregulation of: ( i) the mitogen-activated protein kinase kinase, and ( ii) the 42 kDa isotype of mitogen-activated protein kinase ( MAPK). Thus, our data suggested that the antiproliferative effects of resveratrol might be mediated via modulation in the expression and function of cell cycle regulatory proteins cyclin-D1 and -D2, cdk-2, -4 and -6, and WAF1/p21. Our data further suggest that the modulation of cki-cyclin-cdk network by resveratrol may be associated with inhibition of the MAPK pathway. We suggest that resveratrol may be useful for the prevention of UVB-mediated cutaneous damages including skin cancer.	Univ Wisconsin, Med Sci Ctr, Dept Dermatol, Madison, WI 53706 USA; Univ Wisconsin, Ctr Comprehens Canc, Madison, WI USA; Univ Wisconsin, Mol & Environm Toxicol Ctr, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Ahmad, N (corresponding author), Univ Wisconsin, Med Sci Ctr, Dept Dermatol, 1300 Univ Ave, Madison, WI 53706 USA.	nahmad@wisc.edu	Ahmad, Nihal/AAR-4249-2021	Ahmad, Nihal/0000-0002-4239-9887	NATIONAL CANCER INSTITUTE [R03CA099076, R03CA098368] Funding Source: NIH RePORTER; NCI NIH HHS [R03 CA 99076, R03 CA 98368] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abrieu A, 1997, EMBO J, V16, P6407, DOI 10.1093/emboj/16.21.6407; Adhami VM, 2003, NEOPLASIA, V5, P74, DOI 10.1016/S1476-5586(03)80019-2; Adhami VM, 2001, BIOCHEM BIOPH RES CO, V288, P579, DOI 10.1006/bbrc.2001.5819; Afaq F, 2003, ONCOGENE, V22, P9254, DOI 10.1038/sj.onc.1207035; Afaq F, 2003, TOXICOL APPL PHARM, V186, P28, DOI 10.1016/S0041-008X(02)00014-5; Afaq F, 2002, FRONT BIOSCI-LANDMRK, V7, pD784, DOI 10.2741/afaq; Ahmad N, 2001, CLIN CANCER RES, V7, P1466; Ahmad N, 2001, SKIN PHARMACOL APPL, V14, P69, DOI 10.1159/000056336; Ahmed NU, 1999, J DERMATOL SCI, V19, P175, DOI 10.1016/S0923-1811(98)00068-1; Bickers D R, 2000, J Dermatol, V27, P691; Black HS, 1997, J PHOTOCH PHOTOBIO B, V40, P29, DOI 10.1016/S1011-1344(97)00021-3; Bowden GT, 2004, NAT REV CANCER, V4, P23, DOI 10.1038/nrc1253; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Chen WX, 1999, ONCOGENE, V18, P7469, DOI 10.1038/sj.onc.1203210; Chen WX, 2001, ONCOGENE, V20, P3921, DOI 10.1038/sj.onc.1204530; de Gruijl FR, 2002, SKIN PHARMACOL APPL, V15, P316, DOI 10.1159/000064535; Dreher F, 2001, CURR PROBL DERMATOL, V29, P157; Eckert RL, 2002, J INVEST DERM SYMP P, V7, P36, DOI 10.1046/j.1523-1747.2002.19634.x; Einspahr JG, 2003, RECENT RESULTS CANC, V163, P151; F'guyer S, 2003, PHOTODERMATOL PHOTO, V19, P56, DOI 10.1034/j.1600-0781.2003.00019.x; Gillitzer R, 2001, J LEUKOCYTE BIOL, V69, P513; Hatoko M, 2001, ANN PLAS SURG, V47, P425, DOI 10.1097/00000637-200110000-00011; Katiyar SK, 2001, TOXICOL APPL PHARM, V176, P110, DOI 10.1006/taap.2001.9276; Katiyar SK, 1999, CARCINOGENESIS, V20, P2117, DOI 10.1093/carcin/20.11.2117; Katiyar SK, 2001, J LEUKOCYTE BIOL, V69, P719; Katiyar SK, 1997, JNCI-J NATL CANCER I, V89, P556, DOI 10.1093/jnci/89.8.556; Kim AL, 2002, PHOTOCHEM PHOTOBIOL, V75, P58, DOI 10.1562/0031-8655(2002)075<0058:SSAOCE>2.0.CO;2; Kulms D, 2002, J DERMATOL, V29, P189, DOI 10.1111/j.1346-8138.2002.tb00248.x; Lu YP, 1999, CANCER RES, V59, P4591; Lu YP, 2000, CANCER RES, V60, P4785; Murphy M, 2002, J CLIN PATHOL, V55, P829, DOI 10.1136/jcp.55.11.829; Naylor MF, 1997, ARCH DERMATOL, V133, P373, DOI 10.1001/archderm.133.3.373; Petrocelli T, 2000, ONCOGENE, V19, P4480, DOI 10.1038/sj.onc.1203808; Petrocelli T, 1996, ONCOGENE, V12, P1387; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Sander CS, 2003, BRIT J DERMATOL, V148, P913, DOI 10.1046/j.1365-2133.2003.05303.x; Scharffetter-Kochanek K, 1997, BIOL CHEM, V378, P1247; Terada Y, 1999, KIDNEY INT, V56, P1258, DOI 10.1046/j.1523-1755.1999.00704.x; Terada Y, 1999, KIDNEY INT, V56, P1378, DOI 10.1046/j.1523-1755.1999.00665.x; Tyrrell RM, 1996, BIOESSAYS, V18, P139, DOI 10.1002/bies.950180210; Wang WG, 2003, CANCER BIOL THER, V2, pS55; Yamamoto H, 2002, CANCER RES, V62, P1641; Yano S, 2003, BIOCHEM BIOPH RES CO, V301, P841, DOI 10.1016/S0006-291X(03)00060-3	43	100	110	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2004	23	30					5151	5160		10.1038/sj.onc.1207666	http://dx.doi.org/10.1038/sj.onc.1207666			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	834AE	15122319				2022-12-28	WOS:000222382500005
J	Guccione, E; Lethbridge, KJ; Killick, N; Leppard, KN; Banks, L				Guccione, E; Lethbridge, KJ; Killick, N; Leppard, KN; Banks, L			HPV E6 proteins interact with specific PML isoforms and allow distinctions to be made between different POD structures	ONCOGENE			English	Article						HPV; E6; PML; PODs	HUMAN-PAPILLOMAVIRUS TYPE-16; ACUTE PROMYELOCYTIC LEUKEMIA; CERVICAL-CARCINOMA CELLS; NUCLEAR-BODY FORMATION; HUMAN CYTOMEGALOVIRUS; PREMATURE SENESCENCE; HUMAN KERATINOCYTES; ONCOGENIC DOMAINS; SP100 PROTEINS; CAPSID PROTEIN	Mucosal human papillomaviruses (HPVs) are the causative agents of a number of human pathologies, including benign condylomas, as well as of the majority of cervical cancers and their high-grade precursor lesions. Although the viral E6 protein is known to be essential for driving malignant progression of HPV-infected cells, there are still many uncertainties about its mode of action. In this study, we have analysed the intracellular distribution of the E6 oncoproteins from the high-risk HPV-18 and the low-risk HPV-11. We show that both E6 proteins localize within the nucleus in nuclear bodies that are confocal with the promyelocytic leukaemia (PML) protein. Using a panel of different PML isoforms, we demonstrate specific co-localization between the E6 proteins and PML isoforms I-IV, but not with PML isoforms V and VI. We also demonstrate the interaction between E6 and a subset of PML isoforms in vivo. As a consequence of this interaction, the insoluble form of PML IV is destabilized by HPV-18 E6 through a proteasome-dependent pathway. Interestingly, both HPV-11 E6 and HPV-18 E6 can readily overcome PML IV-induced cellular senescence in primary cells. These results show separable functions for different PML isoforms that are specifically targeted by the HPV E6 oncoproteins.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England	International Center for Genetic Engineering & Biotechnology (ICGEB); University of Warwick	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.	banks@icgeb.org	guccione, ernesto/G-9874-2011; Leppard, Keith N/A-1853-2009	Leppard, Keith N/0000-0003-2155-7919				Ahn JH, 1997, J VIROL, V71, P4599, DOI 10.1128/JVI.71.6.4599-4613.1997; Ahn JH, 1998, MOL CELL BIOL, V18, P4899, DOI 10.1128/MCB.18.8.4899; ALCALAY M, 1992, P NATL ACAD SCI USA, V89, P4840, DOI 10.1073/pnas.89.11.4840; Alcalay M, 1998, MOL CELL BIOL, V18, P1084, DOI 10.1128/MCB.18.2.1084; Alvarez-Salas LM, 1998, P NATL ACAD SCI USA, V95, P1189, DOI 10.1073/pnas.95.3.1189; ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; BARBOSA MS, 1989, ONCOGENE, V4, P1529; Becker KA, 2003, VIROLOGY, V314, P161, DOI 10.1016/S0042-6822(03)00447-1; BEDELL MA, 1989, J VIROL, V63, P1247, DOI 10.1128/JVI.63.3.1247-1255.1989; Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; Butz K, 2000, P NATL ACAD SCI USA, V97, P6693, DOI 10.1073/pnas.110538897; CHEN Z, 1992, LEUKEMIA LYMPHOMA, V8, P253, DOI 10.3109/10428199209051004; Day PM, 1998, J VIROL, V72, P142, DOI 10.1128/JVI.72.1.142-150.1998; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DIPAOLO J A, 1986, Toxicologic Pathology, V14, P417; DOEBERITZ MV, 1992, INT J CANCER, V51, P831; Duprez E, 1999, J CELL SCI, V112, P381; DURST M, 1987, ONCOGENE, V1, P251; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EVERETT RD, 1994, EMBO J, V13, P5062, DOI 10.1002/j.1460-2075.1994.tb06835.x; Everett RD, 1998, J VIROL, V72, P6581, DOI 10.1128/JVI.72.8.6581-6591.1998; Ferbeyre G, 2000, GENE DEV, V14, P2015; Florin L, 2002, VIROLOGY, V295, P97, DOI 10.1006/viro.2002.1360; Florin L, 2002, J VIROL, V76, P10009, DOI 10.1128/JVI.76.19.10009-10014.2002; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P10978, DOI 10.1073/pnas.97.20.10978; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Guccione E, 2002, VIROLOGY, V293, P20, DOI 10.1006/viro.2001.1290; Heino P, 2000, VIROLOGY, V276, P304, DOI 10.1006/viro.2000.0342; Ishov AM, 2002, J VIROL, V76, P7705, DOI 10.1128/JVI.76.15.7705-7712.2002; Jang MS, 2002, BIOCHEM BIOPH RES CO, V295, P495, DOI 10.1016/S0006-291X(02)00699-X; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Jiang M, 2002, ONCOGENE, V21, P6041, DOI 10.1038/sj.onc.1205878; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; KANDA T, 1988, VIROLOGY, V165, P321, DOI 10.1016/0042-6822(88)90694-0; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; Li H, 2000, CURR OPIN CELL BIOL, V12, P641, DOI 10.1016/S0955-0674(00)00144-7; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Muller S, 1999, J VIROL, V73, P5137; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; MUNGER K, 1989, J VIROL, V63, P4417; Muratani M, 2002, NAT CELL BIOL, V4, P106, DOI 10.1038/ncb740; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Pearson M, 2001, ONCOGENE, V20, P7250, DOI 10.1038/sj.onc.1204856; Pim D, 1997, ONCOGENE, V15, P257, DOI 10.1038/sj.onc.1201202; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Swindle CS, 1999, J VIROL, V73, P1001, DOI 10.1128/JVI.73.2.1001-1009.1999; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; VOUSDEN KH, 1988, ONCOGENE RES, V3, P167; Wells SI, 2000, EMBO J, V19, P5762, DOI 10.1093/emboj/19.21.5762; Wiesmeijer K, 2002, J STRUCT BIOL, V140, P180, DOI 10.1016/S1047-8477(02)00529-4; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; Wu WS, 2001, MOL CELL BIOL, V21, P2259, DOI 10.1128/MCB.21.7.2259-2268.2001; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690; ZUR HH, 1987, APPL PATHOL, V5, P19	61	30	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2004	23	27					4662	4672		10.1038/sj.onc.1207631	http://dx.doi.org/10.1038/sj.onc.1207631			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZX	15107834				2022-12-28	WOS:000221799200002
J	Shigesada, K; van de Sluis, B; Liu, PP				Shigesada, K; van de Sluis, B; Liu, PP			Mechanism of leukemogenesis by the inv(16) chimeric gene CBFB/PEBP2B-MHY11	ONCOGENE			English	Article						CBF beta-MYH11; CBF beta-SMMHC; inv(16); leukemia; hematopoiesis	ACUTE MYELOID-LEUKEMIA; MYOSIN HEAVY-CHAIN; SMOOTH-MUSCLE MYOSIN; CBF-BETA-SMMHC; ZINC-FINGER PROTEIN; TRANSCRIPTION FACTOR; FUSION GENE; DNA-BINDING; RUNT DOMAIN; MYELOGENOUS LEUKEMIA	Inv(16)(p13q22) is associated with acute myeloid leukemia subtype M4Eo that is characterized by the presence of myelomonocytic blasts and atypical eosinophils. This chromosomal rearrangement results in the fusion of CBFB and MYH11 genes. CBFbeta normally interacts with RUNX1 to form a transcriptionally active nuclear complex. The MYH11 gene encodes the smooth muscle myosin heavy chain. The CBFbeta-SMMHC fusion protein is capable of binding to RUNX1 and form dimers and multimers through its myosin tail. Previous results from transgenic mouse models show that Cbfb-MYH11 is able to inhibit dominantly Runx1 function in hematopoiesis, and is a key player in the pathogenesis of leukemia. In recent years, molecular and cellular biological studies have led to the proposal of several models to explain the function of CBFbeta-SMMHC. In this review, we will first focus our attention on the molecular mechanisms proposed in the recent publications. We will next examine recent gene expression pro. ling studies on inv(16) leukemia cells. Finally, we will describe a recent study from one of our labs on the identification of cooperating genes for leukemogenesis with CBFB-MYH11.	Kyoto Univ, Inst Virus Res, Dept Cell Biol, Kyoto 6068507, Japan; NHGRI, Oncogenesis & Dev Sect, NIH, Bethesda, MD 20892 USA	Kyoto University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Shigesada, K (corresponding author), Kyoto Univ, Inst Virus Res, Dept Cell Biol, Kyoto 6068507, Japan.	kshigesa@virus.kyoto-u.ac.jp; pliu@mail.nih.gov	Liu, Paul/A-7976-2012	Liu, Paul/0000-0002-6779-025X	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000030, ZIAHG000030] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Abdollahi A, 1997, ONCOGENE, V14, P1973, DOI 10.1038/sj.onc.1201034; Adya N, 1998, MOL CELL BIOL, V18, P7432, DOI 10.1128/MCB.18.12.7432; Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Astrom AK, 1999, CANCER RES, V59, P918; Backstrom S, 2002, J MOL BIOL, V322, P259, DOI 10.1016/S0022-2836(02)00702-7; Bravo J, 2001, NAT STRUCT BIOL, V8, P371, DOI 10.1038/86264; Cameron ER, 2003, BLOOD CELL MOL DIS, V30, P194, DOI 10.1016/S1079-9796(03)00031-7; Cao WS, 1997, ONCOGENE, V15, P1315, DOI 10.1038/sj.onc.1201305; Cao WS, 1998, J BIOL CHEM, V273, P31534, DOI 10.1074/jbc.273.47.31534; Care RS, 2003, BRIT J HAEMATOL, V121, P775, DOI 10.1046/j.1365-2141.2003.04362.x; Castilla LH, 1999, NAT GENET, V23, P144, DOI 10.1038/13776; Castilla LH, 2004, P NATL ACAD SCI USA, V101, P4924, DOI 10.1073/pnas.0400930101; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; Chung CH, 2002, NAT GENET, V32, P533, DOI 10.1038/ng1038; COFFEY RJ, 1988, MOL CELL BIOL, V8, P3088, DOI 10.1128/MCB.8.8.3088; Debernardi S, 2003, GENE CHROMOSOME CANC, V37, P149, DOI 10.1002/gcc.10198; Dunant NM, 2000, CELL SIGNAL, V12, P317, DOI 10.1016/S0898-6568(00)00073-5; Durst KL, 2003, MOL CELL BIOL, V23, P607, DOI 10.1128/MCB.23.2.607-619.2003; ERICKSON P, 1992, BLOOD, V80, P1825; Fortunel N, 2000, Hematol J, V1, P126, DOI 10.1038/sj.thj.6200021; Gilliland DG, 2002, BLOOD, V100, P1532, DOI 10.1182/blood-2002-02-0492; Gilliland DG, 2002, SEMIN HEMATOL, V39, P6, DOI 10.1053/shem.2002.36921; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Guo WH, 2002, ONCOGENE, V21, P8351, DOI 10.1038/sj.onc.1206037; Hanlon L, 2003, J VIROL, V77, P1059, DOI 10.1128/JVI.77.2.1059-1068.2003; Haviernik P, 2002, J GEN VIROL, V83, P819, DOI 10.1099/0022-1317-83-4-819; Hensen K, 2002, CANCER RES, V62, P1510; Huang G, 2001, EMBO J, V20, P723, DOI 10.1093/emboj/20.4.723; Huang G, 2004, BLOOD, V104, p105A, DOI 10.1182/blood.V104.11.358.358; Huang SM, 2001, ONCOGENE, V20, P2134, DOI 10.1038/sj.onc.1204298; Ikebe M, 2001, J BIOL CHEM, V276, P30293, DOI 10.1074/jbc.M101969200; Imai Y, 2004, MOL CELL BIOL, V24, P1033, DOI 10.1128/MCB.24.3.1033-1043.2004; Inoue K, 2003, BLOOD CELL MOL DIS, V30, P157, DOI 10.1016/S1079-9796(03)00032-9; Kalev-Zylinska ML, 2003, DEV DYNAM, V228, P323, DOI 10.1002/dvdy.10388; Kanno Y, 1998, MOL CELL BIOL, V18, P4252, DOI 10.1128/MCB.18.7.4252; Kanto S, 2000, LEUKEMIA, V14, P1253, DOI 10.1038/sj.leu.2401821; Kas K, 1998, J BIOL CHEM, V273, P23026, DOI 10.1074/jbc.273.36.23026; Kas K, 1997, NAT GENET, V15, P170, DOI 10.1038/ng0297-170; Kogan SC, 1998, P NATL ACAD SCI USA, V95, P11863, DOI 10.1073/pnas.95.20.11863; Kohlmann A, 2003, GENE CHROMOSOME CANC, V37, P396, DOI 10.1002/gcc.10225; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kummalue T, 2002, MOL CELL BIOL, V22, P8278, DOI 10.1128/MCB.22.23.8278-8291.2002; Kundu M, 2002, BLOOD, V100, P2449, DOI 10.1182/blood-2002-04-1064; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; LIU P, 1994, COLD SPRING HARB SYM, V59, P547, DOI 10.1101/SQB.1994.059.01.061; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Liu PP, 1996, GENE CHROMOSOME CANC, V16, P77, DOI 10.1002/(SICI)1098-2264(199606)16:2<77::AID-GCC1>3.0.CO;2-#; LIU PP, 1995, BLOOD, V85, P2289, DOI 10.1182/blood.V85.9.2289.bloodjournal8592289; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; LU J, 1995, MOL CELL BIOL, V15, P1651; Lukasik SM, 2002, NAT STRUCT BIOL, V9, P674, DOI 10.1038/nsb831; Lutterbach B, 1999, P NATL ACAD SCI USA, V96, P12822, DOI 10.1073/pnas.96.22.12822; Miller JD, 2001, BLOOD, V97, P2248, DOI 10.1182/blood.V97.8.2248; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Otto F, 2003, LEUKEMIA, V17, P1677, DOI 10.1038/sj.leu.2403007; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Schnittger S, 2003, BLOOD, V102, P2746, DOI 10.1182/blood-2003-03-0880; Schoch C, 2002, P NATL ACAD SCI USA, V99, P10008, DOI 10.1073/pnas.142103599; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; Sohn RL, 1997, J MOL BIOL, V266, P317, DOI 10.1006/jmbi.1996.0790; Spengler D, 1997, EMBO J, V16, P2814, DOI 10.1093/emboj/16.10.2814; Stewart M, 1997, P NATL ACAD SCI USA, V94, P8646, DOI 10.1073/pnas.94.16.8646; Tahirov TH, 2001, CELL, V104, P755, DOI 10.1016/S0092-8674(01)00271-9; Tang YY, 2000, J BIOL CHEM, V275, P39579, DOI 10.1074/jbc.M007350200; TRYBUS KM, 1984, J BIOL CHEM, V259, P8564; Trybus KM, 1997, P NATL ACAD SCI USA, V94, P48, DOI 10.1073/pnas.94.1.48; VIEILLEGROSJEAN I, 1995, J BIOL CHEM, V270, P4544, DOI 10.1074/jbc.270.9.4544; Voz ML, 2000, CANCER RES, V60, P106; Voz ML, 1998, ONCOGENE, V16, P1409, DOI 10.1038/sj.onc.1201660; WADA M, 2004, ONCOGENE, V26, P26; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Warren AJ, 2000, EMBO J, V19, P3004, DOI 10.1093/emboj/19.12.3004; Wijmenga C, 1996, P NATL ACAD SCI USA, V93, P1630, DOI 10.1073/pnas.93.4.1630; WISNIEWSKI D, 1994, LEUKEMIA, V8, P688; WOLFF L, 1991, J VIROL, V65, P3607, DOI 10.1128/JVI.65.7.3607-3616.1991; Wu XL, 2003, SCIENCE, V300, P1749, DOI 10.1126/science.1083413; Xu JQ, 1996, J CELL BIOL, V134, P53, DOI 10.1083/jcb.134.1.53; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303	81	62	65	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2004	23	24					4297	4307		10.1038/sj.onc.1207748	http://dx.doi.org/10.1038/sj.onc.1207748			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823BZ	15156186				2022-12-28	WOS:000221586000015
J	Mayhew, CN; Perkin, LM; Zhang, XP; Sage, J; Jacks, T; Knudsen, ES				Mayhew, CN; Perkin, LM; Zhang, XP; Sage, J; Jacks, T; Knudsen, ES			Discrete signaling pathways participate in RB-dependent responses to chemotherapeutic agents	ONCOGENE			English	Article						cell cycle checkpoints; chemotherapeutics; immortalization; thymidylate synthase; retinoblastoma tumor suppressor	RETINOBLASTOMA TUMOR-SUPPRESSOR; CELL-CYCLE ARREST; LARGE T-ANTIGEN; DNA-DAMAGE; FUNCTIONAL INACTIVATION; THYMIDYLATE SYNTHETASE; GENE-EXPRESSION; G(1) ARREST; P53; PROTEIN	The retinoblastoma (RB) tumor suppressor has been proposed to function as a key mediator of cell cycle checkpoints induced by chemotherapeutic agents. However, these prior studies have relied on embryonic fibroblasts harboring chronic loss of RB, a condition under which compensation of RB functions is known to occur. Here we utilized primary adult. broblasts derived from mice harboring loxP sites flanking exon 3 of the Rb gene to delineate the action of RB in the chemotherapeutic response. In this system we find that targeted disruption of Rb leads to little overt change in cell cycle distribution. However, these cells exhibited deregulation of RB/E2F target genes and became aneuploid following culture in the absence of RB. When challenged with both DNA damaging and antimetabolite chemotherapeutics, RB was required for primary adult cells to undergo DNA damage checkpoint responses and loss of RB resulted in enhanced aneuploidy following challenge. In contrast, following spontaneous immortalization and the loss of functional p53 signaling, the antimetabolite 5-fluorouracil (5-FU) failed to induce arrest despite the presence of RB. In these immortal cultures RB/E2F targets were deregulated in a complex, gene-specific manner and RB was required for the checkpoint response to camptothecin (CPT). Mechanistic analyses of the checkpoint responses in primary cells indicated that loss of RB leads to increased p53 signaling and decreased viability following both CPT and 5-FU treatment. However, the mechanism through which these agents act to facilitate cell cycle inhibition through RB were distinct. These studies underscore the critical role of RB in DNA-damage checkpoint signaling and demonstrate that RB mediates chemotherapeutic-induced cell cycle inhibition in adult. broblasts by distinct mechanisms.	Univ Cincinnati, Coll Med, Dept Cell Biol, Vontz Ctr Mol Studies, Cincinnati, OH 45267 USA; MIT, Ctr Canc Res, Dept Biol, Cambridge, MA 02139 USA; MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA	University System of Ohio; University of Cincinnati; Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Knudsen, ES (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol, Vontz Ctr Mol Studies, Cincinnati, OH 45267 USA.	erik.knudsen@uc.edu	Mayhew, Christopher N/AGB-4929-2022		NATIONAL CANCER INSTITUTE [T32CA059268] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA 59268] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Angus SP, 2002, J BIOL CHEM, V277, P44376, DOI 10.1074/jbc.M205911200; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Avni D, 2003, MOL CELL, V12, P735, DOI 10.1016/S1097-2765(03)00355-1; Balsitis SJ, 2003, MOL CELL BIOL, V23, P9094, DOI 10.1128/MCB.23.24.9094-9103.2003; Banerjee D, 2002, BBA-MOL BASIS DIS, V1587, P164, DOI 10.1016/S0925-4439(02)00079-0; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Bartkova J, 1997, Prog Cell Cycle Res, V3, P211; Berkovich E, 2003, ONCOGENE, V22, P161, DOI 10.1038/sj.onc.1206144; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Brugarolas J, 1999, P NATL ACAD SCI USA, V96, P1002, DOI 10.1073/pnas.96.3.1002; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Di Leonardo A, 1997, CANCER RES, V57, P1013; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EL DW, 1993, CELL, V75, P817; Flatt PM, 2000, DRUG METAB REV, V32, P283, DOI 10.1081/DMR-100102335; Guo N, 2000, J BIOL CHEM, V275, P1715, DOI 10.1074/jbc.275.3.1715; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Harrington EA, 1998, P NATL ACAD SCI USA, V95, P11945, DOI 10.1073/pnas.95.20.11945; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Helt AM, 2003, CARCINOGENESIS, V24, P159, DOI 10.1093/carcin/24.2.159; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Knudsen KE, 1999, J BIOL CHEM, V274, P27632, DOI 10.1074/jbc.274.39.27632; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; Lan ZD, 2002, J BIOL CHEM, V277, P8372, DOI 10.1074/jbc.M108906200; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lentini L, 2002, NEOPLASIA, V4, P380, DOI 10.1038/sj.neo.7900256; LI WW, 1995, P NATL ACAD SCI USA, V92, P10436, DOI 10.1073/pnas.92.22.10436; Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074; Longley DB, 2002, CANCER RES, V62, P2644; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MacPherson D, 2003, MOL CELL BIOL, V23, P1044, DOI 10.1128/MCB.23.3.1044-1053.2003; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Markey MP, 2002, CANCER RES, V62, P6587; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; MUDRAK I, 1994, MOL CELL BIOL, V14, P1886, DOI 10.1128/MCB.14.3.1886; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; OGRIS E, 1993, J VIROL, V67, P1765, DOI 10.1128/JVI.67.4.1765-1771.1993; Peters GJ, 2002, BBA-MOL BASIS DIS, V1587, P194, DOI 10.1016/S0925-4439(02)00082-0; Philips A, 1998, ONCOGENE, V16, P1373, DOI 10.1038/sj.onc.1201655; Polager S, 2002, ONCOGENE, V21, P437, DOI 10.1038/sj.onc.1205102; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; RITTLING SR, 1992, ONCOGENE, V7, P935; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; SANTI DV, 1974, BIOCHEMISTRY-US, V13, P471, DOI 10.1021/bi00700a012; Siddiqui H, 2003, MOL CELL BIOL, V23, P7719, DOI 10.1128/MCB.23.21.7719-7731.2003; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; SMITH ML, 1994, EXP CELL RES, V215, P386, DOI 10.1006/excr.1994.1356; SOMMER H, 1974, BIOCHEM BIOPH RES CO, V57, P689, DOI 10.1016/0006-291X(74)90601-9; Song SY, 1998, P NATL ACAD SCI USA, V95, P2290, DOI 10.1073/pnas.95.5.2290; Stewart ZA, 2001, CHEM RES TOXICOL, V14, P243, DOI 10.1021/tx000199t; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Zhang HS, 2001, ONCOGENE, V20, P3134, DOI 10.1038/sj.onc.1204338; Zheng L, 2002, ADV CANCER RES, V85, P13, DOI 10.1016/S0065-230X(02)85002-3	77	38	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4107	4120		10.1038/sj.onc.1207503	http://dx.doi.org/10.1038/sj.onc.1207503			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15064736				2022-12-28	WOS:000221520200009
J	Preto, A; Singhrao, SK; Haughton, MF; Kipling, D; Wynford-Thomas, D; Jones, CJ				Preto, A; Singhrao, SK; Haughton, MF; Kipling, D; Wynford-Thomas, D; Jones, CJ			Telomere erosion triggers growth arrest but not cell death in human cancer cells retaining wild-type p53: implications for antitelomerase therapy	ONCOGENE			English	Article						p53; telomerase; cancer; senescence; therapy	THYROID EPITHELIAL-CELLS; TUMOR-SUPPRESSOR GENE; LIFE-SPAN; HUMAN FIBROBLASTS; MUTATIONS; SENESCENCE; INHIBITION; EXPRESSION; MECHANISMS; LINES	Telomerase activity in tumours is often associated with p53 mutation. Many antitelomerase therapies take advantage of the inability of cells expressing mutant p53 to undergo replicative senescence, since this allows telomere erosion to continue until 'crisis', hence providing the desired cytotoxic effect. However, some tumour types, including breast, melanomas and thyroid, retain wild-type p53 function and the effectiveness of antitelomerase therapies in such tumour cells have not been adequately addressed. To explore this, we made use of two thyroid cancer cell lines K1 and K2, which retain wt p53. Telomere erosion induced by the expression of a dominant-negative (DN) hTERT resulted in delayed onset of growth arrest in K1 and K2 cells, reminiscent of replicative senescence, with low levels of BrdU labelling and apoptosis, associated with high p21(WAF1) and senescence-associated beta galactosidase expression. In contrast, abrogation of p53 function by the expression of HPV16 E6 in K1 and K2 cells either at the same time as DNhTERT or just prior to the onset of senescence allowed cells to continue growing until 'crisis'. Likewise, microinjection of a p53 neutralizing antibody into 'senescent' K1 DNhTERT cells permitted re-entry into the cell cycle. We conclude that thyroid tumour cells with wild-type p53 retain an intact p53-mediated growth arrest response to telomere erosion. This raises the intriguing question of why, therefore, p53 mutation is not selected for in such cancers, and also calls into question the therapeutic value of telomerase inhibitors in such cases.	Univ Wales Coll Med, Dept Pathol, Cardiff CF14 4XN, S Glam, Wales; Univ Porto, IPATIMUP, Inst Mol Pathol & Immunol, P-4200465 Oporto, Portugal	Cardiff University; Universidade do Porto	Jones, CJ (corresponding author), Univ Wales Coll Med, Dept Pathol, Heath Pk, Cardiff CF14 4XN, S Glam, Wales.	Jonescj@cf.ac.uk	Preto, Ana/H-8112-2012	Preto, Ana/0000-0002-7302-0630; Jones, Christopher/0000-0002-5447-8187				Balint E, 2001, BRIT J CANCER, V85, P1813, DOI 10.1054/bjoc.2001.2128; Bond JA, 1996, INT J CANCER, V67, P563, DOI 10.1002/(SICI)1097-0215(19960807)67:4<563::AID-IJC16>3.0.CO;2-8; BOND JA, 1995, CANCER RES, V55, P2404; Bond JA, 1999, MOL CELL BIOL, V19, P3103; Brousset P, 1997, J CLIN ENDOCR METAB, V82, P4214, DOI 10.1210/jc.82.12.4214; Crook T, 2000, ONCOGENE, V19, P3439, DOI 10.1038/sj.onc.1203656; Davis T, 2003, J CELL SCI, V116, P1349, DOI 10.1242/jcs.00331; Delhommeau FO, 2002, ONCOGENE, V21, P8262, DOI 10.1038/sj.onc.1206054; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; FLORENES VA, 1994, BRIT J CANCER, V69, P253, DOI 10.1038/bjc.1994.48; Gire V, 1998, MOL CELL BIOL, V18, P1611, DOI 10.1128/MCB.18.3.1611; Goldman MA, 2003, DRUG DISCOV TODAY, V8, P294, DOI 10.1016/S1359-6446(03)02625-4; Granger MP, 2002, CRIT REV ONCOL HEMAT, V41, P29, DOI 10.1016/S1040-8428(01)00188-3; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hudson JD, 1999, J EXP MED, V190, P1375, DOI 10.1084/jem.190.10.1375; Jones CJ, 1996, MOL CELL ENDOCRINOL, V116, P115, DOI 10.1016/0303-7207(95)03697-0; Jones CJ, 1998, EXP CELL RES, V240, P333, DOI 10.1006/excr.1998.3944; LUBBE J, 1994, J INVEST DERMATOL, V102, P819, DOI 10.1111/1523-1747.ep12381544; Matthews P, 2001, J PATHOL, V194, P183, DOI 10.1002/path.848; Pharoah PDP, 1999, BRIT J CANCER, V80, P1968, DOI 10.1038/sj.bjc.6690628; Saretzki G, 2003, CANCER LETT, V194, P209, DOI 10.1016/S0304-3835(02)00708-5; SHAY JW, 1993, ONCOGENE, V8, P1407; Soares P, 2003, ONCOGENE, V22, P4578, DOI 10.1038/sj.onc.1206706; Soussi T, 2000, ANN NY ACAD SCI, V910, P121; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; Webley K, 2000, MOL CELL BIOL, V20, P2803, DOI 10.1128/MCB.20.8.2803-2808.2000; WYLLIE FS, 1995, ONCOGENE, V10, P49; Wyllie FS, 1999, BRIT J CANCER, V79, P1111, DOI 10.1038/sj.bjc.6690177; Wynford-Thomas D, 1998, CARCINOGENESIS, V19, P29, DOI 10.1093/carcin/19.1.29; WynfordThomas D, 1997, HORM RES, V47, P145, DOI 10.1159/000185458	30	15	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4136	4145		10.1038/sj.onc.1207564	http://dx.doi.org/10.1038/sj.onc.1207564			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15064743				2022-12-28	WOS:000221520200012
J	Wang, JW; Gamsby, JJ; Highfill, SL; Mora, LB; Bloom, GC; Yeatman, TJ; Pan, TC; Ramne, AL; Chodosh, LA; Cress, WD; Chen, JD; Kerr, WG				Wang, JW; Gamsby, JJ; Highfill, SL; Mora, LB; Bloom, GC; Yeatman, TJ; Pan, TC; Ramne, AL; Chodosh, LA; Cress, WD; Chen, JD; Kerr, WG			Deregulated expression of LRBA facilitates cancer cell growth	ONCOGENE			English	Article						LRBA; gene expression profiling; RNA interference; p53; E2F	CHEDIAK-HIGASHI-SYNDROME; KINASE ANCHOR PROTEIN; MAMMALIAN-CELLS; IDENTIFICATION; GENE; P53; CLASSIFICATION; INVOLVEMENT; PATHWAYS; RECEPTOR	LRBA expression is induced by mitogens in lymphoid and myeloid cells. The Drosophila LRBA orthologue rugose/ DAKAP550 is involved in Notch, Ras and EGFR pathways. These findings suggest that LRBA could play a role in cell types that have increased proliferative and survival capacity. Here, we show by microarray and real-time PCR analyses that LRBA is overexpressed in several different cancers relative to their normal tissue controls. We also show that LRBA promoter activity and endogenous LRBA mRNA levels are reduced by p53 and increased by E2F1, indicating that mutations in the tumor suppressors p53 and Rb could contribute to the deregulation of LRBA. Furthermore, inhibition of LRBA expression by RNA interference, or inhibition of its function by a dominant-negative mutant, leads to significant growth inhibition of cancer cells, demonstrating that deregulated expression of LRBA contributes to the altered growth properties of a cancer cell. Finally, we show that the phosphorylation of EGFR is affected by the dominant-negative mutant, suggesting LRBA plays a role in the mammalian EGFR pathway. These findings demonstrate that LRBA facilitates cancer cell growth and thus LRBA may represent a novel molecular target for cancer therapy.	Immunol Programs, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffitt Comprehens Canc Ctr & Res Inst, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem, Tampa, FL 33612 USA; Mol Oncol Programs, Tampa, FL 33612 USA; Gastrointestinal Programs, Tampa, FL 33612 USA; Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Dept Canc Biol, Philadelphia, PA 19104 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Kerr, WG (corresponding author), 12902 Magnolia Dr,SRB-2, Tampa, FL 33612 USA.	kerrw@moffitt.usf.edu	Gamsby, Joshua J/H-9606-2014; Wang, Jia-Wang/I-4966-2012; Kerr, William G/B-8616-2015	Kerr, William G/0000-0002-4720-7135	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072523] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054767] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS027405] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL72523] Funding Source: Medline; NIDDK NIH HHS [R01 DK54767] Funding Source: Medline; NINDS NIH HHS [P01 NS27405] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Blomberg N, 1999, TRENDS BIOCHEM SCI, V24, P441, DOI 10.1016/S0968-0004(99)01472-3; Bloom G, 2004, AM J PATHOL, V164, P9, DOI 10.1016/S0002-9440(10)63090-8; Dyomin VG, 2002, GENOMICS, V80, P158, DOI 10.1006/geno.2002.6822; Han JD, 1997, J BIOL CHEM, V272, P26611, DOI 10.1074/jbc.272.42.26611; Harborth J, 2001, J CELL SCI, V114, P4557; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Jogl G, 2002, EMBO J, V21, P4785, DOI 10.1093/emboj/cdf502; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Kerr WG, 1996, P NATL ACAD SCI USA, V93, P3947, DOI 10.1073/pnas.93.9.3947; Kwak E, 1999, MOL BIOL CELL, V10, P4429, DOI 10.1091/mbc.10.12.4429; Li D, 2001, CELL MOL LIFE SCI, V58, P2085, DOI 10.1007/PL00000838; Miller WR, 2002, ANN NY ACAD SCI, V968, P37, DOI 10.1111/j.1749-6632.2002.tb04325.x; MORRIS C, 2002, BREAST CANC RES TREA, V75; Nagle DL, 1996, NAT GENET, V14, P307, DOI 10.1038/ng1196-307; Ohtani Kiyoshi, 1999, Frontiers in Bioscience, V4, pd793, DOI 10.2741/Ohtani; Segui B, 2001, J CLIN INVEST, V108, P143, DOI 10.1172/JCI200111498; Shamloula HK, 2002, GENETICS, V161, P693; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Spritz RA, 1998, J CLIN IMMUNOL, V18, P97, DOI 10.1023/A:1023247215374; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang JW, 2001, J IMMUNOL, V166, P4586, DOI 10.4049/jimmunol.166.7.4586; Wang XL, 2000, J NEUROSCI, V20, P8551; Warrington JA, 2000, PHYSIOL GENOMICS, V2, P143, DOI 10.1152/physiolgenomics.2000.2.3.143; Wiley HS, 2003, EXP CELL RES, V284, P78, DOI 10.1016/S0014-4827(03)00002-8	29	55	60	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4089	4097		10.1038/sj.onc.1207567	http://dx.doi.org/10.1038/sj.onc.1207567			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15064745				2022-12-28	WOS:000221520200007
J	Yatabe, Y; Mitsudomi, T; Takahashi, T				Yatabe, Y; Mitsudomi, T; Takahashi, T			Maspin expression in normal lung and non-small-cell lung cancers: cellular property-associated expression under the control of promoter DNA methylation	ONCOGENE			English	Article						maspin; non-small-cell lung cancers; intratumor heterogeneity; promoter DNA methylation; cellular properties	THYROID TRANSCRIPTION FACTOR; MAMMARY EPITHELIAL-CELLS; MESSENGER-RNA EXPRESSION; SUPPRESSOR GENE MASPIN; HUMAN BREAST-CANCER; PROGNOSTIC-SIGNIFICANCE; ADENOCARCINOMAS; CARCINOMAS; P53; PATTERNS	Maspin has been demonstrated to be a suppressor of invasion and cell motility in vitro, whereas in vivo analyses have reported that increased expression of maspin is associated with malignant behavior. The present study examined maspin expression in normal lung and non-small-cell lung cancers. Only proximal airway cells in the normal lung expressed maspin, and the expression was associated with decreased methylation. This association was also observed in non-small-cell lung cancers, but the expression was quite different among histologic subtypes; 20 of 21 squamous cell carcinomas showed intense, uniform expression, whereas the expression status varied among adenocarcinomas. Of the 119 adenocarcinomas, 60 were negative, 23 positive and 36 showed a heterogeneous expression pattern. The expression was inversely correlated with markers of peripheral airway cells. Taken together, the results suggest that maspin may be expressed in association with the proximal airway cell type. It is of note that the heterogeneous expression pattern of maspin is quite distinctive, showing geographic positivity in the individual tumors. Separate analysis of methylation status in positive and negative portions of individual tumors provided an instance of intratumor diversity associated with promoter DNA methylation.	Aichi Canc Ctr Hosp, Dept Pathol & Mol Diagnost, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr Hosp, Dept Thorac Surg, Nagoya, Aichi 464, Japan; Aichi Canc Ctr, Res Inst, Div Mol Oncol, Nagoya, Aichi 464, Japan	Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center	Yatabe, Y (corresponding author), Aichi Canc Ctr Hosp, Dept Pathol & Mol Diagnost, Chikusa Ku, Nagoya, Aichi 4648681, Japan.	yyatabe@aichi-cc.jp	Takahashi, Takashi/I-7262-2014; YATABE, Yasushi/J-6461-2014	Takahashi, Takashi/0000-0003-0615-7001; YATABE, Yasushi/0000-0003-1788-559X; Mitsudomi, Tetsuya/0000-0001-9860-8505				Achiwa H, 1999, CLIN CANCER RES, V5, P1001; Bass R, 2002, J BIOL CHEM, V277, P46845, DOI 10.1074/jbc.C200532200; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Bieche I, 2003, BRIT J CANCER, V88, P863, DOI 10.1038/sj.bjc.6600812; Day ML, 1999, J BIOL CHEM, V274, P9656, DOI 10.1074/jbc.274.14.9656; Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5; Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Goldstein NS, 2001, AM J CLIN PATHOL, V116, P319, DOI 10.1309/550P-QLJX-D84W-F6DN; Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727; Greene FL, 2002, AJCC CANC STAGING MA, DOI DOI 10.1007/978-1-4757-3656-4; Hida T, 1998, CANCER RES, V58, P3761; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; Jiang N, 2002, ONCOGENE, V21, P4089, DOI 10.1038/sj.onc.1205507; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; KAWAI J, 1993, NUCLEIC ACIDS RES, V21, P5604, DOI 10.1093/nar/21.24.5604; Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045; Lau SK, 2002, MODERN PATHOL, V15, P538, DOI 10.1038/modpathol.3880560; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Maass N, 2002, BIOCHEM BIOPH RES CO, V297, P125, DOI 10.1016/S0006-291X(02)02136-8; Maass N, 2001, CLIN CANCER RES, V7, P812; Marchetti A, 1996, J PATHOL, V179, P254, DOI 10.1002/(SICI)1096-9896(199607)179:3<254::AID-PATH589>3.0.CO;2-J; Markl IDC, 2001, CANCER RES, V61, P5875; MOHANDAS T, 1981, SCIENCE, V211, P393, DOI 10.1126/science.6164095; Nass SJ, 2000, CANCER RES, V60, P4346; Nishio M, 1997, CLIN CANCER RES, V3, P1051; Oshiro MM, 2003, ONCOGENE, V22, P3624, DOI 10.1038/sj.onc.1206545; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; SHENG SJ, 1994, J BIOL CHEM, V269, P30988; Sood AK, 2002, CLIN CANCER RES, V8, P2924; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; TSUCHIYA E, 1995, J CANCER RES CLIN, V121, P577, DOI 10.1007/BF01197773; Umekita Y, 2002, INT J CANCER, V100, P452, DOI 10.1002/ijc.10500; Waridel F, 1997, ONCOGENE, V14, P163, DOI 10.1038/sj.onc.1200812; Yatabe Y, 2000, AM J PATHOL, V157, P985, DOI 10.1016/S0002-9440(10)64611-1; Yatabe Y, 2001, P NATL ACAD SCI USA, V98, P10839, DOI 10.1073/pnas.191225998; Yatabe Y, 1998, CANCER RES, V58, P1042; Yatabe Y, 2002, AM J SURG PATHOL, V26, P767, DOI 10.1097/00000478-200206000-00010; Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	43	48	57	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 20	2004	23	23					4041	4049		10.1038/sj.onc.1207557	http://dx.doi.org/10.1038/sj.onc.1207557			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15048080				2022-12-28	WOS:000221520200001
J	Yatabe, N; Kyo, S; Maida, Y; Nishi, H; Nakamura, M; Kanaya, T; Tanaka, M; Isaka, K; Ogawa, S; Inoue, M				Yatabe, N; Kyo, S; Maida, Y; Nishi, H; Nakamura, M; Kanaya, T; Tanaka, M; Isaka, K; Ogawa, S; Inoue, M			HIF-1-mediated activation of telomerase in cervical cancer cells	ONCOGENE			English	Article						hypoxia; telomerase; HIF-1; hTERT; cervical cancer	HYPOXIA-INDUCIBLE FACTOR-1; FACTOR 1-ALPHA; C-MYC; UNFAVORABLE PROGNOSIS; TUMOR ANGIOGENESIS; GENE-EXPRESSION; O-2 TENSION; FACTOR-I; TRANSCRIPTION; OVEREXPRESSION	Hypoxia-inducible factor 1 (HIF-1) is a key regulator of O-2 homeostasis, which regulates the expression of several genes linked to angiogenesis and energy metabolism. Tumor hypoxia has been shown to be associated with poor prognosis in a variety of tumors, and HIF-1 induced by hypoxia plays pivotal roles in tumor progression. The presence of putative HIF-1-binding sites on the promoter of human telomerase reverse transcriptase gene ( hTERT) prompted us to examine the involvement of HIF-1 in the regulation of hTERT and telomerase in tumor hypoxia. The telomeric repeat amplification protocol (TRAP) assay revealed that hypoxia activated telomerase in cervical cancer ME180 cells, with peak induction at 24-48 h of hypoxia. Notably, hTERT mRNA expression was upregulated at 6-12 h of hypoxia, concordant with the elevation of HIF-1 protein levels at 6 h. hTERT protein levels were subsequently upregulated at 24 h and later. Luciferase assays using reporter plasmids containing hTERT core promoter revealed that hTERT transcription was significantly activated in hypoxia and by HIF-1 overexpression, and that the two putative binding sites within the core promoter are responsible for this activation. Chromatin immunoprecipitation assay identfied the specific binding of HIF-1 to these sites (competing with c-Myc), which was enhanced in hypoxia. The present findings suggest that hypoxia activates telomerase via transcriptional activation of hTERT, and that HIF-1 plays a critical role as a transcription factor. They also suggest the existence of novel mechanisms of telomerase activation in cancers, and have implications for the molecular basis of hypoxia-induced tumor progression and HIF-1-based cancer gene therapy.	Kanazawa Univ, Sch Med, Dept Obstet & Gynecol, Kanazawa, Ishikawa 9208641, Japan; Tokyo Med Univ, Dept Obstet & Gynecol, Shinjuku Ku, Tokyo 1600023, Japan; Kanazawa Univ, Sch Med, Dept Neuroanat, Kanazawa, Ishikawa 9208641, Japan	Kanazawa University; Tokyo Medical University; Kanazawa University	Kyo, S (corresponding author), Kanazawa Univ, Sch Med, Dept Obstet & Gynecol, 13-1 Takaramachi, Kanazawa, Ishikawa 9208641, Japan.	satoruky@med.kanazawa-u.ac.jp						Akakura N, 2001, CANCER RES, V61, P6548; Birner P, 2000, CANCER RES, V60, P4693; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Coquelle A, 1998, MOL CELL, V2, P259, DOI 10.1016/S1097-2765(00)80137-9; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Greenberg RA, 1999, CELL, V97, P515, DOI 10.1016/S0092-8674(00)80761-8; HOCKEL M, 1993, RADIOTHER ONCOL, V26, P45, DOI 10.1016/0167-8140(93)90025-4; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Jiang BH, 1997, CANCER RES, V57, P5328; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Krishnamachary B, 2003, CANCER RES, V63, P1138; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; Mazure NM, 2002, CANCER RES, V62, P1158; Minamino T, 2001, MOL CELL BIOL, V21, P3336, DOI 10.1128/MCB.21.10.3336-3342.2001; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Ravi R, 2000, GENE DEV, V14, P34; RUSSO CA, 1995, CANCER RES, V55, P1122; Schindl M, 2002, CLIN CANCER RES, V8, P1831; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Seimiya H, 1999, BIOCHEM BIOPH RES CO, V260, P365, DOI 10.1006/bbrc.1999.0910; Semenza GL, 2000, GENE DEV, V14, P1983; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Sivridis E, 2002, CANCER-AM CANCER SOC, V95, P1055, DOI 10.1002/cncr.10774; Takakura M, 1999, CANCER RES, V59, P551; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198; Yasumoto S, 1996, ONCOGENE, V13, P433	30	99	108	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3708	3715		10.1038/sj.onc.1207460	http://dx.doi.org/10.1038/sj.onc.1207460			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15048086	Green Submitted			2022-12-28	WOS:000221101700023
J	Nandan, MO; Yoon, HS; Zhao, WD; Ouko, LA; Chanchevalap, S; Yang, VW				Nandan, MO; Yoon, HS; Zhao, WD; Ouko, LA; Chanchevalap, S; Yang, VW			Kruppel-like factor 5 mediates the transforming activity of oncogenic H-Ras	ONCOGENE			English	Article						IKLF; transformation; mitogen-activated protein kinase; Egr1; cyclin D1; proliferation; small interfering RNA; anchorage-independent growth	SMOOTH-MUSCLE-CELLS; BTEB2 TRANSCRIPTION FACTOR; PROTEIN-KINASE ACTIVATION; CYCLIN D1; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; PLASMA-MEMBRANE; RAF-1 PROTEIN; NIH 3T3-CELLS	Previous studies indicate that Kruppel-like factor 5 (KLF5), also known as intestinal-enriched Kruppel-like factor (IKLF), is a positive regulator of cell proliferation and gives rise to a transformed phenotype when overexpressed. Here we demonstrate that levels of KLF5 transcript and protein are significantly elevated in oncogenic H-Ras-transformed NIH3T3 cells. These cells display an accelerated rate of proliferation in both serum-containing and serum-deprived media and form anchorage-independent colonies in soft agar assays. H-Ras-transformed cells also contain elevated mitogen-activated protein kinase (MAPK) activity. When treated with inhibitors of MEK ( MAPK kinase), H-Ras-transformed cells lose their growth advantage and no longer form colonies. Significantly, levels of KLF5 transcript and protein are substantially reduced in H-Ras-transformed cells treated with MEK inhibitors. Moreover, inhibition of KLF5 expression in H-Ras-transformed cells with KLF5-specific small interfering RNA ( siRNA) leads to a decreased rate of proliferation and a significant reduction in colony formation. H-Ras-transformed cells also contain elevated levels of Egr1 that are diminished by MEK inhibitors. Inhibition of Egr1 by siRNA results in a reduced level of KLF5, indicating that Egr1 mediates the inductive action of MAPK on KLF5. Lastly, KLF5 activates expression of cyclin D1. These findings indicate that the increased expression of KLF5 in H-Ras-transformed cells is secondary to increased MAPK activity from H-Ras overexpression and that the elevated level of KLF5 is in part responsible for the proproliferative and transforming activities of oncogenic H-Ras.	Emory Univ, Sch Med, Dept Med, Div Digest Dis, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Hematol & Oncol, Winship Canc Inst, Atlanta, GA 30322 USA	Emory University; Emory University	Yang, VW (corresponding author), Emory Univ, Sch Med, Dept Med, Div Digest Dis, 201 Whitehead Res Bldg,615 Michael St, Atlanta, GA 30322 USA.	vyang@emory.edu		Mandayam, Nandan/0000-0002-4061-9348	NCI NIH HHS [CA84197, R01 CA084197] Funding Source: Medline; NIDDK NIH HHS [R01 DK052230, DK64399, DK52230, R24 DK064399] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R24DK064399] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; Chen C, 2002, ONCOGENE, V21, P6567, DOI 10.1038/sj.onc.1205817; Chen C, 2003, PROSTATE, V55, P81, DOI 10.1002/pros.10205; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; Conkright MD, 1999, NUCLEIC ACIDS RES, V27, P1263, DOI 10.1093/nar/27.5.1263; Crossley M, 1996, MOL CELL BIOL, V16, P1695; Dang DT, 2000, INT J BIOCHEM CELL B, V32, P1103, DOI 10.1016/S1357-2725(00)00059-5; Dang DT, 2002, NUCLEIC ACIDS RES, V30, P2736, DOI 10.1093/nar/gkf400; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DeSilva DR, 1998, J IMMUNOL, V160, P4175; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DOBROWOLSKI S, 1994, MOL CELL BIOL, V14, P5441, DOI 10.1128/MCB.14.8.5441; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; El-Shemerly MYM, 1997, J BIOL CHEM, V272, P30599, DOI 10.1074/jbc.272.49.30599; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FILMUS J, 1994, ONCOGENE, V9, P3627; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; Gebelein B, 1998, J CLIN INVEST, V102, P1911, DOI 10.1172/JCI1919; Hoshino Y, 2000, CIRCULATION, V102, P2528, DOI 10.1161/01.CIR.102.20.2528; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; Kawai-Kowase K, 1999, CIRC RES, V85, P787, DOI 10.1161/01.RES.85.9.787; Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Kullmann M, 2002, GENE DEV, V16, P3087, DOI 10.1101/gad.248902; KUO ML, 1993, CANCER LETT, V74, P197, DOI 10.1016/0304-3835(93)90243-3; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; MUSZYNSKI KW, 1995, J EXP MED, V181, P2189, DOI 10.1084/jem.181.6.2189; NORI M, 1992, MOL CELL BIOL, V12, P936, DOI 10.1128/MCB.12.3.936; Ogata T, 2000, J THORAC CARDIOV SUR, V119, P983, DOI 10.1016/S0022-5223(00)70093-6; Ohnishi S, 2000, DEV DYNAM, V217, P421, DOI 10.1002/(SICI)1097-0177(200004)217:4<421::AID-DVDY9>3.0.CO;2-1; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Rajendran RR, 2003, J BIOL CHEM, V278, P4628, DOI 10.1074/jbc.M210066200; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; Shi HP, 1999, NUCLEIC ACIDS RES, V27, P4807, DOI 10.1093/nar/27.24.4807; Shie JL, 2000, AM J PHYSIOL-GASTR L, V279, pG806, DOI 10.1152/ajpgi.2000.279.4.G806; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Simmen RCM, 2002, FRONT BIOSCI-LANDMRK, V7, pD1556, DOI 10.2741/simmen; Sun RG, 2001, J BIOL CHEM, V276, P6897, DOI 10.1074/jbc.C000870200; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; Turner J, 1999, TRENDS BIOCHEM SCI, V24, P236, DOI 10.1016/S0968-0004(99)01406-1; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Wartmann M, 1997, J BIOL CHEM, V272, P3915, DOI 10.1074/jbc.272.7.3915; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; Winston JT, 1996, ONCOGENE, V12, P127; Yang JJ, 1998, MOL CELL BIOL, V18, P2586, DOI 10.1128/MCB.18.5.2586; Yoon HS, 2003, J BIOL CHEM, V278, P2101, DOI 10.1074/jbc.M211027200; Ziemer LT, 2001, MOL CELL BIOL, V21, P562, DOI 10.1128/MCB.21.2.562-574.2001	62	119	129	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3404	3413		10.1038/sj.onc.1207397	http://dx.doi.org/10.1038/sj.onc.1207397			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15077182	Green Accepted			2022-12-28	WOS:000220975000015
J	Sarrio, D; Perez-Mies, B; Hardisson, D; Moreno-Bueno, G; Suarez, A; Cano, A; Martinez-Perez, J; Gamallo, C; Palacios, J				Sarrio, D; Perez-Mies, B; Hardisson, D; Moreno-Bueno, G; Suarez, A; Cano, A; Martinez-Perez, J; Gamallo, C; Palacios, J			Cytoplasmic localization of p120ctn and E-cadherin loss characterize lobular breast carcinoma from preinvasive to metastatic lesions	ONCOGENE			English	Article						lobular breast cancer; p120ctn; E-cadherin; catenins	TYROSINE PHOSPHORYLATION; MESENCHYMAL TRANSITIONS; CATENIN EXPRESSION; BETA-CATENIN; IN-SITU; ADHESION; P120(CTN); PROTEIN; CANCER; SRC	Accumulating evidences indicate that p120 catenin, a member of the E-cadherin (E-CD)/catenin adhesion complex, plays a role in tumor invasion. To establish the expression pattern of p120 in breast cancer, we analysed 326 breast tissue biopsies by tissue microarray. Most of the lobular tumors (88%) showed exclusive cytoplasmic localization, and 6% of them also had p120 nuclear staining. Cytoplasmic p120 strongly associated with complete loss of E-CD and beta-catenin not only in lobular carcinoma and its metastases but also in atypical lobular hyperplasias. In the latter, loss of heterozygosity of E-CD gene was also observed. Complete loss of E-CD and cytoplasmic and nuclear p120 staining was also observed in primary lobular cancer cell cultures generated by us. In ductal tumors, by contrast, reduction of p120 and E-CD in membrane was very common (57 and 53%, respectively), whereas cytoplasmic p120 staining was rarely seen. This simultaneous reduction of membranous E-CD and p120 was not associated with increased Src kinase activity. To demonstrate that cytoplasmic p120 localization was a consequence of the absence of E-CD, the endogenous E-CD was re-expressed in MDA-231 cells by 5-Aza-2'-deoxycytidine (5Aza) treatment. After treatment, p120 shifted from the cytoplasm to the membrane, where it colocalized with endogenous E-CD. Additionally, suppressing E-CD expression in Madin-Darby canine kidney cells by stable transfection of the transcriptional repressors Snail, E47 or Slug, provokes p120 cytoplasmic localization and p120 isoform switching. In conclusion, abnormal cytoplasmic and nuclear localization of p120, which are mediated by the absence of E-CD, characteristically occur in the early stages of lobular breast cancer and are maintained during tumor progression to metastasis. Consequently, p120 may be an important mediator of the oncogenic effects derived from E-CD inactivation, including enhanced motility and invasion, in lobular breast cancer.	CNIO, Programa Patol Mol, Madrid, Spain; Hosp La Paz, Dept Pathol, Madrid, Spain; UAM, CSIC, Inst Invest Biomed Alberto Sols, Madrid, Spain; La Princesa Hosp, Dept Pathol, Madrid, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Hospital Universitario La Paz; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Hospital de La Princesa	Palacios, J (corresponding author), CNIO, Programa Patol Mol, C Melchor Fernandez Almagro 3, Madrid, Spain.	jpalacios@cnio.es	Hardisson, David/AAN-3833-2020; Martin-Perez, Jorge/A-3522-2008; Moreno-Bueno, Gema/K-9354-2016; Palacios, Jose/AAV-3765-2020; Hardisson, David/E-2832-2010; Hardisson, David/A-6259-2011; SARRIO, DAVID/Y-8903-2019	Martin-Perez, Jorge/0000-0002-2292-0057; Moreno-Bueno, Gema/0000-0002-5030-6687; Hardisson, David/0000-0002-2183-3699; Sarrio, David/0000-0003-4886-8290; Perez Mies, Belen/0000-0001-5764-5182				Aho S, 2002, J CELL SCI, V115, P1391; Anastasiadis PZ, 2000, J CELL SCI, V113, P1319; Anastasiadis PZ, 2001, CURR OPIN CELL BIOL, V13, P604, DOI 10.1016/S0955-0674(00)00258-1; Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; Beavon IRG, 2000, EUR J CANCER, V36, P1607, DOI 10.1016/S0959-8049(00)00158-1; Berx G, 1998, HUM MUTAT, V12, P226, DOI 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; Daniel JM, 1999, MOL CELL BIOL, V19, P3614; DANIEL JM, 1995, MOL CELL BIOL, V15, P4819; Daniel JM, 1997, BIOESSAYS, V19, P883, DOI 10.1002/bies.950191008; Dillon DA, 1998, AM J PATHOL, V152, P75; Droufakou S, 2001, INT J CANCER, V92, P404, DOI 10.1002/ijc.1208; GAMALLO C, 1993, AM J PATHOL, V142, P987; GRAFF JR, 1995, CANCER RES, V55, P5195; Husmark J, 1999, INT J CANCER, V83, P692, DOI 10.1002/(SICI)1097-0215(19991126)83:5<692::AID-IJC21>3.0.CO;2-1; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Jawhari AU, 1999, J PATHOL, V189, P180, DOI 10.1002/(SICI)1096-9896(199910)189:2<180::AID-PATH414>3.0.CO;2-2; Jiang WG, 2000, SURG ONCOL, V9, P151, DOI 10.1016/S0960-7404(01)00010-X; KEISERBILCK A, 1998, GENOMICS, V50, P129; KOHY N, 2002, INT J CANCER, V104, P44; Lishman SC, 1999, HISTOPATHOLOGY, V35, P195; Lu YJ, 1998, CANCER RES, V58, P4721; Mariner DJ, 2001, J BIOL CHEM, V276, P28006, DOI 10.1074/jbc.M102443200; Mayerle J, 2003, GASTROENTEROLOGY, V124, P949, DOI 10.1053/gast.2003.50142; Mo YY, 1996, CANCER RES, V56, P2633; Montonen O, 2001, J HISTOCHEM CYTOCHEM, V49, P1487, DOI 10.1177/002215540104901202; Moreno-Bueno G, 2002, ONCOGENE, V21, P7981, DOI 10.1038/sj.onc.1205924; Nagafuchi A, 2001, CURR OPIN CELL BIOL, V13, P600, DOI 10.1016/S0955-0674(00)00257-X; Nakopoulou L, 2002, HISTOPATHOLOGY, V40, P536, DOI 10.1046/j.1365-2559.2002.01392.x; Ozawa M, 2001, J CELL SCI, V114, P503; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Prokhortchouk A, 2001, GENE DEV, V15, P1613, DOI 10.1101/gad.198501; REYNOLDS AB, 1992, ONCOGENE, V7, P2439; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Sarrio D, 2003, INT J CANCER, V106, P208, DOI 10.1002/ijc.11197; Thoreson MA, 2002, DIFFERENTIATION, V70, P583, DOI 10.1046/j.1432-0436.2002.700911.x; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; Tomita K, 2000, CANCER RES, V60, P3650; Tran NL, 1999, AM J PATHOL, V155, P787, DOI 10.1016/S0002-9440(10)65177-2; van Hengel J, 1999, P NATL ACAD SCI USA, V96, P7980, DOI 10.1073/pnas.96.14.7980; Vara JAF, 2000, BIOCHEM J, V345, P17, DOI 10.1042/0264-6021:3450017	44	143	157	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3272	3283		10.1038/sj.onc.1207439	http://dx.doi.org/10.1038/sj.onc.1207439			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15077190				2022-12-28	WOS:000220975000002
J	Norbury, CJ; Zhivotovsky, B				Norbury, CJ; Zhivotovsky, B			DNA damage-induced apoptosis	ONCOGENE			English	Review						DNA damage; DNA repair; apoptosis; mechanisms	CYTOCHROME-C RELEASE; ATM-DEPENDENT PHOSPHORYLATION; RADIATION-INDUCED APOPTOSIS; LACKING MITOCHONDRIAL-DNA; TRANSCRIPTION FACTOR-A; PROGRAMMED CELL-DEATH; P53-DEPENDENT APOPTOSIS; THYMOCYTE APOPTOSIS; P53-MEDIATED APOPTOSIS; NUCLEAR-LOCALIZATION	Unicellular organisms respond to the presence of DNA lesions by activating cell cycle checkpoint and repair mechanisms, while multicellular animals have acquired the further option of eliminating damaged cells by triggering apoptosis. Defects in DNA damage-induced apoptosis contribute to tumorigenesis and to the resistance of cancer cells to a variety of therapeutic agents. The intranuclear mechanisms that signal apoptosis after DNA damage overlap with those that initiate cell cycle arrest and DNA repair, and the early events in these pathways are highly conserved. In addition, multiple independent routes have recently been traced by which nuclear DNA damage can be signalled to the mitochondria, tipping the balance in favour of cell death rather than repair and survival. Here, we review current knowledge of nuclear DNA damage signalling, giving particular attention to interactions between these nuclear events and apoptotic processes in other intracellular compartments.	Karolinska Inst, Inst Environm Med, SE-17177 Stockholm, Sweden; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	Karolinska Institutet; University of Oxford	Zhivotovsky, B (corresponding author), Karolinska Inst, Inst Environm Med, Box 210,Nobels Vag 13, SE-17177 Stockholm, Sweden.	boris.zhivotovsky@imm.ki.se	Zhivotovsky, Boris/A-4346-2014	Zhivotovsky, Boris/0000-0002-2238-3482				Adrain C, 2001, EMBO J, V20, P6627, DOI 10.1093/emboj/20.23.6627; Ahn JY, 2000, CANCER RES, V60, P5934; Arnoult D, 2003, EMBO J, V22, P4385, DOI 10.1093/emboj/cdg423; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Baus F, 2003, EMBO J, V22, P3992, DOI 10.1093/emboj/cdg387; BELL DA, 1990, J CLIN INVEST, V85, P1487, DOI 10.1172/JCI114595; Bergamaschi D, 2003, NAT GENET, V33, P162, DOI 10.1038/ng1070; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Bonfoco E, 2001, J BIOL CHEM, V276, P29242, DOI 10.1074/jbc.M100684200; BORISOVA E A, 1984, Radiobiologiya, V24, P607; BURSCH W, 1990, BIOCHEM CELL BIOL, V68, P1071, DOI 10.1139/o90-160; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Caspari T, 2000, CURR BIOL, V10, pR315, DOI 10.1016/S0960-9822(00)00439-5; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; Chakraborty M, 2003, J IMMUNOL, V170, P6338, DOI 10.4049/jimmunol.170.12.6338; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Charette SJ, 2000, MOL CELL BIOL, V20, P7602, DOI 10.1128/MCB.20.20.7602-7612.2000; Charette SJ, 2001, J BIOL CHEM, V276, P36071, DOI 10.1074/jbc.C100340200; Chen LY, 2003, MOL CELL BIOL, V23, P7108, DOI 10.1128/MCB.23.20.7108-7121.2003; Cheung WL, 2003, CELL, V113, P507, DOI 10.1016/S0092-8674(03)00355-6; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Colussi PA, 1998, J BIOL CHEM, V273, P24535, DOI 10.1074/jbc.273.38.24535; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Derry WB, 2001, SCIENCE, V294, P591, DOI 10.1126/science.1065486; Deverman BE, 2002, CELL, V111, P51, DOI 10.1016/S0092-8674(02)00972-8; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Duchaud E, 1996, CANCER RES, V56, P1400; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; Fernandez-Capetillo O, 2002, NAT CELL BIOL, V4, P993, DOI 10.1038/ncb884; Fewell JW, 1996, J CELL SCI, V109, P1937; Foray N, 2003, EMBO J, V22, P2860, DOI 10.1093/emboj/cdg274; Gartner A, 2000, MOL CELL, V5, P435, DOI 10.1016/S1097-2765(00)80438-4; Gomez-Angelats M, 2003, CELL DEATH DIFFER, V10, P791, DOI 10.1038/sj.cdd.4401237; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Higuchi M, 1997, J CLIN INVEST, V99, P1751, DOI 10.1172/JCI119339; Hofmann ER, 2002, CURR BIOL, V12, P1908, DOI 10.1016/S0960-9822(02)01262-9; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; Jiang SN, 1999, J BIOL CHEM, V274, P29905, DOI 10.1074/jbc.274.42.29905; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Kim EJ, 2003, NUCLEIC ACIDS RES, V31, P5356, DOI 10.1093/nar/gkg741; Kim JY, 2002, ONCOGENE, V21, P3139, DOI 10.1038/sj.onc.1205406; Komatsu K, 2000, FEBS LETT, V481, P122, DOI 10.1016/S0014-5793(00)01975-X; Komatsu K, 2000, NAT CELL BIOL, V2, P1, DOI 10.1038/71316; Konishi A, 2003, CELL, V114, P673, DOI 10.1016/S0092-8674(03)00719-0; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Lee E, 1999, IUBMB LIFE, V48, P79, DOI 10.1080/152165499307459; Lee Y, 2001, J NEUROSCI, V21, P6687, DOI 10.1523/JNEUROSCI.21-17-06687.2001; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; MANOME Y, 1993, BIOCHEMISTRY-US, V32, P10607, DOI 10.1021/bi00091a010; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Marchetti P, 1996, CANCER RES, V56, P2033; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; Mendelsohn AR, 2002, P NATL ACAD SCI USA, V99, P6871, DOI 10.1073/pnas.072290599; Michaelson JS, 2003, J CELL SCI, V116, P345, DOI 10.1242/jcs.00234; Michaelson JS, 1999, GENE DEV, V13, P1918, DOI 10.1101/gad.13.15.1918; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MIYASHITA T, 1995, CELL, V80, P293; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; MURGIA M, 1992, J BIOL CHEM, V267, P10939; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; NORBURY C, 1994, BIOCHEM BIOPH RES CO, V202, P1400, DOI 10.1006/bbrc.1994.2086; Norbury CJ, 2001, ANNU REV PHARMACOL, V41, P367, DOI 10.1146/annurev.pharmtox.41.1.367; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Ohiro Y, 2003, MOL CELL BIOL, V23, P322, DOI 10.1128/MCB.23.1.322-334.2003; ONGKEKO W, 1995, J CELL SCI, V108, P2897; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Paroni G, 2002, J BIOL CHEM, V277, P15147, DOI 10.1074/jbc.M112338200; Parrish J, 2001, NATURE, V412, P90, DOI 10.1038/35083608; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Peters M, 2002, P NATL ACAD SCI USA, V99, P11305, DOI 10.1073/pnas.172382899; Read SH, 2002, J CELL BIOL, V159, P739, DOI 10.1083/jcb.200209004; Reinke V, 1997, ONCOGENE, V15, P1527, DOI 10.1038/sj.onc.1201316; Robertson JD, 2000, J BIOL CHEM, V275, P32438, DOI 10.1074/jbc.C000518200; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390; Roos-Mattjus P, 2002, J BIOL CHEM, V277, P43809, DOI 10.1074/jbc.M207272200; Saito S, 2002, J BIOL CHEM, V277, P12491, DOI 10.1074/jbc.C200093200; Sawada M, 2003, NAT CELL BIOL, V5, P320, DOI 10.1038/ncb950; SCHULZEOSTHOFF K, 1994, J CELL BIOL, V127, P15, DOI 10.1083/jcb.127.1.15; Schumacher B, 2001, CURR BIOL, V11, P1722, DOI 10.1016/S0960-9822(01)00534-6; Screaton RA, 2003, P NATL ACAD SCI USA, V100, P5211, DOI 10.1073/pnas.0431215100; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Shearwin-Whyatt LM, 2000, CELL DEATH DIFFER, V7, P155, DOI 10.1038/sj.cdd.4400632; Sheikh MS, 2003, CELL CYCLE, V2, P346, DOI 10.4161/cc.2.4.421; Shen Y, 2001, ADV CANCER RES, V82, P55, DOI 10.1016/S0065-230X(01)82002-9; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Singh KK, 1999, ONCOGENE, V18, P6641, DOI 10.1038/sj.onc.1203056; SKALKA M, 1976, FEBS LETT, V72, P271, DOI 10.1016/0014-5793(76)80984-2; Sogame N, 2003, P NATL ACAD SCI USA, V100, P4696, DOI 10.1073/pnas.0736384100; Song JY, 2003, J BIOL CHEM, V278, P36676, DOI 10.1074/jbc.M303692200; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Tang JT, 1999, ANTICANCER RES, V19, P4959; TEPPER CG, 1993, J CELL BIOCHEM, V52, P352, DOI 10.1002/jcb.240520311; Thornberry NA, 1999, CELL DEATH DIFFER, V6, P1023, DOI 10.1038/sj.cdd.4400607; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; Um JH, 2003, LEUKEMIA RES, V27, P509, DOI 10.1016/S0145-2126(02)00264-3; Vaughan ATM, 2002, APOPTOSIS, V7, P173, DOI 10.1023/A:1014374717773; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Wang JM, 2001, P NATL ACAD SCI USA, V98, P4038, DOI 10.1073/pnas.061038798; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; Wang Y, 2000, GENE DEV, V14, P927; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Waterhouse NJ, 2002, BIOCHIMIE, V84, P113, DOI 10.1016/S0300-9084(02)01379-2; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Westphal CH, 1997, NAT GENET, V16, P397, DOI 10.1038/ng0897-397; Wilson AJ, 2003, CANCER RES, V63, P5401; Woo RA, 2002, EMBO J, V21, P3000, DOI 10.1093/emboj/cdf307; Wu SY, 2002, NEOPLASIA, V4, P486, DOI 10.1038/sj.neo.7900264; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yang CR, 2000, P NATL ACAD SCI USA, V97, P5907, DOI 10.1073/pnas.97.11.5907; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; YONEDA M, 1995, BIOCHEM BIOPH RES CO, V209, P723, DOI 10.1006/bbrc.1995.1559; Yoshida K, 2002, MOL CELL BIOL, V22, P3292, DOI 10.1128/MCB.22.10.3292-3300.2002; Yoshida Y, 2003, CANCER RES, V63, P3729; Yoshida Y, 2002, BIOCHEM BIOPH RES CO, V295, P945, DOI 10.1016/S0006-291X(02)00757-X; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536; Zhou L, 2003, DEV CELL, V4, P599, DOI 10.1016/S1534-5807(03)00085-6; Zhou MX, 2002, J PHARMACOL EXP THER, V303, P124, DOI 10.1124/jpet.102.037192	137	513	553	3	81	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2004	23	16					2797	2808		10.1038/sj.onc.1207532	http://dx.doi.org/10.1038/sj.onc.1207532			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	811VO	15077143				2022-12-28	WOS:000220799600007
J	Sarker, KP; Lee, KY				Sarker, KP; Lee, KY			L6 myoblast differentiation is modulated by Cdk5 via the PI3K-AKT-p70S6K signaling pathway	ONCOGENE			English	Article						myoblast; differentiation; Cdk5; signaling	CYCLIN-DEPENDENT KINASE-5; P70 S6 KINASE; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; MUSCLE DIFFERENTIATION; TYROSINE KINASE; GENE-EXPRESSION; GROWTH-FACTORS; MAP KINASE; ACTIVATION	Cdk5 regulates myogenesis but the signaling cascade through which Cdk5 modulates this process remains to be characterized. Here, we investigated whether PI3K, Akt, p70S6K, p38 MAPK, p44/42 MAPK, and Egr-1 serve as upstream regulators of Cdk5 during L6 myoblast differentiation. Upon serum reduction, we found that besides elevated expression of Cdk5 and its activator, p35, and increased Cdk5/p35 activity, Egr-1, Akt, p70S6K, and p38 MAPK activity were upregulated in differentiating L6 cells. However, p44/42 MAPK was downregulated and SAPK/JNK was unaffected. LY294002, a PI3K inhibitor, blocked the activation of Akt and p70S6K, indicating that Akt and p70S6K activation is linked to PI3K activation. The lack of LY294002 effect on p38 MAPK suggests that p38 MAPK activation is not associated with PI3K activation. Rapamycin, a specific inhibitor of FRAP/mTOR (the upstream kinase of p70S6K), also blocked p70S6K activation, indicating the involvement of FRAP/mTOR activation. LY294002 and rapamycin also blocked the enhancement of Egr-1 level, Cdk5 activity, and myogenin expression, suggesting that upregulation of these factors is coupled to PI3K-p70S6K activation. Overexpression of dominant-negative-Akt also reduced Cdk5/p35 activity and myogenin expression, indicating that the PI3K-p70S6K-Egr-1-Cdk5 signaling cascade is linked to Akt activation. SB2023580, a p38 MAPK inhibitor, had no effect on p70S6K, Egr-1, or Cdk5 activity, suggesting that p38 MAPK activation lies in a pathway distinct from the PI3K-Akt-p70S6K-Egr-1 pathway that we identify as the upstream modulator of Cdk5 activity during L6 myoblast differentiation.	Univ Calgary, Fac Med, Dept Cell Biol & Anat, Canc Biol Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Cell Biol & Anat, Neurosci Res Grp, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary	Lee, KY (corresponding author), Univ Calgary, Fac Med, Dept Cell Biol & Anat, Canc Biol Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	kylee@ucalgary.ca						Agullo G, 1997, BIOCHEM PHARMACOL, V53, P1649, DOI 10.1016/S0006-2952(97)82453-7; ARNOLD HH, 1992, SYM SOC EXP BIOL, V46, P37; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; Chen F, 2001, BLOOD, V97, P3763, DOI 10.1182/blood.V97.12.3763; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Conejo R, 2002, ONCOGENE, V21, P3739, DOI 10.1038/sj.onc.1205469; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Dhavan R, 2001, NAT REV MOL CELL BIO, V2, P749, DOI 10.1038/35096019; Gao CY, 1997, DEV GENET, V20, P267; Gredinger E, 1998, J BIOL CHEM, V273, P10436, DOI 10.1074/jbc.273.17.10436; Guidato S, 1998, J NEUROCHEM, V70, P335; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; Harada S, 2001, DNA CELL BIOL, V20, P223, DOI 10.1089/104454901750219107; Harada T, 2001, NAT CELL BIOL, V3, P453, DOI 10.1038/35074516; Jones NC, 2001, J CELL PHYSIOL, V186, P104, DOI 10.1002/1097-4652(200101)186:1<104::AID-JCP1015>3.0.CO;2-0; Kim S, 2000, J BIOL CHEM, V275, P25979, DOI 10.1074/jbc.M001975200; Kitzmann M, 2001, CELL MOL LIFE SCI, V58, P571, DOI 10.1007/PL00000882; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; Laprise P, 2002, J CELL PHYSIOL, V191, P69, DOI 10.1002/jcp.10075; Lazaro JB, 1997, J CELL SCI, V110, P1251; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; Lee KY, 1997, INT J BIOCHEM CELL B, V29, P951, DOI 10.1016/S1357-2725(97)00048-4; Lee KY, 1996, J BIOL CHEM, V271, P1538, DOI 10.1074/jbc.271.3.1538; LEW J, 1995, TRENDS BIOCHEM SCI, V20, P33, DOI 10.1016/S0968-0004(00)88948-3; LIU JW, 1991, J BIOL CHEM, V266, P5929; MIYAJIMA M, 1995, NEUROREPORT, V6, P1130, DOI 10.1097/00001756-199505300-00014; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; Ostrovsky O, 2003, J BIOL CHEM, V278, P21221, DOI 10.1074/jbc.M211357200; Philpott A, 1997, GENE DEV, V11, P1409, DOI 10.1101/gad.11.11.1409; Reif K, 1997, J BIOL CHEM, V272, P14426, DOI 10.1074/jbc.272.22.14426; Reusch HP, 2001, J BIOL CHEM, V276, P33630, DOI 10.1074/jbc.M105322200; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Rosales JL, 2004, J BIOL CHEM, V279, P1224, DOI 10.1074/jbc.M310867200; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; Sarker KP, 2003, J NEUROCHEM, V85, P50, DOI 10.1046/j.1471-4159.2003.01663.x; Sarker KP, 2000, J MOL NEUROSCI, V15, P243, DOI 10.1385/JMN:15:3:243; Scheid MP, 2002, MOL CELL BIOL, V22, P6247, DOI 10.1128/MCB.22.17.6247-6260.2002; Tamir Y, 2000, J BIOL CHEM, V275, P34424, DOI 10.1074/jbc.M005815200; Tureckova J, 2001, J BIOL CHEM, V276, P39264, DOI 10.1074/jbc.M104991200; Winter B, 2000, J CELL SCI, V113, P4211; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; Zetser A, 2001, DEV BIOL, V240, P168, DOI 10.1006/dbio.2001.0465; ZHANG H, 1993, MOL BIOL CELL, V9, P897	46	40	45	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6064	6070		10.1038/sj.onc.1207819	http://dx.doi.org/10.1038/sj.onc.1207819			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15208659				2022-12-28	WOS:000223261000006
J	Conrotto, P; Corso, S; Gamberini, S; Comoglio, PM; Giordano, S				Conrotto, P; Corso, S; Gamberini, S; Comoglio, PM; Giordano, S			Interplay between scatter factor receptors and B plexins controls invasive growth	ONCOGENE			English	Article						Scatter Factor Receptors; B plexins; invasive growth; tyrosine phosphorylation	MACROPHAGE-STIMULATING PROTEIN; TYROSINE KINASE; SEMAPHORIN RECEPTORS; MET PROTOONCOGENE; SOMATIC MUTATIONS; EPITHELIAL-CELLS; GENE-PRODUCT; ACTIVE RAC; RON GENE; HGF	Met and Ron tyrosine kinases are members of the Scatter Factor Receptor family. Met is the receptor for hepatocyte growth factor while Ron is that for macrophage stimulating protein. On ligand stimulation, activation of these receptors induces 'invasive growth', a complex biological response involved in tissue morphogenesis and, when deregulated, in tumor progression and metastasis. Scatter Factor Receptors share structural homology with Plexins, transmembrane receptors for Semaphorins, a family of ligands originally identified as axon guidance molecules. A physical and functional association between Met and Plexin B1, the prototype of class B Plexin subfamily, has been previously demonstrated. Here, we show that both Met and Ron receptors can interact with each of the three members of class B Plexins, even in the absence of their ligands and that Plexin B1 ligand, Sema 4D, can induce activation of Met and Ron receptors, promoting an invasive response. Furthermore, in some human neoplastic cell lines Plexin B1 is overexpressed, constitutively tyrosine phosphorylated, and associated with Scatter Factor Receptors. These data extend the crosstalk previously described between Met and Plexin B1 to the entire families of Scatter Factor Receptors and class B Plexins and show that interaction with multiple upstream activators can finely tune the invasive growth process both in physiological conditions and in tumor growth and metastatization.	Univ Turin, Sch Med, IRCC, Div Mol Oncol, I-10060 Turin, Italy	University of Turin	Giordano, S (corresponding author), Univ Turin, Sch Med, IRCC, Div Mol Oncol, I-10060 Turin, Italy.	silvia.giordano@ircc.it	Giordano, Silvia/J-9858-2018	Giordano, Silvia/0000-0003-1854-1086; Comoglio, Paolo/0000-0002-7056-5328; CORSO, Simona/0000-0002-5069-1503				Artigiani S, 2003, J BIOL CHEM, V278, P10094, DOI 10.1074/jbc.M210156200; Aurandt J, 2002, P NATL ACAD SCI USA, V99, P12085, DOI 10.1073/pnas.142433199; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Chen YQ, 2002, ONCOGENE, V21, P6382, DOI 10.1038/sj.onc.1205783; Danilkovitch A, 1999, EXP CELL RES, V248, P575, DOI 10.1006/excr.1999.4429; Danilkovitch-Miagkova A, 2002, J CLIN INVEST, V109, P863; Danilkovitch-Miagkova A, 2003, P NATL ACAD SCI USA, V100, P4580, DOI 10.1073/pnas.0837136100; Di Renzo MF, 2000, ONCOGENE, V19, P1547, DOI 10.1038/sj.onc.1203455; Driessens MHE, 2001, CURR BIOL, V11, P339, DOI 10.1016/S0960-9822(01)00092-6; Follenzi A, 2000, ONCOGENE, V19, P3041, DOI 10.1038/sj.onc.1203620; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; Giordano S, 2002, NAT CELL BIOL, V4, P720, DOI 10.1038/ncb843; Giordano S, 1997, P NATL ACAD SCI USA, V94, P13868, DOI 10.1073/pnas.94.25.13868; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; Lee JH, 2000, ONCOGENE, V19, P4947, DOI 10.1038/sj.onc.1203874; Maestrini E, 1996, P NATL ACAD SCI USA, V93, P674, DOI 10.1073/pnas.93.2.674; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; Orian-Rousseau V, 2002, GENE DEV, V16, P3074, DOI 10.1101/gad.242602; Park WS, 1999, CANCER RES, V59, P307; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Perrot V, 2002, J BIOL CHEM, V277, P43115, DOI 10.1074/jbc.M206005200; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Prat M, 1998, J CELL SCI, V111, P237; Santoro MM, 2003, DEV CELL, V5, P257, DOI 10.1016/S1534-5807(03)00201-6; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Swiercz JM, 2002, NEURON, V35, P51, DOI 10.1016/S0896-6273(02)00750-X; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; Vande Woude GF, 1997, CIBA F SYMP, V212, P119; Vikis HG, 2000, P NATL ACAD SCI USA, V97, P12457, DOI 10.1073/pnas.220421797; WANG MH, 1995, P NATL ACAD SCI USA, V92, P3933, DOI 10.1073/pnas.92.9.3933; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; Wang X, 2002, MOL CELL, V9, P411, DOI 10.1016/S1097-2765(02)00439-2; Willett CG, 1998, AM J RESP CELL MOL, V18, P489, DOI 10.1165/ajrcmb.18.4.2978; Winberg ML, 1998, CELL, V95, P903, DOI 10.1016/S0092-8674(00)81715-8; Zhou YQ, 2003, ONCOGENE, V22, P186, DOI 10.1038/sj.onc.1206075	38	136	153	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2004	23	30					5131	5137		10.1038/sj.onc.1207650	http://dx.doi.org/10.1038/sj.onc.1207650			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	834AE	15184888				2022-12-28	WOS:000222382500003
J	Serakinci, N; Guldberg, P; Burns, JS; Abdallah, B; Schrodder, H; Jensen, T; Kassem, M				Serakinci, N; Guldberg, P; Burns, JS; Abdallah, B; Schrodder, H; Jensen, T; Kassem, M			Adult human mesenchymal stem cell as a target for neoplastic transformation	ONCOGENE			English	Article						mesenchymal stem cells; transformation; telomerase	TELOMERASE EXPRESSION; EPITHELIAL-CELLS; BRAIN-TUMORS; CANCER; IMMORTALIZATION; MARROW; MECHANISMS; BMI-1	The neoplastic process may involve a cancer stem cell. This concept has emerged largely from the careful analysis of tumour biopsy systems from haematological, breast and brain tumours. However, the experimental systems necessary to provide the cellular and molecular evidence to support this important concept have been lacking. We have used adult mesenchymal stem cells (hMSC) transduced with the telomerase hTERT gene to investigate the neoplastic potential of adult stem cells. The hTERT-transduced line, hMSC-TERT20 at population doubling level (PDL) 256 showed loss of contact inhibition, anchorage independence and formed tumours in 10/10 mice. hMSC-TERT4 showed loss of contact inhibition at PDL 95, but did not exhibit anchorage independence and did not form tumours in mice. Both lines had a normal karyotype but showed deletion of the Ink4a/ARF locus. At later passage, hMSC-TERT4 also acquired an activating mutation in KRAS. In hMSC-TERT20, expression of the cell cycle-associated gene, DBCCR1 was lost due to promoter hypermethylation. This epigenetic event correlated with acquisition of tumorigenicity. These data suggest that the adult hMSCs can be targets for neoplastic transformation and have implications for the development of novel anticancer therapeutics and for the use of hMSC in tissue engineering and transplantation protocols.	Aarhus Univ, Dept Human Genet, DK-8000 Aarhus C, Denmark; Odense Univ Hosp, Dept Endocrinol, Odense, Denmark; Danish Canc Soc, Inst Canc Biol, Copenhagen, Denmark; Odense Univ Hosp, Inst Pathol, Odense, Denmark	Aarhus University; University of Southern Denmark; Odense University Hospital; Danish Cancer Society; University of Southern Denmark; Odense University Hospital	Serakinci, N (corresponding author), Aarhus Univ, Dept Human Genet, Bartholin Bldg,Univ Pk, DK-8000 Aarhus C, Denmark.	nedi@humgen.au.dk	Abdallah, Basem/G-5667-2017; Burns, Jorge S./J-3395-2012; Kassem, Moustapha/J-7688-2013; Kassem, Moustapha/O-3819-2019; Schrøder, Henrik Daa/E-2077-2013; Burns, Jorge/AAF-5291-2019	Abdallah, Basem/0000-0003-0324-8055; Burns, Jorge S./0000-0002-8602-1536; Kassem, Moustapha/0000-0003-1557-0869; Kassem, Moustapha/0000-0003-1557-0869; Schrøder, Henrik Daa/0000-0001-7588-235X; SERAKINCI, Nedime/0000-0002-1884-0839				AHAJJ M, 2003, P NATL ACAD SCI USA, V100, P3983; Collas P, 2003, TRENDS BIOTECHNOL, V21, P354, DOI 10.1016/S0167-7799(03)00147-1; Dick JE, 2003, P NATL ACAD SCI USA, V100, P3547, DOI 10.1073/pnas.0830967100; Gronbaek K, 2000, LEUKEMIA, V14, P1727, DOI 10.1038/sj.leu.2401901; Hahn WC, 2002, NEW ENGL J MED, V347, P1593, DOI 10.1056/NEJMra021902; Hahn WC, 2001, ANN MED, V33, P123, DOI 10.3109/07853890109002067; Hamad NM, 2002, ONCOGENE, V21, P7121, DOI 10.1038/sj.onc.1205860; Helman LJ, 2003, NAT REV CANCER, V3, P685, DOI 10.1038/nrc1168; Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Korbling M, 2003, NEW ENGL J MED, V349, P570, DOI 10.1056/NEJMra022361; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Lundberg AS, 2002, ONCOGENE, V21, P4577, DOI 10.1038/sj.onc.1205550; Mackall CL, 2002, CANCER CELL, V2, P175, DOI 10.1016/S1535-6108(02)00132-0; Milyavsky M, 2003, CANCER RES, V63, P7147; Nishiyama H, 2001, ONCOGENE, V20, P2956, DOI 10.1038/sj.onc.1204432; Owens DM, 2003, NAT REV CANCER, V3, P444, DOI 10.1038/nrc1096; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Passegue E, 2003, P NATL ACAD SCI USA, V100, P11842, DOI 10.1073/pnas.2034201100; Perez-Losada J, 2003, NAT REV CANCER, V3, P434, DOI 10.1038/nrc1095; Preston SL, 2003, J CLIN PATHOL-MOL PA, V56, P86, DOI 10.1136/mp.56.2.86; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Shi ST, 2002, NAT BIOTECHNOL, V20, P587, DOI 10.1038/nbt0602-587; Simonsen JL, 2002, NAT BIOTECHNOL, V20, P592, DOI 10.1038/nbt0602-592; Singh SK, 2003, CANCER RES, V63, P5821; Wang J, 2000, NATURE, V405, P755, DOI 10.1038/35015674	27	281	310	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					5095	5098		10.1038/sj.onc.1207651	http://dx.doi.org/10.1038/sj.onc.1207651			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15107831				2022-12-28	WOS:000222237300017
J	Mishra, SK; Yang, ZB; Mazumdar, A; Talukder, AH; Larose, L; Kumar, R				Mishra, SK; Yang, ZB; Mazumdar, A; Talukder, AH; Larose, L; Kumar, R			Metastatic tumor antigen 1 short form (MTA1s) associates with casein kinase I-gamma 2, an estrogen-responsive kinase	ONCOGENE			English	Article						metastasis-associated protein-1 short form; casein kinase I-gamma 2; estrogen response element	PROTEIN-KINASE; BETA-CATENIN; RECEPTOR-ALPHA; I EPSILON; PHOSPHORYLATION; EXPRESSION; COMPLEX; CLONING; FAMILY; NURD	Recent studies have shown that metastasis-associated protein-1 short form (MTA1s) - metastatic tumor antigen 1 short form sequesters estrogen receptor-alpha (ER-alpha) in the cytoplasm of breast cancer cells. Using a yeast two-hybrid screening to clone MTA1s-interacting proteins, we identified casein kinase I-gamma 2 (CKI-gamma2, a ubiquitously expressed cytoplasmic kinase) as an MTA1s-binding protein. We show that MTA1s interacts with CKI-gamma2 both in vitro and in vivo and colocalizes in the cytoplasm. In addition, we found that CKI-gamma2 can phosphorylate MTA1s, but not ER, in an antiestrogen-dependent manner and that estrogen stimulates CKI-gamma2 activity that could be effectively blocked by a specific inhibitor of CKI. CKI-gamma2 could further potentiate the ER corepressive function of MTA1s. Kinase dead CK1-gamma2 could not repress estrogen-induced ER transactivation functions. Results from mutagenesis studies suggest that substitution of the serine residue at 321 to alanine, which is a possible CKI-gamma2 phopshorylation site in MTA1s, results in a significant reduction in the ability of MTA1s to repress ER transactivation. These findings identified MTA1s as a target of CKI-gamma2, and provided new evidence to suggest that CKI-gamma2 phosphorylates and modulates the functions of MTA1s, and that these extranuclear effects of estrogen might have important implications in regulating the functions of MTA1s in human mammary epithelial and cancer cells.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; McGill Univ, Dept Expt Med, Montreal, PQ H3A 2B2, Canada	University of Texas System; UTMD Anderson Cancer Center; McGill University	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol 108, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rkumar@mdanderson.org		Mishra, Sandip/0000-0002-0776-6581	NCI NIH HHS [CA90970, CA098823] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098823, R01CA090970] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARNOLD SF, 1995, J STEROID BIOCHEM, V55, P163, DOI 10.1016/0960-0760(95)00177-2; Bioukar EB, 1999, J BIOL CHEM, V274, P21457, DOI 10.1074/jbc.274.30.21457; Cegielska A, 1998, J BIOL CHEM, V273, P1357, DOI 10.1074/jbc.273.3.1357; Cooper CD, 2002, J BIOL CHEM, V277, P44962, DOI 10.1074/jbc.M209427200; DAHMUS ME, 1981, J BIOL CHEM, V256, P1239; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; Dubois T, 2001, J BIOL CHEM, V276, P18757, DOI 10.1074/jbc.M010005200; Dumaz N, 1999, FEBS LETT, V463, P312, DOI 10.1016/S0014-5793(99)01647-6; FLOTOW H, 1989, J BIOL CHEM, V264, P9126; Garcia-Rostan G, 1999, CANCER RES, V59, P1811; Garcia-Rostan G, 2001, AM J PATHOL, V158, P987, DOI 10.1016/S0002-9440(10)64045-X; GRASSER FA, 1988, VIROLOGY, V165, P13, DOI 10.1016/0042-6822(88)90653-8; GRAVES PR, 1995, J BIOL CHEM, V270, P21689, DOI 10.1074/jbc.270.37.21689; Gross SD, 1998, CELL SIGNAL, V10, P699, DOI 10.1016/S0898-6568(98)00042-4; Kitabayashi AN, 1997, GENOMICS, V46, P133, DOI 10.1006/geno.1997.4991; Kleene R, 1999, J CELL SCI, V112, P2539; KNIPPSCHILD U, 1995, ONCOGENE, V11, P683; Kreegipuu A, 1998, FEBS LETT, V430, P45, DOI 10.1016/S0014-5793(98)00503-1; Kumar R, 2003, SEMIN ONCOL, V30, P30, DOI 10.1053/j.seminoncol.2003.08.005; Kumar R, 2003, CELL, V113, P142, DOI 10.1016/S0092-8674(03)00274-5; Kumar R, 2002, NATURE, V418, P654, DOI 10.1038/nature00889; Lussier G, 1997, J BIOL CHEM, V272, P2688, DOI 10.1074/jbc.272.5.2688; Mahoney MG, 2002, ONCOGENE, V21, P2161, DOI 10.1038/sj.onc.1205277; Marin O, 2003, P NATL ACAD SCI USA, V100, P10193, DOI 10.1073/pnas.1733909100; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; Mishra SK, 2003, J BIOL CHEM, V278, P19209, DOI 10.1074/jbc.M301968200; Rivers A, 1998, J BIOL CHEM, V273, P15980, DOI 10.1074/jbc.273.26.15980; SIMKOWSKI KW, 1980, J BIOL CHEM, V255, P6456; TOH Y, 1994, J BIOL CHEM, V269, P22958; Tzeng DZ, 1996, BIOCHEM BIOPH RES CO, V223, P554, DOI 10.1006/bbrc.1996.0933; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; ZHAI LM, 1995, J BIOL CHEM, V270, P12717, DOI 10.1074/jbc.270.21.12717; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924	34	28	33	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2004	23	25					4422	4429		10.1038/sj.onc.1207569	http://dx.doi.org/10.1038/sj.onc.1207569			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	824CJ	15077195				2022-12-28	WOS:000221661300008
J	Hecker, TP; Ding, Q; Rege, TA; Hanks, SK; Gladson, CL				Hecker, TP; Ding, Q; Rege, TA; Hanks, SK; Gladson, CL			Overexpression of FAK promotes Ras activity through the formation of a FAK/p120RasGAP complex in malignant astrocytoma cells	ONCOGENE			English	Article						focal adhesion kinase (FAK); Ras; RasGAP; astrocytoma; glioma; glioblastoma; proliferation	FOCAL ADHESION KINASE; TYROSINE PHOSPHORYLATION; SRC TRANSFORMATION; P21 GTPASE; V-SRC; ACTIVATION; GAP; PATHWAY; DOMAIN; PROLIFERATION	Focal adhesion kinase (FAK) signaling may be mediated through the modulation of Ras activity. We have shown previously that grade III malignant astrocytoma biopsy samples exhibit elevated levels of FAK, and that overexpression of FAK in U-251MG malignant astrocytoma cells promotes the phosphorylation of Shc, a potential upstream mediator of Ras activity. Here, we report that overexpression of FAK promotes Ras activity in U-251MG malignant astrocytoma cells cultured in aggregate suspension or as monolayers adherent to vitronectin. The overexpression of FAK also promoted the association of FAK with p120RasGAP, which is a negative regulator of Ras activity, in the U-251MG cells cultured in aggregate suspension, with this association being abrogated upon plating of the cells onto vitronectin. An association of FAK with p120RasGAP also was observed in malignant astrocytoma biopsy samples, but not in normal brain samples. As overexpression of FAK in U-251MG cells in aggregate suspension culture reduced the amount of p120RasGAP complexed with active Ras, we hypothesize that the association of FAK with p120 RasGAP may facilitate Ras activity. The overexpression of a mutated FAK in which the Y397 had been mutated to F did not result in the formation of the FAK/p120RasGAP complex and did not promote Ras activity, indicating that the Y397 residue of FAK plays a role in the formation of this complex and in the activation of Ras. Moreover, the overexpression of mutated FAK (397F) was found to inhibit anchorage-independent growth. These data provide the basis for a previously undescribed mechanism in which the elevated expression of FAK can promote Ras activity through its competitive recruitment of p120RasGAP, thereby diminishing the association of p120RasGAP with active Ras.	Univ Alabama, Dept Pathol, Div Neuropathol, LHRB 567, Birmingham, AL 35294 USA; Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama, Med Scientist Training Program, Birmingham, AL 35294 USA; Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37232 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Vanderbilt University	Gladson, CL (corresponding author), Univ Alabama, Dept Pathol, Div Neuropathol, LHRB 567, 701 S 19th St, Birmingham, AL 35294 USA.	gladson@uab.edu			NATIONAL CANCER INSTITUTE [R01CA097100, R01CA059958] Funding Source: NIH RePORTER; NCI NIH HHS [CA97100, CA59958] Funding Source: Medline; NIGMS NIH HHS [GM49882] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; Cacalano NA, 2001, NAT CELL BIOL, V3, P460, DOI 10.1038/35074525; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; Ding H, 2001, CANCER RES, V61, P3826; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; Guha A, 1997, ONCOGENE, V15, P2755, DOI 10.1038/sj.onc.1201455; Guha A, 1998, CAN J NEUROL SCI, V25, P267, DOI 10.1017/S0317167100034272; Hecker TP, 2002, CANCER RES, V62, P2699; Kashige N, 2000, P NATL ACAD SCI USA, V97, P2093, DOI 10.1073/pnas.040547997; Kiyokawa E, 1997, CRIT REV ONCOGENESIS, V8, P329, DOI 10.1615/CritRevOncog.v8.i4.30; KLEIHUES P, 1993, BRAIN PATHOL, V3, P255, DOI 10.1111/j.1750-3639.1993.tb00752.x; Kornberg LJ, 1998, HEAD NECK-J SCI SPEC, V20, P745, DOI 10.1002/(SICI)1097-0347(199812)20:8<745::AID-HED14>3.0.CO;2-Z; LIEUBEAUTEILLET R, 1995, CANCER RES, V58, P4957; Luzi L, 2000, CURR OPIN GENET DEV, V10, P668, DOI 10.1016/S0959-437X(00)00146-5; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; Mohan PM, 1999, CANCER RES, V59, P3369; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Polte TR, 1997, J BIOL CHEM, V272, P5501, DOI 10.1074/jbc.272.9.5501; Renshaw MW, 1999, J CELL BIOL, V147, P611, DOI 10.1083/jcb.147.3.611; Roy S, 2002, J CELL BIOCHEM, V84, P377, DOI 10.1002/jcb.10025; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; SCHLAEPFER DD, 1994, NATURE, V372, P786; Serpente N, 1996, MOL CELL NEUROSCI, V7, P391, DOI 10.1006/mcne.1996.0028; Sieg DJ, 1999, J CELL SCI, V112, P2677; Slack JK, 2001, ONCOGENE, V20, P1152, DOI 10.1038/sj.onc.1204208; Tocque B, 1997, CELL SIGNAL, V9, P153, DOI 10.1016/S0898-6568(96)00135-0; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; Wang DY, 2000, J CELL SCI, V113, P4221; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413	34	53	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					3962	3971		10.1038/sj.onc.1207541	http://dx.doi.org/10.1038/sj.onc.1207541			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15077193				2022-12-28	WOS:000221382000008
J	Pinte, S; Guerardel, C; Deltour-Balerdi, S; Godwin, AK; Leprince, D				Pinte, S; Guerardel, C; Deltour-Balerdi, S; Godwin, AK; Leprince, D			Identification of a second G-C-rich promoter conserved in the human, murine and rat tumor suppressor genes HIC1	ONCOGENE			English	Article						HIC1; 17p13.3; MDS; BTB/POZ; promoter; CpG island; 5 '-UTR	MILLER-DIEKER-SYNDROME; DNA METHYLATION; CHROMOSOME 17P13.3; BREAST-CANCER; EXPRESSION; HYPERMETHYLATION; REGION; MOUSE; MICE; P53	The BTB/POZ transcriptional repressor HIC1 (Hypermethylated in Cancer 1) is a tumor suppressor gene located at chromosome 17p13.3, a region frequently hypermethylated or deleted in human tumors and in a contiguous-gene syndrome, the Miller-Dieker syndrome. The human and murine HIC1 genes are composed of two alternative 5' exons, 1a and 1b fused to a large second coding exon 2. Exon 1a is a noncoding exon associated with a major G-C-rich promoter whereas exon 1b is a downstream coding exon associated with a minor TATA box promoter. By human-mouse genome comparison, we have identified a short upstream conserved sequence containing G-C boxes which were shown to be functional. Transcripts initiating from this new promoter were detected in various human and mouse tissues and contained a long 5'-UTR sequence, called 1c which encompass the G-C-rich promoter associated with exon 1a and uses the same splice donor site. RT-PCR analyses of two primary breast epithelial cell lines identified two other 5'-UTRs generated by alternative splicing within exon 1c. Our results thus highlight the existence of an unexpected complex transcriptional regulation of HIC1.	Inst Pasteur, Inst Biol Lille, CNRS, UMR 8526, F-59017 Lille, France; Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Fox Chase Cancer Center	Leprince, D (corresponding author), Inst Pasteur, Inst Biol Lille, CNRS, UMR 8526, 1 Rue Calmette, F-59017 Lille, France.	dominique.leprince@ibl.fr		Leprince, Dominique/0000-0002-1999-0775	NCI NIH HHS [P50 CA83638] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA083638] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Baylin SB, 1998, ADV CANCER RES, V72, P141; Bruening W, 1999, CANCER RES, V59, P4973; Carter MG, 2000, HUM MOL GENET, V9, P413, DOI 10.1093/hmg/9.3.413; Chen WY, 2003, NAT GENET, V33, P197, DOI 10.1038/ng1077; Deltour S, 1999, P NATL ACAD SCI USA, V96, P14831, DOI 10.1073/pnas.96.26.14831; Feltus FA, 2003, P NATL ACAD SCI USA, V100, P12253, DOI 10.1073/pnas.2037852100; Fujii H, 1998, ONCOGENE, V16, P2159, DOI 10.1038/sj.onc.1201976; Grimm C, 1999, HUM MOL GENET, V8, P697, DOI 10.1093/hmg/8.4.697; Guerardel C, 2001, J BIOL CHEM, V276, P3078, DOI 10.1074/jbc.M008690200; Han BG, 2003, ONCOGENE, V22, P5325, DOI 10.1038/sj.onc.1206783; Kanai Y, 1999, HEPATOLOGY, V29, P703, DOI 10.1002/hep.510290338; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Liscia DS, 1999, BRIT J CANCER, V80, P821, DOI 10.1038/sj.bjc.6690427; MAKOSWALES M, 1995, NAT MED, V1, P570; Melki JR, 1999, LEUKEMIA, V13, P877, DOI 10.1038/sj.leu.2401401; Phillips NJ, 1996, CANCER LETT, V102, P85, DOI 10.1016/0304-3835(96)04169-9; Rood BR, 2002, CANCER RES, V62, P3794; Schultz DC, 1996, CANCER RES, V56, P1997; Yingling J, 2003, AM J HUM GENET, V73, P475, DOI 10.1086/378096; Yuasa Y, 2002, MECH AGEING DEV, V123, P1649, DOI 10.1016/S0047-6374(02)00100-8	22	16	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					4023	4031		10.1038/sj.onc.1207504	http://dx.doi.org/10.1038/sj.onc.1207504			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15007385				2022-12-28	WOS:000221382000015
J	Tanaka, T; Akatsuka, S; Ozeki, M; Shirase, T; Hiai, H; Toyokuni, S				Tanaka, T; Akatsuka, S; Ozeki, M; Shirase, T; Hiai, H; Toyokuni, S			Redox regulation of annexin 2 and its implications for oxidative stress-induced renal carcinogenesis and metastasis	ONCOGENE			English	Article						annexin 2; iron; redox regulation; carcinogenesis; metastasis; renal cell carcinoma	TUMOR-SUPPRESSOR GENE; ROUS-SARCOMA-VIRUS; FERRIC NITRILOTRIACETATE; CELL CARCINOMA; WISTAR RATS; INSULIN-RECEPTOR; KINASE SUBSTRATE; RESPONSE GENES; ALLELIC LOSS; II TETRAMER	Ferric nitrilotriacetate (Fe-NTA) induces oxidative renal damage leading to a high incidence of renal cell carcinoma (RCC) in rats. Differential display analysis of such RCCs revealed elevated expression of annexin 2 (Anx2), a substrate for kinases and a receptor for tissue-type plasminogen activator and plasminogen. We conducted this study to clarify the significance of Anx2 in Fenton reaction-based carcinogenesis. Messenger RNA and protein levels of Anx2 were increased time-dependently in the rat kidney after Fe-NTA administration as well as in LLC-PK1 cells after exposure to H2O2. The latter was inhibited by pretreatment with N-acetylcysteine, pyrrolidine dithiocarbamate or catalase. Immunohistochemistry revealed negligible staining in the normal renal proximal tubules, but strong staining in regenerating proximal tubules, karyomegalic cells and RCCs. Metastasizing RCCs showed higher Anx2 protein levels. Anx2 was phosphorylated at serine and tyrosine residues in these cells and coimmunoprecipitated with phosphorylated actin. Overexpression of Anx2 induced a higher cell proliferation rate in LLC-PK1 cells. In contrast, a decrease in proliferation leading to apoptosis was observed after Anx2 antisense treatment to cell lines established from Fe-NTA-induced RCCs. These results suggest that Anx2 is regulated by redox status, and that persistent operation of this adaptive mechanism plays a role in the proliferation and metastasis of oxidative stress-induced cancer.	Kyoto Univ, Grad Sch Med, Dept Pathol & Biol Dis, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University	Toyokuni, S (corresponding author), Kyoto Univ, Grad Sch Med, Dept Pathol & Biol Dis, Sakyo Ku, Kyoto 6068501, Japan.	toyokuni@path1.med.kyoto-u.ac.jp	Akatsuka, Shinya/C-9806-2010; Toyokuni, Shinya/C-1358-2010; Toyokuni, Shinya/ABE-7714-2021	Akatsuka, Shinya/0000-0002-9944-8803; Toyokuni, Shinya/0000-0002-5757-1109; Toyokuni, Shinya/0000-0002-5757-1109				Aarli A, 1997, APMIS, V105, P699, DOI 10.1111/j.1699-0463.1997.tb05073.x; AMES BN, 1991, OXIDATIVE DAMAGE & REPAIR, P181; Biener Y, 1996, J BIOL CHEM, V271, P29489, DOI 10.1074/jbc.271.46.29489; Chacko G, 1998, J BIOL CHEM, V273, P19840, DOI 10.1074/jbc.273.31.19840; Chetcuti A, 2001, CANCER RES, V61, P6331; CHIANG YP, 1993, CANCER RES, V53, P6017; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; EBINA Y, 1986, J NATL CANCER I, V76, P107; Emoto K, 2001, ANTICANCER RES, V21, P1339; ERIKSON E, 1981, J BIOL CHEM, V256, P1381; Forman HJ, 2002, MOL CELL BIOCHEM, V234, P49, DOI 10.1023/A:1015913229650; FROHLICH M, 1990, MOL CELL BIOL, V10, P3216, DOI 10.1128/MCB.10.6.3216; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Goldman LA, 1996, BIOTECHNIQUES, V21, P1013; GOULD KL, 1986, MOL CELL BIOL, V6, P2738, DOI 10.1128/MCB.6.7.2738; HAIGLER HT, 1987, J BIOL CHEM, V262, P6921; Hajjar KA, 1998, J INVEST MED, V46, P364; Hajjar KA, 1997, ANN NY ACAD SCI, V811, P337, DOI 10.1111/j.1749-6632.1997.tb52013.x; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; HAMAZAKI S, 1988, TOXICOL APPL PHARM, V92, P500, DOI 10.1016/0041-008X(88)90190-1; HAMAZAKI S, 1985, TOXICOL APPL PHARM, V77, P267, DOI 10.1016/0041-008X(85)90326-6; Hiroyasu M, 2002, AM J PATHOL, V160, P419, DOI 10.1016/S0002-9440(10)64860-2; HULL RN, 1976, IN VITRO CELL DEV B, V12, P670, DOI 10.1007/BF02797469; JINDAL HK, 1991, J BIOL CHEM, V266, P5169; JOHNSTONE SA, 1992, J BIOL CHEM, V267, P25976; JONES PG, 1992, J BIOL CHEM, V267, P13993; Konig J, 1998, J BIOL CHEM, V273, P19679, DOI 10.1074/jbc.273.31.19679; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; KUMBLE KD, 1992, CANCER RES, V52, P163; KUMBLE KD, 1992, J CELL SCI, V101, P35; Langen R, 1998, P NATL ACAD SCI USA, V95, P14060, DOI 10.1073/pnas.95.24.14060; LI JL, 1987, CANCER RES, V47, P1867; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; Liu L, 1996, AM J PHYSIOL-LUNG C, V270, pL668, DOI 10.1152/ajplung.1996.270.4.L668; Menell JS, 1999, NEW ENGL J MED, V340, P994, DOI 10.1056/NEJM199904013401303; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; Nakanishi H, 1996, JPN J CANCER RES, V87, P1218, DOI 10.1111/j.1349-7006.1996.tb03136.x; Nishiyama Y, 1995, JPN J CANCER RES, V86, P1150, DOI 10.1111/j.1349-7006.1995.tb03308.x; NOSE K, 1991, EUR J BIOCHEM, V201, P99, DOI 10.1111/j.1432-1033.1991.tb16261.x; OZAKI T, 1993, ONCOGENE, V8, P1707; Paciucci R, 1998, ONCOGENE, V16, P625, DOI 10.1038/sj.onc.1201564; RADKE K, 1979, P NATL ACAD SCI USA, V76, P5212, DOI 10.1073/pnas.76.10.5212; RADKE K, 1980, CELL, V21, P821, DOI 10.1016/0092-8674(80)90445-6; Ramasamy S, 1998, J LIPID RES, V39, P268; REEVES SA, 1992, CANCER RES, V52, P6871; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; Tanaka T, 2000, AM J PATHOL, V156, P2149, DOI 10.1016/S0002-9440(10)65085-7; Tanaka T, 1997, LAB INVEST, V77, P145; Tanaka T, 1999, ONCOGENE, V18, P3793, DOI 10.1038/sj.onc.1202707; TOYOKUNI S, 1990, CANCER RES, V50, P5574; Toyokuni S, 1999, PATHOL INT, V49, P91, DOI 10.1046/j.1440-1827.1999.00829.x; TOYOKUNI S, 1994, INT J CANCER, V57, P123, DOI 10.1002/ijc.2910570122; TOYOKUNI S, 1995, FEBS LETT, V358, P1, DOI 10.1016/0014-5793(94)01368-B; Toyokuni S, 2003, PATHOL INT, V53, P259, DOI 10.1046/j.1320-5463.2003.01465.x; Toyokuni S, 1997, LAB INVEST, V76, P365; TOYOKUNI S, 1994, P NATL ACAD SCI USA, V91, P2616, DOI 10.1073/pnas.91.7.2616; Toyokuni S, 1997, FREE RADICAL BIO MED, V22, P1019, DOI 10.1016/S0891-5849(96)00489-3; TOYOKUNI S, 1995, INT J CANCER, V62, P309, DOI 10.1002/ijc.2910620313; Wu T, 1997, J BIOL CHEM, V272, P17145, DOI 10.1074/jbc.272.27.17145; Zhang DX, 1997, CANCER RES, V57, P2410; Zhao WQ, 2003, J BIOL CHEM, V278, P4205, DOI 10.1074/jbc.M210545200; Zhou S, 2003, MUTAGENESIS, V18, P287, DOI 10.1093/mutage/18.3.287	64	78	91	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					3980	3989		10.1038/sj.onc.1207555	http://dx.doi.org/10.1038/sj.onc.1207555			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15048081				2022-12-28	WOS:000221382000010
J	Cronauer, MV; Schulz, WA; Burchardt, T; Ackermann, R; Burchardt, M				Cronauer, MV; Schulz, WA; Burchardt, T; Ackermann, R; Burchardt, M			Inhibition of p53 function diminishes androgen receptor-mediated signaling in prostate cancer cell lines	ONCOGENE			English	Article						androgen receptor; p53; prostate cancer; pifithrin; MDM2; probasin promoter	WILD-TYPE P53; CARCINOMA-CELLS; TRANSCRIPTIONAL ACTIVITY; GLUCOCORTICOID-RECEPTOR; MUTATIONS; PROTEIN; GROWTH; EXPRESSION; ADENOVIRUS; APOPTOSIS	Current therapy for advanced prostate cancer is mainly based on androgen deprivation, although most patients relapse to androgen-insensitive disease. Several mechanisms contributing to androgen-independent growth including alterations in the structure or expression of the androgen receptor (AR) and its cofactors have been identified. Recent evidence suggests that p53 is involved in androgen signaling. The analysis of the effect of p53 on androgen signaling was performed in 22Rv1 and LNCaP prostate cancer cells that express both p53 and AR. The overexpression of p53 diminished the androgenic response in both cell lines in a reporter gene assay. Conversely, the inhibition of p53 by three different p53 inhibitors, Pifithrin-1alpha (PFT-1alpha), an inhibitor of p53-dependent transactivation; MDM2, a regulator of p53 expression; and a dominant-negative N-terminally truncated p53 gene also reduced transactivation of androgen-dependent reporter genes. The inactivation of p53 by PFT-1alpha decreased AR-protein expression in both 22Rv1 and LNCaP cells. Our findings confirm that the overexpression of wild-type p53 decreases androgen function, whereas p53 expression at physiological levels stabilizes AR signaling. Thus, our findings suggest that there is a balance of AR and p53 expression during the androgen-dependent growth of prostate cancer, which is obliterated during further progression of the disease.	Univ Dusseldorf, Dept Urol, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Burchardt, M (corresponding author), Univ Dusseldorf, Dept Urol, D-40225 Dusseldorf, Germany.	mb706@hotmail.com	Schulz, Wolfgang A./A-6523-2008; Cronauer, Marcus/AAG-7457-2021; Schulz, Wolfgang/N-3402-2019	Schulz, Wolfgang/0000-0002-2196-463X				Agus DB, 1999, J NATL CANCER I, V91, P1869, DOI 10.1093/jnci/91.21.1869; APRIKIAN AG, 1994, J UROLOGY, V151, P1276, DOI 10.1016/S0022-5347(17)35231-X; Asschert JGW, 1999, INT J CANCER, V81, P236, DOI 10.1002/(SICI)1097-0215(19990412)81:2<236::AID-IJC12>3.0.CO;2-R; Burchardt M, 2001, PROSTATE, V48, P225, DOI 10.1002/pros.1101; CALEFFI M, 1994, CANCER, V73, P2147, DOI 10.1002/1097-0142(19940415)73:8<2147::AID-CNCR2820730820>3.0.CO;2-5; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; Chen TS, 2000, CANCER RES, V60, P2132; Coffey RNT, 2002, PROSTATE, V53, P300, DOI 10.1002/pros.10159; Coursen JD, 1997, MOL CARCINOGEN, V19, P191; Cronauer MV, 2000, BRIT J CANCER, V82, P39; Cronauer MV, 1997, IN VITRO CELL DEV-AN, V33, P742; CULIG Z, 1993, MOL ENDOCRINOL, V7, P1541, DOI 10.1210/me.7.12.1541; Culig Z, 2002, MOL CELL ENDOCRINOL, V197, P231, DOI 10.1016/S0303-7207(02)00263-0; Eastham JA, 1995, CLIN CANCER RES, V1, P1111; Eastham JA, 2000, J UROLOGY, V164, P814, DOI 10.1016/S0022-5347(05)67320-X; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Freedland SJ, 2003, PROSTATE, V55, P299, DOI 10.1002/pros.10226; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Gurova KV, 2002, ONCOGENE, V21, P153, DOI 10.1038/sj.onc.1205001; HASSE A, 1992, BIOCHIM BIOPHYS ACTA, V1131, P16, DOI 10.1016/0167-4781(92)90092-E; Heisler LE, 1997, MOL CELL ENDOCRINOL, V126, P59, DOI 10.1016/S0303-7207(96)03970-6; Hobisch A, 1998, CANCER RES, V58, P4640; ISAACS WB, 1991, CANCER RES, V51, P4716; Jacobberger JW, 1999, CYTOMETRY, V38, P201, DOI 10.1002/(SICI)1097-0320(19991015)38:5<201::AID-CYTO2>3.0.CO;2-F; Javelaud D, 2002, J BIOL CHEM, V277, P37949, DOI 10.1074/jbc.M204497200; Kelly KJ, 2003, J AM SOC NEPHROL, V14, P128, DOI 10.1097/01.ASN.0000040596.23073.01; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Komarova EA, 2003, J BIOL CHEM, V278, P15465, DOI 10.1074/jbc.C300011200; Kremenetskaya OS, 1997, ONCOL RES, V9, P155; Lee YG, 2001, IN VIVO, V15, P157; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Lin HY, 2002, J UROLOGY, V168, P748, DOI 10.1016/S0022-5347(05)64739-8; Makri D, 1998, INT J ONCOL, V12, P621; MARTH C, 1990, CANCER RES, V50, P7037; Meyers FJ, 1998, CANCER, V83, P2534, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2534::AID-CNCR19>3.3.CO;2-M; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NAVONE NM, 1993, J NATL CANCER I, V85, P1657, DOI 10.1093/jnci/85.20.1657; Nesslinger NJ, 2003, CANCER RES, V63, P2228; Osman I, 1999, CLIN CANCER RES, V5, P2082; Patel BJ, 2000, J UROLOGY, V164, P1420, DOI 10.1016/S0022-5347(05)67210-2; Peehl DM, 1994, ATLAS HUMAN TUMOR CE, P387; Pocard M, 1996, ONCOGENE, V12, P875; RUBIN SJ, 1991, J SURG ONCOL, V46, P31, DOI 10.1002/jso.2930460108; RUNNEBAUM IB, 1994, FEBS LETT, V353, P29, DOI 10.1016/0014-5793(94)00953-8; Schumacher G, 2001, INT J CANCER, V91, P159, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1026>3.3.CO;2-E; Sengupta S, 2001, GENE DEV, V15, P2367, DOI 10.1101/gad.202201; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Shenk JL, 2001, J BIOL CHEM, V276, P38472, DOI 10.1074/jbc.M103652200; Shi XB, 2002, PROSTATE, V51, P59, DOI 10.1002/pros.10072; Sinisl AA, 2002, IN VITRO CELL DEV-AN, V38, P165; Sramkoski RM, 1999, IN VITRO CELL DEV-AN, V35, P403; SRIVASTAVA S, 1995, UROLOGY, V46, P843, DOI 10.1016/S0090-4295(99)80355-0; Steinhoff C, 2002, INT J ONCOL, V21, P1033; Tepper CG, 2002, CANCER RES, V62, P6606; Yap N, 1996, P NATL ACAD SCI USA, V93, P4273, DOI 10.1073/pnas.93.9.4273; Yu CL, 1997, BIOCHEM BIOPH RES CO, V239, P617, DOI 10.1006/bbrc.1997.7522; Yu CL, 1997, CANCER LETT, V116, P191, DOI 10.1016/S0304-3835(97)00186-9	57	77	78	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3541	3549		10.1038/sj.onc.1207346	http://dx.doi.org/10.1038/sj.onc.1207346			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15077179				2022-12-28	WOS:000221101700005
J	Wada, T; Penninger, JM				Wada, T; Penninger, JM			Mitogen-activated protein kinases in apoptosis regulation	ONCOGENE			English	Review						stress; programmed cell death; signal transduction; JNK/SAPK; ERK; p38-MAPK	N-TERMINAL KINASE; SIGNAL-TRANSDUCTION PATHWAYS; CELL-CYCLE PROGRESSION; MEF2 TRANSCRIPTION FACTOR; TNF RECEPTOR 1; MAP KINASE; C-JUN; GENE-EXPRESSION; MICE LACKING; KAPPA-B	Cells are continuously exposed to a variety of environmental stresses and have to decide 'to be or not to be' depending on the types and strength of stress. Among the many signaling pathways that respond to stress, mitogen-activated protein kinase (MAPK) family members are crucial for the maintenance of cells. Three subfamilies of MAPKs have been identified: extracellular signal-regulated kinases (ERKs), c-Jun N-terminal kinases (JNKs), and p38-MAPKs. It has been originally shown that ERKs are important for cell survival, whereas JNKs and p38-MAPKs were deemed stress responsive and thus involved in apoptosis. However, the regulation of apoptosis by MAPKs is more complex than initially thought and often controversial. In this review, we discuss MAPKs in apoptosis regulation with attention to mouse genetic models and critically point out the multiple roles of MAPKs.	Austrian Acad Sci, Inst Mol Biotechnol, A-1030 Vienna, Austria	Austrian Academy of Sciences; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA)	Penninger, JM (corresponding author), Austrian Acad Sci, Inst Mol Biotechnol, Dr Bohr Gasse 3-5, A-1030 Vienna, Austria.	josef.penninger@imba.oeaw.ac.at	Penninger, Josef M/I-6860-2013	Penninger, Josef M/0000-0002-8194-3777				Abe MK, 2002, J BIOL CHEM, V277, P16733, DOI 10.1074/jbc.M112483200; Abe MK, 2001, J BIOL CHEM, V276, P21272, DOI 10.1074/jbc.M100026200; Abe MK, 1999, MOL CELL BIOL, V19, P1301; Adams RH, 2000, MOL CELL, V6, P109, DOI 10.1016/S1097-2765(00)00012-5; AHN NG, 1991, J BIOL CHEM, V266, P4220; ALBEROLAILA J, 1995, NATURE, V373, P620, DOI 10.1038/373620a0; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; Aoki H, 2002, J BIOL CHEM, V277, P10244, DOI 10.1074/jbc.M112355200; Arbour N, 2002, J EXP MED, V195, P801, DOI 10.1084/jem.20011481; Balaban N, 1996, BBA-MOL CELL RES, V1314, P147, DOI 10.1016/S0167-4889(96)00068-7; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Belanger LF, 2003, MOL CELL BIOL, V23, P4778, DOI 10.1128/MCB.23.14.4778-4787.2003; Blaeser F, 2000, J BIOL CHEM, V275, P197, DOI 10.1074/jbc.275.1.197; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOS JL, 1989, CANCER RES, V49, P4682; BOULTON TG, 1990, J BIOL CHEM, V265, P2713; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Caffrey DR, 1999, J MOL EVOL, V49, P567, DOI 10.1007/PL00006578; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chauhan D, 2003, J BIOL CHEM, V278, P17593, DOI 10.1074/jbc.C300076200; Chen SJ, 2003, J BIOL CHEM, V278, P19526, DOI 10.1074/jbc.M300780200; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Chen ZH, 1999, ONCOGENE, V18, P173, DOI 10.1038/sj.onc.1202276; COFFER PJ, 1995, ONCOGENE, V11, P561; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dent P, 2003, ONCOGENE, V22, P5885, DOI 10.1038/sj.onc.1206701; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DHANWADA KR, 1995, ONCOGENE, V11, P1947; Diehl NL, 2000, J EXP MED, V191, P321, DOI 10.1084/jem.191.2.321; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; Dong C, 2000, NATURE, V405, P91, DOI 10.1038/35011091; Dougherty CJ, 2002, BIOCHEM J, V362, P561, DOI 10.1042/0264-6021:3620561; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; English JM, 2002, TRENDS PHARMACOL SCI, V23, P40, DOI 10.1016/S0165-6147(00)01865-4; Fields PE, 1996, SCIENCE, V271, P1276, DOI 10.1126/science.271.5253.1276; Fleming Y, 2000, BIOCHEM J, V352, P145, DOI 10.1042/0264-6021:3520145; Ganiatsas S, 1998, P NATL ACAD SCI USA, V95, P6881, DOI 10.1073/pnas.95.12.6881; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; Ge BX, 2002, SCIENCE, V295, P1291, DOI 10.1126/science.1067289; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Giroux S, 1999, CURR BIOL, V9, P369, DOI 10.1016/S0960-9822(99)80164-X; Guo ZJ, 2002, MOL CELL BIOL, V22, P5761, DOI 10.1128/MCB.22.16.5761-5768.2002; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Han JH, 2000, TRENDS CARDIOVAS MED, V10, P19, DOI 10.1016/S1050-1738(00)00039-6; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; Hilger RA, 2002, ONKOLOGIE, V25, P511, DOI 10.1159/000068621; Holbrook N J, 1996, EXS, V77, P273; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Irigoyen JP, 1997, J BIOL CHEM, V272, P1904, DOI 10.1074/jbc.272.3.1904; Ito M, 1999, MOL CELL BIOL, V19, P7539; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; Juretic N, 2001, J CELL BIOCHEM, V83, P92, DOI 10.1002/jcb.1211; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kavanagh BD, 1998, RADIAT RES, V149, P579, DOI 10.2307/3579904; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; KING KL, 1995, J CELL BIOCHEM, V58, P175, DOI 10.1002/jcb.240580206; Kishimoto H, 2003, J BIOL CHEM, V278, P16595, DOI 10.1074/jbc.M213182200; Kitagawa D, 2002, J BIOL CHEM, V277, P366, DOI 10.1074/jbc.M107110200; Kolodziejczyk SM, 1999, CURR BIOL, V9, P1203, DOI 10.1016/S0960-9822(00)80027-5; Konishi Y, 2002, MOL CELL, V9, P1005, DOI 10.1016/S1097-2765(02)00524-5; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Latinis KM, 1996, BLOOD, V87, P871, DOI 10.1182/blood.V87.3.871.bloodjournal873871; Laurent G, 2001, BLOOD, V98, P913, DOI 10.1182/blood.V98.4.913; Leach JK, 2001, CANCER RES, V61, P3894; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; Lee SH, 2001, J BIOL CHEM, V276, P25066, DOI 10.1074/jbc.M010892200; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Li W, 1996, SCIENCE, V271, P1272, DOI 10.1126/science.271.5253.1272; Lin A, 2003, BIOESSAYS, V25, P17, DOI 10.1002/bies.10204; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; Lin WC, 2000, ONCOGENE, V19, P5680, DOI 10.1038/sj.onc.1203924; Lisovsky M, 2002, CURR BIOL, V12, P53, DOI 10.1016/S0960-9822(01)00628-5; Liu B, 2001, BRIT J CANCER, V85, P303, DOI 10.1054/bjoc.2001.1910; Liu LD, 2003, P NATL ACAD SCI USA, V100, P8532, DOI 10.1073/pnas.1332804100; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lu HT, 1999, EMBO J, V18, P1845, DOI 10.1093/emboj/18.7.1845; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; Lu XH, 1997, J BIOL CHEM, V272, P24751, DOI 10.1074/jbc.272.40.24751; Mao ZX, 1999, J BIOL CHEM, V274, P31102, DOI 10.1074/jbc.274.43.31102; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Mathas S, 2002, EMBO J, V21, P4104, DOI 10.1093/emboj/cdf389; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; McKinsey TA, 2002, TRENDS BIOCHEM SCI, V27, P40, DOI 10.1016/S0968-0004(01)02031-X; Mehta PB, 2003, ONCOGENE, V22, P1381, DOI 10.1038/sj.onc.1206154; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; Mody N, 2001, FEBS LETT, V502, P21, DOI 10.1016/S0014-5793(01)02651-5; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Naya FJ, 2002, NAT MED, V8, P1303, DOI 10.1038/nm789; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Nishina H, 1999, DEVELOPMENT, V126, P505; Nishitai G, 2004, J BIOL CHEM, V279, P1621, DOI 10.1074/jbc.M310335200; Okamoto S, 2000, P NATL ACAD SCI USA, V97, P7561, DOI 10.1073/pnas.130502697; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Pages G, 1999, SCIENCE, V286, P1374, DOI 10.1126/science.286.5443.1374; Park JM, 2002, SCIENCE, V297, P2048, DOI 10.1126/science.1073163; Pearson G, 2001, J BIOL CHEM, V276, P7927, DOI 10.1074/jbc.M009764200; Platanias LC, 2003, BLOOD, V101, P4667, DOI 10.1182/blood-2002-12-3647; Porras A, 2004, MOL BIOL CELL, V15, P922, DOI 10.1091/mbc.E03-08-0592; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Regan CP, 2002, P NATL ACAD SCI USA, V99, P9248, DOI 10.1073/pnas.142293999; Robinson D, 1996, P NATL ACAD SCI USA, V93, P5958, DOI 10.1073/pnas.93.12.5958; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; Rowinsky EK, 1999, J CLIN ONCOL, V17, P3631, DOI 10.1200/JCO.1999.17.11.3631; Sabapathy K, 2001, J EXP MED, V193, P317, DOI 10.1084/jem.193.3.317; Sabapathy K, 1999, CURR BIOL, V9, P116, DOI 10.1016/S0960-9822(99)80065-7; Sadoshima J, 2002, J CLIN INVEST, V110, P271, DOI 10.1172/JCI200214938; Salmon RA, 1997, J IMMUNOL, V159, P5309; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Sarkar D, 2002, P NATL ACAD SCI USA, V99, P10054, DOI 10.1073/pnas.152327199; Sasaki T, 2001, J EXP MED, V194, P757, DOI 10.1084/jem.194.6.757; SchmidtUllrich RK, 1997, ONCOGENE, V15, P1191, DOI 10.1038/sj.onc.1201275; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Sebolt-Leopold JS, 2000, ONCOGENE, V19, P6594, DOI 10.1038/sj.onc.1204083; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Shi Y, 2003, MOL CELL BIOL, V23, P7732, DOI 10.1128/MCB.23.21.7732-7741.2003; Sohn SJ, 2002, J BIOL CHEM, V277, P43344, DOI 10.1074/jbc.M207573200; Stadheim TA, 2002, LEUKEMIA RES, V26, P55, DOI 10.1016/S0145-2126(01)00099-6; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Su Gloria H, 2002, Hum Mutat, V19, P81, DOI 10.1002/humu.9002; Suzaki Y, 2002, J BIOL CHEM, V277, P9614, DOI 10.1074/jbc.M111790200; Swat W, 1998, IMMUNITY, V8, P625, DOI 10.1016/S1074-7613(00)80567-1; Takeda K, 2003, CELL STRUCT FUNCT, V28, P23; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; Tamura K, 2000, CELL, V102, P221, DOI 10.1016/S0092-8674(00)00027-1; Tanaka N, 2002, EMBO REP, V3, P785, DOI 10.1093/embo-reports/kvf153; Teng DHF, 1997, CANCER RES, V57, P4177; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tournier C, 2001, GENE DEV, V15, P1419, DOI 10.1101/gad.888501; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wada T, 2004, NAT CELL BIOL, V6, P215, DOI 10.1038/ncb1098; Wada T, 2001, J BIOL CHEM, V276, P30892, DOI 10.1074/jbc.M011780200; WADMAN IA, 1994, ONCOGENE, V9, P3713; Wang XK, 2002, J BIOL CHEM, V277, P43968, DOI 10.1074/jbc.M206837200; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Watanabe T, 2002, DEV BIOL, V250, P332, DOI 10.1006/dbio.2002.0781; Watson FL, 2001, NAT NEUROSCI, V4, P981, DOI 10.1038/nn720; Weldon CB, 2002, SURGERY, V132, P293, DOI 10.1067/msy.2002.125389; Werlen G, 2003, SCIENCE, V299, P1859, DOI 10.1126/science.1067833; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Williams N, 1996, SCIENCE, V271, P1234, DOI 10.1126/science.271.5253.1234; Wilson DJ, 1996, EUR J IMMUNOL, V26, P989, DOI 10.1002/eji.1830260505; Woodgett JR, 1996, CANCER SURV, V27, P127; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; YAN MH, 1994, NATURE, V372, P798; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yang DD, 1998, IMMUNITY, V9, P575, DOI 10.1016/S1074-7613(00)80640-8; Yosimichi G, 2001, EUR J BIOCHEM, V268, P6058, DOI 10.1046/j.0014-2956.2001.02553.x; Youn HD, 2000, EMBO J, V19, P4323, DOI 10.1093/emboj/19.16.4323; Yu R, 1996, CANCER LETT, V107, P73, DOI 10.1016/0304-3835(96)04345-5; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zetser A, 1999, J BIOL CHEM, V274, P5193, DOI 10.1074/jbc.274.8.5193; Zhang J, 2000, J EXP MED, V191, P1017, DOI 10.1084/jem.191.6.1017; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	195	1178	1237	4	95	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2004	23	16					2838	2849		10.1038/sj.onc.1207556	http://dx.doi.org/10.1038/sj.onc.1207556			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	811VO	15077147				2022-12-28	WOS:000220799600011
J	Punj, V; Bhattacharyya, S; Saint-Dic, D; Vasu, C; Cunningham, EA; Graves, J; Yamada, T; Constantinou, AI; Christov, K; White, B; Li, G; Majumdar, D; Chakrabarty, AM; Das Gupta, TK				Punj, V; Bhattacharyya, S; Saint-Dic, D; Vasu, C; Cunningham, EA; Graves, J; Yamada, T; Constantinou, AI; Christov, K; White, B; Li, G; Majumdar, D; Chakrabarty, AM; Das Gupta, TK			Bacterial cupredoxin azurin as an inducer of apoptosis and regression in human breast cancer	ONCOGENE			English	Article						cupredoxin azurin; breast cancer; apoptosis	SUPPRESSOR PROTEIN P53; CELL-CYCLE ARREST; MCF7 CELLS; CASPASE 3; TUMOR; ACTIVATION; DEATH; BAX; DNA; MITOCHONDRIA	Azurin, a copper-containing redox protein released by the pathogenic bacterium Pseudomonas aeruginosa, is highly cytotoxic to the human breast cancer cell line MCF-7, but is less cytotoxic toward p53-negative (MDA-MB-157) or nonfunctional p53 cell lines like MDD2 and MDA-MB-231. The purpose of this study was to investigate the underlying mechanism of the action of bacterial cupredoxin azurin in the regression of breast cancer and its potential chemotherapeutic efficacy. Azurin enters into the cytosol of MCF-7 cells and travels to the nucleus, enhancing the intracellular levels of p53 and Bax, thereby triggering the release of mitochondrial cytochrome c into the cytosol. This process activates the caspase cascade (including caspase-9 and caspase-7), thereby initiating the apoptotic process. Our results indicate that azurin-induced cell death stimuli are amplified in the presence of p53. In vivo injection of azurin in immunodeficient mice harboring xenografted human breast cancer cells in the mammary fat pad leads to statistically significant regression (85%, P = 0.0179, Kruskal-Wallis Test) of the tumor. In conclusion, azurin blocks breast cancer cell proliferation and induces apoptosis through the mitochondrial pathway both in vitro and in vivo, thereby suggesting a potential chemotherapeutic application of this bacterial cupredoxin for the treatment of breast cancer.	Univ Illinois, Dept Surg Oncol, Chicago, IL 60612 USA; Univ Illinois, Dept Microbiol & Immunol, Chicago, IL 60612 USA; Univ Illinois, Dept Surg, Chicago, IL 60612 USA; Univ Illinois, Dept Math Stat & Comp Sci, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Das Gupta, TK (corresponding author), Univ Illinois, Dept Surg Oncol, 840 S Wood St,M-C 820, Chicago, IL 60612 USA.	tkdg@uic.edu	Johnson, Michael D. L./B-4352-2012; Li, Gang/AAD-4952-2021; Bhattacharyya, Suchita/V-5390-2019; White, Bethany E. Perez/AAF-7256-2020	Bhattacharyya, Suchita/0000-0002-6775-630X; Perez White, Bethany/0000-0002-5594-0599; vasu, chenthamarakshan/0000-0002-1772-6508; Das Gupta, Tapas K./0000-0001-6437-6320; Constantinou, Andreas/0000-0003-0365-1821; Yamada, Tohru/0000-0001-6594-3534	NATIONAL CANCER INSTITUTE [T32CA009432, R03CA095712, R01CA096517] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004050] Funding Source: NIH RePORTER; NCI NIH HHS [CA96517, CA95712, CA09432] Funding Source: Medline; NIEHS NIH HHS [ES04050-17] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alexandroff AB, 1999, LANCET, V353, P1689, DOI 10.1016/S0140-6736(98)07422-4; ALTMANN KH, 2000, BIOCHIM BIOPHYS ACTA, V1470, P78; Asher G, 2001, P NATL ACAD SCI USA, V98, P1188, DOI 10.1073/pnas.021558898; Bange J, 2001, NAT MED, V7, P548, DOI 10.1038/87872; Blanc C, 2000, CANCER RES, V60, P4386; Budhram-Mahadeo V, 1999, J BIOL CHEM, V274, P15237, DOI 10.1074/jbc.274.21.15237; Chakrabarty AM, 2003, J BACTERIOL, V185, P2683, DOI 10.1128/JB.185.9.2683-2686.2003; Chandler JM, 1998, J BIOL CHEM, V273, P10815, DOI 10.1074/jbc.273.18.10815; Chou TC, 1998, P NATL ACAD SCI USA, V95, P9642, DOI 10.1073/pnas.95.16.9642; Coley WB, 1911, SURG GYNECOL OBSTET, V13, P174; Cowan CM, 2001, J NEUROSCI, V21, P7099, DOI 10.1523/JNEUROSCI.21-18-07099.2001; Cuvillier O, 2001, CELL DEATH DIFFER, V8, P162, DOI 10.1038/sj.cdd.4400793; da Rocha Adriana B., 2001, Current Opinion in Pharmacology, V1, P364; Dang LH, 2001, P NATL ACAD SCI USA, V98, P15155, DOI 10.1073/pnas.251543698; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Eilon GF, 2000, CANCER CHEMOTH PHARM, V45, P183; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Gajate C, 2000, INT J CANCER, V85, P674, DOI 10.1002/(SICI)1097-0215(20000301)85:5<674::AID-IJC13>3.0.CO;2-Z; Goto M, 2003, MOL MICROBIOL, V47, P549, DOI 10.1046/j.1365-2958.2003.03317.x; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; He ZW, 2003, CANCER RES, V63, P4396; Heerdt BG, 1999, CANCER RES, V59, P1584; Hishikawa K, 1999, J BIOL CHEM, V274, P37461, DOI 10.1074/jbc.274.52.37461; Hu CCA, 2001, FEBS LETT, V503, P65, DOI 10.1016/S0014-5793(01)02691-6; Hu HB, 2002, INT J CANCER, V102, P250, DOI 10.1002/ijc.10707; Hunter CA, 2001, J IMMUNOL, V166, P5878, DOI 10.4049/jimmunol.166.10.5878; Jain RK, 2001, P NATL ACAD SCI USA, V98, P14748, DOI 10.1073/pnas.261606598; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Kagawa S, 2001, CLIN CANCER RES, V7, P1474; LAMOUREUX G, 1976, BCG CANC IMMUNOTHERA; Le XF, 2001, ONCOGENE, V20, P8258, DOI 10.1038/sj.onc.1205039; Lee ATC, 2003, CANCER CELL INT, V3, DOI 10.1186/1475-2867-3-16; Liang Y, 2001, ONCOGENE, V20, P6570, DOI 10.1038/sj.onc.1204815; Marcelli M, 1998, CANCER RES, V58, P76; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Mc Gee MM, 2002, FEBS LETT, V515, P66, DOI 10.1016/S0014-5793(02)02440-7; Meller R, 2002, NEUROSCI LETT, V324, P33, DOI 10.1016/S0304-3940(02)00166-0; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Mooney LM, 2002, BRIT J CANCER, V87, P909, DOI 10.1038/sj.bjc.6600541; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; Onuki R, 2003, ANTISENSE NUCLEIC A, V13, P75, DOI 10.1089/108729003321629629; Paglia P, 1998, CANCER IMMUNOL IMMUN, V46, P88, DOI 10.1007/s002620050466; Pawelek JM, 1997, CANCER RES, V57, P4537; Punj V, 2003, CELL MICROBIOL, V5, P225, DOI 10.1046/j.1462-5822.2003.00269.x; Punj V, 2003, BIOCHEM BIOPH RES CO, V312, P109, DOI 10.1016/j.bbrc.2003.09.217; Raffo AJ, 2000, ONCOGENE, V19, P6216, DOI 10.1038/sj.onc.1203995; RALPH P, 1975, NATURE, V257, P393, DOI 10.1038/257393a0; RUNNEBAUM IB, 1994, ANTICANCER RES, V14, P1137; Salomons GS, 1997, INT J CANCER, V71, P959, DOI 10.1002/(SICI)1097-0215(19970611)71:6<959::AID-IJC9>3.0.CO;2-X; Salti GI, 2000, EUR J CANCER, V36, P796, DOI 10.1016/S0959-8049(00)00017-4; Saunders PA, 2000, ANAL BIOCHEM, V284, P114, DOI 10.1006/abio.2000.4690; Schiffman K, 2002, BREAST CANCER RES TR, V74, P17, DOI 10.1023/A:1016009317796; Sinha G, 2003, NAT MED, V9, P1229, DOI 10.1038/nm1003-1229a; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Sznol M, 2000, J CLIN INVEST, V105, P1027, DOI 10.1172/JCI9818; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Tangri S, 2001, J EXP MED, V194, P833, DOI 10.1084/jem.194.6.833; Tong WG, 2002, MOL CANCER THER, V1, P929; Torchilin VP, 2003, DRUG DISCOV TODAY, V8, P259, DOI 10.1016/S1359-6446(03)02623-0; Wojciechowski J, 2003, INT J CANCER, V106, P486, DOI 10.1002/ijc.11290; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Yamada T, 2002, P NATL ACAD SCI USA, V99, P14098, DOI 10.1073/pnas.222539699; Yamada T, 2002, INFECT IMMUN, V70, P7054, DOI 10.1128/IAI.70.12.7054-7062.2002; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536	66	113	144	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2004	23	13					2367	2378		10.1038/sj.onc.1207376	http://dx.doi.org/10.1038/sj.onc.1207376			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806IN	14981543				2022-12-28	WOS:000220427700011
J	Xin, H; Pereira-Smith, OM; Choubey, D				Xin, H; Pereira-Smith, OM; Choubey, D			Role of IFI 16 in cellular senescence of human fibroblasts	ONCOGENE			English	Article						interferon-inducible IFI 16; fibroblasts; senescence; immortalization; DNA methylation	HUMAN TELOMERASE; NEGATIVE REGULATOR; ID PROTEINS; INTERFERON; EXPRESSION; GENE; FAMILY; CELLS; P202; P53	Defects in interferon (IFN) signaling that result in loss of expression of IFN-inducible proteins are associated with cellular immortalization, an important early event in the development of human cancer. Here we report that loss of IFN-inducible IFI 16 expression in human fibroblasts allows bypass of cellular senescence. We found that levels of IFI 16 mRNA and protein were higher in human old versus young fibroblasts and immortalization of fibroblasts with telomerase resulted in decreased expression of IFI 16. Moreover, overexpression of IFI 16 in immortalized fibroblasts strongly inhibited cell proliferation. Interestingly, knockdown of IFI 16 expression in fibroblasts inhibited p53-mediated transcription, downregulated p21(WAF1) expression, and extended the proliferation potential. Importantly, treatment of immortal cell lines with 5-aza-2'-deoxycytidine, an inhibitor of DNA methyltransferase, resulted in upregulation of IFI 16. Our observations support the idea that increased levels of IFI 16 in older populations of human fibroblasts contribute to cellular senescence.	Loyola Univ, Med Ctr, Stritch Sch Med, Dept Radiat Oncol, Maywood, IL 60153 USA; Univ Texas, Hlth Sci Ctr, Sam & Ann Barshop Ctr Longet & Aging Studies, San Antonio, TX USA	Loyola University Chicago; University of Texas System; University of Texas Health San Antonio	Choubey, D (corresponding author), Loyola Univ, Med Ctr, Stritch Sch Med, Dept Radiat Oncol, 2160 S 1st Ave,Mail Code 114B, Maywood, IL 60153 USA.	dchoube@lumc.edu	Choubey, Divaker/A-4771-2008		NATIONAL INSTITUTE ON AGING [P01AG020752, R03AG022124] Funding Source: NIH RePORTER; NIA NIH HHS [AG022124, P01 AG20752] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aglipay JA, 2003, ONCOGENE, V22, P8931, DOI 10.1038/sj.onc.1207057; Akca H, 2003, SCAND J CLIN LAB INV, V63, P505, DOI 10.1080/00365510310003382; Alani RM, 1999, P NATL ACAD SCI USA, V96, P9637, DOI 10.1073/pnas.96.17.9637; Alani RM, 2001, P NATL ACAD SCI USA, V98, P7812, DOI 10.1073/pnas.141235398; Asefa B, 2004, BLOOD CELL MOL DIS, V32, P155, DOI 10.1016/j.bcmd.2003.10.002; Bertram MJ, 1999, MOL CELL BIOL, V19, P1479; Borden EC, 2000, SEMIN CANCER BIOL, V10, P125, DOI 10.1006/scbi.2000.0315; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Campisi J, 2003, NAT REV CANCER, V3, P339, DOI 10.1038/nrc1073; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Choubey D, 2002, FRONT BIOSCI-LANDMRK, V7, pE252, DOI 10.2741/choubey; CHOUBEY D, 1995, J BIOL CHEM, V270, P6134, DOI 10.1074/jbc.270.11.6134; Choubey D, 2000, J BIOL REG HOMEOS AG, V14, P187; Cong YS, 2002, MICROBIOL MOL BIOL R, V66, P407, DOI 10.1128/MMBR.66.3.407-425.2002; DAWSON MJ, 1995, BIOCHEM BIOPH RES CO, V214, P152, DOI 10.1006/bbrc.1995.2269; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; FUJIUCHI N, 2004, J BIOL CHEM     0227; Gutterman JU, 1999, CELL GROWTH DIFFER, V10, P93; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HENSLER PJ, 1994, MOL CELL BIOL, V14, P2291, DOI 10.1128/MCB.14.4.2291; Johnstone RW, 2000, ONCOGENE, V19, P6033, DOI 10.1038/sj.onc.1204005; Johnstone RW, 1999, MOL CELL BIOL, V19, P5833; Karlsson C, 1996, CANCER RES, V56, P241; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KINGSMORE SF, 1989, EMBO J, V8, P4073, DOI 10.1002/j.1460-2075.1989.tb08591.x; Kulaeva OI, 2003, ONCOGENE, V22, P4118, DOI 10.1038/sj.onc.1206594; Kwak JC, 2003, J BIOL CHEM, V278, P40899, DOI 10.1074/jbc.M308012200; Lee SH, 2003, ONCOGENE, V22, P381, DOI 10.1038/sj.onc.1206133; LENGYEL P, 1995, SEMIN VIROL, V6, P203, DOI 10.1006/smvy.1995.0025; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Raffaella R, 2004, EXP CELL RES, V293, P331, DOI 10.1016/j.yexcr.2003.10.014; Sangfelt O, 1999, ONCOGENE, V18, P2798, DOI 10.1038/sj.onc.1202609; SEN GC, 1992, J BIOL CHEM, V267, P5017; Sharpless NE, 2002, CELL, V110, P9, DOI 10.1016/S0092-8674(02)00818-8; Shou JY, 2002, P NATL ACAD SCI USA, V99, P2830, DOI 10.1073/pnas.052705299; Sikder HA, 2003, CANCER CELL, V3, P525, DOI 10.1016/S1535-6108(03)00141-7; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; Smith LL, 2003, NAT CELL BIOL, V5, P474, DOI 10.1038/ncb985; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Takaoka A, 2003, NATURE, V424, P516, DOI 10.1038/nature01850; Untergasser G, 2002, CANCER RES, V62, P6255; Wang H, 1999, GENOMICS, V60, P281, DOI 10.1006/geno.1999.5923; Xin H, 2003, ONCOGENE, V22, P4831, DOI 10.1038/sj.onc.1206754; Young JI, 2003, J BIOL CHEM, V278, P19904, DOI 10.1074/jbc.M301685200	44	55	59	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2004	23	37					6209	6217		10.1038/sj.onc.1207836	http://dx.doi.org/10.1038/sj.onc.1207836			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	847NC	15208661				2022-12-28	WOS:000223399000005
J	Pawar, SA; Szentirmay, MN; Hermeking, H; Sawadogo, M				Pawar, SA; Szentirmay, MN; Hermeking, H; Sawadogo, M			Evidence for a cancer-specific switch at the CDK4 promoter with loss of control by both USF and c-Myc	ONCOGENE			English	Article						USF; c-Myc; CDK4; breast cancer; promoter; transcription activation; E box; dominant-negative mutants; mammary epithelial cells	TRANSCRIPTION FACTOR USF; DNA-BINDING; ACTIVATES TRANSCRIPTION; DEPENDENT KINASES; PROTEIN; CELLS; GENE; EXPRESSION; PROLIFERATION; UPSTREAM	USF and c-Myc are basic helix-loop-helix transcription factors with similar DNA-binding specificities, but antagonistic effects on cellular transformation. In order to determine how these opposite functions correlate with the transcriptional activities of the two factors on particular downstream targets, we investigated the roles of USF and c-Myc in expression of CDK4, a known direct target of cMyc. Overexpression of either c-Myc or USF2, but not USF1, stimulated the expression of CDK4 promoter-driven reporter genes in the non-tumorigenic mammary epithelial MCF-10A cells. Dominant-negative mutants specific to either Myc or USF family proteins inhibited reporter gene activity as well as endogenous CDK4 expression, demonstrating involvement of both USF and Myc in CDK4 transcriptional control. In contrast, in two different breast cancer cell lines where USF is transcriptionally inactive and c-Myc is overexpressed, CDK4 promoter activity was no longer responsive to either transcription factor. Accordingly, chromatin immunoprecipitation revealed significantly lower levels of both USF and c-Myc bound to the endogenous CDK4 promoter in breast cancer cells than in MCF-10A cells, with a concomitant decrease in associated histone H3 acetylation. These results suggest that a major switch in the transcriptional control of CDK4 occurs during breast carcinogenesis, with likely alteration of cell cycle regulation.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Max Planck Inst Biochem, D-82152 Martinsried, Germany	University of Texas System; UTMD Anderson Cancer Center; Max Planck Society	Sawadogo, M (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, 1515 Holcombe Blvd, Houston, TX 77030 USA.	msawadog@mdanderson.org	Pawar, Snehalata/ABD-4557-2020	Pawar, Snehalata/0000-0003-3992-2494	NATIONAL CANCER INSTITUTE [P30CA016672, R01CA079578] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, CA79578] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		An HX, 1999, AM J PATHOL, V154, P113, DOI 10.1016/S0002-9440(10)65257-1; Athanikar JN, 1998, P NATL ACAD SCI USA, V95, P4935, DOI 10.1073/pnas.95.9.4935; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENDALL AJ, 1994, NUCLEIC ACIDS RES, V22, P2801, DOI 10.1093/nar/22.14.2801; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; Dang CV, 1999, MOL CELL BIOL, V19, P1; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; FISHER DE, 1991, GENE DEV, V5, P2342, DOI 10.1101/gad.5.12a.2342; Hadsell DL, 2003, MOL ENDOCRINOL, V17, P2251, DOI 10.1210/me.2002-0031; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HARPER JW, 1993, CELL, V75, P805; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Hurlin PJ, 2003, EMBO J, V22, P4584, DOI 10.1093/emboj/cdg442; Ismail PM, 1999, ONCOGENE, V18, P5582, DOI 10.1038/sj.onc.1202932; Ito, 1996, Breast Cancer, V3, P93, DOI 10.1007/BF02966969; KIRSCHBAUM BJ, 1992, MOL CELL BIOL, V12, P5094, DOI 10.1128/MCB.12.11.5094; Krylov D, 1997, P NATL ACAD SCI USA, V94, P12274, DOI 10.1073/pnas.94.23.12274; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; Lazarov M, 2002, NAT MED, V8, P1105, DOI 10.1038/nm779; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; Luo X, 1996, MOL CELL BIOL, V16, P1367; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; PERSSON H, 1985, MOL CELL BIOL, V5, P2903, DOI 10.1128/MCB.5.11.2903; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Qyang YB, 1999, MOL CELL BIOL, V19, P1508; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; Rodriguez-Puebla ML, 2002, AM J PATHOL, V161, P405, DOI 10.1016/S0002-9440(10)64196-X; Sasano H, 1997, ANTICANCER RES, V17, P3685; SAWADOGO M, 1988, J BIOL CHEM, V263, P11994; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sirito M, 1998, P NATL ACAD SCI USA, V95, P3758, DOI 10.1073/pnas.95.7.3758; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Sotillo R, 2001, EMBO J, V20, P6637, DOI 10.1093/emboj/20.23.6637; Swanson HI, 1999, NUCLEIC ACIDS RES, V27, P3205, DOI 10.1093/nar/27.15.3205; Szentirmay MN, 2003, J BIOL CHEM, V278, P37231, DOI 10.1074/jbc.M305791200; Tsutsui T, 1999, MOL CELL BIOL, V19, P7011; VANDYKE MW, 1992, GENE, V111, P99, DOI 10.1016/0378-1119(92)90608-R; Weissman JDJ, 2000, J BIOL CHEM, V275, P10160, DOI 10.1074/jbc.275.14.10160; YASUMOTO KI, 1994, MOL CELL BIOL, V14, P8058, DOI 10.1128/MCB.14.12.8058; Zou XH, 2002, GENE DEV, V16, P2923, DOI 10.1101/gad.1033002	45	25	27	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6125	6135		10.1038/sj.onc.1207806	http://dx.doi.org/10.1038/sj.onc.1207806			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15208653				2022-12-28	WOS:000223261000012
J	Daniotti, M; Oggionni, M; Ranzani, T; Vallacchi, V; Carnpi, V; Di Stasi, D; Della Torre, G; Perrone, F; Luoni, C; Suardi, S; Frattini, M; Pilotti, S; Anichini, A; Tragni, G; Parmiani, G; Pierotti, MA; Rodolfo, M				Daniotti, M; Oggionni, M; Ranzani, T; Vallacchi, V; Carnpi, V; Di Stasi, D; Della Torre, G; Perrone, F; Luoni, C; Suardi, S; Frattini, M; Pilotti, S; Anichini, A; Tragni, G; Parmiani, G; Pierotti, MA; Rodolfo, M			BRAF alterations are associated with complex mutational profiles in malignant melanoma	ONCOGENE			English	Article						melanoma; BRAF; NRAS; PTEN; TP53; CDKN2A	N-RAS MUTATIONS; TUMOR-SUPPRESSOR GENE; CUTANEOUS MELANOMA; CELL LINES; P53 MUTATIONS; METASTATIC MELANOMA; HUMAN CANCER; PTEN; SUSCEPTIBILITY; PATHWAYS	To evaluate the mutational profiles associated with BRAF mutations in human melanoma, we have studied BRAF, RAS, PTEN, TP53, CDKN2A and CDK4 genes and their expression in melanoma lesions. Owing to the lack of sufficient material from fresh specimens, we employed short-term cell lines obtained from melanoma biopsies. In all, 41 melanoma obtained from eight primary lesions, 20 nodal, 11 cutaneous and two visceral metastases from patients with sporadic (n=31), familial (n=4) and multiple melanoma (n=2) were analysed. The results revealed novel missense mutations in the BRAF, PTEN, CDKN2A and CDK4 genes. Overall, activating mutations of BRAF and loss of functional p16 and ARF were detected in the majority of melanomas (29/41, 36/41 and 29/41, respectively), while PTEN alterations/loss, NRAS and TP53 mutations occurred less frequently (6/41, 6/41 and 10/41, respectively). In the resulting 12 mutational profiles, p16/ARF loss associated with mutated BRAF(V599E) was the most represented (n=15). In addition, TP53 and PTEN mutations were always accompanied with BRAF alterations, while PTEN loss was found in association with CDKN2A or TP53 mutations in the absence of BRAF activation. The p16/ARFDelta+BRAF/RAS profile was significantly associated with a longer survival, while complex mutational profiles were detected in highly aggressive disease and poor survival. These data support the existence of several molecularly defined melanoma groups which likely reflect different clinical/biological behaviour, thus suggesting that a more extensive molecular classification of melanoma would significantly impact its clinical management.	Ist Nazl Studio & Cura Tumori, Unit Melanoma Genet, I-20133 Milan, Italy; Ist Nazl Studio & Cura Tumori, Dept Pathol, I-20133 Milan, Italy; Ist Nazl Studio & Cura Tumori, Unit Mol Mech Tumour Growth & Progress, I-20133 Milan, Italy; Ist Nazl Studio & Cura Tumori, Unit Human Tumour Immunobiol, I-20133 Milan, Italy; Ist Nazl Studio & Cura Tumori, Unit Immunotherapy Human Tumours, I-20133 Milan, Italy; FIRC Inst Mol Oncol, IFOM, I-20139 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; IFOM - FIRC Institute of Molecular Oncology	Rodolfo, M (corresponding author), Ist Nazl Studio & Cura Tumori, Unit Melanoma Genet, Via Venezian 1, I-20133 Milan, Italy.	monica.rodolfo@istitutotumori.mi.it	Pierotti, Marco Alessandro/AAC-4728-2022; rodolfo, monica/H-2671-2012; Perrone, Federica/S-6171-2016; Anichini, Andrea/K-1434-2016; Vallacchi, Viviana/K-5709-2016	Pierotti, Marco Alessandro/0000-0002-7431-8332; rodolfo, monica/0000-0002-9196-0298; Perrone, Federica/0000-0003-4406-8245; Anichini, Andrea/0000-0001-5096-5538; Vallacchi, Viviana/0000-0002-2819-0630				ALBINO AP, 1989, ONCOGENE, V4, P1363; Bertram CG, 2002, J INVEST DERMATOL, V119, P961, DOI 10.1046/j.1523-1747.2002.01825.x; Brose MS, 2002, CANCER RES, V62, P6997; Cascinelli N, 2001, LANCET, V358, P866, DOI 10.1016/S0140-6736(01)06068-8; Castellano M, 1999, MELANOMA RES, V9, P421, DOI 10.1097/00008390-199910000-00001; Castellano M, 1997, CANCER RES, V57, P4868; Ceha HM, 1998, BIOCHEM BIOPH RES CO, V249, P550, DOI 10.1006/bbrc.1998.9183; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Deichmann M, 2002, BRIT J CANCER, V87, P1431, DOI 10.1038/sj.bjc.6600653; Dong JL, 2003, CANCER RES, V63, P3883; DONGHI R, 1993, J CLIN INVEST, V91, P1753, DOI 10.1172/JCI116385; Eskandarpour M, 2003, J NATL CANCER I, V95, P790, DOI 10.1093/jnci/95.11.790; Esteller M, 2000, CANCER RES, V60, P129; EYCHENE A, 1995, ONCOGENE, V10, P1159; Fargnoli MC, 1998, J INVEST DERMATOL, V111, P1202, DOI 10.1046/j.1523-1747.1998.00412.x; Frisk T, 2002, GENE CHROMOSOME CANC, V35, P74, DOI 10.1002/gcc.10098; Gorden A, 2003, CANCER RES, V63, P3955; Guldberg P, 1997, CANCER RES, V57, P3660; Harris CC, 1996, BRIT J CANCER, V73, P261, DOI 10.1038/bjc.1996.47; Hashemi J, 2002, CANCER LETT, V180, P211, DOI 10.1016/S0304-3835(02)00027-7; Hayward NK, 2003, ONCOGENE, V22, P3053, DOI 10.1038/sj.onc.1206445; Hayward NK, 1999, MOLECULAR PATHOLOGY OF EARLY CANCER, P207; Hussein MR, 2003, EUR J CANCER PREV, V12, P93, DOI 10.1097/00008469-200304000-00002; Ku JL, 1999, LARYNGOSCOPE, V109, P976, DOI 10.1097/00005537-199906000-00025; Kumar R, 2003, ONCOGENE, V22, P9217, DOI 10.1038/sj.onc.1206909; Kumar R, 2003, CLIN CANCER RES, V9, P3362; LUPETTI R, 1994, MELANOMA RES, V4, P11, DOI 10.1097/00008390-199402000-00003; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Papp T, 1996, J CANCER RES CLIN, V122, P541, DOI 10.1007/BF01213550; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Pollock PM, 2000, CLIN LAB MED, V20, P667; Ragnarsson-Olding BK, 2002, MELANOMA RES, V12, P453, DOI 10.1097/00008390-200209000-00007; Rizos H, 2001, J BIOL CHEM, V276, P41424, DOI 10.1074/jbc.M105299200; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Satyamoorthy K, 2003, CANCER RES, V63, P756; Trotman LC, 2003, CANCER CELL, V3, P97, DOI 10.1016/S1535-6108(03)00022-9; Tsao H, 2004, J INVEST DERMATOL, V122, P337, DOI 10.1046/j.0022-202X.2004.22243.x; Tsao H, 2000, CANCER RES, V60, P1800; Walker GJ, 2002, J INVEST DERMATOL, V119, P783, DOI 10.1046/j.1523-1747.2002.00217.x; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Wu H, 2003, ONCOGENE, V22, P3113, DOI 10.1038/sj.onc.1206451; Zerp SF, 1999, BRIT J CANCER, V79, P921, DOI 10.1038/sj.bjc.6690147; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zhou XP, 2000, AM J PATHOL, V157, P1123, DOI 10.1016/S0002-9440(10)64627-5	44	151	164	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2004	23	35					5968	5977		10.1038/sj.onc.1207780	http://dx.doi.org/10.1038/sj.onc.1207780			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15195137				2022-12-28	WOS:000222941100011
J	Altomare, DA; Wang, HQ; Skele, KL; De Rienzo, A; Klein-Szanto, AJ; Godwin, AK; Testa, JR				Altomare, DA; Wang, HQ; Skele, KL; De Rienzo, A; Klein-Szanto, AJ; Godwin, AK; Testa, JR			AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth	ONCOGENE			English	Article						AKT; protein kinase B; mTOR; LY294002; ovarian cancer; rapamycin	AKT/PROTEIN KINASE-B; UP-REGULATION; CONSTITUTIVE ACTIVATION; OVEREXPRESSION; CHEMOTHERAPY; INHIBITION; RESISTANCE; PATHWAY; BREAST; LEADS	Activation of the PI3K/AKT pathway may contribute to tumorigenesis. AKT mediates survival signals that protect cells from apoptosis and, thus, is a potentially important therapeutic target. To determine the frequency of AKT activation in human ovarian cancer, we screened a tumor tissue microarray with a phospho-specific pan-AKT (Ser473) antibody, which revealed elevated staining in 21 of 31 (68%) ovarian carcinomas. Phospho-AKT staining was associated with that of phospho (active)mTOR in 27 of 31 (87%) ovarian tumors, with 17 (55%) tumors showing elevated phospho-mTOR positivity. We tested the effects of AKT/mTOR activation on the therapeutic sensitivity of ovarian cancer cells. Pretreatment of SKOV3 cells, which exhibit constitutive AKT activity under low serum conditions, with the PI3K inhibitor LY294002 augmented cisplatin-induced apoptosis. In contrast, ovarian cancer cell lines OVCAR4 and OVCAR5, which have low basal levels of AKT activity, did not show increased cisplatin-induced apoptosis when pretreated with LY294002. In addition, inhibition of mTOR activity with rapamycin resulted in 1 arrest in SKOV3 cells, but not in OVCAR4 or OVCAR5 cells. Collectively, these findings indicate that active AKT and downstream mTOR represent potentially important therapeutic and/or chemopreventive targets in ovarian cancer.	Fox Chase Canc Ctr, Ovarian Canc Programs, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Testa, JR (corresponding author), Fox Chase Canc Ctr, Ovarian Canc Programs, 333 Cottman Ave, Philadelphia, PA 19111 USA.	jr_testa@fccc.edu			NCI NIH HHS [P50 CA083638, CA77429, CA83638, P30 CA006927, CA06927, R01 CA077429] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077429, P30CA006927, P50CA083638] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altomare DA, 2003, J CELL BIOCHEM, V88, P470, DOI 10.1002/jcb.10287; Arboleda MJ, 2003, CANCER RES, V63, P196; Brognard J, 2001, CANCER RES, V61, P3986; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Dhawan P, 2002, CANCER RES, V62, P7335; Gupta AK, 2002, CLIN CANCER RES, V8, P885; Hu LM, 2002, CANCER RES, V62, P1087; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Page C, 2000, ANTICANCER RES, V20, P407; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016/S1368-7646(02)00120-6; Yuan ZQ, 2000, ONCOGENE, V19, P2324, DOI 10.1038/sj.onc.1203598	18	335	347	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2004	23	34					5853	5857		10.1038/sj.onc.1207721	http://dx.doi.org/10.1038/sj.onc.1207721			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KW	15208673				2022-12-28	WOS:000222629800015
J	Penninkhof, F; Grootegoed, JA; Blok, LJ				Penninkhof, F; Grootegoed, JA; Blok, LJ			Identification of REPS2 as a putative modulator of NF-kappa B activity in prostate cancer cells	ONCOGENE			English	Article						REPS2; p65; NF-kappa B/p65; prostate cancer; apoptosis; cell survival	TYROSINE KINASE SUBSTRATE; INTERLEUKIN-6 EXPRESSION; CONSTITUTIVE ACTIVATION; CRYSTAL-STRUCTURE; EH DOMAINS; PROTEIN; YEAST; EPS15; TRANSFORMATION; SPECIFICITY	The protein REPS2 is implicated in growth factor receptor-mediated endocytosis and signalling, and its expression is downregulated in androgen-independent prostate cancer cells. Herein, the NF-kappaB subunit p65 is identified as a human REPS2 protein partner, interacting with the EH domain of REPS2. Using crystal structure data from literature and experimental data from yeast and mammalian two-hybrid analysis, the results indicate that the NPF-motif in p65 acts as binding site for the EH domain in REPS2. However, in cultured prostate cancer cells, the REPS2-p65 interaction is triggered upon stimulation with phorbol ester (PMA). This indicates that PMA-sensitive signalling pathways can affect the interaction between REPS2 and p65. During prostate cancer progression from androgen-dependent to androgen-independent growth, downregulation of REPS2 is accompanied by upregulation of NF-kappaB activity. This might involve loss of REPS2-p65 interaction, which would lead to increased NF-kappaB activity. Androgen-deprivation causes apoptosis of prostate cancer cells, and activated NF-kappaB is a known inhibitor of apoptosis. Hence, decreased expression of REPS2 might be a key factor, causing prostate cancer cells to become resistant to induction of apoptosis by androgen deprivation.	Erasmus Univ, Med Ctr, Dept Reprod & Dev, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	Blok, LJ (corresponding author), Erasmus Univ, Med Ctr, Dept Reprod & Dev, POB 1738, NL-3000 DR Rotterdam, Netherlands.	l.blok@erasmusmc.nl						Chang GTG, 1997, CANCER RES, V57, P4075; Chen CD, 2002, MOL CELL BIOL, V22, P2862, DOI 10.1128/MCB.22.8.2862-2870.2002; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; de Beer T, 2000, NAT STRUCT BIOL, V7, P1018, DOI 10.1038/80924; de Beer T, 1998, SCIENCE, V281, P1357, DOI 10.1126/science.281.5381.1357; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; Ikeda M, 1998, J BIOL CHEM, V273, P814, DOI 10.1074/jbc.273.2.814; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Kimura K, 2002, CELL DEATH DIFFER, V9, P972, DOI 10.1038/sj.cdd.4401049; Ling MT, 2003, ONCOGENE, V22, P4498, DOI 10.1038/sj.onc.1206693; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; Oosterhoff JK, 2003, ONCOGENE, V22, P2920, DOI 10.1038/sj.onc.1206397; Palayoor ST, 1999, ONCOGENE, V18, P7389, DOI 10.1038/sj.onc.1203160; Paoluzi S, 1998, EMBO J, V17, P6541, DOI 10.1093/emboj/17.22.6541; Park JI, 2003, ONCOGENE, V22, P4314, DOI 10.1038/sj.onc.1206478; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; Santolini E, 1999, EXP CELL RES, V253, P186, DOI 10.1006/excr.1999.4694; Steiner H, 2003, AM J PATHOL, V162, P655, DOI 10.1016/S0002-9440(10)63859-X; Sumitomo M, 1999, J UROLOGY, V161, P674, DOI 10.1016/S0022-5347(01)61993-1; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WONG WT, 1995, P NATL ACAD SCI USA, V92, P9530, DOI 10.1073/pnas.92.21.9530; Zerbini LF, 2003, CANCER RES, V63, P2206	28	16	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5607	5615		10.1038/sj.onc.1207750	http://dx.doi.org/10.1038/sj.onc.1207750			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15184881	Green Published			2022-12-28	WOS:000222629500005
J	Fernandez, P; Carretero, J; Medina, PP; Jimenez, AI; Rodriguez-Perales, S; Paz, MF; Cigudosa, JC; Esteller, M; Lombardia, L; Morente, M; Sanchez-Verde, L; Sotelo, T; Sanchez-Cespedes, M				Fernandez, P; Carretero, J; Medina, PP; Jimenez, AI; Rodriguez-Perales, S; Paz, MF; Cigudosa, JC; Esteller, M; Lombardia, L; Morente, M; Sanchez-Verde, L; Sotelo, T; Sanchez-Cespedes, M			Distinctive gene expression of human lung adenocarcinomas carrying LKB1 mutations	ONCOGENE			English	Article						LKB1/STK11; Peutz-Jeghers syndrome; lung adenocarcinomas; cDNA microarrays	PEUTZ-JEGHERS-SYNDROME; SERINE/THREONINE PROTEIN-KINASE; SERINE-THREONINE KINASE; TUMOR-SUPPRESSOR; SOMATIC MUTATIONS; GROWTH ARREST; KNOCKOUT MICE; IN-VIVO; CANCER; LKB1/STK11	LKB1, a tumor-suppressor gene that codifies for a serine/threonine kinase, is mutated in the germ-line of patients affected with the Peutz-Jeghers syndrome (PJS), which have an increased incidence of several cancers including gastrointestinal, pancreatic and lung carcinomas. Regarding tumors arising in non-PJS patients, we recently observed that at least one-third of lung adenocarcinomas (LADs) harbor somatic LKB1 gene mutations, supporting a role for LKB1 in the origin of some sporadic tumors. To characterize the pattern of LKB1 mutations in LADs further, we first screened for LKB1 gene alterations ( gene mutations, promoter hypermethylation and homozygous deletions) in 19 LADs and, in agreement with our previous data, five of them (26%) were shown to harbor mutations, all of which gave rise to a truncated protein. Recent reports demonstrate that LKB1 is able to suppress cell growth, but little is known about the specific mechanism by which it functions. To further our understanding of LKB1 function, we analysed global expression in lung primary tumors using cDNA microarrays to identify LKB1-specific variations in gene expression. In all, 34 transcripts, 24 of which corresponded to known genes, differed significantly between tumors with and without LKB1 gene alterations. Among the most remarkable findings was deregulation of transcripts involved in signal transduction (e.g. FRAP1/mTOR, ARAF1 and ROCK2), cytoskeleton (e.g. MPP1), transcription factors (e.g. MEIS2, ATF5), metabolism of AMP (AMPD3 and APRT) and ubiquitinization (e.g. USP16 and UBE2L3). Real-time quantitative RT-PCR on 15 tumors confirmed the upregulation of the homeobox MEIS2 and of the AMP-metabolism AMPD3 transcripts in LKB1-mutant tumors. In addition, immunohistochemistry in 10 of the lung tumors showed the absence of phosphorylated FRAP1/mTOR protein in LKB1-mutant tumors, indicating that LKB1 mutations do not lead to FRAP1/mTOR protein kinase activation. In conclusion, our results reveal that several important factors contribute to LKB1-mediated carcinogenesis in LADs, confirming previous observations and identifying new putative pathways that should help to elucidate the biological role of LKB1.	Spanish Natl Canc Ctr, Lymphomas & Lung Canc Lab, Madrid, Spain; Spanish Natl Canc Ctr, Cytogenet Unit, Madrid, Spain; Spanish Natl Canc Ctr, Canc Epigenet Lab, Madrid, Spain; Spanish Natl Canc Ctr, Tumor Bank, Madrid, Spain; Spanish Natl Canc Ctr, Immunohistochem Unit, Madrid, Spain; Spanish Natl Canc Ctr, Histol Unit, Madrid, Spain; Hosp Univ 12 Octubre, Dept Pathol, Madrid, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); Hospital Universitario 12 de Octubre	Sanchez-Cespedes, M (corresponding author), Spanish Natl Canc Ctr, Lymphomas & Lung Canc Lab, Madrid, Spain.	msanchez@cnio.es	Rodriguez-Perales, Sandra/T-7667-2017; Vico, Pedro Pablo Medina/D-1688-2013; Carretero, Julian/N-5214-2014; Esteller, Manel/L-5956-2014; Cigudosa, Juan C/E-4105-2016; Sanchez-Cespedes, Montse/H-8485-2012	Rodriguez-Perales, Sandra/0000-0001-7221-3636; Vico, Pedro Pablo Medina/0000-0002-7834-7093; Carretero, Julian/0000-0001-7269-8506; Esteller, Manel/0000-0003-4490-6093; Sanchez-Cespedes, Montse/0000-0002-6045-5627; Fernandez, Paloma/0000-0001-5941-8442; Morente, Manuel M/0000-0001-6004-330X				Avizienyte E, 1999, AM J PATHOL, V154, P677, DOI 10.1016/S0002-9440(10)65314-X; Bardeesy N, 2002, NATURE, V419, P162, DOI 10.1038/nature01045; Boudeau J, 2003, EMBO J, V22, P5102, DOI 10.1093/emboj/cdg490; CARRETERO J, 2004, ONCOGENE        0315; Choe G, 2003, CANCER RES, V63, P2742; Collins SP, 2000, BIOCHEM J, V345, P673, DOI 10.1042/0264-6021:3450673; Esteller M, 2000, ONCOGENE, V19, P164, DOI 10.1038/sj.onc.1203227; Geerts D, 2003, CANCER LETT, V197, P87, DOI 10.1016/S0304-3835(03)00087-9; GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404; HANSSEN AMN, 1995, J MED GENET, V32, P117, DOI 10.1136/jmg.32.2.117; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Herrero J, 2001, BIOINFORMATICS, V17, P126, DOI 10.1093/bioinformatics/17.2.126; JEGHERS H, 1949, NEW ENGL J MED, V241, P1031, DOI 10.1056/NEJM194912292412601; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Jimenez AI, 2003, CANCER RES, V63, P1382; Karuman P, 2001, MOL CELL, V7, P1307, DOI 10.1016/S1097-2765(01)00258-1; Kemp BE, 1999, TRENDS BIOCHEM SCI, V24, P22, DOI 10.1016/S0968-0004(98)01340-1; Marignani PA, 2001, J BIOL CHEM, V276, P32415, DOI 10.1074/jbc.C100207200; Martin SG, 2003, NATURE, V421, P379, DOI 10.1038/nature01296; Miyoshi H, 2002, CANCER RES, V62, P2261; Nakau M, 2002, CANCER RES, V62, P4549; Nezu J, 1999, BIOCHEM BIOPH RES CO, V261, P750, DOI 10.1006/bbrc.1999.1047; Rossi DJ, 2002, P NATL ACAD SCI USA, V99, P12327, DOI 10.1073/pnas.192301399; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Sapkota GP, 2002, BIOCHEM J, V368, P507, DOI 10.1042/BJ20021284; Sapkota GP, 2001, J BIOL CHEM, V276, P19469, DOI 10.1074/jbc.M009953200; Schimanski CC, 1999, CANCER RES, V59, P5169; Smith DP, 1999, HUM MOL GENET, V8, P1479, DOI 10.1093/hmg/8.8.1479; Smith DP, 2001, HUM MOL GENET, V10, P2869, DOI 10.1093/hmg/10.25.2869; Su GH, 1999, AM J PATHOL, V154, P1835, DOI 10.1016/S0002-9440(10)65440-5; Su JY, 1996, J BIOL CHEM, V271, P14430, DOI 10.1074/jbc.271.24.14430; Tiainen M, 1999, P NATL ACAD SCI USA, V96, P9248, DOI 10.1073/pnas.96.16.9248; Tiainen M, 2002, HUM MOL GENET, V11, P1497, DOI 10.1093/hmg/11.13.1497; Tracey L, 2002, AM J PATHOL, V161, P1825, DOI 10.1016/S0002-9440(10)64459-8; Watts JL, 2000, DEVELOPMENT, V127, P1467; Ylikorkala A, 2001, SCIENCE, V293, P1323, DOI 10.1126/science.1062074; Yoo LI, 2002, NAT REV CANCER, V2, P529, DOI 10.1038/nrc843; Zhang X, 2002, GENE DEV, V16, P2097, DOI 10.1101/gad.1007602	39	55	63	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					5084	5091		10.1038/sj.onc.1207665	http://dx.doi.org/10.1038/sj.onc.1207665			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15077168				2022-12-28	WOS:000222237300015
J	Qiu, GH; Tan, LKS; Loh, KS; Lim, CY; Srivastava, G; Tsai, ST; Tsao, SW; Tao, Q				Qiu, GH; Tan, LKS; Loh, KS; Lim, CY; Srivastava, G; Tsai, ST; Tsao, SW; Tao, Q			The candidate tumor suppressor gene BLU, located at the commonly deleted region 3p21.3, is an E2F-regulated, stress-responsive gene and inactivated by both epigenetic and genetic mechanisms in nasopharyngeal carcinoma	ONCOGENE			English	Article						3p21; NPC; BLU; RASSF1A; methylation; heat shock	EPSTEIN-BARR-VIRUS; HUMAN-CHROMOSOME 3P21.3; DE-NOVO METHYLATION; ABERRANT PROMOTER HYPERMETHYLATION; HOMOZYGOUS DELETION; LUNG-CANCER; CPG ISLANDS; SHORT ARM; REPRESSES TRANSCRIPTION; DNA METHYLATION	Loss of heterozygosity at 3p21 is common in various cancers including nasopharyngeal carcinoma (NPC). BLU is one of the candidate tumor suppressor genes (TSGs) in this region. Ectopic expression of BLU results in the inhibition of colony formation of cancer cells, suggesting that BLU is a tumor suppressor. We have identified a functional BLU promoter and found that it can be activated by environmental stresses such as heat shock, and is regulated by E2F. The promoter and first exon are located within a CpG island. BLU is highly expressed in testis and normal upper respiratory tract tissues including nasopharynx. However, in all seven NPC cell lines examined, BLU expression was downregulated and inversely correlated with promoter hypermethylation. Biallelic epigenetic inactivation of BLU was also observed in three cell lines. Hypermethylation was further detected in 19/29 (66%) of primary NPC tumors, but not in normal nasopharyngeal tissues. Treatment of NPC cell lines with 5-aza-2'-deoxycytidine activated BLU expression along with promoter demethylation. Although hypermethylation of RASSF1A, another TSG located immediately downstream of BLU, was detected in 20/27 (74%) of NPC tumors, no correlation between the hypermethylation of these two TSGs was observed (P=0.6334). In addition to methylation, homozygous deletion of BLU was found in 7/29 (24%) of tumors. Therefore, BLU is a stress-responsive gene, being disrupted in 83% (24/29) of NPC tumors by either epigenetic or genetic mechanisms. Our data are consistent with the interpretation that BLU is a TSG for NPC.	Div Johns Hopkins Singapore, Canc Epigenet Tumor Virol Lab, Singapore 117597, Singapore; Natl Univ Singapore, Dept Otolaryngol, Singapore 117548, Singapore; Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Natl Cheng Kung Univ, Dept Otolaryngol, Tainan 70101, Taiwan; Univ Hong Kong, Dept Anat, Hong Kong, Hong Kong, Peoples R China; Johns Hopkins, Sydney Kimmel Comprehens Canc Ctr, Baltimore, MD USA	National University of Singapore; University of Hong Kong; National Cheng Kung University; University of Hong Kong; Johns Hopkins University; Johns Hopkins Medicine	Tao, Q (corresponding author), Div Johns Hopkins Singapore, Canc Epigenet Tumor Virol Lab, CRC MD11 Level 5,NUS,10 Med Dr, Singapore 117597, Singapore.	taoqia@jhs.com.sg	Tao, Qian/T-4743-2018; Tsao, George/C-4422-2009; QIU, GUO-HUA/B-5806-2011	Tao, Qian/0000-0001-5383-4808; QIU, GUO-HUA/0000-0001-6202-4284				Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; AGATHANGGELOU A, 2002, AM ASS CANC RES 93 A; Armstrong RW, 2000, INT J EPIDEMIOL, V29, P991, DOI 10.1093/ije/29.6.991; Astuti D, 2001, ONCOGENE, V20, P7573, DOI 10.1038/sj.onc.1204968; Balmain A, 2002, NATURE, V417, P235, DOI 10.1038/417235a; Baylin SB, 1998, ADV CANCER RES, V72, P141; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; BUSSON P, 1988, INT J CANCER, V42, P599, DOI 10.1002/ijc.2910420422; Byun DS, 2001, CANCER RES, V61, P7034; Campanero MR, 2000, P NATL ACAD SCI USA, V97, P6481, DOI 10.1073/pnas.100340697; CHAN ATC, 2004, IN PRESS J CLIN ONCO, V20; Chen YJ, 1999, GENE CHROMOSOME CANC, V25, P169, DOI 10.1002/(SICI)1098-2264(199906)25:2<169::AID-GCC13>3.3.CO;2-9; Cheng Y, 1998, P NATL ACAD SCI USA, V95, P3042, DOI 10.1073/pnas.95.6.3042; Cheung ST, 1999, INT J CANCER, V83, P121, DOI 10.1002/(SICI)1097-0215(19990924)83:1<121::AID-IJC21>3.0.CO;2-F; Chien G, 2001, CANCER GENET CYTOGEN, V126, P63, DOI 10.1016/S0165-4608(00)00392-7; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Deng LW, 1998, GENE CHROMOSOME CANC, V23, P21, DOI 10.1002/(SICI)1098-2264(199809)23:1<21::AID-GCC4>3.0.CO;2-8; Dong SM, 2001, J NATL CANCER I, V93, P858, DOI 10.1093/jnci/93.11.858; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; EFFERT P, 1992, J VIROL, V66, P3768, DOI 10.1128/JVI.66.6.3768-3775.1992; Esteller M, 1999, CANCER RES, V59, P67; Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3; Fang Y, 2001, GENE CHROMOSOME CANC, V30, P254, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1086>3.0.CO;2-D; Feng P, 2000, J GEN VIROL, V81, P2417, DOI 10.1099/0022-1317-81-10-2417; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Giot L, 2003, SCIENCE, V302, P1727, DOI 10.1126/science.1090289; GLASER R, 1989, P NATL ACAD SCI USA, V86, P9524, DOI 10.1073/pnas.86.23.9524; Goessl C, 2000, CANCER RES, V60, P5941; Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727; Hu LF, 1996, GENE CHROMOSOME CANC, V17, P118, DOI 10.1002/(SICI)1098-2264(199610)17:2<118::AID-GCC7>3.0.CO;2-8; HUANG DP, 1991, CANCER GENET CYTOGEN, V54, P91, DOI 10.1016/0165-4608(91)90035-S; HUANG DP, 1994, CANCER RES, V54, P4003; Hui ABY, 1999, INT J CANCER, V82, P498, DOI 10.1002/(SICI)1097-0215(19990812)82:4<498::AID-IJC5>3.0.CO;2-S; Jalbout M, 2003, CANCER LETT, V193, P75, DOI 10.1016/S0304-3835(02)00697-3; Ji L, 2002, CANCER RES, V62, P2715; Kochetkova M, 2002, CANCER RES, V62, P4599; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Kourea HP, 1999, AM J PATHOL, V155, P1855, DOI 10.1016/S0002-9440(10)65504-6; LeBoeuf RD, 1998, J BIOL CHEM, V273, P361, DOI 10.1074/jbc.273.1.361; Lee MG, 2001, CANCER RES, V61, P6688; Lerman MI, 2000, CANCER RES, V60, P6116; Liu L, 2000, J Tongji Med Univ, V20, P336; LIU L, 2000, J TONGJI MED U, V20, P342; Lo KW, 1996, CANCER RES, V56, P2721; Lo KW, 2000, CANCER RES, V60, P3348; Lo KW, 2001, CANCER RES, V61, P3877; LO KW, 1994, INT J ONCOL, V4, P1359; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; Murray PG, 2004, ONCOGENE, V23, P1326, DOI 10.1038/sj.onc.1207313; Nass SJ, 2000, CANCER RES, V60, P4346; Nguyen C, 2001, J NATL CANCER I, V93, P1465, DOI 10.1093/jnci/93.19.1465; Nosaka K, 2000, CANCER RES, V60, P1043; Palmisano WA, 2000, CANCER RES, V60, P5954; Raab-Traub N, 1992, Semin Cancer Biol, V3, P297; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Rosas SLB, 2001, CANCER RES, V61, P939; Singal R, 2001, BLOOD, V98, P3441, DOI 10.1182/blood.V98.12.3441; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Srivastava G, 2000, BLOOD, V95, P2443, DOI 10.1182/blood.V95.7.2443.007k18_2443_2445; SUN Y, 1993, ONCOGENE, V8, P791; Sung NS, 2000, INT J CANCER, V86, P244, DOI 10.1002/(SICI)1097-0215(20000415)86:2<244::AID-IJC14>3.3.CO;2-M; Tao Q, 1999, AM J PATHOL, V155, P619, DOI 10.1016/S0002-9440(10)65157-7; Tao Q, 1998, BLOOD, V91, P1373, DOI 10.1182/blood.V91.4.1373; Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091; Tsang YS, 1999, INT J CANCER, V83, P305, DOI 10.1002/(SICI)1097-0215(19991029)83:3<305::AID-IJC3>3.0.CO;2-D; Tsao SW, 2002, BBA-MOL CELL RES, V1590, P150, DOI 10.1016/S0167-4889(02)00208-2; Turker MS, 2002, ONCOGENE, V21, P5388, DOI 10.1038/sj.onc.1205599; VANGROENINGEN CJ, 1986, CANCER RES, V46, P4831; Vokes EE, 1997, LANCET, V350, P1087, DOI 10.1016/S0140-6736(97)07269-3; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wijermans P, 2000, J CLIN ONCOL, V18, P956, DOI 10.1200/JCO.2000.18.5.956; Yan PS, 2003, CANCER RES, V63, P6178; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835; ZHANG SH, 1983, INT J CANCER, V31, P587, DOI 10.1002/ijc.2910310509	75	109	121	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2004	23	27					4793	4806		10.1038/sj.onc.1207632	http://dx.doi.org/10.1038/sj.onc.1207632			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZX	15122337				2022-12-28	WOS:000221799200015
J	Hensen, EF; Jordanova, ES; van Minderhout, IJHM; Hogendoorn, PCW; Taschner, PEM; van der Mey, AGL; Devilee, P; Cornelisse, CJ				Hensen, EF; Jordanova, ES; van Minderhout, IJHM; Hogendoorn, PCW; Taschner, PEM; van der Mey, AGL; Devilee, P; Cornelisse, CJ			Somatic loss of maternal chromosome 11 causes parent-of-origin-dependent inheritance in SDHD-linked paraganglioma and phaeochromocytoma families	ONCOGENE			English	Article						paraganglioma; phaeochromocytoma; imprinting; SDHD; inheritance; monosomy 11	COMPARATIVE GENOMIC HYBRIDIZATION; BECKWITH-WIEDEMANN SYNDROME; NONCHROMAFFIN PARAGANGLIOMAS; HEREDITARY PARAGANGLIOMA; NECK PARAGANGLIOMAS; GLOMUS TUMORS; GENE; DNA; HEAD; HETEROZYGOSITY	Germline mutations in succinate dehydrogenase subunits B, C and D (SDHB, SDHC and SDHD), genes encoding subunits of mitochondrial complex II, cause hereditary paragangliomas and phaeochromocytomas. In SDHB (1p36)- and SDHC (1q21)-linked families, disease inheritance is autosomal dominant. In SDHD (11q23)linked families, the disease phenotype is expressed only upon paternal transmission of the mutation, consistent with maternal imprinting. However, SDHD shows biallelic expression in brain, kidney and lymphoid tissues (Baysal et al., 2000). Moreover, consistent loss of the wild-type (wt) maternal allele in SDHD-linked tumours suggests expression of the maternal SDHD allele in normal paraganglia. Here we demonstrate exclusive loss of the entire maternal chromosome 11 in SDHD-linked paragangliomas and phaeochromocytomas, suggesting that combined loss of the wt SDHD allele and maternal 11p region is essential for tumorigenesis. We hypothesize that this is driven by selective loss of one or more imprinted genes in the 11p15 region. In paternally, but not in maternally derived SDHD mutation carriers, this can be achieved by a single event, that is, non-disjunctional loss of the maternal chromosome 11. Thus, the exclusive paternal transmission of the disease can be explained by a somatic genetic mechanism targeting both the SDHD gene on 11q23 and a paternally imprinted gene on 11p15.5, rather than imprinting of SDHD.	Leiden Univ, Med Ctr, Dept Pathol, NL-2333 ZA Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Otolaryngol & Head & Neck Surg, NL-2333 ZA Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Human Genet, NL-2333 ZA Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Cornelisse, CJ (corresponding author), Leiden Univ, Med Ctr, Dept Pathol, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands.	c.j.cornelisse@lumc.nl	Hogendoorn, Pancras/O-6494-2019; Taschner, Peter/J-8853-2014; Hogendoorn, Pancras C.W./H-5859-2015; DEVILEE, PETER/ABR-2140-2022	Hogendoorn, Pancras/0000-0002-1513-8104; Taschner, Peter/0000-0001-9621-465X; Hogendoorn, Pancras C.W./0000-0002-1513-8104; Jordanova, Ekaterina/0000-0003-3890-7102; Jordanova, Ekaterina S./0000-0002-8121-1322				ABELN ECA, 1994, BRIT J CANCER, V70, P255, DOI 10.1038/bjc.1994.289; Astrom K, 2003, HUM GENET, V113, P228, DOI 10.1007/s00439-003-0969-6; Astuti D, 2001, AM J HUM GENET, V69, P49, DOI 10.1086/321282; Balmain A, 2003, NAT GENET, V33, P238, DOI 10.1038/ng1107; Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; Baysal BE, 1997, AM J HUM GENET, V60, P121; BEERMAN H, 1990, INT J CANCER, V45, P34, DOI 10.1002/ijc.2910450108; Biggs PJ, 2003, ONCOGENE, V22, P3288, DOI 10.1038/sj.onc.1206384; Burns JL, 2001, DEVELOPMENT, V128, P3819; COOKE HJ, 1979, NUCLEIC ACIDS RES, V6, P3177, DOI 10.1093/nar/6.10.3177; Dannenberg H, 2001, AM J PATHOL, V158, P1937, DOI 10.1016/S0002-9440(10)64662-7; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dekker PBD, 2003, HUM PATHOL, V34, P690, DOI 10.1016/S0046-8177(03)00237-5; Devilee P, 2001, TRENDS GENET, V17, P569, DOI 10.1016/S0168-9525(01)02416-7; DEVILEE P, 1994, GENE CHROMOSOME CANC, V11, P71, DOI 10.1002/gcc.2870110202; Edstrom E, 2000, AM J PATHOL, V156, P651, DOI 10.1016/S0002-9440(10)64769-4; Eng C, 2003, NAT REV CANCER, V3, P193, DOI 10.1038/nrc1013; Fournet JC, 2001, AM J PATHOL, V158, P2177, DOI 10.1016/S0002-9440(10)64689-5; Gicquel C, 1997, J CLIN ENDOCR METAB, V82, P2559, DOI 10.1210/jc.82.8.2559; Haralambieva E, 2002, J PATHOL, V198, P163, DOI 10.1002/path.1197; Jordanova ES, 2002, GENE CHROMOSOME CANC, V35, P38, DOI 10.1002/gcc.10093; Li YM, 1998, J BIOL CHEM, V273, P28247, DOI 10.1074/jbc.273.43.28247; Lui WO, 2002, ONCOGENE, V21, P1117, DOI 10.1038/sj.onc.1205149; MARIMAN ECM, 1993, HUM GENET, V91, P357, DOI 10.1007/BF00217356; Niemann S, 2000, NAT GENET, V26, P268, DOI 10.1038/81551; Runge S, 2000, J BIOL CHEM, V275, P29562, DOI 10.1074/jbc.M001156200; Schadt EE, 2003, NATURE, V422, P297, DOI 10.1038/nature01434; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; Tycko B, 2000, J CLIN INVEST, V105, P401, DOI 10.1172/JCI9462; van Schothorst EM, 1998, AM J HUM GENET, V63, P468, DOI 10.1086/301951; van Schothorst EM, 1998, HUM PATHOL, V29, P1045, DOI 10.1016/S0046-8177(98)90411-7; VANDERMEY AGL, 1991, BRIT J CANCER, V63, P298, DOI 10.1038/bjc.1991.69; VANDERMEY AGL, 1989, LANCET, V2, P1291; WAYE JS, 1987, CHROMOSOMA, V95, P182, DOI 10.1007/BF00330349; WAZIRI M, 1983, J PEDIATR-US, V102, P873, DOI 10.1016/S0022-3476(83)80014-6; Weksberg R, 1996, MED PEDIATR ONCOL, V27, P462, DOI 10.1002/(SICI)1096-911X(199611)27:5<462::AID-MPO13>3.0.CO;2-C	36	106	113	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4076	4083		10.1038/sj.onc.1207591	http://dx.doi.org/10.1038/sj.onc.1207591			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15064708				2022-12-28	WOS:000221520200005
J	Schwindling, SL; Noll, A; Montenarh, M; Gotz, C				Schwindling, SL; Noll, A; Montenarh, M; Gotz, C			Mutation of a CK2 phosphorylation site in cdc25C impairs importin alpha/beta binding and results in cytoplasmic retention	ONCOGENE			English	Article						protein kinase CK2; phosphorylation; importin alpha/beta; nuclear import; cdc25C	CASEIN KINASE-II; NUCLEAR-LOCALIZATION SEQUENCE; CYCLIN-DEPENDENT KINASES; PORE-TARGETING COMPLEX; 14-3-3 PROTEIN-BINDING; POLO-LIKE KINASE; CELL-CYCLE; T-ANTIGEN; BETA-SUBUNIT; MITOTIC PHOSPHORYLATION	cdc25C is a phosphatase, which activates the mitosis-promoting factor cyclin B1/cdc2 by dephosphorylation, and thus triggers G(2)/M transition. The activity of cdc25C itself is controlled by phosphorylation of certain amino-acid residues, which among other things determines the subcellular localization of the enzyme. Here, we describe a new phosphorylation site at threonine 236 of cdc25C, which is phosphorylated by protein kinase CK2. This phosphorylation site is located near the nuclear localization signal ( amino acids 239 - 245). We demonstrate that cdc25C interacts with importin beta and the importin alpha/beta heterodimer but not with importin a. We further found that a cdc25C phosphorylation mutant where threonine 236 was replaced by aspartic acid as well as cdc25C phosphorylated by CK2 binds importin b or the importin alpha/beta heterodimer less efficiently than wild type or the corresponding alanine mutant. Furthermore, the cdc25C(T236D) shows a retarded uptake into the nucleus in a cell import assay. Inhibition of protein kinase CK2 enzyme activity in vivo resulted in an enhanced nuclear localization of cdc25C. Thus, phosphorylation of cdc25C at threonine 236 is an important signal for the retention of cdc25C in the cytoplasm.	Univ Saarland, D-66421 Homburg, Germany	Saarland University	Gotz, C (corresponding author), Univ Saarland, Gebaude 44, D-66421 Homburg, Germany.	bccgoe@uniklinik-saarland.de	Montenarh, Mathias/AAB-6689-2020					ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Ahmed K, 2002, TRENDS CELL BIOL, V12, P226, DOI 10.1016/S0962-8924(02)02279-1; BOSC DG, 1995, J BIOL CHEM, V270, P25872, DOI 10.1074/jbc.270.43.25872; Briggs LJ, 2001, BIOCHEM J, V353, P69, DOI 10.1042/bj3530069; Bureik M, 1997, BIOL CHEM, V378, P1361, DOI 10.1515/bchm.1997.378.11.1361; CARDENAS ME, 1992, EMBO J, V11, P1785, DOI 10.1002/j.1460-2075.1992.tb05230.x; Cingolani G, 2002, MOL CELL, V10, P1345, DOI 10.1016/S1097-2765(02)00727-X; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; Daum JR, 1998, J BIOL CHEM, V273, P30622, DOI 10.1074/jbc.273.46.30622; Dotan I, 2001, BIOCHEM BIOPH RES CO, V288, P603, DOI 10.1006/bbrc.2001.5804; Escargueil AE, 2000, J BIOL CHEM, V275, P34710, DOI 10.1074/jbc.M005179200; Faust M, 2002, CELL MOL LIFE SCI, V59, P2155, DOI 10.1007/s000180200022; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; Fontes MRM, 2003, BIOCHEM J, V375, P339, DOI 10.1042/BJ20030510; Forwood JK, 1999, BIOCHEM BIOPH RES CO, V257, P731, DOI 10.1006/bbrc.1999.0370; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Gabrielli BG, 1997, J BIOL CHEM, V272, P28607, DOI 10.1074/jbc.272.45.28607; Gotz C, 1999, EUR J BIOCHEM, V266, P493, DOI 10.1046/j.1432-1327.1999.00882.x; GRANKOWSKI N, 1991, EUR J BIOCHEM, V198, P25, DOI 10.1111/j.1432-1033.1991.tb15982.x; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Graves PR, 2001, ONCOGENE, V20, P1839, DOI 10.1038/sj.onc.1204259; HANNA DE, 1995, J BIOL CHEM, V270, P25905, DOI 10.1074/jbc.270.43.25905; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, J CELL SCI, P75; Hubner S, 1997, J BIOL CHEM, V272, P17191, DOI 10.1074/jbc.272.27.17191; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; IMAMOTO N, 1995, FEBS LETT, V368, P415; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; JANS DA, 1995, BIOCHEM J, V311, P705, DOI 10.1042/bj3110705; Karlsson C, 1999, J CELL BIOL, V146, P573, DOI 10.1083/jcb.146.3.573; Kasahara H, 1999, MOL CELL BIOL, V19, P526; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lam MHC, 1999, J BIOL CHEM, V274, P18559, DOI 10.1074/jbc.274.26.18559; Li DX, 1999, J BIOL CHEM, V274, P32988, DOI 10.1074/jbc.274.46.32988; Li J, 1997, P NATL ACAD SCI USA, V94, P502, DOI 10.1073/pnas.94.2.502; Li Y, 2002, BIOCHEM BIOPH RES CO, V298, P439, DOI 10.1016/S0006-291X(02)02470-1; LITCHFIELD DW, 1992, J BIOL CHEM, V267, P13943; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; LITCHFIELD DW, 1995, BBA-MOL CELL RES, V1269, P69, DOI 10.1016/0167-4889(95)00100-7; LORENZ A, 1992, INT J ONCOL, V1, P571; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; MEGGIO F, 1993, BIOCHIM BIOPHYS ACTA, V1164, P223, DOI 10.1016/0167-4838(93)90252-M; Miller ME, 2001, J CELL SCI, V114, P1811; Montenarh M, 2003, ADV CLIN EXP MED, V12, P15; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; MULNERLORILLON O, 1990, EUR J BIOCHEM, V193, P529, DOI 10.1111/j.1432-1033.1990.tb19368.x; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Palacios I, 1996, J CELL BIOL, V133, P485, DOI 10.1083/jcb.133.3.485; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; PIWNICAWORMS H, 1991, COLD SH Q B, V56, P567; Qian YW, 2001, MOL BIOL CELL, V12, P1791, DOI 10.1091/mbc.12.6.1791; Quimby BB, 2001, CELL MOL LIFE SCI, V58, P1766, DOI 10.1007/PL00000816; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; Roshak AK, 2000, CELL SIGNAL, V12, P405, DOI 10.1016/S0898-6568(00)00080-2; RUSSO GL, 1992, J BIOL CHEM, V267, P20317; Schneider E, 2002, ONCOGENE, V21, P5031, DOI 10.1038/sj.onc.1205690; Seger D, 1998, J BIOL CHEM, V273, P24805, DOI 10.1074/jbc.273.38.24805; STRAUSFELD U, 1994, J BIOL CHEM, V269, P5989; Theis-Febvre N, 2003, ONCOGENE, V22, P220, DOI 10.1038/sj.onc.1206107; Toyoshima-Morimoto F, 2002, EMBO REP, V3, P341, DOI 10.1093/embo-reports/kvf069; Walworth NC, 2000, CURR OPIN CELL BIOL, V12, P697, DOI 10.1016/S0955-0674(00)00154-X; Xiao CY, 1998, FEBS LETT, V440, P297, DOI 10.1016/S0014-5793(98)01478-1; Yim H, 1999, PLANTA MED, V65, P9, DOI 10.1055/s-1999-13953; YU IJ, 1991, J CELL BIOL, V114, P1217, DOI 10.1083/jcb.114.6.1217; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766	71	23	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4155	4165		10.1038/sj.onc.1207566	http://dx.doi.org/10.1038/sj.onc.1207566			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15064744				2022-12-28	WOS:000221520200014
J	Hoon, DSB; Spugnardi, M; Kuo, C; Huang, SK; Morton, DL; Taback, B				Hoon, DSB; Spugnardi, M; Kuo, C; Huang, SK; Morton, DL; Taback, B			Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients	ONCOGENE			English	Article						MGMT; RAR-beta 2; RASSF1A; methylation; melanoma	ABERRANT PROMOTER METHYLATION; CPG ISLAND HYPERMETHYLATION; POLYMERASE-CHAIN-REACTION; DNA METHYLATION; PROGNOSTIC-SIGNIFICANCE; MULTIPLE GENES; CANCER; RASSF1A; EXPRESSION; MARKERS	Aberrant methylation of CpG islands in promoter regions of tumor suppressor genes (TSG) has been demonstrated in epithelial origin tumors. However, the methylation pro. ling of tumor-related gene promoter regions in cutaneous melanoma tumors has not been reported. Seven known or candidate TSGs that are frequently hypermethylated in carcinomas were assessed by methylation-specific polymerase chain reaction (MSP) in 15 melanoma cell lines and 130 cutaneous melanoma tumors. Four TSGs were frequently hypermethylated in 86 metastatic tumor specimens: retinoic acid receptor-beta2 (RAR-beta2) (70%), RAS association domain family protein 1A (RASSF1A) (57%), and O-6-methylguanine DNA methylatransferase (MGMT) (34%), and death-associated protein kinase (DAPK) (19%). Hypermethylation of MGMT, RASSF1A, and DAPK was significantly lower in primary melanomas (n = 20) compared to metastatic melanomas. However, hypermethylation of RAR-beta2 was 70% in both primary and metastatic melanomas. Cell lines had hypermethylation profiles similar to those of metastatic melanomas. The analysis of these four markers of metastatic tumors demonstrated that 97% had greater than or equal to1 gene(s) and 59% had greater than or equal to2 genes hypermethylated. The methylation of genes was verified by bisulfite sequencing. The mRNA transcripts could be re-expressed in melanoma cell lines having hypermethylated genes following treatment with 5'-aza 2'-deoxycytidine (5Aza-dC). Analysis of melanoma patients' plasma (preoperative blood; n = 31) demonstrated circulating hypermethylated MGMT, RAR-beta2, and RASSF1A DNA for at least one of the markers in 29% of the patients. Our findings indicate that the incidence of TSG hypermethylation increases during tumor progression. Methylation of TSG may play a significant role in cutaneous melanoma progression.	St Johns Hlth Ctr, John Wayne Canc Inst, Dept Mol Oncol, Santa Monica, CA 90404 USA; St Johns Hlth Ctr, John Wayne Canc Inst, Div Surg Oncol, Santa Monica, CA 90404 USA	John Wayne Cancer Institute; John Wayne Cancer Institute	Hoon, DSB (corresponding author), St Johns Hlth Ctr, John Wayne Canc Inst, Dept Mol Oncol, 2200 Santa Monica Blvd, Santa Monica, CA 90404 USA.	hoon@jwci.org	Hoon, Dave SB/C-7146-2018	Hoon, Dave SB/0000-0003-1915-3683	NATIONAL CANCER INSTITUTE [R21CA100314, P01CA029605] Funding Source: NIH RePORTER; NCI NIH HHS [P0 CA 13917, R21 CA100314, P0 CA 29605, P01 CA029605, P01 CA029605-270006] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bostick PJ, 1999, J CLIN ONCOL, V17, P3238, DOI 10.1200/JCO.1999.17.10.3238; Chen CM, 2003, AM J PATHOL, V163, P37, DOI 10.1016/S0002-9440(10)63628-0; Christmann M, 2001, INT J CANCER, V92, P123, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1160>3.3.CO;2-M; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Demary K, 2001, ENDOCRINOLOGY, V142, P2600, DOI 10.1210/en.142.6.2600; Eads CA, 1999, CANCER RES, V59, P2302; Esteller M, 1999, CANCER RES, V59, P793; Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024; Esteller M, 2001, CANCER RES, V61, P3225; Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3; Fujiwara Y, 1999, CANCER RES, V59, P1567; Goessl C, 2000, CANCER RES, V60, P5941; Harden SV, 2003, CLIN CANCER RES, V9, P1370; Jeronimo C, 2001, J NATL CANCER I, V93, P1747, DOI 10.1093/jnci/93.22.1747; Johnson PJ, 2002, CLIN CHEM, V48, P1186; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kurie JM, 2003, J NATL CANCER I, V95, P206, DOI 10.1093/jnci/95.3.206; Lo KW, 2001, CANCER RES, V61, P3877; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Maruyama R, 2001, CANCER RES, V61, P8659; Paz MF, 2003, CANCER RES, V63, P1114; Pfeifer GP, 2002, BIOL CHEM, V383, P907, DOI 10.1515/BC.2002.097; Rosas SLB, 2001, CANCER RES, V61, P939; Shi HD, 2003, CANCER RES, V63, P2164; Sidransky D, 2002, NAT REV CANCER, V2, P210, DOI 10.1038/nrc755; Sirchia SM, 2002, CANCER RES, V62, P2455; Smiraglia DJ, 2001, HUM MOL GENET, V10, P1413, DOI 10.1093/hmg/10.13.1413; Spanjaard RA, 1997, J BIOL CHEM, V272, P18990, DOI 10.1074/jbc.272.30.18990; Spugnardi M, 2003, CANCER RES, V63, P1639; Taback B, 2001, CANCER RES, V61, P5723; Takeuchi H, 2003, CANCER RES, V63, P441; Toyooka S, 2003, INT J CANCER, V103, P153, DOI 10.1002/ijc.10787; Ueki T, 2000, CANCER RES, V60, P1835; Usadel H, 2002, CANCER RES, V62, P371; Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826; Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606; Zochbauer-Muller S, 2001, CANCER RES, V61, P249	40	181	201	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					4014	4022		10.1038/sj.onc.1207505	http://dx.doi.org/10.1038/sj.onc.1207505			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15064737	Green Accepted			2022-12-28	WOS:000221382000014
J	Dietze, EC; Troch, MM; Bean, GR; Heffner, JB; Bowie, ML; Rosenberg, P; Ratliff, B; Seewaldt, VL				Dietze, EC; Troch, MM; Bean, GR; Heffner, JB; Bowie, ML; Rosenberg, P; Ratliff, B; Seewaldt, VL			Tamoxifen and tamoxifen ethyl bromide induce apoptosis in acutely damaged mammary epithelial cells through modulation of AKT activity	ONCOGENE			English	Article						tamoxifen; apoptosis; AKT; plasma membrane; mammary epithelial cells	ESTROGEN-RECEPTOR-ALPHA; PROTEIN-KINASE-B; BREAST-CANCER; MEMBRANE-RECEPTOR; GROWTH ARREST; ER-ALPHA; ACTIVATION; ANTIESTROGEN; PATHWAY; P53	Normal human mammary epithelial cells (HMECs), unlike estrogen receptor-positive (ER+) breast cancers, typically express low nuclear levels of ER (ER-'poor'). We previously demonstrated that 1.0 muM tamoxifen (Tam) induced apoptosis in ER-'poor' HMECs acutely transduced with human papillomavirus-16 E6 (HMEC-E6) through a rapid mitochondrial signaling pathway. Here, we show that plasma membrane-associated E2-binding sites initiate the rapid apoptotic effects of Tam in HMEC-E6 cells through modulation of AKT activity. At equimolar concentrations, Tam and tamoxifen ethyl bromide (QTam), a membrane impermeant analog of Tam, rapidly induced apoptosis in HMEC-E6 cells associated with an even more rapid decrease in phosphorylation of AKT at serine-473. Treatment of HMEC-E6 cells with 1.0 muM QTam resulted in a 50% decrease in mitochondrial transmembrane potential, sequential activation of caspase-9 and -3, and a 90% decrease in AKT Ser-473 phosphorylation. The effects of both Tam and QTam were blocked by expression of constitutively active AKT (myristoylated AKT or AKT-Thr308Asp/Ser473Asp). These data indicate that Tam and QTam induce apoptosis in HMEC-E6 cells through a plasma membrane-activated AKT-signaling pathway that results in (1) decreased AKT phosphorylation at Ser-473, (2) mitochondrial membrane depolarization, and (3) activated caspase-9 and -3.	Duke Univ, Med Ctr, Dept Med, Div Med Oncol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Div Cardiol, Durham, NC 27710 USA	Duke University; Duke University	Seewaldt, VL (corresponding author), DUMC, Box 2628, Durham, NC 27710 USA.	seewa001@mc.duke.edu		Rosenberg, Paul/0000-0002-5659-160X	NATIONAL CANCER INSTITUTE [R01CA098441, R01CA088799, P30CA014236] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK035816] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA88799, R01CA98441, 2P30CA14236-26] Funding Source: Medline; NIDDK NIH HHS [2P30DK 35816-11] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allen MC, 2000, BBA-BIOMEMBRANES, V1509, P229, DOI 10.1016/S0005-2736(00)00297-2; Anderson E, 1998, J MAMMARY GLAND BIOL, V3, P23, DOI 10.1023/A:1018718117113; Aoudjit F, 2001, ONCOGENE, V20, P4995, DOI 10.1038/sj.onc.1204554; ARONICA SM, 1994, P NATL ACAD SCI USA, V91, P8517, DOI 10.1073/pnas.91.18.8517; Behl C, 2002, NAT REV NEUROSCI, V3, P433, DOI 10.1038/nrn846; BOSERMA AWM, 1996, CYTOMETRY, V24, P123; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Chambliss KL, 2002, MOL ENDOCRINOL, V16, P938, DOI 10.1210/me.16.5.938; Demers GW, 1996, J VIROL, V70, P6862, DOI 10.1128/JVI.70.10.6862-6869.1996; Dick GM, 2002, MOL PHARMACOL, V61, P1105, DOI 10.1124/mol.61.5.1105; Dietze EC, 2001, J BIOL CHEM, V276, P5384, DOI 10.1074/jbc.M007915200; Doolan CM, 2003, MOL CELL ENDOCRINOL, V199, P87, DOI 10.1016/S0303-7207(02)00303-9; FERNANDEZ A, 1993, GEN PHARMACOL-VASC S, V24, P391, DOI 10.1016/0306-3623(93)90322-O; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Friedman ZY, 1998, CANCER INVEST, V16, P391, DOI 10.3109/07357909809115779; Ho KJ, 2002, ARTERIOSCL THROM VAS, V22, P1952, DOI 10.1161/01.ATV.0000041200.85946.4A; Hutchinson J, 2001, MOL CELL BIOL, V21, P2203, DOI 10.1128/MCB.21.6.2203-2212.2001; Improta-Brears T, 1999, P NATL ACAD SCI USA, V96, P4686, DOI 10.1073/pnas.96.8.4686; JARMAN M, 1986, ANTI-CANCER DRUG DES, V1, P259; JOHNSON LV, 1980, P NATL ACAD SCI-BIOL, V77, P990, DOI 10.1073/pnas.77.2.990; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KIRK J, 1994, BIOCHEM PHARMACOL, V48, P277, DOI 10.1016/0006-2952(94)90098-1; Kousteni S, 2002, SCIENCE, V298, P843, DOI 10.1126/science.1074935; Kozikowski AP, 2003, J AM CHEM SOC, V125, P1144, DOI 10.1021/ja0285159; Levin ER, 2002, STEROIDS, V67, P471, DOI 10.1016/S0039-128X(01)00179-9; Li L, 2003, P NATL ACAD SCI USA, V100, P4807, DOI 10.1073/PNAS.0831079100; Linford N, 2000, J NEUROCYTOL, V29, P367, DOI 10.1023/A:1007113323582; Marquez DC, 2001, ONCOGENE, V20, P5420, DOI 10.1038/sj.onc.1204729; O'Regan RM, 2002, LANCET ONCOL, V3, P207, DOI 10.1016/S1470-2045(02)00711-8; Okano J, 2000, J BIOL CHEM, V275, P30934, DOI 10.1074/jbc.M004112200; Pietras RJ, 2001, ENDOCRINE, V14, P417, DOI 10.1385/ENDO:14:3:417; Razandi M, 2000, MOL ENDOCRINOL, V14, P1434, DOI 10.1210/me.14.9.1434; Razandi M, 2003, MOL CELL BIOL, V23, P1633, DOI 10.1128/MCB.23.5.1633-1646.2003; Razandi M, 2002, MOL ENDOCRINOL, V16, P100, DOI 10.1210/me.16.1.100; Razandi M, 2003, J BIOL CHEM, V278, P2701, DOI 10.1074/jbc.M205692200; Ropero AB, 2002, MOL ENDOCRINOL, V16, P497, DOI 10.1210/me.16.3.497; Scheid MP, 2003, FEBS LETT, V546, P108, DOI 10.1016/S0014-5793(03)00562-3; Schlegel A, 1999, J BIOL CHEM, V274, P33551, DOI 10.1074/jbc.274.47.33551; Schwertfeger KL, 2001, MOL ENDOCRINOL, V15, P867, DOI 10.1210/me.15.6.867; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; Seewaldt VL, 1999, CELL GROWTH DIFFER, V10, P49; Seewaldt VL, 1997, CELL GROWTH DIFFER, V8, P631; Seewaldt VL, 2001, CANCER RES, V61, P616; Seewaldt VL, 2001, J CELL BIOL, V155, P471, DOI 10.1083/jcb.200011001; Seewaldt VL, 1999, EXP CELL RES, V249, P70, DOI 10.1006/excr.1999.4462; Seewaldt VL, 1997, EXP CELL RES, V236, P16, DOI 10.1006/excr.1997.3694; Segars JH, 2002, TRENDS ENDOCRIN MET, V13, P349, DOI 10.1016/S1043-2760(02)00633-1; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Song RXD, 2002, MOL ENDOCRINOL, V16, P116, DOI 10.1210/me.16.1.116; Stampfer M, 1985, J TISSUE CULTURE MET, V9, P107; Stoica GE, 2003, MOL ENDOCRINOL, V17, P818, DOI 10.1210/me.2002-0330; Stoica GE, 2003, ONCOGENE, V22, P2073, DOI 10.1038/sj.onc.1206311; Strange R, 2001, MICROSC RES TECHNIQ, V52, P171, DOI 10.1002/1097-0029(20010115)52:2<171::AID-JEMT1003>3.3.CO;2-K; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016/S1368-7646(02)00120-6; Whitehead JP, 2001, J BIOL CHEM, V276, P27816, DOI 10.1074/jbc.M011590200; Zhang ZG, 2002, BIOCHEM BIOPH RES CO, V294, P926, DOI 10.1016/S0006-291X(02)00348-0	60	15	16	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2004	23	21					3851	3862		10.1038/sj.onc.1207480	http://dx.doi.org/10.1038/sj.onc.1207480			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	818JX	14990993				2022-12-28	WOS:000221242500012
J	Gascoyne, DM; Thomas, GR; Latchman, DS				Gascoyne, DM; Thomas, GR; Latchman, DS			The effects of Brn-3a on neuronal differentiation and apoptosis are differentially modulated by EWS and its oncogenic derivative EWS/Fli-1	ONCOGENE			English	Article						POU domain; Ewing's sarcoma; neuronal differentiation	TRANSCRIPTION FACTORS BRN-3A; RNA-POLYMERASE-II; DNA-BINDING; POU TRANSCRIPTION; GENE-EXPRESSION; FUSION PROTEIN; EWS/ETS FUSIONS; GROWTH ARREST; EWING FAMILY; CELL-LINES	The Brn-3 family of POU (Pit-Oct-Unc) homeodomain transcription factors regulate differentiation of neuronal cell types. The transcriptional activator Brn-3a is expressed in Ewing's sarcomas, which also express characteristic chimaeric proteins as a consequence of fusion of the TET family gene EWS to one of several ETS genes. We have previously demonstrated a physical interaction between Brn-3a and EWS proteins, and show here that the C-terminal POU domain but not N-terminal activation domain of Brn-3a can interact in vitro with the RNA-binding domain of EWS. Likely due to POU domain homology, the related factor Brn-3b can also interact with EWS, but to a lesser extent than Brn-3a. Importantly, Brn-3a but not Brn-3b interacts in vitro with chimaeric EWS/Fli-1, EWS/ATF-1 and EWS/ERG proteins. Furthermore, overexpression of EWS/Fli-1 but not EWS or Fli-1 inhibits Brn-3a-associated growth arrest and neurite outgrowth in neuronal cells, and specifically inhibits Brn-3a-dependent activation of p21 and SNAP-25 transcription. In contrast, upregulation of Bcl-2 expression and inhibition of apoptosis by Brn-3a is antagonized more by EWS than by EWS/Fli-1. These data demonstrate that oncogenic rearrangement of EWS to produce EWS/Fli-1 may enhance the antiapoptotic effect of Brn-3a and inhibit its ability to promote neuronal differentiation.	UCL, Inst Child Hlth, Med Mol Biol Unit, London WC1N 1EHUCL, England	University of London; University College London	Gascoyne, DM (corresponding author), UCL, Inst Child Hlth, Med Mol Biol Unit, 30 Guilford St, London WC1N 1EHUCL, England.	d.gascoyne@ich.ucl.ac.uk			Medical Research Council [G9901318] Funding Source: Medline; MRC [G9901318] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ANDERSEN B, 1994, J BIOL CHEM, V269, P29335; Araya N, 2003, J BIOL CHEM, V278, P5427, DOI 10.1074/jbc.M210234200; Arvand A, 2001, ONCOGENE, V20, P5747, DOI 10.1038/sj.onc.1204598; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; Budhram-Mahadeo V, 1999, ONCOGENE, V18, P6684, DOI 10.1038/sj.onc.1203072; Budhram-Mahadeo V, 1998, MOL CELL BIOL, V18, P1029, DOI 10.1128/MCB.18.2.1029; Budram-Mahadeo V, 2002, ONCOGENE, V21, P6123, DOI 10.1038/sj.onc.1205842; Chansky HA, 2001, CANCER RES, V61, P3586; COLLUM RG, 1992, NUCLEIC ACIDS RES, V20, P4919, DOI 10.1093/nar/20.18.4919; Dauphinot L, 2001, ONCOGENE, V20, P3258, DOI 10.1038/sj.onc.1204437; Eliazer S, 2003, MOL CELL BIOL, V23, P482, DOI 10.1128/MCB.23.2.482-492.2003; Ensor E, 2001, J BIOL CHEM, V276, P5204, DOI 10.1074/jbc.M007068200; Erkman L, 1996, NATURE, V381, P603, DOI 10.1038/381603a0; Frass B, 2002, BBA-GENE STRUCT EXPR, V1579, P207, DOI 10.1016/S0167-4781(02)00540-7; Gascoyne DM, 2003, J BIOL CHEM, V278, P18022, DOI 10.1074/jbc.M301812200; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Huang EJ, 1999, DEVELOPMENT, V126, P2869; Im YH, 2000, CANCER RES, V60, P1536; Jaishankar S, 1999, ONCOGENE, V18, P5592, DOI 10.1038/sj.onc.1202940; LAKIN ND, 1995, J BIOL CHEM, V270, P15858, DOI 10.1074/jbc.270.26.15858; Lessnick SL, 2002, CANCER CELL, V1, P393, DOI 10.1016/S1535-6108(02)00056-9; Li KKC, 2000, J BIOL CHEM, V275, P23053, DOI 10.1074/jbc.M002961200; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; MAO XH, 1994, J BIOL CHEM, V269, P18216; Matsumoto Y, 2001, BRIT J CANCER, V84, P768, DOI 10.1054/bjoc.2000.1652; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; McEvilly RJ, 1996, NATURE, V384, P574, DOI 10.1038/384574a0; Melot T, 2001, EUR J BIOCHEM, V268, P3483, DOI 10.1046/j.1432-1327.2001.02251.x; MORRIS PJ, 1994, MOL CELL BIOL, V14, P6907, DOI 10.1128/MCB.14.10.6907; Morris PJ, 1997, NEUROREPORT, V8, P2041, DOI 10.1097/00001756-199705260-00047; Nakatani F, 2003, J BIOL CHEM, V278, P15105, DOI 10.1074/jbc.M211470200; Ndisang D, 1999, J BIOL CHEM, V274, P28521, DOI 10.1074/jbc.274.40.28521; Nishimori H, 2002, ONCOGENE, V21, P8302, DOI 10.1038/sj.onc.1206025; OHNO T, 1994, ONCOGENE, V9, P3087; OUCHIDA M, 1995, ONCOGENE, V11, P1049; Perez-Sanchez C, 2002, NUCLEIC ACIDS RES, V30, P4872, DOI 10.1093/nar/gkf610; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; PLOUGASTEL B, 1993, GENOMICS, V18, P609, DOI 10.1016/S0888-7543(05)80363-5; Rossow KL, 2001, CANCER RES, V61, P2690; Ryabinin AE, 1995, J MOL NEUROSCI, V6, P201, DOI 10.1007/BF02736765; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Smith MD, 1996, INT J CANCER, V67, P653; Smith MD, 2001, MOL CELL NEUROSCI, V17, P460, DOI 10.1006/mcne.2000.0927; Smith MD, 1997, MOL CELL BIOL, V17, P345, DOI 10.1128/MCB.17.1.345; Smith MD, 1998, NUCLEIC ACIDS RES, V26, P4100, DOI 10.1093/nar/26.18.4100; Teitell MA, 1999, LAB INVEST, V79, P1535; THEIL T, 1993, NUCLEIC ACIDS RES, V21, P5921, DOI 10.1093/nar/21.25.5921; Thomas GR, 2002, CANCER BIOL THER, V1, P428, DOI 10.4161/cbt.1.4.23; Thompson AD, 1999, ONCOGENE, V18, P5506, DOI 10.1038/sj.onc.1202928; Uranishi H, 2001, J BIOL CHEM, V276, P13395, DOI 10.1074/jbc.M011176200; Wagner KD, 2003, GENE, V305, P217, DOI 10.1016/S0378-1119(02)01231-3; Welford SM, 2001, J BIOL CHEM, V276, P41977, DOI 10.1074/jbc.M106757200; WOOD JN, 1990, P ROY SOC B-BIOL SCI, V241, P187, DOI 10.1098/rspb.1990.0084; Xiang MQ, 1996, P NATL ACAD SCI USA, V93, P11950, DOI 10.1073/pnas.93.21.11950; Yang L, 2000, J BIOL CHEM, V275, P37612, DOI 10.1074/jbc.M005739200; Yi HK, 1997, ONCOGENE, V14, P1259, DOI 10.1038/sj.onc.1201099	59	21	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2004	23	21					3830	3840		10.1038/sj.onc.1207497	http://dx.doi.org/10.1038/sj.onc.1207497			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	818JX	15021903				2022-12-28	WOS:000221242500010
J	Herbst, A; Salghetti, SE; Kim, SY; Tansey, WP				Herbst, A; Salghetti, SE; Kim, SY; Tansey, WP			Multiple cell-type-specific elements regulate Myc protein stability	ONCOGENE			English	Article						Myc; Myc box; ubiquitin; proteasome; transcription	ACTIVATION-DOMAIN FUNCTION; C-MYC; IN-VIVO; UBIQUITIN; PROTEASOME; DEGRADATION; ONCOPROTEIN; PROTEOLYSIS; TRANSACTIVATION; EXPRESSION	Myc is a highly unstable transcription factor that is destroyed by ubiquitin (Ub)-mediated proteolysis. We have previously identified an amino-terminal 'degron' within Myc that signals its destruction; this degron spans the transcriptional activation domain of Myc, and includes two highly conserved regions called Myc boxes I and II. We now report the identification of a second element-the D-element-which is also required for Myc proteolysis. The centrally located D-element is distinct from the PEST domain in Myc, but includes Myc box III, a third highly conserved region with no previously known function. We show that deletion of the D-element stabilizes the Myc protein without affecting its ubiquitylation, and report that the D-element and the degron act in a cell-type-specific manner to direct Myc proteolysis. These data thus demonstrate that Myc stability is regulated at both the ubiquitylation and postubiquitylation levels, and reveal that substrates of the Ub-proteasome system can be targeted for destruction differently in different cell types.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; SUNY Stony Brook, Genet Program, Stony Brook, NY 11794 USA	Cold Spring Harbor Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Tansey, WP (corresponding author), Friedrich Miescher Inst, Maulbeerstr 66, CH-4058 Basel, Switzerland.	tansey@cshl.edu			NCI NIH HHS [CA-13106, CA45508] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA045508, P01CA013106] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATCHLEY WR, 1995, P NATL ACAD SCI USA, V92, P10217, DOI 10.1073/pnas.92.22.10217; Bahram F, 2000, BLOOD, V95, P2104, DOI 10.1182/blood.V95.6.2104; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; Bloom J, 2003, CELL, V115, P71, DOI 10.1016/S0092-8674(03)00755-4; Bres V, 2003, NAT CELL BIOL, V5, P754, DOI 10.1038/ncb1023; Chen L, 2000, ARCH BIOCHEM BIOPHYS, V374, P306, DOI 10.1006/abbi.1999.1603; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; CONKLIN DS, 1993, MOL CELL BIOL, V13, P2041, DOI 10.1128/MCB.13.4.2041; Conzen SD, 2000, MOL CELL BIOL, V20, P6008, DOI 10.1128/MCB.20.16.6008-6018.2000; DOTTO GP, 1986, EMBO J, V5, P2853, DOI 10.1002/j.1460-2075.1986.tb04579.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Flinn EM, 1998, MOL CELL BIOL, V18, P5961, DOI 10.1128/MCB.18.10.5961; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Greer SF, 2003, NAT IMMUNOL, V4, P1074, DOI 10.1038/ni985; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Gross-Mesilaty S, 1998, P NATL ACAD SCI USA, V95, P8058, DOI 10.1073/pnas.95.14.8058; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; Hannon GJ, 1999, SCIENCE, V283, P1129, DOI 10.1126/science.283.5405.1129; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Herbst A, 2000, MOL BIOL REP, V27, P203, DOI 10.1023/A:1011008018565; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LOGAN J, 1981, VIROLOGY, V115, P419, DOI 10.1016/0042-6822(81)90126-4; MORTIMER RK, 1986, GENETICS, V113, P35; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Oster SK, 2003, ONCOGENE, V22, P1998, DOI 10.1038/sj.onc.1206228; PRASAD I, 1976, J VIROL, V18, P436, DOI 10.1128/JVI.18.2.436-444.1976; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Rudolph C, 1999, ANAL BIOCHEM, V269, P66, DOI 10.1006/abio.1999.3095; Ryan KM, 1996, BIOCHEM J, V314, P713, DOI 10.1042/bj3140713; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; SARID J, 1987, P NATL ACAD SCI USA, V84, P170, DOI 10.1073/pnas.84.1.170; Sherman F., 1986, METHODS YEAST GENETI; SPENCER CA, 1991, ADV CANCER RES, V56, P1; Spotts GD, 1997, MOL CELL BIOL, V17, P1459, DOI 10.1128/MCB.17.3.1459; Tanaka M, 1996, P NATL ACAD SCI USA, V93, P4311, DOI 10.1073/pnas.93.9.4311; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Tworkowski KA, 2002, ONCOGENE, V21, P8515, DOI 10.1038/sj.onc.1205976; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; Xie YM, 2002, NAT CELL BIOL, V4, P1003, DOI 10.1038/ncb889	47	40	42	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2004	23	21					3863	3871		10.1038/sj.onc.1207492	http://dx.doi.org/10.1038/sj.onc.1207492			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	818JX	15021906				2022-12-28	WOS:000221242500013
J	Vega, MI; Huerta-Yepaz, S; Garban, H; Jazirehi, A; Emmanouilides, C; Bonavida, B				Vega, MI; Huerta-Yepaz, S; Garban, H; Jazirehi, A; Emmanouilides, C; Bonavida, B			Rituximab inhibits p38 MAPK activity in 2F7 BNHL and decreases IL-10 transcription: Pivotal role of p38 MAPK in drug resistance	ONCOGENE			English	Article						Rituximab; non-Hodgkin's lymphoma; p38 MAPK; NF-kappa B; chemosensitization	NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; NON-HODGKINS-LYMPHOMA; HUMAN INTERLEUKIN-10 PROMOTER; MONOCLONAL-ANTIBODIES; GENE-EXPRESSION; CELL-LINE; TNF-ALPHA; IN-VIVO; INDUCTION	We have recently reported that Rituximab (anti-CD20) sensitizes drug-resistant 2F7 and 10C9 B Non-Hodgkin's lymphoma (NHL) cell lines to the apoptotic effects of various chemotherapeutic drugs by downregulation of IL-10 and Bcl-2 expression. The mechanism by which Rituximab induces downregulation of IL-10 was examined. We hypothesized that Rituximab may inhibit p38 MAPK activity that regulates IL-10 expression via Sp1. Treatment of 2F7 cells with Rituximab or the p38 inhibitor SB203580 inhibited the constitutive p38 MAPK activity and resulted in the inhibition of Sp1, IL-10, STAT3, and Bcl-2. Inhibition of the Src-family PTKs, Lyn, and Src-family PTKs upstream signaling molecules of the p38MAPK pathway, by PP2, a specific Src-family kinase inhibitor, resulted in the inhibition of p38MAPK and IL-10 expression. In addition to p38 MAPK, Rituximab also inhibited NF-kappaB activity. Inhibition of the Src PTKs, MAPK, and NF-kappaB activities by Rituximab or by specific chemical inhibitors sensitized the cells to CDDP-mediated apoptosis. The above signaling-mediated effects by Rituximab were observed with similar kinetics beginning at 1 h following treatment. Thus, altogether, these results demonstrate that signaling by Rituximab results in the inhibition of the p38MAPK pathway, which in turn inhibits the transcription of IL-10 via Sp1. Inhibition of the IL-10 autocrine/paracrine loop results in the inhibition of STAT3 activity and, consequently, inhibition of Bcl-2 expression and sensitization to drugs-apoptosis. Further, Rituximab-mediated signaling identifies several new intracellular targets in NHL that may be of potential therapeutic interest for the development of new drugs in the treatment of drug-refractory NHL tumor cells.	Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	Bonavida, B (corresponding author), Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Microbiol Immunol & Mol Genet, 10833 Le Conte Ave,A2-060 CHS, Los Angeles, CA 90095 USA.	bbonavida@mednet.ucla.edu	Vega, Mario/AAZ-4315-2020	Vega, Mario I/0000-0002-3932-2483; Garban, Hermes/0000-0001-7754-5357	FIC NIH HHS [D43 TW00013-14] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [D43TW000013] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Alas S, 2001, CLIN CANCER RES, V7, P709; ALAS S, 2001, CAN RES, V6, P1; Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456; Brightbill HD, 2000, J IMMUNOL, V164, P1940, DOI 10.4049/jimmunol.164.4.1940; Carter AB, 1999, J BIOL CHEM, V274, P30858, DOI 10.1074/jbc.274.43.30858; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Coiffier B, 2003, BLOOD REV, V17, P25, DOI 10.1016/S0268-960X(02)00059-0; Demidem A, 1997, CANCER BIOTHER RADIO, V12, P177, DOI 10.1089/cbr.1997.12.177; Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133; Eliopoulos AG, 1999, J BIOL CHEM, V274, P16085, DOI 10.1074/jbc.274.23.16085; Eskdale J, 1997, IMMUNOGENETICS, V46, P120, DOI 10.1007/s002510050250; Foey AD, 1998, J IMMUNOL, V160, P920; Foran JM, 2002, BEST PRACT RES CL HA, V15, P449, DOI 10.1053/beha.2002.0222; FREEDMAN AS, 1991, HEMATOL ONCOL CLIN N, V5, P871, DOI 10.1016/S0889-8588(18)30390-3; Gan XH, 1999, CELL IMMUNOL, V193, P125, DOI 10.1006/cimm.1999.1457; Garban HJ, 2001, J IMMUNOL, V167, P75, DOI 10.4049/jimmunol.167.1.75; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; Han QW, 2002, J BIOL CHEM, V277, P48379, DOI 10.1074/jbc.M209542200; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; Hu XT, 2001, CANCER RES, V61, P6290; Huhn D, 2001, BLOOD, V98, P1326, DOI 10.1182/blood.V98.5.1326; Jazirehi AR, 2003, MOL CANCER THER, V2, P1183; KUBE D, 1995, CYTOKINE, V7, P1, DOI 10.1006/cyto.1995.1001; LEVINE AM, 1992, BLOOD, V80, P8; LIDA M, 1999, LEUKEMIA, V13, P585; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Ma W, 2001, J BIOL CHEM, V276, P13664, DOI 10.1074/jbc.M011157200; Martin-Blanco E, 2000, BIOESSAYS, V22, P637, DOI 10.1002/1521-1878(200007)22:7<637::AID-BIES6>3.0.CO;2-E; Miki H, 1999, ANTICANCER RES, V19, P5283; Mori N, 1997, EUR J HAEMATOL, V59, P162; Pedersen IM, 2002, BLOOD, V99, P1314, DOI 10.1182/blood.V99.4.1314; Polyak MJ, 1998, J IMMUNOL, V161, P3242; REFF ME, 1994, BLOOD, V83, P435; Riley LK, 2000, SEMIN ONCOL, V27, P17, DOI 10.1053/sonc.2000.20424; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Sato N, 1997, J BIOL CHEM, V272, P17485, DOI 10.1074/jbc.272.28.17485; Semac I, 2003, CANCER RES, V63, P534; Shan D, 1998, BLOOD, V91, P1644, DOI 10.1182/blood.V91.5.1644.1644_1644_1652; STASHENKO P, 1980, J IMMUNOL, V125, P1678; Steinman RA, 2003, ONCOGENE, V22, P3608, DOI 10.1038/sj.onc.1206523; TEDDER TE, 1994, IMMUNOL TODAY, V15, P450, DOI 10.1016/0167-5699(94)90276-3; Thieblemont C, 2002, INT J HEMATOL, V76, P394, DOI 10.1007/BF02982804; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Vockerodt M, 2001, VIROLOGY, V280, P183, DOI 10.1006/viro.2000.0768; Voorzanger N, 1996, CANCER RES, V56, P5499; Wang DZ, 2001, J BIOL CHEM, V276, P3650, DOI 10.1074/jbc.M006115200	47	112	122	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3530	3540		10.1038/sj.onc.1207336	http://dx.doi.org/10.1038/sj.onc.1207336			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15077178				2022-12-28	WOS:000221101700004
J	Xie, TX; Wei, DY; Liu, MG; Gao, AC; Ali-Osman, F; Sawaya, R; Huang, SY				Xie, TX; Wei, DY; Liu, MG; Gao, AC; Ali-Osman, F; Sawaya, R; Huang, SY			Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis	ONCOGENE			English	Article						Stat3; MMP-2; invasion; metastasis; melanoma	PROSTATE-CANCER CELLS; IV COLLAGENASE; GELATINASE-A; TISSUE INHIBITOR; GROWTH-FACTOR; CONSTITUTIVE ACTIVATION; TRANSCRIPTION FACTORS; MELANOMA PROGRESSION; MALIGNANT-MELANOMA; SUPPRESSES GROWTH	The expression of matrix metalloproteinase-2 (MMP-2) has been linked with tumor invasion, angiogenesis, and metastasis. However, the molecular basis for MMP-2 overexpression in tumor cells remains unclear. In this study, by using K-1735 melanoma system, we demonstrated that highly metastatic C4, M 2, and X21 tumor cells express elevated MMP-2 mRNA and enzymatic activity, whereas poorly metastatic C10, C19, and C23 tumor cells express much lower levels. Moreover, a concomitant elevated Stat3 activity has been detected in these metastatic tumor cells that overexpress MMP-2. Transfection of constitutively activated Stat3 into poorly metastatic C23 tumor cells directly activated the MMP-2 promoter, whereas the expression of a dominant-negative Stat3 in highly metastatic C4 tumor cells inhibited the MMP-2 promoter. A high-affinity Stat3-binding element was identified in the MMP-2 promoter and Stat3 protein bound directly to the MMP-2 promoter. Blockade of activated Stat3 through expression of a dominant-negative Stat3 significantly suppressed MMP-2 expression in the metastatic tumor cells. Therefore, overexpression of MMP-2 in the metastatic melanoma cells can be attributed to elevated Stat3 activity, and Stat3 upregulates the transcription of MMP-2 through direct interaction with the MMP-2 promoter. Furthermore, blockade of activated Stat3 in highly metastatic C4 cells significantly suppressed the invasiveness of the tumor cells, inhibited tumor growth, and prevented metastasis in nude mice. Collectively, these studies suggest that Stat3 signaling directly regulates MMP-2 expression, tumor invasion, and metastasis, and that Stat3 activation might be a crucial event in the development of metastasis.	Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Unit 064, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA; Roswell Pk Canc Inst, Dept Med & Pharmacol, Buffalo, NY 14263 USA; Univ Texas, Grad Sch Biomed Sci, Program Canc Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Roswell Park Cancer Institute; University of Texas System; University of Texas System; UTMD Anderson Cancer Center	Huang, SY (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Unit 064, 1515 Holcombe Blvd, Houston, TX 77030 USA.	suhuang@mdanderson.org						AUKERMAN SL, 1986, JNCI-J NATL CANCER I, V77, P915; Bian JH, 1997, MOL CELL BIOL, V17, P6330, DOI 10.1128/MCB.17.11.6330; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Coussens LM, 1996, CHEM BIOL, V3, P895, DOI 10.1016/S1074-5521(96)90178-7; Curran S, 1999, J PATHOL, V189, P300, DOI 10.1002/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.0.CO;2-C; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; En-Nia A, 2002, BIOCHEM J, V362, P693, DOI 10.1042/0264-6021:3620693; Fang JM, 2000, P NATL ACAD SCI USA, V97, P3884, DOI 10.1073/pnas.97.8.3884; FIDLER IJ, 1986, CANCER RES, V46, P5167; GouilleuxGruart V, 1996, BLOOD, V87, P1692; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; HARENDZA S, 1995, J BIOL CHEM, V270, P18786, DOI 10.1074/jbc.270.32.18786; Hofmann UB, 2000, J PATHOL, V191, P245; Hofmann UB, 1999, BRIT J CANCER, V81, P774, DOI 10.1038/sj.bjc.6690763; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; Huang SY, 2002, J NATL CANCER I, V94, P1134; Huang SY, 2001, ONCOGENE, V20, P4188, DOI 10.1038/sj.onc.1204535; Itoh T, 1998, CANCER RES, V58, P1048; Ivanov VN, 2001, MOL CELL, V7, P517, DOI 10.1016/S1097-2765(01)00199-X; Kaptein A, 1996, J BIOL CHEM, V271, P5961, DOI 10.1074/jbc.271.11.5961; Kossakowska AE, 1999, BLOOD, V94, P2080, DOI 10.1182/blood.V94.6.2080.418k30_2080_2089; KRIPKE ML, 1979, JNCI-J NATL CANCER I, V63, P541, DOI 10.1093/jnci/63.3.541; Kurschat P, 1999, J BIOL CHEM, V274, P21056, DOI 10.1074/jbc.274.30.21056; Kurschat P, 2002, J PATHOL, V197, P179, DOI 10.1002/path.1080; Lee AY, 1997, P NATL ACAD SCI USA, V94, P4424, DOI 10.1073/pnas.94.9.4424; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Luca M, 1997, AM J PATHOL, V151, P1105; MAUVIEL A, 1993, J CELL BIOCHEM, V53, P288, DOI 10.1002/jcb.240530404; Mertens PR, 2002, J BIOL CHEM, V277, P24875, DOI 10.1074/jbc.M200445200; Mertens PR, 1997, J BIOL CHEM, V272, P22905, DOI 10.1074/jbc.272.36.22905; Miyake H, 1997, J UROLOGY, V157, P2351, DOI 10.1016/S0022-5347(01)64779-7; Moon A, 2000, INT J CANCER, V85, P176, DOI 10.1002/(SICI)1097-0215(20000115)85:2<176::AID-IJC5>3.0.CO;2-E; Moses MA, 1997, STEM CELLS, V15, P180, DOI 10.1002/stem.150180; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Ni Z, 2000, CANCER RES, V60, P1225; Niu G, 2002, ONCOGENE, V21, P7001, DOI 10.1038/sj.onc.1205859; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Niu GL, 1999, CANCER RES, V59, P5059; OVERALL CM, 1991, J BIOL CHEM, V266, P14064; Polette M, 1998, INT J BIOCHEM CELL B, V30, P1195, DOI 10.1016/S1357-2725(98)00083-1; SEFTOR REB, 1993, CANCER RES, V53, P3411; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Stetler-Stevenson W G, 2001, Surg Oncol Clin N Am, V10, P383; StetlerStevenson WG, 1996, SEMIN CANCER BIOL, V7, P147, DOI 10.1006/scbi.1996.0020; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; TALMADGE JE, 1982, J NATL CANCER I, V69, P975; Thant AA, 1999, ONCOGENE, V18, P6555, DOI 10.1038/sj.onc.1203049; Vaisanen A, 1996, J PATHOL, V180, P283; Vaisanen A, 1998, J PATHOL, V186, P51; van der Zee E, 1998, J PERIODONTAL RES, V33, P65; WATSON CJ, 1995, BRIT J CANCER, V71, P840, DOI 10.1038/bjc.1995.162; Wei DY, 2003, ONCOGENE, V22, P319, DOI 10.1038/sj.onc.1206122; Yan CH, 2002, J BIOL CHEM, V277, P10804, DOI 10.1074/jbc.M112069200; Yu AE, 1996, BIOCHEM CELL BIOL, V74, P823, DOI 10.1139/o96-088; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	59	431	483	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3550	3560		10.1038/sj.onc.1207383	http://dx.doi.org/10.1038/sj.onc.1207383			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15116091				2022-12-28	WOS:000221101700006
J	Giannini, G; Rinaldi, C; Ristori, E; Ambrosini, MI; Cerignoli, F; Viel, A; Bidoli, E; Berni, S; D'Amati, G; Scambia, G; Frati, L; Screpanti, I; Gulino, A				Giannini, G; Rinaldi, C; Ristori, E; Ambrosini, MI; Cerignoli, F; Viel, A; Bidoli, E; Berni, S; D'Amati, G; Scambia, G; Frati, L; Screpanti, I; Gulino, A			Mutations of an intronic repeat induce impaired MRE11 expression in primary human cancer with microsatellite instability	ONCOGENE			English	Article						MRE11; MMR defect; colorectal cancer; NBS1; DNA double strand breaks repair	STRAND BREAK REPAIR; DEFICIENT COLORECTAL CANCERS; MISMATCH REPAIR; TARGET GENES; DNA-REPAIR; MONONUCLEOTIDE REPEATS; FRAMESHIFT MUTATIONS; COLON-CANCER; PROTEIN; INACTIVATION	Frequent mutations of coding nucleotide repeats are thought to contribute significantly to carcinogenesis associated with microsatellite instability (MSI). We have shown that shortening of the poly(T) 11 within the polypyrimidine stretch/accessory splicing signal of human MRE11 leads to the reduced expression and functional impairment of the MRE11/NBS1/RAD50 complex. This mutation was selectively found in mismatch repair (MMR) defective cell lines and potentially identifies MRE11 as a novel target for MSI. Here, we examined 70 microsatellite unstable primary human cancers and we report that MRE11 mutations occur in 83.7 and 50% of the colorectal and endometrial cancers, respectively. In the colorectal cancer series, mutated MRE11 is more frequently associated with advanced age at diagnosis and A/B stages. Biallelic mutations were present in 38.8% of the cases and more frequently associated with lower (G1/G2) grade tumors. Impaired MRE11 expression was prevalent in primary colorectal tumors with larger and biallelic shortening of the poly(T)11. Immunohistochemistry confirmed the impaired MRE11 expression and revealed NBS1-defective expression in MRE11 mutated cancers. Together with the observation that perturbation of the MRE11/NBS1/RAD50 complex predisposes to cancer, our work highlights MRE11 as a new common target in the MMR deficient tumorigenesis and suggests its role in colorectal carcinogenesis.	Univ Roma La Sapienza, Policlin Umberto I, Dept Expt Med & Pathol, I-00161 Rome, Italy; Neuromed Inst, Pozzilli, Italy; Univ Aquila, Dept Expt Med, Laquila L7100, Italy; Ctr Riferimento Oncol, IRCCS, Div Expt Oncol 1, I-33081 Aviano, Italy; Ctr Riferimento Oncol, IRCCS, Dept Preclin & Epidemiol Res, I-33081 Aviano, Italy; Univ Sacred Heart, Dept Gynecol, I-00168 Rome, Italy; Cenci Bolognetti Fdn, Inst Pasteur, I-00161 Rome, Italy	Sapienza University Rome; University Hospital Sapienza Rome; IRCCS Neuromed; University of L'Aquila; IRCCS Aviano (CRO); IRCCS Aviano (CRO); Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Fondazione Cenci Bolognetti	Giannini, G (corresponding author), Univ Roma La Sapienza, Policlin Umberto I, Dept Expt Med & Pathol, Viale Regina Elena 324, I-00161 Rome, Italy.	giuseppe.giannini@uniroma1.it	Bidoli, Ettore/AAC-1762-2020; Viel, Alessandra/J-7116-2018; Frati, Luigi/ABI-7437-2020; Giannini, Giuseppe/B-5672-2013; d'Amati, Giulia/F-1251-2011	Bidoli, Ettore/0000-0001-8273-9084; Viel, Alessandra/0000-0003-2804-0840; Giannini, Giuseppe/0000-0003-0299-4056; d'Amati, Giulia/0000-0002-6959-691X				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Bender CF, 2002, GENE DEV, V16, P2237, DOI 10.1101/gad.1007902; Boland CR, 1998, CANCER RES, V58, P5248; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Casorelli I, 2003, DNA REPAIR, V2, P547, DOI 10.1016/S1568-7864(03)00020-X; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; Duval A, 2002, ONCOGENE, V21, P8062, DOI 10.1038/sj.onc.1206013; Duval A, 2002, CANCER RES, V62, P2447; Fleiss J. L., 1981, STAT METHODS RATES P, V2, P22; Fukuda T, 2001, CANCER RES, V61, P23; Giannini G, 2002, EMBO REP, V3, P248, DOI 10.1093/embo-reports/kvf044; Hangaishi A, 2002, BLOOD, V99, P3075, DOI 10.1182/blood.V99.8.3075; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Kang J, 2002, EMBO J, V21, P1447, DOI 10.1093/emboj/21.6.1447; Kim NG, 2002, ONCOGENE, V21, P5081, DOI 10.1038/sj.onc.1205703; Kim NG, 2001, CANCER RES, V61, P36; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Matsuoka S, 2001, CANCER RES, V61, P5362; Mori Y, 2002, CANCER RES, V62, P3641; Park J, 2002, CANCER RES, V62, P1284; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Peltomaki P, 2001, HUM MOL GENET, V10, P735, DOI 10.1093/hmg/10.7.735; Perucho M, 2003, ONCOGENE, V22, P2223, DOI 10.1038/sj.onc.1206580; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Schaffner C, 2000, P NATL ACAD SCI USA, V97, P2773, DOI 10.1073/pnas.050400997; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; Stankovic T, 1999, LANCET, V353, P26, DOI 10.1016/S0140-6736(98)10117-4; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Tessitore A, 2003, GENE CHROMOSOME CANC, V36, P198, DOI 10.1002/gcc.10145; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Varon R, 2001, CANCER RES, V61, P3570; Woerner SM, 2003, ONCOGENE, V22, P2226, DOI 10.1038/sj.onc.1206421; Xiao YH, 1997, NUCLEIC ACIDS RES, V25, P2985, DOI 10.1093/nar/25.15.2985; Zhang L, 2001, CANCER RES, V61, P3801	36	93	97	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 8	2004	23	15					2640	2647		10.1038/sj.onc.1207409	http://dx.doi.org/10.1038/sj.onc.1207409			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	810OZ	15048091	Green Published			2022-12-28	WOS:000220714900005
J	Bandyopadhyay, S; Pai, SK; Hirota, S; Hosobe, S; Takano, Y; Saito, K; Piquemal, D; Commes, T; Watabe, M; Gross, SC; Wang, Y; Ran, S; Watabe, K				Bandyopadhyay, S; Pai, SK; Hirota, S; Hosobe, S; Takano, Y; Saito, K; Piquemal, D; Commes, T; Watabe, M; Gross, SC; Wang, Y; Ran, S; Watabe, K			Role of the putative tumor metastasis suppressor gene Drg-1 in breast cancer progression	ONCOGENE			English	Article						marker; metastasis; invasion; methylation	PROTEIN; DIFFERENTIATION; EXPRESSION; MOTILITY; GROWTH; CAP43	The differentiation-related gene-1 (Drg-1) was first identified as a gene strongly upregulated by induction of differentiation in colon carcinoma cells in vitro, and later the same gene was shown to suppress tumorigenicity of human bladder cancer cells in vivo. On the other hand, we and others have demonstrated that the Drg-1 gene suppresses prostate and colon cancer metastases in mouse models. In the context of such potential organ-specific differential function of the Drg-1 gene, the present study was designed to clarify the expression status, regulation and function of Drg-1 in the case of human breast cancer. We found that the expression of the Drg-1 protein was significantly reduced in breast tumor cells, particularly in patients with lymph node or bone metastasis as compared to those with localized breast cancer. Drg-1 expression also exhibited significant inverse correlation with the disease-free survival rate of patients and emerged as an independent prognostic factor. The downregulation of the Drg-1 gene appeared to be largely at the RNA level, and the DNA methylation inhibitor, 5-Azacytidine, significantly elevated the Drg-1 gene expression in various breast tumor cell lines. Furthermore, we found that overexpression of the Drg-1 gene suppresses the invasiveness of breast cancer cells in vitro, and this suppression was also achieved by treatment of cells with 5-Azacytidine. Together, our results strongly suggest functional involvement of the Drg-1 gene in suppressing the metastatic advancement of human breast cancer.	So Illinois Univ, Sch Med, Dept Med Microbiol & Immunol, Springfield, IL 62702 USA; Akita Red Cross Hosp, Akita, Japan; Univ Montpellier II, Montpellier, France	Southern Illinois University System; Southern Illinois University; Akita Red Cross Hospital; Universite de Montpellier	Watabe, K (corresponding author), So Illinois Univ, Sch Med, Dept Med Microbiol & Immunol, 801 N Rutledge St, Springfield, IL 62702 USA.	kwatabe@siumed.edu		Piquemal, David/0000-0002-5870-4276; commes, therese/0000-0002-7918-0176	NATIONAL CANCER INSTITUTE [R01CA089438] Funding Source: NIH RePORTER; NCI NIH HHS [5R01CA89438] Funding Source: Medline; PHS HHS [1R15V50079473] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bandyopadhyay S, 2003, CANCER RES, V63, P1731; Davol PA, 2003, CANCER RES, V63, P6772; Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3; Guang RJ, 2000, CANCER RES, V60, P749; Hartsough MT, 2001, CANCER RES, V61, P2320; Kim HL, 2001, CANCER RES, V61, P2833; Kokame K, 1996, J BIOL CHEM, V271, P29659, DOI 10.1074/jbc.271.47.29659; Krueger JS, 2001, ONCOGENE, V20, P4209, DOI 10.1038/sj.onc.1204541; Kurdistani SK, 1998, CANCER RES, V58, P4439; Lin TM, 1997, P NATL ACAD SCI USA, V94, P4988, DOI 10.1073/pnas.94.10.4988; Masuda K, 2003, INT J CANCER, V105, P803, DOI 10.1002/ijc.11152; Okuda T, 1999, BIOCHEM BIOPH RES CO, V266, P208, DOI 10.1006/bbrc.1999.1780; Park H, 2000, BIOCHEM BIOPH RES CO, V276, P321, DOI 10.1006/bbrc.2000.3475; Ulrix W, 1999, FEBS LETT, V455, P23, DOI 10.1016/S0014-5793(99)00845-5; Unoki M, 2001, ONCOGENE, V20, P4457, DOI 10.1038/sj.onc.1204608; vanBelzen N, 1997, LAB INVEST, V77, P85; Yamada SD, 2002, CANCER RES, V62, P6717; Zhou DJ, 1998, CANCER RES, V58, P2182	18	148	158	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5675	5681		10.1038/sj.onc.1207734	http://dx.doi.org/10.1038/sj.onc.1207734			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15184886				2022-12-28	WOS:000222629500012
J	Edinger, AL; Thompson, CB				Edinger, AL; Thompson, CB			An activated mTOR mutant supports growth factor-independent, nutrient-dependent cell survival	ONCOGENE			English	Article						4F2hc; Akt; apoptosis; growth factor; mTOR	PROTEIN-KINASE B; FORKHEAD TRANSCRIPTION FACTOR; TUMOR-SUPPRESSOR PROTEINS; COMPLEX GENE-PRODUCTS; RNA 5' CAP; MAMMALIAN TARGET; AMINO-ACID; SIGNALING PATHWAY; TOR PROTEINS; RAPAMYCIN	In yeast, TOR couples cellular growth and metabolism to the availability of extracellular nutrients. In contrast, mammalian TOR kinase activity has been reported to be regulated by growth factor stimulation via the PI3K/Akt pathway. Consistent with this, growth factor deprivation results in dephosphorylation of the mTOR target proteins p70S6k and 4EBP1 in the face of abundant extracellular nutrients. To determine whether the activation of mTOR was sufficient to support cell survival in the absence of other growth factor-mediated signal transduction, we evaluated the ability of a growth factor-independent mTOR mutant, DeltaTOR, to protect cells from growth factor deprivation. DeltaTOR- but not wild-type mTOR-expressing cells were protected from many of the sequelae of growth factor deprivation including amino-acid transporter degradation, reduction of the glycolytic rate, cellular atrophy, decreased mitochondrial membrane potential, and Bax activation. Furthermore, DeltaTOR expression increased growth factor-independent, nutrient-dependent cell survival and enhanced the ability of p53-/- MEFs to form colonies in soft agar. These results suggest that activating mutations of mTOR can contribute to apoptotic resistance and might contribute to cellular transformation.	Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Thompson, CB (corresponding author), Univ Penn, Abramson Family Canc Res Inst, 450 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	craig@mail.med.upenn.edu						Abraham RT, 2002, CELL, V111, P9, DOI 10.1016/S0092-8674(02)01009-7; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Degenhardt K, 2002, CANCER CELL, V2, P193, DOI 10.1016/S1535-6108(02)00126-5; Deves R, 2000, J MEMBRANE BIOL, V173, P165, DOI 10.1007/s002320001017; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Edinger AL, 2002, MOL BIOL CELL, V13, P2276, DOI 10.1091/mbc.01-12-0584; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; Hidalgo M, 2000, ONCOGENE, V19, P6680, DOI 10.1038/sj.onc.1204091; Hosoi H, 1999, CANCER RES, V59, P886; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; Kwabi-Addo B, 2001, P NATL ACAD SCI USA, V98, P11563, DOI 10.1073/pnas.201167798; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LI LM, 1989, JNCI-J NATL CANCER I, V81, P1406, DOI 10.1093/jnci/81.18.1406; Manning BD, 2003, BIOCHEM SOC T, V31, P573, DOI 10.1042/BST0310573; McManus EJ, 2002, NAT CELL BIOL, V4, pE214, DOI 10.1038/ncb0902-e214; Mills GB, 2001, P NATL ACAD SCI USA, V98, P10031, DOI 10.1073/pnas.191379498; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; Peng T, 2002, MOL CELL BIOL, V22, P5575, DOI 10.1128/MCB.22.15.5575-5584.2002; Plas DR, 2001, J BIOL CHEM, V276, P12041, DOI 10.1074/jbc.M010551200; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Raught B, 2001, P NATL ACAD SCI USA, V98, P7037, DOI 10.1073/pnas.121145898; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Sekulic A, 2000, CANCER RES, V60, P3504; Shinjyo T, 2001, MOL CELL BIOL, V21, P854, DOI 10.1128/MCB.21.3.854-864.2001; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Vogt PK, 2001, TRENDS MOL MED, V7, P482, DOI 10.1016/S1471-4914(01)02161-X; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999	55	68	70	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5654	5663		10.1038/sj.onc.1207738	http://dx.doi.org/10.1038/sj.onc.1207738			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15133498				2022-12-28	WOS:000222629500010
J	Al Moustafa, AE; Foulkes, WD; Wong, A; Jallal, H; Batist, G; Yu, QY; Herlyn, M; Sicinski, P; Alaoui-Jamali, MA				Al Moustafa, AE; Foulkes, WD; Wong, A; Jallal, H; Batist, G; Yu, QY; Herlyn, M; Sicinski, P; Alaoui-Jamali, MA			Cyclin D1 is essential for neoplastic transformation induced by both E6/E7 and E6/E7/ErbB-2 cooperation in normal cells	ONCOGENE			English	Article						cyclin D1; E6/E7 of HPV; ErbB-2; cell transformation	HUMAN-PAPILLOMAVIRUS INFECTION; GENE AMPLIFICATION; CERVICAL-CANCER; UTERINE CERVIX; GROWTH-FACTOR; IN-VIVO; EXPRESSION; CARCINOMA; P53; OVEREXPRESSION	More than 25% of head and neck squamous cell carcinomas (HNSCC) and 99% of cervical cancers (CxCa) are positive for high-risk human papillomaviruses (HPVs). Furthermore, the type I tyrosine kinase receptor ErbB-2 is overexpressed in at least 30% of HNSCC and CxCa. Recently, we demonstrated that E6/E7 of HPV type 16 cooperate with ErbB-2 to induce cell transformation of human normal oral epithelial ( NOE) cells. This is accompanied by overexpression of cyclin D1 in NOE cells. To determine the role of cyclin D1 in E6/E7/ErbB-2 cooperation, we examined the independent effects of E6/E7 and ErbB-2, and the combined effect of E6/E7 and ErbB-2 in mouse normal embryonic. broblast (NEF), wild type (wt), and knockout cyclin D1 ( D1(-/-)) cells. We report that NEF-wt cells transduced with E6/E7 alone and E6/E7/ ErbB-2 together form small and large tumors in nude mice, respectively, as well as different sized colonies in soft agar; whereas ErbB-2 alone elicits neither tumor formation in vivo nor colony formation in soft agar. More importantly, E6/E7, ErbB-2 and E6/E7/ ErbB-2 together all fail to induce neoplastic transformation of cyclin D1(-/-) cells in vivo and in vitro. Furthermore, using antisense cyclin D1 we completely inhibited tumor and colony formation of NEF-wt-E6/E7 and wt-E6/E7-ErbB-2 as well as human NOE-E6/E7-ErbB-2-transformed cells. These analyses reveal that cyclin D1 is the downstream target of the neoplastic transformation induced by E6/E7 or E6/E7/ ErbB-2 cooperation in normal cells. Our data suggest that anti-cyclin D1 therapy may be highly specific in the treatment of all human cancers expressing high-risk HPVs or HPVs/ErbB-2.	McGill Univ, Program Canc Genet, Montreal, PQ H3T 1E2, Canada; McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Lady Davis Inst Med Res, Ctr Expt Therapeut Canc,Dept Oncol, Montreal, PQ, Canada; McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Lady Davis Inst Med Res, Ctr Expt Therapeut Canc,Dept Med, Montreal, PQ, Canada; McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Lady Davis Inst Med Res, Ctr Expt Therapeut Canc,Dept Pathol, Montreal, PQ, Canada; McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Lady Davis Inst Med Res, Ctr Expt Therapeut Canc,Dept Pharmacol & Therapeu, Montreal, PQ, Canada; Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	McGill University; Lady Davis Institute; McGill University; Lady Davis Institute; McGill University; Lady Davis Institute; McGill University; Lady Davis Institute; McGill University; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; The Wistar Institute; Fox Chase Cancer Center	Al Moustafa, AE (corresponding author), McGill Univ, Program Canc Genet, 3755 Ch Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.	aalmoust@ldi.jgh.mcgill.ca	Foulkes, William D./AAR-9586-2021	Foulkes, William D./0000-0001-7427-4651				Al Moustafa AE, 2004, ONCOGENE, V23, P350, DOI 10.1038/sj.onc.1207148; Almadori G, 2002, HEAD NECK-J SCI SPEC, V24, P597, DOI 10.1002/hed.10097; Carraresi L, 2001, ONCOGENE, V20, P8148, DOI 10.1038/sj.onc.1205007; Cheung TH, 2001, CANCER LETT, V166, P199, DOI 10.1016/S0304-3835(01)00457-8; Clifford GM, 2003, BRIT J CANCER, V88, P63, DOI 10.1038/sj.bjc.6600688; Decker T, 2002, LEUKEMIA, V16, P327, DOI 10.1038/sj.leu.2402389; Eckert RL, 2000, INT J ONCOL, V16, P853; Gasco M, 2003, ORAL ONCOL, V39, P222, DOI 10.1016/S1368-8375(02)00163-X; Gillison ML, 2000, JNCI-J NATL CANCER I, V92, P709, DOI 10.1093/jnci/92.9.709; Ibrahim SO, 1999, ORAL ONCOL, V35, P302, DOI 10.1016/S1368-8375(98)00120-1; Ke LD, 1999, ORAL ONCOL, V35, P415, DOI 10.1016/S1368-8375(99)00015-9; Lee JS, 2002, GYNECOL ONCOL, V85, P469, DOI 10.1006/gyno.2002.6648; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Liu SC, 2002, MOL CARCINOGEN, V34, P131, DOI 10.1002/mc.10057; Moreno V, 2002, LANCET, V359, P1085, DOI 10.1016/S0140-6736(02)08150-3; Niv A, 2000, J LARYNGOL OTOL, V114, P41, DOI 10.1258/0022215001903870; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Rousseau A, 2001, ORAL ONCOL, V37, P268, DOI 10.1016/S1368-8375(00)00114-7; Sauter ER, 2002, CANCER GENE THER, V9, P807, DOI 10.1038/sj.cgt.7700492; Sauter ER, 1999, CANCER RES, V59, P4876; Sauter ER, 2002, CANCER RES, V62, P3200; Sauter ER, 2000, CLIN CANCER RES, V6, P654; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Wilkman TSE, 1998, INT J ORAL MAX SURG, V27, P209, DOI 10.1016/S0901-5027(98)80012-X; Xia WY, 1997, CLIN CANCER RES, V3, P3; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500	28	31	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2004	23	30					5252	5256		10.1038/sj.onc.1207679	http://dx.doi.org/10.1038/sj.onc.1207679			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	834AE	15229656				2022-12-28	WOS:000222382500014
J	Pang, R; Yuen, J; Yuen, MF; Lai, CL; Lee, TKW; Man, K; Poon, RTP; Fan, ST; Wong, CM; Ng, IOL; Kwong, YL; Tse, E				Pang, R; Yuen, J; Yuen, MF; Lai, CL; Lee, TKW; Man, K; Poon, RTP; Fan, ST; Wong, CM; Ng, IOL; Kwong, YL; Tse, E			PIN1 overexpression and beta-catenin gene mutations are distinct oncogenic events in human hepatocellular carcinoma	ONCOGENE			English	Article						PIN1; peptidyl-prolyl-isomerase; beta-catenin; hepatocellular carcinoma	CYCLIN D1 OVEREXPRESSION; TARGET; AMPLIFICATION; ACTIVATION; EXPRESSION; FREQUENT; PATHWAY; CANCER; MOUSE	The peptidyl-proplyl-isomerase, PIN1, upregulates beta-catenin by inhibiting its interaction with APC. beta-catenin accumulation occurs in about 70% of hepatocellular carcinoma (HCC), of which only 20% are due to beta-catenin mutations. The role of PIN1 in beta-catenin upregulation in HCC was investigated. PIN1 was shown to be overexpressed in more than 50% of HCC. All cases with PIN1 overexpression also showed beta-catenin accumulation, with 68% of cases showing concomitant beta-catenin and cyclin D1 accumulation. PIN1 was shown to contribute to beta-catenin and cyclin D1 overexpression directly by in vitro cell-line transfection experiments. Finally, we showed that PIN1 overexpression and beta-catenin gene mutations appeared to be mutually exclusive events, leading to beta-catenin accumulation in HCC. These results showed that PIN1 overexpression leading to beta-catenin accumulation might be a critical event in hepatocarcinogenesis, and that PIN1 is a potential target for therapeutic intervention in HCC.	Univ Hong Kong, Queen Mary Hosp, Dept Med, Div Haematol Oncol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Dept Med, Div Gastroenterol & Hepatol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong; University of Hong Kong	Kwong, YL (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Med, Div Haematol Oncol, Hong Kong, Hong Kong, Peoples R China.	ylkwong@hku.hk; ewctse@hku.hk.or	Fan, Sheung Tat/C-4138-2009; Tse, Eric/ABB-4021-2020; WONG, Chun-Ming/A-6739-2009	Tse, Eric/0000-0002-8351-4722; WONG, Chun-Ming/0000-0002-2497-7858; Lai, Ching-Lung/0000-0002-5927-2436; Ng, Irene Oi-lin/0000-0001-7532-2029; Lee, Kin Wah/0000-0003-0682-322X				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Brown JJ, 2000, HEPATOLOGY, V31, P173, DOI 10.1002/hep.510310126; Chen TC, 1998, CANCER LETT, V134, P23, DOI 10.1016/S0304-3835(98)00238-9; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Deane NG, 2001, CANCER RES, V61, P5389; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Huang H, 1999, AM J PATHOL, V155, P1795, DOI 10.1016/S0002-9440(10)65496-X; Ihara A, 1996, HEPATOLOGY, V23, P1441, DOI 10.1053/jhep.1996.v23.pm0008675162; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Joo M, 2001, LIVER, V21, P89, DOI 10.1034/j.1600-0676.2001.021002089.x; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Liou YC, 2002, P NATL ACAD SCI USA, V99, P1335, DOI 10.1073/pnas.032404099; Manickan E, 2001, J BIOL CHEM, V276, P13989, DOI 10.1074/jbc.M009770200; Miyoshi Y, 1998, CANCER RES, V58, P2524; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NISHIDA N, 1994, CANCER RES, V54, P3107; Ryo A, 2003, J CELL SCI, V116, P773, DOI 10.1242/jcs.00276; Ryo A, 2002, MOL CELL BIOL, V22, P5281, DOI 10.1128/MCB.22.15.5281-5295.2002; Ryo A, 2001, NAT CELL BIOL, V3, P793, DOI 10.1038/ncb0901-793; Santoni-Rugiu E, 1998, CANCER RES, V58, P123; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Taniguchi K, 2002, ONCOGENE, V21, P4863, DOI 10.1038/sj.onc.1205591; Wong CM, 2001, CANCER-AM CANCER SOC, V92, P136, DOI 10.1002/1097-0142(20010701)92:1<136::AID-CNCR1301>3.0.CO;2-R; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459; ZHANG YJ, 1993, BIOCHEM BIOPH RES CO, V196, P1010, DOI 10.1006/bbrc.1993.2350	25	92	102	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4182	4186		10.1038/sj.onc.1207493	http://dx.doi.org/10.1038/sj.onc.1207493			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15064734				2022-12-28	WOS:000221520200018
J	Ordway, JM; Williams, K; Curran, T				Ordway, JM; Williams, K; Curran, T			Transcription repression in oncogenic transformation: common targets of epigenetic repression in cells transformed by Fos, Ras or Dnmt1	ONCOGENE			English	Article						methylation; silencing; cancer	TUMOR-SUPPRESSOR GENE; KINASE-C SUBSTRATE; HISTONE DEACETYLASE INHIBITION; MAMMARY EPITHELIAL-CELLS; CPG-BINDING PROTEIN; DNA-METHYLTRANSFERASE; MOLECULAR CLASSIFICATION; EXPRESSION PATTERNS; METHYLATED DNA; CANCER	Fos and Ras function in both dependent and independent signal transduction pathways, and sustained activity of either oncogene is sufficient to induce cell transformation and tumorigenesis. Increased DNA (cytosine-5) methyl-transferse (Dnmt1) activity is involved in the mechanism of transformation by both oncogenes, suggesting that inappropriate epigenetic transcription regulation may be a common route of oncogenesis, and that cell transformation may model aspects of the epigenetic deregulation that often occurs in tumors. Here, we have taken a microarray-based gene expression approach to identify differentially expressed genes in cells transformed by c-fos, v-fos, ras or Dnmt1. The cohort of genes differentially expressed in all four transformation systems includes an over-representation of repressed genes, many of which have been functionally implicated in the suppression of transformation or tumorigenesis. Furthermore, we identified four potential tumor suppressor genes subject to epigenetic transcriptional repression in transformed cells. The results emphasize the role of transcription repression in oncogenesis, and they provide insights into the potential common epigenetic mechanisms impacting cell transformation.	St Jude Childrens Res Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA; Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England	St Jude Children's Research Hospital; University of Bath	Curran, T (corresponding author), St Jude Childrens Res Hosp, Dept Dev Neurobiol, 332 N Lauderdale St, Memphis, TN 38105 USA.	fos1@aol.com	Curran, Tom/C-1164-2008; Curran, Tom/D-7515-2011; Curran, Thomas/AAE-7631-2019; Curran, Tom/F-5234-2018	Curran, Tom/0000-0003-1444-7551; Curran, Thomas/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551	NATIONAL CANCER INSTITUTE [T32CA009346, R01CA084139] Funding Source: NIH RePORTER; NCI NIH HHS [CA 09346-20, R01 CA 84139] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdollahi A, 1997, CANCER RES, V57, P2029; Abdollahi A, 1999, ONCOGENE, V18, P6477, DOI 10.1038/sj.onc.1203067; Abdollahi A, 2003, J BIOL CHEM, V278, P6041, DOI 10.1074/jbc.M210361200; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bilanges B, 2001, ONCOGENE, V20, P1246, DOI 10.1038/sj.onc.1204237; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cheng JC, 2003, J NATL CANCER I, V95, P399, DOI 10.1093/jnci/95.5.399; CHOI YC, 1991, J BIOL CHEM, V266, P20504; Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699; Cohen SB, 2001, ONCOGENE, V20, P141, DOI 10.1038/sj.onc.1204077; CROSS SH, 1994, NAT GENET, V6, P236, DOI 10.1038/ng0394-236; Dale L, 1999, BIOESSAYS, V21, P751, DOI 10.1002/(SICI)1521-1878(199909)21:9<751::AID-BIES6>3.0.CO;2-I; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; FEINBERG AP, 1988, CANCER RES, V48, P1159; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; GRAFF JR, 1995, CANCER RES, V55, P5195; Hajra KM, 2002, GENE CHROMOSOME CANC, V34, P255, DOI 10.1002/gcc.10083; Hedenfalk I, 2003, P NATL ACAD SCI USA, V100, P2532, DOI 10.1073/pnas.0533805100; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Henningfeld KA, 2000, J BIOL CHEM, V275, P21827, DOI 10.1074/jbc.M000978200; Howe JR, 2001, NAT GENET, V28, P184, DOI 10.1038/88919; Huang SM, 2000, MOL CELL BIOL, V20, P1855, DOI 10.1128/MCB.20.5.1855-1867.2000; ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235; John RM, 1998, GENOME ANAL, V2, P217; Johnston IMP, 2000, ONCOGENE, V19, P5348, DOI 10.1038/sj.onc.1203927; JONES PA, 1985, CELL, V40, P485, DOI 10.1016/0092-8674(85)90192-8; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594; Kimura H, 2003, J BIOL CHEM, V278, P4806, DOI 10.1074/jbc.M209923200; Kleeff J, 1999, GASTROENTEROLOGY, V116, P1202, DOI 10.1016/S0016-5085(99)70024-7; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; LABOW MA, 1990, MOL CELL BIOL, V10, P3343, DOI 10.1128/MCB.10.7.3343; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; LI L, 2003, CANC RES; Lin XY, 2000, MOL CELL BIOL, V20, P7259, DOI 10.1128/MCB.20.19.7259-7272.2000; Lin XY, 1997, CANCER RES, V57, P2304; Lin XY, 1996, J BIOL CHEM, V271, P28430, DOI 10.1074/jbc.271.45.28430; LIN XY, 1995, MOL CELL BIOL, V15, P2754; MACLEOD AR, 1995, J BIOL CHEM, V270, P11327, DOI 10.1074/jbc.270.19.11327; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; MILLER AD, 1985, J VIROL, V55, P521, DOI 10.1128/JVI.55.3.521-526.1985; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Nutt CL, 2003, CANCER RES, V63, P1602; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; Piras G, 2000, MOL CELL BIOL, V20, P3308, DOI 10.1128/MCB.20.9.3308-3315.2000; Raida M, 1999, INT J CANCER, V83, P38, DOI 10.1002/(SICI)1097-0215(19990924)83:1<38::AID-IJC8>3.3.CO;2-2; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Scandura JM, 2002, ONCOGENE, V21, P3422, DOI 10.1038/sj.onc.1205315; Shi Y, 2003, TRENDS GENET, V19, P9, DOI 10.1016/S0168-9525(02)00005-7; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Spengler D, 1997, EMBO J, V16, P2814, DOI 10.1093/emboj/16.10.2814; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Tamura G, 2000, J NATL CANCER I, V92, P569, DOI 10.1093/jnci/92.7.569; Varrault A, 2001, J BIOL CHEM, V276, P18653, DOI 10.1074/jbc.C100095200; Varrault A, 1998, P NATL ACAD SCI USA, V95, P8835, DOI 10.1073/pnas.95.15.8835; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; Xia W, 2001, CANCER RES, V61, P5644; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416; ZHANG M, 1995, CANCER RES, V55, P2537; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	76	62	63	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2004	23	21					3737	3748		10.1038/sj.onc.1207483	http://dx.doi.org/10.1038/sj.onc.1207483			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	818JX	14990994				2022-12-28	WOS:000221242500001
J	Chauhan, D; Li, GL; Hideshima, T; Podar, K; Shringarpure, R; Mitsiades, C; Munshi, N; Yew, PR; Anderson, KC				Chauhan, D; Li, GL; Hideshima, T; Podar, K; Shringarpure, R; Mitsiades, C; Munshi, N; Yew, PR; Anderson, KC			Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341	ONCOGENE			English	Article						Bortezomib/PS-341; multiple myeloma; apoptosis; 2-Methoxyestradiol; dexamethasone	MULTIPLE-MYELOMA; INDUCED APOPTOSIS; POLY(ADP-RIBOSE) POLYMERASE; OLIGONUCLEOTIDE ARRAYS; MITOCHONDRIAL PROTEIN; DRUG-RESISTANCE; CELL-CYCLE; MM CELLS; INTERLEUKIN-6; DEXAMETHASONE	The ubiquitin-conjugating enzyme CDC34 (UBC3) is linked to cell cycle progression in diverse cell types; however, its role in multiple myeloma ( MM) pathogenesis is unclear. Here, we show that CDC34 is highly expressed in patient MM cells and MM cell lines versus normal cells. Blocking CDC34 using a dominant-negative strategy enhances the anti-MM activity of Bortezomib/ Proteasome inhibitor PS-341, dexamethasone (Dex) and 2-Methoxyestradiol (2ME2). The expression of wild-type CDC34 reduces Dex-induced cytotoxicity in MM cells. Moreover, inhibition of CDC34 enzymatic activity abrogates interleukin-6-induced protection against Dex-induced apoptosis. Together, these findings provide evidence that ( 1) CDC34 expression is associated with growth and survival of MM cells and ( 2) blocking CDC34 activity not only enhances anti-MM activity of Bortezomib and 2ME2 but also overcomes IL-6-triggered Dex-resistance.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA; Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Texas System; University of Texas Health San Antonio	Anderson, KC (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.	kenneth_anderson@dfci.harvard.edu	Munshi, Nikhil/ABE-2338-2021; Podar, Klaus/ABD-1112-2020	Podar, Klaus/0000-0002-7414-3632	NCI NIH HHS [R01 CA50947, P01 CA 78373, IP50 CA 10070] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050947] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Block K, 2001, J BIOL CHEM, V276, P41049, DOI 10.1074/jbc.M106453200; Chauhan D, 1999, ONCOGENE, V18, P6733, DOI 10.1038/sj.onc.1203082; Chauhan D, 2003, BLOOD, V102, P3379, DOI 10.1182/blood-2003-05-1417; Chauhan D, 2003, J BIOL CHEM, V278, P17593, DOI 10.1074/jbc.C300076200; Chauhan D, 2003, BLOOD, V101, P3606, DOI 10.1182/blood-2002-10-3146; Chauhan D, 2002, BLOOD, V100, P2187, DOI 10.1182/blood-2002-02-0376; Chauhan D, 1997, BLOOD, V89, P227, DOI 10.1182/blood.V89.1.227.227_227_234; Chauhan D, 1996, BLOOD, V87, P1104, DOI 10.1182/blood.V87.3.1104.bloodjournal8731104; Chauhan D, 2001, J BIOL CHEM, V276, P24453, DOI 10.1074/jbc.C100074200; Chauhan D, 2000, J BIOL CHEM, V275, P27845; Chen YH, 1996, BLOOD, V87, P314, DOI 10.1182/blood.V87.1.314.bloodjournal871314; De Vos J, 2002, ONCOGENE, V21, P6848, DOI 10.1038/sj.onc.1205868; DESNOYERS S, 1994, ANAL BIOCHEM, V218, P470, DOI 10.1006/abio.1994.1212; Eliseeva E, 2001, CELL GROWTH DIFFER, V12, P427; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; HARDIN J, 1994, BLOOD, V84, P3063; Hideshima T, 2000, BLOOD, V96, P2943, DOI 10.1182/blood.V96.9.2943; Hwang GW, 2002, FASEB J, V16, P709, DOI 10.1096/fj.01-0899fje; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Li YZ, 1999, MOL MED, V5, P232, DOI 10.1007/BF03402120; MOALLI PA, 1992, BLOOD, V79, P213; Rowley M, 2000, BLOOD, V96, P3175, DOI 10.1182/blood.V96.9.3175.h8003175_3175_3180; Tanaka K, 2001, BBA-MOL BASIS DIS, V1536, P1, DOI 10.1016/S0925-4439(01)00026-6; Verma R, 1997, MOL BIOL CELL, V8, P1427, DOI 10.1091/mbc.8.8.1427; Yew PR, 1997, SCIENCE, V277, P1672, DOI 10.1126/science.277.5332.1672	25	45	45	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3597	3602		10.1038/sj.onc.1207458	http://dx.doi.org/10.1038/sj.onc.1207458			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15094775				2022-12-28	WOS:000221101700011
J	Todd, DE; Densham, RM; Molton, SA; Balmanno, K; Newson, C; Weston, CR; Garner, AP; Scott, L; Cook, SJ				Todd, DE; Densham, RM; Molton, SA; Balmanno, K; Newson, C; Weston, CR; Garner, AP; Scott, L; Cook, SJ			ERK1/2 and p38 cooperate to induce a p21(CIP1)-dependent G(1) cell cycle arrest	ONCOGENE			English	Article						ERK; JNK; MEKK; p21(CIP)1; p38; Raf	MESSENGER-RNA STABILIZATION; SIGNAL-REGULATED KINASE; KAPPA-B ACTIVATION; DEPENDENT KINASES; CDK INHIBITORS; RETINOBLASTOMA PROTEIN; DNA-DAMAGE; TRANSCRIPTION FACTORS; UV-RADIATION; HUMAN CANCER	To study the mechanisms by which mitogen- and stress-activated protein kinases regulate cell cycle re-entry, we have used a panel of conditional kinases that stimulate defined MAPK or SAPK cascades. Activation of DeltaMEKK3:ER* during serum restimulation of quiescent cells causes a strong activation of JNK1 and p38alpha but only a modest potentiation of serum-stimulated ERK1/2 activity. In CCl39 cells this promoted a sustained G(1) arrest that correlated with decreased expression of cyclin D1 and Cdc25A, increased expression of p21(CIP1) and inhibition of CDK2 activity. In Rat-1 cells, in which p21(CIP1) expression is silenced by methylation, DeltaMEKK3:ER* activation caused only a transient delay in the S phase entry rather than a sustained G(1) arrest. Furthermore, p21(CIP1-/-) 3T3 cells were defective for the DeltaMEKK3:ER*- induced G(1) cell cycle arrest compared to their wild-type counterparts. These results suggest that activated DeltaMEKK3: ER* inhibits the G(1)-->S progression by two kinetically distinct mechanisms, with expression of p21(CIP1) being required to ensure a sustained G(1) cell cycle arrest. The ERK1/2 and p38alphabeta pathways cooperated to induce p21(CIP1) expression and inhibition of p38alphabeta caused a partial reversal of the cell cycle arrest. In contrast, selective activation of ERK1/2 by DeltaRaf-1:ER* did not inhibit serum stimulated cell cycle re-entry. Finally, selective activation of JNK by DeltaMEKK1: ER* failed to inhibit cell cycle re-entry, even in cells that retained wild-type p53, arguing against a major role for JNK alone in antagonizing the G(1)-->S transition.	Babraham Inst, Signalling Programme, Cambridge CB2 4AT, England; Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Beatson Institute	Cook, SJ (corresponding author), Babraham Inst, Signalling Programme, Babraham Hall, Cambridge CB2 4AT, England.	simon.cook@bbsrc.ac.uk	Densham, Ruth/AAO-1971-2020	Densham, Ruth/0000-0003-4490-2842; Balmanno, Kathryn/0000-0002-6417-3889	Biotechnology and Biological Sciences Research Council [BBS/E/B/0000H457, BBS/E/B/0000C199] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; Allan LA, 2000, MOL CELL BIOL, V20, P1291, DOI 10.1128/MCB.20.4.1291-1298.2000; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Balmanno K, 1999, ONCOGENE, V18, P3085, DOI 10.1038/sj.onc.1202647; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; Casanovas O, 2000, J BIOL CHEM, V275, P35091, DOI 10.1074/jbc.M006324200; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; CLARKE PR, 1995, CURR BIOL, V5, P40, DOI 10.1016/S0960-9822(95)00013-3; Cook SJ, 1999, MOL CELL BIOL, V19, P330; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Deacon K, 1999, J BIOL CHEM, V274, P16604, DOI 10.1074/jbc.274.23.16604; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ellinger-Ziegelbauer H, 1999, MOL CELL BIOL, V19, P3857; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Garner AP, 2002, ONCOGENE, V21, P8089, DOI 10.1038/sj.onc.1206000; Geng Y, 1996, ONCOGENE, V12, P1173; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; KASTAN MB, 1991, CANCER RES, V51, P6304; Kim GY, 2002, J BIOL CHEM, V277, P29792, DOI 10.1074/jbc.M201299200; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; McMahon M, 2001, BBA-REV CANCER, V1471, pM63, DOI 10.1016/S0304-419X(00)00027-5; Molnar A, 1997, J BIOL CHEM, V272, P13229, DOI 10.1074/jbc.272.20.13229; Molton SA, 2003, ONCOGENE, V22, P4690, DOI 10.1038/sj.onc.1206692; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Park JS, 2000, MOL BIOL CELL, V11, P2915, DOI 10.1091/mbc.11.9.2915; Persons DL, 2000, J BIOL CHEM, V275, P35778, DOI 10.1074/jbc.M004267200; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Sanchez-Prieto R, 2000, CANCER RES, V60, P2464; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shirane M, 1999, J BIOL CHEM, V274, P13886, DOI 10.1074/jbc.274.20.13886; Squires MS, 2002, BIOCHEM J, V366, P673, DOI 10.1042/BJ20020372; TISHLER RB, 1993, CANCER RES, V53, P2212; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Ussat S, 2002, BIOCHEM BIOPH RES CO, V294, P672, DOI 10.1016/S0006-291X(02)00532-6; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang S, 1999, EMBO J, V18, P1559, DOI 10.1093/emboj/18.6.1559; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Weston CR, 2003, ONCOGENE, V22, P1281, DOI 10.1038/sj.onc.1206261; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	70	70	75	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3284	3295		10.1038/sj.onc.1207467	http://dx.doi.org/10.1038/sj.onc.1207467			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	14981547				2022-12-28	WOS:000220975000003
J	Gamble, SC; Odontiadis, M; Waxman, J; Westbrook, JA; Dunn, MJ; Wait, R; Lam, EWF; Bevan, CL				Gamble, SC; Odontiadis, M; Waxman, J; Westbrook, JA; Dunn, MJ; Wait, R; Lam, EWF; Bevan, CL			Androgens target prohibitin to regulate proliferation of prostate cancer cells	ONCOGENE			English	Article						androgen; prohibitin; prostate cancer	POLYACRYLAMIDE-GELS; RECEPTOR GENE; CELLULAR SENESCENCE; MASS-SPECTROMETRY; PROTEIN DATABASE; HORMONAL-THERAPY; EXPRESSION; IDENTIFICATION; REPRESSION; RB	Proteins involved in the growth response of prostate cancer cells to androgen were investigated by comparing the proteomes of LNCaP cells treated with vehicle or androgen. Whole-cell lysates were separated by two-dimensional PAGE, and HPLC-MS/MS was used to identify androgen-regulated proteins. Prohibitin, a protein with cell-cycle regulatory activity, was shown to be downregulated by 50% following androgen stimulation. Western blot and reverse transcription-PCR experiments confirmed the result and showed that regulation occurs at the level of transcription. To determine the importance of prohibitin in androgen-stimulated growth, we used transient transfection to overexpress the protein and RNA interference to knock down the protein. Subsequent FACS analysis showed that cells with reduced levels of prohibitin showed a slight but reproducible increase in the percentage of population in cell cycle, while cells with increased prohibitin levels showed a clear reduction in the percentage entering cell cycle, following dihydrotestosterone stimulation, when compared to untransfected controls. Confocal microscopy showed localization of prohibitin in the nucleus as well as the mitochondria of LNCaP cells. It therefore seems that the regulation of prohibitin is a vital part of the cellular growth response to androgen stimulation in LNCaPs and prohibitin may have a nuclear regulatory role in cell-cycle progression.	Hammersmith Hosp, Imperial Coll London, Dept Canc Med, London W12 0NN, England; Harefield Hosp, Imperial Coll Sch Med, Heart Sci Ctr, Harefield UB9 6JH, Middx, England; Inst Psychiat, Dept Neurosci, London SE5 8AF, England; Univ London Imperial Coll Sci & Technol, Fac Med, Kennedy Inst Rheumatol Div, London W6 8LH, England	Imperial College London; Imperial College London; Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital; University of London; King's College London; Imperial College London; University of Oxford	Bevan, CL (corresponding author), Hammersmith Hosp, Imperial Coll London, Dept Canc Med, London W12 0NN, England.	charlotte.bevan@imperial.ac.uk	Bevan, Charlotte L/K-2276-2012; Lam, Eric W-F/AAW-8566-2020; Bevan, Charlotte/T-7769-2019	Bevan, Charlotte L/0000-0002-7533-0552; Lam, Eric W-F/0000-0003-1274-3576; 				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Coates PJ, 2001, EXP CELL RES, V265, P262, DOI 10.1006/excr.2001.5166; Coates PJ, 1997, CURR BIOL, V7, P607, DOI 10.1016/S0960-9822(06)00261-2; CORBETT JM, 1994, ELECTROPHORESIS, V15, P1459, DOI 10.1002/elps.11501501209; Dixit VD, 2003, ENDOCRINOLOGY, V144, P1496, DOI 10.1210/en.2002-220955; Fellenberg J, 2003, INT J CANCER, V105, P636, DOI 10.1002/ijc.11135; Gharahdaghi F, 1999, ELECTROPHORESIS, V20, P601, DOI 10.1002/(SICI)1522-2683(19990301)20:3<601::AID-ELPS601>3.0.CO;2-6; Gottlieb B, 1997, NUCLEIC ACIDS RES, V25, P158, DOI 10.1093/nar/25.1.158; GRAYHACK JT, 1987, CANCER, V60, P589, DOI 10.1002/1097-0142(19870801)60:3+<589::AID-CNCR2820601526>3.0.CO;2-R; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; IKONEN E, 1995, FEBS LETT, V358, P273, DOI 10.1016/0014-5793(94)01444-6; JENO P, 1995, ANAL BIOCHEM, V224, P75, DOI 10.1006/abio.1995.1010; Jupe ER, 1996, EXP CELL RES, V224, P128, DOI 10.1006/excr.1996.0120; Koivisto P, 1998, AM J PATHOL, V152, P1; KRAUSS MR, 1990, BIOTECHNIQUES, V8, P218; LIU XT, 1994, BIOCHEM BIOPH RES CO, V201, P409, DOI 10.1006/bbrc.1994.1716; Mackey AJ, 2002, MOL CELL PROTEOMICS, V1, P139, DOI 10.1074/mcp.M100004-MCP200; MCCLUNG JK, 1989, BIOCHEM BIOPH RES CO, V164, P1316, DOI 10.1016/0006-291X(89)91813-5; Nijtmans LGJ, 2002, CELL MOL LIFE SCI, V59, P143, DOI 10.1007/s00018-002-8411-0; NUELL MJ, 1991, MOL CELL BIOL, V11, P1372, DOI 10.1128/MCB.11.3.1372; Peterziel H, 1999, ONCOGENE, V18, P6322, DOI 10.1038/sj.onc.1203032; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Slade MJ, 1999, J CLIN ONCOL, V17, P870, DOI 10.1200/JCO.1999.17.3.870; Steglich G, 1999, MOL CELL BIOL, V19, P3435; Thompson WE, 2001, ENDOCRINOLOGY, V142, P4076, DOI 10.1210/en.142.9.4076; Thompson WE, 1999, ANAT REC, V256, P40, DOI 10.1002/(SICI)1097-0185(19990901)256:1<40::AID-AR6>3.0.CO;2-X; Vander Heiden MG, 2002, J BIOL CHEM, V277, P44870, DOI 10.1074/jbc.M204888200; Verrijdt G, 2003, MOL GENET METAB, V78, P175, DOI 10.1016/S1096-7192(03)00003-9; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Wait R, 2002, ELECTROPHORESIS, V23, P3418, DOI 10.1002/1522-2683(200210)23:19&lt;3418::AID-ELPS3418&gt;3.0.CO;2-7; Wait R, 2001, ELECTROPHORESIS, V22, P3043, DOI 10.1002/1522-2683(200108)22:14<3043::AID-ELPS3043>3.0.CO;2-M; Wang S, 2002, EMBO J, V21, P3019, DOI 10.1093/emboj/cdf302; Wang S, 1999, MOL CELL BIOL, V19, P7447; Wang S, 1999, ONCOGENE, V18, P3501, DOI 10.1038/sj.onc.1202684; Wang S, 2002, ONCOGENE, V21, P8388, DOI 10.1038/sj.onc.1205944; Weekes J, 1999, ELECTROPHORESIS, V20, P898, DOI 10.1002/(SICI)1522-2683(19990101)20:4/5<898::AID-ELPS898>3.0.CO;2-B; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Woodlock TJ, 2001, BLOOD CELL MOL DIS, V27, P27, DOI 10.1006/bcmd.2000.0348; Yan JX, 2000, ELECTROPHORESIS, V21, P3666, DOI 10.1002/1522-2683(200011)21:17<3666::AID-ELPS3666>3.0.CO;2-6	40	84	97	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2004	23	17					2996	3004		10.1038/sj.onc.1207444	http://dx.doi.org/10.1038/sj.onc.1207444			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	812NC	14968116				2022-12-28	WOS:000220845200003
J	Kamio, M; Yoshida, T; Ogata, H; Douchi, T; Nagata, Y; Inoue, M; Hasegawa, M; Yonemitsu, Y; Yoshimura, A				Kamio, M; Yoshida, T; Ogata, H; Douchi, T; Nagata, Y; Inoue, M; Hasegawa, M; Yonemitsu, Y; Yoshimura, A			SOC1 inhibits HPV-E7-mediated transformation by inducing degradation of E7 protein	ONCOGENE			English	Article						cytokine; SOCS; papilloma viruses; interferon gamma; E7; proteasome	HUMAN PAPILLOMAVIRUS TYPE-16; SENDAI-VIRUS; SIGNAL-TRANSDUCTION; GROWTH-SUPPRESSION; NEGATIVE REGULATOR; GENE-TRANSFER; CELL-LINES; BOX MOTIF; INTERFERON; SOCS-1	Human papilloma viruses (HPVs) are small double-stranded DNA viruses that infect mucosal and cutaneous epithelium and induce cervical cancer. It has been shown that interferon (IFN)gamma suppresses proliferation of HPV-infected cells by suppressing expression of HPV E7. Here, we found that IFNgamma induces not only suppression of E7 transcription but also proteasome-dependent degradation. Suppressor of cytokine signaling-1 (SOCS1)/JAB, a suppressor of cytokine signaling, is known to be induced by IFNgamma, and functions as an antioncogene against various hematopoietic oncogenic proteins. SOCS1 contains the SOCS-box, which is shown to recruit ubiquitin transferase to the molecules that interact with SOCS1. We found that SOCS1 interacted with HPV E7 protein and induced ubiquitination and degradation of E7 in a SOCS-box-dependent manner. SOCS1 overexpression also increased Rb protein levels and suppressed proliferation of cervical cancer cell lines infected with HPV. Moreover, E7 protein levels were higher and Rb protein levels were lower in SOCS1-deficient fibroblasts infected with retrovirus vector carrying E7 gene than in wild-type fibroblasts. E7 induced anchorage-independent growth in SOCS1-deficient fibroblasts, but not in wild-type cells. These data suggested that SOCS1 plays an important role in regulating the levels of E7 protein and their transforming potential, and could be a new therapeutic tool for HPV-mediated tumors.	Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, Fukuoka 8128582, Japan; Kagoshima Univ, Fac Med, Dept Obstet & Gynecol, Kagoshima 8900054, Japan; DNAVEC Res Inc, Tsukuba, Ibaraki, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Pathol, Div Pathophysiol & Expt Pathol,Higash Ku, Fukuoka 8128582, Japan	Kyushu University; Kagoshima University; DNAVEC Corporation; Kyushu University	Yoshimura, A (corresponding author), Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	yakihiko@bioreg.kyushu-u.ac.jp	Yoshimura, Akihiko/K-5515-2013					BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; De Sepulveda P, 1999, EMBO J, V18, P904; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Galm O, 2003, BLOOD, V101, P2784, DOI 10.1182/blood-2002-06-1735; Gross G, 1997, INTERVIROLOGY, V40, P368, DOI 10.1159/000150569; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Ilangumaran S, 2003, J BIOL CHEM, V278, P41871, DOI 10.1074/jbc.M308382200; Jeon JH, 2002, EXP MOL MED, V34, P496, DOI 10.1038/emm.2002.69; Jones DL, 1996, SEMIN CANCER BIOL, V7, P327, DOI 10.1006/scbi.1996.0042; Kalvakolanu DV, 1996, CANCER INVEST, V14, P25, DOI 10.3109/07357909609018435; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kato A, 1996, GENES CELLS, V1, P569, DOI 10.1046/j.1365-2443.1996.d01-261.x; Kawazoe Y, 2001, J EXP MED, V193, P263, DOI 10.1084/jem.193.2.263; Kim KY, 2000, J GEN VIROL, V81, P695, DOI 10.1099/0022-1317-81-3-695; Kolakofsky D, 1998, J VIROL, V72, P891, DOI 10.1128/JVI.72.2.891-899.1998; Koromilas AE, 2001, CYTOKINE GROWTH F R, V12, P157, DOI 10.1016/S1359-6101(00)00023-X; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; MUNGER K, 1989, J VIROL, V63, P4417; Nagai H, 2003, J HUM GENET, V48, P65, DOI 10.1007/s100380300008; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; Reinstein E, 2000, ONCOGENE, V19, P5944, DOI 10.1038/sj.onc.1203989; Rottapel R, 2002, ONCOGENE, V21, P4351, DOI 10.1038/sj.onc.1205537; Sakai Y, 1999, FEBS LETT, V456, P221, DOI 10.1016/S0014-5793(99)00960-6; Sasaki A, 2000, J BIOL CHEM, V275, P29338, DOI 10.1074/jbc.M003456200; SELVEY LA, 1994, J GEN VIROL, V75, P1647, DOI 10.1099/0022-1317-75-7-1647; Shouda T, 2001, J CLIN INVEST, V108, P1781, DOI 10.1172/JCI200113568; Song MM, 1998, J BIOL CHEM, V273, P35056, DOI 10.1074/jbc.273.52.35056; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; TAN TMC, 1995, CANCER RES, V55, P4599; Tomoda K, 2002, J BIOL CHEM, V277, P2302, DOI 10.1074/jbc.M104431200; Um SJ, 2000, INT J CANCER, V85, P416, DOI 10.1002/(SICI)1097-0215(20000201)85:3<416::AID-IJC19>3.3.CO;2-V; Venturini F, 1999, NUCLEIC ACIDS RES, V27, P1585, DOI 10.1093/nar/27.7.1585; Wang J, 2001, ONCOGENE, V20, P4740, DOI 10.1038/sj.onc.1204655; WATANABE S, 1989, J VIROL, V63, P965, DOI 10.1128/JVI.63.2.965-969.1989; WOODWORTH CD, 1992, CANCER RES, V52, P456; WU EW, 1993, J VIROL, V67, P2402, DOI 10.1128/JVI.67.4.2402-2407.1993; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yonemitsu Y, 1998, INT J ONCOL, V12, P1277; Yonemitsu Y, 2000, NAT BIOTECHNOL, V18, P970, DOI 10.1038/79463; Yoshida T, 2002, J EXP MED, V196, P641, DOI 10.1084/jem.20012127; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071	48	59	63	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2004	23	17					3107	3115		10.1038/sj.onc.1207453	http://dx.doi.org/10.1038/sj.onc.1207453			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	812NC	15021916	Bronze			2022-12-28	WOS:000220845200015
J	Lyakhovich, A; Shekhar, MPV				Lyakhovich, A; Shekhar, MPV			RAD6B overexpression confers chemoresistance: RAD6 expression during cell cycle and its redistribution to chromatin during DNA damage-induced response	ONCOGENE			English	Article						postreplication repair; ubiquitin conjugating enzyme; cell cycle; adriamycin; cisplatin	SACCHAROMYCES-CEREVISIAE RAD6; UBIQUITIN-CONJUGATING ENZYMES; 2 HUMAN HOMOLOGS; POSTREPLICATION REPAIR; GENE-PRODUCT; PROTEIN; MUTAGENESIS; HHR6A; P53; INACTIVATION	The HR6A and HR6B genes, homologs of the yeast RAD6 gene, encode ubiquitin conjugating enzymes that are required for postreplication repair (PRR) of DNA and damage-induced mutagenesis. We show here that consistent with its role as a PRR protein, HR6 protein (referred as RAD6) expression is cell cycle regulated, with maximal levels expressed in late S/G2 phases of the cell cycle. Exposure of MCF10A cells to adriamycin (ADR) causes enhancement in the levels of RAD6B mRNA and protein. Inclusion of actinomycin D abolishes both basal and ADR-induced RAD6B transcription indicating that ADR-induced effects on RAD6B transcription result from an increase in transcriptional activity rather than from regulation of RAD6B mRNA stability. The increase in RAD6 protein expression observed in ADR-treated cells is dependent upon transcription and de novo protein synthesis, as addition of actinomycin D and cycloheximide eliminated the induction effects. Using in vivo crosslinking experiments, we demonstrate that only a small proportion of RAD6 is associated with chromatin in untreated MCF10A cells. However, treatment with ADR or cisplatin is accompanied by a significant increase and redistribution of RAD6 to DNA, and RAD6, RAD18, PCNA, phosphohistone H3, as well as p53 proteins are all found in the DNA fractions. These findings suggest that although RAD6 protein is present in the nucleus, its recruitment to the chromatin appears to be modulated by DNA damage. Whereas MCF10A cells engineered to overexpress ectopic RAD6B are significantly more resistant to ADR and cisplatin as compared to empty vector-transfected cells, MCF10A cells stably transfected with antisense RAD6B display hypersensitivity to these damage-inducing drugs. Analysis of PRR capacities in cisplatin-treated MCF10A cells stably transfected with empty vector, RAD6B or antisense RAD6B showed that whereas RAD6B-overexpressing and vector control MCF10A cells possessed the ability to convert newly synthesized DNA to higher molecular weight species, MCF10A cells depleted of RAD6B are PRR-compromised. Although no human diseases have been linked to mutations in the PRR pathway genes, these data suggest that RAD6 may play an essential role in DNA damage tolerance and recovery via modulation of PRR, and that imbalances in the levels of RAD6 could lead to changes in drug sensitivity and damage-induced mutagenesis.	Karmanos Canc Inst, Breast Canc Program, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University	Shekhar, MPV (corresponding author), Karmanos Canc Inst, Breast Canc Program, 110 E Warren Ave, Detroit, MI 48201 USA.	shekharm@karmanos.org	Lyakhovich, Alex/B-4410-2008; Lyakhovich, Alex/B-4410-2008	Lyakhovich, Alex/0000-0002-8279-4697; Shekhar, Malathy/0000-0003-2721-7202; Lyakhovich, Alex/0000-0001-5347-403X				Bailly V, 1997, J BIOL CHEM, V272, P23360, DOI 10.1074/jbc.272.37.23360; Broomfield S, 1998, P NATL ACAD SCI USA, V95, P5678, DOI 10.1073/pnas.95.10.5678; Broomfield S, 2001, MUTAT RES-DNA REPAIR, V486, P167, DOI 10.1016/S0921-8777(01)00091-X; Cejka P, 2001, GENETICS, V159, P953; ELLISON KS, 1991, J BIOL CHEM, V266, P24116; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Haynes R.H., 1981, MOL BIOL YEAST SACCH, P371; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; Kim H, 2001, ONCOGENE, V20, P3306, DOI 10.1038/sj.onc.1204423; KOKEN MHM, 1992, GENOMICS, V12, P447, DOI 10.1016/0888-7543(92)90433-S; Koken MHM, 1996, DEV BIOL, V173, P119, DOI 10.1006/dbio.1996.0011; KOKEN MHM, 1991, P NATL ACAD SCI USA, V88, P8865, DOI 10.1073/pnas.88.20.8865; KUPIEC M, 1984, CURR GENET, V8, P559, DOI 10.1007/BF00395700; LAWRENCE C, 1994, BIOESSAYS, V16, P253, DOI 10.1002/bies.950160408; LAWRENCE CW, 1982, ADV GENET, V21, P173, DOI 10.1016/S0065-2660(08)60299-0; LEHMANN AR, 1975, P NATL ACAD SCI USA, V72, P219, DOI 10.1073/pnas.72.1.219; LEHMANN AR, 1972, J MOL BIOL, V66, P319, DOI 10.1016/0022-2836(72)90418-4; Lyakhovich A, 2003, MOL CELL BIOL, V23, P2463, DOI 10.1128/MCB.23.7.2463-2475.2003; McDonald JP, 1997, GENETICS, V147, P1557; PRAKASH S, 1990, EUKARYOTIC NUCLEUS, V1, P275; REYNOLDS P, 1985, P NATL ACAD SCI USA, V82, P168, DOI 10.1073/pnas.82.1.168; ROCHE H, 1995, GENETICS, V140, P443; Roest HP, 1996, CELL, V86, P799, DOI 10.1016/S0092-8674(00)80154-3; Shekhar MPV, 2002, CANCER RES, V62, P2115; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SOLOMON MJ, 1985, P NATL ACAD SCI USA, V82, P6470, DOI 10.1073/pnas.82.19.6470; SOULE HD, 1990, CANCER RES, V50, P6075; SUNG P, 1991, J MOL BIOL, V221, P745, DOI 10.1016/0022-2836(91)80169-U; SUNG P, 1990, P NATL ACAD SCI USA, V87, P2695, DOI 10.1073/pnas.87.7.2695; Torres-Ramos CA, 2002, MOL CELL BIOL, V22, P2419, DOI 10.1128/MCB.22.7.2419-2426.2002; Ulrich HD, 2000, EMBO J, V19, P3388, DOI 10.1093/emboj/19.13.3388; Wood A, 2003, MOL CELL, V11, P267, DOI 10.1016/S1097-2765(02)00802-X; Xiao W, 2000, GENETICS, V155, P1633; Xin H, 2000, NUCLEIC ACIDS RES, V28, P2847, DOI 10.1093/nar/28.14.2847	35	37	39	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2004	23	17					3097	3106		10.1038/sj.onc.1207449	http://dx.doi.org/10.1038/sj.onc.1207449			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	812NC	14981545				2022-12-28	WOS:000220845200014
J	Cregan, SP; Dawson, VL; Slack, RS				Cregan, SP; Dawson, VL; Slack, RS			Role of AIF in caspase-dependent and caspase-independent cell death	ONCOGENE			English	Review						apoptosis; caspase; AIF; PARP-1; mitochondria	APOPTOSIS-INDUCING FACTOR; CYTOCHROME-C RELEASE; POLY(ADP-RIBOSE) POLYMERASE GENE; MITOCHONDRIAL PERMEABILITY TRANSITION; DEPRIVED SYMPATHETIC NEURONS; CEREBELLAR GRANULE CELLS; OXYGEN-GLUCOSE DEPRIVATION; ENDOPLASMIC-RETICULUM CA2+; NITRIC-OXIDE; DNA-DEGRADATION	The major challenge in treating cancer is that many tumor cells carry mutations in key apoptotic genes such as p53, Bcl family proteins or those affecting caspase signaling. Such defects render treatment with traditional chemotherapeutic agents ineffective. Many studies have demonstrated the importance of caspase-independent cell death pathways in injury, degenerative diseases and tumor tissue. It is now recognized that in addition to their critical role in the production of cellular energy, mitochondria are also the source of key proapoptotic molecules involved in caspase activation. More recently, it has been discovered that in response to apoptotic stimuli, mitochondria can also release caspase-independent cell death effectors such as AIF and Endonuclease G. In this review, we examine the role of Bcl family proteins and poly(ADP-ribose) polymerase-1 signaling in the regulation of these apoptotic pathways and address the ongoing controversies in this field. Continued study of the mechanisms of apoptosis including caspase-independent death processes are likely to reveal novel therapeutic targets for the treatment of diverse human pathologies including cancer, neurodegenerative diseases and acute injuries such as stroke or myocardial infarction.	Univ Ottawa, Ottawa Hlth Res Inst, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada; Johns Hopkins Univ, Inst Cell Engn, Dept Neurol Neurosci & Physiol, Baltimore, MD 21205 USA	University of Ottawa; Ottawa Hospital Research Institute; Johns Hopkins University	Slack, RS (corresponding author), Univ Ottawa, Ottawa Hlth Res Inst, Dept Cellular & Mol Med, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.	rslack@uottawa.ca	Cregan, Sean/M-3205-2013; Dawson, Valina/Y-9757-2019	Dawson, Valina/0000-0002-2915-3970; Slack, Ruth/0000-0002-1552-2835	NINDS NIH HHS [NS39148] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS039148] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alonso M, 2003, MOL CANCER THER, V2, P139; Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Arnoult D, 2003, EMBO J, V22, P4385, DOI 10.1093/emboj/cdg423; Arnoult D, 2002, J CELL BIOL, V159, P923, DOI 10.1083/jcb.200207071; Basanez G, 2001, J BIOL CHEM, V276, P31083, DOI 10.1074/jbc.M103879200; BECKMAN JS, 1991, J DEV PHYSIOL, V15, P53; BECKMAN JS, 1993, BIOCHEM SOC T, V21, P330, DOI 10.1042/bst0210330; BENJAMIN RC, 1980, J BIOL CHEM, V255, P493; Betarbet R, 2002, BRAIN PATHOL, V12, P499; Bidere N, 2003, J BIOL CHEM, V278, P31401, DOI 10.1074/jbc.M301911200; Bowes J, 1998, EUR J PHARMACOL, V359, P143, DOI 10.1016/S0014-2999(98)00638-4; Braun JS, 2002, J CLIN INVEST, V109, P19; Braun JS, 2001, J INFECT DIS, V184, P1300, DOI 10.1086/324013; Burkart V, 1999, NAT MED, V5, P314, DOI 10.1038/6535; Cao GD, 2003, J CEREBR BLOOD F MET, V23, P1137, DOI 10.1097/01.WCB.0000087090.01171.E7; Castilho RF, 1998, J NEUROSCI, V18, P10277; Chang LK, 2003, J CELL BIOL, V162, P245, DOI 10.1083/jcb.200302109; Chang LK, 2002, J CELL BIOL, V157, P771, DOI 10.1083/jcb.200112130; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Cregan SP, 2002, J CELL BIOL, V158, P507, DOI 10.1083/jcb.200202130; Cregan SP, 1999, J NEUROSCI, V19, P7860; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Dalkara T, 1998, PROG BRAIN RES, V118, P231; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; Deshmukh M, 2000, J CELL BIOL, V150, P131, DOI 10.1083/jcb.150.1.131; Deshmukh M, 1998, NEURON, V21, P695, DOI 10.1016/S0896-6273(00)80587-5; Devarajan E, 2002, ONCOGENE, V21, P8843, DOI 10.1038/sj.onc.1206044; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Du LN, 2003, J BIOL CHEM, V278, P18426, DOI 10.1074/jbc.M301295200; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Endres M, 1998, NEUROSCI LETT, V248, P41, DOI 10.1016/S0304-3940(98)00224-9; Ferri KF, 2000, CELL DEATH DIFFER, V7, P1137, DOI 10.1038/sj.cdd.4400748; Fletcher GC, 2000, J CELL BIOL, V150, P741, DOI 10.1083/jcb.150.4.741; Fonfria E, 2002, EUR J NEUROSCI, V16, P2013, DOI 10.1046/j.1460-9568.2002.02269.x; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Germain M, 2002, J BIOL CHEM, V277, P18053, DOI 10.1074/jbc.M201235200; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Goto S, 2002, STROKE, V33, P1101, DOI 10.1161/01.STR.0000014203.65693.1E; Granville DJ, 2001, CELL CALCIUM, V30, P343, DOI 10.1054/ceca.2001.0243; Granville DJ, 2001, AM J PATHOL, V159, P305, DOI 10.1016/S0002-9440(10)61696-3; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; GWAG BJ, 1995, NEUROSCIENCE, V68, P615, DOI 10.1016/0306-4522(95)00232-8; HELLER B, 1995, J BIOL CHEM, V270, P11176, DOI 10.1074/jbc.270.19.11176; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Hu YM, 1999, EMBO J, V18, P3586, DOI 10.1093/emboj/18.13.3586; Jambrina E, 2003, J BIOL CHEM, V278, P14134, DOI 10.1074/jbc.M211388200; Johnson MD, 1999, J NEUROSCI, V19, P2996; Joseph B, 2002, ONCOGENE, V21, P65, DOI 10.1038/sj/onc/1205018; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Karbowski M, 2002, J CELL BIOL, V159, P931, DOI 10.1083/jcb.200209124; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kim GT, 2003, BIOCHEM BIOPH RES CO, V309, P619, DOI 10.1016/j.bbrc.2003.08.045; Klein JA, 2002, NATURE, V419, P367, DOI 10.1038/nature01034; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kondo S, 2000, CANCER RES, V60, P4328; KUKREJA RC, 1992, CARDIOVASC RES, V26, P641, DOI 10.1093/cvr/26.7.641; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; LAUTIER D, 1993, MOL CELL BIOCHEM, V122, P171, DOI 10.1007/BF01076101; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lee ST, 1999, ONCOGENE, V18, P3520, DOI 10.1038/sj.onc.1202716; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Leist M, 1997, BIOCHEM BIOPH RES CO, V233, P518, DOI 10.1006/bbrc.1997.6491; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liao DJ, 2003, LAB INVEST, V83, P1437, DOI 10.1097/01.LAB.0000090153.13977.AE; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; Loeffler M, 2001, FASEB J, V15, P758, DOI 10.1096/fj.00-0388com; Lowe Scott W., 1995, Current Opinion in Oncology, V7, P547, DOI 10.1097/00001622-199511000-00013; Mandir AS, 2000, J NEUROSCI, V20, P8005; Martinou I, 1999, J CELL BIOL, V144, P883, DOI 10.1083/jcb.144.5.883; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Masutani M, 1999, P NATL ACAD SCI USA, V96, P2301, DOI 10.1073/pnas.96.5.2301; Mattson MP, 2000, J NEUROSCI, V20, P1358; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; MENISSIERDEMURCIA J, 1989, J MOL BIOL, V210, P229, DOI 10.1016/0022-2836(89)90302-1; MEYER FB, 1989, BRAIN RES REV, V14, P227, DOI 10.1016/0165-0173(89)90002-7; Miller TM, 1997, J CELL BIOL, V139, P205, DOI 10.1083/jcb.139.1.205; Miramar MD, 2001, J BIOL CHEM, V276, P16391, DOI 10.1074/jbc.M010498200; Murahashi H, 2003, J LEUKOCYTE BIOL, V73, P399, DOI 10.1189/jlb.0702335; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315; Nutt LK, 2002, J BIOL CHEM, V277, P9219, DOI 10.1074/jbc.M106817200; Ohiro Y, 2002, FEBS LETT, V524, P163, DOI 10.1016/S0014-5793(02)03049-1; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; Park DS, 1998, J NEUROSCI, V18, P830; Parone PA, 2002, BIOCHIMIE, V84, P105, DOI 10.1016/S0300-9084(02)01380-9; Parrish JZ, 2003, EMBO J, V22, P3451, DOI 10.1093/emboj/cdg320; Pieper AA, 2000, MOL MED, V6, P271, DOI 10.1007/BF03401936; Pieper AA, 1999, P NATL ACAD SCI USA, V96, P3059, DOI 10.1073/pnas.96.6.3059; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; Ruffolo SC, 2000, CELL DEATH DIFFER, V7, P1101, DOI 10.1038/sj.cdd.4400739; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Sasaki M, 2000, P NATL ACAD SCI USA, V97, P8617, DOI 10.1073/pnas.97.15.8617; Sattler R, 2000, J MOL MED, V78, P3, DOI 10.1007/s001090000077; SCHWARCZ R, 1982, NEUROSCIENCE, V7, P1771, DOI 10.1016/0306-4522(82)90034-3; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Shall S, 2000, MUTAT RES-DNA REPAIR, V460, P1, DOI 10.1016/S0921-8777(00)00016-1; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2001, J CELL BIOL, V152, P237, DOI 10.1083/jcb.152.2.237; Slagsvold HH, 2003, BRAIN RES, V984, P111, DOI 10.1016/S0006-8993(03)03119-6; Smulson ME, 2000, ADV ENZYME REGUL, V40, P183, DOI 10.1016/S0065-2571(99)00024-2; Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454; Stefanis L, 1999, J NEUROSCI, V19, P6235; Stout AK, 1998, NAT NEUROSCI, V1, P366, DOI 10.1038/1577; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; van Loo G, 2001, CELL DEATH DIFFER, V8, P1136, DOI 10.1038/sj.cdd.4400944; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Wang PH, 1996, J BIOL CHEM, V271, P29223, DOI 10.1074/jbc.271.46.29223; Wang XC, 2002, SCIENCE, V298, P1587, DOI 10.1126/science.1076194; Weiss JN, 2003, CIRC RES, V93, P292, DOI 10.1161/01.RES.0000087542.26971.D4; Wu M, 2002, J BIOL CHEM, V277, P25617, DOI 10.1074/jbc.M202285200; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Ye H, 2002, NAT STRUCT BIOL, V9, P680, DOI 10.1038/nsb836; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; YU SW, 2003, NEUROBIOL DIS; Zhang XP, 2002, J NEUROCHEM, V82, P181, DOI 10.1046/j.1471-4159.2002.00975.x; Zhu CL, 2003, J NEUROCHEM, V86, P306, DOI 10.1046/j.1471-4159.2003.01832.x; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	135	422	447	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2004	23	16					2785	2796		10.1038/sj.onc.1207517	http://dx.doi.org/10.1038/sj.onc.1207517			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	811VO	15077142				2022-12-28	WOS:000220799600006
J	Distelhorst, CW; Shore, GC				Distelhorst, CW; Shore, GC			Bcl-2 and calcium: controversy beneath the surface	ONCOGENE			English	Review						Bcl-2; calcium; endoplasmic reticulum	CYTOCHROME-C RELEASE; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; ENDOPLASMIC-RETICULUM CA2+; INTRACELLULAR CA2+; CELL-DEATH; OXIDATIVE STRESS; APOPTOSIS; HOMEOSTASIS; STORES; BAX	The function of Bcl-2 family members on the endoplasmic reticulum has received increasing attention in recent years. The endoplasmic reticulum is the major organelle involved in intracellular calcium homeostasis and calcium signaling, including calcium signals that mediate apoptosis induction by anticancer drugs. But currently a controversy exists regarding reported effects of Bcl-2 on the calcium concentration within the lumen of the endoplasmic reticulum. Although several prominent reports indicate that Bcl-2 overexpression is associated with a decrease in luminal calcium, there are a large number of reports indicating that Bcl-2 either does not decrease luminal calcium or actually increases luminal calcium. This review summarizes this vast array of conflicting findings, and analyses potential reasons why different conclusions have been reached by different laboratories. Future directions are emphasized that might bring clarity to this important area of apoptosis biology.	Case Western Reserve Univ, Sch Med, Div Hematol Oncol, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Ctr Comprehens Canc, Div Hematol Oncol, Cleveland, OH 44106 USA; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada	Case Western Reserve University; University Hospitals of Cleveland; McGill University; McGill University	Distelhorst, CW (corresponding author), Case Western Reserve Univ, Sch Med, Div Hematol Oncol, BRB329,10900 Euclid Ave, Cleveland, OH 44106 USA.	cwd@case.edu						BAFFY G, 1993, J BIOL CHEM, V268, P6511; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Bian XP, 1997, AM J PHYSIOL-CELL PH, V272, pC1241, DOI 10.1152/ajpcell.1997.272.4.C1241; Bootman MD, 2001, J CELL SCI, V114, P2213; Breckenridge DG, 2003, J CELL BIOL, V160, P1115, DOI 10.1083/jcb.200212059; Breckenridge DG, 2002, P NATL ACAD SCI USA, V99, P4331, DOI 10.1073/pnas.072088099; Breckenridge DG, 2003, ONCOGENE, V22, P8608, DOI 10.1038/sj.onc.1207108; BROSTROM CO, 1990, ANNU REV PHYSIOL, V52, P577; Demaurex N, 2003, SCIENCE, V300, P65, DOI 10.1126/science.1083628; Distelhorst CW, 1996, CELL CALCIUM, V19, P473, DOI 10.1016/S0143-4160(96)90056-1; Distelhorst CW, 2003, BIOCHEM SOC T, V31, P958; Distelhorst CW, 1996, ONCOGENE, V12, P2051; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; Germain M, 2002, J BIOL CHEM, V277, P18053, DOI 10.1074/jbc.M201235200; GERMAIN M, 2003, SCI STKE, pPE10; Hajnoczky G, 2003, BIOCHEM BIOPH RES CO, V304, P445, DOI 10.1016/S0006-291X(03)00616-8; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; Ichimiya M, 1998, AM J PHYSIOL-CELL PH, V275, pC832, DOI 10.1152/ajpcell.1998.275.3.C832; Kaufmann T, 2003, J CELL BIOL, V160, P53, DOI 10.1083/jcb.200210084; Kuo TH, 1998, ONCOGENE, V17, P1903, DOI 10.1038/sj.onc.1202110; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Li C, 2002, P NATL ACAD SCI USA, V99, P9830, DOI 10.1073/pnas.152571899; Liu H, 1997, J BIOL CHEM, V272, P21751, DOI 10.1074/jbc.272.35.21751; LODISH HF, 1992, J BIOL CHEM, V267, P12753; MAGNELLI L, 1994, BIOCHEM BIOPH RES CO, V204, P84, DOI 10.1006/bbrc.1994.2429; Mathai JP, 2002, ONCOGENE, V21, P2534, DOI 10.1038/sj.onc.1205340; Mery L, 1996, J BIOL CHEM, V271, P9332, DOI 10.1074/jbc.271.16.9332; Nutt LK, 2002, J BIOL CHEM, V277, P20301, DOI 10.1074/jbc.M201604200; Oakes SA, 2003, BIOCHEM PHARMACOL, V66, P1335, DOI 10.1016/S0006-2952(03)00482-9; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Pan Z, 2000, J BIOL CHEM, V275, P19978, DOI 10.1074/jbc.M908329199; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; Petersen OH, 2002, BIOL RES, V35, P177, DOI 10.4067/S0716-97602002000200008; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; Putney JW, 2001, J CELL SCI, V114, P2223; Rizzuto R, 2003, ONCOGENE, V22, P8619, DOI 10.1038/sj.onc.1207105; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Shirane M, 2003, NAT CELL BIOL, V5, P28, DOI 10.1038/ncb894; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Thomenius MJ, 2003, J BIOL CHEM, V278, P6243, DOI 10.1074/jbc.M208878200; Thrower EC, 2001, TRENDS PHARMACOL SCI, V22, P580, DOI 10.1016/S0165-6147(00)01809-5; Uhlmann EJ, 1998, J BIOL CHEM, V273, P17926, DOI 10.1074/jbc.273.28.17926; Vanden Abeele F, 2002, CANCER CELL, V1, P169; Wang NS, 2001, J BIOL CHEM, V276, P44117, DOI 10.1074/jbc.M101958200; Wei HF, 1998, J NEUROCHEM, V70, P2305; Williams SS, 2000, CANCER RES, V60, P4358; Yu ZF, 1999, EXP NEUROL, V155, P302, DOI 10.1006/exnr.1998.7002; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533; Zhu LP, 1999, J BIOL CHEM, V274, P33267, DOI 10.1074/jbc.274.47.33267; Zong WX, 2003, J CELL BIOL, V162, P59, DOI 10.1083/jcb.200302084	54	85	91	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2004	23	16					2875	2880		10.1038/sj.onc.1207519	http://dx.doi.org/10.1038/sj.onc.1207519			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	811VO	15077150				2022-12-28	WOS:000220799600014
J	Mosser, DD; Morimoto, RI				Mosser, DD; Morimoto, RI			Molecular chaperones and the stress of oncogenesis	ONCOGENE			English	Review						heat-shock proteins; molecular chaperones; apoptosis; hsp90; hsp70; hsp27	N-TERMINAL KINASE; HUMAN HSP70 PROMOTER; SHOCK-PROTEIN HSP70; HEAT-SHOCK-PROTEIN-70 INHIBITS APOPTOSIS; C-DEPENDENT ACTIVATION; HEAT-SHOCK; CYTOCHROME-C; CELL-DEATH; NEGATIVE REGULATOR; JNK PHOSPHORYLATION	Protein-damaging stresses induce the expression of 'heat-shock proteins', which have essential roles in protecting cells from the potentially lethal effects of stress and proteotoxicity. These stress-protective heat-shock proteins are often overexpressed in cells of various cancers and have been suggested to be contributing factors in tumorigenesis. An underlying basis of oncogenesis is the acquisition and accumulation of mutations that provide the transformed cell with the combined characteristics of deregulated cell proliferation and suppressed cell death. Heat-shock proteins with dual roles as regulators of protein conformation and stress sensors may therefore have intriguing and central roles in both cell proliferation and apoptosis. It has been established that heat-shock proteins exhibit specificity to particular classes of polypeptide substrates and client proteins in vivo, and that chaperones can stabilize mutations that affect the folded conformation. Likewise, overexpression of chaperones has also been shown to protect cells against apoptotic cell death. The involvement of chaperones, therefore, in such diverse roles might suggest novel anticancer therapeutic approaches targeting heat-shock protein function for a broad spectrum of tumor types.	Univ Guelph, Dept Mol Biol & Genet, Guelph, ON N1G 2W1, Canada; Northwestern Univ, Rice Inst Biomed Res, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	University of Guelph; Northwestern University	Mosser, DD (corresponding author), Univ Guelph, Dept Mol Biol & Genet, Guelph, ON N1G 2W1, Canada.	rmosser@uoguelph.ca; r-morimoto@northwestern.edu	Mosser, Dick D/A-7391-2008	Mosser, Richard/0000-0002-9183-2288	NIGMS NIH HHS [R37 GM038109] Funding Source: Medline; PHS HHS [38109] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903; Arnoult D, 2002, J CELL BIOL, V159, P923, DOI 10.1083/jcb.200207071; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Beere HM, 2001, TRENDS CELL BIOL, V11, P6, DOI 10.1016/S0962-8924(00)01874-2; Bimston D, 1998, EMBO J, V17, P6871, DOI 10.1093/emboj/17.23.6871; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Buzzard KA, 1998, J BIOL CHEM, V273, P17147, DOI 10.1074/jbc.273.27.17147; Charette SJ, 2000, MOL CELL BIOL, V20, P7602, DOI 10.1128/MCB.20.20.7602-7612.2000; CHENG LL, 1992, BIOCHIM BIOPHYS ACTA, V1132, P26, DOI 10.1016/0167-4781(92)90048-5; Creagh EM, 2000, EXP CELL RES, V257, P58, DOI 10.1006/excr.2000.4856; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Donovan N, 2002, J BIOL CHEM, V277, P40944, DOI 10.1074/jbc.M206113200; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; Fan MY, 2000, J BIOL CHEM, V275, P29980, DOI 10.1074/jbc.M003776200; FEDER JH, 1992, GENE DEV, V6, P1402, DOI 10.1101/gad.6.8.1402; FERRIS DK, 1988, P NATL ACAD SCI USA, V85, P3850, DOI 10.1073/pnas.85.11.3850; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Gabai VL, 2000, MOL CELL BIOL, V20, P6826, DOI 10.1128/MCB.20.18.6826-6836.2000; Gabai VL, 2002, MOL CELL BIOL, V22, P3415, DOI 10.1128/MCB.22.10.3415-3424.2002; Gabai VL, 2002, J APPL PHYSIOL, V92, P1743, DOI 10.1152/japplphysiol.01101.2001; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; GaleaLauri J, 1996, J IMMUNOL, V157, P4109; Garrido C, 1999, FASEB J, V13, P2061, DOI 10.1096/fasebj.13.14.2061; Garrido C, 1998, CANCER RES, V58, P5495; Guay J, 1997, J CELL SCI, V110, P357; Gurbuxani S, 2003, ONCOGENE, V22, P6669, DOI 10.1038/sj.onc.1206794; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Haslbeck Martin, 2002, Prog Mol Subcell Biol, V28, P37; HEADS RJ, 1995, J MOL CELL CARDIOL, V27, P1669, DOI 10.1016/S0022-2828(95)90722-X; Helmbrecht K, 2000, CELL PROLIFERAT, V33, P341, DOI 10.1046/j.1365-2184.2000.00189.x; Hettinga JVE, 1996, INT J CANCER, V67, P800; Hoang AT, 2000, AM J PATHOL, V156, P857, DOI 10.1016/S0002-9440(10)64954-1; HOHFELD J, 1995, CELL, V83, P589; Isaacs JS, 2003, CANCER CELL, V3, P213, DOI 10.1016/S1535-6108(03)00029-1; JAATTELA M, 1995, INT J CANCER, V60, P689, DOI 10.1002/ijc.2910600520; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Jolly C, 1997, HUM GENET, V101, P81, DOI 10.1007/s004390050591; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kamal A, 2003, NATURE, V425, P407, DOI 10.1038/nature01913; KAMPINGA HH, 1994, BIOCHEM BIOPH RES CO, V204, P1170, DOI 10.1006/bbrc.1994.2586; Kampinga HH, 2003, MOL CELL BIOL, V23, P4948, DOI 10.1128/MCB.23.14.4948-4958.2003; Kamradt MC, 2001, J BIOL CHEM, V276, P16059, DOI 10.1074/jbc.C100107200; KINGSTON RE, 1986, MOL CELL BIOL, V6, P3180, DOI 10.1128/MCB.6.9.3180; KINGSTON RE, 1984, NATURE, V312, P280, DOI 10.1038/312280a0; Konishi H, 1997, FEBS LETT, V410, P493, DOI 10.1016/S0014-5793(97)00541-3; Krilleke D, 2003, INT J CANCER, V107, P520, DOI 10.1002/ijc.11331; Lambert H, 1999, J BIOL CHEM, V274, P9378, DOI 10.1074/jbc.274.14.9378; LANDRY J, 1992, J BIOL CHEM, V267, P794; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; Lei K, 2002, MOL CELL BIOL, V22, P4929, DOI 10.1128/MCB.22.13.4929-4942.2002; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Lepock JR, 2003, INT J HYPERTHER, V19, P252, DOI 10.1080/0265673031000065042; Lewis J, 2000, J BIOL CHEM, V275, P10519, DOI 10.1074/jbc.275.14.10519; Li CY, 2000, J BIOL CHEM, V275, P25665, DOI 10.1074/jbc.M906383199; LI GC, 1992, P NATL ACAD SCI USA, V89, P2036, DOI 10.1073/pnas.89.6.2036; Liossis SNC, 1997, J IMMUNOL, V158, P5668; Ma N, 2001, INT J RADIAT ONCOL, V50, P1041, DOI 10.1016/S0360-3016(01)01596-6; Mao HP, 2003, J BIOL CHEM, V278, P18214, DOI 10.1074/jbc.M300126200; Mathew A, 2001, MOL CELL BIOL, V21, P7163, DOI 10.1128/MCB.21.21.7163-7171.2001; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; Michels AA, 1997, J BIOL CHEM, V272, P33283, DOI 10.1074/jbc.272.52.33283; MILARSKI KL, 1986, P NATL ACAD SCI USA, V83, P9517, DOI 10.1073/pnas.83.24.9517; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; MOSSER DD, 1992, J CELL PHYSIOL, V151, P561, DOI 10.1002/jcp.1041510316; Mosser DD, 2000, MOL CELL BIOL, V20, P7146, DOI 10.1128/MCB.20.19.7146-7159.2000; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Nishitai G, 2004, J BIOL CHEM, V279, P1621, DOI 10.1074/jbc.M310335200; Nollen EAA, 2002, J CELL SCI, V115, P2809; Nollen EAA, 1999, MOL CELL BIOL, V19, P2069; Nollen EAA, 2001, J BIOL CHEM, V276, P4677, DOI 10.1074/jbc.M009745200; Nylandsted J, 2000, P NATL ACAD SCI USA, V97, P7871, DOI 10.1073/pnas.97.14.7871; Palacios C, 2001, CURR BIOL, V11, P1439, DOI 10.1016/S0960-9822(01)00426-2; Pandey P, 2000, EMBO J, V19, P4310, DOI 10.1093/emboj/19.16.4310; Pandey P, 2000, ONCOGENE, V19, P1975, DOI 10.1038/sj.onc.1203531; Park HS, 2002, MOL CELL BIOL, V22, P7721, DOI 10.1128/MCB.22.22.7721-7730.2002; Park HS, 2001, EMBO J, V20, P446, DOI 10.1093/emboj/20.3.446; Parsell D.A., 1994, BIOL HEAT SHOCK PROT, P457; Paul C, 2002, MOL CELL BIOL, V22, P816, DOI 10.1128/MCB.22.3.816-834.2002; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Rane MJ, 2003, J BIOL CHEM, V278, P27828, DOI 10.1074/jbc.M303417200; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Samali A, 2001, CELL STRESS CHAPERON, V6, P49, DOI 10.1379/1466-1268(2001)006<0049:HPMOTC>2.0.CO;2; Schulte TW, 1996, MOL CELL BIOL, V16, P5839; Seo JS, 1996, BIOCHEM BIOPH RES CO, V218, P582, DOI 10.1006/bbrc.1996.0103; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Shin BK, 2003, J BIOL CHEM, V278, P7607, DOI 10.1074/jbc.M210455200; Song JW, 2001, NAT CELL BIOL, V3, P276, DOI 10.1038/35060068; STEGE GJJ, 1994, EXP CELL RES, V214, P279, DOI 10.1006/excr.1994.1259; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; Takayama S, 2001, NAT CELL BIOL, V3, pE237, DOI 10.1038/ncb1001-e237; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Townsend PA, 2003, BBA-REV CANCER, V1603, P83, DOI 10.1016/S0304-419X(03)00002-7; Tran SEF, 2003, CELL DEATH DIFFER, V10, P1137, DOI 10.1038/sj.cdd.4401278; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Volloch V, 1998, CELL STRESS CHAPERON, V3, P265, DOI 10.1054/csac.1998.0120; Volloch VZ, 1999, ONCOGENE, V18, P3648, DOI 10.1038/sj.onc.1202525; VOLM M, 1995, CANCER LETT, V95, P195, DOI 10.1016/0304-3835(95)03893-2; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; WEI YQ, 1995, CANCER IMMUNOL IMMUN, V40, P73, DOI 10.1007/s002620050146; Whitmarsh AJ, 2001, GENE DEV, V15, P2421, DOI 10.1101/gad.922801; WILLIAMS GT, 1989, MOL CELL BIOL, V9, P2574, DOI 10.1128/MCB.9.6.2574; Woessmann W, 1999, J CELL BIOCHEM, V74, P648, DOI 10.1002/(SICI)1097-4644(19990915)74:4<648::AID-JCB14>3.0.CO;2-6; WU BJ, 1986, MOL CELL BIOL, V6, P2994, DOI 10.1128/MCB.6.8.2994; WU BJ, 1985, P NATL ACAD SCI USA, V82, P6070, DOI 10.1073/pnas.82.18.6070; WU BJ, 1987, P NATL ACAD SCI USA, V84, P2203, DOI 10.1073/pnas.84.8.2203; WU BJ, 1986, P NATL ACAD SCI USA, V83, P629, DOI 10.1073/pnas.83.3.629; Yaglom J, 2003, MOL CELL BIOL, V23, P3813, DOI 10.1128/MCB.23.11.3813-3824.2003; Yaglom JA, 1999, J BIOL CHEM, V274, P20223, DOI 10.1074/jbc.274.29.20223; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	125	410	434	0	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2004	23	16					2907	2918		10.1038/sj.onc.1207529	http://dx.doi.org/10.1038/sj.onc.1207529			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	811VO	15077153				2022-12-28	WOS:000220799600017
J	Adriaenssens, E; Mougel, A; Goormachtigh, G; Loing, E; Fafeur, V; Auriault, C; Coll, J				Adriaenssens, E; Mougel, A; Goormachtigh, G; Loing, E; Fafeur, V; Auriault, C; Coll, J			A novel dominant-negative mutant form of Epstein-Barr virus latent membrane protein-1 (LMP1) selectively and differentially impairs LMP1 and TNF signaling pathways	ONCOGENE			English	Article						EBV; LMP1; dominant-negative; signal; TNF; apoptosis	NF-KAPPA-B; LYMPHOCYTE GROWTH TRANSFORMATION; NECROSIS-FACTOR RECEPTOR; REED-STERNBERG CELLS; BINDING-SITE; HUMAN TRAF2; ACTIVATION; EXPRESSION; TRANSDUCTION; DOMAIN	The latent membrane protein-1 (LMP1) is an integral membrane molecule expressed by Epstein-Barr virus (EBV) during viral latency and displays properties of a constitutively activated member of the TNF receptor family. LMP1 is required for B-cell or monocyte immortalization induced by EBV and is sufficient to transform rodent fibroblasts. Transforming potential of LMP1 is mediated by its cytoplasmic C-terminal domain, which activates various cellular signaling pathways including NFkappaB and JNK. In this report, we constructed mutants of LMP1 with preserved membrane spanning domain but mutated in the C- terminal domain and a second truncated C- terminal LMP1 fused to the enhanced green fluorescent protein. This latter mutant, termed LMP1-CT, impairs signaling by ectopic LMP1 as well as endogenous EBV-expressed wild-type (wt) LMP1. In contrast to dominant-negative mutants of LMP1 with preserved membrane spanning domains, LMP1-CT was unable to bind wt LMP1 to form an inactive complex. Its dominant-negative effects were due to binding and sequestration of LMP1 adapters TRAF2 and TRADD as assessed by coimmunoprecipitation experiments and confocal analysis. The effect was selective since LMP1-CT did not inhibit IL-1beta-induced signaling, whereas it impaired TNF-triggered NFkappaB and JNK signals without affecting TNF-induced apoptosis. In addition and in contrast to LMP1 constructs with membrane localization, LMP-CT did not display cytostatic properties in noninfected cells. Importantly, LMP1-CT inhibited survival induced by LMP1 in an EBV-transformed T-cell line expressing the type II viral latency commonly found in the majority of EBV-associated human tumors. These data demonstrate that LMP1-CT is a new tool to explore the differences between LMP1 and TNF signaling and may facilitate the design of molecules with potential therapeutic roles.	Inst Biol Lille, CNRS, UMR 8527, F-59021 Lille, France; Sedac Therapeut, F-59120 Loos, France; Inst Biol Lille, CNRS, UMR 8117, F-59021 Lille, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS)	Coll, J (corresponding author), Inst Biol Lille, CNRS, UMR 8527, BP 447, F-59021 Lille, France.	jean.coll@ibl.fr	Fafeur, Veronique/L-9072-2018	Goormachtigh, Gautier/0000-0003-1736-8269				Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Brennan P, 2001, J BIOL CHEM, V276, P1195, DOI 10.1074/jbc.M005461200; Brodeur SR, 1997, J BIOL CHEM, V272, P19777, DOI 10.1074/jbc.272.32.19777; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; Coffin WF, 2003, J VIROL, V77, P3749, DOI 10.1128/JVI.77.6.3749-3758.2003; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Devergne O, 1998, J VIROL, V72, P7900, DOI 10.1128/JVI.72.10.7900-7908.1998; Eliopoulos AG, 1999, J BIOL CHEM, V274, P16085, DOI 10.1074/jbc.274.23.16085; Eliopoulos AG, 2001, SEMIN CANCER BIOL, V11, P435, DOI 10.1006/scbi.2001.0410; Eliopoulos AG, 1998, ONCOGENE, V16, P1731, DOI 10.1038/sj.onc.1201694; Floettmann JE, 1997, ONCOGENE, V15, P1851, DOI 10.1038/sj.onc.1201359; Gires O, 1999, EMBO J, V18, P3064, DOI 10.1093/emboj/18.11.3064; GREGORY CD, 1988, J EXP MED, V167, P1811, DOI 10.1084/jem.167.6.1811; Groux H, 1997, BLOOD, V89, P4521, DOI 10.1182/blood.V89.12.4521; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; Higuchi M, 2002, J VIROL, V76, P455, DOI 10.1128/JVI.76.1.455-459.2002; Horie R, 2002, AM J PATHOL, V160, P1647, DOI 10.1016/S0002-9440(10)61112-1; Horie R, 2002, ONCOGENE, V21, P2493, DOI 10.1038/sj.onc.1205337; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hueber AO, 2003, CELL DEATH DIFFER, V10, P7, DOI 10.1038/sj.cdd.4401155; Izumi KM, 1999, J VIROL, V73, P9908, DOI 10.1128/JVI.73.12.9908-9916.1999; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P1447, DOI 10.1073/pnas.94.4.1447; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; Kaykas A, 2000, ONCOGENE, V19, P1400, DOI 10.1038/sj.onc.1203365; Kaykas A, 2001, EMBO J, V20, P2641, DOI 10.1093/emboj/20.11.2641; Kieser A, 1999, EMBO J, V18, P2511, DOI 10.1093/emboj/18.9.2511; Kulwichit W, 1998, P NATL ACAD SCI USA, V95, P11963, DOI 10.1073/pnas.95.20.11963; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LIEBOWITZ D, 1986, J VIROL, V58, P233, DOI 10.1128/JVI.58.1.233-237.1986; Masy E, 2002, J VIROL, V76, P6460, DOI 10.1128/JVI.76.13.6460-6472.2002; McWhirter SM, 1999, P NATL ACAD SCI USA, V96, P8408, DOI 10.1073/pnas.96.15.8408; Park YC, 2000, CELL, V101, P777, DOI 10.1016/S0092-8674(00)80889-2; Park YC, 1999, NATURE, V398, P533, DOI 10.1038/19110; RICKINSON AB, 1996, FIELDS VIROLOGY, P2397; ROWE M, 1995, EUR J IMMUNOL, V25, P1374, DOI 10.1002/eji.1830250536; Schultheiss U, 2001, EMBO J, V20, P5678, DOI 10.1093/emboj/20.20.5678; Tsao DHH, 2000, MOL CELL, V5, P1051, DOI 10.1016/S1097-2765(00)80270-1; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; Wang S, 1996, CANCER RES, V56, P4610; Werneburg BG, 2001, J BIOL CHEM, V276, P43334, DOI 10.1074/jbc.M104994200; Ye X, 1999, J BIOL CHEM, V274, P30202, DOI 10.1074/jbc.274.42.30202	43	9	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 8	2004	23	15					2681	2693		10.1038/sj.onc.1207432	http://dx.doi.org/10.1038/sj.onc.1207432			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	810OZ	14767477	Green Published			2022-12-28	WOS:000220714900010
J	Gangisetty, O; Lauffart, B; Sondarva, GV; Chelsea, DM; Still, IH				Gangisetty, O; Lauffart, B; Sondarva, GV; Chelsea, DM; Still, IH			The transforming acidic coiled coil proteins interact with nuclear histone acetyltransferases	ONCOGENE			English	Article						breast cancer; histone acetyltransferase; TACC; nucleus; chromatin	ACUTE MYELOID-LEUKEMIA; BREAST-TUMOR SUPPRESSOR; MESSENGER-RNA; ACETYLASE COMPLEX; HUMAN CANCERS; GENE FAMILY; D-TACC; MICROTUBULES; CLONING; CELLS	Dysregulation of the human transforming acidic coiled coil (TACC) genes is thought to be important in the development of multiple myeloma, breast and gastric cancer. However, even though these proteins have been implicated in the control of cell growth and differentiation, the mechanism by which they function still remains to be clarified. Using the yeast two-hybrid assay, we have now identified the histone acetyltransferase (HAT) hGCN5L2 as a TACC2-binding protein. GST pull-down analysis subsequently confirmed that all human TACC family members can bind in vitro to hGCN5L2. The authenticity of these interactions was validated by coimmunoprecipitation assays within the human embryonic kidney cell line HEK293, which identified the TACC2s isoform as a component consistently bound to several different members of HAT family. This raises the possibility that aberrant expression of one or more TACC proteins may affect gene regulation through their interaction with components of chromatin remodeling complexes, thus contributing to tumorigenesis.	Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA; Quark Biotech, Cleveland, OH 44106 USA	Roswell Park Cancer Institute	Still, IH (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Elm & Carlton St, Buffalo, NY 14263 USA.	Ivan.still@roswellpark.org		Gangisetty, Omkaram/0000-0001-6280-0642	NCI NIH HHS [CA 16056] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aitola M, 2003, J HISTOCHEM CYTOCHEM, V51, P455, DOI 10.1177/002215540305100407; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Chaffanet M, 1999, GENE CHROMOSOME CANC, V26, P161, DOI 10.1002/(SICI)1098-2264(199910)26:2<161::AID-GCC8>3.3.CO;2-Y; Chen HM, 2000, MOL BIOL CELL, V11, P1357, DOI 10.1091/mbc.11.4.1357; Conte N, 2002, ONCOGENE, V21, P5619, DOI 10.1038/sj.onc.1205658; Conte N, 2003, ONCOGENE, V22, P8102, DOI 10.1038/sj.onc.1206972; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Gergely F, 2002, BIOESSAYS, V24, P915, DOI 10.1002/bies.10162; Gergely F, 2000, P NATL ACAD SCI USA, V97, P14352, DOI 10.1073/pnas.97.26.14352; Giet R, 2002, J CELL BIOL, V156, P437, DOI 10.1083/jcb.200108135; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; Lauffart B, 2003, GENOMICS, V81, P192, DOI 10.1016/S0888-7543(02)00039-3; Lauffart B, 2002, BIOCHEM J, V363, P195, DOI 10.1042/0264-6021:3630195; Le Bot N, 2003, CURR BIOL, V13, P1499, DOI 10.1016/S0960-9822(03)00577-3; Lee MJ, 2001, NAT CELL BIOL, V3, P643, DOI 10.1038/35083033; Line A, 2002, CANCER GENET CYTOGEN, V139, P78, DOI 10.1016/S0165-4608(02)00607-6; Martinez E, 2001, MOL CELL BIOL, V21, P6782, DOI 10.1128/MCB.21.20.6782-6795.2001; Martinez E, 1998, J BIOL CHEM, V273, P23781, DOI 10.1074/jbc.273.37.23781; Niederacher D, 1997, GENE CHROMOSOME CANC, V18, P181, DOI 10.1002/(SICI)1098-2264(199703)18:3<181::AID-GCC5>3.0.CO;2-Y; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Piekorz RP, 2002, EMBO J, V21, P653, DOI 10.1093/emboj/21.4.653; Pu JJ, 2001, CYTOKINE, V13, P129, DOI 10.1006/cyto.2000.0812; Sadek CM, 2000, MECH DEVELOP, V97, P13, DOI 10.1016/S0925-4773(00)00415-9; Sadek CM, 2003, GENE EXPR PATTERNS, V3, P203, DOI 10.1016/S1567-133X(02)00066-2; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; Srayko M, 2003, CURR BIOL, V13, P1506, DOI 10.1016/S0960-9822(03)00597-9; Stebbins-Boaz B, 1999, MOL CELL, V4, P1017, DOI 10.1016/S1097-2765(00)80230-0; Still IH, 1999, ONCOGENE, V18, P4032, DOI 10.1038/sj.onc.1202801; Still IH, 1999, GENOMICS, V58, P165, DOI 10.1006/geno.1999.5829; Tangir J, 1996, ONCOGENE, V12, P735; TIEN AC, 2003, MOL CELL PROTEOMICS; Xu WT, 1998, MOL CELL BIOL, V18, P5659, DOI 10.1128/MCB.18.10.5659; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	34	33	40	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2004	23	14					2559	2563		10.1038/sj.onc.1207424	http://dx.doi.org/10.1038/sj.onc.1207424			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808GQ	14767476				2022-12-28	WOS:000220558000014
J	Abal, M; Bras-Goncalves, R; Judde, JG; Fsihi, H; de Cremoux, P; Louvard, D; Magdelenat, H; Robine, S; Poupon, MF				Abal, M; Bras-Goncalves, R; Judde, JG; Fsihi, H; de Cremoux, P; Louvard, D; Magdelenat, H; Robine, S; Poupon, MF			Enhanced sensitivity to irinotecan by Cdk1 inhibition in the p53-deficient HT29 human colon cancer cell line	ONCOGENE			English	Article						colorectal cancer; irinotecan; p53-dependent sensitivity; cdk-inh1; CYC-202; Roscovitine	COLORECTAL-CANCER; TOPOISOMERASE-I; CARCINOMA CELLS; MICROSATELLITE INSTABILITY; DIFFERENT P53; DNA-DAMAGE; CAMPTOTHECIN; APOPTOSIS; CYTOTOXICITY; XENOGRAFTS	Mutations in the tumor-suppressor gene p53 have been associated with advanced colorectal cancer (CRC). Irinotecan (CPT-11), a DNA topoisomerase 1 inhibitor, has been recently incorporated to the adjuvant therapy. Since the DNA-damage checkpoint depends on p53 activation, the status of p53 might critically influence the response to CPT-11. We analysed the sensitivity to CPT-11 in the human colon cancer cell line HT29 (mut p53) and its wild-type (wt)-p53 stably transfected subclone HT29-A4. Cell-cycle analysis in synchronised cells demonstrated the activation of transfected wt-p53 and a p21(WAF1/CIP1)-dependent cell-cycle blockage in the S phase. Activated wt-p53 increased apoptosis and enhanced sensitivity to CPT-11. In p53-deficient cells, cDNA-macroarray analysis and western blotting showed an accumulation of the cyclin-dependent kinase (cdk) 1/cyclin B complex. Subsequent p53-independent activation of the cdk-inhibitor (cdk-I) p21(WAF1/CIP1) prevented cell-cycle progression. Cdk1 induction was exploited in vivo to improve the sensitivity to CPT-11 by additional treatment with the cdk-I CYC-202. We demonstrate a gain of sensitivity to CPT-11 in a p53-mutated colon cancer model either by restoring wild-type p53 function or by sequential treatment with cdk-Is. Considering that mutations in p53 are among the most common genetic alterations in CRC, a therapeutic approach specifically targeting p53-deficient tumors could greatly improve the treatment outcomes.	Inst Curie, UMR 147, CNRS, F-75248 Paris, France; Inst Curie, Transfer Lab, CNRS, F-75248 Paris, France; Inst Curie, UMR 144, CNRS, F-75248 Paris, France; Inst Curie, Dept Tumor Biol, CNRS, Med Sect, F-75248 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Poupon, MF (corresponding author), Inst Curie, UMR 147, CNRS, Rue Ulm, F-75248 Paris, France.	Marie-France.Poupon@curie.fr	FSIHI, Hafida/H-9852-2014	Abal Posada, Miguel/0000-0003-3533-7781				Arends JW, 2000, J PATHOL, V190, P412; Blagosklonny MV, 1998, INT J CANCER, V75, P933, DOI 10.1002/(SICI)1097-0215(19980316)75:6<933::AID-IJC17>3.0.CO;2-3; Bras-Goncalves RA, 2001, GASTROENTEROLOGY, V120, P874, DOI 10.1053/gast.2001.22440; Bras-Goncalves RA, 2000, BRIT J CANCER, V82, P913, DOI 10.1054/bjoc.1999.1019; Chauvier D, 2002, INT J ONCOL, V20, P855; de Cremoux P, 1999, J NATL CANCER I, V91, P641, DOI 10.1093/jnci/91.7.641; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fishman A D, 2001, Clin Colorectal Cancer, V1, P20, DOI 10.3816/CCC.2001.n.002; Gryfe R, 1997, CURR PROB CANCER, V21, P238, DOI 10.1016/S0147-0272(97)80003-7; Gupta M, 1997, CLIN CANCER RES, V3, P1653; Janssen KP, 2002, GASTROENTEROLOGY, V123, P492, DOI 10.1053/gast.2002.34786; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; KJELDSEN E, 1992, J MOL BIOL, V228, P1025, DOI 10.1016/0022-2836(92)90310-G; Lansiaux A, 2001, ANTICANCER RES, V21, P471; Liu WM, 1998, INT J ONCOL, V12, P793; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Magrini R, 2002, INT J CANCER, V101, P23, DOI 10.1002/ijc.10565; McClue SJ, 2002, INT J CANCER, V102, P463, DOI 10.1002/ijc.10738; Motwani M, 2001, CLIN CANCER RES, V7, P4209; Oren M, 2002, BIOCHEM PHARMACOL, V64, P865, DOI 10.1016/S0006-2952(02)01149-8; Pocard M, 1996, ONCOGENE, V12, P875; Rougier P, 2001, Clin Colorectal Cancer, V1, P87, DOI 10.3816/CCC.2001.n.008; Shao RG, 1997, CANCER RES, V57, P4029; Shao RG, 2001, ONCOGENE, V20, P1852, DOI 10.1038/sj.onc.1204264; SHIMIZU T, 1995, CANCER RES, V55, P228; Smith G, 2002, P NATL ACAD SCI USA, V99, P9433, DOI 10.1073/pnas.122612899; Sobrero A, 2000, EUR J CANCER, V36, P559, DOI 10.1016/S0959-8049(99)00314-7; TANIZAWA A, 1994, J NATL CANCER I, V86, P836, DOI 10.1093/jnci/86.11.836; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Vanhoefer U, 2001, J CLIN ONCOL, V19, P1501, DOI 10.1200/JCO.2001.19.5.1501; Whitacre CM, 1999, CLIN CANCER RES, V5, P665; Xie XJ, 2000, CANCER CHEMOTH PHARM, V45, P362, DOI 10.1007/s002800051003	32	37	41	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2004	23	9					1737	1744		10.1038/sj.onc.1207299	http://dx.doi.org/10.1038/sj.onc.1207299			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	800LH	15001986				2022-12-28	WOS:000220029300009
J	Heroult, M; Bernard-Pierrot, I; Delbe, J; Hamma-Kourbali, Y; Katsoris, M; Barritault, D; Papadimitriou, E; Plouet, J; Courty, J				Heroult, M; Bernard-Pierrot, I; Delbe, J; Hamma-Kourbali, Y; Katsoris, M; Barritault, D; Papadimitriou, E; Plouet, J; Courty, J			Heparin affin regulatory peptide binds to vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis	ONCOGENE			English	Article						HARP; angiogenesis; VEGF; inhibition	MELANOMA CELL-ADHESION; FACTOR GENE-EXPRESSION; C-TERMINAL PEPTIDES; IN-VITRO; THERAPEUTIC IMPLICATIONS; POTENT INHIBITOR; TUBE FORMATION; TUMOR-GROWTH; PLEIOTROPHIN; HARP	Heparin affin regulatory peptide (HARP) is an heparin-binding molecule involved in the regulation of cell proliferation and differentiation. Here, we report that HARP inhibited the biological activity induced by the 165-amino-acid form of vascular endothelial growth factor (VEGF(165)) on human umbilical vein endothelial cells. Endothelial-cell proliferation induced by VEGF(165) showed about 50% inhibition in the presence of HARP in a concentration of 3 nM. In similar range of concentrations, HARP blocked tube formation induced by VEGF(165) in three-dimensional angiogenesis assay. In vivo studies showed that HARP inhibited the VEGF(165)-induced Matrigel(TM) infiltration of endothelial cells. We then investigated the mechanisms of this inhibition and shown that HARP inhibited the binding of I-125-VEGF(165) to the VEGF receptors of endothelial cells. Additional studies using VEGF soluble receptors indicated that binding of I-125-VEGF(165) to kinase insert domain-containing receptor and neuropilin receptor was inhibited by HARP, but conversely the binding of I-125-VEGF(165) to fms-like tyrosine kinase I receptor was unaffected. A competitive affinity-binding assay demonstrated that HARP interacted directly with VEGF(165) with a dissociation coefficient of 1.38 nM. Binding assay using deletion mutants of HARP revealed that the thrombospondin type-1 repeats domains were involved in this interaction. These data demonstrate for the first time that the angiogenic factor HARP can also negatively regulates the angiogenic activity of VEGF(165).	Univ Paris 12, Lab Rech Croissance Cellulaire Reaparat & Regener, FRE 2412, CNRS, F-94010 Ceteil, France; Univ Patras, Dept Biol, Div Genet Cell & Dev Biol, GR-26504 Patras, Greece; Univ Patras, Mol Pharmacol Lab, Dept Pharm, GR-26504 Patras, Greece; CNRS, Lab Biol Mol Eucaryote, UPR 9006, F-31062 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); University of Patras; University of Patras; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Courty, J (corresponding author), Univ Paris 12, Lab Rech Croissance Cellulaire Reaparat & Regener, FRE 2412, CNRS, Ave Gen de Gaulle, F-94010 Ceteil, France.	courty@univ-paris12.f	Hamma-Kourbali, Yamina/R-3692-2018; Delbe, Jean/R-3680-2018; Papadimitriou, Evangelia/ABG-1356-2020; Courty, Jose/Q-3702-2018; Papadimitriou, Evangelia/F-3396-2010	Hamma-Kourbali, Yamina/0000-0002-2754-8928; Papadimitriou, Evangelia/0000-0001-6429-4325; 				Bernard-Pierrot I, 2002, J BIOL CHEM, V277, P32071, DOI 10.1074/jbc.M202747200; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Brigstock DR, 1997, J BIOL CHEM, V272, P20275, DOI 10.1074/jbc.272.32.20275; Choudhuri R, 1997, CANCER RES, V57, P1814; CLAPP C, 1993, ENDOCRINOLOGY, V133, P1292, DOI 10.1210/en.133.3.1292; COURTY J, 1991, BIOCHEM BIOPH RES CO, V180, P145, DOI 10.1016/S0006-291X(05)81267-7; Cross MJ, 2001, TRENDS PHARMACOL SCI, V22, P201, DOI 10.1016/S0165-6147(00)01676-X; Delbe J, 1999, PATHOL BIOL, V47, P352; FANG WJ, 1992, J BIOL CHEM, V267, P25889; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GUO NH, 1992, J BIOL CHEM, V267, P19349; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; GUPTA SK, 1995, P NATL ACAD SCI USA, V92, P7799, DOI 10.1073/pnas.92.17.7799; Igarashi A, 1996, J INVEST DERMATOL, V106, P729, DOI 10.1111/1523-1747.ep12345771; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; Inoki I, 2001, FASEB J, V15, P219, DOI 10.1096/fj.01-0332fje; Iruela-Arispe ML, 1999, CIRCULATION, V100, P1423, DOI 10.1161/01.CIR.100.13.1423; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Kilpelainen I, 2000, J BIOL CHEM, V275, P13564, DOI 10.1074/jbc.275.18.13564; LAAROUBI K, 1994, GROWTH FACTORS, V10, P89, DOI 10.3109/08977199409010982; Lao YH, 2001, INT J BIOCHEM CELL B, V33, P357, DOI 10.1016/S1357-2725(01)00023-1; Ledoux D, 1997, J HISTOCHEM CYTOCHEM, V45, P1239, DOI 10.1177/002215549704500907; MAIONE TE, 1991, CANCER RES, V51, P2077; Milhiet PE, 1998, J ENDOCRINOL, V158, P389, DOI 10.1677/joe.0.1580389; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P543; MYERS EW, 1988, COMPUT APPL BIOSCI, V4, P11, DOI 10.1093/bioinformatics/4.1.11; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Papadimitriou E, 2001, BIOCHEM BIOPH RES CO, V282, P306, DOI 10.1006/bbrc.2001.4574; Papadimitriou E, 2000, BIOCHEM BIOPH RES CO, V274, P242, DOI 10.1006/bbrc.2000.3126; Pipili-Synetos E, 1998, BRIT J PHARMACOL, V125, P1252, DOI 10.1038/sj.bjp.0702191; PLOUET J, 1990, J BIOL CHEM, V265, P22071; Plouet J, 1997, J BIOL CHEM, V272, P13390, DOI 10.1074/jbc.272.20.13390; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; Rauvala H, 2000, MATRIX BIOL, V19, P377, DOI 10.1016/S0945-053X(00)00084-6; RAUVALA H, 1989, EMBO J, V8, P2933, DOI 10.1002/j.1460-2075.1989.tb08443.x; Robinson CJ, 2001, J CELL SCI, V114, P853; SEDDON AP, 1994, PROTEIN EXPRES PURIF, V5, P14, DOI 10.1006/prep.1994.1002; Shimo T, 1999, J BIOCHEM-TOKYO, V126, P137, DOI 10.1093/oxfordjournals.jbchem.a022414; Shimo T, 1998, J BIOCHEM-TOKYO, V124, P130, DOI 10.1093/oxfordjournals.jbchem.a022071; Souttou B, 2001, J CELL PHYSIOL, V187, P59, DOI 10.1002/1097-4652(2001)9999:9999<00::AID-JCP1051>3.0.CO;2-F; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; Tomanek RJ, 2000, ANAT RECORD, V261, P126, DOI 10.1002/1097-0185(20000615)261:3<126::AID-AR7>3.0.CO;2-4; Vacherot F, 1999, PROSTATE, V38, P126, DOI 10.1002/(SICI)1097-0045(19990201)38:2<126::AID-PROS6>3.0.CO;2-C	49	66	68	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2004	23	9					1745	1753		10.1038/sj.onc.1206879	http://dx.doi.org/10.1038/sj.onc.1206879			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	800LH	15001987				2022-12-28	WOS:000220029300010
J	Huang, H; Okamoto, Y; Yokoo, H; Heppner, FL; Vital, A; Fevre-Montange, M; Jouvet, A; Yonekawa, Y; Lazaridis, EN; Kleihues, P; Ohgaki, H				Huang, H; Okamoto, Y; Yokoo, H; Heppner, FL; Vital, A; Fevre-Montange, M; Jouvet, A; Yonekawa, Y; Lazaridis, EN; Kleihues, P; Ohgaki, H			Gene expression profiling and subgroup identification of oligodendrogliomas	ONCOGENE			English	Article						oligodendroglioma; low-grade astrocytoma; cDNA array; LOH 1p; LOH 19q; TP53 mutations	CELL-CYCLE; MICROARRAY; SURVIVAL; RECEPTOR; GLIOMAS; MARKER; GRADE; OLIG2; JUND; 19Q	The histological diagnosis of low-grade astrocytomas and oligodendrogliomas (WHO grade II) is often challenging, particularly in cases that show both astrocytic and oligodendroglial differentiation. We carried out gene expression profiling on 17 oligodendrogliomas (93% with LOH 1p and/or 19q) and 15 low-grade astrocytomas (71% with a TP53 mutation), using a cDNA array containing 1176 cancer-related genes. In oligodendrogliomas, 40 genes showed on average higher expression (at least a two-fold increase) than in astrocytomas, including DES, TDGF1, TGF-beta, GABA-BR1A, Histone H4, CDKN1A, PCDH43, Rho7 and Jun-D, while 39 genes were expressed at lower levels (at least a two-fold decrease), including JNK2, ITGB4, JNK3A2, RhoC, IFI-56K, AAD14 and EGFR. Immunohistochemistry revealed nuclear staining of Jun-D in oligodendrogliomas, in contrast to the inummoreactivity of cytoplasm and cell processes in low-grade astrocytomas. Partial least-squares analysis of the 79 genes at least two-fold differentially expressed between oligodendrogliomas and low-grade astrocytomas demonstrated perfect separation of oligodendrogliomas from low-grade astrocytomas and normal cerebral white matter. Clustering analysis based on the entire gene set divided the 17 subjects with oligodendrogliomas into two subgroups with significantly different survival (log-rank test, P = 0.0305; survival to 5-years, 80 vs 0%, P = 0.048). These results demonstrate that oligodendrogliomas and low-grade astrocytomas differ in their gene expression profiles, and that there are subgroups of oligodendroglioma with distinct expression profiles related to clinical outcome.	Int Agcy Res Canc, F-69372 Lyon 08, France; Univ Zurich Hosp, Inst Neuropathol, CH-8091 Zurich, Switzerland; Victor Segalen Univ, Dept Neuropathol, F-33076 Bordeaux, France; Neurol & Neurosurg Hosp, Dept Neuropathol, F-69394 Lyon, France; Univ Zurich Hosp, Dept Neurosurg, CH-8091 Zurich, Switzerland	World Health Organization; International Agency for Research on Cancer (IARC); University of Zurich; University Zurich Hospital; UDICE-French Research Universities; Universite de Bordeaux; CHU Lyon; University of Zurich; University Zurich Hospital	Ohgaki, H (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	ohgaki@iarc.fr	Heppner, Frank/ABH-8393-2020	Heppner, Frank/0000-0001-9816-8917				Azzarelli BN, 2003, J NEUROPATH EXP NEUR, V62, P544; Blumcke I, 2001, J NEUROPATH EXP NEUR, V60, P984; Cairncross JG, 1998, J NATL CANCER I, V90, P1473, DOI 10.1093/jnci/90.19.1473; DURAND JF, 2001, GUIDE UTILISATION RE; Fuller GN, 1999, CANCER RES, V59, P4228; Grifa A, 1998, BIOCHEM BIOPH RES CO, V250, P240, DOI 10.1006/bbrc.1998.9296; Gunthert AR, 2002, BIOCHEM BIOPH RES CO, V294, P11, DOI 10.1016/S0006-291X(02)00427-8; Gutmann DH, 2002, CANCER RES, V62, P2085; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Huang HT, 2000, CANCER RES, V60, P6868; Ino Y, 2001, CLIN CANCER RES, V7, P839; KLEIHUES P, 2000, DIFFUSE ASTROCYTOMA, P22; Li T, 2002, J BIOL CHEM, V277, P32668, DOI 10.1074/jbc.M203519200; Ligon KL, 2003, J NEUROPATH EXP NEUR, V62, P544; Lu QR, 2001, P NATL ACAD SCI USA, V98, P10851, DOI 10.1073/pnas.181340798; Marie Y, 2001, LANCET, V358, P298, DOI 10.1016/S0140-6736(01)05499-X; Markert JM, 2001, PHYSIOL GENOMICS, V5, P21, DOI 10.1152/physiolgenomics.2001.5.1.21; Miettinen HE, 2001, J NEURO-ONCOL, V55, P29, DOI 10.1023/A:1012961918848; Mukasa A, 2002, ONCOGENE, V21, P3961, DOI 10.1038/sj.onc.1205495; Nguyen DV, 2002, BIOINFORMATICS, V18, P39, DOI 10.1093/bioinformatics/18.1.39; Nigro JM, 2001, AM J PATHOL, V158, P1253, DOI 10.1016/S0002-9440(10)64076-X; Nutt CL, 2003, CANCER RES, V63, P1602; OBATA S, 1995, J CELL SCI, V108, P3765; Ohnishi A, 2003, J NEUROPATH EXP NEUR, V62, P1052, DOI 10.1093/jnen/62.10.1052; Perry JR, 2001, CURR OPIN NEUROL, V14, P705, DOI 10.1097/00019052-200112000-00005; Peters HC, 1998, NEUROGENETICS, V2, P47, DOI 10.1007/s100480050051; REIFENBERGER G, 2000, OLIGODENDROGLIOMA PA, P56; REIFENBERGER J, 1994, AM J PATHOL, V145, P1175; Rickman DS, 2001, CANCER RES, V61, P6885; Sallinen SL, 2000, CANCER RES, V60, P6617; SANO K, 1993, EMBO J, V12, P2249, DOI 10.1002/j.1460-2075.1993.tb05878.x; Schafer JL., 1997, ANAL INCOMPLETE MULT, DOI 10.1201/9781439821862; Smith JS, 2000, J CLIN ONCOL, V18, P636, DOI 10.1200/JCO.2000.18.3.636; Tanwar MK, 2002, CANCER RES, V62, P4364; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Wagner EF, 2001, ONCOGENE, V20, P2334, DOI 10.1038/sj.onc.1204416; Watanabe K, 1996, BRAIN PATHOL, V6, P217, DOI 10.1111/j.1750-3639.1996.tb00848.x; Watanabe T, 2002, ACTA NEUROPATHOL, V103, P267, DOI 10.1007/s004010100464; Watson MA, 2001, CANCER RES, V61, P1825; Zerbini LF, 2003, CANCER RES, V63, P2206	40	38	42	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2004	23	35					6012	6022		10.1038/sj.onc.1207781	http://dx.doi.org/10.1038/sj.onc.1207781			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15208679	Bronze			2022-12-28	WOS:000222941100017
J	Wotton, SF; Blyth, K; Kilbey, A; Jenkins, A; Terry, A; Bernardin-Fried, F; Friedman, AD; Baxter, EW; Neil, JC; Cameron, ER				Wotton, SF; Blyth, K; Kilbey, A; Jenkins, A; Terry, A; Bernardin-Fried, F; Friedman, AD; Baxter, EW; Neil, JC; Cameron, ER			RUNX1 transformation of primary embryonic fibroblasts is revealed in the absence of p53	ONCOGENE			English	Article						RUNX1; oncogene; MEF; p53; TGF beta	ACUTE LYMPHOBLASTIC-LEUKEMIA; DOMAIN TRANSCRIPTION FACTOR; T(8/21) FUSION PROTEIN; ACUTE MYELOID-LEUKEMIA; GROWTH-FACTOR BETA-1; T-CELL DEVELOPMENT; TGF-BETA; OSTEOBLAST DIFFERENTIATION; NEOPLASTIC TRANSFORMATION; NIH3T3 CELLS	The mammalian Runx gene family (Runx1-3) are transcription factors that play essential, lineage-specific roles in development. A growing body of evidence implicates these genes as mutational targets in cancer where, in different contexts, individual family members have been reported to act as tumour suppressors, dominant oncogenes or mediators of metastasis. We are exploring these paradoxical observations by ectopic expression of RUNX genes in primary murine embryonic fibroblasts where, in common with a number of other dominant oncogenes, RUNX1 induces senescence-like growth arrest in the presence of an intact p19(ARF)-p53 pathway. We now report that, in MEFs lacking functional p53, RUNX1 has apparently prooncogenic effects on cell growth that include cytoskeletal reorganization, reduced contact inhibition at confluence and accelerated tumour expansion in vivo. On the other hand, RUNX1 conferred no obvious growth advantage at low cell density and actually delayed entry of primary MEFs into S phase. We also found that ectopic RUNX1 interferes with the morphological and growth responses of p53-null MEFs to TGFbeta indicating that these effects are mediated by overlapping pathways. These observations help to elucidate the context-dependent consequences of loss and gain of Runx activity.	Univ Glasgow, Mol Oncol Lab, Inst Comparat Med, Fac Vet Med, Glasgow G61 1QH, Lanark, Scotland; Johns Hopkins Univ, Div Pediat Oncol, Baltimore, MD 21231 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	University of Glasgow; Johns Hopkins University; Fred Hutchinson Cancer Center	Wotton, SF (corresponding author), Univ Glasgow, Mol Oncol Lab, Inst Comparat Med, Fac Vet Med, Bearsdon Rd, Glasgow G61 1QH, Lanark, Scotland.	S.Wotton@vet.gla.ac.uk		Blyth, Karen/0000-0002-9304-439X				Bae SC, 2001, J BONE JOINT SURG AM, V83A, pS48; Baxter EW, 2001, J VIROL, V75, P9790, DOI 10.1128/JVI.75.20.9790-9798.2001; Bernardin F, 2002, ONCOGENE, V21, P3247, DOI 10.1038/sj.onc.1205447; Blyth K, 2001, ONCOGENE, V20, P295, DOI 10.1038/sj.onc.1204090; Blyth K, 2000, ONCOGENE, V19, P773, DOI 10.1038/sj.onc.1203321; Brubaker KD, 2003, PROSTATE, V56, P13, DOI 10.1002/pros.10233; Cameron ER, 2003, BLOOD CELL MOL DIS, V30, P194, DOI 10.1016/S1079-9796(03)00031-7; Chow M, 2000, P NATL ACAD SCI USA, V97, P174, DOI 10.1073/pnas.97.1.174; Chow M, 2000, CANCER RES, V60, P6510; Cordenonsi M, 2003, CELL, V113, P301, DOI 10.1016/S0092-8674(03)00308-8; Dal Cin P, 2001, GENE CHROMOSOME CANC, V30, P407, DOI 10.1002/1098-2264(2001)9999:9999<::AID-GCC1107>3.0.CO;2-C; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Frank R, 1995, ONCOGENE, V11, P2667; Frank RC, 1999, ONCOGENE, V18, P1701, DOI 10.1038/sj.onc.1202459; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Harewood L, 2003, LEUKEMIA, V17, P547, DOI 10.1038/sj.leu.2402849; Ito Y, 2003, CURR OPIN GENET DEV, V13, P43, DOI 10.1016/S0959-437X(03)00007-8; Jakubowiak A, 2000, J BIOL CHEM, V275, P40282, DOI 10.1074/jbc.C000485200; Ji CH, 1998, J CELL BIOCHEM, V69, P353, DOI 10.1002/(SICI)1097-4644(19980601)69:3<353::AID-JCB12>3.3.CO;2-W; Kurokawa M, 1996, ONCOGENE, V12, P883; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Lou JR, 2000, ONCOGENE, V19, P2695, DOI 10.1038/sj.onc.1203588; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Mikhail FM, 2002, LEUKEMIA, V16, P658, DOI 10.1038/sj.leu.2402399; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Moustakas A, 1999, J CELL SCI, V112, P1169; Nelson PJ, 2002, KIDNEY INT S1, V61, P99, DOI DOI 10.1046/J.1523-1755.2002.0610S1099.X; Niini T, 2000, HAEMATOLOGICA, V85, P362; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Preudhomme C, 2000, BLOOD, V96, P2862, DOI 10.1182/blood.V96.8.2862.h8002862_2862_2869; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Sakamoto Y, 1999, CANCER LETT, V136, P159, DOI 10.1016/S0304-3835(98)00318-8; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Speck NA, 2002, NAT REV CANCER, V2, P502, DOI 10.1038/nrc840; Stewart M, 2002, J VIROL, V76, P4364, DOI 10.1128/JVI.76.9.4364-4369.2002; Stewart M, 1997, P NATL ACAD SCI USA, V94, P8646, DOI 10.1073/pnas.94.16.8646; Strom DK, 2000, J BIOL CHEM, V275, P3438, DOI 10.1074/jbc.275.5.3438; Sun LX, 2001, CANCER RES, V61, P4994; Vaillant F, 2002, J IMMUNOL, V169, P2866, DOI 10.4049/jimmunol.169.6.2866; Vaillant F, 1999, ONCOGENE, V18, P7124, DOI 10.1038/sj.onc.1203202; Wotton S, 2002, CANCER RES, V62, P7181; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Yeung F, 2002, J BIOL CHEM, V277, P2468, DOI 10.1074/jbc.M105947200; Zhang YW, 2000, P NATL ACAD SCI USA, V97, P10549, DOI 10.1073/pnas.180309597	52	45	46	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	2004	23	32					5476	5486		10.1038/sj.onc.1207729	http://dx.doi.org/10.1038/sj.onc.1207729			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15133495				2022-12-28	WOS:000222588400007
J	Erez, A; Perelman, M; Hewitt, SM; Cojacaru, G; Goldberg, I; Shahar, I; Yaron, P; Muler, I; Campaner, S; Amariglio, N; Rechavi, G; Kirsch, IR; Krupsky, M; Kaminski, N; Izraeli, S				Erez, A; Perelman, M; Hewitt, SM; Cojacaru, G; Goldberg, I; Shahar, I; Yaron, P; Muler, I; Campaner, S; Amariglio, N; Rechavi, G; Kirsch, IR; Krupsky, M; Kaminski, N; Izraeli, S			Sil overexpression in lung cancer characterizes tumors with increased mitotic activity	ONCOGENE			English	Article						Sil; mitosis; lung cancer; carcinogenesis	CELL-CYCLE; GENE; CHECKPOINT; EXPRESSION; IDENTIFICATION	Sil (SCL interrupting locus) was cloned from the most common chromosomal rearrangement in T-cell acute lymphoblastic leukemia. It is an immediate early gene whose expression is associated with cell proliferation. Sil protein levels are tightly regulated during the cell cycle, reaching peak levels in mitosis and disappearing on transition to G1. A recent study found Sil to be one of 17 genes whose overexpression in primary adenocarcinomas predicts metastatic spread. We hypothesized that Sil might have a role in carcinogenesis. To address this question, we utilized several approaches. Using a multi-tumor tissue array, we found that Sil protein expression was increased mostly in lung cancer, but also at lower levels, in a subset of other tumors. Microarray gene expression analysis and immunohistochemistry of lung cancer samples verified these observations. Sil gene expression in lung cancer correlated with the expression of several kinetochore check-point genes and with the histopathologic mitotic index. The se observations suggest that overexpression of the Sil gene characterizes tumors with increased mitotic activity.	Chaim Sheba Med Ctr, Chaim Sheba Canc Res Ctr, Dept Pediat Hematooncol, IL-52621 Tel Hashomer, Israel; Chaim Sheba Med Ctr, Chaim Sheba Canc Res Ctr, Dept Pathol, IL-52621 Tel Hashomer, Israel; NIH, Ctr Adv Technol, Bethesda, MD 20892 USA; Chaim Sheba Med Ctr, Chaim Sheba Canc Res Ctr, Dept Funct Gen, IL-52621 Tel Hashomer, Israel; Compugen LTD, Tel Aviv, Israel; Chaim Sheba Med Ctr, Chaim Sheba Canc Res Ctr, Dept Pulm Med, IL-52621 Tel Hashomer, Israel; Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel; NCI, NIH, Bethesda, MD 20892 USA; Univ Pittsburgh, Med Ctr, Dorothy P & Richard P Simmons Ctr, Pittsburgh, PA 15261 USA	Chaim Sheba Medical Center; Chaim Sheba Medical Center; National Institutes of Health (NIH) - USA; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Kaminski, N (corresponding author), Univ Pittsburgh, Med Ctr, Dorothy P & Richard P Simmons Ctr Interstitial Lu, NW 628 MUH,3459 5th Av, Pittsburgh, PA 15261 USA.	kaminskin@upmc.edu; sizraeli@post.tau.ac.il		Kaminski, Naftali/0000-0001-5917-4601; CAMPANER, Stefano/0000-0003-4547-6849; Hewitt, Stephen/0000-0001-8283-1788	DIVISION OF CLINICAL SCIENCES - NCI [Z01SC006579] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [Z01SC010364] Funding Source: NIH RePORTER	DIVISION OF CLINICAL SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; APLAN PD, 1991, MOL CELL BIOL, V11, P5462, DOI 10.1128/MCB.11.11.5462; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; CollazoGarcia N, 1995, GENOMICS, V30, P506, DOI 10.1006/geno.1995.1271; Golling G, 2002, NAT GENET, V31, P135, DOI 10.1038/ng896; Izraeli S, 2001, GENESIS, V31, P72, DOI 10.1002/gene.10004; Izraeli S, 1999, NATURE, V399, P691, DOI 10.1038/21429; Izraeli S, 1997, CELL GROWTH DIFFER, V8, P1171; Kaminski N, 2002, AM J RESP CELL MOL, V27, P125, DOI 10.1165/ajrcmb.27.2.f247; Liu ST, 2003, MOL BIOL CELL, V14, P1638, DOI 10.1091/mbc.02-05-0074; Lynch J, 2002, J PATHOL, V196, P275, DOI 10.1002/path.1045; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Ortiz LA, 2003, P NATL ACAD SCI USA, V100, P8407, DOI 10.1073/pnas.1432929100; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Rattner JB, 1996, J CELL BIOL, V134, P1097, DOI 10.1083/jcb.134.5.1097; Starr DA, 2000, J CELL SCI, V113, P1939; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; Travis WD, 1999, HISTOLOGICAL TYPING; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030; Zhou J, 2002, J CELL SCI, V115, P3547, DOI 10.1242/jcs.00029	22	44	48	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2004	23	31					5371	5377		10.1038/sj.onc.1207685	http://dx.doi.org/10.1038/sj.onc.1207685			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15107824				2022-12-28	WOS:000222491600012
J	Yokota, T; Matsuzaki, Y; Miyazawa, K; Zindy, F; Roussel, MF; Sakai, T				Yokota, T; Matsuzaki, Y; Miyazawa, K; Zindy, F; Roussel, MF; Sakai, T			Histone deacetylase inhibitors activate INK4d gene through Sp1 site in its promoter	ONCOGENE			English	Article						histone deacetylase inhibitors; p19(INK4d); Sp1; Sp3; HDAC2; promoter activation	DEPENDENT KINASE INHIBITOR; CELL-CYCLE ARREST; TRICHOSTATIN-A; TRANSCRIPTIONAL REPRESSION; RETINOBLASTOMA PROTEIN; P21/WAF1/CIP1 GENE; N-COR; BUTYRATE; P19(INK4D); REGULATORS	Histone deacetylase (HDAC) inhibitors are known to arrest human tumor cells at the G1 phase of the cell cycle and activate the cyclin-dependent kinase inhibitor, p21(WAF1/Cip1). However, several studies have suggested the existence of a p21(WAF1/Cip1)-independent molecular pathway. We report here that HDAC inhibitors activate a member of the INK4 family, the INK4d gene, causing G1 phase arrest, in the human T cell leukemia cell line, Jurkat. One of the major Trichostatin A (TSA)-responsive elements is a specific Sp1 binding site in the INK4d promoter. Electrophoretic mobility-shift assay revealed that Sp1 and Sp3 can specifically interact with this Sp1 binding site. Furthermore, using chromatin immunoprecipitation assay, we demonstrated that HDAC2 was present in the INK4d proximal promoter region in the absence, but not the presence, of TSA. Taken together, these results suggest that treatment with TSA transcriptionally activates INK4d by releasing HDAC2 from the histone-DNA complex at the INK4d promoter. Using a p21(WAF1/Cip1)-deleted human colorectal carcinoma cell line, HCT116 p21 (-/-), we show that upregulation of p19(INK4d) by TSA is associated with inhibition of cell proliferation. Moreover, mouse embryo fibroblasts lacking Ink4d were resistant to the growth inhibitory effects of TSA as compared to their wild-type counterpart. Our findings suggest that p19(INK4d) in addition to p21(WAF1/Cip1) is an important molecular target of HDAC inhibitors inducing growth arrest.	Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Targeting Canc Prevent, Kamigyo Ku, Kyoto 6028566, Japan; Kyoto Prefectural Univ Med, Dept Digest Surg, Kamigyo Ku, Kyoto 6028566, Japan; St Jude Childrens Res Hosp, Dept Tumor Cell Biol & Genet, Memphis, TN 38105 USA	Kyoto Prefectural University of Medicine; Kyoto Prefectural University of Medicine; St Jude Children's Research Hospital	Sakai, T (corresponding author), Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Targeting Canc Prevent, Kamigyo Ku, Kyoto 6028566, Japan.	tsakai@koto.kpu-m.ac.jp	Roussel, Martine F/F-1469-2016	Roussel, Martine F/0000-0002-1740-8139	NATIONAL CANCER INSTITUTE [P30CA021765, P01CA071907] Funding Source: NIH RePORTER; NCI NIH HHS [CA71907, CA 21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; BORGONOVO BL, 1996, EUR J HAEMATOL, V56, P313; Chang ST, 1996, BIOCHEM BIOPH RES CO, V221, P594, DOI 10.1006/bbrc.1996.0641; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Choi HS, 2002, BIOCHEM BIOPH RES CO, V296, P1005, DOI 10.1016/S0006-291X(02)02001-6; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; Guan KL, 1996, MOL BIOL CELL, V7, P57, DOI 10.1091/mbc.7.1.57; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Hitomi T, 2003, FEBS LETT, V554, P347, DOI 10.1016/S0014-5793(03)01186-4; Kim YB, 2000, J ANTIBIOT, V53, P1191, DOI 10.7164/antibiotics.53.1191; Lagger G, 2003, MOL CELL BIOL, V23, P2669, DOI 10.1128/MCB.23.8.2669-2679.2003; Matsuzaki Y, 2002, FEBS LETT, V517, P272, DOI 10.1016/S0014-5793(02)02647-9; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Piekarz RL, 2001, BLOOD, V98, P2865, DOI 10.1182/blood.V98.9.2865; Ruas M, 1998, BIOCHIM BIOPHYS ACTA, V1378, P115, DOI 10.1016/s0304-419x(98)00017-1; SAKAI T, 1996, JPN J HYG, V50, P1036; SAMBROOK J, 2001, CLONING LAB MANUAL; Schreiber M, 1999, ONCOGENE, V18, P1663, DOI 10.1038/sj.onc.1202466; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sowa Y, 1999, CANCER RES, V59, P4266; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Sowa Y, 2000, BIOFACTORS, V12, P283, DOI 10.1002/biof.5520120142; Sun JM, 2002, J BIOL CHEM, V277, P35783, DOI 10.1074/jbc.C200378200; Suzuki T, 1999, VIROLOGY, V259, P384, DOI 10.1006/viro.1999.9760; Vaziri C, 1998, CELL GROWTH DIFFER, V9, P465; Wharton W, 2000, J BIOL CHEM, V275, P33981, DOI 10.1074/jbc.M005600200; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Won J, 2002, J BIOL CHEM, V277, P38230, DOI 10.1074/jbc.M206064200; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YOSHIDA M, 1988, EXP CELL RES, V177, P122, DOI 10.1016/0014-4827(88)90030-4; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Zariwala M, 1996, ONCOGENE, V13, P2033; Zhang Y, 2002, J BIOL CHEM, V277, P33431, DOI 10.1074/jbc.M204417200; Zindy F, 2000, MOL CELL BIOL, V20, P372, DOI 10.1128/MCB.20.1.372-378.2000	40	73	76	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 8	2004	23	31					5340	5349		10.1038/sj.onc.1207689	http://dx.doi.org/10.1038/sj.onc.1207689			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15107822				2022-12-28	WOS:000222491600009
J	Enomoto, Y; Enomoto, K; Kitamura, T; Kanda, T				Enomoto, Y; Enomoto, K; Kitamura, T; Kanda, T			Keratinocyte-specific POU transcription factor hSkn-1a represses the growth of cervical cancer cell lines	ONCOGENE			English	Article						hSkn-1a; cervical cancer; keratinocyte differentiation; POU-transcription factor	DIFFERENTIATION; EXPRESSION; GENE; PROMOTER; ELEGANS; DOMAIN; OCT-1	The POU transcription factor human Skn-1a (hSkn-1a) specifically promotes the proliferation of keratinocytes and enhances their differentiation. We examined the effects of hSkn-1a on cervical cancer cell lines of epithelial origin, in which the differentiation program is interrupted. From HeLa/Tet-On, a clone that can be induced to make hSkn-1a by doxycycline (HeLa/hSkn-1a) was prepared and characterized. Shortly after the induction, the cells expressed cytokeratin 10 (K10), a major marker protein in differentiating keratinocytes. While maintained for several days in the presence of doxycycline, the HeLa/hSkn-1a cells showed a slightly prolonged time of population doubling, the occasional appearance of. at cells with lowered DNA synthesis, and a low level of apoptotic DNA fragmentation. In SiHa and HeLa S3 cultures, K10 mRNA and apoptotic DNA fragmentation were detected at 48 h after infection with an adenoviral vector capable of expressing hSkn-1a. A colony inhibition assay showed that the growth of HeLa S3, SiHa, CaSki, and C-33A cells was repressed, as seen from the decreased number and average size of the drug-resistant colonies at 2 or 3 weeks after transfection with a plasmid that can express hSkn-1a and neomycin resistance gene. These results suggest that the expression of hSkn-1a represses the growth of the cervical cancer cells through the partial resumption of the differentiation pathway followed by slow suppression of cell replication and apoptosis.	Natl Inst Infect Dis, Div Mol Genet, Shinjuku Ku, Tokyo 1628640, Japan; Univ Tokyo, Fac Med, Dept Urol, Bunkyo Ku, Tokyo 1138655, Japan	National Institute of Infectious Diseases (NIID); University of Tokyo	Kanda, T (corresponding author), Natl Inst Infect Dis, Div Mol Genet, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628640, Japan.	kanda@nih.go.jp	Kitamura, Toshio/AAA-2071-2021					Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; ANDERSEN B, 1993, SCIENCE, V260, P78, DOI 10.1126/science.7682011; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; Enomoto K, 2003, BIOCHEM BIOPH RES CO, V303, P580, DOI 10.1016/S0006-291X(03)00395-4; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; Fischer DF, 1996, MOL CELL BIOL, V16, P5365, DOI 10.1128/mcb.16.10.5365; Fusenig N E, 1995, Recent Results Cancer Res, V139, P1; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; Hietala KA, 1997, J PATHOL, V183, P305; Hildesheim J, 2001, J CELL SCI, V114, P1913; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; Jang SI, 2000, J BIOL CHEM, V275, P15295, DOI 10.1074/jbc.275.20.15295; Kukimoto I, 2001, J VIROL, V75, P9302, DOI 10.1128/JVI.75.19.9302-9311.2001; WATANABE S, 1993, JPN J CANCER RES, V84, P1043, DOI 10.1111/j.1349-7006.1993.tb02799.x; Welter JF, 1996, J BIOL CHEM, V271, P14727, DOI 10.1074/jbc.271.25.14727	15	11	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					5014	5022		10.1038/sj.onc.1207653	http://dx.doi.org/10.1038/sj.onc.1207653			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15077167				2022-12-28	WOS:000222237300007
J	Kanda, N; Seno, H; Konda, Y; Marusawa, H; Kanai, M; Nakajima, T; Kawashima, T; Nanakin, A; Sawabu, T; Uenoyama, Y; Sekikawa, A; Kawada, M; Suzuki, K; Kayahara, T; Fukui, H; Sawada, M; Chiba, T				Kanda, N; Seno, H; Konda, Y; Marusawa, H; Kanai, M; Nakajima, T; Kawashima, T; Nanakin, A; Sawabu, T; Uenoyama, Y; Sekikawa, A; Kawada, M; Suzuki, K; Kayahara, T; Fukui, H; Sawada, M; Chiba, T			STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells	ONCOGENE			English	Article						STAT3; survivin; cancer; stomach	SIGNALING INDUCES APOPTOSIS; EPIDERMAL-GROWTH-FACTOR; TRANSCRIPTION FACTOR; MESSENGER-RNA; HUMAN OVARIAN; DNA-BINDING; INHIBITION; GENE; INTERLEUKIN-6; RESISTANCE	Signal transduction and activator of transcription 3(STAT3) signaling is constitutively activated in various tumors, and is involved in cell survival and proliferation during oncogenesis. There are few reports, however, on the role of STAT3 signaling in gastric cancer. The aim of the present study was to clarify the role of STAT3 signaling in apoptosis and cellular proliferation in gastric cancer. Here we reported that STAT3 was constitutively activated in various human gastric cancer cells and its inhibition by ectopic dominant-negative STAT3 or Janus kinase inhibitor, tyrphostin AG490, induced apoptosis. Furthermore, STAT3 inhibition markedly decreased survivin expression, and forced expression of survivin rescued AGS cells from apoptosis induced by STAT3 inhibition. Although some reports demonstrated that the PI3K/Akt pathway regulates survivin expression, inhibition of the PI3K/Akt pathway did not affect survivin expression in AGS and MKN1 cells. Finally, activated form of STAT3, Tyr-705 phospho-stat3, was found in the nucleus of cancer cells in 11 of 40 (27.5%) human gastric cancer specimens. These findings suggest that constitutively activated STAT3 signaling supports gastric cancer cell survival in association with survivin expression.	Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Seno, H (corresponding author), Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Sakyo Ku, Shogoin Kawara Cho 54, Kyoto 6068507, Japan.	seno@kuhp.kyoto-u.ac.jp	Kanai, Motomu/J-6807-2016	Kanai, Motomu/0000-0003-1977-7648; Marusawa, Hiroyuki/0000-0002-4286-2712; Seno, Hiroshi/0000-0002-8509-8128				AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Aoki Y, 2003, BLOOD, V101, P1535, DOI 10.1182/blood-2002-07-2130; Bisping G, 2003, BLOOD, V101, P2775, DOI 10.1182/blood-2002-09-2907; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Bromberg JF, 2001, BIOESSAYS, V23, P161, DOI 10.1002/1521-1878(200102)23:2<161::AID-BIES1023>3.0.CO;2-0; Buettner R, 2002, CLIN CANCER RES, V8, P945; Burke WM, 2001, ONCOGENE, V20, P7925, DOI 10.1038/sj.onc.1204990; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Fukuda S, 2001, BLOOD, V98, P2091, DOI 10.1182/blood.V98.7.2091; Gianani R, 2001, HUM PATHOL, V32, P119, DOI 10.1053/hupa.2001.21897; Giri D, 2001, AM J PATHOL, V159, P2159, DOI 10.1016/S0002-9440(10)63067-2; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Ikeguchi M, 2002, BRIT J CANCER, V87, P883, DOI 10.1038/sj.bjc.6600546; Izuishi K, 2000, CANCER RES, V60, P6201; Kanai M, 2003, ONCOGENE, V22, P548, DOI 10.1038/sj.onc.1206109; Kawasaki H, 1998, CANCER RES, V58, P5071; Konno R, 2000, MOL HUM REPROD, V6, P529, DOI 10.1093/molehr/6.6.529; Kube D, 2001, BLOOD, V98, P762, DOI 10.1182/blood.V98.3.762; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Marusawa H, 2003, EMBO J, V22, P2729, DOI 10.1093/emboj/cdg263; Monzo M, 1999, J CLIN ONCOL, V17, P2100, DOI 10.1200/JCO.1999.17.7.2100; Mora LB, 2002, CANCER RES, V62, P6659; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; Rahaman SO, 2002, ONCOGENE, V21, P8404, DOI 10.1038/sj.onc.1206047; Real PJ, 2002, ONCOGENE, V21, P7611, DOI 10.1038/sj.onc.1206004; RUFFJAMISON S, 1994, J BIOL CHEM, V269, P21933; Sasse J, 1997, MOL CELL BIOL, V17, P4677, DOI 10.1128/MCB.17.8.4677; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; Swana HS, 1999, NEW ENGL J MED, V341, P452, DOI 10.1056/NEJM199908053410614; Tran J, 2002, P NATL ACAD SCI USA, V99, P4349, DOI 10.1073/pnas.072586399; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; Werner M, 2001, J CANCER RES CLIN, V127, P207, DOI 10.1007/s004320000195; Zaffaroni N, 2002, CELL MOL LIFE SCI, V59, P1406, DOI 10.1007/s00018-002-8518-3; Zhang T, 2001, CANCER RES, V61, P8664; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806	42	259	307	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2004	23	28					4921	4929		10.1038/sj.onc.1207606	http://dx.doi.org/10.1038/sj.onc.1207606			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	830EK	15077160	Green Submitted			2022-12-28	WOS:000222104200013
J	Drivdahl, R; Haugk, KH; Sprenger, CC; Nelson, PS; Tennant, MK; Plymate, SR				Drivdahl, R; Haugk, KH; Sprenger, CC; Nelson, PS; Tennant, MK; Plymate, SR			Suppression of growth and tumorigenicity in the prostate tumor cell line M12 by overexpression of the transcription factor SOX9	ONCOGENE			English	Article						SOX9; prostate; androgens; IGF; cancer	PROTEIN-RELATED PROTEIN-1; MANGANESE SUPEROXIDE-DISMUTASE; ANDROGEN RECEPTOR; CANCER CELLS; EPITHELIAL-CELLS; BINDING; EXPRESSION; GENES; SEX; KINASE	Overexpression of mac25 in the prostate cancer cell line M12 effects a dramatic reversal of the transformed phenotype. cDNA array analysis of RNA from cells overproducing the mac25 protein (M12/mac25) indicated upregulation of the sex determining transcription factor SOX9. In this study, we have confirmed increased expression of SOX9 in M12/mac25 cells and have further investigated the physiological effects of increased SOX9 production. Greatly increased levels of SOX9 RNA and mature protein were demonstrated in cells transfected with a SOX9 cDNA (M12/SOX9), and gel mobility shift assays confirmed binding of nuclear protein from these cells to an oligonucleotide containing the SOX9 consensus binding sequence. M12/SOX9 cells assumed the spindle-shaped morphology characteristic of M12/mac25 cells, suggesting that SOX9 mediates some effects of mac25. Elevated expression of SOX9 resulted in a decreased rate of cellular proliferation, cell cycle arrest in G0/G1, and increased sensitivity to apoptosis. Tumor development in athymic nude mice was inhibited by 80%. Finally, prostate-specific antigen and the androgen receptor, two genes whose expression is characteristic of differentiated cells, were both upregulated in M12/SOX9 cells. These data indicate that SOX9 contributes to growth regulation by mac25 via inhibition of cell growth and promotion of differentiation.	Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98105 USA; Univ Washington, Sch Med, Dept Med, Seattle, WA 98105 USA; Univ Washington, Sch Med, Mol & Cell Biol Program, Seattle, WA 98105 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98107 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center	Plymate, SR (corresponding author), Univ Washington, Harborview Med Ctr, Box 359755,325 9th Ave, Seattle, WA 98104 USA.	splymate@u.washington.edu			NCI NIH HHS [R01-CA56283, P01-CA85859] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA085859] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Afonja O, 2002, ONCOGENE, V21, P7850, DOI 10.1038/sj.onc.1205985; Bae VL, 1998, PROSTATE, V34, P275, DOI 10.1002/(SICI)1097-0045(19980301)34:4<275::AID-PROS5>3.0.CO;2-G; Bowles J, 2001, GENOME BIOL, V2; Burger AM, 1998, ONCOGENE, V16, P2459, DOI 10.1038/sj.onc.1201772; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clarkson MJ, 2002, TRENDS ENDOCRIN MET, V13, P106, DOI 10.1016/S1043-2760(01)00541-0; Damon SE, 1998, ENDOCRINOLOGY, V139, P3456, DOI 10.1210/en.139.8.3456; Drivdahl RH, 2001, ENDOCRINOLOGY, V142, P1990, DOI 10.1210/en.142.5.1990; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOURNEY RM, 1989, FOCUS, V10, P5; Graff JR, 2000, J BIOL CHEM, V275, P24500, DOI 10.1074/jbc.M003145200; Graves JAM, 1998, BIOESSAYS, V20, P264, DOI 10.1002/(SICI)1521-1878(199803)20:3&lt;264::AID-BIES10&gt;3.0.CO;2-1; Healy C, 1999, DEV DYNAM, V215, P69, DOI 10.1002/(SICI)1097-0177(199905)215:1<69::AID-DVDY8>3.3.CO;2-E; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; Hwa V, 1998, J CLIN ENDOCR METAB, V83, P4355, DOI 10.1210/jc.83.12.4355; Kanai Y, 1999, HUM MOL GENET, V8, P691, DOI 10.1093/hmg/8.4.691; Kato MV, 1996, ONCOGENE, V12, P1361; Kent J, 1996, DEVELOPMENT, V122, P2813; Kishibe J, 2000, J BIOL CHEM, V275, P15321, DOI 10.1074/jbc.275.20.15321; KOMATSU K, 2001, BIOCHEM BIOPH RES CO, V276, P109; Koopman P, 2001, J EXP ZOOL, V290, P463, DOI 10.1002/jez.1089; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; Li N, 1998, J CELL PHYSIOL, V175, P359, DOI 10.1002/(SICI)1097-4652(199806)175:3<359::AID-JCP14>3.0.CO;2-0; Lin HK, 2001, P NATL ACAD SCI USA, V98, P7200, DOI 10.1073/pnas.121173298; Lopez-Bermejo A, 2000, ENDOCRINOLOGY, V141, P4072, DOI 10.1210/en.141.11.4072; Lu S, 2000, MOL ENDOCRINOL, V14, P753, DOI 10.1210/me.14.5.753; Marshall OJ, 2000, MOL GENET METAB, V71, P455, DOI 10.1006/mgme.2000.3081; Millikan LE, 1999, CLIN DERMATOL, V17, P353, DOI 10.1016/S0738-081X(99)00018-8; Murakami S, 2000, P NATL ACAD SCI USA, V97, P1113, DOI 10.1073/pnas.97.3.1113; Murillo H, 2001, ENDOCRINOLOGY, V142, P4795, DOI 10.1210/en.142.11.4795; MURPHY M, 1993, CELL GROWTH DIFFER, V4, P715; Oberley LW, 2001, ANTIOXID REDOX SIGN, V3, P461, DOI 10.1089/15230860152409095; Oh YM, 1996, J BIOL CHEM, V271, P30322, DOI 10.1074/jbc.271.48.30322; Olney PN, 1999, AM J MED GENET, V84, P20, DOI 10.1002/(SICI)1096-8628(19990507)84:1<20::AID-AJMG5>3.3.CO;2-E; Panda DK, 2001, J BIOL CHEM, V276, P41229, DOI 10.1074/jbc.M104231200; PEEHL DM, 1986, IN VITRO CELL DEV B, V22, P82; Plymate SR, 2003, ONCOGENE, V22, P1024, DOI 10.1038/sj.onc.1206210; Preiss S, 2001, J BIOL CHEM, V276, P27864, DOI 10.1074/jbc.M101278200; Reinikainen P, 1996, ENDOCRINOLOGY, V137, P4351, DOI 10.1210/en.137.10.4351; Rhee S G, 2000, Sci STKE, V2000, ppe1; Rosenthal DS, 1997, EXP CELL RES, V232, P313, DOI 10.1006/excr.1997.3536; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Simbulan-Rosenthal CM, 1999, MOL CELL BIOCHEM, V193, P137, DOI 10.1023/A:1006988832729; Spokony RF, 2002, DEVELOPMENT, V129, P421; Sprenger CC, 1999, CANCER RES, V59, P2370; Sprenger CC, 2002, ONCOGENE, V21, P140, DOI 10.1038/sj.onc.1205021; SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472; Tran CP, 2002, MOL CANCER RES, V1, P113; ULLRICH A, 1984, EMBO J, V3, P361, DOI 10.1002/j.1460-2075.1984.tb01812.x; Vidal VPI, 2001, NAT GENET, V28, P216, DOI 10.1038/90046; Vleminckx K, 1999, BIOESSAYS, V21, P211, DOI 10.1002/(SICI)1521-1878(199903)21:3<211::AID-BIES5>3.3.CO;2-G; Wilson EM, 2001, J CLIN ENDOCR METAB, V86, P4504, DOI 10.1210/jc.86.9.4504; Wilson HMP, 2002, CELL GROWTH DIFFER, V13, P205; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458	55	50	57	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2004	23	26					4584	4593		10.1038/sj.onc.1207603	http://dx.doi.org/10.1038/sj.onc.1207603			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZV	15077158				2022-12-28	WOS:000221799000008
J	Delva, L; Gallais, I; Guillouf, C; Denis, N; Orvain, C; Moreau-Gachelin, F				Delva, L; Gallais, I; Guillouf, C; Denis, N; Orvain, C; Moreau-Gachelin, F			Multiple functional domains of the oncoproteins Spi-1/PU.1 and TLS are involved in their opposite splicing effects in erythroleukemic cells	ONCOGENE			English	Article						Spi-1/PU.1; TLS; erythroleukemia; transcription factor; splicing interference	RNA-BINDING PROTEIN; HUMAN MYELOID-LEUKEMIA; TRANSCRIPTION FACTOR PU.1; POLYMERASE-II; CHROMOSOMAL TRANSLOCATION; DNA-BINDING; PUTATIVE ONCOGENE; ACTIVATION DOMAIN; TERMINAL DOMAIN; IN-VIVO	The hematopoietic transcription factor Spi-1/PU.1 is an oncoprotein participating to the malignant transformation of proerythroblasts in the Friend erythroleukemia or in the erythroleukemic process developed in spi-1 transgenic mice. Overexpression of Spi-1 in proerythroblasts blocks their differentiation. We have shown that Spi-1 promotes the use of the proximal 5'-splice site during the E1A pre-mRNA splicing and interferes with the effect of TLS (Translocated in LipoSarcoma) in this splicing assay. TLS was identified from chromosomal translocations in human liposarcoma and acute myeloid leukemia. Here, we determine the function of Spi-1 domains in splicing and in the interference with TLS. In transient transfection assays in erythroid cells, we show that the DNA binding domain cooperates with the transactivation domain or the PEST region of Spi-1 to modify the function of TLS in splicing. Interestingly, the 27 C-terminal amino acids, which determine the DNA binding activity of Spi-1, are necessary for the splicing function of Spi-1 as well as for its ability to interfere with TLS. Finally, we demonstrate that in leukemic proerythroblasts overexpressing Spi-1, TLS has lost its splicing effect. Thus, we hypothesize that oncogenic pathways in proerythroblasts may involve the ability of Spi-1 to alter splicing.	Inst Curie, INSERM, U528, Sect Rech, F-75248 Paris 05, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Moreau-Gachelin, F (corresponding author), Inst Curie, INSERM, U528, Sect Rech, 26 Rue Ulm, F-75248 Paris 05, France.	framoreau@curie.fr		DELVA, Laurent/0000-0002-1086-3964				Auboeuf D, 2002, SCIENCE, V298, P416, DOI 10.1126/science.1073734; Baechtold H, 1999, J BIOL CHEM, V274, P34337, DOI 10.1074/jbc.274.48.34337; Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; Bertrand P, 1999, ONCOGENE, V18, P4515, DOI 10.1038/sj.onc.1203048; Brass AL, 1999, EMBO J, V18, P977, DOI 10.1093/emboj/18.4.977; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; CALVIO C, 1995, RNA, V1, P724; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DELGADO MD, 1994, ONCOGENE, V9, P1723; Du L, 1997, J CELL BIOL, V136, P5, DOI 10.1083/jcb.136.1.5; FU XD, 1995, RNA, V1, P663; Ge H, 1998, MOL CELL, V2, P751, DOI 10.1016/S1097-2765(00)80290-7; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; Hallier M, 1998, J BIOL CHEM, V273, P4838, DOI 10.1074/jbc.273.9.4838; Hallier M, 1996, J BIOL CHEM, V271, P11177, DOI 10.1074/jbc.271.19.11177; ICHIKAWA H, 1994, CANCER RES, V54, P2865; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Knoop LL, 2000, J BIOL CHEM, V275, P24865, DOI 10.1074/jbc.M001661200; Knoop LL, 2001, J BIOL CHEM, V276, P22317, DOI 10.1074/jbc.M008950200; Kuroda M, 2000, EMBO J, V19, P453, DOI 10.1093/emboj/19.3.453; Lerga A, 2001, J BIOL CHEM, V276, P6807, DOI 10.1074/jbc.M008304200; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; Nerlov C, 2000, BLOOD, V95, P2543, DOI 10.1182/blood.V95.8.2543.008k19_2543_2551; OHNO T, 1994, ONCOGENE, V9, P3087; PAHL HL, 1993, J BIOL CHEM, V268, P5014; Perkel JM, 1998, J IMMUNOL, V160, P241; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; Powers CA, 1998, MOL ENDOCRINOL, V12, P4, DOI 10.1210/mend.12.1.0043; PRASAD DDK, 1994, ONCOGENE, V9, P3717; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RAYGALLET D, 1995, ONCOGENE, V11, P303; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; Scott EW, 1997, IMMUNITY, V6, P437, DOI 10.1016/S1074-7613(00)80287-3; SCREATON GR, 1995, EMBO J, V14, P4336, DOI 10.1002/j.1460-2075.1995.tb00108.x; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; STOLOW DT, 1995, NUCLEIC ACIDS RES, V23, P835, DOI 10.1093/nar/23.5.835; Uranishi H, 2001, J BIOL CHEM, V276, P13395, DOI 10.1074/jbc.M011176200; Wu SP, 1997, EMBO J, V16, P4421, DOI 10.1093/emboj/16.14.4421; Yamamoto H, 1999, ONCOGENE, V18, P1495, DOI 10.1038/sj.onc.1202427; Yang L, 2000, MOL CELL BIOL, V20, P3345, DOI 10.1128/MCB.20.10.3345-3354.2000; Yang L, 1998, J BIOL CHEM, V273, P27761, DOI 10.1074/jbc.273.43.27761; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975; Zhang P, 2000, BLOOD, V96, P2641; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513	55	22	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2004	23	25					4389	4399		10.1038/sj.onc.1207578	http://dx.doi.org/10.1038/sj.onc.1207578			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	824CJ	15064749				2022-12-28	WOS:000221661300005
J	Babic, I; Jakymiw, A; Fujita, DJ				Babic, I; Jakymiw, A; Fujita, DJ			The RNA binding protein Sam68 is acetylated in tumor cell lines, and its acetylation correlates with enhanced RNA binding activity	ONCOGENE			English	Article						acetylation; Sam68; RNA binding; breast cancer; gene expression	HUMAN-IMMUNODEFICIENCY-VIRUS; NUCLEAR-LOCALIZATION SIGNAL; KH-DOMAIN; POSTTRANSCRIPTIONAL REGULATION; TRANSCRIPTIONAL ACTIVITY; MAMMALIAN PROTEINS; CYCLE PROGRESSION; HIV REPLICATION; SRC SUBSTRATE; COFACTOR CBP	Sam68 ((S) under bar rc-(a) under bar ssociated in mitosis; 68 kDa) is a member of the STAR ((s) under bar ignal (t) under bar ransduction and (a) under bar ctivation of RNA) family of KH domain-containing RNA binding proteins. Accumulating evidence suggests that it plays an important role in cell cycle control. Tyrosine phosphorylation by Src family kinases and breast tumor kinase can negatively regulate its RNA binding activity. To date, there are no reports of a factor, such as a phosphatase, which can positively regulate Sam68 association with RNA. Acetylation is a reversible post-translational modification known to influence the activity of DNA binding proteins. However, acetylation of a cellular RNA binding protein as a mechanism for regulating its activity has not yet been reported. Here we demonstrate Sam68 to be acetylated in vivo. A screen of several human mammary epithelial cell lines revealed variations in Sam68 acetylation. Interestingly, the highest level of acetylation was found in tumorigenic breast cancer cell lines. The screen also showed a positive correlation between Sam68 acetylation and its ability to bind RNA. The acetyltransferase CBP was shown to acetylate Sam68 and enhance its binding to poly(U) RNA. These results suggest that Sam68 association with RNA substrates may be positively regulated by acetylation, and that enhanced acetylation and RNA binding activity of Sam68 may play a role in tumor cell proliferation.	Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	University of Calgary	Fujita, DJ (corresponding author), Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada.	ibabic@ucalgary.ca; dfujita@ucalgary.ca		Jakymiw, Andrew/0000-0001-6431-8753				Ait-Si-Ali S, 2000, ONCOGENE, V19, P2430, DOI 10.1038/sj.onc.1203562; Arning S, 1996, RNA, V2, P794; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bannister AJ, 2000, CURR BIOL, V10, P467, DOI 10.1016/S0960-9822(00)00445-0; Barlat I, 1997, J BIOL CHEM, V272, P3129, DOI 10.1074/jbc.272.6.3129; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Chen TP, 1998, MOL CELL BIOL, V18, P4863, DOI 10.1128/MCB.18.8.4863; Chen TP, 1997, MOL CELL BIOL, V17, P5707, DOI 10.1128/MCB.17.10.5707; Coyle JH, 2003, MOL CELL BIOL, V23, P92, DOI 10.1128/MCB.23.1.92-103.2003; CRUZALVAREZ M, 1987, J BIOL CHEM, V262, P13377; Derry JJ, 2000, MOL CELL BIOL, V20, P6114, DOI 10.1128/MCB.20.16.6114-6126.2000; Di Fruscio M, 1999, P NATL ACAD SCI USA, V96, P2710, DOI 10.1073/pnas.96.6.2710; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Grossman JS, 1998, RNA, V4, P613, DOI 10.1017/S1355838298971448; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Harfmann AM, 1999, MOL BIOL CELL, V10, P3909, DOI 10.1091/mbc.10.11.3909; Hong W, 2002, MOL CANCER RES, V1, P48; Ishidate T, 1997, FEBS LETT, V409, P237, DOI 10.1016/S0014-5793(97)00455-9; JONES AR, 1995, GENE DEV, V9, P1491, DOI 10.1101/gad.9.12.1491; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; LHERNAULT SW, 1985, BIOCHEMISTRY-US, V24, P473, DOI 10.1021/bi00323a034; Li QH, 2002, FEBS LETT, V525, P145, DOI 10.1016/S0014-5793(02)03103-4; Lin Q, 1997, J BIOL CHEM, V272, P27274, DOI 10.1074/jbc.272.43.27274; Mandal M, 2001, J BIOL CHEM, V276, P9699, DOI 10.1074/jbc.M008514200; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Matter N, 2002, NATURE, V420, P691, DOI 10.1038/nature01153; Mueller F, 2003, BRIT J CANCER, V88, P699, DOI 10.1038/sj.bjc.6600790; Perrotti D, 2002, ONCOGENE, V21, P8577, DOI 10.1038/sj.onc.1206085; Reddy TR, 2000, ONCOGENE, V19, P3570, DOI 10.1038/sj.onc.1203676; Reddy TR, 1999, NAT MED, V5, P635, DOI 10.1038/9479; Reddy TR, 2002, J BIOL CHEM, V277, P5778, DOI 10.1074/jbc.M106836200; Resnick RJ, 1997, ONCOGENE, V15, P1247, DOI 10.1038/sj.onc.1201289; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; Soros VB, 2001, J VIROL, V75, P8203, DOI 10.1128/JVI.75.17.8203-8215.2001; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Stoss O, 2001, J BIOL CHEM, V276, P8665, DOI 10.1074/jbc.M006851200; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; Vernet C, 1997, TRENDS GENET, V13, P479, DOI 10.1016/S0168-9525(97)01269-9; Vervoorts J, 2003, EMBO REP, V4, P484, DOI 10.1038/sj.embor.embor821; VOGEL LB, 1995, J BIOL CHEM, V270, P2506, DOI 10.1074/jbc.270.6.2506; WANG LL, 1995, J BIOL CHEM, V270, P2010, DOI 10.1074/jbc.270.5.2010; Wu J, 1999, J BIOL CHEM, V274, P29202, DOI 10.1074/jbc.274.41.29202; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855	46	62	65	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2004	23	21					3781	3789		10.1038/sj.onc.1207484	http://dx.doi.org/10.1038/sj.onc.1207484			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	818JX	15021911				2022-12-28	WOS:000221242500005
J	Hashimoto, M; Ichihara, M; Watanabe, T; Kawai, K; Koshikawa, K; Yuasa, N; Takahashi, T; Yatabe, Y; Murakumo, Y; Zhang, JM; Nimura, Y; Takahashi, M				Hashimoto, M; Ichihara, M; Watanabe, T; Kawai, K; Koshikawa, K; Yuasa, N; Takahashi, T; Yatabe, Y; Murakumo, Y; Zhang, JM; Nimura, Y; Takahashi, M			Expression of CD109 in human cancer	ONCOGENE			English	Article						CD109; squamous cell carcinoma; lung carcinoma; esophageal carcinoma	PLATELETS; PROTEINS; CELLS	It was recently reported that the human CD109 gene encodes a glycosyl-phosphatidylinositol-anchored glycoprotein that is a member of the alpha(2)-macroglobulin/C3, C4, C5 family of thioester-containing proteins. In this study, we found that the expression of mouse CD109 gene was upregulated in NIH3T3 cells expressing RET tyrosine kinase with a multiple endocrine neoplasia 2B mutation. Northern blot analysis showed a high level of expression of the CD109 gene only in the testis in normal human and mouse tissues. In addition, its expression was high in some human tumor cell lines, which included squamous cell carcinoma and glioblastoma cell lines, whereas it was undetectable in neuroblastoma and small-cell lung carcinoma cell lines. When CD109 expression was examined in 33 cases of human lung cell carcinomas by quantitative RT-PCR, a significant high expression of CD109 was detected in about half of squamous cell carcinomas examined, but not in adenocarcinoma, large-cell carcinoma and small-cell carcinoma. Similarly, upregulation of CD109 was observed in nine out of 17 esophageal squamous cell carcinomas. Thus, these results suggested that CD109 might be a useful molecular target for the development of new therapeutics for malignant tumors, such as squamous cell carcinoma.	Nagoya Univ, Grad Sch Med, Dept Pathol, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Grad Sch Med, Dept Surg, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Grad Sch Med, Ctr Neural Dis & Canc, Div Mol Pathol,Showa Ku, Nagoya, Aichi 4668550, Japan; Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr, Dept Pathol & Mol Diagnost, Chikusa Ku, Nagoya, Aichi 4648681, Japan	Nagoya University; Nagoya University; Nagoya University; Aichi Cancer Center; Aichi Cancer Center	Takahashi, M (corresponding author), Nagoya Univ, Grad Sch Med, Dept Pathol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	mtakaha@med.nagoya-u.ac.jp	Takahashi, Takashi/I-7262-2014; Takahashi, Masahide/AAN-4770-2020; TAKAHASHI, Masahide/I-7244-2014; Kumi, Kawai/I-6275-2014; YATABE, Yasushi/J-6461-2014	Takahashi, Takashi/0000-0003-0615-7001; Takahashi, Masahide/0000-0002-2803-2683; Kumi, Kawai/0000-0002-7772-2605; YATABE, Yasushi/0000-0003-1788-559X				HAREGEWOIN A, 1994, CELL IMMUNOL, V156, P357, DOI 10.1006/cimm.1994.1181; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; Lin M, 2002, BLOOD, V99, P1683, DOI 10.1182/blood.V99.5.1683; Murray LJ, 1999, EXP HEMATOL, V27, P1282, DOI 10.1016/S0301-472X(99)00071-5; Rappold I, 1997, BLOOD, V90, P111; SMITH JW, 1995, BLOOD, V86, P2807; Solomon KR, 1998, BIOCHEM J, V334, P325, DOI 10.1042/bj3340325; SUTHERLAND DR, 1991, BLOOD, V77, P84; SUTHERLAND DR, 1998, LEUKOCYTE TYPING, V6, P714; SUTHERLAND DR, 1995, LEUKOCYTE TYPING, V5, P1767; Takahashi M, 2001, CYTOKINE GROWTH F R, V12, P361, DOI 10.1016/S1359-6101(01)00012-0; Watanabe T, 2002, AM J PATHOL, V161, P249, DOI 10.1016/S0002-9440(10)64176-4; YEO EL, 1992, BLOOD, V80, P56	13	68	71	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3716	3720		10.1038/sj.onc.1207418	http://dx.doi.org/10.1038/sj.onc.1207418			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15116102				2022-12-28	WOS:000221101700024
J	Terrinoni, A; Ranalli, M; Cadot, B; Leta, A; Bagetta, G; Vousden, KH; Melino, G				Terrinoni, A; Ranalli, M; Cadot, B; Leta, A; Bagetta, G; Vousden, KH; Melino, G			p73-alpha is capable of inducing scotin and ER stress	ONCOGENE			English	Article						apoptosis; p73; p63; p53; scotin; endoplasmic reticulum; ER; calnexin; gadd 153	KINASE C-ABL; ENDOPLASMIC-RETICULUM; APOPTOTIC RESPONSE; P73; P53; GENE; DIFFERENTIATION; TARGET; P63; NEUROBLASTOMA	p73, like its family member p53, can induce programmed cell death following DNA damage. Here, we report that this mechanism also involves endoplasmic reticulum (ER) stress and the transactivation of scotin, a protein identified recently as a p53 target able to induce ER stress. By using Tet-On inducible cell lines (Saos 2 osteosarcoma cells that lack p53), we observed that TAp73alpha elicits significant alterations in the morphology of the ER system, namely in the. ne subcellular localization of calnexin. We found that both TAp73alpha and p53 are strong inducers of scotin. On the other hand, the transcriptionally deficient short isoforms DeltaNp73alpha did not upregulate the steady-state mRNA level of scotin, as evaluated by real-time RT-PCR. Following the induction of scotin, ER staining with calnexin showed evidence of morphological alteration, with variations in the intracellular concentration of free calcium, visualized by fluo-3 staining. The induction of ER stress by p73 was further supported by the transcriptional induction of Gadd 153, a transcription factor induced under ER stress conditions. In conclusion, the data reported indicate the ability of TAp73alpha and p53 (not DeltaNp73alpha) to elicit scotin transactivation and ER stress. This molecular mechanism might contribute to the effector events inducing apoptosis downstream of p73.	Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, IRCCS, IDI,Biochem Lab, I-00133 Rome, Italy; Univ Calabria, Dept Pharmacobiol, I-87036 Cosenza, Italy; Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England	IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Rome Tor Vergata; University of Calabria; Beatson Institute; University of Leicester	Melino, G (corresponding author), Via Montpellier 1, I-00133 Rome, Italy.	gerry.melino@uniroma2.it	Bagetta, Giacinto/N-9716-2018; CADOT, bruno/E-1710-2013; Bagetta, Giacinto/E-8402-2012; TERRINONI, Alessandro/J-1533-2012	Bagetta, Giacinto/0000-0001-8540-6218; CADOT, bruno/0000-0002-1888-3898; Bagetta, Giacinto/0000-0001-8540-6218; TERRINONI, Alessandro/0000-0002-7442-2252	Telethon [E.1224] Funding Source: Medline	Telethon(Fondazione Telethon)		Agami R, 1999, NATURE, V399, P809; Bourdon JC, 2002, J CELL BIOL, V158, P235, DOI 10.1083/jcb.200203006; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; De Laurenzi V, 2000, BIOCHEM BIOPH RES CO, V273, P342, DOI 10.1006/bbrc.2000.2932; De Laurenzi V, 2000, J BIOL CHEM, V275, P15226, DOI 10.1074/jbc.275.20.15226; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Fillippovich I, 2001, ONCOGENE, V20, P514, DOI 10.1038/sj.onc.1204118; Gong JG, 1999, NATURE, V399, P806; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Matsumoto M, 1996, FEBS LETT, V395, P143, DOI 10.1016/0014-5793(96)01016-2; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Melino G, 2003, TRENDS BIOCHEM SCI, V28, P663, DOI 10.1016/j.tibs.2003.10.004; Nakano K, 2000, ONCOGENE, V19, P4283, DOI 10.1038/sj.onc.1203774; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; Tschan MP, 2000, BIOCHEM BIOPH RES CO, V277, P62, DOI 10.1006/bbrc.2000.3627; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zhu JH, 1998, CANCER RES, V58, P5061; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	28	44	46	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3721	3725		10.1038/sj.onc.1207342	http://dx.doi.org/10.1038/sj.onc.1207342			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15116103				2022-12-28	WOS:000221101700025
J	Pandolfi, PP				Pandolfi, PP			Aberrant mRNA translation in cancer pathogenesis: an old concept revisited comes finally of age	ONCOGENE			English	Article						mRNA translation; ribosome; cell size; nucleolus; tumor suppressor; Dkc1	RIBOSOMAL-RNA; PROTEIN; TRANSFORMATION; B23	As the molecular processes that control mRNA translation and ribosome biogenesis in the eukaryotic cell are extremely complex and multilayered, their deregulation can in principle occur at multiple levels, leading to both disease and cancer pathogenesis. For a long time, it was speculated that disruption of these processes may participate in tumorigenesis, but this notion was, until recently, solely supported by correlative studies. Strong genetic support is now being accrued, while new molecular links between tumor-suppressive and oncogenic pathways and the control of protein synthetic machinery are being unraveled. The importance of aberrant protein synthesis in tumorigenesis is further underscored by the discovery that compounds such as Rapamycin, known to modulate signaling pathways regulatory of this process, are effective anticancer drugs. A number of fundamental questions remain to be addressed and a number of novel ones emerge as this exciting field evolves.	Mem Sloan Kettering Canc Ctr, Mol & Dev Biol Lab, Dept Pathol, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Pandolfi, PP (corresponding author), Mem Sloan Kettering Canc Ctr, Mol & Dev Biol Lab, Dept Pathol, Program Mol Biol, 1275 York Ave,Box 110, New York, NY 10021 USA.	p-pandol@ski.mskcc.org						Bader AG, 2004, ONCOGENE, V23, P3145, DOI 10.1038/sj.onc.1207550; Bernardi R, 2003, NAT MED, V9, P24, DOI 10.1038/nm0103-24; Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; Clemens MJ, 2004, ONCOGENE, V23, P3180, DOI 10.1038/sj.onc.1207544; De Benedetti A, 2004, ONCOGENE, V23, P3189, DOI 10.1038/sj.onc.1207545; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Holland EC, 2004, ONCOGENE, V23, P3138, DOI 10.1038/sj.onc.1207590; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Mamane Y, 2004, ONCOGENE, V23, P3172, DOI 10.1038/sj.onc.1207549; Perrotti D, 2004, ONCOGENE, V23, P3222, DOI 10.1038/sj.onc.1207543; Pianese G., 1896, BEITR PATHOL ANAT AL, V142, P1; Piazza F, 2001, ONCOGENE, V20, P7216, DOI 10.1038/sj.onc.1204855; Rajasekhar VK, 2004, ONCOGENE, V23, P3248, DOI 10.1038/sj.onc.1207546; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; Rosenwald IB, 2004, ONCOGENE, V23, P3230, DOI 10.1038/sj.onc.1207552; Ruggero D, 2003, SCIENCE, V299, P259, DOI 10.1126/science.1079447; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; RUGGERO D, 2004, IN PRESS NATURE MED; Savkur RS, 1998, NUCLEIC ACIDS RES, V26, P4508, DOI 10.1093/nar/26.19.4508; Schmidt EV, 2004, ONCOGENE, V23, P3217, DOI 10.1038/sj.onc.1207548; Stoneley M, 2004, ONCOGENE, V23, P3200, DOI 10.1038/sj.onc.1207551; White RJ, 2004, ONCOGENE, V23, P3208, DOI 10.1038/sj.onc.1207547	24	56	56	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2004	23	18					3134	3137		10.1038/sj.onc.1207618	http://dx.doi.org/10.1038/sj.onc.1207618			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	813AJ	15094762				2022-12-28	WOS:000220879700001
J	Zhang, M; Altuwaijri, S; Yeh, S				Zhang, M; Altuwaijri, S; Yeh, S			RRR-alpha-tocopheryl succinate inhibits human prostate cancer cell invasiveness	ONCOGENE			English	Article						alpha-vitamin E succinate; prostate cancer tumor invasion; matrix metalloproteinases	VITAMIN-E SUCCINATE; TUMOR-CELLS; EXPRESSION; INVASION; GROWTH; METALLOPROTEINASES; PROLIFERATION; METASTASES; SECRETION; RECEPTOR	RRR-alpha-tocopheryl succinate (alpha-vitamin E succinate, VES), one of the vitamin E derivatives, can effectively inhibit the proliferation of human prostate cancer cells. However, little is known about its effect on prostate cancer cell invasive ability. Tumor metastasis is a complex process and the extracellular matrix (ECM) is the first barrier that tumor cells encounter. Therefore, we tested the effect of VES on the invasion of different prostate tumor cells, PC-3, DU-145, and LNCaP, through Matrigel, a reconstituted ECM, using an in vitro cell invasion assay. The invasion of PC-3 and DU-145 cells through Matrigel was inhibited by 20 muM VES after treating for 24 h. The condition did not alter cell survival, cell cycle, cell adhesion or cell motility. We further investigated whether the ability of VES to inhibit prostate cancer cell invasiveness was associated with its ability to inhibit the activity of matrix metalloproteinases (MMPs), the key enzymes in the proteolysis of basement membrane during invasion. PC-3 and DU-145 cells that were treated with VES showed a significant reduction in the levels of MMP-9 in the culture medium. In contrast, LNCaP cells, which did not secrete MMP-9, were poorly invasive in Matrigel and were hardly affected by treatment with VES. This is the first report suggesting that VES inhibits human prostate cancer cell invasiveness and the reduction of secreted MMP-9 activity could be one of the contributory factors, which points to the potential use of VES in the prevention and therapy of prostate cancer invasion.	Univ Rochester, Dept Urol, Rochester, NY 14642 USA; Univ Rochester, Dept Pathol, Rochester, NY 14642 USA; Peking Univ, Inst Urol, Beijing 100871, Peoples R China	University of Rochester; University of Rochester; Peking University	Yeh, S (corresponding author), Univ Rochester, Dept Urol, Rochester, NY 14642 USA.	shuyuan_yeh@urmc.rochester.edu			NIDDK NIH HHS [DK60912] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060912] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBINI A, 1987, CANCER RES, V47, P3239; Barnett KT, 2002, J SURG RES, V106, P292, DOI 10.1006/jsre.2002.6466; CHEESEMAN KH, 1995, FREE RADICAL BIO MED, V19, P591, DOI 10.1016/0891-5849(95)00083-A; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Denmeade SR, 1997, BRIT J UROL, V79, P2, DOI 10.1111/j.1464-410X.1997.tb00794.x; HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029; HERRON GS, 1986, J BIOL CHEM, V261, P2814; Hu YC, 2002, J BIOL CHEM, V277, P33571, DOI 10.1074/jbc.M203531200; IWAMOTO Y, 1992, ADV EXP MED BIOL, V324, P141; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; JIANG WG, 1994, BRIT J SURG, V81, P1576, DOI 10.1002/bjs.1800811107; Kampa M, 2000, NUTR CANCER, V37, P223, DOI 10.1207/S15327914NC372_16; Li YW, 2002, CANCER LETT, V186, P157, DOI 10.1016/S0304-3835(02)00349-X; LOKESHWAR BL, 1993, CANCER RES, V53, P4493; Nagakawa O, 1998, CANCER LETT, V133, P27, DOI 10.1016/S0304-3835(98)00186-4; Ni J, 2003, BIOCHEM BIOPH RES CO, V300, P357, DOI 10.1016/S0006-291X(02)02851-6; Prasad KN, 2003, J AM COLL NUTR, V22, P108, DOI 10.1080/07315724.2003.10719283; Rasmussen HS, 1997, PHARMACOL THERAPEUT, V75, P69, DOI 10.1016/S0163-7258(97)00023-5; SOKOL RJ, 1993, GASTROENTEROLOGY, V104, P1727, DOI 10.1016/0016-5085(93)90652-S; Stearns ME, 1996, INVAS METAST, V16, P116; STEPHENSON RA, 1992, J NATL CANCER I, V84, P951, DOI 10.1093/jnci/84.12.951; TERRANOVA VP, 1986, JNCI-J NATL CANCER I, V77, P311; Van den Steen PE, 2002, CRIT REV BIOCHEM MOL, V37, P375, DOI 10.1080/10409230290771546; Weber T, 2002, CLIN CANCER RES, V8, P863; Zhang Y, 2002, P NATL ACAD SCI USA, V99, P7408, DOI 10.1073/pnas.102014399; Zi XL, 2000, CANCER RES, V60, P5617	26	64	67	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2004	23	17					3080	3088		10.1038/sj.onc.1207435	http://dx.doi.org/10.1038/sj.onc.1207435			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	812NC	15048090				2022-12-28	WOS:000220845200012
J	Menez, J; Chansac, BL; Dorothee, G; Vergnon, I; Jalil, A; Carlier, MF; Chouaib, S; Mami-Chouaib, F				Menez, J; Chansac, BL; Dorothee, G; Vergnon, I; Jalil, A; Carlier, MF; Chouaib, S; Mami-Chouaib, F			Mutant alpha-actinin-4 promotes tumorigenicity and regulates cell motility of a human lung carcinoma	ONCOGENE			English	Article						alpha-actinin-4; tumor suppressor gene; cytoskeleton; cell migration; lung carcinoma	HUMAN NEUROBLASTOMA-CELLS; ALPHA-ACTININ; T-LYMPHOCYTES; POINT MUTATION; TUMOR; EXPRESSION; ADHESION; PROTEIN; FIBRONECTIN; INVASION	The precise role of alpha-actinin-4 encoding gene (ACTN4) is not very well understood. It has been reported to elicit tumor suppressor activity and to regulate cellular motility. To further assess the function of human ACTN4, we studied a lung carcinoma cell line expressing a mutated alpha-actinin-4, which is recognized as a tumor antigen by autologous CD8(+) cytotoxic T lymphocytes (CTL). Confocal immunofluorescence microscopy indicated that, while wild-type (WT) alpha-actinin-4 stains into actin cytoskeleton and cell surface ruffles, the mutated protein is only dispersed in the cytoplasm of the lung carcinoma cells. This loss of association with the cell surface did not appear to correlate with a decrease in in vitro alpha-actinin-4 crosslinking to filamentous (F)-actin. Interestingly, experiments using cell lines stably expressing ACTN4 demonstrated that as opposed to WT gene, mutant ACTN4 was unable to inhibit tumor cell growth in vitro and in vivo. Moreover, the expression of mutant alpha-actinin-4 resulted in the loss of tumor cell capacity to migrate. The identification of an inactivating mutation in ACTN4 emphasizes its role as a tumor suppressor gene and underlines the involvement of cytoskeleton alteration in tumor development and metastasis.	Inst Gustave Roussy, INSERM, U487,Inst Federat Rech 54, Lab Cytokines & Immunol Tumeurs Humaines, F-94805 Villejuif, France; CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Mami-Chouaib, F (corresponding author), Inst Gustave Roussy, INSERM, U487,Inst Federat Rech 54, Lab Cytokines & Immunol Tumeurs Humaines, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	cfathia@igr.fr	Chouaib, Salem/F-7939-2016; Mami-Chouaib, Fathia/E-5267-2016; DOROTHEE, Guillaume/O-9760-2016	DOROTHEE, Guillaume/0000-0001-5763-3632; JALIL, Abdelali/0000-0003-2710-8735				Akamatsu H, 1996, CANCER RES, V56, P4541; Araki N, 2000, J CELL SCI, V113, P3329; Asselin-Paturel C, 1998, INT J CANCER, V77, P7, DOI 10.1002/(SICI)1097-0215(19980703)77:1<7::AID-IJC2>3.0.CO;2-Y; Beck-Engeser GB, 2001, J EXP MED, V194, P285, DOI 10.1084/jem.194.3.285; BEGGS AH, 1992, J BIOL CHEM, V267, P9281; BenZeev A, 1997, CURR OPIN CELL BIOL, V9, P99, DOI 10.1016/S0955-0674(97)80158-5; BENZEEV A, 1994, ADV EXP MED BIOL, V358, P147; BOYD J, 1995, P NATL ACAD SCI USA, V92, P11534, DOI 10.1073/pnas.92.25.11534; Bullions LC, 1997, MOL CELL BIOL, V17, P4501, DOI 10.1128/MCB.17.8.4501; BURRIDGE K, 1990, CELL DIFFER DEV, V32, P337, DOI 10.1016/0922-3371(90)90048-2; CARPEN O, 1992, J CELL BIOL, V118, P1223, DOI 10.1083/jcb.118.5.1223; DAVISON MD, 1988, CELL, V52, P159, DOI 10.1016/0092-8674(88)90503-X; Djinovic-Carugo K, 1999, CELL, V98, P537, DOI 10.1016/S0092-8674(00)81981-9; Dorothee G, 2002, J IMMUNOL, V169, P809, DOI 10.4049/jimmunol.169.2.809; Echchakir H, 2001, CANCER RES, V61, P4078; Echchakir H, 2002, P NATL ACAD SCI USA, V99, P9358, DOI 10.1073/pnas.142308199; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; FUJIMORI T, 1993, MOL BIOL CELL, V4, P37, DOI 10.1091/mbc.4.1.37; GEIGER B, 1992, COLD SPRING HARB SYM, V57, P631, DOI 10.1101/SQB.1992.057.01.069; Gimona M, 1996, P NATL ACAD SCI USA, V93, P9618, DOI 10.1073/pnas.93.18.9618; GLUCK U, 1994, J CELL SCI, V107, P1773; GLUCK U, 1993, P NATL ACAD SCI USA, V90, P383, DOI 10.1073/pnas.90.2.383; Gonzalez AM, 2001, J CELL SCI, V114, P4197; Haber D, 1997, NAT GENET, V16, P320, DOI 10.1038/ng0897-320; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; Hynes RO, 1992, CURR OPIN GENET DEV, V2, P621, DOI 10.1016/S0959-437X(05)80182-0; JANMEY PA, 1995, CURR OPIN CELL BIOL, V7, P111, DOI 10.1016/0955-0674(95)80052-2; Jiang W G, 1995, Eur J Surg Oncol, V21, P307, DOI 10.1016/S0748-7983(95)91690-3; Kaplan JM, 2000, NAT GENET, V24, P251, DOI 10.1038/73456; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; Kos CH, 2003, J CLIN INVEST, V111, P1683, DOI 10.1172/JCI200317988; MILLAKE DB, 1989, NUCLEIC ACIDS RES, V17, P6725, DOI 10.1093/nar/17.16.6725; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Nikolopoulos SN, 2000, ONCOGENE, V19, P380, DOI 10.1038/sj.onc.1203310; OTEY CA, 1993, J BIOL CHEM, V268, P21193; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; Robbins PF, 1996, J EXP MED, V183, P1185, DOI 10.1084/jem.183.3.1185; Spengler BA, 1997, ONCOL RES, V9, P467; TSUKITA S, 1993, J CELL BIOL, V123, P1049, DOI 10.1083/jcb.123.5.1049; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; WACHSSTOCK DH, 1987, BIOCHEM BIOPH RES CO, V146, P554, DOI 10.1016/0006-291X(87)90564-X; Wang HY, 2002, J EXP MED, V195, P1397, DOI 10.1084/jem.20020141; ZUTTER MM, 1995, P NATL ACAD SCI USA, V92, P7411, DOI 10.1073/pnas.92.16.7411	46	37	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2004	23	15					2630	2639		10.1038/sj.onc.1207347	http://dx.doi.org/10.1038/sj.onc.1207347			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	810OZ	15048094				2022-12-28	WOS:000220714900004
J	Bharadwaj, R; Yu, HT				Bharadwaj, R; Yu, HT			The spindle checkpoint, aneuploidy, and cancer	ONCOGENE			English	Review						cell cycle; the spindle; checkpoint; ubiquitination; genetic instability; kinetochore; APC/C	ANAPHASE-PROMOTING COMPLEX; AURORA-B KINASE; KINETOCHORE-MICROTUBULE ATTACHMENT; MITOTIC CHECKPOINT; ASSEMBLY CHECKPOINT; CHROMOSOME SEGREGATION; BUDDING YEAST; SACCHAROMYCES-CEREVISIAE; UNATTACHED KINETOCHORES; MAMMALIAN-CELLS	Cancer cells contain abnormal number of chromosomes ( aneuploidy), which is a prevalent form of genetic instability in human cancers. Defects in a cell cycle surveillance mechanism called the spindle checkpoint contribute to chromosome instability and aneuploidy. In response to straying chromosomes in mitosis, the spindle checkpoint inhibits the ubiquitin ligase activity of the anaphase-promoting complex or cyclosome (APC/C), thus preventing precocious chromosome segregation and ensuring the accurate partition of the genetic material. We review recent progress toward the understanding of the molecular mechanism of the spindle checkpoint and its role in guarding genome integrity at the chromosome level.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Yu, HT (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	hongtao.yu@utsouthwestern.edu	高, 雨莉/HGU-8187-2022	Yu, Hongtao/0000-0002-8861-049X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061542] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM61542] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrieu A, 2000, CELL, V102, P817, DOI 10.1016/S0092-8674(00)00070-2; Abrieu A, 2001, CELL, V106, P83, DOI 10.1016/S0092-8674(01)00410-X; Arnaoutov A, 2003, DEV CELL, V5, P99, DOI 10.1016/S1534-5807(03)00194-1; Basto R, 2000, NAT CELL BIOL, V2, P939, DOI 10.1038/35046592; Basu J, 1999, J CELL BIOL, V146, P13, DOI 10.1083/jcb.146.1.13; Biggins S, 2001, GENE DEV, V15, P3118, DOI 10.1101/gad.934801; Bolton MA, 2002, MOL BIOL CELL, V13, P3064, DOI 10.1091/mbc.E02-02-0092; Brady DM, 2000, CURR BIOL, V10, P675, DOI 10.1016/S0960-9822(00)00515-7; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chan GKT, 2000, NAT CELL BIOL, V2, P944, DOI 10.1038/35046598; Chen RH, 1998, J CELL BIOL, V143, P283, DOI 10.1083/jcb.143.2.283; Chen RH, 2002, J CELL BIOL, V158, P487, DOI 10.1083/jcb.200204048; Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242; Chung EN, 2003, NAT CELL BIOL, V5, P748, DOI 10.1038/ncb1022; Chung EN, 2002, MOL BIOL CELL, V13, P1501, DOI 10.1091/mbc.02-01-0003; Cleveland DW, 2003, CELL, V112, P407, DOI 10.1016/S0092-8674(03)00115-6; DeLuca JG, 2002, J CELL BIOL, V159, P549, DOI 10.1083/jcb.200208159; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; Dobles M, 2000, CELL, V101, P635, DOI 10.1016/S0092-8674(00)80875-2; Fang GW, 2002, MOL BIOL CELL, V13, P755, DOI 10.1091/mbc.01-09-0437; Fang GW, 1999, PHILOS T ROY SOC B, V354, P1583, DOI 10.1098/rstb.1999.0502; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Fraschini R, 2001, EMBO J, V20, P6648, DOI 10.1093/emboj/20.23.6648; Freed E, 1999, GENE DEV, V13, P2242, DOI 10.1101/gad.13.17.2242; Gorbsky GJ, 1998, J CELL BIOL, V141, P1193, DOI 10.1083/jcb.141.5.1193; Gorbsky GJ, 2001, CURR BIOL, V11, pR1001, DOI 10.1016/S0960-9822(01)00609-1; Gstaiger M, 1999, EXP CELL RES, V247, P554, DOI 10.1006/excr.1999.4386; Habu T, 2002, EMBO J, V21, P6419, DOI 10.1093/emboj/cdf659; Hardwick KC, 2000, J CELL BIOL, V148, P871, DOI 10.1083/jcb.148.5.871; Hardwick KG, 1996, SCIENCE, V273, P953, DOI 10.1126/science.273.5277.953; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092; Hilioti Z, 2001, CURR BIOL, V11, P1347, DOI 10.1016/S0960-9822(01)00399-2; Hoffman DB, 2001, MOL BIOL CELL, V12, P1995, DOI 10.1091/mbc.12.7.1995; Hori T, 2003, J CELL SCI, V116, P3347, DOI 10.1242/jcs.00645; Howell BJ, 2000, J CELL BIOL, V150, P1233, DOI 10.1083/jcb.150.6.1233; Howell BJ, 2001, J CELL BIOL, V155, P1159, DOI 10.1083/jcb.200105093; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Hoyt MA, 2001, J CELL BIOL, V154, P909, DOI 10.1083/jcb.200108010; Hwang LH, 1998, SCIENCE, V279, P1041, DOI 10.1126/science.279.5353.1041; Jablonski SA, 1998, CHROMOSOMA, V107, P386, DOI 10.1007/s004120050322; Jallepalli PV, 2001, NAT REV CANCER, V1, P109, DOI 10.1038/35101065; Jones MH, 1999, MOL BIOL CELL, V10, P2377, DOI 10.1091/mbc.10.7.2377; Kallio MJ, 2002, CURR BIOL, V12, P900, DOI 10.1016/S0960-9822(02)00887-4; Kallio MJ, 2002, J CELL BIOL, V158, P841, DOI 10.1083/jcb.200201135; Kang JS, 2001, J CELL BIOL, V155, P763, DOI 10.1083/jcb.200105029; Kapoor TM, 2000, J CELL BIOL, V150, P975, DOI 10.1083/jcb.150.5.975; Kim SH, 1998, SCIENCE, V279, P1045, DOI 10.1126/science.279.5353.1045; Kitagawa K, 2003, MOL CELL, V11, P1201, DOI 10.1016/S1097-2765(03)00145-X; Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Li Y, 1997, P NATL ACAD SCI USA, V94, P12431, DOI 10.1073/pnas.94.23.12431; Li YM, 2002, GENE DEV, V16, P183, DOI 10.1101/gad.959402; Liu ST, 2003, NAT CELL BIOL, V5, P341, DOI 10.1038/ncb953; Luo XL, 2000, NAT STRUCT BIOL, V7, P224; Luo XL, 2002, MOL CELL, V9, P59, DOI 10.1016/S1097-2765(01)00435-X; Mao YH, 2003, CELL, V114, P87, DOI 10.1016/S0092-8674(03)00475-6; Martin-Lluesma S, 2002, SCIENCE, V297, P2267, DOI 10.1126/science.1075596; McCleland ML, 2003, GENE DEV, V17, P101, DOI 10.1101/gad.1040903; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Millband DN, 2002, TRENDS CELL BIOL, V12, P205, DOI 10.1016/S0962-8924(02)02276-6; Millband DN, 2002, MOL CELL BIOL, V22, P2728, DOI 10.1128/MCB.22.8.2728-2742.2002; Murata-Hori M, 2002, CURR BIOL, V12, P894, DOI 10.1016/S0960-9822(02)00848-5; Murata-Hori M, 2002, MOL BIOL CELL, V13, P1099, DOI 10.1091/mbc.01-09-0467; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Nasmyth K, 2000, SCIENCE, V288, P1379, DOI 10.1126/science.288.5470.1379; Nasmyth K, 2002, SCIENCE, V297, P559, DOI 10.1126/science.1074757; Newman JRS, 2000, P NATL ACAD SCI USA, V97, P13203, DOI 10.1073/pnas.97.24.13203; Nicklas RB, 2001, J CELL SCI, V114, P4173; Ohshima K, 2000, CANCER LETT, V158, P141, DOI 10.1016/S0304-3835(00)00512-7; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Pfleger CM, 2001, GENE DEV, V15, P2396, DOI 10.1101/gad.918201; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; Ru HY, 2002, ONCOGENE, V21, P4673, DOI 10.1038/sj.onc.1205585; Seeley TW, 1999, BIOCHEM BIOPH RES CO, V257, P589, DOI 10.1006/bbrc.1999.0514; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Shannon KB, 2002, MOL BIOL CELL, V13, P3706, DOI 10.1091/mbc.E02-03-0137; Sironi L, 2002, EMBO J, V21, P2496, DOI 10.1093/emboj/21.10.2496; Skoufias DA, 2001, P NATL ACAD SCI USA, V98, P4492, DOI 10.1073/pnas.081076898; Stern BM, 2001, CURR BIOL, V11, P1462, DOI 10.1016/S0960-9822(01)00451-1; Stern BM, 2002, CURR BIOL, V12, pR316, DOI 10.1016/S0960-9822(02)00828-X; Stucke VM, 2002, EMBO J, V21, P1723, DOI 10.1093/emboj/21.7.1723; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Tanaka TU, 2002, CELL, V108, P317, DOI 10.1016/S0092-8674(02)00633-5; Tanaka TU, 2002, CURR OPIN CELL BIOL, V14, P365, DOI 10.1016/S0955-0674(02)00328-9; Tang ZY, 2001, DEV CELL, V1, P227, DOI 10.1016/S1534-5807(01)00019-3; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Taylor SS, 1998, J CELL BIOL, V142, P1, DOI 10.1083/jcb.142.1.1; Wang XS, 2001, J BIOL CHEM, V276, P26559, DOI 10.1074/jbc.M101083200; Warren CD, 2002, MOL BIOL CELL, V13, P3029, DOI 10.1091/mbc.E02-04-0203; Wassmann K, 2003, EMBO J, V22, P797, DOI 10.1093/emboj/cdg071; Wassmann K, 1998, P NATL ACAD SCI USA, V95, P11193, DOI 10.1073/pnas.95.19.11193; Wassmann K, 2001, CURR OPIN GENET DEV, V11, P83, DOI 10.1016/S0959-437X(00)00161-1; Waters JC, 1998, J CELL BIOL, V141, P1181, DOI 10.1083/jcb.141.5.1181; Wigge PA, 2001, J CELL BIOL, V152, P349, DOI 10.1083/jcb.152.2.349; Winey M, 2002, ONCOGENE, V21, P6161, DOI 10.1038/sj.onc.1205712; Wojcik E, 2001, NAT CELL BIOL, V3, P1001, DOI 10.1038/ncb1101-1001; Wu HY, 2000, ONCOGENE, V19, P4557, DOI 10.1038/sj.onc.1203803; Yamaguchi S, 2003, EMBO J, V22, P1075, DOI 10.1093/emboj/cdg100; Yu HG, 1999, J CELL BIOL, V145, P425, DOI 10.1083/jcb.145.3.425; Yu HT, 2002, CURR OPIN CELL BIOL, V14, P706, DOI 10.1016/S0955-0674(02)00382-4; Yu HT, 1998, SCIENCE, V279, P1219, DOI 10.1126/science.279.5354.1219; Zhang YK, 2001, MOL CELL BIOL, V21, P5190, DOI 10.1128/MCB.21.15.5190-5199.2001; Zhou J, 2002, J BIOL CHEM, V277, P17200, DOI 10.1074/jbc.M110369200; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	107	414	433	0	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2004	23	11					2016	2027		10.1038/sj.onc.1207374	http://dx.doi.org/10.1038/sj.onc.1207374			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	803EC	15021889				2022-12-28	WOS:000220213400006
J	Pan, ZQ; Kentsis, A; Dias, DC; Yamoah, K; Wu, K				Pan, ZQ; Kentsis, A; Dias, DC; Yamoah, K; Wu, K			Nedd8 on cullin: building an expressway to protein destruction	ONCOGENE			English	Review						Nedd8; ubiquitin; proteolysis; cullins; E3 ligase	ANAPHASE-PROMOTING COMPLEX; UBIQUITIN LIGASE ACTIVITY; F-BOX PROTEIN; TUMOR-SUPPRESSOR COMPLEX; CELL-CYCLE PROGRESSION; KAPPA-B-ALPHA; COP9 SIGNALOSOME; CAENORHABDITIS-ELEGANS; CONJUGATION PATHWAY; AUXIN RESPONSE	This review summarizes recent advances concerning the Nedd8 regulatory pathway in four areas. One, substantial progress has been made in delineating the role of cullin family proteins, the only known substrates of the Nedd8 modi. cation system. Cullins are molecular scaffolds responsible for assembling the ROC1/Rbx1 RING-based E3 ubiquitin ligases, of which several play a direct role in tumorigenesis. Two, a large body of work has helped elucidate the molecular details underlying the Nedd8 modi. cation reaction, which results in covalent conjugation of a Nedd8 moiety onto a conserved cullin lysine residue. Three, studies using a variety of genetic model systems have established an essential role for Nedd8 in cell cycle control and in embryogenesis by upregulating the activities of cullin-based E3 ligases. In vitro experiments have revealed a direct role for Nedd8 in activating ubiquitination. Construction of a model of the ROC1/ Rbx1-CUL1-Nedd8 structure suggests a mechanism by which the cullin-linked Nedd8 may assist the neighboring ROC1/Rbx1 in landing and positioning the E2 conjugating enzyme for the ubiquitin transfer reaction. Finally, increasing evidence indicates that removal of Nedd8 from its cullin targets, by the action of COP9 Signalosome and possibly other proteases, plays a significant role in the regulation of cullin-mediated proteolysis.	CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Pan, ZQ (corresponding author), CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA.	zhen-qiang.pan@mssm.edu		Kentsis, Alex/0000-0002-8063-9191	NATIONAL CANCER INSTITUTE [R01CA095634, R01CA088991, R01CA080728] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061051] Funding Source: NIH RePORTER; NCI NIH HHS [CA095634, CA 80728, CA 88991] Funding Source: Medline; NIGMS NIH HHS [GM61051] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arai T, 2003, P NATL ACAD SCI USA, V100, P9855, DOI 10.1073/pnas.1733908100; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Bohnsack RN, 2003, J BIOL CHEM, V278, P26823, DOI 10.1074/jbc.M303177200; Brower CS, 2002, P NATL ACAD SCI USA, V99, P10353, DOI 10.1073/pnas.162424199; Burnatowska-Hledin M, 2000, AM J PHYSIOL-CELL PH, V279, pC266, DOI 10.1152/ajpcell.2000.279.1.C266; Carroll CW, 2002, NAT CELL BIOL, V4, P880, DOI 10.1038/ncb871; Chamovitz DA, 2002, CURR BIOL, V12, pR232, DOI 10.1016/S0960-9822(02)00775-3; Chen A, 2000, J BIOL CHEM, V275, P15432, DOI 10.1074/jbc.M907300199; Chen XA, 2001, J BIOL CHEM, V276, P48175, DOI 10.1074/jbc.M106808200; Chow NW, 1996, J BIOL CHEM, V271, P11339, DOI 10.1074/jbc.271.19.11339; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; Cope GA, 2003, CELL, V114, P663, DOI 10.1016/S0092-8674(03)00722-0; Cope GA, 2002, SCIENCE, V298, P608, DOI 10.1126/science.1075901; Dealy MJ, 1999, NAT GENET, V23, P245, DOI 10.1038/13886; del Pozo JC, 2002, PLANT CELL, V14, P421, DOI 10.1105/tpc.010282; del Pozo JC, 1998, SCIENCE, V280, P1760, DOI 10.1126/science.280.5370.1760; DeRenzo C, 2003, NATURE, V424, P685, DOI 10.1038/nature01887; Dharmasiri S, 2003, EMBO J, V22, P1762, DOI 10.1093/emboj/cdg190; Dias DC, 2002, P NATL ACAD SCI USA, V99, P16601, DOI 10.1073/pnas.252646399; Doronkin S, 2003, DEV CELL, V4, P699, DOI 10.1016/S1534-5807(03)00121-7; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Feng H, 1999, NAT CELL BIOL, V1, P486, DOI 10.1038/70272; Furukawa M, 2003, NAT CELL BIOL, V5, P1001, DOI 10.1038/ncb1056; Furukawa M, 2002, J BIOL CHEM, V277, P15758, DOI 10.1074/jbc.M108565200; Furukawa M, 2000, MOL CELL BIOL, V20, P8185, DOI 10.1128/MCB.20.21.8185-8197.2000; Gan-Erdene T, 2003, J BIOL CHEM, V278, P28892, DOI 10.1074/jbc.M302890200; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Geyer R, 2003, MOL CELL, V12, P783, DOI 10.1016/S1097-2765(03)00341-1; Gong LM, 2000, J BIOL CHEM, V275, P14212, DOI 10.1074/jbc.275.19.14212; Gong LM, 1999, J BIOL CHEM, V274, P12036, DOI 10.1074/jbc.274.17.12036; Groisman R, 2003, CELL, V113, P357, DOI 10.1016/S0092-8674(03)00316-7; HANDELI S, 1992, CELL, V71, P599, DOI 10.1016/0092-8674(92)90594-3; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1998, GENE DEV, V12, P901, DOI 10.1101/gad.12.7.901; Hori T, 1999, ONCOGENE, V18, P6829, DOI 10.1038/sj.onc.1203093; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jones D, 2000, DEV BIOL, V226, P152, DOI 10.1006/dbio.2000.9847; Kamitani T, 2001, J BIOL CHEM, V276, P46655, DOI 10.1074/jbc.M108636200; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kamura T, 1999, GENE DEV, V13, P2928, DOI 10.1101/gad.13.22.2928; Kamura T, 2001, J BIOL CHEM, V276, P29748, DOI 10.1074/jbc.M103093200; Kawakami T, 2001, EMBO J, V20, P4003, DOI 10.1093/emboj/20.15.4003; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Kito K, 2001, J BIOL CHEM, V276, P20603, DOI 10.1074/jbc.M100920200; KOHRMAN DC, 1992, J VIROL, V66, P1752, DOI 10.1128/JVI.66.3.1752-1760.1992; Kominami K, 1998, EMBO J, V17, P5388, DOI 10.1093/emboj/17.18.5388; Kurz T, 2002, SCIENCE, V295, P1294, DOI 10.1126/science.1067765; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; Li BH, 2002, MOL CELL BIOL, V22, P4997, DOI 10.1128/MCB.22.14.4997-5005.2002; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Liakopoulos D, 1998, EMBO J, V17, P2208, DOI 10.1093/emboj/17.8.2208; Linghu B, 2002, EUKARYOT CELL, V1, P491, DOI 10.1128/EC.1.3.491-494.2002; Liu C, 2003, GENE DEV, V17, P1130, DOI 10.1101/gad.1090803; Liu JD, 2002, MOL CELL, V10, P1511, DOI 10.1016/S1097-2765(02)00783-9; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Lykke-Andersen K, 2003, MOL CELL BIOL, V23, P6790, DOI 10.1128/MCB.23.19.6790-6797.2003; Mendoza HM, 2003, J BIOL CHEM, V278, P25637, DOI 10.1074/jbc.M212948200; Michel JJ, 2003, J BIOL CHEM, V278, P22828, DOI 10.1074/jbc.M210358200; Min KW, 2003, J BIOL CHEM, V278, P15905, DOI 10.1074/jbc.M213070200; Morimoto M, 2000, BIOCHEM BIOPH RES CO, V270, P1093, DOI 10.1006/bbrc.2000.2576; Morimoto M, 2003, BIOCHEM BIOPH RES CO, V301, P392, DOI 10.1016/S0006-291X(02)03051-6; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Nayak S, 2002, CURR BIOL, V12, P277, DOI 10.1016/S0960-9822(02)00682-6; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; Ohh M, 2002, EMBO REP, V3, P177, DOI 10.1093/embo-reports/kvf028; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Osaka F, 2000, EMBO J, V19, P3475, DOI 10.1093/emboj/19.13.3475; Osaka F, 1998, GENE DEV, V12, P2263, DOI 10.1101/gad.12.15.2263; Oshikawa K, 2003, BIOCHEM BIOPH RES CO, V303, P1209, DOI 10.1016/S0006-291X(03)00501-1; Ou CY, 2002, GENE DEV, V16, P2403, DOI 10.1101/gad.1011402; Passmore LA, 2003, EMBO J, V22, P786, DOI 10.1093/emboj/cdg084; Patton EE, 1998, GENE DEV, V12, P692, DOI 10.1101/gad.12.5.692; PICKART CM, 1985, J BIOL CHEM, V260, P7903; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pintard L, 2003, NATURE, V425, P311, DOI 10.1038/nature01959; Pintard L, 2003, CURR BIOL, V13, P911, DOI 10.1016/S0960-9822(03)00336-1; Podust VN, 2000, P NATL ACAD SCI USA, V97, P4579, DOI 10.1073/pnas.090465597; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Read MA, 2000, MOL CELL BIOL, V20, P2326, DOI 10.1128/MCB.20.7.2326-2333.2000; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Schwechheimer C, 2001, SCIENCE, V292, P1379, DOI 10.1126/science.1059776; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Shiyanov P, 1999, J BIOL CHEM, V274, P35309, DOI 10.1074/jbc.274.50.35309; Singer JD, 1999, GENE DEV, V13, P2375, DOI 10.1101/gad.13.18.2375; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Tateishi K, 2001, J CELL BIOL, V155, P571, DOI 10.1083/jcb.200104035; Tsai SC, 2000, J BIOL CHEM, V275, P3239, DOI 10.1074/jbc.275.5.3239; Wada H, 1998, BIOCHEM BIOPH RES CO, V251, P688, DOI 10.1006/bbrc.1998.9532; Wada H, 1999, BIOCHEM BIOPH RES CO, V257, P100, DOI 10.1006/bbrc.1999.0339; Walden H, 2003, NATURE, V422, P330, DOI 10.1038/nature01456; Wang XP, 2002, MOL BIOL CELL, V13, P646, DOI 10.1091/mbc.01-08-0427; Whitby FG, 1998, J BIOL CHEM, V273, P34983, DOI 10.1074/jbc.273.52.34983; Wirbelauer C, 2000, EMBO J, V19, P5362, DOI 10.1093/emboj/19.20.5362; Wu K, 2000, J BIOL CHEM, V275, P32317, DOI 10.1074/jbc.M004847200; Wu K, 2002, J BIOL CHEM, V277, P516, DOI 10.1074/jbc.M108008200; Wu K, 2003, J BIOL CHEM, V278, P28882, DOI 10.1074/jbc.M302888200; Wu K, 2000, MOL CELL BIOL, V20, P1382, DOI 10.1128/MCB.20.4.1382-1393.2000; Xu L, 2003, NATURE, V425, P316, DOI 10.1038/nature01985; Yan J, 2003, MOL CELL BIOL, V23, P6798, DOI 10.1128/MCB.23.19.6798-6808.2003; Yang XM, 2002, CURR BIOL, V12, P667, DOI 10.1016/S0960-9822(02)00791-1; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; Yu HT, 1998, SCIENCE, V279, P1219, DOI 10.1126/science.279.5354.1219; Zachariae W, 1998, SCIENCE, V279, P1216, DOI 10.1126/science.279.5354.1216; Zhang Y, 2003, EMBO J, V22, P6057, DOI 10.1093/emboj/cdg577; Zheng JY, 2002, MOL CELL, V10, P1519, DOI 10.1016/S1097-2765(02)00784-0; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zhong WW, 2003, NATURE, V423, P885, DOI 10.1038/nature01747; Zhou CS, 2001, BMC BIOCHEM, V2, DOI 10.1186/1471-2091-2-7; Zhou CS, 2003, MOL CELL, V11, P927, DOI 10.1016/S1097-2765(03)00136-9	116	325	344	2	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 15	2004	23	11					1985	1997		10.1038/sj.onc.1207414	http://dx.doi.org/10.1038/sj.onc.1207414			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	803EC	15021886	Bronze			2022-12-28	WOS:000220213400003
J	Chendil, D; Ranga, RS; Meigooni, D; Sathishkumar, S; Ahmed, MM				Chendil, D; Ranga, RS; Meigooni, D; Sathishkumar, S; Ahmed, MM			Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3	ONCOGENE			English	Article						prostate; curcumin; radiation; TNF-alpha; NF kappa B; Bcl-2; apoptosis	NF-KAPPA-B; CHEMOPREVENTIVE AGENT; CYCLE PROGRESSION; GENE-EXPRESSION; APOPTOSIS; ACTIVATION; BCL-2; PROLIFERATION; INHIBITION; INDUCTION	Curcumin (Diferuloylmethane) is a major chemical component of turmeric (curcuma longa) and is used as a spice to give a specific flavor and yellow color in Asian food. Curcumin exhibits growth inhibitory effects in a broad range of tumors as well as in TPA-induced skin tumors in mice. This study was undertaken to investigate the radiosensitizing effects of curcumin in p53 mutant prostate cancer cell line PC-3. Compared to cells that were irradiated alone (SF2=0.635; D-0=231 cGy), curcumin at 2 and 4 muM concentrations in combination with radiation showed significant enhancement to radiation-induced clonogenic inhibition (SF2=0.224: D-0=97 cGy and SF2=0.080: D-0=38 cGy) and apoptosis. It has been reported that curcumin inhibits TNF-alpha-induced NFkappaB activity that is essential for Bcl-2 protein induction. In PC-3 cells, radiation upregulated TNF-alpha protein leading to an increase in NFkappaB activity resulting in the induction of Bcl-2 protein. However, curcumin in combination with radiation treated showed inhibition of TNF-alpha-mediated NFkappaB activity resulting in bcl-2 protein downregulation. Bax protein levels remained constant in these cells after radiation or curcumin plus radiation treatments. However, the downregulation of Bcl-2 and no changes in Bax protein levels in curcumin plus radiation-treated PC-3 cells, together, altered the Bcl2:Bax ratio and this caused the enhanced radiosensitization effect. In addition, significant activation of cytochrome c and caspase-9 and -3 were observed in curcumin plus radiation treatments. Together, these mechanisms strongly suggest that the natural compound curcumin is a potent radio-sesitizer, and it acts by overcoming the effects of radiation-induced prosurvival gene expression in prostate cancer.	Univ Kentucky, Coll Hlth Sci, Div Clin Hlth Sci, Dept Clin Sci, Lexington, KY 40536 USA; Univ Kentucky, Dept Radiat Med, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Chendil, D (corresponding author), Univ Kentucky, Coll Hlth Sci, Div Clin Hlth Sci, Dept Clin Sci, Room 209D,900 S Limestone St, Lexington, KY 40536 USA.	dchen2@uky.edu	Ahmed, Mansoor/AAK-5988-2020					Ahmed MM, 1996, J BIOL CHEM, V271, P29231, DOI 10.1074/jbc.271.46.29231; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bhaumik S, 1999, FEBS LETT, V456, P311, DOI 10.1016/S0014-5793(99)00969-2; Bierhaus A, 1997, THROMB HAEMOSTASIS, V77, P772; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; Chen H, 1999, ANTICANCER RES, V19, P3675; Chen HW, 1998, BRIT J PHARMACOL, V124, P1029, DOI 10.1038/sj.bjp.0701914; Chendil D, 2002, CANCER BIOL THER, V1, P152, DOI 10.4161/cbt.61; Cheng AL, 2001, ANTICANCER RES, V21, P2895; Dixon EP, 1997, BRAIN RES, V776, P222, DOI 10.1016/S0006-8993(97)01040-8; DONG ZG, 1995, CARCINOGENESIS, V16, P749, DOI 10.1093/carcin/16.4.749; Dorai T, 2001, PROSTATE, V47, P293, DOI 10.1002/pros.1074; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; HALLAHAN DE, 1989, P NATL ACAD SCI USA, V86, P10104, DOI 10.1073/pnas.86.24.10104; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Huang MT, 1998, CARCINOGENESIS, V19, P1697, DOI 10.1093/carcin/19.9.1697; HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292; Inayat MS, 2002, CANCER BIOL THER, V1, P539, DOI 10.4161/cbt.1.5.174; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Jee SH, 1998, J INVEST DERMATOL, V111, P656, DOI 10.1046/j.1523-1747.1998.00352.x; Jiang MC, 1996, NUTR CANCER, V26, P111, DOI 10.1080/01635589609514468; Jobin C, 1999, J IMMUNOL, V163, P3474; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Khar A, 1999, FEBS LETT, V445, P165, DOI 10.1016/S0014-5793(99)00114-3; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuo ML, 1996, BBA-MOL BASIS DIS, V1317, P95, DOI 10.1016/S0925-4439(96)00032-4; Mehta K, 1997, ANTI-CANCER DRUG, V8, P470, DOI 10.1097/00001813-199706000-00010; Mohandas K M, 1999, Indian J Gastroenterol, V18, P118; Mow BMF, 2001, CURR OPIN ONCOL, V13, P453, DOI 10.1097/00001622-200111000-00007; Mukhopadhyay A, 2001, ONCOGENE, V20, P7597, DOI 10.1038/sj.onc.1204997; Ohta T, 1997, J BIOL CHEM, V272, P23111, DOI 10.1074/jbc.272.37.23111; Piwocka K, 1999, EXP CELL RES, V249, P299, DOI 10.1006/excr.1999.4480; Plummer SM, 1999, ONCOGENE, V18, P6013, DOI 10.1038/sj.onc.1202980; RAO CV, 1995, CANCER RES, V55, P2310; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHARMA OP, 1976, BIOCHEM PHARMACOL, V25, P1811, DOI 10.1016/0006-2952(76)90421-4; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Sikora E, 1997, BIOCHEM PHARMACOL, V54, P899, DOI 10.1016/S0006-2952(97)00251-7; Singh AK, 1996, CANCER LETT, V107, P109, DOI 10.1016/0304-3835(96)04357-1; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wilkinson S, 2002, J UROLOGY, V168, P2505, DOI 10.1016/S0022-5347(05)64178-X	48	229	245	0	19	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2004	23	8					1599	1607		10.1038/sj.onc.1207284	http://dx.doi.org/10.1038/sj.onc.1207284			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778BP	14985701				2022-12-28	WOS:000189219500014
J	Karasarides, M; Chiloeches, A; Hayward, R; Niculescu-Duvaz, D; Scanlon, I; Friedlos, F; Ogilvie, L; Hedley, D; Martin, J; Marshall, CJ; Springer, CJ; Marais, R				Karasarides, M; Chiloeches, A; Hayward, R; Niculescu-Duvaz, D; Scanlon, I; Friedlos, F; Ogilvie, L; Hedley, D; Martin, J; Marshall, CJ; Springer, CJ; Marais, R			B-RAF is a therapeutic target in melanoma	ONCOGENE			English	Article						B-RAF; melanoma; RNA interference; proliferation; apoptosis; BAY43-9006	SIGNALING PATHWAY; BRAF MUTATIONS; APOPTOSIS; CANCER; ACTIVATION; GENE; INHIBITOR; NEOPLASIA; CARCINOMA; CELLS	B-RAF is a serine/threonine-specific protein kinase that is mutated in approximately 70% of human melanomas. However, the role of this signalling molecule in cancer is unclear. Here, we show that ERK is constitutively activated in melanoma cells expressing oncogenic B-RAF and that this activity is required for proliferation. B-RAF depletion by siRNA blocks ERK activity, whereas A-RAF and C-RAF depletion do not affect ERK signalling. B-RAF depletion inhibits DNA synthesis and induces apoptosis in three melanoma cell lines and we show that the RAF inhibitor BAY43-9006 also blocks ERK activity, inhibits DNA synthesis and induces cell death in these cells. BAY43-9006 targets B-RAF signalling in vivo and induces a substantial growth delay in melanoma tumour xenografts. Our data demonstrate that oncogenic B-RAF activates ERK signalling, induces proliferation and protects cells from apoptosis, demonstrating that it is an important therapeutic target and thus provides novel strategies for clinical management of melanoma and other cancers.	Inst Canc Res, Canc Res UK Ctr Cell & Mol Biol, Signal Transduct Team, London SW3 6JB, England; Inst Canc Res, Gene & Oncogene Targeting Team, Sutton SM2 5NG, Surrey, England; Inst Canc Res, Canc Res UK Ctr Cell & Mol Biol, Oncogene Team, London SW3 6JB, England	Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK; Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Marais, R (corresponding author), Inst Canc Res, Canc Res UK Ctr Cell & Mol Biol, Signal Transduct Team, 237 Fulham Rd, London SW3 6JB, England.	richard.marais@icr.ac.uk	Chiloeches, Antonio/Z-5993-2019	Antonio, Chiloeches Galvez/0000-0001-7162-330X; Marais, Richard/0000-0001-7484-4183; Springer, Caroline/0000-0002-0650-4002				Alavi A, 2003, SCIENCE, V301, P94, DOI 10.1126/science.1082015; Brose MS, 2002, CANCER RES, V62, P6997; Chiloeches A, 2001, MOL CELL BIOL, V21, P2423, DOI 10.1128/MCB.21.7.2423-2434.2001; Cohen Y, 2003, INVEST OPHTH VIS SCI, V44, P2876, DOI 10.1167/iovs.02-1329; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; Hingorani SR, 2003, CANCER RES, V63, P5198; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; Kimura ET, 2003, CANCER RES, V63, P1454; Lau QC, 1998, ONCOGENE, V16, P1899, DOI 10.1038/sj.onc.1201709; LEEVERS SJ, 1993, THESIS U LONDON LOND; Lyons JF, 2001, ENDOCR-RELAT CANCER, V8, P219, DOI 10.1677/erc.0.0080219; Mandic A, 2001, MELANOMA RES, V11, P11, DOI 10.1097/00008390-200102000-00002; Marais R, 1996, CANCER RES, V56, P4735; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Satyamoorthy K, 2003, CANCER RES, V63, P756; Singer G, 2003, J NATL CANCER I, V95, P484, DOI 10.1093/jnci/95.6.484; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Tuveson DA, 2003, CANCER CELL, V4, P95, DOI 10.1016/S1535-6108(03)00189-2; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433; Wiese S, 2001, NAT NEUROSCI, V4, P137, DOI 10.1038/83960; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293; Workman P, 1998, BRIT J CANCER, V77, P1; Yuen ST, 2002, CANCER RES, V62, P6451	29	354	378	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2004	23	37					6292	6298		10.1038/sj.onc.1207785	http://dx.doi.org/10.1038/sj.onc.1207785			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	847NC	15208680				2022-12-28	WOS:000223399000013
J	Zhang, H; Herbert, BS; Pan, KH; Shay, JW; Cohen, SN				Zhang, H; Herbert, BS; Pan, KH; Shay, JW; Cohen, SN			Disparate effects of telomere attrition on gene expression during replicative senescence of human mammary epithelial cells cultured under different conditions	ONCOGENE			English	Article						replicative senescence; telomere shortening; microarray; mammary epithelial cells; culture conditions	LIFE-SPAN; REVERSE-TRANSCRIPTASE; PREMATURE SENESCENCE; CELLULAR SENESCENCE; HUMAN FIBROBLASTS; DNA MICROARRAYS; MITOTIC CLOCK; P16(INK4A); EXTENSION; IMMORTALIZATION	Telomere shortening in populations of human mammary epithelial cells (HMECs) that survive early replicative arrest (M0) by the inactivation of p16(INK4A) during cell culture on plastic dishes leads to a state of permanent replicative arrest termed senescence. While culture of HMECs on feeder layers abrogates M0 and p16(INK4A) inactivation, progressive telomere attrition in these cells also eventually results in permanent replicative arrest. Expression of telomerase prevents both senescence on plastic (S-P) and senescence on feeder layers (S-FL) in HMECs, as it does also in cultured primary human fibroblasts. We report here that the gene expression profiles of senescence in HMECs of the same lineage maintained under different culture conditions showed surprisingly little commonality. Moreover, neither of these senescence-associated profiles in HMECs resembles the pro. le for senescence in human fibroblasts. These results indicate that senescence-associated alterations in gene expression resulting from telomere attrition are affected by culture conditions as well as by cell origins, and argue that replicative senescence at the molecular level is a diverse rather than unique cellular process.	Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA; Indiana Univ, Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA; Stanford Univ, Sch Med, Program Biomed Informat, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA	Stanford University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Indiana University System; Indiana University-Purdue University Indianapolis; Stanford University; Stanford University	Cohen, SN (corresponding author), Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA.	sncohen@stanford.edu	Shay, Jerry W/F-7878-2011		NCI NIH HHS [CA70907] Funding Source: Medline; NIA NIH HHS [AG07992] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG007992] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; CHEN Q, 1995, P NATL ACAD SCI USA, V92, P4337, DOI 10.1073/pnas.92.10.4337; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Herbert BS, 2002, ONCOGENE, V21, P7897, DOI 10.1038/sj.onc.1205902; Holt SE, 1996, NAT BIOTECHNOL, V14, P836, DOI 10.1038/nbt0796-836; Hooijberg E, 2000, J IMMUNOL, V165, P4239, DOI 10.4049/jimmunol.165.8.4239; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; Ogryzko VV, 1996, MOL CELL BIOL, V16, P5210; Pan KH, 2002, P NATL ACAD SCI USA, V99, P2118, DOI 10.1073/pnas.251687398; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; Ramirez RD, 2003, ONCOGENE, V22, P433, DOI 10.1038/sj.onc.1206046; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579; Rufer N, 2001, BLOOD, V98, P597, DOI 10.1182/blood.V98.3.597; SAGER R, 1991, ENVIRON HEALTH PERSP, V93, P59, DOI 10.2307/3431170; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Stewart SA, 2003, NAT GENET, V33, P492, DOI 10.1038/ng1127; Troyanskaya O, 2001, BIOINFORMATICS, V17, P520, DOI 10.1093/bioinformatics/17.6.520; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; VONZGLINICKI T, 1995, EXP CELL RES, V220, P186, DOI 10.1006/excr.1995.1305; Wright WE, 2002, NAT BIOTECHNOL, V20, P682, DOI 10.1038/nbt0702-682; Wright WE, 2001, CURR OPIN GENET DEV, V11, P98, DOI 10.1016/S0959-437X(00)00163-5; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; Yaswen P, 2001, J MAMMARY GLAND BIOL, V6, P223, DOI 10.1023/A:1011364925259; Zhang H, 2003, P NATL ACAD SCI USA, V100, P3251, DOI 10.1073/pnas.2627983100; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	40	19	22	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2004	23	37					6193	6198		10.1038/sj.onc.1207834	http://dx.doi.org/10.1038/sj.onc.1207834			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	847NC	15195144				2022-12-28	WOS:000223399000003
J	Foster, CS; Falconer, A; Dodson, AR; Norman, AR; Dennis, N; Fletcher, A; Southgate, C; Dowe, A; Dearnaley, D; Jhavar, S; Eeles, R; Feber, A; Cooper, CS				Foster, CS; Falconer, A; Dodson, AR; Norman, AR; Dennis, N; Fletcher, A; Southgate, C; Dowe, A; Dearnaley, D; Jhavar, S; Eeles, R; Feber, A; Cooper, CS			Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome	ONCOGENE			English	Article						E2F3 gene; prostate cancer; EZH2 gene	RENAL-CELL CARCINOMA; BLADDER-CANCER; BREAST-CANCER; GENE; PROLIFERATION; EXPRESSION; TFE3; P53; EZH2; ADENOCARCINOMAS	E2F transcription factors, including EM, directly modulate expression of EZH2. Recently, overexpression of the EZH2 gene has been implicated in the development of human prostate cancer. In tissue microrarray studies we now show that expression of high levels of nuclear E2F3 occurs in a high proportion (98/147, 67%) of human prostate cancers, but is a rare event in non-neoplastic prostatic epithelium suggesting a role for E2F3 overexpression in prostate carcinogenesis. Patients with prostate cancer exhibiting immunohistochemically detectable nuclear E2F3 expression have poorer overall survival (P=0.0022) and cause-specific survival (P=0.0047) than patients without detectable E2F3 expression. When patients are stratified according to the maximum percentage of EM-positive nuclei identified within their prostate cancers (up to 20, 21-40%, etc.), there is an increasingly significant association between E2F3 staining and risk of death both for overall survival (P=0.0014) and for cause-specific survival (P=0.0004). Multivariate analyses select E2F3 expression as an independent factor predicting overall survival (unstratified P=0.0103, stratified P=0.0086) and cause-specific survival (unstratified P=0.0288, stratified P=0.0072). When these results are considered together with published data on EZH2 and on the E2F3 control protein pRB, we conclude that the pRB-E2F3-EZH2 control axis may have a critical role in modulating aggressiveness of individual human prostate cancer.	Canc Res Inst, Sect Mol Carcinogenesis, Male Urol Canc Res Ctr, Sutton, Surrey, England; Univ Liverpool, Dept Pathol & Mol Genet, Liverpool, Merseyside, England; Canc Res Inst, Sect Canc Genet, Male Urol Canc Res Ctr, Sutton, Surrey, England; Royal Marsden NHS Trust, Sutton, Surrey, England	University of London; Institute of Cancer Research - UK; University of Liverpool; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust	Cooper, CS (corresponding author), Canc Res Inst, Sect Mol Carcinogenesis, Male Urol Canc Res Ctr, Sutton, Surrey, England.	colin.cooper@icr.ac.uk	Dearnaley, David P/J-2318-2014	Dearnaley, David P/0000-0002-3954-2806; Eeles, Rosalind/0000-0002-3698-6241; Feber, Andrew/0000-0001-5282-0498				Bostwick D G, 1999, Semin Urol Oncol, V17, P222; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; BROOKS JD, 1995, PROSTATE, V26, P35, DOI 10.1002/pros.2990260108; Chakravarti A, 2003, J CLIN ONCOL, V21, P3328, DOI 10.1200/JCO.2003.12.151; Clark J, 1997, ONCOGENE, V15, P2233, DOI 10.1038/sj.onc.1201394; CORDONCARDO C, 1994, CANCER RES, V54, P794; Cornford P, 1999, AM J PATHOL, V154, P137, DOI 10.1016/S0002-9440(10)65260-1; Cox D. R., 1984, ANAL SURVIVAL DATA; Feber A, 2004, ONCOGENE, V23, P1627, DOI 10.1038/sj.onc.1207274; Foster CS, 2000, PROSTATE, P4; Foster CS, 2000, SCAND J UROL NEPHROL, V34, P19, DOI 10.1080/003655900750169284; FOSTER CS, 2001, CURR DIAGN PATHOL, V7, P4; GAO X, 1995, ONCOGENE, V11, P1395; Giangrande PH, 2003, MOL CELL BIOL, V23, P3707, DOI 10.1128/MCB.23.11.3707-3720.2003; Greene FL, 2002, AJCC CANC STAGING HD; HEIDENBERG HB, 1995, J UROLOGY, V154, P414, DOI 10.1016/S0022-5347(01)67065-4; Huang E, 2003, NAT GENET, V34, P226, DOI 10.1038/ng1167; Humbert PO, 2000, GENE DEV, V14, P690; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kibel AS, 2000, UROLOGY, V55, P316, DOI 10.1016/S0090-4295(99)00478-1; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Konishi N, 2002, JPN J CANCER RES, V93, P767, DOI 10.1111/j.1349-7006.2002.tb01318.x; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Leite KRM, 2001, MODERN PATHOL, V14, P428, DOI 10.1038/modpathol.3880330; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Osman I, 1999, CLIN CANCER RES, V5, P2082; Shaaban AM, 2002, AM J SURG PATHOL, V26, P421, DOI 10.1097/00000478-200204000-00003; Sidhar SK, 1996, HUM MOL GENET, V5, P1333, DOI 10.1093/hmg/5.9.1333; Skalsky YM, 2001, ONCOGENE, V20, P178, DOI 10.1038/sj.onc.1204056; Sobin LH, 1997, TNM CLASSIFICATION M, P170; Theodorescu D, 1997, J UROLOGY, V158, P131, DOI 10.1097/00005392-199707000-00040; Tomovska S, 2001, INT J ONCOL, V18, P1239; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593	36	134	143	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2004	23	35					5871	5879		10.1038/sj.onc.1207800	http://dx.doi.org/10.1038/sj.onc.1207800			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15184867				2022-12-28	WOS:000222941100001
J	Armes, JE; Hammet, F; de Silva, M; Ciciulla, J; Ramus, SJ; Soo, WK; Mahoney, A; Yarovaya, N; Henderson, MA; Gish, K; Hutchins, AM; Price, GR; Venter, DJ				Armes, JE; Hammet, F; de Silva, M; Ciciulla, J; Ramus, SJ; Soo, WK; Mahoney, A; Yarovaya, N; Henderson, MA; Gish, K; Hutchins, AM; Price, GR; Venter, DJ			Candidate tumor-suppressor genes on chromosome arm 8p in early-onset and high-grade breast cancers	ONCOGENE			English	Article						breast cancer; comparative genomic hybridization; expression microarrays; tumor-suppressor genes; chromosome 8	COMPARATIVE GENOMIC HYBRIDIZATION; ACTIVATED PROTEIN-KINASE; YOUNG-WOMEN; CARCINOMA; REGION; PCM-1; RISK; POLYMORPHISMS; ABERRATIONS; APOPTOSIS	Loss of genetic material from chromosome arm 8p occurs commonly in breast carcinomas, suggesting that this region is the site of one or more tumor-suppressor genes (TSGs). Comparative genomic hybridization analysis showed that 8p loss is more common in breast cancers from pre-menopausal compared with post-menopausal patients, as well as in high-grade breast cancers, regardless of the menopausal status. Subsequent high-resolution gene expression profiling of genes mapped to chromosome arm 8p, on an extended cohort of clinical tumor samples, indicated a similar dichotomy of breast cancer clinicopathologic types. Some of these genes showed differential downregulation in early-onset and later-onset, high-grade cancers compared with lower-grade, later-onset cancers. Three such genes were analysed further by in situ technologies, performed on tissue microarrays representing breast tumor and normal tissue samples. PCM1, which encodes a centrosomal protein, and DUSP4/MKP-2, which encodes a MAP kinase phosphatase, both showed frequent gene and protein loss in carcinomas. In contrast, there was an excess of cases showing loss of expression in the absence of reduced gene copy number of SFRP1, which encodes a dominant-negative receptor for Wnt-family ligands. These candidate TSGs may constitute some of the molecular drivers of chromosome arm 8p loss in breast carcinogenesis.	St Vincents Hosp, Dept Anat Pathol, Fitzroy, Vic 3065, Australia; Victorian Breast Canc Res Consortium, Mol Pathol Lab, Melbourne, Vic, Australia; Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia; Royal Childrens Hosp, Canc Genom Lab, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia; Univ Melbourne, Peter MacCallum Canc Inst, Melbourne, Vic 3010, Australia; Univ Melbourne, Dept Surg, Melbourne, Vic 3010, Australia; Prot Design Labs, Fremont, CA 94555 USA; Womens & Childrens Hlth, Melbourne, Vic 3053, Australia	St Vincent's Hospital Melbourne; University of Melbourne; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; Peter Maccallum Cancer Center; University of Melbourne; University of Melbourne	Armes, JE (corresponding author), St Vincents Hosp, Dept Anat Pathol, Fitzroy, Vic 3065, Australia.	jane.armes@svhm.org.au	Susan, Ramus/C-1607-2008; Armes, Jane/D-6396-2012; Ramus, Susan/AAG-8352-2019; Price, Gareth/A-4832-2017	Armes, Jane/0000-0002-2215-0347; Ramus, Susan/0000-0003-0005-7798; Soo, Wee Kheng/0000-0002-5774-9800; Price, Gareth/0000-0003-2439-8650				Adelaide J, 1998, GENE CHROMOSOME CANC, V22, P186, DOI 10.1002/(SICI)1098-2264(199807)22:3<186::AID-GCC4>3.0.CO;2-S; Allen DG, 2000, BRIT J CANCER, V83, P1659, DOI 10.1054/bjoc.2000.1509; BALCZON R, 1994, J CELL BIOL, V124, P783, DOI 10.1083/jcb.124.5.783; Band PR, 2002, LANCET, V360, P1044, DOI 10.1016/S0140-6736(02)11140-8; Bouras T, 2002, CANCER RES, V62, P1289; Charafe-Jauffret E, 2002, INT J ONCOL, V21, P989; Corvi R, 2000, ONCOGENE, V19, P4236, DOI 10.1038/sj.onc.1203772; Dammermann A, 2002, J CELL BIOL, V159, P255, DOI 10.1083/jcb.200204023; Glynne R, 2000, NATURE, V403, P672, DOI 10.1038/35001102; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; Ishibe N, 1998, CANCER RES, V58, P667; Kollias J, 1997, BRIT J CANCER, V75, P1318, DOI 10.1038/bjc.1997.223; Konig JJ, 1999, UROL RES, V27, P3, DOI 10.1007/s002400050082; Kubo A, 2003, J CELL SCI, V116, P919, DOI 10.1242/jcs.00282; Lai H, 2002, CANCER BIOL THER, V1, P31, DOI 10.4161/cbt.1.1.37; Lingle WL, 1999, AM J PATHOL, V155, P1941, DOI 10.1016/S0002-9440(10)65513-7; Liu QQ, 2001, J CELL SCI, V114, P797; MARCUS JN, 1994, MONOGR NATL CANC I, V16, P23; Matsushima M, 1998, GENE CHROMOSOME CANC, V21, P230, DOI 10.1002/(SICI)1098-2264(199803)21:3<230::AID-GCC7>3.0.CO;2-0; Melkonyan HS, 1997, P NATL ACAD SCI USA, V94, P13636, DOI 10.1073/pnas.94.25.13636; RADFORD DM, 1995, CANCER RES, V55, P3399; Saito H, 1997, J BIOL CHEM, V272, P8157, DOI 10.1074/jbc.272.13.8157; Santen RJ, 2002, J STEROID BIOCHEM, V80, P239, DOI 10.1016/S0960-0760(01)00189-3; Sigbjornsdottir BI, 2000, J MED GENET, V37, P342, DOI 10.1136/jmg.37.5.342; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Thor AD, 2002, HUM PATHOL, V33, P628, DOI 10.1053/hupa.2002.124034; Ugolini F, 1999, ONCOGENE, V18, P1903, DOI 10.1038/sj.onc.1202739; Venables W., 2002, MODERN APPL STAT S, VFourth; Waite KA, 2002, AM J HUM GENET, V70, P829, DOI 10.1086/340026; Walker RA, 1996, BRIT J CANCER, V74, P1796, DOI 10.1038/bjc.1996.632; Wang HY, 2003, CANCER LETT, V191, P229, DOI 10.1016/S0304-3835(02)00612-2; Willis S, 2003, GENE CHROMOSOME CANC, V36, P382, DOI 10.1002/gcc.10138; Xiong P, 2001, CANCER RES, V61, P8465; Yokota T, 1999, CANCER-AM CANCER SOC, V85, P447; Zhou ZJ, 1998, INT J CANCER, V78, P95, DOI 10.1002/(SICI)1097-0215(19980925)78:1<95::AID-IJC15>3.0.CO;2-4	35	92	98	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5697	5702		10.1038/sj.onc.1207740	http://dx.doi.org/10.1038/sj.onc.1207740			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15184884				2022-12-28	WOS:000222629500016
J	Macdonald, M; Wan, Y; Wang, W; Roberts, E; Cheung, TH; Erickson, R; Knuesel, MT; Liu, XD				Macdonald, M; Wan, Y; Wang, W; Roberts, E; Cheung, TH; Erickson, R; Knuesel, MT; Liu, XD			Control of cell cycle-dependent degradation of c-Ski proto-oncoprotein by Cdc34	ONCOGENE			English	Article						Cdc34; Ski; SnoN; protein degradation; ubiquitin; cell cycle	TRANSFORMING-GROWTH-FACTOR; HISTONE DEACETYLASE COMPLEX; ANAPHASE-PROMOTING COMPLEX; SKELETAL-MUSCLE; INDUCED TRANSCRIPTION; UBIQUITIN LIGASE; SMAD PROTEINS; CDNA CLONES; IN-VIVO; SNON	It is known that excess amounts of Ski, or any member of its proto-oncoprotein family, causes disruption of the transforming growth factor beta signal transduction pathway, thus causing oncogenic transformation of cells. Previous studies indicate that Ski is a relatively unstable protein whose expression levels can be regulated by ubiquitin-mediated proteolysis. Here, we investigate the mechanism by which the stability of Ski is regulated. We show that the steady-state levels of Ski protein are controlled post-translationally by cell cycle-dependent proteolysis, wherein Ski is degraded during the interphase of the cell cycle but is relatively stable during mitosis. Furthermore, we demonstrate that the ubiquitin-conjugating enzyme Cdc34 mediates cell cycle-dependent Ski degradation both in vitro and in vivo. Overexpression of dominant-negative Cdc34 stabilizes Ski and enhances its ability to antagonize TGF-beta signaling. Our data suggest that regulated proteolysis of Ski is one of the key mechanisms that control the threshold levels of this proto-oncoprotein, and thus prevents epithelial cells from becoming TGF-beta resistant.	Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA; Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	University of Colorado System; University of Colorado Boulder; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Liu, XD (corresponding author), Univ Colorado, Dept Chem & Biochem, Campus Box 215, Boulder, CO 80309 USA.	xuedong.liu@colorado.edu		LIU, XUEDONG/0000-0001-7209-4964; Knuesel, Matthew/0000-0002-1441-8614	NATIONAL CANCER INSTITUTE [R01CA095527] Funding Source: NIH RePORTER; NCI NIH HHS [CA95527-01, R01 CA095527] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; AMBROSE MR, 1995, DNA CELL BIOL, V14, P701, DOI 10.1089/dna.1995.14.701; Berk M, 1997, GENE DEV, V11, P2029, DOI 10.1101/gad.11.16.2029; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; BOYER PL, 1993, ONCOGENE, V8, P457; Cohen SB, 1999, NUCLEIC ACIDS RES, V27, P1006, DOI 10.1093/nar/27.4.1006; COLMENARES C, 1991, J VIROL, V65, P4929, DOI 10.1128/JVI.65.9.4929-4935.1991; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; FUMAGALLI S, 1993, MELANOMA RES, V3, P23, DOI 10.1097/00008390-199304000-00004; GRIMES HL, 1993, ONCOGENE, V8, P2863; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HEYMAN HC, 1994, J BIOL CHEM, V269, P26996; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Jin JP, 2003, CANCER CELL, V3, P517, DOI 10.1016/S1535-6108(03)00145-4; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LI Y, 1986, J VIROL, V57, P1065, DOI 10.1128/JVI.57.3.1065-1072.1986; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Liu XD, 2000, ANAL BIOCHEM, V280, P20, DOI 10.1006/abio.2000.4478; Liu XD, 2001, CYTOKINE GROWTH F R, V12, P1, DOI 10.1016/S1359-6101(00)00031-9; Luo KX, 2003, J BONE JOINT SURG AM, V85A, P39, DOI 10.2106/00004623-200300003-00008; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Medrano EE, 2003, ONCOGENE, V22, P3123, DOI 10.1038/sj.onc.1206452; Michael WM, 1998, SCIENCE, V282, P1886, DOI 10.1126/science.282.5395.1886; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; NAGASE T, 1993, J BIOL CHEM, V268, P13710; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; Pati D, 1999, MOL CELL BIOL, V19, P5001; PEARSONWHITE S, 1993, NUCLEIC ACIDS RES, V21, P4632, DOI 10.1093/nar/21.19.4632; PearsonWhite S, 1997, NUCLEIC ACIDS RES, V25, P2930, DOI 10.1093/nar/25.14.2930; PLON SE, 1993, P NATL ACAD SCI USA, V90, P10484, DOI 10.1073/pnas.90.22.10484; Prunier C, 2003, J BIOL CHEM, V278, P26249, DOI 10.1074/jbc.M304459200; Reed JA, 2001, CANCER RES, V61, P8074; Shinagawa T, 2000, EMBO J, V19, P2280, DOI 10.1093/emboj/19.10.2280; STAVNEZER E, 1986, J VIROL, V57, P1073, DOI 10.1128/JVI.57.3.1073-1083.1986; Stroschein SL, 2001, GENE DEV, V15, P2822; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; SUTRAVE P, 1990, MOL CELL BIOL, V10, P3137, DOI 10.1128/MCB.10.6.3137; SUTRAVE P, 1990, GENE DEV, V4, P1462, DOI 10.1101/gad.4.9.1462; Sutrave P, 2000, GENE, V241, P107, DOI 10.1016/S0378-1119(99)00461-8; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Wan Y, 2001, MOL CELL, V8, P1027, DOI 10.1016/S1097-2765(01)00382-3; Wu JW, 2002, CELL, V111, P357, DOI 10.1016/S0092-8674(02)01006-1; Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797; Yew PR, 1997, SCIENCE, V277, P1672, DOI 10.1126/science.277.5332.1672; Zhang F, 2003, CANCER RES, V63, P5005; Zheng GX, 1997, J BIOL CHEM, V272, P31855, DOI 10.1074/jbc.272.50.31855	50	22	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5643	5653		10.1038/sj.onc.1207733	http://dx.doi.org/10.1038/sj.onc.1207733			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15122324				2022-12-28	WOS:000222629500009
J	Meyer, RD; Singh, A; Majnoun, F; Latz, C; Lashkari, K; Rahimi, N				Meyer, RD; Singh, A; Majnoun, F; Latz, C; Lashkari, K; Rahimi, N			Substitution of C-terminus of VEGFR-2 with VEGFR-1 promotes VEGFR-1 activation and endothelial cell proliferation	ONCOGENE			English	Article						VEGFR-1; VEGFR-2; angiogenesis; tyrosine kinase activation; tyrosine phosphorylation; endothelial cells	GROWTH-FACTOR RECEPTOR; TYROSINE KINASE; SIGNAL-TRANSDUCTION; CARBOXYL-TERMINUS; FLT-1 VEGFR-1; KDR; DOMAIN; PHOSPHORYLATION; ANGIOGENESIS; NEUROPILIN-1	VEGFR-1 is devoid of ligand-dependent tyrosine autophosphorylation and its activation is not associated with proliferation of endothelial cells. The molecular mechanism responsible for this characteristic of VEGFR-1 is not known. In this study, we show that VEGFR-1 is devoid of ligand-dependent downregulation and failed to stimulate intracellular calcium release, cell migration and angiogenesis in vitro. To understand the molecular mechanisms responsible for the poor tyrosine autophosphorylation of VEGFR-1, we have either deleted the carboxyl terminus of VEGFR-1 or exchanged it with the carboxyl terminus of VEGFR-2. The deletion of carboxyl terminus of VEGFR-1 did not reverse its defective ligand-dependent autophosphorylation. The carboxyl terminus-swapped VEGFR-1, however, displayed ligand-dependent autophosphorylation, downregulation and also conveyed strong mitogenic responses. Thus, the carboxyl tail of VEGFR-1 restrains the ligand-dependent kinase activation and. downregulation of VEGFR-1 and its ability to convey the angiogenic responses in endothelial cells.	Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Harvard Univ, Sch Med, Dept Ophthalmol, Schepens Eye Res Inst, Boston, MA 02114 USA	Boston University; Boston University; Harvard University; Harvard Medical School; Schepens Eye Research Institute	Rahimi, N (corresponding author), Boston Univ, Sch Med, Dept Ophthalmol, 715 Albany St,Room 921L, Boston, MA 02118 USA.	nrahimi@bu.edu	Latz, Catharina/AAM-9079-2020	Rahimi, Nader/0000-0002-6745-1725; Lashkari, Kameran/0000-0003-3855-0246	NATIONAL EYE INSTITUTE [R01EY012997, R03EY013706] Funding Source: NIH RePORTER; NEI NIH HHS [R03 EY013706, EY 0137061, EY 012997, R01 EY012997] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALIMANDI M, 1995, ONCOGENE, V10, P1813; Athanassiades A, 1998, PLACENTA, V19, P465, DOI 10.1016/S0143-4004(98)91039-6; Autiero M, 2003, NAT MED, V9, P936, DOI 10.1038/nm884; Breier G, 2000, ADV EXP MED BIOL, V476, P57; CHOU YH, 1991, P NATL ACAD SCI USA, V88, P4897, DOI 10.1073/pnas.88.11.4897; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fong GH, 1999, DEVELOPMENT, V126, P3015; Gille H, 2001, J BIOL CHEM, V276, P3222, DOI 10.1074/jbc.M002016200; Gille H, 2000, EMBO J, V19, P4064, DOI 10.1093/emboj/19.15.4064; Gruenberg J, 2001, NAT REV MOL CELL BIO, V2, P721, DOI 10.1038/35096054; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; Kanno S, 2000, ONCOGENE, V19, P2138, DOI 10.1038/sj.onc.1203533; Kearney JB, 2002, BLOOD, V99, P2397, DOI 10.1182/blood.V99.7.2397; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Klepeis VE, 2001, J CELL SCI, V114, P4185; Korff T, 1999, J CELL SCI, V112, P3249; Lee P, 2002, P NATL ACAD SCI USA, V99, P10470, DOI 10.1073/pnas.162366299; LI W, 1991, CELL REGUL, V2, P641, DOI 10.1091/mbc.2.8.641; Mashiba S, 1999, BIOCHEM BIOPH RES CO, V258, P674, DOI 10.1006/bbrc.1999.0611; Meyer RD, 2004, J BIOL CHEM, V279, P735, DOI 10.1074/jbc.M305575200; Meyer RD, 2003, J BIOL CHEM, V278, P16347, DOI 10.1074/jbc.M300259200; Meyer RD, 2002, J BIOL CHEM, V277, P27081, DOI 10.1074/jbc.M110544200; MOSSIE K, 1995, ONCOGENE, V11, P2179; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Neufeld G, 1996, CANCER METAST REV, V15, P153, DOI 10.1007/BF00437467; Niu XL, 2002, J BIOL CHEM, V277, P31768, DOI 10.1074/jbc.M203995200; Parks AL, 2000, DEVELOPMENT, V127, P1373; Rahimi N, 2000, J BIOL CHEM, V275, P16986, DOI 10.1074/jbc.M000528200; SEEDORF K, 1992, MOL CELL BIOL, V12, P4347, DOI 10.1128/MCB.12.10.4347; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shibuya M, 2001, CELL STRUCT FUNCT, V26, P25, DOI 10.1247/csf.26.25; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Suarez S, 2001, J CELL SCI, V114, P1229; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WALTON GM, 1990, J BIOL CHEM, V265, P1750; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Zeng HY, 2003, J BIOL CHEM, V278, P20738, DOI 10.1074/jbc.M209712200	45	25	25	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2004	23	32					5523	5531		10.1038/sj.onc.1207712	http://dx.doi.org/10.1038/sj.onc.1207712			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15107818	Green Accepted			2022-12-28	WOS:000222588400012
J	Schmidt-Hansen, B; Ornas, D; Grigorian, M; Klingelhofer, J; Tulchinsky, E; Lukanidin, E; Ambartsumian, N				Schmidt-Hansen, B; Ornas, D; Grigorian, M; Klingelhofer, J; Tulchinsky, E; Lukanidin, E; Ambartsumian, N			Extracellular S100A4(mts1) stimulates invasive growth of mouse endothelial cells and modulates MMP-13 matrix metalloproteinase activity	ONCOGENE			English	Article						metastasis-promoting; S100A4; extracellular; activity; MMP-13 induction; angiogenesis	METASTASIS-ASSOCIATED PROTEIN; FACTOR-KAPPA-B; TUMOR-CELLS; IN-VITRO; DIFFERENTIAL REGULATION; PLASMINOGEN-ACTIVATOR; COLLAGENASE-3 MMP-13; PROGNOSTIC MARKERS; SIGNALING PATHWAYS; OSTEOSARCOMA CELLS	S100A4(mts1) protein expression has been strongly associated with metastatic tumor progression. It has been suggested as a prognostic marker for a number of human cancers. It is proposed that extracellular S100A4 accelerates cancer progression by stimulating the motility of endothelial cells, thereby promoting angiogenesis. Here we show that in 3D culture mouse endothelial cells (SVEC 4-10) respond to recombinant S100A4 by stimulating invasive growth of capillary-like structures. The outgrowth is not dependent on the stimulation of cell proliferation, but rather correlates with the transcriptional modulation of genes involved in the proteolytic degradation of extracellular matrix (ECM). Treatment of SVEC 4-10 with the S100A4 protein leads to the transcriptional activation of collagenase 3 (MMP-13) mRNA followed by subsequent release of the protein from the cells. beta-Casein zymography demonstrates enhancement of proteolytic activity associated with MMP-13. This observation indicates that extracellular S100A4 stimulates the production of ECM degrading enzymes from endothelial cells, thereby stimulating the remodeling of ECM. This could explain the angiogenic and metastasis-stimulating activity of S100A4(mts1).	Danish Canc Soc, Dept Mol Canc Biol, Inst Canc Biol, DK-2100 Copenhagen, Denmark; Univ Leicester, Dept Canc Studies & Mol Med, Leicester LE 7LX, Leics, England	Danish Cancer Society; University of Leicester	Ambartsumian, N (corresponding author), Danish Canc Soc, Dept Mol Canc Biol, Inst Canc Biol, Strand Blvd 49, DK-2100 Copenhagen, Denmark.	na@cancer.dk	Tulchinsky, Eugene/ABD-7070-2021; Klingelhöfer, Jörg/C-1676-2013					Airola K, 1997, J INVEST DERMATOL, V109, P225, DOI 10.1111/1523-1747.ep12319441; Ambartsumian N, 2001, ONCOGENE, V20, P4685, DOI 10.1038/sj.onc.1204636; AMBARTSUMIAN N, IN PRESS CELL BIOL L; Ambartsumian NS, 1996, ONCOGENE, V13, P1621; Andersen K, 1998, ANTICANCER RES, V18, P3299; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Belot N, 2002, BBA-PROTEINS PROTEOM, V1600, P74, DOI 10.1016/S1570-9639(02)00447-8; Bjornland K, 2001, J PEDIATR SURG, V36, P1040, DOI 10.1053/jpsu.2001.24735; Bjornland K, 1999, CANCER RES, V59, P4702; Bond M, 2001, CARDIOVASC RES, V50, P556, DOI 10.1016/S0008-6363(01)00220-6; BRAUNHUT SJ, 1994, J BIOL CHEM, V269, P13472; Cazorla M, 1998, J PATHOL, V186, P144, DOI 10.1002/(SICI)1096-9896(1998100)186:2<144::AID-PATH147>3.0.CO;2-#; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Davies BR, 2002, J PATHOL, V196, P292, DOI 10.1002/path.1051; Davies MPA, 1996, ONCOGENE, V13, P1631; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Donato R, 2003, MICROSC RES TECHNIQ, V60, P540, DOI 10.1002/jemt.10296; Duarte WR, 2003, J BONE MINER RES, V18, P493, DOI 10.1359/jbmr.2003.18.3.493; Duffy MJ, 2000, BREAST CANCER RES, V2, P252, DOI 10.1186/bcr65; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; Endo H, 2002, J BIOL CHEM, V277, P26396, DOI 10.1074/jbc.M202244200; FERNANDEZRESA P, 1995, ANAL BIOCHEM, V224, P434, DOI 10.1006/abio.1995.1063; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FORD HL, 1995, ONCOGENE, V10, P1597; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; Grigorian M, 1996, INT J CANCER, V67, P831, DOI 10.1002/(SICI)1097-0215(19960917)67:6<831::AID-IJC13>3.0.CO;2-4; Grigorian M, 2001, J BIOL CHEM, V276, P22699, DOI 10.1074/jbc.M010231200; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hattori Y, 2003, EXP MOL PATHOL, V74, P230, DOI 10.1016/S0014-4800(03)00014-5; Heikkila P, 2002, ANTI-CANCER DRUG, V13, P245, DOI 10.1097/00001813-200203000-00006; Heizmann CW, 2002, FRONT BIOSCI-LANDMRK, V7, pD1356, DOI 10.2741/heizmann; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; Johansson N, 1999, AM J PATHOL, V154, P469, DOI 10.1016/S0002-9440(10)65293-5; Johansson N, 1997, AM J PATHOL, V151, P499; Kim HG, 2000, BIOCHEM BIOPH RES CO, V269, P401; Kriajevska M, 1998, J BIOL CHEM, V273, P9852, DOI 10.1074/jbc.273.16.9852; Kriajevska M, 2002, J BIOL CHEM, V277, P5229, DOI 10.1074/jbc.M110976200; KRIAJEVSKA MV, 1994, J BIOL CHEM, V269, P19679; Lemaitre V, 1997, BIOCHEM BIOPH RES CO, V230, P202, DOI 10.1006/bbrc.1996.5924; Lloyd BH, 1998, ONCOGENE, V17, P465, DOI 10.1038/sj.onc.1201948; Maelandsmo GM, 1996, CANCER RES, V56, P5490; Mengshol JA, 2000, ARTHRITIS RHEUM, V43, P801, DOI 10.1002/1529-0131(200004)43:4<801::AID-ANR10>3.0.CO;2-4; Mikkelsen SE, 2001, J NEUROCHEM, V79, P767, DOI 10.1046/j.1471-4159.2001.00605.x; Novitskaya V, 2000, J BIOL CHEM, V275, P41278, DOI 10.1074/jbc.M007058200; OCONNELL KA, 1990, J IMMUNOL, V144, P521; Peeters-Joris C, 1998, BBA-MOL CELL RES, V1405, P14, DOI 10.1016/S0167-4889(98)00094-9; Pepper MS, 2001, ARTERIOSCL THROM VAS, V21, P1104, DOI 10.1161/hq0701.093685; Philip S, 2003, J BIOL CHEM, V278, P14487, DOI 10.1074/jbc.M207309200; Platt-Higgins AM, 2000, INT J CANCER, V89, P198, DOI 10.1002/(SICI)1097-0215(20000320)89:2<198::AID-IJC16>3.0.CO;2-L; Qian XH, 1997, EXP CELL RES, V235, P403, DOI 10.1006/excr.1997.3681; Rosty C, 2002, AM J PATHOL, V160, P45, DOI 10.1016/S0002-9440(10)64347-7; Stamenkovic I, 2000, SEMIN CANCER BIOL, V10, P415, DOI 10.1006/scbi.2000.0379; Takenaga K, 1997, ONCOGENE, V14, P331, DOI 10.1038/sj.onc.1200820; Tulchinsky E, 1997, J BIOL CHEM, V272, P4828, DOI 10.1074/jbc.272.8.4828; Uozumi M, 2000, CANCER LETT, V149, P135, DOI 10.1016/S0304-3835(99)00352-3; Vallone D, 1997, EMBO J, V16, P5310, DOI 10.1093/emboj/16.17.5310; Vihinen P, 2002, INT J CANCER, V99, P157, DOI 10.1002/ijc.10329; Vincenti MP, 2002, ARTHRITIS RES, V4, P157, DOI 10.1186/ar401; Wang H, 2000, BIOCHEM BIOPH RES CO, V272, P900, DOI 10.1006/bbrc.2000.2852; Wilasrusmee C, 2002, J SURG RES, V104, P131, DOI 10.1006/jsre.2002.6429; Yeow KM, 2002, MATRIX BIOL, V21, P75, DOI 10.1016/S0945-053X(01)00180-9; Yonemura Y, 2000, CLIN CANCER RES, V6, P4234; Yu WH, 2001, ANAL BIOCHEM, V293, P38, DOI 10.1006/abio.2001.5099; Zaragoza C, 2002, KIDNEY INT, V61, P804, DOI 10.1046/j.1523-1755.2002.00224.x; Zaragoza C, 2002, MOL PHARMACOL, V62, P927, DOI 10.1124/mol.62.4.927	66	171	181	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2004	23	32					5487	5495		10.1038/sj.onc.1207720	http://dx.doi.org/10.1038/sj.onc.1207720			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15122322				2022-12-28	WOS:000222588400008
J	Honda, K; Yamada, T; Seike, M; Hayashida, Y; Idogawa, M; Kondo, T; Ino, Y; Hirohashi, S				Honda, K; Yamada, T; Seike, M; Hayashida, Y; Idogawa, M; Kondo, T; Ino, Y; Hirohashi, S			Alternative splice variant of actinin-4 in small cell lung cancer	ONCOGENE			English	Article						actin; actinin-4; alternative splicing; cancer-testis antigen; small-cell lung cancer	ALPHA-ACTININ-4; ACTN4	Tumor-associated alternative RNA splicing has gained considerable attention. We identified a novel alternative splice variant RNA of actinin-4 in human small cell lung caner (SCLC). Expression of the splice variant was highly specific to SCLC cell lines (10/10), biopsies (3/3), and testis. The variant encoded a peptide with a three amino-acid change in exon 8, where the germline missense mutation takes place in familial focal segmental glomerulosclerosis (FSGS). The variant protein showed high affinity to filamentous actin polymers and was not localized with cortical actin. Alternatively spliced actinin-4 may be a new diagnostic marker of SCLC and a candidate target for selective therapy.	Natl Canc Ctr, Res Inst, Canc Proteom Project, Chuo Ku, Tokyo 1040045, Japan	National Cancer Center - Japan	Yamada, T (corresponding author), Natl Canc Ctr, Res Inst, Canc Proteom Project, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	tyamada@gan2.res.ncc.go.jp	Idogawa, Masashi/B-5208-2008; Kondo, Tadashi/I-4819-2019	Idogawa, Masashi/0000-0002-8507-1726; Kondo, Tadashi/0000-0001-6405-7792				Araki N, 2000, J CELL SCI, V113, P3329; Arora VK, 2003, ACTA CYTOL, V47, P216, DOI 10.1159/000326507; Behrens J, 1992, Semin Cell Biol, V3, P169; CARNEY DN, 1985, SEMIN ONCOL, V12, P289; Djinovic-Carugo K, 2002, FEBS LETT, V513, P119, DOI 10.1016/S0014-5793(01)03304-X; dos Santos NR, 2000, CANCER RES, V60, P1654; Echchakir H, 2001, CANCER RES, V61, P4078; Hirohashi S, 2003, CANCER SCI, V94, P575, DOI 10.1111/j.1349-7006.2003.tb01485.x; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; Jager E, 1999, CANCER METAST REV, V18, P143, DOI 10.1023/A:1006220707618; Kaplan JM, 2000, NAT GENET, V24, P251, DOI 10.1038/73456; Levi F, 1996, EUR J CANCER, V32A, P652, DOI 10.1016/0959-8049(95)00582-X; Michaud JL, 2003, J AM SOC NEPHROL, V14, P1200, DOI 10.1097/01.ASN.0000059864.88610.5E; Nikolopoulos SN, 2000, ONCOGENE, V19, P380, DOI 10.1038/sj.onc.1203310; SHIMOSATO Y, 1986, CANCER LETT, V33, P241, DOI 10.1016/0304-3835(86)90064-9; Small JV, 1999, CURR OPIN CELL BIOL, V11, P54, DOI 10.1016/S0955-0674(99)80007-6	16	46	51	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2004	23	30					5257	5262		10.1038/sj.onc.1207652	http://dx.doi.org/10.1038/sj.onc.1207652			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	834AE	15122314				2022-12-28	WOS:000222382500015
J	Lakka, SS; Gondi, CS; Yanamandra, N; Olivero, WC; Dinh, DH; Gujrati, M; Rao, JS				Lakka, SS; Gondi, CS; Yanamandra, N; Olivero, WC; Dinh, DH; Gujrati, M; Rao, JS			Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis	ONCOGENE			English	Article						siRNA; proteases; glioma; invasion; angiogenesis	HUMAN BRAIN-TUMORS; IN-VITRO; MATRIX METALLOPROTEINASES; IV COLLAGENASE; ANTISENSE OLIGONUCLEOTIDES; BASEMENT-MEMBRANE; MAMMALIAN-CELLS; PLASMA-MEMBRANE; MESSENGER-RNA; MATRIX-METALLOPROTEINASE-9	Extracellular proteases have been shown to cooperatively influence matrix degradation and tumor cell invasion through proteolytic cascades, with individual proteases having distinct roles in tumor growth, invasion, migration and angiogenesis. Matrix metalloproteases (MMP)-9 and cathepsin B have been shown to participate in the processes of tumor growth, vascularization and invasion of gliomas. In the present study, we used a cytomegalovirus promoter-driven DNA template approach to induce hairpin RNA (hpRNA)-triggered RNA interference (RNAi) to block MMP-9 and cathepsin B gene expression with a single construct. Transfection of a plasmid vector-expressing double-stranded RNA (dsRNA) for MMP-9 and cathepsin B significantly inhibited MMP-9 and cathepsin B expression and reduced the invasive behavior of SNB19, glioblastoma cell line in Matrigel and spheroid invasion models. Downregulation of MMP-9 and cathepsin B using RNAi in SNB19 cells reduced cell-cell interaction of human microvascular endothelial cells, resulting in the disruption of capillary network formation in both in vitro and in vivo models. Direct intratumoral injections of plasmid DNA expressing hpRNA for MMP-9 and cathepsin B significantly inhibited established glioma tumor growth and invasion in intracranial tumors in vivo. Further intraperitoneal (ip) injections of plasmid DNA expressing hpRNA for MMP-9 and cathepsin B completely regressed pre-established tumors for a long time (4 months) without any indication of these tumor cells. For the first time, these observations demonstrate that the simultaneous RNAi-mediated targeting of MMP-9 and cathepsin B has potential application for the treatment of human gliomas.	Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Program Canc Biol, Peoria, IL 61656 USA; Univ Illinois, Dept Neurosurg, Peoria, IL USA; Univ Illinois, Dept Pathol, Peoria, IL USA	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria	Rao, JS (corresponding author), Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Program Canc Biol, Box 1649, Peoria, IL 61656 USA.	jsrao@uic.edu		Gondi, Christopher/0000-0002-3036-9920	NATIONAL CANCER INSTITUTE [R01CA085216, R01CA075557] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047699] Funding Source: NIH RePORTER; NCI NIH HHS [CA 75557, CA 85216] Funding Source: Medline; NINDS NIH HHS [NS47699] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arkona C, 1996, BIOL CHEM, V377, P695, DOI 10.1515/bchm3.1996.377.11.695; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Bertrand JR, 2002, BIOCHEM BIOPH RES CO, V296, P1000, DOI 10.1016/S0006-291X(02)02013-2; Bervar A, 2003, BIOL CHEM, V384, P447, DOI 10.1515/BC.2003.050; Boike G, 1992, Melanoma Res, V1, P333, DOI 10.1097/00008390-199201000-00004; Chandrasekar N, 2000, CLIN EXP METASTAS, V18, P337, DOI 10.1023/A:1010833730407; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; EMMERTBUCK MR, 1994, AM J PATHOL, V145, P1285; Go Y, 1997, CLIN EXP METASTAS, V15, P440, DOI 10.1023/A:1018410523635; GUINEC N, 1993, BIOL CHEM H-S, V374, P1135, DOI 10.1515/bchm3.1993.374.7-12.1135; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; HIMELSTEIN BP, 1994, INVAS METAST, V14, P246; Hua J, 1996, CANCER RES, V56, P5279; Itoh T, 1999, CLIN EXP METASTAS, V17, P177, DOI 10.1023/A:1006603723759; Jen KY, 2000, STEM CELLS, V18, P307, DOI 10.1634/stemcells.18-5-307; Kachra Z, 1999, CLIN EXP METASTAS, V17, P555, DOI 10.1023/A:1006760632766; KOBAYASHI H, 1992, CANCER RES, V52, P3610; KOBAYASHI H, 1993, BIOCHIM BIOPHYS ACTA, V1178, P55, DOI 10.1016/0167-4889(93)90109-3; Kondraganti S, 2000, CANCER RES, V60, P6851; Konduri SD, 2001, ONCOGENE, V20, P6938, DOI 10.1038/sj.onc.1204847; Lakka SS, 2002, ONCOGENE, V21, P8011, DOI 10.1038/sj.onc.1205894; Lakka SS, 2000, CLIN EXP METASTAS, V18, P245, DOI 10.1023/A:1006724826083; LEUNIG M, 1992, CANCER RES, V52, P6553; Lewis DL, 2002, NAT GENET, V32, P107, DOI 10.1038/ng944; LIOTTA LA, 1986, ANNU REV BIOCHEM, V55, P1037, DOI 10.1146/annurev.biochem.55.1.1037; Mai JX, 2002, BIOL CHEM, V383, P1407, DOI 10.1515/BC.2002.159; McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a; Miyagishi M, 2003, ANTISENSE NUCLEIC A, V13, P1, DOI 10.1089/108729003764097296; Mohanam S, 2001, ONCOGENE, V20, P3665, DOI 10.1038/sj.onc.1204480; Pozzi A, 2002, ONCOGENE, V21, P272, DOI 10.1038/sj.onc.1205045; Premzl A, 2003, EXP CELL RES, V283, P206, DOI 10.1016/S0014-4827(02)00055-1; Raithatha SA, 2000, NEURO-ONCOLOGY, V2, P145, DOI 10.1093/neuonc/2.3.145; RAO JS, 1993, CANCER RES, V53, P2208; REDWOOD SM, 1992, CANCER, V69, P1212; Rooprai HK, 1998, INT J ONCOL, V13, P1153; Simon C, 1998, CANCER RES, V58, P1135; SLOANE BF, 1986, P NATL ACAD SCI USA, V83, P2483, DOI 10.1073/pnas.83.8.2483; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Zamore PD, 2001, NAT STRUCT BIOL, V8, P746, DOI 10.1038/nsb0901-746	43	245	276	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2004	23	27					4681	4689		10.1038/sj.onc.1207616	http://dx.doi.org/10.1038/sj.onc.1207616			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZX	15122332				2022-12-28	WOS:000221799200004
J	Dong, ZZ; Liu, LH; Han, BG; Pincheira, R; Zhang, JT				Dong, ZZ; Liu, LH; Han, BG; Pincheira, R; Zhang, JT			Role of eIF3 p170 in controlling synthesis of ribonucleotide reductase M2 and cell growth	ONCOGENE			English	Article						eIF3; anchorage-independent cell growth; p170; ribonucleotide reductase; translation initiation factor; antisense cDNA	MALIGNANT-TRANSFORMATION; PROTEIN-SYNTHESIS; GENE-EXPRESSION; MESSENGER-RNA; SUBUNIT; TRANSLATION; CYCLE; R2; OVEREXPRESSION; PROLIFERATION	Translation initiation in eukaryotes is a rate-limiting step in protein synthesis. It is a complicated process that involves many eukaryotic initiation factors (eIFs). Altering the expression level or the function of eIFs may influence the synthesis of some proteins and consequently cause abnormal cell growth and malignant transformation. P170, the largest putative subunit of eIF3, has been found elevated in human breast, cervical, esophageal, and lung cancers, suggesting that p170 may have a potential role in malignant transformation and/or cell growth control. Our recent studies suggested that p170 is likely a translational regulator and it may mediate the effect of mimosine on the translation of a subset mRNAs. Mimosine, a plant nonprotein amino acid, inhibits mammalian DNA synthesis, an essential event of cell growth. The rate-limiting step in DNA synthesis is the conversion of the ribonucleotides to their corresponding deoxyribonucleotides catalysed by ribonucleotide reductase of which the activity is regulated by the level of its M2 subunit. It has been reported that inhibiting the activity of M2 also inhibits cell growth. To understand the relationship between protein and DNA synthesis and between p170 and cell growth control, we investigated in this study whether p170 regulates the synthesis of M2 and, thus, cell growth. We found that altering the expression level of p170 changes the synthesis rate of both M2 and DNA. Decreasing p170 expression in human lung cancer cell line H1299 and breast cancer cell line MCF7 significantly reversed their malignant growth phenotype. However, the overall [S-35] methionine incorporation following dramatic decrease in p170 expression was only similar to25% less than the control cells. These observations, together with our previous findings, suggest that p170 may regulate the translation of a subset mRNAs and its elevated expression level may be important for cancer cell growth and for maintaining their malignant phenotype.	Indiana Univ, Sch Med,Ctr Canc, Dept Pharmacol & Toxicol, Walther Oncol Ctr,Walther Canc Inst, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Zhang, JT (corresponding author), Indiana Univ, Sch Med,Ctr Canc, Dept Pharmacol & Toxicol, Walther Oncol Ctr,Walther Canc Inst, 1044 W Walnut St,R4-166, Indianapolis, IN 46202 USA.	jianzhan@iupui.edu	Zhang, Jian-Ting/L-8334-2015	Pincheira, Roxana/0000-0003-4277-5245	NCI NIH HHS [CA64539, CA94961] Funding Source: Medline; NIGMS NIH HHS [GM59475] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA094961, R01CA064539, R29CA064539] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059475] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abid MR, 1999, J BIOL CHEM, V274, P35991, DOI 10.1074/jbc.274.50.35991; AMARA FM, 1994, J BIOL CHEM, V269, P6709; Andrus L, 1998, BIOCHEM PHARMACOL, V55, P1807, DOI 10.1016/S0006-2952(98)00053-7; Bachmann F, 1997, CANCER RES, V57, P988; BENNE R, 1976, P NATL ACAD SCI USA, V73, P3005, DOI 10.1073/pnas.73.9.3005; BJORKLUND S, 1992, EMBO J, V11, P4953, DOI 10.1002/j.1460-2075.1992.tb05602.x; BJORKLUND S, 1990, BIOCHEMISTRY-US, V29, P5452; Block KL, 1998, J BIOL CHEM, V273, P31901, DOI 10.1074/jbc.273.48.31901; Buratti E, 1998, NUCLEIC ACIDS RES, V26, P3179, DOI 10.1093/nar/26.13.3179; Chaudhuri J, 1997, J BIOL CHEM, V272, P30975, DOI 10.1074/jbc.272.49.30975; Chen GP, 1999, INT J CANCER, V84, P95, DOI 10.1002/(SICI)1097-0215(19990420)84:2<95::AID-IJC1>3.0.CO;2-N; Chen SY, 2000, ANTISENSE NUCLEIC A, V10, P111, DOI 10.1089/oli.1.2000.10.111; De Benedetti A, 1999, INT J BIOCHEM CELL B, V31, P59, DOI 10.1016/S1357-2725(98)00132-0; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; Dellas A, 1998, CANCER, V83, P1376, DOI 10.1002/(SICI)1097-0142(19981001)83:7<1376::AID-CNCR15>3.0.CO;2-1; Dong ZZ, 1998, AM J PHYSIOL-GASTR L, V274, pG535, DOI 10.1152/ajpgi.1998.274.3.G535; Dong ZZ, 2003, MOL BIOL CELL, V14, P3942, DOI 10.1091/mbc.E02-12-0784; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; ENGSTROM Y, 1985, J BIOL CHEM, V260, P9114; ERIKSSON S, 1984, J BIOL CHEM, V259, P1695; Fan HZ, 1996, P NATL ACAD SCI USA, V93, P14036, DOI 10.1073/pnas.93.24.14036; Fernandez J, 2002, J BIOL CHEM, V277, P2050, DOI 10.1074/jbc.M109199200; FukuchiShimogori T, 1997, CANCER RES, V57, P5041; GILBERT DM, 1995, J BIOL CHEM, V270, P9597, DOI 10.1074/jbc.270.16.9597; Han BG, 2002, MOL CELL BIOL, V22, P7372, DOI 10.1128/MCB.22.21.7372-7384.2002; HANAUSKEABEL HM, 1994, BBA-MOL CELL RES, V1221, P115, DOI 10.1016/0167-4889(94)90003-5; HANAUSKEABEL HM, 1995, FEBS LETT, V366, P92, DOI 10.1016/0014-5793(95)00493-S; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P637; HURTA RAR, 1995, J CELL BIOCHEM, V57, P543, DOI 10.1002/jcb.240570319; JIANG W, 1993, ONCOGENE, V8, P3447; Kalejta RF, 1997, EXP CELL RES, V231, P173, DOI 10.1006/excr.1996.3444; KANG HA, 1994, J BIOL CHEM, V269, P3934; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Lee Y, 2003, CANCER RES, V63, P2802; Li Q, 1998, TOXICOL APPL PHARM, V150, P154, DOI 10.1006/taap.1998.8394; Manjeshwar S, 1999, MOL CARCINOGEN, V24, P188, DOI 10.1002/(SICI)1098-2744(199903)24:3<188::AID-MC5>3.0.CO;2-#; MANN GJ, 1988, CANCER RES, V48, P5151; Mayeur GL, 2002, FEBS LETT, V514, P49, DOI 10.1016/S0014-5793(02)02307-4; Methot N, 1996, MOL CELL BIOL, V16, P5328; Methot N, 1997, J BIOL CHEM, V272, P1110, DOI 10.1074/jbc.272.2.1110; Park JB, 2000, BIOCHEM BIOPH RES CO, V267, P651, DOI 10.1006/bbrc.1999.1980; Pincheira R, 2001, BRIT J CANCER, V84, P1520, DOI 10.1054/bjoc.2001.1828; Sambrook J, 1989, MOL CLONING; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; WRIGHT JA, 1990, BIOCHEM CELL BIOL, V68, P1364, DOI 10.1139/o90-199; YARBRO JW, 1992, SEMIN ONCOL, V19, P1; Zhou B, 2001, CYTOGENET CELL GENET, V95, P52, DOI 10.1159/000057017; ZHOU BS, 1995, CANCER RES, V55, P1328; Zhou BS, 1998, CLIN EXP METASTAS, V16, P43	50	83	97	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2004	23	21					3790	3801		10.1038/sj.onc.1207465	http://dx.doi.org/10.1038/sj.onc.1207465			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	818JX	15094776				2022-12-28	WOS:000221242500006
J	Dai, ZY; Popkie, AP; Zhu, WG; Timmers, CD; Raval, A; Tannehill-Gregg, S; Morrison, CD; Auer, H; Kratzke, RA; Niehans, G; Amatschek, S; Sommergruber, W; Leone, GW; Rosol, T; Otterson, GA; Plass, C				Dai, ZY; Popkie, AP; Zhu, WG; Timmers, CD; Raval, A; Tannehill-Gregg, S; Morrison, CD; Auer, H; Kratzke, RA; Niehans, G; Amatschek, S; Sommergruber, W; Leone, GW; Rosol, T; Otterson, GA; Plass, C			Bone morphogenetic protein 3B silencing in non-small-cell lung cancer	ONCOGENE			English	Article						bone morphogenetic protein 3B (BMP3B); DNA methylation; non-small-cell lung cancer	GROWTH-FACTOR-BETA; DIFFERENTIALLY METHYLATED SEQUENCES; CPG ISLAND AMPLIFICATION; TUMOR-SUPPRESSOR; DNA METHYLATION; MESSENGER-RNAS; CDNA CLONING; EXPRESSION; GENE; IDENTIFICATION	Bone morphogenetic protein 3B (BMP3B) is a member of the TGF-beta superfamily. The BMP3B promoter sequence was previously identified as a target for aberrant DNA methylation in non-small-cell lung cancer (NSCLC). Aberrant DNA hypermethylation in the BMP3B promoter is associated with downregulation of BMP3B transcription in both primary human lung cancers as well as lung cancer cell lines. In order to understand the mechanisms of BMP3B silencing in lung cancer, a sample set of 91 primary NSCLCs was used to detect aberrant BMP3B promoter methylation, mutations in the coding sequence of BMP3B, and loss of heterozygosity (LOH). Our results showed that 45 of 91 ( or 49.5%) tested primary NSCLCs exhibited increased promoter methylation, and 40% demonstrated LOH in at least one of the flanking microsatellite markers sJRH and D10S196 (63 kb upstream or 3.338 Mbp downstream of BMP3B). The lung cancer cell line A549, a type II alveolar epithelial human lung cancer cell line, is characterized by aberrant DNA promoter methylation. We used retroviral vector constructs containing the BMP3B cDNA to re-express the gene in A549 cells and to investigate the effects on cell growth. No change in the cell growth rate was observed after BMP3B re-expression, as compared to the vector controls. Although the number of colonies formed in anchorage-dependent assays was only slightly decreased, the colony-forming ability of A549 cells after BMP3B expression in anchorage-independent assays in soft agar was significantly reduced to 10% (P<0.005, t-test). Moreover, the in vivo tumorigenicity assay in nude mice indicated that cells re-expressing BMP3B grew significantly slower than cells not expressing BMP3B (P<0.05, t-test). In conclusion, this study provides evidence that BMP3B expression is repressed by different mechanisms in lung cancer, and that the silencing of BMP3B promotes lung tumor development.	Ohio State Univ, Div Human Canc Genet, Dept Mol Virol Immunol & Med Genet, Human Canc Genet Program, Columbus, OH 43210 USA; Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA; Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA; Ohio State Univ, Dept Internal Med, Div Hematol Oncol, Columbus, OH 43210 USA; Ohio State Univ, Dept Vet Biosci, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; Minneapolis VA Med Ctr, Minneapolis, MN 55417 USA; Boehringer Ingelheim, A-1120 Vienna, Austria; Univ Vienna, Dept Dermatol, A-1090 Vienna, Austria	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; Boehringer Ingelheim; University of Vienna	Plass, C (corresponding author), Ohio State Univ, Div Human Canc Genet, Dept Mol Virol Immunol & Med Genet, Human Canc Genet Program, Med Res Facil 494A,420 W 12th Ave, Columbus, OH 43210 USA.	plass-1@medctr.osu.edu	zhu, wei-guo/E-1334-2012; Rosol, Thomas/G-9585-2011; Plass, Christoph/H-7192-2014	Rosol, Thomas/0000-0003-3737-1190; Zhu, Wei-Guo/0000-0001-8385-6581	NCI NIH HHS [R01 CA93548, P30 CA16058] Funding Source: Medline; NIDCR NIH HHS [R01 DE13123] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016058, R01CA093548] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013123] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Akhurst RJ, 2002, J CLIN INVEST, V109, P1533, DOI 10.1172/JCI200215970; Baylin SB, 1998, ADV CANCER RES, V72, P141; CAULIN C, 1995, CELL GROWTH DIFFER, V6, P1027; Colasante A, 1997, AM J RESP CRIT CARE, V156, P968, DOI 10.1164/ajrccm.156.3.9701122; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Dai ZY, 2001, NEOPLASIA, V3, P314, DOI 10.1038/sj.neo.7900162; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; DERYNCK R, 1987, CANCER RES, V47, P707; Faucheux C, 1997, BIOCHEM BIOPH RES CO, V241, P787, DOI 10.1006/bbrc.1997.7792; Girard L, 2000, CANCER RES, V60, P4894; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hino J, 1996, BIOCHEM BIOPH RES CO, V223, P304, DOI 10.1006/bbrc.1996.0889; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; KESKIOJA J, 1988, J BIOL CHEM, V263, P3111; Kiemer AK, 2001, ONCOGENE, V20, P6679, DOI 10.1038/sj.onc.1204872; LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733; Liang GG, 2002, METHODS, V27, P150, DOI 10.1016/S1046-2023(02)00068-3; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Miyazono K, 2001, J CELL PHYSIOL, V187, P265, DOI 10.1002/jcp.1080; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Plass C, 2002, EUR J HUM GENET, V10, P6, DOI 10.1038/sj.ejhg.5200768; Ridley A, 2000, NATURE, V406, P466, DOI 10.1038/35020170; Samuel W, 2002, J BIOL CHEM, V277, P59, DOI 10.1074/jbc.M108730200; Sasaki H, 2002, JPN J CLIN ONCOL, V32, P85, DOI 10.1093/jjco/hyf021; SKONIER J, 1992, DNA CELL BIOL, V11, P511, DOI 10.1089/dna.1992.11.511; Smiraglia DJ, 2002, ONCOGENE, V21, P5414, DOI 10.1038/sj.onc.1205608; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Toyota M, 1999, CANCER RES, V59, P2307; Toyota Minoru, 2002, Methods Mol Biol, V200, P101; Verrecchia F, 2002, J INVEST DERMATOL, V118, P211, DOI 10.1046/j.1523-1747.2002.01641.x; Zhu WG, 2001, ONCOGENE, V20, P7787, DOI 10.1038/sj.onc.1204970; Zhu WG, 2001, CANCER RES, V61, P1327	36	42	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3521	3529		10.1038/sj.onc.1207441	http://dx.doi.org/10.1038/sj.onc.1207441			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15116090				2022-12-28	WOS:000221101700003
J	Stoneley, M; Willis, AE				Stoneley, M; Willis, AE			Cellular internal ribosome entry segments: structures, trans-acting factors and regulation of gene expression	ONCOGENE			English	Article						internal ribosome entry; IRES; translation; protein synthesis	SITE-MEDIATED TRANSLATION; TRACT-BINDING-PROTEIN; 5' UNTRANSLATED REGION; X-LINKED INHIBITOR; C-MYC-IRES; MESSENGER-RNA; INITIATION-FACTOR; IN-VITRO; NONTRANSLATED REGION; VIRUS	Initiation of translation in eukaryotic cells can occur by two distinct mechanisms, cap-dependent scanning and internal ribosome entry. The latter mechanism requires the formation of a complex RNA structural element termed an internal ribosome entry segment (IRES). IRESs are located in the 50 untranslated region of the message, and in the presence of trans-acting factors allow the ribosome to be recruited to a site that is a considerable distance from the cap structure. Many cellular mRNAs have now been shown to contain IRESs and it is likely that up to 10% of all mRNAs have the capability to initiate translation by this mechanism. The majority of IRESs that have been identified thus far are found in mRNAs whose protein products are associated with the control of cell growth and cell death, including many growth factors, proto-oncogenes and proteins required for apoptosis. In this review, we discuss the cellular situations when IRESs are required, the trans-acting factors that are necessary for IRES function and deregulation of IRES-mediated translation in tumorigenesis.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	University of Leicester	Willis, AE (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.	ms63@le.ac.uk; aew5@le.ac.uk		Willis, Anne/0000-0002-1470-8531				Belsham GJ, 2000, COLD SPRING HARBOR M, V39, P869; Bonnal S, 2003, J BIOL CHEM, V278, P39330, DOI 10.1074/jbc.M305580200; BONNEAU AM, 1987, J BIOL CHEM, V262, P11134; Chappell SA, 2000, P NATL ACAD SCI USA, V97, P1536, DOI 10.1073/pnas.97.4.1536; Chappell SA, 2000, ONCOGENE, V19, P4437, DOI 10.1038/sj.onc.1203791; Chappell SA, 2003, J BIOL CHEM, V278, P33793, DOI 10.1074/jbc.M303495200; Clemens MJ, 2000, CELL DEATH DIFFER, V7, P603, DOI 10.1038/sj.cdd.4400695; Coldwell MJ, 2000, ONCOGENE, V19, P899, DOI 10.1038/sj.onc.1203407; Coldwell MJ, 2001, ONCOGENE, V20, P4095, DOI 10.1038/sj.onc.1204547; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; Creancier L, 2000, J CELL BIOL, V150, P275, DOI 10.1083/jcb.150.1.275; Creancier L, 2001, MOL CELL BIOL, V21, P1833, DOI 10.1128/MCB.21.5.1833-1840.2001; De Quinto SL, 2000, RNA, V6, P1380, DOI 10.1017/S1355838200000753; Evans JR, 2003, ONCOGENE, V22, P8012, DOI 10.1038/sj.onc.1206645; Fernandez J, 2002, J BIOL CHEM, V277, P2050, DOI 10.1074/jbc.M109199200; Fernandez J, 2001, J BIOL CHEM, V276, P12285, DOI 10.1074/jbc.M009714200; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Henis-Korenblit S, 2000, MOL CELL BIOL, V20, P496, DOI 10.1128/MCB.20.2.496-506.2000; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Holcik M, 2003, MOL CELL BIOL, V23, P280, DOI 10.1128/MCB.23.1.280-288.2003; Holcik M, 2000, ONCOGENE, V19, P4174, DOI 10.1038/sj.onc.1203765; Holcik M, 2000, MOL CELL BIOL, V20, P4648, DOI 10.1128/MCB.20.13.4648-4657.2000; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; Hu MCY, 1999, P NATL ACAD SCI USA, V96, P1339, DOI 10.1073/pnas.96.4.1339; Huez I, 1998, MOL CELL BIOL, V18, P6178, DOI 10.1128/MCB.18.11.6178; Jackson RJ, 2000, COLD SPRING HARBOR M, V39, P127; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; JANG SK, 1989, J VIROL, V63, P1651, DOI 10.1128/JVI.63.4.1651-1660.1989; Johannes G, 1999, P NATL ACAD SCI USA, V96, P13118, DOI 10.1073/pnas.96.23.13118; Jopling CL, 2004, RNA, V10, P287, DOI 10.1261/rna.5138804; Jopling CL, 2001, ONCOGENE, V20, P2664, DOI 10.1038/sj.onc.1204404; Kieft JS, 2002, NAT STRUCT BIOL, V9, P370, DOI 10.1038/nsb781; Kim YK, 2000, J MOL BIOL, V304, P119, DOI 10.1006/jmbi.2000.4179; Kolupaeva VG, 1998, J BIOL CHEM, V273, P18599, DOI 10.1074/jbc.273.29.18599; Kullmann M, 2002, GENE DEV, V16, P3087, DOI 10.1101/gad.248902; Le Quesne JPC, 2001, J MOL BIOL, V310, P111, DOI 10.1006/jmbi.2001.4745; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; Martinez-Salas E, 2001, J GEN VIROL, V82, P973, DOI 10.1099/0022-1317-82-5-973; Miskimins WK, 2001, MOL CELL BIOL, V21, P4960, DOI 10.1128/MCB.21.15.4960-4967.2001; Mitchell SA, 2003, MOL CELL, V11, P757, DOI 10.1016/S1097-2765(03)00093-5; Mitchell SA, 2001, MOL CELL BIOL, V21, P3364, DOI 10.1128/MCB.21.10.3364-3374.2001; Morrish BC, 2002, MOL CELL BIOL, V22, P6089, DOI 10.1128/MCB.22.17.6089-6099.2002; Nevins TA, 2003, J BIOL CHEM, V278, P3572, DOI 10.1074/jbc.M206781200; Paulin FEM, 1996, ONCOGENE, V13, P505; Paulin FEM, 1998, NUCLEIC ACIDS RES, V26, P3097, DOI 10.1093/nar/26.13.3097; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; Pickering BM, 2003, NUCLEIC ACIDS RES, V31, P639, DOI 10.1093/nar/gkg146; PICKERING BM, 2004, IN PRESS MOL CELL BI; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; SHIKOKI K, 2003, NUCLEIC ACIDS RES, V30, P2851; Sizova DV, 1998, J VIROL, V72, P4775, DOI 10.1128/JVI.72.6.4775-4782.1998; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; Stoneley M, 2000, MOL CELL BIOL, V20, P1162, DOI 10.1128/MCB.20.4.1162-1169.2000; Stoneley M, 2000, NUCLEIC ACIDS RES, V28, P687, DOI 10.1093/nar/28.3.687; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; Subkhankulova T, 2001, BIOCHEM J, V359, P183, DOI 10.1042/0264-6021:3590183; West MJ, 1998, ONCOGENE, V17, P769, DOI 10.1038/sj.onc.1201990; Wilson JE, 2000, CELL, V102, P511, DOI 10.1016/S0092-8674(00)00055-6; Yaman I, 2003, CELL, V113, P519, DOI 10.1016/S0092-8674(03)00345-3; Yang Q, 1997, NUCLEIC ACIDS RES, V25, P2800, DOI 10.1093/nar/25.14.2800	61	281	297	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2004	23	18					3200	3207		10.1038/sj.onc.1207551	http://dx.doi.org/10.1038/sj.onc.1207551			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	813AJ	15094769				2022-12-28	WOS:000220879700008
J	Shay, JW; Roninson, IB				Shay, JW; Roninson, IB			Hallmarks of senescence in carcinogenesis and cancer therapy	ONCOGENE			English	Review						replicative senescence; STASIS; telomeres; chemotherapy; apoptosis; mitotic catastrophe	CELL-CYCLE ARREST; CERVICAL-CARCINOMA CELLS; HUMAN TUMOR-CELLS; TERMINAL PROLIFERATION ARREST; TELOMERASE-DEFICIENT MICE; LACKING FUNCTIONAL P53; IMMORTAL HUMAN-CELLS; GROWTH ARREST; HUMAN FIBROBLASTS; REPLICATIVE SENESCENCE	Cellular senescence is a signal transduction program leading to irreversible cell cycle arrest. This growth arrest can be triggered by many different mechanisms including recognition by cellular sensors of DNA double-strand breaks leading to the activation of cell cycle checkpoint responses and recruitment of DNA repair foci. Senescence is initiated by the shortening of telomeres (replicative senescence) or by other endogenous and exogenous acute and chronic stress signals (STASIS: stress or aberrant signaling-induced senescence). The process of carcinogenesis involves a series of changes that allow tumor cells to bypass the senescence program. Nevertheless, tumor cells retain the capacity to undergo senescence. Treatment of tumor cells with many conventional anticancer therapies activates DNA damage signaling pathways, which induce apoptosis in some cells and senescence in others. Overexpression of tumor suppressors or inhibition of oncogenes can also induce rapid senescence in tumor cells. Senescent cells, while not dividing, remain metabolically active and produce many secreted factors, some of which stimulate and others inhibit the growth of tumors. The emerging knowledge about the pathways that lead to senescence and determine the pattern of gene expression in senescent cells may lead to more effective treatments for cancer.	Ordway Res Inst, Ctr Canc, Albany, NY 12208 USA	Ordway Research Institute	Roninson, IB (corresponding author), Ordway Res Inst, Ctr Canc, 150 New Scotland Ave, Albany, NY 12208 USA.	roninson@ordwayresearch.org	Shay, Jerry W/F-7878-2011; Roninson, Igor/K-1310-2017	Roninson, Igor/0000-0002-9211-1327	NATIONAL CANCER INSTITUTE [R01CA089636, P50CA070907, R01CA062099] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017921, R01AG007992] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA070907, R01 CA62099, R01 CA89636] Funding Source: Medline; NIA NIH HHS [R01 AG07992, R01 AG17921] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Bailey SM, 2001, SCIENCE, V293, P2462, DOI 10.1126/science.1062560; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; BATAINI JP, 1988, AM J SURG, V155, P754, DOI 10.1016/S0002-9610(88)80037-0; Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Beausejour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417; Bertram MJ, 1999, MOL CELL BIOL, V19, P1479; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; BLACKBURN EH, 1978, J MOL BIOL, V120, P33, DOI 10.1016/0022-2836(78)90294-2; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Bryan TM, 1999, CURR OPIN CELL BIOL, V11, P318, DOI 10.1016/S0955-0674(99)80043-X; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Campisi J, 2000, IN VIVO, V14, P183; Campisi J, 2001, EXP GERONTOL, V36, P607, DOI 10.1016/S0531-5565(00)00230-8; Chang BD, 2002, P NATL ACAD SCI USA, V99, P389, DOI 10.1073/pnas.012602599; Chang BD, 1999, CANCER RES, V59, P3761; Chang BD, 2000, ONCOGENE, V19, P2165, DOI 10.1038/sj.onc.1203573; Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; CHEN Q, 1994, P NATL ACAD SCI USA, V91, P4130, DOI 10.1073/pnas.91.10.4130; Chen QJ, 2001, MOL CELL BIOL, V21, P1819, DOI 10.1128/MCB.21.5.1819-1827.2001; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; Christov KT, 2003, EUR J CANCER, V39, P230, DOI 10.1016/S0959-8049(02)00497-5; Cohen H, 2001, P NATL ACAD SCI USA, V98, P3174, DOI 10.1073/pnas.061579598; Cong YS, 2002, MICROBIOL MOL BIOL R, V66, P407, DOI 10.1128/MMBR.66.3.407-425.2002; COOKE HJ, 1986, COLD SPRING HARB SYM, V51, P213, DOI 10.1101/SQB.1986.051.01.026; COX JD, 1983, INT J RADIAT ONCOL, V9, P299, DOI 10.1016/0360-3016(83)90287-0; Crescenzi E, 2003, BIOCHEM J, V375, P263, DOI 10.1042/BJ20030868; Dai CY, 2000, ONCOGENE, V19, P1613, DOI 10.1038/sj.onc.1203438; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; DeFilippis RA, 2003, J VIROL, V77, P1551, DOI 10.1128/JVI.77.2.1551-1563.2003; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; DePinho RA, 2000, NATURE, V408, P248, DOI 10.1038/35041694; di Fagagna FD, 2003, NATURE, V426, P194, DOI 10.1038/nature02118; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dokmanovic M, 2002, CANCER BIOL THER, V1, P24, DOI 10.4161/cbt.1.1.35; DOTTO GP, 2000, BIOCHIM BIOPHYS ACTA, V1471, P43; Drayton S, 2002, CURR OPIN GENET DEV, V12, P98, DOI 10.1016/S0959-437X(01)00271-4; Dubrana K, 2001, CURR OPIN CELL BIOL, V13, P281, DOI 10.1016/S0955-0674(00)00210-6; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Elenbaas B, 2001, EXP CELL RES, V264, P169, DOI 10.1006/excr.2000.5133; Elmore LW, 2002, J BIOL CHEM, V277, P35509, DOI 10.1074/jbc.M205477200; Fang L, 1999, ONCOGENE, V18, P2789, DOI 10.1038/sj.onc.1202615; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Gasser SM, 2000, SCIENCE, V288, P1377, DOI 10.1126/science.288.5470.1377; Gonzalez-Suarez E, 2000, NAT GENET, V26, P114, DOI 10.1038/79089; Goodwin EC, 2001, CELL GROWTH DIFFER, V12, P525; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P10978, DOI 10.1073/pnas.97.20.10978; Gorbunova V, 2003, J BIOL CHEM, V278, P7692, DOI 10.1074/jbc.M212944200; Goytisolo FA, 2000, J EXP MED, V192, P1625, DOI 10.1084/jem.192.11.1625; Greenberg RA, 1999, CELL, V97, P515, DOI 10.1016/S0092-8674(00)80761-8; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hall AHS, 2003, J VIROL, V77, P6066, DOI 10.1128/JVI.77.10.6066-6069.2003; Han ZY, 2002, J BIOL CHEM, V277, P17154, DOI 10.1074/jbc.M112401200; Haq R, 2002, CANCER RES, V62, P5076; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HART RW, 1974, P NATL ACAD SCI USA, V71, P2169, DOI 10.1073/pnas.71.6.2169; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; Herbert BS, 2001, JNCI-J NATL CANCER I, V93, P39, DOI 10.1093/jnci/93.1.39; Holt SE, 1999, J CELL PHYSIOL, V180, P10, DOI 10.1002/(SICI)1097-4652(199907)180:1<10::AID-JCP2>3.0.CO;2-D; Holt SE, 1997, EUR J CANCER, V33, P761, DOI 10.1016/S0959-8049(97)00066-X; Kapahi P, 1999, FREE RADICAL BIO MED, V26, P495, DOI 10.1016/S0891-5849(98)00323-2; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Katakura Y, 1999, BIOCHEM BIOPH RES CO, V255, P110, DOI 10.1006/bbrc.1999.0129; Kim JH, 2003, BIOCHEM J, V373, P523, DOI 10.1042/BJ20030363; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim SH, 1999, NAT GENET, V23, P405, DOI 10.1038/70508; KIRKWOOD TBL, 1988, CIBA F SYMP, V134, P193; Kirkwood TBL, 2000, NATURE, V408, P233, DOI 10.1038/35041682; Komarova EA, 1998, ONCOGENE, V17, P1089, DOI 10.1038/sj.onc.1202303; Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Lee KH, 2001, P NATL ACAD SCI USA, V98, P3381, DOI 10.1073/pnas.051629198; Li BB, 2000, CELL, V101, P471, DOI 10.1016/S0092-8674(00)80858-2; LINDSEY J, 1991, MUTAT RES, V256, P45, DOI 10.1016/0921-8734(91)90032-7; Lingner J, 1998, CURR OPIN GENET DEV, V8, P226, DOI 10.1016/S0959-437X(98)80145-7; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Lock RB, 1996, CANCER RES, V56, P4006; LOO DT, 1987, SCIENCE, V236, P200, DOI 10.1126/science.3494308; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; Mathon NF, 2001, SCIENCE, V291, P872, DOI 10.1126/science.1056782; Michishita E, 1999, J BIOCHEM-TOKYO, V126, P1052; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; Park JI, 2000, J CANCER RES CLIN, V126, P455, DOI 10.1007/s004320050013; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; Ravi RK, 1999, J CELL BIOCHEM, V72, P458, DOI 10.1002/(SICI)1097-4644(19990315)72:4<458::AID-JCB2>3.0.CO;2-C; Rebbaa A, 2003, ONCOGENE, V22, P2805, DOI 10.1038/sj.onc.1206366; Reincke BS, 2003, J CELL PHYSIOL, V194, P303, DOI 10.1002/jcp.10201; Rizki A, 2001, NATURE, V411, P713, DOI 10.1038/35079641; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; Roninson IB, 2003, CANCER RES, V63, P2705; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Roninson IB, 2002, CANCER LETT, V179, P1, DOI 10.1016/S0304-3835(01)00847-3; RONINSON IB, 2002, J CELL BIOCHEM, P1; RONINSON IB, 2002, DRUG RESIST UPDATE, V252, P1; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Rudolph KL, 2001, NAT GENET, V28, P155, DOI 10.1038/88871; Ruth AC, 2000, CANCER RES, V60, P2576; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shay Jerry W., 1996, Current Opinion in Oncology, V8, P66, DOI 10.1097/00001622-199601000-00012; Shay JW, 1996, TRENDS GENET, V12, P129, DOI 10.1016/0168-9525(96)30018-8; SHAY JW, 1995, MOL MED TODAY, V1, P378, DOI 10.1016/S1357-4310(95)93872-9; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; Shay JW, 2001, SCIENCE, V291, P839, DOI 10.1126/science.1058546; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Shore D, 1997, TRENDS BIOCHEM SCI, V22, P233, DOI 10.1016/S0968-0004(97)01082-7; Smogorzewska A, 2002, EMBO J, V21, P4338, DOI 10.1093/emboj/cdf433; Sprenger CC, 2002, ONCOGENE, V21, P140, DOI 10.1038/sj.onc.1205021; Stansel RM, 2001, EMBO J, V20, P5532; Stein GH, 1999, MOL CELL BIOL, V19, P2109; Stewart SA, 2002, P NATL ACAD SCI USA, V99, P12606, DOI 10.1073/pnas.182407599; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; Suzuki T, 2001, EXP GERONTOL, V36, P465, DOI 10.1016/S0531-5565(00)00223-0; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Tang DG, 2001, SCIENCE, V291, P868, DOI 10.1126/science.1056780; te Poele RH, 2002, CANCER RES, V62, P1876; Terao Y, 2001, INT J CANCER, V94, P257, DOI 10.1002/ijc.1448; Tombor B, 2003, BIOCHEM BIOPH RES CO, V303, P800, DOI 10.1016/S0006-291X(03)00402-9; Tominaga K, 2002, MECH AGEING DEV, V123, P927, DOI 10.1016/S0047-6374(02)00030-1; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Wainwright LJ, 2001, P NATL ACAD SCI USA, V98, P9396, DOI 10.1073/pnas.161288698; Wang XH, 1998, CANCER RES, V58, P5019; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Wellinger RJ, 1997, EUR J CANCER, V33, P735, DOI 10.1016/S0959-8049(97)00067-1; Wells SI, 2000, EMBO J, V19, P5762, DOI 10.1093/emboj/19.21.5762; Wong KK, 2000, NAT GENET, V26, P85, DOI 10.1038/79232; Wright WE, 2000, NAT MED, V6, P849, DOI 10.1038/78592; WRIGHT WE, 1992, EXP GERONTOL, V27, P383, DOI 10.1016/0531-5565(92)90069-C; Wright WE, 1996, DEV GENET, V18, P173; Wright WE, 2002, NAT BIOTECHNOL, V20, P682, DOI 10.1038/nbt0702-682; Wright WE, 2001, CURR OPIN GENET DEV, V11, P98, DOI 10.1016/S0959-437X(00)00163-5; Wright Woodring E., 1996, V16, P153; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Zhu HM, 2002, CELL CYCLE, V1, P59, DOI 10.4161/cc.1.1.101; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997; Zhu WY, 1997, EXP CELL RES, V234, P293, DOI 10.1006/excr.1997.3589	160	389	416	2	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2004	23	16					2919	2933		10.1038/sj.onc.1207518	http://dx.doi.org/10.1038/sj.onc.1207518			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	811VO	15077154				2022-12-28	WOS:000220799600018
J	Huang, DT; Walden, H; Duda, D; Schulman, BA				Huang, DT; Walden, H; Duda, D; Schulman, BA			Ubiquitin-like protein activation	ONCOGENE			English	Review						ubiquitin; E1; ubiquitin activating enzyme; SUMO; NEDD8; MoeB	CONJUGATING ENZYME COMPLEX; TUMOR-SUPPRESSOR P53; CYCLE MUTANT TS85; CRYSTAL-STRUCTURE; CELL-CYCLE; ESCHERICHIA-COLI; LUNG-CANCER; DNA-REPAIR; KAPPA-B; U-BOX	Post-translational covalent attachment of ubiquitin and ubiquitin-like proteins (ubls) has emerged as a predominant cellular regulatory mechanism, with important roles in controlling cell division, signal transduction, embryonic development, endocytic trafficking and the immune response. Ubls function by remodeling the surface of their target proteins, changing their target's half-life, enzymatic activity, protein - protein interactions, subcellular localization or other properties. At least 10 different ubiquitin-like modi. cations exist in mammals, and attachment of different ubls to a target leads to different biological consequences. Ubl-conjugation cascades are initiated by activating enzymes, which also coordinate the ubls with their downstream pathways. A number of biochemical and structural studies have provided insights into the mechanism of ubl-activating enzymes and their roles in ubl conjugation cascades.	St Jude Childrens Res Hosp, Dept Biol Struct, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Genet, Memphis, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital	Schulman, BA (corresponding author), St Jude Childrens Res Hosp, Dept Biol Struct, MS 311, Memphis, TN 38105 USA.	Brenda.schulman@stjude.org	Huang, Danny/AAM-3631-2021	Huang, Danny/0000-0002-6192-259X	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069530] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA21765] Funding Source: Medline; NIGMS NIH HHS [R01GM69530] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Appleyard MVCL, 1998, J BIOL CHEM, V273, P14869, DOI 10.1074/jbc.273.24.14869; Aravind L, 2000, CURR BIOL, V10, pR132, DOI 10.1016/S0960-9822(00)00398-5; Bayer P, 1998, J MOL BIOL, V280, P275, DOI 10.1006/jmbi.1998.1839; Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; Bellon SF, 1997, NAT STRUCT BIOL, V4, P586, DOI 10.1038/nsb0797-586; Bencsath KP, 2002, J BIOL CHEM, V277, P47938, DOI 10.1074/jbc.M207442200; Bernier-Villamor V, 2002, CELL, V108, P345, DOI 10.1016/S0092-8674(02)00630-X; Bohnsack RN, 2003, J BIOL CHEM, V278, P26823, DOI 10.1074/jbc.M303177200; BORTHAKUR D, 1990, MOL GEN GENET, V221, P227, DOI 10.1007/BF00261725; BURCH TJ, 1994, BIOCHEMISTRY-US, V33, P7300, DOI 10.1021/bi00189a035; CIECHANOVER A, 1984, CELL, V37, P57, DOI 10.1016/0092-8674(84)90300-3; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; CIECHANOVER A, 1981, P NATL ACAD SCI-BIOL, V78, P761, DOI 10.1073/pnas.78.2.761; del Pozo JC, 1999, P NATL ACAD SCI USA, V96, P15342, DOI 10.1073/pnas.96.26.15342; del Pozo JC, 1998, SCIENCE, V280, P1760, DOI 10.1126/science.280.5370.1760; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; Dittmar GAG, 2002, SCIENCE, V295, P2442, DOI 10.1126/science.1069989; FINLEY D, 1984, CELL, V37, P43, DOI 10.1016/0092-8674(84)90299-X; Freed E, 1999, GENE DEV, V13, P2242, DOI 10.1101/gad.13.17.2242; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; Furukawa K, 2000, J BIOL CHEM, V275, P7462, DOI 10.1074/jbc.275.11.7462; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Giraud MF, 1998, ACTA CRYSTALLOGR D, V54, P891, DOI 10.1107/S0907444998002480; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; Gong LM, 1999, FEBS LETT, V448, P185, DOI 10.1016/S0014-5793(99)00367-1; Gong LM, 1999, J BIOL CHEM, V274, P12036, DOI 10.1074/jbc.274.17.12036; HAAS AL, 1982, J BIOL CHEM, V257, P2543; HAAS AL, 1983, BIOCHEMISTRY-US, V22, P4388, DOI 10.1021/bi00288a007; HAAS AL, 1982, J BIOL CHEM, V257, P329; HAAS AL, 1987, J BIOL CHEM, V262, P11315; HAAS AL, 1988, J BIOL CHEM, V263, P13268; HAAS AL, 1988, J BIOL CHEM, V263, P13258; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; HATFIELD PM, 1990, J BIOL CHEM, V265, P15813; Hay RT, 2001, TRENDS BIOCHEM SCI, V26, P332, DOI 10.1016/S0968-0004(01)01849-7; Hershko A, 2000, NAT MED, V6, P1073, DOI 10.1038/80384; HERSHKO A, 1981, J BIOL CHEM, V256, P1525; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hicke L, 2001, CELL, V106, P527, DOI 10.1016/S0092-8674(01)00485-8; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; Hochstrasser M, 2000, SCIENCE, V289, P563, DOI 10.1126/science.289.5479.563; Hochstrasser M, 1998, GENE DEV, V12, P901, DOI 10.1101/gad.12.7.901; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Hofmann K, 1998, J MOL BIOL, V282, P195, DOI 10.1006/jmbi.1998.1998; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Huang L, 1999, SCIENCE, V286, P1321, DOI 10.1126/science.286.5443.1321; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Jones D, 2000, DEV BIOL, V226, P152, DOI 10.1006/dbio.2000.9847; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kishino T, 1997, NAT GENET, V15, P70, DOI 10.1038/ng0197-70; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; KOK K, 1993, P NATL ACAD SCI USA, V90, P6071, DOI 10.1073/pnas.90.13.6071; Komatsu M, 2001, J BIOL CHEM, V276, P9846, DOI 10.1074/jbc.M007737200; Kumar S, 1997, J BIOL CHEM, V272, P13548, DOI 10.1074/jbc.272.21.13548; Kurz T, 2002, SCIENCE, V295, P1294, DOI 10.1126/science.1067765; Kwon YT, 2002, SCIENCE, V297, P96, DOI 10.1126/science.1069531; Lake MW, 2001, NATURE, V414, P325, DOI 10.1038/35104586; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; Larsen CN, 2002, J PROTEOME RES, V1, P411, DOI 10.1021/pr025522n; Leimkuhler S, 2001, J BIOL CHEM, V276, P34695, DOI 10.1074/jbc.M102787200; Liakopoulos D, 1999, P NATL ACAD SCI USA, V96, P5510, DOI 10.1073/pnas.96.10.5510; Liakopoulos D, 1998, EMBO J, V17, P2208, DOI 10.1093/emboj/17.8.2208; Liu YC, 1999, P NATL ACAD SCI USA, V96, P4313, DOI 10.1073/pnas.96.8.4313; LOEB KR, 1992, J BIOL CHEM, V267, P7806; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; MacQuillan GC, 2003, J MED VIROL, V70, P219, DOI 10.1002/jmv.10381; Matsuura T, 1997, NAT GENET, V15, P74, DOI 10.1038/ng0197-74; MCGRATH JP, 1991, EMBO J, V10, P227, DOI 10.1002/j.1460-2075.1991.tb07940.x; McKenna S, 2001, J BIOL CHEM, V276, P40120, DOI 10.1074/jbc.M102858200; McLaughlin PMJ, 2000, INT J CANCER, V85, P871, DOI 10.1002/(SICI)1097-0215(20000315)85:6<871::AID-IJC22>3.0.CO;2-O; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Mizushima N, 1998, J BIOL CHEM, V273, P33889, DOI 10.1074/jbc.273.51.33889; Moraes TF, 2001, NAT STRUCT BIOL, V8, P669, DOI 10.1038/90373; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Narasimhan J, 1996, J BIOL CHEM, V271, P324, DOI 10.1074/jbc.271.1.324; Nicholl MJ, 2000, J GEN VIROL, V81, P2215, DOI 10.1099/0022-1317-81-9-2215; Ohi MD, 2003, NAT STRUCT BIOL, V10, P250, DOI 10.1038/nsb906; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Osaka F, 1998, GENE DEV, V12, P2263, DOI 10.1101/gad.12.15.2263; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Palenchar PM, 2000, J BIOL CHEM, V275, P8283, DOI 10.1074/jbc.275.12.8283; Pawson T, 2000, GENE DEV, V14, P1027; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; Paz Y, 2000, J BIOL CHEM, V275, P25445, DOI 10.1074/jbc.C000307200; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; PICKART CM, 1985, J BIOL CHEM, V260, P1573; PICKART CM, 1994, J BIOL CHEM, V269, P7115; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; PITLUK ZW, 1995, MOL CELL BIOL, V15, P1210; PITTERLE DM, 1993, J BIOL CHEM, V268, P13499; Pitterle DM, 1998, IN VIVO, V12, P643; PITTERLE DM, 1993, J BIOL CHEM, V268, P13506; Pringa E, 2001, J BIOL CHEM, V276, P19617, DOI 10.1074/jbc.M100192200; Raasi S, 2001, J BIOL CHEM, V276, P35334, DOI 10.1074/jbc.M105139200; Ramelot Theresa A., 2003, Journal of Structural and Functional Genomics, V4, P25, DOI 10.1023/A:1024674220425; Rao-Naik C, 1998, J BIOL CHEM, V273, P34976, DOI 10.1074/jbc.273.52.34976; Read MA, 2000, MOL CELL BIOL, V20, P2326, DOI 10.1128/MCB.20.7.2326-2333.2000; RECHSTEINER M, 1998, UBIQUITIN BIOL CELL, P147; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; Rudolph MJ, 2001, NAT STRUCT BIOL, V8, P42; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Schwartz DC, 2003, TRENDS BIOCHEM SCI, V28, P321, DOI 10.1016/S0968-0004(03)00113-0; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; Sheng WY, 2002, PROTEIN SCI, V11, P1482, DOI 10.1110/ps.0201602; Shintani T, 1999, EMBO J, V18, P5234, DOI 10.1093/emboj/18.19.5234; Sidow A, 1999, NAT GENET, V23, P104, DOI 10.1038/12709; Sloper-Mould KE, 2001, J BIOL CHEM, V276, P30483, DOI 10.1074/jbc.M103248200; SULLIVAN ML, 1991, J BIOL CHEM, V266, P23878; Swanson R, 2000, FEBS LETT, V477, P193, DOI 10.1016/S0014-5793(00)01802-0; Tanida I, 1999, MOL BIOL CELL, V10, P1367, DOI 10.1091/mbc.10.5.1367; Tanida I, 2001, J BIOL CHEM, V276, P1701, DOI 10.1074/jbc.C000752200; Tateishi K, 2001, J CELL BIOL, V155, P571, DOI 10.1083/jcb.200104035; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Taylor SV, 1998, J BIOL CHEM, V273, P16555, DOI 10.1074/jbc.273.26.16555; Tong H, 1997, J BIOL CHEM, V272, P21381, DOI 10.1074/jbc.272.34.21381; Tyers M, 2000, CURR OPIN GENET DEV, V10, P54, DOI 10.1016/S0959-437X(99)00049-0; VanDemark AP, 2001, CELL, V105, P711, DOI 10.1016/S0092-8674(01)00387-7; VanDemark AP, 2003, NAT STRUCT BIOL, V10, P244, DOI 10.1038/nsb0403-244; VanDemark AP, 2002, CURR OPIN STRUC BIOL, V12, P822, DOI 10.1016/S0959-440X(02)00389-5; Vazquez F, 2001, J BIOL CHEM, V276, P48627, DOI 10.1074/jbc.C100556200; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; VIJAYKUMAR S, 1985, P NATL ACAD SCI USA, V82, P3582, DOI 10.1073/pnas.82.11.3582; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; Wada H, 1999, BIOCHEM BIOPH RES CO, V257, P100, DOI 10.1006/bbrc.1999.0339; Wada H, 1999, J BIOL CHEM, V274, P36025, DOI 10.1074/jbc.274.50.36025; Walden H, 2003, NATURE, V422, P330, DOI 10.1038/nature01456; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Wang CY, 2001, NAT STRUCT BIOL, V8, P47; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Whitby FG, 1998, J BIOL CHEM, V273, P34983, DOI 10.1074/jbc.273.52.34983; Wilkinson KD, 1997, FASEB J, V11, P1245, DOI 10.1096/fasebj.11.14.9409543; WILKINSON KD, 1990, BIOCHEMISTRY-US, V29, P7373, DOI 10.1021/bi00484a004; Wilkinson KD, 1998, UBIQUITIN BIOL CELL, P99; Xi J, 2001, P NATL ACAD SCI USA, V98, P8513, DOI 10.1073/pnas.141226698; Yaffe MB, 2002, NAT REV MOL CELL BIO, V3, P177, DOI 10.1038/nrm759; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; Yewdell JW, 2001, CURR OPIN IMMUNOL, V13, P13, DOI 10.1016/S0952-7915(00)00175-8; York IA, 1999, IMMUNOL REV, V172, P49, DOI 10.1111/j.1600-065X.1999.tb01355.x; Yuan WM, 2001, EMBO J, V20, P362, DOI 10.1093/emboj/20.3.362; ZACKSENHAUS E, 1990, EMBO J, V9, P2923, DOI 10.1002/j.1460-2075.1990.tb07483.x; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	168	61	68	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2004	23	11					1958	1971		10.1038/sj.onc.1207393	http://dx.doi.org/10.1038/sj.onc.1207393			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	803EC	15021884				2022-12-28	WOS:000220213400001
J	Kim, O; Jiang, TY; Xie, XQ; Guo, ZY; Chen, HG; Qiu, Y				Kim, O; Jiang, TY; Xie, XQ; Guo, ZY; Chen, HG; Qiu, Y			Synergism of cytoplasmic kinases in IL6-induced ligand-independent activation of androgen receptor in prostate cancer cells	ONCOGENE			English	Article						protein kinase; prostate cancer; androgen independence; cytokine	PLECKSTRIN-HOMOLOGY DOMAIN; FOCAL ADHESION KINASE; TYROSINE KINASE; INTERLEUKIN-6 RECEPTOR; SIGNAL-TRANSDUCTION; CARCINOMA-CELLS; GENE-EXPRESSION; PIM-1 KINASE; SERUM LEVELS; PH-DOMAIN	IL6 is a pleiotropic cytokine which has been implicated in ligand-independent activation of androgen receptor in prostate cancer cells. Here, we present the evidence that two cytoplasmic kinases Pim1 and Etk are involved in this process. We showed that Pim1 is expressed in all prostate cancer cell lines examined. Both the expression level and the kinase activity of Pim1 are regulated by IL6 in these cells. Furthermore, we showed that IL6 downstream tyrosine kinase Etk can induce tyrosine phosphorylation of Pim1 which is correlated with its kinase activity. Mutation of the conserved Tyrosine 218 in the activation loop results in reduced kinase activity of Pim1. Interestingly, Etk can also be activated by Pim1 when they are coexpressed in prostate cancer cells, suggesting a possible positive feedback loop between Etk and Pim1. It appears that both Pim1 and Etk are required for IL6-induced activation of androgen receptor-mediated transcription in prostate cancer cells because overexpression of the kinase-deficient form of either Pim1 or Etk dramatically blocks the IL6 effect. Coexpression of the two kinases together but neither one alone is sufficient to activate ARE-containing promoter. Taken together, our data suggest a synergism of Ser/Thr kinase Pim1 and tyrosine kinase Etk in IL6 signaling and provide new insights into ligand-independent activation of androgen receptor in prostate cancer cells.	Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Qiu, Y (corresponding author), Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, 655 W Baltimore St, Baltimore, MD 21201 USA.	yqiu@som.umaryland.edu			NCI NIH HHS [CA85380, PC020169] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085380] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe Y, 1991, Rinsho Ketsueki, V32, P1458; Adler HL, 1999, J UROLOGY, V161, P182, DOI 10.1016/S0022-5347(01)62092-5; Akimoto S, 1998, ENDOCR J, V45, P183, DOI 10.1507/endocrj.45.183; AMSON R, 1989, P NATL ACAD SCI USA, V86, P8857, DOI 10.1073/pnas.86.22.8857; BELLIDO T, 1995, J CLIN INVEST, V95, P2886, DOI 10.1172/JCI117995; BREUER M, 1989, NATURE, V340, P61, DOI 10.1038/340061a0; Chen RY, 2001, NAT CELL BIOL, V3, P439, DOI 10.1038/35074500; Chen TS, 2000, CANCER RES, V60, P2132; CUYPERS HT, 1984, CELL, V37, P141; DAYNES RA, 1993, J IMMUNOL, V150, P5219; Debes JD, 2002, CANCER RES, V62, P5632; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; HIRANO T, 1992, CHEM IMMUNOL, V51, P153; Hobisch A, 1998, CANCER RES, V58, P4640; Jaster R, 1999, CELL SIGNAL, V11, P769, DOI 10.1016/S0898-6568(99)00050-9; Keller ET, 1996, J BIOL CHEM, V271, P26267, DOI 10.1074/jbc.271.42.26267; Kim O, 2002, J BIOL CHEM, V277, P30066, DOI 10.1074/jbc.M201713200; Lee LF, 2001, MOL CELL BIOL, V21, P8385, DOI 10.1128/MCB.21.24.8385-8397.2001; Lilly M, 1999, ONCOGENE, V18, P4022, DOI 10.1038/sj.onc.1202741; LILLY M, 1992, ONCOGENE, V7, P727; Lin DL, 2001, CLIN CANCER RES, V7, P1773; Matikainen S, 1999, BLOOD, V93, P1980, DOI 10.1182/blood.V93.6.1980.406k20_1980_1991; Okamoto M, 1998, PROSTATE, V35, P255, DOI 10.1002/(SICI)1097-0045(19980601)35:4<255::AID-PROS4>3.0.CO;2-F; PLANTE M, 1994, CANCER, V73, P1882, DOI 10.1002/1097-0142(19940401)73:7<1882::AID-CNCR2820730718>3.0.CO;2-R; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; Shirogane T, 1999, IMMUNITY, V11, P709, DOI 10.1016/S1074-7613(00)80145-4; SIEGALL CB, 1990, CANCER RES, V50, P7786; SIEGSMUND MJ, 1994, J UROLOGY, V151, P1396, DOI 10.1016/S0022-5347(17)35267-9; Smith PC, 2001, PROSTATE, V48, P47; Smith PC, 2001, CYTOKINE GROWTH F R, V12, P33, DOI 10.1016/S1359-6101(00)00021-6; UEDA T, 1994, J GASTROENTEROL, V29, P423, DOI 10.1007/BF02361238; Ueda T, 2002, J BIOL CHEM, V277, P7076, DOI 10.1074/jbc.M108255200; Xue LY, 1999, ONCOGENE, V18, P3391, DOI 10.1038/sj.onc.1202687; Yang HB, 2002, J BIOL CHEM, V277, P30219, DOI 10.1074/jbc.M111933200; Zhang JF, 2000, ENDOCRINOLOGY, V141, P4698, DOI 10.1210/en.141.12.4698; Zhu N, 2002, J IMMUNOL, V168, P744, DOI 10.4049/jimmunol.168.2.744	38	61	71	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	2004	23	10					1838	1844		10.1038/sj.onc.1207304	http://dx.doi.org/10.1038/sj.onc.1207304			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	801XV	14981536				2022-12-28	WOS:000220129500005
J	Joers, A; Jaks, V; Kase, J; Maimets, T				Joers, A; Jaks, V; Kase, J; Maimets, T			p53-dependent transcription can exhibit both on/off and graded response after genotoxic stress	ONCOGENE			English	Article						p53; transcription; DNA damage; GFP; flow cytometry	P53 PROTEIN; GENE-EXPRESSION; ACTIVATION; APOPTOSIS; MDM-2; TRANSACTIVATION; PARTICIPATION; ACCUMULATION; DEFICIENT; MEDIATOR	The p53 protein is a central player in cellular response to DNA damage. Induction of p53 by DNA-damaging agents involves elevation of its steady-state level and activation of its potency as a transcription factor. In the cell population, these responses can occur either homogeneously (where every single cell responds simultaneously and similarly to its neighbor) or heterogeneously (where only some cells of a population respond and the number of these increases with increasing dose of inducer). We have studied here the p53 response to DNA-damaging agents (camptothecin, mitomycin C) in individual cells. We show that the level of p53 protein is increased in every single cell of the population homogeneously, while the p53-dependent transcription can be subject to an on/off-type response. Depending on the structure of the target promoter, p53-dependent transcription can be regulated according to the binary or graded model. The on/off-type transcriptional activation pattern of p53 defines two distinct subpopulations of cells after DNA damage.	Univ Tartu, Inst Mol & Cell Biol, Dept Cell Biol, EE-51010 Tartu, Estonia; Estonian Bioctr, EE-51010 Tartu, Estonia	University of Tartu; Estonian Biocentre	Joers, A (corresponding author), Univ Tartu, Inst Mol & Cell Biol, Dept Cell Biol, Riia 23, EE-51010 Tartu, Estonia.	ajoers@ebc.ee	Maimets, Toivo/E-9268-2017; Jaks, Viljar/H-2467-2012	Maimets, Toivo/0000-0001-6461-3365; Jaks, Viljar/0000-0002-2221-6262; Roostalu, Johanna/0000-0002-6757-0468; Joers, Arvi/0000-0003-2083-3977				Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Biggar SR, 2001, EMBO J, V20, P3167, DOI 10.1093/emboj/20.12.3167; Blake WJ, 2003, NATURE, V422, P633, DOI 10.1038/nature01546; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; de Krom M, 2002, MOL CELL, V9, P1319, DOI 10.1016/S1097-2765(02)00558-0; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elowitz MB, 2002, SCIENCE, V297, P1183, DOI 10.1126/science.1070919; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; Fu LN, 1997, EMBO J, V16, P4117, DOI 10.1093/emboj/16.13.4117; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Graubert TA, 1998, NUCLEIC ACIDS RES, V26, P2849, DOI 10.1093/nar/26.12.2849; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; KASTAN MB, 1991, CANCER RES, V51, P6304; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Li XQ, 1998, J BIOL CHEM, V273, P34970, DOI 10.1074/jbc.273.52.34970; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rossi FMV, 2000, MOL CELL, V6, P723, DOI 10.1016/S1097-2765(00)00070-8; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sharpless NE, 2002, CELL, V110, P9, DOI 10.1016/S0092-8674(02)00818-8; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1	40	29	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2004	23	37					6175	6185		10.1038/sj.onc.1207864	http://dx.doi.org/10.1038/sj.onc.1207864			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	847NC	15208667				2022-12-28	WOS:000223399000001
J	Deans, AJ; Simpson, KJ; Trivett, MK; Brown, MA; McArthur, GA				Deans, AJ; Simpson, KJ; Trivett, MK; Brown, MA; McArthur, GA			Brca1 inactivation induces p27Kip1-dependent cell cycle arrest and delayed development in the mouse mammary gland	ONCOGENE			English	Article						p27; BRCA1; mammary development; mouse model; cell cycle	DEPENDENT KINASE INHIBITOR; HEREDITARY BREAST-CANCER; TUMOR SUPPRESSION; OVARIAN-CANCER; DNA-REPAIR; P27(KIP1); EXPRESSION; P27; MUTATIONS; LINE	One common characteristic of breast cancers arising in carriers of the predisposition gene BRCA1 is a loss of expression of the CDK inhibitor p27(Kip1) (p27), suggesting that p27 interacts epistatically with BRCA1. To investigate this relationship, we examined expression of p27 in mice expressing a dominant negative allele of Brca1 (MMTV-trBr) in the mammary gland. While these mice rarely develop tumors, they showed a 50% increase in p27 protein and a delay in mammary gland development associated with reduced proliferation. In contrast, on a p27 heterozygote background, MMTV-trBrca1 mice showed an increase in S phase cells, and normal mammary development. p27 was the only protein in the cyclin cyclin-dependent kinase network to show altered expression, suggesting that it may be a central mediator of cell cycle arrest in response to loss of function of BRCA1. Furthermore, in human mammary epithelial MCF7 cells expressing BRCA1-specific RNAi and in the BRCA1-deficient human tumor cell line HCC1937, p27 is elevated at the mRNA level compared to cells expressing wild-type BRCA1. We hypothesize that disruption of BRCA1 induces an increase in p27 that inhibits proliferation. Accordingly, reduction in p27 expression leads to enhancement of cellular proliferation in the absence of BRCA1.	Peter MacCallum Canc Ctr, Trescowthick Res Labs, Mol Oncol Lab, Melbourne, Vic 3002, Australia; Univ Melbourne, Dept Med St Vincents, Parkville, Vic 3052, Australia; Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia; Peter MacCallum Canc Ctr, Dept Pathol, Melbourne 3002, Australia; Univ Queensland, Dept Biochem & Mol Biol, Brisbane, Qld 4072, Australia; Peter MacCallum Canc Ctr, Dept Haematol & Med Oncol, Melbourne 3002, Australia	Peter Maccallum Cancer Center; University of Melbourne; University of Melbourne; Peter Maccallum Cancer Center; University of Queensland; Peter Maccallum Cancer Center	McArthur, GA (corresponding author), Peter MacCallum Canc Ctr, Locked Bag 1,A Beckett St, Melbourne, Vic 8006, Australia.	grant.mcarthur@petermac.org	Deans, Andrew/U-3515-2019; Brown, Melissa A/F-1451-2010; Deans, Andrew J/E-5817-2011	Deans, Andrew/0000-0002-5271-4422; Deans, Andrew J/0000-0002-5271-4422; Simpson, Kaylene/0000-0001-9136-1781				Armes JE, 2002, PATHOLOGY, V34, P309, DOI 10.1080/00313020220147113; Brown MA, 2002, TRANSGENIC RES, V11, P467, DOI 10.1023/A:1020348025139; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Chappuis PO, 2000, J CLIN ONCOL, V18, P4045, DOI 10.1200/JCO.2000.18.24.4045; Chen A, 2002, J BIOL CHEM, V277, P22085, DOI 10.1074/jbc.M201252200; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Craig C, 1997, ONCOGENE, V14, P2283, DOI 10.1038/sj.onc.1201064; Cressman VL, 1999, MOL CELL BIOL, V19, P7061; Crook T, 1998, ONCOGENE, V17, P1681, DOI 10.1038/sj.onc.1202106; Davison EA, 2003, MOL ENDOCRINOL, V17, P2436, DOI 10.1210/me.2003-0199; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Dong YS, 2003, MOL CELL, V12, P1087, DOI 10.1016/S1097-2765(03)00424-6; Eisinger F, 1996, CANCER RES, V56, P471; Fan SJ, 2001, ONCOGENE, V20, P8215, DOI 10.1038/sj.onc.1205033; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Fujieda S, 1999, INT J CANCER, V84, P315, DOI 10.1002/(SICI)1097-0215(19990621)84:3<315::AID-IJC20>3.0.CO;2-U; Ganesan S, 2002, CELL, V111, P393, DOI 10.1016/S0092-8674(02)01052-8; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Hakansson S, 1997, AM J HUM GENET, V60, P1068; Humphreys RC, 1997, MOL ENDOCRINOL, V11, P801, DOI 10.1210/me.11.6.801; Jackson RJ, 2002, ONCOGENE, V21, P8486, DOI 10.1038/sj.onc.1205946; Jazaeri AA, 2002, JNCI-J NATL CANCER I, V94, P990, DOI 10.1093/jnci/94.13.990; Johannsson OT, 1997, EUR J CANCER, V33, P362, DOI 10.1016/S0959-8049(96)00469-8; Kauraniemi P, 2000, CANCER RES, V60, P5323; KAVANAUGH MP, 1994, P NATL ACAD SCI USA, V91, P7071, DOI 10.1073/pnas.91.15.7071; Kudo Y, 2000, CANCER LETT, V151, P217, DOI 10.1016/S0304-3835(99)00419-X; Lakhani SR, 2002, J CLIN ONCOL, V20, P2310, DOI 10.1200/JCO.2002.09.023; Liu DF, 1999, J CLIN LAB ANAL, V13, P291, DOI 10.1002/(SICI)1098-2825(1999)13:6<291::AID-JCLA7>3.0.CO;2-K; Lloyd RV, 1999, AM J PATHOL, V154, P313, DOI 10.1016/S0002-9440(10)65277-7; Marcus JN, 1996, CANCER-AM CANCER SOC, V77, P697, DOI 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W; Martins CP, 2002, EMBO J, V21, P3739, DOI 10.1093/emboj/cdf364; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Muraoka RS, 2001, J CELL BIOL, V153, P917, DOI 10.1083/jcb.153.5.917; Nadeau G, 2000, EMBO REP, V1, P260, DOI 10.1093/embo-reports/kvd059; Niwa Y, 2000, JPN J CANCER RES, V91, P519, DOI 10.1111/j.1349-7006.2000.tb00976.x; Pharoah PDP, 1999, CANCER RES, V59, P868; Philipp-Staheli J, 2002, CANCER CELL, V1, P355, DOI 10.1016/S1535-6108(02)00054-5; Russo J, 2001, Breast J, V7, P278, DOI 10.1046/j.1524-4741.2001.21033.x; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Stoppa-Lyonnet D, 2000, J CLIN ONCOL, V18, P4053, DOI 10.1200/JCO.2000.18.24.4053; Sylvain V, 2002, INT J ONCOL, V20, P845; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Vaziri SAJ, 2001, J CLIN PATHOL-MOL PA, V54, P259, DOI 10.1136/mp.54.4.259; Wagner T, 1999, GENOMICS, V62, P369, DOI 10.1006/geno.1999.6026; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Ye QN, 2001, J CELL BIOL, V155, P911, DOI 10.1083/jcb.200108049	52	11	12	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6136	6145		10.1038/sj.onc.1207805	http://dx.doi.org/10.1038/sj.onc.1207805			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15208652				2022-12-28	WOS:000223261000013
J	Seo, T; Park, J; Lim, C; Choe, J				Seo, T; Park, J; Lim, C; Choe, J			Inhibition of nuclear factor kappa B activity by viral interferon regulatory factor 3 of Kaposi's sarcoma-associated herpesvirus	ONCOGENE			English	Article						KSHV; VIRF3; NF-kappa B; IKK	IKK-ALPHA; INDUCED APOPTOSIS; DNA-SEQUENCES; TUMOR-SUPPRESSOR; MICE LACKING; BETA; ACTIVATION; SUBUNIT; PROTEIN; TNF	Nuclear factor-kappaB (NF-kappaB) is a transcription factor that plays an important role in the immune system and cell death. Many viral proteins modulate NF-kappaB to escape host immune surveillance, promote cell survival, and enhance viral replication. In the present study, we show that NF-kappaB activity is downmodulated by viral interferon regulatory factor 3 (vIRF3), which is encoded by Kaposi's sarcoma-associated herpesvirus open-reading frame K10.5. vIRF3 repressed NF-kappaB-dependent transcription in a dose-dependent manner and inhibited the activation of NF-kappaB induced by tumor necrosis factor (TNF)-alpha. In vivo studies showed vIRF3 inhibited IkappaB kinase beta (IKKbeta) activity, but not IKKalpha activity, resulting in reduced IkappaB phosphorylation. Immunofluorescence assays showed that vIRF3 interfered with nuclear translocation of NF-kappaB. In addition, consistent with the inhibition of NF-kappaB activity, vIRF3 sensitized cells to TNF-alpha-induced apoptosis. While vIRF3 interacts with IKKbeta in vitro and in 293T cells, we were unable to demonstrate vIRF3-IKKbeta interaction in BCBL-1 cells. Our results indicate that vIRF3 can regulate the host immune system and apoptosis via inhibition of NF-kappaB activity.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST)	Choe, J (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.	jchoe@kaist.ac.kr	Lim, Chunghun/AAB-1253-2020; Choe, Joonho/F-3066-2011	Lim, Chunghun/0000-0001-8473-9272; 				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Bakker TR, 1999, INT J CANCER, V80, P320; Barnes B, 2002, J INTERF CYTOK RES, V22, P59, DOI 10.1089/107999002753452665; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Brown HJ, 2003, J VIROL, V77, P8532, DOI 10.1128/JVI.77.15.8532-8540.2003; Burysek L, 1999, J VIROL, V73, P7334; Burysek L, 1999, J HUMAN VIROL, V2, P19; Burysek L, 2001, J VIROL, V75, P2345, DOI 10.1128/JVI.75.5.2345-2352.2001; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; Ganem D, 1997, CELL, V91, P157, DOI 10.1016/S0092-8674(00)80398-0; Gao SJ, 1997, ONCOGENE, V15, P1979, DOI 10.1038/sj.onc.1201571; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Hiscott J, 2001, J CLIN INVEST, V107, P143, DOI 10.1172/JCI11918; Hu JD, 2002, J INTERF CYTOK RES, V22, P1017, DOI 10.1089/107999002760624242; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Li M, 2000, MOL CELL BIOL, V20, P8254, DOI 10.1128/MCB.20.21.8254-8263.2000; Li MT, 1998, J VIROL, V72, P5433, DOI 10.1128/JVI.72.7.5433-5440.1998; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Liu L, 2002, J BIOL CHEM, V277, P13745, DOI 10.1074/jbc.M110480200; Lubyova B, 2004, J BIOL CHEM, V279, P7643, DOI 10.1074/jbc.M309485200; Lubyova B, 2000, J VIROL, V74, P8194, DOI 10.1128/JVI.74.17.8194-8201.2000; Moore PS, 1998, TRENDS GENET, V14, P144, DOI 10.1016/S0168-9525(98)01408-5; Nakamura H, 2001, J VIROL, V75, P7572, DOI 10.1128/JVI.75.16.7572-7582.2001; Ouaaz F, 1999, J EXP MED, V189, P999, DOI 10.1084/jem.189.6.999; Rivas C, 2001, J VIROL, V75, P429, DOI 10.1128/JVI.75.1.429-438.2001; Rothwarf D M, 1999, Sci STKE, V1999, pRE1, DOI 10.1126/stke.1999.5.re1; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Seo T, 2002, J VIROL, V76, P8797, DOI 10.1128/JVI.76.17.8797-8807.2002; Seo T, 2001, J VIROL, V75, P6193, DOI 10.1128/JVI.75.13.6193-6198.2001; Seo T, 2000, BIOCHEM BIOPH RES CO, V270, P23, DOI 10.1006/bbrc.2000.2393; Shao RP, 1999, J BIOL CHEM, V274, P21495, DOI 10.1074/jbc.274.31.21495; Shao RP, 1997, J BIOL CHEM, V272, P32739, DOI 10.1074/jbc.272.52.32739; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Simeonidis S, 1999, P NATL ACAD SCI USA, V96, P49, DOI 10.1073/pnas.96.1.49; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Spitkovsky D, 2002, J BIOL CHEM, V277, P25576, DOI 10.1074/jbc.M201884200; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; VAN AD, 1996, SCIENCE, V274, P787; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zimring JC, 1998, J VIROL, V72, P701, DOI 10.1128/JVI.72.1.701-707.1998	55	47	49	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6146	6155		10.1038/sj.onc.1207807	http://dx.doi.org/10.1038/sj.onc.1207807			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15208654				2022-12-28	WOS:000223261000014
J	Muhlethaler-Mottet, A; Bourloud, KB; Auderset, K; Joseph, JM; Gross, N				Muhlethaler-Mottet, A; Bourloud, KB; Auderset, K; Joseph, JM; Gross, N			Drug-mediated sensitization to TRAIL-induced apoptosis in caspase-8-complemented neuroblastoma cells proceeds via activation of intrinsic and extrinsic pathways and caspase-dependent cleavage of XIAP, Bcl-x(L) and RIP	ONCOGENE			English	Article						apoptosis; TRAIL; caspase-8; neuroblastoma; chemotherapeutic drugs; cycloheximide	DEATH RECEPTORS 4; CYTOCHROME-C; LIGAND TRAIL; APO-2 LIGAND; TUMOR-CELLS; EXPRESSION; PROTEIN; CD95; AMPLIFICATION; RESISTANCE	Neuroblastorna (NB) is a childhood neoplasm which heterogeneous behavior can be explained by differential regulation of apoptosis. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively induces rapid apoptosis in most tumor cells and thus represents a promising anticancer agent. We have reported silencing of caspase-8 expression in highly malignant NB cells as a possible mechanism of resistance to TRAIL-induced apoptosis. To explore the particular contribution of caspase-8 in such resistance, retroviral-mediated stable caspase-8 expression was induced in the IGR-N91 cells. As a result, sensitivity to TRAIL was fully restored in the caspase-8-complemented cells. TRAIL-induced cell death could be further enhanced by cotreatment of IGR-N91-C8 and SH-EP cells with cycloheximide or subtoxic concentrations of chemotherapeutic drugs in a caspase-dependent manner. Sensitization to TRAIL involved enhanced death receptor DR5 expression, activation of Bid and the complete caspases cascade. Interestingly, combined treatments also enhanced the cleavage-mediated inactivation of antiapoptotic molecules, XIAP, Bcl-x(L) and RIP. Our results show that restoration of active caspase-8 expression in a caspase-8-deficient NB cell line is necessary and sufficient to fully restore TRAIL sensitivity. Moreover, the synergistic effect of drugs and TRAIL results from activation of the caspase cascade via a mitochondrial pathway-mediated amplification loop and from the inactivation of apoptosis inhibitors.	CHU Vaudois, Dept Pediat, CH-1011 Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Gross, N (corresponding author), CHU Vaudois, Dept Pediat, CH-1011 Lausanne, Switzerland.	nicole.gross@chuv.hospvd.ch	Mühlethaler-Mottet, Annick/H-2848-2019	Mühlethaler-Mottet, Annick/0000-0001-8274-0907				Altieri DC, 2003, ADV CANCER RES, V88, P31, DOI 10.1016/S0065-230X(03)88303-3; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Benedict CA, 2001, J BIOL CHEM, V276, P3270, DOI 10.1074/jbc.M008218200; Brambilla E, 1996, AM J PATHOL, V149, P1941; Brodeur GM, 1997, J PEDIAT HEMATOL ONC, V19, P93, DOI 10.1097/00043426-199703000-00001; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Eggert A, 2001, CANCER RES, V61, P1314; French LE, 1999, NAT MED, V5, P146, DOI 10.1038/5505; Fulda S, 2000, CANCER RES, V60, P3947; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Harada K, 2002, CANCER RES, V62, P5897; Hopkins-Donaldson S, 2002, ONCOGENE, V21, P6132, DOI 10.1038/sj.onc.1205879; Hopkins-Donaldson S, 2000, CANCER RES, V60, P4315; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Jazirehi AR, 2001, CLIN CANCER RES, V7, P3874; Johnson DE, 2000, CANCER RES, V60, P1818; Keane MM, 1999, CANCER RES, V59, P734; Kim JW, 2000, ONCOGENE, V19, P4491, DOI 10.1038/sj.onc.1203796; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Lacour S, 2003, ONCOGENE, V22, P1807, DOI 10.1038/sj.onc.1206127; Lacour S, 2001, CANCER RES, V61, P1645; Lee SH, 1999, CANCER RES, V59, P5683; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Martinon F, 2000, FEBS LETT, V468, P134, DOI 10.1016/S0014-5793(00)01212-6; Micheau O, 1999, BIOCHEM BIOPH RES CO, V256, P603, DOI 10.1006/bbrc.1999.0391; Mizutani Y, 1999, CLIN CANCER RES, V5, P2605; Nagane M, 2001, APOPTOSIS, V6, P191, DOI 10.1023/A:1011336726649; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Park WS, 2002, ONCOGENE, V21, P2919, DOI 10.1038/sj.onc.1205394; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; REED JC, 1991, CANCER RES, V51, P6529; Rodriguez-Lopez AM, 2001, MOL PHARMACOL, V59, P135, DOI 10.1124/mol.59.1.135; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Sheikh MS, 1998, CANCER RES, V58, P1593; Shin MS, 2001, CANCER RES, V61, P4942; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Sokol RJ, 2001, PEDIATR RES, V49, P519, DOI 10.1203/00006450-200104000-00014; SONEOKA Y, 1995, NUCLEIC ACIDS RES, V23, P628, DOI 10.1093/nar/23.4.628; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; THORNE M, 1997, NATURE, V386, P517; Vassal G, 1997, EUR J CANCER, V33, P2011, DOI 10.1016/S0959-8049(97)00296-7; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; Wajant H, 2002, APOPTOSIS, V7, P449, DOI 10.1023/A:1020039225764; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yang XH, 2003, CANCER LETT, V197, P137, DOI 10.1016/S0304-3835(03)00093-4; Zhang XD, 1999, CANCER RES, V59, P2747; Zhang XD, 2001, CANCER RES, V61, P7339	59	61	66	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2004	23	32					5415	5425		10.1038/sj.onc.1207704	http://dx.doi.org/10.1038/sj.onc.1207704			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15094781				2022-12-28	WOS:000222588400001
J	Akula, SM; Ford, PW; Whitman, AG; Hamden, KE; Shelton, JG; McCubrey, JA				Akula, SM; Ford, PW; Whitman, AG; Hamden, KE; Shelton, JG; McCubrey, JA			Raf promotes human herpesvirus-8 (HHV-8/KSHV) infection	ONCOGENE			English	Article						HHV-8; KSHV; Raf; VEGF; HB-EGF	SARCOMA-ASSOCIATED HERPESVIRUS; ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR SYNTHESIS; IMMUNODEFICIENCY-VIRUS TYPE-1; ABROGATE CYTOKINE DEPENDENCY; SIGNAL-REGULATED KINASE; SMOOTH-MUSCLE-CELLS; KAPOSIS-SARCOMA; ENDOTHELIAL-CELLS; TARGET-CELLS	Human herpesvirus-8 (HHV-8/KSHV) is etiologically associated with Kaposi's sarcoma (KS) and other tumors. Constitutive activation of the mitogen-activated protein kinase ( MAPK) signaling pathway has been associated with a variety of tumors, including AIDS-related KS. The oncoprotein Raf is situated at a pivotal position in regulating the MAPK pathway. Hence, we analysed the effect of oncoprotein Raf on HHV-8 infectious entry into target cells. Here we report Raf expression to significantly enhance HHV-8 infection of target cells. These findings implicate a role for Raf not only in the infectious entry of HHV-8 but also in modulating KS pathogenesis.	E Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Greenville, NC 27858 USA	University of North Carolina; East Carolina University	Akula, SM (corresponding author), E Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Greenville, NC 27858 USA.	akulas@mail.ecu.edu		McCubrey, James/0000-0001-6027-3156	NCI NIH HHS [R01CA098195] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098195] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ablashi DV, 2002, CLIN MICROBIOL REV, V15, P439, DOI 10.1128/CMR.15.3.439-464.2002; ADAMS V, 1995, J MED VIROL, V46, P189, DOI 10.1002/jmv.1890460304; Akula SM, 2003, J VIROL, V77, P7978, DOI 10.1128/JVI.77.14.7978-7990.2003; Akula SM, 2002, CELL, V108, P407, DOI 10.1016/S0092-8674(02)00628-1; Akula SM, 2001, VIROLOGY, V282, P245, DOI 10.1006/viro.2000.0851; Akula SM, 2001, VIROLOGY, V284, P235, DOI 10.1006/viro.2001.0921; Aoki Y, 2001, LEUKEMIA LYMPHOMA, V41, P229, DOI 10.3109/10428190109057978; Aoki Y, 2000, J HEMATOTH STEM CELL, V9, P137, DOI 10.1089/152581600319351; BAILER RT, 1995, J INTERF CYTOK RES, V15, P473, DOI 10.1089/jir.1995.15.473; Bairey O, 2004, LEUKEMIA RES, V28, P243, DOI 10.1016/S0145-2126(03)00256-X; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Baumann B, 2000, P NATL ACAD SCI USA, V97, P4615, DOI 10.1073/pnas.080583397; Birkmann A, 2001, J VIROL, V75, P11583, DOI 10.1128/JVI.75.23.11583-11593.2001; Blackbourn DJ, 2000, AIDS, V14, P1123, DOI 10.1097/00002030-200006160-00009; Blasig C, 1997, J VIROL, V71, P7963, DOI 10.1128/JVI.71.10.7963-7968.1997; BLOTNICK S, 1994, P NATL ACAD SCI USA, V91, P2890, DOI 10.1073/pnas.91.8.2890; Cerimele F, 2001, J VIROL, V75, P2435, DOI 10.1128/JVI.75.5.2435-2443.2001; Chandran B, 1998, VIROLOGY, V243, P208, DOI 10.1006/viro.1998.9055; Chang FM, 2001, ONCOGENE, V20, P4354, DOI 10.1038/sj.onc.1204564; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chong H, 2003, CELL SIGNAL, V15, P463, DOI 10.1016/S0898-6568(02)00139-0; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; De Clercq E, 2001, REV MED VIROL, V11, P381, DOI 10.1002/rmv.336; De Vos J, 2001, BLOOD, V98, P771, DOI 10.1182/blood.V98.3.771; ELLIS PD, 2001, BIOCHEM J, V15, P99; Ensoli B, 2000, SEMIN CANCER BIOL, V10, P367, DOI 10.1006/scbi.2000.0329; Ensoli B, 2001, EUR J CANCER, V37, P1251, DOI 10.1016/S0959-8049(01)00121-6; Faris M, 1996, AIDS, V10, P369, DOI 10.1097/00002030-199604000-00004; Gallo RC, 1998, SCIENCE, V282, P1837, DOI 10.1126/science.282.5395.1837; Ganem D, 1998, CURR CLIN TOPICS INF, V18, P237; Geraminejad P, 2002, J AM ACAD DERMATOL, V47, P641, DOI 10.1067/mjd.2002.128383; GIRALDO G, 1980, INT J CANCER, V26, P23, DOI 10.1002/ijc.2910260105; Gorden A, 2003, CANCER RES, V63, P3955; Hayward GS, 2003, CANCER CELL, V3, P1, DOI 10.1016/S1535-6108(03)00002-3; Hermouet S, 2003, NEW ENGL J MED, V348, P178, DOI 10.1056/NEJM200301093480219; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1995, J CELL BIOL, V128, P929, DOI 10.1083/jcb.128.5.929; Hilger RA, 2002, ONKOLOGIE, V25, P511, DOI 10.1159/000068621; Hoyle PE, 2000, LEUKEMIA, V14, P642, DOI 10.1038/sj.leu.2401720; Iivanainen E, 2003, FASEB J, V17, P1609, DOI 10.1096/fj.02-0939com; Ingram JL, 2003, AM J PHYSIOL-LUNG C, V284, pL774, DOI 10.1152/ajplung.00189.2002; Janssen RAJ, 1998, J BIOL CHEM, V273, P32182, DOI 10.1074/jbc.273.48.32182; Karkkainen MJ, 2000, ONCOGENE, V19, P5598, DOI 10.1038/sj.onc.1203855; Kempf W, 1996, BIOCHEM MOL MED, V58, P1, DOI 10.1006/bmme.1996.0025; Le Gall M, 2003, J CELL PHYSIOL, V196, P98, DOI 10.1002/jcp.10276; Lee John T Jr, 2002, Expert Opin Ther Targets, V6, P659; Marshall CJ, 1996, NATURE, V383, P127, DOI 10.1038/383127a0; Masood R, 2002, AM J PATHOL, V160, P23, DOI 10.1016/S0002-9440(10)64344-1; Masson-Gadais B, 2003, CELL STRESS CHAPERON, V8, P37, DOI 10.1379/1466-1268(2003)8<37:IVRFVA>2.0.CO;2; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; McCubrey JA, 1998, LEUKEMIA, V12, P1903, DOI 10.1038/sj.leu.2401215; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Monini P, 1996, INT J CANCER, V66, P717, DOI 10.1002/(SICI)1097-0215(19960611)66:6<717::AID-IJC1>3.3.CO;2-N; Morand P, 1999, LEUKEMIA LYMPHOMA, V35, P379, DOI 10.3109/10428199909145743; Myoung H, 2003, CANCER SCI, V94, P215, DOI 10.1111/j.1349-7006.2003.tb01422.x; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; Naranatt PP, 2003, J VIROL, V77, P1524, DOI 10.1128/JVI.77.2.1524-1539.2003; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; Planz O, 2001, J VIROL, V75, P4871, DOI 10.1128/JVI.75.10.4871-4877.2001; Popik W, 1996, MOL CELL BIOL, V16, P6532; RAAB G, 1994, BIOCHEM BIOPH RES CO, V204, P592, DOI 10.1006/bbrc.1994.2500; RAAB G, 1997, BIOCHIM BIOPHYS ACTA, V1333, P179; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Sebolt-Leopold JS, 2000, ONCOGENE, V19, P6594, DOI 10.1038/sj.onc.1204083; Shelton JG, 2003, LEUKEMIA, V17, P1765, DOI 10.1038/sj.leu.2403052; SHEN H, 1993, BLOOD, V81, P2767; Sirianni MC, 1997, LANCET, V349, P255, DOI 10.1016/S0140-6736(05)64866-0; Spear PG, 2003, J VIROL, V77, P10179, DOI 10.1128/JVI.77.19.10179-10185.2003; Takenaka M, 2003, BIOCHEM BIOPH RES CO, V301, P198, DOI 10.1016/S0006-291X(02)03014-0; THOMPSON SA, 1994, J BIOL CHEM, V269, P2541; Tokuda H, 2003, ARCH BIOCHEM BIOPHYS, V415, P117, DOI 10.1016/S0003-9861(03)00225-X; Vieira J, 2001, J VIROL, V75, P1378, DOI 10.1128/JVI.75.3.1378-1386.2001; Wang FZ, 2001, J VIROL, V75, P7517, DOI 10.1128/JVI.75.16.7517-7527.2001; Wang H, 1998, CIRC RES, V83, P832, DOI 10.1161/01.RES.83.8.832; Weinstein-Oppenheimer CR, 2002, CANCER BIOL THER, V1, P256, DOI 10.4161/cbt.77; Woods D, 2001, MOL CELL BIOL, V21, P3192, DOI 10.1128/MCB.21.9.3192-3205.2001; Yang SY, 2002, ARTERIOSCL THROM VAS, V22, P1797, DOI 10.1161/01.ATV.0000038995.31179.24; Yang XY, 1999, J VIROL, V73, P3460, DOI 10.1128/JVI.73.4.3460-3466.1999; Yoshiizumi K, 2003, BIOORGAN MED CHEM, V11, P433, DOI 10.1016/S0968-0896(02)00426-1; Zhang L, 2002, CANCER RES, V62, P5463; Zhu LJ, 1999, VIROLOGY, V262, P237, DOI 10.1006/viro.1999.9900	84	33	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2004	23	30					5227	5241		10.1038/sj.onc.1207643	http://dx.doi.org/10.1038/sj.onc.1207643			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	834AE	15122343				2022-12-28	WOS:000222382500012
J	Oh, J; Takahashi, R; Adachi, E; Kondo, S; Kuratomi, S; Noma, A; Alexander, DB; Motoda, H; Okada, A; Seiki, M; Itoh, T; Itohara, S; Takahashi, C; Noda, M				Oh, J; Takahashi, R; Adachi, E; Kondo, S; Kuratomi, S; Noma, A; Alexander, DB; Motoda, H; Okada, A; Seiki, M; Itoh, T; Itohara, S; Takahashi, C; Noda, M			Mutations in two matrix metalloproteinase genes, MMP-2 and MT1-MMP, are synthetic lethal in mice	ONCOGENE			English	Article						MMP-2; MT1-MMP; angiogenesis; myogenesis	CENTRAL CORE DISEASE; ARTERIAL ENLARGEMENT; EXTRACELLULAR-MATRIX; CONGENITAL MYOPATHIES; IV COLLAGENASE; KEY REGULATOR; GELATINASE-A; ANGIOGENESIS; EXPRESSION; ACTIVATION	The matrix metalloproteinase (MMP) family (similar to25 members in mammals) has been implicated in extracellular matrix remodeling associated with embryonic development, cancer formation and progression, and various other physiological and pathological events. Inactivating mutations in individual matrix metalloproteinase genes in mice described so far, however, are nonlethal at least up to the first few weeks after birth, suggesting functional redundancy among MMP family members. Here, we report that mice lacking two MMPs, MMP-2 (nonmembrane type) and MT1-MMP ( membrane type), die immediately after birth with respiratory failure, abnormal blood vessels, and immature muscle fibers reminiscent of central core disease. In the absence of MMP-2 and MT1-MMP, myoblast fusion in vitro is also significantly retarded. These findings suggest functional overlap in mice between the two MMPs with distinct molecular natures.	Kyoto Univ, Sch Med, Dept Mol Oncol, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Med, Dept Pathol & Tumor Biol, Sakyo Ku, Kyoto 6068501, Japan; Kitasato Univ, Grad Sch Med Sci, Dept Physiol & Biophys, Kanagawa 2288555, Japan; Kyoto Univ, Grad Sch Med, Dept Phys & Biophys, Sakyo Ku, Kyoto 6068501, Japan; Univ Tokyo, Inst Med Sci, Div Canc Cell Res, Tokyo 1088639, Japan; Shionogi & Co Ltd, Discovery Res Labs, Fukushima Ku, Osaka 5530002, Japan; RIKEN, Brain Sci Inst, Lab Behav Genet, Wako, Saitama 3510198, Japan	Kyoto University; Kyoto University; Kitasato University; Kyoto University; University of Tokyo; Shionogi & Company Limited; RIKEN	Noda, M (corresponding author), Kyoto Univ, Sch Med, Dept Mol Oncol, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan.	mnoda@virus.kyoto-u.ac.jp	Itohara, Shigeyoshi/I-8769-2012; Seiki, Motoharu/K-9443-2015	Itohara, Shigeyoshi/0000-0002-2410-9989; Oh, Junseo/0000-0002-0754-4946				Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; COUCH CB, 1983, CELL, V32, P257, DOI 10.1016/0092-8674(83)90516-0; de Kleijn DPV, 2001, FEBS LETT, V501, P37, DOI 10.1016/S0014-5793(01)02622-9; Deryugina EI, 2002, CANCER RES, V62, P580; Durbeej M, 1998, CURR OPIN CELL BIOL, V10, P594, DOI 10.1016/S0955-0674(98)80034-3; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; FAHIME EE, 2000, EXP CELL RES, V258, P279; FANANAPAZIR L, 1993, P NATL ACAD SCI USA, V90, P3993, DOI 10.1073/pnas.90.9.3993; Fang JM, 2000, P NATL ACAD SCI USA, V97, P3884, DOI 10.1073/pnas.97.8.3884; FELIPE MI, 1983, HISTOCHEM PATHOL, P319; FURST DO, 1989, J CELL BIOL, V109, P517, DOI 10.1083/jcb.109.2.517; Haas TL, 2000, AM J PHYSIOL-HEART C, V279, pH1540, DOI 10.1152/ajpheart.2000.279.4.H1540; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Itoh T, 1997, J BIOL CHEM, V272, P22389, DOI 10.1074/jbc.272.36.22389; Itoh T, 1998, CANCER RES, V58, P1048; Karwowski JK, 1999, J SURG RES, V87, P122, DOI 10.1006/jsre.1999.5707; Lattanzi G, 2000, BIOCHEM BIOPH RES CO, V277, P639, DOI 10.1006/bbrc.2000.3735; Mazzieri R, 1997, EMBO J, V16, P2319, DOI 10.1093/emboj/16.9.2319; Morrison CJ, 2001, J BIOL CHEM, V276, P47402, DOI 10.1074/jbc.M108643200; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Oh J, 2001, CELL, V107, P789, DOI 10.1016/S0092-8674(01)00597-9; PODLESKI TR, 1979, EXP CELL RES, V122, P317, DOI 10.1016/0014-4827(79)90308-2; REPONEN P, 1992, J BIOL CHEM, V267, P7856; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1996, FEBS LETT, V393, P101, DOI 10.1016/0014-5793(96)00861-7; Sho E, 2002, EXP MOL PATHOL, V73, P142, DOI 10.1006/exmp.2002.2457; Stetler-Stevenson WG, 1999, J CLIN INVEST, V103, P1237, DOI 10.1172/JCI6870; Tronc F, 2000, ARTERIOSCL THROM VAS, V20, pE120, DOI 10.1161/01.ATV.20.12.e120; Tubridy N, 2001, CURR OPIN NEUROL, V14, P575, DOI 10.1097/00019052-200110000-00005; VANDERVEN PFM, 1995, J NEUROL SCI, V129, P199, DOI 10.1016/0022-510X(94)00282-S; VITA G, 1994, J NEUROL SCI, V124, P71, DOI 10.1016/0022-510X(94)90013-2; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197	36	103	105	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					5041	5048		10.1038/sj.onc.1207688	http://dx.doi.org/10.1038/sj.onc.1207688			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15064723				2022-12-28	WOS:000222237300010
J	de Bruijn, MFTR; Speck, NA				de Bruijn, MFTR; Speck, NA			Core-binding factors in hematopoiesis and immune function	ONCOGENE			English	Review						Runx1; Runx2; Runx3; CBF beta; AML1; hematopoiesis; hematopoietic stem cells	ACUTE MYELOID-LEUKEMIA; RUNX3 TRANSCRIPTION FACTOR; T-CELL DEVELOPMENT; STEM-CELLS; ENDOTHELIAL-CELLS; FETAL LIVER; EMBRYONIC HEMATOPOIESIS; EXPRESSION PATTERN; LINEAGE ANALYSIS; GENE-EXPRESSION	Core binding factors are heterodimeric transcription factors containing a DNA binding Runx1, Runx2, or Runx3 subunit, along with a non DNA binding CBFbeta subunit. All four subunits are required at one or more stages of hematopoiesis. This review describes the role of Runx1 and CBFb in the initiation of hematopoiesis in the embryo, and in the emergence of hematopoietic stem cells. We also discuss the later stages of hematopoiesis for which members of the core binding factor family are required, as well as the recently described roles for these proteins in autoimmunity.	Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA; John Radcliffe Hosp, Weatherall Inst Mol Med, MRC, Mol Haematol Unit, Oxford OX3 9DS, England	Dartmouth College; University of Oxford	Speck, NA (corresponding author), Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA.	nancy.speck@dartmouth.edu			Medical Research Council [MC_U137970202] Funding Source: Medline; MRC [MC_U137970202] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Agata Y, 1996, INT IMMUNOL, V8, P765, DOI 10.1093/intimm/8.5.765; Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; BAE SC, 1993, ONCOGENE, V8, P809; Basecke J, 2002, ANN HEMATOL, V81, P254, DOI 10.1007/s00277-002-0453-8; BERGER R, 1982, BLOOD, V59, P171; Bjerregaard MD, 2003, BLOOD, V101, P4322, DOI 10.1182/blood-2002-03-0835; BORAL AL, 1989, J VIROL, V63, P76, DOI 10.1128/JVI.63.1.76-84.1989; Burel SA, 2001, MOL CELL BIOL, V22, P144; Burns CE, 2002, EXP HEMATOL, V30, P1381, DOI 10.1016/S0301-472X(02)00955-4; Cai ZL, 2000, IMMUNITY, V13, P423, DOI 10.1016/S1074-7613(00)00042-X; Castilla LH, 1999, NAT GENET, V23, P144, DOI 10.1038/13776; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; Chimienti G, 2000, BLOOD CELL MOL DIS, V26, P186, DOI 10.1006/bcmd.2000.0295; Choi K, 1998, DEVELOPMENT, V125, P725; Chung YS, 2002, DEVELOPMENT, V129, P5511, DOI 10.1242/dev.00149; Ciau-Uitz A, 2000, CELL, V102, P787, DOI 10.1016/S0092-8674(00)00067-2; CURTIS DJ, 2004, BLOOD           0115; de Bruijn MFTR, 2000, EMBO J, V19, P2465, DOI 10.1093/emboj/19.11.2465; de Guzman CG, 2002, MOL CELL BIOL, V22, P5506, DOI 10.1128/MCB.22.15.5506-5517.2002; DOWTON SB, 1985, BLOOD, V65, P557; Dzierzak E, 1998, IMMUNOL TODAY, V19, P228, DOI 10.1016/S0167-5699(98)01258-4; Ehlers M, 2003, J IMMUNOL, V171, P3594, DOI 10.4049/jimmunol.171.7.3594; Elagib KE, 2003, BLOOD, V101, P4333, DOI 10.1182/blood-2002-09-2708; Elefanty AG, 1999, BLOOD, V94, P3754, DOI 10.1182/blood.V94.11.3754.423k05_3754_3763; Fainaru O, 2004, EMBO J, V23, P969, DOI 10.1038/sj.emboj.7600085; Fraser ST, 2003, DEV GROWTH DIFFER, V45, P63; Fujimoto T, 2001, GENES CELLS, V6, P1113, DOI 10.1046/j.1365-2443.2001.00490.x; GERRARD JM, 1991, BRIT J HAEMATOL, V79, P246, DOI 10.1111/j.1365-2141.1991.tb04529.x; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; Gill J, 2003, IMMUNOL REV, V195, P28, DOI 10.1034/j.1600-065X.2003.00077.x; Godin I, 2002, NAT REV IMMUNOL, V2, P593, DOI 10.1038/nri857; Gottgens B, 2004, MOL CELL BIOL, V24, P1870, DOI 10.1128/MCB.24.5.1870-1883.2004; Hall MA, 2003, P NATL ACAD SCI USA, V100, P992, DOI 10.1073/pnas.0237324100; HALLBERG B, 1992, NUCLEIC ACIDS RES, V20, P6495, DOI 10.1093/nar/20.24.6495; Hayashi K, 2000, J IMMUNOL, V165, P6816, DOI 10.4049/jimmunol.165.12.6816; Hayashi K, 2001, J IMMUNOL, V167, P4957, DOI 10.4049/jimmunol.167.9.4957; Helms C, 2003, NAT GENET, V35, P349, DOI 10.1038/ng1268; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; HSIANG YHH, 1993, J IMMUNOL, V150, P3905; Huang G, 2001, EMBO J, V20, P723, DOI 10.1093/emboj/20.4.723; Hug BA, 2002, CANCER RES, V62, P2906; Ichikawa M, 2004, NAT MED, V10, P299, DOI 10.1038/nm997; Imai Y, 1998, BIOCHEM BIOPH RES CO, V252, P582, DOI 10.1006/bbrc.1998.9705; Itoh K, 2002, J IMMUNOL, V168, P541, DOI 10.4049/jimmunol.168.2.541; Jaffredo T, 1998, DEVELOPMENT, V125, P4575; Jaffredo T, 2000, DEV BIOL, V224, P204, DOI 10.1006/dbio.2000.9799; Kalev-Zylinska ML, 2002, DEVELOPMENT, V129, P2015; Kataoka H, 2000, MECH DEVELOP, V98, P139, DOI 10.1016/S0925-4773(00)00445-7; Kohzaki H, 1999, ONCOGENE, V18, P4055, DOI 10.1038/sj.onc.1202735; Komine O, 2003, J EXP MED, V198, P51, DOI 10.1084/jem.20021200; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kundu M, 2002, BLOOD, V100, P2449, DOI 10.1182/blood-2002-04-1064; Lacaud G, 2002, BLOOD, V100, P458, DOI 10.1182/blood-2001-12-0321; Lauzurica P, 1997, J EXP MED, V185, P1193, DOI 10.1084/jem.185.7.1193; Le XF, 1999, J BIOL CHEM, V274, P21651, DOI 10.1074/jbc.274.31.21651; Levanon D, 1996, DNA CELL BIOL, V15, P175, DOI 10.1089/dna.1996.15.175; Levanon D, 2001, MECH DEVELOP, V109, P413, DOI 10.1016/S0925-4773(01)00537-8; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Levanon D, 2001, GENE, V262, P23, DOI 10.1016/S0378-1119(00)00532-1; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; Lewis AF, 1999, J VIROL, V73, P5535, DOI 10.1128/JVI.73.7.5535-5547.1999; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Lind EF, 2001, J EXP MED, V194, P127, DOI 10.1084/jem.194.2.127; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Lorsbach RB, 2004, BLOOD, V103, P2522, DOI 10.1182/blood-2003-07-2439; LUDDY RE, 1978, CANCER, V41, P1959, DOI 10.1002/1097-0142(197805)41:5<1959::AID-CNCR2820410540>3.0.CO;2-8; Medvinsky AL, 1996, BLOOD, V87, P557, DOI 10.1182/blood.V87.2.557.bloodjournal872557; Meyers S, 1996, ONCOGENE, V13, P303; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Mikkola HKA, 2003, NATURE, V421, P547, DOI 10.1038/nature01345; Miller J, 2002, NAT GENET, V32, P645, DOI 10.1038/ng1049; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Mukouyama Y, 2000, DEV BIOL, V220, P27, DOI 10.1006/dbio.2000.9617; Niki M, 1997, P NATL ACAD SCI USA, V94, P5697, DOI 10.1073/pnas.94.11.5697; Nishikawa S, 1998, DEVELOPMENT, V125, P1747; Nishikawa S, 1998, IMMUNITY, V8, P761, DOI 10.1016/S1074-7613(00)80581-6; Nishimura H, 1999, IMMUNITY, V11, P141, DOI 10.1016/S1074-7613(00)80089-8; Nishimura M, 2004, BLOOD, V103, P562, DOI 10.1182/blood-2003-06-2109; North T, 1999, DEVELOPMENT, V126, P2563; North TE, 2004, STEM CELLS, V22, P158, DOI 10.1634/stemcells.22-2-158; North TE, 2002, IMMUNITY, V16, P661, DOI 10.1016/S1074-7613(02)00296-0; Oberlin E, 2002, DEVELOPMENT, V129, P4147; Okazaki T, 2001, P NATL ACAD SCI USA, V98, P13866, DOI 10.1073/pnas.231486598; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Pozner A, 2000, MOL CELL BIOL, V20, P2297, DOI 10.1128/MCB.20.7.2297-2307.2000; Prokunina L, 2002, NAT GENET, V32, P666, DOI 10.1038/ng1020; PROSSER HM, 1992, P NATL ACAD SCI USA, V89, P9934, DOI 10.1073/pnas.89.20.9934; Puig-Kroger A, 2003, BLOOD, V102, P3252, DOI 10.1182/blood-2003-02-0618; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Sanchez MJ, 1999, DEVELOPMENT, V126, P3891; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; Sato T, 2003, IMMUNOL LETT, V89, P39, DOI 10.1016/S0165-2478(03)00103-2; Shi MJ, 1998, J IMMUNOL, V161, P6751; Silver L, 1997, BLOOD, V89, P1154, DOI 10.1182/blood.V89.4.1154; Sinclair AM, 1999, DEV BIOL, V209, P128, DOI 10.1006/dbio.1999.9236; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; SPECK NA, 1987, MOL CELL BIOL, V7, P1101, DOI 10.1128/MCB.7.3.1101; SPECK NA, 1990, GENE DEV, V4, P233, DOI 10.1101/gad.4.2.233; Starr TK, 2003, ANNU REV IMMUNOL, V21, P139, DOI 10.1146/annurev.immunol.21.120601.141107; SWIRSKY DM, 1984, BRIT J HAEMATOL, V56, P199, DOI 10.1111/j.1365-2141.1984.tb03948.x; Sykes DB, 2001, BLOOD, V98, P2308, DOI 10.1182/blood.V98.8.2308; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Telfer JC, 2004, J IMMUNOL, V172, P4359, DOI 10.4049/jimmunol.172.7.4359; Telfer JC, 2001, DEV BIOL, V229, P363, DOI 10.1006/dbio.2000.9991; THORNELL A, 1988, MOL CELL BIOL, V8, P1625, DOI 10.1128/MCB.8.4.1625; Tokuhiro S, 2003, NAT GENET, V35, P341, DOI 10.1038/ng1267; Tracey WD, 1998, DEVELOPMENT, V125, P1371; Vaillant F, 1999, ONCOGENE, V18, P7124, DOI 10.1038/sj.onc.1203202; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Woolf E, 2003, P NATL ACAD SCI USA, V100, P7731, DOI 10.1073/pnas.1232420100; Yannoutsos N, 2004, NAT IMMUNOL, V5, P443, DOI 10.1038/ni1053; Yano M, 1997, BLOOD, V89, P4317, DOI 10.1182/blood.V89.12.4317; Yokomizo T, 2000, BLOOD, V96, p283A; Yokomizo T, 2001, GENES CELLS, V6, P13, DOI 10.1046/j.1365-2443.2001.00393.x; Yuan YZ, 2001, P NATL ACAD SCI USA, V98, P10398, DOI 10.1073/pnas.171321298; Zent CS, 1996, P NATL ACAD SCI USA, V93, P1044, DOI 10.1073/pnas.93.3.1044; Zhao FQ, 2002, INT IMMUNOL, V14, P1383, DOI 10.1093/intimm/dxf103	126	187	189	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2004	23	24					4238	4248		10.1038/sj.onc.1207763	http://dx.doi.org/10.1038/sj.onc.1207763			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823BZ	15156179				2022-12-28	WOS:000221586000008
J	Chae, HD; Yun, J; Bang, YJ; Shin, DY				Chae, HD; Yun, J; Bang, YJ; Shin, DY			Cdk2-dependent phosphorylation of the NF-Y transcription factor is essential for the expression of the cell cycle-regulatory genes and cell cycle G1/S and G2/M transitions	ONCOGENE			English	Article						NF-Y; cell cycle; cdc2; cdk2; G1/G2	CCAAT-BINDING PROTEIN; MACROPHAGE DIFFERENTIATION; G(2) ARREST; KINASE; DNA; SENESCENCE; INHIBITION; COMPLEX; P53; ACTIVATION	We previously reported that cdk2 phosphorylates two serine residues near the DNA-binding domain of the YA subunit of NF-Y transcription factor and this phosphorylation is essential for DNA binding of NF-Y. In this study, we examined the effects of a phosphorylation-deficient mutant form of YA, YA-aa, in which the two serine residues are replaced with alanine, on the cell cycle and expression of the NF-Y target genes. Transient transfection assays show that YA-aa inhibits transcription from the NF-Y target promoters, such as cdc2, cyclin A, and cdc25C. Moreover, this inhibitory function of YA-aa can be suppressed by the expression of wild-type YA, implying that YA-aa inhibits transcription of those NF-Y target genes by inactivating wild-type YA. Since NF-Y target genes include the cell cycle-regulatory genes that ensure orderly progression of the cell cycle, we examined the effects of YA-aa in cell cycle progression. We constructed a recombinant adenovirus encoding YA-aa and found that YA-aa expression leads to repression of cell cycle-regulatory genes, such as cyclin A, RNR R2, DNA polymerase a, cdc2, cyclin B, and cdc25C. Consistently, YA-aa expression results in the inactivation of both cdc2 and cdk2. Furthermore, cell cycle analysis reveals that YA-aa induces cell cycle arrest at both G1 and G2/M. These results suggest that cdk2-dependent phosphorylation of NF-Y is essential for the expression of the cell cycle-regulatory genes and therefore for cell cycle progression at both G1/S and G2/M.	Dankook Univ, Coll Med, Dept Microbiol, Natl Res Lab, Cheonan 330714, South Korea; Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul 110799, South Korea	Dankook University; Seoul National University (SNU)	Shin, DY (corresponding author), Dankook Univ, Coll Med, Dept Microbiol & Immunol, Cheonan 330714, South Korea.	dreamer@dku.edu	Chae, Hee-Don/D-2620-2011; Bang, Yung Jue/J-2759-2012	Bang, Yung Jue/0000-0001-6000-4597				BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P2685, DOI 10.1093/nar/23.14.2685; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Currie RA, 1998, J BIOL CHEM, V273, P18220, DOI 10.1074/jbc.273.29.18220; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; Duronio RJ, 1996, GENE DEV, V10, P2505, DOI 10.1101/gad.10.19.2505; Farina A, 1999, ONCOGENE, V18, P2818, DOI 10.1038/sj.onc.1202472; Gerrish K, 2001, J BIOL CHEM, V276, P47775, DOI 10.1074/jbc.M109244200; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; Hu QH, 2000, J BIOL CHEM, V275, P4435, DOI 10.1074/jbc.275.6.4435; Jung MS, 2001, ONCOGENE, V20, P5818, DOI 10.1038/sj.onc.1204748; LI XY, 1992, J BIOL CHEM, V267, P8984; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; Marziali G, 1997, MOL CELL BIOL, V17, P1387, DOI 10.1128/MCB.17.3.1387; Marziali G, 1999, BLOOD, V93, P519, DOI 10.1182/blood.V93.2.519.402a01_519_526; Matuoka K, 1999, EXP CELL RES, V253, P365, DOI 10.1006/excr.1999.4605; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; PANG JH, 1993, J BIOL CHEM, V268, P2909; Park J S, 2001, Cancer Res Treat, V33, P236, DOI 10.4143/crt.2001.33.3.236; Park M, 2000, CANCER RES, V60, P542; Schreiber M, 1999, ONCOGENE, V18, P1663, DOI 10.1038/sj.onc.1202466; Sinha S, 1996, MOL CELL BIOL, V16, P328; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677; Yun JH, 2003, J BIOL CHEM, V278, P36966, DOI 10.1074/jbc.M305178200; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	28	54	54	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4084	4088		10.1038/sj.onc.1207482	http://dx.doi.org/10.1038/sj.onc.1207482			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15064732				2022-12-28	WOS:000221520200006
J	Chiarugi, P; Taddei, ML; Schiavone, N; Papucci, L; Giannoni, E; Fiaschi, T; Capaccioli, S; Raugei, G; Ramponi, G				Chiarugi, P; Taddei, ML; Schiavone, N; Papucci, L; Giannoni, E; Fiaschi, T; Capaccioli, S; Raugei, G; Ramponi, G			LMW-PTP is a positive regulator of tumor onset and growth	ONCOGENE			English	Article						LMW-PTP; tumor onset; tumor progression; ephrin receptors; cell adhesion	PROTEIN-TYROSINE-PHOSPHATASE; HUMAN BREAST-CANCER; FACTOR RECEPTOR; BETA-CATENIN; E-CADHERIN; CELL-PROLIFERATION; EPH RECEPTORS; KINASE; PHOSPHORYLATION; EXPRESSION	Low molecular weight protein tyrosine phosphatases (LMW-PTPs) are an enzyme family that plays a key role in cell proliferation control by dephosphorylating/inactivating both tyrosine kinase receptors ( such as PDGF, insulin, and ephrin receptors) and docking proteins (such, as beta-catenin) endowed with both adhesion and transcriptional activity. Besides being a frequent event in human tumors, overexpression of LMW-PTP has been recently demonstrated to be sufficient to induce neoplastic transformation. We recently demonstrated that overexpression of LMW-PTP strongly potentiates the stability of cell-cell contacts at the adherens junction level, which powerfully suggests that LMW-PTP may also contribute to cancer invasivity. Focusing on mechanisms by which LMW-PTP is involved in cancer onset and progression, the emerging picture is that LMW-PTP strongly increases fibronectin-mediated cell adhesion and mobility but, paradoxically, decreases cell proliferation. Nevertheless, LMW-PTP-transfected NIH3T3 fibroblasts engrafted in nude mice induce the onset of larger fibrosarcomas, which are endowed with higher proliferation activity as compared to mock-transfected controls. Quite opposite effects have been obtained with engrafted fibroblasts transfected with a dominant-negative form of LMW-PTP. Notably, in sarcoma extracts, LMW-PTP overexpression greatly influences the ephrin A2 (EphA2) but not PDGF receptor or beta-catenin tyrosine phosphorylation. The high association of dephosphorylated EphA2 overexpression with most human cancers and our observation that cell growth stimulation by LMW-PTP overexpression is restricted to the in vivo model, strongly suggest that LMW-PTP oncogenic potential is mediated by its EphA2 tyrosine dephosphorylating activity.	Univ Florence, Dept Biochem Sci, Ctr Res Transfer & High Educ Study Mol & Clin Lev, I-50134 Florence, Italy; Univ Florence, Dept Expt Pathol & Oncol, I-50121 Florence, Italy	University of Florence; University of Florence	Raugei, G (corresponding author), Univ Florence, Dept Biochem Sci, Ctr Res Transfer & High Educ Study Mol & Clin Lev, Viale Morgagni 50, I-50134 Florence, Italy.	raugei@scibio.unifi.it	Giannoni, Elisa/AAE-2092-2020; Chiarugi, Paola/CDD-7988-2022	Giannoni, Elisa/0000-0001-7136-1098; Papucci, Laura/0000-0002-8450-7428; Schiavone, Nicola/0000-0002-1592-4244; raugei, giovanni/0000-0003-1294-786X; Chiarugi, Paola/0000-0001-7655-2969				Albini A, 2001, CANCER RES, V61, P8171; Beavon IRG, 2000, EUR J CANCER, V36, P1607, DOI 10.1016/S0959-8049(00)00158-1; Bonvini P, 2001, CANCER RES, V61, P1671; Borner C, 1996, J BIOL CHEM, V271, P12695, DOI 10.1074/jbc.271.22.12695; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; Bruce V, 1999, BRAIN RES, V821, P169, DOI 10.1016/S0006-8993(99)01112-9; Bucciantini M, 1998, FEBS LETT, V422, P213, DOI 10.1016/S0014-5793(98)00009-X; CANCE WG, 1995, BREAST CANCER RES TR, V35, P105, DOI 10.1007/BF00694751; Carles-Kinch K, 2002, CANCER RES, V62, P2840; Cates CA, 1996, CANCER LETT, V110, P49, DOI 10.1016/S0304-3835(96)04459-X; Cavallaro U, 2001, BBA-REV CANCER, V1552, P39, DOI 10.1016/S0304-419X(01)00038-5; Chiarugi P, 2000, J BIOL CHEM, V275, P4640, DOI 10.1074/jbc.275.7.4640; CHIARUGI P, 1995, FEBS LETT, V372, P49, DOI 10.1016/0014-5793(95)00947-8; Chiarugi P, 1997, BIOCHEM BIOPH RES CO, V238, P676, DOI 10.1006/bbrc.1997.7355; Chiarugi P, 2000, J BIOL CHEM, V275, P37619, DOI 10.1074/jbc.M006375200; COBB BS, 1993, ONCOGENE, V8, P2897; Comoglio PM, 2002, J CLIN INVEST, V109, P857, DOI 10.1172/JCI200215392; EASTY DJ, 1995, CANCER RES, V55, P2528; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Formigli L, 2000, J CELL PHYSIOL, V182, P41, DOI 10.1002/(SICI)1097-4652(200001)182:1<41::AID-JCP5>3.0.CO;2-7; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Kikawa KD, 2002, J BIOL CHEM, V277, P39274, DOI 10.1074/jbc.M207127200; Kopreski MS, 1996, ANTICANCER RES, V16, P3037; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; Liekens S, 2001, INT J CANCER, V92, P161, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1183>3.0.CO;2-K; LIU XQ, 1994, RECENT PROG HORM RES, V49, P149; LOWER EE, 1993, BREAST CANCER RES TR, V26, P217, DOI 10.1007/BF00665799; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; O'Reilly AM, 2000, MOL CELL BIOL, V20, P299, DOI 10.1128/MCB.20.1.299-311.2000; Orsulic S, 2000, J CELL SCI, V113, P1793; Papucci L, 2002, ANTISENSE NUCLEIC A, V12, P21, DOI 10.1089/108729002753670238; Park EK, 2002, MOL CELL BIOL, V22, P3404, DOI 10.1128/MCB.22.10.3404-3414.2002; Ramponi G, 1997, BBA-PROTEIN STRUCT M, V1341, P137, DOI 10.1016/S0167-4838(97)00087-3; RAMPONI G, 1989, FEBS LETT, V250, P469, DOI 10.1016/0014-5793(89)80778-1; Raugei G, 2002, CELL MOL LIFE SCI, V59, P941, DOI 10.1007/s00018-002-8481-z; Rigacci S, 1999, FEBS LETT, V459, P191, DOI 10.1016/S0014-5793(99)01234-X; Ronnstrand L, 2001, INT J CANCER, V91, P757, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1136>3.0.CO;2-J; Ronnstrand L, 1999, ONCOGENE, V18, P3696, DOI 10.1038/sj.onc.1202705; SOMMERS CL, 1994, CANCER RES, V54, P3544; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; Taddei ML, 2002, CANCER RES, V62, P6489; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Varelias A, 2002, CANCER, V95, P862, DOI 10.1002/cncr.10749; YAGEL S, 1989, CANCER RES, V49, P3553; Zantek ND, 1999, CELL GROWTH DIFFER, V10, P629; Zantek ND, 2001, CLIN CANCER RES, V7, P3640; Zelinski DP, 2001, CANCER RES, V61, P2301; Zhang ZY, 2001, CURR OPIN CHEM BIOL, V5, P416, DOI 10.1016/S1367-5931(00)00223-4	48	87	89	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					3905	3914		10.1038/sj.onc.1207508	http://dx.doi.org/10.1038/sj.onc.1207508			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15021900	Bronze			2022-12-28	WOS:000221382000003
J	Furuta, S; Hidaka, E; Ogata, A; Yokota, S; Kamata, T				Furuta, S; Hidaka, E; Ogata, A; Yokota, S; Kamata, T			Ras is involved in the negative control of autophagy through the class IPI3-kinase	ONCOGENE			English	Article						autophagy; PI3-kinase; Ras	PHOSPHOINOSITIDE 3-OH KINASE; PROTEIN-DEGRADATION; HT-29 CELLS; MACROAUTOPHAGY; GROWTH; TRANSFORMATION; PROTEOLYSIS; HEPATOCYTES; INHIBITION; MECHANISMS	Ras proteins exert a pivotal regulatory function in signal transduction involved in cell proliferation and their activation mutation leads to malignant cell transformation. However, the role of Ras proteins in autophagy, an intracellular protein degradation process in cell growth control is unknown. In the present study, we demonstrate that the degradation of long-lived proteins in NIH3T3 cells in response to nutrient starvation was significantly suppressed by oncogenic RasVal12 transformation in a rapamycin ( mTOR inhibitor)-sensitive manner. Morphologic observations also show the decrease in the formation of autophagic vacuoles upon the Ras transformation. Furthermore, epidermal growth factor or serum downregulated the protein degradation induced by serum starvation and the dominant-negative RasAsn17 mutant counteracted this suppressive effect, indicating that Ras mediates the growth factor downregulation of autophagy. The suppression of protein degradation by the activated RasVal12 was mediated by the class I phosphatidyl inositol 3-kinase (PI3-kinase), but not either or Raf Ral GDS. Consistent with this, RasVal12 and class I PI3-kinase inhibited the rate of autophagic sequestration of LDH. These data suggest that Ras plays a critical role as a negative regulator for nutrient deprivation-induced autophagy through the class I PI3-kinase signaling pathway.	Shinshu Univ, Sch Med, Dept Mol Biol & Biochem, Nagano 3908621, Japan; Shinshu Univ, Sch Med, Dept Lab Med, Nagano 3908621, Japan; Yamanashi Univ, Sch Med, Biol Lab, Tamaho, Yamanashi 4093898, Japan	Shinshu University; Shinshu University; University of Yamanashi	Kamata, T (corresponding author), Shinshu Univ, Sch Med, Dept Mol Biol & Biochem, Asahi 3-1-1, Nagano 3908621, Japan.	kamatat@sch.md.shinshu-u.ac.jp						Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200; BALLARD FJ, 1980, J CELL PHYSIOL, V105, P335, DOI 10.1002/jcp.1041050216; Blommaart EFC, 1997, HISTOCHEM J, V29, P365, DOI 10.1023/A:1026486801018; DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923; Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; Franch HA, 2001, J BIOL CHEM, V276, P19126, DOI 10.1074/jbc.M101777200; Furuta S, 2002, ONCOGENE, V21, P7060, DOI 10.1038/sj.onc.1205790; HOURI JJ, 1995, BIOCHEM J, V309, P521, DOI 10.1042/bj3090521; KAMATA T, 1988, P NATL ACAD SCI USA, V85, P5799, DOI 10.1073/pnas.85.16.5799; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; OGIERDENIS E, 2003, BIOCHIM BIOPHYS ACTA, V1366, P177; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; Oldham S, 2003, TRENDS CELL BIOL, V13, P79, DOI 10.1016/S0962-8924(02)00042-9; Pattingre S, 2003, J BIOL CHEM, V278, P16667, DOI 10.1074/jbc.M210998200; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; SCHWARZE PE, 1985, EXP CELL RES, V157, P15, DOI 10.1016/0014-4827(85)90148-X; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; SLUIJTERS DA, 2000, BIOCHEM J, V351, P545; YOKOTA S, 1993, EUR J CELL BIOL, V62, P372	24	119	127	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					3898	3904		10.1038/sj.onc.1207539	http://dx.doi.org/10.1038/sj.onc.1207539			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15064741				2022-12-28	WOS:000221382000002
J	Yeh, PY; Chuang, SE; Yeh, KH; Song, YC; Chang, LLY; Cheng, AL				Yeh, PY; Chuang, SE; Yeh, KH; Song, YC; Chang, LLY; Cheng, AL			Phosphorylation of p53 on Thr55 by ERK2 is necessary for doxorubicin-induced p53 activation and cell death	ONCOGENE			English	Article						ERK2; p53; p53Thr55; doxorubicin; Bcl-2	TUMOR-SUPPRESSOR P53; IN-VITRO; PROTEIN-KINASE; TARGET GENES; CISPLATIN; CANCER; APOPTOSIS; BCL-2; VIVO; INHIBITION	We recently reported that exposure of human cervical carcinoma cells to doxorubicin results in extracellular signal-regulated kinase (ERK) 2 activation, which in turn phosphorylates p53 on a previously uncharacterized site, Thr55. This study sought to clarify the biological significance of doxorubicin-induced Thr55 phosphorylation. In breast carcinoma MCF7 cells, doxorubicin (300 nM) activated ERK2 and induced phosphorylation of p53 on Thr55 residues. Pretreatment of MCF7 cells with an ERK2 chemical inhibitor, PD98059 or U0126, blocked doxorubicin-induced p53 activation and suppressed phosphorylation of p53Thr55. MCF55a cells were established by transfection of full-length p53 carrying Thr55 mutation (Thr to Ala) into MCF7 cells. Doxorubicin ( 500 nM) could not induce p53 activation in MCF55a cells, which showed significantly increased drug resistance toward doxorubicin. While the expression of the apoptotic protein, Bax, showed no difference between MCF7 and MCF55a cells, Bcl-2, an antiapoptotic protein, was constitutively expressed in MCF55a cells. The increase of Bcl-2 protein and/or Bcl-2/Bax ratio might at least partly contribute to the drug resistance of MCF55a cells. In summary, our results suggest that phosphorylation of p53Thr55 by ERK2 is important for doxorubicin-induced p53 activation and cell death.	Natl Taiwan Univ Hosp, Dept Oncol, Taipei 10016, Taiwan; Natl Taiwan Univ, Coll Med, Ctr Canc Res, Taipei 10018, Taiwan; Natl Hlth Res Inst, Div Canc Res, Taipei, Taiwan; Far Eastern Mem Hosp, Dept Med Res, Taipei, Taiwan; Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 10016, Taiwan; Natl Taiwan Univ, Coll Med, Inst Toxicol, Taipei 10018, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Health Research Institutes - Taiwan; Far Eastern Memorial Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University	Cheng, AL (corresponding author), Natl Taiwan Univ Hosp, Dept Oncol, Taipei 10016, Taiwan.	andrew@ha.mc.ntu.edu.tw	Yeh, Kun-Huei/HGD-3316-2022; Chuang, Shuang-En/D-2080-2010	YEH, Kun-Huei/0000-0002-7306-174X; Cheng, Ann-Lii/0000-0002-9152-6512; Song, Ying-Chyi/0000-0003-0279-4652				Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; de Almodovar CR, 2001, ONCOGENE, V20, P7128, DOI 10.1038/sj.onc.1204887; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FAN SJ, 1995, CANCER RES, V55, P1649; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GUILLOUF C, 1995, ONCOGENE, V10, P2263; HALDAR S, 1994, CANCER RES, V54, P2095; Hayakawa J, 1999, J BIOL CHEM, V274, P31648, DOI 10.1074/jbc.274.44.31648; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Liu L, 1999, MOL CELL BIOL, V19, P1202; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Persons DL, 1999, CLIN CANCER RES, V5, P1007; Persons DL, 2000, J BIOL CHEM, V275, P35778, DOI 10.1074/jbc.M004267200; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sax JK, 2003, CELL DEATH DIFFER, V10, P413, DOI 10.1038/sj.cdd.4401227; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Shieh SY, 2000, GENE DEV, V14, P289; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Wang LQ, 2001, J BIOL CHEM, V276, P43604, DOI 10.1074/jbc.M106570200; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; Woessmann W, 2002, CANCER CHEMOTH PHARM, V50, P397, DOI 10.1007/s00280-002-0502-y; Yeh PY, 2002, BIOCHEM PHARMACOL, V63, P1423, DOI 10.1016/S0006-2952(02)00908-5; Yeh PY, 2001, BIOCHEM BIOPH RES CO, V284, P880, DOI 10.1006/bbrc.2001.5043; Zhao RB, 2000, GENE DEV, V14, P981	48	65	66	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3580	3588		10.1038/sj.onc.1207426	http://dx.doi.org/10.1038/sj.onc.1207426			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15116093				2022-12-28	WOS:000221101700009
J	Adachi, H; Majima, S; Kon, S; Kobayashi, T; Kajino, K; Mitani, H; Hirayama, Y; Shiina, H; Igawa, M; Hino, O				Adachi, H; Majima, S; Kon, S; Kobayashi, T; Kajino, K; Mitani, H; Hirayama, Y; Shiina, H; Igawa, M; Hino, O			Niban gene is commonly expressed in the renal tumors: a new candidate marker for renal carcinogenesis	ONCOGENE			English	Article						Niban; Tsc2 mutant (Eker) rats; multistep renal carcinogenesis; tumor marker; human renal cell carcinoma	EKER RAT MODEL; EMBRYONIC LETHALITY; PREDISPOSING GENE; TSC2 MUTATION; CELL-GROWTH; COMPLEX; CARCINOMA; PATHWAY; TARGET	Functional inactivation of tuberous sclerosis 2 gene (Tsc2) leads to renal carcinogenesis in the hereditary renal carcinoma Eker rat models. Recent studies revealed a role of tuberin, a TSC2 product, in suppressing the p70 S6 kinase (p70S6K) activity via inhibition of mammalian target of rapamycin (mTOR). Phosphorylated S6 protein, a substrate of p70S6K, was expressed in the early lesions in Eker rats, and this expression was suppressed by the treatment of rapamycin, an inhibitor of mTOR. We previously isolated the novel gene Niban expressed in renal carcinogenesis of Eker rats. In this study, we demonstrated that the expression of Niban was detected from early preneoplastic lesions in Eker rats. Interestingly, in contrast to the phosphorylated S6 protein, the expression of Niban was unchanged and early lesions still remained even after treatment with rapamycin. These results might suggest the existence of another pathway independent of mTOR-S6K pathway in Tsc2 mutant renal carcinogenesis. In addition, Nib an was also expressed in other renal carcinoma models, including Tsc1 and Tsc2 knockout mice, and various types of human renal cell carcinomas. Thus, Nib an was commonly expressed in renal carcinomas and might be a new marker for renal carcinogenesis.	Japanese Fdn Canc Res, Inst Canc, Dept Expt Pathol, Toshima Ku, Tokyo 1708455, Japan; Shimane Univ, Sch Med, Dept Urol, Izumo, Shimane 6938501, Japan; Immunobiol Labs Co Ltd, Fujioka, Gunma 3750005, Japan	Japanese Foundation for Cancer Research; Shimane University; Immuno-Biological Laboratories Co. Ltd.	Hino, O (corresponding author), Japanese Fdn Canc Res, Inst Canc, Dept Expt Pathol, Toshima Ku, 1-37-1 Kami Ikebukuro, Tokyo 1708455, Japan.	ohino@ims.u-tokyo.ac.jp	Kon, Shigeyuki/A-3809-2012					Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; EKER R, 1961, NATURE, V189, P858, DOI 10.1038/189858b0; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; HINO O, 1993, P NATL ACAD SCI USA, V90, P327, DOI 10.1073/pnas.90.1.327; HINO O, 1994, BIOCHEM BIOPH RES CO, V203, P1302, DOI 10.1006/bbrc.1994.2324; Hino O, 2003, CANCER SCI, V94, P142, DOI 10.1111/j.1349-7006.2003.tb01410.x; Hino O, 2001, JPN J CANCER RES, V92, P1147, DOI 10.1111/j.1349-7006.2001.tb02133.x; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Kenerson HL, 2002, CANCER RES, V62, P5645; Kobayashi T, 1999, CANCER RES, V59, P1206; KOBAYASHI T, 1995, NAT GENET, V9, P70, DOI 10.1038/ng0195-70; Kobayashi T, 2003, P JPN ACAD B-PHYS, V79, P22, DOI 10.2183/pjab.79B.22; Kobayashi T, 2001, P NATL ACAD SCI USA, V98, P8762, DOI 10.1073/pnas.151033798; Kon S, 2000, J CELL BIOCHEM, V77, P487; KUBO Y, 1995, CANCER RES, V55, P989; Majima S, 2000, JPN J CANCER RES, V91, P869, DOI 10.1111/j.1349-7006.2000.tb01027.x; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Okimoto K, 2000, JPN J CANCER RES, V91, P1096, DOI 10.1111/j.1349-7006.2000.tb00890.x; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Takahashi R, 1999, EXP ANIM TOKYO, V48, P255, DOI 10.1538/expanim.48.255; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; YEUNG RS, 1994, P NATL ACAD SCI USA, V91, P11413, DOI 10.1073/pnas.91.24.11413	23	31	34	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3495	3500		10.1038/sj.onc.1207468	http://dx.doi.org/10.1038/sj.onc.1207468			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	14990989				2022-12-28	WOS:000220975000025
J	Barsyte-Lovejoy, D; Mao, DYL; Penn, LZ				Barsyte-Lovejoy, D; Mao, DYL; Penn, LZ			c-Myc represses the proximal promoters of GADD45a and GADD153 by a post-RNA polymerase II recruitment mechanism	ONCOGENE			English	Article						c-Myc oncogene; transcription; repression; growth arrest; RNA polymerase II	MEDIATED TRANSCRIPTIONAL REPRESSION; CDK INHIBITOR P15(INK4B); GROWTH ARREST GENES; DIHYDROFOLATE-REDUCTASE; ENDOPLASMIC-RETICULUM; FACTORS C/EBP; CAD PROMOTER; FACTOR MIZ-1; CELL-GROWTH; DNA-DAMAGE	The c-Myc cellular oncogene has diverse activities, including transformation, proliferation, and apoptosis. These activities are dependent on the ability of c-Myc to regulate gene transcription. c-Myc downregulates the GADD45a and GADD153 (DDTI3) genes that are induced in response to genotoxic stresses and that encode protein products with antiproliferative activities. We show that c-Myc represses the expression of GADD45a and GADD153 in response to thapsigargin, a nongenotoxic stress, as well as other endoplasmic reticulum ( ER) stress agents. c-Myc represses both the basal expression and the magnitude of ER stress induction of GADD gene transcription. This repression requires the minimal promoter region of GADD45a and GADD153 and is not dependent on the ER stress element or p53-binding sites in the regulatory regions of these genes. Further analysis by chromatin immunoprecipitation shows that c-Myc binds to the minimal promoter region of GADD45a and GADD153 in vivo. c-Myc-associated protein X (Max) is also bound to both GADD gene promoters, whereas c-Myc interacting zinc-finger protein 1(Miz-1) is bound to the GADD153, but not GADD45a, promoter. RNA polymerase II(RNAPII) is recruited to the GADD gene promoters in the presence and absence of c-Myc, which suggests that c-Myc represses these genes through a post-RNAPII recruitment mechanism.	Princess Margaret Hosp, Ontario Canc Inst, Div Cellular & Mol Biol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto	Penn, LZ (corresponding author), Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	lpenn@uhnres.utoronto.ca		Penn, Linda/0000-0001-8133-5459				Abcouwer SF, 1999, J BIOL CHEM, V274, P28645, DOI 10.1074/jbc.274.40.28645; Amundson SA, 1998, ONCOGENE, V17, P2149, DOI 10.1038/sj.onc.1202136; Bowen H, 2003, J BIOL CHEM, V278, P36017, DOI 10.1074/jbc.M304301200; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Carrier F, 1999, MOL CELL BIOL, V19, P1673; Chen CH, 1996, ONCOGENE, V13, P1659; Cheng CH, 2003, MOL CELL BIOL, V23, P1961, DOI 10.1128/MCB.23.6.1961-1967.2003; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; Corey LL, 2003, GENE DEV, V17, P1392, DOI 10.1101/gad.1071803; Dang CV, 1999, MOL CELL BIOL, V19, P1; Eberhardy SR, 2001, J BIOL CHEM, V276, P48562, DOI 10.1074/jbc.M109014200; Eberhardy SR, 2002, J BIOL CHEM, V277, P40156, DOI 10.1074/jbc.M207441200; Facchini LM, 1997, MOL CELL BIOL, V17, P100, DOI 10.1128/MCB.17.1.100; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Gartel AL, 2003, EXP CELL RES, V283, P17, DOI 10.1016/S0014-4827(02)00020-4; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Graunke DM, 1999, NUCLEIC ACIDS RES, V27, P3881, DOI 10.1093/nar/27.19.3881; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Izumi H, 2001, J CELL SCI, V114, P1533; Kime L, 2003, BIOCHEM J, V370, P291, DOI 10.1042/BJ20021679; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; Lee LA, 1996, J CLIN INVEST, V97, P1687, DOI 10.1172/JCI118595; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; MAI S, 1994, NUCLEIC ACIDS RES, V22, P2264, DOI 10.1093/nar/22.12.2264; Mao DYL, 2003, CURR BIOL, V13, P882, DOI 10.1016/S0960-9822(03)00297-5; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; Maytin EV, 1998, J INVEST DERMATOL, V110, P238, DOI 10.1046/j.1523-1747.1998.00123.x; O'Connell BC, 2003, J BIOL CHEM, V278, P12563, DOI 10.1074/jbc.M210462200; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Oster SK, 2003, ONCOGENE, V22, P1998, DOI 10.1038/sj.onc.1206228; Outinen PA, 1999, BLOOD, V94, P959, DOI 10.1182/blood.V94.3.959.415k20_959_967; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; Piluso D, 2002, J BIOL CHEM, V277, P46799, DOI 10.1074/jbc.M206226200; PRICE BD, 1992, CANCER RES, V52, P3814; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Ubeda M, 2000, NUCLEIC ACIDS RES, V28, P4987, DOI 10.1093/nar/28.24.4987; Vairapandi M, 2000, J BIOL CHEM, V275, P16810, DOI 10.1074/jbc.275.22.16810; Wanzel M, 2003, TRENDS CELL BIOL, V13, P146, DOI 10.1016/S0962-8924(03)00003-5; Watson JD, 2002, J BIOL CHEM, V277, P36921, DOI 10.1074/jbc.M201493200; Wu SQ, 2003, ONCOGENE, V22, P351, DOI 10.1038/sj.onc.1206145; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; Ziegelbauer J, 2001, MOL CELL, V8, P339, DOI 10.1016/S1097-2765(01)00313-6; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	52	52	52	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3481	3486		10.1038/sj.onc.1207487	http://dx.doi.org/10.1038/sj.onc.1207487			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15021909				2022-12-28	WOS:000220975000023
J	Mitra, J; Enders, GH				Mitra, J; Enders, GH			Cyclin A/Cdk2 complexes regulate activation of Cdk1 and Cdc25 phosphatases in human cells	ONCOGENE			English	Article						cell cycle; Cdk1; Cdk2; Cdc25B; Cdc25C; G2	CYCLIN-DEPENDENT KINASES; DNA-DAMAGE; MAMMALIAN-CELLS; PROTEIN-KINASE; HELA-CELLS; S-PHASE; MITOSIS; PHOSPHORYLATION; CHECKPOINT; EXTRACTS	Mitotic entry, a critical decision point for maintaining genetic stability, is governed by the cyclin B/Cyclin dependent kinase 1 (Cdc2) complex. In Xenopus oocytes and early embryos, accumulation of cyclin B activates Cdk1, which then phosphorylates and activates the positive regulator Cdc25 in an autocatalytic feedback loop. However, cyclin B levels do not increase as some human cells approach mitosis, and the key factors regulating Cdk1 activation in human cells are unknown. We report here that reducing cyclin A expression by RNA interference (RNAi) in primary human fibroblasts inhibited activation of Cdc25B and Cdc25C and dephosphorylation of Cdk1 on tyrosine (tyr) 15. These results were reproduced in U2-OS cells by inducing the expression of a dominant-negative (dn) mutant of Cdk2, the principal cyclin A binding partner. Cdk2-dn induction could inhibit Cdc25B activity and foster Cdk1 tyr phosphorylation within the S phase, temporally dissociating these events from Cdk1 activation at mitosis. In contrast, reducing Cdk1 expression delayed mitotic entry without markedly impairing Cdc25B or Cdc25C activity. These results suggest that cyclin A/Cdk2 complexes are key regulators of Cdc25 and Cdk1 activation in human cells. This pathway appears to be commonly deregulated in cancer.	Univ Penn, Dept Med, GI Div, CRB, Philadelphia, PA 19104 USA; Univ Penn, Dept Genet, Philadelphia, PA 19104 USA; Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Mitra, J (corresponding author), Univ Penn, Dept Med, GI Div, CRB, Room 600,415 Curie Blvd, Philadelphia, PA 19104 USA.	jmitra@mail.med.upenn.edu; endersgh@mail.med.upenn.edu	Mitra, Joydeep/GQP-7505-2022		NIDDK NIH HHS [P30 DK50306, P30 DK050306, K01 DK061280, 1-K01-DK61280-01] Funding Source: Medline; NIGMS NIH HHS [R01 GM065514-02, R01 GM065514] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK061280, P30DK050306] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065514] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; Baldin V, 1997, ONCOGENE, V14, P2485, DOI 10.1038/sj.onc.1201063; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Bulavin DV, 2002, CURR OPIN GENET DEV, V12, P92, DOI 10.1016/S0959-437X(01)00270-2; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; Ellinger-Ziegelbauer H, 2000, GENES CELLS, V5, P491, DOI 10.1046/j.1365-2443.2000.00337.x; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Gabrielli BG, 1997, J BIOL CHEM, V272, P28607, DOI 10.1074/jbc.272.45.28607; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Goldstone S, 2001, ONCOGENE, V20, P921, DOI 10.1038/sj.onc.1204177; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; Hu B, 2001, MOL CELL BIOL, V21, P2755, DOI 10.1128/MCB.21.8.2755-2766.2001; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lammer C, 1998, J CELL SCI, V111, P2445; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8672, DOI 10.1073/pnas.132269599; Maller JL, 1991, CURR OPIN CELL BIOL, V3, P269; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; Mundt KE, 1997, BIOCHEM BIOPH RES CO, V239, P377, DOI 10.1006/bbrc.1997.7378; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; Nishijima H, 1997, J CELL BIOL, V138, P1105, DOI 10.1083/jcb.138.5.1105; NORBURY C, 1990, CIBA F SYMP, V150, P168; NOVAK B, 1993, J CELL SCI, V106, P1153; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; PARKER LL, 1995, P NATL ACAD SCI USA, V92, P9638, DOI 10.1073/pnas.92.21.9638; Poon RYC, 1997, CANCER RES, V57, P5168; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; STRAUSFELD U, 1994, J BIOL CHEM, V269, P5989; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9; Theis-Febvre N, 2003, ONCOGENE, V22, P220, DOI 10.1038/sj.onc.1206107; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593	41	61	66	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3361	3367		10.1038/sj.onc.1207446	http://dx.doi.org/10.1038/sj.onc.1207446			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	14767478	Green Accepted			2022-12-28	WOS:000220975000010
J	Alphonse, G; Bionda, C; Aloy, MT; Ardail, D; Rousson, R; Rodriguez-Lafrasse, C				Alphonse, G; Bionda, C; Aloy, MT; Ardail, D; Rousson, R; Rodriguez-Lafrasse, C			Overcoming resistance to gamma-rays in squamous carcinoma cells by poly-drug elevation of ceramide levels	ONCOGENE			English	Article						SQ20B cells; SCC61 cells; gamma-irradiation; apoptosis; inhibitors of sphingolipid metabolism	RADIATION-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; NIEMANN-PICK DISEASE; CANCER-CELLS; GLUCOSYLCERAMIDE SYNTHASE; IONIZING-RADIATION; LEUKEMIA-CELLS; DNA-DAMAGE; TUMOR-CELL; SPHINGOMYELINASE	Recent strategies to sensitize radioresistant tumours are based on combining gamma-irradiation with inducers of apoptosis. We report that the combination of three inhibitors of sphingolipid metabolism, DL-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol. HCl(DL-PDMP) +imipramine+/-D-erythro-2-(N-myristoylamino)-1-phenyl-1-propanol (D-MAPP), with 10-Gy irradiation triggers both mitotic and apoptotic killing in radioresistant SQ20B squamous carcinoma cells. In these cells, apoptosis is defective due to a lack of ceramide generation upstream, which cannot be explained by sphingomyelinase (neutral and acidic) deficiency or rapid derivation to the sphingolipid pathway. We present evidence of a functional transduction death pathway when ceramide generation is restored, which involves the mitochondrial-mediated pathway coupled to alterations in redox status and to executive caspases activation. The poly-drug treatment restored apoptosis to levels similar to those observed in radiosensitive SCC61 squamous carcinoma cells. Simultaneous exposure to gamma-irradiation and poly-drug treatment acted synergistically in SQ20B cells to produce a marked increase in both mitochondrial dysfunction and caspase cleavage, which led to a 7.8-fold increase in apoptosis within 48 h, relative to irradiated cells. Moreover, the results suggest that the ceramide released by irradiation or poly-drug treatment converges upon common cellular targets. Modulation of endogenous ceramide levels by inhibitors of sphingolipid metabolism may represent a new cellular target for the sensitization of radioresistant tumours to gamma-ray therapy.	Lyon Sud Med Sch, Dept Biochem, INSERM, U189, F-69921 Oullins, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Rodriguez-Lafrasse, C (corresponding author), Lyon Sud Med Sch, Dept Biochem, INSERM, U189, BP12, F-69921 Oullins, France.	rodriguez@lyon-sud.univ-lyon1.fr	Alphonse, Gersende/G-7721-2018; Rodriguez-Lafrasse, Claire/G-7741-2018					Alphonse G, 2002, INT J RADIAT BIOL, V78, P821, DOI 10.1080/09553000210153943; Bidere N, 2003, J BIOL CHEM, V278, P31401, DOI 10.1074/jbc.M301911200; Bielawska A, 1996, J BIOL CHEM, V271, P12646, DOI 10.1074/jbc.271.21.12646; Birbes H, 2002, ADV ENZYME REGUL, V42, P113, DOI 10.1016/S0065-2571(01)00026-7; Bruno AP, 1998, CELL DEATH DIFFER, V5, P172, DOI 10.1038/sj.cdd.4400330; Chmura SJ, 1997, CANCER RES, V57, P4340; Chmura SJ, 1997, CANCER RES, V57, P1270; Choi MS, 2003, GENE, V315, P113, DOI 10.1016/S0378-1119(03)00721-2; Cuvillier O, 2001, BLOOD, V98, P2828, DOI 10.1182/blood.V98.9.2828; Daniel PT, 2000, LEUKEMIA, V14, P2035, DOI 10.1038/sj.leu.2401940; Decaudin D, 1998, INT J ONCOL, V12, P141; di Bartolomeo S, 2001, BIOCHEM BIOPH RES CO, V288, P269, DOI 10.1006/bbrc.2001.5748; El-Assaad W, 2003, BIOCHEM J, V376, P725, DOI 10.1042/BJ20030888; Fiske CH, 1925, J BIOL CHEM, V66, P375; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Gewirtz DA, 2000, BREAST CANCER RES TR, V62, P223, DOI 10.1023/A:1006414422919; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; Grazide S, 2002, FASEB J, V16, P1685, DOI 10.1096/fj.01-0794fje; Gulbins E, 2003, ONCOGENE, V22, P7070, DOI 10.1038/sj.onc.1207146; Ito A, 1999, BBA-MOL CELL RES, V1452, P263, DOI 10.1016/S0167-4889(99)00131-7; Itoh M, 2003, CLIN CANCER RES, V9, P415; Jacobson K, 1999, TRENDS CELL BIOL, V9, P87, DOI 10.1016/S0962-8924(98)01495-0; Jafrezou JP, 2001, FASEB J, V15, P123, DOI 10.1096/fj.00-0305com; Kimura K, 2003, CELL DEATH DIFFER, V10, P240, DOI 10.1038/sj.cdd.4401145; Kokunai T, 2001, J NEURO-ONCOL, V51, P111, DOI 10.1023/A:1010645205169; Kolesnick R, 2003, ONCOGENE, V22, P5897, DOI 10.1038/sj.onc.1206702; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Lavie Y, 1996, J BIOL CHEM, V271, P19530, DOI 10.1074/jbc.271.32.19530; Lavrentiadou SN, 2001, AM J RESP CELL MOL, V25, P676, DOI 10.1165/ajrcmb.25.6.4321; Lee JU, 1999, EUR J CANCER, V35, P1374, DOI 10.1016/S0959-8049(99)00134-3; Li W, 2000, FEBS LETT, V470, P35, DOI 10.1016/S0014-5793(00)01286-2; Lin JY, 2001, ANTICANCER RES, V21, P831; Liu B, 1997, J BIOL CHEM, V272, P16281, DOI 10.1074/jbc.272.26.16281; Liu B, 1998, J BIOL CHEM, V273, P11313, DOI 10.1074/jbc.273.18.11313; Liu YY, 2000, J BIOL CHEM, V275, P7138, DOI 10.1074/jbc.275.10.7138; Liu YY, 1999, EXP CELL RES, V252, P464, DOI 10.1006/excr.1999.4649; Lozano J, 2001, J BIOL CHEM, V276, P442, DOI 10.1074/jbc.M006353200; Lucci A, 1998, ANTICANCER RES, V18, P475; MATSUO N, 1992, BIOCHIM BIOPHYS ACTA, V1116, P97, DOI 10.1016/0304-4165(92)90105-4; MCILWRATH AJ, 1994, CANCER RES, V54, P3718; Mendez AJ, 2001, J BIOL CHEM, V276, P3158, DOI 10.1074/jbc.M007717200; Michael JM, 1997, CANCER RES, V57, P3600; NEUSCHWANDERTETRI BA, 1989, ANAL BIOCHEM, V179, P236, DOI 10.1016/0003-2697(89)90121-8; Pena LA, 2000, CANCER RES, V60, P321; Perry DK, 1999, BIOCHEM SOC T, V27, P399, DOI 10.1042/bst0270399; Petit PX, 1997, MOL CELL BIOCHEM, V174, P185, DOI 10.1023/A:1006848205880; Radin NS, 2003, BIOCHEM J, V371, P243, DOI 10.1042/BJ20021878; Raisova M, 2002, FEBS LETT, V516, P47, DOI 10.1016/S0014-5793(02)02472-9; Ramstedt B, 2002, FEBS LETT, V531, P33, DOI 10.1016/S0014-5793(02)03406-3; Riboni L, 2002, GLIA, V39, P105, DOI 10.1002/glia.10087; Rodriguez-Lafrasse C, 2002, INT J CANCER, V101, P589, DOI 10.1002/ijc.10652; Rodriguez-Lafrasse C, 2001, BIOCHEM J, V357, P407, DOI 10.1042/0264-6021:3570407; RODRIGUEZLAFRASSE C, 1994, BBA-MOL BASIS DIS, V1226, P138, DOI 10.1016/0925-4439(94)90021-3; ROSENWALD AG, 1994, J LIPID RES, V35, P1232; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Sautin Y, 2000, THYROID, V10, P733, DOI 10.1089/thy.2000.10.733; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Selzner M, 2001, CANCER RES, V61, P1233; Shi YQ, 2001, RADIAT ENVIRON BIOPH, V40, P301, DOI 10.1007/s00411-001-0124-5; Shinoura N, 2001, INT J CANCER, V93, P252, DOI 10.1002/ijc.1327; Sietsma H, 2000, CLIN CANCER RES, V6, P942; Solary E, 2001, THERAPIE, V56, P511; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Sugiki H, 2000, BRIT J DERMATOL, V143, P1154, DOI 10.1046/j.1365-2133.2000.03882.x; Tepper AD, 2000, J BIOL CHEM, V275, P34810, DOI 10.1074/jbc.M005142200; Tepper AD, 1999, J CLIN INVEST, V103, P971, DOI 10.1172/JCI5457; Thomas RL, 1999, J BIOL CHEM, V274, P30580, DOI 10.1074/jbc.274.43.30580; VANIER MT, 1980, CLIN CHIM ACTA, V106, P257, DOI 10.1016/0009-8981(80)90309-5; Veldman RJ, 2003, FASEB J, V17, P1144, DOI 10.1096/fj.02-1053fje; Yokogawa K, 2002, METHOD FIND EXP CLIN, V24, P81, DOI 10.1358/mf.2002.24.2.677131	70	55	57	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2004	23	15					2703	2715		10.1038/sj.onc.1207357	http://dx.doi.org/10.1038/sj.onc.1207357			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	810OZ	15048093				2022-12-28	WOS:000220714900012
J	Zhang, HG; Wang, JH; Yang, XW; Hsu, HC; Mountz, JD				Zhang, HG; Wang, JH; Yang, XW; Hsu, HC; Mountz, JD			Regulation of apoptosis proteins in cancer cells by ubiquitin	ONCOGENE			English	Review						cancer; apoptosis; ubiquitin proteasome inhibitor; TRAIL; BAX; NF-kappa B; p53; Mdm2	NF-KAPPA-B; PROTEASOME PATHWAY; LIGASE ACTIVITY; MEDIATED DEGRADATION; CASPASE ACTIVITY; FLIP PROTEIN; IN-VITRO; C-FLIP; P53; TRAIL	Ubiquitin inhibitors act at many levels to enhance apoptosis signaling. For TNF-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis signaling, there are at least five mechanisms by which apoptosis are regulated by the ubiquitin - proteasome pathway. First, proteasome inhibitors can decrease Fas-like inhibitor protein ( FLIP) protein levels in tumors, resulting in increased apoptosis signaling due to increased caspase-8 activation. This appears to involve the ubiquitin ligase TNF receptor activation factor-2 (TRAF2) and acts indirectly by causing cell-cycle arrest at a stage where there is high degradation of the FLIP - TRAF2 complex. Second, the regulation of the proapoptotic Bcl-2 family member BAX occurs indirectly. Apoptosis signaling and caspase activation results in a confirmation change in the normally monomeric BAX, which exposes the BH3 domain of BAX, leading to dimerization and resistance to ubiquitin degradation. BAX then translocates into the mitochondria, resulting in the release of proapoptotic mitochondrial factors such as cytochrome c and second mitochondria-derived activator of caspase ( SMAC). This results in the activation of caspase-9 and formation of the apoptosome and efficient apoptosis signaling. A third mechanism of the regulation of TRAIL signaling in the ubiquitin - proteasome pathway is mediated by the inhibitor of apoptosis proteins (IAP) E3 ligases. These IAPs can directly bind to caspases but also can act as ubiquitin ligases for caspases, resulting in the degradation of these caspases. IAP binding to caspases can be inhibited by SMAC, which exhibits a caspase-9 homology domain. The fourth mechanism for apoptosis activation by proteasome inhibitors is through the stabilization of the inhibitor of the kappaB (IkappaB)/NF-kappaB complex and prevention of nuclear translocation of the antiapoptosis transcription factor NFkappaB. During TRAIL-DR4, DR5 signaling, this pathway is activated by interactions of activated Fas-associated death domain with activated receptor-interacting protein ( RIP), which in turn activates NF-kappaB-inducing kinase and phosphorylates IkappaB. Therefore, the inhibition of IkappaB degradation blocks this RIP-mediated antiapoptosis signaling event. Last, p53 protein levels, and susceptibility to apoptosis, can be deregulated by the human homolog Hdm2 (Mdm2) E3 ligase. This process is inhibited by p53 phosphorylation and by sequestration of Mdm2 by ARF. Better mechanisms to inhibit the ubiquitin - proteasome pathway targeted at the ubiquitin - proteasome degradation process itself, or more specifically at the E3 ligases known to modulate and downregulate proapoptosis pathways will lead to the enhancement of TRAIL apoptosis signaling and better cancer therapeutic outcomes act through this pathway.	Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA; Vet Adm Med Ctr, Birmingham, AL 35233 USA	University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Mountz, JD (corresponding author), Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, 701 S 19th St,LHRB 473, Birmingham, AL 35294 USA.	john.mountz@ccc.uab.edu			NCI NIH HHS [CA 20408] Funding Source: Medline; NIAID NIH HHS [R01 AI 42900] Funding Source: Medline; NIA NIH HHS [R01 AG 11653] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA020408] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042900] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011653] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Argentini M, 2000, ONCOGENE, V19, P3849, DOI 10.1038/sj.onc.1203737; Baetu TM, 2002, CYTOKINE GROWTH F R, V13, P199, DOI 10.1016/S1359-6101(02)00006-0; Basu A, 2002, INT J ONCOL, V21, P597; Bodmer JL, 1997, IMMUNITY, V6, P79, DOI 10.1016/S1074-7613(00)80244-7; Bothner B, 2001, J MOL BIOL, V314, P263, DOI 10.1006/jmbi.2001.5110; Breitschopf K, 2000, J BIOL CHEM, V275, P21648, DOI 10.1074/jbc.M001083200; Brichese L, 2002, EXP CELL RES, V278, P101, DOI 10.1006/excr.2002.5563; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; Chang YC, 1998, CELL GROWTH DIFFER, V9, P79; de Rozieres S, 2000, ONCOGENE, V19, P1691, DOI 10.1038/sj.onc.1203468; Dewson G, 2003, ONCOGENE, V22, P2643, DOI 10.1038/sj.onc.1206326; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Fukazawa T, 2001, ONCOGENE, V20, P5225, DOI 10.1038/sj.onc.1204673; Gottifredi V, 2001, SCIENCE, V292, P1851, DOI 10.1126/science.1062238; Gu JJ, 2002, J BIOL CHEM, V277, P19251, DOI 10.1074/jbc.C200150200; Haas AL, 1997, FASEB J, V11, P1257; HAAS AL, 1995, J BIOL CHEM, V270, P9407, DOI 10.1074/jbc.270.16.9407; He HL, 1998, J BIOL CHEM, V273, P25015, DOI 10.1074/jbc.273.39.25015; Holley CL, 2002, NAT CELL BIOL, V4, P439, DOI 10.1038/ncb798; Huang HK, 2000, J BIOL CHEM, V275, P26661; Jesenberger V, 2002, NAT REV MOL CELL BIO, V3, P112, DOI 10.1038/nrm731; Johnson TR, 2003, ONCOGENE, V22, P4953, DOI 10.1038/sj.onc.1206656; Kiechle FL, 2002, CLIN CHIM ACTA, V326, P27, DOI 10.1016/S0009-8981(02)00297-8; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Leverkus M, 2003, MOL CELL BIOL, V23, P777, DOI 10.1128/MCB.23.3.777-790.2003; Li BY, 2000, P NATL ACAD SCI USA, V97, P3850, DOI 10.1073/pnas.070047997; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; MacFarlane M, 2002, J BIOL CHEM, V277, P36611, DOI 10.1074/jbc.M200317200; Martin SJ, 2002, CELL, V109, P793, DOI 10.1016/S0092-8674(02)00802-4; Martinou I, 1998, NEUROREPORT, V9, P15, DOI 10.1097/00001756-199801050-00004; Olson MR, 2003, J BIOL CHEM, V278, P4028, DOI 10.1074/jbc.M209734200; ORIAN A, 1995, J BIOL CHEM, V270, P21707, DOI 10.1074/jbc.270.37.21707; Park SJ, 2001, BIOCHEM BIOPH RES CO, V289, P1205, DOI 10.1006/bbrc.2001.6086; Rivera-Walsh I, 2001, J BIOL CHEM, V276, P40385, DOI 10.1074/jbc.C100501200; Rossi D, 2003, HAEMATOLOGICA, V88, P212; Sayers TJ, 2003, BLOOD, V102, P303, DOI 10.1182/blood-2002-09-2975; Sengupta S, 2000, EMBO J, V19, P6051, DOI 10.1093/emboj/19.22.6051; Silke J, 2000, CELL DEATH DIFFER, V7, P1275, DOI 10.1038/sj.cdd.4400790; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Srivastava RK, 2001, NEOPLASIA, V3, P535, DOI 10.1038/sj.neo.7900203; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; WANG Q, 2003, J BIOL CHEM; Wesierska-Gadek J, 2002, INT J CANCER, V101, P128, DOI 10.1002/ijc.10580; Wilson R, 2002, NAT CELL BIOL, V4, P445, DOI 10.1038/ncb799; Wu JW, 2001, MOL CELL, V8, P95, DOI 10.1016/S1097-2765(01)00282-9; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yang YL, 2000, CELL RES, V10, P169, DOI 10.1038/sj.cr.7290046; Zhou T, 2002, IMMUNOL RES, V26, P323, DOI 10.1385/IR:26:1-3:323	57	212	227	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2004	23	11					2009	2015		10.1038/sj.onc.1207373	http://dx.doi.org/10.1038/sj.onc.1207373			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	803EC	15021888				2022-12-28	WOS:000220213400005
J	Amin, DN; Perkins, AS; Stern, DF				Amin, DN; Perkins, AS; Stern, DF			Gene expression profiling of ErbB receptor and ligand-dependent transcription	ONCOGENE			English	Article						ErbB; HER-2; breast cancer; microarray; immediate early genes	HUMAN-BREAST-CANCER; EPIDERMAL-GROWTH-FACTOR; CONSTITUTIVELY ACTIVE ERBB4; CDNA MICROARRAY ANALYSIS; TRANSGENIC MICE REVEALS; MAMMARY-GLAND; LOBULOALVEOLAR DEVELOPMENT; TYROSINE KINASES; PROTEIN-KINASE; UP-REGULATION	Overexpression of ErbB2 and ErbB4 receptors in breast cancers may be accompanied by contrasting clinical outcomes. To investigate the molecular mechanisms contributing to these differences, we undertook a comparative study of gene expression regulated by the two receptors. Agonistic antibodies were employed to activate ErbB2 and ErbB4 in isolation from the other ErbBs in breast cancer cells. Gene expression pro. ling using a 16 755-gene oligonucleotide array was performed to identify transcriptional targets of receptor activation. Our results indicate that, in the same cell line, ErbB2 and ErbB4 activation influence gene transcription differentially. Although there are genes that are regulated by signaling from both receptors, there are also receptor-specific targets that are preferentially regulated by each receptor. We further show that two ligands acting via the same receptor homodimer may activate different subsets of genes. Many of the induced genes are hitherto unidentified targets of ErbB signaling. These include ErbB4 targets EPS15R, GATA4, and RAB2 and ErbB2-activated HRY/HES1 and PPAP2A. Targets of ErbB2 homodimer signaling may be especially important as markers in breast cancer, where ErbB2 homodimerization mediated by overexpression and ligand-independent activation is common.	Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA	Yale University; Yale University	Stern, DF (corresponding author), Childrens Hosp, Dept Surg Res, Boston, MA 02115 USA.	DF.Stern@yale.edu			NATIONAL CANCER INSTITUTE [R01CA080065] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA80065] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alaoui-Jamali MA, 2003, CANCER RES, V63, P3764; Andrechek ER, 2003, CANCER RES, V63, P4920; Bacus SS, 1996, AM J PATHOL, V148, P549; Baulida J, 1996, J BIOL CHEM, V271, P5251; Burke CL, 1998, MOL CELL BIOL, V18, P5371, DOI 10.1128/MCB.18.9.5371; Chen XM, 1996, J BIOL CHEM, V271, P7620, DOI 10.1074/jbc.271.13.7620; Chuaqui RF, 2002, NAT GENET, V32, P509, DOI 10.1038/ng1034; Cohen BM, 1996, J BIOL CHEM, V271, P4813; da Silva AJ, 2002, J INTERF CYTOK RES, V22, P173, DOI 10.1089/107999002753536149; DECKER SJ, 1990, BIOCHEM BIOPH RES CO, V166, P615, DOI 10.1016/0006-291X(90)90853-F; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Dupont J, 2003, RECENT PROG HORM RES, V58, P325, DOI 10.1210/rp.58.1.325; Dupont J, 2001, ENDOCRINOLOGY, V142, P4969, DOI 10.1210/en.142.11.4969; Evans PC, 2001, BIOCHEM J, V357, P617, DOI 10.1042/0264-6021:3570617; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Ferguson KM, 2003, MOL CELL, V11, P507, DOI 10.1016/S1097-2765(03)00047-9; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; Geymayer S, 2000, FASEB J, V14, P1159, DOI 10.1096/fasebj.14.9.1159; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; Halgren RG, 2001, NUCLEIC ACIDS RES, V29, P582, DOI 10.1093/nar/29.2.582; Hirata H, 2002, SCIENCE, V298, P840, DOI 10.1126/science.1074560; Hobbs SS, 2002, ONCOGENE, V21, P8442, DOI 10.1038/sj.onc.1205960; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Jones FE, 1999, ONCOGENE, V18, P3481, DOI 10.1038/sj.onc.1202698; Jones FE, 1999, J CELL BIOL, V147, P77, DOI 10.1083/jcb.147.1.77; Kew TY, 2000, BRIT J CANCER, V82, P1163, DOI 10.1054/bjoc.1999.1057; Knowlden JM, 1998, ONCOGENE, V17, P1949, DOI 10.1038/sj.onc.1202107; Kumar-Sinha C, 2003, CANCER RES, V63, P132; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; Lesa GM, 1997, MOL BIOL CELL, V8, P779, DOI 10.1091/mbc.8.5.779; Li L, 2002, ONCOGENE, V21, P4900, DOI 10.1038/sj.onc.1205634; Mackay A, 2003, ONCOGENE, V22, P2680, DOI 10.1038/sj.onc.1206349; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mulligan C, 2002, J BIOL CHEM, V277, P42480, DOI 10.1074/jbc.M206206200; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Neve RM, 2002, ONCOGENE, V21, P4567, DOI 10.1038/sj.onc.1205555; Oh JJ, 1999, NUCLEIC ACIDS RES, V27, P4008, DOI 10.1093/nar/27.20.4008; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; Ota T, 2002, J CELL PHYSIOL, V193, P299, DOI 10.1002/jcp.10170; Pawson T, 1999, CELL, V97, P675, DOI 10.1016/S0092-8674(00)80779-5; Penington DJ, 2002, CELL GROWTH DIFFER, V13, P247; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; POLLARD JW, 1994, P NATL ACAD SCI USA, V91, P9312, DOI 10.1073/pnas.91.20.9312; PUPA SM, 1993, ONCOGENE, V8, P2917; Rangel LBA, 2003, CLIN CANCER RES, V9, P2567; Richer JK, 2002, J BIOL CHEM, V277, P5209, DOI 10.1074/jbc.M110090200; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Sapi E, 1998, J SOC GYNECOL INVEST, V5, P94, DOI 10.1016/S1071-5576(97)00108-1; Sartor CI, 2001, MOL CELL BIOL, V21, P4265, DOI 10.1128/MCB.21.13.4265-4275.2001; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; Schroeder JA, 1998, CELL GROWTH DIFFER, V9, P451; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Srinivasan R, 1998, J PATHOL, V185, P236, DOI 10.1002/(SICI)1096-9896(199807)185:3<236::AID-PATH118>3.0.CO;2-7; STANCOVSKI I, 1991, P NATL ACAD SCI USA, V88, P8691, DOI 10.1073/pnas.88.19.8691; Stern DF, 2003, EXP CELL RES, V284, P89, DOI 10.1016/S0014-4827(02)00103-9; Stern DF, 2000, BREAST CANCER RES, V2, P176, DOI 10.1186/bcr51; Suo Z, 2002, J PATHOL, V196, P17, DOI 10.1002/path.1003; Sweeney C, 2000, J BIOL CHEM, V275, P19803, DOI 10.1074/jbc.C901015199; Sweeney C, 2001, J BIOL CHEM, V276, P22685, DOI 10.1074/jbc.M100602200; Tang CK, 1999, CANCER RES, V59, P5315; Taylor E, 2001, BIOTECHNIQUES, V31, P62, DOI 10.2144/01311st01; Tidcombe H, 2003, P NATL ACAD SCI USA, V100, P8281, DOI 10.1073/pnas.1436402100; Tisdale EJ, 1999, MOL BIOL CELL, V10, P1837, DOI 10.1091/mbc.10.6.1837; Tseng GC, 2001, NUCLEIC ACIDS RES, V29, P2549, DOI 10.1093/nar/29.12.2549; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Vadlamudi RK, 2000, MOL CELL BIOL, V20, P9092, DOI 10.1128/MCB.20.23.9092-9101.2000; Vecchi M, 1996, J BIOL CHEM, V271, P18989, DOI 10.1074/jbc.271.31.18989; Vogt U, 1998, GENE, V223, P375, DOI 10.1016/S0378-1119(98)00454-5; Waterman H, 1998, J BIOL CHEM, V273, P13819, DOI 10.1074/jbc.273.22.13819; Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754; Williams EE, 2003, CANCER LETT, V192, P67, DOI 10.1016/S0304-3835(02)00690-0; Wilson KS, 2002, AM J PATHOL, V161, P1171, DOI 10.1016/S0002-9440(10)64394-5; Witton CJ, 2003, J PATHOL, V200, P290, DOI 10.1002/path.1370; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yip SS, 2000, INT J CANCER, V88, P363, DOI 10.1002/1097-0215(20001101)88:3<363::AID-IJC7>3.0.CO;2-4; Zhou W, 2002, INFLAMM RES, V51, P91, DOI 10.1007/BF02684009	83	19	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2004	23	7					1428	1438		10.1038/sj.onc.1207257	http://dx.doi.org/10.1038/sj.onc.1207257			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	775HZ	14973552				2022-12-28	WOS:000189035800010
J	Bertucci, F; Salas, S; Eysteries, S; Nasser, V; Finetti, P; Ginestier, C; Charafe-Jauffret, E; Loriod, B; Bachelart, L; Montfort, J; Victorero, G; Viret, F; Ollendorff, V; Fert, V; Giovaninni, M; Delpero, JR; Nguyen, C; Viens, P; Monges, G; Birnbaum, D; Houlgatte, R				Bertucci, F; Salas, S; Eysteries, S; Nasser, V; Finetti, P; Ginestier, C; Charafe-Jauffret, E; Loriod, B; Bachelart, L; Montfort, J; Victorero, G; Viret, F; Ollendorff, V; Fert, V; Giovaninni, M; Delpero, JR; Nguyen, C; Viens, P; Monges, G; Birnbaum, D; Houlgatte, R			Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters	ONCOGENE			English	Review						colon cancer; DNA microarray; expression profiles; microsatellite instability; prognosis	COMPARATIVE GENOMIC HYBRIDIZATION; RECEPTOR-INTERACTING PROTEIN; HUMAN COLORECTAL-CANCER; HUMAN PROSTATE-CANCER; BREAST-CANCER; MICROSATELLITE INSTABILITY; CDNA MICROARRAYS; GASTRIC-CANCER; OLIGONUCLEOTIDE ARRAYS; OVARIAN-CARCINOMA	Different diagnostic and prognostic groups of colorectal carcinoma (CRC) have been defined. However, accurate diagnosis and prediction of survival are sometimes difficult. Gene expression pro. ling might improve these classifications and bring new insights into underlying molecular mechanisms. We pro. led 50 cancerous and noncancerous colon tissues using DNA microarrrays consisting of similar to8000 spotted human cDNA. Global hierarchical clustering was to some extent able to distinguish clinically relevant subgroups, normal versus cancer tissues and metastatic versus nonmetastatic tumours. Supervised analyses improved these segregations by identifying sets of genes that discriminated between normal and tumour tissues, tumours associated or not with lymph node invasion or genetic instability, and tumours from the right or left colon. A similar approach identified a gene set that divided patients with significantly different 5-year survival (100% in one group and 40% in the other group; P = 0.005). Discriminator genes were associated with various cellular processes. An immunohistochemical study on 382 tumour and normal samples deposited onto a tissue microarray subsequently validated the upregulation of NM23 in CRC and a downregulation in poor prognosis tumours. These results suggest that microarrays may provide means to improve the classification of CRC, provide new potential targets against carcinogenesis and new diagnostic and/or prognostic markers and therapeutic targets.	INSERM, U119, F-13009 Marseille, France; Inst J Paoli I Calmettes, Dept Mol Oncol, F-13009 Marseille, France; Inst J Paoli I Calmettes, Dept Med Oncol, F-13009 Marseille, France; Univ Mediterranee, Fac Med, Marseille, France; Inst J Paoli I Calmettes, Dept Biopathol, F-13009 Marseille, France; INSERM, Lab TAGC, F-13258 Marseille, France; Inst Mediterraneen Rech Nutr, Marseille, France; Ipsogen SA, Marseille, France; Inst J Paoli I Calmettes, Dept Chirurg, F-13009 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC)	Birnbaum, D (corresponding author), INSERM, U119, IFR57,27 Bd Lei Roure, F-13009 Marseille, France.	birnbaum@marseille.inserm.fr	Nguyen, Catherine/M-4119-2016; Ginestier, Christophe/M-8828-2017; loriod, beatrice bl/L-2948-2016; Houlgatte, Remi/P-3020-2017; Finetti, Pascal/O-8669-2017; Charafe-Jauffret, emmanuelle/P-6009-2017	Nguyen, Catherine/0000-0001-9376-6360; Ginestier, Christophe/0000-0002-7477-3837; loriod, beatrice bl/0000-0001-5801-2264; DELPERO, JEAN ROBERT/0000-0002-0000-1332; Finetti, Pascal/0000-0002-2674-3123; Bertucci, Francois/0000-0002-0157-0959; Ollendorff, Vincent/0000-0001-9751-2202; Charafe-Jauffret, emmanuelle/0000-0002-0286-1299				Agrawal D, 2002, J NATL CANCER I, V94, P513; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Alon U, 1999, P NATL ACAD SCI USA, V96, P6745, DOI 10.1073/pnas.96.12.6745; Backert S, 1999, INT J CANCER, V82, P868, DOI 10.1002/(SICI)1097-0215(19990909)82:6<868::AID-IJC16>3.0.CO;2-W; Bardelli A, 2003, SCIENCE, V300, P949, DOI 10.1126/science.1082596; Barker N, 2000, ADV CANCER RES, V77, P1; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Berney CR, 1999, ANN SURG, V230, P179, DOI 10.1097/00000658-199908000-00007; Bertucci F, 1999, ONCOGENE, V18, P3905, DOI 10.1038/sj.onc.1202731; Bertucci F, 2001, LANCET ONCOL, V2, P674, DOI 10.1016/S1470-2045(01)00557-5; Bertucci F, 2002, HUM MOL GENET, V11, P863, DOI 10.1093/hmg/11.8.863; Bertucci F, 2000, HUM MOL GENET, V9, P2981, DOI 10.1093/hmg/9.20.2981; Bertucci F, 1999, HUM MOL GENET, V8, P1715, DOI 10.1093/hmg/8.9.1715; Bettuzzi S, 2000, CANCER RES, V60, P1472; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Birkenkamp-Demtroder K, 2002, CANCER RES, V62, P4352; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chen LM, 2002, INT J CANCER, V97, P323, DOI 10.1002/ijc.1601; Chen X, 2002, MOL BIOL CELL, V13, P1929, DOI 10.1091/mbc.02-02-0023; Devilard E, 2002, ONCOGENE, V21, P3095, DOI 10.1038/sj.onc.1205418; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Dunican DS, 2002, ONCOGENE, V21, P3253, DOI 10.1038/sj.onc.1205431; Dursun A, 2002, PATHOLOGY, V34, P427, DOI 10.1080/0031302021000009342; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Ernst T, 2002, AM J PATHOL, V160, P2169, DOI 10.1016/S0002-9440(10)61165-0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Filippova GN, 1998, GENE CHROMOSOME CANC, V22, P26, DOI 10.1002/(SICI)1098-2264(199805)22:1<26::AID-GCC4>3.0.CO;2-9; FREDERIKSEN CM, 2003, J CANCER RES CLIN, V15, P15; Furstenberger G, 2002, LANCET ONCOL, V3, P298, DOI 10.1016/S1470-2045(02)00731-3; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Ginestier C, 2002, AM J PATHOL, V161, P1223, DOI 10.1016/S0002-9440(10)64399-4; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Grant DS, 2002, ONCOGENE, V21, P4765, DOI 10.1038/sj.onc.1205595; Gunther K, 2002, J SURG RES, V103, P68, DOI 10.1006/jsre.2001.6312; Hegde P, 2001, CANCER RES, V61, P7792; Hermanto U, 2002, MOL CELL BIOL, V22, P2345, DOI 10.1128/MCB.22.7.2345-2365.2002; Hippo Y, 2001, CANCER RES, V61, P889; Hippo Y, 2002, CANCER RES, V62, P233; Hoos A, 2001, LAB INVEST, V81, P1331, DOI 10.1038/labinvest.3780347; Huang E, 2003, LANCET, V361, P1590, DOI 10.1016/S0140-6736(03)13308-9; Iacobuzio-Donahue CA, 2003, AM J PATHOL, V162, P1151, DOI 10.1016/S0002-9440(10)63911-9; Iacopetta B, 2002, INT J CANCER, V101, P403, DOI 10.1002/ijc.10635; Indinnimeo M, 1997, CANCER LETT, V111, P1, DOI 10.1016/S0304-3835(96)04472-2; Ishikawa S, 2001, GENE, V267, P101, DOI 10.1016/S0378-1119(01)00378-X; Kajiyama H, 2003, CANCER RES, V63, P2278; Katakura H, 2002, ANN THORAC SURG, V73, P1060, DOI 10.1016/S0003-4975(01)03597-4; Kiely PA, 2002, J BIOL CHEM, V277, P22581, DOI 10.1074/jbc.M201758200; Kitahara O, 2001, CANCER RES, V61, P3544; KODERA Y, 1994, CANCER, V73, P259, DOI 10.1002/1097-0142(19940115)73:2<259::AID-CNCR2820730205>3.0.CO;2-V; Korn WM, 1999, GENE CHROMOSOME CANC, V25, P82, DOI 10.1002/(SICI)1098-2264(199906)25:2<82::AID-GCC2>3.0.CO;2-6; Lee JC, 2001, J SURG ONCOL, V76, P58, DOI 10.1002/1096-9098(200101)76:1<58::AID-JSO1010>3.0.CO;2-D; LEVEDAKOU EN, 1992, INT J CANCER, V52, P534, DOI 10.1002/ijc.2910520406; Lin YM, 2002, ONCOGENE, V21, P4120, DOI 10.1038/sj.onc.1205518; Lindmark G, 1996, BRIT J CANCER, V74, P1413, DOI 10.1038/bjc.1996.557; Lindor NM, 2002, J CLIN ONCOL, V20, P1043, DOI 10.1200/JCO.20.4.1043; Luo J, 2001, CANCER RES, V61, P4683; Maaser K, 2002, CLIN CANCER RES, V8, P3205; Magrangeas F, 2003, BLOOD, V101, P4998, DOI 10.1182/blood-2002-11-3385; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Markowitz SD, 2002, CANCER CELL, V1, P233, DOI 10.1016/S1535-6108(02)00053-3; Matei D, 2002, ONCOGENE, V21, P6289, DOI 10.1038/sj.onc.1205785; McDermott NC, 2000, J PATHOL, V190, P157; Merritt J A, 1985, Prog Clin Biol Res, V202, P423; Mohr S, 2002, J CLIN ONCOL, V20, P3165, DOI 10.1200/JCO.2002.12.073; Nabeshima K, 2002, CANCER LETT, V176, P101, DOI 10.1016/S0304-3835(01)00742-X; Nakagawa H, 1998, CANCER RES, V58, P5176; Niu Y, 2002, INT J CANCER, V98, P754, DOI 10.1002/ijc.10136; Notterman DA, 2001, CANCER RES, V61, P3124; Paris S, 2002, INT J CANCER, V97, P615, DOI 10.1002/ijc.10120; Peltomaki P, 2003, J CLIN ONCOL, V21, P1174, DOI 10.1200/JCO.2003.04.060; Perrin J, 2001, INT J ONCOL, V19, P891; Platzer P, 2002, CANCER RES, V62, P1134; Reinmuth N, 2002, LAB INVEST, V82, P1377, DOI 10.1097/01.LAB.0000032411.41603.C2; Resta N, 1998, CANCER RES, V58, P4799; Richter J, 2000, AM J PATHOL, V157, P787, DOI 10.1016/S0002-9440(10)64592-0; Ried T, 1996, GENE CHROMOSOME CANC, V15, P234, DOI 10.1002/(SICI)1098-2264(199604)15:4<234::AID-GCC5>3.0.CO;2-2; Sagawa N, 2003, BRIT J CANCER, V88, P606, DOI 10.1038/sj.bjc.6600739; SANTRA M, 1995, P NATL ACAD SCI USA, V92, P7016, DOI 10.1073/pnas.92.15.7016; Shaffer AL, 2001, IMMUNITY, V15, P375, DOI 10.1016/S1074-7613(01)00194-7; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Steeg PS, 2003, NAT REV CANCER, V3, P55, DOI 10.1038/nrc967; Sterner-Kock A, 2002, GENE DEV, V16, P2264, DOI 10.1101/gad.229102; Stremmel C, 2002, INT J COLORECTAL DIS, V17, P131, DOI 10.1007/s00384-001-0370-7; Takahashi M, 2001, P NATL ACAD SCI USA, V98, P9754, DOI 10.1073/pnas.171209998; Tamura G, 1996, J PATHOL, V180, P371, DOI 10.1002/(SICI)1096-9896(199612)180:4<371::AID-PATH704>3.0.CO;2-2; Tas F, 2002, AM J CLIN ONCOL-CANC, V25, P164, DOI 10.1097/00000421-200204000-00012; THEILLET C, 1993, GENE CHROMOSOME CANC, V7, P219, DOI 10.1002/gcc.2870070407; Troup S, 2003, CLIN CANCER RES, V9, P207; Tureci O, 2003, FASEB J, V17, P376, DOI 10.1096/fj.02-0478com; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Wahlberg SS, 2002, CANCER RES, V62, P3485; Walch ET, 1999, CLIN EXP METASTAS, V17, P307, DOI 10.1023/A:1006652605568; Wang QS, 1998, CARCINOGENESIS, V19, P2001, DOI 10.1093/carcin/19.11.2001; Wang S, 2002, ONCOGENE, V21, P8388, DOI 10.1038/sj.onc.1205944; Welsh JB, 2001, CANCER RES, V61, P5974; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; WEST M, 2001, P NATL ACAD SCI USA, V18, P18; Williams NS, 2003, CLIN CANCER RES, V9, P931; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268; Zhou XP, 1998, GENE CHROMOSOME CANC, V21, P101, DOI 10.1002/(SICI)1098-2264(199802)21:2<101::AID-GCC4>3.0.CO;2-4; Zou TT, 2002, ONCOGENE, V21, P4855, DOI 10.1038/sj.onc.1205613	102	264	288	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2004	23	7					1377	1391		10.1038/sj.onc.1207262	http://dx.doi.org/10.1038/sj.onc.1207262			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	775HZ	14973550				2022-12-28	WOS:000189035800005
J	Schubert, S; Horstmann, S; Bartusel, T; Klempnauer, KH				Schubert, S; Horstmann, S; Bartusel, T; Klempnauer, KH			The cooperation of B-Myb with the coactivator p300 is orchestrated by cyclins A and D1	ONCOGENE			English	Article						B-myb; p300; cyclin A; cyclin D1; acetylation	CBP-INDUCED STIMULATION; CELL-CYCLE; TRANSCRIPTION FACTOR; RETINOBLASTOMA PROTEIN; C-MYB; ESTROGEN-RECEPTOR; MOLECULAR-CLONING; DEPENDENT-KINASE; GENE-EXPRESSION; V-MYB	B-Myb is a highly conserved member of the Myb family of transcription factors whose activity is regulated during the cell cycle. Previous work has shown that the activity of B-Myb is stimulated by cyclin A/Cdk2-dependent phosphorylation whereas interaction of B-Myb with cyclin D1 inhibits its activity. Here, we have investigated the role of p300 as a coactivator for B-Myb. We show that B-Myb-dependent transactivation is stimulated by p300 as a result of interaction between B-Myb and p300. We have mapped the sequences responsible for the interaction of B-Myb and p300 to the E1A-binding region of p300 and the transactivation domain of B-Myb, respectively. Furthermore, our data suggest that phosphorylation of B-Myb stimulates its acetylation by p300 and that the acetylation of B-Myb is necessary for the full stimulation of its transactivation potential by p300. We have also studied the effect of cyclin D1 on the cooperation of B-Myb and p300. Based on our results we propose that cyclin D1 inhibits the activity of B-Myb by interfering with the interaction of B-Myb and p300. The data reported here provide novel insight into the mechanisms by which the activity of B-Myb is regulated during the cell cycle. Taken together they suggest that the coactivator p300 plays an important role in this regulation and that the cooperation of B-Myb and p300 is orchestrated by cyclins A and D1.	Univ Munster, Inst Biochem, D-48149 Munster, Germany	University of Munster	Klempnauer, KH (corresponding author), Univ Munster, Inst Biochem, Wilhelm Klemm Str 2, D-48149 Munster, Germany.	klempna@uni-muenster.de	Buchinger, Sebastian/M-3003-2013	Buchinger, Sebastian/0000-0003-4859-8972				Ait-Si-Ali S, 2000, ONCOGENE, V19, P2430, DOI 10.1038/sj.onc.1203562; Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; ARSURA M, 1992, BLOOD, V79, P2708; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bannister AJ, 1995, ONCOGENE, V11, P2509; Bartsch O, 1999, EUR J BIOCHEM, V260, P384, DOI 10.1046/j.1432-1327.1999.00191.x; BERNARDS R, 1999, BIOCHIM BIOPHYS ACTA, V1424, P17; Bessa M, 2001, ONCOGENE, V20, P3376, DOI 10.1038/sj.onc.1204439; Bienvenu F, 2001, J BIOL CHEM, V276, P16840, DOI 10.1074/jbc.M100795200; BOUWMEESTER T, 1992, MECH DEVELOP, V37, P57, DOI 10.1016/0925-4773(92)90015-C; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Charrasse S, 2000, ONCOGENE, V19, P2986, DOI 10.1038/sj.onc.1203618; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Facchinetti V, 1997, BIOCHEM J, V324, P729, DOI 10.1042/bj3240729; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; Ganter B, 1998, EMBO J, V17, P255, DOI 10.1093/emboj/17.1.255; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; Goodman RH, 2000, GENE DEV, V14, P1553; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Hasan S, 2001, NATURE, V410, P387, DOI 10.1038/35066610; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hirai H, 1996, MOL CELL BIOL, V16, P6457; Horstmann S, 2000, ONCOGENE, V19, P5428, DOI 10.1038/sj.onc.1203937; Horstmann S, 2000, ONCOGENE, V19, P298, DOI 10.1038/sj.onc.1203302; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Inoue K, 1998, MOL CELL BIOL, V18, P1590, DOI 10.1128/MCB.18.3.1590; Janknecht R, 1996, ONCOGENE, V12, P1961; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; Johnson LR, 2002, J BIOL CHEM, V277, P4088, DOI 10.1074/jbc.M105112200; Johnson TK, 1999, J BIOL CHEM, V274, P36741, DOI 10.1074/jbc.274.51.36741; Kamano H, 1995, ONCOGENE, V11, P2575; Kamano H, 1997, ONCOGENE, V14, P1223, DOI 10.1038/sj.onc.1200945; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; Li XL, 2002, MOL CELL BIOL, V22, P3663, DOI 10.1128/MCB.22.11.3663-3673.2002; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Ratineau C, 2002, J BIOL CHEM, V277, P8847, DOI 10.1074/jbc.M110747200; Robinson C, 1996, ONCOGENE, V12, P1855; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Sano Y, 2001, J BIOL CHEM, V276, P3674, DOI 10.1074/jbc.M006896200; Saville MK, 1998, ONCOGENE, V17, P2679, DOI 10.1038/sj.onc.1202503; Schwartz C, 2003, EMBO J, V22, P882, DOI 10.1093/emboj/cdg076; SHERR CJ, 1995, P ASSOC AM PHYSICIAN, V107, P181; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Sitzmann J, 1996, ONCOGENE, V12, P1889; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Skapek SX, 1996, MOL CELL BIOL, V16, P7043; Tomita A, 2000, ONCOGENE, V19, P444, DOI 10.1038/sj.onc.1203329; Tsukiyama T, 1997, CURR OPIN GENET DEV, V7, P182, DOI 10.1016/S0959-437X(97)80127-X; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7; Ziebold U, 1997, ONCOGENE, V15, P1011, DOI 10.1038/sj.onc.1201282; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	73	22	23	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2004	23	7					1392	1404		10.1038/sj.onc.1207255	http://dx.doi.org/10.1038/sj.onc.1207255			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	775HZ	14973551				2022-12-28	WOS:000189035800006
J	Olschlager, V; Pleschka, S; Fischer, T; Rziha, HJ; Wurzer, W; Stitz, L; Rapp, UR; Ludwig, S; Planz, O				Olschlager, V; Pleschka, S; Fischer, T; Rziha, HJ; Wurzer, W; Stitz, L; Rapp, UR; Ludwig, S; Planz, O			Lung-specific expression of active Raf kinase results in increased mortality of influenza A virus-infected mice	ONCOGENE			English	Article						influenza A virus; lung tumor; C-Raf; MEK; ERK; in vivo; mouse	PSEUDORABIES VIRUS; TRANSGENIC MICE; GENE-EXPRESSION; CANCER; PROTEIN; VACCINATION; PROPAGATION; ACTIVATION; TUMORS	Alterations in signalling via the Raf/MEK/ERK pathway interfere with influenza A virus replication in cell culture. While virus yields are reduced in cells expressing dominant-negative Raf or ERK, virus propagation is enhanced upon expression of constitutively active Raf or MEK. To study the impact of active Raf on influenza virus propagation in vivo, we investigated transgenic mice expressing an activated mutant of c-Raf (Raf-BxB) in the main target tissue of influenza virus, the lung. Raf-BxB expression results in multicentric alveolar adenomas. Influenza virus A infection of Raf-BxB mice results in increased disease symptoms and higher mortality rates. The immune response against viral pathogens in transgenic animals did not differ from wild-type mice as determined by the use of a Pseudorabies virus (PRV) as a model for a viral infection not affecting the lung. No significant differences of influenza virus titers in the lung of Raf-BxB and wild-type mice were observed. However, immunohistology revealed increased numbers of influenza NP-positive cells in the alveolar linings of Raf-BxB mice, demonstrating the strong tropism of influenza virus for cells expressing active Raf. These findings disclose the possibility to use modified influenza virus for the therapy of tumors with an activated Ras/Raf signalling pathway.	Bundesforsch Anstalt Viruskrankheiten Tiere, Inst Immunol, Tubingen, Germany; Univ Giessen, Inst Med Virol, D-35390 Giessen, Germany; Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, D-97070 Wurzburg, Germany; Univ Dusseldorf, Inst Mol Med, D-4000 Dusseldorf, Germany	Justus Liebig University Giessen; University of Wurzburg; Heinrich Heine University Dusseldorf	Planz, O (corresponding author), Bundesforsch Anstalt Viruskrankheiten Tiere, Inst Immunol, Paul Ehrlich Str 28, Tubingen, Germany.	oliver.planz@tue.bfav.de	Pleschka, Stephan/HGU-9354-2022	Pleschka, Stephan/0000-0002-7372-7089; Ludwig, Stephan/0000-0003-4490-3052				Anderson H, 1999, BRIT J CANCER, V80, P219, DOI 10.1038/sj.bjc.6690342; Arrowood JR, 2002, ANN PHARMACOTHER, V36, P1219; Bergmann M, 2001, CANCER RES, V61, P8188; BOS JL, 1989, CANCER RES, V49, P4682; Brydak LB, 2000, DRUGS, V60, P35, DOI 10.2165/00003495-200060010-00004; CARD JP, 1995, CRIT REV NEUROBIOL, V9, P137; Couch Robert B., 1997, American Journal of Medicine, V102, P2, DOI 10.1016/S0002-9343(97)00003-X; Fischer T, 2003, J VIROL, V77, P9312, DOI 10.1128/JVI.77.17.9312-9323.2003; HALL WJ, 1976, AM REV RESPIR DIS, V113, P141; Kerkhoff E, 2000, CELL GROWTH DIFFER, V11, P185; KORFHAGEN TR, 1990, P NATL ACAD SCI USA, V87, P6122, DOI 10.1073/pnas.87.16.6122; LITTLE JW, 1976, ANN INTERN MED, V85, P177, DOI 10.7326/0003-4819-85-2-177; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; Ludwig S, 2003, TRENDS MOL MED, V9, P46, DOI 10.1016/S1471-4914(02)00010-2; Ludwig S, 2001, J BIOL CHEM, V276, P10990, DOI 10.1074/jbc.M009902200; MARSHALL M, 1995, MOL REPROD DEV, V42, P493, DOI 10.1002/mrd.1080420418; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Naumann U, 1997, Recent Results Cancer Res, V143, P237; Ober BT, 1998, J VIROL, V72, P4866, DOI 10.1128/JVI.72.6.4866-4873.1998; Olshaker JS, 2003, EMERG MED CLIN N AM, V21, P353, DOI 10.1016/S0733-8627(03)00018-X; Palese P, 1996, P NATL ACAD SCI USA, V93, P11354, DOI 10.1073/pnas.93.21.11354; PESCHKE T, 1993, IMMUNOBIOLOGY, V189, P340, DOI 10.1016/S0171-2985(11)80365-7; Pleschka S, 2001, NAT CELL BIOL, V3, P301, DOI 10.1038/35060098; Porter DD, 1999, CLIN INFECT DIS, V29, P437, DOI 10.1086/520230; Ramakrishna G, 2000, EXP LUNG RES, V26, P659, DOI 10.1080/01902140150216747; SCHOLTISSEK C, 1997, ARCH VIROL         S, V13, P99; Steinhauer DA, 2002, ANNU REV GENET, V36, P305, DOI 10.1146/annurev.genet.36.052402.152757; von Gise A, 2001, MOL CELL BIOL, V21, P2324, DOI 10.1128/MCB.21.7.2324-2336.2001; Wurzer WJ, 2003, EMBO J, V22, P2717, DOI 10.1093/emboj/cdg279	29	37	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6639	6646		10.1038/sj.onc.1207883	http://dx.doi.org/10.1038/sj.onc.1207883			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15235583				2022-12-28	WOS:000223530800011
J	Wagner, KW; Sapinoso, LM; El-Rifai, W; Frierson, HF; Butz, N; Mestan, J; Hofmann, F; Deveraux, QL; Hampton, GM				Wagner, KW; Sapinoso, LM; El-Rifai, W; Frierson, HF; Butz, N; Mestan, J; Hofmann, F; Deveraux, QL; Hampton, GM			Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin	ONCOGENE			English	Article						UbcH10; gene expression; DNA amplification; RNA interference; TRAIL/DR5; apoptosis	ANAPHASE-PROMOTING COMPLEX; INDUCED APOPTOSIS; CANCER-TREATMENT; PROSTATE-CANCER; EXPRESSION; PROTEOLYSIS; CELLS; MITOSIS; TARGETS; MARKERS	Gene expression pro. ling of anatomically diverse carcinomas and their corresponding normal tissues was used to identify genes with cancer-associated expression. We show here that the ubiquitin conjugase, UbcH10, is significantly overexpressed in many different types of cancers and is associated with the degree of tumor differentiation in carcinomas of the breast, lung, ovary and bladder, as well as in glioblastomas. We also show that UbcH10 overexpression in gastro-esophageal, and probably other carcinomas may be a direct consequence of chromosomal amplification at the UbcH10 locus, 20q13.1, a region known to be amplified in diverse tumors. To evaluate whether inhibition of UbcH10 function may be therapeutically relevant in cancer, we used small interfering RNAs (siRNAs) to silence UbcH10 transcription selectively. Diminution of UbcH10 expression significantly inhibited both tumor and normal cell proliferation without inducing cell death. However, when combined with agonists of the DR5/TRAIL receptor, siRNAs directed against the UbcH10 transcript dramatically enhanced killing of cancer cells, but not of proliferating primary human epithelial cells or fibroblasts. Together, these data demonstrate that UbcH10 plays an important role in tumor development and that its inhibition in combination with agonists of the TRAIL receptor may provide an enhanced therapeutic index.	Novartis Res Fdn, Gen Inst, San Diego, CA 92121 USA; Univ Virginia, Hlth Sci Ctr, Digest Hlth Ctr Excellence, Charlottesville, VA USA; Univ Virginia, Hlth Sci Ctr, Dept Pathol, Charlottesville, VA USA; Novartis Pharma AG, Novartis Inst BioMed Res, Basel, Switzerland	Novartis; University of Virginia; University of Virginia; Novartis	Hampton, GM (corresponding author), Novartis Res Fdn, Gen Inst, 10675 John Jay Hopkins Dr, San Diego, CA 92121 USA.	hampton@gnf.org						Arvand A, 1998, ONCOGENE, V17, P2039, DOI 10.1038/sj.onc.1202129; Borkhardt A, 2002, CANCER CELL, V2, P167, DOI 10.1016/S1535-6108(02)00129-0; Boye J, 2003, ANN ONCOL, V14, P520, DOI 10.1093/annonc/mdg175; Cuthill S, 1999, GENE CHROMOSOME CANC, V26, P304, DOI 10.1002/(SICI)1098-2264(199912)26:4<304::AID-GCC4>3.0.CO;2-1; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; El-Rifai W, 2001, GASTROENTEROLOGY, V121, P592, DOI 10.1053/gast.2001.27215; Fulda S, 2004, CANCER RES, V64, P337, DOI 10.1158/0008-5472.CAN-03-1656; Goke R, 2001, DIGESTION, V64, P75, DOI 10.1159/000048843; Grunwald V, 2003, JNCI-J NATL CANCER I, V95, P851, DOI 10.1093/jnci/95.12.851; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; Jazaeri AA, 2003, MOL CARCINOGEN, V36, P53, DOI 10.1002/mc.10098; Jin ZY, 2002, CELL CYCLE, V1, P82, DOI 10.4161/cc.1.1.104; LaTulippe E, 2002, CANCER RES, V62, P4499; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Mayer RJ, 2000, NAT REV MOL CELL BIO, V1, P145; O'Dwyer M E, 2000, Lancet Oncol, V1, P207, DOI 10.1016/S1470-2045(00)00149-2; Okamoto Y, 2003, CANCER RES, V63, P4167; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sebti SM, 2000, ONCOGENE, V19, P6584, DOI 10.1038/sj.onc.1204146; Stennicke H R, 2000, Symp Soc Exp Biol, V52, P13; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Townsley FM, 1997, P NATL ACAD SCI USA, V94, P2362, DOI 10.1073/pnas.94.6.2362; Watanabe T, 2002, JPN J CANCER RES, V93, P1114, DOI 10.1111/j.1349-7006.2002.tb01213.x; Welsh JB, 2001, CANCER RES, V61, P5974; Welsh JB, 2003, P NATL ACAD SCI USA, V100, P3410, DOI 10.1073/pnas.0530278100; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Yamanaka A, 2000, MOL BIOL CELL, V11, P2821, DOI 10.1091/mbc.11.8.2821	30	110	124	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6621	6629		10.1038/sj.onc.1207861	http://dx.doi.org/10.1038/sj.onc.1207861			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15208666				2022-12-28	WOS:000223530800009
J	Armstrong, F; Duplantier, MM; Trempat, P; Hieblot, C; Lamant, L; Espinos, E; Racaud-Sultan, C; Allouche, M; Campo, E; Delsol, G; Touriol, C				Armstrong, F; Duplantier, MM; Trempat, P; Hieblot, C; Lamant, L; Espinos, E; Racaud-Sultan, C; Allouche, M; Campo, E; Delsol, G; Touriol, C			Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells	ONCOGENE			English	Article						anaplastic lymphoma kinase (ALK); anaplastic large-cell lymphoma; X-ALK variants	ANAPLASTIC LYMPHOMA KINASE; NON-HODGKINS-LYMPHOMA; GROWTH-FACTOR; TYROSINE KINASE; TROPOMYOSIN SYNTHESIS; ATIC-ALK; GENE; NPM; TRANSLOCATIONS; SUPPRESSION	Majority of anaplastic large-cell lymphomas (ALCLs) are associated with the t(2;5)(p23; q35) translocation, fusing the NPM ( nucleophosmin) and ALK (anaplastic lymphoma kinase) genes (NPM-ALK). Recent studies demonstrated that ALK may also be involved in variant translocations, namely, t(1;2)(q25;p23), t(2;3)(p23;q21), t(2;17)(p23;q23) and inv(2)(p23q35), which create the TPM3-ALK, TFG-ALK5, CLTC-ALK, and ATIC-ALK fusion genes, respectively. Although overexpression of NPM-ALK has previously been shown to transform fibroblasts, the transforming potential of variant X-ALK proteins has not been precisely investigated. We stably transfected the cDNAs coding for NPM-ALK, TPM3-ALK, TFG-ALK, CLTC-ALK or ATIC-ALK into nonmalignant NIH3T3 cells. All X-ALK variants are tyrosine phosphorylated and their subcellular distribution was in agreement with that observed in tumors. Moreover, our results show that the in vitro transforming capacity of NIH3T3-transfected cells are in relation to the level of X-ALK fusion proteins excepted for TPM3-ALK for which there is an inverse correlation. The differences between the five X-ALK variants with regard to proliferation rate, colony formation in soft agar, invasion, migration through the endothelial barrier and tumorigenicity seem to be due to differential activation of various signaling pathways such as PI3-kinase/AKT. These findings may have clinical implications in the pathogenesis and prognosis of ALK-positive ALCLs.	Ctr Physiopathol Toulouse Purpan, INSERM, U563, Dept Oncogenesis & Signaling Hematopoiet Cells, Toulouse, France; CHU Rangueil, INSERM, U589, F-31054 Toulouse, France; Univ Barcelona, Hosp Clin, Pathol Lab, E-08036 Barcelona, Spain	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Barcelona; Hospital Clinic de Barcelona	Delsol, G (corresponding author), CHU Purpan, Anat Pathol Lab, Pl Dr Baylac, F-31059 Toulouse, France.	delsol.g@chu-toulouse.fr	Campo, Elias/AAC-5593-2019; TOURIOL, Christian/O-8949-2014; Hieblot, Corinne/O-4734-2019; Espinos, Estelle/A-4661-2015; Allouche, Michele/P-4865-2019	Campo, Elias/0000-0001-9850-9793; TOURIOL, Christian/0000-0003-1219-4693; Espinos, Estelle/0000-0002-5693-8941; Racaud-Sultan, Claire/0000-0002-6549-1088				Arnaud E, 1999, MOL CELL BIOL, V19, P505; Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; Bowden ET, 2002, J BIOL CHEM, V277, P35862, DOI 10.1074/jbc.M203963200; Bridge JA, 2001, AM J PATHOL, V159, P411, DOI 10.1016/S0002-9440(10)61711-7; Calo V, 2003, J CELL PHYSIOL, V197, P157, DOI 10.1002/jcp.10364; CHIARLE R, 2002, BLOOD, V7, P7; Colleoni GWB, 2000, AM J PATHOL, V156, P781, DOI 10.1016/S0002-9440(10)64945-0; Cools J, 2002, GENE CHROMOSOME CANC, V34, P354, DOI 10.1002/gcc.10033; COOPER HL, 1985, MOL CELL BIOL, V5, P972, DOI 10.1128/MCB.5.5.972; COOPER HL, 1987, CANCER RES, V47, P4493; Cooper JA, 2002, CURR BIOL, V12, pR523, DOI 10.1016/S0960-9822(02)01028-X; Duyster J, 2001, ONCOGENE, V20, P5623, DOI 10.1038/sj.onc.1204594; Falini B, 2002, BLOOD, V99, P409, DOI 10.1182/blood.V99.2.409; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; HENDRICKS M, 1981, P NATL ACAD SCI-BIOL, V78, P5633, DOI 10.1073/pnas.78.9.5633; Hernandez L, 1999, BLOOD, V94, P3265; JOOSS KU, 1995, ONCOGENE, V10, P603; Kuefer MU, 1997, BLOOD, V90, P2901, DOI 10.1182/blood.V90.8.2901; Lamant L, 2000, AM J PATHOL, V156, P1711, DOI 10.1016/S0002-9440(10)65042-0; Lamant L, 2003, GENE CHROMOSOME CANC, V37, P427, DOI 10.1002/gcc.10232; Lamant L, 1999, BLOOD, V93, P3088; Lawrence B, 2000, AM J PATHOL, V157, P377, DOI 10.1016/S0002-9440(10)64550-6; Lee TH, 2003, J BIOL CHEM, V278, P5277, DOI 10.1074/jbc.M210063200; Ma ZG, 2000, BLOOD, V95, P2144, DOI 10.1182/blood.V95.6.2144; Mason DY, 1998, CANCER RES, V58, P1057; Miething C, 2003, ONCOGENE, V22, P4642, DOI 10.1038/sj.onc.1206575; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; MORRIS SW, 1995, SCIENCE, V267, P316, DOI 10.1126/science.267.5196.316-b; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; Powers C, 2002, J BIOL CHEM, V277, P14153, DOI 10.1074/jbc.M112354200; Prasad SC, 1997, ELECTROPHORESIS, V18, P629, DOI 10.1002/elps.1150180348; Pulford K, 1997, BLOOD, V89, P1394, DOI 10.1182/blood.V89.4.1394; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; SAWYERS CL, 1994, CELL, V77, P171, DOI 10.1016/0092-8674(94)90307-7; Schweitzer KM, 1997, LAB INVEST, V76, P25; Slupianek A, 2001, CANCER RES, V61, P2194; Sotsios Y, 2000, IMMUNOL REV, V177, P217, DOI 10.1034/j.1600-065X.2000.17712.x; Stoica GE, 2002, J BIOL CHEM, V277, P35990, DOI 10.1074/jbc.M205749200; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; TAKENAGA K, 1988, BIOCHEM BIOPH RES CO, V157, P1111, DOI 10.1016/S0006-291X(88)80988-4; TAKENAGA K, 1994, CANCER LETT, V87, P47, DOI 10.1016/0304-3835(94)90408-1; Tort F, 2001, LAB INVEST, V81, P419, DOI 10.1038/labinvest.3780249; Touriol C, 2000, BLOOD, V95, P3204, DOI 10.1182/blood.V95.10.3204.010k04_3204_3207; Trinei M, 2000, CANCER RES, V60, P793; URBANCIKOVA M, 1982, NEOPLASMA, V29, P655; Weber KSC, 2001, MOL BIOL CELL, V12, P3074, DOI 10.1091/mbc.12.10.3074; West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016/S1368-7646(02)00120-6; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YAMAJI H, 1992, APPL MICROBIOL BIOT, V37, P244; Zamo A, 2002, ONCOGENE, V21, P1038, DOI 10.1038/sj.onc.1205152; Zhang Q, 2002, J IMMUNOL, V168, P466, DOI 10.4049/jimmunol.168.1.466	54	99	103	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6071	6082		10.1038/sj.onc.1207813	http://dx.doi.org/10.1038/sj.onc.1207813			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15208656				2022-12-28	WOS:000223261000007
J	Seidel, B; Braeg, S; Adler, G; Wedlich, D; Menke, A				Seidel, B; Braeg, S; Adler, G; Wedlich, D; Menke, A			E- and N-cadherin differ with respect to their associated p120(ctn) isoforms and their ability to suppress invasive growth in pancreatic cancer cells	ONCOGENE			English	Article						pancreatic cancer; E-cadherin; N-cadherin; p120(ctn) isoforms; tyrosine phosphorylation	MEMBRANE-PROXIMAL REGION; LYMPH-NODE METASTASIS; CYTOPLASMIC DOMAIN; P120 CATENIN; TYROSINE PHOSPHORYLATION; ADHESION ACTIVITY; ALPHA-CATENIN; BETA-CATENIN; V-SRC; DISTINCT MECHANISMS	E-cadherin functions as suppressor of invasion in epithelial cells and its loss is described in many invasive carcinomas. In some tumours, the disappearance of E-cadherin has been correlated with upregulation of other classical cadherins, such as N- or P-cadherin. To analyse the different cellular functions of cadherin molecules, we stably expressed E-cadherin or N-cadherin in the E- and N-cadherin-deficient pancreatic tumour cell line MIA PaCa-2. Only E-cadherin was able to induce a mesenchymal-epithelial transition and suppressed invasion of MIA PaCa-2 cells. Furthermore, only re-expression of E-cadherin resulted in an upregulation of alpha- and beta-catenin mRNAs and protein concentrations. Ectopically expressed N-cadherin failed to assemble cadherin/catenin Adhesion complexes and failed to inhibit invasion. Analysis of p12(ctn), which was associated with both cadherins, demonstrated that E-cadherin was linked to a shorter isoform of p120(ctn). In contrast, N-cadherin was associated with the long, 120 kDa p120(ctn) isoforms. In addition, p120(ctn) connected with N-cadherin was phosphorylated at tyrosine residues, whereas the isoform linked to E-cadherin was not phosphorylated. Thus, the differences between E- and N-cadherin in recruiting different phosphorylated isoforms of p120(ctn) to the membrane might be responsible for the inability of N-cadherin to replace E-cadherin as suppressor of invasion in pancreatic carcinoma cells.	Univ Ulm, Dept Internal Med 1, D-89081 Ulm, Germany; Univ Karlsruhe, Inst Zool 2, D-76131 Karlsruhe, Germany	Ulm University; Helmholtz Association; Karlsruhe Institute of Technology	Menke, A (corresponding author), Univ Ulm, Dept Internal Med 1, D-89081 Ulm, Germany.	andre.menke@medizin.uni-ulm.de						Aho S, 2002, J CELL SCI, V115, P1391; Anastasiadis PZ, 2000, J CELL SCI, V113, P1319; Aono S, 1999, J CELL BIOL, V145, P551, DOI 10.1083/jcb.145.3.551; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Birchmeier C, 1996, ACTA ANAT, V156, P217; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Bruns Christiane J., 1999, Neoplasia (New York), V1, P50, DOI 10.1038/sj.neo.7900005; Chen HY, 1997, J CELL SCI, V110, P345; Christofori G, 2003, EMBO J, V22, P2318, DOI 10.1093/emboj/cdg228; Daniel JM, 1999, MOL CELL BIOL, V19, P3614; Finnemann S, 1997, J BIOL CHEM, V272, P11856, DOI 10.1074/jbc.272.18.11856; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Giehl K, 2000, ONCOGENE, V19, P2930, DOI 10.1038/sj.onc.1203612; Grosheva I, 2001, J CELL SCI, V114, P695; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; Hazan RB, 1996, CELL ADHES COMMUN, V4, P399, DOI 10.3109/15419069709004457; HERRENKNECHT K, 1991, P NATL ACAD SCI USA, V88, P9156, DOI 10.1073/pnas.88.20.9156; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Jaggi M, 2002, CELL COMMUN ADHES, V9, P103, DOI 10.1080/15419060214150; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Karayiannakis AJ, 2001, ANTICANCER RES, V21, P4127; Karayiannakis AJ, 1998, ANTICANCER RES, V18, P4177; Keilhack H, 2000, J BIOL CHEM, V275, P26376, DOI 10.1074/jbc.M001315200; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Kern S, 2001, CANCER RES, V61, P4923; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; Lowy AM, 2002, SURGERY, V132, P141, DOI 10.1067/msy.2002.125168; Mareel M, 1997, J CELL PHYSIOL, V173, P271, DOI 10.1002/(SICI)1097-4652(199711)173:2<271::AID-JCP34>3.0.CO;2-G; Menke A, 2001, CANCER RES, V61, P3508; Menke A, 1997, GASTROENTEROLOGY, V113, P295, DOI 10.1016/S0016-5085(97)70107-0; Mo YY, 1996, CANCER RES, V56, P2633; Montonen O, 2001, J HISTOCHEM CYTOCHEM, V49, P1487, DOI 10.1177/002215540104901202; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; Navarro P, 1998, J CELL BIOL, V140, P1475, DOI 10.1083/jcb.140.6.1475; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; Ohkubo T, 1999, J BIOL CHEM, V274, P21409, DOI 10.1074/jbc.274.30.21409; Ozawa M, 2003, J BIOL CHEM, V278, P46014, DOI 10.1074/jbc.M307778200; Ozawa M, 2001, J CELL SCI, V114, P503; Ozawa M, 1998, J CELL BIOL, V142, P1605, DOI 10.1083/jcb.142.6.1605; OZAWA M, 1990, J CELL BIOL, V111, P1645, DOI 10.1083/jcb.111.4.1645; Papkoff J, 1997, J BIOL CHEM, V272, P4536; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Piedra J, 2003, MOL CELL BIOL, V23, P2287, DOI 10.1128/MCB.23.7.2287-2297.2003; PIGNATELLI M, 1994, J PATHOL, V174, P243, DOI 10.1002/path.1711740403; POSTON GJ, 1991, GUT, V32, P800, DOI 10.1136/gut.32.7.800; RASBRIDGE SA, 1993, J PATHOL, V169, P245, DOI 10.1002/path.1711690211; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; SCHIPPER JH, 1991, CANCER RES, V51, P6328; SHIBAMOTO S, 1995, J CELL BIOL, V128, P949, DOI 10.1083/jcb.128.5.949; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; Tran NL, 1999, AM J PATHOL, V155, P787, DOI 10.1016/S0002-9440(10)65177-2; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Weinel RJ, 1996, INT J PANCREATOL, V19, P25; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779; Yap AS, 2003, J CELL BIOL, V160, P11, DOI 10.1083/jcb.200208156	60	66	70	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2004	23	32					5532	5542		10.1038/sj.onc.1207718	http://dx.doi.org/10.1038/sj.onc.1207718			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15107817				2022-12-28	WOS:000222588400013
J	Iida, S; Hirota, T; Morisaki, T; Marumoto, T; Hara, T; Kuninaka, S; Honda, S; Kosai, K; Kawasuji, M; Pallas, DC; Saya, H				Iida, S; Hirota, T; Morisaki, T; Marumoto, T; Hara, T; Kuninaka, S; Honda, S; Kosai, K; Kawasuji, M; Pallas, DC; Saya, H			Tumor suppressor WARTS ensures genomic integrity by regulating both mitotic progression and G(1) tetraploidy checkpoint function	ONCOGENE			English	Article						cell cycle; mitotic kinase; spindle checkpoint; p53; polyploid	HUMAN HOMOLOG; SPINDLE; KINASE; CELLS; TRANSITION; ANAPHASE; MITOSIS; LATS1; CENTROSOME; METAPHASE	Defects in chromosomes or mitotic spindles activate the spindle checkpoint, resulting in cell cycle arrest at prometaphase. The prolonged activation of spindle checkpoint generally leads to mitotic exit without segregation after a transient mitotic arrest and the consequent formation of tetraploid G(1) cells. These tetraploid cells are usually blocked to enter the subsequent S phase by the activation of p53/pRb pathway, which is referred to as the G(1) tetraploidy checkpoint. A human homologue of the Drosophila warts tumor suppressor, WARTS, is an evolutionarily conserved serine-threonine kinase and implicated in development of human tumors. We previously showed that WARTS plays a crucial role in controlling mitotic progression by forming a regulatory complex with zyxin, a regulator of actin. lament assembly, on mitotic apparatus. However, when WARTS is activated during cell cycle and how the loss of WARTS function leads to tumorigenesis have not been elucidated. Here we show that WARTS is activated during mitosis in mammalian cells, and that overexpression of a kinase-inactive WARTS in Rat1 fibroblasts significantly induced mitotic delay. This delay resulted from prolonged activation of the spindle assembly checkpoint and was frequently followed by mitotic slippage and the development of tetraploidy. The resulting tetraploid cells then abrogated the G(1) tetraploidy checkpoint and entered S phase to achieve a DNA content of 8N. This impairment of G(1) tetraploidy checkpoint was caused as a consequence of failure to induce p53 expression by expressing a kinase-inactive WARTS. WARTS thus plays a critical role in maintenance of ploidy through its actions in both mitotic progression and the G(1) tetraploidy checkpoint.	Kumamoto Univ, Grad Sch Med Sci, Dept Tumor Genet & Biol, Kumamoto 8608556, Japan; Kumamoto Univ, Grad Sch Med Sci, Dept Cardiovasc Surg, Kumamoto 8608556, Japan; Kurume Univ, Cognit & Mol Res Inst Brain Dis, Div Gene Therapy & Regenerat Med, Kurume, Fukuoka 8300011, Japan; Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Winship Canc Ctr, Atlanta, GA 30322 USA	Kumamoto University; Kumamoto University; Kurume University; Emory University; Emory University	Saya, H (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Dept Tumor Genet & Biol, 1-1-1 Honjo, Kumamoto 8608556, Japan.	hsaya@gpo.kumamoto-u.ac.jp	Saya, Hideyuki/J-4325-2013; Kuninaka, Shinji/J-7158-2013		NCI NIH HHS [R01 CA057327] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057327] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hirota T, 2000, J CELL BIOL, V149, P1073, DOI 10.1083/jcb.149.5.1073; Hisaoka M, 2002, LAB INVEST, V82, P1427, DOI 10.1097/01.LAB.0000032381.68634.CA; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Margolis RL, 2003, J CELL BIOCHEM, V88, P673, DOI 10.1002/jcb.10411; Marumoto T, 2003, J BIOL CHEM, V278, P51786, DOI 10.1074/jbc.M306275200; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; Nishiyama Y, 1999, FEBS LETT, V459, P159, DOI 10.1016/S0014-5793(99)01224-7; SHACKNEY SE, 1989, CANCER RES, V49, P3344; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Tao WF, 1999, NAT GENET, V21, P177, DOI 10.1038/5960; TOYN JH, 1994, EMBO J, V13, P1103, DOI 10.1002/j.1460-2075.1994.tb06359.x; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; Xia H, 2002, ONCOGENE, V21, P1233, DOI 10.1038/sj.onc.1205174; Yang XL, 2001, ONCOGENE, V20, P6516, DOI 10.1038/sj.onc.1204817; Yasui Y, 1998, J CELL BIOL, V143, P1249, DOI 10.1083/jcb.143.5.1249	24	70	72	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2004	23	31					5266	5274		10.1038/sj.onc.1207623	http://dx.doi.org/10.1038/sj.onc.1207623			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15122335				2022-12-28	WOS:000222491600002
J	Ludes-Meyers, JH; Kil, H; Bednarek, AK; Drake, J; Bedford, MT; Aldaz, CM				Ludes-Meyers, JH; Kil, H; Bednarek, AK; Drake, J; Bedford, MT; Aldaz, CM			WWOX binds the specific proline-rich ligand PPXY: identification of candidate interacting proteins	ONCOGENE			English	Article						tumor suppressors; WW domain; protein-protein interaction	DOMAIN-CONTAINING OXIDOREDUCTASE; FRA16D; COMMON; GENES; MOTIF	WWOX, the gene that maps to common chromosomal fragile site FRA16D, is frequently affected by aberrations in multiple types of cancers. WWOX encodes a 46 kDa protein that contains two WW domains and a short-chain oxidoreductase (SDR) domain. We recently demonstrated that ectopic expression of WWOX inhibits xenograft tumor growth of tumorigenic breast cancer cells. Little is known of the biochemical function(s) of WWOX. The SDR domain is predicted to be involved in sex-steroid metabolism and the WW domains are likely involved in protein-protein interactions. In this report, we identify the specific proline-rich ligand for WWOX as PPXY and show that the amino-terminal WW domain is responsible for this interaction. Using the WWOX WW domains as a probe, we screened high-density protein arrays and identified five candidate-binding partners. The binding to one of these candidates, small membrane protein of the lysosome/late endosome (SIMPLE), was further analysed, and we observed that a specific PPSY motif in the SIMPLE amino-acid sequence was required to interact with the amino-terminal WW domain of WWOX. In addition, immunofluorescence staining demonstrated that endogenous WWOX and SIMPLE co-localize to perinuclear compartments of MCF-7 human breast cancer cells. These studies demonstrate that WWOX contains a Group I WW domain that binds known cellular proteins containing the specific ligand PPXY. Identification and characterization of WWOX interacting proteins will lead to an understanding of the biological functions of WWOX in normal and tumor cells.	Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, Smithville, TX 78957 USA; Med Univ Lodz, IPh&B Dept Med Biochem, PL-92215 Lodz, Poland	University of Texas System; UTMD Anderson Cancer Center; Medical University Lodz	Aldaz, CM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, POB 389, Smithville, TX 78957 USA.	maldaz@odin.mdacc.tmc.edu	Aldaz, C. Marcelo/E-7868-2011; Bedford, Mark T/E-7856-2011; Bednarek, Andrzej K./S-9664-2016	Aldaz, C. Marcelo/0000-0002-2453-2939; Bednarek, Andrzej K./0000-0002-4570-4154	NATIONAL CANCER INSTITUTE [R01CA102444] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA102444, R01 CA102444-06A1, R01 CA102444-03, R01 CA102444-01, R01 CA102444-02, R01 CA102444-05, R01 CA102444-07, R01 CA102444-04, R01 CA 102 444] Funding Source: Medline; NIEHS NIH HHS [P30 ES007784, ES07784] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bedford MT, 2000, J BIOL CHEM, V275, P10359, DOI 10.1074/jbc.275.14.10359; Bedford MT, 1998, P NATL ACAD SCI USA, V95, P10602, DOI 10.1073/pnas.95.18.10602; Bednarek AK, 2000, CANCER RES, V60, P2140; Bednarek AK, 2001, CANCER RES, V61, P8068; Bussow K, 1998, NUCLEIC ACIDS RES, V26, P5007, DOI 10.1093/nar/26.21.5007; Chan DC, 1996, EMBO J, V15, P1045, DOI 10.1002/j.1460-2075.1996.tb00442.x; Chang NS, 2003, J BIOL CHEM, V278, P9195, DOI 10.1074/jbc.M208373200; Chang NS, 2001, J BIOL CHEM, V276, P3361, DOI 10.1074/jbc.M007140200; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Jolliffe CN, 2000, BIOCHEM J, V351, P557, DOI 10.1042/0264-6021:3510557; Kallberg Y, 2002, PROTEIN SCI, V11, P636, DOI 10.1110/ps.26902; Kasanov J, 2001, CHEM BIOL, V8, P231, DOI 10.1016/S1074-5521(01)00005-9; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Ludes-Meyers JH, 2003, CYTOGENET GENOME RES, V100, P101, DOI 10.1159/000072844; Matsuda A, 2003, ONCOGENE, V22, P3307, DOI 10.1038/sj.onc.1206406; Moriwaki Y, 2001, J BIOL CHEM, V276, P23065, DOI 10.1074/jbc.M011660200; Otte L, 2003, PROTEIN SCI, V12, P491, DOI 10.1110/ps.0233203; Sambrook J., 2001, MOL CLONING LAB MANU; Sudol M, 2000, CELL, V103, P1001, DOI 10.1016/S0092-8674(00)00203-8; Winfield SL, 1997, GENOME RES, V7, P1020, DOI 10.1101/gr.7.10.1020	21	96	102	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					5049	5055		10.1038/sj.onc.1207680	http://dx.doi.org/10.1038/sj.onc.1207680			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15064722	Green Accepted			2022-12-28	WOS:000222237300011
J	Zanier, R; Briot, D; du Villard, JAD; Sarasin, A; Rosselli, F				Zanier, R; Briot, D; du Villard, JAD; Sarasin, A; Rosselli, F			Fanconi anemia C gene product regulates expression of genes involved in differentiation and inflammation	ONCOGENE			English	Article						Fanconi anemia; leukemia; gene expression; microarray; DNA repair	NECROSIS-FACTOR-ALPHA; CELL MYELOPROLIFERATIVE DISORDER; HEMATOPOIETIC STEM-CELLS; MYELOID-LEUKEMIA CELLS; GROWTH-FACTOR; PROTEIN; COMPLEMENTATION; TRANSCRIPTION; INTERACTS; RECEPTOR	Loss of Fanconi anemia ( FA) proteins activity by recessive inherited mutations in one of the FA genes leads to a disease characterized by bone marrow failure, myeloid leukemia and DNA damage hypersensitivity. The aim of this work was to improve our understanding of the FA syndrome de. ning the transcription profile of the FA complementation group C (FANCC)-deficient cells in comparison to their ectopically corrected counterpart using oligonucleotide microarrays. In this way, 49 RNAs have been isolated, which showed a consistent differential pattern of expression among FANCC mutated and corrected cells. The observed specific changes in gene expression suggest that FANCC regulates specifically myeloid differentiation and unmasks a previously unsuspected anti-inflammatory role for the FA proteins. In spite of the DNA damage hypersensitivity of the syndrome, no gene coding for a protein directly involved in DNA repair/damage response was found to be deregulated in our analysis. This observation suggests that FANCC does not directly control genes involved in DNA repair at the transcriptional level, but does not exclude a regulation at the translational or post-translational level, or by protein/protein interactions. The potential role of the differentially expressed genes in FA phenotype as well as a functional- and cellular-based clustering of the identified genes are presented and discussed.	Inst Gustave Roussy, CNRS, UPR 2169, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Rosselli, F (corresponding author), Inst Gustave Roussy, CNRS, UPR 2169, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	rosselli@igr.fr	Filippo, Rosselli/AAO-6393-2020	Filippo, Rosselli/0000-0003-1080-5745				Ahmad SI, 2002, BIOESSAYS, V24, P439, DOI 10.1002/bies.10082; Alter BP, 1996, AM J HEMATOL, V53, P99, DOI 10.1002/(SICI)1096-8652(199610)53:2<99::AID-AJH7>3.3.CO;2-M; BEDFORD FK, 1993, NUCLEIC ACIDS RES, V21, P1245, DOI 10.1093/nar/21.5.1245; Benezra M, 2003, J BIOL CHEM, V278, P26333, DOI 10.1074/jbc.M303076200; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Curtis DJ, 2000, EXP HEMATOL, V28, P1250, DOI 10.1016/S0301-472X(00)00537-3; D'Andrea AD, 2003, NAT REV CANCER, V3, P23, DOI 10.1038/nrc970; Dolis D, 1997, BIOPHYS CHEM, V68, P221, DOI 10.1016/S0301-4622(97)00048-3; Folias A, 2002, HUM MOL GENET, V11, P2591, DOI 10.1093/hmg/11.21.2591; Grompe M, 2001, HUM MOL GENET, V10, P2253, DOI 10.1093/hmg/10.20.2253; Hanada T, 2002, CYTOKINE GROWTH F R, V13, P413, DOI 10.1016/S1359-6101(02)00026-6; Hansen GM, 1999, ONCOGENE, V18, P6531, DOI 10.1038/sj.onc.1203023; Hashimoto S, 1999, BLOOD, V94, P845, DOI 10.1182/blood.V94.3.845.415k09_845_852; Hoatlin ME, 1999, BLOOD, V94, P3737, DOI 10.1182/blood.V94.11.3737.423k39_3737_3747; HROMAS R, 1993, BIOCHEM BIOPH RES CO, V195, P976, DOI 10.1006/bbrc.1993.2140; Jobin C, 1999, J IMMUNOL, V163, P3474; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; Karanu FN, 2000, J EXP MED, V192, P1365, DOI 10.1084/jem.192.9.1365; Lehnert M, 1996, EUR J CANCER, V32A, P912, DOI 10.1016/0959-8049(96)00069-X; Li PX, 2000, J BIOL CHEM, V275, P20127, DOI 10.1074/jbc.M909580199; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Li YL, 1997, J CLIN INVEST, V100, P2873, DOI 10.1172/JCI119836; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; MACDONALD D, 1995, LEUKEMIA, V9, P1628; MANFIOLETTI G, 1995, BLOOD, V85, P1237, DOI 10.1182/blood.V85.5.1237.bloodjournal8551237; Mills JC, 2001, NAT CELL BIOL, V3, pE175, DOI 10.1038/35087108; Orkin SH, 2000, NAT REV GENET, V1, P57, DOI 10.1038/35049577; Otsuki T, 2001, HUM MOL GENET, V10, P2651, DOI 10.1093/hmg/10.23.2651; Pallis M, 2000, BLOOD, V95, P2897, DOI 10.1182/blood.V95.9.2897.009k14_2897_2904; Pang QS, 2001, BLOOD, V97, P1644, DOI 10.1182/blood.V97.6.1644; Pang QS, 2001, EMBO J, V20, P4478, DOI 10.1093/emboj/20.16.4478; Popovici C, 1999, BLOOD, V93, P1381, DOI 10.1182/blood.V93.4.1381.404k30_1381_1389; Popovici C, 1998, P NATL ACAD SCI USA, V95, P5712, DOI 10.1073/pnas.95.10.5712; Reber M, 2001, MECH DEVELOP, V100, P75, DOI 10.1016/S0925-4773(00)00493-7; ROSSELLI F, 1994, BLOOD, V83, P1216; Rousset S, 2002, PHOTOCHEM PHOTOBIOL, V75, P159, DOI 10.1562/0031-8655(2002)075<0159:MAIFAF>2.0.CO;2; Ruppitsch W, 1997, HUM GENET, V99, P710, DOI 10.1007/s004390050437; Schreuder H, 1997, NATURE, V386, P194, DOI 10.1038/386194a0; SCHULTZ JC, 1993, AM J HEMATOL, V42, P196, DOI 10.1002/ajh.2830420211; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0; Sullivan DM, 1996, INVEST OPHTH VIS SCI, V37, P766; Sun ZX, 2001, GENE DEV, V15, P3217, DOI 10.1101/gad946701; Tohda S, 2001, LEUKEMIA LYMPHOMA, V42, P467, DOI 10.3109/10428190109064603; TRONCHE F, 1992, BIOESSAYS, V14, P579, DOI 10.1002/bies.950140902; Walker L, 2001, STEM CELLS, V19, P543, DOI 10.1634/stemcells.19-6-543; WALSH CE, 1994, J CLIN INVEST, V94, P1440, DOI 10.1172/JCI117481; Ward PA, 2002, MOL CELL BIOCHEM, V234, P225, DOI 10.1023/A:1015944709177; Xie Y, 2000, BRIT J HAEMATOL, V111, P1057, DOI 10.1111/j.1365-2141.2000.02450.x; Zhang F, 1999, CARCINOGENESIS, V20, P445, DOI 10.1093/carcin/20.3.445	49	31	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					5004	5013		10.1038/sj.onc.1207677	http://dx.doi.org/10.1038/sj.onc.1207677			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15077170				2022-12-28	WOS:000222237300006
J	Kandouz, M; Bier, A; Carystinos, GD; Alaoui-Jamali, MA; Batist, G				Kandouz, M; Bier, A; Carystinos, GD; Alaoui-Jamali, MA; Batist, G			Connexin43 pseudogene is expressed in tumor cells and inhibits growth	ONCOGENE			English	Article						Connexin43; pseudogene; transcription; translation; cancer	LIVE MAMMALIAN-CELLS; GAP-JUNCTIONS; CHROMOSOMAL LOCALIZATION; PROCESSED PSEUDOGENES; PROTEOME EVOLUTION; BREAST-CANCER; GENE FAMILY; MUTATIONS; COMMUNICATION; PROMOTER	Pseudogenes are classically thought of as nonfunctional DNA sequences due to their inability to be translated, or to produce a functional protein. Gap junctions, a multiprotein complex made of proteins called connexins, are involved in intercellular communication and are deregulated in many cancers. Connexin43 (Cx43) is the only connexin for which a pseudogene has been reported so far. The Cx43 pseudogene (PsiCx43) has all of the features of an expressed gene. We identified the presence of a PsiCx43 mRNA transcript in several cancer cell lines and in none of the normal mammary epithelial cells studied. Using an in vitro translation assay, we found that the PsiCx43 coding plasmid could be translated into a 43 kDa protein. This was further confirmed by expressing a PsiCx43-green fluorescence protein fusion protein in breast cancer MCF-7 cells. We then examined the functional significance of the PsiCx43. In both MTT growth and colony formation assays, significant growth inhibition was observed, a feature common to cells overexpressing the Cx43 gene. However, using a scrape-loading assay, we could not detect any effect on gap junctional intercellular communication. Based on our findings, PsiCx43 joins and enlarges the thus far restricted group of functionally transcribed and translated pseudogenes.	McGill Univ, Lady Davis Inst Med Res, Montreal Ctr Expt Therapeut Canc, Dept Oncol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Lady Davis Inst Med Res, Montreal Ctr Expt Therapeut Canc, Dept Pharmacol & Therapeut, Montreal, PQ H3T 1E2, Canada; McGill Univ, Lady Davis Inst Med Res, Montreal Ctr Expt Therapeut Canc, Dept Expt Med, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; Lady Davis Institute; McGill University; Lady Davis Institute; McGill University	Batist, G (corresponding author), McGill Univ, Lady Davis Inst Med Res, Montreal Ctr Expt Therapeut Canc, Dept Oncol, Montreal, PQ H3T 1E2, Canada.	gbatist@onc.jgh.mcgill.ca						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDREA JE, 1995, BIOCHEM J, V310, P835, DOI 10.1042/bj3100835; BERGOFFEN J, 1993, SCIENCE, V262, P2039, DOI 10.1126/science.8266101; Boschan C, 2002, GENOMICS, V79, P387, DOI 10.1006/geno.2001.6715; BRITZCUNNINGHAM SH, 1995, NEW ENGL J MED, V332, P1323, DOI 10.1056/NEJM199505183322002; Cai J, 1998, INT J MOL MED, V1, P273; Carystinos GD, 2001, J MAMMARY GLAND BIOL, V6, P431, DOI 10.1023/A:1014787014851; Carystinos GD, 2003, MOL PHARMACOL, V63, P821, DOI 10.1124/mol.63.4.821; CHAKRABARTI R, 1995, GENE, V153, P163, DOI 10.1016/0378-1119(94)00751-D; ELFGANG C, 1995, J CELL BIOL, V129, P805, DOI 10.1083/jcb.129.3.805; ELFOULY MH, 1987, EXP CELL RES, V168, P422, DOI 10.1016/0014-4827(87)90014-0; FISHMAN GI, 1991, GENOMICS, V10, P250, DOI 10.1016/0888-7543(91)90507-B; FLAGGNEWTON J, 1979, J MEMBRANE BIOL, V50, P65, DOI 10.1007/BF01868788; Foote CI, 1998, J CELL BIOL, V140, P1187, DOI 10.1083/jcb.140.5.1187; Harrison P, 2002, J MOL BIOL, V316, P409, DOI 10.1006/jmbi.2001.5343; Harrison PM, 2002, J MOL BIOL, V318, P1155, DOI 10.1016/S0022-2836(02)00109-2; Hirotsune S, 2003, NATURE, V423, P91, DOI 10.1038/nature01535; Hirschi KK, 1996, CELL GROWTH DIFFER, V7, P861; Jordan K, 1999, MOL BIOL CELL, V10, P2033, DOI 10.1091/mbc.10.6.2033; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; Kleene KC, 1999, GENOMICS, V61, P194, DOI 10.1006/geno.1999.5945; Korneev SA, 1999, J NEUROSCI, V19, P7711; Laird DW, 1999, CANCER RES, V59, P4104; Laird DW, 2001, METH MOL B, V154, P135; MCCARREY JR, 1990, NUCLEIC ACIDS RES, V18, P949, DOI 10.1093/nar/18.4.949; Mighell AJ, 2000, FEBS LETT, V468, P109, DOI 10.1016/S0014-5793(00)01199-6; Moorby C, 2001, EXP CELL RES, V271, P238, DOI 10.1006/excr.2001.5357; Moran JV, 1999, SCIENCE, V283, P1530, DOI 10.1126/science.283.5407.1530; Paznekas WA, 2003, AM J HUM GENET, V72, P408, DOI 10.1086/346090; Puget N, 2002, AM J HUM GENET, V70, P858, DOI 10.1086/339434; RENAUDIE F, 1992, MAMM GENOME, V2, P143, DOI 10.1007/BF00302872; SORGE J, 1990, J CLIN INVEST, V86, P1137, DOI 10.1172/JCI114818; Sun D, 1998, CYTOGENET CELL GENET, V81, P79, DOI 10.1159/000014993; Tanooka H, 1998, CANCER RES, V58, P5649; Thiele H, 2000, EUR J BIOCHEM, V267, P5473, DOI 10.1046/j.1432-1327.2000.01609.x; Torrents D, 2003, GENOME RES, V13, P2559, DOI 10.1101/gr.1455503; Uechi T, 2002, NUCLEIC ACIDS RES, V30, P5369, DOI 10.1093/nar/gkf696; VENANCE L, 1995, NATURE, V376, P590, DOI 10.1038/376590a0; Vine AL, 2002, CANCER METAST REV, V21, P199, DOI 10.1023/A:1021250624933; WILLECKE K, 1990, EUR J CELL BIOL, V53, P275; Yamasaki H, 1996, CARCINOGENESIS, V17, P1199, DOI 10.1093/carcin/17.6.1199; Zhang CL, 2000, ONCOGENE, V19, P4346, DOI 10.1038/sj.onc.1203795; Zhang ZL, 2003, GENOME RES, V13, P2541, DOI 10.1101/gr.1429003	43	71	76	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2004	23	27					4763	4770		10.1038/sj.onc.1207506	http://dx.doi.org/10.1038/sj.onc.1207506			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZX	15122329				2022-12-28	WOS:000221799200011
J	Vares, G; Ory, K; Lectard, B; Levalois, C; Altmeyer-Morel, S; Chevillard, S; Lebeau, J				Vares, G; Ory, K; Lectard, B; Levalois, C; Altmeyer-Morel, S; Chevillard, S; Lebeau, J			Progesterone prevents radiation-induced apoptosis in breast cancer cells	ONCOGENE			English	Article						progesterone; apoptosis; breast; cancer	P53 TUMOR-SUPPRESSOR; MAMMARY-GLAND; HORMONAL-REGULATION; GROWTH-INHIBITION; EPITHELIAL-CELLS; MENSTRUAL-CYCLE; CROSS-TALK; DNA-DAMAGE; BCL-2; RECEPTOR	Sex steroid hormones play an essential role in the control of homeostasis in the mammary gland. Although the involvement of progesterone in cellular proliferation and differentiation is well established, its exact role in the control of cell death still remains unclear. As dysregulation of the apoptotic process plays an important role in the pathogenesis of breast cancer, we investigated the regulation of apoptosis by progesterone in various breast cancer cell lines. Our results show that progesterone treatment protects against radiation-induced apoptosis. This prevention appears to be mediated by the progesterone receptor and is unrelated to p53 status. There is also no correlation with the intrinsic hormonal effect on cell proliferation, as the presence of cells in a particular phase of the cell cycle. Surprisingly, progesterone partly allows bypassing of the irradiation-induced growth arrest in G(2)/M in PgR + cells, leading to an increase in cell proliferation after irradiation. One consequence of this effect is a higher rate of chromosome damage in these proliferating progesterone-treated cells compared to what is observed in untreated irradiated cells. We propose that progesterone, by inhibiting apoptosis and promoting the proliferation of cells with DNA damage, potentially facilitates the emergence of genetic mutations that may play a role in malignant transformation.	CEA, DSV, DRR, LCE, F-92265 Fontenay Aux Roses, France	CEA	Lebeau, J (corresponding author), CEA, DSV, DRR, LCE, 60-68 Ave GenLeclerc,BP6, F-92265 Fontenay Aux Roses, France.	lebeau@dsvidf.cea.fr	Vares, Guillaume/S-6530-2019; Vares, Guillaume/A-9257-2011	Vares, Guillaume/0000-0002-6191-9032; Vares, Guillaume/0000-0002-6191-9032; Chevillard, Sylvie/0000-0001-5889-4041				Alkhalaf M, 2002, EUR J CANCER PREV, V11, P481, DOI 10.1097/00008469-200210000-00011; BARDON S, 1987, CANCER RES, V47, P1441; Bernstein L, 2002, J MAMMARY GLAND BIOL, V7, P3, DOI 10.1023/A:1015714305420; Biri A, 2002, MUTAT RES-GEN TOX EN, V521, P113, DOI 10.1016/S1383-5718(02)00217-6; Butt AJ, 2000, J BIOL CHEM, V275, P39174, DOI 10.1074/jbc.M908888199; CLARKE CL, 1990, ENDOCR REV, V11, P266, DOI 10.1210/edrv-11-2-266; FENECH M, 1985, MUTAT RES, V147, P29, DOI 10.1016/0165-1161(85)90015-9; FENG ZW, 1995, J CELL BIOL, V131, P1095, DOI 10.1083/jcb.131.4.1095; FERGUSON DJP, 1981, BRIT J CANCER, V44, P177, DOI 10.1038/bjc.1981.168; Flototto T, 2001, HORM METAB RES, V33, P451, DOI 10.1055/s-2001-16936; Formby B, 1998, ANN CLIN LAB SCI, V28, P360; Formby B, 1999, MOL CELL BIOCHEM, V202, P53, DOI 10.1023/A:1007081021483; Gompel A, 2000, STEROIDS, V65, P593, DOI 10.1016/S0039-128X(00)00172-0; Graham JD, 1997, ENDOCR REV, V18, P502, DOI 10.1210/er.18.4.502; Groshong SD, 1997, MOL ENDOCRINOL, V11, P1593, DOI 10.1210/me.11.11.1593; Heermeier K, 1996, MECH DEVELOP, V56, P197, DOI 10.1016/0925-4773(96)88032-4; HURD C, 1995, J BIOL CHEM, V270, P28507, DOI 10.1074/jbc.270.48.28507; JUENGEL JL, 1993, ENDOCRINOLOGY, V132, P249, DOI 10.1210/en.132.1.249; Kandouz M, 1999, J STEROID BIOCHEM, V69, P463, DOI 10.1016/S0960-0760(99)00069-2; Kao GD, 2001, ONCOGENE, V20, P3486, DOI 10.1038/sj.onc.1204445; Kester HA, 2003, EXP CELL RES, V284, P264, DOI 10.1016/S0014-4827(02)00017-4; Kester HA, 1997, J BIOL CHEM, V272, P16637, DOI 10.1074/jbc.272.26.16637; KirschVolders M, 1997, MUTAT RES-GEN TOX EN, V392, P19, DOI 10.1016/S0165-1218(97)00042-6; Kumar R, 2000, ENDOCR-RELAT CANCER, V7, P257, DOI 10.1677/erc.0.0070257; Lanari C, 2002, BREAST CANCER RES, V4, P240, DOI 10.1186/bcr539; Lange CA, 1999, MOL ENDOCRINOL, V13, P829, DOI 10.1210/me.13.6.829; Lebeau J, 2002, ANTICANCER RES, V22, P2161; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin VCL, 2003, AM J PATHOL, V162, P1781, DOI 10.1016/S0002-9440(10)64313-1; LUCIANO AM, 1994, BIOL REPROD, V51, P646, DOI 10.1095/biolreprod51.4.646; LUKIC B, 1987, MUTAT RES, V191, P121, DOI 10.1016/0165-7992(87)90140-0; Lydon JP, 1999, CANCER RES, V59, P4276; Metcalfe AD, 1999, J CELL SCI, V112, P1771; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; Murdoch WJ, 2002, MOL CELL ENDOCRINOL, V186, P61, DOI 10.1016/S0303-7207(01)00675-X; Musgrove EA, 1998, MOL CELL BIOL, V18, P1812, DOI 10.1128/MCB.18.4.1812; Ory K, 2001, BREAST CANCER RES TR, V68, P187, DOI 10.1023/A:1012288510743; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; Pecci A, 1997, J BIOL CHEM, V272, P11791, DOI 10.1074/jbc.272.18.11791; ROTELLO RJ, 1992, AM J PATHOL, V140, P449; SABOURIN JC, 1994, INT J CANCER, V59, P1, DOI 10.1002/ijc.2910590102; Schorr K, 1999, J MAMMARY GLAND BIOL, V4, P153, DOI 10.1023/A:1018773123899; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; Sutherland RL, 1998, J MAMMARY GLAND BIOL, V3, P63, DOI 10.1023/A:1018774302092; Thordarson G, 2001, CARCINOGENESIS, V22, P1027, DOI 10.1093/carcin/22.7.1027	45	22	24	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2004	23	26					4603	4613		10.1038/sj.onc.1207601	http://dx.doi.org/10.1038/sj.onc.1207601			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZV	15064714				2022-12-28	WOS:000221799000010
J	Knockaert, M; Blondel, M; Bach, S; Leost, M; Elbi, C; Hager, GL; Nagy, SR; Han, D; Denison, M; Ffrench, M; Ryan, XZP; Magiatis, P; Polychronopoulos, P; Greengard, P; Skaltsounis, L; Meijer, L				Knockaert, M; Blondel, M; Bach, S; Leost, M; Elbi, C; Hager, GL; Nagy, SR; Han, D; Denison, M; Ffrench, M; Ryan, XZP; Magiatis, P; Polychronopoulos, P; Greengard, P; Skaltsounis, L; Meijer, L			Independent actions on cyclin-dependent kinases and aryl hydrocarbon receptor mediate the antiproliferative effects of indirubins	ONCOGENE			English	Article						aryl hydrocarbon receptor; indirubin; cyclin-dependent kinase; glycogen synthase kinase; GSK-3 beta; kinase inhibitor; cancer	AH RECEPTOR; CELL-CYCLE; ARYLHYDROCARBON RECEPTOR; CRYSTAL-STRUCTURE; DIOXIN RECEPTOR; MESSENGER-RNAS; TYRIAN PURPLE; MICE LACKING; EXPRESSION; PROTEIN	Indirubin, a bis-indole obtained from various natural sources, is responsible for the reported antileukemia activity of a Chinese Medicinal recipe, Danggui Longhui Wan. However, its molecular mechanism of action is still not well understood. In addition to inhibition of cyclin-dependent kinases and glycogen synthase kinase-3, indirubins have been reported to activate the aryl hydrocarbon receptor (AhR), a cotranscriptional factor. Here, we confirm the interaction of AhR and indirubin using a series of indirubin derivatives and show that their binding modes to AhR and to protein kinases are unrelated. As reported for other AhR ligands, binding of indirubins to AhR leads to its nuclear translocation. Furthermore, the apparent survival of AhR-/- and +/+ cells, as measured by the MTT assay, is equally sensitive to the kinase-inhibiting indirubins. Thus, the cytotoxic effects of indirubins are AhR-independent and more likely to be linked to protein kinase inhibition. In contrast, a dramatic cytostatic effect, as measured by actual cell counts and associated with a sharp G1 phase arrest, is induced by 1-methyl-indirubins, a subfamily of AhR-active but kinase-inactive indirubins. As shown for TCDD (dioxin), this effect appears to be mediated through the AhR-dependent expression of p27(KIP1). Altogether these results suggest that AhR activation, rather than kinase inhibition, is responsible for the cytostatic effects of some indirubins. In contrast, kinase inhibition, rather than AhR activation, represents the main mechanism underlying the cytotoxic properties of this class of promising antitumor molecules.	CNRS, Cell Cycle Grp, F-29682 Roscoff, France; Biol Stn, F-29682 Roscoff, France; NCI, Lab Receptor Biol & Gene Express, NIH, Bethesda, MD 20892 USA; Univ Calif Davis, Dept Environm Toxicol, Davis, CA 95616 USA; Univ Lyon 1, Lab Cytol Analyt & Cytogenet Mol, F-69373 Lyon 08, France; Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA; Univ Athens, Dept Pharm, Div Pharmacognosy & Nat Prod Chem, GR-15771 Athens, Greece	Centre National de la Recherche Scientifique (CNRS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of California System; University of California Davis; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Rockefeller University; National & Kapodistrian University of Athens	Meijer, L (corresponding author), CNRS, Cell Cycle Grp, BP 74, F-29682 Roscoff, France.	meijer@sb-roscoff.fr	Magiatis, Prokopios/A-2008-2008; skaltsounis, alexios leandros/AAE-9617-2019; BACH, Stéphane/ABD-5865-2020; Blondel, Marc/AAJ-9049-2020	Blondel, Marc/0000-0003-4897-2995; Magiatis, Prokopios/0000-0002-0399-5344; , laurent/0000-0003-3511-4916	NATIONAL CANCER INSTITUTE [Z01BC005450] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES004699] Funding Source: NIH RePORTER; NIEHS NIH HHS [5P42ES04699] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abdelrahim M, 2003, MOL PHARMACOL, V63, P1373, DOI 10.1124/mol.63.6.1373; Adachi J, 2001, J BIOL CHEM, V276, P31475, DOI 10.1074/jbc.C100238200; Andersson P, 2002, P NATL ACAD SCI USA, V99, P9990, DOI 10.1073/pnas.152706299; [Anonymous], 1992, CHIN DRUGS PLANT ORI; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Balfour-Paul Jenny, 1998, INDIGO; Bergander L, 2003, DRUG METAB DISPOS, V31, P233, DOI 10.1124/dmd.31.2.233; Borgne A, 1996, J BIOL CHEM, V271, P27847, DOI 10.1074/jbc.271.44.27847; Bradshaw TD, 2002, CURR PHARM DESIGN, V8, P2475, DOI 10.2174/1381612023392784; Chotani G, 2000, BBA-PROTEIN STRUCT M, V1543, P434, DOI 10.1016/S0167-4838(00)00234-X; Cooksey CJ, 2001, MOLECULES, V6, P736, DOI 10.3390/60900736; Damiens E, 2001, ONCOGENE, V20, P3786, DOI 10.1038/sj.onc.1204503; Davies TG, 2001, STRUCTURE, V9, P389, DOI 10.1016/S0969-2126(01)00598-6; DEALLER SF, 1988, J CLIN MICROBIOL, V26, P2152, DOI 10.1128/JCM.26.10.2152-2156.1988; Denison MS, 1998, TARG ORG T, P3; Denison MS, 2003, ANNU REV PHARMACOL, V43, P309, DOI 10.1146/annurev.pharmtox.43.100901.135828; Elbi C, 2002, MOL BIOL CELL, V13, P2001, DOI 10.1091/mboc.13.6.mk0602002001; Elferink CJ, 2001, MOL PHARMACOL, V59, P664, DOI 10.1124/mol.59.4.664; Elferink Cornelis J, 2003, Prog Cell Cycle Res, V5, P261; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; FFRENCH M, 1985, CYTOMETRY, V6, P47, DOI 10.1002/cyto.990060109; FUKUNAGA BN, 1995, J BIOL CHEM, V270, P29270, DOI 10.1074/jbc.270.49.29270; Ge NL, 1998, J BIOL CHEM, V273, P22708, DOI 10.1074/jbc.273.35.22708; Gillam EMJ, 2000, BIOCHEMISTRY-US, V39, P13817, DOI 10.1021/bi001229u; Guthrie C, 1991, GUIDE YEAST GENETICS; Hahn ME, 2002, CHEM-BIOL INTERACT, V141, P131, DOI 10.1016/S0009-2797(02)00070-4; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; Hayashibara T, 2003, BIOCHEM BIOPH RES CO, V300, P128, DOI 10.1016/S0006-291X(02)02793-6; Heath-Pagliuso S, 1998, BIOCHEMISTRY-US, V37, P11508, DOI 10.1021/bi980087p; Hoessel R, 1999, NAT CELL BIOL, V1, P60, DOI 10.1038/9035; Jacobs MN, 2003, J STEROID BIOCHEM, V84, P117, DOI 10.1016/S0960-0760(03)00021-9; Jain S, 1998, MECH DEVELOP, V73, P117, DOI 10.1016/S0925-4773(98)00038-0; Joiakim A, 2003, DRUG METAB DISPOS, V31, P1279, DOI 10.1124/dmd.31.11.1279; Kawanishi M, 2003, MUTAT RES-GEN TOX EN, V540, P99, DOI 10.1016/S1383-5718(03)00174-8; Knockaert M, 2002, TRENDS PHARMACOL SCI, V23, P417, DOI 10.1016/S0165-6147(02)02071-0; Koliopanos A, 2002, ONCOGENE, V21, P6059, DOI 10.1038/sj.onc.1205633; Kolluri SK, 2001, CANCER RES, V61, P8534; Kolluri SK, 1999, GENE DEV, V13, P1742, DOI 10.1101/gad.13.13.1742; Kuchenhoff A, 1999, FERTIL STERIL, V71, P354, DOI 10.1016/S0015-0282(98)00437-3; Kuramoto N, 2003, J NEUROCHEM, V85, P264, DOI 10.1046/j.1471-4159.2003.01679.x; Lahvis GP, 2000, P NATL ACAD SCI USA, V97, P10442, DOI 10.1073/pnas.190256997; Leclerc S, 2001, J BIOL CHEM, V276, P251, DOI 10.1074/jbc.M002466200; Ma Q, 1996, MOL CELL BIOL, V16, P2144; MacNeil IA, 2001, J MOL MICROB BIOTECH, V3, P301; Marko D, 2001, BRIT J CANCER, V84, P283, DOI 10.1054/bjoc.2000.1546; Maugard T, 2001, PHYTOCHEMISTRY, V58, P897, DOI 10.1016/S0031-9422(01)00335-1; Meijer L, 2003, CHEM BIOL, V10, P1255, DOI 10.1016/j.chembiol.2003.11.010; Miller CA, 1997, J BIOL CHEM, V272, P32824, DOI 10.1074/jbc.272.52.32824; Miller CA, 1999, TOXICOL APPL PHARM, V160, P297, DOI 10.1006/taap.1999.8769; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nagy SR, 2002, TOXICOL SCI, V65, P200, DOI 10.1093/toxsci/65.2.200; Nagy SR, 2002, BIOCHEMISTRY-US, V41, P861, DOI 10.1021/bi011373v; PETERS JM, 1995, TOXICOL APPL PHARM, V134, P214, DOI 10.1006/taap.1995.1186; Petersen SL, 2000, J COMP NEUROL, V427, P428, DOI 10.1002/1096-9861(20001120)427:3<428::AID-CNE9>3.0.CO;2-P; Polychronopoulos P, 2004, J MED CHEM, V47, P935, DOI 10.1021/jm031016d; Primot A, 2000, PROTEIN EXPRES PURIF, V20, P394, DOI 10.1006/prep.2000.1321; Procopio M, 2002, EUR J BIOCHEM, V269, P13, DOI 10.1046/j.0014-2956.2002.02619.x; RANNUG U, 1992, MUTAT RES, V282, P219, DOI 10.1016/0165-7992(92)90099-4; Rowlands JC, 1997, CRIT REV TOXICOL, V27, P109, DOI 10.3109/10408449709021615; Safe S, 2002, INT J ONCOL, V20, P1123; Safe S, 2001, TOXICOL LETT, V120, P1, DOI 10.1016/S0378-4274(01)00301-0; Salomon-Nguyen F, 2000, P NATL ACAD SCI USA, V97, P6757, DOI 10.1073/pnas.120162297; Santini RP, 2001, J PHARMACOL EXP THER, V299, P718; Schmidt JV, 1996, P NATL ACAD SCI USA, V93, P6731, DOI 10.1073/pnas.93.13.6731; Shimizu Y, 2000, P NATL ACAD SCI USA, V97, P779, DOI 10.1073/pnas.97.2.779; Song JS, 2002, P NATL ACAD SCI USA, V99, P14694, DOI 10.1073/pnas.232562899; Spink BC, 2003, BIOCHEM PHARMACOL, V66, P2313, DOI 10.1016/j.bcp.2003.08.019; Wei YD, 2000, ARCH BIOCHEM BIOPHYS, V383, P99, DOI 10.1006/abbi.2000.2037; Weiss C, 1996, EXP CELL RES, V226, P154, DOI 10.1006/excr.1996.0214; Wolff S, 2001, MOL PHARMACOL, V59, P716, DOI 10.1124/mol.59.4.716; Xiao ZJ, 2002, LEUKEMIA LYMPHOMA, V43, P1763, DOI 10.1080/1042819021000006295; Yoon BI, 2002, TOXICOL SCI, V70, P150, DOI 10.1093/toxsci/70.1.150	72	87	94	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2004	23	25					4400	4412		10.1038/sj.onc.1207535	http://dx.doi.org/10.1038/sj.onc.1207535			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	824CJ	15077192				2022-12-28	WOS:000221661300006
J	Little, KC; Chartrand, P				Little, KC; Chartrand, P			Genomic DNA is captured and amplified during double-strand break (DSB) repair in human cells	ONCOGENE			English	Article						DNA repair; human genome; double-strand break (DSB); amplification; SV40	ATAXIA-TELANGIECTASIA; INTEGRATION SITE; MAMMALIAN CHROMOSOME; BROKEN CHROMOSOMES; SIMIAN-VIRUS-40; SV40; SEQUENCES; IDENTIFICATION; AMPLIFICATION; EXPRESSION	Genomic stability is maintained by the surveillance and repair of DNA damage. Here, we describe a mechanism whereby repair of extrachromosomal DNA double-strand breaks (DSBs) in human cells can be accompanied by capture of genomic DNA fragments. The availability of the human genome sequence enabled us to characterize these inserts in cells from a normal individual and from a patient with ataxia telangiectasia ( AT), deficient for the damage response kinase ATM and prone to genomic instability. We find AT cells exhibit insertions of human chromosomal DNA fragments in excess of 17 kb during DSB repair, whereas we detected no such genomic inserts in normal cells. However, the presence of simian virus 40 (SV40), used to transform these cell lines, resulted in capture of genomic DNA associated with sites of viral integration in both cell types. The genomic instability at sites of SV40 integration was exported to other sites of DNA damage, and acquisition of the viral origin of replication resulted in gene amplification through autonomous replication of the plasmid harbouring the repaired extrachromosomal DSB. Should this same phenomenon apply to the repair of chromsomal DSBs, genome rearrangements made possible via this DSB insertional repair pose risks to genomic integrity, and may contribute to tumorigenic progression.	Hop Notre Dame de Bon Secours, Ctr Rech CHUM, Montreal, PQ H2L 4M1, Canada; McGill Univ, Dept Med, Div Expt Med, Montreal, PQ H3A 1A3, Canada; Univ Montreal, Inst Canc Montreal, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Dept Pathol & Biol Cellulaire, Montreal, PQ H2L 4M1, Canada	Universite de Montreal; McGill University; Universite de Montreal; Universite de Montreal	Chartrand, P (corresponding author), Hop Notre Dame de Bon Secours, Ctr Rech CHUM, 1560 Rue Sherbrooke Est,Room Y4622, Montreal, PQ H2L 4M1, Canada.	pierre.chartrand@umontreal.ca						Allen C, 2003, DNA REPAIR, V2, P1147, DOI 10.1016/S1568-7864(03)00139-3; BENNER SE, 1991, ANTI-CANCER DRUG, V2, P11, DOI 10.1097/00001813-199102000-00002; Carbone M, 2003, INT J CANCER, V106, P140, DOI 10.1002/ijc.11189; Corbin S, 2002, CANCER RES, V62, P3477; COX R, 1986, MOL BIOL MED, V3, P229; CROCE CM, 1977, P NATL ACAD SCI USA, V74, P315, DOI 10.1073/pnas.74.1.315; Dar ME, 1997, MUTAT RES-DNA REPAIR, V384, P169, DOI 10.1016/S0921-8777(97)00021-9; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; Garcea RL, 2003, J VIROL, V77, P5039, DOI 10.1128/JVI.77.9.5039-5045.2003; Gazdar AF, 2002, NAT REV CANCER, V2, P957, DOI 10.1038/nrc947; Gorbunova V, 1997, NUCLEIC ACIDS RES, V25, P4650, DOI 10.1093/nar/25.22.4650; HARA H, 1987, EXP CELL RES, V168, P531, DOI 10.1016/0014-4827(87)90025-5; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; Huang KC, 1999, VIROLOGY, V262, P457, DOI 10.1006/viro.1999.9952; HWANG SP, 1980, VIROLOGY, V105, P196, DOI 10.1016/0042-6822(80)90167-1; Jasani B, 2001, SEMIN CANCER BIOL, V11, P49, DOI 10.1006/scbi.2000.0346; KAO CH, 1993, GENE CHROMOSOME CANC, V8, P155, DOI 10.1002/gcc.2870080304; KUCHERLAPATI R, 1978, P NATL ACAD SCI USA, V75, P4460, DOI 10.1073/pnas.75.9.4460; Lednicky JA, 1997, J GEN VIROL, V78, P1697, DOI 10.1099/0022-1317-78-7-1697; Li YL, 2001, ENVIRON MOL MUTAGEN, V37, P128, DOI 10.1002/em.1020; Lieber MR, 2003, NAT REV MOL CELL BIO, V4, P712, DOI 10.1038/nrm1202; Lin YF, 2001, NUCLEIC ACIDS RES, V29, P3975, DOI 10.1093/nar/29.19.3975; Lin YF, 2001, GENETICS, V158, P1665; Lobrich M, 2000, GENE CHROMOSOME CANC, V27, P59; MARLHENS F, 1988, ANN GENET-PARIS, V31, P81; MAULBECKER C, 1992, J VIROL, V66, P2195, DOI 10.1128/JVI.66.4.2195-2207.1992; Mendoza SM, 1998, ONCOGENE, V17, P2457, DOI 10.1038/sj.onc.1202179; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; Moore JK, 1996, NATURE, V383, P644, DOI 10.1038/383644a0; MURNANE JP, 1985, EXP CELL RES, V158, P119, DOI 10.1016/0014-4827(85)90437-9; Popescu NC, 2003, CANCER LETT, V192, P1, DOI 10.1016/S0304-3835(02)00596-7; POWELL S, 1993, MUTAT RES, V294, P9, DOI 10.1016/0921-8777(93)90053-J; RABIN M, 1984, J VIROL, V49, P445, DOI 10.1128/JVI.49.2.445-451.1984; Ricchetti M, 1999, NATURE, V402, P96, DOI 10.1038/47076; ROSCHEISEN C, 1994, SOMAT CELL MOLEC GEN, V20, P493, DOI 10.1007/BF02255840; ROTH DB, 1986, MOL CELL BIOL, V6, P4295, DOI 10.1128/MCB.6.12.4295; RUNGER TM, 1992, MUTAT RES, V293, P47, DOI 10.1016/0921-8777(92)90007-P; Salomon S, 1998, EMBO J, V17, P6086, DOI 10.1093/emboj/17.20.6086; Sargent RG, 1997, MOL CELL BIOL, V17, P267, DOI 10.1128/MCB.17.1.267; Schwab M, 1998, BIOESSAYS, V20, P473, DOI 10.1002/(SICI)1521-1878(199806)20:6<473::AID-BIES5>3.3.CO;2-N; Shera KA, 2001, J VIROL, V75, P12339, DOI 10.1128/JVI.75.24.12339-12346.2001; Shivapurkar N, 2002, LANCET, V359, P851, DOI 10.1016/S0140-6736(02)07921-7; Singer MJ, 2000, P NATL ACAD SCI USA, V97, P7921, DOI 10.1073/pnas.130194897; Stewart AR, 1998, J NEUROVIROL, V4, P182; Tachibana A, 2002, BIOCHEM BIOPH RES CO, V297, P275, DOI 10.1016/S0006-291X(02)02191-5; TATSUMIMIYAJIMA J, 1993, MUTAT RES, V294, P317, DOI 10.1016/0921-8777(93)90014-8; Testa JR, 1998, CANCER RES, V58, P4505; Valerie K, 2003, ONCOGENE, V22, P5792, DOI 10.1038/sj.onc.1206679; Vilchez RA, 2003, AM J MED, V114, P675, DOI 10.1016/S0002-9343(03)00087-1; Vilenchik MM, 2003, P NATL ACAD SCI USA, V100, P12871, DOI 10.1073/pnas.2135498100; Wurtele H, 2003, GENE THER, V10, P1791, DOI 10.1038/sj.gt.3302074; YANO O, 1991, CELL STRUCT FUNCT, V16, P63, DOI 10.1247/csf.16.63; Yu X, 1999, MOL CELL, V4, P873, DOI 10.1016/S1097-2765(00)80397-4; Zhou Y, 2003, CANCER RES, V63, P5781	54	12	12	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4166	4172		10.1038/sj.onc.1207570	http://dx.doi.org/10.1038/sj.onc.1207570			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15048077				2022-12-28	WOS:000221520200015
J	Cheng, NL; Janumyan, YM; Didion, L; Van Hofwegen, C; Yang, E; Knudson, CM				Cheng, NL; Janumyan, YM; Didion, L; Van Hofwegen, C; Yang, E; Knudson, CM			Bcl-2 inhibition of T-cell proliferation is related to prolonged T-cell survival	ONCOGENE			English	Article						apoptosis; Bax; proliferation; T cells; quiescent; p27; Bcl-2	CYCLE ENTRY; TRANSGENIC MICE; PARADOXICAL INHIBITION; REDUCES PROLIFERATION; IN-VIVO; C-MYC; EXPRESSION; DEATH; APOPTOSIS; BAX	Bcl-2 promotes oncogenesis by inhibiting cell death. Bcl-2 also inhibits proliferation and suppresses tumorigenesis in some settings. To clarify the role of the antiproliferative function of Bcl-2, mice expressing a mutant form of Bcl-2 reported to lack antiproliferative activity were generated (tyrosine 28 to alanine, Bcl-2-Y28A). As expected, both wild type (WT) and Bcl-2-Y28A inhibited apoptosis similarly. In contrast to previous results in cell lines, Bcl-2-Y28A inhibited T-cell proliferation identical to WT-Bcl-2. Significantly, both Bcl-2-Y28A and WT-Bcl-2 inhibited proliferation of T cells isolated from older animals, but not proliferation of T cells from immature mice. Instead, inhibition of cell activation correlated with T-cell size, p27 levels, and RNA content, all indicators of quiescent G0 arrest. Consistent with this model, Bcl-2 inhibition of T-cell proliferation was reversed by expression of Bax, again correlating cell proliferation with cell size. These experiments do not support genetically separate effects of Bcl-2 on apoptosis and proliferation. Instead, the data support a model in which Bcl-2 and Bax regulate T-cell proliferation by changes in T-cell size and by increasing the markers of quiescent G0 arrest. These changes likely result from prolonged T-cell survival.	Univ Iowa, Roy J & Lucille P Carver Coll Med, Dept Pathol, Iowa City, IA 52242 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Pediat, Nashville, TN 37232 USA	University of Iowa; Vanderbilt University; Vanderbilt University	Knudson, CM (corresponding author), Univ Iowa, Roy J & Lucille P Carver Coll Med, Dept Pathol, 3160 ML, Iowa City, IA 52242 USA.	c-knudson@uiowa.edu		Knudson, Charles Michael/0000-0003-3964-5466; Janumyan, Yelena/0000-0001-9860-6366	NATIONAL CANCER INSTITUTE [R01CA078443, R01CA088967] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008554] Funding Source: NIH RePORTER; NCI NIH HHS [1R01CA88967, 1R01CA78443] Funding Source: Medline; NIGMS NIH HHS [T32GM08554] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bairey O, 1999, CLIN CANCER RES, V5, P2860; Buglioni S, 1999, INT J CANCER, V84, P545, DOI 10.1002/(SICI)1097-0215(19991222)84:6<545::AID-IJC1>3.0.CO;2-2; Bureau F, 2002, BLOOD, V99, P3683, DOI 10.1182/blood.V99.10.3683; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; DARZYNKIEWICZ Z, 1980, P NATL ACAD SCI-BIOL, V77, P6696, DOI 10.1073/pnas.77.11.6696; de la Coste A, 1999, CANCER RES, V59, P5017; GARVIN AM, 1990, INT IMMUNOL, V2, P173, DOI 10.1093/intimm/2.2.173; Greider C, 2002, ONCOGENE, V21, P7765, DOI 10.1038/sj.onc.1205928; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Harris MH, 2000, CELL DEATH DIFFER, V7, P1182, DOI 10.1038/sj.cdd.4400781; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Hogarth LA, 1999, BLOOD, V93, P2671, DOI 10.1182/blood.V93.8.2671.408k26_2671_2678; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; Janumyan YM, 2003, EMBO J, V22, P5459, DOI 10.1093/emboj/cdg533; Kaklamanis L, 1998, BRIT J CANCER, V77, P1864, DOI 10.1038/bjc.1998.310; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; Knudson CM, 2001, CANCER RES, V61, P659; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; LINETTE GP, 1995, BLOOD, V86, P1255, DOI 10.1182/blood.V86.4.1255.bloodjournal8641255; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; Luke JJ, 2003, CELL DEATH DIFFER, V10, P740, DOI 10.1038/sj.cdd.4401233; MacCarthy-Morrogh L, 1999, BIOCHEM SOC T, V27, P785, DOI 10.1042/bst0270785; Manne U, 1997, INT J CANCER, V74, P346, DOI 10.1002/(SICI)1097-0215(19970620)74:3<346::AID-IJC19>3.0.CO;2-9; MARVEL J, 1994, ONCOGENE, V9, P1117; Meterissian SH, 2001, ANN SURG ONCOL, V8, P533, DOI 10.1245/aso.2001.8.6.533; Murphy KL, 1999, ONCOGENE, V18, P6597, DOI 10.1038/sj.onc.1203099; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; OFNER D, 1995, BRIT J CANCER, V72, P981, DOI 10.1038/bjc.1995.446; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OReilly LA, 1997, J IMMUNOL, V159, P2301; OReilly LA, 1997, INT IMMUNOL, V9, P1291, DOI 10.1093/intimm/9.9.1291; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; PIETENPOL JA, 1994, CANCER RES, V54, P3714; Rathmell JC, 2000, MOL CELL, V6, P683, DOI 10.1016/S1097-2765(00)00066-6; Rossiter H, 2001, CANCER RES, V61, P3619; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SILVESTRINI R, 1994, J NATL CANCER I, V86, P499, DOI 10.1093/jnci/86.7.499; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; Uhlmann EJ, 1996, CANCER RES, V56, P2506; Vairo G, 2000, MOL CELL BIOL, V20, P4745, DOI 10.1128/MCB.20.13.4745-4753.2000; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0	43	43	43	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2004	23	21					3770	3780		10.1038/sj.onc.1207478	http://dx.doi.org/10.1038/sj.onc.1207478			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	818JX	15034548				2022-12-28	WOS:000221242500004
J	Weinmann, M; Jendrossek, V; Handrick, R; Guner, D; Goecke, B; Belka, C				Weinmann, M; Jendrossek, V; Handrick, R; Guner, D; Goecke, B; Belka, C			Molecular ordering of hypoxia-induced apoptosis: critical involvement of the mitochondrial death pathway in a FADD/caspase-8 independent manner	ONCOGENE			English	Article						hypoxia; apoptosis; mitochondria; FADD; Bcl-2; caspase-8	DRUG-INDUCED APOPTOSIS; NEURONAL CELL-DEATH; TYROSINE KINASE LCK; IONIZING-RADIATION; CYTOCHROME-C; LYMPHOMA-CELLS; P53-DEPENDENT APOPTOSIS; DIFFERENTIAL REGULATION; CASPASE-3 ACTIVATION; SERUM DEPRIVATION	Dys-regulated growth and improper angiogenesis commonly lead to areas of hypoxia in human tumors. Hypoxia is known to be associated with a worse outcome since a lack of oxygen interferes with the efficacy of chemotherapy or radiotherapy. In parallel, hypoxia-induced apoptosis may also impose a selection pressure favoring growth of more resistant tumor cells. However, the mechanisms of hypoxia-induced apoptosis and the relative contribution of intrinsic and extrinsic apoptotic pathways are not understood. Therefore, Jurkat cell lines with defined defects in the extrinsic or intrinsic signaling cascades were used to evaluate the role of either pathway for induction of apoptosis under hypoxic conditions. Jurkat cells were incubated in hypoxia and the rate of apoptosis induction was determined by Western blotting, fluorescence microscopy and flow cytometry. Hypoxia-induced apoptosis was not affected by lack of caspase-8 or FADD, whereas overexpression of Bcl-2 or expression of dominant-negative caspase-9 mutant rendered the cells resistant to hypoxia-induced apoptosis. These results suggest that hypoxia-induced apoptosis mainly relies on intrinsic, mitochondrial pathways, whereas extrinsic pathways have no significant implications in this process. Thus, in human tumors, hypoxia will mainly lead to the selection of hypoxia-resistant cells with defects in mitochondrial apoptosis signaling pathways.	Univ Tubingen, Dept Radiat Oncol, D-72076 Tubingen, Germany; Charite Berlin, Dept Radiat Oncol, Berlin, Germany	Eberhard Karls University of Tubingen; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Belka, C (corresponding author), Univ Tubingen, Dept Radiat Oncol, Hoppe Seylerstr 3, D-72076 Tubingen, Germany.	claus.belka@uni-tuebingen.de	Jendrossek, Verena/AAH-4967-2019	Jendrossek, Verena/0000-0003-1058-2107				Alarcon R M, 2001, Novartis Found Symp, V240, P115; Banasiak KJ, 1998, BRAIN RES, V797, P295, DOI 10.1016/S0006-8993(98)00286-8; Banasiak KJ, 1999, MOL BRAIN RES, V72, P214, DOI 10.1016/S0169-328X(99)00189-8; Belka C, 1998, RADIAT RES, V149, P588, DOI 10.2307/3579905; Belka C, 2003, STRAHLENTHER ONKOL, V179, P141, DOI 10.1007/s00066-003-1047-7; Belka C, 2003, ONCOGENE, V22, P176, DOI 10.1038/sj.onc.1206103; Belka C, 2002, INT J RADIAT BIOL, V78, P643, DOI 10.1080/09553000210137680; Belka C, 1999, ONCOGENE, V18, P4983, DOI 10.1038/sj.onc.1202878; Belka C, 1999, INT J RADIAT BIOL, V75, P1257, DOI 10.1080/095530099139412; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Bialik S, 1997, J CLIN INVEST, V100, P1363, DOI 10.1172/JCI119656; Blagosklonny MV, 1998, J BIOL CHEM, V273, P11995, DOI 10.1074/jbc.273.20.11995; Chao W, 2002, J BIOL CHEM, V277, P31639, DOI 10.1074/jbc.M204104200; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Felderhoff-Mueser U, 2000, BRAIN PATHOL, V10, P17; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Gibson ME, 2001, MOL MED, V7, P644, DOI 10.1007/BF03401871; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Jendrossek V, 2003, FASEB J, V17, P1547, DOI 10.1096/fj.02-0947fje; Jendrossek V, 2003, ONCOGENE, V22, P2621, DOI 10.1038/sj.onc.1206355; Khurana P, 2002, NEUROCHEM RES, V27, P931, DOI 10.1023/A:1020347732741; Kim CY, 1997, CANCER RES, V57, P4200; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; KISCHKEL FC, 2001, J BIOL CHEM, V2, P2; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kowaltowski AJ, 2002, J BIOL CHEM, V277, P42802, DOI 10.1074/jbc.M207765200; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LOPEZHERNANDEZ FJ, 2003, CELL DEATH DIFFER, V24, P24; Malhotra R, 2001, AM J PHYSIOL-CELL PH, V281, pC1596, DOI 10.1152/ajpcell.2001.281.5.C1596; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Mogi M, 2001, LAB INVEST, V81, P177, DOI 10.1038/labinvest.3780225; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Park WY, 2002, ONCOGENE, V21, P8521, DOI 10.1038/sj.onc.1205977; Qin JZ, 2002, ONCOGENE, V21, P2991, DOI 10.1038/sj.onc.1205404; Renz A, 2001, BLOOD, V98, P1542, DOI 10.1182/blood.V98.5.1542; Rudner J, 2002, APOPTOSIS, V7, P441, DOI 10.1023/A:1020087108926; Rudner J, 2001, J CELL SCI, V114, P4161; Rudner J, 2001, INT J RADIAT BIOL, V77, P1, DOI 10.1080/095530001453069; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Shimizu S, 1996, CANCER RES, V56, P2161; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Steinbach JP, 2003, CELL DEATH DIFFER, V10, P823, DOI 10.1038/sj.cdd.4401252; Stepczynska A, 2001, ONCOGENE, V20, P1193, DOI 10.1038/sj.onc.1204221; Suzuki H, 2001, ONCOGENE, V20, P5779, DOI 10.1038/sj.onc.1204742; Tamatani M, 1998, MOL BRAIN RES, V58, P27, DOI 10.1016/S0169-328X(98)00095-3; Tsujimoto Yoshihide, 1997, Leukemia (Basingstoke), V11, P380; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Weinmann M, 2004, INT J RADIAT ONCOL, V58, P386, DOI 10.1016/j.ijrobp.2003.09.052; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Yaniv G, 2002, CARDIOVASC RES, V54, P611, DOI 10.1016/S0008-6363(02)00264-X; Yoshimura S, 1998, J BIOL CHEM, V273, P6921, DOI 10.1074/jbc.273.12.6921; Zhu H, 2000, CELL DEATH DIFFER, V7, P773, DOI 10.1038/sj.cdd.4400721	64	50	50	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2004	23	21					3757	3769		10.1038/sj.onc.1207481	http://dx.doi.org/10.1038/sj.onc.1207481			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	818JX	15034549				2022-12-28	WOS:000221242500003
J	Maschler, S; Grunert, S; Danielopol, A; Beug, H; Wirl, G				Maschler, S; Grunert, S; Danielopol, A; Beug, H; Wirl, G			Enhanced tenascin-C expression and matrix deposition during Ras/TGF-beta-induced progression of mammary tumor cells	ONCOGENE			English	Article						tenascin-C; Ha-Ras; TGF beta; mammary tumorigenesis; epithelial/mesenchymal transition	GROWTH-FACTOR-BETA; SIGNAL-REGULATED KINASE; EXTRACELLULAR-MATRIX; BREAST-CANCER; EPITHELIAL-CELLS; SURFACE TRANSGLUTAMINASE; DIFFERENTIAL EXPRESSION; DOWN-REGULATION; PROTEIN CAUSES; H-RAS	Overexpression of tenascin-C (TN-C) in breast carcinomas has been associated with a migratory or even invasive tumor cell phenotype. The mechanisms regulating expression and matrix deposition of TN-C in normal and cancerous breast tissues are, however, little understood. Here, we demonstrate that mouse mammary epithelial cells (EpH4) trans formed by oncogenic Ha-Ras (EpRas) overexpress TN-C, which accumulates in the cytoplasm. When EpRas cells undergo epithelial-mesenchymal transition (EMT) in response to TGFbeta1, they secrete TN-C into the culture medium. In EpRas cells undergoing TGFbeta1-induced EMT in three-dimensional (3D)-collagen gel cultures, TN-C was deposited into an extracellular matrix (ECM) already containing fibronectin and perlecan. Under less physiological 2D plastic cultures, EpRas cells undergoing EMT failed to deposit TN-C into an ( apparently incomplete) ECM. Ras-downstream signaling was dissected by pharmacological inhibitors and effector-specific Ras mutants (V12S35, V12C40), specifically inhibiting or activating ERK/MAPK or PI3K signaling, respectively. We showed that TN-C overexpression required a hyperactive ERK/MAPK-signaling pathway, while elevated PI3K signaling did not enhance TN-C expression. Similarly, tumors induced by cells exhibiting hyperactive ERK/MAPK signaling showed expression of TN-C in the tumor cells themselves, while only endothelial cells expressed TN-C in tumors caused by the V12C40 mutant ( incapable of EMT in vivo). Taken together, our data indicate that hyperactive ERK/MAPK signaling causes enhanced expression of TN-C, while its secretion is induced by TGFb1 and both signals cooperate in TN-C matrix deposition. Importantly, both signals also cooperate to induce EMT in vitro and tumor progression/ metastasis in vivo.	Inst Mol Pathol, A-1030 Vienna, Austria; Austrian Acad Sci, Inst Mol Biol, A-5020 Salzburg, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Austrian Academy of Sciences	Beug, H (corresponding author), Inst Mol Pathol, Dr Bohrgasse 7, A-1030 Vienna, Austria.	beug@nt.imp.univie.ac.at	Gruenert, Stefan/B-7598-2016; Gruenert, Stefan/T-7755-2019	Gruenert, Stefan/0000-0003-0241-9297; Gruenert, Stefan/0000-0003-0241-9297				Adams M, 2002, CANCER RES, V62, P3289; Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Akhurst RJ, 2002, J CLIN INVEST, V109, P1533, DOI 10.1172/JCI200215970; Akimov SS, 2001, J CELL SCI, V114, P2989; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Belkin AM, 2001, J BIOL CHEM, V276, P18415, DOI 10.1074/jbc.M010135200; BOS JL, 1989, CANCER RES, V49, P4682; Brenner KA, 2000, ONCOGENE, V19, P3156, DOI 10.1038/sj.onc.1203626; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; CANFIELD AE, 1995, J CELL SCI, V108, P797; CARNEMOLLA B, 1992, EUR J BIOCHEM, V205, P561, DOI 10.1111/j.1432-1033.1992.tb16813.x; CHAMMAS R, 1994, J CELL SCI, V107, P1031; Chen YH, 2000, MOL BIOL CELL, V11, P849, DOI 10.1091/mbc.11.3.849; Chiquet-Ehrismann R, 2003, J PATHOL, V200, P488, DOI 10.1002/path.1415; CHIQUETEHRISMANN R, 1991, CELL REGUL, V2, P927, DOI 10.1091/mbc.2.11.927; CHIQUETEHRISMANN R, 1986, CELL, V47, P131, DOI 10.1016/0092-8674(86)90374-0; CHIQUETEHRISMANN R, 1988, CELL, V53, P383, DOI 10.1016/0092-8674(88)90158-4; CHIQUETEHRISMANN R, 1989, CANCER RES, V49, P4322; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNG CY, 1995, J BIOL CHEM, V270, P29012, DOI 10.1074/jbc.270.48.29012; Chung CY, 1997, J CELL SCI, V110, P1413; CHUNG CY, 1994, J CELL BIOL, V126, P539, DOI 10.1083/jcb.126.2.539; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; Dandachi N, 2001, J PATHOL, V193, P181, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH752>3.0.CO;2-V; Defilippi P, 1997, ONCOGENE, V14, P1933, DOI 10.1038/sj.onc.1201027; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Deryugina EI, 1996, J CELL SCI, V109, P643; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Felding-Habermann B, 2001, P NATL ACAD SCI USA, V98, P1853, DOI 10.1073/pnas.98.4.1853; Fialka I, 1996, J CELL BIOL, V132, P1115, DOI 10.1083/jcb.132.6.1115; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; Haklai R, 1998, BIOCHEMISTRY-US, V37, P1306, DOI 10.1021/bi972032d; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Huang WT, 2001, CANCER RES, V61, P8586; Jahkola T, 1998, BRIT J CANCER, V78, P1507, DOI 10.1038/bjc.1998.714; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Janda E, 2002, ONCOGENE, V21, P5148, DOI 10.1038/sj.onc.1205661; Jansen B, 1999, P NATL ACAD SCI USA, V96, P14019, DOI 10.1073/pnas.96.24.14019; Jechlinger M, 2003, ONCOGENE, V22, P7155, DOI 10.1038/sj.onc.1206887; Jones FS, 2000, DEV DYNAM, V218, P235, DOI 10.1002/(SICI)1097-0177(200006)218:2<235::AID-DVDY2>3.3.CO;2-7; Jones PL, 2000, MATRIX BIOL, V19, P581, DOI 10.1016/S0945-053X(00)00106-2; Jones PL, 2001, LANCET, V357, P1992, DOI 10.1016/S0140-6736(00)05133-3; LIGHTNER VA, 1994, EXP CELL RES, V210, P177, DOI 10.1006/excr.1994.1027; Martin D, 2003, J CELL BIOL, V160, P171, DOI 10.1083/jcb.200206109; Mettouchi A, 1997, MOL CELL BIOL, V17, P3202, DOI 10.1128/MCB.17.6.3202; Midwood KS, 2002, MOL BIOL CELL, V13, P3601, DOI 10.1091/mbc.E02-05-0292; Miyakis S, 1998, BIOCHEM BIOPH RES CO, V251, P609, DOI 10.1006/bbrc.1998.9527; Moon A, 2000, INT J CANCER, V85, P176, DOI 10.1002/(SICI)1097-0215(20000115)85:2<176::AID-IJC5>3.0.CO;2-E; Muraoka RS, 2002, J CLIN INVEST, V109, P1551, DOI 10.1172/JCI200215234; Nagata M, 2003, INT J CANCER, V106, P683, DOI 10.1002/ijc.11283; Oft M, 2002, NAT CELL BIOL, V4, P487, DOI 10.1038/ncb807; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; PEARSON CA, 1988, EMBO J, V7, P2977, DOI 10.1002/j.1460-2075.1988.tb03160.x; Portella G, 1998, CELL GROWTH DIFFER, V9, P393; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; REICHMANN E, 1989, J CELL BIOL, V108, P1127, DOI 10.1083/jcb.108.3.1127; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; RETTIG WJ, 1994, J CELL SCI, V107, P487; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; SAGINATI M, 1992, EUR J BIOCHEM, V205, P545, DOI 10.1111/j.1432-1033.1992.tb16811.x; SAKAI T, 1995, INT J CANCER, V63, P720, DOI 10.1002/ijc.2910630519; Shields JM, 2002, MOL CELL BIOL, V22, P2304, DOI 10.1128/MCB.22.7.2304-2317.2002; Siegel PM, 2003, P NATL ACAD SCI USA, V100, P8430, DOI 10.1073/pnas.0932636100; Swindle CS, 2001, J CELL BIOL, V154, P459, DOI 10.1083/jcb.200103103; Taipale J, 1998, ADV CANCER RES, V75, P87, DOI 10.1016/S0065-230X(08)60740-X; Tokes AM, 1999, PATHOL RES PRACT, V195, P821; Tsunoda T, 2003, AM J PATHOL, V162, P1857, DOI 10.1016/S0002-9440(10)64320-9; Ward Y, 2001, MOL CELL BIOL, V21, P5958, DOI 10.1128/MCB.21.17.5958-5969.2001; Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773; Weeks BH, 2001, CANCER RES, V61, P7435; WELLER A, 1991, J CELL BIOL, V112, P355, DOI 10.1083/jcb.112.2.355; WIRL G, 1995, J CELL SCI, V108, P2445; Woods D, 2001, MOL CELL BIOL, V21, P3192, DOI 10.1128/MCB.21.9.3192-3205.2001; Yang YA, 2002, J CLIN INVEST, V109, P1607, DOI 10.1172/JCI200215333; Yoshida T, 1997, J PATHOL, V182, P421; Zagzag D, 2002, CANCER RES, V62, P2660	77	41	42	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3622	3633		10.1038/sj.onc.1207403	http://dx.doi.org/10.1038/sj.onc.1207403			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15116096				2022-12-28	WOS:000221101700014
J	Sullivan, A; Syed, N; Gasco, M; Bergamaschi, D; Trigiante, G; Attard, M; Hiller, L; Farrell, PJ; Smith, P; Lu, X; Crook, T				Sullivan, A; Syed, N; Gasco, M; Bergamaschi, D; Trigiante, G; Attard, M; Hiller, L; Farrell, PJ; Smith, P; Lu, X; Crook, T			Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo	ONCOGENE			English	Article						carcinoma; p53; SNP; apoptosis; clinical outcome	COLORECTAL-CANCER CELLS; P53-DEPENDENT APOPTOSIS; PUMA; VARIANTS; MEDIATOR; AGENTS; NOXA	A single-nucleotide polymorphism (SNP) in exon 4 results in expression of either arginine (72R) or proline (72P) at codon 72 of p53. We demonstrate that the in vitro response of cells exposed to anticancer agents is strongly influenced by this SNP in wild-type p53. In inducible systems and in cells expressing the endogenous protein, expression of 72P wild-type p53 results in a predominant G1 arrest, with only a minor apoptosis, at drug concentrations causing extensive apoptosis in cells expressing the 72R wild-type variant. The superior apoptosis-inducing activity of the 72R form correlates with more efficient induction of specific apoptosis-associated genes, and is maximal in the presence of serine 46 (S46). In vivo, the outcome of chemo-radiotherapy of squamous carcinomas is more favourable in cancers retaining a wild-type 72R allele, such cases having higher response rates and longer survival than those with wild-type 72P. Together, these results reveal that this SNP is an important determinant of response to anticancer agents in cells expressing wild-type p53. Analysis of complete p53 genotype (mutation and SNP) merits detailed investigation as a simple means for prediction of treatment response and survival in clinical oncology.	St Marys Hosp, Imperial Coll Fac Med, Ludwig Inst Canc Res, London W1, England; S Croce & Carle Hosp, Dept Med Oncol, I-12100 Cuneo, Italy; Univ Birmingham, Canc Res UK Clin Trials Unit, Birmingham, W Midlands, England	Imperial College London; Ludwig Institute for Cancer Research; Cancer Research UK; University of Birmingham	Crook, T (corresponding author), St Marys Hosp, Imperial Coll Fac Med, Ludwig Inst Canc Res, Norfolk Pl, London W1, England.	t.crook@ic.ac.uk		Farrell, Paul/0000-0002-6754-9351; Bergamaschi, Daniele/0000-0002-3955-1091; Lu, Xin/0000-0002-6587-1152				ALLDAY MJ, 1995, EMBO J, V14, P4994, DOI 10.1002/j.1460-2075.1995.tb00182.x; Baptiste N, 2002, ONCOGENE, V21, P9, DOI 10.1038/sj/onc/1205015; Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; Pim D, 2004, INT J CANCER, V108, P196, DOI 10.1002/ijc.11548; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Shibue T, 2003, GENE DEV, V17, P2233, DOI 10.1101/gad.1103603; SJALANDER A, 1995, HUM HERED, V45, P144, DOI 10.1159/000154275; Thomas M, 1999, MOL CELL BIOL, V19, P1092; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100	26	215	235	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3328	3337		10.1038/sj.onc.1207428	http://dx.doi.org/10.1038/sj.onc.1207428			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15077186				2022-12-28	WOS:000220975000007
J	Henry-Mowatt, J; Dive, C; Martinou, JC; James, D				Henry-Mowatt, J; Dive, C; Martinou, JC; James, D			Role of mitochondrial membrane permeabilization in apoptosis and cancer	ONCOGENE			English	Review						mitochondria; cancer therapy; apoptosis; Bcl-2 family; permeability transition pore	CYTOCHROME-C RELEASE; PROGRAMMED CELL-DEATH; ADENINE-NUCLEOTIDE TRANSLOCATOR; HISTONE DEACETYLASE INHIBITOR; WD-40 REPEAT REGION; BCL-2 FAMILY; IN-VIVO; MICROSATELLITE INSTABILITY; CHEMOTHERAPEUTIC DRUGS; ENDOPLASMIC-RETICULUM	The release of proteins from the intermembrane space of mitochondria is one of the pivotal events in the apoptotic process, which can lead to the activation of caspases and the ultimate demise of the cell. How these proteins exit the mitochondria is still a matter of intense debate. Here, we discuss the possible mechanisms behind the release of apoptogenic proteins, the ways in which cancer cells subvert these mechanisms, and the therapeutic regimens that aim to promote the timely loss of integrity of the outer mitochondrial membrane.	Univ Geneva, Dept Cell Biol, CH-1211 Geneva 4, Switzerland; Paterson Inst Canc Res, Cellular & Mol Pharmacol Grp, Manchester M20 4BX, Lancs, England	University of Geneva; Paterson Institute for Cancer Research	James, D (corresponding author), Univ Geneva, Dept Cell Biol, Quai Ernest Ansermet 30, CH-1211 Geneva 4, Switzerland.	dominic.james@cellbio.unige.ch	James, Dominic/G-6435-2016	James, Dominic/0000-0002-0452-2178; martinou, Jean-claude/0000-0002-9847-2051; Dive, Caroline/0000-0002-1726-8850				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Adrain C, 1999, J BIOL CHEM, V274, P20855, DOI 10.1074/jbc.274.30.20855; AmaranteMendes GP, 1997, CELL DEATH DIFFER, V4, P548, DOI 10.1038/sj.cdd.4400276; Amundson SA, 2000, CANCER RES, V60, P6101; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Arnoult D, 2003, EMBO J, V22, P4385, DOI 10.1093/emboj/cdg423; Arnt CR, 2002, J BIOL CHEM, V277, P44236, DOI 10.1074/jbc.M207578200; Azoulay-Zohar H, 2004, BIOCHEM J, V377, P347, DOI 10.1042/BJ20031465; Banerjee D, 2001, Curr Opin Investig Drugs, V2, P574; Barbu A, 2002, MOL CELL ENDOCRINOL, V190, P75, DOI 10.1016/S0303-7207(02)00009-6; Bottero V, 2001, CANCER RES, V61, P7785; Boya P, 2003, ONCOGENE, V22, P6220, DOI 10.1038/sj.onc.1206827; Breckenridge DG, 2003, J CELL BIOL, V160, P1115, DOI 10.1083/jcb.200212059; Bryson JM, 2002, J BIOL CHEM, V277, P11392, DOI 10.1074/jbc.M110927200; Cain K, 2002, BIOCHIMIE, V84, P203, DOI 10.1016/S0300-9084(02)01376-7; Cassina AM, 2000, J BIOL CHEM, V275, P21409, DOI 10.1074/jbc.M909978199; Catasus L, 2000, CANCER, V88, P2290, DOI 10.1002/(SICI)1097-0142(20000515)88:10<2290::AID-CNCR13>3.3.CO;2-9; Cheong JW, 2003, CLIN CANCER RES, V9, P5018; Chun KH, 2003, CANCER RES, V63, P3826; Collins TJ, 2002, EMBO J, V21, P1616, DOI 10.1093/emboj/21.7.1616; Colombini M, 1980, Ann N Y Acad Sci, V341, P552, DOI 10.1111/j.1749-6632.1980.tb47198.x; Colquhoun A, 1998, BIOCHEM MOL BIOL INT, V45, P331; Csordas G, 2002, EMBO J, V21, P2198, DOI 10.1093/emboj/21.9.2198; Cusack JC, 2003, ANN SURG ONCOL, V10, P852, DOI 10.1245/ASO.2003.07.518; De Giorgi F, 2002, FASEB J, V16, P607, DOI 10.1096/fj.01-0269fje; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Deshmukh M, 2000, J CELL BIOL, V150, P131, DOI 10.1083/jcb.150.1.131; Deveraux Quinn L., 2001, Cardiology Clinics, V19, P57; Dewson G, 2003, ONCOGENE, V22, P2643, DOI 10.1038/sj.onc.1206326; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Duvoix A, 2003, BIOCHEM PHARMACOL, V66, P1475, DOI 10.1016/S0006-2952(03)00501-X; Dvorakova K, 2002, MOL CANCER THER, V1, P185; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; El-Deiry WS, 2003, ONCOGENE, V22, P7486, DOI 10.1038/sj.onc.1206949; Epand RF, 2002, BIOCHEM J, V367, P849, DOI 10.1042/BJ20020986; Epand RF, 2004, BIOCHEM J, V377, P509, DOI 10.1042/BJ20030938; Epand RF, 2002, BIOCHEM BIOPH RES CO, V298, P744, DOI 10.1016/S0006-291X(02)02544-5; Epand RF, 2002, J BIOL CHEM, V277, P32632, DOI 10.1074/jbc.M202396200; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Esposti MD, 2001, MOL CELL BIOL, V21, P7268, DOI 10.1128/MCB.21.21.7268-7276.2001; Esposti MD, 2003, BIOCHEM BIOPH RES CO, V304, P455, DOI 10.1016/S0006-291X(03)00617-X; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Fisk HA, 1997, J CELL BIOL, V138, P485, DOI 10.1083/jcb.138.3.485; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Fukazawa T, 2003, J BIOL CHEM, V278, P25428, DOI 10.1074/jbc.M302058200; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Gottlieb RA, 2000, DRUG NEWS PERSPECT, V13, P471; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Guo F, 2002, BLOOD, V99, P3419, DOI 10.1182/blood.V99.9.3419; Gurbuxani S, 2003, ONCOGENE, V22, P6669, DOI 10.1038/sj.onc.1206794; Haga N, 2003, ONCOGENE, V22, P5579, DOI 10.1038/sj.onc.1206576; Hajnoczky G, 2001, IUBMB LIFE, V52, P237, DOI 10.1080/15216540152846055; Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300-9084(02)01375-5; Hardwick JM, 2002, MOL CELL, V10, P963, DOI 10.1016/S1097-2765(02)00751-7; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; Hu YM, 1998, J BIOL CHEM, V273, P33489, DOI 10.1074/jbc.273.50.33489; Hu YP, 2003, CLIN CANCER RES, V9, P2826; HUNTER DR, 1976, J BIOL CHEM, V251, P5069; Iaccarino I, 2003, CELL DEATH DIFFER, V10, P599, DOI 10.1038/sj.cdd.4401211; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Inoue K, 2000, LEUKEMIA RES, V24, P255, DOI 10.1016/S0145-2126(99)00182-4; James DI, 2003, J BIOL CHEM, V278, P36373, DOI 10.1074/jbc.M303758200; Juin P, 2002, MOL CELL BIOL, V22, P6158, DOI 10.1128/MCB.22.17.6158-6169.2002; Ka H, 2003, CANCER LETT, V196, P143, DOI 10.1016/S0304-3835(03)00238-6; Kannan, 2000, Pathophysiology, V7, P153, DOI 10.1016/S0928-4680(00)00053-5; Karbowski M, 2002, J CELL BIOL, V159, P931, DOI 10.1083/jcb.200209124; Karbowski M, 2003, CELL DEATH DIFFER, V10, P870, DOI 10.1038/sj.cdd.4401260; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karran P, 2000, CURR OPIN GENET DEV, V10, P144, DOI 10.1016/S0959-437X(00)00069-1; Kaufmann SH, 2003, ONCOGENE, V22, P7414, DOI 10.1038/sj.onc.1206945; Kim JS, 2003, BIOCHEM BIOPH RES CO, V304, P463, DOI 10.1016/S0006-291X(03)00618-1; Kim SH, 1999, CANCER RES, V59, P4012; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Li JL, 2001, ENDOCRINOLOGY, V142, P370, DOI 10.1210/en.142.1.370; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Lim MLR, 2001, FEBS LETT, V503, P69, DOI 10.1016/S0014-5793(01)02693-X; Lohret TA, 1996, J BIOL CHEM, V271, P4846; Ly JD, 2003, APOPTOSIS, V8, P115, DOI 10.1023/A:1022945107762; Makin G, 2000, CELL TISSUE RES, V301, P143, DOI 10.1007/s004419900160; Martelli AM, 2003, LEUKEMIA, V17, P1794, DOI 10.1038/sj.leu.2403044; Martinou I, 1999, J CELL BIOL, V144, P883, DOI 10.1083/jcb.144.5.883; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Moncada S, 2002, NAT REV MOL CELL BIO, V3, P214, DOI 10.1038/nrm762; Mortenson M.M., 2003, J SURG RES, V114, P302, DOI DOI 10.1016/J.JSS.2003.08.103; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; Nutt LK, 2002, J BIOL CHEM, V277, P20301, DOI 10.1074/jbc.M201604200; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; Pacher P, 2001, EMBO J, V20, P4107, DOI 10.1093/emboj/20.15.4107; Pastorino JG, 2002, J BIOL CHEM, V277, P7610, DOI 10.1074/jbc.M109950200; Patterson SD, 2000, CELL DEATH DIFFER, V7, P137, DOI 10.1038/sj.cdd.4400640; Pavlov EV, 2001, J CELL BIOL, V155, P725, DOI 10.1083/jcb.200107057; Rapizzi E, 2002, J CELL BIOL, V159, P613, DOI 10.1083/jcb.200205091; Reed JC, 2002, NAT REV DRUG DISCOV, V1, P111, DOI 10.1038/nrd726; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Reed JC, 2002, MOL CELL, V9, P1, DOI 10.1016/S1097-2765(02)00437-9; Rosato RR, 2003, CANCER RES, V63, P3637; Roucou X, 2002, BIOCHEM J, V368, P915, DOI 10.1042/BJ20020972; Roucou X, 2002, BIOCHEM J, V363, P547, DOI 10.1042/0264-6021:3630547; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Santel A, 2001, J CELL SCI, V114, P867; Sax JK, 2002, NAT CELL BIOL, V4, P842, DOI 10.1038/ncb866; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; SCORRANO L, 2003, CELL DEATH DIFFER, V8, P8; Shi YG, 2001, NAT STRUCT BIOL, V8, P394, DOI 10.1038/87548; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Singh TR, 2003, CANCER RES, V63, P5390; Smaili SS, 2001, CELL DEATH DIFFER, V8, P909, DOI 10.1038/sj.cdd.4400889; Smirnova E, 1998, J CELL BIOL, V143, P351, DOI 10.1083/jcb.143.2.351; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Swamy SMK, 2003, MOL CELL BIOCHEM, V245, P127, DOI 10.1023/A:1022807207948; Tamm I, 2000, CLIN CANCER RES, V6, P1796; THOMAS SM, 1989, BIOCHIM BIOPHYS ACTA, V1002, P189, DOI 10.1016/0005-2760(89)90286-5; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; Vaux DL, 1998, SPRINGER SEMIN IMMUN, V19, P271, DOI 10.1007/BF00787224; von Ahsen O, 2000, J CELL BIOL, V150, P1027, DOI 10.1083/jcb.150.5.1027; Von Ahsen O, 2000, CELL DEATH DIFFER, V7, P1192, DOI 10.1038/sj.cdd.4400782; Wacheck V, 2003, BRIT J CANCER, V89, P1352, DOI 10.1038/sj.bjc.6601254; Wagenknecht B, 2000, J NEUROCHEM, V75, P2288, DOI 10.1046/j.1471-4159.2000.0752288.x; Waterhouse NJ, 2002, BIOCHIMIE, V84, P113, DOI 10.1016/S0300-9084(02)01379-2; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; WEI YQ, 1995, CANCER IMMUNOL IMMUN, V40, P73, DOI 10.1007/s002620050146; Wigdal SS, 2002, J NEUROCHEM, V82, P1029, DOI 10.1046/j.1471-4159.2002.01049.x; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang L, 2003, CANCER RES, V63, P6815; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zamzami N, 2003, CURR BIOL, V13, pR71, DOI 10.1016/S0960-9822(02)01433-1; Zhang JH, 2003, P NATL ACAD SCI USA, V100, P15782, DOI 10.1073/pnas.2636393100; Zhang XD, 2003, BIOCHEM PHARMACOL, V66, P1537, DOI 10.1016/S0006-2952(03)00509-4	139	232	242	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2004	23	16					2850	2860		10.1038/sj.onc.1207534	http://dx.doi.org/10.1038/sj.onc.1207534			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	811VO	15077148				2022-12-28	WOS:000220799600012
J	Fukao, T; Chen, P; Ren, J; Kaneko, H; Zhang, GX; Kondo, M; Yamamoto, K; Furuichi, Y; Takeda, S; Kondo, N; Lavin, MF				Fukao, T; Chen, P; Ren, J; Kaneko, H; Zhang, GX; Kondo, M; Yamamoto, K; Furuichi, Y; Takeda, S; Kondo, N; Lavin, MF			Disruption of the BLM gene in ATM-null DT40 cells does not exacerbate either phenotype	ONCOGENE			English	Article						ataxia-telangiectasia; Bloom syndrome; DNA damage; DT40 cells; gene disruption	BLOOMS-SYNDROME GENE; DOUBLE-STRAND BREAKS; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; DNA-DAMAGE; DEPENDENT PHOSPHORYLATION; RECOMBINATIONAL REPAIR; GENOMIC INSTABILITY; SYNDROME PROTEIN; S-PHASE	Bloom syndrome and ataxia-telangiectasia are autosomal recessive human disorders characterized by immunodeficiency, genome instability and predisposition to develop cancer. Recent data reveal that the products of these two genes, BLM and ATM, interact and function together in recognizing abnormal DNA structures. To investigate the function of these two molecules in DNA damage recognition, we generated double knockouts of ATM(-/-) BLM-/- in the DT40 chicken B-lymphocyte cell line. The double mutant cells were viable and exhibited a variety of characteristics of both ATM(-/-) and BLM-/- cells. There was no evidence for exacerbation of either phenotype; however, the more extreme radiosensitivity seen in ATM(-/-) and the elevated sister chromatid exchange seen in BLM-/- cells were retained in the double mutants. These results suggest that ATM and BLM have largely distinct roles in recognizing different forms of damage in DNA, but are also compatible with partially overlapping functions in recognizing breaks in radiation-damaged DNA.	Royal Brisbane Hosp, Res Unit, Queensland Canc Fund, Queensland Inst Med Res, Herston, Qld 4029, Australia; Gifu Univ, Sch Med, Dept Pediat, Gifu 5008076, Japan; Shandong Univ, Sch Med, Dept Haematol & Oncol, Shandong, Peoples R China; Kanazawa Univ, Canc Res Inst, Dept Mol Pathol, Kanazawa, Ishikawa 9200934, Japan; GeneCare Res Inst, Kamakura, Kanagawa 2470063, Japan; Kyoto Univ, Dept Radiat Genet, Kyoto 6068501, Japan; Univ Queensland, Royal Brisbane Hosp, Dept Surg, Brisbane, Qld 4072, Australia	Cancer Council Queensland; QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; Gifu University; Shandong University; Kanazawa University; Kyoto University; Royal Brisbane & Women's Hospital; University of Queensland	Lavin, MF (corresponding author), Royal Brisbane Hosp, Res Unit, Queensland Canc Fund, Queensland Inst Med Res, Herston, Qld 4029, Australia.	martinL@qimr.edu.au	Lavin, Martin F/F-5961-2014	Lavin, Martin F/0000-0002-5940-4769; Takeda, Shunichi/0000-0002-7924-7991				Ababou M, 2000, ONCOGENE, V19, P5955, DOI 10.1038/sj.onc.1204003; Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; ARLETT CF, 1979, ACTA BIOL MED GER, V38, P1277; AURIAS A, 1980, MUTAT RES, V69, P369, DOI 10.1016/0027-5107(80)90101-3; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; BEAMISH H, 2002, J BIOL CHEM; Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; Buscemi G, 2001, MOL CELL BIOL, V21, P5214, DOI 10.1128/MCB.21.15.5214-5222.2001; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; CHAGANTI RS, 1974, P NATL ACAD SCI USA, V71, P4508, DOI 10.1073/pnas.71.11.4508; Chen P, 1999, ONCOGENE, V18, P249, DOI 10.1038/sj.onc.1202257; CHEN PC, 1978, NATURE, V274, P484, DOI 10.1038/274484a0; Chester N, 1998, GENE DEV, V12, P3382, DOI 10.1101/gad.12.21.3382; CORNFORTH MN, 1985, SCIENCE, V227, P1589, DOI 10.1126/science.3975628; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Dong ZW, 1999, J BIOL CHEM, V274, P19513, DOI 10.1074/jbc.274.28.19513; Dutertre S, 2000, ONCOGENE, V19, P2731, DOI 10.1038/sj.onc.1203595; Ellis NA, 1999, AM J HUM GENET, V65, P1368, DOI 10.1086/302616; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; Foray N, 1997, INT J RADIAT BIOL, V72, P271, DOI 10.1080/095530097143266; Franchitto A, 2002, J CELL BIOL, V157, P19, DOI 10.1083/jcb.200110009; Fukao T, 1999, BLOOD, V94, P1998; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Gaymes TJ, 2002, ONCOGENE, V21, P2525, DOI 10.1038/sj.onc.1205331; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; Gueven N, 2001, J BIOL CHEM, V276, P8884, DOI 10.1074/jbc.M006190200; HAND R, 1975, P NATL ACAD SCI USA, V72, P758, DOI 10.1073/pnas.72.2.758; HOULDSWORTH J, 1980, NUCLEIC ACIDS RES, V8, P3709, DOI 10.1093/nar/8.16.3709; Imamura O, 2001, ONCOGENE, V20, P1143, DOI 10.1038/sj.onc.1204195; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; Kozlov S, 2003, J BIOL CHEM, V278, P9309, DOI 10.1074/jbc.M300003200; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; LAVIN MF, 2003, IN PRESS IMMUNOLOGIC; Lim J, 2000, MOL CELL BIOCHEM, V212, P51, DOI 10.1023/A:1007148719497; LONN U, 1990, CANCER RES, V50, P3141; Luo CM, 1996, J BIOL CHEM, V271, P4497; Luo GB, 2000, NAT GENET, V26, P424, DOI 10.1038/82548; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; Morrison C, 2000, EMBO J, V19, P463, DOI 10.1093/emboj/19.3.463; PANDITA TK, 1994, MUTAT RES, V310, P1013; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Shiloh Y, 2001, ADV CANCER RES, V83, P209, DOI 10.1016/S0065-230X(01)83007-4; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Takao N, 1999, ONCOGENE, V18, P7002, DOI 10.1038/sj.onc.1203172; Taniguchi T, 2002, CELL, V109, P459, DOI 10.1016/S0092-8674(02)00747-X; TAYLOR AMR, 1976, BRIT J RADIOL, V49, P561; Wang WS, 2000, EMBO J, V19, P3428, DOI 10.1093/emboj/19.13.3428; Wang Y, 2000, GENE DEV, V14, P927; Wu L, 2001, J BIOL CHEM, V276, P19375, DOI 10.1074/jbc.M009471200; Yamagata K, 1998, P NATL ACAD SCI USA, V95, P8733, DOI 10.1073/pnas.95.15.8733; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; ZAMPETTIBOSSELER F, 1981, INT J RADIAT BIOL, V39, P547, DOI 10.1080/09553008114550651; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083	60	5	5	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2004	23	8					1498	1506		10.1038/sj.onc.1207276	http://dx.doi.org/10.1038/sj.onc.1207276			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778BP	14985700				2022-12-28	WOS:000189219500002
J	Li, JF; Wang, FL; Protopopov, A; Malyukova, A; Kashuba, V; Minna, JD; Lerman, MI; Klein, G; Zabarovsky, E				Li, JF; Wang, FL; Protopopov, A; Malyukova, A; Kashuba, V; Minna, JD; Lerman, MI; Klein, G; Zabarovsky, E			Inactivation of RASSF1C during in vivo tumor growth identifies it as a tumor suppressor gene	ONCOGENE			English	Article						tumor suppressor gene; human chromosome 3p; gene mutation; lung cancer; renal carcinoma; prostate cancer	HUMAN-CHROMOSOME 3P21.3; HOMOZYGOUS DELETION REGION; EPIGENETIC INACTIVATION; CELL-GROWTH; LUNG; CANCER; SEARCH; BREAST; CONSTRUCTION; INHIBITION	RASSF1A, a major member of the RASSF1 gene family, is silenced by promoter methylation at a high frequency in a large number of human solid tumors. Controlled expression of RASSF1A reverts the tumorigenic phenotype of several human cancer cell lines. Here we investigated another main isoform, RASSF1C, and compared it with RASSF1A in the gene inactivation test (GIT), based on a tetracycline regulation system. In the small-cell lung cancer (SCLC) line U2020, only RASSF1A has shown growth inhibitory activity in vitro, while in the prostate cell line LNCaP and renal cell carcinoma (RCC) line KRC/Y both RASSF1A and RASSF1C showed similar (approximately 90%) suppressing activity in vitro. Both RASSF1C and RASSF1A suppressed the tumorigenicity of the KRC/Y RCC cell line in SCID mice. Mutations, deletions and loss of expression of RASSF1A and RASSF1C transgenes were identified in all 15 grown SCID tumors. In contrast, the mutant RASSF1A containing Cys65Arg and Val211Ala had reduced growth suppression activity both in vitro and in vivo and did not show any further changes in four grown SCID tumors. In addition, RASSF1C was shown to induce cell cycle arrest in KRC/Y cells. These results strongly imply that like RASSF1A the RASSF1C gene could serve a tumor suppressor function.	Karolinska Inst, Microbiol & Tumorbiol Ctr, S-17177 Stockholm, Sweden; Natl Acad Sci Ukraine, Inst Mol Biol & Genet, UA-03143 Kiev, Ukraine; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol, Dallas, TX 75390 USA; Natl Canc Inst, Canc Causing Genes Sect, Immunobiol Lab, Ctr Canc Res, Frederick, MD 21702 USA; Russian Acad Sci, Engelhardt Inst Mol Biol, Moscow 119991, Russia; Karolinska Inst, Ctr Genom & Bioinformat, S-17177 Stockholm, Sweden	Karolinska Institutet; National Academy of Sciences Ukraine; Institute of Molecular Biology & Genetics of NASU; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; Karolinska Institutet	Li, JF (corresponding author), Karolinska Inst, Microbiol & Tumorbiol Ctr, S-17177 Stockholm, Sweden.	jinli@ki.se; eugzab@ki.se	Zabarovsky, Eugene R/A-6645-2010; Kashuba, Vladimir I/N-3732-2017; Kashuba, Vladimir/AAO-7742-2020	Kashuba, Vladimir I/0000-0001-9416-8282; 	NATIONAL CANCER INSTITUTE [P50CA070907, R01CA071618] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER; NCI NIH HHS [CA71618, P50 CA 70907, N01-CO-56000] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Alimov A, 2000, ONCOGENE, V19, P1392, DOI 10.1038/sj.onc.1203449; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Hingorani SR, 2003, CURR OPIN GENET DEV, V13, P6, DOI 10.1016/S0959-437X(02)00017-5; Imreh S, 2003, GENE CHROMOSOME CANC, V38, P307, DOI 10.1002/gcc.10271; Ji L, 2002, CANCER RES, V62, P2715; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Kuzmin I, 2002, CANCER RES, V62, P3498; Lee MG, 2001, CANCER RES, V61, P6688; Lerman MI, 2000, CANCER RES, V60, P6116; Li JF, 1999, FEBS LETT, V451, P289, DOI 10.1016/S0014-5793(99)00598-0; Lo KW, 2001, CANCER RES, V61, P3877; Maruyama R, 2001, CANCER RES, V61, P8659; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Protopopov A, 2003, CANCER RES, V63, P404; Protopopov AI, 2002, J GENE MED, V4, P397, DOI 10.1002/jgm.283; Rubins JB, 2001, J LAB CLIN MED, V138, P101, DOI 10.1067/mlc.2001.116591; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; Senchenko V, 2003, ONCOGENE, V22, P2984, DOI 10.1038/sj.onc.1206429; SENCHENKO VN, 2004, IN PRESS ONCOGENE; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Tomizawa Y, 2001, P NATL ACAD SCI USA, V98, P13954, DOI 10.1073/pnas.231490898; Tse C, 2002, CANCER RES, V62, P542; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Wei MH, 1996, CANCER RES, V56, P1487; Xiang RH, 2002, CANCER RES, V62, P2637; ZABAROVSKY ER, 1990, NUCLEIC ACIDS RES, V18, P6319, DOI 10.1093/nar/18.21.6319; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835	31	43	50	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2004	23	35					5941	5949		10.1038/sj.onc.1207789	http://dx.doi.org/10.1038/sj.onc.1207789			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15208682				2022-12-28	WOS:000222941100008
J	Elhasid, R; Sahar, D; Merling, A; Zivony, Y; Rotem, A; Ben-Arush, M; Izraeli, S; Bercovich, D; Larisch, S				Elhasid, R; Sahar, D; Merling, A; Zivony, Y; Rotem, A; Ben-Arush, M; Izraeli, S; Bercovich, D; Larisch, S			Mitochondrial pro-apoptotic ARTS protein is lost in the majority of acute lymphoblastic leukemia patients	ONCOGENE			English	Article						ARTS; mitochandria; apoptosis; leukemia	ACUTE MYELOID-LEUKEMIA; SEPTIN-LIKE FUSION; DNA METHYLATION; GENE; MLL; HEMATOPOIESIS; EXPRESSION; REGION; TUMORS; DEATH	Acquired resistance towards apoptosis is the hallmark of most if not all types of cancer. We have previously identified and characterized ARTS, a broadly expressed protein localized to mitochondria. ARTS was initially shown to mediate TGF-beta induced apoptosis. Recently, we have found that high levels of ARTS induce apoptosis without additional pro-apoptotic stimuli. Further, ARTS promotes apoptosis in response to a wide variety of proapoptotic stimuli. Here, we report that the expression of ARTS is lost in all lymphoblasts of more than 70% of childhood acute lymphoblastic leukemia (ALL) patients. The loss of ARTS is specific, as the related non-apoptotic protein H5, bearing 83% identity to ARTS, is unaffected. During remission, ARTS expression is detected again in almost all patients. Two leukemic cell lines, ALL-1 and HL-60 lacking ARTS, were resistant to apoptotic induction by ara-C. Transfection of ARTS into these cells restored their ability to undergo apoptosis in response to this chemotherapeutic agent. We found that methylation process contributes to the loss of ARTS expression. We conclude that the loss of ARTS may provide a selective advantage for cells to escape apoptosis thereby contributing to their transformation to malignant lymphoblasts. We therefore propose that ARTS can function as a tumor suppressor protein in childhood ALL.	Rambam Med Ctr, Apoptosis & Carcinogenesis Res Lab, Dept Pathol, IL-31096 Haifa, Israel; Rambam Med Ctr, Pediat Hematooncol Dept, IL-31096 Haifa, Israel; Rambam Med Ctr, Mol Hematol Lab, IL-31096 Haifa, Israel; Tel Aviv Univ, Sackler Fac Med, Sheba Med Ctr, Canc Res Ctr, IL-52621 Tel Hashomer, Israel; Migal Galilee Technol Ctr, IL-11016 Kiryat Shmona, Israel	Rambam Health Care Campus; Technion Israel Institute of Technology; Rambam Health Care Campus; Technion Israel Institute of Technology; Rambam Health Care Campus; Technion Israel Institute of Technology; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Larisch, S (corresponding author), Rambam Med Ctr, Apoptosis & Carcinogenesis Res Lab, Dept Pathol, IL-31096 Haifa, Israel.	s_larisch@rambam.health.gov.il						Attardi LD, 1999, CELL MOL LIFE SCI, V55, P48, DOI 10.1007/s000180050269; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; Domen J, 2000, IMMUNOL RES, V22, P83, DOI 10.1385/IR:22:2-3:83; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; ERIKSON J, 1986, P NATL ACAD SCI USA, V83, P1807, DOI 10.1073/pnas.83.6.1807; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Field CM, 1999, TRENDS CELL BIOL, V9, P387, DOI 10.1016/S0962-8924(99)01632-3; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Gottfried Y, 2004, EMBO J, V23, P1627, DOI 10.1038/sj.emboj.7600155; Greaves M, 2002, BRIT MED J, V324, P283, DOI 10.1136/bmj.324.7332.283; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hetts SW, 1998, JAMA-J AM MED ASSOC, V279, P300, DOI 10.1001/jama.279.4.300; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Jain PK, 2003, ANN NY ACAD SCI, V983, P71, DOI 10.1111/j.1749-6632.2003.tb05963.x; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Kalikin LM, 2000, GENOMICS, V63, P165, DOI 10.1006/geno.1999.6077; Karpf AR, 2002, ONCOGENE, V21, P5496, DOI 10.1038/sj.onc.1205602; Kartmann B, 2001, J CELL SCI, V114, P839; Kinoshita M, 2002, DEV CELL, V3, P791, DOI 10.1016/S1534-5807(02)00366-0; Larisch S, 2000, NAT CELL BIOL, V2, P915, DOI 10.1038/35046566; Malfoy B., 2000, J CELL SCI, V113, P3887; McKenna SL, 1997, ADV CANCER RES, V71, P121, DOI 10.1016/S0065-230X(08)60098-6; Megonigal MD, 1998, P NATL ACAD SCI USA, V95, P6413, DOI 10.1073/pnas.95.11.6413; Meier P, 2000, NATURE, V407, P796, DOI 10.1038/35037734; Osaka M, 1999, P NATL ACAD SCI USA, V96, P6428, DOI 10.1073/pnas.96.11.6428; PUI CH, 1995, NEW ENGL J MED, V332, P1618, DOI 10.1056/NEJM199506153322407; Rinkenberger JL, 1997, CURR OPIN GENET DEV, V7, P589, DOI 10.1016/S0959-437X(97)80004-4; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; Rubnitz JE, 2003, CANCER TREAT REV, V29, P31, DOI 10.1016/S0305-7372(02)00106-8; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; ZAGONEL V, 1993, LEUKEMIA, V7, P30	36	56	61	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2004	23	32					5468	5475		10.1038/sj.onc.1207725	http://dx.doi.org/10.1038/sj.onc.1207725			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15122323				2022-12-28	WOS:000222588400006
J	Saleem, M; Afaq, F; Adhami, VM; Mukhtar, H				Saleem, M; Afaq, F; Adhami, VM; Mukhtar, H			Lupeol modulates NF-kappa B and PI3K/Akt pathways and inhibits skin cancer in CD-1 mice	ONCOGENE			English	Article						lupeol; chemoprevention; NF-kappa B; PI3K/Akt; skin cancer	ORNITHINE-DECARBOXYLASE ACTIVITY; SENCAR MOUSE SKIN; GREEN TEA; TUMOR PROMOTION; ANTIINFLAMMATORY TRITERPENOIDS; SIGNAL-TRANSDUCTION; PROSTATE-CANCER; CELL-LINE; IN-VITRO; CHEMOPREVENTION	Chemoprevention has become an effective cancer control modality; however, the search for novel agent(s) for the armamentarium of cancer chemoprevention continues. We argue that agents capable for inhibition of promotion stage of tumorigenesis with the ability to intervene at several critical pathways in the tumorigenesis process will have greater advantage over other single-target agents. Lupeol, a triterpene, is the principal constituent of common fruit plants such as olive, mango,. g and medicinal herbs that have been used to treat skin aliments. Lupeol has been reported to possess a wide range of medicinal properties that include strong antioxidant, antimutagenic, anti-inflammatory and antiarthritic effects. In the present study, we show that Lupeol possesses antitumor-promoting effects in a mouse skin tumorigenesis model. We first determined the effect of topical application of Lupeol to CD-1 mouse against 12-O-tetradecanoylphorbol- 13-acetate (TPA)-induced conventional markers and other novel markers of skin tumor promotion. We found that topical application of Lupeol (1 - 2 mg/mouse) 30 min prior to TPA (3.2 nmol/mouse) application onto the skin of CD-1 mice afforded significant inhibition, in a time- and dose-dependent manner, against TPA-mediated increase in (i) skin edema and hyperplasia, (ii) epidermal ornithine decarboxylase (ODC) activity, and (iii) protein expression of ODC, cyclo-oxygenase-2 and nitric oxide synthase. As of the role of nuclear factor kappa B (NF-kappaB) and phosphatidyl inositol 3-kinase (PI3K)/Akt signaling in tumor promotion, we next determined the effect of topical application of Lupeol to mouse skin against these signaling pathways. We found that Lupeol treatment to mouse skin resulted in the inhibition of TPA-induced ( i) activation of PI3K, ( ii) phosphorylation of Akt at Thr(308), ( iii) activation of NF-kappaB and IKKalpha, and (iv) degradation and phosphorylation of IkappaBalpha. The animals pretreated with Lupeol showed significantly reduced tumor incidence, lower tumor body burden and a significant delay in the latency period for tumor appearance. At the termination of the experiment at 28 weeks, 100% of the animals in TPA-treated group exhibited seven to eight tumors/mouse, whereas only 53% of the mice receiving Lupeol prior to TPA treatment exhibited one to three tumors/mouse. These results for the first time provide evidence that Lupeol possesses antiskin tumor-promoting effects in CD-1 mouse and inhibits conventional as well as novel biomarkers of tumor promotion. We suggest that Lupeol is an attractive antitumor-promoting agent that must be evaluated in tumor models other than skin carcinogenesis.	Univ Wisconsin, Med Sci Ctr, Dept Dermatol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Mukhtar, H (corresponding author), Univ Wisconsin, Med Sci Ctr, Dept Dermatol, 1300 Univ Ave,B-25, Madison, WI 53706 USA.	hmukhtar@wisc.edu	Saleem, Mohammad/GVS-9221-2022; Adhami, Vaqar/AAY-2837-2020	Saleem, Mohammad/0000-0002-7422-7967; Adhami, Vaqar/0000-0002-2048-4570	NATIONAL CANCER INSTITUTE [R03CA099909, R01CA078809] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 78809, R03 CA 99909] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Afaq F, 2003, ONCOGENE, V22, P1035, DOI 10.1038/sj.onc.1206206; Ahmad N, 2000, CLIN CANCER RES, V6, P1524; Ahmad N, 2001, AM J PATHOL, V159, P885, DOI 10.1016/S0002-9440(10)61764-6; ANJANEYLU V, 1982, Indian Journal of Pharmaceutical Sciences, V44, P58; Auvinen M, 1997, JNCI-J NATL CANCER I, V89, P533, DOI 10.1093/jnci/89.8.533; Badria FA, 2003, Z NATURFORSCH C, V58, P505; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beveridge THJ, 2002, J AGR FOOD CHEM, V50, P744, DOI 10.1021/jf010701v; BHIMANI RS, 1993, CANCER RES, V53, P4528; Bickers D R, 2000, J Dermatol, V27, P691; Bours V, 2000, BIOCHEM PHARMACOL, V60, P1085, DOI 10.1016/S0006-2952(00)00391-9; Callejas NA, 1999, J CELL SCI, V112, P3147; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Chun Kyung-Soo, 2002, Journal of Environmental Pathology Toxicology and Oncology, V21, P131; Conney AH, 1997, P SOC EXP BIOL MED, V216, P234, DOI 10.3181/00379727-216-44173; DIGIOVANNI J, 1991, PROG EXP TUMOR RES, V33, P192; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Einspahr JG, 2003, RECENT RESULTS CANC, V163, P151; Epinat JC, 1999, ONCOGENE, V18, P6896, DOI 10.1038/sj.onc.1203218; Fernandez MA, 2001, J PHARM PHARMACOL, V53, P1533, DOI 10.1211/0022357011777909; FOURNET A, 1992, J ETHNOPHARMACOL, V37, P159, DOI 10.1016/0378-8741(92)90074-2; FURSTENBERGER G, 1985, ARACHIDONIC ACID MET, P49; Geetha T, 2001, J ETHNOPHARMACOL, V76, P77, DOI 10.1016/S0378-8741(01)00175-1; Geetha T, 1999, MOL CELL BIOCHEM, V201, P83, DOI 10.1023/A:1007056300503; Guevara AP, 1996, MUTAT RES-ENVIR MUTA, V361, P67, DOI 10.1016/S0165-1161(96)90240-X; Gupta S, 2002, CANCER METAST REV, V21, P363, DOI 10.1023/A:1021275330385; Gupta S, 2001, SKIN PHARMACOL APPL, V14, P373, DOI 10.1159/000056371; Gupta S, 1999, CANCER RES, V59, P2115; Hasmeda M, 1999, PLANTA MED, V65, P14, DOI 10.1055/s-1999-13954; Hata K, 2003, J BIOCHEM, V134, P441, DOI 10.1093/jb/mvg162; Hata K, 2002, J NAT PROD, V65, P645, DOI 10.1021/np0104673; HERSCHMAN HR, 1994, CANCER METAST REV, V13, P241, DOI 10.1007/BF00666095; Hodges LD, 2003, MOL CELL BIOCHEM, V252, P97, DOI 10.1023/A:1025569805468; ISRAEL A, 1995, TRENDS GENET, V11, P203, DOI 10.1016/S0168-9525(00)89045-9; Kakuda R, 2002, PHYTOCHEMISTRY, V59, P791, DOI 10.1016/S0031-9422(02)00021-3; Katiyar SK, 1999, CARCINOGENESIS, V20, P2117, DOI 10.1093/carcin/20.11.2117; Katiyar SK, 1996, CANCER RES, V56, P1023; Katiyar SK, 1997, CARCINOGENESIS, V18, P497, DOI 10.1093/carcin/18.3.497; Katiyar SK, 1997, CARCINOGENESIS, V18, P1911, DOI 10.1093/carcin/18.10.1911; Kim DJ, 2003, MUTAT RES-FUND MOL M, V523, P99, DOI 10.1016/S0027-5107(02)00325-1; Liang YC, 2002, NUTR CANCER, V42, P217, DOI 10.1207/S15327914NC422_11; Lin LC, 2001, J NAT PROD, V64, P674, DOI 10.1021/np000569d; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; Mills GB, 2003, SEMIN ONCOL, V30, P93, DOI 10.1053/j.seminoncol.2003.08.011; Miura K, 2001, PHYTOCHEMISTRY, V58, P1171, DOI 10.1016/S0031-9422(01)00341-7; Mohan RR, 1999, CLIN CANCER RES, V5, P143; Moriarity DM, 1998, PLANTA MED, V64, P370, DOI 10.1055/s-2006-957454; Nagaraj M, 2000, J APPL TOXICOL, V20, P413, DOI 10.1002/1099-1263(200009/10)20:5<413::AID-JAT706>3.0.CO;2-Y; NAKADATE T, 1985, JPN J PHARMACOL, V37, P253, DOI 10.1254/jjp.37.253; Nikiema JB, 2001, PHYTOTHER RES, V15, P131, DOI 10.1002/ptr.700; Osaki M, 2004, J CANCER RES CLIN, V130, P8, DOI 10.1007/s00432-003-0505-z; Pereira AD, 2003, Z NATURFORSCH C, V58, P201; Rajic A, 2000, PLANTA MED, V66, P206, DOI 10.1055/s-2000-8657; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Saeed MA, 2002, FITOTERAPIA, V73, P417, DOI 10.1016/S0367-326X(02)00127-2; Saleem M, 2001, PHARMACOL RES, V43, P127, DOI 10.1006/phrs.2000.0710; Saleem R, 2003, BIOL PHARM BULL, V26, P41, DOI 10.1248/bpb.26.41; Seo HJ, 2002, INT J CANCER, V100, P456, DOI 10.1002/ijc.10489; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; SOSA A, 1963, B SOC CHIM BIOL, V45, P117; Stambolic V, 1999, ONCOGENE, V18, P6094, DOI 10.1038/sj.onc.1203126; Sunitha S, 2001, FITOTERAPIA, V72, P516, DOI 10.1016/S0367-326X(01)00259-3; Surh YJ, 2003, NAT REV CANCER, V3, P768, DOI 10.1038/nrc1189; Thomas T, 2003, J CELL MOL MED, V7, P113, DOI 10.1111/j.1582-4934.2003.tb00210.x; Ulubelen A, 1997, J NAT PROD, V60, P1275, DOI 10.1021/np9700681; VERMA AK, 1979, CANCER RES, V39, P419; Vidya L, 2002, PHYTOTHER RES, V16, P514, DOI 10.1002/ptr.940; Wada S, 2001, J NAT PROD, V64, P1545, DOI 10.1021/np010176u; Ziegler HL, 2002, ANTIMICROB AGENTS CH, V46, P1441, DOI 10.1128/AAC.46.5.1441-1446.2002	72	201	212	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2004	23	30					5203	5214		10.1038/sj.onc.1207641	http://dx.doi.org/10.1038/sj.onc.1207641			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	834AE	15122342				2022-12-28	WOS:000222382500010
J	Felicetti, F; Bottero, L; Felli, N; Mattia, G; Labbaye, C; Alvino, E; Peschle, C; Colombo, MP; Care, A				Felicetti, F; Bottero, L; Felli, N; Mattia, G; Labbaye, C; Alvino, E; Peschle, C; Colombo, MP; Care, A			Role of PLZF in melanoma progression	ONCOGENE			English	Article						PLZF; homeobox gene; cDNA expression array; melanoma; tumor progression	ACUTE PROMYELOCYTIC LEUKEMIA; ZINC-FINGER GENE; GROWTH-FACTOR; TRANSCRIPTION FACTOR; INTEGRIN EXPRESSION; CELL-GROWTH; PROTEIN; HOXB7; ALPHA; ALPHA(V)BETA(3)	The promyelocytic leukemia zinc finger (PLZF) protein has been described as a transcriptional repressor of homeobox (HOX)-containing genes during embryogenesis. As we previously demonstrated a functional link between overexpression of HOXB7 and melanoma progression.. we investigated the lack of PLZF as the possible cause of HOXB7 constitutive activation in these neoplastic cells. Accordingly, we found PLZF expression in melanocytes, but not in melanoma cells, a pattern inversely related to that of HOXB7. PLZF retroviral gene transduction was then performed in a panel of melanoma cell lines, and tumorigenicity was compared with that of empty vector-transduced control cell lines. Evaluation of in vitro migration, invasion and adhesion indicated that PLZF gene transduction induced a less malignant phenotype, as confirmed through in vitro studies performed in athymic nude mice. This reduced tumorigenicity was not coupled with HOXB7 repression. In order to find more about the molecular targets of PLZF, the gene expression profiles of PLZF- and empty vector-transduced A375 melanoma cells were analysed by Atlas Cancer macro-array. Among several genes modulated by PLZF enforced expression, of particular interest were integrin alphavbeta3, osteonectin/SPARC and matrix metalloprotease-9 that were downmodulated, and the tyrosinase-related protein-1 that was upregulated in all the analysed samples. This profile confirms the reduced tumorigenic phenotype with reversion to a more differentiated, melanocyte like, pattern, thus suggesting a suppressor role for PLZF in solid tumors. Moreover, these results indicate that PLZF and HOXB7 are functionally independent and that their coupled deregulation may account for most of the alterations described in melanomas.	Ist Super Sanita, Dept Hematol Oncol & Mol Med, I-00161 Rome, Italy; CNR, Inst Neurobiol & Mol Med, I-00100 Rome, Italy; Ist Nazl Tumori, Dept Expt Oncol, Immunotherapy & Gene Therapy Unit, I-20133 Milan, Italy	Istituto Superiore di Sanita (ISS); Consiglio Nazionale delle Ricerche (CNR); Fondazione IRCCS Istituto Nazionale Tumori Milan	Care, A (corresponding author), Ist Super Sanita, Dept Hematol Oncol & Mol Med, Viale Regina Elena 299, I-00161 Rome, Italy.	a.care@iss.it	felli, nadia/G-2088-2012; CARE', Alessandra/H-5090-2016; Alvino, Ester/J-8148-2012; Mattia, Gianfranco/K-5194-2016; Colombo, Mario P./V-7166-2017; Felicetti, Federica/N-7077-2017; Labbaye, Catherine/J-9930-2016	felli, nadia/0000-0001-6763-3361; CARE', Alessandra/0000-0003-4106-3342; Alvino, Ester/0000-0001-9467-7634; Mattia, Gianfranco/0000-0001-7047-6360; Colombo, Mario P./0000-0003-0042-7955; Felicetti, Federica/0000-0003-4628-0696; Labbaye, Catherine/0000-0003-1255-4396				Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907; ALBINI A, 1987, CANCER RES, V47, P3239; Alvino E, 2002, J INVEST DERMATOL, V118, P79, DOI 10.1046/j.0022-202x.2001.01611.x; Barna M, 2002, DEV CELL, V3, P499, DOI 10.1016/S1534-5807(02)00289-7; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; BOUKERCHE H, 1995, BRIT J CANCER, V72, P108, DOI 10.1038/bjc.1995.285; Care A, 1998, ONCOGENE, V16, P3285, DOI 10.1038/sj.onc.1201875; Care A, 1996, MOL CELL BIOL, V16, P4842; Care A, 2001, CANCER RES, V61, P6532; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; COHEN T, 1990, NUCLEIC ACIDS RES, V18, P2807, DOI 10.1093/nar/18.9.2807; COOK M, 1995, P NATL ACAD SCI USA, V92, P2249, DOI 10.1073/pnas.92.6.2249; Dhordain P, 2000, ONCOGENE, V19, P6240, DOI 10.1038/sj.onc.1203976; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; Dubrulle J, 2002, CURR OPIN GENET DEV, V12, P519, DOI 10.1016/S0959-437X(02)00335-0; Fang D, 2002, NUCLEIC ACIDS RES, V30, P3096, DOI 10.1093/nar/gkf424; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hoatlin ME, 1999, BLOOD, V94, P3737, DOI 10.1182/blood.V94.11.3737.423k39_3737_3747; Hofmann UB, 2000, J INVEST DERMATOL, V115, P625, DOI 10.1046/j.1523-1747.2000.00114.x; Krug U, 2002, ONCOGENE, V21, P3475, DOI 10.1038/sj.onc.1205322; Labbaye C, 2002, ONCOGENE, V21, P6669, DOI 10.1038/sj.onc.1205884; Lacal PM, 2000, J INVEST DERMATOL, V115, P1000, DOI 10.1046/j.1523-1747.2000.00199.x; Ledda MF, 1997, NAT MED, V3, P171, DOI 10.1038/nm0297-171; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; McPherson LA, 1997, P NATL ACAD SCI USA, V94, P4342, DOI 10.1073/pnas.94.9.4342; Meccia E, 2003, BBA-GENE STRUCT EXPR, V1626, P1, DOI 10.1016/S0167-4781(03)00018-6; Niu J, 2002, INT J CANCER, V99, P529, DOI 10.1002/ijc.10397; Nomura N, 1994, DNA Res, V1, P27, DOI 10.1093/dnares/1.1.27; OHASHI K, 1994, ONCOGENE, V9, P699; Parrado A, 2000, Hematol J, V1, P15, DOI 10.1038/sj.thj.6200012; Pati D, 2002, MOL CELL BIOL, V22, P8267, DOI 10.1128/MCB.22.23.8267-8277.2002; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; Satyamoorthy K, 2002, CANCER BIOL THER, V1, P14, DOI 10.4161/cbt.1.1.32; Seftor REB, 1998, AM J PATHOL, V153, P1347, DOI 10.1016/S0002-9440(10)65719-7; Sturm RA, 2002, CANCER RES, V62, P226; Van Belle PA, 1999, HUM PATHOL, V30, P562, DOI 10.1016/S0046-8177(99)90202-2; vandenOord JJ, 1997, AM J PATHOL, V151, P665; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375	40	56	62	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2004	23	26					4567	4576		10.1038/sj.onc.1207597	http://dx.doi.org/10.1038/sj.onc.1207597			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZV	15077196				2022-12-28	WOS:000221799000006
J	Riesterer, O; Zingg, D; Hummerjohann, J; Bodis, S; Pruschy, M				Riesterer, O; Zingg, D; Hummerjohann, J; Bodis, S; Pruschy, M			Degradation of PKB/Akt protein by inhibition of the VEGF receptor/mTOR pathway in endothelial cells	ONCOGENE			English	Article						PKB/Akt; VEGF receptor; rapamycin; PTK787/ZK222584; protein degradation	AKT/PROTEIN KINASE-B; SIGNAL-TRANSDUCTION PATHWAY; TUMOR RADIATION RESPONSE; PROSTATE-CANCER CELLS; GROWTH-FACTOR; IONIZING-RADIATION; PANCREATIC-CANCER; COLON-CANCER; ANGIOGENESIS; EXPRESSION	An intact VEGF receptor/PI3K/PKB/Akt signaling cascade protects endothelial cells from apoptotic stress-stimuli and mediates the formation of new blood vessels in pathological conditions such as cancer. Therefore, downregulation of this signaling cascade is of clinical interest for antiangiogenic cancer therapy. In this report, we demonstrate that VEGF controls the protein stability of the serine-threonine kinase PKB/Akt via inhibition of PKB/Akt protein degradation. VEGF deprivation or blockage of the VEGF signal transduction cascade with the VEGF receptor tyrosine kinase inhibitor PTK787/ZK222584 resulted in a specific decrease of the PKB/Akt protein level and subsequent cellular restimulation with VEGF rescued its stability. Real-time quantitative RTPCR analysis demonstrated that VEGF does not regulate PKB/Akt gene expression. On the other hand, broad range inhibitors of caspases and the proteasome complex prevented VEGF-dependent downregulation of the PKB/Akt protein level indicating that PKB/Akt protein stability is regulated by VEGF-controlled proteolysis. Inhibition of the VEGF receptor and PKB/Akt-downstream PIK-related mTOR-kinase by rapamycin also neutralized the VEGF-protective effect in an PKB/Akt gene expression-independent way but results in proteolysis-dependent reduction of PKB/Akt protein stability. These results demonstrate a novel regulatory mechanism of the activated VEGF receptor/mTOR-signal transduction pathway to control the protein stability of PKB/Akt and survival threshold in endothelial cells.	Univ Zurich Hosp, Dept Radiat Oncol, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Med Oncol, CH-8091 Zurich, Switzerland	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital	Pruschy, M (corresponding author), Univ Zurich Hosp, Dept Radiat Oncol, CH-8091 Zurich, Switzerland.	martin.pruschy@usz.ch		Bodis, Stephan/0000-0003-1078-8711; Riesterer, Oliver/0000-0002-9508-0546; Pruschy, Martin/0000-0002-3124-9015				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1999, MOL CELL BIOL, V19, P5061; Bachelder RE, 1999, J CELL BIOL, V147, P1063, DOI 10.1083/jcb.147.5.1063; Bachelder RE, 2001, J BIOL CHEM, V276, P34702, DOI 10.1074/jbc.M102806200; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; BROWN LF, 1993, AM J PATHOL, V143, P1255; BROWN LF, 1993, CANCER RES, V53, P4727; Bruns CJ, 2000, CANCER, V89, P488, DOI 10.1002/1097-0142(20000801)89:3<488::AID-CNCR3>3.3.CO;2-O; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chan J, 2002, CANCER CELL, V1, P257, DOI 10.1016/S1535-6108(02)00042-9; Chaudhry IH, 2001, HISTOPATHOLOGY, V39, P409, DOI 10.1046/j.1365-2559.2001.01230.x; Decker T, 2003, BLOOD, V101, P278, DOI 10.1182/blood-2002-01-0189; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Eshleman JS, 2002, CANCER RES, V62, P7291; Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Geng L, 2001, CANCER RES, V61, P2413; Geoerger B, 2001, CANCER RES, V61, P1527; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Gorski DH, 1999, CANCER RES, V59, P3374; Griffin RJ, 2002, CANCER RES, V62, P1702; Grunwald V, 2002, CANCER RES, V62, P6141; Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128; Gupta VK, 2002, CANCER J, V8, P47, DOI 10.1097/00130404-200201000-00009; Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hess C, 2001, BRIT J CANCER, V85, P2010, DOI 10.1054/bjoc.2001.2166; Hidalgo M, 2000, ONCOGENE, V19, P6680, DOI 10.1038/sj.onc.1204091; Humar R, 2002, FASEB J, V16, DOI 10.1096/fj.01-0658com; Ikeda N, 1999, BRIT J CANCER, V79, P1553, DOI 10.1038/sj.bjc.6690248; Itakura J, 2000, INT J CANCER, V85, P27; Jain RK, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.37265; Joukov V, 1997, J CELL PHYSIOL, V173, P211, DOI 10.1002/(SICI)1097-4652(199711)173:2<211::AID-JCP23>3.0.CO;2-H; Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kozin SV, 2001, CANCER RES, V61, P39; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Law BK, 2002, MOL CELL BIOL, V22, P8184, DOI 10.1128/MCB.22.23.8184-8198.2002; Lee CG, 2000, CANCER RES, V60, P5565; Li JR, 2000, J BIOL CHEM, V275, P13026, DOI 10.1074/jbc.275.17.13026; Madhusudan S, 2002, CURR OPIN PHARMACOL, V2, P403, DOI 10.1016/S1471-4892(02)00184-4; Manley PW, 2002, EXPERT OPIN INV DRUG, V11, P1715, DOI 10.1517/13543784.11.12.1715; Martin D, 2002, J BIOL CHEM, V277, P42943, DOI 10.1074/jbc.M201070200; Matter A, 2001, DRUG DISCOV TODAY, V6, P1005, DOI 10.1016/S1359-6446(01)01939-0; Nelsen CJ, 2003, J BIOL CHEM, V278, P3656, DOI 10.1074/jbc.M209374200; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Scappaticci FA, 2002, J CLIN ONCOL, V20, P3906, DOI 10.1200/JCO.2002.01.033; Shaheen RM, 1999, CANCER RES, V59, P5412; Shi YJ, 2002, CANCER RES, V62, P5027; Solit DB, 2003, CANCER RES, V63, P2139; Sun L, 2000, DRUG DISCOV TODAY, V5, P344, DOI 10.1016/S1359-6446(00)01534-8; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; TAKAHASHI Y, 1995, CANCER RES, V55, P3964; Takahashi Y, 1996, CLIN CANCER RES, V2, P1679; Tenzer A, 2001, CANCER RES, V61, P8203; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Weidner Noel, 1996, P167; Wood JM, 2000, CANCER RES, V60, P2178; Xu J, 2002, J BIOL CHEM, V277, P35561, DOI 10.1074/jbc.M203805200; Yao Y, 2001, ACTA NEUROCHIR, V143, P159, DOI 10.1007/s007010170122; Yu Y, 1999, J CELL PHYSIOL, V178, P235, DOI 10.1002/(SICI)1097-4652(199902)178:2<235::AID-JCP13>3.3.CO;2-J; Zhong H, 2000, CANCER RES, V60, P1541	68	65	67	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 3	2004	23	26					4624	4635		10.1038/sj.onc.1207596	http://dx.doi.org/10.1038/sj.onc.1207596			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZV	15064712				2022-12-28	WOS:000221799000012
J	Iyer, NG; Ozdag, H; Caldas, C				Iyer, NG; Ozdag, H; Caldas, C			p300/CBP and cancer	ONCOGENE			English	Article						p300; CBP; mutations; translocations	RUBINSTEIN-TAYBI-SYNDROME; ACUTE MYELOID-LEUKEMIA; CREB-BINDING-PROTEIN; TUMOR-SUPPRESSOR GENE; TRANSCRIPTIONAL COACTIVATOR P300; ACUTE MONOCYTIC LEUKEMIA; CBP-INDUCED STIMULATION; HISTONE ACETYLTRANSFERASE; DNA-DAMAGE; CHROMOSOME-TRANSLOCATION	p300 and cyclic AMP response element-binding protein (CBP) are adenoviral E1A-binding proteins involved in multiple cellular processes, and function as transcriptional co-factors and histone acetyltransferases. Germline mutation of CBP results in Rubinstein - Taybi syndrome, which is characterized by an increased predisposition to childhood malignancies. Furthermore, soma tic mutations of p300 and CBP occur in a number of malignancies. Chromosome translocations target CBP and, less commonly, p300 in acute myeloid leukemia and treatment-related hematological disorders. p300 mutations in solid tumors result in truncated p300 protein products or amino-acid substitutions in critical protein domains, and these are often associated with inactivation of the second allele. A mouse model confirms that p300 and CBP function as suppressors of hematological tumor formation. The involvement of these proteins in critical tumorigenic pathways (including TGF-beta, p53 and Rb) provides a mechanistic route as to how their inactivation could result in cancer.	Univ Cambridge, Hutchison MRC Res Ctr, Dept Oncol, Canc Gen Program, Cambridge CB2 2XZ, England	University of Cambridge	Caldas, C (corresponding author), Univ Cambridge, Hutchison MRC Res Ctr, Dept Oncol, Canc Gen Program, Cambridge CB2 2XZ, England.	carloscaldas-cc234@cam.ac.uk	Caldas, Carlos/U-7250-2019; Caldas, Carlos/A-7543-2008; Özdag, Hilal/C-9929-2009	Caldas, Carlos/0000-0003-3547-1489; Özdag, Hilal/0000-0001-7940-2499				Ait-Si-Ali S, 2000, ONCOGENE, V19, P2430, DOI 10.1038/sj.onc.1203562; ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; Allione F, 1998, INT J CANCER, V75, P181, DOI 10.1002/(SICI)1097-0215(19980119)75:2<181::AID-IJC3>3.0.CO;2-Q; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bandyopadhyay D, 2002, CANCER RES, V62, P6231; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bannister AJ, 2000, CURR BIOL, V10, P467, DOI 10.1016/S0960-9822(00)00445-0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bannister AJ, 1995, ONCOGENE, V11, P2509; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Bryan EJ, 2002, INT J CANCER, V102, P137, DOI 10.1002/ijc.10682; Bryan EJ, 1996, CANCER RES, V56, P719; Cao D, 2003, CELL, V113, P533, DOI 10.1016/S0092-8674(03)00353-2; Chaffanet M, 2000, GENE CHROMOSOME CANC, V28, P138, DOI 10.1002/(SICI)1098-2264(200006)28:2<138::AID-GCC2>3.0.CO;2-2; Champagne N, 2001, ONCOGENE, V20, P404, DOI 10.1038/sj.onc.1204114; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Chan HM, 2001, J CELL SCI, V114, P2363; CHEN LC, 1992, J NATL CANCER I, V84, P506, DOI 10.1093/jnci/84.7.506; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; Dornan D, 2003, J BIOL CHEM, V278, P13431, DOI 10.1074/jbc.M211460200; Duriez C, 1997, GASTROEN CLIN BIOL, V21, P358; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eckner R, 1996, MOL CELL BIOL, V16, P3454; ENGLEFIELD P, 1994, BRIT J CANCER, V70, P905, DOI 10.1038/bjc.1994.418; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Ghosh AK, 2000, ONCOGENE, V19, P3546, DOI 10.1038/sj.onc.1203693; Giles RH, 1997, LEUKEMIA, V11, P2087, DOI 10.1038/sj.leu.2400882; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Giles RH, 1997, GENOMICS, V42, P96, DOI 10.1006/geno.1997.4699; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; Goodman RH, 2000, GENE DEV, V14, P1553; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Grossman SR, 2001, EUR J BIOCHEM, V268, P2773, DOI 10.1046/j.1432-1327.2001.02226.x; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; Ito Y, 2003, CURR OPIN GENET DEV, V13, P43, DOI 10.1016/S0959-437X(03)00007-8; Kawai H, 2001, J BIOL CHEM, V276, P45928, DOI 10.1074/jbc.M107770200; Kitabayashi I, 2001, EMBO J, V20, P7184, DOI 10.1093/emboj/20.24.7184; Kitabayashi I, 2001, LEUKEMIA, V15, P89, DOI 10.1038/sj.leu.2401983; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Kung AL, 2000, GENE DEV, V14, P272; LAI JL, 1985, CANCER GENET CYTOGEN, V17, P365, DOI 10.1016/0165-4608(85)90121-9; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Lipinski KS, 1999, VIROLOGY, V255, P94, DOI 10.1006/viro.1998.9583; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; MILLER RW, 1995, AM J MED GENET, V56, P112, DOI 10.1002/ajmg.1320560125; Miyakawa A, 1998, INT J ONCOL, V13, P705; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; Muraoka M, 1996, ONCOGENE, V12, P1565; Nishimori H, 2000, J NEURO-ONCOL, V46, P17, DOI 10.1023/A:1006404110073; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Ohshima T, 2001, BIOCHEM BIOPH RES CO, V281, P569, DOI 10.1006/bbrc.2001.4389; Oike Y, 1999, BLOOD, V93, P2771; Oike Y, 1999, HUM MOL GENET, V8, P387, DOI 10.1093/hmg/8.3.387; Ozdag H, 2002, BRIT J CANCER, V87, P1162, DOI 10.1038/sj.bjc.6600554; Panagopoulos I, 2001, HUM MOL GENET, V10, P395, DOI 10.1093/hmg/10.4.395; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; Petrij F, 2000, J MED GENET, V37, P168, DOI 10.1136/jmg.37.3.168; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Polesskaya A, 2001, J BIOL CHEM, V276, P44502, DOI 10.1074/jbc.M106501200; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Rebel VI, 2002, P NATL ACAD SCI USA, V99, P14789, DOI 10.1073/pnas.232568499; Rowley JD, 1997, BLOOD, V90, P535; RUBINSTEIN JH, 1990, AM J MED GENET, P3; RUTTLEDGE MH, 1994, GENE CHROMOSOME CANC, V10, P122, DOI 10.1002/gcc.2870100207; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Satake N, 1997, GENE CHROMOSOME CANC, V20, P60, DOI 10.1002/(SICI)1098-2264(199709)20:1<60::AID-GCC9>3.3.CO;2-O; SHIN E, 1993, JPN J CANCER RES, V84, P402, DOI 10.1111/j.1349-7006.1993.tb00150.x; Smits PHM, 1996, ONCOGENE, V12, P1529; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Suganuma T, 2002, P NATL ACAD SCI USA, V99, P13073, DOI 10.1073/pnas.192586699; TAKAHASHI K, 1993, HEPATOLOGY, V17, P794, DOI 10.1002/hep.1840170508; TAKEMURA R, 1992, J CELL SCI, V103, P953; Taki T, 1997, BLOOD, V89, P3945, DOI 10.1182/blood.V89.11.3945; Tillinghast GW, 2003, GENE CHROMOSOME CANC, V37, P121, DOI 10.1002/gcc.10195; Tomita A, 2000, ONCOGENE, V19, P444, DOI 10.1038/sj.onc.1203329; TWIST EC, 1994, HUM MOL GENET, V3, P147, DOI 10.1093/hmg/3.1.147; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yuan ZM, 1999, ONCOGENE, V18, P5714, DOI 10.1038/sj.onc.1202930; Yuan ZM, 1999, J BIOL CHEM, V274, P1883, DOI 10.1074/jbc.274.4.1883; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999	90	451	464	1	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2004	23	24					4225	4231		10.1038/sj.onc.1207118	http://dx.doi.org/10.1038/sj.onc.1207118			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823BZ	15156177				2022-12-28	WOS:000221586000006
J	Han, SY; Iliopoulos, D; Druck, T; Guler, G; Grubbs, CJ; Pereira, M; Zhang, ZQ; You, M; Lubet, RA; Fong, LYY; Huebner, K				Han, SY; Iliopoulos, D; Druck, T; Guler, G; Grubbs, CJ; Pereira, M; Zhang, ZQ; You, M; Lubet, RA; Fong, LYY; Huebner, K			CpG methylation in the Fhit regulatory region: relation to Fhit expression in murine tumors	ONCOGENE			English	Article						CpG island methylation; Fhit promoter; epigenetics; tumor suppressor; gene inactivation; homozygous deletion	DNA METHYLATION; GENE-EXPRESSION; BLADDER-CANCER; LUNG; PROFILE; BREAST; INACTIVATION; BREAKPOINT; CARCINOMA; 3P14.2	To determine if: (1) 5' CpG island methylation is related to Fhit inactivation; (2) there are tumor or carcinogen-specific methylation patterns, we examined 35 CpG sites in the promoter, exon and intron 1 of the mouse Fhit gene. In primary tumors of lung, urinary bladder and tongue, induced by different carcinogens, 15-35% of sites were methylated, with specific methylation patterns associated with each cancer type, suggesting cancer- or tissue-specific methylation patterns. The methylation patterns were associated with reduced Fhit expression, as determined by immunohistochemical analyses. Methylation of rat Fhit 5' CpGs in mammary adenocarcinomas, detected by methylation specific PCR amplification, also correlated with reduced gene expression. Thus, there was an overall association between promoter/exon 1 methylation and decreased Fhit expression. In contrast, in cancer- derived cell lines 70-95% of the CpG sites were methylated. This is the first detailed study of the relationship between Fhit 5' CpG island methylation and Fhit expression in murine tumors, our main models for preclinical cancer studies, and provides evidence that loss of Fhit expression and methylation are correlated in these mouse models and these models will be useful to examine the complex relationships among gene expression, methylation patterns and organ specific city.	Thomas Jefferson Univ, Kimmel Canc Ctr, BLSB 1008, Philadelphia, PA 19107 USA; Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA; Med Coll Ohio, Dept Pathol, Toledo, OH 43699 USA; Washington Univ, Dept Surg, St Louis, MO USA; NCI, Div Canc Prevent & Control, DCPC, Rockville, MD 20852 USA; Hacettepe Univ, Dept Pathol, TR-06100 Ankara, Turkey	Jefferson University; University of Alabama System; University of Alabama Birmingham; Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Hacettepe University	Huebner, K (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, BLSB 1008, 233 S 10th St, Philadelphia, PA 19107 USA.	K_Huebner@mail.jci.tju.edu	GULER, GULNUR/I-9887-2013; Iliopoulos, Dimitrios/AAE-9106-2019	Fong, Louise/0000-0001-7654-7035	NCI NIH HHS [N01-CN-15128, N01-CN-25007, N01-CN-15113, CA77738, CA56036] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA056036, P01CA077738] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Baffa R, 2000, AM J PATHOL, V156, P419, DOI 10.1016/S0002-9440(10)64745-1; BAYLIN SB, 1986, CANCER RES, V46, P2917; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Clark SJ, 2002, ONCOGENE, V21, P5380, DOI 10.1038/sj.onc.1205598; Druck T, 1997, CANCER RES, V57, P504; Druck T, 1998, ONCOL RES, V10, P341; Dumon KR, 2001, P NATL ACAD SCI USA, V98, P3346, DOI 10.1073/pnas.061020098; Esteller M, 2001, CANCER RES, V61, P3225; Fong LYY, 2000, P NATL ACAD SCI USA, V97, P4742, DOI 10.1073/pnas.080063497; Glover TW, 1998, CANCER RES, V58, P3409; Gonzalgo ML, 1998, CANCER RES, V58, P1245; Grubbs CJ, 2000, CANCER RES, V60, P5599; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Huebner K, 2001, NAT REV CANCER, V1, P214, DOI 10.1038/35106058; Ingvarsson S, 1999, CANCER RES, V59, P2682; Kolomietz E, 2003, LEUKEMIA, V17, P1313, DOI 10.1038/sj.leu.2402969; LUBET RA, 2003, UNPUB CARCINOGENESIS; Maruyama R, 2001, CANCER RES, V61, P8659; Nigro JM, 2001, AM J PATHOL, V158, P1253, DOI 10.1016/S0002-9440(10)64076-X; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Paz MF, 2003, CANCER RES, V63, P1114; Pekarsky Y, 1998, CANCER RES, V58, P3401; Skopelitou AS, 2001, IN VIVO, V15, P169; Soejima K, 2003, ONCOGENE, V22, P4723, DOI 10.1038/sj.onc.1206510; Sozzi G, 1998, CANCER RES, V58, P5032; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Sutherland JE, 2001, MUTAT RES-FUND MOL M, V479, P225, DOI 10.1016/S0027-5107(01)00163-4; Tanaka H, 1998, CANCER RES, V58, P3429; WARY KK, 1993, CANCER RES, V53, P1498; Zanesi N, 2001, P NATL ACAD SCI USA, V98, P10250, DOI 10.1073/pnas.191345898; Zochbauer-Muller S, 2001, CANCER RES, V61, P3581	33	22	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					3990	3998		10.1038/sj.onc.1207526	http://dx.doi.org/10.1038/sj.onc.1207526			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15007387				2022-12-28	WOS:000221382000011
J	Schreiber, K; Cannon, RE; Karrison, T; Beck-Engeser, G; Huo, DZ; Tennant, RW; Jensen, H; Kast, WM; Krausz, T; Meredith, SC; Chen, LP; Schreiber, H				Schreiber, K; Cannon, RE; Karrison, T; Beck-Engeser, G; Huo, DZ; Tennant, RW; Jensen, H; Kast, WM; Krausz, T; Meredith, SC; Chen, LP; Schreiber, H			Strong synergy between mutant ras and HPV16 E6/E7 in the development of primary tumors	ONCOGENE			English	Article						HPV 16; human papilloma virus 16; E6/E7; vHa ras; transgenic mice; synergy; primary tumors	HUMAN-PAPILLOMAVIRUS TYPE-16; T-LYMPHOCYTE EPITOPE; TRANSGENIC MICE; HA-RAS; CERVICAL-CANCER; K-RAS; HIGH PREVALENCE; UTERINE CERVIX; HIGH-RISK; INTRAEPITHELIAL NEOPLASIA	E6/E7 oncogenes of high-risk human papilloma virus (HPV) subtypes are essential for the development of certain types of cancers. However, these oncogenes are insufficient to transform normal cells into an immortalized or malignant state. Mutant Ha-ras cooperates with E6/E7 of HPV subtype 16 in transformation of cells in vitro and may contribute to some HPV-associated cancers in humans. This study investigates whether HPV16 E6/E7 and v-Ha-ras synergize in vivo. FVB/n mice transgenic for v-Ha-ras gene (R+) were crossed with transgenic C57BL/6 mice that harbor E6/E7 of HPV16 (E+). Beginning at about 3 months of age, the bitransgenic E+R+(C57BL/6 x FVB/n) F1 mice developed mouth, eye and ear tumors. By 6 months, the prevalence of these types of mouth, eye and ear tumors was 100, 71 and 79% respectively in the E+R+ mice. Most tumors grew progressively until the mice had to be killed. The median times for the appearance of the first mouth, eye and ear tumor were 3.6, 4.3 and 4.2 months, respectively. For the two singly transgenic groups of mice, the prevalence of mouth, eye and ear tumors was 0, 0 and 6% (E-R+) and 0, 0 and 0% (E+R-), respectively, and the median time to first tumor was greater than 12 months for singly transgenic mice (E-R+, E+R-). Thus, a remarkable synergy occurred between the v-Ha-ras and HPV16 E6/E7 oncogenes in the development of primary tumors in mice.	Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; NIEHS, Lab Environm Carcinogenesis & Mutagenesis, Res Triangle Pk, NC 27709 USA; Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA; Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA 90089 USA; Mayo Clin, Dept Immunol, Rochester, MN 55905 USA	University of Chicago; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Chicago; University of Southern California; Mayo Clinic	Schreiber, H (corresponding author), Univ Chicago, Dept Pathol, 5841 S Maryland Ave,MC 3008, Chicago, IL 60637 USA.	hszz@midway.uchicago.edu		Jensen, Heather/0000-0002-1712-9682; Kast, W Martin/0000-0003-2321-3159	NATIONAL CANCER INSTITUTE [R01CA022677, P01CA097296] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES021175, Z01ES100610] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA22677, P01-CA97296, R01-CA37516] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alonio LV, 2003, J CLIN VIROL, V27, P263, DOI 10.1016/S1386-6532(02)00181-6; Alonio LV, 2000, MEDICINA-BUENOS AIRE, V60, P895; ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; BAILLEUL B, 1990, CELL, V62, P697, DOI 10.1016/0092-8674(90)90115-U; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; BERGMANN K, 1994, INT J CANCER, V59, P463, DOI 10.1002/ijc.2910590405; BRESLOW N, 1970, BIOMETRIKA, V57, P579, DOI 10.2307/2334776; Campo MS, 1998, TRENDS MICROBIOL, V6, P424, DOI 10.1016/S0966-842X(98)01385-7; Coussens LM, 1996, AM J PATHOL, V149, P1899; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; CRIPE TP, 1987, EMBO J, V6, P3745, DOI 10.1002/j.1460-2075.1987.tb02709.x; CROOK T, 1988, P NATL ACAD SCI USA, V85, P8820, DOI 10.1073/pnas.85.23.8820; Daniel D, 2003, J EXP MED, V197, P1017, DOI 10.1084/jem.20021047; Dokianakis DN, 1999, ONCOL REP, V6, P1327; DRINKWATER NR, 1991, PROG EXP TUMOR RES, V33, P1; Eiben GL, 2002, CANCER RES, V62, P5792; FELTKAMP MCW, 1995, EUR J IMMUNOL, V25, P2638, DOI 10.1002/eji.1830250935; FELTKAMP MCW, 1993, EUR J IMMUNOL, V23, P2242, DOI 10.1002/eji.1830230929; Gillison, 2000, Br J Surg, V87, P362, DOI 10.1046/j.1365-2168.2000.01383-3.x; Girardi M, 2001, SCIENCE, V294, P605, DOI 10.1126/science.1063916; GLOSS B, 1987, EMBO J, V6, P3735, DOI 10.1002/j.1460-2075.1987.tb02708.x; Golijow CD, 1999, GYNECOL ONCOL, V75, P108, DOI 10.1006/gyno.1999.5528; GREENHALGH DA, 1994, CELL GROWTH DIFFER, V5, P667; HANSEN LA, 1994, MOL CARCINOGEN, V9, P143, DOI 10.1002/mc.2940090306; *IARC, 1995, IARC MON EV CARC RIS, V64, P245; *IARC, 1995, IARC MON EV CARC RIS, V64, P65; Janicek MF, 2001, CA-CANCER J CLIN, V51, P92, DOI 10.3322/canjclin.51.2.92; Jin YT, 1997, AM J PATHOL, V150, P1327; Kantz DC, 1999, BIOTECHNIQUES, V27, P278, DOI 10.2144/99272bm13; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Klug SJ, 2001, CANCER EPIDEM BIOMAR, V10, P1009; Klussmann JP, 2001, CANCER-AM CANCER SOC, V92, P2875, DOI 10.1002/1097-0142(20011201)92:11&lt;2875::AID-CNCR10130&gt;3.0.CO;2-7; LAMBERT PF, 1993, P NATL ACAD SCI USA, V90, P5583, DOI 10.1073/pnas.90.12.5583; LEDER A, 1990, P NATL ACAD SCI USA, V87, P9178, DOI 10.1073/pnas.87.23.9178; Lee JH, 1996, GYNECOL ONCOL, V62, P49, DOI 10.1006/gyno.1996.0188; Lin XH, 1996, J CELL BIOCHEM, V63, P463, DOI 10.1002/(SICI)1097-4644(19961215)63:4<463::AID-JCB8>3.0.CO;2-R; Mazurek S, 2001, ONCOGENE, V20, P6891, DOI 10.1038/sj.onc.1204792; Melero I, 1997, J VIROL, V71, P3998, DOI 10.1128/JVI.71.5.3998-4004.1997; Mouron SA, 2000, MUTAT RES-GEN TOX EN, V469, P127, DOI 10.1016/S1383-5718(00)00066-8; Pedroza-Saavedra A, 2000, ARCH VIROL, V145, P603, DOI 10.1007/s007050050050; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; Prokopakis P, 2002, ONCOL REP, V9, P129; RESSING ME, 1995, J IMMUNOL, V154, P5934; Riley RR, 2003, CANCER RES, V63, P4862; Ringstrom E, 2002, CLIN CANCER RES, V8, P3187; RIOU G, 1988, ONCOGENE, V3, P329; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Schlecht NF, 2003, JNCI-J NATL CANCER I, V95, P1336, DOI 10.1093/jnci/djg037; Scott IU, 2002, OPHTHALMOLOGY, V109, P542, DOI 10.1016/S0161-6420(01)00991-5; Siegel CT, 2000, J EXP MED, V191, P1945, DOI 10.1084/jem.191.11.1945; Song SY, 1999, J VIROL, V73, P5887, DOI 10.1128/JVI.73.7.5887-5893.1999; Stenzel A, 2001, PATHOL RES PRACT, V197, P597, DOI 10.1016/S0344-0338(04)70133-8; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; Thompson KL, 1998, TOXICOL PATHOL, V26, P548, DOI 10.1177/019262339802600411; Tsai ST, 1997, INT J CANCER, V71, P208; WILLIS G, 1993, GYNECOL ONCOL, V49, P359, DOI 10.1006/gyno.1993.1140; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690	58	24	26	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					3972	3979		10.1038/sj.onc.1207507	http://dx.doi.org/10.1038/sj.onc.1207507			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15077191				2022-12-28	WOS:000221382000009
J	Nicotera, P; Merlino, G				Nicotera, P; Merlino, G			Regulation of the apoptosis-necrosis switch	ONCOGENE			English	Review						apoptosis; necrosis; ATP; NO; nitric oxide; neurons	NEURONAL CELL-DEATH; METHYL-D-ASPARTATE; NITRIC-OXIDE NO; MITOCHONDRIAL RESPIRATORY-CHAIN; NF-KAPPA-B; S-NITROSYLATION; NEUROBLASTOMA-CELLS; INHIBITS APOPTOSIS; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; LIPID-PEROXIDATION	Execution of the apoptotic program involves a relatively limited number of pathways. According to a general view, these would converge to activate the caspase family of proteases. However, there is increasing evidence that apoptotic-like features can also be found when caspases are inhibited. Moreover, under pathological conditions, apoptosis and nonapoptotic death paradigms are often interwined, which suggest that, in vivo, cells may use diverging execution pathways. Molecular switches between apoptosis and necrosis include adenosine triphosphate-dependent steps in the activation of caspases or steps sensitive to reactive oxygen/nitrogen species. In turn, caspase activation can cause necrosis by promoting ion overload.	Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England; Fdn S Lucia, I-00179 Rome, Italy; Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, Rome, Italy	University of Leicester; IRCCS Santa Lucia; University of Rome Tor Vergata	Nicotera, P (corresponding author), Univ Leicester, MRC, Toxicol Unit, Hodgkin Bldg,Lancaster Rd, Leicester LE1 9HN, Leics, England.	pn10@le.ac.uk			Telethon [E.1224] Funding Source: Medline	Telethon(Fondazione Telethon)		Adjei PN, 1996, J CLIN INVEST, V98, P2588, DOI 10.1172/JCI119078; ANKARCRONA M, 1994, EXP CELL RES, V213, P172, DOI 10.1006/excr.1994.1187; BAGETTA G, 1993, BIOCHEM BIOPH RES CO, V197, P1132, DOI 10.1006/bbrc.1993.2595; Becker K, 1998, NAT STRUCT BIOL, V5, P267, DOI 10.1038/nsb0498-267; Bernassola F, 2001, J CELL BIOCHEM, V82, P123, DOI 10.1002/jcb.1143; Bernassola F, 1999, ANN NY ACAD SCI, V887, P83, DOI 10.1111/j.1749-6632.1999.tb07924.x; BLANCO FJ, 1995, AM J PATHOL, V146, P75; BOLANOS JP, 1995, J NEUROCHEM, V64, P1965; Bonfoco E, 1996, J NEUROCHEM, V67, P2484; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Borner C, 1999, CELL DEATH DIFFER, V6, P497, DOI 10.1038/sj.cdd.4400525; Bossy-Wetzel E, 2003, CELL DEATH DIFFER, V10, P757, DOI 10.1038/sj.cdd.4401244; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Brune B, 1997, J BIOL CHEM, V272, P7253, DOI 10.1074/jbc.272.11.7253; Brune B, 1999, CELL DEATH DIFFER, V6, P969, DOI 10.1038/sj.cdd.4400582; Catani MV, 1998, BIOCHEM BIOPH RES CO, V249, P275, DOI 10.1006/bbrc.1998.9130; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2; Clementi E, 1996, LIFE SCI, V59, P389, DOI 10.1016/0024-3205(96)00317-7; CORASANITI MT, 1994, NEUROPHARMACOLOGY, V33, P1071, DOI 10.1016/0028-3908(94)90145-7; CORASANITI MT, 1992, NEUROSCI LETT, V147, P221, DOI 10.1016/0304-3940(92)90600-C; CORASANITI MT, 1995, NEURODEGENERATION, V4, P315, DOI 10.1016/1055-8330(95)90021-7; Dimmeler S, 1999, CELL DEATH DIFFER, V6, P964, DOI 10.1038/sj.cdd.4400581; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Ellerby HM, 1997, J NEUROSCI, V17, P6165; Enikolopov G, 1999, CELL DEATH DIFFER, V6, P956, DOI 10.1038/sj.cdd.4400577; Eu JP, 2003, P NATL ACAD SCI USA, V100, P15229, DOI 10.1073/pnas.2433468100; FEHSEL K, 1995, J IMMUNOL, V155, P2858; Foster MW, 2003, TRENDS MOL MED, V9, P160, DOI 10.1016/S1471-4914(03)00028-5; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Gow AJ, 1998, NATURE, V391, P169, DOI 10.1038/34402; Grimm LM, 1996, EMBO J, V15, P3835, DOI 10.1002/j.1460-2075.1996.tb00757.x; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; Hess DT, 2001, NAT CELL BIOL, V3, pE46, DOI 10.1038/35055152; Hirsch T, 1997, ONCOGENE, V15, P1573, DOI 10.1038/sj.onc.1201324; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; KANETO H, 1995, DIABETES, V44, P733, DOI 10.2337/diabetes.44.7.733; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kim WK, 1999, NEURON, V24, P461, DOI 10.1016/S0896-6273(00)80859-4; Kim YM, 1998, J BIOL CHEM, V273, P31437, DOI 10.1074/jbc.273.47.31437; Kim YM, 1997, J BIOL CHEM, V272, P1402, DOI 10.1074/jbc.272.2.1402; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; KIM YM, 1995, J BIOL CHEM, V270, P5710, DOI 10.1074/jbc.270.11.5710; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; LEIST M, 1995, J IMMUNOL, V154, P1307; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Leist M, 1998, EXP CELL RES, V239, P183, DOI 10.1006/excr.1997.4026; Leist M, 1999, EXP CELL RES, V249, P396, DOI 10.1006/excr.1999.4514; Li JR, 1999, CELL DEATH DIFFER, V6, P952, DOI 10.1038/sj.cdd.4400579; Li JR, 1997, BIOCHEM BIOPH RES CO, V240, P419, DOI 10.1006/bbrc.1997.7672; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; Lipton SA, 1999, CELL DEATH DIFFER, V6, P943, DOI 10.1038/sj.cdd.4400580; Liu LM, 1999, CELL DEATH DIFFER, V6, P937, DOI 10.1038/sj.cdd.4400578; LOCKSHIN RICHARD A., 1965, J INSECT PHYSIOL, V11, P123, DOI 10.1016/0022-1910(65)90099-5; Lovat PE, 2003, J CELL BIOCHEM, V89, P698, DOI 10.1002/jcb.10551; Maccarrone M, 2000, J BIOL CHEM, V275, P31938, DOI 10.1074/jbc.M005722200; Maccarrone M, 1998, FEBS LETT, V434, P421, DOI 10.1016/S0014-5793(98)01026-6; Manabe S, 2003, INVEST OPHTH VIS SCI, V44, P385, DOI 10.1167/iovs.02-0187; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; Mannick JB, 1997, J BIOL CHEM, V272, P24125, DOI 10.1074/jbc.272.39.24125; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; Marshall HE, 2001, BIOCHEMISTRY-US, V40, P1688, DOI 10.1021/bi002239y; Matsumoto A, 2003, SCIENCE, V301, P657, DOI 10.1126/science.1079319; Matthews JR, 1996, NUCLEIC ACIDS RES, V24, P2236, DOI 10.1093/nar/24.12.2236; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Melino G, 2000, CELL MOL LIFE SCI, V57, P612, DOI 10.1007/PL00000723; Melino G, 2000, CANCER RES, V60, P2377; Melino G, 1997, NATURE, V388, P432, DOI 10.1038/41237; Messmer UK, 1996, EUR J PHARMACOL, V302, P171, DOI 10.1016/0014-2999(96)00055-6; Mohr S, 1996, J BIOL CHEM, V271, P4209; MONCADA S, 1991, PHARMACOL REV, V43, P109; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Nicotera P, 1999, TRENDS PHARMACOL SCI, V20, P46, DOI 10.1016/S0165-6147(99)01304-8; Nicotera P, 1997, Adv Neurol, V72, P95; Nicotera P, 1999, CELL DEATH DIFFER, V6, P931, DOI 10.1038/sj.cdd.4400583; Petersen A, 2001, HUM MOL GENET, V10, P1243, DOI 10.1093/hmg/10.12.1243; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; Rossi A, 2000, J INVEST DERMATOL, V115, P731, DOI 10.1046/j.1523-1747.2000.00116.x; ROY B, 1995, BIOCHEMISTRY-US, V34, P5411, DOI 10.1021/bi00016a012; RUBBO H, 1994, J BIOL CHEM, V269, P26066; SALGO MG, 1995, ARCH BIOCHEM BIOPHYS, V322, P500, DOI 10.1006/abbi.1995.1493; Sarin A, 1997, IMMUNITY, V6, P209, DOI 10.1016/S1074-7613(00)80427-6; Schneiderhan N, 2003, ONCOGENE, V22, P2857, DOI 10.1038/sj.onc.1206431; Schwab BL, 2002, CELL DEATH DIFFER, V9, P818, DOI 10.1038/sj.cdd.4401042; SCHWARTZ LM, 1993, P NATL ACAD SCI USA, V90, P980, DOI 10.1073/pnas.90.3.980; SCHWARTZ LM, 1993, IMMUNOL TODAY, V14, P582, DOI 10.1016/0167-5699(93)90197-S; SCHWARZ MA, 1995, P NATL ACAD SCI USA, V92, P4452, DOI 10.1073/pnas.92.10.4452; SCHWEICHEL JU, 1973, TERATOLOGY, V7, P253, DOI 10.1002/tera.1420070306; Sciorati C, 1997, J BIOL CHEM, V272, P23211, DOI 10.1074/jbc.272.37.23211; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; So HS, 1998, BIOCHEM BIOPH RES CO, V247, P809, DOI 10.1006/bbrc.1998.8788; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; Stamler JS, 1998, NAT STRUCT BIOL, V5, P247, DOI 10.1038/nsb0498-247; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Stamler JS, 2001, PHYSIOL REV, V81, P209, DOI 10.1152/physrev.2001.81.1.209; Stamler JS, 1997, NEURON, V18, P691, DOI 10.1016/S0896-6273(00)80310-4; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; Stamler JS, 1996, J CLIN INVEST, V97, P2165, DOI 10.1172/JCI118656; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Suschek CV, 1999, J BIOL CHEM, V274, P6130, DOI 10.1074/jbc.274.10.6130; Suzuki H, 2003, NEURON, V39, P1005, DOI 10.1016/j.neuron.2003.08.015; Syntichaki P, 2002, NATURE, V419, P939, DOI 10.1038/nature01108; TABUCHI A, 1994, FEBS LETT, V351, P123, DOI 10.1016/0014-5793(94)00839-6; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Vieira HLA, 2001, ONCOGENE, V20, P4305, DOI 10.1038/sj.onc.1204575; Volbracht C, 2001, MOL MED, V7, P36, DOI 10.1007/BF03401837; Volbracht C, 1999, MOL MED, V5, P477; Wang X, 2003, CELL DEATH DIFFER, V10, P468, DOI 10.1038/sj.cdd.4401181; Wang XJ, 2002, J BIOL CHEM, V277, P15697, DOI 10.1074/jbc.M112068200; WELSH N, 1991, ENDOCRINOLOGY, V129, P3167, DOI 10.1210/endo-129-6-3167; WINK DA, 1993, P NATL ACAD SCI USA, V90, P9813, DOI 10.1073/pnas.90.21.9813; Xu Keli, 2001, ScientificWorldJournal, V1, P129, DOI 10.1100/tsw.2001.224; Yasuda Masahiro, 1998, Journal of Toxicological Sciences, V23, P389; Yuan J, 2003, NEURON, V40, P401, DOI 10.1016/S0896-6273(03)00601-9; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500	122	179	191	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2004	23	16					2757	2765		10.1038/sj.onc.1207559	http://dx.doi.org/10.1038/sj.onc.1207559			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	811VO	15077139	Green Submitted			2022-12-28	WOS:000220799600003
J	Pommier, Y; Sordet, O; Antony, S; Hayward, RL; Kohn, KW				Pommier, Y; Sordet, O; Antony, S; Hayward, RL; Kohn, KW			Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks	ONCOGENE			English	Review						cancer chemotherapy; apoptosis; multidrug resistance; camptothecins	NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; ETOPOSIDE-INDUCED APOPTOSIS; SURVIVAL-SIGNALING PATHWAY; PROMOTES CELL-SURVIVAL; BCL-2 FAMILY-MEMBERS; PROTEASOME INHIBITOR PS-341; COLORECTAL-CANCER CELLS; CYTOCHROME-C RELEASE; PROTEIN-KINASE B/AKT	Intrinsic (innate) and acquired (adaptive) resistance to chemotherapy critically limits the outcome of cancer treatments. For many years, it was assumed that the interaction of a drug with its molecular target would yield a lethal lesion, and that determinants of intrinsic drug resistance should therefore be sought either at the target level (quantitative changes or/and mutations) or upstream of this interaction, in drug metabolism or drug transport mechanisms. It is now apparent that independent of the factors above, cellular responses to a molecular lesion can determine the outcome of therapy. This review will focus on programmed cell death (apoptosis) and on survival pathways (Bcl-2, Apaf-1, AKT, NF-kappaB) involved in multidrug resistance. We will present our molecular interaction mapping conventions to summarize the AKT and IkappaB/NF-kappaB networks. They complement the p53, Chk2 and c-Abl maps published recently. We will also introduce the 'permissive apoptosis-resistance' model for the selection of multidrug-resistant cells.	NCI, Mol Pharmacol Lab, Ctr Canc Res, NIH,DHHS, Bethesda, MD 20892 USA; Western Gen Hosp, Canc Res United Kingdom, Edinburgh EH4 2XU, Midlothian, Scotland	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Edinburgh	Pommier, Y (corresponding author), Inst Pasteur, Lab Genom Stabil, Pavillon Fernbach,Room 26,25 Rue Dr Roux, F-75724 Paris, France.	pommiery@pasteur.fr	Sordet, Olivier/M-3271-2014	Sordet, Olivier/0000-0001-6027-4925	NATIONAL CANCER INSTITUTE [Z01BC006150, Z01BC006192, ZIABC006150, ZIABC006192] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andjelkovic M, 1999, MOL CELL BIOL, V19, P5061; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Arch RH, 2000, BIOCHEM BIOPH RES CO, V272, P936, DOI 10.1006/bbrc.2000.2873; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; Arlt A, 2003, ONCOGENE, V22, P3243, DOI 10.1038/sj.onc.1206390; Arsura M, 2000, MOL CELL BIOL, V20, P5381, DOI 10.1128/MCB.20.15.5381-5391.2000; Bakker TR, 1999, INT J CANCER, V80, P320; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Bartke T, 2001, ONCOGENE, V20, P571, DOI 10.1038/sj.onc.1204124; Bayon Y, 2003, MOL CELL BIOL, V23, P1061, DOI 10.1128/MCB.23.3.1061-1074.2003; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BESSHO R, 1994, BIOCHEM PHARMACOL, V48, P1883, DOI 10.1016/0006-2952(94)90586-X; Bettaieb Ali, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P307, DOI 10.2174/1568011033482396; Bharti AC, 2002, BIOCHEM PHARMACOL, V64, P883, DOI 10.1016/S0006-2952(02)01154-1; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Bouillet P, 2002, J CELL SCI, V115, P1567; Brangi M, 1999, CANCER RES, V59, P5938; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Burks DJ, 1998, J BIOL CHEM, V273, P31061, DOI 10.1074/jbc.273.47.31061; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cataldi A, 2003, J CELL BIOCHEM, V89, P956, DOI 10.1002/jcb.10560; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chan TA, 2000, GENE DEV, V14, P1584; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chipuk JE, 2001, J BIOL CHEM, V276, P26614, DOI 10.1074/jbc.M100913200; Cho S, 1998, BIOCHEM BIOPH RES CO, V253, P104, DOI 10.1006/bbrc.1998.9697; Cox MM, 2001, P NATL ACAD SCI USA, V98, P8173, DOI 10.1073/pnas.131004998; Cusack JC, 2001, CANCER RES, V61, P3535; Cusack JC, 2003, CANCER TREAT REV, V29, P21, DOI 10.1016/S0305-7372(03)00079-3; Cusack JC, 2000, CANCER RES, V60, P2323; D'Acquisto F, 2000, GENE THER, V7, P1731, DOI 10.1038/sj.gt.3301295; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; Derenne S, 2002, BLOOD, V100, P194, DOI 10.1182/blood.V100.1.194; Desai AA, 2003, ONCOGENE, V22, P6621, DOI 10.1038/sj.onc.1206958; Deveraux QL, 1999, J CLIN IMMUNOL, V19, P388, DOI 10.1023/A:1020502800208; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; EINHOLD WC, 2003, CANCER RES, V63, P1000; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Epinat JC, 1999, ONCOGENE, V18, P6896, DOI 10.1038/sj.onc.1203218; Flynn V, 2003, INT J ONCOL, V23, P317; FRANTZ B, 1995, SCIENCE, V270, P2017, DOI 10.1126/science.270.5244.2017; Fu WN, 2003, ONCOGENE, V22, P451, DOI 10.1038/sj.onc.1206147; Fujita N, 2003, CANCER CHEMOTH PHARM, V52, pS24, DOI 10.1007/s00280-003-0591-2; Fujita N, 2002, J BIOL CHEM, V277, P10346, DOI 10.1074/jbc.M106736200; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gupta M, 1997, CLIN CANCER RES, V3, P1653; Habib AA, 2001, J BIOL CHEM, V276, P8865, DOI 10.1074/jbc.M008458200; Hacker H, 2002, CANCER CELL, V2, P431, DOI 10.1016/S1535-6108(02)00213-1; Han ZY, 2002, J BIOL CHEM, V277, P17154, DOI 10.1074/jbc.M112401200; Hayward RL, 2003, CLIN CANCER RES, V9, P2856; Hermeking H, 2003, NAT REV CANCER, V3, P931, DOI 10.1038/nrc1230; Hill MM, 2002, PHARMACOL THERAPEUT, V93, P243, DOI 10.1016/S0163-7258(02)00193-6; Hong SY, 2000, J BIOL CHEM, V275, P18022, DOI 10.1074/jbc.M001202200; Hopkins-Donaldson S, 2003, INT J CANCER, V106, P160, DOI 10.1002/ijc.11209; Hu YM, 1999, EMBO J, V18, P3586, DOI 10.1093/emboj/18.13.3586; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Huang H, 2001, J BIOL CHEM, V276, P38830, DOI 10.1074/jbc.M103632200; Huang S, 2000, CLIN CANCER RES, V6, P2573; Jia WT, 2003, BLOOD, V102, P1824, DOI 10.1182/blood-2002-12-3785; Jiang ZH, 2003, J NEUROCHEM, V84, P273, DOI 10.1046/j.1471-4159.2003.01522.x; Jobin C, 1998, GUT, V42, P779, DOI 10.1136/gut.42.6.779; Jones DR, 2000, ANN THORAC SURG, V70, P930, DOI 10.1016/S0003-4975(00)01635-0; Kamal A, 2003, NATURE, V425, P407, DOI 10.1038/nature01913; KAMESAKI S, 1993, CANCER RES, V53, P4251; Kapahi P, 2000, J BIOL CHEM, V275, P36062, DOI 10.1074/jbc.M007204200; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Karpinich NO, 2002, J BIOL CHEM, V277, P16547, DOI 10.1074/jbc.M110629200; Kasibhatla S, 1999, J BIOL CHEM, V274, P987, DOI 10.1074/jbc.274.2.987; Kasof GM, 2001, ONCOGENE, V20, P7965, DOI 10.1038/sj.onc.1204985; Katsuyama K, 1998, ARTERIOSCL THROM VAS, V18, P1796, DOI 10.1161/01.ATV.18.11.1796; Kohn KW, 1999, MOL BIOL CELL, V10, P2703, DOI 10.1091/mbc.10.8.2703; Kohn KW, 2001, CHAOS, V11, P84, DOI 10.1063/1.1338126; KOHN KW, 2004, NATURE ENCY HUMAN GE, V1, P457; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Kroemer G, 1999, BIOCHEM SOC SYMP, V66, P1; Kunstle G, 2002, MOL CELL BIOL, V22, P1513, DOI 10.1128/MCB.22.5.1513-1525.2002; Lai EC, 2003, J CELL BIOL, V162, P365, DOI 10.1083/jcb.200307087; Larochette N, 1999, EXP CELL RES, V249, P413, DOI 10.1006/excr.1999.4519; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Levkau B, 1999, NAT CELL BIOL, V1, P227, DOI 10.1038/12050; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li XX, 2002, EXP HEMATOL, V30, P285, DOI 10.1016/S0301-472X(02)00777-4; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Ling MT, 2003, ONCOGENE, V22, P4498, DOI 10.1038/sj.onc.1206693; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lutz RJ, 2000, BIOCHEM SOC T, V28, P51, DOI 10.1042/bst0280051; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Marinovich M, 1996, EXP CELL RES, V226, P98, DOI 10.1006/excr.1996.0207; MCNULTY SE, PIGMENT CELL RES, V14, P456; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Micheau O, 1997, J NATL CANCER I, V89, P783, DOI 10.1093/jnci/89.11.783; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Muerkoster S, 2003, INT J CANCER, V104, P469, DOI 10.1002/ijc.10963; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Nakashio A, 2000, CANCER RES, V60, P5303; Nieves-Neira W, 1999, INT J CANCER, V82, P396, DOI 10.1002/(SICI)1097-0215(19990730)82:3<396::AID-IJC13>3.0.CO;2-Z; Nomura M, 2003, J BIOL CHEM, V278, P2058, DOI 10.1074/jbc.M207880200; Ozes ON, 1999, NATURE, V401, P82; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Paillard F, 1999, HUM GENE THER, V10, P1, DOI 10.1089/10430349950019138; Pandey P, 2000, EMBO J, V19, P4310, DOI 10.1093/emboj/19.16.4310; Parcellier A, 2003, BIOCHEM BIOPH RES CO, V304, P505, DOI 10.1016/S0006-291X(03)00623-5; Pieper GM, 1997, J CARDIOVASC PHARM, V30, P528, DOI 10.1097/00005344-199710000-00019; Poulaki V, 2002, AM J PATHOL, V161, P2229, DOI 10.1016/S0002-9440(10)64499-9; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Ravagnan L, 2002, J CELL PHYSIOL, V192, P131, DOI 10.1002/jcp.10111; Ravagnan L, 1999, ONCOGENE, V18, P2537, DOI 10.1038/sj.onc.1202625; Ray RB, 1998, J BIOL CHEM, V273, P2256, DOI 10.1074/jbc.273.4.2256; Reed JC, 2002, NAT REV DRUG DISCOV, V1, P111, DOI 10.1038/nrd726; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Reuther JY, 1999, J BIOL CHEM, V274, P20664, DOI 10.1074/jbc.274.29.20664; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Sachdev S, 1998, MOL CELL BIOL, V18, P2524, DOI 10.1128/MCB.18.5.2524; Saga Y, 2002, CLIN CANCER RES, V8, P1248; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Sarto C, 2000, ELECTROPHORESIS, V21, P1218, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1218::AID-ELPS1218>3.3.CO;2-8; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Sato S, 2002, J BIOL CHEM, V277, P39360, DOI 10.1074/jbc.M205141200; Sato S, 2002, ONCOGENE, V21, P1727, DOI 10.1038/sj.onc.1205225; Sato T, 2003, CANCER SCI, V94, P467, DOI 10.1111/j.1349-7006.2003.tb01466.x; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schmitt CA, 2002, J MOL MED-JMM, V80, P137, DOI 10.1007/s00109-001-0293-3; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Schmitt CA, 2000, NAT MED, V6, P1029, DOI 10.1038/79542; SCHOTT AF, 1995, ONCOGENE, V11, P1389; Shao RG, 2001, ONCOGENE, V20, P1852, DOI 10.1038/sj.onc.1204264; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Solary E, 2003, LEUKEMIA LYMPHOMA, V44, P563, DOI 10.1080/1042819021000038001; Sordet O, 2001, BLOOD, V97, P3931, DOI 10.1182/blood.V97.12.3931; Sordet Olivier, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P271, DOI 10.2174/1568011033482378; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; STAAL FJT, 1993, AIDS RES HUM RETROV, V9, P299, DOI 10.1089/aid.1993.9.299; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stroh C, 2003, ONCOGENE, V22, P5367, DOI 10.1038/sj.onc.1206544; Sunwoo JB, 2001, CLIN CANCER RES, V7, P1419; Tang D, 2001, J BIOL CHEM, V276, P30461, DOI 10.1074/jbc.M102045200; Tang GL, 2001, MOL CELL, V8, P1005, DOI 10.1016/S1097-2765(01)00380-X; Theodorakis P, 2002, CANCER RES, V62, P3373; Troussard AA, 2003, J BIOL CHEM, V278, P22374, DOI 10.1074/jbc.M303083200; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; Tzung SP, 2001, NAT CELL BIOL, V3, P183, DOI 10.1038/35055095; Usami I, 1998, BIOCHEM PHARMACOL, V55, P185, DOI 10.1016/S0006-2952(97)00429-2; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vaux DL, 2003, BIOCHEM BIOPH RES CO, V304, P499, DOI 10.1016/S0006-291X(03)00622-3; Vermeulen L, 2002, BIOCHEM PHARMACOL, V64, P963, DOI 10.1016/S0006-2952(02)01161-9; Vieira Helena L. A., 2002, Oncogene, V21, P1963, DOI 10.1038/sj.onc.1205270; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Walczak H, 2000, CANCER RES, V60, P3051; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; WALTON MI, 1993, CANCER RES, V53, P1853; Wan X, 2002, CELL DEATH DIFFER, V9, P414, DOI 10.1038/sj.cdd.4400982; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang JL, 2000, CANCER RES, V60, P1498; Wang YQ, 2002, NAT CELL BIOL, V4, P888, DOI 10.1038/ncb872; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Wisniewski D, 1999, BLOOD, V93, P2707, DOI 10.1182/blood.V93.8.2707.408k17_2707_2720; Wu H, 2003, ONCOGENE, V22, P3113, DOI 10.1038/sj.onc.1206451; Yasui H, 2003, CANCER, V97, P1412, DOI 10.1002/cncr.11210; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yuan XJ, 2002, ONCOGENE, V21, P319, DOI 10.1038/sj/onc/1205054; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhou G, 1997, J BIOL CHEM, V272, P15174, DOI 10.1074/jbc.272.24.15174	202	470	495	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2004	23	16					2934	2949		10.1038/sj.onc.1207515	http://dx.doi.org/10.1038/sj.onc.1207515			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	811VO	15077155				2022-12-28	WOS:000220799600019
J	Warming, S; Suzuki, T; Yamaguchi, TP; Jenkins, NA; Copeland, NG				Warming, S; Suzuki, T; Yamaguchi, TP; Jenkins, NA; Copeland, NG			Early B-cell factor-associated zinc-finger gene is a frequent target of retroviral integration in murine B-cell lymphomas	ONCOGENE			English	Article						EBFAZ; EVI3; B-cell lymphoma	ACUTE LYMPHOBLASTIC-LEUKEMIA; PRE-B; PROTEIN; MOUSE; IDENTIFICATION; EXPRESSION; LAMBDA-5; STRAINS; CLONING; LOCUS	The early B-cell factor (EBF)-associated zinc-finger protein (EBFAZ) binds to and negatively regulates EBF, a basic helix-loop-helix transcription factor required for B-cell lineage commitment and development of the olfactory epithelium. It also binds to SMA- and MAD-related protein 1 (SMAD1) and SMAD4 in response to bone morphogenic protein 2 (BMP2) signaling. It is highly related to ecotropic viral integration site 3 (EVI3), a protein that, like EBFAZ, contains 30 Kruppel-like zinc finger repeats. In previous studies, we showed that Evi3 is a frequent target of retroviral integration in AKXD27 B-cell lymphomas. Here, we show that EBFAZ is also a frequent target. Integrations at Ebfaz and Evi3 are mutually exclusive, suggesting that they function in the same tumor pathway. Lymphomas with integrations at Ebfaz or Evi3 express the pre-B-cell-specific marker immunoglobulin lambda chain 5, and contain immunoglobulin heavy-chain rearrangements, suggesting that they are blocked at an early B-cell stage. Unlike Evi3, which is expressed at low levels in normal B cells, or Ebfaz, which is not expressed in B cells, both genes are highly expressed following viral integration. Collectively, our results suggest that ectopic expression of Ebfaz can substitute for the upregulated expression of Evi3 in B-cell disease and highlight the importance of this gene family in hematopoietic cancer.	NCI, Mouse Canc Genet Program, Ctr Canc Res, Frederick, MD 21702 USA; NCI, Canc & Dev Lab, Ctr Canc Res, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Copeland, NG (corresponding author), NCI, Mouse Canc Genet Program, Ctr Canc Res, W 7th St & Ft Detrick, Frederick, MD 21702 USA.	copeland@ncifcrf.gov	Warming, Soren/ABD-5729-2021	Warming, Soren/0000-0002-5721-0741	NATIONAL CANCER INSTITUTE [ZIABC010345, Z01BC010345] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		COFFMAN RL, 1981, NATURE, V289, P681, DOI 10.1038/289681a0; GILBERT DJ, 1993, J VIROL, V67, P2083, DOI 10.1128/JVI.67.4.2083-2090.1993; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; Heerema NA, 1999, LEUKEMIA, V13, P679, DOI 10.1038/sj.leu.2401413; Hiai H, 2003, CANCER SCI, V94, P847, DOI 10.1111/j.1349-7006.2003.tb01365.x; HILDEN JM, 1995, BLOOD, V86, P3876, DOI 10.1182/blood.V86.10.3876.bloodjournal86103876; JUSTICE MJ, 1994, J VIROL, V68, P1293, DOI 10.1128/JVI.68.3.1293-1300.1994; KUDO A, 1987, EMBO J, V6, P2267, DOI 10.1002/j.1460-2075.1987.tb02500.x; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; MUCENSKI ML, 1986, MOL CELL BIOL, V6, P4236, DOI 10.1128/MCB.6.12.4236; SAKAGUCHI N, 1986, NATURE, V324, P579, DOI 10.1038/324579a0; Schebesta M, 2002, CURR OPIN IMMUNOL, V14, P216, DOI 10.1016/S0952-7915(02)00324-2; Seong C, 1998, BRIT J HAEMATOL, V101, P189, DOI 10.1046/j.1365-2141.1998.00657.x; Sigvardsson M, 1997, IMMUNITY, V7, P25, DOI 10.1016/S1074-7613(00)80507-5; Smadja NV, 2001, BLOOD, V98, P2229, DOI 10.1182/blood.V98.7.2229; SUZUKI T, 2002, NAT GENET, V19, P19; Tsai RYL, 1998, MOL CELL BIOL, V18, P6447, DOI 10.1128/MCB.18.11.6447; Tsai RYL, 1997, J NEUROSCI, V17, P4159; Warming S, 2003, BLOOD, V101, P1934, DOI 10.1182/blood-2002-08-2652	19	23	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2004	23	15					2727	2731		10.1038/sj.onc.1207452	http://dx.doi.org/10.1038/sj.onc.1207452			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	810OZ	15048087				2022-12-28	WOS:000220714900014
J	Young, AP; Longmore, GD				Young, AP; Longmore, GD			Differential regulation of apoptotic genes by Rb in human versus mouse cells	ONCOGENE			English	Article						Rb; E2F; apoptosis; human versus mouse	RETINOBLASTOMA SUSCEPTIBILITY GENE; TUMOR-SUPPRESSOR; KINASE-ACTIVITY; E2F PROTEINS; IN-VIVO; EXPRESSION; CYCLE; ACTIVATION; MECHANISMS; CANCER	The retinoblastoma protein (Rb) controls cellular proliferation and suppresses tumor formation through its effects upon E2F transcriptional regulation of the cell cycle. Unexpectedly, however, in proliferating human cells, Rb was present at the promoters of eight of eight E2F-regulated apoptotic genes tested, but zero of six E2F-regulated cell cycle genes tested. Binding of apoptotic gene promoters by Rb was constitutive, and inhibition of Rb in human cells by E2Fdb or E1A expression resulted in induction of these apoptotic genes and efficient cell death. E1A induced apoptosis much more efficiently in human fibroblasts than in mouse fibroblasts, suggesting a difference in susceptibility to loss of Rb function between human cells and mouse cells. Abrogation of Rb function in mouse cells did not induce expression of these apoptotic genes. Underlying this species difference in susceptibility to apoptosis following loss of Rb function was the absence of Rb on apoptotic gene promoters in mouse cells. Rb protein levels were 20-35-fold higher in primary human cells than in primary mouse cells. The constitutive repression of a multitude of apoptotic genes by Rb in human cells but not in mouse cells may provide a partial explanation for the well-known difference between human and mouse cells in transformation and tumorigenic potential.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Longmore, GD (corresponding author), Washington Univ, Sch Med, Dept Med, 4940 Parkview Pl, St Louis, MO 63110 USA.	glongmor@im.wustl.edu						Balmain A, 2002, CELL, V108, P145, DOI 10.1016/S0092-8674(02)00622-0; Black EP, 2003, CANCER RES, V63, P3716; BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; Bosco G, 2001, NAT CELL BIOL, V3, P289, DOI 10.1038/35060086; Chau BN, 2003, NAT REV CANCER, V3, P130, DOI 10.1038/nrc993; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Forsyth NR, 2002, DIFFERENTIATION, V69, P188, DOI 10.1046/j.1432-0436.2002.690412.x; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Fu XY, 1999, CELL DEATH DIFFER, V6, P1201, DOI 10.1038/sj.cdd.4400613; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hallstrom TC, 2003, P NATL ACAD SCI USA, V100, P10848, DOI 10.1073/pnas.1831408100; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; Ma DD, 2003, J BIOL CHEM, V278, P19358, DOI 10.1074/jbc.M301761200; Marie H, 2003, J BIOL CHEM, V278, P1220, DOI 10.1074/jbc.M205391200; Maronpot R, 1999, PATHOLOGY MOUSE; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; RASSOULZADEGAN M, 1983, P NATL ACAD SCI-BIOL, V80, P4354, DOI 10.1073/pnas.80.14.4354; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Reed SI, 1997, CANCER SURV, V29, P7; Samuelson AV, 1997, P NATL ACAD SCI USA, V94, P12094, DOI 10.1073/pnas.94.22.12094; Sedivy JM, 1998, P NATL ACAD SCI USA, V95, P9078, DOI 10.1073/pnas.95.16.9078; SHAY JW, 1993, EXP CELL RES, V209, P45, DOI 10.1006/excr.1993.1283; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; STERNER JM, 1995, J BIOL CHEM, V270, P9281, DOI 10.1074/jbc.270.16.9281; Takahashi Y, 2000, GENE DEV, V14, P804; Tamrakar S, 2000, FRONT BIOSCI-LANDMRK, V5, pD121, DOI 10.2741/Tamrakar; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Wang J, 1996, CELL GROWTH DIFFER, V7, P1471; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wells J, 2003, ONCOGENE, V22, P1445, DOI 10.1038/sj.onc.1206264; White E, 2001, ONCOGENE, V20, P7836, DOI 10.1038/sj.onc.1204861; Wright WE, 2000, NAT MED, V6, P849, DOI 10.1038/78592; Wu LZ, 2003, NATURE, V421, P942, DOI 10.1038/nature01417; Young AP, 2003, ONCOGENE, V22, P7209, DOI 10.1038/sj.onc.1206804; Young AP, 2004, ONCOGENE, V23, P2587, DOI 10.1038/sj.onc.1207330; Zhao JJ, 2003, CANCER CELL, V3, P483, DOI 10.1016/S1535-6108(03)00088-6	55	24	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2004	23	15					2587	2599		10.1038/sj.onc.1207330	http://dx.doi.org/10.1038/sj.onc.1207330			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	810OZ	15048095				2022-12-28	WOS:000220714900001
J	Ward, KR; Zhang, KX; Somasiri, AM; Roskelley, CD; Schrader, JW				Ward, KR; Zhang, KX; Somasiri, AM; Roskelley, CD; Schrader, JW			Expression of activated M-Ras in a murine mammary epithelial cell line induces epithelial-mesenchymal transition and tumorigenesis	ONCOGENE			English	Article						activated M-Ras; activated p21 Ras; epithelial-mesenchymal transition; transformation; tumorigenesis	R-RAS; BREAST-CANCER; GENE FAMILY; P21 RAS; PROTEIN; GROWTH; TRANSFORMATION; M-RAS/R-RAS3; IDENTIFICATION; GTPASE	The expression of activated mutants of M-Ras (G22V or Q71L), but not wild-type M-Ras, in a murine mammary epithelial cell line, scp2, resulted in epithelial - mesenchymal transition (EMT) and oncogenic transformation. Cells expressing constitutively active M-Ras continued to grow in the absence of serum and exhibited a loss of the epithelial markers cytokeratin, E-cadherin and beta-catenin, together with a gain of the mesenchymal marker vimentin, a loss of contact inhibition in monolayer growth and a gain of the capacity for anchorage-independent growth. Moreover, unlike the parental cells, they failed to form differentiated mammospheres on Matrigel and instead formed branched networks of cells that grew and invaded the Matrigel. The expression of activated p21 Ras (G12V H-Ras or Q61K N-Ras) also resulted in EMT and tumorigenesis, although there was evidence that expression of higher levels was toxic. Tumors derived from scp2 cells expressing activated M-Ras exhibited activation of Akt and of ERK. The levels of expression of Q71L M-Ras and G12V H-Ras required for tumorigenesis were comparable, although higher levels of the weaker G22V M-Ras mutant were selected for in vivo. These data indicate that the expression of activated mutants of M-Ras was sufficient for oncogenic transformation of a murine mammary epithelial cell line.	Univ British Columbia, Biomed Res Ctr, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Anat & Cell Biol, Vancouver, BC V5Z 1M9, Canada	University of British Columbia; University of British Columbia	Schrader, JW (corresponding author), Univ British Columbia, Biomed Res Ctr, 2222 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	john@brc.ubc.ca	Roskelley, Calvin D/F-4630-2011					Barker KT, 1998, BRIT J CANCER, V78, P296, DOI 10.1038/bjc.1998.490; Boon K, 2002, P NATL ACAD SCI USA, V99, P11287, DOI 10.1073/pnas.152324199; BOS JL, 1990, CANCER RES, V50, P1352; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BOS JL, 1989, CANCER RES, V49, P4682; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; Clark GJ, 1996, ONCOGENE, V12, P169; COX AD, 1994, ONCOGENE, V9, P3281; CRISSMAN HA, 1985, SCIENCE, V228, P1321, DOI 10.1126/science.2408339; DANIELSON KG, 1984, P NATL ACAD SCI-BIOL, V81, P3756, DOI 10.1073/pnas.81.12.3756; Desprez Pierre-Yves, 1993, Molecular and Cellular Differentiation, V1, P99; Ehrhardt A, 2002, EXP HEMATOL, V30, P1089, DOI 10.1016/S0301-472X(02)00904-9; Ehrhardt GRA, 1999, BLOOD, V94, P2433, DOI 10.1182/blood.V94.7.2433.419k31_2433_2444; Ehrhardt GRA, 2001, ONCOGENE, V20, P188, DOI 10.1038/sj.onc.1204053; Fanton CP, 2001, J BIOL CHEM, V276, P18871, DOI 10.1074/jbc.M011514200; Gao XL, 2001, J BIOL CHEM, V276, P42219, DOI 10.1074/jbc.M105760200; Grill B, 2002, BLOOD, V100, P3183, DOI 10.1182/blood-2002-01-0154; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Janda E, 2002, ONCOGENE, V21, P5148, DOI 10.1038/sj.onc.1205661; Kimmelman A, 1997, ONCOGENE, V15, P2675, DOI 10.1038/sj.onc.1201674; Kimmelman AC, 2000, ONCOGENE, V19, P2014, DOI 10.1038/sj.onc.1203530; Lochter A, 1997, J BIOL CHEM, V272, P5007, DOI 10.1074/jbc.272.8.5007; Louahed J, 1999, BLOOD, V94, P1701, DOI 10.1182/blood.V94.5.1701.417k29_1701_1710; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; MACMANUS MP, 1990, EXP HEMATOL, V18, P848; Matsumoto K, 1997, ONCOGENE, V15, P2409, DOI 10.1038/sj.onc.1201416; Miyakis S, 1998, BIOCHEM BIOPH RES CO, V251, P609, DOI 10.1006/bbrc.1998.9527; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; NODA M, 1993, BIOCHIM BIOPHYS ACTA, V1155, P97, DOI 10.1016/0304-419X(93)90024-7; Ohba Y, 2000, J BIOL CHEM, V275, P20020, DOI 10.1074/jbc.M000981200; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pritchard C, 1997, NAT GENET, V16, P214, DOI 10.1038/ng0797-214; Pruitt K, 2002, J BIOL CHEM, V277, P31808, DOI 10.1074/jbc.M203964200; Quilliam LA, 1999, J BIOL CHEM, V274, P23850, DOI 10.1074/jbc.274.34.23850; Quilliam LA, 2001, METHOD ENZYMOL, V333, P187; Rebhun JF, 2000, J BIOL CHEM, V275, P34901, DOI 10.1074/jbc.M005327200; Roskelley CD, 2000, METH MOL B, V136, P27; Tombes RM, 1998, BIOCHEM J, V330, P1451; TREMBLAY PJ, 1989, MOL CELL BIOL, V9, P854, DOI 10.1128/MCB.9.2.854; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598	42	34	36	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1187	1196		10.1038/sj.onc.1207226	http://dx.doi.org/10.1038/sj.onc.1207226			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14961075				2022-12-28	WOS:000188892200002
J	You, L; He, B; Xu, ZD; Uematsu, K; Mazieres, J; Mikami, I; Reguart, N; Moody, TW; Kitajewski, J; McCormick, F; Jablons, DM				You, L; He, B; Xu, ZD; Uematsu, K; Mazieres, J; Mikami, I; Reguart, N; Moody, TW; Kitajewski, J; McCormick, F; Jablons, DM			Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells	ONCOGENE			English	Article						Wnt signaling; apoptosis; lung cancer	HUMAN COLORECTAL-CANCER; BETA-CATENIN; SURVIVIN EXPRESSION; INDUCED APOPTOSIS; COLON-CARCINOMA; UP-REGULATION; C-MYC; PATHWAY; WNT-2; GENE	In this report, we have demonstrated that Wnt-2 protein is overexpressed in freshly resected human non-small-cell lung cancer (NSCLC) tissues. We have also developed a monoclonal antibody against the N-terminus of human Wnt-2 protein. This monoclonal antibody induces apoptosis in human NSCLC cell lines that overexpress Wnt-2 protein. Incubation of this antibody with normal human airway cells lacking Wnt-2 expression does not induce apoptosis. Wnt-2 signaling blockade by the anti-Wnt-2 antibody is confirmed by downregulation of cytosolic beta-catenin and reduction in TCF-dependent transcriptional activity (TOPFLASH assay). In addition, Wnt-2-specific small interfering RNA (siRNA) treatment in the NSCLC cell line A549 also downregulated cytosolic beta-catenin and induced apoptosis. Moreover, downregulation of an inhibitor of apoptosis family protein, Survivin, was noticed both in the Wnt-2 antibody- and siRNA-treated NSCLC cells, suggesting that inhibition of Wnt-2-mediated signaling induces apoptosis through inactivating Survinin.	Univ Calif San Francisco, Ctr Comprehens Canc, Dept Surg, Thorac Oncol Lab, San Francisco, CA 94115 USA; NCI, Off Director, Ctr Canc Res, Bethesda, MD 20892 USA; Columbia Univ Coll Phys & Surg, Dept Pathol & Obstet & Gynecol, New York, NY 10032 USA	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Columbia University	Jablons, DM (corresponding author), Ctr Canc, Dept Surg, 1600 Divisadero St,C322C,Box 1674, San Francisco, CA 94115 USA.	jablonsd@surgery.ucsf.edu	MAZIERES, JULIEN/M-3986-2014	MAZIERES, JULIEN/0000-0002-5921-7613	NCI NIH HHS [R01 CA093708-01A3, R01 CA093708] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093708] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; BLASBAND A, 1992, ONCOGENE, V7, P153; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87; Dale TC, 1996, CANCER RES, V56, P4320; Dann CE, 2001, NATURE, V412, P86, DOI 10.1038/35083601; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Holcombe RF, 2002, J CLIN PATHOL-MOL PA, V55, P220, DOI 10.1136/mp.55.4.220; Hsieh JC, 1999, P NATL ACAD SCI USA, V96, P3546, DOI 10.1073/pnas.96.7.3546; HUGUET EL, 1994, CANCER RES, V54, P2615; Ioannidis V, 2001, NAT IMMUNOL, V2, P691, DOI 10.1038/90623; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Katoh M, 2001, INT J ONCOL, V19, P1003; Kim PJ, 2003, LANCET, V362, P205, DOI 10.1016/S0140-6736(03)13910-4; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Olie RA, 2000, CANCER RES, V60, P2805; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Pham K, 2003, J CLIN PATHOL-MOL PA, V56, P280, DOI 10.1136/mp.56.5.280; Polakis P, 2000, GENE DEV, V14, P1837; Reya T, 2000, IMMUNITY, V13, P15, DOI 10.1016/S1074-7613(00)00004-2; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Shih IM, 2000, CANCER RES, V60, P1671; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Smith K, 1999, BRIT J CANCER, V81, P496, DOI 10.1038/sj.bjc.6690721; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Uematsu K, 2003, CANCER RES, V63, P4547; Uthoff SMS, 2001, MOL CARCINOGEN, V31, P56, DOI 10.1002/mc.1039; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Vider BZ, 1996, ONCOGENE, V12, P153; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; You ZB, 2002, J CELL BIOL, V157, P429, DOI 10.1083/jcb.200201110; Zhang T, 2001, CANCER RES, V61, P8664	38	213	234	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6170	6174		10.1038/sj.onc.1207844	http://dx.doi.org/10.1038/sj.onc.1207844			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15208662				2022-12-28	WOS:000223261000017
J	Nagayama, S; Iiizumi, M; Katagiri, T; Toguchida, J; Nakamura, Y				Nagayama, S; Iiizumi, M; Katagiri, T; Toguchida, J; Nakamura, Y			Identification of PDZK4, a novel human gene with PDZ domains, that is upregulated in synovial sarcomas	ONCOGENE			English	Article						synovial sarcomas; PDZ domain; upregulation; small interfering RNA	SOFT-TISSUE SARCOMAS; PROTEIN; CHEMOTHERAPY; DOXORUBICIN; IFOSFAMIDE; ASSOCIATION; COMPLEXES; SSX; SYT	In an earlier study designed to investigate molecular mechanisms of carcinogenesis in synovial sarcomas (SSs), we applied a cDNA microarray to detect human genes with significantly increased expression in SS cells. Among the genes selected in this way, we identified a novel transcript, subsequently designated PDZK4 (PDZ domain-containing 4), that was specifically upregulated in all of the 13 SS cases we examined. On Northern blots of normal human tissues, the PDZK4 transcript was expressed only in fetal brain. Immmunocytochemical staining of transfected COS7 cells showed that the PDZK4 gene product localized mainly under the plasma membrane. Treatment of human SS cells with small interfering RNA (siRNA) inhibited the expression of PDZK4 and resulted in the suppression of tumor-cell growth. Induction of exogenous PDZK4 expression promoted growth of T98G and COS7 cells in which no endogenous expression of PDZK4 was observed. Taken together, these findings strongly suggest that inappropriate expression of PDZK4 might play an important role in the proliferation of SS cells and that the gene might be a suitable molecular target for designing of novel drugs to treat SS patients.	Univ Tokyo, Inst Med Sci, Mol Med Lab, Human Genet Unit, Tokyo 1088639, Japan; Kyoto Univ, Dept Surg & Surg Basic Sci, Grad Sch Med, Kyoto 6068507, Japan; Kyoto Univ, Inst Frontier Med Sci, Kyoto 6068507, Japan	University of Tokyo; Kyoto University; Kyoto University	Nakamura, Y (corresponding author), Univ Tokyo, Inst Med Sci, Mol Med Lab, Human Genet Unit, Tokyo 1088639, Japan.	yusuke@ims.u-tokyo.ac.jp						ANTMAN K, 1993, J CLIN ONCOL, V11, P1276, DOI 10.1200/JCO.1993.11.7.1276; Bezprozvanny I, 2001, P NATL ACAD SCI USA, V98, P787, DOI 10.1073/pnas.98.3.787; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; Crist WM, 2001, J CLIN ONCOL, V19, P3091, DOI 10.1200/JCO.2001.19.12.3091; dos Santos NR, 2001, GENE CHROMOSOME CANC, V30, P1, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1056>3.0.CO;2-G; Edmonson JH, 2002, CANCER, V94, P786, DOI 10.1002/cncr.10259; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Ferguson WS, 2001, CANCER INVEST, V19, P292, DOI 10.1081/CNV-100102557; Frustaci S, 2001, J CLIN ONCOL, V19, P1238, DOI 10.1200/JCO.2001.19.5.1238; Hirao K, 2000, J BIOL CHEM, V275, P2966, DOI 10.1074/jbc.275.4.2966; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Mizuno K, 2003, J BIOL CHEM, V278, P31240, DOI 10.1074/jbc.M303593200; Nagai M, 2001, P NATL ACAD SCI USA, V98, P3843, DOI 10.1073/pnas.061036798; Nagayama S, 2002, CANCER RES, V62, P5859; Ohno S, 2001, CURR OPIN CELL BIOL, V13, P641, DOI 10.1016/S0955-0674(00)00264-7; Patel SR, 1998, AM J CLIN ONCOL-CANC, V21, P317, DOI 10.1097/00000421-199806000-00025; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; *SARC MET COLL, 1998, LANCET, V350, P1647; Shoji H, 2000, J BIOL CHEM, V275, P5485, DOI 10.1074/jbc.275.8.5485; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; van de Rijn M, 1999, AM J CLIN PATHOL, V112, P43; WEISS SW, 2001, ENZINGER WEISSS SOFT; Wunder JS, 1998, J BONE JOINT SURG AM, V80A, P1020, DOI 10.2106/00004623-199807000-00011; Xu JG, 2001, J BIOL CHEM, V276, P41310, DOI 10.1074/jbc.M107480200	25	22	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2004	23	32					5551	5557		10.1038/sj.onc.1207710	http://dx.doi.org/10.1038/sj.onc.1207710			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15077175				2022-12-28	WOS:000222588400015
J	Hatakeyama, M; Yumoto, N; Yu, X; Shirouzu, M; Yokoyama, S; Konagaya, A				Hatakeyama, M; Yumoto, N; Yu, X; Shirouzu, M; Yokoyama, S; Konagaya, A			Transformation potency of ErbB heterodimer signaling is determined by B-Raf kinase	ONCOGENE			English	Article						ErbB; B-Raf; transformation; PP2A; PKA	EPIDERMAL-GROWTH-FACTOR; PROTEIN PHOSPHATASE 2A; PLECKSTRIN HOMOLOGY DOMAIN; MAP KINASE; ACTIVATION; PHOSPHORYLATION; DEPHOSPHORYLATION; DIFFERENTIATION; IDENTIFICATION; TRANSDUCTION	Cellular transformation occurs only in cells that express both ErbB1 and ErbB4 receptors, but not in cells expressing only one or the other of these receptors. However, when both receptors are coexpressed and ligand-stimulated, they interact with virtually the same adaptor/effector proteins as when expressed singly. To reveal the underlying regulatory mechanism of the kinase/phosphatase network in ErbB homo- and heterodimer receptor signaling, extracellular signal-regulated kinase (ERK) and Akt activities were evaluated in the presence of several enzyme inhibitors in ligand-induced cells expressing ErbB1 (E1), ErbB4 (E4), and ErbB1/ErbB4 (E1/4) receptor. The PP2A inhibitor okadaic acid showed receptor-specific inhibitory profiles for ERK and Akt activities. Moreover, B-Raf isolated only from E1/4 cells could induce in vitro phosphorylation for MEK; this B-Raf kinase activity was abolished by pretreatment of the cells with okadaic acid. Our study further showed that the E1/4 cell-specific B-Raf activity was stimulated by PLCgamma and subsequent Rap1 activation. The present study suggests that B-Raf kinase, which was specifically activated in the cells coexpressing ErbB1 and ErbB4 receptors, elevates total ERK activity within the cell and, therefore, can induce cellular transformation.	RIKEN Genom Sci Ctr, Bioinformat Grp, Tsurumi Ku, Kanagawa 2300045, Japan; RIKEN Genom Sci Ctr, Prot Res Grp, Tsurumi Ku, Kanagawa 2300045, Japan; Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1130033, Japan; SPring8, RIKEN Harima Inst, Cellular Signaling Lab, Sayo, Hyogo 6795148, Japan; SPring8, RIKEN Harima Inst, Structurome Grp, Sayo, Hyogo 6795148, Japan	RIKEN; RIKEN; University of Tokyo; Japan Synchrotron Radiation Research Institute; RIKEN; Japan Synchrotron Radiation Research Institute; RIKEN	Hatakeyama, M (corresponding author), RIKEN Genom Sci Ctr, Bioinformat Grp, Tsurumi Ku, 1-7-22 Suehiro Cho, Kanagawa 2300045, Japan.	marikoh@gsc.riken.jp	Okada, Mariko/N-6933-2015; Yokoyama, Shigeyuki/N-6911-2015; Konagaya, Akihiko/F-9302-2014; Shirouzu, Mikako/A-6521-2016	Yokoyama, Shigeyuki/0000-0003-3133-7338; 				Abraham D, 2000, J BIOL CHEM, V275, P22300, DOI 10.1074/jbc.M003259200; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Andjelkovic M, 1999, MOL CELL BIOL, V19, P5061; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Brose MS, 2002, CANCER RES, V62, P6997; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; Chong H, 2003, CELL SIGNAL, V15, P463, DOI 10.1016/S0898-6568(02)00139-0; Cohen BD, 1996, J BIOL CHEM, V271, P30897, DOI 10.1074/jbc.271.48.30897; Dhillon AS, 2002, MOL CELL BIOL, V22, P3237, DOI 10.1128/MCB.22.10.3237-3246.2002; Guo FF, 2001, J BIOL CHEM, V276, P25568, DOI 10.1074/jbc.M101277200; Hatakeyama M, 2003, BIOCHEM J, V373, P451, DOI 10.1042/BJ20021824; Heinrich R, 2002, MOL CELL, V9, P957, DOI 10.1016/S1097-2765(02)00528-2; Ivaska J, 2002, MOL CELL BIOL, V22, P1352, DOI 10.1128/MCB.22.5.1352-1359.2002; Jaumot M, 2001, ONCOGENE, V20, P3949, DOI 10.1038/sj.onc.1204526; Jones JT, 1999, FEBS LETT, V447, P227, DOI 10.1016/S0014-5793(99)00283-5; Kao SC, 2001, J BIOL CHEM, V276, P18169, DOI 10.1074/jbc.M008870200; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Kim JH, 2002, EUR J BIOCHEM, V269, P2323, DOI 10.1046/j.1432-1033.2002.02877.x; Kubicek M, 2002, J BIOL CHEM, V277, P7913, DOI 10.1074/jbc.M108733200; MacNicol MC, 1999, J BIOL CHEM, V274, P13193, DOI 10.1074/jbc.274.19.13193; Oehrl W, 2003, J BIOL CHEM, V278, P17819, DOI 10.1074/jbc.M209951200; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; Papin C, 1998, J BIOL CHEM, V273, P24939, DOI 10.1074/jbc.273.38.24939; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PERALDI P, 1995, FEBS LETT, V357, P290, DOI 10.1016/0014-5793(94)01376-C; Resjo S, 2002, CELL SIGNAL, V14, P231, DOI 10.1016/S0898-6568(01)00238-8; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Sable CL, 1998, J BIOL CHEM, V273, P29600, DOI 10.1074/jbc.273.45.29600; Shelly M, 1998, J BIOL CHEM, V273, P10496, DOI 10.1074/jbc.273.17.10496; Simon MA, 2000, CELL, V103, P13, DOI 10.1016/S0092-8674(00)00100-8; Strack S, 2002, J BIOL CHEM, V277, P41525, DOI 10.1074/jbc.M203767200; Thomas CC, 2002, CURR BIOL, V12, P1256, DOI 10.1016/S0960-9822(02)00972-7; Tzahar E, 1998, EMBO J, V17, P5948, DOI 10.1093/emboj/17.20.5948; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Tzahar E, 1997, EMBO J, V16, P4938, DOI 10.1093/emboj/16.16.4938; Wang LM, 1998, P NATL ACAD SCI USA, V95, P6809, DOI 10.1073/pnas.95.12.6809; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zhang K, 1996, J BIOL CHEM, V271, P3884; Zhou B, 2002, J BIOL CHEM, V277, P31818, DOI 10.1074/jbc.M203969200; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	45	9	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					5023	5031		10.1038/sj.onc.1207664	http://dx.doi.org/10.1038/sj.onc.1207664			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15064721				2022-12-28	WOS:000222237300008
J	Deng, QD; Huang, S				Deng, QD; Huang, S			PRDM5 is silenced in human cancers and has growth suppressive activities	ONCOGENE			English	Article						PRDM5 (PRDM5); PR/SET domain; tumor suppressors; 4q25-q26; PRDM2	HUMAN HEPATOCELLULAR-CARCINOMA; ZINC-FINGER PROTEIN; PR-DOMAIN FAMILY; CPG ISLANDS; SET DOMAIN; HISTONE METHYLTRANSFERASES; GENE-EXPRESSION; CHROMOSOMES 4Q; RIZ1; FREQUENT	Several genes that contain the PR (PRDI-BF1 and RIZ) domain have been linked with human cancers. We describe here a new PR-domain-containing gene designated as PRDM5 (PFM2). A PRDM5 cDNA was isolated based on its homology to the PR domain of RIZ1 (PRDM2). The gene encodes an open reading frame of 630 amino acids and contains a PR domain in the NH-terminal region followed by 16 zinc finger motifs. Radiation hybrid analysis mapped PRDM5 to human chromosome 4q26, a region thought to harbor tumor suppressor genes for breast, ovarian, liver, lung, colon, and other cancers. The gene has a CpG island promoter and is silenced in human breast, ovarian, and liver cancers. A recombinant adenovirus expressing PRDM5 caused G2/M arrest and apoptosis upon infection of tumor cells. These results suggest that inactivation of PRDM5 may play a role in carcinogenesis.	Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Huang, S (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	shuang@burnham.org			NATIONAL CANCER INSTITUTE [R01CA076146] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA76146] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arribas R, 1999, LAB INVEST, V79, P111; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; BUYSE IM, 1995, P NATL ACAD SCI USA, V92, P4467, DOI 10.1073/pnas.92.10.4467; Cardoso C, 1998, HUM MOL GENET, V7, P679, DOI 10.1093/hmg/7.4.679; Chittka A, 1999, P NATL ACAD SCI USA, V96, P10705, DOI 10.1073/pnas.96.19.10705; Chou YHW, 1998, CANCER LETT, V123, P1, DOI 10.1016/S0304-3835(97)00276-0; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Cui XM, 1998, NAT GENET, V18, P331, DOI 10.1038/ng0498-331; Du Y, 2001, CANCER RES, V61, P8094; Fang W, 2000, GENE CHROMOSOME CANC, V28, P269, DOI 10.1002/1098-2264(200007)28:3<269::AID-GCC4>3.3.CO;2-B; Fang W, 2001, BRIT J CANCER, V84, P743, DOI 10.1054/bjoc.2000.1667; Fears S, 1996, P NATL ACAD SCI USA, V93, P1642, DOI 10.1073/pnas.93.4.1642; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; He LS, 1998, CANCER RES, V58, P4238; HEON E, 1995, HUM MOL GENET, V4, P1435, DOI 10.1093/hmg/4.8.1435; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Huang S, 1998, J BIOL CHEM, V273, P15933, DOI 10.1074/jbc.273.26.15933; Huang S, 2002, NAT REV CANCER, V2, P469, DOI 10.1038/nrc819; HUANG S, 1994, CELL, V78, P9, DOI 10.1016/0092-8674(94)90565-7; Jiang GL, 1999, INT J CANCER, V83, P541, DOI 10.1002/(SICI)1097-0215(19991112)83:4<541::AID-IJC17>3.0.CO;2-F; Jiang GL, 2000, HISTOL HISTOPATHOL, V15, P109, DOI 10.14670/HH-15.109; KELLER AD, 1991, GENE DEV, V5, P868, DOI 10.1101/gad.5.5.868; Kim KC, 2003, CANCER BIOL THER, V2, P491, DOI 10.4161/cbt.2.5.629; Kim KC, 2003, CANCER RES, V63, P7619; Lin Y, 1997, SCIENCE, V276, P596, DOI 10.1126/science.276.5312.596; Liu LM, 1997, J BIOL CHEM, V272, P2984, DOI 10.1074/jbc.272.5.2984; MITRA AB, 1994, CANCER RES, V54, P4481; Pershouse MA, 1997, ONCOGENE, V14, P369, DOI 10.1038/sj.onc.1200836; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Piao Z, 1998, INT J CANCER, V79, P356, DOI 10.1002/(SICI)1097-0215(19980821)79:4<356::AID-IJC8>3.0.CO;2-U; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Rozenblatt-Rosen O, 1998, P NATL ACAD SCI USA, V95, P4152, DOI 10.1073/pnas.95.8.4152; Schneider R, 2002, TRENDS BIOCHEM SCI, V27, P396, DOI 10.1016/S0968-0004(02)02141-2; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Schwendel A, 1998, BRIT J CANCER, V78, P806, DOI 10.1038/bjc.1998.583; Shivapurkar N, 1999, CLIN CANCER RES, V5, P17; Sonoda G, 1997, GENE CHROMOSOME CANC, V20, P320; Steele-Perkins G, 2001, GENE DEV, V15, P2250, DOI 10.1101/gad.870101; Tirkkonen M, 1997, CANCER RES, V57, P1222; TURNER CA, 1994, CELL, V77, P297, DOI 10.1016/0092-8674(94)90321-2; Wang XL, 1999, ONCOGENE, V18, P823, DOI 10.1038/sj.onc.1202318; Xie M, 1997, J BIOL CHEM, V272, P26360, DOI 10.1074/jbc.272.42.26360; Yang XH, 1999, GENOMICS, V61, P319, DOI 10.1006/geno.1999.5967	44	78	83	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2004	23	28					4903	4910		10.1038/sj.onc.1207615	http://dx.doi.org/10.1038/sj.onc.1207615			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	830EK	15077163				2022-12-28	WOS:000222104200011
J	Li, L; Hooi, D; Chhabra, SR; Pritchard, D; Shaw, PE				Li, L; Hooi, D; Chhabra, SR; Pritchard, D; Shaw, PE			Bacterial N-acylhomoserine lactone-induced apoptosis in breast carcinoma cells correlated with down-modulation of STAT3	ONCOGENE			English	Article						apoptosis; autocrine signal; Janus kinases; cell cycle	PSEUDOMONAS-AERUGINOSA; CONSTITUTIVE ACTIVATION; SIGNALING PATHWAY; CANCER CELLS; C-MYC; SURVIVAL; GROWTH; KINASE; SRC; DIFFERENTIATION	Cell growth is promoted by mitogens and survival factors, which activate intracellular signalling pathways to control cell cycle progression and cellular integrity. Proliferation signals are transmitted through Ras and Rho family small G-proteins coupled to mitogen-activated protein kinase ( MAPK) cascades, while survival signals are propagated by lipid-dependent kinases such as phosphatidylinositide 3-kinases (PI3Ks) and protein kinase B (Akt/PKB). Recently, signal transducer and activator of transcription ( STAT) proteins were identified as positive regulators of proliferation in a variety of cell types. Persistent activation of these pathways is associated with tumour cell growth, whereas their inhibition can halt proliferation and precipitate apoptotic cell death. The human pathogen Pseudomonas aeruginosa uses quorum-sensing signal molecules (QSSMs) to regulate virulence gene expression. QSSMs also suppress host immune responses although the mechanism of suppression is unknown. Here, we demonstrate that the QSSM N-(3-oxododecanoyl)-L-homoserine lactone (OdDHL) from P. aeruginosa blocks proliferation and induces apoptosis in human BC cell lines. Analyses of signalling events reveal that OdDHL has little or no effect on MAPK cascades, partially inhibits the Akt/PKB pathway and ablates STAT3 activity. Pharmacological inhibition of each pathway independently indicates that STAT3 activity is critical for BC cell proliferation and survival, while a constitutively active STAT3 confers resistance to OdDHL. These results support the notion of OdDHL as a bioactive molecule in eukaryotic systems and a paradigm for a novel class of antiproliferative compounds.	Univ Nottingham, Queens Med Ctr, Sch Biomed Sci, Nottingham NG7 2UH, England; Univ Nottingham, Sch Pharm, Immune Modulat Res Grp, Nottingham NG7 2RD, England	University of Nottingham; University of Nottingham	Shaw, PE (corresponding author), Univ Nottingham, Queens Med Ctr, Sch Biomed Sci, Nottingham NG7 2UH, England.	peter.shaw@nottingham.ac.uk		SHAW, Peter/0000-0002-2598-4283				Bild AH, 2002, EMBO J, V21, P3255, DOI 10.1093/emboj/cdf351; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Burke WM, 2001, ONCOGENE, V20, P7925, DOI 10.1038/sj.onc.1204990; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Gooch JL, 1999, CANCER LETT, V144, P31, DOI 10.1016/S0304-3835(99)00208-6; Haan S, 2000, BIOCHEM J, V345, P417, DOI 10.1042/0264-6021:3450417; Hasegawa T, 2003, BLOOD, V101, P1164, DOI 10.1182/blood-2002-05-1505; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Kotenko SV, 2000, ONCOGENE, V19, P2557, DOI 10.1038/sj.onc.1203524; Lackmann M, 1998, GROWTH FACTORS, V16, P39, DOI 10.3109/08977199809017490; Li L, 2002, J BIOL CHEM, V277, P17397, DOI 10.1074/jbc.M109962200; Lin TS, 2000, ONCOGENE, V19, P2496, DOI 10.1038/sj.onc.1203486; Liu HT, 2003, BLOOD, V102, P344, DOI 10.1182/blood-2002-11-3396; MCGAHON AJ, 1995, J BIOL CHEM, V270, P22625, DOI 10.1074/jbc.270.38.22625; Meyer T, 2002, EMBO J, V21, P344, DOI 10.1093/emboj/21.3.344; Mochizuki T, 1999, J BIOL CHEM, V274, P18659, DOI 10.1074/jbc.274.26.18659; Ndubuisi MI, 1999, J BIOL CHEM, V274, P25499, DOI 10.1074/jbc.274.36.25499; Pesci EC, 1997, J BACTERIOL, V179, P3127, DOI 10.1128/jb.179.10.3127-3132.1997; Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Seidel HM, 2000, ONCOGENE, V19, P2645, DOI 10.1038/sj.onc.1203550; Shen YH, 2001, P NATL ACAD SCI USA, V98, P1543, DOI 10.1073/pnas.041588198; Shirogane T, 1999, IMMUNITY, V11, P709, DOI 10.1016/S1074-7613(00)80145-4; Simon AR, 2000, SCIENCE, V290, P144, DOI 10.1126/science.290.5489.144; Smith RS, 2002, J BACTERIOL, V184, P1132, DOI 10.1128/jb.184.4.1132-1139.2002; Smithgall TE, 2000, ONCOGENE, V19, P2612, DOI 10.1038/sj.onc.1203477; Telford G, 1998, INFECT IMMUN, V66, P36, DOI 10.1128/IAI.66.1.36-42.1998; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WINSON MK, 1995, P NATL ACAD SCI USA, V92, P9427, DOI 10.1073/pnas.92.20.9427; Yamauchi T, 2000, J BIOL CHEM, V275, P33937, DOI 10.1074/jbc.M000743200	39	107	111	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2004	23	28					4894	4902		10.1038/sj.onc.1207612	http://dx.doi.org/10.1038/sj.onc.1207612			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	830EK	15064716				2022-12-28	WOS:000222104200010
J	Brabender, J; Marjoram, P; Salonga, D; Metzger, R; Schneider, PM; Park, JM; Schneider, S; Holscher, AH; Yin, J; Meltzer, SJ; Danenberg, KD; Danenberg, PV; Lord, RV				Brabender, J; Marjoram, P; Salonga, D; Metzger, R; Schneider, PM; Park, JM; Schneider, S; Holscher, AH; Yin, J; Meltzer, SJ; Danenberg, KD; Danenberg, PV; Lord, RV			A multigene expression panel for the molecular diagnosis of Barrett's esophagus and Barrett's adenocarcinoma of the esophagus	ONCOGENE			English	Article						Barrett's esophagus; esophageal adenocarcinoma; gene expression; quantititative real-time RT-PCR	MESSENGER-RNA EXPRESSION; ARTIFICIAL NEURAL NETWORKS; CDNA MICROARRAYS; LUNG-CANCER; DISTINGUISH; METAPLASIA; APOPTOSIS; DYSPLASIA; SEQUENCE; SYNTHASE	In order to identify genes or combination of genes that have the power to discriminate between premalignant Barrett's esophagus and Barrett's associated adenocarcinoma, we analysed a panel of 23 genes using quantitative real-time RT-PCR (qRT-PCR, Taqman(R)) and bioinformatic tools. The genes chosen were either known to be associated with Barrett's carcinogenesis or were filtered from a previous cDNA microarray study on Barrett's adenocarcinoma. A total of 98 tissues, obtained from 19 patients with Barrett's esophagus (BE group) and 20 patients with Barrett's associated esophageal adenocarcinoma (EA group), were studied. Triplicate analysis for the full 23 gene of interest panel, and analysis of an internal control gene, was performed for all samples, for a total of more than 9016 single PCR reactions. We found distinct classes of gene expression patterns in the different types of tissues. The most informative genes clustered in six different classes and had significantly different expression levels in Barrett's esophagus tissues compared to adenocarcinoma tissues. Linear discriminant analysis (LDA) distinguished four genetically different groups. The normal squamous esophagus tissues from patients with BE or EA were not distinguishable from one another, but Barrett's esophagus tissues could be distinguished from adenocarcinoma tissues. Using the most informative genes, obtained from a logistic regression analysis, we were able to completely distinguish between benign Barrett's and Barrett's adenocarcinomas. This study provides the first non-array parallel mRNA quantitation analysis of a panel of genes in the Barrett's esophagus model of multistage carcinogenesis. Our results suggest that mRNA expression quantitation of a panel of genes can discriminate between premalignant and malignant Barrett's disease. Logistic regression and LDAs can be used to further identify, from the complete panel, gene subsets with the power to make these diagnostic distinctions. Expression analysis of a limited number of highly selected genes may have clinical usefulness for the treatment of patients with this disease.	Univ Cologne, Dept Visceral & Vasc Surg, D-50931 Cologne, Germany; Univ So Calif, Dept Prevent Med, Los Angeles, CA 90033 USA; Response Genet Inc, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA; Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA; Univ Maryland, Sch Med, Baltimore, MD 21201 USA; VA Med Ctr, Baltimore, MD 21201 USA; Univ So Calif, Keck Sch Med, Dept Surg, Los Angeles, CA 90033 USA	University of Cologne; University of Southern California; University of Southern California; University of Southern California; University System of Maryland; University of Maryland Baltimore; University of Southern California	Brabender, J (corresponding author), Univ Cologne, Dept Visceral & Vasc Surg, Joseph Stelzmann Str 9, D-50931 Cologne, Germany.	jan.brabender@t-online.de	Marjoram, Paul/A-3066-2008	Lord, Reginald V N/0000-0001-7475-492X	NCI NIH HHS [CA95323, CA85069, CA77057, CA098450, CA01808, CA 71716] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077057, R01CA095323, R21CA098450, R01CA071716, U01CA085069, R01CA001808] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brabender J, 2002, J GASTROINTEST SURG, V6, P359, DOI 10.1016/S1091-255X(02)00003-3; Brabender J, 2003, BRIT J CANCER, V89, P1508, DOI 10.1038/sj.bjc.6601324; Brabender J, 2002, CLIN CANCER RES, V8, P438; Brabender J, 2001, J GASTROINTEST SURG, V5, P174, DOI 10.1016/S1091-255X(01)80031-7; Brabender J, 2001, J SURG RES, V99, P301, DOI 10.1006/jsre.2001.6186; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cohen O, 2001, CELL DEATH DIFFER, V8, P6, DOI 10.1038/sj.cdd.4400794; Devesa SS, 1998, CANCER, V83, P2049, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2049::AID-CNCR1>3.0.CO;2-2; DUBOIT S, 2002, J AM STAT ASSOC, V8, P77; Eads CA, 1999, CANCER RES, V59, P2302; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Khan J, 2001, NAT MED, V7, P673, DOI 10.1038/89044; Lord RVN, 2000, J GASTROINTEST SURG, V4, P135, DOI 10.1016/S1091-255X(00)80049-9; Lord RVN, 2001, SURGERY, V129, P267, DOI 10.1067/msy.2001.110856; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; SCHERF U, 2001, P ANN M AM ASS CANC, V42, pA3288; Selaru FM, 2002, GASTROENTEROLOGY, V122, P606, DOI 10.1053/gast.2002.31904; Selaru FM, 2002, ONCOGENE, V21, P475, DOI 10.1038/sj.onc.1205111; Suda Yasuo, 1999, Gastric Cancer, V2, P165, DOI 10.1007/s101200050041; Terashima M, 2002, ANTICANCER RES, V22, P761; Virmani AK, 2002, CANCER EPIDEM BIOMAR, V11, P291; Wilson KT, 1998, CANCER RES, V58, P2929; Woodward TA, 2000, ANTICANCER RES, V20, P2427; Xu Y, 2002, CANCER RES, V62, P3493; Zou TT, 2002, ONCOGENE, V21, P4855, DOI 10.1038/sj.onc.1205613	27	50	53	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 10	2004	23	27					4780	4788		10.1038/sj.onc.1207663	http://dx.doi.org/10.1038/sj.onc.1207663			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZX	15107828				2022-12-28	WOS:000221799200013
J	Thomas-Mudge, RJ; Okada-Ban, M; Vandenbroucke, F; Vincent-Salomon, A; Girault, JM; Thiery, JP; Jouanneau, J				Thomas-Mudge, RJ; Okada-Ban, M; Vandenbroucke, F; Vincent-Salomon, A; Girault, JM; Thiery, JP; Jouanneau, J			Nuclear FGF-2 facilitates cell survival in vitro and during establishment of metastases	ONCOGENE			English	Article						nuclear FGF-2; metastases; apoptosis; survival	FIBROBLAST-GROWTH-FACTOR; GREEN FLUORESCENT PROTEIN; BLADDER-CARCINOMA CELLS; KINASE-C-DELTA; CANCER CELLS; REGULATES BCL-2; MELANOMA-CELLS; TUMOR-CELLS; FACTOR BFGF; EXPRESSION	Nuclear-targeted high molecular weight 24 kDa fibroblast growth factor 2 (FGF-2) may induce specific cell functions through intracrine mechanisms. The role of nuclear FGF-2 on the metastatic potential of carcinoma cells was examined by conditional FGF-2 expression, which demonstrated that spontaneous metastasis in nude mice is a direct consequence of its expression. The lung colonizing capacities of fluorescent nuclear FGF-2-expressing cells following intravenous injection was also investigated. All cells reaching the lung extravasated as soon as 5 min following injection with similar in vivo behavior during the first 24 h. However, after 2 days, dramatic differences were observed between the FGF-2 and parental cells: most control cells underwent apoptosis, while the FGF-2-producing cells instigated a survival program and proliferated. Therefore, sustained apoptosis in vivo prevents growth of metastatic foci, while nuclear FGF-2 induction of a survival program is responsible for growth of the lung metastases. In vitro serum deprivation assays also established that 24 kDa FGF-2 expression improves carcinoma cell survival. This study provides both in vitro and in vivo evidence that the role of the nuclear 24kDa FGF-2 isoform in carcinoma is the promotion of cell survival, thereby defining its association with poor prognosis in some human carcinomas.	Inst Curie, Div Res, CNRS, UMR 144, F-75248 Paris 05, France; Inst Curie, Div Med, Dept Biol, F-75248 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Jouanneau, J (corresponding author), Inst Curie, Div Res, CNRS, UMR 144, F-75248 Paris 05, France.	Jacqueline.Jounneau@curie.fr	Thiery, Jean Paul/M-9387-2019; Thiery, Jean Paul/H-1550-2011	Thiery, Jean Paul/0000-0003-0478-5020; Mudge, Rachel/0000-0002-5727-3240				Al-Mehdi AB, 2000, NAT MED, V6, P100, DOI 10.1038/71429; Arnaud E, 1999, MOL CELL BIOL, V19, P505; Boelaert K, 2003, J CLIN ENDOCR METAB, V88, P2341, DOI 10.1210/jc.2002-021113; Bold RJ, 2001, CANCER-AM CANCER SOC, V92, P1122, DOI 10.1002/1097-0142(20010901)92:5<1122::AID-CNCR1429>3.0.CO;2-H; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; Cameron MD, 2000, CANCER RES, V60, P2541; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Delrieu I, 2000, FEBS LETT, V468, P6, DOI 10.1016/S0014-5793(00)01189-3; Farina KL, 1998, CANCER RES, V58, P2528; Fukui S, 2003, CANCER, V97, P3061, DOI 10.1002/cncr.11450; Fukui S, 2002, J NEURO-ONCOL, V57, P221, DOI 10.1023/A:1015763725104; Funato N, 1997, BIOCHEM BIOPH RES CO, V240, P21, DOI 10.1006/bbrc.1997.7588; Gaubert F, 2001, J BIOL CHEM, V276, P1545, DOI 10.1074/jbc.M001184200; Giavazzi R, 2001, CANCER RES, V61, P309; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gualandris A, 1999, J CELL PHYSIOL, V181, P273, DOI 10.1002/(SICI)1097-4652(199911)181:2<273::AID-JCP9>3.0.CO;2-#; Hajihosseini MK, 1999, MOL CELL NEUROSCI, V14, P468, DOI 10.1006/mcne.1999.0800; Karsan A, 1997, AM J PATHOL, V151, P1775; Konig A, 1997, LEUKEMIA, V11, P258, DOI 10.1038/sj.leu.2400556; KOOP S, 1995, CANCER RES, V55, P2520; Luzzi KJ, 1998, AM J PATHOL, V153, P865, DOI 10.1016/S0002-9440(10)65628-3; Maloof P, 1999, BREAST CANCER RES TR, V56, P153; Miyake H, 1999, BRIT J CANCER, V79, P1651, DOI 10.1038/sj.bjc.6690264; Naumov GN, 1999, J CELL SCI, V112, P1835; Okada-Ban M, 1999, ONCOGENE, V18, P6719, DOI 10.1038/sj.onc.1203092; Okada-Ban M, 2000, INT J BIOCHEM CELL B, V32, P263, DOI 10.1016/S1357-2725(99)00133-8; Pardo OE, 2002, J BIOL CHEM, V277, P12040, DOI 10.1074/jbc.M109006200; Pardo OE, 2003, MOL CELL BIOL, V23, P7600, DOI 10.1128/MCB.23.21.7600-7610.2003; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Rosini P, 2002, PROSTATE, V53, P310, DOI 10.1002/pros.10164; SAVAGNER P, 1994, MOL BIOL CELL, V5, P851, DOI 10.1091/mbc.5.8.851; Sun CP, 2001, J CELL PHYSIOL, V186, P457, DOI 10.1002/1097-4652(2000)9999:999<000::AID-JCP1044>3.0.CO;2-2; Takaoka A, 1997, ONCOGENE, V14, P2971, DOI 10.1038/sj.onc.1201147; TOYOSHIMA K, 1971, JNCI-J NATL CANCER I, V47, P979; Van den Berghe L, 2000, MOL ENDOCRINOL, V14, P1709, DOI 10.1210/me.14.11.1709; Wert MM, 2000, BIOCHEM J, V352, P175, DOI 10.1042/0264-6021:3520175; Wieder R, 1997, GROWTH FACTORS, V15, P41, DOI 10.3109/08977199709002111; Wong CW, 2001, CANCER RES, V61, P333	38	25	26	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2004	23	27					4771	4779		10.1038/sj.onc.1207638	http://dx.doi.org/10.1038/sj.onc.1207638			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZX	15122340				2022-12-28	WOS:000221799200012
J	Cameron, ER; Neil, JC				Cameron, ER; Neil, JC			The Runx genes: lineage-specific oncogenes and tumor suppressors	ONCOGENE			English	Article						Runx; Amh1; corebinding factor; oncogene; leukemia	ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; MYOSIN HEAVY-CHAIN; T(8/21) FUSION PROTEIN; AML1 TRANSCRIPTION FACTOR; T-CELL DEVELOPMENT; CBF-BETA-SMMHC; DNA-BINDING; AML1/PEBP2-ALPHA-B GENE; POINT MUTATIONS	The Runx genes present a challenge to the simple binary classification of cancer genes as oncogenes or tumor suppressors. There is evidence that loss of function of two of the three mammalian Runx genes promotes cancer, but in a highly lineage-restricted manner. In human leukemias, the RUNX1 gene is involved in various chromosomal translocation events that create oncogenic fusion proteins, at least some of which appear to function as dominant-negative inhibitors of the normal gene product. Paradoxically, evidence is mounting that structurally intact Runx genes are also oncogenic when overexpressed. All the three murine genes act as targets for transcriptional activation by retroviral insertional mutagenesis, and the oncogenic potential of Runx2 has been confirmed in transgenic mice. Moreover, the RUNX1 gene is often amplified or overexpressed in cases of acute leukemia. The state of progress in elucidating the oncogenic roles of the Runx genes is the subject of this review, and we draw together recent observations in a tentative model for the effects of Runx deregulation on hematopoietic cell differentiation. We suggest that lineage-specific factors determine the sensitivity to the oncogenic effects of loss or overexpression of Runx factors.	Univ Glasgow, Sch Vet, Inst Comparat Med, Mol Oncol Lab, Glasgow G61 1QH, Lanark, Scotland	University of Glasgow	Cameron, ER (corresponding author), Univ Glasgow, Sch Vet, Inst Comparat Med, Mol Oncol Lab, Glasgow G61 1QH, Lanark, Scotland.	e.r.cameron@vet.gla.ac.uk						Adya N, 1998, MOL CELL BIOL, V18, P7432, DOI 10.1128/MCB.18.12.7432; Al-Obaidi MSJ, 2002, LEUKEMIA, V16, P669, DOI 10.1038/sj/leu/2402435; Alvarez Y, 2003, CANCER GENET CYTOGEN, V140, P58, DOI 10.1016/S0165-4608(02)00639-8; Bangsow C, 2001, GENE, V279, P221, DOI 10.1016/S0378-1119(01)00760-0; Bernardin F, 2002, ONCOGENE, V21, P3247, DOI 10.1038/sj.onc.1205447; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; Blyth K, 2001, ONCOGENE, V20, P295, DOI 10.1038/sj.onc.1204090; Busson-Le Coniat M, 2001, GENE CHROMOSOME CANC, V32, P244, DOI 10.1002/gcc.1188; Cameron ER, 2003, BLOOD CELL MOL DIS, V30, P194, DOI 10.1016/S1079-9796(03)00031-7; Canon J, 2000, SEMIN CELL DEV BIOL, V11, P327, DOI 10.1006/scdb.2000.0185; Cao WS, 1997, ONCOGENE, V15, P1315, DOI 10.1038/sj.onc.1201305; Castilla LH, 1999, NAT GENET, V23, P144, DOI 10.1038/13776; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; Coffman JA, 2003, CELL BIOL INT, V27, P315, DOI 10.1016/S1065-6995(03)00018-0; Dal Cin P, 2001, GENE CHROMOSOME CANC, V30, P407, DOI 10.1002/1098-2264(2001)9999:9999<::AID-GCC1107>3.0.CO;2-C; de Guzman CG, 2002, MOL CELL BIOL, V22, P5506, DOI 10.1128/MCB.22.15.5506-5517.2002; Downing JR, 2000, SEMIN CELL DEV BIOL, V11, P347, DOI 10.1006/scdb.2000.0183; Durst KL, 2003, MOL CELL BIOL, V23, P607, DOI 10.1128/MCB.23.2.607-619.2003; Elagib KE, 2003, BLOOD, V101, P4333, DOI 10.1182/blood-2002-09-2708; ERICKSON P, 1992, BLOOD, V80, P1825; Fears S, 1997, P NATL ACAD SCI USA, V94, P1949, DOI 10.1073/pnas.94.5.1949; Frank R, 1995, ONCOGENE, V11, P2667; Frank RC, 1999, ONCOGENE, V18, P1701, DOI 10.1038/sj.onc.1202459; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Harewood L, 2003, LEUKEMIA, V17, P547, DOI 10.1038/sj.leu.2402849; Hasle H, 2001, LANCET ONCOL, V2, P429, DOI 10.1016/S1470-2045(00)00435-6; Hayashi K, 2001, J IMMUNOL, V167, P4957, DOI 10.4049/jimmunol.167.9.4957; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; Hilgenfeld E, 2001, BRIT J HAEMATOL, V113, P305, DOI 10.1046/j.1365-2141.2001.02723.x; Kakazu N, 1999, GENE CHROMOSOME CANC, V26, P336, DOI 10.1002/(SICI)1098-2264(199912)26:4<336::AID-GCC8>3.3.CO;2-8; Kanno Y, 1998, MOL CELL BIOL, V18, P4252, DOI 10.1128/MCB.18.7.4252; Kim R, 2003, J VIROL, V77, P2056, DOI 10.1128/JVI.77.3.2056-2062.2003; Klampfer L, 1996, P NATL ACAD SCI USA, V93, P14059, DOI 10.1073/pnas.93.24.14059; KNUDSON AG, 1986, ANNU REV GENET, V20, P231; Kogan SC, 1998, P NATL ACAD SCI USA, V95, P11863, DOI 10.1073/pnas.95.20.11863; Kurokawa M, 1996, J BIOL CHEM, V271, P16870, DOI 10.1074/jbc.271.28.16870; Kurokawa M, 1996, ONCOGENE, V12, P883; Lange B, 2000, BRIT J HAEMATOL, V110, P512, DOI 10.1046/j.1365-2141.2000.02027.x; Lanza C, 1997, LEUKEMIA, V11, P820, DOI 10.1038/sj.leu.2400651; Levanon D, 1996, DNA CELL BIOL, V15, P175, DOI 10.1089/dna.1996.15.175; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Lou JR, 2000, ONCOGENE, V19, P2695, DOI 10.1038/sj.onc.1203588; Lukasik SM, 2002, NAT STRUCT BIOL, V9, P674, DOI 10.1038/nsb831; Lund AH, 2002, NAT GENET, V32, P160, DOI 10.1038/ng956; Lutterbach B, 1999, P NATL ACAD SCI USA, V96, P12822, DOI 10.1073/pnas.96.22.12822; Mathew S, 2001, LEUKEMIA, V15, P468, DOI 10.1038/sj.leu.2401989; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Mikhail FM, 2002, LEUKEMIA, V16, P658, DOI 10.1038/sj.leu.2402399; Mikkers H, 2002, NAT GENET, V32, P459, DOI 10.1038/ng1102-459b; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Morel F, 2002, CANCER GENET CYTOGEN, V137, P142, DOI 10.1016/S0165-4608(02)00566-6; Niini T, 2000, HAEMATOLOGICA, V85, P362; NISSON PE, 1992, CANCER GENET CYTOGEN, V63, P81, DOI 10.1016/0165-4608(92)90384-K; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Penther D, 2002, LEUKEMIA, V16, P1131, DOI 10.1038/sj.leu.2402479; Pozner A, 2000, MOL CELL BIOL, V20, P2297, DOI 10.1128/MCB.20.7.2297-2307.2000; Preudhomme C, 2000, BLOOD, V96, P2862, DOI 10.1182/blood.V96.8.2862.h8002862_2862_2869; Robertson AJ, 2002, MECH DEVELOP, V117, P327, DOI 10.1016/S0925-4773(02)00201-0; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; ROWLEY JD, 1981, LANCET, V2, P1020; Shields PG, 2000, J CLIN ONCOL, V18, P2309, DOI 10.1200/JCO.2000.18.11.2309; Shimada H, 2000, BLOOD, V96, P655; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Stewart M, 2002, J VIROL, V76, P4364, DOI 10.1128/JVI.76.9.4364-4369.2002; Stewart M, 1997, P NATL ACAD SCI USA, V94, P8646, DOI 10.1073/pnas.94.16.8646; Stewart M, 1996, J GEN VIROL, V77, P443, DOI 10.1099/0022-1317-77-3-443; Streubel B, 2001, CANCER GENET CYTOGEN, V124, P42, DOI 10.1016/S0165-4608(00)00318-6; Strom DK, 2000, J BIOL CHEM, V275, P3438, DOI 10.1074/jbc.275.5.3438; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; Uchida H, 1999, ONCOGENE, V18, P1015, DOI 10.1038/sj.onc.1202383; Vaillant F, 2002, J IMMUNOL, V169, P2866, DOI 10.4049/jimmunol.169.6.2866; Vaillant F, 1999, ONCOGENE, V18, P7124, DOI 10.1038/sj.onc.1203202; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Wheeler JC, 2000, SEMIN CELL DEV BIOL, V11, P369, DOI 10.1006/scdb.2000.0184; Wotton S, 2002, CANCER RES, V62, P7181; Yang YD, 2002, CANCER RES, V62, P2232; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; ZAIMAN AL, 1995, J VIROL, V69, P2898, DOI 10.1128/JVI.69.5.2898-2906.1995	86	127	131	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2004	23	24					4308	4314		10.1038/sj.onc.1207130	http://dx.doi.org/10.1038/sj.onc.1207130			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823BZ	15156187				2022-12-28	WOS:000221586000016
J	Levanon, D; Groner, Y				Levanon, D; Groner, Y			Structure and regulated expression of mammalian RUNX genes	ONCOGENE			English	Review						gene structure; promoter analysis; translation control; signaling pathways; tissue-specific expression	ACUTE MYELOID-LEUKEMIA; BONE MORPHOGENETIC PROTEIN-2; T-CELL DEVELOPMENT; GROWTH-FACTOR-BETA; OSTEOSARCOMA ROS17/2.8 CELLS; HEMATOPOIETIC STEM-CELLS; HUMAN CBFA1 GENE; TRANSCRIPTION FACTOR; OSTEOBLAST DIFFERENTIATION; CHONDROCYTE DIFFERENTIATION	The RUNX are key regulators of lineage-specific gene expression in major developmental pathways. The expression of RUNX genes is tightly regulated, leading to a highly specific spatio/temporal expression pattern and to distinct phenotypes of gene knockouts. This review highlights the extensive structural similarities between the three mammalian RUNX genes and delineates how regulation of their expression at the levels of transcription and translation are orchestrated into the unique RUNX expression pattern.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Groner, Y (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.	yoram.groner@weizmann.ac.il						Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254; AVRAHAM KB, 1995, GENOMICS, V25, P603, DOI 10.1016/0888-7543(95)80073-U; BAE SC, 1995, GENE, V159, P245, DOI 10.1016/0378-1119(95)00060-J; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; Bae SC, 2000, GENE, V241, P255, DOI 10.1016/S0378-1119(99)00488-6; Banerjee C, 2001, ENDOCRINOLOGY, V142, P4026, DOI 10.1210/en.142.9.4026; Bangsow C, 2001, GENE, V279, P221, DOI 10.1016/S0378-1119(01)00760-0; Ben Aziz-Aloya R, 1998, CELL DEATH DIFFER, V5, P765, DOI 10.1038/sj.cdd.4400415; BONEWALD LF, 1994, J CELL BIOCHEM, V55, P350, DOI 10.1002/jcb.240550312; Cai ZL, 2000, IMMUNITY, V13, P423, DOI 10.1016/S1074-7613(00)00042-X; CALABI F, 1995, GENOMICS, V26, P607, DOI 10.1016/0888-7543(95)80184-N; Cameron ER, 2003, BLOOD CELL MOL DIS, V30, P194, DOI 10.1016/S1079-9796(03)00031-7; CENTRELLA M, 1994, ENDOCR REV, V15, P27, DOI 10.1210/er.15.1.27; Choi KY, 2002, EXP MOL MED, V34, P426, DOI 10.1038/emm.2002.60; Coffman JA, 2003, CELL BIOL INT, V27, P315, DOI 10.1016/S1065-6995(03)00018-0; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; D'Souza RN, 1999, DEVELOPMENT, V126, P2911; Deftos ML, 2000, IMMUNITY, V13, P73, DOI 10.1016/S1074-7613(00)00009-1; Drissi H, 2002, J CELL BIOCHEM, V86, P403, DOI 10.1002/jcb.10238; Drissi H, 2000, J CELL PHYSIOL, V184, P341, DOI 10.1002/1097-4652(200009)184:3<341::AID-JCP8>3.0.CO;2-Z; Drissi H, 2002, EXP CELL RES, V274, P323, DOI 10.1006/excr.2002.5474; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Ducy P, 2000, DEV DYNAM, V219, P461, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1074>3.0.CO;2-C; Eggers JH, 2002, GENE, V291, P159, DOI 10.1016/S0378-1119(02)00592-9; Ehrlich M, 2003, J CELL BIOCHEM, V88, P899, DOI 10.1002/jcb.10464; Enomoto-Iwamoto M, 2001, OSTEOARTHR CARTILAGE, V9, pS76, DOI 10.1053/joca.2001.0448; Etoh T, 2004, AM J PATHOL, V164, P689, DOI 10.1016/S0002-9440(10)63156-2; Evans CJ, 2003, DEV CELL, V5, P673, DOI 10.1016/S1534-5807(03)00335-6; Fainaru O, 2004, EMBO J, V23, P969, DOI 10.1038/sj.emboj.7600085; Fossett N, 2001, DIFFERENTIATION, V69, P83, DOI 10.1046/j.1432-0436.2001.690202.x; Fujiwara M, 1999, BBA-GENE STRUCT EXPR, V1446, P265, DOI 10.1016/S0167-4781(99)00113-X; Geoffroy V, 1998, MAMM GENOME, V9, P54, DOI 10.1007/s003359900679; Ghozi MC, 1996, P NATL ACAD SCI USA, V93, P1935, DOI 10.1073/pnas.93.5.1935; Gilbert L, 2002, J BIOL CHEM, V277, P2695, DOI 10.1074/jbc.M106339200; Guo WH, 2002, ONCOGENE, V21, P8351, DOI 10.1038/sj.onc.1206037; Hayashi K, 2000, J IMMUNOL, V165, P6816, DOI 10.4049/jimmunol.165.12.6816; Hayashi K, 2001, J IMMUNOL, V167, P4957, DOI 10.4049/jimmunol.167.9.4957; Inada M, 1999, DEV DYNAM, V214, P279, DOI 10.1002/(SICI)1097-0177(199904)214:4<279::AID-AJA1>3.0.CO;2-W; Inoue K, 2002, NAT NEUROSCI, V5, P946, DOI 10.1038/nn925; Ito Y, 2003, CURR OPIN GENET DEV, V13, P43, DOI 10.1016/S0959-437X(03)00007-8; ITO Y, 1997, ONCOGENES TRANSCRIPT, V2, P107; Jimenez MJG, 2001, J CELL BIOL, V155, P1333, DOI 10.1083/jcb.200106147; Kalev-Zylinska ML, 2002, DEVELOPMENT, V129, P2015; Kanzler B, 1998, DEVELOPMENT, V125, P2587; Kataoka H, 2000, MECH DEVELOP, V98, P139, DOI 10.1016/S0925-4773(00)00445-7; Kim IS, 1999, MECH DEVELOP, V80, P159, DOI 10.1016/S0925-4773(98)00210-X; Komori T, 2003, J BONE MINER METAB, V21, P193, DOI 10.1007/s00774-002-0408-0; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kundu M, 2002, NAT GENET, V32, P639, DOI 10.1038/ng1050; Le XF, 1999, J BIOL CHEM, V274, P21651, DOI 10.1074/jbc.274.31.21651; Lebestky T, 2003, GENE DEV, V17, P348, DOI 10.1101/gad.1052803; Lebestky T, 2000, SCIENCE, V288, P146, DOI 10.1126/science.288.5463.146; Lecka-Czernik B, 1999, J CELL BIOCHEM, V74, P357, DOI 10.1002/(SICI)1097-4644(19990901)74:3<357::AID-JCB5>3.0.CO;2-7; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Lee KS, 2002, ONCOGENE, V21, P7156, DOI 10.1038/sj.onc.1205937; Lee MH, 1999, J CELL BIOCHEM, V73, P114, DOI 10.1002/(SICI)1097-4644(19990401)73:1<114::AID-JCB13>3.3.CO;2-D; Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200; Lengner CJ, 2002, MECH DEVELOP, V114, P167, DOI 10.1016/S0925-4773(02)00050-3; Levanon D, 1996, DNA CELL BIOL, V15, P175, DOI 10.1089/dna.1996.15.175; Levanon D, 2003, BLOOD CELL MOL DIS, V30, P161, DOI 10.1016/S1079-9796(03)00023-8; Levanon D, 2003, EMBO REP, V4, P560, DOI 10.1038/sj.embor.embor868; Levanon D, 2001, MECH DEVELOP, V109, P413, DOI 10.1016/S0925-4773(01)00537-8; Levanon D, 2001, GENE, V262, P23, DOI 10.1016/S0378-1119(00)00532-1; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; Li J, 1998, J BIOL CHEM, V273, P31009, DOI 10.1074/jbc.273.47.31009; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Lian JB, 2003, J CELL PHYSIOL, V196, P301, DOI 10.1002/jcp.10316; Liu B, 2003, BLOOD, V101, P124, DOI 10.1182/blood-2002-02-0398; LORSBACH RB, 2003, IN PRESS BLOOD; Miller J, 2002, NAT GENET, V32, P645, DOI 10.1038/ng1049; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; Mukouyama Y, 2000, DEV BIOL, V220, P27, DOI 10.1006/dbio.2000.9617; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Namba K, 2000, ONCOGENE, V19, P106, DOI 10.1038/sj.onc.1203257; Nibu K, 2000, BIOCHEM BIOPH RES CO, V279, P172, DOI 10.1006/bbrc.2000.3899; North T, 1999, DEVELOPMENT, V126, P2563; North TE, 2002, IMMUNITY, V16, P661, DOI 10.1016/S1074-7613(02)00296-0; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Otto F, 2003, J CELL BIOCHEM, V89, P9, DOI 10.1002/jcb.10491; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Park MH, 2001, J BONE MINER RES, V16, P885, DOI 10.1359/jbmr.2001.16.5.885; Pozner A, 2000, MOL CELL BIOL, V20, P2297, DOI 10.1128/MCB.20.7.2297-2307.2000; Rennert J, 2003, BMC EVOL BIOL, V3, DOI 10.1186/1471-2148-3-4; Rini D, 2001, GENE, V273, P13, DOI 10.1016/S0378-1119(01)00579-0; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; Satokata I, 2000, NAT GENET, V24, P391, DOI 10.1038/74231; Shi MJ, 1998, J IMMUNOL, V161, P6751; SIMEONE A, 1995, DEV DYNAM, V203, P61, DOI 10.1002/aja.1002030107; Spender LC, 2002, J VIROL, V76, P4919, DOI 10.1128/JVI.76.10.4919-4927.2002; Spinella-Jaegle S, 2001, J CELL SCI, V114, P2085; Stewart M, 2002, J VIROL, V76, P4364, DOI 10.1128/JVI.76.9.4364-4369.2002; Stewart M, 1997, P NATL ACAD SCI USA, V94, P8646, DOI 10.1073/pnas.94.16.8646; Stricker S, 2003, DEV COMP IMMUNOL, V27, P673, DOI 10.1016/S0145-305X(03)00037-5; Stricker S, 2002, DEV BIOL, V245, P95, DOI 10.1006/dbio.2002.0640; Sudhakar S, 2001, BIOCHEM BIOPH RES CO, V289, P616, DOI 10.1006/bbrc.2001.6033; Sun LX, 2001, CANCER RES, V61, P4994; Takamoto M, 2003, J ENDOCRINOL, V177, P413, DOI 10.1677/joe.0.1770413; Takeda S, 2001, GENE DEV, V15, P467, DOI 10.1101/gad.845101; TANAKA K, 1995, BIOCHEM BIOPH RES CO, V211, P1023, DOI 10.1006/bbrc.1995.1913; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Telfer JC, 2001, DEV BIOL, V229, P363, DOI 10.1006/dbio.2000.9991; Thirunavukkarasu K, 1998, MOL CELL BIOL, V18, P4197, DOI 10.1128/MCB.18.7.4197; Tou LQ, 2001, MOL CELL ENDOCRINOL, V183, P71, DOI 10.1016/S0303-7207(01)00594-9; Tribioli C, 1999, DEVELOPMENT, V126, P5699; Tsuji K, 2001, J BONE MINER METAB, V19, P213, DOI 10.1007/s007740170023; Vagner S, 2001, EMBO REP, V2, P893, DOI 10.1093/embo-reports/kve208; Vaillant F, 2002, J IMMUNOL, V169, P2866, DOI 10.4049/jimmunol.169.6.2866; Waki T, 2003, CANCER SCI, V94, P360, DOI 10.1111/j.1349-7006.2003.tb01447.x; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Woolf E, 2003, P NATL ACAD SCI USA, V100, P7731, DOI 10.1073/pnas.1232420100; Xiao ZS, 1998, GENE, V214, P187, DOI 10.1016/S0378-1119(98)00227-3; Xiao ZS, 2001, J CELL BIOCHEM, V82, P647, DOI 10.1002/jcb.1192; Xiao ZS, 2003, J CELL BIOCHEM, V88, P493, DOI 10.1002/jcb.10375; Yamashiro T, 2002, MECH DEVELOP, V119, pS107, DOI 10.1016/S0925-4773(03)00101-1; Yoshida CA, 2002, NAT GENET, V32, P633, DOI 10.1038/ng1015; Yousfi M, 2002, BIOCHEM BIOPH RES CO, V297, P641, DOI 10.1016/S0006-291X(02)02260-X; Zambotti A, 2002, J BIOL CHEM, V277, P41497, DOI 10.1074/jbc.M204271200; Zhang YW, 1997, ONCOGENE, V15, P367, DOI 10.1038/sj.onc.1201352; Zhang YW, 1997, MOL CELL BIOL, V17, P4133, DOI 10.1128/MCB.17.7.4133; Zhou YX, 2000, HUM MOL GENET, V9, P2001, DOI 10.1093/hmg/9.13.2001	123	215	221	2	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2004	23	24					4211	4219		10.1038/sj.onc.1207670	http://dx.doi.org/10.1038/sj.onc.1207670			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823BZ	15156175				2022-12-28	WOS:000221586000004
J	Chen, J; Yu, WM; Bunting, KD; Qu, CK				Chen, J; Yu, WM; Bunting, KD; Qu, CK			A negative role of SHP-2 tyrosine phosphatase in growth factor-dependent hematopoietic cell survival	ONCOGENE			English	Article						SHP-2; tyrosine phosphatase; hematopoietic cell survival; STAT5; IL-3	CYCLE PROGRESSION; BONE-MARROW; STAT5; PROTEIN; EXPRESSION; DIFFERENTIATION; PHOSPHORYLATION; APOPTOSIS; BINDING; DEATH	SHP-2 tyrosine phosphatase is highly expressed in hematopoietic cells; however, the function of SHP-2 in hematopoietic cell processes is not fully understood. Recent identification of SHP-2 mutations in childhood leukemia further emphasizes the importance of SHP-2 regulation in hematopoietic cells. We previously reported that SHP-2 played a positive role in IL-3-induced activation of Jak2 kinase in a catalytic-dependent manner. Interestingly, enforced expression of wild-type (WT) SHP-2 in Ba/F3 cells enhanced growth factor deprivation-induced apoptosis. Biochemical analyses revealed that although IL-3 activation of Jak2 kinase was increased, tyrosyl phosphorylation of its downstream substrate STAT5 was disproportionately decreased by the overexpression of SHP-2. Following IL-3 deprivation, the tyrosyl phosphorylation of STAT5 that is required for its antiapoptotic activity was rapidly diminished in SHP-2 overexpressing cells. As a result, reduction of the putative downstream targets of STAT5- Bcl-X-L and pim-1 was accelerated by overexpression of SHP-2. Further investigation showed that SHP-2 associated with STAT5, and that it was indeed able to dephosphorylate STAT5. Finally, overexpression of SHP-2 in primary bone marrow hematopoietic progenitor cells compromised their differentiative and proliferative potential, and enhanced growth factor withdrawal-induced cell death. And, the effect of SHP-2 overexpression on growth factor-dependent survival was diminished in STAT5-deficient hematopoietic cells. Taken together, these results suggest that SHP-2 tyrosine phosphatase negatively regulates hematopoietic cell survival by dephosphorylation of STAT5.	Amer Red Cross, Jerome H Holland Lab Biomed Sci, Dept Hematopoiesis, Rockville, MD 20855 USA; George Washington Univ, Med Ctr, Dept Anat & Cell Biol, Washington, DC 20037 USA	American Red Cross; George Washington University	Qu, CK (corresponding author), Amer Red Cross, Jerome H Holland Lab Biomed Sci, Dept Hematopoiesis, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.	quc@usa.redcross.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068212] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059380] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL68212] Funding Source: Medline; NIDDK NIH HHS [R01 DK059380] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aoki N, 2000, J BIOL CHEM, V275, P39718, DOI 10.1074/jbc.M005615200; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; Bone H, 1997, J BIOL CHEM, V272, P14470, DOI 10.1074/jbc.272.22.14470; Bunting KD, 2002, BLOOD, V99, P479, DOI 10.1182/blood.V99.2.479; Chan RJ, 2003, BLOOD, V102, P2074, DOI 10.1182/blood-2003-04-1171; CHEN Y, 2003, J BIOL CHEM, V278, P165; Chughtai N, 2002, J BIOL CHEM, V277, P31107, DOI 10.1074/jbc.M200156200; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Dragovich T, 1998, ONCOGENE, V17, P3207, DOI 10.1038/sj.onc.1202587; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; Persons DA, 1999, BLOOD, V93, P488, DOI 10.1182/blood.V93.2.488.402k17_488_499; Qu CK, 1998, ONCOGENE, V17, P433, DOI 10.1038/sj.onc.1201920; Qu CK, 2002, BBA-MOL CELL RES, V1592, P297, DOI 10.1016/S0167-4889(02)00322-1; Qu CK, 2001, BLOOD, V97, P911, DOI 10.1182/blood.V97.4.911; Qu CK, 1998, MOL CELL BIOL, V18, P6075, DOI 10.1128/MCB.18.10.6075; Qu CK, 1997, MOL CELL BIOL, V17, P5499, DOI 10.1128/MCB.17.9.5499; Rane SG, 2002, ONCOGENE, V21, P3334, DOI 10.1038/sj.onc.1205398; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Shelburne CP, 2003, BLOOD, V102, P1290, DOI 10.1182/blood-2002-11-3490; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; Shinjyo T, 2001, MOL CELL BIOL, V21, P854, DOI 10.1128/MCB.21.3.854-864.2001; Silva M, 1999, J BIOL CHEM, V274, P22165, DOI 10.1074/jbc.274.32.22165; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; Tartaglia M, 2003, NAT GENET, V34, P148, DOI 10.1038/ng1156; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Wang DM, 2000, EMBO J, V19, P392, DOI 10.1093/emboj/19.3.392; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; Wheadon H, 2003, BIOCHEM J, V376, P147, DOI 10.1042/BJ20031160; Wickremasinghe RG, 1999, BLOOD, V93, P3587, DOI 10.1182/blood.V93.11.3587.411k46_3587_3600; Yu CL, 2000, J BIOL CHEM, V275, P599, DOI 10.1074/jbc.275.1.599; Yu WM, 2003, ONCOGENE, V22, P5995, DOI 10.1038/sj.onc.1206846; Yu WM, 2002, BLOOD, V99, P2351, DOI 10.1182/blood.V99.7.2351; Yuan LP, 2003, J BIOL CHEM, V278, P15208, DOI 10.1074/jbc.M211327200; Zamorano J, 1998, J IMMUNOL, V160, P3502; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	42	35	37	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3659	3669		10.1038/sj.onc.1207471	http://dx.doi.org/10.1038/sj.onc.1207471			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15116097				2022-12-28	WOS:000221101700018
J	EL Naaman, C; Grum-Schwensen, B; Mansouri, A; Grigorian, M; Santoni-Rugiu, E; Hansen, T; Kriajevska, M; Schafer, BW; Heizmann, CW; Lukanidin, E; Ambartsumian, N				EL Naaman, C; Grum-Schwensen, B; Mansouri, A; Grigorian, M; Santoni-Rugiu, E; Hansen, T; Kriajevska, M; Schafer, BW; Heizmann, CW; Lukanidin, E; Ambartsumian, N			Cancer predisposition in mice deficient for the metastasis-associated Mts1(S100A4) gene	ONCOGENE			English	Article						animal models; Mts1(S100A4); p53; tumor development; tumor suppressor activity	TUMOR-SUPPRESSOR GENE; PROTEIN S100A4 P9KA; BINDING PROTEIN; WILD-TYPE; P53; EXPRESSION; CALCIUM; TARGET; CELLS; TP53	Metastasis-promoting Mts1(S100A4) protein belongs to the S100 family of Ca2+-binding proteins. A mouse strain with a germ-line inactivation of the S100A4 gene was generated. The mice were viable and did not display developmental abnormalities in the postnatal period. However, an abnormal sex ratio was observed in the litters with the S100A4-/- genotype, raising the possibility of a certain level of embryonic lethality in this strain. In all, 10% of 10-14-month-old S100A4-null animals developed tumors. This is a characteristic feature of mouse strains with inactivated tumor suppressor genes. Spontaneous tumors of S100A4-/- mice were p53 positive. Recently, we have shown that S100A4 interacts with p53 tumor suppressor protein and induces apoptosis. We proposed that impairment of this interaction could affect the apoptosis-promoting function of p53 that is involved in its tumor suppressor activity. The frequency of apoptosis in the spleen of S100A4-/- animals after whole-body gamma-irradiation was reduced compared to the wild-type animals. The same was true for the transcriptional activation of the p53 target genes - waf/p21/cip1 and bax. Taken together, these observations indicate that spontaneous tumors in S100A4-/- mice are a result of functional destabilization of p53 tumor suppressor gene.	Danish Canc Soc, Dept Mol Canc Biol, DK-2100 Copenhagen, Denmark; Max Planck Inst Biophys Chem, Dept Mol Cell Biol, D-37077 Gottingen, Germany; Rigshosp, Dept Pathol, DK-2100 Copenhagen, Denmark; Univ Zurich, Dept Pediat, Div Clin Chem & Biochem, CH-8032 Zurich, Switzerland	Danish Cancer Society; Max Planck Society; Rigshospitalet; University of Copenhagen; University of Zurich	Ambartsumian, N (corresponding author), Danish Canc Soc, Dept Mol Canc Biol, Strandblvd 49, DK-2100 Copenhagen, Denmark.	na@cancer.dk	Santoni-Rugiu, Eric/H-4913-2019; Santoni-Rugiu, Eric/AAH-3368-2020; Hansen, Thomas Folkmann/O-5965-2014; Hansen, Thomas/GWZ-2858-2022	Santoni-Rugiu, Eric/0000-0002-2283-3535; Hansen, Thomas Folkmann/0000-0001-6703-7762; Grum-Schwensen, Birgitte/0000-0001-6677-1869; Schafer, Beat/0000-0001-5988-2915				Al-Haddad S, 1999, AM J PATHOL, V155, P2057, DOI 10.1016/S0002-9440(10)65524-1; Ambartsumian N, 2001, ONCOGENE, V20, P4685, DOI 10.1038/sj.onc.1204636; Ambartsumian N, 1999, INVAS METAST, V18, P96; Ambartsumian NS, 1996, ONCOGENE, V13, P1621; ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; Bian JH, 1997, MOL CELL BIOL, V17, P6330, DOI 10.1128/MCB.17.11.6330; Borresen-Dale AL, 2003, HUM MUTAT, V21, P292, DOI 10.1002/humu.10174; Bourdon JC, 1997, ONCOGENE, V14, P85, DOI 10.1038/sj.onc.1200804; Bouvard V, 2000, ONCOGENE, V19, P649, DOI 10.1038/sj.onc.1203366; Buzard GS, 1996, MUTAT RES-REV GENET, V365, P43, DOI 10.1016/S0165-1110(96)90011-1; Cazorla M, 1998, MOL CARCINOGEN, V21, P251, DOI 10.1002/(SICI)1098-2744(199804)21:4<251::AID-MC4>3.0.CO;2-N; Chen DS, 1996, BIOCHEM SOC T, V24, pS352, DOI 10.1042/bst024352s; Chen HL, 2001, BIOCHEM BIOPH RES CO, V286, P1212, DOI 10.1006/bbrc.2001.5517; Christensen CRL, 1998, CANCER RES, V58, P1238; Cohn MA, 2001, NUCLEIC ACIDS RES, V29, P3335, DOI 10.1093/nar/29.16.3335; Da Silva IDCG, 2000, INT J ONCOL, V16, P231; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Davies BR, 2002, J PATHOL, V196, P292, DOI 10.1002/path.1051; DAVIES M, 1995, DNA CELL BIOL, V14, P825, DOI 10.1089/dna.1995.14.825; Davies MPA, 1996, ONCOGENE, V13, P1631; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Du XJ, 2002, MOL CELL BIOL, V22, P2821, DOI 10.1128/MCB.22.8.2821-2829.2002; Duddy SK, 1999, TOXICOL APPL PHARM, V156, P106, DOI 10.1006/taap.1999.8631; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Endo H, 2002, J BIOL CHEM, V277, P26396, DOI 10.1074/jbc.M202244200; Fei PW, 2002, CANCER RES, V62, P7316; Feng G, 2001, CANCER RES, V61, P7999; FORD HL, 1995, ONCOGENE, V10, P1597; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Grigorian M, 2001, J BIOL CHEM, V276, P22699, DOI 10.1074/jbc.M010231200; Hakem R, 2001, ANNU REV GENET, V35, P209, DOI 10.1146/annurev.genet.35.102401.090432; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Heizmann CW, 2002, FRONT BIOSCI-LANDMRK, V7, pD1356, DOI 10.2741/heizmann; Hobbs JAR, 2003, MOL CELL BIOL, V23, P2564, DOI 10.1128/MCB.23.7.2564-2576.2003; Hsieh HL, 2002, J CELL SCI, V115, P3149; Iacopetta B, 2003, HUM MUTAT, V21, P271, DOI 10.1002/humu.10175; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Johnson DG, 2000, MOL CARCINOGEN, V27, P151, DOI 10.1002/(SICI)1098-2744(200003)27:3<151::AID-MC1>3.0.CO;2-C; Klingelhofer J, 1997, DEV DYNAM, V210, P87, DOI 10.1002/(SICI)1097-0177(199710)210:2<87::AID-AJA2>3.0.CO;2-5; Komarova EA, 2000, ONCOGENE, V19, P3791, DOI 10.1038/sj.onc.1203717; Kriajevska M, 2002, J BIOL CHEM, V277, P5229, DOI 10.1074/jbc.M110976200; KRIAJEVSKA MV, 1994, J BIOL CHEM, V269, P19679; Kuperwasser C, 2000, AM J PATHOL, V157, P2151, DOI 10.1016/S0002-9440(10)64853-5; Lukanidin EM, 1996, CURR TOP MICROBIOL, V213, P171; Mandinova A, 1998, J CELL SCI, V111, P2043; Manitz MP, 2003, MOL CELL BIOL, V23, P1034, DOI 10.1128/MCB.23.3.1034-1043.2003; Mansouri A, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 3, P478; Mashimo T, 1998, P NATL ACAD SCI USA, V95, P11307, DOI 10.1073/pnas.95.19.11307; Mazzucchelli L, 2002, AM J PATHOL, V160, P7, DOI 10.1016/S0002-9440(10)64342-8; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; Meuwissen R, 2001, EXP CELL RES, V264, P100, DOI 10.1006/excr.2000.5146; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; Novitskaya V, 2000, J BIOL CHEM, V275, P41278, DOI 10.1074/jbc.M007058200; Passey RJ, 1999, J IMMUNOL, V163, P2209; PEDROCCHI M, 1994, INT J CANCER, V57, P684, DOI 10.1002/ijc.2910570513; Pelc P, 2003, HISTOPATHOLOGY, V42, P387, DOI 10.1046/j.1365-2559.2003.01588.x; Platt-Higgins AM, 2000, INT J CANCER, V89, P198, DOI 10.1002/(SICI)1097-0215(20000320)89:2<198::AID-IJC16>3.0.CO;2-L; Ridinger K, 1998, BBA-MOL CELL RES, V1448, P254, DOI 10.1016/S0167-4889(98)00137-2; Rosty C, 2002, AM J PATHOL, V160, P45, DOI 10.1016/S0002-9440(10)64347-7; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; SAUER B, 1993, METHOD ENZYMOL, V225, P890; Schafer BW, 2000, J BIOL CHEM, V275, P30623, DOI 10.1074/jbc.M002260200; Schuijer M, 2003, HUM MUTAT, V21, P285, DOI 10.1002/humu.10181; Staib F, 2003, HUM MUTAT, V21, P201, DOI 10.1002/humu.10176; Sun YB, 2000, J BIOL CHEM, V275, P11327, DOI 10.1074/jbc.275.15.11327; Sun YB, 1999, J BIOL CHEM, V274, P11535, DOI 10.1074/jbc.274.17.11535; Teratani T, 2002, BIOCHEM BIOPH RES CO, V291, P623, DOI 10.1006/bbrc.2002.6494; TURUSOV V, 1994, PATHOLOGY TUMORS LAB, V2; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; WETERMAN MAJ, 1993, CANCER RES, V53, P6061; Wu GS, 1998, ONCOGENE, V16, P2177, DOI 10.1038/sj.onc.1201755; Xiong ZG, 2000, EXP CELL RES, V257, P281, DOI 10.1006/excr.2000.4902; Yonemura Y, 2000, CLIN CANCER RES, V6, P4234	75	52	55	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3670	3680		10.1038/sj.onc.1207420	http://dx.doi.org/10.1038/sj.onc.1207420			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15116098				2022-12-28	WOS:000221101700019
J	De Benedetti, A; Graff, JR				De Benedetti, A; Graff, JR			eIF-4E expression and its role in malignancies and metastases	ONCOGENE			English	Review						eIF-4E oncogene; tumor vascularization; tumor progression; protein translation; tumor marker; metastasis	INITIATION-FACTOR 4E; CAP-BINDING PROTEIN; ENDOTHELIAL GROWTH-FACTOR; MESSENGER-RNA TRANSLATION; INTERNAL RIBOSOME ENTRY; HUMAN-TUMOR-CELLS; MYC-DEPENDENT APOPTOSIS; RAT EMBRYO FIBROBLASTS; 5' UNTRANSLATED REGION; WILD-TYPE P53	The contribution of the mRNA cap-binding protein, eIF-4E, to malignant transformation and progression has been illuminated over the past decade. eIF-4E overexpression has been demonstrated in human tumors of the breast, head and neck, colon, prostate, bladder, cervix and lung, and has been related to disease progression. Overexpression of eIF-4E in experimental models dramatically alters cellular morphology, enhances proliferation and induces cellular transformation, tumorigenesis and metastasis. Conversely, blocking eIF-4E function by expression of antisense RNA, or overexpression of the inhibitory eIF-4E binding proteins (4E-BPs), suppresses cellular transformation, tumor growth, tumor invasiveness and metastasis. Although eIF-4E regulates the recruitment of mRNA to ribosomes, and thereby globally regulates cap-dependent protein synthesis, eIF-4E contributes to malignancy by selectively enabling the translation of a limited pool of mRNAs - those that generally encode key proteins involved in cellular growth, angiogenesis, survival and malignancy (e.g. cyclin D1, c-myc, vascular endothelial growth factor, matrix metalloprotease 9). A deeper understanding of the role of eIF-4E in regulating the translation of the diverse gene products involved in all aspects of malignancy will improve the capacity to exploit eIF-4E as a therapeutic target and as a marker for human cancer progression.	Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Canc Div, Indianapolis, IN 46285 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Eli Lilly	De Benedetti, A (corresponding author), Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, 1501 Kings Highway,POB 33932, Shreveport, LA 71130 USA.	adeben@lsuhsc.edu		de benedetti, arrigo/0000-0002-4198-8647				Abid MR, 1999, J BIOL CHEM, V274, P35991, DOI 10.1074/jbc.274.50.35991; Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Anthony B, 1996, INT J CANCER, V65, P858, DOI 10.1002/(SICI)1097-0215(19960315)65:6<858::AID-IJC25>3.0.CO;2-Z; ARRICK BA, 1991, MOL CELL BIOL, V11, P4306, DOI 10.1128/MCB.11.9.4306; Auvinen M, 1997, CANCER RES, V57, P3016; Bamford RN, 1996, P NATL ACAD SCI USA, V93, P2897, DOI 10.1073/pnas.93.7.2897; BASERGA R, 1990, CANCER RES, V50, P6769; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; Berkel HJ, 2001, CANCER EPIDEM BIOMAR, V10, P663; BOMMER UA, 1994, CELL MOL BIOL RES, V40, P633; Brown CY, 1999, ONCOGENE, V18, P5631, DOI 10.1038/sj.onc.1202949; Calkhoven CF, 2000, GENE DEV, V14, P1920; Capoulade C, 1998, ONCOGENE, V16, P1603, DOI 10.1038/sj.onc.1201702; Carter PS, 1999, ONCOGENE, V18, P4326, DOI 10.1038/sj.onc.1202890; Cher ML, 1996, CANCER RES, V56, P3091; Child SJ, 1999, INT J BIOCHEM CELL B, V31, P201, DOI 10.1016/S1357-2725(98)00068-5; Crew JP, 2000, BRIT J CANCER, V82, P161; DARVEAU A, 1985, P NATL ACAD SCI USA, V82, P2315, DOI 10.1073/pnas.82.8.2315; De Benedetti Arrigo, 1994, Molecular and Cellular Differentiation, V2, P347; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; DeFatta RJ, 1999, INT J CANCER, V80, P516, DOI 10.1002/(SICI)1097-0215(19990209)80:4<516::AID-IJC6>3.3.CO;2-Z; Defatta RJ, 2003, INT J ONCOL, V23, P1709; DeFatta RJ, 2002, CANCER GENE THER, V9, P505, DOI 10.1038/sj.cgt.7700469; DeFatta RJ, 2002, CANCER GENE THER, V9, P573, DOI 10.1038/sj.cgt.7700468; DeFatta RJ, 2000, LARYNGOSCOPE, V110, P928, DOI 10.1097/00005537-200006000-00007; DUNCAN R, 1987, J BIOL CHEM, V262, P380; FAGAN RJ, 1991, J BIOL CHEM, V266, P16518; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; Franklin S, 1999, ARCH OTOLARYNGOL, V125, P177, DOI 10.1001/archotol.125.2.177; Gao MX, 1998, J BIOL CHEM, V273, P4622, DOI 10.1074/jbc.273.8.4622; GEBALLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159, DOI 10.1016/0968-0004(94)90277-1; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; GOSPODAROWICZ D, 1987, J CELL PHYSIOL, P15; Graff Jeremy R, 2002, Expert Opin Ther Targets, V6, P103, DOI 10.1517/14728222.6.1.103; GRAFF JR, 1995, INT J CANCER, V60, P255; Graff JR, 1997, BIOCHEM BIOPH RES CO, V240, P15, DOI 10.1006/bbrc.1997.7592; Graff JR, 2003, CLIN EXP METASTAS, V20, P265, DOI 10.1023/A:1022943419011; Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Hensold JO, 1997, NUCLEIC ACIDS RES, V25, P2869, DOI 10.1093/nar/25.14.2869; Hernandez-Munoz I, 2003, CANCER RES, V63, P4188; Hidalgo M, 2000, ONCOGENE, V19, P6680, DOI 10.1038/sj.onc.1204091; HIREMATH LS, 1985, J BIOL CHEM, V260, P7843; Holmlund JT, 1999, CURR OPIN MOL THER, V1, P372; Hoover DS, 1997, CELL GROWTH DIFFER, V8, P1371; Huang SL, 2003, CANCER BIOL THER, V2, P222, DOI 10.4161/cbt.2.3.360; Jiang Y, 2002, CANCER RES, V62, P1910; Jones RM, 1996, MOL CELL BIOL, V16, P4754; KEREKATTE V, 1995, INT J CANCER, V64, P27, DOI 10.1002/ijc.2910640107; Kevil C, 1995, ONCOGENE, V11, P2339; Kevil CG, 1996, INT J CANCER, V65, P785, DOI 10.1002/(SICI)1097-0215(19960315)65:6<785::AID-IJC14>3.0.CO;2-3; KLAGSBRUN M, 1986, P NATL ACAD SCI USA, V83, P2448, DOI 10.1073/pnas.83.8.2448; KLEIN PS, 1994, SCIENCE, V265, P803, DOI 10.1126/science.8047887; Koch G, 1980, Ann N Y Acad Sci, V339, P280, DOI 10.1111/j.1749-6632.1980.tb15984.x; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Landers JE, 1997, CANCER RES, V57, P3562; LANDERS JE, 1994, ONCOGENE, V9, P2745; LAZARISKARATZAS A, 1992, GENE DEV, V6, P1631, DOI 10.1101/gad.6.9.1631; LAZARISKARATZAS A, 1992, MOL CELL BIOL, V12, P1234, DOI 10.1128/MCB.12.3.1234; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Li BDL, 2002, ANN SURG, V235, P732, DOI 10.1097/00000658-200205000-00016; Li BDL, 1997, CANCER-AM CANCER SOC, V79, P2385; Li BDL, 1998, ANN SURG, V227, P756, DOI 10.1097/00000658-199805000-00016; Li S, 2003, J BIOL CHEM, V278, P3015, DOI 10.1074/jbc.M208821200; Li Y, 2001, ONCOGENE, V20, P726, DOI 10.1038/sj.onc.1204147; LODISH HF, 1974, NATURE, V251, P385, DOI 10.1038/251385a0; Luan FL, 2003, KIDNEY INT, V63, P917, DOI 10.1046/j.1523-1755.2003.00805.x; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MARTH JD, 1988, NATURE, V332, P171, DOI 10.1038/332171a0; MATHEWSGREER J, 2002, J APPL RES, V2, P77; MIYAGI Y, 1995, CANCER LETT, V91, P247, DOI 10.1016/0304-3835(95)03737-H; MORLEY SJ, 1994, MOL BIOL REP, V19, P221, DOI 10.1007/BF00986964; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nathan CA, 1997, ONCOGENE, V15, P1087, DOI 10.1038/sj.onc.1201272; Nathan CAO, 1997, ONCOGENE, V15, P579, DOI 10.1038/sj.onc.1201216; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; NIELSEN FC, 1990, J BIOL CHEM, V265, P13431; Noma T, 1991, GROWTH FACTORS, V4, P247, DOI 10.3109/08977199109043910; Pardo OE, 2002, J BIOL CHEM, V277, P12040, DOI 10.1074/jbc.M109006200; PELLETIER J, 1987, BIOCHEM CELL BIOL, V65, P576, DOI 10.1139/o87-074; Peralba JM, 2003, CLIN CANCER RES, V9, P2887; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Polunovsky VA, 1996, MOL CELL BIOL, V16, P6573; Polunovsky VA, 2000, J BIOL CHEM, V275, P24776, DOI 10.1074/jbc.M001938200; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; RAO CD, 1988, MOL CELL BIOL, V8, P284, DOI 10.1128/MCB.8.1.284; Raught B, 1996, CANCER RES, V56, P4382; Reddy KS, 1997, CANCER GENET CYTOGEN, V95, P206, DOI 10.1016/S0165-4608(96)00424-4; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; RHOADS RE, 1993, PROG NUCLEIC ACID RE, V46, P183, DOI 10.1016/S0079-6603(08)61022-3; RINKERSCHAEFFER CW, 1993, INT J CANCER, V55, P841, DOI 10.1002/ijc.2910550525; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; Rosenwald IB, 1999, ONCOGENE, V18, P2507, DOI 10.1038/sj.onc.1202563; Rosenwald IB, 2001, CANCER-AM CANCER SOC, V92, P2164, DOI 10.1002/1097-0142(20011015)92:8<2164::AID-CNCR1559>3.0.CO;2-A; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; SAITO H, 1983, P NATL ACAD SCI-BIOL, V80, P7476, DOI 10.1073/pnas.80.24.7476; Scheper GC, 2002, EUR J BIOCHEM, V269, P5350, DOI 10.1046/j.1432-1033.2002.03291.x; SCHINDLER R, 1990, J BIOL CHEM, V265, P10232; Scott PAE, 1998, BRIT J CANCER, V77, P2120, DOI 10.1038/bjc.1998.356; Seki N, 2002, CLIN CANCER RES, V8, P3046; SHANTZ LM, 1994, CANCER RES, V54, P2313; Shantz LM, 1996, CANCER RES, V56, P3265; SHANTZ LM, 1994, BIOCHEM J, V302, P765, DOI 10.1042/bj3020765; Shevde LA, 2003, CANCER LETT, V198, P1, DOI 10.1016/S0304-3835(03)00304-5; Short JD, 2002, J BIOL CHEM, V277, P32697, DOI 10.1074/jbc.M204553200; Sillje HHW, 2001, CURR BIOL, V11, P1068, DOI 10.1016/S0960-9822(01)00298-6; Simizu S, 2003, CANCER LETT, V193, P83, DOI 10.1016/S0304-3835(02)00719-X; SMITH R, 1988, EMBO J, V7, P1013, DOI 10.1002/j.1460-2075.1988.tb02908.x; Stacey DW, 2003, CURR OPIN CELL BIOL, V15, P158, DOI 10.1016/S0955-0674(03)00008-5; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; Tamm I, 2001, LANCET, V358, P489, DOI 10.1016/S0140-6736(01)05629-X; Tan A, 2000, ONCOGENE, V19, P1437, DOI 10.1038/sj.onc.1203446; THACH RE, 1992, CELL, V68, P177, DOI 10.1016/0092-8674(92)90461-K; THEILLET C, 1989, ONCOGENE, V4, P915; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; WANG CY, 1993, CELL GROWTH DIFFER, V4, P871; Wang ST, 1999, AM J PATHOL, V155, P247, DOI 10.1016/S0002-9440(10)65118-8; WELLSTEIN A, 1990, CELL GROWTH DIFFER, V1, P63; WELLSTEIN A, 1991, MOL F ONCOLOGY, P403; WILLIAMS J, 1998, AACR SPEC C ANG CANC; Wood MW, 1996, J BIOL CHEM, V271, P8115, DOI 10.1074/jbc.271.14.8115; Yang YJ, 2003, WORLD J GASTROENTERO, V9, P1707, DOI 10.3748/wjg.v9.i8.1707; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x; Zhong H, 1999, CANCER RES, V59, P5830; Zimmer SG, 2000, ANTICANCER RES, V20, P1343	135	601	630	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2004	23	18					3189	3199		10.1038/sj.onc.1207545	http://dx.doi.org/10.1038/sj.onc.1207545			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	813AJ	15094768				2022-12-28	WOS:000220879700007
J	Janne, PA; Li, C; Zhao, XJ; Girard, L; Chen, TH; Minna, J; Christiani, DC; Johnson, BE; Meyerson, M				Janne, PA; Li, C; Zhao, XJ; Girard, L; Chen, TH; Minna, J; Christiani, DC; Johnson, BE; Meyerson, M			High-resolution single-nucleotide polymorphism array and clustering analysis of loss of heterozygosity in human lung cancer cell lines	ONCOGENE			English	Article						lung neoplasm; non-small cell; small-cell carcinoma; loss of heterozygosity; single-nucleotide polymorphism	GENOME-WIDE DETECTION; GENE-EXPRESSION; TUMOR PROGRESSION; BLADDER-CANCER; ADENOCARCINOMA; CARCINOMAS; CLASSIFICATION; PATTERNS; SURVIVAL; DNA	Chromosomal loss of heterozygosity (LOH) is a common mechanism for the inactivation of tumor suppressor genes in human epithelial cancers. Hybridization to single-nucleotide polymorphism (SNP) arrays is an efficient method to detect genome-wide cancer LOH. Here, we survey LOH patterns in a panel of 33 human lung cancer cell lines using SNP array hybridization containing 1500 SNPs. We compared the LOH patterns generated by SNP array hybridization to those previously obtained by 399 microsatellite markers and find a high degree of concordance between the two methods. A novel informatics platform, dChipSNP, was used to perform hierarchical tumor clustering based on genome-wide LOH patterns. We demonstrate that this method can separate non-small-cell and small-cell lung cancer samples based on their shared LOH. Furthermore, we analysed seven human lung cancer cell lines using a novel 10000 SNP array and demonstrate that this is an efficient and reliable method of high-density allelotyping. Using this array, we identified small regions of LOH that were not detected by lower density SNP arrays or by standard microsatellite marker panels.	Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Boston, MA USA; Dana Farber Canc Inst, Dept Biostat Sci, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Pulm & Crit Care Unit, Boston, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard T.H. Chan School of Public Health; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Massachusetts General Hospital	Meyerson, M (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, Mayer 446,44 Binney St, Boston, MA 02115 USA.	matthew_meyerson@dfci.harvard.edu	Meyerson, Matthew L/E-7123-2012; Wang, Weili/D-1546-2011		NATIONAL CANCER INSTITUTE [K12CA087723, R01CA092824, P50CA070907, P30CA006516] Funding Source: NIH RePORTER; NCI NIH HHS [1K12CA87723-01, 2P30 CA06516-39, P50CA70907, R01CA92824] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Dumur CI, 2003, GENOMICS, V81, P260, DOI 10.1016/S0888-7543(03)00020-X; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; FONG KM, 1994, GENE CHROMOSOME CANC, V10, P183, DOI 10.1002/gcc.2870100306; FONG KM, 1995, CANCER RES, V55, P220; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Girard L, 2000, CANCER RES, V60, P4894; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Hoque MO, 2003, CANCER RES, V63, P2216; JANNE PA, 2002, P AM ASS CAN RES, V43, pA3147; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Kennedy GC, 2003, NAT BIOTECHNOL, V21, P1233, DOI 10.1038/nbt869; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Lieberfarb ME, 2003, CANCER RES, V63, P4781; LIN M, 2003, IN PRESS BIOINFORMAT; Lindblad-Toh K, 2000, NAT BIOTECHNOL, V18, P1001, DOI 10.1038/79269; Mei R, 2000, GENOME RES, V10, P1126, DOI 10.1101/gr.10.8.1126; Mitsudomi T, 1996, CLIN CANCER RES, V2, P1185; Osada H, 2002, ONCOGENE, V21, P7421, DOI 10.1038/sj.onc.1205802; Primdahl H, 2002, J NATL CANCER I, V94, P216; Reich DE, 2003, NAT GENET, V33, P457, DOI 10.1038/ng1133; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; Sekido Y, 2003, ANNU REV MED, V54, P73, DOI 10.1146/annurev.med.54.101601.152202; Stanton SE, 2000, GENE CHROMOSOME CANC, V27, P323, DOI 10.1002/(SICI)1098-2264(200003)27:3<323::AID-GCC14>3.0.CO;2-P; Tseng JE, 1999, CANCER RES, V59, P4798; Virmani AK, 1998, GENE CHROMOSOME CANC, V21, P308, DOI 10.1002/(SICI)1098-2264(199804)21:4<308::AID-GCC4>3.0.CO;2-2; WANG ZC, 2003, IN PRESS CANC RES; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835	30	79	92	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2004	23	15					2716	2726		10.1038/sj.onc.1207329	http://dx.doi.org/10.1038/sj.onc.1207329			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	810OZ	15048096				2022-12-28	WOS:000220714900013
J	Izzi, L; Attisano, L				Izzi, L; Attisano, L			Regulation of the TGF beta signalling pathway by ubiquitin-mediated degradation	ONCOGENE			English	Review						smad; smurf; ubiquitination	ANAPHASE-PROMOTING COMPLEX; PROTEASOMAL DEGRADATION; DEPENDENT DEGRADATION; NUCLEAR EXPORT; PROTEIN; LIGASE; RECEPTOR; SMURF1; SMAD2; FAMILY	The transforming growth factor-beta (TGFbeta) superfamily controls a plethora of biological responses, and alterations in its signalling pathway are associated with a range of human diseases, including cancer. TGFbeta superfamily ligands signal through a heteromeric complex of Ser/ Thr kinase receptors that propagate the signal to the Smad family of intracellular proteins. The ubiquitin-mediated proteasomal degradation pathway is an evolutionary conserved cascade that tightly regulates TGFbeta superfamily signalling. Both the size of the Smad pool in unstimulated cells and Smad protein levels subsequent to the activation of the pathway are controlled by ubiquitination. E3 ligases are components of the ubiquitin-degradation complex that specifically recognize targeted proteins and the E3 ligases, Smad ubiquitination-related factor 1 (Smurf1), Smurf2 and SCF/Roc1 have been implicated in Smad degradation. The Smurfs are of particular importance to TGFbeta signalling, as Smads also function as adapters that recruit the Smurfs to various pathway components including the TGFbeta receptor complex and the transcriptional repressor, SnoN, and thereby regulate the degradation of these Smad-associating proteins. Thus, by controlling the level of Smads as well as positive and negative regulators of the pathway, Smurfs provide for complex and. ne control of signalling output. Finally, growing evidence demonstrates that ubiquitination and proteasomal degradation is also implicated in the turnover of tumor-derived Smad mutants and may thus contribute to disease progression.	Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Attisano, L (corresponding author), Univ Toronto, Dept Biochem, Med Sci Bldg,Room 6336, Toronto, ON M5S 1A8, Canada.	liliana.attisano@utoronto.ca	高, 雨莉/HGU-8187-2022					ARORA K, 1994, GENE DEV, V8, P2588, DOI 10.1101/gad.8.21.2588; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Desterro JMP, 2000, CELL MOL LIFE SCI, V57, P1207, DOI 10.1007/PL00000760; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Dumont E, 2003, J BIOL CHEM, V278, P24881, DOI 10.1074/jbc.M212496200; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Ehrlich M, 2001, J CELL SCI, V114, P1777; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Fukuchi M, 2002, CANCER RES, V62, P7162; Fukuchi M, 2001, MOL BIOL CELL, V12, P1431, DOI 10.1091/mbc.12.5.1431; Gronroos E, 2002, MOL CELL, V10, P483, DOI 10.1016/S1097-2765(02)00639-1; Gruendler C, 2001, J BIOL CHEM, V276, P46533, DOI 10.1074/jbc.M105500200; Hayes S, 2002, J CELL BIOL, V158, P1239, DOI 10.1083/jcb.200204088; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Imoto S, 2003, J BIOL CHEM, V278, P34253, DOI 10.1074/jbc.M304961200; Itoh S, 1998, J BIOL CHEM, V273, P29195, DOI 10.1074/jbc.273.44.29195; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Lee PSW, 2003, J BIOL CHEM, V278, P27853, DOI 10.1074/jbc.M301755200; Lin X, 2003, J BIOL CHEM, V278, P31043, DOI 10.1074/jbc.C300112200; Lin X, 2003, J BIOL CHEM, V278, P18714, DOI 10.1074/jbc.M302243200; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Liu XH, 2000, EMBO J, V19, P6759, DOI 10.1093/emboj/19.24.6759; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; Long JY, 2003, P NATL ACAD SCI USA, V100, P9791, DOI 10.1073/pnas.1733973100; Lu ZX, 2002, J BIOL CHEM, V277, P29363, DOI 10.1074/jbc.M203495200; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Maurice D, 2001, J BIOL CHEM, V276, P43175, DOI 10.1074/jbc.M105895200; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Moren A, 2000, ONCOGENE, V19, P4396, DOI 10.1038/sj.onc.1203798; Moren A, 2003, J BIOL CHEM, V278, P33571, DOI 10.1074/jbc.M300159200; Moustakas A, 2001, J CELL SCI, V114, P4359; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Murakami G, 2003, MOL BIOL CELL, V14, P2809, DOI 10.1091/mbc.E02-07-0441; Penheiter SG, 2002, MOL CELL BIOL, V22, P4750, DOI 10.1128/MCB.22.13.4750-4759.2002; Podos SD, 2001, DEV CELL, V1, P567, DOI 10.1016/S1534-5807(01)00057-0; Saha D, 2001, J BIOL CHEM, V276, P29531, DOI 10.1074/jbc.M100069200; Schwartz DC, 2003, TRENDS BIOCHEM SCI, V28, P321, DOI 10.1016/S0968-0004(03)00113-0; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Stroschein SL, 2001, GENE DEV, V15, P2822; Subramaniam V, 2003, BRIT J CANCER, V89, P1538, DOI 10.1038/sj.bjc.6601301; Suzuki C, 2002, J BIOL CHEM, V277, P39919, DOI 10.1074/jbc.M201901200; Tajima Y, 2003, J BIOL CHEM, V278, P10716, DOI 10.1074/jbc.M212663200; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Wan M, 2002, EMBO REP, V3, P171, DOI 10.1093/embo-reports/kvf024; Wan Y, 2001, MOL CELL, V8, P1027, DOI 10.1016/S1097-2765(01)00382-3; Wang HR, 2003, SCIENCE, V302, P1775, DOI 10.1126/science.1090772; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; Xu J, 2000, P NATL ACAD SCI USA, V97, P4820, DOI 10.1073/pnas.97.9.4820; Ying SX, 2003, J BIOL CHEM, V278, P39029, DOI 10.1074/jbc.M301193200; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhao M, 2003, J BIOL CHEM, V278, P27939, DOI 10.1074/jbc.M304132200; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	61	210	232	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2004	23	11					2071	2078		10.1038/sj.onc.1207412	http://dx.doi.org/10.1038/sj.onc.1207412			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	803EC	15021894				2022-12-28	WOS:000220213400011
J	Reis, EM; Nakaya, HI; Louro, R; Canavez, FC; Flatschart, AVF; Almeida, GT; Egidio, CM; Paquola, AC; Machado, AA; Festa, F; Yamamoto, D; Alvarenga, R; da Silva, CC; Brito, GC; Simon, SD; Moreira, CA; Leite, KR; Camara-Lopes, LH; Campos, FS; Gimba, E; Vignal, GM; El-Dorry, H; Sogayar, MC; Barcinski, MA; da Silva, AM; Verjovski-Almeida, S				Reis, EM; Nakaya, HI; Louro, R; Canavez, FC; Flatschart, AVF; Almeida, GT; Egidio, CM; Paquola, AC; Machado, AA; Festa, F; Yamamoto, D; Alvarenga, R; da Silva, CC; Brito, GC; Simon, SD; Moreira, CA; Leite, KR; Camara-Lopes, LH; Campos, FS; Gimba, E; Vignal, GM; El-Dorry, H; Sogayar, MC; Barcinski, MA; da Silva, AM; Verjovski-Almeida, S			Antisense intronic non-coding RNA levels correlate to the degree of tumor differentiation in prostate cancer	ONCOGENE			English	Article						prostate cancer; Gleason score; intronic transcripts; antisense RNA; microarray	GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVITY; SEQUENCE; HUMAN-CHROMOSOME-21; SITES	A large fraction of transcripts are expressed antisense to introns of known genes in the human genome. Here we show the construction and use of a cDNA microarray platform enriched in intronic transcripts to assess their biological relevance in pathological conditions. To validate the approach, prostate cancer was used as a model, and 27 patient tumor samples with Gleason scores ranging from 5 to 10 were analyzed. We find that a considerably higher fraction (6.6%,[23/346]) of intronic transcripts are significantly correlated (Pless than or equal to0.001) to the degree of prostate tumor differentiation ( Gleason score) when compared to transcripts from unannotated genomic regions (1%,[6/539]) or from exons of known genes (2%,[27/1369]). Among the top twelve transcripts most correlated to tumor differentiation, six are antisense intronic messages as shown by orientation-specific RTPCR or Northern blot analysis with strand-specific riboprobe. Orientation-specific real-time RT-PCR with six tumor samples, confirmed the correlation ( P = 0.024) between the low/high degrees of tumor differentiation and antisense intronic RASSF1 transcript levels. The need to use intron arrays to reveal the transcriptome profile of antisense intronic RNA in cancer has clearly emerged.	Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05508900 Sao Paulo, Brazil; Univ Sao Paulo, Inst Quim, Lab Bioinformat, BR-05508900 Sao Paulo, Brazil; Hosp Israelita Albert Einstein, Div Oncol, BR-05651901 Sao Paulo, Brazil; Hosp Sirio Libanes, Lab Patol Cirurg & Mol, BR-01308050 Sao Paulo, Brazil; Inst Nacl Canc MS, BR-20230130 Rio De Janeiro, Brazil	Universidade de Sao Paulo; Universidade de Sao Paulo; Hospital Israelita Albert Einstein; Hospital Sirio Libanes	Verjovski-Almeida, S (corresponding author), Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05508900 Sao Paulo, Brazil.	verjo@iq.usp.br	Reis, Eduardo M/H-2008-2011; LEITE, KATIA RM/C-2055-2008; Gimba, Etel/B-4473-2016; Brito, Glauber/C-4415-2013; Tesaarin e Almeida, Giulliana/F-5936-2013; Sogayar, Mari C/B-3980-2017; Nakaya, Helder/AAF-1738-2020; Gimba, Etel/H-7195-2012; moreira-filho, carlos alberto/J-2551-2014; da Silva, Aline Maria/C-3649-2012; Reis, Eduardo Moraes Rego/AAF-3553-2020; Nakaya, Helder I/A-1397-2010; Verjovski-Almeida, Sergio/E-4082-2012	Reis, Eduardo M/0000-0002-9556-3070; LEITE, KATIA RM/0000-0002-2615-7730; Brito, Glauber/0000-0002-9887-3939; Sogayar, Mari C/0000-0003-4805-4609; Nakaya, Helder/0000-0001-5297-9108; moreira-filho, carlos alberto/0000-0003-3433-4714; da Silva, Aline Maria/0000-0001-9249-4922; Nakaya, Helder I/0000-0001-5297-9108; Verjovski-Almeida, Sergio/0000-0002-6356-2401; Festa, Fernanda/0000-0002-2822-823X				Best CJM, 2003, DIAGN MOL PATHOL, V12, P63, DOI 10.1097/00019606-200306000-00001; Brentani H, 2003, P NATL ACAD SCI USA, V100, P13418, DOI 10.1073/pnas.1233632100; Brunschwig EB, 2003, CANCER RES, V63, P1568; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Camargo AA, 2001, P NATL ACAD SCI USA, V98, P12103, DOI 10.1073/pnas.201182798; Cawley S, 2004, CELL, V116, P499, DOI 10.1016/S0092-8674(04)00127-8; Chen GQ, 2000, GENE, V249, P1, DOI 10.1016/S0378-1119(00)00161-X; Epstein JI, 1996, AM J SURG PATHOL, V20, P286, DOI 10.1097/00000478-199603000-00004; Gemmill RM, 1998, P NATL ACAD SCI USA, V95, P9572, DOI 10.1073/pnas.95.16.9572; Gleason DF, 1977, UROLOGIC PATHOLOGY P, P171; Iseli C, 1999, Proc Int Conf Intell Syst Mol Biol, P138; Kampa D, 2004, GENOME RES, V14, P331, DOI 10.1101/gr.2094104; Kapranov P, 2002, SCIENCE, V296, P916, DOI 10.1126/science.1068597; KHOCHBIN S, 1989, EMBO J, V8, P4107, DOI 10.1002/j.1460-2075.1989.tb08595.x; Kiyosawa H, 2003, GENOME RES, V13, P1324, DOI 10.1101/gr.982903; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Lee JT, 1999, NAT GENET, V21, P400, DOI 10.1038/7734; Liu LM, 2002, ONCOGENE, V21, P6835, DOI 10.1038/sj.onc.1205814; Liu YL, 1996, GENOMICS, V31, P58, DOI 10.1006/geno.1996.0009; McManus MT, 2003, SEMIN CANCER BIOL, V13, P253, DOI 10.1016/S1044-579X(03)00038-5; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; Neto ED, 2000, P NATL ACAD SCI USA, V97, P3491; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Rinn JL, 2003, GENE DEV, V17, P529, DOI 10.1101/gad.1055203; Sanchez-Carbayo M, 2002, CANCER RES, V62, P6973; Shendure J, 2002, GENOME BIOL, V3; Shoemaker DD, 2001, NATURE, V409, P922, DOI 10.1038/35057141; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Sleutels F, 2000, CURR OPIN GENET DEV, V10, P229, DOI 10.1016/S0959-437X(00)00062-9; Sorek R, 2003, NUCLEIC ACIDS RES, V31, P1067, DOI 10.1093/nar/gkg170; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; TASHEVA ES, 1995, GENE DEV, V9, P304, DOI 10.1101/gad.9.3.304; Tufarelli C, 2003, NAT GENET, V34, P157, DOI 10.1038/ng1157; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Yelin R, 2003, NAT BIOTECHNOL, V21, P379, DOI 10.1038/nbt808	37	115	141	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6684	6692		10.1038/sj.onc.1207880	http://dx.doi.org/10.1038/sj.onc.1207880			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15221013				2022-12-28	WOS:000223530800017
J	Kowolik, CM; Liang, SJ; Yu, Y; Yee, JK				Kowolik, CM; Liang, SJ; Yu, Y; Yee, JK			Cre-mediated reversible immortalization of human renal proximal tubular epithelial cells	ONCOGENE			English	Article						immortalization; lentiviral vector; telomerase; T antigen; kidney	HUMAN-FIBROBLASTS; TELOMERASE ACTIVATION; CELLULAR SENESCENCE; CATALYTIC SUBUNIT; HUMAN HEPATOCYTES; DOME FORMATION; IN-VIVO; EXPRESSION; ONCOGENE; TRANSFORMATION	Primary human renal proximal tubule epithelial cells (RPTECs) are of limited use for basic research and for clinical applications due to their limited lifespan in culture. Here we used two lentivirus vectors carrying the human telomerase (hTERT) and the SV40T antigen (Tag) flanked by loxP sites to reversibly immortalize RPTECs. Transduced RPTEC clones continued to proliferate while retaining biochemical and functional characteristics of primary cells. The clones exhibited contact-inhibited, anchorage- and growth factor-dependent growth and did not form tumors in nude mice, suggesting that the cells were not transformed. Transient Cre expression in these cells led to efficient proviral deletion, upregulation of some renal specific activities, and decreased growth rates. Ultimately, the cells underwent replicative senescence, indicating intact cell cycle control. Thus, reversible immortalization allows the expansion of human RPTECs, leading to large production of RPTECs that retain most tissue-specific properties.	City Hope Natl Med Ctr, Beckman Res Inst, Dept Virol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope	Yee, JK (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Virol, Miller Bldg 110,1500 E Duarte Rd, Duarte, CA 91010 USA.	jyee@coh.org			NCI NIH HHS [R21 CA101629] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA101629] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berghella L, 1999, HUM GENE THER, V10, P1607, DOI 10.1089/10430349950017617; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Burger AM, 1998, INT J ONCOL, V13, P1043; Condon J, 2002, BIOL REPROD, V67, P506, DOI 10.1095/biolreprod67.2.506; DEYOUNG LM, 1978, CANCER RES, V38, P3697; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DREHER D, 1992, AM J PHYSIOL, V262, pC358, DOI 10.1152/ajpcell.1992.262.2.C358; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HURLIN PJ, 1989, P NATL ACAD SCI USA, V86, P187, DOI 10.1073/pnas.86.1.187; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; JOLY V, 1990, J PHARMACOL EXP THER, V255, P17; Kawano Y, 2003, BLOOD, V101, P532, DOI 10.1182/blood-2002-04-1268; Kim BH, 2000, EXP MOL MED, V32, P29, DOI 10.1038/emm.2000.6; Kim D, 2002, KIDNEY INT, V61, P464, DOI 10.1046/j.1523-1755.2002.00153.x; Kim H, 2002, BIOCHEM J, V365, P765, DOI 10.1042/BJ20011848; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Kobayashi N, 2000, SCIENCE, V287, P1258, DOI 10.1126/science.287.5456.1258; Kowolik CM, 2002, MOL THER, V5, P762, DOI 10.1006/mthe.2002.0603; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEVER JE, 1979, P NATL ACAD SCI USA, V76, P1323, DOI 10.1073/pnas.76.3.1323; Montalto MC, 1999, J CELL PHYSIOL, V180, P46, DOI 10.1002/(SICI)1097-4652(199907)180:1<46::AID-JCP5>3.0.CO;2-K; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; O'Hare MJ, 2001, P NATL ACAD SCI USA, V98, P646, DOI 10.1073/pnas.98.2.646; Pfeifer A, 2001, P NATL ACAD SCI USA, V98, P11450, DOI 10.1073/pnas.201415498; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; RABITO CA, 1980, J MEMBRANE BIOL, V54, P31, DOI 10.1007/BF01875374; Racusen LC, 1997, J LAB CLIN MED, V129, P318, DOI 10.1016/S0022-2143(97)90180-3; RHIM JS, 1985, SCIENCE, V227, P1250, DOI 10.1126/science.2579430; Rudolph AE, 1999, J BIOL CHEM, V274, P11824, DOI 10.1074/jbc.274.17.11824; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; RYAN MJ, 1994, KIDNEY INT, V45, P48, DOI 10.1038/ki.1994.6; Sharma GG, 2003, ONCOGENE, V22, P131, DOI 10.1038/sj.onc.1206063; SHAY JW, 1993, EXP CELL RES, V209, P45, DOI 10.1006/excr.1993.1283; Silver DP, 2001, MOL CELL, V8, P233, DOI 10.1016/S1097-2765(01)00295-7; STEVENSON M, 1986, MOL CELL BIOL, V6, P3410, DOI 10.1128/MCB.6.10.3410; Westerman KA, 1996, P NATL ACAD SCI USA, V93, P8971, DOI 10.1073/pnas.93.17.8971; WRIGHT WE, 1992, TRENDS GENET, V8, P193, DOI 10.1016/0168-9525(92)90232-S; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; YOAKUM GH, 1985, SCIENCE, V227, P1174, DOI 10.1126/science.3975607	40	24	28	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2004	23	35					5950	5957		10.1038/sj.onc.1207801	http://dx.doi.org/10.1038/sj.onc.1207801			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15208689				2022-12-28	WOS:000222941100009
J	Sgarbanti, M; Arguello, M; tenOever, BR; Battistini, A; Lin, RT; Hiscott, J				Sgarbanti, M; Arguello, M; tenOever, BR; Battistini, A; Lin, RT; Hiscott, J			A requirement for NF-kappa B induction in the production of replication-competent HHV-8 virions	ONCOGENE			English	Article						HHV8; NF-kappa B; herpesvirus; lytic infection	SARCOMA-ASSOCIATED HERPESVIRUS; PRIMARY EFFUSION LYMPHOMA; PROTEIN-COUPLED RECEPTOR; ENDOTHELIAL-CELLS; GENE-EXPRESSION; HUMAN-HERPESVIRUS-8 INFECTION; DNA-SEQUENCES; IKK-GAMMA; KINASE; ALPHA	The gammaherpesvirus human herpesvirus 8 (HHV-8) infects endothelial and B-lymphoid cells and is responsible for the development of Kaposi's sarcoma and primary effusion lymphoma (PEL). In the present study, we demonstrate that the activation of the NF-kappaB pathway during HHV-8 lytic replication is required for the generation of replication-competent virions capable of initiating a de novo infection of endothelial cells. In the HHV-8-positive PEL cell line BCBL-1, tetradecanoyl phorbol acetate (TPA) induction of the lytic cycle activates the NF-kappaB pathway, and this activation requires the induction of the IKKbeta component of the classical IkappaB kinase (IKK) complex. To further investigate the role of NF-kappaB activation in HHV-8 lytic replication, the NF-kappaB super-repressor IkappaBalpha-2NDelta4 was introduced into BCBL-1 cells by retroviral transduction. Expression of IkappaBalpha-2NDelta4 completely abolished NF-kappaB activity, as demonstrated by the loss of NF-kappaB DNA-binding activity and the absence of expression of the endogenous, NF-kappaB-regulated IkappaBalpha gene. NF-kappaB blockade dramatically impaired the ability of HHV-8 to produce infectious particles capable of initiating an effective de novo infection of endothelial EA.hy926 cells, as demonstrated by the lack of viral protein production in the target cells. Diminished infectivity did not appear to be caused by a reduction in virus titer, as demonstrated by equivalent viral DNA content in the supernatant of TPA-stimulated BCBL-1 and BCBL-1/2N4 cells. Although the viral and/or cellular products affected by NF-kappaB inactivation remain to be fully characterized, these data demonstrate an unexpected role for NF-kappaB induction during lytic reactivation in the production of replication-competent HHV-8 virions.	McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Microbiol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Immunol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada; Ist Super Sanita, Virol Lab, I-00161 Rome, Italy	Lady Davis Institute; McGill University; McGill University; McGill University; McGill University; Istituto Superiore di Sanita (ISS)	Lin, RT (corresponding author), McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, 3755 Cote Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.	john.hiscott@mcgill.ca	SGARBANTI, MARCO/C-2962-2016; Lin, Rongtuan/A-1442-2008; BATTISTINI, ANGELA/C-2944-2016	SGARBANTI, MARCO/0000-0002-0433-5110; Lin, Rongtuan/0000-0002-2238-3503; 				ANTOINE N, 1994, CANCER RES, V54, P2073; Arguello M, 2003, ONCOGENE, V22, P964, DOI 10.1038/sj.onc.1206270; Arvanitakis L, 1996, BLOOD, V88, P2648, DOI 10.1182/blood.V88.7.2648.bloodjournal8872648; Asou H, 1998, BLOOD, V91, P2475, DOI 10.1182/blood.V91.7.2475.2475_2475_2481; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Beauparlant P, 1996, J BIOL CHEM, V271, P10690, DOI 10.1074/jbc.271.18.10690; Brown HJ, 2003, J VIROL, V77, P8532, DOI 10.1128/JVI.77.15.8532-8540.2003; Cannon M, 2003, J VIROL, V77, P57, DOI 10.1128/JVI.77.1.57-67.2003; Carbone A, 2000, LEUKEMIA, V14, P1301, DOI 10.1038/sj.leu.2401802; CESARMAN E, 1995, BLOOD, V86, P2708, DOI 10.1182/blood.V86.7.2708.bloodjournal8672708; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chatterjee M, 2002, SCIENCE, V298, P1432, DOI 10.1126/science.1074883; Chiou CJ, 2002, J VIROL, V76, P3421, DOI 10.1128/JVI.76.7.3421-3439.2002; Ciufo DM, 2001, J VIROL, V75, P5614, DOI 10.1128/JVI.75.12.5614-5626.2001; Curreli F, 2002, J VIROL, V76, P5208, DOI 10.1128/JVI.76.10.5208-5219.2002; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Drexler HG, 1998, LEUKEMIA, V12, P1507, DOI 10.1038/sj.leu.2401160; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Flore O, 1998, NATURE, V394, P588, DOI 10.1038/29093; Gaidano G, 1997, BLOOD, V89, P3755; Guo HG, 2003, J VIROL, V77, P2631, DOI 10.1128/JVI.77.4.2631-2639.2003; Gurer C, 2002, J VIROL, V76, P4666, DOI 10.1128/JVI.76.9.4666-4670.2002; Gwack Y, 2001, J VIROL, V75, P1909, DOI 10.1128/JVI.75.4.1909-1917.2001; Harhaj EW, 2000, ONCOGENE, V19, P1448, DOI 10.1038/sj.onc.1203445; Hiscott J, 2001, J CLIN INVEST, V107, P143, DOI 10.1172/JCI11918; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Ishii T, 2001, ONCOGENE, V20, P1900, DOI 10.1038/sj.onc.1204267; Jenner RG, 2001, J VIROL, V75, P891, DOI 10.1128/JVI.75.2.891-902.2001; Jones KD, 1999, BLOOD, V94, P2871; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Keller SA, 2000, BLOOD, V96, P2537; Kwon H, 1998, J BIOL CHEM, V273, P7431, DOI 10.1074/jbc.273.13.7431; Lagunoff M, 2002, J VIROL, V76, P2440, DOI 10.1128/JVI.76.5.2440-2448.2002; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; Lin RT, 2001, ONCOGENE, V20, P800, DOI 10.1038/sj.onc.1204163; Lin RT, 1996, MOL CELL BIOL, V16, P1401; Liu L, 2002, J BIOL CHEM, V277, P13745, DOI 10.1074/jbc.M110480200; Matolcsy A, 1998, AM J PATHOL, V153, P1609, DOI 10.1016/S0002-9440(10)65749-5; Means RE, 2002, EMBO J, V21, P1638, DOI 10.1093/emboj/21.7.1638; Miller G, 1997, J VIROL, V71, P314, DOI 10.1128/JVI.71.1.314-324.1997; Monini P, 1999, BLOOD, V93, P4044; Montaner S, 2001, CANCER RES, V61, P2641; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; Moses AV, 1999, J VIROL, V73, P6892, DOI 10.1128/JVI.73.8.6892-6902.1999; Nador RG, 1996, BLOOD, V88, P645, DOI 10.1182/blood.V88.2.645.bloodjournal882645; Nicholas J, 1997, J VIROL, V71, P1963, DOI 10.1128/JVI.71.3.1963-1974.1997; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pati S, 2001, J VIROL, V75, P8660, DOI 10.1128/JVI.75.18.8660-8673.2001; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Sakurada S, 2001, J VIROL, V75, P7717, DOI 10.1128/JVI.75.16.7717-7722.2001; Sarid R, 1999, ADV VIRUS RES, V52, P139, DOI 10.1016/S0065-3527(08)60299-7; Schwarz M, 2001, J IMMUNOL, V167, P505, DOI 10.4049/jimmunol.167.1.505; Smit MJ, 2002, J VIROL, V76, P1744, DOI 10.1128/JVI.76.4.1744-1752.2002; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Sun R, 1999, J VIROL, V73, P2232, DOI 10.1128/JVI.73.3.2232-2242.1999; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Sun SC, 2000, AIDS RES HUM RETROV, V16, P1591, DOI 10.1089/08892220050193001; Webb JH, 1999, FEBS LETT, V444, P136, DOI 10.1016/S0014-5793(99)00025-3; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445; Yu YM, 1999, J GEN VIROL, V80, P83, DOI 10.1099/0022-1317-80-1-83; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	64	31	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2004	23	34					5770	5780		10.1038/sj.onc.1207707	http://dx.doi.org/10.1038/sj.onc.1207707			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KW	15235582				2022-12-28	WOS:000222629800006
J	Iacovoni, JS; Cohen, SB; Berg, T; Vogt, PK				Iacovoni, JS; Cohen, SB; Berg, T; Vogt, PK			v-Jun targets showing an expression pattern that correlates with the transformed cellular phenotype	ONCOGENE			English	Article						Jun; AP-1; target genes; coordinate expression; reversion; oncogenic transformation; DNA microarray	C-JUN; ONCOGENE JUN; IN-VIVO; PROTEIN; CELLS; AP-1; GENE; SRC; FIBROBLASTS; SEQUENCE	Targets of the oncogenic transcription factor v-Jun in the murine cell line C3H 10T1/2 cells have been identified using DNA microarrays. Two targets, Akap12 and Marcks, are downregulated in transformed cells and are known tumor suppressor genes. Overexpression of either Akap12 or Marcks in v-Jun-transformed cells reverses the transformed phenotype and leads to the re-expression of the other tumor suppressor gene, suggesting that these two genes cooperate in the establishment of the nontransformed state. Reverted cells continue to express v-Jun at high levels and also re-express c-Jun, which is normally repressed by v-Jun. A panel of six cell lines has been generated to evaluate the expression levels of other v-Jun targets in 10T1/2 cells. With these cells, we find that the upregulated target Sprr1a has an expression pattern that correlates with the transformed phenotype.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Novartis Res Fdn, Genom Inst, Dept Prot Sci, La Jolla, CA 92121 USA; Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany	Scripps Research Institute; Novartis; Max Planck Society	Vogt, PK (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	pkvogt@scripps.edu	Berg, Thorsten/A-1306-2012; Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500	NCI NIH HHS [CA79616, CA78045, CA78230] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079616, P01CA078045, R01CA078230] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CAVALIERI F, 1985, VIROLOGY, V143, P680, DOI 10.1016/0042-6822(85)90412-X; Cohen SB, 2001, ONCOGENE, V20, P141, DOI 10.1038/sj.onc.1204077; FRANKFORT BJ, 1995, BIOCHEM BIOPH RES CO, V206, P916, DOI 10.1006/bbrc.1995.1130; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Gao MH, 1996, CANCER RES, V56, P4229; Gelman IH, 2002, FRONT BIOSCI-LANDMRK, V7, pD1782, DOI 10.2741/gelman; GROVE BD, 1994, ANAT REC, V239, P231, DOI 10.1002/ar.1092390302; Hartl M, 2003, CURR CANCER DRUG TAR, V3, P41, DOI 10.2174/1568009033333781; Hussain S, 1998, CELL GROWTH DIFFER, V9, P677; Iacovoni JS, 2003, BIOINFORMATICS, V19, P2316, DOI 10.1093/bioinformatics/btg304; JOSEPH CK, 1992, J BIOL CHEM, V267, P1327; Kartasova T, 1996, J INVEST DERMATOL, V106, P294, DOI 10.1111/1523-1747.ep12340741; Kilbey A, 1996, ONCOGENE, V12, P2409; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; Lin XY, 1996, J BIOL CHEM, V271, P28430, DOI 10.1074/jbc.271.45.28430; LIN XY, 1995, MOL CELL BIOL, V15, P2754; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; NISHIMURA T, 1988, ONCOGENE, V3, P659; REED JC, 1991, CELL SIGNAL, V3, P569, DOI 10.1016/0898-6568(91)90033-Q; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; Schlingemann J, 2003, INT J CANCER, V104, P699, DOI 10.1002/ijc.11008; Wheeler DL, 2002, NUCLEIC ACIDS RES, V30, P13, DOI 10.1093/nar/30.1.13	24	9	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5703	5706		10.1038/sj.onc.1207737	http://dx.doi.org/10.1038/sj.onc.1207737			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15133497				2022-12-28	WOS:000222629500017
J	Ala-aho, R; Ahonen, M; George, SJ; Heikkila, J; Grenman, R; Kallajoki, M; Kahari, VM				Ala-aho, R; Ahonen, M; George, SJ; Heikkila, J; Grenman, R; Kallajoki, M; Kahari, VM			Targeted inhibition of human collagenase-3 (MMP-13) expression inhibits squamous cell carcinoma growth in vivo	ONCOGENE			English	Article						collagenase; squamous cell carcinoma; invasion; ribozyme	ACTIVATED PROTEIN-KINASE; MATRIX METALLOPROTEINASE-13; TISSUE INHIBITOR; HUMAN KERATINOCYTES; FACTOR-BETA; RIBOZYMES; INVASION; CANCER; INFLAMMATION; CHONDROCYTES	Squamous cell carcinomas (SCCs) of the head and neck are characterized by a high tendency for local invasion and metastasis to lymph nodes. Collagenase-3 (MMP-13) is specifically expressed by tumor cells in SCCs of the head and neck and its expression correlates with their invasion capacity. To specifically examine the role of MMP-13 in the growth and invasion of SCC, we constructed a hammerhead ribozyme targeted against human MMP-13 mRNA. The anti-MMP-13 ribozyme effectively cleaved MMP-13 transcripts in vitro. Adenoviral delivery of the anti-MMP-13 ribozyme to cutaneous metastatic SCC cells in culture resulted in potent and specific inhibition of the production of proMMP-13 and markedly suppressed invasion of SCC cells through Matrigel. In addition, adenoviral delivery of anti-MMP-13 ribozyme promoted apoptosis in SCC cells within 72 h. Intratumoral injection of anti-MMP-13 ribozyme coding adenovirus into human SCC xenografts established in SCID mice potently suppressed tumor growth, inhibited MMP-13 expression and gelatinolytic activity and reduced the number of proliferating cells within the tumors. These results provide evidence for an important role for MMP-13 in SCC growth and invasion and identify MMP-13 as a promising target for ribozyme-based therapy of SCC in vivo.	Univ Turku, Dept Med Biochem & Mol Biol, FIN-20520 Turku, Finland; Univ Turku, Dept Dermatol, FIN-20520 Turku, Finland; Univ Turku, Ctr Biotechnol, SF-20500 Turku, Finland; Bristol Royal Infirm & Gen Hosp, Bristol Heart Inst, Bristol BS2 8HW, Avon, England; Abo Akad Univ, Dept Biochem & Pharm, FIN-20520 Turku, Finland; Univ Turku, Cent Hosp, Dept Otorhinolaryngol Head & Neck Surg, FIN-20520 Turku, Finland; Univ Turku, Cent Hosp, Dept Pathol, FIN-20520 Turku, Finland	University of Turku; University of Turku; University of Turku; Bristol Royal Infirmary; University of Bristol; Abo Akademi University; University of Turku; University of Turku	Kahari, VM (corresponding author), Univ Turku, Dept Med Biochem & Mol Biol, Kiinamyllynkatu 10, FIN-20520 Turku, Finland.	veli-matti.kahari@utu.fi	Kahari, Veli-Matti/T-4925-2019; Kähäri, Veli-Matti/E-5144-2011	Kahari, Veli-Matti/0000-0003-2421-9368; Kähäri, Veli-Matti/0000-0003-2421-9368				Ahonen M, 2003, ONCOGENE, V22, P2121, DOI 10.1038/sj.onc.1206292; Ahonen M, 2002, MOL THER, V5, P705, DOI 10.1006/mthe.2002.0606; Airola K, 1999, BRIT J CANCER, V80, P733, DOI 10.1038/sj.bjc.6690417; Airola K, 1997, J INVEST DERMATOL, V109, P225, DOI 10.1111/1523-1747.ep12319441; Ala-aho R, 2000, ONCOGENE, V19, P248, DOI 10.1038/sj.onc.1203306; Ala-Aho R, 2002, INT J CANCER, V97, P283, DOI 10.1002/ijc.1619; Ala-Aho R, 2002, ONCOGENE, V21, P1187, DOI 10.1038/sj.onc.1205198; Ashworth JL, 1999, BIOCHEM J, V340, P171, DOI 10.1042/0264-6021:3400171; Bostrom PJ, 2000, INT J CANCER, V88, P417, DOI 10.1002/1097-0215(20001101)88:3<417::AID-IJC14>3.3.CO;2-7; BOUKAMP P, 1990, CANCER RES, V50, P2840; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Cazorla M, 1998, J PATHOL, V186, P144, DOI 10.1002/(SICI)1096-9896(1998100)186:2<144::AID-PATH147>3.0.CO;2-#; Etoh T, 2000, GUT, V47, P50, DOI 10.1136/gut.47.1.50; Fernando FS, 2001, J MOL MED-JMM, V79, P695, DOI 10.1007/s001090100272; Fosang AJ, 1996, FEBS LETT, V380, P17, DOI 10.1016/0014-5793(95)01539-6; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; George SJ, 2000, CIRCULATION, V101, P296, DOI 10.1161/01.CIR.101.3.296; Hernandez YJ, 1999, J VIROL, V73, P8549, DOI 10.1128/JVI.73.10.8549-8558.1999; Hua J, 1996, CANCER RES, V56, P5279; Jarvis TC, 2000, J IMMUNOL, V165, P493, DOI 10.4049/jimmunol.165.1.493; Johansson N, 1999, AM J PATHOL, V154, P469, DOI 10.1016/S0002-9440(10)65293-5; Johansson N, 1997, DEV DYNAM, V208, P387, DOI 10.1002/(SICI)1097-0177(199703)208:3<387::AID-AJA9>3.0.CO;2-E; Johansson N, 1997, CELL GROWTH DIFFER, V8, P243; Johansson N, 1997, AM J PATHOL, V151, P499; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Knauper V, 1997, EUR J BIOCHEM, V248, P369, DOI 10.1111/j.1432-1033.1997.00369.x; Knauper V, 1997, J BIOL CHEM, V272, P7608, DOI 10.1074/jbc.272.12.7608; Lewin AS, 2001, TRENDS MOL MED, V7, P221, DOI 10.1016/S1471-4914(01)01965-7; Lindy O, 1997, ARTHRITIS RHEUM-US, V40, P1391, DOI 10.1002/art.1780400806; Lu Y, 1998, DNA CELL BIOL, V17, P643, DOI 10.1089/dna.1998.17.643; Mao DL, 1999, BIOCHEM BIOPH RES CO, V261, P904, DOI 10.1006/bbrc.1999.1142; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; McQuibban GA, 2001, J BIOL CHEM, V276, P43503, DOI 10.1074/jbc.M107736200; Murphy G, 1997, MATRIX BIOL, V15, P511, DOI 10.1016/S0945-053X(97)90025-1; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Nielsen BS, 2001, CANCER RES, V61, P7091; Nikkola J, 2001, MELANOMA RES, V11, P157, DOI 10.1097/00008390-200104000-00011; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Pavco PA, 2000, CLIN CANCER RES, V6, P2094; Ravanti L, 2001, FASEB J, V15, P1098, DOI 10.1096/fj.00-0588fje; Ravanti L, 1999, J BIOL CHEM, V274, P2446, DOI 10.1074/jbc.274.4.2446; Ravanti L, 1999, J BIOL CHEM, V274, P37292, DOI 10.1074/jbc.274.52.37292; Reboul P, 1996, J CLIN INVEST, V97, P2011, DOI 10.1172/JCI118636; Sukhova GK, 1999, CIRCULATION, V99, P2503, DOI 10.1161/01.CIR.99.19.2503; Uitto VJ, 1998, AM J PATHOL, V152, P1489; Uria JA, 1998, AM J PATHOL, V153, P91, DOI 10.1016/S0002-9440(10)65549-6; Usman N, 2000, J CLIN INVEST, V106, P1197, DOI 10.1172/JCI11631; Vaalamo M, 1998, AM J PATHOL, V152, P1005; Vaalamo M, 1997, J INVEST DERMATOL, V109, P96, DOI 10.1111/1523-1747.ep12276722; Vihinen P, 2002, INT J CANCER, V99, P157, DOI 10.1002/ijc.10329; WILKINSON GWG, 1992, NUCLEIC ACIDS RES, V20, P2233, DOI 10.1093/nar/20.9.2233	51	63	67	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2004	23	30					5111	5123		10.1038/sj.onc.1207678	http://dx.doi.org/10.1038/sj.onc.1207678			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	834AE	15094779				2022-12-28	WOS:000222382500001
J	Fujii, K; Goldman, EH; Park, HR; Zhang, LX; Chen, J; Fu, HA				Fujii, K; Goldman, EH; Park, HR; Zhang, LX; Chen, J; Fu, HA			Negative control of apoptosis signal-regulating kinase 1 through phosphorylation of Ser-1034	ONCOGENE			English	Article						ASK1; apoptosis; phosphorylation; 14-3-3; kinase; survival signaling	ACTIVATED PROTEIN-KINASE; CELL-DEATH; 1 ASK1; PATHWAYS; STRESS; DISSOCIATION; THIOREDOXIN; INHIBITOR; SURVIVAL; LIFE	Apoptosis signal-regulating kinase 1 (ASK1) is a serine/threonine kinase that mediates cell stress signaling initiated by diverse stimuli, such as H2O2 and TNFalpha. Owing to its critical role in promoting apoptosis, ASK1 activity is highly controlled in cells. Phosphorylation of ASK1 at Thr-845 has been correlated with its activation, while phosphorylation at Ser-967 negatively controls its death promoting activity. Here, we report the identification of a novel phosphorylation site at Ser-1034 in the C-terminal regulatory domain of ASK1. Mutating Ser-1034 to an unphosphorylatable Ala led to increased catalytic activity of ASK1 and enhanced proapoptotic function of ASK1. Thus, the proapoptotic function of ASK1 is suppressed in part by phosphorylation at its C-terminal regulatory domain, which may couple upstream survival kinases to the death regulatory machinery.	Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Grad Program Mol & Syst Pharmacol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Grad Program Biochem Cell & Dev Biol, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University	Fu, HA (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA.	hfu@emory.edu		Park, Hae Ryoun/0000-0003-1908-0824; Zhang, Lixin/0000-0003-0894-9520	NIGMS NIH HHS [GM60033, GM53165] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM053165, R01GM053165, R01GM060033] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chen J, 2001, P NATL ACAD SCI USA, V98, P7783, DOI 10.1073/pnas.141224398; Chen ZH, 1999, ONCOGENE, V18, P173, DOI 10.1038/sj.onc.1202276; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Goldman EH, 2004, J BIOL CHEM, V279, P10442, DOI 10.1074/jbc.M311129200; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Hatai T, 2000, J BIOL CHEM, V275, P26576, DOI 10.1074/jbc.M003412200; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Matsuura H, 2002, J BIOL CHEM, V277, P40703, DOI 10.1074/jbc.M202004200; Matsuzawa A, 2001, J BIOCHEM-TOKYO, V130, P1; Morita K, 2001, EMBO J, V20, P6028, DOI 10.1093/emboj/20.21.6028; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Park HS, 2002, MOL CELL BIOL, V22, P7721, DOI 10.1128/MCB.22.22.7721-7730.2002; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Song JJ, 2002, J BIOL CHEM, V277, P46566, DOI 10.1074/jbc.M206826200; Tobiume K, 2002, J CELL PHYSIOL, V191, P95, DOI 10.1002/jcp.10080; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Wang TH, 1999, J BIOL CHEM, V274, P8208, DOI 10.1074/jbc.274.12.8208; Wang XHS, 1996, J BIOL CHEM, V271, P31607; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511; Zou XH, 2001, MOL CELL BIOL, V21, P4818, DOI 10.1128/MCB.21.14.4818-4828.2001	28	37	40	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					5099	5104		10.1038/sj.onc.1207668	http://dx.doi.org/10.1038/sj.onc.1207668			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15094778				2022-12-28	WOS:000222237300018
J	Abadie, A; Besancon, F; Wietzerbin, J				Abadie, A; Besancon, F; Wietzerbin, J			Type I interferon and TNF alpha cooperate with type II interferon for TRAIL induction and triggering of apoptosis in SK-N-MC EWING tumor cells	ONCOGENE			English	Article						Ewing's sarcoma; TRAIL; apoptosis; IFN alpha; IFN gamma; TNF alpha	NECROSIS-FACTOR-ALPHA; KAPPA-B ACTIVITY; LIGAND TRAIL; SARCOMA FAMILY; TRANSCRIPTIONAL ACTIVATION; TUMORICIDAL ACTIVITY; RETINOIC ACID; APO2 LIGAND; IFN-GAMMA; T-CELLS	Ewing's sarcoma is the second most common human bone tumor in childhood. Here, we investigated the sensitivity of the Ewing tumor cell line, SK-N-MC, to the apoptotic effect of type I (IFNalpha) and type II (IFNgamma) interferons and TNFalpha. We demonstrate that although IFNalpha and TNFalpha alone are unable to induce cell death, they act in synergy with IFNgamma to induce SK-N-MC cell apoptosis. The synergistic induction of apoptosis correlated with the synergistic induction of TNFalpha-related apoptosis-inducing ligand ( TRAIL) mRNA and TRAIL protein synthesis as well as of TRAIL secretion. Preparations of inducer-free supernatants from SK-N-MC cells stimulated with combinations of cytokines were shown to be cytotoxic for untreated SK-N-MC cells. This cytotoxicity was partially inhibited by addition of TRAILR2/Fc fusion protein, indicating that the secreted TRAIL mediates, at least in part, the apoptotic effect displayed by the supernatants of stimulated SK-N-MC cells. We have shown that the presence of IFNgamma is required to allow the sustained expression of IRF1 in SK-N-MC cells stimulated by addition of IFNalpha or TNFalpha suggesting that IRF1 plays a role in the synergistic induction of apoptosis by combinations of cytokines. Furthermore, we have shown that inhibition of NF-kappaB activation contributes to the IFNgamma-mediated sensitization to the apoptotic effect of TNFalpha. To our knowledge, this is the first report showing that interferon/cytokine combinations are able to induce TRAIL gene expression and TRAIL protein synthesis and secretion in Ewing sarcoma-derived cells. We believe that the observations reported here might contribute to the development of alternative new approaches to the treatment of Ewing tumors resistant to conventional therapy.	Inst Curie, INSERM, U365, Sect Rech, F-75248 Paris 05, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Wietzerbin, J (corresponding author), Inst Curie, INSERM, U365, Sect Rech, 26 Rue Ulm, F-75248 Paris 05, France.	jeanne.wietzerbin@curie.fr						Altucci L, 2001, NAT MED, V7, P680, DOI 10.1038/89050; Arvand A, 2001, ONCOGENE, V20, P5747, DOI 10.1038/sj.onc.1204598; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; AURIAS A, 1983, NEW ENGL J MED, V309, P496; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Borden, 1998, Oncologist, V3, P198; Borden EC, 2000, SEMIN CANCER BIOL, V10, P125, DOI 10.1006/scbi.2000.0315; Chawla-Sarkar M, 2003, APOPTOSIS, V8, P237, DOI 10.1023/A:1023668705040; Cheshire JL, 1997, MOL CELL BIOL, V17, P6746, DOI 10.1128/MCB.17.11.6746; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; de Alava E, 2000, J CLIN ONCOL, V18, P204, DOI 10.1200/JCO.2000.18.1.204; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Fanger NA, 1999, J EXP MED, V190, P1155, DOI 10.1084/jem.190.8.1155; Fizazi K, 1998, J CLIN ONCOL, V16, P3736, DOI 10.1200/JCO.1998.16.12.3736; Griffith TS, 1998, J IMMUNOL, V161, P2833; Griffith TS, 1999, J EXP MED, V189, P1343, DOI 10.1084/jem.189.8.1343; Horowitz Marc E., 1997, P831; Javelaud D, 2002, INT J CANCER, V98, P193, DOI 10.1002/ijc.10192; Javelaud D, 2000, ONCOGENE, V19, P61, DOI 10.1038/sj.onc.1203246; Javelaud D, 2001, ONCOGENE, V20, P4365, DOI 10.1038/sj.onc.1204570; Kayagaki N, 1999, J EXP MED, V189, P1451, DOI 10.1084/jem.189.9.1451; Kontny HU, 2001, CELL DEATH DIFFER, V8, P506, DOI 10.1038/sj.cdd.4400836; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; Kretz-Remy C, 2001, J BIOL CHEM, V276, P43723, DOI 10.1074/jbc.M010821200; Kumar A, 2001, ONCOGENE, V20, P1010, DOI 10.1038/sj.onc.1204154; Langaas V, 2001, ANTICANCER RES, V21, P3733; LAWRENCE D, 2001, NATURE, V7, P382; Lejeune FJ, 2002, J CLIN INVEST, V110, P433, DOI 10.1172/JCI200216493; LIENARD D, 1992, J CLIN ONCOL, V10, P52, DOI 10.1200/JCO.1992.10.1.52; Linder RE, 1997, REPROD TOXICOL, V11, P681, DOI 10.1016/S0890-6238(97)00031-2; Lindner DJ, 1997, CLIN CANCER RES, V3, P931; LIU SQ, 1995, NAT MED, V1, P267, DOI 10.1038/nm0395-267; Martinez-Lorenzo MJ, 1998, EUR J IMMUNOL, V28, P2714, DOI 10.1002/(SICI)1521-4141(199809)28:09<2714::AID-IMMU2714>3.0.CO;2-9; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; Mitsiades N, 2001, CANCER RES, V61, P2704; MUNOZ E, 1994, J VIROL, V68, P8035; Nesterov A, 2002, ONCOGENE, V21, P1135, DOI 10.1038/sj.onc.1205151; Oshima K, 2001, CYTOKINE, V14, P193, DOI 10.1006/cyto.2001.0873; Pfeffer LM, 1998, CANCER RES, V58, P2489; Pinkerton CR, 2001, EUR J CANCER, V37, P1338, DOI 10.1016/S0959-8049(01)00131-9; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Rodriguez-Galindo C, 2003, MED PEDIATR ONCOL, V40, P276, DOI 10.1002/mpo.10240; Sanceau J, 2000, ONCOGENE, V19, P3372, DOI 10.1038/sj.onc.1203670; Sanceau J, 2002, ONCOGENE, V21, P7700, DOI 10.1038/sj.onc.1205881; Shankar AG, 2003, MED PEDIATR ONCOL, V40, P141, DOI 10.1002/mpo.10248; Shin EC, 2001, INT J CANCER, V93, P262, DOI 10.1002/ijc.1310; SINGH RK, 1995, P NATL ACAD SCI USA, V92, P4562, DOI 10.1073/pnas.92.10.4562; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Suk K, 2001, FEBS LETT, V495, P66, DOI 10.1016/S0014-5793(01)02335-3; Suk K, 2001, J BIOL CHEM, V276, P13153, DOI 10.1074/jbc.M007646200; Toomey NL, 2001, ONCOGENE, V20, P7029, DOI 10.1038/sj.onc.1204895; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; Van Valen F, 2000, INT J CANCER, V88, P252, DOI 10.1002/1097-0215(20001015)88:2<252::AID-IJC17>3.0.CO;2-U; VANVALEN F, 1993, J CANCER RES CLIN, V119, P615, DOI 10.1007/BF01372725; Wadler, 1997, Oncologist, V2, P254; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wandinger KP, 2003, LANCET, V361, P2036, DOI 10.1016/S0140-6736(03)13641-0; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Zhang CH, 1996, J IMMUNOL, V157, P3980; [No title captured]	62	17	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2004	23	28					4911	4920		10.1038/sj.onc.1207614	http://dx.doi.org/10.1038/sj.onc.1207614			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	830EK	15077162				2022-12-28	WOS:000222104200012
J	Delaval, B; Ferrand, A; Conte, N; Larroque, C; Hernandez-Verdun, D; Prigent, C; Birnbaum, D				Delaval, B; Ferrand, A; Conte, N; Larroque, C; Hernandez-Verdun, D; Prigent, C; Birnbaum, D			Aurora B TACC1 protein complex in cytokinesis	ONCOGENE			English	Article						Aurora kinase; cell division; cytokinesis; microtubule; midbody; TACC protein; Taxin; RNAi	COILED-COIL; CHROMOSOME SEGREGATION; CENTROSOMAL PROTEIN; BREAST-CANCER; CELL-CYCLE; A KINASE; SPINDLE; MITOSIS; REGULATORS; FAMILY	Taxins are a family of centrosomal proteins important for the regulation of mitosis and microtubule dynamics. Cytokinesis, the last step of M phase, is essential for chromosomal integrity and cell division. It is highly regulated and involves a reorganization of microtubules and actin filaments. We show here that TACC1 localizes diffusely to the midzone spindle in anaphase and strongly to the midbody during cytokinesis, indicating a possible involvement of this protein in the exit of M phase. TACC1 also relocalizes to the nucleolus in interphase. We demonstrate that TACC1 and the mitotic kinase Aurora B belong to the same complex during cytokinesis. We further show that Aurora B knocked down by RNA-mediated interference prevents the formation of the midbody-and consequently affects TACC1 localization at this site-and leads to abnormal cell division and multinucleated cells.	Inst J Paoli I Calmettes, INSERM, U119, Dept Mol Oncol, F-13009 Marseille, France; CRLC Val Aurelle Paul Lamarque, INSERM, E229, Montpellier, France; Univ Rennes 1, Fac Med, CNRS,UMR Genet & Dev 6061, Grp Cycle Cellulaire, Rennes, France; Inst Jacques Monod, CNRS, F-75251 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Centre National de la Recherche Scientifique (CNRS); Universite de Rennes; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Birnbaum, D (corresponding author), Inst J Paoli I Calmettes, INSERM, U119, Dept Mol Oncol, 27 Bd Lei Roure,IFR57, F-13009 Marseille, France.	birnbaurn@marseille.inserm.fr		Conte, Nathalie/0000-0002-1010-3121; Birnbaum, Daniel/0000-0001-7920-9883				Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; Bolton MA, 2002, MOL BIOL CELL, V13, P3064, DOI 10.1091/mbc.E02-02-0092; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; CHARRASSE S, 1995, EUR J BIOCHEM, V234, P406, DOI 10.1111/j.1432-1033.1995.406_b.x; Charrasse S, 2000, EXP CELL RES, V254, P249, DOI 10.1006/excr.1999.4740; Chen HM, 2000, MOL BIOL CELL, V11, P1357, DOI 10.1091/mbc.11.4.1357; Conte N, 2002, ONCOGENE, V21, P5619, DOI 10.1038/sj.onc.1205658; Conte N, 2003, ONCOGENE, V22, P8102, DOI 10.1038/sj.onc.1206972; Cremet JY, 2003, MOL CELL BIOCHEM, V243, P123, DOI 10.1023/A:1021608012253; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; Gergely F, 2003, GENE DEV, V17, P336, DOI 10.1101/gad.245603; Gergely F, 2002, BIOESSAYS, V24, P915, DOI 10.1002/bies.10162; Giet R, 2002, J CELL BIOL, V156, P437, DOI 10.1083/jcb.200108135; Giet R, 1999, J CELL SCI, V112, P3591; Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092; Hernandez-Verdun D, 2002, J CELL SCI, V115, P2265; Honda R, 2003, MOL BIOL CELL, V14, P3325, DOI 10.1091/mbc.E02-11-0769; Kallio MJ, 2002, CURR BIOL, V12, P900, DOI 10.1016/S0960-9822(02)00887-4; Katayama Hiroshi, 2003, Cancer and Metastasis Reviews, V22, P451, DOI 10.1023/A:1023789416385; Kawajiri A, 2003, MOL BIOL CELL, V14, P1489, DOI 10.1091/mbc.E02-09-0612; Keryer G, 2003, MOL BIOL CELL, V14, P2436, DOI 10.1091/mbc.E02-09-0614; Lappin TR, 2002, LEUKEMIA LYMPHOMA, V43, P1455, DOI 10.1080/1042819022386644; Lauffart B, 2002, BIOCHEM J, V363, P195, DOI 10.1042/0264-6021:3630195; MARASCO WA, 1994, ARCH VIROL, V139, P133, DOI 10.1007/BF01309460; Maxwell CA, 2003, MOL BIOL CELL, V14, P2262, DOI 10.1091/mbc.E02-07-0377; Minoshima Y, 2003, DEV CELL, V4, P549, DOI 10.1016/S1534-5807(03)00089-3; Murnion ME, 2001, J BIOL CHEM, V276, P26656, DOI 10.1074/jbc.M102288200; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Piekorz RP, 2002, EMBO J, V21, P653, DOI 10.1093/emboj/21.4.653; Robinson DN, 2000, TRENDS CELL BIOL, V10, P228, DOI 10.1016/S0962-8924(00)01747-5; ROUSSEL P, 1993, J CELL SCI, V104, P327; Schumacher JM, 1998, J CELL BIOL, V143, P1635, DOI 10.1083/jcb.143.6.1635; Steadman BT, 2002, J BIOL CHEM, V277, P30165, DOI 10.1074/jbc.M201914200; Stebbins-Boaz B, 1999, MOL CELL, V4, P1017, DOI 10.1016/S1097-2765(00)80230-0; Still IH, 1999, ONCOGENE, V18, P4032, DOI 10.1038/sj.onc.1202801; Still IH, 1999, GENOMICS, V58, P165, DOI 10.1006/geno.1999.5829; Sugiyama K, 2002, ONCOGENE, V21, P3103, DOI 10.1038/sj.onc.1205432; Takahashi M, 1999, J BIOL CHEM, V274, P17267, DOI 10.1074/jbc.274.24.17267; Tatsuka M, 1998, CANCER RES, V58, P4811; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Terada Y, 2001, CELL STRUCT FUNCT, V26, P653, DOI 10.1247/csf.26.653; Tien AC, 2004, MOL CELL PROTEOMICS, V3, P93, DOI 10.1074/mcp.M300072-MCP200; Wheatley SP, 2001, CURR BIOL, V11, P886, DOI 10.1016/S0960-9822(01)00238-X	44	42	46	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2004	23	26					4516	4522		10.1038/sj.onc.1207593	http://dx.doi.org/10.1038/sj.onc.1207593			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZV	15064709				2022-12-28	WOS:000221799000002
J	Yamamoto, Y; Irie, K; Asada, M; Mino, A; Mandai, K; Takai, Y				Yamamoto, Y; Irie, K; Asada, M; Mino, A; Mandai, K; Takai, Y			Direct binding of the human homologue of the Drosophila disc large tumor suppressor gene to seven-pass transmembrane proteins, tumor endothelial marker 5 (TEM5), and a novel TEM5-like protein	ONCOGENE			English	Article						hDlg; TEM5; tumor suppressor; G-protein-coupled receptor; PDZ domain	COUPLED RECEPTORS; CELL-ADHESION; GUANYLATE KINASES; K+ CHANNELS; SAP97; MEMBRANE; FAMILY; JUNCTIONS; DLG; PROLIFERATION	The human homologue of the Drosophila discs large tumor suppressor gene ( hDlg) is a member of the membrane-associated guanylate kinase family with three PSD-95/Dlg/ZO-1 (PDZ) domains. hDlg has been shown to bind tumor suppressor proteins, adenomatous polyposis coli (APC) and protein tyrosine phosphatase and tensin homologue ( PTEN), and several viral oncoproteins, and has been implicated in the negative regulation of cell proliferation. hDlg has furthermore been shown to localize at the plasma membrane of synapses and to scaffold cell surface receptors and channels. In epithelial cells, hDlg localizes at the basolateral plasma membrane, but its localization mechanism is unknown. We searched here for a transmembrane protein that directly bound to hDlg. hDlg bound tumor endothelial marker 5 (TEM5), a seven-pass transmembrane protein that is homologous to the family B of G-protein-coupled receptors (GPCRs). TEM5 has previously been reported to display elevated expression during tumor angiogenesis and neoangiogenesis. The PDZ domains of hDlg bound the C-terminal PDZ-binding motif of TEM5. The expression of TEM5 was detected in endothelial cells of embryonic liver, where hDlg colocalized with TEM5. hDlg furthermore bound a novel seven-pass transmembrane protein, which was homologous to TEM5, and was named here a TEM5-like protein (TEM5-like). These results suggest that hDlg localizes at the plasma membrane through TEM5 and TEM5-like and furthermore scaffolds these GPCRs in endothelial cells during tumor angiogenesis and neoangiogenesis.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan	Osaka University	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	ytakai@molbio.med.osaka-u.ac.jp		Mandai, Kenji/0000-0002-0115-6635				BALDWIN HS, 1994, DEVELOPMENT, V120, P2539; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Budnik V, 1996, CURR OPIN NEUROBIOL, V6, P858, DOI 10.1016/S0959-4388(96)80038-9; Cai C, 2002, J BIOL CHEM, V277, P31484, DOI 10.1074/jbc.M204354200; Carson-Walter EB, 2001, CANCER RES, V61, P6649; Chothia C, 1997, ANNU REV BIOCHEM, V66, P823, DOI 10.1146/annurev.biochem.66.1.823; Dimitratos SD, 1999, BIOESSAYS, V21, P912, DOI 10.1002/(SICI)1521-1878(199911)21:11<912::AID-BIES3>3.0.CO;2-Z; Fredriksson R, 2003, BIOCHEM BIOPH RES CO, V301, P725, DOI 10.1016/S0006-291X(03)00026-3; Fujiwara T, 1998, MOL BIOL CELL, V9, P1221, DOI 10.1091/mbc.9.5.1221; Hanada T, 1997, J BIOL CHEM, V272, P26899, DOI 10.1074/jbc.272.43.26899; Humbert P, 2003, BIOESSAYS, V25, P542, DOI 10.1002/bies.10286; Ide N, 1999, ONCOGENE, V18, P7810, DOI 10.1038/sj.onc.1203153; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Kim E, 1996, NEUROPHARMACOLOGY, V35, P993, DOI 10.1016/0028-3908(96)00093-7; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leonard AS, 1998, J BIOL CHEM, V273, P19518, DOI 10.1074/jbc.273.31.19518; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Murata M, 2001, AM J PHYSIOL-HEART C, V281, pH2575, DOI 10.1152/ajpheart.2001.281.6.H2575; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Reuver SM, 1998, J CELL SCI, V111, P1071; Stacey M, 2000, TRENDS BIOCHEM SCI, V25, P284, DOI 10.1016/S0968-0004(00)01583-8; Takai Y, 2003, CANCER SCI, V94, P655, DOI 10.1111/j.1349-7006.2003.tb01499.x; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Tejedor FJ, 1997, J NEUROSCI, V17, P152, DOI 10.1523/JNEUROSCI.17-01-00152.1997; Thomas U, 1997, MECH DEVELOP, V62, P161, DOI 10.1016/S0925-4773(97)00658-8; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X	31	37	45	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					3889	3897		10.1038/sj.onc.1207495	http://dx.doi.org/10.1038/sj.onc.1207495			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15021905				2022-12-28	WOS:000221382000001
J	Kumar, AS; Naruszewicz, I; Wang, P; Leung-Hagesteijn, C; Hannigan, GE				Kumar, AS; Naruszewicz, I; Wang, P; Leung-Hagesteijn, C; Hannigan, GE			ILKAP regulates ILK signaling and inhibits anchorage-independent growth	ONCOGENE			English	Article						ILKAP; ILK signaling; GSK3 beta; oncogenesis; phosphatase	INTEGRIN-LINKED KINASE; GLYCOGEN-SYNTHASE KINASE; PROTEIN-TYROSINE PHOSPHATASE-1; PROSTATE-CANCER CELLS; TUMOR-SUPPRESSOR; CYCLIN D1; BETA-CATENIN; SERINE/THREONINE PHOSPHATASES; DEPENDENT REGULATION; PATHWAYS	ILKAP is a protein phosphatase 2C that selectively associates with integrin linked kinase, ILK, to modulate cell adhesion and growth factor signaling. We investigated the role of endogenous cellular ILKAP in antagonizing ILK signaling of two key targets, PKB and GSK3beta. Silencing of endogenous ILKAP by short interfering RNA ( siRNA) stimulated GSK3beta phosphorylation at S9, with no effect on PKB S473 phosphorylation. In LNCaP prostate carcinoma cells, transient or stable expression of ILKAP suppressed ILK immune complex kinase activity, demonstrating an interaction between ILKAP and ILK. Consistent with the silencing data, ILKAP inhibition of ILK selectively inhibited S9 phosphorylation of GSK3beta without affecting S473 phosphorylation of PKB. The ILKAP-mediated inhibition of S9 phosphorylation was rescued by overexpression of ILK, but not by a dominant-negative ILK mutant. The expression level of cyclin D1, a target of ILK-GSK3beta signaling, was inversely correlated with ILKAP protein levels, suggesting that antagonism of ILK modulates cell cycle progression. ILKAP expression increased the proportion of LNCaP cells in G1, relative to vector control cells, and siRNA suppression of ILKAP increased entry of cells into the S phase, consistent with ILK antagonism. Anchorage-independent growth of LNCaP cells was inhibited by ILKAP, suggesting a critical role in the suppression of cellular transformation. Taken together, our results indicate that endogenous ILKAP activity inhibits the ILK-GSK3beta signaling axis, and suggest that ILKAP activity plays an important role in inhibiting oncogenic transformation.	Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; Hosp Sick Children, Res Inst, Canc Res Program, Toronto, ON M5G 1X8, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Hannigan, GE (corresponding author), Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada.	hannigan@sickkids.ca	Hannigan, Greg/A-5092-2009					Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Attwell S, 2000, ONCOGENE, V19, P3811, DOI 10.1038/sj.onc.1203711; Barford D, 1998, ANNU REV BIOPH BIOM, V27, P133, DOI 10.1146/annurev.biophys.27.1.133; Barker N, 2000, BIOESSAYS, V22, P961; Cheng AY, 1999, GENE DEV, V13, P2946, DOI 10.1101/gad.13.22.2946; Chung DH, 1998, VIRCHOWS ARCH, V433, P113, DOI 10.1007/s004280050225; Coffer PJ, 1998, BIOCHEM J, V335, P1; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Dai DL, 2003, CLIN CANCER RES, V9, P4409; Das AK, 1996, EMBO J, V15, P6798, DOI 10.1002/j.1460-2075.1996.tb01071.x; Dedhar S, 2000, CURR OPIN CELL BIOL, V12, P250, DOI 10.1016/S0955-0674(99)00083-6; Dedhar S, 1999, TRENDS CELL BIOL, V9, P319, DOI 10.1016/S0962-8924(99)01612-8; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Deng JT, 2001, J BIOL CHEM, V276, P16365, DOI 10.1074/jbc.M011634200; DEPAOLIROACH AA, 1994, ADV ENZYME REGUL, V34, P199, DOI 10.1016/0065-2571(94)90017-5; Diehl JA, 2002, CANCER BIOL THER, V1, P226, DOI 10.4161/cbt.72; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Downes CP, 2001, BIOCHEM SOC T, V29, P846, DOI 10.1042/BST0290846; Graff JR, 2001, CLIN CANCER RES, V7, P1987; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Ito R, 2003, VIRCHOWS ARCH, V442, P118, DOI 10.1007/s00428-002-0718-6; Ivaska J, 2002, MOL CELL BIOL, V22, P1352, DOI 10.1128/MCB.22.5.1352-1359.2002; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kim L, 2000, CURR OPIN GENET DEV, V10, P508, DOI 10.1016/S0959-437X(00)00120-9; Koh CG, 2002, CURR BIOL, V12, P317, DOI 10.1016/S0960-9822(02)00652-8; Leslie NR, 2000, BIOCHEM J, V346, P827, DOI 10.1042/0264-6021:3460827; Leung-Hagesteijn C, 2001, EMBO J, V20, P2160, DOI 10.1093/emboj/20.9.2160; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Marotta A, 2001, ONCOGENE, V20, P6250, DOI 10.1038/sj.onc.1204791; Marsolier MC, 2000, GENETICS, V154, P1523; Morimoto AM, 2000, ONCOGENE, V19, P200, DOI 10.1038/sj.onc.1203288; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Noguchi T, 2001, J BIOL CHEM, V276, P15216, DOI 10.1074/jbc.M007208200; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Novak A, 1999, CELL MOL LIFE SCI, V56, P523, DOI 10.1007/s000180050449; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Polakis P, 2000, GENE DEV, V14, P1837; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Rodriguez PL, 1998, PLANT MOL BIOL, V38, P919, DOI 10.1023/A:1006054607850; Rosenberger G, 2003, HUM MOL GENET, V12, P155, DOI 10.1093/hmg/ddg019; Strovel ET, 2000, J BIOL CHEM, V275, P2399, DOI 10.1074/jbc.275.4.2399; Takada T, 2002, J BIOL CHEM, V277, P34359, DOI 10.1074/jbc.M206541200; Takekawa M, 1998, EMBO J, V17, P4744, DOI 10.1093/emboj/17.16.4744; Tan KML, 2001, J BIOL CHEM, V276, P44193, DOI 10.1074/jbc.M105880200; Tong Y, 1998, J BIOL CHEM, V273, P35282, DOI 10.1074/jbc.273.52.35282; Troussard AA, 2003, J BIOL CHEM, V278, P22374, DOI 10.1074/jbc.M303083200; Troussard AA, 2000, ONCOGENE, V19, P5444, DOI 10.1038/sj.onc.1203928; Wan XS, 2003, ONCOL REP, V10, P1569; White DE, 2001, ONCOGENE, V20, P7064, DOI 10.1038/sj.onc.1204910; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528	56	71	78	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3454	3461		10.1038/sj.onc.1207473	http://dx.doi.org/10.1038/sj.onc.1207473			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	14990992				2022-12-28	WOS:000220975000020
J	Rae, FK; Martinez, G; Gillinder, KR; Smith, A; Shooter, G; Forrest, AR; Grimmond, SM; Little, MH				Rae, FK; Martinez, G; Gillinder, KR; Smith, A; Shooter, G; Forrest, AR; Grimmond, SM; Little, MH			Anlaysis of complementary expression profiles following WT1 induction versus repression reveals the cholesterol/fatty acid synthetic pathways as a possible major target of WT1	ONCOGENE			English	Article						WT1; mevalonate; cholesterol; expression profiling	TUMOR-SUPPRESSOR GENE; DENSITY-LIPOPROTEIN RECEPTOR; WILMS-TUMOR; ORNITHINE-DECARBOXYLASE; MUTANT PROTEINS; BINDING; CELLS; MUTATIONS; RAS; WILMS-TUMOR-1	The Wilms' tumour suppressor gene, WT1, encodes a zinc-finger protein that is mutated in Wilms' tumours and other malignancies. WT1 is one of the earliest genes expressed during kidney development. WT1 proteins can activate and repress putative target genes in vitro, although the in vivo relevance of such target genes often remains unverified. To better understand the role of WT1 in tumorigenesis and kidney development, we need to identify downstream target genes. In this study, we have expression pro. led human embryonic kidney 293 cells stably transfected to allow inducible WT1 expression and mouse mesonephric M15 cells transfected with a WT1 antisense construct to abolish endogenous expression of all WT1 isoforms to identify WT1-responsive genes. The complementary overlap between the two cell lines revealed a pronounced repression of genes involved in cholesterol biosynthesis by WT1. This pathway is transcriptionally regulated by the sterol responsive element-binding proteins (SREBPs). Here, we provide evidence that the C-terminal end of the WT1 protein can directly interact with SREBP, suggesting that WT1 may modify the transcriptional function of SREBPs via a direct protein-protein interaction. Therefore, the tumour suppressor activities of WT1 may be achieved by repressing the mevalonate pathway, thereby controlling cellular proliferation and promoting terminal differentiation.	Univ Queensland, Queensland Biosci Precinct, Inst Mol Biosci, Brisbane, Qld 4072, Australia	University of Queensland	Little, MH (corresponding author), Univ Queensland, Queensland Biosci Precinct, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	m.little@imb.uq.edu.au	Little, Melissa H/A-6170-2010; Grimmond, Sean/K-3246-2019; Gillinder, Kevin/I-6224-2013; Smith, Aaron/A-8329-2010; Forrest, Alistair/A-6597-2008; Grimmond, Sean M/J-5304-2016	Little, Melissa H/0000-0003-0380-2263; Grimmond, Sean/0000-0002-8102-7998; Gillinder, Kevin/0000-0002-1221-9718; Forrest, Alistair/0000-0003-4543-1675; Grimmond, Sean M/0000-0002-8102-7998				Bassa BV, 1999, BBA-MOL CELL RES, V1449, P137, DOI 10.1016/S0167-4889(99)00007-5; Bruening W, 1996, J BIOL CHEM, V271, P8646, DOI 10.1074/jbc.271.15.8646; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHRISTIANSEN JH, 1995, MECH DEVELOP, V51, P341, DOI 10.1016/0925-4773(95)00383-5; Davies RC, 1998, GENE DEV, V12, P3217, DOI 10.1101/gad.12.20.3217; Denoyelle C, 2003, CELL SIGNAL, V15, P327, DOI 10.1016/S0898-6568(02)00124-9; DENYS P, 1967, ARCH FR PEDIATR, V24, P729; DRASH A, 1970, J PEDIATR-US, V76, P585, DOI 10.1016/S0022-3476(70)80409-7; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Grimmond S, 2000, HUM MOL GENET, V9, P1553, DOI 10.1093/hmg/9.10.1553; Gurates B, 2002, J CLIN ENDOCR METAB, V87, P4369, DOI 10.1210/jc.2002-020522; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; Hammes A, 2001, CELL, V106, P319, DOI 10.1016/S0092-8674(01)00453-6; HEWITT SM, 1995, CANCER RES, V55, P5386; Holmes G, 1997, BIOCHEM BIOPH RES CO, V233, P723, DOI 10.1006/bbrc.1997.6545; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; KingUnderwood L, 1996, BLOOD, V87, P2171, DOI 10.1182/blood.V87.6.2171.bloodjournal8762171; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LADANYI M, 1994, CANCER RES, V54, P2837; Ladomery M, 2003, J CELL SCI, V116, P1539, DOI 10.1242/jcs.00324; Ladomery MR, 1999, J BIOL CHEM, V274, P36520, DOI 10.1074/jbc.274.51.36520; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; Lee SB, 2001, EXP CELL RES, V264, P74, DOI 10.1006/excr.2000.5131; Lee SB, 1999, CELL, V98, P663, DOI 10.1016/S0092-8674(00)80053-7; Lee TH, 2001, PHYSIOL GENOMICS, V7, P187, DOI 10.1152/physiolgenomics.00046.2001; Li RS, 1999, EXP CELL RES, V247, P257, DOI 10.1006/excr.1998.4361; Little M, 1999, BIOESSAYS, V21, P191, DOI 10.1002/(SICI)1521-1878(199903)21:3<191::AID-BIES3>3.3.CO;2-#; Little M, 1997, HUM MUTAT, V9, P209, DOI 10.1002/(SICI)1098-1004(1997)9:3<209::AID-HUMU2>3.0.CO;2-2; Llorente-Cortes V, 2002, CIRCULATION, V106, P3104, DOI 10.1161/01.CIR.0000041434.28573.0B; Lopez D, 2001, ENDOCRINOLOGY, V142, P5097, DOI 10.1210/en.142.12.5097; LUO XN, 1995, ONCOGENE, V11, P743; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; Magee T, 1999, CELL, V98, P9, DOI 10.1016/S0092-8674(00)80601-7; MCKNIGHT GL, 1992, J BIOL CHEM, V267, P12131; Moshier JA, 1996, NUCLEIC ACIDS RES, V24, P1149, DOI 10.1093/nar/24.6.1149; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; Oda H, 1999, KIDNEY INT, V56, pS2, DOI 10.1046/j.1523-1755.1999.07101.x; Palmer RE, 2001, CURR BIOL, V11, P1805, DOI 10.1016/S0960-9822(01)00560-7; PARK S, 1993, NAT GENET, V4, P415, DOI 10.1038/ng0893-415; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PRITCHARDJONES K, 1994, HUM MOL GENET, V3, P1633, DOI 10.1093/hmg/3.9.1633; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; REDDY JC, 1995, J BIOL CHEM, V270, P29976; REDDY JC, 1995, J BIOL CHEM, V270, P10878, DOI 10.1074/jbc.270.18.10878; Sakakura Y, 2001, BIOCHEM BIOPH RES CO, V286, P176, DOI 10.1006/bbrc.2001.5375; Scharnhorst V, 1999, J BIOL CHEM, V274, P23456, DOI 10.1074/jbc.274.33.23456; Sim EUH, 2002, ONCOGENE, V21, P2948, DOI 10.1038/sj.onc.1205373; Simms LA, 1995, EUR J CANCER, V31A, P2270, DOI 10.1016/0959-8049(95)00474-2; Stanhope-Baker P, 2000, J BIOL CHEM, V275, P38139, DOI 10.1074/jbc.M004901200; Tanaka TS, 2000, P NATL ACAD SCI USA, V97, P9127, DOI 10.1073/pnas.97.16.9127; Thate C, 1998, ONCOGENE, V17, P1287, DOI 10.1038/sj.onc.1202055; Valerius MT, 2002, P NATL ACAD SCI USA, V99, P8090, DOI 10.1073/pnas.122229199	56	22	23	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2004	23	17					3067	3079		10.1038/sj.onc.1207360	http://dx.doi.org/10.1038/sj.onc.1207360			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	812NC	15021918				2022-12-28	WOS:000220845200011
J	Tambe, Y; Isono, T; Haraguchi, S; Yoshioka-Yamashita, A; Yutsudo, M; Inoue, H				Tambe, Y; Isono, T; Haraguchi, S; Yoshioka-Yamashita, A; Yutsudo, M; Inoue, H			A novel apoptotic pathway induced by the drs tumor suppressor gene	ONCOGENE			English	Article						drs; apoptosis; endoplasmic reticulum caspase-12; ASY/Nogo-B/RTN-x(S)	ENDOPLASMIC-RETICULUM STRESS; MESSENGER-RNA; DOWN-REGULATION; CYTOCHROME-C; CASPASE-12; RECEPTOR; PROTEIN; CELLS; BCL-2; SELECTINS	The drs gene was originally isolated as a suppressor against v-src transformation. Expression of drs mRNA was markedly downregulated in a variety of human cancer cell lines and tissues, suggesting that the drs gene acts as a tumor suppressor. In this study, we found that ectopic expression of the Drs protein induced apoptosis in human cancer cell lines. Analyses using deletion mutants of drs revealed that both the C-terminal region and the three consensus repeats in the N-terminal region are essential for the induction of apoptosis. Caspase-12, -9, and -3 were sequentially activated by drs, and specific inhibitors of caspase-3 and -9 suppressed drs-induced apoptosis. The release of cytochrome c from the mitochondria into the cytoplasm was not observed in apoptosis by drs, suggesting that the mitochondrial pathway does not mediate drs-induced apoptosis. Furthermore, we found that the Drs protein can interact with ASY/Nogo-B/RTN-x(S), an apoptosis-inducing protein localized in the endoplasmic reticulum, and that coexpression of these genes increased the efficiency of apoptosis. These results indicated that Drs induces apoptosis by a novel pathway mediated by ASY/Nogo-B/RTN-x(S), caspase-12, -9, and -3.	Shiga Univ Med Sci, Dept Microbiol, Shiga 5202192, Japan; Shiga Univ Med Sci, Cent Res Lab, Shiga 5202192, Japan; Osaka Univ, Microbial Dis Res Inst, Osaka 5650871, Japan	Shiga University of Medical Science; Shiga University of Medical Science; Osaka University	Inoue, H (corresponding author), Shiga Univ Med Sci, Dept Microbiol, Shiga 5202192, Japan.	hirokazu@belle.shiga-med.ac.jp						Annis MG, 2001, ONCOGENE, V20, P1939, DOI 10.1038/sj.onc.1204288; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; Bitko V, 2001, J CELL BIOCHEM, V80, P441, DOI 10.1002/1097-4644(20010301)80:3<441::AID-JCB170>3.0.CO;2-C; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Hacki J, 2000, ONCOGENE, V19, P2286, DOI 10.1038/sj.onc.1203592; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hetz C, 2003, EMBO J, V22, P5435, DOI 10.1093/emboj/cdg537; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Inoue H, 1998, J VIROL, V72, P2532, DOI 10.1128/JVI.72.3.2532-2537.1998; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Kim CJ, 2003, HUM PATHOL, V34, P654, DOI 10.1016/S0046-8177(03)00240-5; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li Q, 2001, ONCOGENE, V20, P3929, DOI 10.1038/sj.onc.1204536; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Mukaisho K, 2002, JPN J CANCER RES, V93, P888, DOI 10.1111/j.1349-7006.2002.tb01334.x; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; NORMAN DG, 1991, J MOL BIOL, V219, P717, DOI 10.1016/0022-2836(91)90666-T; Oertle T, 2003, ONCOGENE, V22, P1390, DOI 10.1038/sj.onc.1206278; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Pan J, 1996, FEBS LETT, V383, P21; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; REID KBM, 1989, IMMUNOL TODAY, V10, P177, DOI 10.1016/0167-5699(89)90317-4; Rudner J, 2001, J CELL SCI, V114, P4161; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Shen Y, 2001, ADV CANCER RES, V82, P55, DOI 10.1016/S0065-230X(01)82002-9; Shimakage M, 2000, INT J CANCER, V87, P5, DOI 10.1002/1097-0215(20000701)87:1<5::AID-IJC2>3.0.CO;2-Y; Shimakage M, 2002, HUM PATHOL, V33, P615, DOI 10.1053/hupa.2002.125373; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; Tagami S, 2000, ONCOGENE, V19, P5736, DOI 10.1038/sj.onc.1203948; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; Yamashita A, 1999, ONCOGENE, V18, P4777, DOI 10.1038/sj.onc.1202852	36	37	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2004	23	17					2977	2987		10.1038/sj.onc.1207419	http://dx.doi.org/10.1038/sj.onc.1207419			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	812NC	15021917				2022-12-28	WOS:000220845200001
J	Muller, S; Ledl, A; Schmidt, D				Muller, S; Ledl, A; Schmidt, D			SUMO: a regulator of gene expression and genome integrity	ONCOGENE			English	Review						SUMO; ubiquitin; transcription; DNA repair	UBIQUITIN-LIKE PROTEINS; NUCLEAR-PORE COMPLEX; COVALENT MODIFICATION; TOPOISOMERASE-I; ANDROGEN RECEPTOR; ACTIVATED STAT; E3 LIGASE; TRANSCRIPTIONAL ACTIVATION; FUNCTIONAL INTERACTIONS; PROGESTERONE-RECEPTOR	Post-translational modi. cation with the ubiquitin-like SUMO protein is involved in the regulation of many cellular key processes. The SUMO system modulates signal transduction pathways, including cytokine, Wnt, growth factor and steroid hormone signalling. SUMO frequently restrains the activity of downstream transcription factors in these pathways presumably by facilitating the recruitment of corepressors or mediating the assembly of repressor complexes. Additionally, evidence is accumulating that SUMO controls pathways important for the surveillance of genome integrity. SUMO regulates the PML/p53 tumour suppressor network, a key determinant in the cellular response to DNA damage. Moreover, proteins that maintain genomic stability by functioning at the interface between DNA replication, recombination and repair processes undergo SUMOylation. We will discuss some key findings that exemplify the role of SUMO in transcriptional regulation and genome surveillance.	Max Planck Inst Biochem, Dept Mol Cell Biol, D-82152 Martinsried, Germany	Max Planck Society	Muller, S (corresponding author), Max Planck Inst Biochem, Dept Mol Cell Biol, Klopferspitz 18, D-82152 Martinsried, Germany.	stmuelle@biochem.mpg.de		Muller, Stefan/0000-0002-8792-7700				Abdel-Hafiz H, 2002, J BIOL CHEM, V277, P33950, DOI 10.1074/jbc.M204573200; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Bachant J, 2002, MOL CELL, V9, P1169, DOI 10.1016/S1097-2765(02)00543-9; Baumann CT, 2001, MOL ENDOCRINOL, V15, P485, DOI 10.1210/me.15.4.485; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Bernier-Villamor V, 2002, CELL, V108, P345, DOI 10.1016/S0092-8674(02)00630-X; Bies J, 2002, J BIOL CHEM, V277, P8999, DOI 10.1074/jbc.M110453200; Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; BOSSIS G, 2003, UNPUB; Chauchereau A, 2003, J BIOL CHEM, V278, P12335, DOI 10.1074/jbc.M207148200; Chen LH, 2003, ONCOGENE, V22, P5348, DOI 10.1038/sj.onc.1206851; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; Dahle O, 2003, EUR J BIOCHEM, V270, P1338, DOI 10.1046/j.1432-1033.2003.03504.x; David G, 2002, J BIOL CHEM, V277, P23658, DOI 10.1074/jbc.M203690200; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Dotzlaw H, 2002, MOL ENDOCRINOL, V16, P661, DOI 10.1210/me.16.4.661; Eaton EM, 2003, J BIOL CHEM, V278, P33416, DOI 10.1074/jbc.M305680200; Epps JL, 1998, CURR BIOL, V8, P1277, DOI 10.1016/S0960-9822(07)00538-6; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Galy A, 2002, DEV BIOL, V248, P251, DOI 10.1006/dbio.2002.0736; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Gottifredi V, 2001, TRENDS CELL BIOL, V11, P184, DOI 10.1016/S0962-8924(01)01983-3; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Hang J, 2002, J BIOL CHEM, V277, P19961, DOI 10.1074/jbc.M201799200; Hardeland U, 2002, EMBO J, V21, P1456, DOI 10.1093/emboj/21.6.1456; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; Hirano Y, 2003, J BIOL CHEM, V278, P16809, DOI 10.1074/jbc.M212448200; Ho JCY, 2001, NUCLEIC ACIDS RES, V29, P4179, DOI 10.1093/nar/29.20.4179; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Horie K, 2002, ONCOGENE, V21, P7913, DOI 10.1038/sj.onc.1205917; Imoto S, 2003, J BIOL CHEM, V278, P34253, DOI 10.1074/jbc.M304961200; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; Jimenez-Lara AM, 2002, FEBS LETT, V526, P142, DOI 10.1016/S0014-5793(02)03154-X; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kawabe Y, 2000, J BIOL CHEM, V275, P20963, DOI 10.1074/jbc.C000273200; Khan MM, 2001, MOL CELL, V7, P1233, DOI 10.1016/S1097-2765(01)00257-X; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Kotaja N, 2002, J BIOL CHEM, V277, P30283, DOI 10.1074/jbc.M204768200; Kurki S, 2003, J CELL SCI, V116, P3917, DOI 10.1242/jcs.00714; Kwek SSS, 2001, ONCOGENE, V20, P2587, DOI 10.1038/sj.onc.1204362; Le Drean Y, 2002, ENDOCRINOLOGY, V143, P3482, DOI 10.1210/en.2002-220135; Lee PSW, 2003, J BIOL CHEM, V278, P27853, DOI 10.1074/jbc.M301755200; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Li WH, 2000, NUCLEIC ACIDS RES, V28, P1145, DOI 10.1093/nar/28.5.1145; Lin X, 2003, J BIOL CHEM, V278, P31043, DOI 10.1074/jbc.C300112200; Lin X, 2003, J BIOL CHEM, V278, P18714, DOI 10.1074/jbc.M302243200; Long JY, 2003, P NATL ACAD SCI USA, V100, P9791, DOI 10.1073/pnas.1733973100; Louria-Hayon I, 2003, J BIOL CHEM, V278, P33134, DOI 10.1074/jbc.M301264200; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mao Y, 2000, J BIOL CHEM, V275, P26066, DOI 10.1074/jbc.M001831200; Mao Y, 2000, P NATL ACAD SCI USA, V97, P4046, DOI 10.1073/pnas.080536597; Matsuzaki K, 2003, BIOCHEM BIOPH RES CO, V306, P32, DOI 10.1016/S0006-291X(03)00910-0; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Megidish T, 2002, J BIOL CHEM, V277, P8255, DOI 10.1074/jbc.C200001200; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Miyauchi Y, 2002, J BIOL CHEM, V277, P50131, DOI 10.1074/jbc.M208319200; Mo YY, 2002, J BIOL CHEM, V277, P2958, DOI 10.1074/jbc.M108263200; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Nakagawa K, 2002, FEBS LETT, V530, P204, DOI 10.1016/S0014-5793(02)03486-5; Nelson V, 2001, APOPTOSIS, V6, P221, DOI 10.1023/A:1011392811628; Nishida T, 2000, EUR J BIOCHEM, V267, P6423, DOI 10.1046/j.1432-1327.2000.01729.x; Nishida T, 2002, J BIOL CHEM, V277, P41311, DOI 10.1074/jbc.M206741200; Orlando V, 2003, CELL, V112, P599, DOI 10.1016/S0092-8674(03)00157-0; Panse VG, 2003, NAT CELL BIOL, V5, P21, DOI 10.1038/ncb893; Pearson M, 2001, ONCOGENE, V20, P7250, DOI 10.1038/sj.onc.1204856; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Pichler A, 2002, TRAFFIC, V3, P381, DOI 10.1034/j.1600-0854.2002.30601.x; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Rallabhandi P, 2002, J BIOL CHEM, V277, P40020, DOI 10.1074/jbc.M200388200; Rivera OJ, 2003, MOL ENDOCRINOL, V17, P128, DOI 10.1210/me.2002-0165; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rogers RS, 2003, J BIOL CHEM, V278, P30091, DOI 10.1074/jbc.M301344200; Ross S, 2002, MOL CELL, V10, P831, DOI 10.1016/S1097-2765(02)00682-2; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Saitoh H, 2002, J BIOL CHEM, V277, P4755, DOI 10.1074/jbc.M104453200; Sapetschnig A, 2002, EMBO J, V21, P5206, DOI 10.1093/emboj/cdf510; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Schmidt D, 2003, CELL MOL LIFE SCI, V60, P2561, DOI 10.1007/s00018-003-3129-1; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Seeler JS, 1999, CURR OPIN GENET DEV, V9, P362, DOI 10.1016/S0959-437X(99)80054-9; Seeler JS, 2001, ONCOGENE, V20, P7243, DOI 10.1038/sj.onc.1204758; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shen ZY, 1996, GENOMICS, V37, P183, DOI 10.1006/geno.1996.0540; Shuai K, 2000, ONCOGENE, V19, P2638, DOI 10.1038/sj.onc.1203522; Stelter P, 2003, NATURE, V425, P188, DOI 10.1038/nature01965; Subramanian L, 2003, J BIOL CHEM, V278, P9134, DOI 10.1074/jbc.M210440200; Takahashi Y, 2001, J BIOL CHEM, V276, P48973, DOI 10.1074/jbc.M109295200; Takahashi Y, 2001, GENE, V275, P223, DOI 10.1016/S0378-1119(01)00662-X; Takahashi Y, 2000, J BIOCHEM-TOKYO, V128, P723, DOI 10.1093/oxfordjournals.jbchem.a022807; Tian S, 2002, BIOCHEM J, V367, P907, DOI 10.1042/BJ20021085; Tojo M, 2002, J BIOL CHEM, V277, P46576, DOI 10.1074/jbc.M205987200; Tussie-Luna MI, 2002, P NATL ACAD SCI USA, V99, P12807, DOI 10.1073/pnas.192464499; Ungureanu D, 2003, BLOOD, V102, P3311, DOI 10.1182/blood-2002-12-3816; Verdin E, 2003, TRENDS GENET, V19, P286, DOI 10.1016/S0168-9525(03)00073-8; Verger A, 2003, EMBO REP, V4, P137, DOI 10.1038/sj.embor.embor738; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Wei XL, 2003, J BIOL CHEM, V278, P29288, DOI 10.1074/jbc.M212215200; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; West SC, 2003, NAT REV MOL CELL BIO, V4, P435, DOI 10.1038/nrm1127; Wible BA, 2002, J BIOL CHEM, V277, P17852, DOI 10.1074/jbc.M201689200; Wood LD, 2003, P NATL ACAD SCI USA, V100, P3257, DOI 10.1073/pnas.0637114100; Xirodimas DP, 2002, FEBS LETT, V528, P207, DOI 10.1016/S0014-5793(02)03310-0; Yamamoto H, 2003, EMBO J, V22, P2047, DOI 10.1093/emboj/cdg204; Yang SH, 2003, MOL CELL, V12, P63, DOI 10.1016/S1097-2765(03)00265-X; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; Zhang H, 2002, MOL CELL BIOL, V22, P6498, DOI 10.1128/MCB.22.18.6498-6508.2002; Zhang Q, 2002, J IMMUNOL, V168, P466, DOI 10.4049/jimmunol.168.1.466; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583	125	235	249	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2004	23	11					1998	2008		10.1038/sj.onc.1207415	http://dx.doi.org/10.1038/sj.onc.1207415			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	803EC	15021887				2022-12-28	WOS:000220213400004
J	Kim, H; Nam, SW; Rhee, H; Li, LS; Kang, HJ; Koh, KH; Kim, NK; Song, J; Liu, ETB; Kim, H				Kim, H; Nam, SW; Rhee, H; Li, LS; Kang, HJ; Koh, KH; Kim, NK; Song, J; Liu, ETB; Kim, H			Different gene expression profiles between microsatellite instability-high and microsatellite stable colorectal carcinomas	ONCOGENE			English	Article						colorectal carcinomas; microsatellite instability; oligonucleotide microarray; gene expression profile; molecular classification	COLON-CANCER; OLIGONUCLEOTIDE ARRAYS; TARGET GENES; BETA-CATENIN; SEQUENCES; MUTATIONS; PATHWAY; CARCINOGENESIS; IDENTIFICATION; MICROARRAYS	Recent molecular genetic studies have revealed that two major types of genomic instabilities, chromosomal instability (CIN) and microsatellite instability (MSI), exist in colorectal carcinomas. In order to clarify the molecular signature related to the CIN and MSI in colorectal carcinomas, we performed transcriptomic expression analysis on eight microsatellite instability-high (MSI-H) colorectal carcinomas and compared the results obtained with that of nine microsatellite stable (MSS) colorectal carcinomas using oligonucleotide microarrays containing 17 334 known genes and 1331 unknown genes or expression sequence tags ( ESTs). Unsupervised two-way hierarchical clustering with 5724 genes successfully classified tumors from normal mucosa, and displayed a distinctive MSI-H carcinomas subgroup. Based on intensive filtering, 57 known genes and eight ESTs were found to be highly relevant to the differentiation of MSI-H and MSS colorectal carcinomas. These genes successfully distinguish the new test set of six MSI-H and five MSS colorectal carcinomas. Many up- and downregulated genes in MSI-H colorectal carcinomas were related to the previously reported phenotypic characteristics; increased mucin production and intense peritumoral immune response in MSI-H carcinomas. Some of these differences were confirmed by semiquantitative reverse transcription-PCR and immunohistochemical analysis. Our findings indicate that there are many different genetic and transcriptomic characteristics between MSI-H and MSS colorectal carcinomas, and some of these differently expressed genes can be used as diagnostic or prognostic markers.	Yonsei Univ, Coll Med, Dept Pathol, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Brain Korea Projects Med Sci 21, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Canc Metastasis Res Ctr, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Dept Surg, Seoul 120752, South Korea; Genome Inst Singapore, Singapore 138672, Singapore; Catholic Univ Korea, Coll Med, Dept Pathol, Seoul 137710, South Korea; Sungkyunkwan Univ, Coll Life Sci & Nat Resources, Dept Genet Engn, Suwon 440746, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); Catholic University of Korea; Sungkyunkwan University (SKKU)	Kim, H (corresponding author), Yonsei Univ, Coll Med, Dept Pathol, CPO Box 8044, Seoul 120752, South Korea.	hkyonsei@yumc.yonsei.ac.kr	Liu, Edison/C-4141-2008	Kim, Nam-Kyu/0000-0003-0639-5632; Kim, Hyunki/0000-0003-2292-5584				Alexander J, 2001, AM J PATHOL, V158, P527, DOI 10.1016/S0002-9440(10)63994-6; Alon U, 1999, P NATL ACAD SCI USA, V96, P6745, DOI 10.1073/pnas.96.12.6745; Bertucci F, 2004, ONCOGENE, V23, P1377, DOI 10.1038/sj.onc.1207262; Biemer-Huttmann AE, 2000, CLIN CANCER RES, V6, P1909; Birkenkamp-Demtroder K, 2002, CANCER RES, V62, P4352; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Dunican DS, 2002, ONCOGENE, V21, P3253, DOI 10.1038/sj.onc.1205431; Duval A, 2002, CANCER RES, V62, P2447; Guidoboni M, 2001, AM J PATHOL, V159, P297, DOI 10.1016/S0002-9440(10)61695-1; Hiraga Y, 1998, ONCOLOGY-BASEL, V55, P307, DOI 10.1159/000011868; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KIM HG, 1994, AM J PATHOL, V145, P148; Kim NG, 2002, ONCOGENE, V21, P5081, DOI 10.1038/sj.onc.1205703; Kim NG, 2001, CANCER RES, V61, P36; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kitahara O, 2001, CANCER RES, V61, P3544; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Leung JY, 2002, J BIOL CHEM, V277, P21657, DOI 10.1074/jbc.M200139200; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Mori Y, 2003, CANCER RES, V63, P4577; Notterman DA, 2001, CANCER RES, V61, P3124; Stenger S, 1999, IMMUNOL TODAY, V20, P390, DOI 10.1016/S0167-5699(99)01449-8; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Ward R, 2001, GUT, V48, P821, DOI 10.1136/gut.48.6.821	26	41	44	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2004	23	37					6218	6225		10.1038/sj.onc.1207853	http://dx.doi.org/10.1038/sj.onc.1207853			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	847NC	15208663				2022-12-28	WOS:000223399000006
J	Molist, R; Reinvikos, Y; Dutrillaux, B; Muleris, M				Molist, R; Reinvikos, Y; Dutrillaux, B; Muleris, M			Characterization of a new cytogenetic subtype of ductal breast carcinomas	ONCOGENE			English	Article						comparative genomic hybridization; ductal breast carcinomas; chromosome aberrations; TP53; chromosome gain	COMPARATIVE GENOMIC HYBRIDIZATION; REPLICATION ERROR PHENOTYPE; MICROSATELLITE INSTABILITY; COLORECTAL-CANCER; CHROMOSOMAL EVOLUTION; GENETIC ALTERATIONS; SOLID TUMORS; DNA; PATHWAYS; CARCINOGENESIS	About 50% of ductal breast carcinomas do not yield analysable karyotypes after short-term culturing. Comparison of the cytogenetic subset to the whole data set of tumors revealed that slightly hyperdiploid tumors, that is, with DNA index between 1.05 and 1.3, were under-represented in tumors for which cytogenetic analysis was successful. The purpose of this study was to determine whether the pattern of chromosome imbalances in this subset differs from that generally reported. Comparative genomic hybridization (CGH) was used on 43 primary ductal breast carcinomas selected for slight hyperdiploidy. Microsatellite instability (MSI), TP53 mutation and expression were also investigated. All tumors were MSI negative. In all, 18 tumors (42%) presented mostly unbalanced chromosome rearrangements and DNA amplifications, with only few or no whole chromosome gains (WCG). This pattern of chromosome imbalances corresponds to that described in most breast tumors by previous cytogenetic and CGH analyses. It was associated with TP53 mutation in 17% of tumors. Another subset of 17 tumors (39%) displayed different and new features, characterized by recurrent gains of whole chromosomes 5, 7 and 8 with few chromosome rearrangements, rare DNA amplifications and no TP53 mutation. Eight tumors with as many rearrangements as WCG were left unclassified. We propose that, beside a major pathway characterized by multiple chromosome rearrangements, there is a minor pathway mainly characterized by WCG.	Inst Curie, CNRS, FRE 2584, F-75248 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Muleris, M (corresponding author), Inst Curie, CNRS, FRE 2584, 26 Rue Ulm, F-75248 Paris, France.	martme.muleris@curie.fr						AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Anbazhagan R, 1999, CLIN CANCER RES, V5, P839; Bernardino J, 1997, GENE CHROMOSOME CANC, V19, P195; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; Buerger H, 2001, J PATHOL, V194, P165, DOI 10.1002/path.875; Courjal F, 1997, CANCER RES, V57, P4368; DELATTRE O, 1989, LANCET, V2, P353; Dellas A, 2002, CLIN CANCER RES, V8, P1210; DEVILEE P, 1994, BBA-REV CANCER, V1198, P113, DOI 10.1016/0304-419X(94)90009-4; DUTRILLAUX B, 1990, CANCER GENET CYTOGEN, V49, P203, DOI 10.1016/0165-4608(90)90143-X; DUTRILLAUX B, 1991, BREAST CANCER RES TR, V19, P245, DOI 10.1007/BF01961161; DUTRILLAUX B, 2000, CHROMOSOME GENE ALTE; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Georgiades IB, 1999, ONCOGENE, V18, P7933, DOI 10.1038/sj.onc.1203368; Haydon AMM, 2002, LANCET ONCOL, V3, P83, DOI 10.1016/S1470-2045(02)00649-6; Hoang JM, 1997, CANCER RES, V57, P300; Hoglund M, 2002, CANCER RES, V62, P2675; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; ISOLA JJ, 1995, AM J PATHOL, V147, P905; Jallepalli PV, 2001, NAT REV CANCER, V1, P109, DOI 10.1038/35101065; KALLIONIEMI OP, 1994, GENE CHROMOSOME CANC, V10, P231, DOI 10.1002/gcc.2870100403; Kuukasjarvi T, 1997, CANCER RES, V57, P1597; Lesec G, 1997, INT J ONCOL, V10, P747; LOTHE RA, 1993, CANCER RES, V53, P5849; Loveday RL, 2000, INT J CANCER, V86, P494, DOI 10.1002/(SICI)1097-0215(20000515)86:4<494::AID-IJC8>3.3.CO;2-F; MULERIS M, 1988, CANCER GENET CYTOGEN, V32, P43, DOI 10.1016/0165-4608(88)90310-X; MULERIS M, 1990, CANCER GENET CYTOGEN, V46, P143, DOI 10.1016/0165-4608(90)90100-O; Muleris M, 1996, CANCER GENET CYTOGEN, V92, P11, DOI 10.1016/S0165-4608(96)00116-1; Murata H, 2002, ONCOGENE, V21, P5696, DOI 10.1038/sj.onc.1205683; Nishizaki T, 1997, GENE CHROMOSOME CANC, V19, P267, DOI 10.1002/(SICI)1098-2264(199708)19:4<267::AID-GCC9>3.0.CO;2-V; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; PANDIS N, 1995, GENE CHROMOSOME CANC, V12, P173, DOI 10.1002/gcc.2870120304; Paulson TG, 1996, CANCER RES, V56, P4021; Remvikos Y, 1997, CANCER GENET CYTOGEN, V93, P63, DOI 10.1016/S0165-4608(96)00305-6; REMVIKOS Y, 1995, GENE CHROMOSOME CANC, V12, P272, DOI 10.1002/gcc.2870120406; REMVIKOS Y, 1991, BRIT J CANCER, V64, P501, DOI 10.1038/bjc.1991.338; RIED T, 1995, CANCER RES, V55, P5415; Roylance R, 1999, CANCER RES, V59, P1433; Sandberg AA, 2000, CANCER GENET CYTOGEN, V123, P1, DOI 10.1016/S0165-4608(00)00295-8; Shackney SE, 1997, CYTOMETRY, V29, P1; Shaw JA, 1996, BRIT J CANCER, V73, P1393, DOI 10.1038/bjc.1996.264; Soulie P, 1999, ONCOGENE, V18, P775, DOI 10.1038/sj.onc.1202336; Soussi T, 2000, HUM MUTAT, V15, P105, DOI 10.1002/(SICI)1098-1004(200001)15:1<105::AID-HUMU19>3.0.CO;2-G; Tanner MM, 1998, AM J PATHOL, V153, P191, DOI 10.1016/S0002-9440(10)65560-5; Teixeira MR, 2002, GENE CHROMOSOME CANC, V33, P1, DOI 10.1002/gcc.1206; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Tirkkonen M, 1998, GENE CHROMOSOME CANC, V21, P177, DOI 10.1002/(SICI)1098-2264(199803)21:3<177::AID-GCC1>3.3.CO;2-C; Walsh T, 1998, J PATHOL, V185, P18, DOI 10.1002/(SICI)1096-9896(199805)185:1<18::AID-PATH41>3.0.CO;2-G; Zhou XP, 1998, GENE CHROMOSOME CANC, V21, P101, DOI 10.1002/(SICI)1098-2264(199802)21:2<101::AID-GCC4>3.0.CO;2-4	49	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2004	23	35					5986	5993		10.1038/sj.onc.1207799	http://dx.doi.org/10.1038/sj.onc.1207799			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15208688				2022-12-28	WOS:000222941100013
J	Yamada, S; Ohira, M; Horie, H; Ando, K; Takayasu, H; Suzuki, Y; Sugano, S; Hirata, T; Goto, T; Matsunaga, T; Hiyama, E; Hayashi, Y; Ando, H; Suita, S; Kaneko, M; Sasaki, F; Hashizume, K; Ohnuma, N; Nakagawara, A				Yamada, S; Ohira, M; Horie, H; Ando, K; Takayasu, H; Suzuki, Y; Sugano, S; Hirata, T; Goto, T; Matsunaga, T; Hiyama, E; Hayashi, Y; Ando, H; Suita, S; Kaneko, M; Sasaki, F; Hashizume, K; Ohnuma, N; Nakagawara, A			Expression profiling and differential screening between hepatoblastomas and the corresponding normal livers: Identification of high expression of the PLK1 oncogene as a poor-prognostic indicator of hepatoblastomas	ONCOGENE			English	Article						hepatoblastoma; expression profile; oligocapping cDNA library; PLK1; prognostic factor	POLO-LIKE-KINASE; ALPHA-FETOPROTEIN LEVELS; BETA-CATENIN GENE; HEPATOCELLULAR-CARCINOMA; APC GENE; METASTATIC HEPATOBLASTOMA; CHILDHOOD HEPATOBLASTOMA; CANCER; MUTATIONS; TUMOR	Hepatoblastoma is one of the most common malignant liver tumors in young children. Recent evidences have suggested that the abnormalities in Wnt signaling pathway, as seen in frequent mutation of the beta-catenin gene, may play a role in the genesis of hepatoblastoma. However, the precise mechanism to cause the tumor has been elusive. To identify novel hepatoblastoma-related genes for unveiling the molecular mechanism of the tumorigenesis, a large-scale cloning of cDNAs and differential screening of their expression between hepatoblastomas and the corresponding normal livers were performed. We constructed four full-length-enriched cDNA libraries using an oligo-capping method from the primary tissues which included two hepatoblastomas with high levels of alpha-fetoprotein (AFP), a hepatoblastoma without production of AFP, and a normal liver tissue corresponded to the tumor. Among the 10431 cDNAs randomly picked up and successfully sequenced, 847 (8.1%) were the genes with unknown function. Of interest, the expression profile among the two subsets of hepatoblastoma and a normal liver was extremely different. A semiquantitative RT-PCR analysis showed that 86 out of 1188 genes tested were differentially expressed between hepatoblastomas and the corresponding normal livers, but that only 11 of those were expressed at high levels in the tumors. Notably, PLK1 oncogene was expressed at very high levels in hepatoblastomas as compared to the normal infant's livers. Quantitative real-time RT-PCR analysis for the PLK1 mRNA levels in 74 primary hepatoblastomas and 29 corresponding nontumorous livers indicated that the patients with hepatoblastoma with high expression of PLK1 represented significantly poorer outcome than those with its low expression (5-year survival rate: 55.9 vs 87.0%, respectively, p = 0.042), suggesting that the level of PLK1 expression is a novel marker to predict the prognosis of hepatoblastoma. Thus, the differentially expressed genes we have identified may become a useful tool to develop new diagnostic as well as therapeutic strategies of hepatoblastoma.	Chiba Cancer Ctr Res Inst, Div Biochem, Chiba 2608717, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Tokyo 1088639, Japan; Hisamitsu Pharmaceut Co Inc, Tokyo 1006221, Japan	Chiba Cancer Center; University of Tokyo; Hisamitsu Pharmaceutical Co Ltd	Nakagawara, A (corresponding author), Chiba Cancer Ctr Res Inst, Div Biochem, 666-2 Nitona, Chiba 2608717, Japan.	akiranak@chiba-ccri.chuo.chiba.jp	Hiyama, Eiso/A-2013-2019	Hiyama, Eiso/0000-0001-9179-5037				ALBRECHT S, 1994, CANCER RES, V54, P5041; BRADY RO, 1989, NEUROL CLIN, V7, P75, DOI 10.1016/S0733-8619(18)30829-6; Buendia MA, 2002, MED PEDIATR ONCOL, V39, P530, DOI 10.1002/mpo.10180; BUENDIA MA, 1992, ADV CANCER RES, V59, P167, DOI 10.1016/S0065-230X(08)60306-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAY FJ, 1993, P NATL ACAD SCI USA, V90, P4882, DOI 10.1073/pnas.90.11.4882; Dietzmann K, 2001, J NEURO-ONCOL, V53, P1, DOI 10.1023/A:1011808200978; EXELBY PR, 1975, J PEDIATR SURG, V10, P329; Fukuzawa R, 1999, INT J CANCER, V82, P490, DOI 10.1002/(SICI)1097-0215(19990812)82:4<490::AID-IJC4>3.0.CO;2-I; Giardiello FM, 1996, GUT, V39, P867, DOI 10.1136/gut.39.6.867; Glover DM, 1996, J CELL BIOL, V135, P1681, DOI 10.1083/jcb.135.6.1681; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Gray SG, 2000, BRIT J CANCER, V82, P1561, DOI 10.1054/bjoc.1999.1179; HAAS JE, 1989, CANCER-AM CANCER SOC, V64, P1082, DOI 10.1002/1097-0142(19890901)64:5<1082::AID-CNCR2820640520>3.0.CO;2-G; HAMANAKA R, 1992, J BIOL CHEM, V267, P13160; HATA Y, 1990, JPN J SURG, V20, P498, DOI 10.1007/BF02471004; HATA Y, 1991, CANCER, V68, P2566, DOI 10.1002/1097-0142(19911215)68:12<2566::AID-CNCR2820681206>3.0.CO;2-Z; Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899; Ichimiya S, 1999, ONCOGENE, V18, P1061, DOI 10.1038/sj.onc.1202390; Idilman R, 1998, J VIRAL HEPATITIS, V5, P285, DOI 10.1046/j.1365-2893.1998.00116.x; Kinoshita M, 2002, HEPATOLOGY, V36, P433, DOI 10.1053/jhep.2002.34851; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Knecht R, 1999, CANCER RES, V59, P2794; Koch A, 1999, CANCER RES, V59, P269; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; LI FP, 1987, JAMA-J AM MED ASSOC, V257, P2475, DOI 10.1001/jama.257.18.2475; LI XR, 1995, ONCOGENE, V11, P221; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; MANN JR, 1978, ARCH DIS CHILD, V53, P366, DOI 10.1136/adc.53.5.366; Miao JY, 2003, HEPATOL RES, V25, P174, DOI 10.1016/S1386-6346(02)00264-4; MONTAGNA M, 1994, J CANCER RES CLIN, V120, P732, DOI 10.1007/BF01194272; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nagata T, 2003, CANCER GENET CYTOGEN, V145, P152, DOI 10.1016/S0165-4608(03)00065-7; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; ODA H, 1995, INT J CANCER, V60, P786, DOI 10.1002/ijc.2910600610; Oda H, 1996, CANCER RES, V56, P3320; Okabe H, 2001, CANCER RES, V61, P2129; OKUBO K, 1992, NAT GENET, V2, P173, DOI 10.1038/ng1192-173; ORTEGA JA, 1991, J CLIN ONCOL, V9, P2167, DOI 10.1200/JCO.1991.9.12.2167; Park WS, 2001, J PATHOL, V193, P483; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; RAINIER S, 1995, CANCER RES, V55, P1836; Ribbeck K, 1998, EMBO J, V17, P6587, DOI 10.1093/emboj/17.22.6587; Rimm DL, 1999, AM J PATHOL, V154, P325, DOI 10.1016/S0002-9440(10)65278-9; Ryazanov AG, 1999, CURR BIOL, V9, pR43, DOI 10.1016/S0960-9822(99)80006-2; Sasaki F, 2002, J PEDIATR SURG, V37, P851, DOI 10.1053/jpsu.2002.32886; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; SUDHOF TC, 1987, CELL, V48, P1061, DOI 10.1016/0092-8674(87)90713-6; Suzuki Y, 1997, GENE, V200, P149, DOI 10.1016/S0378-1119(97)00411-3; Takai N, 2001, CANCER LETT, V164, P41, DOI 10.1016/S0304-3835(00)00703-5; Takayasu H, 2001, CLIN CANCER RES, V7, P901; Taniguchi K, 2002, ONCOGENE, V21, P4863, DOI 10.1038/sj.onc.1205591; Thomas D, 2003, EUR J CANCER, V39, P2200, DOI 10.1016/S0959-8049(03)00618-X; Tokumitsu Y, 1999, INT J ONCOL, V15, P687; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; Uotani H, 1998, J PEDIATR SURG, V33, P639, DOI 10.1016/S0022-3468(98)90333-5; VanTornout J, 1997, J CLIN ONCOL, V15, P1190, DOI 10.1200/JCO.1997.15.3.1190; Velculescu VE, 2000, TRENDS GENET, V16, P423, DOI 10.1016/S0168-9525(00)02114-4; von Horn H, 2001, CANCER LETT, V162, P253, DOI 10.1016/S0304-3835(00)00668-6; VONSCHWEINITZ D, 1995, J PEDIATR SURG, V30, P845, DOI 10.1016/0022-3468(95)90762-9; VONSCHWEINITZ D, 1994, EUR J CANCER, V30, P152; Wang J, 2000, ONCOGENE, V19, P1843, DOI 10.1038/sj.onc.1203503; Weber RG, 2000, AM J PATHOL, V157, P571, DOI 10.1016/S0002-9440(10)64567-1; Wei Y, 2000, ONCOGENE, V19, P498, DOI 10.1038/sj.onc.1203356; WEINBERG AG, 1983, HUM PATHOL, V14, P512, DOI 10.1016/S0046-8177(83)80005-7; Wissmann C, 2003, J PATHOL, V201, P204, DOI 10.1002/path.1449; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862; Xu XR, 2001, P NATL ACAD SCI USA, V98, P15089, DOI 10.1073/pnas.241522398; Yun K, 1998, J PATHOL, V185, P91, DOI 10.1002/(SICI)1096-9896(199805)185:1<91::AID-PATH44>3.0.CO;2-K	72	102	136	4	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2004	23	35					5901	5911		10.1038/sj.onc.1207782	http://dx.doi.org/10.1038/sj.onc.1207782			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15221005				2022-12-28	WOS:000222941100004
J	Miyoshi, K; Wakioka, T; Nishinakamura, H; Kamio, M; Yang, L; Inoue, M; Hasegawa, M; Yonemitsu, Y; Komiya, S; Yoshimura, A				Miyoshi, K; Wakioka, T; Nishinakamura, H; Kamio, M; Yang, L; Inoue, M; Hasegawa, M; Yonemitsu, Y; Komiya, S; Yoshimura, A			The Sprouty-related protein, Spred, inhibits cell motility, metastasis, and Rho-mediated actin reorganization	ONCOGENE			English	Article						migration; ERK; Sprouty; metastasis; Rho; signal transduction	SERUM RESPONSE FACTOR; ERK ACTIVATION; SENDAI-VIRUS; DROSOPHILA-SPROUTY; FOCAL ADHESIONS; STRESS FIBERS; ONCOGENIC RAS; KINASE; BINDING; EXPRESSION	Sprouty and the Sprouty-related protein, Spred (Sprouty-related Ena/vasodilator-stimulated phosphoprotein homology-1 (EVH1) domain-containing protein), inhibit Ras-dependent extracellular signal-regulated kinase (ERK) signaling induced by a variety of growth factors. Since Sprouty proteins have been shown to inhibit not only ERK activation but also cell migration, we postulated that Spreds also inhibit cellular migration. Using stably highly metastatic LM8 cells infected with the Spred1-Sendai virus vector, we demonstrated that Spred1 inhibits the metastasis of LM8 cells in nude mice. Spred1 overexpression also inhibited migration of cells in vitro in response to chemokines, CCL19 and CCL21. We also found that Spred1 overexpression dissolved actin-stress fibers. Both EVH1 domain and C-terminal Sprouty-related domain were required for actin reassembly. Spred1 and Spred2 suppressed constitutively activated RhoA (V14RhoA)-induced stress fiber formation and serum response factor activation. Spred1 bound to activated RhoA, but not cdc42 and Rac. Spred1 also inhibited chemokine-induced RhoA activation and active RhoA-induced Rho-kinase activation. These data suggest that Spreds are key regulators of RhoA-mediated cell motility and signal transduction. Furthermore, our study suggests that the induction of Spreds could be a novel strategy for preventing cancer cell metastasis.	Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, Fukuoka 8128582, Japan; Kagoshima Univ, Fac Med, Dept Orthoped Surg, Kagoshima 8908520, Japan; DNAVEC Res Inc, Tsukuba, Ibaraki, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Pathol, Div Pathophysiol & Expt Pathol,Higashi Ku, Fukuoka 8128582, Japan	Kyushu University; Kagoshima University; DNAVEC Corporation; Kyushu University	Yoshimura, A (corresponding author), Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	yakihiko@bioreg.kyushu-u.ac.jp	Yoshimura, Akihiko/K-5515-2013	Inoue, Makoto/0000-0003-0804-7439				Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 2000, EXP CELL RES, V261, P44, DOI 10.1006/excr.2000.5046; Arsenian S, 1998, EMBO J, V17, P6289, DOI 10.1093/emboj/17.21.6289; Bonacchi A, 2001, J BIOL CHEM, V276, P9945, DOI 10.1074/jbc.M010303200; Cabrita MA, 2003, THROMB HAEMOSTASIS, V90, P586, DOI 10.1160/TH03-04-0217; Callebaut I, 1998, FEBS LETT, V441, P181, DOI 10.1016/S0014-5793(98)01541-5; Carnac G, 1998, MOL BIOL CELL, V9, P1891, DOI 10.1091/mbc.9.7.1891; Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; de Maximy AA, 1999, MECH DEVELOP, V81, P213, DOI 10.1016/S0925-4773(98)00241-X; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Hashimoto S, 2002, MECH DEVELOP, V119, pS303, DOI 10.1016/S0925-4773(03)00132-1; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Impagnatiello MA, 2001, J CELL BIOL, V152, P1087, DOI 10.1083/jcb.152.5.1087; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Izawa I, 1998, ONCOGENE, V17, P2863, DOI 10.1038/sj.onc.1202213; Joo A, 2004, ONCOGENE, V23, P726, DOI 10.1038/sj.onc.1207174; Kato A, 1996, GENES CELLS, V1, P569, DOI 10.1046/j.1365-2443.1996.d01-261.x; Kato R, 2003, BIOCHEM BIOPH RES CO, V302, P767, DOI 10.1016/S0006-291X(03)00259-6; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; Kimura K, 2000, J BIOL CHEM, V275, P17233, DOI 10.1074/jbc.C000212200; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; Kolakofsky D, 1998, J VIROL, V72, P891, DOI 10.1128/JVI.72.2.891-899.1998; Kramer S, 1999, DEVELOPMENT, V126, P2515; Kranenburg O, 1997, J CELL SCI, V110, P2417; Lee SH, 2001, J BIOL CHEM, V276, P4128, DOI 10.1074/jbc.M006922200; Leung T, 1996, MOL CELL BIOL, V16, P5313; Lim J, 2000, J BIOL CHEM, V275, P32837, DOI 10.1074/jbc.M002156200; Minowada G, 1999, DEVELOPMENT, V126, P4465; Prehoda KE, 1999, CELL, V97, P471, DOI 10.1016/S0092-8674(00)80757-6; Reich A, 1999, DEVELOPMENT, V126, P4139; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sakai Y, 1999, FEBS LETT, V456, P221, DOI 10.1016/S0014-5793(99)00960-6; Sasaki A, 2003, NAT CELL BIOL, V5, P427, DOI 10.1038/ncb978; Sasaki A, 2001, J BIOL CHEM, V276, P36804, DOI 10.1074/jbc.C100386200; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Tefft JD, 1999, CURR BIOL, V9, P219, DOI 10.1016/S0960-9822(99)80094-3; Wakioka T, 2001, NATURE, V412, P647, DOI 10.1038/35088082; Wei L, 1998, J BIOL CHEM, V273, P30287, DOI 10.1074/jbc.273.46.30287; Yigzaw Y, 2001, J BIOL CHEM, V276, P22742, DOI 10.1074/jbc.M100123200; Yonemitsu Y, 2000, NAT BIOTECHNOL, V18, P970, DOI 10.1038/79463; Zhong CL, 1997, MOL BIOL CELL, V8, P2329, DOI 10.1091/mbc.8.11.2329	43	73	77	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5567	5576		10.1038/sj.onc.1207759	http://dx.doi.org/10.1038/sj.onc.1207759			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15184877				2022-12-28	WOS:000222629500001
J	Berthou, S; Aebersold, DM; Schmidt, LS; Stroka, D; Heigl, C; Streit, B; Stalder, D; Gruber, G; Liang, CX; Howlett, AR; Candinas, D; Greiner, RH; Lipson, KE; Zimmer, Y				Berthou, S; Aebersold, DM; Schmidt, LS; Stroka, D; Heigl, C; Streit, B; Stalder, D; Gruber, G; Liang, CX; Howlett, AR; Candinas, D; Greiner, RH; Lipson, KE; Zimmer, Y			The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants	ONCOGENE			English	Article						Met receptor; activating mutation; receptor tyrosine kinase inhibitor	GROWTH-FACTOR RECEPTOR; GASTROINTESTINAL STROMAL TUMORS; PAPILLARY RENAL-CARCINOMAS; CHRONIC MYELOID-LEUKEMIA; FACTOR SCATTER FACTOR; TYROSINE KINASE; SOMATIC MUTATIONS; C-MET; CYTOGENETIC RESPONSES; IMATINIB MESYLATE	Point mutations constitute a major mode of oncogenic activation of the Met receptor tyrosine kinase. Met is aberrantly activated in many types of human malignancies and its deregulated activity is correlated with aggressive tumor traits such as abnormal proliferation and survival, leading to tumor growth, local invasion and metastasis. Here we report that the Met kinase inhibitor SU11274 differentially affects the kinase activity and subsequent signaling of various mutant forms of Met. Two Met variants tested, M1268T and H1112Y, were potently inhibited by 2 muM SU11274, while two other variants, L1213V and Y1248H, remained resistant under similar experimental conditions. Inhibition of the kinase altered cell proliferation, morphology and motility, while cells containing resistant mutants appeared unaffected by the compound. The basis for the sensitivity or resistance to SU11274 is discussed in terms of the position of the mutations predicted from a homology model.	Univ Bern, Dept Clin Res, CH-3010 Bern, Switzerland; Univ Bern, Inselspital, Dept Radiat Oncol, CH-3010 Bern, Switzerland; SAIC Frederick Inc, Basic Res Program, NCI Frederick, Ft Detrick, MD 21702 USA; Univ Bern, Inselspital, Dept Visceral Surg, CH-3010 Bern, Switzerland; SUGEN Inc, San Francisco, CA 94080 USA	University of Bern; University of Bern; University Hospital of Bern; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Bern; University Hospital of Bern; Pfizer	Zimmer, Y (corresponding author), Univ Bern, Dept Clin Res, Murtenstr 35-D-809, CH-3010 Bern, Switzerland.	yitzhak.zimmer@dkf5.unibe.ch	Stroka, Deborah M/F-1806-2013; Aebersold, Daniel Matthias/C-2946-2013	Aebersold, Daniel Matthias/0000-0002-9493-3834; Stroka, Deborah/0000-0002-3517-3871; Lipson, Kenneth/0000-0001-8847-6051	PHS HHS [N01-C0-12400] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Aebersold DM, 2003, ONCOGENE, V22, P8519, DOI 10.1038/sj.onc.1206968; Azam M, 2003, CELL, V112, P831, DOI 10.1016/S0092-8674(03)00190-9; Bardelli A, 1998, P NATL ACAD SCI USA, V95, P14379, DOI 10.1073/pnas.95.24.14379; Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139; Danilkovitch-Miagkova A, 2002, J CLIN INVEST, V109, P863; de Silva MV, 2003, PATHOL ONCOL RES, V9, P13, DOI 10.1007/BF03033708; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Di Renzo MF, 2000, ONCOGENE, V19, P1547, DOI 10.1038/sj.onc.1203455; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Giordano S, 2000, FASEB J, V14, P399, DOI 10.1096/fasebj.14.2.399; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; Haddad R, 2001, ANTICANCER RES, V21, P4243; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; Lee JH, 2000, ONCOGENE, V19, P4947, DOI 10.1038/sj.onc.1203874; Longati P, 2001, CURR DRUG TARGETS, V2, P41, DOI 10.2174/1389450013348920; Lorenzato A, 2002, CANCER RES, V62, P7025; Ma PC, 2003, CANCER RES, V63, P6272; Maulik G, 2002, CYTOKINE GROWTH F R, V13, P41, DOI 10.1016/S1359-6101(01)00029-6; Miller M, 2001, PROTEINS, V44, P32, DOI 10.1002/prot.1069; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; Park WS, 1999, CANCER RES, V59, P307; REGECAMBRIN G, 1992, CANCER GENET CYTOGEN, V64, P170, DOI 10.1016/0165-4608(92)90350-H; Roumiantsev S, 2002, P NATL ACAD SCI USA, V99, P10700, DOI 10.1073/pnas.162140299; Sattler M, 2003, CANCER RES, V63, P5462; Schiering N, 2003, P NATL ACAD SCI USA, V100, P12654, DOI 10.1073/pnas.1734128100; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schmidt L, 1999, ONCOGENE, V18, P2343, DOI 10.1038/sj.onc.1202547; Talpaz M, 2002, BLOOD, V99, P1928, DOI 10.1182/blood.V99.6.1928; To CTT, 1998, ONCOL REP, V5, P1013; van Oosterom AT, 2001, LANCET, V358, P1421, DOI 10.1016/S0140-6736(01)06535-7; Wang XY, 2003, MOL CANCER THER, V2, P1085	33	153	167	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2004	23	31					5387	5393		10.1038/sj.onc.1207691	http://dx.doi.org/10.1038/sj.onc.1207691			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15064724				2022-12-28	WOS:000222491600014
J	Hirai, I; Sasaki, T; Wang, HG				Hirai, I; Sasaki, T; Wang, HG			Human hRad1 but not hRad9 protects hHus1 from ubiquitin-proteasomal degradation	ONCOGENE			English	Article						Hus1; ubiquitination; proteasomal degradation; checkpoint	DNA-DAMAGE CHECKPOINT; HUMAN RAD9; DEPENDENT PHOSPHORYLATION; SLIDING CLAMP; FACTOR-C; COMPLEX; PROTEINS; ACTIVATION; RADIATION; RESPONSES	Three of the Rad family proteins, Rad9, Rad1, and Hus1, can interact with each other and form a heterotrimeric complex that is thought to play a role in the sensing step of the DNA integrity checkpoint pathways, but the nature of the Rad9 - Rad1 - Hus1 complex assembly remains enigmatic. Here, we demonstrate that the human hRad1 protein plays a significant role as molecular chaperone in the process of the hRad9 - hRad1 - hHus1 heterotrimeric complex formation. In contrast to hRad1, hHus1 is an unstable protein that is actively degraded via the ubiquitin - proteasome pathway. We show that treating cells with proteasome-specific inhibitors stabilizes hHus1 expression. Moreover, hRad1 can associate with hHus1 in the absence of hRad9 and protect hHus1 from ubiquitination and degradation in the cytoplasm. Importantly, genotoxic stress induces hRad1 expression and stabilizes the hHus1 protein. Taken together, these findings suggest a novel role of hRad1 as a potential intrinsic chaperone in the stabilization of hHus1 for the hRad9 - hRad1 - hHus1 checkpoint complex formation.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Oncol, Tampa, FL 33612 USA; Sapporo Med Univ, Sch Med, Inst Canc, Dept Biochem, Sapporo, Hokkaido 0608556, Japan	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Sapporo Medical University	Wang, HG (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.	wanghg@moffitt.usf.edu	Wang, Hong-Gang/A-3018-2015	Wang, Hong-Gang/0000-0003-0551-0571	NCI NIH HHS [CA90315] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090315] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bao SD, 2001, NATURE, V411, P969, DOI 10.1038/35082110; Bendjennat M, 2003, CELL, V114, P599, DOI 10.1016/j.cell.2003.08.001; Bermudez VP, 2003, P NATL ACAD SCI USA, V100, P1633, DOI 10.1073/pnas.0437927100; Burtelow MA, 2001, J BIOL CHEM, V276, P25903, DOI 10.1074/jbc.M102946200; Chen MJ, 2001, J BIOL CHEM, V276, P16580, DOI 10.1074/jbc.M008871200; Fink AL, 1999, PHYSIOL REV, V79, P425, DOI 10.1152/physrev.1999.79.2.425; Foray N, 2003, EMBO J, V22, P2860, DOI 10.1093/emboj/cdg274; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; Goetz MP, 2003, ANN ONCOL, V14, P1169, DOI 10.1093/annonc/mdg316; Griffith JD, 2002, J BIOL CHEM, V277, P15233, DOI 10.1074/jbc.C200129200; GRIFFITHS DJF, 1995, EMBO J, V14, P5812, DOI 10.1002/j.1460-2075.1995.tb00269.x; Hirai I, 2002, J BIOL CHEM, V277, P25722, DOI 10.1074/jbc.M203079200; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Kaur R, 2001, MOL BIOL CELL, V12, P3744, DOI 10.1091/mbc.12.12.3744; Kondo T, 1999, MOL CELL BIOL, V19, P1136; Lee MW, 2003, ONCOGENE, V22, P6340, DOI 10.1038/sj.onc.1206729; Majka J, 2003, P NATL ACAD SCI USA, V100, P2249, DOI 10.1073/pnas.0437148100; McBride WH, 2003, ONCOGENE, V22, P5755, DOI 10.1038/sj.onc.1206676; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Post S, 2001, P NATL ACAD SCI USA, V98, P13102, DOI 10.1073/pnas.231364598; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Roos-Mattjus P, 2003, J BIOL CHEM, V278, P24428, DOI 10.1074/jbc.M301544200; St Onge RP, 2003, J BIOL CHEM, V278, P26620, DOI 10.1074/jbc.M303134200; St Onge RP, 1999, MOL BIOL CELL, V10, P1985; Tsurimoto T., 1999, FRONT BIOSCI, V4, P849; Venclovas C, 2000, NUCLEIC ACIDS RES, V28, P2481, DOI 10.1093/nar/28.13.2481; Wang X, 2003, GENE DEV, V17, P965, DOI 10.1101/gad.1065103; Yoshida K, 2003, EMBO J, V22, P1431, DOI 10.1093/emboj/cdg134; Yoshida K, 2002, MOL CELL BIOL, V22, P3292, DOI 10.1128/MCB.22.10.3292-3300.2002; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302	32	9	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2004	23	30					5124	5130		10.1038/sj.onc.1207658	http://dx.doi.org/10.1038/sj.onc.1207658			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	834AE	15122316				2022-12-28	WOS:000222382500002
J	Keith, WN				Keith, WN			From stem cells to cancer: balancing immortality and neoplasia	ONCOGENE			English	Editorial Material						mesenchyme; stem cell; cancer stem cell; telomerase; neoplasia; mesenchymal stem cell	TELOMERASE EXPRESSION; BRAIN-TUMORS; IDENTIFICATION	In this issue of Oncogene, Serakinci et al show that adult stem cells can be targets for neoplastic transformation. After transducing human adult mesenchymal stem cells (hMSC) with the telomerase hTERT gene, and growing them for many population doublings in culture, Serakinci et al observed that the transduced cells developed characteristics consistent with transformation including loss of contact inhibition, anchorage independence and tumour formation in mice. Underlying these changes were alterations to genes involved in cell cycle regulation and senescence as well as oncogene activation. The importance of these observations is twofold. Firstly, showing that stem cells can become tumours raises a note of caution for stem cell therapeutics. Secondly, the findings lend support to the stem cell hypothesis of cancer development, and provide an experimental system in which the tantalizing hint of new diagnostic, prognostic, and therapeutic opportunities offered by this concept can be explored further.	Univ Glasgow, Canc Res UK Beatson Labs, Ctr Oncol & Appl Pharmacol, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute; University of Glasgow	Keith, WN (corresponding author), Univ Glasgow, Canc Res UK Beatson Labs, Ctr Oncol & Appl Pharmacol, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	n.keith@beatson.gla.ac.uk	Keith, Nicol/D-3325-2009	Keith, Nicol/0000-0001-7862-3580				Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100; Marx J, 2003, SCIENCE, V301, P1308, DOI 10.1126/science.301.5638.1308; Passegue E, 2003, P NATL ACAD SCI USA, V100, P11842, DOI 10.1073/pnas.2034201100; Preston SL, 2003, J CLIN PATHOL-MOL PA, V56, P86, DOI 10.1136/mp.56.2.86; SERAKINCI N, 2004, IN PRESS ONCOGENE; Shi ST, 2002, NAT BIOTECHNOL, V20, P587, DOI 10.1038/nbt0602-587; Simonsen JL, 2002, NAT BIOTECHNOL, V20, P592, DOI 10.1038/nbt0602-592; Singh SK, 2003, CANCER RES, V63, P5821; Tuan RS, 2003, ARTHRITIS RES THER, V5, P32, DOI 10.1186/ar614; Zimmermann S, 2003, LEUKEMIA, V17, P1146, DOI 10.1038/sj.leu.2402962	11	30	33	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					5092	5094		10.1038/sj.onc.1207762	http://dx.doi.org/10.1038/sj.onc.1207762			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15107816				2022-12-28	WOS:000222237300016
J	Rabenau, KE; O'Toole, JM; Bassi, R; Kotanides, H; Witte, L; Ludwig, DL; Pereira, DS				Rabenau, KE; O'Toole, JM; Bassi, R; Kotanides, H; Witte, L; Ludwig, DL; Pereira, DS			DEGA/AMIGO-2, a leucine-rich repeat family member, differentially expressed in human gastric adenocarcinoma: effects on ploidy, chromosomal stability, cell adhesion/migration and tumorigenicity	ONCOGENE			English	Article						tumorigenicity; ploidy; chromosomal instability; leucine-rich repeat; gastric adenocarcinoma; antisense	GENOMIC INSTABILITY; FREQUENT AMPLIFICATION; MOLECULAR-BIOLOGY; GENE; CANCER; CARCINOMA; HER-2/NEU; ONCOGENE; MUTATION; LAMININ	We have discovered DEGA, a novel cDNA differentially expressed in human gastric adenocarcinomas. The DEGA gene product contains a signal peptide,five leucine-rich repeat motifs and a single IgG, and transmembrane domain, suggesting its residence on the plasma membrane. Transfection of 293 cells with a DEGA-GFP fusion construct confirmed its cell surface localization. Although the cytosolic portion of the DEGA gene product does not contain known protein domains, approximately one-fifth of these residues are either a serine or a threonine, suggesting that DEGA may play a role in signal transduction. BLAST searches revealed DEGA to be an exact match to AMIGO-2, a recently identified, but functionally uncharacterized protein related to AMIGO, a leucine-rich repeat containing cell adhesion molecule implicated in axon tract development. In this report, we show that DEGA/AMIGO-2 mRNA is differentially expressed in similar to45% of tumor versus normal tissue from gastric adenocarcinoma patients. Stable expression of a DEGA/AMIGO-2 antisense construct in the gastric adenocarcinoma cell line, AGS, led to altered morphology, increased ploidy, chromosomal instability, decreased cell adhesion/migration, and a nearly complete abrogation of tumorigenicity in nude mice. These findings suggest a potential etiologic role for DEGA/AMIGO-2 in gastric adenocarcinoma.	ImClone Syst Inc, Dept Mol & Cellular Biol, New York, NY 10014 USA; ImClone Syst Inc, Dept Immunol, New York, NY 10014 USA	Eli Lilly; Eli Lilly	Pereira, DS (corresponding author), ImClone Syst Inc, Dept Mol & Cellular Biol, 180 Varick St, New York, NY 10014 USA.	Daniel.Pereira@imclone.com						AKAMA Y, 1995, JPN J CANCER RES, V86, P617, DOI 10.1111/j.1349-7006.1995.tb02442.x; Arber N, 1996, GASTROENTEROLOGY, V110, P669, DOI 10.1053/gast.1996.v110.pm8608874; Cahill DP, 1999, TRENDS CELL BIOL, V9, pM57, DOI 10.1016/S0962-8924(99)01661-X; Chan AOO, 1999, J GASTROEN HEPATOL, V14, P1150, DOI 10.1046/j.1440-1746.1999.02000.x; Crookes PF, 2002, CLIN OBSTET GYNECOL, V45, P892, DOI 10.1097/00003081-200209000-00036; Danesh J, 1999, ALIMENT PHARM THERAP, V13, P851; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; Ebert MPA, 2000, EUR J GASTROEN HEPAT, V12, P795, DOI 10.1097/00042737-200012070-00013; El-Rifai W, 2002, SEMIN RADIAT ONCOL, V12, P128, DOI 10.1053/srao.2002.30815; Hocking AM, 1998, MATRIX BIOL, V17, P1; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; KOBE B, 1995, CURR OPIN STRUC BIOL, V5, P409, DOI 10.1016/0959-440X(95)80105-7; Kono K, 2000, TUMOR BIOL, V21, P139, DOI 10.1159/000030120; Konturek P C, 2001, Med Sci Monit, V7, P1092; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; Kuja-Panula J, 2003, J CELL BIOL, V160, P963, DOI 10.1083/jcb.200209074; KUNIYASU H, 1993, INT J CANCER, V55, P72, DOI 10.1002/ijc.2910550114; KUNIYASU H, 1992, BIOCHEM BIOPH RES CO, V189, P227, DOI 10.1016/0006-291X(92)91548-5; MAFUNE K, 1992, J SURG RES, V52, P340, DOI 10.1016/0022-4804(92)90113-E; MAYER B, 1993, LANCET, V342, P1019, DOI 10.1016/0140-6736(93)92879-X; Moayyedi P, 2002, BMJ-BRIT MED J, V325, P1399, DOI 10.1136/bmj.325.7377.1399; Musio A, 2003, CANCER RES, V63, P2855; Nowak MA, 2002, P NATL ACAD SCI USA, V99, P16226, DOI 10.1073/pnas.202617399; Phillips RL, 2000, SCIENCE, V288, P1635, DOI 10.1126/science.288.5471.1635; Ross JS, 2001, CANCER INVEST, V19, P554, DOI 10.1081/CNV-100103852; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; Shun CT, 2001, ONCOLOGY-BASEL, V60, P339, DOI 10.1159/000058530; Sieber OM, 2003, NAT REV CANCER, V3, P701, DOI 10.1038/nrc1170; TERRANOVA VP, 1986, P NATL ACAD SCI USA, V83, P465, DOI 10.1073/pnas.83.2.465; Tomlinson I, 1999, NAT MED, V5, P11, DOI 10.1038/4687; Woo DK, 2001, INT J CANCER, V95, P108, DOI 10.1002/1097-0215(20010320)95:2<108::AID-IJC1019>3.0.CO;2-#; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Yasui W, 2001, Gastric Cancer, V4, P113, DOI 10.1007/PL00011733; YOKOZAKI H, 1994, CANCER LETT, V83, P229, DOI 10.1016/0304-3835(94)90324-7	38	43	50	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					5056	5067		10.1038/sj.onc.1207681	http://dx.doi.org/10.1038/sj.onc.1207681			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15107827				2022-12-28	WOS:000222237300012
J	Espert, L; Rey, C; Gonzalez, L; Degols, G; Chelbi-Alix, MK; Mechti, N; Gongora, C				Espert, L; Rey, C; Gonzalez, L; Degols, G; Chelbi-Alix, MK; Mechti, N; Gongora, C			The exonuclease ISG20 is directly induced by synthetic dsRNA via NF-kappa B and IRF1 activation	ONCOGENE			English	Article						ISG20; dsRNA; NF-kappa B; IRF1; transcription; interferon	DOUBLE-STRANDED-RNA; REGULATORY FACTOR-I; PROTEIN-KINASE-R; GENE-EXPRESSION; NUCLEAR-MATRIX; VIRUS; APOPTOSIS; INDUCTION; PATHWAY; STRESS	Many interferon (IFN)-stimulated genes are also induced by double-stranded RNA (dsRNA), a component closely associated with the IFN system in the context of virus-host interactions. Recently, we demonstrated that the IFN-induced 3' --> 5' exonuclease ISG20 possesses antiviral activities against RNA viruses. Here we show that ISG20 induction by synthetic dsRNA (pIpC) is stronger and faster than its induction by IFN. Two families of transcription factors are implicated in the transcriptional activation of ISG20 by dsRNA. Initially, the NF-kappaB factors p50 and p65 bind and activate the kappaB element of the Isg20 promoter. This is followed by IRFI binding to the ISRE. As pIpC often induces protein movements in the cells, we questioned whether it could influence ISG20 localization. Interestingly and contrary to IFN, dsRNA induces a nuclear matrix enrichment of the ISG20 protein. dsRNA induction of ISG20 via NF-kappaB and its antiviral activity led us to suggest that ISG20 could participate in the cellular response to virus infection.	CNRS, UMR 5160, EFS, F-34094 Montpellier 5, France; Inst Andre Lwoff, CNRS, UPR 9045, F-94801 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS)	Gongora, C (corresponding author), CNRS, UMR 5160, EFS, 240 Ave Emile Jeanbrau, F-34094 Montpellier 5, France.	celine.gongora@ibph.pharma.univ.montp1.fr	Espert, Lucile/ABF-5614-2021	GONGORA, Celine/0000-0001-9034-4031				Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; BANDYOPADHYAY SK, 1995, J BIOL CHEM, V270, P19624, DOI 10.1074/jbc.270.33.19624; Behr M, 2001, J INTERF CYTOK RES, V21, P981, DOI 10.1089/107999001753289596; Blair LA, 2002, J BIOL CHEM, V277, P359, DOI 10.1074/jbc.M109819200; Deppert W, 2000, CRIT REV EUKAR GENE, V10, P45; DiazGuerra M, 1997, VIROLOGY, V236, P354, DOI 10.1006/viro.1997.8719; Doyle SE, 2002, IMMUNITY, V17, P251, DOI 10.1016/S1074-7613(02)00390-4; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Espert L, 2003, J BIOL CHEM, V278, P16151, DOI 10.1074/jbc.M209628200; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Geiss G, 2001, J BIOL CHEM, V276, P30178, DOI 10.1074/jbc.C100137200; Gongora C, 2000, NUCLEIC ACIDS RES, V28, P2333, DOI 10.1093/nar/28.12.2333; Gongora C, 1997, J BIOL CHEM, V272, P19457, DOI 10.1074/jbc.272.31.19457; Hummer BT, 2001, J VIROL, V75, P7774, DOI 10.1128/JVI.75.16.7774-7777.2001; Iordanov MS, 2001, MOL CELL BIOL, V21, P61, DOI 10.1128/MCB.21.1.61-72.2001; Iordanov MS, 2000, MOL CELL BIOL, V20, P617, DOI 10.1128/MCB.20.2.617-627.2000; Jacobs BL, 1996, VIROLOGY, V219, P339, DOI 10.1006/viro.1996.0259; Kaufman RJ, 1999, P NATL ACAD SCI USA, V96, P11693, DOI 10.1073/pnas.96.21.11693; Kehoe KE, 2001, J IMMUNOL, V167, P2496, DOI 10.4049/jimmunol.167.5.2496; Mori K, 2001, MOL CELL ENDOCRINOL, V184, P77, DOI 10.1016/S0303-7207(01)00641-4; Nguyen LH, 2001, BIOCHEMISTRY-US, V40, P7174, DOI 10.1021/bi010141t; Okorokov AL, 2002, ONCOGENE, V21, P356, DOI 10.1038/sj.onc.1205112; Peters KL, 2002, P NATL ACAD SCI USA, V99, P6322, DOI 10.1073/pnas.092133199; Roti JLR, 1997, CRIT REV EUKAR GENE, V7, P343, DOI 10.1615/CritRevEukarGeneExpr.v7.i4.30; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Saura M, 1999, J MOL BIOL, V289, P459, DOI 10.1006/jmbi.1999.2752; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; TEN RM, 1993, CR ACAD SCI III-VIE, V316, P496; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978	31	38	42	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2004	23	26					4636	4640		10.1038/sj.onc.1207586	http://dx.doi.org/10.1038/sj.onc.1207586			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZV	15064705				2022-12-28	WOS:000221799000013
J	Castedo, M; Perfettini, JL; Roumier, T; Yakushijin, K; Horne, D; Medema, R; Kroemer, G				Castedo, M; Perfettini, JL; Roumier, T; Yakushijin, K; Horne, D; Medema, R; Kroemer, G			The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe	ONCOGENE			English	Article						aneuploidy; cancer; caspases; Chk-2; programmed cell death	DNA-DAMAGE CHECKPOINT; GLYCOPROTEIN COMPLEX; APOPTOSIS; ACTIVATION; P53; PHOSPHORYLATION; LOCALIZATION; CHECKING; CDC25C; DEATH	Fusion between nonsynchronized cells leads to the formation of heterokarya which transiently activate Cyclin-dependent kinase 1 (Cdk1)/cyclin B1 and enter the prophase of the cell cycle, where they arrest due to a loss of Cdk1/cyclin B1 activity, activate p53, disorganize centrosomes, and undergo apoptosis. Here, we show that the down regulation of Cdk1/cyclin B is secondary to the activation of the DNA structure checkpoint kinase Chk2. Thus, syncytia generated by the fusion of asynchronous HeLa cells contain elevated levels of active Chk2 but not Chk1. Chk2 bearing the activating phosphorylation on threonine-68 accumulates in BRCA1 nuclear bodies when the cells arrest at the G2/M boundary. Inhibition of Chk2 by transfection of a dominant-negative Chk2 mutant or a chemical inhibitor, debromohymenialdesine, stabilizes centrosomes, maintains high cyclin B1 levels, and allows for a prolonged activation of Cdk1. Under these conditions, multinuclear HeLa syncytia do not arrest at the G2/M boundary and rather enter mitotis and subsequently die during the metaphase of the cell cycle. This mitotic catastrophe is associated with the activation of the proapoptotic caspase-3. Inhibition of caspases allows the cells to go beyond the metaphase arrest, indicating that apoptosis is responsible for cell death by mitotic catastrophe. In another, completely different model of mitotic catastrophe, namely 14.3.3sigma-deficient HCT116 colon carcinoma cells treated with doxorubicin, Chk2 activation was also found to be deficient as compared to 14.3.3sigma-sufficient controls. Inhibition of Chk2 again facilitated the induction of mitotic catastrophe in HCT116 wild-type cells. In conclusion, a conflict in cell cycle progression or DNA damage can lead to mitotic catastrophe, provided that the checkpoint kinase Chk2 is inhibited. Inhibition of Chk2 thus can sensitize proliferating cells to chemotherapy-induced apoptosis.	Inst Gustave Roussy, CNRS, UMR 8125, F-94805 Villejuif, France; Oregon State Univ, Dept Chem, Corvallis, OR 97331 USA; Netherlands Canc Inst, Div Mol Biol H8, NL-1066 CX Amsterdam, Netherlands	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Oregon State University; Netherlands Cancer Institute	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, UMR 8125, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	Medema, Rene H/E-2981-2013; KROEMER, Guido/B-4263-2013; PERFETTINI, Jean-Luc/N-4699-2017; Medema, Rene H/G-5415-2011; Kroemer, Guido/AAY-9859-2020	KROEMER, Guido/0000-0002-9334-4405; PERFETTINI, Jean-Luc/0000-0002-2427-2604; Medema, Rene/0000-0002-6754-0381				Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Boya P, 2003, J EXP MED, V197, P1323, DOI 10.1084/jem.20021952; Castedo M, 2002, CELL DEATH DIFFER, V9, P1287, DOI 10.1038/sj.cdd.4401130; Castedo M, 2004, ONCOGENE, V23, P4362, DOI 10.1038/sj.onc.1207572; Castedo M, 2001, J EXP MED, V194, P1097, DOI 10.1084/jem.194.8.1097; Castedo M, 2002, EMBO J, V21, P4070, DOI 10.1093/emboj/cdf391; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chehab NH, 2000, GENE DEV, V14, P278; Curman D, 2001, J BIOL CHEM, V276, P17914, DOI 10.1074/jbc.M100728200; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Ferri KF, 2000, CELL DEATH DIFFER, V7, P1137, DOI 10.1038/sj.cdd.4400748; Ferri KF, 2000, J EXP MED, V192, P1081, DOI 10.1084/jem.192.8.1081; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Hirose Y, 2001, CANCER RES, V61, P5843; Hu BC, 2001, J BIOL CHEM, V276, P17693, DOI 10.1074/jbc.M009340200; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Lock RB, 1996, CANCER RES, V56, P4006; Lou ZK, 2003, NATURE, V421, P957, DOI 10.1038/nature01447; Lukas C, 2003, NAT CELL BIOL, V5, P255, DOI 10.1038/ncb945; Mackey MA, 1996, CANCER RES, V56, P1770; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; McGowan CH, 2002, BIOESSAYS, V24, P502, DOI 10.1002/bies.10101; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PERFETTINI JL, 2004, IN PRESS J EXP MED; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Roumier T, 2003, BIOCHEM PHARMACOL, V66, P1321, DOI 10.1016/S0006-2952(03)00480-5; Senderowicz AM, 2003, CANCER CHEMOTH PHARM, V52, pS61, DOI 10.1007/s00280-003-0624-x; Seo GJ, 2003, BIOCHEM BIOPH RES CO, V304, P339, DOI 10.1016/S0006-291X(03)00589-8; Shieh SY, 2000, GENE DEV, V14, P289; Smits VAJ, 2001, BBA-GENE STRUCT EXPR, V1519, P1, DOI 10.1016/S0167-4781(01)00204-4; Sosa ACB, 2000, J ORG CHEM, V65, P610, DOI 10.1021/jo991277o; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Takada S, 2003, CELL, V113, P87, DOI 10.1016/S0092-8674(03)00202-2; Tsvetkov L, 2003, J BIOL CHEM, V278, P8468, DOI 10.1074/jbc.M211202200; Vahteristo P, 2002, AM J HUM GENET, V71, P432, DOI 10.1086/341943; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Xu JH, 2003, FEBS LETT, V545, P209, DOI 10.1016/S0014-5793(03)00536-2; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869; Yu Q, 2002, CANCER RES, V62, P5743	46	136	144	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2004	23	25					4353	4361		10.1038/sj.onc.1207573	http://dx.doi.org/10.1038/sj.onc.1207573			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	824CJ	15048074				2022-12-28	WOS:000221661300001
J	Castedo, M; Perfettini, JL; Roumier, T; Valent, A; Raslova, H; Yakushijin, K; Horne, D; Feunteun, J; Lenoir, G; Medema, R; Vainchenker, W; Kroemer, G				Castedo, M; Perfettini, JL; Roumier, T; Valent, A; Raslova, H; Yakushijin, K; Horne, D; Feunteun, J; Lenoir, G; Medema, R; Vainchenker, W; Kroemer, G			Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy	ONCOGENE			English	Article						aneuploidy; cancer; caspases; Chk-2; programmed cell death	CYTOCHROME-C RELEASE; GLYCOPROTEIN COMPLEX; CHECKPOINT KINASE-2; TUMOR-CELLS; MITOCHONDRIA; CASPASE-2; P53; INSTABILITY; CANCER; ACTIVATION	A conflict in cell cycle progression or DNA damage can lead to mitotic catastrophe when the DNA structure checkpoints are inactivated, for instance when the checkpoint kinase Chk2 is inhibited. Here we show that in such conditions, cells die during the metaphase of the cell cycle, as a result of caspase activation and subsequent mitochondrial damage. Molecular ordering of these phenomena reveals that mitotic catastrophe occurs in a p53-independent manner and involves a primary activation of caspase-2, upstream of cytochrome c release, followed by caspase-3 activation and chromatin condensation. Suppression of caspase-2 by RNA interference or pseudosubstrate inhibitors as well as blockade of the mitochondrial membrane permeabilization prevent the mitotic catastrophe and allow cells to further proceed the cell cycle beyond the metaphase, leading to asymmetric cell division. Heterokarya generated by the fusion of nonsynchronized cells can be driven to divide into three or more daughter cells when Chk2 and caspases are simultaneously inhibited. Such multipolar divisions, resulting from suppressed mitotic catastrophe, lead to the asymmetric distribution of cytoplasm (anisocytosis), DNA (anisokaryosis) and chromosomes (aneuploidy). Similarly, in a model of DNA damage-induced mitotic catastrophe, suppression of apoptosis leads to the generation of aneuploid cells. Our findings delineate a molecular pathway through which DNA damage, failure to arrest the cell cycle and inhibition of apoptosis can favor the occurrence of cytogenetic abnormalities that are likely to participate in oncogenesis.	Inst Gustave Roussy, CNRS, UMR 8125, F-94805 Villejuif, France; Inst Gustave Roussy, Lab Gen Cellulaire Canc, F-94805 Villejuif, France; Inst Gustave Roussy, INSERM, U362, F-94805 Villejuif, France; Oregon State Univ, Dept Chem, Corvallis, OR 97331 USA; Netherlands Canc Inst, Div Mol Biol H8, NL-1066 CX Amsterdam, Netherlands	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Oregon State University; Netherlands Cancer Institute	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, UMR 8125, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	Feunteun, Jean/AAZ-1267-2020; PERFETTINI, Jean-Luc/N-4699-2017; Raslova, Hana/N-3562-2018; Medema, Rene H/E-2981-2013; KROEMER, Guido/B-4263-2013; Medema, Rene H/G-5415-2011; Kroemer, Guido/AAY-9859-2020	PERFETTINI, Jean-Luc/0000-0002-2427-2604; Raslova, Hana/0000-0001-8846-5299; KROEMER, Guido/0000-0002-9334-4405; Feunteun, Jean/0000-0003-1212-9189; Medema, Rene/0000-0002-6754-0381; Vainchenker, William/0000-0003-4705-202X				Ahn JW, 2003, J BIOL CHEM, V278, P20480, DOI 10.1074/jbc.M213185200; Brenner C, 2000, SCIENCE, V289, P1150, DOI 10.1126/science.289.5482.1150; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Burns TF, 2003, MOL CELL BIOL, V23, P5556, DOI 10.1128/MCB.23.16.5556-5571.2003; Castedo M, 2004, ONCOGENE, V23, P4353, DOI 10.1038/sj.onc.1207573; Castedo M, 2001, J EXP MED, V194, P1097, DOI 10.1084/jem.194.8.1097; Castedo M, 2002, EMBO J, V21, P4070, DOI 10.1093/emboj/cdf391; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Choma D, 2001, BRIT J CANCER, V85, P14, DOI 10.1054/bjoc.2001.1892; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; DeWitt N, 2002, NATURE, V416, P354, DOI 10.1038/416354a; Ferri KF, 2000, CELL DEATH DIFFER, V7, P1137, DOI 10.1038/sj.cdd.4400748; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Ferri KF, 2000, J EXP MED, V192, P1081, DOI 10.1084/jem.192.8.1081; Ferri KF, 2000, EXP CELL RES, V261, P119, DOI 10.1006/excr.2000.5062; Goldmacher VS, 1999, P NATL ACAD SCI USA, V96, P12536, DOI 10.1073/pnas.96.22.12536; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Jallepalli PV, 2001, NAT REV CANCER, V1, P109, DOI 10.1038/35101065; Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960-9822(98)70156-3; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Lock RB, 1996, CANCER RES, V56, P4006; Lockshin RA, 2002, CURR OPIN CELL BIOL, V14, P727, DOI 10.1016/S0955-0674(02)00383-6; Masuda A, 2002, ONCOGENE, V21, P6884, DOI 10.1038/sj.onc.1205566; Mendelsohn AR, 2002, P NATL ACAD SCI USA, V99, P6871, DOI 10.1073/pnas.072290599; Nabha SM, 2002, CLIN CANCER RES, V8, P2735; Paroni G, 2002, J BIOL CHEM, V277, P15147, DOI 10.1074/jbc.M112338200; Penninger JM, 2003, NAT CELL BIOL, V5, P97, DOI 10.1038/ncb0203-97; Penninger JM, 1998, ADV IMMUNOL, V68, P51, DOI 10.1016/S0065-2776(08)60558-1; Raslova H, 2003, BLOOD, V101, P541, DOI 10.1182/blood-2002-05-1553; Ravagnan L, 2002, J CELL PHYSIOL, V192, P131, DOI 10.1002/jcp.10111; Read SH, 2002, J CELL BIOL, V159, P739, DOI 10.1083/jcb.200209004; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Roschke AV, 2002, NEOPLASIA, V4, P19, DOI 10.1038/sj.neo.7900197; Ruth AC, 2000, CANCER RES, V60, P2576; Shih IM, 2001, CANCER RES, V61, P818; Slovak ML, 2000, BLOOD, V96, P4075, DOI 10.1182/blood.V96.13.4075; Sosa ACB, 2000, J ORG CHEM, V65, P610, DOI 10.1021/jo991277o; Takada S, 2003, CELL, V113, P87, DOI 10.1016/S0092-8674(03)00202-2; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Tort F, 2002, BLOOD, V100, P4602, DOI 10.1182/blood-2002-04-1078; Valent A, 2001, AM J PATHOL, V158, P1579, DOI 10.1016/S0002-9440(10)64112-0; Vieira HLA, 2001, ONCOGENE, V20, P4305, DOI 10.1038/sj.onc.1204575; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang XD, 2001, GENE DEV, V15, P2922; Wurmser AE, 2002, NATURE, V416, P485, DOI 10.1038/416485a; Zamzami N, 2003, CURR BIOL, V13, pR71, DOI 10.1016/S0960-9822(02)01433-1	54	252	263	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2004	23	25					4362	4370		10.1038/sj.onc.1207572	http://dx.doi.org/10.1038/sj.onc.1207572			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	824CJ	15048075				2022-12-28	WOS:000221661300002
J	Durst, KL; Hiebert, SW				Durst, KL; Hiebert, SW			Role of RUNX family members in transcriptional repression and gene silencing	ONCOGENE			English	Article						RUNX; AML; repression; transcription; silencing; histone deacetylases	ACUTE MYELOID-LEUKEMIA; MULTIPLE CHROMOSOMAL TRANSLOCATIONS; CORE-BINDING FACTOR; MYOSIN HEAVY-CHAIN; FUSION PROTEIN; FUNCTIONAL COOPERATION; HISTONE H3; DOMAIN PROTEINS; C/EBP-ALPHA; DNA-BINDING	RUNX family members are DNA-binding transcription factors that regulate the expression of genes involved in cellular differentiation and cell cycle progression. The RUNX family includes three mammalian RUNX proteins (RUNX1, - 2, - 3) and two homologues in Drosophila. Experiments in Drosophila and mouse indicate that the RUNX proteins are required for gene silencing of engrailed and CD4, respectively. RUNX-mediated repression involves recruitment of corepressors such as mSin3A and Groucho as well as histone deacetylases. Furthermore, RUNX1 and RUNX3 associate with SUV39H1, a histone methyltransferase involved in gene silencing. RUNX1 is frequently targeted in human leukemia by chromosomal translocations that fuse the DNA-binding domain of RUNX1 to other transcription factors and corepressor molecules. The resulting leukemogenic fusion proteins are transcriptional repressors that form stable complexes with corepressors, histone deacetylases and histone methyltransferases. Thus, transcriptional repression and gene silencing through RUNX1 contribute to the mechanisms of leukemogenesis of the fusion proteins. Therapies directed at the associated cofactors may be beneficial for treatment of these leukemias.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Hiebert, SW (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, PRB 512,23rd & Pierce, Nashville, TN 37232 USA.	scott.hiebert@mcmail.vanderbilt.edu						Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Canon J, 2000, SEMIN CELL DEV BIOL, V11, P327, DOI 10.1006/scdb.2000.0185; Durst KL, 2003, MOL CELL BIOL, V23, P607, DOI 10.1128/MCB.23.2.607-619.2003; ERICKSON P, 1992, BLOOD, V80, P1825; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Gu TL, 2000, MOL CELL BIOL, V20, P91, DOI 10.1128/MCB.20.1.91-103.2000; Guidez F, 2000, BLOOD, V96, P2557; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Imai Y, 1998, BIOCHEM BIOPH RES CO, V252, P582, DOI 10.1006/bbrc.1998.9705; Jakubowiak A, 2000, J BIOL CHEM, V275, P40282, DOI 10.1074/jbc.C000485200; Javed A, 2000, J CELL SCI, V113, P2221; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Mao SF, 1999, MOL CELL BIOL, V19, P3635; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Pardali E, 2000, J BIOL CHEM, V275, P3552, DOI 10.1074/jbc.275.5.3552; Pelletier N, 2002, ONCOGENE, V21, P2729, DOI 10.1038/sj.onc.1205367; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wang LL, 2001, ONCOGENE, V20, P3716, DOI 10.1038/sj.onc.1204479; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982-7992.2002; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Wheeler JC, 2000, SEMIN CELL DEV BIOL, V11, P369, DOI 10.1006/scdb.2000.0184; Wheeler JC, 2002, NAT GENET, V32, P206, DOI 10.1038/ng942; Woolf E, 2003, P NATL ACAD SCI USA, V100, P7731, DOI 10.1073/pnas.1232420100; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; Zhang Y, 2000, J BIOL CHEM, V275, P16979, DOI 10.1074/jbc.M001526200	48	147	151	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2004	23	24					4220	4224		10.1038/sj.onc.1207122	http://dx.doi.org/10.1038/sj.onc.1207122			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823BZ	15156176				2022-12-28	WOS:000221586000005
J	Brignone, C; Bradley, KE; Kisselev, AF; Grossman, SR				Brignone, C; Bradley, KE; Kisselev, AF; Grossman, SR			A post-ubiquitination role for MDM2 and hHR23A in the p53 degradation pathway	ONCOGENE			English	Article						p53; hHR23; Rad23; MDM2; proteasome; ubiquitin	DNA-REPAIR; UBA DOMAINS; PROTEASOME; PROTEIN; RAD23; BINDING; PROMOTES; SUBUNIT; STABILITY; INTERACT	Abrogation of ubiquitin/proteasome-dependent turnover of p53 is critical for its activation. UbL-UBA proteins, including human homolog of Rad23 (hHR23) proteins, may regulate proteasomal degradation of substrates such as p53, due to their ability to interact with both ubiquitinated substrates and the proteasome. siRNA-mediated depletion of hHR23A or hHR23B in human cell lines accelerated p53 degradation. In contrast, overexpression of hHR23 proteins led to the accumulation of ubiquitinated p53, and purified hHR23 proteins also blocked p53 proteasome degradation in vitro. An hHR23-MDM2 complex was identified, suggesting that MDM2 and hHR23 cooperate in the regulation of p53 proteasome degradation. Consistent with this hypothesis, an MDM2 mutant that demonstrated increased binding in vivo to hHR23A was able to ubiquitinate, but not degrade p53. Moreover, the defective phenotype of this MDM2 mutant was rescued by siRNA knockdown of hHR23A. Our data indicate that MDM2 acts at a step in the p53 degradation pathway after ubiquitination, to counteract hHR23 inhibition of p53 turnover. Moreover, our data suggest the possibility that ubiquitin ligase/UbL-UBA protein complexes, as exemplified by the MDM2/hHR23 complex, may serve a general role in regulating substrate degradation by the proteasome.	Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Harvard Medical School; University of Massachusetts System; University of Massachusetts Worcester	Grossman, SR (corresponding author), Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA.	steven.grossman@umassmed.edu			NATIONAL CANCER INSTITUTE [R01CA107532] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046147, R01GM051923] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA107532, R01 CA107532-01] Funding Source: Medline; NIGMS NIH HHS [GM46147-10, GM51923-08] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Bertolaet BL, 2001, NAT STRUCT BIOL, V8, P417, DOI 10.1038/87575; Chen L, 2001, EMBO REP, V2, P933, DOI 10.1093/embo-reports/kve203; Elsasser S, 2002, NAT CELL BIOL, V4, P725, DOI 10.1038/ncb845; Funakoshi M, 2002, P NATL ACAD SCI USA, V99, P745, DOI 10.1073/pnas.012585199; Glockzin S, 2003, MOL CELL BIOL, V23, P8960, DOI 10.1128/MCB.23.24.8960-8969.2003; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hiyama H, 1999, J BIOL CHEM, V274, P28019, DOI 10.1074/jbc.274.39.28019; Kisselev AF, 2002, J BIOL CHEM, V277, P22260, DOI 10.1074/jbc.M112360200; Kleijnen MF, 2000, MOL CELL, V6, P409, DOI 10.1016/S1097-2765(00)00040-X; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kumar S, 1999, J BIOL CHEM, V274, P18785, DOI 10.1074/jbc.274.26.18785; Lambertson D, 1999, GENETICS, V153, P69; Ng JMY, 2003, GENE DEV, V17, P1630, DOI 10.1101/gad.260003; Ortolan TG, 2000, NAT CELL BIOL, V2, P601, DOI 10.1038/35023547; Raasi S, 2003, J BIOL CHEM, V278, P8951, DOI 10.1074/jbc.M212841200; Rao H, 2002, J BIOL CHEM, V277, P11691, DOI 10.1074/jbc.M200245200; Reardon JT, 1996, J BIOL CHEM, V271, P19451, DOI 10.1074/jbc.271.32.19451; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WEI X, 2003, J BIOL CHEM; Wilkinson CRM, 2001, NAT CELL BIOL, V3, P939, DOI 10.1038/ncb1001-939; Zhu QZ, 2001, CANCER RES, V61, P64; Zhu QZ, 2001, J BIOL CHEM, V276, P29695, DOI 10.1074/jbc.M102634200	25	57	58	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4121	4129		10.1038/sj.onc.1207540	http://dx.doi.org/10.1038/sj.onc.1207540			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15064742				2022-12-28	WOS:000221520200010
J	Guillemard, V; Saragovi, HU				Guillemard, V; Saragovi, HU			Prodrug chemotherapeutics bypass p-glycoprotein resistance and kill tumors in vivo with high efficacy and target-dependent selectivity	ONCOGENE			English	Article						prodrug; chemotherapy; resistance; target; selectivity; efficacy	GROWTH-FACTOR RECEPTOR; MULTIDRUG-RESISTANCE; MONOCLONAL-ANTIBODY; CARCINOEMBRYONIC ANTIGEN; CELLS; DOXORUBICIN; CANCER; TRANSPORTERS; PERIODATE; OXIDATION	Doxorubicin intercalates into DNA, causes double-strand breaks, and leads to apoptotic death. Limitations to the efficacy and therapeutic index of doxorubicin include poor tumor selectivity, high systemic toxicity, and the development of resistance, especially p-glycoprotein (p-gp)mediated. We chemically coupled doxorubicin to a monoclonal antibody directed to the insulin-like growth factor-1 receptor, a receptor highly overexpressed in most tumors and validated as a tumor target. The prodrug conjugate bounded to tumor cells selectively, and accumulated efficiently and only in receptor-expressing cells. The conjugate was processed to release free doxorubicin inside target cells leading to selective toxicity, had >200-fold improved therapeutic index, and in vivo reduced tumor load with no systemic toxicity. Importantly, the prodrug conjugate is not subject to p-gp efflux and can bypass resistance in vivo. Our studies de. ne a strategy to develop improved and more selective anticancer agents.	McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Lady Davis Inst, Jewish Gen Hosp, Dept Oncol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Lady Davis Inst, Jewish Gen Hosp, Ctr Canc, Montreal, PQ H3T 1E2, Canada	McGill University; Lady Davis Institute; McGill University; Lady Davis Institute; McGill University	Saragovi, HU (corresponding author), McGill Univ, Dept Pharmacol & Therapeut, 3655 Drummond Ave,1320, Montreal, PQ H3G 1Y6, Canada.	uri@pharma.mcgill.ca			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038569] Funding Source: NIH RePORTER; NINDS NIH HHS [R01-NS38569] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams TE, 2000, CELL MOL LIFE SCI, V57, P1050, DOI 10.1007/PL00000744; Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Berezov A, 2002, J BIOL CHEM, V277, P28330, DOI 10.1074/jbc.M202880200; Berezov A, 2001, J MED CHEM, V44, P2565, DOI 10.1021/jm000527m; Casares S, 2001, NAT BIOTECHNOL, V19, P142, DOI 10.1038/84404; da Rocha Adriana B., 2001, Current Opinion in Pharmacology, V1, P364; Fakata KL, 1998, LIFE SCI, V62, P2441, DOI 10.1016/S0024-3205(98)00227-6; Fritzer M, 1996, BIOCHEM PHARMACOL, V51, P489, DOI 10.1016/0006-2952(95)02225-2; Garsky VM, 2001, J MED CHEM, V44, P4216, DOI 10.1021/jm0101996; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Guillemard V, 2001, CANCER RES, V61, P694; Hage DS, 1997, BIOCONJUGATE CHEM, V8, P914, DOI 10.1021/bc970112o; Hailey J, 2002, MOL CANCER THER, V1, P1349; KATO H, 1993, J BIOL CHEM, V268, P2655; King HD, 1999, BIOCONJUGATE CHEM, V10, P279, DOI 10.1021/bc980100i; Langer M, 2001, J MED CHEM, V44, P1341, DOI 10.1021/jm001065f; Maliartchouk S, 1997, J NEUROSCI, V17, P6031; Matsui H, 2002, LEUKEMIA, V16, P813, DOI 10.1038/sj.leu.2402459; Monneret C, 2001, EUR J MED CHEM, V36, P483, DOI 10.1016/S0223-5234(01)01244-2; MOSCOW JA, 1988, J NATL CANCER I, V80, P14, DOI 10.1093/jnci/80.1.14; Munns J, 1998, BRIT J UROL, V82, P284; Nagy A, 1998, P NATL ACAD SCI USA, V95, P1794, DOI 10.1073/pnas.95.4.1794; Omelyanenko V, 1996, J DRUG TARGET, V3, P357, DOI 10.3109/10611869608996827; Salerno M, 2002, BIOCHEM PHARMACOL, V63, P1471, DOI 10.1016/S0006-2952(02)00895-X; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; Screaton RA, 1997, J CELL BIOL, V137, P939, DOI 10.1083/jcb.137.4.939; Shawver LK, 2002, CANCER CELL, V1, P117, DOI 10.1016/S1535-6108(02)00039-9; Stan AC, 1999, CANCER RES, V59, P115; Tan B, 2000, CURR OPIN ONCOL, V12, P450, DOI 10.1097/00001622-200009000-00011; TANNOCK IF, 1992, BASIC SCI ONCOLOGY, P305; TEWEY KM, 1984, J BIOL CHEM, V259, P9182; TRAIL PA, 1993, SCIENCE, V261, P212, DOI 10.1126/science.8327892; WOLFE CAC, 1995, ANAL BIOCHEM, V231, P123, DOI 10.1006/abio.1995.1511; Yang XD, 1999, CANCER RES, V59, P1236	36	47	58	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3613	3621		10.1038/sj.onc.1207463	http://dx.doi.org/10.1038/sj.onc.1207463			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15034547				2022-12-28	WOS:000221101700013
J	Robb, VA; Li, W; Gutmann, DH				Robb, VA; Li, W; Gutmann, DH			Disruption of 14-3-3 binding does not impair Protein 4.1B growth suppression	ONCOGENE			English	Article						14-3-3; Protein 4.1B; DAL-1; meningioma	TYROSINE KINASE SUBSTRATE; TUMOR-SUPPRESSOR; SPORADIC MENINGIOMAS; NF2 GENE; MERLIN EXPRESSION; HUMAN GLIOMA; CELL-GROWTH; LUNG-CANCER; DAL-1; ASSOCIATION	Meningiomas are common central nervous system tumors; however, the mechanisms underlying their pathogenesis are largely unknown. Collaborative studies from our laboratory demonstrated a direct association of 14-3-3 with the meningioma tumor suppressor Protein 4.1B, which was not observed with other members of the Protein 4.1 family, including the NF2 meningioma tumor suppressor, merlin/schwannomin. Given the role of 14-3-3 in the regulation of cell proliferation and apoptosis, we sought to determine the functional significance of 14-3-3 binding to Protein 4.1B growth suppression. Based on comparative binding studies performed with additional members of the Protein 4.1 family, we generated specific missense mutations within the minimal growth suppressor fragment of Protein 4.1B (DAL-1, differentially expressed in adenocarcinoma of the lung). Complementary in vitro GST affinity chromatography and in vivo interaction experiments demonstrated that the F359Y mutation abrogated binding to 14-3-3, but did not impair DAL-1 binding to other known Protein 4.1B interacting proteins. Similar to wild-type DAL-1, the expression of the F359Y DAL-1 14-3-3-binding mutant resulted in reduced Protein 4.1B-deficient IOMM-Lee and CH157-MN meningioma cell line colony formation. Moreover, similar to wild-type DAL-1, the stable expression of the DAL-1 F359Y mutant significantly reduced cell proliferation in independently isolated IOMM-Lee clones, as assessed by thymidine incorporation. Collectively, these results suggest that binding to 14-3-3 is not essential for the growth suppressor function of Protein 4.1B in meningiomas.	Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Washington University (WUSTL)	Gutmann, DH (corresponding author), Washington Univ, Sch Med, Dept Neurol, Box 8111,660 S Euclid Ave, St Louis, MO 63110 USA.	gutmannd@neuro.wustl.edu		Gutmann, David/0000-0002-3127-5045	NCI NIH HHS [1-F32-CA-097816-01] Funding Source: Medline; NINDS NIH HHS [NS35848, NS41520] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA097816] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035848, R01NS041520] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Charboneau AL, 2002, INT J CANCER, V100, P181, DOI 10.1002/ijc.10470; Chishti AH, 1998, TRENDS BIOCHEM SCI, V23, P281, DOI 10.1016/S0968-0004(98)01237-7; Denisenko-Nehrbass N, 2003, EUR J NEUROSCI, V17, P411, DOI 10.1046/j.1460-9568.2003.02441.x; Gimm JA, 2002, BIOCHEMISTRY-US, V41, P7275, DOI 10.1021/bi0256330; Goutebroze L, 2000, MOL CELL BIOL, V20, P1699, DOI 10.1128/MCB.20.5.1699-1712.2000; Gutmann DH, 1997, NEUROLOGY, V49, P267, DOI 10.1212/WNL.49.1.267; Gutmann DH, 2001, HUM MOL GENET, V10, P825, DOI 10.1093/hmg/10.8.825; Gutmann DH, 2001, NEUROBIOL DIS, V8, P266, DOI 10.1006/nbdi.2000.0376; Gutmann DH, 2000, HUM MOL GENET, V9, P1495, DOI 10.1093/hmg/9.10.1495; Huynh DP, 1997, J NEUROPATH EXP NEUR, V56, P382, DOI 10.1097/00005072-199704000-00007; LEE WH, 1990, NEUROSURGERY, V27, P389, DOI 10.1227/00006123-199009000-00008; Leone PE, 1999, ONCOGENE, V18, P2231, DOI 10.1038/sj.onc.1202531; McBride AE, 2001, CELL, V106, P5, DOI 10.1016/S0092-8674(01)00423-8; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; Perry A, 2000, J NEUROPATH EXP NEUR, V59, P872, DOI 10.1093/jnen/59.10.872; Robb VA, 2003, NEUROBIOL DIS, V13, P191, DOI 10.1016/S0969-9961(03)00071-8; RUTTLEDGE MH, 1994, NAT GENET, V6, P180, DOI 10.1038/ng0294-180; Schulze KMM, 2002, HUM MOL GENET, V11, P69, DOI 10.1093/hmg/11.1.69; Scoles DR, 2000, HUM MOL GENET, V9, P1567, DOI 10.1093/hmg/9.11.1567; Scoles DR, 2002, HUM MOL GENET, V11, P3179, DOI 10.1093/hmg/11.25.3179; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; Sun CX, 2002, HUM MOL GENET, V11, P3167, DOI 10.1093/hmg/11.25.3167; Tran YK, 1999, CANCER RES, V59, P35; Tsai JC, 1999, LASER SURG MED, V24, P296, DOI 10.1002/(SICI)1096-9101(1999)24:4<296::AID-LSM7>3.0.CO;2-F; TSAI JC, 1995, J NEUROSURG, V82, P864, DOI 10.3171/jns.1995.82.5.0864; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; Ueki K, 1999, CANCER RES, V59, P5995; Weber RG, 1997, P NATL ACAD SCI USA, V94, P14719, DOI 10.1073/pnas.94.26.14719; Yageta M, 2002, CANCER RES, V62, P5129; Yu TX, 2002, BIOCHEM J, V365, P783, DOI 10.1042/BJ20020060; Zhang SH, 1997, J BIOL CHEM, V272, P27281, DOI 10.1074/jbc.272.43.27281	33	14	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3589	3596		10.1038/sj.onc.1207445	http://dx.doi.org/10.1038/sj.onc.1207445			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15116094				2022-12-28	WOS:000221101700010
J	Strand, S; Vollmer, P; van den Abeelen, L; Gottfried, D; Alla, V; Heid, H; Kuball, J; Theobald, M; Galle, PR; Strand, D				Strand, S; Vollmer, P; van den Abeelen, L; Gottfried, D; Alla, V; Heid, H; Kuball, J; Theobald, M; Galle, PR; Strand, D			Cleavage of CD95 by matrix metalloproteinase-7 induces apoptosis resistance in tumour cells	ONCOGENE			English	Article						CD95; MMP-7; apoptosis; immune evasion	FAS LIGAND; SOLUBLE FAS; IN-VIVO; SERUM; ESCAPE; KILL	The ability of tumour cells to resist apoptosis-inducing signals by cytotoxic T cells may decide the success or failure of tumour elimination. An important effector of apoptosis is the CD95/CD95 ligand system (APO-1/Fas) that mediates perforin-independent cytotoxic T-cell killing of tumour cells. We propose a new strategy by which tumour cells can resist CD95-induced apoptosis. We identified matrix metalloproteinase-7, MMP-7 (Martilysin), as the first physiologically relevant protease that can specifically cleave CD95. MMP-7 is of unique importance because it is produced by the tumour cells themselves at early stages of tumour development. Microsequencing of the positions in CD95 cleaved by MMP-7 revealed two sites in the N-terminal extracellular domain of CD95, important for preligand assembly of CD95. MMP-7 cleavage of CD95 results in reduced CD95 surface expression and decreased CD95-mediated apoptosis sensitivity of tumour cells. Treatment of MMP-7-positive HT-29 tumour cells with MMP-7-antisense oligonucleotides led to an increase in CD95-mediated apoptosis sensitivity. Finally, specific cytotoxic T-cell killing was reduced in the presence of MMP-7. Thus, MMP-7 expression in tumour cells may contribute to an apoptosis-resistant phenotype, which ultimately promotes immune escape. This activity may account for the well-established role of MMP-7 in early tumour development.	Johannes Gutenberg Univ Mainz, Dept Internal Med 1, D-55101 Mainz, Germany; German Canc Res Ctr, Dept Cell Biol, D-69120 Heidelberg, Germany; Johannes Gutenberg Univ Mainz, Dept Hematol & Oncol, D-55101 Mainz, Germany	Johannes Gutenberg University of Mainz; Helmholtz Association; German Cancer Research Center (DKFZ); Johannes Gutenberg University of Mainz	Strand, D (corresponding author), Johannes Gutenberg Univ Mainz, Dept Internal Med 1, Obere Zahlbacherstr 63, D-55101 Mainz, Germany.	sstrand@mail.uni-mainz.de	Galle, Peter R/T-5292-2018; Galle, Peter/ABE-2872-2021	Galle, Peter R/0000-0001-8294-0992; Galle, Peter/0000-0001-8294-0992				Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fingleton B, 2001, NEOPLASIA, V3, P459, DOI 10.1038/sj.neo.7900190; Galle PR, 1998, SEMIN LIVER DIS, V18, P141, DOI 10.1055/s-2007-1007150; GALLE PR, 1995, J EXP MED, V182, P1223, DOI 10.1084/jem.182.5.1223; Khong HT, 2002, NAT IMMUNOL, V3, P999, DOI 10.1038/ni1102-999; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Lustgarten J, 1997, HUM IMMUNOL, V52, P109, DOI 10.1016/S0198-8859(96)00292-3; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; Mitsiades N, 2001, CANCER RES, V61, P577; Mizutani Y, 2001, CANCER, V92, P287, DOI 10.1002/1097-0142(20010715)92:2<287::AID-CNCR1321>3.0.CO;2-4; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nonomura N, 2000, UROLOGY, V55, P151, DOI 10.1016/S0090-4295(99)00379-9; Osorio LM, 2001, EUR J HAEMATOL, V66, P342, DOI 10.1034/j.1600-0609.2001.066005342.x; Pikul S, 1998, J MED CHEM, V41, P3568, DOI 10.1021/jm980253r; Powell WC, 1999, CURR BIOL, V9, P1441, DOI 10.1016/S0960-9822(00)80113-X; Rosenberg SA, 1999, IMMUNITY, V10, P281, DOI 10.1016/S1074-7613(00)80028-X; Rudolph-Owen LA, 1998, CANCER RES, V58, P5500; Seki N, 2002, J IMMUNOL, V168, P3484, DOI 10.4049/jimmunol.168.7.3484; Shresta S, 1998, CURR OPIN IMMUNOL, V10, P581, DOI 10.1016/S0952-7915(98)80227-6; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Strand S, 1998, NAT MED, V4, P588, DOI 10.1038/nm0598-588; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; Tanaka M, 1998, NAT MED, V4, P31, DOI 10.1038/nm0198-031; Theobald M, 1995, P NATL ACAD SCI USA, V92, P11993, DOI 10.1073/pnas.92.26.11993; Ugurel S, 2001, CLIN CANCER RES, V7, P1282; Vargo-Gogola T, 2002, CANCER RES, V62, P5559; Wilson CL, 1997, P NATL ACAD SCI USA, V94, P1402, DOI 10.1073/pnas.94.4.1402; Woessner J.F., 2000, PROTEIN PROFILE SER	30	95	104	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3732	3736		10.1038/sj.onc.1207387	http://dx.doi.org/10.1038/sj.onc.1207387			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15077180				2022-12-28	WOS:000221101700027
J	Leung, SW; Wloga, EH; Castro, AF; Nguyen, T; Bronson, RT; Yamasaki, L				Leung, SW; Wloga, EH; Castro, AF; Nguyen, T; Bronson, RT; Yamasaki, L			A dynamic switch in Rb+/- mediated neuroendocrine tumorigenesis	ONCOGENE			English	Article						Rb; tumorigenesis; pituitary	RETINOBLASTOMA GENE; PITUITARY-TUMORS; MICE LACKING; DNA-REPLICATION; TARGETED DISRUPTION; MICROARRAY ANALYSIS; DEFICIENT CELLS; CHIMERIC MICE; G(1) CONTROL; LUNG-CANCER	Rb+/- mice develop a complex spectrum of neuroendocrine tumors on a mixed genetic (129Sv x C57BL/6) background. To understand how the 129Sv and C57BL/6 contributions affect Rb+/- tumorigenesis, we serially backcrossed Rb+/- animals to the 129Sv or C57BL/6 strain, and analysed their pathological profiles. Strikingly, the length of survival and the penetrance, severity and multiplicity of neuroendocrine tumors switch dramatically between Rb+/- animals from the two genetic backgrounds. In fact, the 129Sv background significantly enhances both the initiation and progression of tumorigenesis in the intermediate lobe of the pituitary (ILP) in Rb+/- animals. This is due to the surprising fact that ILPs from wild-type 129Sv animals are inherently abnormal, and thus greatly predisposed to neoplasia. This is likely to explain the high incidence of ILP tumors, an otherwise rare tumor type in wild-type mice, in numerous knockout studies performed on the 129Sv strain, and raises the intriguing possibility that the classic Rb+/- neuroendocrine tumors may fade away in another as of yet unidentified inbred strain. Finally, we have increased the utility of the Rb+/- tumor model, since Rb+/- animals on the C57BL/6 background develop high-penetrance tumors of the anterior lobe of the pituitary, a class of tumors estimated to occur in 20-25% of humans.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Tufts Univ, Sch Vet Med, Boston, MA 02111 USA	Columbia University; Tufts University	Yamasaki, L (corresponding author), Columbia Univ, Dept Biol Sci, 1102 Fairchild Bldg,Mail Code 2428, New York, NY 10027 USA.	ly63@columbia.edu			NATIONAL CANCER INSTITUTE [R01CA079646] Funding Source: NIH RePORTER; NCI NIH HHS [5-R01-CA79646] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Asa SL, 2002, NAT REV CANCER, V2, P836, DOI 10.1038/nrc926; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Cloud JE, 2002, MOL CELL BIOL, V22, P2663, DOI 10.1128/MCB.22.8.2663-2672.2002; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; CRYNS VL, 1993, J CLIN ENDOCR METAB, V77, P644, DOI 10.1210/jc.77.3.644; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; de Bruin A, 2003, P NATL ACAD SCI USA, V100, P6546, DOI 10.1073/pnas.1031853100; DEVOS S, 1995, GENE CHROMOSOME CANC, V14, P164; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Franklin DS, 2000, MOL CELL BIOL, V20, P6147, DOI 10.1128/MCB.20.16.6147-6158.2000; Franklin DS, 1998, GENE DEV, V12, P2899, DOI 10.1101/gad.12.18.2899; GARY KA, 1992, INT J DEV NEUROSCI, V10, P131, DOI 10.1016/0736-5748(92)90041-W; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARRISON DJ, 1995, ONCOGENE, V10, P1615; HAYASHI N, 1994, BIOCHEM BIOPH RES CO, V202, P1426, DOI 10.1006/bbrc.1994.2090; HU NP, 1994, ONCOGENE, V9, P1021; Humbert PO, 2000, GENE DEV, V14, P690; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Kalma Y, 2001, ONCOGENE, V20, P1379, DOI 10.1038/sj.onc.1204230; Kinzler KW, 1998, SCIENCE, V280, P1036, DOI 10.1126/science.280.5366.1036; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Knudson AG, 1997, ANN NY ACAD SCI, V833, P58, DOI 10.1111/j.1749-6632.1997.tb48593.x; Kratzke RA, 1996, CANCER RES, V56, P3415; LeCouter JE, 1998, DEVELOPMENT, V125, P4669; LeCouter JE, 1998, MOL CELL BIOL, V18, P7455, DOI 10.1128/MCB.18.12.7455; Lee EY, 2002, CANCER CELL, V2, P463, DOI 10.1016/S1535-6108(02)00207-6; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; LI Y, 1994, MOL CELL BIOL, V14, P1861, DOI 10.1128/MCB.14.3.1861; Ma YH, 2002, ARCH BIOCHEM BIOPHYS, V399, P212, DOI 10.1006/abbi.2002.2761; MAANDAG ECR, 1994, EMBO J, V13, P4260, DOI 10.1002/j.1460-2075.1994.tb06746.x; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nikitin AY, 1999, P NATL ACAD SCI USA, V96, P3916, DOI 10.1073/pnas.96.7.3916; Nikitin AY, 1996, GENE DEV, V10, P1870, DOI 10.1101/gad.10.15.1870; OKAMOTO A, 1995, CANCER RES, V55, P1448; Park MS, 1999, P NATL ACAD SCI USA, V96, P6382, DOI 10.1073/pnas.96.11.6382; Peeper DS, 2001, NAT CELL BIOL, V3, P198, DOI 10.1038/35055110; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Simpson DJ, 2000, CANCER RES, V60, P1211; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Tsai KY, 2002, P NATL ACAD SCI USA, V99, P16865, DOI 10.1073/pnas.262499599; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Wells J, 2002, P NATL ACAD SCI USA, V99, P3890, DOI 10.1073/pnas.062047499; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WILLIAMS BO, 1994, EMBO J, V13, P4251, DOI 10.1002/j.1460-2075.1994.tb06745.x; WINDLE JJ, 1990, NATURE, V343, P665, DOI 10.1038/343665a0; Wu LZ, 2003, NATURE, V421, P942, DOI 10.1038/nature01417; Yamasaki L, 1998, NAT GENET, V18, P360, DOI 10.1038/ng0498-360; YAMASAKI L, 2003, SIGNAL TRANSDUCTION, P209; ZACKSENHAUS E, 1993, MOL CELL BIOL, V13, P4588, DOI 10.1128/MCB.13.8.4588; Ziebold U, 2003, MOL CELL BIOL, V23, P6542, DOI 10.1128/MCB.23.18.6542-6552.2003	59	29	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3296	3307		10.1038/sj.onc.1207457	http://dx.doi.org/10.1038/sj.onc.1207457			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15021915				2022-12-28	WOS:000220975000004
J	Tarbe, NG; Rio, MC; Weidle, UH				Tarbe, NG; Rio, MC; Weidle, UH			SMAGP, a new small trans-membrane glycoprotein altered in cancer	ONCOGENE			English	Article						SMAGP; cancer; cell-cell junction; protein 4.1; MAGUK; glycosylation	CELL-CELL ADHESION; GENOMIC ORGANIZATION; SORTING SIGNALS; METASTASIS; TUMOR; CARCINOMA; BREAST; GENE; PREDICTION; EXPRESSION	Using the Affymetrix array technology, we previously identified an EST strongly expressed in several metastatic cell lines. In the present study, we cloned the corresponding cDNA that encodes a new glycoprotein composed of 97 amino acids and containing a trans-membrane domain. Therefore, we named it SMAGP for Small trans-Membrane And Glycosylated Protein. SMAGP is strongly conserved during evolution. It is expressed by normal epithelia of various organs, the protein being notably localized to the lateral face of the plasma membrane of cohesive well-polarized epithelial cells. In addition, SMAGP contains binding domains for the protein 4.1 and the PDZ domain of MAGUK proteins. Similar protein features are observed in several cell-surface proteins involved via ternary complexes in intercellular processes leading to cytoskeleton assembly as well as intracellular signalling. Thus, SMAGP might similarly be involved in a scaffolding protein complex, and therefore participate in the epithelium organization or in subsequent functions. Immunohistochemical data obtained using human breast, colon and lung cancer samples sustain this hypothesis since they showed that, in both primary tumours and metastases, reduced expression and/or cytoplasmic redistribution of SMAGP is superimposable with low histological tumour differentiation features, namely a lack of epithelial cell polarity and disorganized tissue phenotype.	Univ Strasbourg 1, INSERM, U596,CNRS,UMR 7104, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, CU Strasbourg, France; Roche Diagnost GmbH, Pharma Res, D-82377 Penzberg, Germany	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Roche Holding	Rio, MC (corresponding author), Univ Strasbourg 1, INSERM, U596,CNRS,UMR 7104, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries,BP10142, F-67404 Illkirch Graffenstaden, CU Strasbourg, France.	rio@igbmc.u-strasbg.fr						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Biederer T, 2001, J BIOL CHEM, V276, P47869, DOI 10.1074/jbc.M105287200; Biederer T, 2002, SCIENCE, V297, P1525, DOI 10.1126/science.1072356; BRATTAIN MG, 1981, CANCER RES, V41, P1751; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Claas C, 1998, J CELL BIOL, V141, P267, DOI 10.1083/jcb.141.1.267; Florea L, 1998, GENOME RES, V8, P967, DOI 10.1101/gr.8.9.967; Fukata M, 2001, NAT REV MOL CELL BIO, V2, P887, DOI 10.1038/35103068; FUKUDA M, 1987, J BIOL CHEM, V262, P11952; Greenwood E, 2003, NAT REV CANCER, V3, P549, DOI 10.1038/nrc1155; Grille SJ, 2003, CANCER RES, V63, P2172; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HANSEN JE, 1995, BIOCHEM J, V308, P801, DOI 10.1042/bj3080801; Hunter KW, 2001, CANCER RES, V61, P8866; Jeanplong F, 2001, MOL CELL BIOCHEM, V220, P31, DOI 10.1023/A:1010801511963; Jensen LJ, 2002, J MOL BIOL, V319, P1257, DOI 10.1016/S0022-2836(02)00379-0; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Lozano E, 2003, BIOESSAYS, V25, P452, DOI 10.1002/bies.10262; Marfatia SM, 1997, J BIOL CHEM, V272, P24191, DOI 10.1074/jbc.272.39.24191; Masuda M, 2002, J BIOL CHEM, V277, P31014, DOI 10.1074/jbc.M203620200; MATZKU S, 1983, INVAS METAST, V3, P109; Nawrocki B, 1998, AM J PATHOL, V153, P1521, DOI 10.1016/S0002-9440(10)65740-9; NERI A, 1982, J NATL CANCER I, V68, P507; Nestl A, 2001, CANCER RES, V61, P1569; Nielsen H, 1999, PROTEIN ENG, V12, P3, DOI 10.1093/protein/12.1.3; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; Rodriguez-Boulan E, 1999, TRENDS CELL BIOL, V9, P291, DOI 10.1016/S0962-8924(99)01595-0; Rogers GR, 1997, GENOMICS, V39, P127, DOI 10.1006/geno.1996.4501; Rosel M, 1998, ONCOGENE, V17, P1989, DOI 10.1038/sj.onc.1202079; Skubitz Amy P N, 2002, Cancer Treat Res, V107, P305; Steeg PS, 2003, NAT REV CANCER, V3, P55, DOI 10.1038/nrc967; Sy Man-Sun, 1997, Current Opinion in Oncology, V9, P108; Tarbe N, 2002, ANTICANCER RES, V22, P2015; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wahlberg JM, 1997, J CELL BIOL, V137, P555, DOI 10.1083/jcb.137.3.555; Welch DR, 1997, CLIN EXP METASTAS, V15, P272, DOI 10.1023/A:1018477516367; Wurfel J, 1999, ONCOGENE, V18, P2323, DOI 10.1038/sj.onc.1202542; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	39	8	10	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3395	3403		10.1038/sj.onc.1207469	http://dx.doi.org/10.1038/sj.onc.1207469			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15021913				2022-12-28	WOS:000220975000014
J	Lockshin, RA; Zakeri, Z				Lockshin, RA; Zakeri, Z			Caspase-independent cell death?	ONCOGENE			English	Review						caspase; caspase-independent; apoptosis; programmed cell death; lysosome; autophagocytosis; protease	MITOCHONDRIAL PERMEABILITY TRANSITION; NEMATODE CAENORHABDITIS-ELEGANS; HUMAN EPIDERMAL-KERATINOCYTES; LENS FIBER DIFFERENTIATION; TERMINAL DIFFERENTIATION; DROSOPHILA CASPASE; CYTOCHROME-C; MEMBRANE PERMEABILIZATION; MORPHOLOGICAL-CHANGES; NUCLEAR DEGENERATION	Many cells die with apoptotic morphology and with documented activation of an effector caspase, but there are also many exceptions. Cells frequently display activation of other proteases, including granzymes, lysosomal cathepsins, matrix metalloproteinases, and proteasomal proteases, and others display morphologies that are not fully consistent with classical apoptosis. In some experimental situations, evidence of caspase-dependent death is indirect, demonstrating that the cell can activate caspases rather than that it does. In other situations, such as involution of mammary or prostate tissue, many cells display autophagic or other morphology different from apoptosis, and there is considerable evidence for the activation of a lysosomal system. Prior to total collapse and necrosis, cells that are in trouble can activate numerous physiological pathways toward self-destruction. Intrinsic or extrinsic routes to effector caspase activation are frequently the most rapid and efficient. If neither of these routes is immediately available, owing to mutation, genetic manipulation, inhibitor, or the biology of the cell, other routes may be followed, leading to variant forms of cell death that may display one or more characteristics of apoptosis. Experimental and therapeutic procedures must account for this possibility.	CUNY Queens Coll, Dept Biol, Flushing, NY 11367 USA; CUNY, Grad Ctr, Flushing, NY 11367 USA; St Johns Univ, Dept Biol Sci, Jamaica, NY 11439 USA	City University of New York (CUNY) System; Queens College NY (CUNY); City University of New York (CUNY) System; Saint John's University	Lockshin, RA (corresponding author), CUNY Queens Coll, Dept Biol, 65-30 Kissena Blvd, Flushing, NY 11367 USA.	lockshin@stjohns.edu						Allombert-Blaise C, 2003, CELL DEATH DIFFER, V10, P850, DOI 10.1038/sj.cdd.4401245; Andersson M, 2003, EXP EYE RES, V76, P175, DOI 10.1016/S0014-4835(02)00283-X; Arama E, 2003, DEV CELL, V4, P687, DOI 10.1016/S1534-5807(03)00120-5; Baehrecke EH, 2003, DEV CELL, V4, P608, DOI 10.1016/S1534-5807(03)00134-5; Bauvy C, 2001, EXP CELL RES, V268, P139, DOI 10.1006/excr.2001.5285; Berg CP, 2001, CELL DEATH DIFFER, V8, P1197, DOI 10.1038/sj.cdd.4400905; BOLOGNIA JL, 1995, AM J MED, V98, pS99, DOI 10.1016/S0002-9343(99)80066-7; BOWEN ID, 1993, CELL BIOL INT, V17, P13, DOI 10.1006/cbir.1993.1002; Boya P, 2003, J EXP MED, V197, P1323, DOI 10.1084/jem.20021952; Bratosin D, 2001, CELL DEATH DIFFER, V8, P1143, DOI 10.1038/sj.cdd.4400946; Cakouros D, 2002, J CELL BIOL, V157, P985, DOI 10.1083/jcb.200201034; Cerri PS, 2003, J PERIODONTAL RES, V38, P223, DOI 10.1034/j.1600-0765.2003.02006.x; Chua CC, 2003, BBA-MOL CELL RES, V1642, P79, DOI 10.1016/S0167-4889(03)00100-9; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; Clarke PGH, 1996, ANAT EMBRYOL, V193, P81; COTMAN CW, 1998, CELLS DIE COMPREHENS, P385; Counis MF, 1998, CELL DEATH DIFFER, V5, P251, DOI 10.1038/sj.cdd.4400351; Dahm R, 2002, OPHTHALMIC RES, V34, P288, DOI 10.1159/000065605; Dahm R, 1997, BIOCHEM SOC T, V25, pS584, DOI 10.1042/bst025s584; Dahm R, 1999, OPHTHALMIC RES, V31, P163, DOI 10.1159/000055530; Daugas E, 2001, CELL DEATH DIFFER, V8, P1131, DOI 10.1038/sj.cdd.4400953; Dorstyn L, 1999, P NATL ACAD SCI USA, V96, P4307, DOI 10.1073/pnas.96.8.4307; Dorstyn L, 1999, J BIOL CHEM, V274, P30778, DOI 10.1074/jbc.274.43.30778; Elmore SP, 2001, FASEB J, V15, P2286, DOI 10.1096/fj.01-0206fje; Fromm L, 1997, DEV GENET, V20, P276, DOI 10.1002/(SICI)1520-6408(1997)20:3<276::AID-DVG10>3.0.CO;2-6; Gandarillas A, 1999, EXP DERMATOL, V8, P71, DOI 10.1111/j.1600-0625.1999.tb00350.x; Gao CY, 1997, DEV GENET, V20, P267; Gniadecki R, 2001, EXP DERMATOL, V10, P71, DOI 10.1034/j.1600-0625.2001.010002071.x; Gorski SM, 2003, CURR BIOL, V13, P358, DOI 10.1016/S0960-9822(03)00082-4; HAAS AL, 1995, J BIOL CHEM, V270, P9407, DOI 10.1074/jbc.270.16.9407; HALABY R, 1994, BIOCHEM CELL BIOL, V72, P597, DOI 10.1139/o94-079; Harvey NL, 2001, J BIOL CHEM, V276, P25342, DOI 10.1074/jbc.M009444200; HELMINEN HJ, 1968, J ULTRA MOL STRUCT R, V25, P240, DOI 10.1016/S0022-5320(68)80072-3; Hensey C, 1999, ANN NY ACAD SCI, V887, P105, DOI 10.1111/j.1749-6632.1999.tb07926.x; Hikim APS, 2003, J STEROID BIOCHEM, V85, P175, DOI 10.1016/S0960-0760(03)00193-6; HORVITZ HR, 1983, COLD SPRING HARB SYM, V48, P453, DOI 10.1101/SQB.1983.048.01.050; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; Ishizaki Y, 1998, J CELL BIOL, V140, P153, DOI 10.1083/jcb.140.1.153; Jaattela M, 2003, NAT IMMUNOL, V4, P416, DOI 10.1038/ni0503-416; Jellinger KA, 2001, J ALZHEIMERS DIS, V3, P31, DOI 10.3233/JAD-2001-3106; Jochova J, 1997, CELL DEATH DIFFER, V4, P140, DOI 10.1038/sj.cdd.4400216; Jochova J, 1997, DEV GENET, V21, P249, DOI 10.1002/(SICI)1520-6408(1997)21:4<249::AID-DVG2>3.0.CO;2-7; KANE DJ, 1995, J NEUROSCI RES, V40, P269, DOI 10.1002/jnr.490400216; KERR JFR, 1971, J PATHOL, V105, P13, DOI 10.1002/path.1711050103; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KERR JFR, 1974, J CELL SCI, V14, P571; Kierszenbaum AL, 2001, MOL REPROD DEV, V58, P1, DOI 10.1002/1098-2795(200101)58:1&lt;1::AID-MRD1&gt;3.0.CO;2-0; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Lambert E, 2003, BIOCHEM J, V372, P767, DOI 10.1042/BJ20030187; LANG F, 2003, PFLUGERS ARCH, V121, P919; Lang KS, 2004, CELL DEATH DIFFER, V11, P231, DOI 10.1038/sj.cdd.4401311; Lang KS, 2003, CELL DEATH DIFFER, V10, P249, DOI 10.1038/sj.cdd.4401144; Lee CY, 2000, CELL RES, V10, P193, DOI 10.1038/sj.cr.7290048; Lee CY, 2003, CURR BIOL, V13, P350, DOI 10.1016/S0960-9822(03)00085-X; Lemasters JJ, 2002, ANTIOXID REDOX SIGN, V4, P769, DOI 10.1089/152308602760598918; Lemasters JJ, 1998, BIOFACTORS, V8, P283, DOI 10.1002/biof.5520080316; Lippens S, 2000, CELL DEATH DIFFER, V7, P1218, DOI 10.1038/sj.cdd.4400785; Lockshin RA, 2001, NAT REV MOL CELL BIO, V2, P545, DOI 10.1038/35080097; LOCKSHIN RA, 1969, LYSOSOM BIOL PATHOL, P363; Macho A, 1997, J IMMUNOL, V158, P4612; Mammone T, 1998, SKIN PHARMACOL APPL, V11, P152, DOI 10.1159/000029821; Mammone T, 2000, CELL BIOL TOXICOL, V16, P293, DOI 10.1023/A:1026746330146; Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115; Miller TM, 1997, J CELL BIOL, V139, P205, DOI 10.1083/jcb.139.1.205; Mogi M, 2003, J BIOL CHEM, V278, P47477, DOI 10.1074/jbc.M307055200; Mori M, 2003, J CELL PHYSIOL, V195, P290, DOI 10.1002/jcp.10245; NORSGAARD H, 1994, ARCH GERONTOL GERIAT, P185, DOI 10.1016/S0167-4943(05)80064-0; Oppenheim RW, 2001, J NEUROSCI, V21, P4752, DOI 10.1523/JNEUROSCI.21-13-04752.2001; Perfettini JL, 2003, NAT IMMUNOL, V4, P308, DOI 10.1038/ni0403-308; POLAKOWSKA RR, 1994, DEV DYNAM, V199, P176, DOI 10.1002/aja.1001990303; Print CG, 2000, BIOESSAYS, V22, P423, DOI 10.1002/(SICI)1521-1878(200005)22:5&lt;423::AID-BIES4&gt;3.0.CO;2-0; Raff MC, 2002, SCIENCE, V296, P868, DOI 10.1126/science.1068613; SANCHEZPRIETO R, 1995, ONCOGENE, V11, P675; Sanders EJ, 2003, DIFFERENTIATION, V71, P425, DOI 10.1046/j.1432-0436.2003.7107005.x; Sanders EJ, 2002, J ANAT, V201, P121, DOI 10.1046/j.1469-7580.2002.00081.x; SASAKI K, 1993, J ANAT, V183, P113; Schotte P, 1999, FEBS LETT, V442, P117, DOI 10.1016/S0014-5793(98)01640-8; SCHWEICHEL JU, 1973, TERATOLOGY, V7, P253, DOI 10.1002/tera.1420070306; SMITH FF, 1992, MOL REPROD DEV, V33, P363, DOI 10.1002/mrd.1080330402; Sordet O, 2002, BLOOD, V100, P4446, DOI 10.1182/blood-2002-06-1778; Sun JS, 2003, J BIOMED MATER RES A, V64A, P616, DOI 10.1002/jbm.a.10439; TAMADA Y, 1994, BRIT J DERMATOL, V131, P521; Tolkovsky AM, 2002, BIOCHIMIE, V84, P233, DOI 10.1016/S0300-9084(02)01371-8; Torriglia A, 2001, EXP EYE RES, V72, P443, DOI 10.1006/exer.2000.0969; Vaux DL, 1996, MICROSC RES TECHNIQ, V34, P259, DOI 10.1002/(SICI)1097-0029(19960615)34:3<259::AID-JEMT8>3.0.CO;2-K; WEBER R, 1969, LYSOSOM BIOL PATHOL, V1, P437; Weil M, 1999, CURR BIOL, V9, P361, DOI 10.1016/S0960-9822(99)80162-6; WEINBERG WC, 1995, ONCOGENE, V10, P2271; Weisfelner Michelle Emily, 2003, J Drugs Dermatol, V2, P385; Wride MA, 1999, DEV BIOL, V213, P142, DOI 10.1006/dbio.1999.9375; Wride MA, 2000, APOPTOSIS, V5, P203, DOI 10.1023/A:1009653326511; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; Xue L, 2001, CURR BIOL, V11, P361, DOI 10.1016/S0960-9822(01)00100-2; Xue LZ, 1999, MOL CELL NEUROSCI, V14, P180, DOI 10.1006/mcne.1999.0780; Yao K, 2003, CHINESE MED J-PEKING, V116, P1034; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; ZAKERI Z, 1992, MOL REPROD DEV, V33, P373, DOI 10.1002/mrd.1080330403; ZAKERI Z, 1990, J CELL BIOL, V111, P337; ZAKERI ZF, 1993, FASEB J, V7, P470, DOI 10.1096/fasebj.7.5.8462789; Zamzami N, 1997, J BIOENERG BIOMEMBR, V29, P185, DOI 10.1023/A:1022694131572; Zhuang SG, 2003, ONCOGENE, V22, P4413, DOI 10.1038/sj.onc.1206604	104	163	175	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2004	23	16					2766	2773		10.1038/sj.onc.1207514	http://dx.doi.org/10.1038/sj.onc.1207514			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	811VO	15077140				2022-12-28	WOS:000220799600004
J	Castellone, MD; Celetti, A; Guarino, V; Cirafici, AM; Basolo, F; Giannini, R; Medico, E; Kruhoffer, M; Orntoft, TF; Curcio, F; Fusco, A; Melillo, RM; Santoro, M				Castellone, MD; Celetti, A; Guarino, V; Cirafici, AM; Basolo, F; Giannini, R; Medico, E; Kruhoffer, M; Orntoft, TF; Curcio, F; Fusco, A; Melillo, RM; Santoro, M			Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells	ONCOGENE			English	Article						kinase; carcinoma; motility; Ras; tyrosine; thyroid	TYROSINE KINASE; IN-VITRO; RET; CD44; ACTIVATION; RECEPTOR; CANCER; LINE; IDENTIFICATION; ONCOPROTEIN	Papillary thyroid carcinomas are characterized by rearrangements of the RET receptor tyrosine kinase generating RET/ PTC oncogenes. Here we show that osteopontin ( OPN), a secreted glycoprotein, is a major RET/ PTC- induced transcriptional target in PC Cl 3 thyroid follicular cells. OPN upregulation depended on the integrity of the RET/ PTC kinase and tyrosines Y1015 and Y1062, two major RET/ PTC autophosphorylation sites. RET/ PT C also induced a strong overexpression of CD44, a cell surface signalling receptor for OPN. Upregulation of CD44 was dependent on RET/ PTC Y1062, as well. Constitutive OPN overexpression or treatment with exogenous recombinant OPN sharply increased proliferation, Matrigel invasion and spreading in collagen gels of RET/ PTC- transformed PC Cl 3 cells. These effects were impaired by the treatment of PC Cl 3- RET/ PTC cells with OPN- and CD44- blocking antibodies. Thus, RET/ PTC signalling triggers an autocrine loop involving OPN and CD44 that sustains proliferation and invasion of transfomed PC Cl 3 thyrocytes.	Univ Naples Federico II, Fac Med, Dipartimento Biol & Patol Cellulare & Mol, CNR,Ist Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Dipartimento Oncol, Pisa, Italy; Univ Turin, Inst Canc Res & Treatment IRCC, Div Mol Oncol, Candiolo, TO, Italy; Aarhus Univ Hosp, Dept Clin Biochem, Mol Diagnost Lab, DK-8000 Aarhus, Denmark; Univ Udine, Dipartimento Patol & Med Sperimentale & Clin, I-33100 Udine, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; Aarhus University; University of Udine	Santoro, M (corresponding author), Univ Naples Federico II, Fac Med, Dipartimento Biol & Patol Cellulare & Mol, CNR,Ist Endocrinol & Oncol Sperimentale, Via S Pansini 5, I-80131 Naples, Italy.	masantor@unina.it	Celetti, Angela/AAY-7172-2020; Giannini, Riccardo/K-4223-2013; Curcio, Francesco/K-4669-2014; Basolo, Fulvio/AAC-2727-2019; Giannini, Riccardo/Q-6087-2019; melillo, rosa marina/O-5255-2015; Medico, Enzo/AAC-3185-2021	Giannini, Riccardo/0000-0001-9740-0219; Basolo, Fulvio/0000-0003-1657-5020; Giannini, Riccardo/0000-0001-9740-0219; Medico, Enzo/0000-0002-3917-2438; MELILLO, Rosa Marina/0000-0002-9233-5275; CASTELLONE, MARIADOMENICA/0000-0003-0507-8037; CURCIO, Francesco/0000-0002-9070-4807; Fusco, Alfredo/0000-0003-3332-5197				Andreozzi F, 2003, ONCOGENE, V22, P2942, DOI 10.1038/sj.onc.1206475; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; Ashkar S, 2000, SCIENCE, V287, P860, DOI 10.1126/science.287.5454.860; Bartolazzi A, 2001, LANCET, V357, P1644, DOI 10.1016/S0140-6736(00)04817-0; Basolo F, 2002, INT J CANCER, V97, P608, DOI 10.1002/ijc.10116; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; Buckwalter TLF, 2002, ONCOGENE, V21, P8166, DOI 10.1038/sj.onc.1205938; Carlomagno F, 2002, CANCER RES, V62, P7284; Castellone MD, 2003, ONCOGENE, V22, P246, DOI 10.1038/sj.onc.1206112; Chabas D, 2001, SCIENCE, V294, P1731, DOI 10.1126/science.1062960; CHANG PL, 1993, CANCER RES, V53, P2217; CURCIO F, 1994, P NATL ACAD SCI USA, V91, P9004, DOI 10.1073/pnas.91.19.9004; ERMAK G, 1995, CANCER RES, V55, P4594; Fagin JA, 2002, ENDOCRINOLOGY, V143, P2025, DOI 10.1210/en.143.6.2025; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; GUO XJ, 1995, MOL CELL BIOL, V15, P476, DOI 10.1128/MCB.15.1.476; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; ISHIZAKA Y, 1990, BIOCHEM BIOPH RES CO, V168, P402, DOI 10.1016/0006-291X(90)92335-W; Iwashita T, 1996, ONCOGENE, V12, P481; Kamikura DM, 2000, MOL CELL BIOL, V20, P3482, DOI 10.1128/MCB.20.10.3482-3496.2000; Kimura T, 2001, ENDOCR REV, V22, P631, DOI 10.1210/er.22.5.631; Legg JW, 2002, NAT CELL BIOL, V4, P399, DOI 10.1038/ncb797; Lin YH, 2000, MOL CELL BIOL, V20, P2734, DOI 10.1128/MCB.20.8.2734-2742.2000; Lin YH, 2001, J BIOL CHEM, V276, P46024, DOI 10.1074/jbc.M105132200; Manie S, 2001, TRENDS GENET, V17, P580, DOI 10.1016/S0168-9525(01)02420-9; Medico E, 2001, CANCER RES, V61, P5861; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; Melillo RM, 2001, MOL CELL BIOL, V21, P4177, DOI 10.1128/MCB.21.13.4177-4187.2001; Mercalli E, 2001, ONCOGENE, V20, P3475, DOI 10.1038/sj.onc.1204462; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Saavedra HI, 2000, ONCOGENE, V19, P3948, DOI 10.1038/sj.onc.1203723; Salvatore D, 2000, J CLIN ENDOCR METAB, V85, P3898, DOI 10.1210/jc.85.10.3898; Santoro M, 1996, ONCOGENE, V12, P1821; Weber GF, 2001, BBA-REV CANCER, V1552, P61, DOI 10.1016/S0304-419X(01)00037-3; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; Weiss JM, 2001, J EXP MED, V194, P1219, DOI 10.1084/jem.194.9.1219; YUE TL, 1994, EXP CELL RES, V214, P459, DOI 10.1006/excr.1994.1282; Zhang GX, 2003, MOL CELL BIOL, V23, P6507, DOI 10.1128/MCB.23.18.6507-6519.2003	39	38	40	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2004	23	12					2188	2196		10.1038/sj.onc.1207322	http://dx.doi.org/10.1038/sj.onc.1207322			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	804EB	14981541				2022-12-28	WOS:000220280900008
J	Shan, ZH; Parker, T; Wiest, JS				Shan, ZH; Parker, T; Wiest, JS			Identifying novel homozygous deletions by microsatellite analysis and characterization of tumor suppressor candidate 1 gene, TUSC1, on chromosome 9p in human lung cancer	ONCOGENE			English	Article						homozygous deletion; chromosome 9; lung cancers; TUSC1; expression; tumor suppressor gene	HETEROZYGOSITY; MELANOMA; REGION; METHYLATION; EPIGENETICS; CARCINOMA; 9P21-22; P15	Loss of heterozygosity (LOH) studies indicate that genetic alterations of chromosome 9p occur in numerous tumor types, suggesting the presence of tumor suppressor genes (TSGs) on chromosome 9p critical in carcinogenesis. Our previous LOH analyses in primary lung tumors led us to propose that chromosome 9p harbors other TSGs important in lung tumorigenesis. In this study, 30 non-small-cell lung cancer and 12 small-cell lung cancer cell lines were screened with 55 markers to identify new regions of homozygous deletion (HD) on chromosome 9p. Three novel noncontiguous homozygously deleted regions were detected and ranged in size from 840 kb to 7.4 Mb. One gene identified in the deletion at D9S126, TUSC1 ( tumor suppressor candidate 1), is an intronless gene. Multiplex polymerase chain reaction and Southern blot confirmed the HD of TUSC1. Northern blot analysis of TUSC1 demonstrated two transcripts of approximately 2 and 1.5 kb that are likely generated by alternative polyadenylation signals. Both transcripts are expressed in several human tissues and share an open-reading frame encoding a peptide of 209 amino acids. Analysing cell line cDNAs by reverse transcriptase (RT)-PCR demonstrated downregulation of TUSC1 in cell lines with or without HDs, suggesting that TUSC1 may play a role in lung tumorigenesis.	NCI, Cellular Carcinogenesis & Tumor Promot Lab, Ctr Canc Res, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wiest, JS (corresponding author), NCI, Cellular Carcinogenesis & Tumor Promot Lab, Ctr Canc Res, Bldg 37,Room 4008,37 Convent Dr MSC4258, Bethesda, MD 20892 USA.	wiestj@mail.nih.gov		Pritchett, Tracy/0000-0002-3336-9336	Intramural NIH HHS [ZIA BC010448-09] Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		An HX, 1996, GENE CHROMOSOME CANC, V17, P14, DOI 10.1002/(SICI)1098-2264(199609)17:1<14::AID-GCC3>3.3.CO;2-Y; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Baylin SB, 1998, ADV CANCER RES, V72, P141; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Castellano M, 1997, CANCER RES, V57, P4868; CHENG JQ, 1993, CANCER RES, V53, P4761; COLEMAN A, 1994, CANCER RES, V54, P344; Hamada K, 1998, GENE CHROMOSOME CANC, V22, P232, DOI 10.1002/(SICI)1098-2264(199807)22:3<232::AID-GCC9>3.0.CO;2-X; Hamada K, 2000, GENE CHROMOSOME CANC, V27, P308, DOI 10.1002/(SICI)1098-2264(200003)27:3<308::AID-GCC12>3.3.CO;2-N; HOLLAND EA, 1994, ONCOGENE, V9, P1361; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Mead LJ, 1997, INT J CANCER, V71, P213; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Oh JJ, 2002, CANCER RES, V62, P3207; Pollock PM, 2001, CANCER RES, V61, P1154; QUELLE DE, 1995, CELL, V83, P993; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Shan ZH, 2003, GENE, V303, P55, DOI 10.1016/S0378-1119(02)01143-5; Sheu JC, 1999, BRIT J CANCER, V80, P468, DOI 10.1038/sj.bjc.6690380; Stranahan PL, 1996, GLYCOCONJUGATE J, V13, P741, DOI 10.1007/BF00702338; Takeuchi S, 1997, LEUKEMIA, V11, P1636, DOI 10.1038/sj.leu.2400817; Wiest JS, 1997, CANCER RES, V57, P1; XIAO S, 1995, CANCER RES, V55, P2968	26	24	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6612	6620		10.1038/sj.onc.1207857	http://dx.doi.org/10.1038/sj.onc.1207857			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15208665	Green Accepted			2022-12-28	WOS:000223530800008
J	Poser, I; Tatzel, J; Kuphal, S; Bosserhoff, AK				Poser, I; Tatzel, J; Kuphal, S; Bosserhoff, AK			Functional role of MIA in melanocytes and early development of melanoma	ONCOGENE			English	Article						melanocytes; melanoma; migration; MIA; array	MATRIX-METALLOPROTEINASE MT1-MMP; INHIBITORY-ACTIVITY; MALIGNANT-MELANOMA; CELL-LINES; INTEGRIN ALPHA-V-BETA-3; PLASMINOGEN ACTIVATORS; IN-VITRO; EXPRESSION; PROGRESSION; PROTEIN	The protein MIA(melanoma inhibitory activity) is highly expressed in malignant melanomas but not in melanocytes. Furthermore, expression of MIA correlates with tumor progression in vivo. Here, MIA-dependent changes of gene expression after long-term inhibition of MIA expression in the human melanoma cell line HMB2 were investigated. Primarily, we observed characteristic changes in cell morphology, and also found re-established cell-cell contacts in MIA-deficient cell clones grown in monolayer culture. Real-time reverse transcription-polymerase chain reaction (RT-PCR) showed a downregulation of N-cadherin expression and a reinduction of E-cadherin expression in the MIA-deficient cell clones. Further, both cancer cDNA array and protein arrays verified a marked downregulation of several other melanoma-associated genes (e.g. membrane-type 1 matrix metalloproteinase tissue-type plasminogen activator integrin beta3, secreted protein acidic and rich in cysteins and fibronectin) in the MIA-deficient melanoma cells, confirmed by real-time RT-PCR and Western blotting. As all these molecules are associated with migration, the effect of MIA on migration of human primary melanocytes was analysed. In the presence of MIA, we observed enhanced migratory ability of melanocytic cells, induction of melanoma-associated genes as well as inhibition of apoptosis due to anoikis. These results suggest that expression of MIA promotes melanoma progression by inducing further melanoma-associated genes.	Univ Regensburg, Inst Pathol, D-93053 Regensburg, Germany	University of Regensburg	Bosserhoff, AK (corresponding author), Univ Regensburg, Inst Pathol, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.	anja.bosserhoff@klinik.uni-regensburg.de	Kuphal, Silke/AAW-2702-2020; Bosserhoff, Anja/GNH-4801-2022	Bosserhoff, Anja/0000-0001-8147-394X				ALIZADEH H, 1995, CURR EYE RES, V14, P449, DOI 10.3109/02713689509003755; BLESCH A, 1994, CANCER RES, V54, P5695; Bosserhoff AK, 1996, J BIOL CHEM, V271, P490, DOI 10.1074/jbc.271.1.490; Bosserhoff AK, 1999, J PATHOL, V187, P446, DOI 10.1002/(SICI)1096-9896(199903)187:4<446::AID-PATH267>3.0.CO;2-Y; Bosserhoff AK, 2003, LAB INVEST, V83, P1583, DOI 10.1097/01.LAB.0000097191.12477.5D; Bosserhoff AK, 1997, CANCER RES, V57, P3149; Bosserhoff AK, 2002, HISTOL HISTOPATHOL, V17, P289, DOI 10.14670/HH-17.289; Bosserhoff AK, 2001, MELANOMA RES, V11, P417, DOI 10.1097/00008390-200108000-00013; Bowen AR, 2003, J INVEST DERMATOL, V120, P48, DOI 10.1046/j.1523-1747.2003.12010.x; deVries TJ, 1996, MELANOMA RES, V6, P79, DOI 10.1097/00008390-199604000-00001; Felding-Habermann B, 2002, CLIN EXP METASTAS, V19, P427, DOI 10.1023/A:1016377114119; Furukawa Y, 2002, J BIOL CHEM, V277, P39760, DOI 10.1074/jbc.M200805200; Guba M, 2000, BRIT J CANCER, V83, P1216, DOI 10.1054/bjoc.2000.1424; Hofmann UB, 2000, J PATHOL, V191, P245; Hofmann UB, 2000, INT J CANCER, V87, P12, DOI 10.1002/1097-0215(20000701)87:1<12::AID-IJC3>3.0.CO;2-A; Hsu MY, 2002, DIFFERENTIATION, V70, P522, DOI 10.1046/j.1432-0436.2002.700906.x; Iida J, 2004, J INVEST DERMATOL, V122, P167, DOI 10.1046/j.0022-202X.2003.22114.x; Jacob K, 1998, MELANOMA RES, V8, P211, DOI 10.1097/00008390-199806000-00003; Krengel S, 2004, J CUTAN PATHOL, V31, P1, DOI 10.1046/j.0303-6987.2004.0106.x; Krengel S, 2002, J CUTAN PATHOL, V29, P390, DOI 10.1034/j.1600-0560.2002.290702.x; Ledda F, 1997, J INVEST DERMATOL, V108, P210, DOI 10.1111/1523-1747.ep12334263; Ledda MF, 1997, NAT MED, V3, P171, DOI 10.1038/nm0297-171; Li G, 2001, CANCER RES, V61, P3819; Lougheed JC, 2001, P NATL ACAD SCI USA, V98, P5515, DOI 10.1073/pnas.091601698; Massi D, 1999, HUM PATHOL, V30, P339, DOI 10.1016/S0046-8177(99)90014-X; MEISSAUER A, 1991, EXP CELL RES, V192, P453, DOI 10.1016/0014-4827(91)90064-2; NATALI PG, 1995, BRIT J CANCER, V71, P1243, DOI 10.1038/bjc.1995.240; NIP J, 1992, J CLIN INVEST, V90, P1406, DOI 10.1172/JCI116007; PAGGI MG, 2003, PIGMENT CELL RES, V16, P589; SAKSELA O, 1984, INT J CANCER, V33, P609, DOI 10.1002/ijc.2910330510; Seftor REB, 2001, CANCER RES, V61, P6322; Selzer E, 1998, MELANOMA RES, V8, P197, DOI 10.1097/00008390-199806000-00001; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Sounni NE, 2002, INT J CANCER, V98, P23, DOI 10.1002/ijc.10134; Stahlecker J, 2000, ANTICANCER RES, V20, P5041; Stoll R, 2003, PROTEIN SCI, V12, P510, DOI 10.1110/ps.0222603; Stoll R, 2001, EMBO J, V20, P340, DOI 10.1093/emboj/20.3.340; Stoll R, 2000, J BIOMOL NMR, V17, P87, DOI 10.1023/A:1008306918293; Sturm RA, 2002, CANCER RES, V62, P226; Van Belle PA, 1999, HUM PATHOL, V30, P562, DOI 10.1016/S0046-8177(99)90202-2; VANGRONINGEN JJM, 1995, CANCER RES, V55, P6237; WOLLINA U, 1991, ANTICANCER RES, V11, P1405	42	36	38	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6115	6124		10.1038/sj.onc.1207797	http://dx.doi.org/10.1038/sj.onc.1207797			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15208686				2022-12-28	WOS:000223261000011
J	Liang, XQ; Avraham, HK; Jiang, SX; Avraham, S				Liang, XQ; Avraham, HK; Jiang, SX; Avraham, S			Genetic alterations of the NRP/B gene are associated with human brain tumors	ONCOGENE			English	Article						NRP/B; alteration; human brain tumor; nuclear matrix protein; Kelch repeat	NUCLEAR-MATRIX PROTEIN; ACTIN-BINDING PROTEIN; HUMAN BREAST-CANCER; MAP KINASE-KINASE; RETINOBLASTOMA PROTEIN; P53 PATHWAY; CELLS; APOPTOSIS; GROWTH; DIFFERENTIATION	Nearly all brain tumors develop following the progressive accumulation of genetic alterations of oncogenes and tumor suppressor genes (such as p53 and retinoblastoma protein). Furthermore, aberrations in the nuclear matrix often contribute to genomic instabilities and the development of cancer. We have previously shown that nuclear-restricted protein/brain (NRP/B), a member of the BTB/Kelch repeat family, is a nuclear matrix protein normally expressed in neurons but not in astrocytes, and that it is an early and specific marker of neurons during the development of the central nervous system. Here, we show aberrant expression of NRP/B in human brain tissues. NRP/B is expressed in the cytoplasm of human brain tumor cells (glioblastoma, GBM) arising from astrocytes. NRP/B mutations (13 mutations in the Kelch domains, two in the intervening sequence (IVS) domain and two in the BTB domain) were detected in brain tumor cell lines (A-172, CCF-STTG1, SK-N-SH and U87-MG) and in primary human malignant GBM tissues (eight samples). More importantly, we found that NRP/B mutants, but not wild-type (wt) NRP/B, increased the activation of ERK and consequently promoted cell proliferation, attenuated caspase activation and suppressed the cellular apoptosis induced by the stressful stimulus cisplatin (10 mum). These events were observed to occur via a p53-mediated pathway. In addition, while wt NRP/B was associated with actin, mutations in the Kelch domains of NRP/B led to its reduced binding affinity to actin. Thus, alterations and gene mutations within the NRP/B gene may contribute to brain tumorigenesis by promoting cell proliferation, suppressing apoptosis and by affecting nuclear cytoskeleton dynamics.	Harvard Univ, Beth Israel Deaconess Med Ctr, Div Expt Med, Harvard Inst Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Avraham, S (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Div Expt Med, Harvard Inst Med, 4 Blackfan Circle, Boston, MA 02215 USA.	savraham@bidmc.harvard.edu		Avraham, Hava/0000-0002-7545-3640	NCI NIH HHS [1 R01 CA096805] Funding Source: Medline; NINDS NIH HHS [1 R01 NS046628-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA096805] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alberti I, 2000, J CELL BIOCHEM, V79, P471, DOI 10.1002/1097-4644(20001201)79:3<471::AID-JCB120>3.3.CO;2-F; Antonyak MA, 2002, ONCOGENE, V21, P5038, DOI 10.1038/sj.onc.1205593; Back SA, 1998, J NEUROSCI, V18, P6241; Besson A, 1999, EUR J BIOCHEM, V263, P605, DOI 10.1046/j.1432-1327.1999.00542.x; Biernat Wojciech, 1998, Polish Journal of Pathology, V49, P267; Bode J, 2000, J CELL BIOCHEM, P3; BOGLER O, 1995, GLIA, V15, P308, DOI 10.1002/glia.440150311; Brehm A, 1999, TRENDS BIOCHEM SCI, V24, P142, DOI 10.1016/S0968-0004(99)01368-7; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Brunagel G, 2002, CANCER RES, V62, P2437; Campbell I, 2000, CANCER GENE THER, V7, P1270, DOI 10.1038/sj.cgt.7700226; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Collins VP, 1998, CANCER SURV, V32, P37; DARDICK I, 1981, AM J PATHOL, V103, P10; Davido T, 2000, J CELL BIOCHEM, P136; Davie JR, 2001, PROG NUCLEIC ACID RE, V65, P299; Deppert W, 2000, J CELL BIOCHEM, P115; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Fueyo J, 1998, NEUROLOGY, V51, P1250, DOI 10.1212/WNL.51.5.1250; Fujita M, 2001, CANCER RES, V61, P7722; Getzenberg RH, 1996, CANCER RES, V56, P1690; Gottlieb TM, 1998, SEMIN CANCER BIOL, V8, P359, DOI 10.1006/scbi.1998.0098; Grim J, 1997, CLIN CANCER RES, V3, P2415; HENSON JW, 1994, ANN NEUROL, V36, P714, DOI 10.1002/ana.410360505; Hernandez MC, 1997, J NEUROSCI, V17, P3038; Ichimura K, 2000, CANCER RES, V60, P417; Ichimura K, 1996, ONCOGENE, V13, P1065; Kim TA, 2000, GENE, V255, P105, DOI 10.1016/S0378-1119(00)00297-3; Kim TA, 1998, J CELL BIOL, V141, P553, DOI 10.1083/jcb.141.3.553; Konety BR, 1999, J CELL BIOCHEM, P183; Kumar S, 2002, SCIENCE, V297, P1290, DOI 10.1126/science.1076118; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Lane DP, 2002, TRENDS MOL MED, V8, pS38, DOI 10.1016/S1471-4914(02)02309-2; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIBERMANN TA, 1985, J CELL SCI, P161; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; Louis DN, 2002, CANCER CELL, V1, P125, DOI 10.1016/S1535-6108(02)00040-5; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Mandell JW, 1998, AM J PATHOL, V153, P1411, DOI 10.1016/S0002-9440(10)65728-8; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Meyers S, 2000, J CELL BIOCHEM, P93; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Prives C, 1999, J PATHOL, V187, P112; Rasheed B K, 1999, Curr Opin Oncol, V11, P162; Reilly KM, 2001, SEMIN CANCER BIOL, V11, P177, DOI 10.1006/scbi.2000.0375; Saunders WS, 2000, P NATL ACAD SCI USA, V97, P303, DOI 10.1073/pnas.97.1.303; SCHMIDT EE, 1994, CANCER RES, V54, P6321; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; Simon M, 1999, ACTA NEUROPATHOL, V98, P444, DOI 10.1007/s004010051107; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Sotolongo B, 2000, J CELL BIOCHEM, P23; Stein G, 2000, J CELL BIOCHEM, P1; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Ueki K, 1996, CANCER RES, V56, P150; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wechsler-Reya R, 2001, ANNU REV NEUROSCI, V24, P385, DOI 10.1146/annurev.neuro.24.1.385; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Xing C, 1999, CARCINOGENESIS, V20, P1201, DOI 10.1093/carcin/20.7.1201; Yang H, 2002, MOL CELL BIOL, V22, P3103, DOI 10.1128/MCB.22.9.3103-3110.2002; Ye JP, 1999, J BIOL CHEM, V274, P34974, DOI 10.1074/jbc.274.49.34974; Zhao L, 2000, J BIOL CHEM, V275, P16845, DOI 10.1074/jbc.275.22.16845	68	40	42	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2004	23	35					5890	5900		10.1038/sj.onc.1207776	http://dx.doi.org/10.1038/sj.onc.1207776			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15208678				2022-12-28	WOS:000222941100003
J	Leong, CTC; Ng, CY; Ng, CP; Ma, ZS; Nguyen, TH; Tay, SK; Huynh, H				Leong, CTC; Ng, CY; Ng, CP; Ma, ZS; Nguyen, TH; Tay, SK; Huynh, H			Molecular cloning, characterization and isolation of novel spliced variants of the human ortholog of a rat estrogen-regulated membrane-associated protein, UO-44	ONCOGENE			English	Article						estrogen regulated; membrane associated; CUB domains; zona-pellucida and HuUO-44	TUMOR-SUPPRESSOR GENE; LONG ARM; EXPRESSION; IDENTIFICATION; CHROMOSOME-10; TAMOXIFEN; UTERUS; DOMAIN; DMBT1; LOCALIZATION	We have previously reported the characterization of an estrogen-regulated rat uterine-ovarian-specific complementary DNA (UO-44). To understand the involvement of this protein in the initiation and progression of human ovarian and uterine cancers, we now report the cloning and characterization of the human ortholog (HuUO-44). HuUO-44 is mapped to chromosome 10q26.13 and contains nine exons. Multiple tissue Northern blot detected two HuU044 transcripts of approximately 2 and 3kb in the pancreas. RT-PCR demonstrated that HuU044 undergoes a complex series of alternative splicing events between exons 2 and 6 that yielded four novel splice variants, HuUO-44A, HuUO-44B, HuUO-44C and HuUO-44D. Putative functional motifs identified in HuU044 are two CUB domains and a zona-pellucida domain. Transfection studies demonstrated the membrane-associated nature of HuU044. By immunohistochemistry, HuU044 was located to the normal ovarian and ovarian tumor epithelial cells; in NIH-OVCAR3 ovarian cancer cells, HuU044 was detected only at the leading edge of the dividing cells. Most importantly, a marked loss in cell attachment and proliferation was observed in NIH-OVCAR3 cells cultured in the presence of a polyclonal HuU044 antiserum. These findings suggest the potential role of HuU044 in cell motility, cell-cell matrices.	Natl Canc Ctr, Mol Endocrinol Lab, Div Cellular & Mol Res, Singapore 169610, Singapore; Singapore Gen Hosp, Dept Obstet & Gynaecol, Singapore 169608, Singapore	National Cancer Centre Singapore (NCCS); Singapore General Hospital	Huynh, H (corresponding author), Natl Canc Ctr, Mol Endocrinol Lab, Div Cellular & Mol Res, Singapore 169610, Singapore.	cmrhth@nccs.com.sg	Nguyen, Hung/M-8118-2014	Nguyen, Hung/0000-0001-8378-555X; Ong, Choon Kiat/0000-0001-6402-4288				AUERSPERG N, 1984, IN VITRO CELL DEV B, V20, P743; Bhatia-Gaur R, 1999, GENE DEV, V13, P966, DOI 10.1101/gad.13.8.966; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; BORK P, 1992, FEBS LETT, V300, P237, DOI 10.1016/0014-5793(92)80853-9; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; Chen DH, 1999, J BIOL CHEM, V274, P32215, DOI 10.1074/jbc.274.45.32215; Clark HF, 2003, GENOME RES, V13, P2265, DOI 10.1101/gr.1293003; EINSPANIER R, 1991, BIOCHEM BIOPH RES CO, V179, P1006, DOI 10.1016/0006-291X(91)91918-3; FUKUSHIMA D, 1993, J BIOL CHEM, V268, P22710; GRAY IC, 1995, CANCER RES, V55, P4800; Gregoire L, 2001, CLIN CANCER RES, V7, P4280; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Hofmann K., 1993, BIOL CHEM H-S, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Huynh H, 2001, ENDOCRINOLOGY, V142, P2985, DOI 10.1210/en.142.7.2985; HUYNH HT, 1993, CANCER RES, V53, P5585; Imamura T, 2002, J BIOL CHEM, V277, P50725, DOI 10.1074/jbc.M204159200; Jovine L, 2002, NAT CELL BIOL, V4, P457, DOI 10.1038/ncb802; Kasik JW, 1998, BIOCHEM J, V330, P947; KATZENELLENBOGE.BS, 1975, BIOCHEMICAL ACTION H, V3, P187; Katzenellenbogen BS, 1997, ENDOCRINOLOGY, V138, P861, DOI 10.1210/en.138.3.861; Kazandi M, 2002, EUR J GYNAECOL ONCOL, V23, P257; Kim SK, 1998, ONCOGENE, V17, P1749, DOI 10.1038/sj.onc.1202073; Lualdi E, 2000, BIOCHEM BIOPH RES CO, V270, P673, DOI 10.1006/bbrc.2000.2478; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Mollenhauer J, 2000, CANCER RES, V60, P1704; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; Nielsen S, 1998, EUR EAT DISORD REV, V6, P4, DOI 10.1002/(SICI)1099-0968(199803)6:1<4::AID-ERV237>3.3.CO;2-G; Nitta M, 2001, GYNECOL ONCOL, V81, P10, DOI 10.1006/gyno.2000.6084; PEIFFER SL, 1995, CANCER RES, V55, P1922; RASHEED BKA, 1995, ONCOGENE, V10, P2243; Scherl-Mostageer M, 2001, ONCOGENE, V20, P4402, DOI 10.1038/sj.onc.1204566; Somerville RPT, 1998, ONCOGENE, V17, P1755, DOI 10.1038/sj.onc.1202066; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; TSAO SW, 1995, EXP CELL RES, V218, P499, DOI 10.1006/excr.1995.1184; WHITE MM, 1995, ENDOCR REV, V16, P739, DOI 10.1210/er.16.6.739; Wu WG, 1999, CANCER RES, V59, P1846; YOSHINAGA K, 1969, ENDOCRINOLOGY, V85, P103, DOI 10.1210/endo-85-1-103	37	19	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5707	5718		10.1038/sj.onc.1207754	http://dx.doi.org/10.1038/sj.onc.1207754			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15184879				2022-12-28	WOS:000222629500018
J	Huang, YC; Chen, JY; Hung, WC				Huang, YC; Chen, JY; Hung, WC			Vitamin D-3 receptor/Sp1 complex is required for the induction of p27(Kip1) expression by vitamin D-3	ONCOGENE			English	Article						vitamin D-3; p27(Kip1); Sp1; small interference RNA; NF-Y	TRANSCRIPTIONAL ACTIVATION; PROMOTER ACTIVITY; GENE-EXPRESSION; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; GROWTH-INHIBITION; CANCER CELLS; NF-Y; SP1; DIFFERENTIATION; 17-BETA-ESTRADIOL	1alpha, 25-dihydroxyvitamin D-3 (vitamin D-3) has been shown to upregulate p27(Kip1) expression via Sp1 and NF-Y binding sites in the p27(Kip1) promoter. However, whether vitamin D-3 receptor (VDR) involves in this process is unclear. In this study, we demonstrated that expression of VDR in SW620 cells, which exhibited low level of endogenous VDR, increased vitamin D-3-stimulated p27(Kip1) promoter activity. On the contrary, suppression of Sp1 expression by small interference RNA reduced the stimulation of p27(Kip1) promoter activity by vitamin D-3 in LNCaP cells. DNA affinity precipitation assay and chromatin immunoprecipitation assay showed that VDR bound to the p27(Kip1) promoter in vitro and in vivo. In addition, we also demonstrated that VDR interacted with Sp1 in vitro and in cells. Collectively, our results suggest that VDR is involved in the induction of p27(Kip1) by vitamin D-3 and may interact with Sp1 to modulate the expression of target genes that lack VDR response element (VDRE) in their promoters.	Kaohsiung Med Univ, Sch Technol Med Sci, Kaohsiung 807, Taiwan; Kaohsiung Med Univ, Grad Inst Med, Kaohsiung 807, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University	Hung, WC (corresponding author), Kaohsiung Med Univ, Sch Technol Med Sci, Kaohsiung 807, Taiwan.	hung1228@ms10.hinet.net						Boyan BD, 2002, STEROIDS, V67, P421, DOI 10.1016/S0039-128X(01)00178-7; Buitrago C, 2000, J CELL BIOCHEM, V79, P274, DOI 10.1002/1097-4644(20001101)79:2<274::AID-JCB100>3.0.CO;2-R; Christakos S, 2003, J CELL BIOCHEM, V88, P238, DOI 10.1002/jcb.10349; Deluca HF, 2001, FASEB J, V15, P2579, DOI 10.1096/fj.01-0433rev; Dong LA, 1999, J BIOL CHEM, V274, P32099, DOI 10.1074/jbc.274.45.32099; Duan R, 1998, ENDOCRINOLOGY, V139, P1981, DOI 10.1210/en.139.4.1981; GARETH IO, 1998, J BIOL CHEM, V273, P10696; Ge YB, 2002, BBA-GENE STRUCT EXPR, V1579, P73, DOI 10.1016/S0167-4781(02)00509-2; Gurlek A, 2002, ENDOCR REV, V23, P763, DOI 10.1210/er.2001-0044; Guyton KZ, 2001, ANNU REV PHARMACOL, V41, P421, DOI 10.1146/annurev.pharmtox.41.1.421; Haidweger E, 2001, J MOL BIOL, V306, P201, DOI 10.1006/jmbi.2000.4406; Harper JW, 1997, CANCER SURV, V29, P91; Hengst L, 1998, CURR TOP MICROBIOL, V227, P25; Hewetson A, 2003, J BIOL CHEM, V278, P40177, DOI 10.1074/jbc.M303921200; Huang YC, 2002, MOL PHARMACOL, V62, P1515, DOI 10.1124/mol.62.6.1515; Inoue T, 1999, J BIOL CHEM, V274, P32309, DOI 10.1074/jbc.274.45.32309; Johnson CS, 2002, CANCER METAST REV, V21, P147, DOI 10.1023/A:1020836226594; Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193; Khorasanizadeh S, 2001, TRENDS BIOCHEM SCI, V26, P384, DOI 10.1016/S0968-0004(01)01800-X; Kim K, 2003, MOL ENDOCRINOL, V17, P804, DOI 10.1210/me.2002-0406; Kumagai T, 2003, J NATL CANCER I, V95, P896, DOI 10.1093/jnci/95.12.896; Liu LT, 2003, CANCER RES, V63, P3069; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Liu W, 2002, AM J PATHOL, V160, P511, DOI 10.1016/S0002-9440(10)64870-5; Lok CN, 2002, BIOCHEM J, V368, P741, DOI 10.1042/BJ20020791; Martinez ME, 1996, JNCI-J NATL CANCER I, V88, P1375, DOI 10.1093/jnci/88.19.1375; Minami S, 1997, FEBS LETT, V411, P1, DOI 10.1016/S0014-5793(97)00660-1; Narvaez CJ, 2001, STEROIDS, V66, P301, DOI 10.1016/S0039-128X(00)00202-6; Olefsky JM, 2001, J BIOL CHEM, V276, P36863, DOI 10.1074/jbc.R100047200; Palmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028; Pan MR, 2002, J BIOL CHEM, V277, P32775, DOI 10.1074/jbc.M202334200; Safe S, 2001, VITAM HORM, V62, P231, DOI 10.1016/S0083-6729(01)62006-5; Schwartz Z, 2003, STEROIDS, V68, P423, DOI 10.1016/S0039-128X(03)00044-8; SHABAHANG M, 1994, CANCER RES, V54, P4057; SHABAHANG M, 1993, CANCER RES, V53, P3712; SHIGEAKI K, 2000, J BIOCH, V127, P717; Sun GL, 1998, MOL ENDOCRINOL, V12, P882, DOI 10.1210/me.12.6.882; TOWERS TL, 1993, P NATL ACAD SCI USA, V90, P6310, DOI 10.1073/pnas.90.13.6310; Valor LM, 2002, J BIOL CHEM, V277, P8866, DOI 10.1074/jbc.M110454200; Vidal M, 2002, MOL CELL BIOL, V22, P2777, DOI 10.1128/MCB.22.8.2777-2787.2002; Wang F, 1998, NUCLEIC ACIDS RES, V26, P3044, DOI 10.1093/nar/26.12.3044; Wang WL, 1999, MOL ENDOCRINOL, V13, P1373, DOI 10.1210/me.13.8.1373; Yang ES, 2002, MOL CELL ENDOCRINOL, V186, P69, DOI 10.1016/S0303-7207(01)00671-2; ZHANG DE, 1994, J IMMUNOL, V153, P3276; Zhu Y, 2002, J BIOL CHEM, V277, P6923, DOI 10.1074/jbc.M108075200	45	64	64	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2004	23	28					4856	4861		10.1038/sj.onc.1207621	http://dx.doi.org/10.1038/sj.onc.1207621			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	830EK	15064717				2022-12-28	WOS:000222104200006
J	Taylor, MD; Zhang, XY; Liu, L; Hui, CC; Mainprize, TG; Scherer, SW; Wainwright, B; Hogg, D; Rutka, JT				Taylor, MD; Zhang, XY; Liu, L; Hui, CC; Mainprize, TG; Scherer, SW; Wainwright, B; Hogg, D; Rutka, JT			Failure of a medulloblastoma-derived mutant of SUFU to suppress WNT signaling	ONCOGENE			English	Article						medulloblastoma; suppressor of fused; SUFU; brain tumor; WNT signaling; cerebellum	ADENOMATOUS POLYPOSIS-COLI; RUBINSTEIN-TAYBI SYNDROME; CENTRAL-NERVOUS-SYSTEM; BETA-CATENIN; CUBITUS INTERRUPTUS; GENE-EXPRESSION; SONIC HEDGEHOG; SPORADIC MEDULLOBLASTOMAS; PATHWAY COMPONENTS; NEGATIVE REGULATOR	Germline mutations of APC in patients with Turcot syndrome (colon cancer and medulloblastoma), was well as somatic mutations of APC, beta-catenin, and Axin in sporadic medulloblastomas (MBs) have shown the importance of WNT signaling in the pathogenesis of MB. A subset of children with MB have germline mutations of SUFU, a known inhibitor of Hedgehog signal transduction. A recent report suggested that murine Sufu can bind beta-catenin, export it from the nucleus, and thereby repress beta-catenin/T-cell factor (Tcf)-mediated transcription. We show that an MB-derived mutant of SUFU has lost the ability to decrease nuclear levels of beta-catenin, and cannot inhibit beta-catenin/Tcf-mediated transcription as compared to wild type SUFU. Our results suggest that loss of function of SUFU results in overactivity of both the Sonic Hedgehog, and the WNT signaling pathways, leading to excessive proliferation and failure to differentiate resulting in MB.	Hosp Sick Children, Div Neurosurg, Arthur & Sonia Labatt Brain Tumour Res Ctr, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Dept Lab Med & Pathobiol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Div Med & Mol Genet, Toronto, ON, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Queensland, Ritchie Res Labs, St Lucia, Qld 4072, Australia	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto; University of Queensland	Rutka, JT (corresponding author), Hosp Sick Children, Div Neurosurg, Arthur & Sonia Labatt Brain Tumour Res Ctr, Suite 1504,555 Univ Ave, Toronto, ON M5G 1X8, Canada.	james.rutka@sickkids.ca	Scherer, Stephen W./B-3785-2013	Scherer, Stephen W./0000-0002-8326-1999; Wainwright, Brandon/0000-0003-0406-2092; Taylor, Michael/0000-0001-7009-3466				Baeza N, 2003, ONCOGENE, V22, P632, DOI 10.1038/sj.onc.1206156; Borycki AG, 2000, DEVELOPMENT, V127, P2075; Cui H, 1998, DEV BRAIN RES, V111, P177, DOI 10.1016/S0165-3806(98)00136-9; Dahmen RP, 2001, CANCER RES, V61, P7039; DICKINSON ME, 1994, DEVELOPMENT, V120, P1453; Ding Q, 1999, CURR BIOL, V9, P1119, DOI 10.1016/S0960-9822(99)80482-5; Eberhart CG, 2000, J NEUROPATH EXP NEUR, V59, P333, DOI 10.1093/jnen/59.4.333; EVANS G, 1993, MED PEDIATR ONCOL, V21, P433, DOI 10.1002/mpo.2950210608; Frayling IM, 1998, P NATL ACAD SCI USA, V95, P10722, DOI 10.1073/pnas.95.18.10722; HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Huang HT, 2000, AM J PATHOL, V156, P433, DOI 10.1016/S0002-9440(10)64747-5; Iwao K, 1998, CANCER RES, V58, P1021; Jia JH, 2002, NATURE, V416, P548, DOI 10.1038/nature733; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Kalderon D, 2002, TRENDS CELL BIOL, V12, P523, DOI 10.1016/S0962-8924(02)02388-7; Kitas G, 2001, CLIN MED, V1, P18, DOI 10.7861/clinmedicine.1-1-18; Koch A, 2001, INT J CANCER, V93, P445, DOI 10.1002/ijc.1342; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Lee CS, 2000, DEVELOPMENT, V127, P109; Lum L, 2003, SCIENCE, V299, P2039, DOI 10.1126/science.1081403; Mainprize T G, 2000, Clin Neurosurg, V47, P259; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Meng XW, 2001, J BIOL CHEM, V276, P40113, DOI 10.1074/jbc.M105317200; Methot N, 2000, DEVELOPMENT, V127, P4001; MILLER RW, 1995, AM J MED GENET, V56, P112, DOI 10.1002/ajmg.1320560125; MORI T, 1994, GENE CHROMOSOME CANC, V9, P168, DOI 10.1002/gcc.2870090304; Mullor JL, 2001, CURR BIOL, V11, P769, DOI 10.1016/S0960-9822(01)00229-9; Murone M, 2000, NAT CELL BIOL, V2, P310, DOI 10.1038/35010610; Nakagawa H, 1999, JPN J CANCER RES, V90, P982, DOI 10.1111/j.1349-7006.1999.tb00845.x; Pearse RV, 1999, DEV BIOL, V212, P323, DOI 10.1006/dbio.1999.9335; Price MA, 2002, CELL, V108, P823, DOI 10.1016/S0092-8674(02)00664-5; Reddy S, 2001, MECH DEVELOP, V107, P69, DOI 10.1016/S0925-4773(01)00452-X; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Skousen GJ, 1996, AM J MED GENET, V66, P367, DOI 10.1002/(SICI)1096-8628(19961218)66:3<367::AID-AJMG27>3.3.CO;2-8; Steigerwald K, 2001, J MED GENET, V38, P257, DOI 10.1136/jmg.38.4.257; Stone DM, 1999, J CELL SCI, V112, P4437; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Taylor MD, 2002, NAT GENET, V31, P306, DOI 10.1038/ng916; Taylor MD, 2001, PEDIATR NEUROSURG, V35, P235, DOI 10.1159/000050428; Taylor MD, 1999, J NEUROSURG, V90, P946, DOI 10.3171/jns.1999.90.5.0946; Taylor MD, 2000, NEUROSURGERY, V47, P888, DOI 10.1097/00006123-200010000-00020; THOMAS KR, 1991, CELL, V67, P969, DOI 10.1016/0092-8674(91)90369-A; van Es JH, 1999, CURR BIOL, V9, P105, DOI 10.1016/S0960-9822(99)80024-4; Vortmeyer AO, 1999, CANCER, V85, P2662, DOI 10.1002/(SICI)1097-0142(19990615)85:12<2662::AID-CNCR24>3.0.CO;2-0; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; Wechsler-Reya RJ, 2003, RECENT PROG HORM RES, V58, P227, DOI 10.1210/rp.58.1.227; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Yokota N, 2002, INT J CANCER, V101, P198, DOI 10.1002/ijc.10559; YONG WH, 1995, NEW ENGL J MED, V333, P524; Zurawel RH, 1998, CANCER RES, V58, P896	53	59	60	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2004	23	26					4577	4583		10.1038/sj.onc.1207605	http://dx.doi.org/10.1038/sj.onc.1207605			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZV	15077159				2022-12-28	WOS:000221799000007
J	Yin, F; Bruemmer, D; Blaschke, F; Hsueh, WA; Law, RE; Van Herle, AJ				Yin, F; Bruemmer, D; Blaschke, F; Hsueh, WA; Law, RE; Van Herle, AJ			Signaling pathways involved in induction of GADD45 gene expression and apoptosis by troglitazone in human MCF-7 breast carcinoma cells	ONCOGENE			English	Article						troglitazone; breast cancer cell; GADD45; JNK; p38; ERK1/2	ACTIVATED RECEPTOR-GAMMA; PROTEIN-KINASE ACTIVATION; PPAR-GAMMA; POSTTRANSCRIPTIONAL REGULATION; LIGAND TROGLITAZONE; GROWTH-INHIBITION; CYCLE ARREST; COLON-CANCER; IN-VITRO; STRESS	We previously reported that the PPARgamma agonist troglitazone (TRO) inhibits proliferation and induces apoptosis in human MCF-7 breast carcinoma cells. To understand the mechanisms of antiproliferative and pro-apoptotic effects of TRO, we screened a limited DNA array containing 23 genes involved in regulating either the cell cycle and/or apoptosis. Four of the 23 genes screened exhibited regulation by TRO, with growth arrest and DNA damage-inducible gene 45 (GADD45) being the most strongly upregulated. TRO induced GADD45 mRNA expression in a time- and dose-dependent manner. Depletion of GADD45 by siRNA abrogated TRO-induced apoptosis in MCF-7 cells demonstrating the physiological relevance of GADD45 upregulation. Signaling pathways mediating TRO-induced GADD45 were also investigated. Several mitogen-activated protein kinase (MAPK) pathways were involved in the induction of GADD45 by TRO. Inhibition of the c-jun N-terminal kinase MAPK pathway by SP600125 partially abolished TRO-induced GADD45 mRNA, and protein expression and apoptosis. In contrast, inhibition of the p38 MAPK pathway by SB203580, or through overexpression of a dominant-negative mutant of p38 MAPK, augmented GADD45 mRNA induction and GADD45 promoter activation as well as cell apoptosis by TRO. Blockade of the extracellular signal-regulated kinase MAPK pathway by PD98059 also enhanced TRO's effects on GADD45 and apoptosis. Two other PPARgamma agonists pioglitazone and rosiglitazone did not induce GADD45 expression. Our finding of GADD45 induction by TRO may provide a new insight concerning the mechanisms for TRO's antiproliferative and pro-apoptotic effects in breast cancer cells.	Univ Calif Los Angeles, David Geffen Sch Med, Div Endocrinol Diabet & Hypertens, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Yin, F (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Endocrinol, 900 Vet Ave,24-130 Warren Hall, Los Angeles, CA 90024 USA.	fyin@mednet.ucla.edu						Asou H, 1999, INT J ONCOL, V15, P1027; Bae MA, 2003, MOL PHARMACOL, V63, P401, DOI 10.1124/mol.63.2.401; Begum NM, 2002, INT J ONCOL, V20, P599; Bruemmer D, 2003, CIRC RES, V93, pE38, DOI 10.1161/01.RES.0000088344.15288.E6; Carrier F, 1999, MOL CELL BIOL, V19, P1673; Chang TH, 2000, CANCER RES, V60, P1129; Chen C, 1998, AM J HEALTH-SYST PH, V55, P905, DOI 10.1093/ajhp/55.9.905; Chen F, 2001, ONCOGENE, V20, P3585, DOI 10.1038/sj.onc.1204442; CHEN IT, 1995, ONCOGENE, V11, P1931; Chitturi S, 2002, SEMIN LIVER DIS, V22, P169, DOI 10.1055/s-2002-30102; Clay CE, 1999, CARCINOGENESIS, V20, P1905, DOI 10.1093/carcin/20.10.1905; Demetri GD, 1999, P NATL ACAD SCI USA, V96, P3951, DOI 10.1073/pnas.96.7.3951; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; FUJIWARA T, 1988, DIABETES, V37, P1549, DOI 10.2337/diabetes.37.11.1549; Haydon RC, 2002, CLIN CANCER RES, V8, P1288; Hisatake J, 2000, CANCER RES, V60, P5494; Huin C, 2002, BIOL CELL, V94, P15, DOI 10.1016/S0248-4900(01)01178-9; KEARSEY JM, 1995, ONCOGENE, V11, P1675; Kostrubsky VE, 2000, DRUG METAB DISPOS, V28, P1192; Kubota T, 1998, CANCER RES, V58, P3344; Kultz D, 1998, J BIOL CHEM, V273, P13645, DOI 10.1074/jbc.273.22.13645; Lowell BB, 1999, CELL, V99, P239, DOI 10.1016/S0092-8674(00)81654-2; Mita H, 2002, MOL CELL BIOL, V22, P4544, DOI 10.1128/MCB.22.13.4544-4555.2002; Mossner R, 2002, J INVEST DERMATOL, V119, P576, DOI 10.1046/j.1523-1747.2002.01861.x; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; Osawa E, 2003, GASTROENTEROLOGY, V124, P361, DOI 10.1053/gast.2003.50067; Otto C, 2002, PHARMACOGENOMICS, V3, P99, DOI 10.1517/14622416.3.1.99; Palakurthi SS, 2001, CANCER RES, V61, P6213; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rishi AK, 1999, NUCLEIC ACIDS RES, V27, P3111, DOI 10.1093/nar/27.15.3111; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Rumi MAK, 2001, BRIT J CANCER, V84, P1640, DOI 10.1054/bjoc.2001.1821; Sakaue M, 1999, MOL PHARMACOL, V55, P668; Sarkar D, 2002, P NATL ACAD SCI USA, V99, P10054, DOI 10.1073/pnas.152327199; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; Sugimura A, 1999, BIOCHEM BIOPH RES CO, V261, P833, DOI 10.1006/bbrc.1999.1049; Takahashi S, 2001, CANCER RES, V61, P1187; Takashima T, 2001, INT J ONCOL, V19, P465; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Tong T, 2001, EXP CELL RES, V269, P64, DOI 10.1006/excr.2001.5312; Wang XT, 1999, J BIOL CHEM, V274, P29599, DOI 10.1074/jbc.274.42.29599; Yang WL, 2001, CARCINOGENESIS, V22, P1379, DOI 10.1093/carcin/22.9.1379; Yin F, 2001, BIOCHEM BIOPH RES CO, V286, P916, DOI 10.1006/bbrc.2001.5491; Yoshizawa K, 2002, CANCER-AM CANCER SOC, V95, P2243, DOI 10.1002/cncr.10906	47	74	77	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2004	23	26					4614	4623		10.1038/sj.onc.1207598	http://dx.doi.org/10.1038/sj.onc.1207598			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZV	15064713				2022-12-28	WOS:000221799000011
J	Yoshida, Y; Izumi, H; Torigoe, T; Ishiguchi, H; Yoshida, T; Itoh, H; Kohno, K				Yoshida, Y; Izumi, H; Torigoe, T; Ishiguchi, H; Yoshida, T; Itoh, H; Kohno, K			Binding of RNA to p53 regulates its oligomerization and DNA-binding activity	ONCOGENE			English	Article						p53; RNA; DNA binding; oligomerization; RNase	TUMOR-SUPPRESSOR PROTEIN; CASEIN KINASE-II; IN-VIVO; PHOSPHORYLATION; DOMAIN; SITE; ACTIVATION; GROWTH; POLYPEPTIDE; COMPLEXES	The C-terminus of p53 is responsible for maintaining the latent, non-DNA-binding form of p53. However, the mechanism by which the C-terminus regulates DNA binding is not yet fully understood. We show here that p53 interacts with RNA via its C-terminal domain and that disruption of this interaction, by RNase A treatment, truncation or phosphorylation of the C-terminus, restores DNA-binding activity. Furthermore, the oligomerization of p53 is significantly enhanced by disrupting the interaction between p53 and RNA. These findings suggest that binding of RNA to p53 is involved in the mechanism of p53 latency.	Univ Occupat & Environm Hlth, Sch Med, Dept Mol Biol, Yahatanishi Ku, Fukuoka 8078555, Japan; Univ Occupat & Environm Hlth, Sch Med, Dept Surg 1, Yahatanishi Ku, Fukuoka 8078555, Japan	University of Occupational & Environmental Health - Japan; University of Occupational & Environmental Health - Japan	Kohno, K (corresponding author), Univ Occupat & Environm Hlth, Sch Med, Dept Mol Biol, Yahatanishi Ku, 1-1 Iseigaoka, Fukuoka 8078555, Japan.	k-kohno@med.uoeh-u.ac.jp		Yoshida, Yoichiro/0000-0001-6583-7352				Ahn J, 2001, NAT STRUCT BIOL, V8, P730, DOI 10.1038/nsb0901-730; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; CLORE GM, 1995, NAT STRUCT BIOL, V2, P321, DOI 10.1038/nsb0495-321; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DU W, 1994, P NATL ACAD SCI USA, V91, P11318, DOI 10.1073/pnas.91.24.11318; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; FILHOL O, 1992, J BIOL CHEM, V267, P20577; FISCELLA M, 1994, ONCOGENE, V9, P3249; FONTOURA BMA, 1992, MOL CELL BIOL, V12, P5145, DOI 10.1128/MCB.12.11.5145; Fontoura BMA, 1997, MOL CELL BIOL, V17, P3146, DOI 10.1128/MCB.17.6.3146; FUCHS B, 1995, ONCOGENE, V10, P789; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Hao MM, 1996, J BIOL CHEM, V271, P29380, DOI 10.1074/jbc.271.46.29380; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Imamura T, 2001, J BIOL CHEM, V276, P7534, DOI 10.1074/jbc.M008143200; Izumi H, 2003, BIOCHEM J, V373, P713, DOI 10.1042/BJ20021902; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Keller DM, 2001, MOL CELL, V7, P283, DOI 10.1016/S1097-2765(01)00176-9; KULESZMARTIN MF, 1994, MOL CELL BIOL, V14, P1698, DOI 10.1128/MCB.14.3.1698; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; Marston NJ, 1998, ONCOGENE, V16, P3123, DOI 10.1038/sj.onc.1201856; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; Miller SJ, 2000, MOL CELL BIOL, V20, P8420, DOI 10.1128/MCB.20.22.8420-8431.2000; Minamoto T, 2001, ONCOGENE, V20, P3341, DOI 10.1038/sj.onc.1204458; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Okamoto T, 2000, ONCOGENE, V19, P6194, DOI 10.1038/sj.onc.1204029; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; SAMAD A, 1991, MOL CELL BIOL, V11, P1598, DOI 10.1128/MCB.11.3.1598; Torigoe T, 2003, NUCLEIC ACIDS RES, V31, P4523, DOI 10.1093/nar/gkg487; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; Yakovleva T, 2002, TRENDS BIOCHEM SCI, V27, P612, DOI 10.1016/S0968-0004(02)02209-0; Yoshida Y, 2003, CANCER RES, V63, P3729; Yoshida Y, 2002, BIOCHEM BIOPH RES CO, V295, P945, DOI 10.1016/S0006-291X(02)00757-X	43	30	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2004	23	25					4371	4379		10.1038/sj.onc.1207583	http://dx.doi.org/10.1038/sj.onc.1207583			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	824CJ	15064727				2022-12-28	WOS:000221661300003
J	Nimer, SD; Moore, MAS				Nimer, SD; Moore, MAS			Effects of the leukemia-associated AML1-ETO protein on hematopoietic stem and progenitor cells	ONCOGENE			English	Article						AML; AML1-ETO; stem cell biology; transcription factors	ACUTE MYELOID-LEUKEMIA; T(8/21) FUSION PROTEIN; ACUTE MYELOGENOUS LEUKEMIA; EMBRYONIC LETHALITY; MURINE MODEL; C/EBP-ALPHA; EXPRESSION; MOUSE; AML1/ETO; RECEPTOR	Insights into the pathogenesis of human leukemia have relied heavily on studies of the identified chromosomal translocations found in this group of malignant diseases. Acquired, balanced translocations in acute myclogenous leukemia (AML) generally involve transcriptional regulatory genes, whereas in the myeloproliferative disorders tyrosine kinases are frequently involved. These rearrangements alter the function of at least one and often both of the involved genes. In this review, we focus on the AML1-ETO (a. k. a. RUNX1-ETO) fusion protein, which is found in t(8; 21) + AML. Expression of AML1-ETO in human hematopoietic stem cells (HSCs) preferentially enhances their maintenance, as opposed to their differentiation. The direct effects of AML1-ETO on human and murine HSCs, and the potentially cooperating events that may contribute to its leukemogenic properties, are discussed.	Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Lab Mol Aspects Hematopoiesis, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Lab Dev Hematopoiesis, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Nimer, SD (corresponding author), Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Lab Mol Aspects Hematopoiesis, 1275 York Ave, New York, NY 10021 USA.	s-nimer@mskcc.org						Abu-Duhier FM, 2003, BRIT J HAEMATOL, V123, P749, DOI 10.1046/j.1365-2141.2003.04681.x; Alcalay M, 2003, J CLIN INVEST, V112, P1751, DOI 10.1172/JCI17595; Bernardi R, 2002, ONCOGENE, V21, P3445, DOI 10.1038/sj.onc.1205313; Bhardwaj G, 2001, NAT IMMUNOL, V2, P172, DOI 10.1038/84282; Bristow CAP, 2003, NUCLEIC ACIDS RES, V31, P2735, DOI 10.1093/nar/gkg401; Burel S, 2003, BLOOD, V102, p585A; CAMMENGA J, 2001, BLOOD, pA1183; Cao WS, 1997, ONCOGENE, V15, P1315, DOI 10.1038/sj.onc.1201305; Care RS, 2003, BRIT J HAEMATOL, V121, P775, DOI 10.1046/j.1365-2141.2003.04362.x; de Guzman CG, 2002, MOL CELL BIOL, V22, P5506, DOI 10.1128/MCB.22.15.5506-5517.2002; DEGREEF GE, 1995, LEUKEMIA, V9, P282; Elsasser A, 2003, ONCOGENE, V22, P5646, DOI 10.1038/sj.onc.1206673; FIALKOW PJ, 1967, P NATL ACAD SCI USA, V58, P1468, DOI 10.1073/pnas.58.4.1468; Forbes LV, 2002, ONCOGENE, V21, P5981, DOI 10.1038/sj.onc.1205767; Frank R, 1995, ONCOGENE, V11, P2667; Frank RC, 1999, ONCOGENE, V18, P1701, DOI 10.1038/sj.onc.1202459; Fukushima T, 2003, LEUKEMIA RES, V27, P387, DOI 10.1016/S0145-2126(02)00214-X; Grisolano JL, 2003, P NATL ACAD SCI USA, V100, P9506, DOI 10.1073/pnas.1531730100; GUERRASIO A, 1995, BRIT J HAEMATOL, V90, P364, DOI 10.1111/j.1365-2141.1995.tb05160.x; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; Jakubowiak A, 2000, J BIOL CHEM, V275, P40282, DOI 10.1074/jbc.C000485200; Jordan CT, 2000, LEUKEMIA, V14, P1777, DOI 10.1038/sj.leu.2401903; Kalev-Zylinska ML, 2002, DEVELOPMENT, V129, P2015; Kondo M, 2003, ANNU REV IMMUNOL, V21, P759, DOI 10.1146/annurev.immunol.21.120601.141007; Kottaridis PD, 2001, BLOOD, V98, P1752, DOI 10.1182/blood.V98.6.1752; Kung AL, 2000, GENE DEV, V14, P272; Lacorazza HD, 2002, BLOOD, V100, p59A; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Ley TJ, 2003, P NATL ACAD SCI USA, V100, P14275, DOI 10.1073/pnas.2335924100; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; Liu BL, 2003, EXP HEMATOL, V31, P824, DOI 10.1016/S0301-472X(03)00161-9; Liu JY, 2003, BLOOD, V102, P1815, DOI 10.1182/blood-2002-12-3772; Mao SF, 1999, MOL CELL BIOL, V19, P3635; Melnick AM, 2000, MOL CELL BIOL, V20, P2075, DOI 10.1128/MCB.20.6.2075-2086.2000; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Miyamoto T, 2000, P NATL ACAD SCI USA, V97, P7521, DOI 10.1073/pnas.97.13.7521; Mulloy JC, 2003, BLOOD, V102, P4369, DOI 10.1182/blood-2003-05-1762; Mulloy JC, 2002, BLOOD, V99, P15, DOI 10.1182/blood.V99.1.15; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Passegue E, 2001, CELL, V104, P21, DOI 10.1016/S0092-8674(01)00188-X; Phan VT, 2003, MOL CELL BIOL, V23, P4573, DOI 10.1128/MCB.23.13.4573-4585.2003; Rangarajan A, 2003, NAT REV CANCER, V3, P952, DOI 10.1038/nrc1235; Reuther GW, 2000, MOL CELL BIOL, V20, P8655, DOI 10.1128/MCB.20.23.8655-8666.2000; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rhoades KL, 2000, BLOOD, V96, P2108; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; Schwieger M, 2002, J EXP MED, V196, P1227, DOI 10.1084/jem.20020824; Shimada H, 2000, BLOOD, V96, P655; Smogorzewska A, 2002, EMBO J, V21, P4338, DOI 10.1093/emboj/cdf433; UCHIDA N, 1992, J EXP MED, V175, P175, DOI 10.1084/jem.175.1.175; Vangala RK, 2003, BLOOD, V101, P270, DOI 10.1182/blood-2002-04-1288; Wechsler J, 2002, NAT GENET, V32, P148, DOI 10.1038/ng955; Wiemels JL, 2002, BLOOD, V99, P3801, DOI 10.1182/blood.V99.10.3801; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Yuan YZ, 2001, P NATL ACAD SCI USA, V98, P10398, DOI 10.1073/pnas.171321298; Zheng R, 2003, BLOOD, V102, p363A	59	46	50	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2004	23	24					4249	4254		10.1038/sj.onc.1207673	http://dx.doi.org/10.1038/sj.onc.1207673			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823BZ	15156180				2022-12-28	WOS:000221586000009
J	Carretero, J; Medina, PP; Pio, R; Montuenga, LM; Sanchez-Cespedes, M				Carretero, J; Medina, PP; Pio, R; Montuenga, LM; Sanchez-Cespedes, M			Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene	ONCOGENE			English	Article						LKB1/STK11; Peutz-Jeghers syndrome; lung adenocarcinomas	PEUTZ-JEGHERS-SYNDROME; SYNDROME KINASE LKB1; SOMATIC MUTATIONS; TOBACCO-SMOKE; DNA-DAMAGE; GROWTH; ADENOCARCINOMA; PATTERNS; ARREST; COMMON	Germline mutations of the LKB1 gene are responsible for Peutz-Jeghers syndrome (PJS), an autosomal dominant inherited disorder bestowing an increased risk of cancer. We have recently demonstrated that LKB1 inactivating mutations are not confined to PJS, but also appear in lung adenocarcinomas of sporadic origin, including primary tumors and lung cancer cell lines. To accurately determine the frequency of inactivating LKB1 gene mutations in lung tumors we have sequenced the complete coding region of LKB1 in 21 additional lung cancer cell lines. Here we describe the mutational status of LKB1 gene in 30 lung cancer cell lines from different histopathological types, including 11 lung adenocarcinomas (LADs) and 11 small cell lung cancers (SCLCs). LKB1 gene alterations were present in six (54%) of the LAD cell lines tested but in none of the other histological types. Similar to our previous observations in primary tumors, all point mutations were of the nonsense or frameshift type, leading to an abnormal, truncated protein. Moreover, 2 cell lines (A427 and H2126) harbored large gene deletions that spanned several exons. Hence, we have identified additional lung cancer cell lines carrying inactivating mutations of the LKB1 tumor suppressor gene, further attesting to the significance of this gene in the development of LADs and providing new natural LKB1 knockouts for studies of the biological function of the LKB1 protein.	CNIO, Mol Pathol Program, Lymphoma & Lung Canc Grp, Madrid 28029, Spain; Univ Navarra, Sch Med, Fdn Appl Med Res, Dept Biochem, E-31080 Pamplona, Spain; Univ Navarra, Sch Med, Fdn Appl Med Res, Dept Histol & Pathol, E-31080 Pamplona, Spain; Univ Navarra, Sch Med, Fdn Appl Med Res, Div Oncol, E-31080 Pamplona, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); University of Navarra; University of Navarra; University of Navarra	Sanchez-Cespedes, M (corresponding author), CNIO, Mol Pathol Program, Lymphoma & Lung Canc Grp, Calle Melchor Fernandez Almagro 3, Madrid 28029, Spain.	msanchez@cnio.es	Pio, Ruben/F-5353-2017; Carretero, Julian/N-5214-2014; Montuenga, Luis M/AAF-7783-2020; Vico, Pedro Pablo Medina/D-1688-2013; Sanchez-Cespedes, Montse/H-8485-2012	Pio, Ruben/0000-0002-6831-6111; Carretero, Julian/0000-0001-7269-8506; Montuenga, Luis M/0000-0002-8739-1387; Vico, Pedro Pablo Medina/0000-0002-7834-7093; Sanchez-Cespedes, Montse/0000-0002-6045-5627				Ahrendt SA, 2001, CANCER, V92, P1525, DOI 10.1002/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO;2-H; Avizienyte E, 1999, AM J PATHOL, V154, P677, DOI 10.1016/S0002-9440(10)65314-X; Baas AF, 2003, EMBO J, V22, P3062, DOI 10.1093/emboj/cdg292; Boudeau J, 2003, EMBO J, V22, P5102, DOI 10.1093/emboj/cdg490; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404; Hainaut P, 2001, CARCINOGENESIS, V22, P367, DOI 10.1093/carcin/22.3.367; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Jimenez AI, 2003, CANCER RES, V63, P1382; Karuman P, 2001, MOL CELL, V7, P1307, DOI 10.1016/S1097-2765(01)00258-1; Marignani PA, 2001, J BIOL CHEM, V276, P32415, DOI 10.1074/jbc.C100207200; Miyaki M, 2000, CANCER RES, V60, P6311; Pfeifer GP, 2002, ONCOGENE, V21, P7435, DOI 10.1038/sj.onc.1205803; Sanchez-Cespedes M, 2003, LUNG CANCER, V40, P111, DOI 10.1016/S0169-5002(03)00033-3; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Sanchez-Cespedes M, 2001, CANCER RES, V61, P1309; Smith DP, 2001, HUM MOL GENET, V10, P2869, DOI 10.1093/hmg/10.25.2869; Spicer J, 2003, ONCOGENE, V22, P4752, DOI 10.1038/sj.onc.1206669; Su GH, 1999, AM J PATHOL, V154, P1835, DOI 10.1016/S0002-9440(10)65440-5; Tiainen M, 1999, P NATL ACAD SCI USA, V96, P9248, DOI 10.1073/pnas.96.16.9248; Virmani AK, 1998, GENE CHROMOSOME CANC, V21, P308, DOI 10.1002/(SICI)1098-2264(199804)21:4<308::AID-GCC4>3.0.CO;2-2; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031	24	106	109	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					4037	4040		10.1038/sj.onc.1207502	http://dx.doi.org/10.1038/sj.onc.1207502			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15021901	Green Published			2022-12-28	WOS:000221382000017
J	Ren, Y; Roy, S; Ding, Y; Iqbal, J; Broome, JD				Ren, Y; Roy, S; Ding, Y; Iqbal, J; Broome, JD			Methylation of the asparagine synthetase promoter in human leukemic cell lines is associated with a specific methyl binding protein	ONCOGENE			English	Article						methyl binding protein; asparagine synthetase; leukemia	SENSING RESPONSE PATHWAY; DNA METHYLATION; GENE; IDENTIFICATION; TRANSCRIPTION; EXPRESSION; REPRESSION; MEDIATOR; FAMILY; SITE	We have examined the methylation profiles of the asparagine synthetase (ASY) promoter in a number of human leukemic cell lines in relation to their asparagine (ASN) requirements in vitro. Cells in which the promoter is highly methylated are auxotrophs and express ASY at very low levels. Electromobility shift assays ( EMSA) of nuclear extracts with oligomers from the promoting region show, in addition to recognized transcription factor binding, a novel methyl binding protein specific for a 12 base consensus sequence, which includes a single methylated CpG. This sequence overlaps that of the amino-acid response unit of the ASY promoter, which is activated byATF4 and C/EBP. Competition by the methyl binding protein could account for the observed failure of the methylated promoter to bind these transcription factors and consequently, although other mechanisms can also be operative, for the specific repression of the gene. The ASY methyl binding protein (ASMB) is present in leukemic lymphoid and myeloid cells irrespective of their methylation status, and in normal lymphocytes after phytohemagglutinin stimulation. It has been purified by affinity chromatography and has a molecular size of 40 kDa in 10% SDS-polyacrylamide gels.	N Shore Univ Hosp, Dept Pathol, Manhasset, NY 11030 USA; NYU, Sch Med, Dept Pathol, New York, NY 10017 USA	Northwell Health; North Shore University Hospital; New York University	Broome, JD (corresponding author), N Shore Univ Hosp, Dept Pathol, Manhasset, NY 11030 USA.	jbroome@nshs.edu						ANDRULIS IL, 1987, MOL CELL BIOL, V7, P2435, DOI 10.1128/MCB.7.7.2435; Ballestar E, 2003, EMBO J, V22, P6335, DOI 10.1093/emboj/cdg604; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; BROOME JD, 1963, J EXP MED, V118, P99, DOI 10.1084/jem.118.1.99; BROOME JD, 1968, J EXP MED, V127, P1055, DOI 10.1084/jem.127.6.1055; Daniel JM, 2002, NUCLEIC ACIDS RES, V30, P2911, DOI 10.1093/nar/gkf398; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Drexler HG., 2001, LEUKEMIA LYMPHOMA CE, P2, DOI [10.1016/B978-012221970-2/50002-4, DOI 10.1016/B978-012221970-2/50002-4]; Ehrlich M., 1993, Experientia Supplementum (Basel), V64, P145; Feng Q, 2001, GENE DEV, V15, P827; Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332; GRECO A, 1989, MOL CELL BIOL, V9, P2350, DOI 10.1128/MCB.9.6.2350; GUERRINI L, 1993, MOL CELL BIOL, V13, P3202, DOI 10.1128/MCB.13.6.3202; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; HOLLER M, 1988, GENE DEV, V2, P1127, DOI 10.1101/gad.2.9.1127; Jones PA, 2002, ONCOGENE, V21, P5358, DOI 10.1038/sj.onc.1205597; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Jost J P, 1993, EXS, V64, P425; JOST JP, 1992, P NATL ACAD SCI USA, V89, P9499, DOI 10.1073/pnas.89.20.9499; KHAN R, 1988, J BIOL CHEM, V263, P14374; Matheson EC, 2003, CARCINOGENESIS, V24, P31, DOI 10.1093/carcin/24.1.31; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; Peng H, 2001, BRIT J CANCER, V85, P930, DOI 10.1054/bjoc.2001.2000; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/bj20020508; Sengupta PK, 1999, J BIOL CHEM, V274, P36649, DOI 10.1074/jbc.274.51.36649; Siu F, 2001, J BIOL CHEM, V276, P48100, DOI 10.1074/jbc.M109533200; Siu F, 2002, J BIOL CHEM, V277, P24120, DOI 10.1074/jbc.M201959200; Wade PA, 2001, ONCOGENE, V20, P3166, DOI 10.1038/sj.onc.1204340; Yoon HG, 2003, MOL CELL, V12, P723, DOI 10.1016/j.molcel.2003.08.008; ZHANG XY, 1993, MOL CELL BIOL, V13, P6810, DOI 10.1128/MCB.13.11.6810; Zhong C, 2003, BIOCHEM J, V372, P603, DOI 10.1042/BJ20030076	35	21	22	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					3953	3961		10.1038/sj.onc.1207498	http://dx.doi.org/10.1038/sj.onc.1207498			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15048083				2022-12-28	WOS:000221382000007
J	Yang, YG; Cortes, U; Patnaik, S; Jasin, M; Wang, ZQ				Yang, YG; Cortes, U; Patnaik, S; Jasin, M; Wang, ZQ			Ablation of PARP-1 does not interfere with the repair of DNA double-strand breaks, but compromises the reactivation of stalled replication forks	ONCOGENE			English	Article						poly(ADP-ribose) polymerase-1; Rad51; homologous recombination; DNA double-strand break repair; replication stall and progression	SISTER-CHROMATID EXCHANGES; HOMOLOGY-DIRECTED REPAIR; POLY(ADP-RIBOSE) POLYMERASE; S-PHASE; RECOMBINATION; DAMAGE; RAD51; STABILITY; PROTEIN; GENOME	Poly(ADP-ribose) polymerase-1 (PARP-1) is an abundant DNA end-sensing and binding molecule. Inactivation of PARP-1 by chemicals and genetic mutations slows cell proliferation, increases sister chromatid exchange (SCE), micronuclei formation and chromosome instability, and shortens telomeres. Given its affinity to DNA breaks and temporal occupation on DNA strand break sites, PARP-1 is proposed to prevent inappropriate DNA recombination. We investigated the potential role of PARP-1 in repair of DNA double-strand breaks (DSBs) and stalled replication forks. PARP-1-/- embryonic stem cells and embryonic fibroblast cells exhibited normal repair of DNA DSBs by either homologous recombination (HR) or nonhomologous end-joining(NHEJ) pathways. Inactivation of PARP-1 did not interfere with gene-targeting efficiency in ES cells. However, PARP-1-/- cells were hypersensitive to the replication damage agent hydroxyurea (HU)-induced cell death and exhibited enhanced SCE formation. Ablation of PARP-1 delayed reactivation of stalled replication forks imposed by HU and re-entry into the G2-M phase after HU release. These data indicate that PARP-1 is dispensable in HR induced by DSBs, but is involved in the repair and reactivation of stalled replication forks.	Int Agcy Res Canc, F-69008 Lyon, France; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	World Health Organization; International Agency for Research on Cancer (IARC); Memorial Sloan Kettering Cancer Center	Wang, ZQ (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69008 Lyon, France.	zqwang@iarc.fr	Yang, Yungui/ABF-2507-2021					Ariumi Y, 1999, ONCOGENE, V18, P4616, DOI 10.1038/sj.onc.1202823; Boulton SJ, 2002, SCIENCE, V295, P127, DOI 10.1126/science.1065986; Burkle A, 2001, BIOESSAYS, V23, P795, DOI 10.1002/bies.1115; CORTES F, 1993, MUTAT RES, V303, P71, DOI 10.1016/0165-7992(93)90097-F; Cox MM, 2001, ANNU REV GENET, V35, P53, DOI 10.1146/annurev.genet.35.102401.090016; COX MM, 2002, MUTAT RES, V10, P107; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Dronkert MLG, 2000, MOL CELL BIOL, V20, P3147, DOI 10.1128/MCB.20.9.3147-3156.2000; Galande S, 1999, J BIOL CHEM, V274, P20521, DOI 10.1074/jbc.274.29.20521; Henrie MS, 2003, DNA REPAIR, V2, P151, DOI 10.1016/S1568-7864(02)00199-4; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; IKUSHIMA T, 1990, CHROMOSOMA, V99, P360, DOI 10.1007/BF01731724; Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687; Krejci L, 2003, NATURE, V423, P305, DOI 10.1038/nature01577; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; Lundin C, 2002, MOL CELL BIOL, V22, P5869, DOI 10.1128/MCB.22.16.5869-5878.2002; Masson JY, 2001, TRENDS BIOCHEM SCI, V26, P131, DOI 10.1016/S0968-0004(00)01742-4; McGlynn P, 2002, NAT REV MOL CELL BIO, V3, P859, DOI 10.1038/nrm951; Menissier-de Murcia J, 2001, MOL CELL BIOL, V21, P1828; Morrison C, 1997, NAT GENET, V17, P479, DOI 10.1038/ng1297-479; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Pierce AJ, 2001, GENE DEV, V15, P3237, DOI 10.1101/gad.946401; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; RAINALDI G, 1984, CHROMOSOMA, V90, P46, DOI 10.1007/BF00352277; Richardson C, 1998, GENE DEV, V12, P3831, DOI 10.1101/gad.12.24.3831; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; Schultz N, 2003, NUCLEIC ACIDS RES, V31, P4959, DOI 10.1093/nar/gkg703; SimbulanRosenthal CM, 1996, BIOCHEMISTRY-US, V35, P11622, DOI 10.1021/bi953010z; Sogo JM, 2002, SCIENCE, V297, P599, DOI 10.1126/science.1074023; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; Tarsounas M, 2003, ONCOGENE, V22, P1115, DOI 10.1038/sj.onc.1206263; Tashiro S, 2000, J CELL BIOL, V150, P283, DOI 10.1083/jcb.150.2.283; Tauchi H, 2002, NATURE, V420, P93, DOI 10.1038/nature01125; Tong WM, 2001, MOL CELL BIOL, V21, P4046, DOI 10.1128/MCB.21.12.4046-4054.2001; Tong WM, 2003, AM J PATHOL, V162, P343, DOI 10.1016/S0002-9440(10)63825-4; Tong WM, 2001, BBA-REV CANCER, V1552, P27, DOI 10.1016/S0304-419X(01)00035-X; Tong WM, 2000, COLD SPRING HARB SYM, V65, P583, DOI 10.1101/sqb.2000.65.583; Tong WM, 2002, CANCER RES, V62, P6990; Veaute X, 2003, NATURE, V423, P309, DOI 10.1038/nature01585; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; Wesierska-Gadek J, 1999, CANCER RES, V59, P28	45	189	195	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2004	23	21					3872	3882		10.1038/sj.onc.1207491	http://dx.doi.org/10.1038/sj.onc.1207491			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	818JX	15021907				2022-12-28	WOS:000221242500014
J	Yoshida, K; Inoue, I				Yoshida, K; Inoue, I			Regulation of Geminin and Cdt1 expression by E2F transcription factors	ONCOGENE			English	Article						Geminin; Cdt1; DNA replication; promoter; transcription; E2F	CELL-CYCLE REGULATION; MURINE THYMIDINE KINASE; DNA-REPLICATION; RETINOBLASTOMA PROTEIN; S-PHASE; DISTINCT ROLES; FAMILY-MEMBERS; BINDING-SITE; IN-VIVO; E GENE	Geminin and Cdt1 play an essential role in the initiation of DNA replication, by regulating the chromatin loading of the MCM complex. In this study, we showed that the transcription of human Geminin and Cdt1, as well as that of MCM7, is activated by transcription factors E2F1-4, but not by factors E2F5-7. Analysis of various Geminin and Cdt1 promoter constructs showed that an E2F-responsive sequence in the vicinity of the transcription initiation site is necessary for the transcriptional activation. The promoter activity for human Geminin was activated by the E7, but not E6, oncogene of human papillomavirus type 16. While E2F1-induced activation of human Cdt1 gene transcription was suppressed by pRb, but not by p107 or p130, its E2F4-induced activation was suppressed by pRb, p107, and p130. Furthermore, the promoter activities of human Geminin and Cdt1 were demonstrated to be growth-dependent. Taken together, the results demonstrate that Geminin and Cdt1 constitute targets for various members of the E2F family of transcription factors, and that expression of Geminin and Cdt1 is perhaps mediated by the activation of a pRb/E2F pathway.	Univ Tokyo, Inst Med Sci, Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Yoshida, K (corresponding author), Univ Tokyo, Inst Med Sci, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	yoshidak@ims.u-tokyo.ac.jp						BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; Botz J, 1996, MOL CELL BIOL, V16, P3401; Boyer SN, 1996, CANCER RES, V56, P4620; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; de Bruin A, 2003, J BIOL CHEM, V278, P42041, DOI 10.1074/jbc.M308105200; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Dhar SK, 2001, CELL, V106, P287, DOI 10.1016/S0092-8674(01)00458-5; Duronio RJ, 1998, MOL CELL BIOL, V18, P141, DOI 10.1128/MCB.18.1.141; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; FURUKAWA Y, 1994, J BIOL CHEM, V269, P26249; Geng Y, 1996, ONCOGENE, V12, P1173; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Hansel DE, 2003, AM J PATHOL, V163, P217, DOI 10.1016/S0002-9440(10)63645-0; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; Huet X, 1996, MOL CELL BIOL, V16, P3789; Humbert PO, 2000, GENE DEV, V14, P690; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; Kulartz M, 2003, BIOCHEM BIOPH RES CO, V305, P412, DOI 10.1016/S0006-291X(03)00773-3; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Li Q, 1999, MOL CELL BIOL, V19, P5339; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Mai S, 1996, ONCOGENE, V12, P277; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Nishitani H, 2001, J BIOL CHEM, V276, P44905, DOI 10.1074/jbc.M105406200; OGRIS E, 1993, J VIROL, V67, P1765, DOI 10.1128/JVI.67.4.1765-1771.1993; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Ohtani K, 1998, ONCOGENE, V17, P1777, DOI 10.1038/sj.onc.1202105; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; Ohtani K, 1999, ONCOGENE, V18, P2299, DOI 10.1038/sj.onc.1202544; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; Rotheneder H, 1999, J MOL BIOL, V293, P1005, DOI 10.1006/jmbi.1999.3213; Schlisio S, 2002, EMBO J, V21, P5775, DOI 10.1093/emboj/cdf577; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shohet JM, 2002, CANCER RES, V62, P1123; Slansky JE, 1996, BIOESSAYS, V18, P55, DOI 10.1002/bies.950180111; Suzuki S, 1998, GENE, V216, P85, DOI 10.1016/S0378-1119(98)00323-0; Takahashi Y, 2000, GENE DEV, V14, P804; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Wohlschlegel JA, 2002, AM J PATHOL, V161, P267, DOI 10.1016/S0002-9440(10)64178-8; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603; ZHANG YH, 1995, ONCOGENE, V10, P2085; zur Hausen H, 1999, SEMIN CANCER BIOL, V9, P405, DOI 10.1006/scbi.1999.0144	54	82	87	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 6	2004	23	21					3802	3812		10.1038/sj.onc.1207488	http://dx.doi.org/10.1038/sj.onc.1207488			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	818JX	14990995				2022-12-28	WOS:000221242500007
J	Dai, Q; Liu, JH; Chen, J; Durrant, D; McIntyre, TM; Lee, RM				Dai, Q; Liu, JH; Chen, J; Durrant, D; McIntyre, TM; Lee, RM			Mitochondrial ceramide increases in UV-irradiated HeLa cells and is mainly derived from hydrolysis of sphingomyelin	ONCOGENE			English	Article						apoptosis; mitochondria; sphingomyelin; ceramide; D609; myriocin; fumonicin B	KINASE-C-DELTA; NOVO SPHINGOLIPID BIOSYNTHESIS; NF-KAPPA-B; CYTOCHROME-C; SERINE PALMITOYLTRANSFERASE; INDUCED APOPTOSIS; CASPASE ACTIVATION; ENDONUCLEASE-G; DISTINCT POOL; P53 PROTEIN	Sphingolipids are important signaling molecules in many biologic processes, but little is known about their organelle-specific roles. Using HeLa cells, we investigated the effects of UV and etoposide-induced apoptosis on the contents of sphingomyelin (SM) and ceramide in subcellular compartments. UV irradiation of HeLa cells increased the levels of SM in all subcellular fractions, but the change was most dramatic in mitochondria. Using diacylglycerol kinase assays to quantify ceramide, we found that the levels of ceramide in mitochondria increased as early as 2 h after UV irradiation and remained elevated at 6 h. The increase in mitochondrial SM and ceramide was inhibited by D609, an inhibitor of sphingomyelinase and SM synthase. The inhibition of sphingolipid production correlated with protection of the mitochondrial transmembrane potential and prevention of cytochrome c release following UV irradiation. In contrast, myriocin, an inhibitor of the de novo ceramide synthesis pathway, only partially suppressed the production of ceramides in mitochondria and cannot suppress UV-induced apoptosis. Fumonicin B1, an inhibitor of ceramide synthase, can only prevent mitochondrial ceramide synthesis and UV-induced apoptosis in a small degree. These results indicate that mitochondrial ceramide production in UV-irradiated HeLa cells is not mediated by the de novo synthesis pathway, but mainly through SM hydrolysis.	Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; Univ Utah, Sect Oncol, Salt Lake City, UT 84112 USA; Univ Utah, Sch Med, Dept Internal Med, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Lee, RM (corresponding author), Univ Utah, Huntsman Canc Inst, 2000 Circle Hope,Suite 5244, Salt Lake City, UT 84112 USA.	ray.lee@hci.utah.edu			NCI NIH HHS [K08CA795093] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Bejaoui K, 2002, J CLIN INVEST, V110, P1301, DOI 10.1172/JCI200216450; Bielawska A, 2001, ANAL BIOCHEM, V298, P141, DOI 10.1006/abio.2001.5342; Birbes H, 2002, ADV ENZYME REGUL, V42, P113, DOI 10.1016/S0065-2571(01)00026-7; Birbes H, 2001, FASEB J, V15, P2669, DOI 10.1096/fj.01-0539com; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brenner C, 2000, SCIENCE, V289, P1150, DOI 10.1126/science.289.5482.1150; Cory S, 1998, BBA-REV CANCER, V1377, pR25, DOI 10.1016/S0304-419X(98)00003-1; Cowen DS, 1996, J BIOL CHEM, V271, P22297, DOI 10.1074/jbc.271.37.22297; Dawkins JL, 2001, NAT GENET, V27, P309, DOI 10.1038/85879; Deng J, 2002, ONCOGENE, V21, P44, DOI 10.1038/sj.onc.1204900; Denning MF, 2002, CELL DEATH DIFFER, V9, P40, DOI 10.1038/sj.cdd.4400929; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; El Bawab S, 2000, J BIOL CHEM, V275, P21508, DOI 10.1074/jbc.M002522200; El Bawab S, 2001, J BIOL CHEM, V276, P16758, DOI 10.1074/jbc.M009331200; FINE JB, 1982, J LIPID RES, V23, P660; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; Garcia-Ruiz C, 2003, J CLIN INVEST, V111, P197, DOI 10.1172/JCI200316010; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; Grether-Beck S, 2000, EMBO J, V19, P5793, DOI 10.1093/emboj/19.21.5793; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Hodgkin MN, 1998, TRENDS BIOCHEM SCI, V23, P200, DOI 10.1016/S0968-0004(98)01200-6; Ito Y, 2001, CELL DEATH DIFFER, V8, P794, DOI 10.1038/sj.cdd.4400886; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Kirschnek S, 2000, J BIOL CHEM, V275, P27316; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Li LW, 1999, MOL CELL BIOL, V19, P8547; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LINARDIC CM, 1994, J BIOL CHEM, V269, P23530; Linn SC, 2001, BIOCHEM SOC T, V29, P831, DOI 10.1042/0300-5127:0290831; Liu JH, 2003, CANCER RES, V63, P1153; Luberto C, 1998, J BIOL CHEM, V273, P14550, DOI 10.1074/jbc.273.23.14550; Luberto C, 2000, J BIOL CHEM, V275, P14760, DOI 10.1074/jbc.275.19.14760; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Merrill AH, 2002, J BIOL CHEM, V277, P25843, DOI 10.1074/jbc.R200009200; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Parrish J, 2001, NATURE, V412, P90, DOI 10.1038/35083608; Perry DK, 2000, J BIOL CHEM, V275, P9078, DOI 10.1074/jbc.275.12.9078; Perry DK, 2000, METHOD ENZYMOL, V312, P22; Perry DK, 2000, ANN NY ACAD SCI, V905, P91; Pettus BJ, 2002, BBA-MOL CELL BIOL L, V1585, P114, DOI 10.1016/S1388-1981(02)00331-1; Richter C, 1999, BIOCHEM SOC SYMP, V66, P27, DOI 10.1042/bss0660027; Sansome C, 2001, FEBS LETT, V488, P110, DOI 10.1016/S0014-5793(00)02368-1; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Schmelz EM, 2000, J NUTR, V130, P522, DOI 10.1093/jn/130.3.522; Schmelz EM, 2001, CANCER RES, V61, P6723; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; Shimeno H, 1998, LIPIDS, V33, P601, DOI 10.1007/s11745-998-0246-2; Sumitomo M, 2002, J CLIN INVEST, V109, P827, DOI 10.1172/JCI200214146; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Uchida Y, 2003, J INVEST DERMATOL, V120, P662, DOI 10.1046/j.1523-1747.2003.12098.x; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang XD, 2001, GENE DEV, V15, P2922; Zhang P, 1997, J BIOL CHEM, V272, P9609	61	69	69	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3650	3658		10.1038/sj.onc.1207430	http://dx.doi.org/10.1038/sj.onc.1207430			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15077187				2022-12-28	WOS:000221101700017
J	Plug-DeMaggio, AW; Sundsvold, T; Wurscher, MA; Koop, JI; Klingelhutz, AJ; McDougall, JK				Plug-DeMaggio, AW; Sundsvold, T; Wurscher, MA; Koop, JI; Klingelhutz, AJ; McDougall, JK			Telomere erosion and chromosomal instability in cells expressing the HPV oncogene 16E6	ONCOGENE			English	Article						human papillomavirus; telomere erosion; HPV 16E6; chromosomal instability; tumorigenesis; anaphase bridges	HUMAN-PAPILLOMAVIRUS TYPE-16; HUMAN EPITHELIAL-CELLS; E6 ONCOPROTEIN; HUMAN KERATINOCYTES; CERVICAL-CARCINOMA; RECURRENT PATTERN; E7 ONCOPROTEIN; GENE-PRODUCT; HTERT GENE; INACTIVATION	Progression to advanced-stage cervical carcinomas is characterized by a recurrent pattern of chromosomal rearrangements. Structural chromosome rearrangements are generated through the fusion of broken chromosome ends. These chromosome breaks may be induced by mutagenic agents such as ionizing radiation, or chromosome ends may be exposed through extensive telomere shortening. The human papilloma virus oncogene 16E6 induces telomerase activity in human keratinocytes, a model system for cervical tumor formation. The present study explores the relationship between 16E6 expression, telomerase activity, and chromosomal instability. We show that the frequency of anaphase bridges is dependent on the level of telomerase activity in 16E6/E7-expressing clones, and is the result of telomere shortening. High frequencies of anaphase bridges, associated with low telomerase activity, correlate with increased chromosome instability. Anaphase bridge formation is also associated with the presence of micronuclei, which are shown to contain unstable chromosomes frequently involved in rearrangements. As anaphase bridges are observed in both high and low telomerase 16E6/E7 clones, but not in hTERT-expressing control clones, expression of 16E6 in these immortalized clones is not sufficient to stabilize shortened telomeres completely. We suggest a model in which HPV-induced tumorigenesis may be dependent on persistent bridge - breakage - fusion cycles that allow for continued genomic rearrangements.	Fred Hutchinson Canc Res Ctr, Canc Biol Program, Seattle, WA 98109 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Plug-DeMaggio, AW (corresponding author), Fred Hutchinson Canc Res Ctr, Canc Biol Program, 1100 Fairview Ave N, Seattle, WA 98109 USA.	ademaggi@fhcrc.org	Klingelhutz, Aloysius/L-9081-2018	Klingelhutz, Aloysius/0000-0003-4258-5046				Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Baege AC, 2002, AM J PATHOL, V160, P1251, DOI 10.1016/S0002-9440(10)62552-7; Chang S, 2001, SEMIN CANCER BIOL, V11, P227, DOI 10.1006/scbi.2000.0374; Demers GW, 1996, J VIROL, V70, P6862, DOI 10.1128/JVI.70.10.6862-6869.1996; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Duensing S, 2002, CANCER RES, V62, P7075; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Filatov L, 1998, ONCOGENE, V16, P1825, DOI 10.1038/sj.onc.1201711; FORD JH, 1988, AM J HUM GENET, V43, P733; Gisselsson D, 2001, AM J PATHOL, V158, P199, DOI 10.1016/S0002-9440(10)63958-2; Gisselsson D, 2001, P NATL ACAD SCI USA, V98, P12683, DOI 10.1073/pnas.211357798; Gisselsson D, 2000, P NATL ACAD SCI USA, V97, P5357, DOI 10.1073/pnas.090013497; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Helt AM, 2002, J VIROL, V76, P10559, DOI 10.1128/JVI.76.20.10559-10568.2002; Heselmeyer K, 1997, GENE CHROMOSOME CANC, V19, P233, DOI 10.1002/(SICI)1098-2264(199708)19:4<233::AID-GCC5>3.0.CO;2-Y; Heselmeyer K, 1996, P NATL ACAD SCI USA, V93, P479, DOI 10.1073/pnas.93.1.479; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; Kirchhoff M, 1999, GENE CHROMOSOME CANC, V24, P144, DOI 10.1002/(SICI)1098-2264(199902)24:2<144::AID-GCC7>3.0.CO;2-9; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lundblad V, 2000, MUTAT RES-FUND MOL M, V451, P227, DOI 10.1016/S0027-5107(00)00052-X; Maser RS, 2002, SCIENCE, V297, P565, DOI 10.1126/science.297.5581.565; Matthews CP, 2000, P SOC EXP BIOL MED, V223, P316, DOI 10.1046/j.1525-1373.2000.22345.x; McClintock B, 1941, GENETICS, V26, P234; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; MUNGER K, 1989, J VIROL, V63, P4417; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; O'Sullivan JN, 2002, NAT GENET, V32, P280, DOI 10.1038/ng989; Plug-Demaggio AW, 2002, ONCOGENE, V21, P7507, DOI 10.1038/sj.onc.1205903; Rudolph KL, 2001, NAT GENET, V28, P155, DOI 10.1038/88871; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Veldman T, 2001, J VIROL, V75, P4467, DOI 10.1128/JVI.75.9.4467-4472.2001; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	37	52	53	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3561	3571		10.1038/sj.onc.1207388	http://dx.doi.org/10.1038/sj.onc.1207388			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15077181				2022-12-28	WOS:000221101700007
J	Fingar, DC; Blenis, J				Fingar, DC; Blenis, J			Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression	ONCOGENE			English	Review						TOR; rapamycin; S6K1; 4E-BP1; cell growth	P70 S6 KINASE; ACTIVATED PROTEIN-KINASE; TUBEROUS SCLEROSIS COMPLEX-1; MESSENGER-RNA TRANSLATION; CYTOSOLIC-BINDING-PROTEIN; TUMOR-SUPPRESSOR GENE; REPRESSOR PHAS-I; MAMMALIAN TARGET; AMINO-ACID; FKBP12-RAPAMYCIN-ASSOCIATED PROTEIN	Cell growth (an increase in cell mass and size through macromolecular biosynthesis) and cell cycle progression are generally tightly coupled, allowing cells to proliferate continuously while maintaining their size. The target of rapamycin (TOR) is an evolutionarily conserved kinase that integrates signals from nutrients (amino acids and energy) and growth factors (in higher eukaryotes) to regulate cell growth and cell cycle progression coordinately. In mammals, TOR is best known to regulate translation through the ribosomal protein S6 kinases (S6Ks) and the eukaryotic translation initiation factor 4E-binding proteins. Consistent with the contribution of translation to growth, TOR regulates cell, organ, and organismal size. The identification of the tumor suppressor proteins tuberous sclerosis1 and 2 (TSC1 and 2) and Ras-homolog enriched in brain (Rheb) has biochemically linked the TOR and phosphatidylinositol 3-kinase (PI3K) pathways, providing a mechanism for the crosstalk that occurs between these pathways. TOR is emerging as a novel antitumor target, since the TOR inhibitor rapamycin appears to be effective against tumors resulting from aberrantly high PI3K signaling. Not only may inhibition of TOR be effective in cancer treatment, but rapamycin is an FDA-approved immunosuppressive and cardiology drug. We review here what is known (and not known) about the function of TOR in cellular and animal physiology.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Univ Michigan, Sch Med, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA	Harvard University; Harvard Medical School; University of Michigan System; University of Michigan	Blenis, J (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.	john_blenis@hms.harvard.edu			NIGMS NIH HHS [GM051405] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; Abraham RT, 2002, CELL, V111, P9, DOI 10.1016/S0092-8674(02)01009-7; Alarcon CM, 1999, MOL BIOL CELL, V10, P2531, DOI 10.1091/mbc.10.8.2531; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Alvarez B, 2003, J BIOL CHEM, V278, P26466, DOI 10.1074/jbc.M300663200; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Beugnet A, 2003, BIOCHEM J, V372, P555, DOI 10.1042/BJ20021266; Biondi RM, 2001, EMBO J, V20, P4380, DOI 10.1093/emboj/20.16.4380; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; Bohni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0; Braun-Dullaeus RC, 2001, ARTERIOSCL THROM VAS, V21, P1152, DOI 10.1161/hq0701.092104; Brennan P, 1999, MOL CELL BIOL, V19, P4729; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Castro AF, 2003, J BIOL CHEM, V278, P32493, DOI 10.1074/jbc.C300226200; CHEATHAM L, 1995, P NATL ACAD SCI USA, V92, P11696, DOI 10.1073/pnas.92.25.11696; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; Chen YH, 2003, ONCOGENE, V22, P3937, DOI 10.1038/sj.onc.1206565; CHEN YQ, 1994, BIOCHEM BIOPH RES CO, V203, P1, DOI 10.1006/bbrc.1994.2140; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Choi JW, 1996, SCIENCE, V273, P239, DOI 10.1126/science.273.5272.239; Choi KM, 2003, J BIOL CHEM, V278, P19667, DOI 10.1074/jbc.M301142200; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; Colombani J, 2003, CELL, V114, P739, DOI 10.1016/S0092-8674(03)00713-X; Conlon IJ, 2001, NAT CELL BIOL, V3, P918, DOI 10.1038/ncb1001-918; Crespo JL, 2002, MICROBIOL MOL BIOL R, V66, P579, DOI 10.1128/MMBR.66.4.579-591.2002; Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; Datar SA, 2000, EMBO J, V19, P4543, DOI 10.1093/emboj/19.17.4543; De Benedetti A, 1999, INT J BIOCHEM CELL B, V31, P59, DOI 10.1016/S1357-2725(98)00132-0; DEGROOT RP, 1994, CELL, V79, P81, DOI 10.1016/0092-8674(94)90402-2; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dolinski K, 1997, P NATL ACAD SCI USA, V94, P13093, DOI 10.1073/pnas.94.24.13093; Dufner A, 1999, MOL CELL BIOL, V19, P4525; Edinger AL, 2002, MOL BIOL CELL, V13, P2276, DOI 10.1091/mbc.01-12-0584; Elit Laurie, 2002, Curr Opin Investig Drugs, V3, P1249; Fang YM, 2003, CURR BIOL, V13, P2037, DOI 10.1016/j.cub.2003.11.021; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Faridi J, 2003, AM J PHYSIOL-ENDOC M, V285, pE964, DOI 10.1152/ajpendo.00239.2003; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004; Flick K, 1998, MOL CELL BIOL, V18, P2492, DOI 10.1128/MCB.18.5.2492; Gallo R, 1999, CIRCULATION, V99, P2164, DOI 10.1161/01.CIR.99.16.2164; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Gao XS, 2000, DEV BIOL, V221, P404, DOI 10.1006/dbio.2000.9680; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Gera JF, 2004, J BIOL CHEM, V279, P2737, DOI 10.1074/jbc.M309999200; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 2001, GENE DEV, V15, P2852; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Goberdhan DCI, 1999, GENE DEV, V13, P3244, DOI 10.1101/gad.13.24.3244; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; Gstaiger M, 2003, SCIENCE, V302, P1208, DOI 10.1126/science.1088401; Hahn WC, 2002, NEW ENGL J MED, V347, P1593, DOI 10.1056/NEJMra021902; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hannan KM, 2003, MOL CELL BIOL, V23, P8862, DOI 10.1128/MCB.23.23.8862-8877.2003; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Hardie DG, 2001, BIOESSAYS, V23, P1112, DOI 10.1002/bies.10009; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; Heesom KJ, 1999, FEBS LETT, V457, P489, DOI 10.1016/S0014-5793(99)01094-7; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Hentges KE, 2001, P NATL ACAD SCI USA, V98, P13796, DOI 10.1073/pnas.241184198; Herbert TP, 2002, J BIOL CHEM, V277, P11591, DOI 10.1074/jbc.M110367200; Hidalgo M, 2000, ONCOGENE, V19, P6680, DOI 10.1038/sj.onc.1204091; Hong SP, 2003, P NATL ACAD SCI USA, V100, P8839, DOI 10.1073/pnas.1533136100; Huang H, 1999, DEVELOPMENT, V126, P5365; Huang S, 2003, CURR OPIN PHARMACOL, V3, P371, DOI 10.1016/S1471-4892(03)00071-7; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Iiboshi Y, 1999, J BIOL CHEM, V274, P1092, DOI 10.1074/jbc.274.2.1092; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Isotani S, 1999, J BIOL CHEM, V274, P34493, DOI 10.1074/jbc.274.48.34493; Jacinto E, 2001, MOL CELL, V8, P1017, DOI 10.1016/S1097-2765(01)00386-0; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; Jiang Y, 1999, EMBO J, V18, P2782, DOI 10.1093/emboj/18.10.2782; JOHNSTON GC, 1977, EXP CELL RES, V105, P79, DOI 10.1016/0014-4827(77)90154-9; Kawasome H, 1998, P NATL ACAD SCI USA, V95, P5033, DOI 10.1073/pnas.95.9.5033; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kim JE, 2000, P NATL ACAD SCI USA, V97, P14340, DOI 10.1073/pnas.011511898; Kimura N, 2003, GENES CELLS, V8, P65, DOI 10.1046/j.1365-2443.2003.00615.x; Kobayashi T, 1999, CANCER RES, V59, P1206; Kobayashi T, 2001, P NATL ACAD SCI USA, V98, P8762, DOI 10.1073/pnas.151033798; KOLTIN Y, 1991, MOL CELL BIOL, V11, P1718, DOI 10.1128/MCB.11.3.1718; Kozma SC, 2002, BIOESSAYS, V24, P65, DOI 10.1002/bies.10031; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; Kwiatkowski DJ, 2003, ANN HUM GENET, V67, P87, DOI 10.1046/j.1469-1809.2003.00012.x; Lawlor MA, 2002, EMBO J, V21, P3728, DOI 10.1093/emboj/cdf387; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; Li SN, 2002, MOL CELL BIOL, V22, P2853, DOI 10.1128/MCB.22.8.2853-2861.2002; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Long XM, 2002, CURR BIOL, V12, P1448, DOI 10.1016/S0960-9822(02)01091-6; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Ly C, 2003, CANCER RES, V63, P5716; Mach KE, 2000, GENETICS, V155, P611; Mahalingam M, 1996, MOL CELL BIOL, V16, P405; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Manning BD, 2003, BIOCHEM SOC T, V31, P573, DOI 10.1042/BST0310573; Manning BD, 2003, TRENDS BIOCHEM SCI, V28, P573, DOI 10.1016/j.tibs.2003.09.003; Marcotrigiano J, 1999, MOL CELL, V3, P707, DOI 10.1016/S1097-2765(01)80003-4; Marks AR, 2003, NEW ENGL J MED, V349, P1307, DOI 10.1056/NEJMp038141; Martin KA, 2004, AM J PHYSIOL-CELL PH, V286, pC507, DOI 10.1152/ajpcell.00201.2003; Martin KA, 2002, ADV CANCER RES, V86, P1, DOI 10.1016/S0065-230X(02)86001-8; Matsumoto S, 2002, GENETICS, V161, P1053; Meyer CA, 2000, EMBO J, V19, P4533, DOI 10.1093/emboj/19.17.4533; Miron M, 2001, NAT CELL BIOL, V3, P596, DOI 10.1038/35078571; Mohi MG, 2004, P NATL ACAD SCI USA, V101, P3130, DOI 10.1073/pnas.0400063101; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Mora A, 2003, EMBO J, V22, P4666, DOI 10.1093/emboj/cdg469; Morice M, 2002, NEW ENGL J MED, V346, P1773, DOI 10.1056/NEJMoa012843; Moser BA, 1997, MOL CELL BIOL, V17, P5648, DOI 10.1128/MCB.17.9.5648; Moses JW, 2003, NEW ENGL J MED, V349, P1315, DOI 10.1056/NEJMoa035071; Mothe-Satney I, 2000, J BIOL CHEM, V275, P33836, DOI 10.1074/jbc.M006005200; Mothe-Satney I, 2000, MOL CELL BIOL, V20, P3558, DOI 10.1128/MCB.20.10.3558-3567.2000; Murata K, 1997, P NATL ACAD SCI USA, V94, P10624, DOI 10.1073/pnas.94.20.10624; Nanahoshi M, 1998, BIOCHEM BIOPH RES CO, V251, P520, DOI 10.1006/bbrc.1998.9493; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; Nojima H, 2003, J BIOL CHEM, V278, P15461, DOI 10.1074/jbc.C200665200; ODLHAM S, 2003, TRENDS CELL BIOL, V13, P79; Oldham S, 2000, GENE DEV, V14, P2689, DOI 10.1101/gad.845700; Onda H, 1999, J CLIN INVEST, V104, P687, DOI 10.1172/JCI7319; OWENS GK, 1995, PHYSIOL REV, V75, P487; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Pende M, 2000, NATURE, V408, P994, DOI 10.1038/35050135; Peng T, 2002, MOL CELL BIOL, V22, P5575, DOI 10.1128/MCB.22.15.5575-5584.2002; Perry J, 2003, CELL, V112, P151, DOI 10.1016/S0092-8674(03)00033-3; Peterson RT, 2000, J BIOL CHEM, V275, P7416, DOI 10.1074/jbc.275.10.7416; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Polymenis M, 1997, GENE DEV, V11, P2522, DOI 10.1101/gad.11.19.2522; Poon M, 1996, J CLIN INVEST, V98, P2277, DOI 10.1172/JCI119038; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Radimerski T, 2002, GENE DEV, V16, P2627, DOI 10.1101/gad.239102; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; RICHARDSON CR, UNPUB; Rintelen F, 2001, P NATL ACAD SCI USA, V98, P15020, DOI 10.1073/pnas.011318098; Rogue M, 2000, ATHEROSCLEROSIS, V153, P315, DOI 10.1016/S0021-9150(00)00421-4; Rohde J, 2001, J BIOL CHEM, V276, P9583, DOI 10.1074/jbc.R000034200; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; Romanelli A, 2002, J BIOL CHEM, V277, P40281, DOI 10.1074/jbc.M205168200; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; Rosner M, 2003, ONCOGENE, V22, P4786, DOI 10.1038/sj.onc.1206776; Rossig L, 2001, MOL CELL BIOL, V21, P5644, DOI 10.1128/MCB.21.16.5644-5657.2001; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; SABATINI DM, 1995, J BIOL CHEM, V270, P20875, DOI 10.1074/jbc.270.36.20875; Sabatini DM, 1999, SCIENCE, V284, P1161, DOI 10.1126/science.284.5417.1161; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Schmidt A, 1996, P NATL ACAD SCI USA, V93, P13780, DOI 10.1073/pnas.93.24.13780; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; Sehgal SN, 2003, TRANSPLANT P, V35, p7S, DOI 10.1016/S0041-1345(03)00211-2; Sekulic A, 2000, CANCER RES, V60, P3504; Shamji AF, 2003, MOL CELL, V12, P271, DOI 10.1016/j.molcel.2003.08.016; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Shigemitsu K, 1999, J BIOL CHEM, V274, P1058, DOI 10.1074/jbc.274.2.1058; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Shioi T, 2000, EMBO J, V19, P2537, DOI 10.1093/emboj/19.11.2537; Shioi T, 2002, MOL CELL BIOL, V22, P2799, DOI 10.1128/MCB.22.8.2799-2809.2002; Shiojima I, 2002, J BIOL CHEM, V277, P37670, DOI 10.1074/jbc.M204572200; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SIEKIERKA JJ, 1990, J BIOL CHEM, V265, P21011; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; STAN R, 1994, J BIOL CHEM, V269, P32027; Stocker H, 2000, CURR OPIN GENET DEV, V10, P529, DOI 10.1016/S0959-437X(00)00123-4; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Stolovich M, 2002, MOL CELL BIOL, V22, P8101, DOI 10.1128/MCB.22.23.8101-8113.2002; Takata M, 1999, J BIOL CHEM, V274, P20611, DOI 10.1074/jbc.274.29.20611; Tang H, 2001, MOL CELL BIOL, V21, P8671, DOI 10.1128/MCB.21.24.8671-8683.2001; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Tapon N, 2001, CURR OPIN CELL BIOL, V13, P731, DOI 10.1016/S0955-0674(00)00284-2; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Tee AR, 2003, J BIOL CHEM, V278, P37288, DOI 10.1074/jbc.M303257200; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; Urano J, 2000, J BIOL CHEM, V275, P11198, DOI 10.1074/jbc.275.15.11198; Vellai T, 2003, NATURE, V426, P620, DOI 10.1038/426620a; Verdu J, 1999, NAT CELL BIOL, V1, P500, DOI 10.1038/70293; Vilella-Bach M, 1999, J BIOL CHEM, V274, P4266, DOI 10.1074/jbc.274.7.4266; Vinals F, 1999, J BIOL CHEM, V274, P26776, DOI 10.1074/jbc.274.38.26776; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Vogt PK, 2001, TRENDS MOL MED, V7, P482, DOI 10.1016/S1471-4914(01)02161-X; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; vonManteuffel SR, 1997, MOL CELL BIOL, V17, P5426, DOI 10.1128/MCB.17.9.5426; Wang XM, 2001, EMBO J, V20, P4370, DOI 10.1093/emboj/20.16.4370; Weigmann K, 1997, DEVELOPMENT, V124, P3555; Weinkove D, 2000, CURR OPIN GENET DEV, V10, P75, DOI 10.1016/S0959-437X(99)00042-8; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; WENG QP, 1995, MOL CELL BIOL, V15, P2333; Westphal RS, 1999, J BIOL CHEM, V274, P687, DOI 10.1074/jbc.274.2.687; WIEDERRECHT G, 1991, P NATL ACAD SCI USA, V88, P1029, DOI 10.1073/pnas.88.3.1029; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Wilson KF, 2000, J BIOL CHEM, V275, P37307, DOI 10.1074/jbc.C000482200; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Yokogami K, 2000, CURR BIOL, V10, P47, DOI 10.1016/S0960-9822(99)00268-7; Zhang HB, 2000, GENE DEV, V14, P2712, DOI 10.1101/gad.835000; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	235	1001	1081	3	96	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2004	23	18					3151	3171		10.1038/sj.onc.1207542	http://dx.doi.org/10.1038/sj.onc.1207542			21	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	813AJ	15094765				2022-12-28	WOS:000220879700004
J	Schmidt, EV				Schmidt, EV			The role of c-myc in regulation of translation initiation	ONCOGENE			English	Article						translational; control; eIF4E; ribosomal synthesis; rDNA transcription	HUMAN TUMOR-CELLS; ORNITHINE-DECARBOXYLASE; MESSENGER-RNA; CYCLIN D1; FACTOR 4E; TRANSCRIPTION FACTOR; PROTEIN-SYNTHESIS; SACCHAROMYCES-CEREVISIAE; INCREASED EXPRESSION; RIBOSOME BIOGENESIS	Translation initiation is important for the regulation of both cell growth and cell division. It is uniquely poised to coordinate overall cell proliferation by its effects on both growth and division. A number of translation initiation factors are transcriptional targets of c-myc in a variety of assays. In particular, the mRNA cap-binding protein eIF4E has a myc-binding sequence in its promoter that is myc responsive in reporter assays and contains a high-affinity myc-binding site in chromosome immunoprecipitation experiments. Several differential expression screens have demonstrated altered levels of eIF4E, along with several other translation initiation factors, in response to alterations of c-myc levels. The potential for eIF4E and other translational control elements to mediate myc's transforming functions is particularly important because eIF4E is itself a known oncogenic factor. The ability of translation initiation factors to affect both cell division control and cell growth control coincides with myc's remarkable effects on both cell growth and cell division.	Massachusetts Gen Hosp, Canc Res Ctr, Boston, MA 02114 USA; MassGen Hosp Children, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Schmidt, EV (corresponding author), Massachusetts Gen Hosp, Canc Res Ctr, 55 Fruit St, Boston, MA 02114 USA.	schmidt@helix.mgh.harvard.edu			NCI NIH HHS [R01-CA63117] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063117] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amati B., 2001, BIOCHIM BIOPHYS ACTA, V1471, P135; Baserga R, 1985, BIOL CELL REPROD; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Brewer JW, 1999, P NATL ACAD SCI USA, V96, P8505, DOI 10.1073/pnas.96.15.8505; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Collier JJ, 2003, J BIOL CHEM, V278, P6588, DOI 10.1074/jbc.M208011200; DUNCAN R, 1985, J BIOL CHEM, V260, P5486; DUNCAN R, 1983, J BIOL CHEM, V258, P7228; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Gallant P, 1996, SCIENCE, V274, P1523, DOI 10.1126/science.274.5292.1523; Gomez-Roman N, 2003, NATURE, V421, P290, DOI 10.1038/nature01327; Greasley PJ, 2000, NUCLEIC ACIDS RES, V28, P446, DOI 10.1093/nar/28.2.446; Haggerty TJ, 2003, P NATL ACAD SCI USA, V100, P5313, DOI 10.1073/pnas.0931346100; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hahn WC, 2002, NEW ENGL J MED, V347, P1593, DOI 10.1056/NEJMra021902; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HANICJOYCE PJ, 1987, EXP CELL RES, V172, P134, DOI 10.1016/0014-4827(87)90100-5; HARTWELL LH, 1977, J CELL BIOL, V75, P422, DOI 10.1083/jcb.75.2.422; Hidalgo M, 2000, ONCOGENE, V19, P6680, DOI 10.1038/sj.onc.1204091; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; IVERSEN OH, 1974, EUR J CANCER, V10, P155, DOI 10.1016/0014-2964(74)90148-0; JOHNSTON GC, 1977, EXP CELL RES, V105, P79, DOI 10.1016/0014-4827(77)90154-9; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; Jones RM, 1996, MOL CELL BIOL, V16, P4754; KILLANDER D, 1965, EXP CELL RES, V40, P12, DOI 10.1016/0014-4827(65)90285-5; Kim S, 2000, P NATL ACAD SCI USA, V97, P11198, DOI 10.1073/pnas.200372597; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Kretzner L, 1992, Curr Top Microbiol Immunol, V182, P435; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Lewis BC, 2000, CANCER RES, V60, P6178; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Lynch M, 2004, J BIOL CHEM, V279, P3327, DOI 10.1074/jbc.M310872200; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; MATTHEWS MB, 2000, TRANSLATIONAL CONTRO, P1020; Nelsen CJ, 2003, J BIOL CHEM, V278, P3656, DOI 10.1074/jbc.M209374200; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5793, DOI 10.1128/MCB.22.16.5793-5800.2002; Orian A, 2003, GENE DEV, V17, P1101, DOI 10.1101/gad.1066903; Osthus RC, 2000, J BIOL CHEM, V275, P21797, DOI 10.1074/jbc.C000023200; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PENA A, 1993, J BIOL CHEM, V268, P27277; Polymenis M, 1999, CURR OPIN GENET DEV, V9, P76, DOI 10.1016/S0959-437X(99)80011-2; Polymenis M, 1997, GENE DEV, V11, P2522, DOI 10.1101/gad.11.19.2522; Pyronnet S, 1996, CANCER RES, V56, P1742; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; Rosenwald IB, 1996, CANCER LETT, V102, P113, DOI 10.1016/0304-3835(96)04171-7; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; Shim H, 1998, P NATL ACAD SCI USA, V95, P1511, DOI 10.1073/pnas.95.4.1511; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; TOBIAS KE, 1995, ONCOGENE, V11, P1721; Trumpp A, 2001, NATURE, V414, P768, DOI 10.1038/414768a; VALERA A, 1995, FASEB J, V9, P1067, DOI 10.1096/fasebj.9.11.7649406; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; Watson JD, 2002, J BIOL CHEM, V277, P36921, DOI 10.1074/jbc.M201493200; Wonsey DR, 2002, P NATL ACAD SCI USA, V99, P6649, DOI 10.1073/pnas.102523299; Wu KJ, 1999, SCIENCE, V283, P676, DOI 10.1126/science.283.5402.676; Zeller KI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r69; Zeller KI, 2001, J BIOL CHEM, V276, P48285, DOI 10.1074/jbc.M108506200	66	119	131	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 19	2004	23	18					3217	3221		10.1038/sj.onc.1207548	http://dx.doi.org/10.1038/sj.onc.1207548			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	813AJ	15094771				2022-12-28	WOS:000220879700010
J	Takahashi, Y; Lallemand-Breitenbach, V; Zhu, J; de The, H				Takahashi, Y; Lallemand-Breitenbach, V; Zhu, J; de The, H			PML nuclear bodies and apoptosis	ONCOGENE			English	Review						SUMO; p53; HIPK2; CHK2; DAXX	ACUTE PROMYELOCYTIC LEUKEMIA; INTERACTING PROTEIN KINASE-2; SUMO-1 INTERACTION MOTIF; PREMATURE SENESCENCE; GROWTH-SUPPRESSOR; P53 ACTIVITY; TRANSCRIPTIONAL ACTIVATION; T(15-17) TRANSLOCATION; SUMO-1-MODIFIED PML; ONCOGENIC DOMAINS	Promyelocytic leukaemia nuclear bodies (PML NBs) are structured protein complexes associated with the nuclear matrix. PML constitutes the scaffold component of NBs and recruits onto these domains a striking variety of proteins, many of which are involved in apoptosis control. Several reports have directly implicated PML in apoptosis and senescence, but the mechanisms by which these are conveyed are still largely unsettled. Recruitment of partner proteins onto NBs is regulated by PML sumolation, a specific post-translational modification also found in many NB-associated proteins. Among these, several are implicated in transcription repression or activation, like the transcriptional repressor Daxx or the transcriptional activator P53. Whether NBs constitute platforms where active sites of enzymatic modifications are carried out, as suggested for P53, sites of intranuclear protein sequestration, as proposed for Daxx or organelles specialized in catabolism, is still debated. A variety of stress-related signalling pathways dramatically modulate the formation of PML NBs, which may provide a clue as to their physiological function.	Univ Paris 07, Hop St Louis, Ctr Hayem,CNRS, UPR 9051,Lab Associe 11,Comite Paris Ligue Canc, F-75475 Paris 10, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	de The, H (corresponding author), Univ Paris 07, Hop St Louis, Ctr Hayem,CNRS, UPR 9051,Lab Associe 11,Comite Paris Ligue Canc, 1 Av C Vellefaux, F-75475 Paris 10, France.	dethe@chu-stlouis.fr		Lallemand, Valerie/0000-0001-9852-204X				Anton LC, 1999, J CELL BIOL, V146, P113, DOI 10.1083/jcb.146.1.113; Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; Borden KLB, 2002, MOL CELL BIOL, V22, P5259, DOI 10.1128/MCB.22.15.5259-5269.2002; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; Ecsedy JA, 2003, MOL CELL BIOL, V23, P950, DOI 10.1128/MCB.23.3.950-960.2003; Emelyanov AV, 2002, J BIOL CHEM, V277, P11156, DOI 10.1074/jbc.M111763200; Engelhardt OG, 2003, EXP CELL RES, V283, P36, DOI 10.1016/S0014-4827(02)00025-3; Eskiw CH, 2002, BIOCHEM CELL BIOL, V80, P301, DOI 10.1139/O02-079; Everett RD, 2000, J VIROL, V74, P9994, DOI 10.1128/JVI.74.21.9994-10005.2000; Everett RD, 1999, J CELL SCI, V112, P4581; Ferbeyre G, 2000, GENE DEV, V14, P2015; FLENGHI L, 1995, BLOOD, V85, P1871, DOI 10.1182/blood.V85.7.1871.bloodjournal8571871; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; GUIOCHONMANTEL A, 1995, MOL ENDOCRINOL, V9, P1791, DOI 10.1210/me.9.12.1791; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Hofmann TG, 2003, CELL DEATH DIFFER, V10, P1290, DOI 10.1038/sj.cdd.4401313; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Jang MS, 2002, BIOCHEM BIOPH RES CO, V295, P495, DOI 10.1016/S0006-291X(02)00699-X; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Kashuba Elena, 2003, Mol Cancer, V2, P18, DOI 10.1186/1476-4598-2-18; Kawai T, 2003, MOL CELL BIOL, V23, P6174, DOI 10.1128/MCB.23.17.6174-6186.2003; Kim EJ, 2002, J BIOL CHEM, V277, P32020, DOI 10.1074/jbc.M200153200; KOKEN MHM, 1995, ONCOGENE, V10, P1315; Kurki S, 2003, J CELL SCI, V116, P3917, DOI 10.1242/jcs.00714; Lafarga M, 2002, MOL BIOL CELL, V13, P2771, DOI 10.1091/mbc.E02-03-0122; Lain S, 1999, EXP CELL RES, V248, P457, DOI 10.1006/excr.1999.4433; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Lehembre F, 2001, ONCOGENE, V20, P1, DOI 10.1038/sj.onc.1204063; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Li RZ, 2000, ONCOGENE, V19, P745, DOI 10.1038/sj.onc.1203385; Louria-Hayon I, 2003, J BIOL CHEM, V278, P33134, DOI 10.1074/jbc.M301264200; Mallette FA, 2004, ONCOGENE, V23, P91, DOI 10.1038/sj.onc.1206886; Maul GG, 1995, J CELL BIOCHEM, V59, P498, DOI 10.1002/jcb.240590410; Megidish T, 2002, J BIOL CHEM, V277, P8255, DOI 10.1074/jbc.C200001200; Michaelson JS, 2003, J CELL SCI, V116, P345, DOI 10.1242/jcs.00234; Michaelson JS, 1999, GENE DEV, V13, P1918, DOI 10.1101/gad.13.15.1918; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Moller A, 2003, CANCER RES, V63, P4310; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Negorev D, 2001, ONCOGENE, V20, P7234, DOI 10.1038/sj.onc.1204764; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Pearson M, 2001, ONCOGENE, V20, P7250, DOI 10.1038/sj.onc.1204856; Pokrovskaja K, 2001, J GEN VIROL, V82, P345, DOI 10.1099/0022-1317-82-2-345; Puccetti E, 2003, ONCOGENE, V22, P6900, DOI 10.1038/sj.onc.1206747; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Regad T, 2001, ONCOGENE, V20, P7274, DOI 10.1038/sj.onc.1204854; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; ROTH MB, 1995, CURR OPIN CELL BIOL, V7, P325, DOI 10.1016/0955-0674(95)80086-7; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Seeler JS, 2001, ONCOGENE, V20, P7243, DOI 10.1038/sj.onc.1204758; Shimoda K, 2002, J IMMUNOL, V169, P4707, DOI 10.4049/jimmunol.169.9.4707; Spector DL, 2001, J CELL SCI, V114, P2891; Stadler M, 1995, ONCOGENE, V11, P2565; Sternsdorf T, 1999, J BIOL CHEM, V274, P12555, DOI 10.1074/jbc.274.18.12555; STUURMAN N, 1992, J CELL SCI, V101, P773; STUURMAN N, 1997, CELL MOL BIOL LETT, V2, P137; TERRIS B, 1995, CANCER RES, V55, P1590; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; Wei XL, 2003, J BIOL CHEM, V278, P29288, DOI 10.1074/jbc.M212215200; Xirodimas DP, 2002, FEBS LETT, V528, P207, DOI 10.1016/S0014-5793(02)03310-0; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752; Zhu HY, 2003, J BIOL CHEM, V278, P49286, DOI 10.1074/jbc.M308302200; Zhu J, 2002, NAT REV CANCER, V2, P705, DOI 10.1038/nrc887; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978	77	138	143	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2004	23	16					2819	2824		10.1038/sj.onc.1207533	http://dx.doi.org/10.1038/sj.onc.1207533			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	811VO	15077145				2022-12-28	WOS:000220799600009
J	Edwards, KM; Munger, K				Edwards, KM; Munger, K			Depletion of physiological levels of the human TID1 protein renders cancer cell lines resistant to apoptosis mediated by multiple exogenous stimuli	ONCOGENE			English	Article						apoptosis; DnaJ; tumor suppressor; mitochondria	CYTOCHROME-C RELEASE; HUMAN DNAJ PROTEIN; ENDOPLASMIC-RETICULUM; CONFORMATIONAL-CHANGE; MOLECULAR CHAPERONES; OXIDATIVE STRESS; BAX; DROSOPHILA; GENE; EXPRESSION	The human homologue of the Drosophila tumor suppressor lethal ( 2) tumorous imaginal discs ( l( 2) tid) gene, hTID1, encodes two proteins derived from alternate mRNA splicing. The splice variants TidL and TidS were previously reported from protein overexpression and dominant-negative mutant protein studies to exhibit opposing biological activities in response to exogenous cytotoxic stimuli. TidL was found to promote apoptosis while TidS suppressed it. To elucidate the physiological function of hTID1, we depleted hTID1 proteins using the technique of RNA interference (RNAi). Here, we show that cells essentially lacking expression of hTID1 proteins are protected from cell death in response to multiple stimuli, including cisplatin, tumor necrosis factor alpha/ cycloheximide and mitomycin C. We also generated stable cell populations depleted of hTID1 proteins by RNAi using DNA vectors. In addition to apoptosis resistance, stable hTID1 knockdown cells exhibited an enhanced ability for anchorage-independent growth, as measured by an increase in soft-agar colony formation. These results suggest that hTID1 functions as an important cell death regulator and raise the interesting possibility that hTID1 could exert tumor suppressor activity.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Munger, K (corresponding author), Harvard Univ, Sch Med, Dept Pathol, NRB 0958,77 Ave Louis Pasteur, Boston, MA 02115 USA.	karl_munger@hms.harvard.edu		Munger, Karl/0000-0003-3288-9935	NATIONAL CANCER INSTITUTE [R01CA081135] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL056949] Funding Source: NIH RePORTER; NCI NIH HHS [CA-81135] Funding Source: Medline; NHLBI NIH HHS [HL56949] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Benedict CA, 2003, CURR OPIN IMMUNOL, V15, P59, DOI 10.1016/S0952-7915(02)00018-3; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Canamasas I, 2003, J BIOL CHEM, V278, P30952, DOI 10.1074/jbc.M304225200; Cheng H, 2002, J BIOL CHEM, V277, P20605, DOI 10.1074/jbc.M201204200; Cheng H, 2001, CURR BIOL, V11, P1771, DOI 10.1016/S0960-9822(01)00540-1; CYR DM, 1992, J BIOL CHEM, V267, P20927; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; Degenhardt K, 2002, J BIOL CHEM, V277, P14127, DOI 10.1074/jbc.M109939200; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Eom CY, 2002, P NATL ACAD SCI USA, V99, P1894, DOI 10.1073/pnas.042689499; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Gajkowska B, 2001, CELL BIOL INT, V25, P725, DOI 10.1006/cbir.2001.0768; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Kelley WL, 1999, CURR BIOL, V9, pR305, DOI 10.1016/S0960-9822(99)80185-7; Kondo S, 1997, EUR J IMMUNOL, V27, P1713, DOI 10.1002/eji.1830270718; Kurzik-Dumke U, 1998, CELL STRESS CHAPERON, V3, P12, DOI 10.1379/1466-1268(1998)003<0012:MLATEO>2.3.CO;2; KURZIKDUMKE U, 1992, DIFFERENTIATION, V51, P91, DOI 10.1111/j.1432-0436.1992.tb00685.x; KURZIKDUMKE U, 1995, DEV GENET, V16, P64, DOI 10.1002/dvg.1020160110; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Maroto R, 1997, J NEUROCHEM, V69, P514; Meacham GC, 1999, EMBO J, V18, P1492, DOI 10.1093/emboj/18.6.1492; Misselwitz B, 1998, MOL CELL, V2, P593, DOI 10.1016/S1097-2765(00)80158-6; Nutt LK, 2002, J BIOL CHEM, V277, P20301, DOI 10.1074/jbc.M201604200; Nutt LK, 2002, J BIOL CHEM, V277, P9219, DOI 10.1074/jbc.M106817200; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; PFANNER N, 1994, TRENDS BIOCHEM SCI, V19, P368, DOI 10.1016/0968-0004(94)90113-9; Sarkar S, 2001, J BIOL CHEM, V276, P49034, DOI 10.1074/jbc.M103683200; Sasaki S, 2002, ONCOGENE, V21, P5024, DOI 10.1038/sj.onc.1205627; Schilling B, 1998, VIROLOGY, V247, P74, DOI 10.1006/viro.1998.9220; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Sundararajan R, 2001, J BIOL CHEM, V276, P45120, DOI 10.1074/jbc.M106386200; Syken J, 2003, ONCOGENE, V22, P4636, DOI 10.1038/sj.onc.1206569; Syken J, 1999, P NATL ACAD SCI USA, V96, P8499, DOI 10.1073/pnas.96.15.8499; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Trentin GA, 2001, J BIOL CHEM, V276, P13087, DOI 10.1074/jbc.M009267200; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Yin X, 2001, GENE, V278, P201, DOI 10.1016/S0378-1119(01)00720-X; Zong WX, 2003, J CELL BIOL, V162, P59, DOI 10.1083/jcb.200302084	50	24	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	2004	23	52					8419	8431		10.1038/sj.onc.1207732	http://dx.doi.org/10.1038/sj.onc.1207732			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867VN	15156195				2022-12-28	WOS:000224870700002
J	Mancini, A; Koch, A; Whetton, AD; Tamura, T				Mancini, A; Koch, A; Whetton, AD; Tamura, T			The M-CSF receptor substrate and interacting protein FMIP is governed in its subcellular localization by protein kinase C-mediated phosphorylation, and thereby potentiates M-CSF-mediated differentiation	ONCOGENE			English	Article						Fms tyrosine kinase; serine phosphorylation; nuclear localization signal; macrophage differentiation; M-CSF-mediated signaling	STIMULATING FACTOR-RECEPTOR; BINDING-SITE; ACTIVATION; MUTATION; MURINE; OSTEOPETROSIS; GRANULOCYTE; SIGNAL; ALPHA; CELLS	Macrophage colony-stimulating factor (M-CSF or CSF-1) and its cognate receptor, the tyrosine kinase c-fms, are essential for monocyte and macrophage development. We have recently identified an Fms-interacting protein (FMIP) that binds transiently to the cytoplasmic domain of activated Fms molecules and is phosphorylated on tyrosine by Fms tyrosine kinase. FMIP is a substrate not only for Fms but also for protein kinase C (PKC). Mutagenesis reveals that this occurs on serines 5 and 6. Adjacent to these sites is a nuclear localization signal (NLS). We show that this NLS is essential for the predominantly nuclear localization of FMIP. Generation of phosphomimetic substitutions on serine residues 5 and 6 confirms that PKC-mediated phosphorylation on this site leads to translocation of FMIP to the cytosol. Furthermore, the mutant FMIP (FMIPSS5,6AA) was detected abundantly in the nucleus even in the presence of activated PKCalpha. Wild-type FMIP and FMIPSS5,6AA inhibited M-CSF-mediated survival signaling, while FMIPSS5,6EE-expressing cells survived and differentiated into macrophages more efficiently than wild-type cells in the presence of M-CSF or TPA. We conclude M-CSF-mediated activation of PKCalpha can potentiate FMIP action to initiate survival/differentiation signaling.	Hannover Med Sch, Inst Biochem, D-30623 Hannover, Germany; Univ Manchester, Dept Biomol Sci, Manchester M60 1QD, Lancs, England; Univ Manchester, Christie Hosp, Fac Med, Manchester M20 9BX, Lancs, England	Hannover Medical School; University of Manchester; Christie NHS Foundation Trust; Christie Hospital; University of Manchester	Tamura, T (corresponding author), Hannover Med Sch, Inst Biochem, OE 4310,Carl Neuberg Str 1, D-30623 Hannover, Germany.	tamura.teruko@mh-hannover.de		WHETTON, ANTHONY D/0000-0002-1098-3878				Bourette RP, 1998, EMBO J, V17, P7273, DOI 10.1093/emboj/17.24.7273; Bourette RP, 1997, EMBO J, V16, P5880, DOI 10.1093/emboj/16.19.5880; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; Dai XM, 2002, BLOOD, V99, P111, DOI 10.1182/blood.V99.1.111; DATTA R, 1992, BLOOD, V79, P904; Friedman AD, 2002, ONCOGENE, V21, P3377, DOI 10.1038/sj.onc.1205324; GLINIAK BC, 1990, CELL, V63, P1073, DOI 10.1016/0092-8674(90)90510-L; HEYWORTH CM, 1992, BLOOD, V80, P2230; MACIEJEWSKI PM, 1995, J BIOL CHEM, V270, P27661, DOI 10.1074/jbc.270.46.27661; Mancini A, 1997, ONCOGENE, V15, P1565, DOI 10.1038/sj.onc.1201518; Mancini A, 2002, J BIOL CHEM, V277, P14635, DOI 10.1074/jbc.M109214200; MARKS SC, 1976, J HERED, V67, P11, DOI 10.1093/oxfordjournals.jhered.a108657; MORRISON P, 1993, J BIOL CHEM, V268, P15536; NAKANO T, 1994, SCIENCE, V265, P1098, DOI 10.1126/science.8066449; Novak U, 1996, ONCOGENE, V13, P2607; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; Pierce A, 1998, J CELL BIOL, V140, P1511, DOI 10.1083/jcb.140.6.1511; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; Tagoh H, 2002, GENE DEV, V16, P1721, DOI 10.1101/gad.222002; Tamura T, 1999, ONCOGENE, V18, P6488, DOI 10.1038/sj.onc.1203062; TROULIARIS S, 1995, J VIROL, V69, P6010, DOI 10.1128/JVI.69.10.6010-6020.1995; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; Wagner S, 2000, EXP CELL RES, V258, P204, DOI 10.1006/excr.2000.4925; WAYS DK, 1991, BLOOD, V78, P2633; WHETTON AD, 1994, J CELL BIOL, V125, P651, DOI 10.1083/jcb.125.3.651; XIE YG, 1993, HUM MOL GENET, V2, P1361; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0; Zhang DE, 1996, CURR TOP MICROBIOL, V211, P137	28	31	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6581	6589		10.1038/sj.onc.1207841	http://dx.doi.org/10.1038/sj.onc.1207841			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15221008				2022-12-28	WOS:000223530800005
J	Senchenko, VN; Liu, J; Loginov, W; Bazov, I; Angeloni, D; Seryogin, Y; Ermilova, V; Kazubskaya, T; Garkavtseva, R; Zabarovska, VI; Kashuba, VI; Kisselev, LL; Minna, JD; Lerman, MI; Klein, G; Braga, EA; Zabarovsky, ER				Senchenko, VN; Liu, J; Loginov, W; Bazov, I; Angeloni, D; Seryogin, Y; Ermilova, V; Kazubskaya, T; Garkavtseva, R; Zabarovska, VI; Kashuba, VI; Kisselev, LL; Minna, JD; Lerman, MI; Klein, G; Braga, EA; Zabarovsky, ER			Discovery of frequent homozygous deletions in chromosome 3p21.3 LUCA and AP20 regions in renal, lung and breast carcinomas	ONCOGENE			English	Article						breast cancer; human chromosome 3p; lung cancer; renal carcinoma; tumour suppressor genes; quantitative real-time PCR	TUMOR-SUPPRESSOR GENE; SINGLE-NUCLEOTIDE POLYMORPHISM; HUMAN EPITHELIAL MALIGNANCIES; REAL-TIME PCR; MOLECULAR-GENETICS; CELL CARCINOMA; SHORT ARM; CANCER; 3P; HETEROZYGOSITY	We searched for chromosome 3p homo- and hemizygous losses in 23 lung cancer cell lines, 53 renal cell and 22 breast carcinoma biopsies using 31 microsatellite markers located in frequently deleted 3p regions. In addition, two sequence-tagged site markers (NLJ-003 and NL3-001) located in the Alu-PCR clone 20 region (AP20) and lung cancer (LUCA) regions, respectively, were used for quantitative real-time PCR (QPCR). We found frequent (10-18%) homozygous deletions (HDs) in both 3p2l.3 regions in the biopsies and lung cancer cell lines. In addition, we discovered that amplification of 3p is a very common (15-42.5%) event in these cancers and probably in other epithelial malignancies. QPCR showed that aberrations of either NLJ-003 or NL3-001 were detected in more than 90% of all studied cases. HDs were frequently detected simultaneously both in NLJ-003 or NL3-001 loci in the same tumour (P < 3-10(-7)). This observation suggests that tumour suppressor genes (TSG) in these regions could have a synergistic effect. The exceptionally high frequency of chromosome aberrations in NLJ-003 and NL3-001 loci suggests that multiple TSG(s) involved in different malignancies are located very near to these markers. Precise mapping of 15 independent HDs in the LUCA region allowed us to establish the smallest HD region in 3p21.3C located between D3S1568 (CACNA2D2 gene) and D3S4604 (SEMA3F gene). This region contains 17 genes. Mapping of 19 HDs in the AP20 region resulted in the localization of the minimal region to the interval flanked by D3S1298 and D3S3623 markers. Only four genes were discovered in this interval, namely, APRG1, ITGA9, HYA22 and VILL.	Karolinska Inst, Ctr Microbiol & Tumor Biol, Ctr Genom & Bioinformat, S-17177 Stockholm, Sweden; Russian Acad Sci, Ctr Bioengn, Moscow 117312, Russia; Russian State Genet Ctr, Moscow 117545, Russia; Natl Canc Inst, Immunobiol Lab, Canc Causing Genes Sect, Ctr Canc Res, Frederick, MD 21702 USA; Russian Acad Med Sci, Blokhin Canc Res Ctr, Moscow 115478, Russia; Russian Acad Sci, Engelhardt Inst Mol Biol, Moscow 119991, Russia; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA	Karolinska Institutet; Research Center of Biotechnology RAS; Russian Academy of Sciences; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); N.N. Blokhin Russian Cancer Research Center; Russian Academy of Medical Sciences; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Zabarovsky, ER (corresponding author), Karolinska Inst, Ctr Microbiol & Tumor Biol, Ctr Genom & Bioinformat, S-17177 Stockholm, Sweden.	eugene.zabarovsky@mtc.ki.se	Zabarovsky, Eugene R/A-6645-2010; Braga, Eleonora A./P-5574-2016; Senchenko, Vera N/C-8992-2014; Kashuba, Vladimir I/N-3732-2017; Loginov, Vytaliy/J-9738-2018; Kashuba, Vladimir/AAO-7742-2020	Senchenko, Vera N/0000-0002-3119-515X; Kashuba, Vladimir I/0000-0001-9416-8282; Loginov, Vytaliy/0000-0003-2668-8096; Bazov, Igor/0000-0003-4388-1656; Braga, Eleonora/0000-0001-5188-4094; Angeloni, Debora/0000-0002-3850-5392	NATIONAL CANCER INSTITUTE [R01CA071618, P50CA070907, Z01BC008579] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER; NCI NIH HHS [P50CA70907, CA71618, N01-CO-56000] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alimov A, 2000, ONCOGENE, V19, P1392, DOI 10.1038/sj.onc.1203449; Angeloni D, 2003, MOL CELL PROBE, V17, P55, DOI 10.1016/S0890-8508(02)00115-9; ANGELONI D, 2001, SOURCEBOOK ASBESTOS, V23, P169; Braga E, 2002, INT J CANCER, V100, P534, DOI 10.1002/ijc.10511; Braga E, 1999, FEBS LETT, V454, P215, DOI 10.1016/S0014-5793(99)00807-8; Daigo Y, 1999, DNA Res, V6, P37, DOI 10.1093/dnares/6.1.37; Danilkovitch-Miagkova A, 2003, P NATL ACAD SCI USA, V100, P4580, DOI 10.1073/pnas.0837136100; Erlandsson R, 1998, CANCER GENET CYTOGEN, V104, P1, DOI 10.1016/S0165-4608(97)00384-1; Girard L, 2000, CANCER RES, V60, P4894; Imreh S, 2003, GENE CHROMOSOME CANC, V38, P307, DOI 10.1002/gcc.10271; Ishikawa S, 1997, DNA Res, V4, P35, DOI 10.1093/dnares/4.1.35; Kashuba VI, 2004, P NATL ACAD SCI USA, V101, P4906, DOI 10.1073/pnas.0401238101; Kashuba VI, 1999, GENE, V239, P259, DOI 10.1016/S0378-1119(99)00411-4; KASHUBA VI, 1995, CANCER GENET CYTOGEN, V81, P144, DOI 10.1016/0165-4608(94)00215-W; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Lerman MI, 2000, CANCER RES, V60, P6116; Lindblad-Toh K, 2000, NAT BIOTECHNOL, V18, P1001, DOI 10.1038/79269; Liu J, 1999, FEBS LETT, V462, P121, DOI 10.1016/S0014-5793(99)01523-9; Phelps RM, 1996, J CELL BIOCHEM, P32; Protopopov A, 2003, CANCER RES, V63, P404; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SEABRIGH.M, 1971, LANCET, V2, P971; Senchenko V, 2003, ONCOGENE, V22, P2984, DOI 10.1038/sj.onc.1206429; Stewart B.W., 2003, WORLD CANC REPORT; vandenBerg A, 1997, GENE CHROMOSOME CANC, V19, P59, DOI 10.1002/(SICI)1098-2264(199706)19:2<59::AID-GCC1>3.3.CO;2-O; Wei MH, 1996, CANCER RES, V56, P1487; Wistuba II, 2000, CANCER RES, V60, P1949; Wistuba II, 2001, SEMIN ONCOL, V28, P3, DOI 10.1053/sonc.2001.25738; Yang QF, 2002, J HUM GENET, V47, P453, DOI 10.1007/s100380200064; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835; Zochbauer-Muller S, 2002, ANNU REV PHYSIOL, V64, P681, DOI 10.1146/annurev.physiol.64.081501.155828	31	80	97	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2004	23	34					5719	5728		10.1038/sj.onc.1207760	http://dx.doi.org/10.1038/sj.onc.1207760			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KW	15208675	Bronze			2022-12-28	WOS:000222629800001
J	You, FL; Chiba, N; Ishioka, C; Parvin, JD				You, FL; Chiba, N; Ishioka, C; Parvin, JD			Expression of an amino-terminal BRCA1 deletion mutant causes a dominant growth inhibition in MCF10A cells	ONCOGENE			English	Article						BRCA1; apoptosis; centrosomes	POLYMERASE-II HOLOENZYME; DNA-DAMAGE RESPONSE; UBIQUITIN LIGASE; OVARIAN-CANCER; BREAST-CANCER; RNA HELICASE; PROTEIN; COMPLEX; TRANSCRIPTION; GENE	Expression of deletion mutants of the breast and ovarian cancer-specific tumor suppressor protein, BRCA1, in the mammary epithelial cell line MCF10A revealed a powerful growth suppressive effect by a mutant that has the amino-terminal 302 amino acids deleted (DeltaN-BRCA1). The growth suppression is associated with an increase in apoptosis and amplification in centrosome number. The growth inhibitory effect of DeltaN-BRCA1 was not observed in cervical epithelial HeLa cells, suggesting that the phenotypes of BRCA1 mutant proteins differ depending on the cell line being tested. An internal domain, including BRCA1 residues 303-1292, caused the suppression of MCF10A cell growth, and the amino terminus of BRCA1 autoinhibited the growth suppression. Single point mutations that disrupted the amino-terminal RING domain of BRCA1 caused significant suppression of growth in MCF10A cells. These results suggest that the proper function of the RING domain, likely to be ubiquitin ligase function, is important in regulating the growth of the mammary epithelial cell line and in autoregulating the powerful internal growth-inhibiting domain of the BRCA1 tumor suppressor.	Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Tohoku Univ, Dept Clin Oncol, Inst Dev Aging & Canc, Aoba Ku, Sendai, Miyagi 9808575, Japan	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Tohoku University	Parvin, JD (corresponding author), Brigham & Womens Hosp, Dept Pathol, NRB 630,77 Ave Louis Pasteur, Boston, MA 02115 USA.	jparvin@rics.bwh.harvard.edu	Parvin, Jeffrey D/C-8955-2009	Ishioka, Chikashi/0000-0002-3023-1227	NCI NIH HHS [CA90281] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090281] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Andrews HN, 2002, J BIOL CHEM, V277, P26225, DOI 10.1074/jbc.M201316200; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; Chen A, 2002, J BIOL CHEM, V277, P22085, DOI 10.1074/jbc.M201252200; Chiba N, 2002, CANCER RES, V62, P4222; Chiba N, 2001, J BIOL CHEM, V276, P38549, DOI 10.1074/jbc.M105227200; Dong YS, 2003, MOL CELL, V12, P1087, DOI 10.1016/S1097-2765(03)00424-6; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; Haile DT, 1999, J BIOL CHEM, V274, P2113, DOI 10.1074/jbc.274.4.2113; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Hsu LC, 2001, CANCER RES, V61, P7713; Hu YF, 1999, GENE DEV, V13, P637, DOI 10.1101/gad.13.6.637; Kleiman FE, 2001, CELL, V104, P743, DOI 10.1016/S0092-8674(02)07059-9; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Narita T, 2003, MOL CELL BIOL, V23, P1863, DOI 10.1128/MCB.23.6.1863-1873.2003; Neish AS, 1998, NUCLEIC ACIDS RES, V26, P847, DOI 10.1093/nar/26.3.847; Paull TT, 2001, P NATL ACAD SCI USA, V98, P6086, DOI 10.1073/pnas.111125998; Schlegel BP, 2000, P NATL ACAD SCI USA, V97, P3148, DOI 10.1073/pnas.070452397; Schlegel BP, 2003, ONCOGENE, V22, P983, DOI 10.1038/sj.onc.1206195; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Snouwaert JN, 1999, ONCOGENE, V18, P7900, DOI 10.1038/sj.onc.1203334; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Starita LM, 2003, CURR OPIN CELL BIOL, V15, P345, DOI 10.1016/S0955-0674(03)00042-5; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Wu-Baer F, 2003, J BIOL CHEM, V278, P34743, DOI 10.1074/jbc.C300249200; Xia Y, 2003, J BIOL CHEM, V278, P5255, DOI 10.1074/jbc.M204591200; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	33	16	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2004	23	34					5792	5798		10.1038/sj.onc.1207739	http://dx.doi.org/10.1038/sj.onc.1207739			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KW	15122325				2022-12-28	WOS:000222629800008
J	Zhou, DJ; Chen, B; Ye, JJ; Chen, SA				Zhou, DJ; Chen, B; Ye, JJ; Chen, SA			A novel crosstalk mechanism between nuclear receptor-mediated and growth factor/Ras-mediated pathways through PNRC-Grb2 interaction	ONCOGENE			English	Article						PNRC; nuclear receptor coactivator; Grb2; growth factor/Ras; signal transduction	ACTIVATED PROTEIN-KINASE; ESTROGEN-RECEPTOR; COACTIVATORS; CELLS; COREPRESSORS; ALPHA-1; BINDING; MOTIF; SH2	It has been demonstrated that proline-rich nuclear receptor coregulatory protein (PNRC) is a nuclear receptor coactivator that interacts with nuclear receptors through an SH3-binding motif located in its C-terminus. In the present report, a physical interaction between PNRC and Grb2 (an adapter protein involved in growth factor/Ras-mediated pathways) has been demonstrated using the GST pull-down assay, the yeast two-hybrid assay, as well as by coimmunoprecipitation. Cotransfection and fluorescence imaging have also confirmed the colocalization of PNRC and Grb2 in mammalian cells. Transient transfection experiments have demonstrated that, by interacting with each other, Grb2 decreases the coactivator activity of PNRC for nuclear receptors, and that PNRC suppresses Grb2-mediated Ras/MAP-kinase activation. Furthermore, it was discovered that HeLa cells overexpressing PNRC grew more slowly when compared to matched controls. Additionally, using a RT-PCR analysis of mRNA on six pairs of cancer/noncancer tissues, PNRC expression was found to be significantly lower in breast cancer tissue than in noncancer tissue. Based on these findings, we believe that PNRC and Grb2, by interacting with each other, can suppress nuclear receptor-mediated regulation and growth factor-mediated regulation in human breast tissue. This is a newly identified crosstalk mechanism for modulating these two important types of regulatory pathways.	Beckman Res Inst City Hope, Dept Surg Res, Duarte, CA 91010 USA; Third Mil Med Univ, Dept Biochem, Chongqing, Peoples R China	City of Hope; Beckman Research Institute of City of Hope; Army Medical University	Chen, SA (corresponding author), Beckman Res Inst City Hope, Dept Surg Res, Duarte, CA 91010 USA.	schen@coh.org			NCI NIH HHS [CA44735] Funding Source: Medline; NIDDK NIH HHS [DK60560] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044735] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060560] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chen S, 2001, J BIOL CHEM, V276, P28465, DOI 10.1074/jbc.M102638200; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; Cussac D, 1999, FASEB J, V13, P31, DOI 10.1096/fasebj.13.1.31; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; Gay B, 1999, INT J CANCER, V83, P235, DOI 10.1002/(SICI)1097-0215(19991008)83:2<235::AID-IJC15>3.0.CO;2-B; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Harris RA, 1999, INT J CANCER, V80, P477, DOI 10.1002/(SICI)1097-0215(19990129)80:3<477::AID-IJC23>3.0.CO;2-W; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; NICHOLSON RI, 1996, HORMONES CANC, P227; Ordentlich P, 2001, CURR TOP MICROBIOL, V254, P101; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Rauh MJ, 1999, MOL CELL BIOL, V19, P8169; Rooij J, 1997, ONCOGENE, V14, P623; RUSSELL KS, 1992, CANCER RES, V52, P6624; Tari AM, 1999, ONCOGENE, V18, P1325, DOI 10.1038/sj.onc.1202422; Verbeek BS, 1997, J PATHOL, V183, P195; Zhou DJ, 2001, NUCLEIC ACIDS RES, V29, P3939, DOI 10.1093/nar/29.19.3939; Zhou DJ, 2000, MOL ENDOCRINOL, V14, P986, DOI 10.1210/me.14.7.986	22	22	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 8	2004	23	31					5394	5404		10.1038/sj.onc.1207695	http://dx.doi.org/10.1038/sj.onc.1207695			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15122321				2022-12-28	WOS:000222491600015
J	Sall, A; Caserta, S; Jolicoeur, P; Franqueville, L; de Turenne-Tessier, M; Ooka, T				Sall, A; Caserta, S; Jolicoeur, P; Franqueville, L; de Turenne-Tessier, M; Ooka, T			Mitogenic activity of Epstein-Barr virus-encoded BARF1 protein	ONCOGENE			English	Article						Epstein-Barr virus; BARF1 gene; growth factor	EPITHELIAL-CELLS; TRANSCRIPTIONAL EXPRESSION; NASOPHARYNGEAL CARCINOMA; MALIGNANT-TRANSFORMATION; GENE; EBV; ESTABLISHMENT; LYMPHOMA; GROWTH; LINE	We previously reported that BARF1 gene has either an immortalizing effect, when expressed in primary primate epithelial cells, or a malignant transforming activity, when expressed in established and nontumoral rodent fibroblast or human B-cell lines. As predicted from sequence analysis, we found that BARF1 coded protein can be secreted from different cell lines, among them BARF1-transfected Balb/c3T3 rodent fibroblasts. Thus, as an initial step to clarify BARF1 oncogenic functions, we investigated whether the secreted form of BARF1 protein can activate the cell cycle as a growth factor. Since efficient BARF1 expression could be obtained from 293-tTA cells infected with a tetracycline-regulatable recombinant adenovirus, secreted BARF1 product could be purified from the culture medium of such cells by ammonium sulfate precipitation, ion exchange chromotography and sucrose gradient sedimentation. We describe in this paper that addition of a purified product of secreted BARF1 protein to serum-free culture medium of Balb/c3T3 rodent fibroblasts, human Louckes B-cell line and primary monkey kidney epithelial cells resulted in a cell cycle activation that was inhibited by affinity-purified anti-BARF1 antibody. Our demonstration of a specific stimulation of cell cycle in vitro by BARF1 secreted product suggests that this EBV-encoded BARF1 protein could act as a growth factor in vivo.	Univ Lyon 1, Fac Med RTH Laennec, CNRS,UMR 5537, Mol Virol Lab, F-69372 Lyon 08, France; Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; National Research Council Canada	Ooka, T (corresponding author), Univ Lyon 1, Fac Med RTH Laennec, CNRS,UMR 5537, Mol Virol Lab, F-69372 Lyon 08, France.	ooka@laennec.univ-lyon1.fr	Caserta, Sergio/E-4602-2012	Caserta, Sergio/0000-0002-4400-0059				Cohen JI, 1999, J VIROL, V73, P7627, DOI 10.1128/JVI.73.9.7627-7632.1999; Danve C, 2001, VIROLOGY, V288, P223, DOI 10.1006/viro.2001.1072; Decaussin G, 2000, CANCER RES, V60, P5584; DETURENNETESSIE.M, UNPUB; Gao YN, 2002, ONCOGENE, V21, P825, DOI 10.1038/sj.onc.1205130; Hayes DP, 1999, J CLIN PATHOL-MOL PA, V52, P97, DOI 10.1136/mp.52.2.97; KARRAN L, 1990, INT J CANCER, V45, P763, DOI 10.1002/ijc.2910450432; Kieff E., 1996, FIELDS VIROLOGY, V2, P2343; Massie B, 1998, CYTOTECHNOLOGY, V28, P53, DOI 10.1023/A:1008013211222; Nishikawa J, 1999, J VIROL, V73, P1286, DOI 10.1128/JVI.73.2.1286-1292.1999; OOKA T, 2001, EBV REP, V8, P177; RICKINSON AB, 2002, FIELDS VIROLOGY, P257; SbihLammali F, 1996, J MED VIROL, V49, P7, DOI 10.1002/(SICI)1096-9071(199605)49:1&lt;7::AID-JMV2&gt;3.0.CO;2-A; Sheng W, 2003, J VIROL, V77, P3859, DOI 10.1128/JVI.77.6.3859-3865.2003; Sheng W, 2001, ONCOGENE, V20, P1176, DOI 10.1038/sj.onc.1204217; Strockbine LD, 1998, J VIROL, V72, P4015, DOI 10.1128/JVI.72.5.4015-4021.1998; Tanner JE, 1997, J INFECT DIS, V175, P38, DOI 10.1093/infdis/175.1.38; WEI MX, 1989, EMBO J, V8, P2897, DOI 10.1002/j.1460-2075.1989.tb08438.x; Wei MX, 1997, ONCOGENE, V14, P3073, DOI 10.1038/sj.onc.1201128; WEI MX, 1994, CANCER RES, V54, P1843; Xue SA, 2002, INT J CANCER, V99, P635, DOI 10.1002/ijc.10372; ZHANG CX, 1992, VIRUS RES, V26, P153, DOI 10.1016/0168-1702(92)90154-2; zur Hausen A, 2000, CANCER RES, V60, P2745	23	36	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2004	23	28					4938	4944		10.1038/sj.onc.1207607	http://dx.doi.org/10.1038/sj.onc.1207607			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	830EK	15064715				2022-12-28	WOS:000222104200015
J	Klucky, B; Koch, B; Radolf, M; Steinlein, P; Wintersberger, E				Klucky, B; Koch, B; Radolf, M; Steinlein, P; Wintersberger, E			Polyomavirus tumorantigens have a profound effect on gene expression in mouse fibroblasts	ONCOGENE			English	Article						T antigens; microarray; gene expression	LARGE T-ANTIGEN; SIMIAN-VIRUS-40 SMALL-T; HUMAN CELL-TRANSFORMATION; CYCLIN-A; TRANS-ACTIVATION; MIDDLE-T; S-PHASE; PROTEIN; GROWTH; TRANSACTIVATION	Polyomavirus (Pv) large and small tumorantigens together are competent to induce S phase in growth-arrested mouse fibroblasts. The capacity of the large tumorantigen to bind the pocket proteins, pRB, p130 and p107, is important for the transactivation of DNA synthesis enzymes and the cyclins E and A, while the interference of small tumorantigen with protein phosphatase PP2A causes a destabilization of the cdk2 inhibitor p27, and thus leads to strong cyclin E- and cyclin A-dependent cdk2 activity. Py small tumorantigen, in addition, is able to transactivate cyclin A. Hence, this protein might have a much wider effect on gene expression in arrested mouse fibroblasts than hitherto suspected. This may have a profound part in the known capacity of Py to form tumors in mice. Therefore, it was interesting to gain an insight into the spectrum of transcriptional deregulation by Py tumorantigens. Accordingly, we performed microarray analysis of quiescent mouse fibroblasts in the absence and presence of small or large tumorantigen. We found that the viral proteins can induce or repress a great variety of genes beyond those involved in the S phase induction and DNA synthesis. The results of the microarray analysis were confirmed for selected genes by several methods, including real-time PCR. Interestingly, a mutation of the binding site for pocket proteins in case of LT and for PP2A in case of ST has a variable effect on the deregulation of genes by the viral proteins depending on the gene in question. In fact, some genes are transactivated by LT as well as ST completely independent of an interaction with their major cellular targets, pocket proteins and PP2A, respectively.	Med Univ Vienna, Div Mol Biol, Inst Med Biochem, A-1030 Vienna, Austria; Inst Mol Pathol, A-1030 Vienna, Austria	Medical University of Vienna; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Wintersberger, E (corresponding author), Med Univ Vienna, Div Mol Biol, Inst Med Biochem, Dr Bohrgasse 9, A-1030 Vienna, Austria.	Erhard.Wintersberger@univie.ac.at		Koch, Birgit/0000-0003-4683-3115				ADAMCZEWSKI JP, 1993, J VIROL, V67, P6551, DOI 10.1128/JVI.67.11.6551-6557.1993; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Benjamin TL, 2001, VIROLOGY, V289, P167, DOI 10.1006/viro.2001.1124; BIKEL I, 1992, J VIROL, V66, P1489, DOI 10.1128/JVI.66.3.1489-1494.1992; CAMPBELL KS, 1995, J VIROL, V69, P3721, DOI 10.1128/JVI.69.6.3721-3728.1995; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Damania B, 1998, MOL CELL BIOL, V18, P3926, DOI 10.1128/MCB.18.7.3926; Eckner R, 1996, MOL CELL BIOL, V16, P3454; Felton-Edkins ZA, 2002, J BIOL CHEM, V277, P48182, DOI 10.1074/jbc.M201333200; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; FROST JA, 1994, MOL CELL BIOL, V14, P6244, DOI 10.1128/MCB.14.9.6244; Gottlieb KA, 2001, MICROBIOL MOL BIOL R, V65, P288, DOI 10.1128/MMBR.65.2.288-318.2001; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Kino T, 2001, GENES CELLS, V6, P441, DOI 10.1046/j.1365-2443.2001.00432.x; Kresse H, 2001, J CELL PHYSIOL, V189, P266, DOI 10.1002/jcp.10030; Lecanda F, 2000, J CELL BIOCHEM, V77, P499, DOI 10.1002/(SICI)1097-4644(20000601)77:3<499::AID-JCB14>3.0.CO;2-0; LOEKEN M, 1988, CELL, V55, P1171, DOI 10.1016/0092-8674(88)90261-9; LOEKEN MR, 1992, J VIROL, V66, P2551, DOI 10.1128/JVI.66.4.2551-2555.1992; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; LUTCHMAN M, 1995, CANCER RES, V55, P2270; Menssen A, 2002, P NATL ACAD SCI USA, V99, P6274, DOI 10.1073/pnas.082005599; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; MUDRAK I, 1994, MOL CELL BIOL, V14, P1886, DOI 10.1128/MCB.14.3.1886; Nemethova M, 1999, J VIROL, V73, P1734, DOI 10.1128/JVI.73.2.1734-1739.1999; OGRIS E, 1993, J VIROL, V67, P1765, DOI 10.1128/JVI.67.4.1765-1771.1993; OGRIS E, 1993, ONCOGENE, V8, P1277; OGRIS E, 1992, J VIROL, V66, P53, DOI 10.1128/JVI.66.1.53-61.1992; Ohtani K, 1999, ONCOGENE, V18, P2299, DOI 10.1038/sj.onc.1202544; PIPAS JM, 1992, J VIROL, V66, P3979, DOI 10.1128/JVI.66.7.3979-3985.1992; Porras A, 1996, J VIROL, V70, P6902; Porras A, 1999, J VIROL, V73, P3102; Sambrook J., 2002, MOL CLONING LAB MANU; Schuchner S, 2001, J VIROL, V75, P6498, DOI 10.1128/JVI.75.14.6498-6507.2001; Schuchner S, 1999, J VIROL, V73, P9266; Shin CS, 2000, J CELL BIOCHEM, V78, P566, DOI 10.1002/1097-4644(20000915)78:4<566::AID-JCB6>3.0.CO;2-K; SONNTAG E, 1993, CELL, V75, P887; Stander M, 1999, CELL TISSUE RES, V296, P221, DOI 10.1007/s004410051283; Tsuruga H, 1997, GENES CELLS, V2, P381, DOI 10.1046/j.1365-2443.1997.1290327.x; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; Yu J, 2001, VIROLOGY, V290, P192, DOI 10.1006/viro.2001.1204	41	12	12	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2004	23	27					4707	4721		10.1038/sj.onc.1207640	http://dx.doi.org/10.1038/sj.onc.1207640			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZX	15122341				2022-12-28	WOS:000221799200006
J	Sun, LX; Vitolo, MI; Qiao, M; Anglin, IE; Passaniti, A				Sun, LX; Vitolo, MI; Qiao, M; Anglin, IE; Passaniti, A			Regulation of TGF beta(1)-mediated growth inhibition and apoptosis by RUNX2 isoforms in endothelial cells	ONCOGENE			English	Article						transcription factors; endothelial cells; proliferation; apoptosis	TRANSCRIPTION FACTOR PEBP2/CBF; ANGIOGENESIS IN-VITRO; FACTOR-BETA; EXTRACELLULAR-MATRIX; TGF-BETA; OSTEOBLAST DIFFERENTIATION; CLEIDOCRANIAL DYSPLASIA; TUMOR ANGIOGENESIS; DEPENDENT KINASE; BONE-DEVELOPMENT	Runx transcription factors regulate viral growth, hematopoiesis, bone formation, angiogenesis, and gastric epithelial development through specific DNA-binding motifs on target gene promoters. Vascular endothelial cells (ECs) express RUNX genes that are activated by angiogenic factors. The RUNX2 gene also activates the vascular endothelial growth factor promoter. Alternatively spliced forms of RUNX genes have been described, but their functions in angiogenesis have not been elucidated. In this study, expression of a novel alternatively spliced variant of RUNX2 (RUNX2Delta8), lacking the region encoded by exon 8, was detected in aortic tissue undergoing angiogenesis in vitro and in ECs. Expression of RUNX2 and RUNX2Delta8 increased in vascular sprouts concomitant with expression of cellular proteases and cytokines known to mediate angiogenesis. RUNX2 DNA-binding activity was expressed in proliferating but not quiescent ECs. Ectopic expression of RUNX2 in ECs increased cell sprouting, cell proliferation, DNA synthesis, and phosphorylation of phosphorylated retinoblastoma relative to control transfectants while RUNX2, but not RUNX2Delta8 transfectants, acquired resistance to growth inhibition by transforming growth factor (TGFbeta(1)). Furthermore, RUNX2Delta8-transfected cells were more sensitive to TGFbeta(1)-induced apoptosis than RUNX2 transfectants. Consistent with these data, the RUNX2 gene was a strong repressor of the promoter of the cyclin-dependent kinase inhibitor, p21(CIP1), while RUNX2Delta8 was a competitive inhibitor of RUNX2 and exhibited weak repression activity. These results support the hypothesis that ECs regulate growth and apoptosis, in part, by alternative splicing events in the RUNX2 transcription factor to affect the TGFbeta(1) signaling pathway. The exon 8 domain of RUNX2 may contribute to the strong repression activity of RUNX2 for some target gene promoters.	Univ Maryland, Sch Med, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Passaniti, A (corresponding author), Univ Maryland, Sch Med, Greenebaum Canc Ctr, 655 W Baltimore St, Baltimore, MD 21201 USA.	apass001@umaryland.edu		Vitolo, Michele/0000-0001-8055-9645	NCI NIH HHS [CA95350-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA095350] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROW MG, 1995, P NATL ACAD SCI USA, V92, P3239, DOI 10.1073/pnas.92.8.3239; ASAHARA T, 1995, CIRCULATION, V92, P365, DOI 10.1161/01.CIR.92.9.365; Baltzinger M, 1999, DEV DYNAM, V216, P420, DOI 10.1002/(SICI)1097-0177(199912)216:4/5<420::AID-DVDY10>3.0.CO;2-C; Beck L, 1997, FASEB J, V11, P365, DOI 10.1096/fasebj.11.5.9141503; Blyth K, 2001, ONCOGENE, V20, P295, DOI 10.1038/sj.onc.1204090; Bravo J, 2001, NAT STRUCT BIOL, V8, P371, DOI 10.1038/86264; Burchardt M, 1999, BIOL REPROD, V60, P398, DOI 10.1095/biolreprod60.2.398; Carmeliet P, 2000, J PATHOL, V190, P387; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ferrara N, 2000, RECENT PROG HORM RES, V55, P15; FLAUMENHAFT R, 1992, J CELL BIOL, V118, P901, DOI 10.1083/jcb.118.4.901; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Geoffroy V, 1998, MAMM GENOME, V9, P54, DOI 10.1007/s003359900679; Gothie E, 2000, J BIOL CHEM, V275, P6922, DOI 10.1074/jbc.275.10.6922; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; Hata-Sugi N, 2002, BIOL PHARM BULL, V25, P446, DOI 10.1248/bpb.25.446; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Huang YQ, 2000, BLOOD, V95, P1993, DOI 10.1182/blood.V95.6.1993; Ito Y, 1999, GENES CELLS, V4, P685, DOI 10.1046/j.1365-2443.1999.00298.x; Ito Y, 2003, CURR OPIN GENET DEV, V13, P43, DOI 10.1016/S0959-437X(03)00007-8; Jakubowiak A, 2000, J BIOL CHEM, V275, P40282, DOI 10.1074/jbc.C000485200; Kalluri R, 2000, CURR OPIN NEPHROL HY, V9, P413, DOI 10.1097/00041552-200007000-00013; Kerbel RS, 2000, CARCINOGENESIS, V21, P505, DOI 10.1093/carcin/21.3.505; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kriventseva EV, 2003, TRENDS GENET, V19, P124, DOI 10.1016/S0168-9525(03)00023-4; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; Lehr JE, 1998, J NATL CANCER I, V90, P118, DOI 10.1093/jnci/90.2.118; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Li WW, 2000, ACAD RADIOL, V7, P800, DOI 10.1016/S1076-6332(00)80629-7; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; Lund AH, 2002, CANCER CELL, V1, P213, DOI 10.1016/S1535-6108(02)00049-1; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; LYONS RM, 1990, EUR J BIOCHEM, V187, P467, DOI 10.1111/j.1432-1033.1990.tb15327.x; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Nagata K, 1996, TRENDS BIOCHEM SCI, V21, P23, DOI 10.1016/0968-0004(96)80881-4; Namba K, 2000, ONCOGENE, V19, P106, DOI 10.1038/sj.onc.1203257; NEWTON LK, 1990, EXP CELL RES, V190, P127, DOI 10.1016/0014-4827(90)90153-2; Ngo CV, 2000, CELL GROWTH DIFFER, V11, P201; NICOSIA RF, 1990, LAB INVEST, V63, P115; NICOSIA RF, 1994, J CELL BIOL, V124, P183, DOI 10.1083/jcb.124.1.183; NICOSIA RF, 1994, AM J PATHOL, V145, P1023; Nor JE, 1999, AM J PATHOL, V154, P375, DOI 10.1016/S0002-9440(10)65284-4; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; PEPPER MS, 1990, J CELL BIOL, V111, P743, DOI 10.1083/jcb.111.2.743; Perry C, 2002, ONCOGENE, V21, P8428, DOI 10.1038/sj.onc.1205945; Pollman MJ, 1999, J CELL PHYSIOL, V178, P359, DOI 10.1002/(SICI)1097-4652(199903)178:3<359::AID-JCP10>3.3.CO;2-F; Rabbani SA, 1998, IN VIVO, V12, P135; Riccioni T, 1998, GENE THER, V5, P747, DOI 10.1038/sj.gt.3300681; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; Roninson IB, 2002, CANCER LETT, V179, P1, DOI 10.1016/S0304-3835(01)00847-3; Sato Y, 2000, PHARMACOL THERAPEUT, V87, P51, DOI 10.1016/S0163-7258(00)00067-X; Selvamurugan N, 2000, J BIOL CHEM, V275, P5037, DOI 10.1074/jbc.275.7.5037; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Smith JS, 2002, TRENDS CELL BIOL, V12, P404, DOI 10.1016/S0962-8924(02)02342-5; Sorek R, 2001, NAT BIOTECHNOL, V19, P196, DOI 10.1038/85613; Stewart M, 1997, P NATL ACAD SCI USA, V94, P8646, DOI 10.1073/pnas.94.16.8646; Sun LX, 2001, CANCER RES, V61, P4994; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; Takakura N, 2000, CELL, V102, P199, DOI 10.1016/S0092-8674(00)00025-8; TAKECHI H, 1994, MOL CELL BIOL, V14, P567, DOI 10.1128/MCB.14.1.567; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Vaillant F, 1999, ONCOGENE, V18, P7124, DOI 10.1038/sj.onc.1203202; Wang WG, 1999, J CELL BIOCHEM, V73, P321; Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982-7992.2002; Westendorf JJ, 1999, J CELL BIOCHEM, P51; Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453; Xiao ZS, 1998, GENE, V214, P187, DOI 10.1016/S0378-1119(98)00227-3; Yang CL, 1996, CELL GROWTH DIFFER, V7, P161; Zelzer E, 2001, MECH DEVELOP, V106, P97, DOI 10.1016/S0925-4773(01)00428-2; Zhang YW, 1997, ONCOGENE, V15, P367, DOI 10.1038/sj.onc.1201352	77	41	42	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2004	23	27					4722	4734		10.1038/sj.onc.1207589	http://dx.doi.org/10.1038/sj.onc.1207589			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZX	15107836				2022-12-28	WOS:000221799200007
J	Zelent, A; Greaves, M; Enver, T				Zelent, A; Greaves, M; Enver, T			Role of the TEL-AML1 fusion gene in the molecular pathogenesis of childhood acute lymphoblastic leukaemia	ONCOGENE			English	Review						prenatal; co-repressor; histone deacetylase; translocation	ACUTE MYELOID-LEUKEMIA; MULTIPLE CHROMOSOMAL TRANSLOCATIONS; ACUTE PROMYELOCYTIC LEUKEMIA; T-CELL-RECEPTOR; TRANSCRIPTION FACTORS; DNA-BINDING; FUNCTIONAL COOPERATION; EMBRYONIC LETHALITY; RUNT DOMAIN; AML1 GENE	Balanced chromosomal translocations are frequently associated with haematopoietic neoplasms and often involve genes that encode transcription factors, which play critical roles in normal haematopoiesis. Fusion oncoproteins that arise from chimeric genes generated by such translocations are usually stable and consistent molecular markers for a given disease subtype and contribute to the leukaemogenic processes. The t(12; 21)(p13; q22) chromosomal translocation is the most frequent illegitimate gene recombination in paediatric cancer, occurring in approximately 25% of common ( c) B-cell precursor acute lymphoblastic leukaemia (cALL) cases. The rearrangement results in the in-frame fusion of the 50 region of the ETS-related gene, TEL (ETV6), to almost the entire AML1 (RUNX1) locus and is associated with favourable prognosis following conventional therapeutic strategies. We discuss here the prenatal origins of the TEL/AML1 translocation as an initiating mutation, the role of TEL-AML1 in cellular transformation and the molecular mechanisms by which the chimeric protein imposes altered patterns of gene expression.	Inst Canc Res, Chester Beatty Labs, Sect Haematol Oncol, London SW3 6JB, England; Univ Oxford, Weatherall Inst Mol Med, MRC, Mol Haematol Unit, Oxford, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Oxford	Zelent, A (corresponding author), Inst Canc Res, Chester Beatty Labs, Sect Haematol Oncol, 237 Fulham Rd, London SW3 6JB, England.	arthur.zelent@icr.ac.uk	Zelent, Arthur/B-3532-2009	Zelent, Arthur/0000-0002-7968-9888				Alexander FE, 2001, CANCER RES, V61, P2542; Andreasson P, 2001, CANCER GENET CYTOGEN, V130, P93, DOI 10.1016/S0165-4608(01)00518-0; Armstrong SA, 2003, CANCER CELL, V3, P173, DOI 10.1016/S1535-6108(03)00003-5; Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; Barr FG, 1998, NAT GENET, V19, P121, DOI 10.1038/475; Berger R, 1997, CANCER GENET CYTOGEN, V94, P8, DOI 10.1016/S0165-4608(96)00351-2; Bernardin F, 2002, CANCER RES, V62, P3904; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Bushweller JH, 2003, BLOOD, V102, p171A; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; Chen GQ, 1999, GENE DEV, V13, P2218, DOI 10.1101/gad.13.17.2218; Enver T, 1998, CELL, V94, P9, DOI 10.1016/S0092-8674(00)81215-5; ERICKSON P, 1992, BLOOD, V80, P1825; Fears S, 1996, GENE CHROMOSOME CANC, V17, P127, DOI 10.1002/(SICI)1098-2264(199610)17:2<127::AID-GCC8>3.3.CO;2-L; Fears S, 1997, P NATL ACAD SCI USA, V94, P1949, DOI 10.1073/pnas.94.5.1949; Fenrick R, 2000, MOL CELL BIOL, V20, P5828, DOI 10.1128/MCB.20.16.5828-5839.2000; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; Ford AM, 2001, BLOOD, V98, P558, DOI 10.1182/blood.V98.3.558; Gamou T, 1998, BLOOD, V91, P4028, DOI 10.1182/blood.V91.11.4028.411a45_4028_4037; Ghia P, 1998, IMMUNOL TODAY, V19, P480, DOI 10.1016/S0167-5699(98)01330-9; Gilliland DG, 2002, CURR OPIN HEMATOL, V9, P274, DOI 10.1097/00062752-200207000-00003; GOLUB T, 1996, BIOCHIM BIOPHYS ACTA, V1288, P7; Golub TR, 1996, CURR TOP MICROBIOL, V211, P279; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Greaves M, 1999, EUR J CANCER, V35, P173, DOI 10.1016/S0959-8049(98)00433-X; Greaves MF, 2003, NAT REV CANCER, V3, P639, DOI 10.1038/nrc1164; Greaves MF, 1997, LANCET, V349, P344, DOI 10.1016/S0140-6736(96)09412-3; Greaves MF, 2003, BLOOD, V102, P2321, DOI 10.1182/blood-2002-12-3817; GREAVES MF, 1988, LEUKEMIA, V2, P120; Grimwade D, 2004, LEUKEMIA, V18, P375, DOI 10.1038/sj.leu.2403234; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Guidez F, 2000, BLOOD, V96, P2557; Guidez F, 1999, BLOOD, V94, p693A; Hassig CA, 1997, CURR OPIN CHEM BIOL, V1, P300, DOI 10.1016/S1367-5931(97)80066-X; He LZ, 1999, ONCOGENE, V18, P5278, DOI 10.1038/sj.onc.1203088; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; Hjalgrim LL, 2002, BRIT J CANCER, V87, P994, DOI 10.1038/sj.bjc.6600601; Hope KJ, 2003, ARCH MED RES, V34, P507, DOI 10.1016/j.arcmed.2003.08.007; Hotfilder M, 2002, BLOOD, V100, P640, DOI 10.1182/blood.V100.2.640; Ichikawa M, 2004, NAT MED, V10, P299, DOI 10.1038/nm997; Imai Y, 1998, BIOCHEM BIOPH RES CO, V252, P582, DOI 10.1006/bbrc.1998.9705; Imai Y, 2004, MOL CELL BIOL, V24, P1033, DOI 10.1128/MCB.24.3.1033-1043.2004; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Knudson A G, 1992, Semin Cancer Biol, V3, P99; Konrad M, 2003, BLOOD, V101, P3635, DOI 10.1182/blood-2002-10-3252; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; Lutterbach B, 1999, P NATL ACAD SCI USA, V96, P12822, DOI 10.1073/pnas.96.22.12822; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; Maia AT, 2004, GENE CHROMOSOME CANC, V39, P335, DOI 10.1002/gcc.20003; Maia AT, 2001, BLOOD, V98, P478, DOI 10.1182/blood.V98.2.478; Maris JM, 2002, CANCER CELL, V2, P447, DOI 10.1016/S1535-6108(02)00206-4; Mavrothalassitis G, 2000, ONCOGENE, V19, P6524, DOI 10.1038/sj.onc.1204045; McLean TW, 1996, BLOOD, V88, P4252; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Mori H, 2002, P NATL ACAD SCI USA, V99, P8242, DOI 10.1073/pnas.112218799; MORROW M, 2004, IN PRESS BLOOD; NISSON PE, 1992, CANCER GENET CYTOGEN, V63, P81, DOI 10.1016/0165-4608(92)90384-K; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okada H, 1998, ONCOGENE, V17, P2287, DOI 10.1038/sj.onc.1202151; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; Petrie K, 2003, J BIOL CHEM, V278, P16059, DOI 10.1074/jbc.M212935200; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Ramakers-van Woerden NL, 2000, BLOOD, V96, P1094; Rego EM, 2001, J EXP MED, V193, P521, DOI 10.1084/jem.193.4.521; Romana SP, 1996, LEUKEMIA, V10, P167; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; ROMANA SP, 1995, BLOOD, V86, P4263, DOI 10.1182/blood.V86.11.4263.bloodjournal86114263; Roulston D, 1998, BLOOD, V92, P2879, DOI 10.1182/blood.V92.8.2879.420k22_2879_2885; Rowley JD, 1998, ANNU REV GENET, V32, P495, DOI 10.1146/annurev.genet.32.1.495; Schwieger M, 2002, J EXP MED, V196, P1227, DOI 10.1084/jem.20020824; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; Smith MT, 2002, BLOOD, V100, P4590, DOI 10.1182/blood-2001-12-0264; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Speck NA, 2002, NAT REV CANCER, V2, P502, DOI 10.1038/nrc840; Strick R, 2000, P NATL ACAD SCI USA, V97, P4790, DOI 10.1073/pnas.070061297; TAKAHASHI A, 1995, BLOOD, V86, P607, DOI 10.1182/blood.V86.2.607.bloodjournal862607; Takahashi Y, 1998, J PEDIAT HEMATOL ONC, V20, P190, DOI 10.1097/00043426-199805000-00002; Taketani T, 2004, BLOOD, V103, P1085, DOI 10.1182/blood-2003-02-0418; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Thompson JR, 2001, LANCET, V358, P1935, DOI 10.1016/S0140-6736(01)06959-8; TSUZUKI S, 2004, IN PRESS P NATL ACAD; Uchida H, 1997, J IMMUNOL, V158, P2251; Van Rompaey L, 2000, ONCOGENE, V19, P5244, DOI 10.1038/sj.onc.1203899; VIDALI G, 1978, P NATL ACAD SCI USA, V75, P2239, DOI 10.1073/pnas.75.5.2239; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Wang LL, 2001, ONCOGENE, V20, P3716, DOI 10.1038/sj.onc.1204479; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; Wiemels JL, 1999, BLOOD, V94, P1057, DOI 10.1182/blood.V94.3.1057.415k10_1057_1062; Wiemels JL, 2000, GENE CHROMOSOME CANC, V29, P219, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1028>3.0.CO;2-D; Wiemels JL, 1999, CANCER RES, V59, P4075; Wiemels JL, 1999, CANCER RES, V59, P4095; Wiemels JL, 2001, P NATL ACAD SCI USA, V98, P4004, DOI 10.1073/pnas.061408298; Wiemels JL, 1999, LANCET, V354, P1499, DOI 10.1016/S0140-6736(99)09403-9; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303	115	106	108	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2004	23	24					4275	4283		10.1038/sj.onc.1207672	http://dx.doi.org/10.1038/sj.onc.1207672			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823BZ	15156184				2022-12-28	WOS:000221586000013
J	Rivat, C; De Wever, O; Bruyneel, E; Mareel, M; Gespach, C; Attoub, S				Rivat, C; De Wever, O; Bruyneel, E; Mareel, M; Gespach, C; Attoub, S			Disruption of STAT3 signaling leads to tumor cell invasion through alterations of homotypic cell-cell adhesion complexes	ONCOGENE			English	Article						beta-catenin; E-cadherin tumor suppressor gene; EGF-R; PI3-kinase; Rho GTPases; Wnt pathway	EPIDERMAL-GROWTH-FACTOR; ANCHORAGE-INDEPENDENT GROWTH; HUMAN COLON-CANCER; BETA-CATENIN; TYROSINE PHOSPHORYLATION; FACTOR RECEPTOR; CONSTITUTIVE ACTIVATION; PHOSPHATIDYLINOSITOL 3-KINASE; EPITHELIAL-CELLS; FOCAL ADHESIONS	STAT3 is frequently overexpressed and constitutively activated by tyrosine phosphorylation during malignant transformation. Despite the clear importance of STAT3 in cell proliferation and survival in diverse human cancers, its possible contribution to tumor cell adhesion, motility and invasion remains hypothetical. We therefore compared the transforming properties of STAT3wt, its constitutively activated dimeric form STAT3C, and the dominant negative mutant STAT3-Y705F in human colorectal HCT8/S11 cancer cells. Both STAT3wt and STAT3C exert a permissive action to the proinvasive activity of the scatter factor HGF in HCT8/S11 cells. In contrast, the monomeric and cytoplasmic mutant Y705F induces a constitutive invasive phenotype through Wnt/Rho-independent and EGFR/PI3-kinase-dependent pathways. Accordingly, Y705F decreases cell-cell homotypic adhesions, and increases cell motility and scattering, as well as lamellipodia-type cellular extensions. STAT3-Y705F-transfected HCT8/S11 cells display an increased tyrosine phosphorylation of the cell-cell adhesion regulator beta-catenin and its dissociation from the invasion suppressor E-cadherin at cell-cell contacts. Our data imply that both invasion promoter and repressor genes are controlled by the canonical STAT3 transcription pathways. Disruption of this cascade by Y705F reveals the proinvasive potential of altered forms of STAT3 as a persistent signaling adaptor in cytokine/transforming growth factor receptor scaffolds and oncogenic pathways.	Hop St Antoine, INSERM, U482, F-75571 Paris 12, France; Univ Hosp, Expt Cancerol Lab, B-9000 Ghent, Belgium	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Ghent University; Ghent University Hospital	Attoub, S (corresponding author), Hop St Antoine, INSERM, U482, 184 Rue Faubourg St Antoine, F-75571 Paris 12, France.	attoub@st-antoine.inserm.fr	de wever, olivier/J-3094-2013; Attoub, Samir/N-6852-2018	de wever, olivier/0000-0002-5453-760X; 				Attoub S, 2000, FASEB J, V14, P2329, DOI 10.1096/fj.00-0162; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; Balsamo J, 1996, J CELL BIOL, V134, P801, DOI 10.1083/jcb.134.3.801; Barbier M, 2001, NATURE, V413, P796, DOI 10.1038/35101660; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Boterberg T, 2000, CELL ADHES COMMUN, V7, P299, DOI 10.3109/15419060009015001; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; BRACKE ME, 2000, COLLAGEN INVASION AS, V58, P81; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Daniel JM, 1997, BIOESSAYS, V19, P883, DOI 10.1002/bies.950191008; Danilkovitch-Miagkova A, 2001, MOL CELL BIOL, V21, P5857, DOI 10.1128/MCB.21.17.5857-5868.2001; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Florenes VA, 1999, ONCOGENE, V18, P1023, DOI 10.1038/sj.onc.1202382; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Goiot H, 2001, GASTROENTEROLOGY, V121, P1417, DOI 10.1053/gast.2001.29581; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hellyer NJ, 1998, BIOCHEM J, V333, P757, DOI 10.1042/bj3330757; Hiscox S, 1999, J CELL SCI, V112, P3081; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Huang M, 2000, GYNECOL ONCOL, V79, P67, DOI 10.1006/gyno.2000.5931; Hwang JH, 2003, MOL ENDOCRINOL, V17, P1155, DOI 10.1210/me.2002-0401; Ichiba M, 1998, J BIOL CHEM, V273, P6132, DOI 10.1074/jbc.273.11.6132; Ilan N, 1999, J CELL SCI, V112, P3005; Irby RB, 2002, CANCER RES, V62, P2669; Kim K, 2001, CELL BIOL INT, V25, P421, DOI 10.1006/cbir.2000.0650; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; Kortylewski M, 1999, ONCOGENE, V18, P3742, DOI 10.1038/sj.onc.1202708; Kotelevets L, 1998, J BIOL CHEM, V273, P14138, DOI 10.1074/jbc.273.23.14138; Laird AD, 2003, MOL CANCER THER, V2, P461; Matsui T, 2002, J BIOL CHEM, V277, P36167, DOI 10.1074/jbc.M203184200; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Ning ZQ, 2001, ONCOGENE, V20, P4528, DOI 10.1038/sj.onc.1204590; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; OSUGI T, 2001, J BIOL CHEM, V14, P14; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Pansky A, 2000, INT J CANCER, V85, P720, DOI 10.1002/(SICI)1097-0215(20000301)85:5<720::AID-IJC20>3.0.CO;2-O; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Price JT, 1996, EUR J CANCER, V32A, P1977, DOI 10.1016/0959-8049(96)00207-9; RADINSKY R, 1995, CLIN CANCER RES, V1, P19; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rodrigues S, 2003, ONCOGENE, V22, P4488, DOI 10.1038/sj.onc.1206685; Rosenblum CI, 1996, ENDOCRINOLOGY, V137, P5178, DOI 10.1210/en.137.11.5178; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Sartor CI, 1997, CANCER RES, V57, P978; Shen YH, 2001, P NATL ACAD SCI USA, V98, P1543, DOI 10.1073/pnas.041588198; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Simon AR, 2000, SCIENCE, V290, P144, DOI 10.1126/science.290.5489.144; Spiotto MT, 2000, PROSTATE, V42, P186, DOI 10.1002/(SICI)1097-0045(20000215)42:3<186::AID-PROS4>3.0.CO;2-E; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Turner T, 1996, CLIN EXP METASTAS, V14, P409, DOI 10.1007/BF00123400; Uttamsingh S, 2003, J BIOL CHEM, V278, P18798, DOI 10.1074/jbc.M211522200; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; VERMEULEN SJ, 1995, CANCER RES, V55, P4722; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Xi SC, 2003, J BIOL CHEM, V278, P31574, DOI 10.1074/jbc.M303499200; Xia L, 2002, J BIOL CHEM, V277, P30716, DOI 10.1074/jbc.M202823200; Xie H, 1998, J CELL SCI, V111, P615; Yarden Y, 2001, EUR J CANCER, V37, pS3; Yoshioka K, 1998, J BIOL CHEM, V273, P5146, DOI 10.1074/jbc.273.9.5146; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhang XK, 1999, MOL CELL BIOL, V19, P7138; Zhang YW, 2002, ONCOGENE, V21, P217, DOI 10.1038/sj/onc/1205004; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	75	35	40	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3317	3327		10.1038/sj.onc.1207437	http://dx.doi.org/10.1038/sj.onc.1207437			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15077188				2022-12-28	WOS:000220975000006
J	Rother, K; Johne, C; Spiesbach, K; Haugwitz, U; Tschop, K; Wasner, M; Klein-Hitpass, L; Moroy, T; Mossner, J; Engeland, K				Rother, K; Johne, C; Spiesbach, K; Haugwitz, U; Tschop, K; Wasner, M; Klein-Hitpass, L; Moroy, T; Mossner, J; Engeland, K			Identification of Tcf-4 as a transcriptional target of p53 signalling	ONCOGENE			English	Article						p53; Tcf-4; promoter; repression; beta-catenin; DNA microarray	SUPPRESSOR PROTEIN P53; HOMOLOGY REGION CHR; BETA-CATENIN; CELL-CYCLE; TUMOR-SUPPRESSOR; DEPENDENT REPRESSION; GENE-EXPRESSION; BINDING; ACTIVATION; CANCER	T-cell factor (Tcf)-4 is a main transcription factor to pass on Wnt/beta-catenin signalling. The tumour suppressor protein p53 contributes as a transcription factor to cell-cycle arrest and apoptosis induction. Mutations of components in p53 and Wnt/beta-catenin signalling networks play a part in tumour formation. Here, we identify the Tcf-4 gene as a downstream effector of p53. Induction of wild-type p53 in a tet-off regulated human colon cell system leads to the reduction of Tcf-4 mRNA and protein levels. Also, mRNA of the Tcf-4 target gene uPAR is downregulated after p53 induction. Expression of a luciferase reporter controlled by the Tcf-4 promoter is repressed by wild-type p53, but not by a p53 mutant deficient in DNA binding. Such a regulation is seen in cell lines of different origin. These findings directly link Wnt/beta-catenin signalling and p53 tumour suppressor function and may provide a mechanism by which loss of p53 function contributes to progression in the adenoma/carcinoma sequence in colon tumours. Furthermore, since Tcf-4 is expressed in many tissues and downregulation of Tcf-4 by p53 is seen in several different cell types, this regulation likely plays a role in proliferation control of all tissues that can express p53 and Tcf-4.	Univ Leipzig, Max Burger Forschungszentrum, Med Klin & Poliklin 2, D-04103 Leipzig, Germany; Univ Essen Gesamthsch Klinikum, Inst Zellbiol, D-45122 Essen, Germany	Leipzig University; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Duisburg Essen	Engeland, K (corresponding author), Univ Leipzig, Max Burger Forschungszentrum, Med Klin & Poliklin 2, Johannisallee 30, D-04103 Leipzig, Germany.	engeland@medizin.uni-eipzig.de	Moroy, Tarik/D-9923-2011; Engeland, Kurt/AAW-9965-2020; Rother, Karen/GQI-3786-2022	Engeland, Kurt/0000-0003-3525-0440; Rother, Karen/0000-0002-0074-7329				Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1990, CANCER RES, V50, P7717; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Barker N, 1999, AM J PATHOL, V154, P29, DOI 10.1016/S0002-9440(10)65247-9; Barker N, 2000, ADV CANCER RES, V77, P1; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Budhram-Mahadeo V, 1999, J BIOL CHEM, V274, P15237, DOI 10.1074/jbc.274.21.15237; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Clevers H, 2000, NAT CELL BIOL, V2, pE177, DOI 10.1038/35036424; Contente A, 2002, NAT GENET, V30, P315, DOI 10.1038/ng836; Damalas A, 1999, EMBO J, V18, P3054, DOI 10.1093/emboj/18.11.3054; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Desdouets C, 1996, FEBS LETT, V385, P34, DOI 10.1016/0014-5793(96)00330-4; Dietz S, 2002, FEBS LETT, V525, P93, DOI 10.1016/S0014-5793(02)03093-4; Duval A, 2000, CANCER RES, V60, P3872; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Haugwitz U, 2002, NUCLEIC ACIDS RES, V30, P1967, DOI 10.1093/nar/30.9.1967; Heinrichs S, 2003, ONCOGENE, V22, P555, DOI 10.1038/sj.onc.1206138; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Huelsken J, 2002, J CELL SCI, V115, P3977, DOI 10.1242/jcs.00089; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Johnson RA, 2001, J BIOL CHEM, V276, P27716, DOI 10.1074/jbc.C100121200; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Krause K, 2001, BIOCHEM BIOPH RES CO, V284, P743, DOI 10.1006/bbrc.2001.5040; Krause K, 2000, NUCLEIC ACIDS RES, V28, P4410, DOI 10.1093/nar/28.22.4410; Lee KC, 1999, MOL CELL BIOL, V19, P1279; Lohr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; MIYASHITA T, 1995, CELL, V80, P293; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Ori A, 1998, EMBO J, V17, P544, DOI 10.1093/emboj/17.2.544; Polakis P, 2000, GENE DEV, V14, P1837; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Rosin-Arbesfeld R, 2003, EMBO J, V22, P1101, DOI 10.1093/emboj/cdg105; Sadot E, 2001, MOL CELL BIOL, V21, P6768, DOI 10.1128/MCB.21.20.6768-6781.2001; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; Thiele A, 2001, J IMMUNOL, V167, P6786, DOI 10.4049/jimmunol.167.12.6786; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang J, 2000, ONCOGENE, V19, P1843, DOI 10.1038/sj.onc.1203503; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Wasner M, 2003, GENE, V312, P225, DOI 10.1016/S0378-1119(03)00618-8; Wasner M, 2003, FEBS LETT, V536, P66, DOI 10.1016/S0014-5793(03)00028-0; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677	70	52	52	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3376	3384		10.1038/sj.onc.1207464	http://dx.doi.org/10.1038/sj.onc.1207464			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	14990988				2022-12-28	WOS:000220975000012
J	Guicciardi, ME; Leist, M; Gores, GJ				Guicciardi, ME; Leist, M; Gores, GJ			Lysosomes in cell death	ONCOGENE			English	Review						cathepsins; Spi2A; TNF alpha	MEDIATED HEPATOCYTE APOPTOSIS; HIPPOCAMPAL NEURONAL DEATH; CATHEPSIN-B CONTRIBUTES; PH-INDUCED INACTIVATION; CYTOCHROME-C RELEASE; OXIDATIVE STRESS; CYSTEINE PROTEASES; MEMBRANE PERMEABILIZATION; INCREASED EXPRESSION; TNF-ALPHA	For many years apoptosis research has focused on caspases and their putative role as sole executioners of programmed cell death. Accumulating information now suggests that lysosomal cathepsins are also pivotally involved in this process, especially in pathological conditions. In particular, the role of lysosomes and lysosomal enzymes in initiation and execution of the apoptotic program has become clear in several models, to the point that the existence of a 'lysosomal pathway of apoptosis' is now generally accepted. This pathway of apoptosis can be activated by death receptors, lipid mediators, and photo-damage. Lysosomal proteases can be released from the lysosomes into the cytosol, where they contribute to the apoptotic cascade upstream of mitochondria. This review focuses on the players and the molecular mechanisms involved in the lysosomal pathway of apoptosis as well as on the importance of this pathway in development and pathology.	Mayo Clin, Coll Med, Rochester, MN 55905 USA; H Lundbeck & Co AS, DK-2500 Valby, Denmark	Mayo Clinic; Lundbeck Corporation	Gores, GJ (corresponding author), Mayo Med Sch Clin & Fdn, 200 1st St SW, Rochester, MN 55905 USA.	gores.gregory@mayo.edu	Leist, Marcel/D-2133-2010	Leist, Marcel/0000-0002-3778-8693	NIDDK NIH HHS [DK63947] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063947] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Antunes F, 2001, BIOCHEM J, V356, P549, DOI 10.1042/0264-6021:3560549; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Bahr BA, 2002, J NEUROCHEM, V83, P481, DOI 10.1046/j.1471-4159.2002.01192.x; BANAYSCHWARTZ M, 1987, NEUROCHEM RES, V12, P361, DOI 10.1007/BF00993246; BERG T, 1995, BIOCHEM J, V307, P313, DOI 10.1042/bj3070313; Bidere N, 2003, J BIOL CHEM, V278, P31401, DOI 10.1074/jbc.M301911200; Boya P, 2003, ONCOGENE, V22, P3927, DOI 10.1038/sj.onc.1206622; Boya P, 2003, J EXP MED, V197, P1323, DOI 10.1084/jem.20021952; Brunk UT, 1999, REDOX REP, V4, P3, DOI 10.1179/135100099101534675; Bursch W, 2001, CELL DEATH DIFFER, V8, P569, DOI 10.1038/sj.cdd.4400852; CAMPO E, 1994, AM J PATHOL, V145, P301; Canbay A, 2003, J CLIN INVEST, V112, P152, DOI 10.1172/JCI200317740; CANTOR AB, 1992, J BIOL CHEM, V267, P23357; CASTIGLIONI T, 1994, HUM PATHOL, V25, P857, DOI 10.1016/0046-8177(94)90003-5; Chapman HA, 1997, ANNU REV PHYSIOL, V59, P63, DOI 10.1146/annurev.physiol.59.1.63; Chi SJ, 1999, ONCOGENE, V18, P2281, DOI 10.1038/sj.onc.1202538; Cirman T, 2004, J BIOL CHEM, V279, P3578, DOI 10.1074/jbc.M308347200; Claus V, 1998, J BIOL CHEM, V273, P9842, DOI 10.1074/jbc.273.16.9842; Cuervo AM, 2000, EXP GERONTOL, V35, P119, DOI 10.1016/S0531-5565(00)00075-9; Dare E, 2001, FREE RADICAL BIO MED, V30, P1347, DOI 10.1016/S0891-5849(01)00526-3; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; Demchik LL, 1999, INT J DEV NEUROSCI, V17, P483, DOI 10.1016/S0736-5748(99)00011-8; Demoz M, 1999, J CELL BIOCHEM, V73, P370, DOI 10.1002/(SICI)1097-4644(19990601)73:3<370::AID-JCB8>3.0.CO;2-N; Demoz M, 2002, BIOL CHEM, V383, P1237, DOI 10.1515/BC.2002.137; Faubion WA, 1999, J CLIN INVEST, V103, P137, DOI 10.1172/JCI4765; Felbor U, 2002, P NATL ACAD SCI USA, V99, P7883, DOI 10.1073/pnas.112632299; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Ferri KF, 2000, NAT CELL BIOL, V2, pE63, DOI 10.1038/35008692; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; Foghsgaard L, 2002, J BIOL CHEM, V277, P39499, DOI 10.1074/jbc.M206669200; Guicciardi ME, 2000, J CLIN INVEST, V106, P1127, DOI 10.1172/JCI9914; Guicciardi ME, 2001, AM J PATHOL, V159, P2045, DOI 10.1016/S0002-9440(10)63056-8; Halangk W, 2000, J CLIN INVEST, V106, P773, DOI 10.1172/JCI9411; Heinrich M, 1999, EMBO J, V18, P5252, DOI 10.1093/emboj/18.19.5252; Hishita T, 2001, CANCER RES, V61, P2878; Houseweart MK, 2003, CELL DEATH DIFFER, V10, P1329, DOI 10.1038/sj.cdd.4401309; Houseweart MK, 2003, J NEUROBIOL, V56, P315, DOI 10.1002/neu.10253; Ishidoh K, 2002, BIOL CHEM, V383, P1827, DOI 10.1515/BC.2002.206; Ishisaka R, 1999, CELL STRUCT FUNCT, V24, P465, DOI 10.1247/csf.24.465; Ishisaka R, 2001, J BIOCHEM-TOKYO, V129, P35, DOI 10.1093/oxfordjournals.jbchem.a002833; JAATTELA M, 1995, ONCOGENE, V10, P2297; Jaattela M, 2002, ANN MED, V34, P480, DOI 10.1080/078538902321012423; Johansson AC, 2003, CELL DEATH DIFFER, V10, P1253, DOI 10.1038/sj.cdd.4401290; Jones B, 1998, AM J PHYSIOL-GASTR L, V275, pG723, DOI 10.1152/ajpgi.1998.275.4.G723; Kagedal K, 2001, FASEB J, V15, P1592, DOI 10.1096/fj.00-0708fje; Kagedal K, 2001, BIOCHEM J, V359, P335, DOI 10.1042/0264-6021:3590335; Katunuma N, 2003, BIOL CHEM, V384, P883, DOI 10.1515/BC.2003.099; Katunuma N, 2001, ADV ENZYME REGUL, V41, P237, DOI 10.1016/S0065-2571(00)00018-2; Koblinski JE, 2000, CLIN CHIM ACTA, V291, P113, DOI 10.1016/S0009-8981(99)00224-7; Koike M, 2000, J NEUROSCI, V20, P6898, DOI 10.1523/JNEUROSCI.20-18-06898.2000; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Leist M, 2001, CELL DEATH DIFFER, V8, P324, DOI 10.1038/sj.cdd.4400859; Levicar N, 2003, ACTA NEUROCHIR, V145, P825, DOI 10.1007/s00701-003-0097-z; Li W, 2000, FEBS LETT, V470, P35, DOI 10.1016/S0014-5793(00)01286-2; Li W, 2003, BIOCHEM J, V371, P429, DOI 10.1042/BJ20021520; Lieuallen K, 2001, HUM MOL GENET, V10, P1867, DOI 10.1093/hmg/10.18.1867; Liu N, 2003, EMBO J, V22, P5313, DOI 10.1093/emboj/cdg510; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Madge LA, 2003, J BIOL CHEM, V278, P21295, DOI 10.1074/jbc.M212837200; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; MATUS A, 1987, BIOCHEMISTRY-US, V26, P8083, DOI 10.1021/bi00399a010; Mayer A, 1997, CANCER INVEST, V15, P106, DOI 10.3109/07357909709115762; Nakagawa T, 1998, SCIENCE, V280, P450, DOI 10.1126/science.280.5362.450; Nakanishi H, 1997, J NEUROCHEM, V68, P739; Nishimura Y, 1998, Pathol Oncol Res, V4, P283; Ollinger K, 2000, ARCH BIOCHEM BIOPHYS, V373, P346, DOI 10.1006/abbi.1999.1567; Ono K, 2003, MOL CELL BIOL, V23, P665, DOI 10.1128/MCB.23.2.665-676.2003; Persson HL, 2003, FREE RADICAL BIO MED, V34, P1295, DOI 10.1016/S0891-5849(03)00106-0; Raha S, 2000, TRENDS BIOCHEM SCI, V25, P502, DOI 10.1016/S0968-0004(00)01674-1; Reiners JJ, 2002, CELL DEATH DIFFER, V9, P934, DOI 10.1038/sj.cdd.4401048; Reinheckel T, 2001, BIOL CHEM, V382, P735, DOI 10.1515/BC.2001.089; REMPEL SA, 1994, CANCER RES, V54, P6027; Roberg K, 1998, AM J PATHOL, V152, P1151; Roberg K, 1999, FREE RADICAL BIO MED, V27, P1228, DOI 10.1016/S0891-5849(99)00146-X; Roberts Lewis R., 1999, Cell Biochemistry and Biophysics, V30, P71, DOI 10.1007/BF02737885; Roberts LR, 1997, GASTROENTEROLOGY, V113, P1714, DOI 10.1053/gast.1997.v113.pm9352877; Roth W, 2000, FASEB J, V14, P2075, DOI 10.1096/fj.99-0970com; SAFTIG P, 1995, EMBO J, V14, P3599, DOI 10.1002/j.1460-2075.1995.tb00029.x; Schotte P, 1998, BIOCHEM BIOPH RES CO, V251, P379, DOI 10.1006/bbrc.1998.9425; Schutze S, 1999, J BIOL CHEM, V274, P10203, DOI 10.1074/jbc.274.15.10203; Shibata M, 1998, BIOCHEM BIOPH RES CO, V251, P199, DOI 10.1006/bbrc.1998.9422; Shuja S, 1996, INT J CANCER, V66, P420, DOI 10.1002/(SICI)1097-0215(19960516)66:4<420::AID-IJC2>3.0.CO;2-Y; SINHA AA, 1995, PROSTATE, V26, P171, DOI 10.1002/pros.2990260402; SMOLEN JE, 1986, BIOCHIM BIOPHYS ACTA, V886, P1, DOI 10.1016/0167-4889(86)90205-3; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; SUKOH N, 1994, CANCER, V74, P46, DOI 10.1002/1097-0142(19940701)74:1<46::AID-CNCR2820740109>3.0.CO;2-G; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; Tobin DJ, 2002, AM J PATHOL, V160, P1807, DOI 10.1016/S0002-9440(10)61127-3; Tsuchiya K, 1999, EXP NEUROL, V155, P187, DOI 10.1006/exnr.1998.6988; Turk B, 2000, BBA-PROTEIN STRUCT M, V1477, P98, DOI 10.1016/S0167-4838(99)00263-0; TURK B, 1993, BIOCHEMISTRY-US, V32, P375, DOI 10.1021/bi00052a046; Turk B, 2002, BIOL CHEM, V383, P1035, DOI 10.1515/BC.2002.112; TURK B, 1995, BIOL CHEM H-S, V376, P225, DOI 10.1515/bchm3.1995.376.4.225; Turk B, 1997, BIOL CHEM, V378, P141; Vancompernolle K, 1998, FEBS LETT, V438, P150, DOI 10.1016/S0014-5793(98)01275-7; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang JH, 1997, AM J PHYSIOL-CELL PH, V272, pC1543, DOI 10.1152/ajpcell.1997.272.5.C1543; WATANABE M, 1989, BIOCHEM MED METAB B, V42, P21, DOI 10.1016/0885-4505(89)90037-6; Welss T, 2003, BIOCHEMISTRY-US, V42, P7381, DOI 10.1021/bi027307q; Werneburg NW, 2002, AM J PHYSIOL-GASTR L, V283, pG947, DOI 10.1152/ajpgi.00151.2002; Wu GS, 1998, ONCOGENE, V16, P2177, DOI 10.1038/sj.onc.1201755; Xing RY, 1998, CANCER RES, V58, P904; Yamashima T, 1998, EUR J NEUROSCI, V10, P1723, DOI 10.1046/j.1460-9568.1998.00184.x; ZDOLSEK J, 1993, FREE RADICAL RES COM, V18, P71, DOI 10.3109/10715769309147344; Zhao M, 2000, FEBS LETT, V485, P104, DOI 10.1016/S0014-5793(00)02195-5; Zhao M, 2001, FEBS LETT, V509, P405, DOI 10.1016/S0014-5793(01)03185-4; Zhao M, 2001, FEBS LETT, V509, P399, DOI 10.1016/S0014-5793(01)03184-2; Zhao M, 2003, EUR J BIOCHEM, V270, P3778, DOI 10.1046/j.1432-1033.2003.03765.x	108	577	598	2	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2004	23	16					2881	2890		10.1038/sj.onc.1207512	http://dx.doi.org/10.1038/sj.onc.1207512			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	811VO	15077151	Green Submitted			2022-12-28	WOS:000220799600015
J	Wang, XF; Wang, QD; Hu, WQ; Evers, BM				Wang, XF; Wang, QD; Hu, WQ; Evers, BM			Regulation of phorbol ester-mediated TRAF1 induction in human colon cancer cells through a PKC/RAF/ERK/NF-kappa B-dependent pathway	ONCOGENE			English	Article						colon cancer; TRAF; PKC; NF-kappa B; ERK	NECROSIS-FACTOR RECEPTOR; PROTEIN-KINASE-C; GERANYLGERANYLTRANSFERASE-I INHIBITOR; SIGNAL-TRANSDUCTION PATHWAY; FACTOR FAMILY PROTEIN; SMOOTH-MUSCLE-CELLS; CYTOPLASMIC DOMAIN; PERSISTENT ACTIVATION; TRANSCRIPTION FACTOR; ADAPTER PROTEINS	Tumor necrosis factor (TNF) receptor-associated factors (TRAFs) are cytoplasmic adapter proteins that link a wide variety of cell surface receptors to the apoptotic signaling cascade. The purpose of this study was to delineate the signaling pathways and TRAF1 promoter elements responsible for phorbol ester-mediated TRAF1 induction in human colon cancers. Here, we found that the PKC activators, phorbol 12-myristate 13-acetate (PMA) and bryostatin I, induced TRAF1 mRNA expression; pretreatment with actinomycin D blocked PMA-mediated TRAF1 expression suggesting induction at the transcriptional level. In contrast, expression of other TRAFs (TRAF2, 3 and 4) was minimally altered by PMA. Various PKC isoform-selective inhibitors blocked PMA-mediated TRAF1 mRNA and promoter stimulation; rottlerin, a selective PKCdelta inhibitor, had no effect suggesting that Ca2+-dependent PKC isoforms (e.g., PKCalpha and betaI) play a role in TRAF1 regulation. In addition, the MEK/ERK inhibitors, PD98059 and UO126, suppressed PMA-stimulated TRAF1 promoter activity indicating a role for ERK in TRAF1 induction. Moreover, cotransfection of a dominant-negative Raf-1 (Raf-C4) significantly reduced PMA-stimulated TRAF1 promoter activity whereas transfection of dominant-negative Ras or treatment with Ras inhibitors had minimal to no effect on TRAF1 induction suggesting dependence on Raf, but not Ras, activation. Finally, site-specific mutagenesis of functional NF-kappaB sites (particularly the most proximal site) in the TRAF1 promoter significantly decreased PMA-mediated promoter activity. In conclusion, our results demonstrate selective induction of TRAF1 in human colon cancer cells through a Ca2+-dependent PKC/Raf-1/ERK/NF-kappaB-dependent pathway.	Univ Texas, Med Branch, Dept Surg, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Evers, BM (corresponding author), Univ Texas, Med Branch, Dept Surg, 301 Univ Blvd, Galveston, TX 77555 USA.	mevers@utmb.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048498] Funding Source: NIH RePORTER; NIDDK NIH HHS [P01 DK35408, R01 DK48498] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; BETZEL C, 1993, BIOCHIM BIOPHYS ACTA, V1161, P47, DOI 10.1016/0167-4838(93)90194-V; BILLMAN GE, 1993, AM J PHYSIOL, V265, pH1529, DOI 10.1152/ajpheart.1993.265.5.H1529; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Brasier AR, 2001, J BIOL CHEM, V276, P32080, DOI 10.1074/jbc.M102949200; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Carpentier I, 1999, FEBS LETT, V460, P246, DOI 10.1016/S0014-5793(99)01356-3; Chen F, 1999, CLIN CHEM, V45, P7; Chiloeches A, 1999, J BIOL CHEM, V274, P19762, DOI 10.1074/jbc.274.28.19762; Deng JO, 2002, CANCER CELL, V2, P323, DOI 10.1016/S1535-6108(02)00154-X; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Dhawan P, 2002, J BIOL CHEM, V277, P7920, DOI 10.1074/jbc.M112210200; Dhillon AS, 2003, MOL CELL BIOL, V23, P1983, DOI 10.1128/MCB.23.6.1983-1993.2003; Dunn IF, 1999, MOL IMMUNOL, V36, P611, DOI 10.1016/S0161-5890(99)00075-9; EVERS BM, 1995, J CLIN INVEST, V95, P2822, DOI 10.1172/JCI117987; Fang XJ, 2002, MOL CELL BIOL, V22, P2099, DOI 10.1128/MCB.22.7.2099-2110.2002; Finder JD, 1997, J BIOL CHEM, V272, P13484, DOI 10.1074/jbc.272.21.13484; Gekeler V, 1996, BRIT J CANCER, V74, P897, DOI 10.1038/bjc.1996.454; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; Han SS, 2002, J BIOCHEM MOL BIOL, V35, P337; HENNINGS H, 1987, CARCINOGENESIS, V8, P1343, DOI 10.1093/carcin/8.9.1343; Hernandez A, 2001, J GASTROINTEST SURG, V5, P56, DOI 10.1016/S1091-255X(01)80014-7; Hipp MS, 2002, EUR J IMMUNOL, V32, P2208, DOI 10.1002/1521-4141(200208)32:8<2208::AID-IMMU2208>3.0.CO;2-2; Inoue J, 2000, EXP CELL RES, V254, P14, DOI 10.1006/excr.1999.4733; Irmler M, 2000, FEBS LETT, V468, P129, DOI 10.1016/S0014-5793(00)01206-0; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; James G, 1996, P NATL ACAD SCI USA, V93, P4454, DOI 10.1073/pnas.93.9.4454; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; Jiang BB, 2002, ARTERIOSCL THROM VAS, V22, P1811, DOI 10.1161/01.ATV.0000037679.60584.3F; Jiang BB, 2001, ARTERIOSCL THROM VAS, V21, P1915, DOI 10.1161/hq1201.099424; JIANG S, 1994, EXP CELL RES, V212, P84, DOI 10.1006/excr.1994.1121; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Ku WC, 1997, BIOCHEM BIOPH RES CO, V241, P730, DOI 10.1006/bbrc.1997.7874; Kurland JF, 2003, J BIOL CHEM, V278, P32465, DOI 10.1074/jbc.M212919200; LEE HC, 1993, J BIOL CHEM, V268, P293; Lee HW, 2002, J BIOL CHEM, V277, P32624, DOI 10.1074/jbc.M200353200; Lee SY, 1996, J EXP MED, V183, P669, DOI 10.1084/jem.183.2.669; LERNER EC, 1995, J BIOL CHEM, V270, P26770, DOI 10.1074/jbc.270.45.26770; Lerner EC, 1997, ONCOGENE, V15, P1283, DOI 10.1038/sj.onc.1201296; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; MOORES SL, 1991, J BIOL CHEM, V266, P14603; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Mulvaney JM, 2000, J BIOL CHEM, V275, P14182, DOI 10.1074/jbc.275.19.14182; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Ni CZ, 2000, P NATL ACAD SCI USA, V97, P10395, DOI 10.1073/pnas.97.19.10395; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Okumura K, 1999, CANCER RES, V59, P2445; Pahl HL, 1996, J EXP MED, V183, P1829, DOI 10.1084/jem.183.4.1829; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Park YC, 1999, NATURE, V398, P533, DOI 10.1038/19110; Pearson G, 2001, J BIOL CHEM, V276, P7927, DOI 10.1074/jbc.M009764200; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SCHABER MD, 1990, J BIOL CHEM, V265, P14701; Schwenzer R, 1999, J BIOL CHEM, V274, P19368, DOI 10.1074/jbc.274.27.19368; Seternes OM, 1999, MOL ENDOCRINOL, V13, P1071, DOI 10.1210/me.13.7.1071; SONG HY, 1995, BIOCHEM J, V309, P825, DOI 10.1042/bj3090825; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Taylor MT, 2000, CANCER RES, V60, P6607; Tsao DHH, 2000, MOL CELL, V5, P1051, DOI 10.1016/S1097-2765(00)80270-1; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Verin AD, 2000, AM J PHYSIOL-LUNG C, V279, pL360, DOI 10.1152/ajplung.2000.279.2.L360; Vuong H, 2000, J BIOL CHEM, V275, P32250, DOI 10.1074/jbc.M005227200; Wajant H, 2000, J BIOL CHEM, V275, P24357, DOI 10.1074/jbc.M000811200; Wajant H, 2001, CELL SIGNAL, V13, P389, DOI 10.1016/S0898-6568(01)00160-7; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang DM, 1998, J BIOL CHEM, V273, P33027, DOI 10.1074/jbc.273.49.33027; Wang QD, 2001, GASTROENTEROLOGY, V120, P1381, DOI 10.1053/gast.2001.24044; Wang QD, 2002, J BIOL CHEM, V277, P36602, DOI 10.1074/jbc.M206306200; WU MH, 1994, EUR J PHARM-ENVIRON, V270, P203, DOI 10.1016/0926-6917(94)90064-7; Zapata JM, 2000, J IMMUNOL, V165, P5084, DOI 10.4049/jimmunol.165.9.5084; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zhao DZ, 2001, J BIOL CHEM, V276, P44464, DOI 10.1074/jbc.M104942200; Zou YZ, 1996, J BIOL CHEM, V271, P33592, DOI 10.1074/jbc.271.52.33592	79	67	71	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	2004	23	10					1885	1895		10.1038/sj.onc.1207312	http://dx.doi.org/10.1038/sj.onc.1207312			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	801XV	14981539				2022-12-28	WOS:000220129500010
J	Nitta, M; Kobayashi, O; Honda, S; Hirota, T; Kuninaka, S; Marumoto, T; Ushio, Y; Saya, H				Nitta, M; Kobayashi, O; Honda, S; Hirota, T; Kuninaka, S; Marumoto, T; Ushio, Y; Saya, H			Spindle checkpoint function is required for mitotic catastrophe induced by DNA-damaging agents	ONCOGENE			English	Article						mitotic catastrophe; spindle checkpoint; DNA damage; p53; time lapse; BubR1	HUMAN LUNG CANCERS; ASSEMBLY CHECKPOINT; MAMMALIAN-CELLS; FREQUENT IMPAIRMENT; LYMPHOMA-CELLS; P53 MUTATION; TUMOR-CELLS; SENSITIVITY; ARREST; LINES	Mitotic catastrophe is an important mechanism for the induction of cell death in cancer cells by antineoplastic agents that damage DNA. This process is facilitated by defects in the G(1) and G(2) checkpoints of the cell cycle that are apparent in most cancer cells and which allow the cells to enter mitosis with DNA damage. We have now characterized the dynamics of mitotic catastrophe induced by DNA-damaging agents in p53-deficient cancer cells. Cells that entered mitosis with DNA damage transiently arrested at metaphase for more than 10 h without segregation of chromosomes and subsequently died directly from metaphase. In those metaphase arrested precatastrophic cells, anaphase-promoting complex appeared to be inactivated and BubR1 was persistently localized at kinetochores, suggesting that spindle checkpoint is activated after the DNA damage. Furthermore, suppression of spindle checkpoint function by BubR1 or Mad2 RNA interference in the DNA damaged cells led to escape from catastrophic death and to subsequent abnormal mitosis. Dysfunction of the spindle checkpoint in p53-deficient cancer cells is thus likely a critical factor in resistance to DNA-damaging therapeutic agents.	Kumamoto Univ, Grad Sch Med Sci, Dept Tumor Genet & Biol, Kumamoto 8608556, Japan; Kumamoto Univ, Grad Sch Med Sci, Dept Neurosurg, Kumamoto 8608556, Japan	Kumamoto University; Kumamoto University	Saya, H (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Dept Tumor Genet & Biol, 1-1-1 Honjo, Kumamoto 8608556, Japan.	hsaya@gpo.kumamoto-u.ac.jp	Kuninaka, Shinji/J-7158-2013; Saya, Hideyuki/J-4325-2013					Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Borel F, 2002, J CELL SCI, V115, P2829; BRACHMAN DG, 1993, CANCER RES, V53, P3667; Bradford CR, 2003, HEAD NECK-J SCI SPEC, V25, P654, DOI 10.1002/hed.10274; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chan TA, 2000, GENE DEV, V14, P1584; den Elzen N, 2001, J CELL BIOL, V153, P121, DOI 10.1083/jcb.153.1.121; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Erenpreisa JE, 2000, CELL BIOL INT, V24, P61, DOI 10.1006/cbir.1999.0466; FAN SJ, 1995, CANCER RES, V55, P1649; FAN SJ, 1994, CANCER RES, V54, P5824; FINGERT HJ, 1986, CANCER RES, V46, P2463; Garber PM, 2002, GENETICS, V161, P521; Goto H, 1999, J BIOL CHEM, V274, P25543, DOI 10.1074/jbc.274.36.25543; Haber JE, 1999, TRENDS BIOCHEM SCI, V24, P271, DOI 10.1016/S0968-0004(99)01413-9; Kapoor TM, 2000, J CELL BIOL, V150, P975, DOI 10.1083/jcb.150.5.975; Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Maringele L, 2002, GENE DEV, V16, P1919, DOI 10.1101/gad.225102; Marumoto T, 2003, J BIOL CHEM, V278, P51786, DOI 10.1074/jbc.M306275200; Masuda A, 2003, AM J PATHOL, V163, P1109, DOI 10.1016/S0002-9440(10)63470-0; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Mikhailov A, 2002, CURR BIOL, V12, P1797, DOI 10.1016/S0960-9822(02)01226-5; O'Connor DS, 2002, CANCER CELL, V2, P43, DOI 10.1016/S1535-6108(02)00084-3; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Ru HY, 2002, ONCOGENE, V21, P4673, DOI 10.1038/sj.onc.1205585; Saeki A, 2002, CANCER-AM CANCER SOC, V94, P2047, DOI 10.1002/cncr.10448; Sausville EA, 2001, J CLIN ONCOL, V19, P2319, DOI 10.1200/JCO.2001.19.8.2319; Servomaa K, 1996, CELL PROLIFERAT, V29, P219, DOI 10.1046/j.1365-2184.1996.01009.x; Shannon KB, 2002, MOL BIOL CELL, V13, P3706, DOI 10.1091/mbc.E02-03-0137; Sudo T, 2004, CANCER RES, V64, P2502, DOI 10.1158/0008-5472.CAN-03-2013; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; Toledo F, 2000, NUCLEIC ACIDS RES, V28, P4805, DOI 10.1093/nar/28.23.4805; Vogt U, 2002, J CANCER RES CLIN, V128, P141, DOI 10.1007/s00432-001-0305-2; Wang H, 2001, GENE DEV, V15, P1361, DOI 10.1101/gad.893201; Wang XH, 2002, CANCER RES, V62, P1662	41	132	143	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6548	6558		10.1038/sj.onc.1207873	http://dx.doi.org/10.1038/sj.onc.1207873			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15221012				2022-12-28	WOS:000223530800002
J	Wada, O; Oishi, H; Takada, I; Yanagisawa, J; Yano, T; Kato, S				Wada, O; Oishi, H; Takada, I; Yanagisawa, J; Yano, T; Kato, S			RETRACTED: BRCA1 function mediates a TRAP/DRIP complex through direct interaction with TRAP220 (Retracted article. See vol. 33, pg. 804, 2014)	ONCOGENE			English	Article; Retracted Publication						BRCA1; TRAP220; breast cancer	ESTROGEN-RECEPTOR; NUCLEAR RECEPTOR; BREAST-CANCER; DNA-REPAIR; TRANSCRIPTIONAL ACTIVATION; OVARIAN-CANCER; PROTEIN; GENE; SUSCEPTIBILITY; COACTIVATOR	Breast cancer susceptibility gene 1 (BRCA1) is a tumor suppressor gene mutated in a high percentage of hereditary breast and ovarian cancers. The multifunctional BRCA1 protein acts on cell cycle control, exerting several highly specialized DNA repair processes through diverse domains. Gene regulation through its C-terminal domain (BRCT) is indispensable for BRCA1-mediated tumor suppression, suggesting the possibility that the BRCT domain interacts with co-regulator complexes. Using a biochemical approach with HeLa S3 nuclear extracts, we isolated BRCT-associated complexes and identified one of the purified components as TRAP220. We then performed interaction studies in vivo (co-immunoprecipitation) and in vitro (glutathione S-transferase pull-down assays) and showed that BRCT directly interacted with TRAP220. This in vitro interaction was completely abolished by BRCT point mutations typical of those found in patients with BRCA1 that lack transactivation function. BRCA1 transactivation function was dependent on TRAP220 expression level in a transient expression assay. Moreover, a cell survival assay showed that antisense TRAP220 expression to disrupt endogenous TRAP220 expression significantly reduced the survival rate potentiated by BRCA1 after DNA damage. These results suggested that a TRAP220 complex play an important role as putative co-activator complexes in BRCA1-mediated tumor suppression.	Univ Tokyo, Inst Mol & Cellular Biol, Bunkyo Ku, Tokyo 1130034, Japan; Univ Tokyo, Dept Obstet & Gynecol, Bunkyo Ku, Tokyo 1138655, Japan; Japan Sci & Technol, SORST, Kawaguchi, Saitama 3320012, Japan	University of Tokyo; University of Tokyo; Japan Science & Technology Agency (JST)	Yano, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biol, Bunkyo Ku, Yayoi 1-1-1, Tokyo 1130034, Japan.	uskato@mail.ecc.u-tokyo.ac.jp	Oishi, Hajime/GRX-5428-2022					Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Cantor SB, 2001, CELL, V105, P149, DOI 10.1016/S0092-8674(01)00304-X; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Fondell JD, 1999, P NATL ACAD SCI USA, V96, P1959, DOI 10.1073/pnas.96.5.1959; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Greenman J, 1998, GENE CHROMOSOME CANC, V21, P244, DOI 10.1002/(SICI)1098-2264(199803)21:3<244::AID-GCC9>3.0.CO;2-#; Gu W, 1999, MOL CELL, V3, P97, DOI 10.1016/S1097-2765(00)80178-1; Humphrey JS, 1997, P NATL ACAD SCI USA, V94, P5820, DOI 10.1073/pnas.94.11.5820; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Kawai H, 2002, ONCOGENE, V21, P7730, DOI 10.1038/sj.onc.1205971; Kitagawa H, 2003, CELL, V113, P905, DOI 10.1016/S0092-8674(03)00436-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Miyake T, 2000, J BIOL CHEM, V275, P40169, DOI 10.1074/jbc.M007138200; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Ohtake F, 2003, NATURE, V423, P545, DOI 10.1038/nature01606; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Watanabe M, 2001, EMBO J, V20, P1341, DOI 10.1093/emboj/20.6.1341; Yanagisawa J, 2002, MOL CELL, V9, P553, DOI 10.1016/S1097-2765(02)00478-1; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747; Zhu YJ, 1999, P NATL ACAD SCI USA, V96, P10848, DOI 10.1073/pnas.96.19.10848	34	31	32	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2004	23	35					6000	6005		10.1038/sj.onc.1207786	http://dx.doi.org/10.1038/sj.onc.1207786			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15208681				2022-12-28	WOS:000222941100015
J	Loong, SLE; Korzh, S; Price, A				Loong, SLE; Korzh, S; Price, A			Reduced DNA-dependent protein kinase activity in two cell lines derived from adult cancer patients with late radionecrosis	ONCOGENE			English	Article						DNA-dependent protein kinase; radiation injury; radiosensitivity	IN-VITRO RADIOSENSITIVITY; STRAND BREAK REPAIR; INTRINSIC RADIOSENSITIVITY; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; RADIOTHERAPY; CARCINOMA; EXPRESSION; ASSAY	Epstein-Barr virus-immortalized lymphoblastoid cell tines were derived from five patients with late radionecrosis. Two of these cell lines exhibited postradiation viability levels intermediate between normal cell fines and that from an individual with ataxia telangiectasia. Compared with controls, these two cell lines exhibited impaired ability to rejoin DNA double-strand breaks on pulsed-field gel electrophoresis and 6-10-fold reduced DNA-dependent protein kinase (DNA-PK) activity in vitro in cell-free extracts. Immunoblotting showed normal levels of Ku70, Ku80 and XRCC4 and the presence of DNA-PKcs in both cell lines. These findings suggest that DNA-PK might be an important factor affecting the predisposition of radiotherapy patients to late radionecrosis.	Univ Edinburgh, Western Gen Hosp, Div Oncogen, Edinburgh EH4 2XU, Midlothian, Scotland; Natl Canc Ctr, Dept Therapeut Radiol, Singapore, Singapore; Natl Canc Ctr, Div Med Sci, Singapore, Singapore	University of Edinburgh; National Cancer Centre Singapore (NCCS); National Cancer Centre Singapore (NCCS)	Price, A (corresponding author), Univ Edinburgh, Western Gen Hosp, Div Oncogen, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.	a.price@ed.ac.uk						Alapetite C, 1999, INT J CANCER, V83, P83, DOI 10.1002/(SICI)1097-0215(19990924)83:1<83::AID-IJC16>3.0.CO;2-8; ALLALUNISTURNER MJ, 1995, RADIAT RES, V144, P288, DOI 10.2307/3578948; ALLALUNISTURNER MJ, 1995, CANCER RES, V55, P5200; Alsbeih G, 2000, INT J RADIAT ONCOL, V46, P143, DOI 10.1016/S0360-3016(99)00409-5; Bjork-Eriksson T, 1998, BRIT J CANCER, V77, P2371, DOI 10.1038/bjc.1998.394; Dibiase SJ, 2000, CANCER RES, V60, P1245; GODSEN CM, 1986, HUMAN CYTOGENETICS P, P31; Herring CJ, 1998, BRIT J CANCER, V78, P1128, DOI 10.1038/bjc.1998.641; ILIAKIS G, 1991, BIOESSAYS, V13, P641; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; O'Driscoll M, 2001, MOL CELL, V8, P1175, DOI 10.1016/S1097-2765(01)00408-7; Polischouk AG, 1999, INT J RADIAT ONCOL, V43, P191, DOI 10.1016/S0360-3016(98)00362-9; PRICE P, 1990, CANCER RES, V50, P1392; Safwat A, 2002, INT J RADIAT ONCOL, V52, P198, DOI 10.1016/S0360-3016(01)02690-6; Sirzen F, 1999, EUR J CANCER, V35, P111, DOI 10.1016/S0959-8049(98)00289-5; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; TAALMAN RDFM, 1983, MUTAT RES, V112, P23, DOI 10.1016/0167-8817(83)90021-4; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; Tucker SL, 1996, RADIOTHER ONCOL, V38, P103, DOI 10.1016/0167-8140(95)01669-4; West CML, 1997, BRIT J CANCER, V76, P1184, DOI 10.1038/bjc.1997.531; West CML, 1998, INT J RADIAT BIOL, V73, P409, DOI 10.1080/095530098142248; Woods T, 2002, NUCLEIC ACIDS RES, V30, P5120, DOI 10.1093/nar/gkf625; Zhao HJ, 2000, CLIN CANCER RES, V6, P1073	23	8	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2004	23	32					5562	5566		10.1038/sj.onc.1207771	http://dx.doi.org/10.1038/sj.onc.1207771			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15184871	Bronze			2022-12-28	WOS:000222588400017
J	Meertens, L; Pise-Masison, C; Quere, N; Brady, J; Gessain, A; Mahieux, R				Meertens, L; Pise-Masison, C; Quere, N; Brady, J; Gessain, A; Mahieux, R			Utilization of the CBP but not the p300 co-activator by human T-lymphotropic virus type-2 Tax for p53 inhibition	ONCOGENE			English	Article						HTLV; tax; p53; CBP/p300; NF-kappa B	CELL LEUKEMIA-VIRUS; NF-KAPPA-B; CREB BINDING-PROTEIN; WILD-TYPE P53; II HTLV-II; TRANSCRIPTIONAL ACTIVATION; TRANSACTIVATION FUNCTION; FUNCTIONAL IMPAIRMENT; ABERRANT EXPRESSION; DOMAIN	We previously reported, both in transfected cells and in human T-cell leukemia virus type-2 subtype B infected cells, that the viral transactivator Tax-2B protein could inhibit p53 functions. We have now investigated the mechanism through which Tax-2B represses p53 using GFPTax-2B fusion proteins. We present evidence that Tax-2B inhibition of p53 function is not linked to CREB/ ATF activation, but is uniquely correlated with the interaction of CREB binding protein (CBP), but not p300, with the C-terminus of Tax-2B. Wild type, but not a Tax-2B-M47 mutant, inhibits p53 function in adherent cells. We demonstrate that both Tax-2B and Tax-2B-M47 can bind p300, while Tax-2B-M47 is impaired for CBP binding. Importantly, transfection of increasing amounts of CBP but not p300 or p300/CBP-associated factor (P/CAF) could rescue p53 transcriptional activity in the presence of Tax-2B in nonlymphocytic cells. In lymphoid cells, Tax-2B mediated inhibition of p53 is correlated with the NF-kappaB pathway activation and could be prevented by the overexpression of an IkappaBalpha mutant. Given the similarities between the functional domains of CBP and p300, these results are intriguing and suggest that Tax-2B must bind the CR2 domain of CBP, but not that of p300 in order to repress p53.	Inst Pasteur, Unite Edpidemiol & Physiopathol Virus Oncogenes, F-75724 Paris 15, France; NCI, Virus Tumor Biol Sect, NIH, Bethesda, MD 20892 USA	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Mahieux, R (corresponding author), Inst Pasteur, Unite Edpidemiol & Physiopathol Virus Oncogenes, 28 Rue Dr Roux, F-75724 Paris 15, France.	rmahieux@pasteur.fr	Meertens, Laurent/E-8043-2017	Meertens, Laurent/0000-0003-2811-3675; mahieux, renaud/0000-0002-5129-6804				ADYA N, 1995, J VIROL, V69, P1834, DOI 10.1128/JVI.69.3.1834-1841.1995; Akagi T, 1997, FEBS LETT, V406, P263, DOI 10.1016/S0014-5793(97)00280-9; Alefantis T, 2003, J BIOL CHEM, V278, P21814, DOI 10.1074/jbc.M211576200; Ariumi Y, 2000, ONCOGENE, V19, P1491, DOI 10.1038/sj.onc.1203450; Bex F, 1998, MOL CELL BIOL, V18, P2392, DOI 10.1128/MCB.18.4.2392; Casoli C, 2004, BLOOD, V103, P995, DOI 10.1182/blood-2003-07-2503; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; Eiraku N, 1996, J VIROL, V70, P1481, DOI 10.1128/JVI.70.3.1481-1492.1996; Endo K, 2002, J VIROL, V76, P2648, DOI 10.1128/JVI.76.6.2648-2653.2002; Fouchard N, 1995, LEUKEMIA, V9, P2087; Gartenhaus RB, 1995, LEUKEMIA, V9, P2082; GESSAIN A, 1985, LANCET, V2, P407; GOREN I, 1995, J VIROL, V69, P5806, DOI 10.1128/JVI.69.9.5806-5811.1995; GRASSMANN R, 1994, ADV CANCER RES, V63, P211, DOI 10.1016/S0065-230X(08)60401-7; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; Harrod R, 2003, J BIOL CHEM, V278, P12310, DOI 10.1074/jbc.M211167200; Hirata A, 2004, VIROLOGY, V318, P327, DOI 10.1016/j.virol.2003.10.006; IJICHI S, 1992, J EXP MED, V176, P293, DOI 10.1084/jem.176.1.293; Iwanaga Y, 1999, J VIROL, V73, P1271, DOI 10.1128/JVI.73.2.1271-1277.1999; Jiang H, 1999, MOL CELL BIOL, V19, P8136; Johnson JM, 2001, INT J EXP PATHOL, V82, P135, DOI 10.1046/j.1365-2613.2001.00191.x; KALYANARAMAN VS, 1982, SCIENCE, V218, P571, DOI 10.1126/science.6981847; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Lewis MJ, 2002, VIROLOGY, V295, P182, DOI 10.1006/viro.2002.1357; Livengood JA, 2002, J BIOL CHEM, V277, P9054, DOI 10.1074/jbc.M108870200; Lu HX, 2002, MOL CELL BIOL, V22, P4450, DOI 10.1128/MCB.22.13.4450-4462.2002; Mahieux R, 2000, J VIROL, V74, P6866, DOI 10.1128/JVI.74.15.6866-6874.2000; Mulloy JC, 1998, J VIROL, V72, P8852, DOI 10.1128/JVI.72.11.8852-8860.1998; Murphy EL, 1997, NEUROLOGY, V48, P315, DOI 10.1212/WNL.48.2.315; NAGAI H, 1991, JPN J CANCER RES, V82, P1421, DOI 10.1111/j.1349-7006.1991.tb01815.x; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; Pise-Masison CA, 2001, J BIOL CHEM, V276, P200, DOI 10.1074/jbc.M005601200; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; REID RL, 1993, ONCOGENE, V8, P3029; Ross TM, 1996, J VIROL, V70, P5194, DOI 10.1128/JVI.70.8.5194-5202.1996; Ross TM, 1997, J VIROL, V71, P8912, DOI 10.1128/JVI.71.11.8912-8917.1997; Ross TM, 2000, J VIROL, V74, P2655, DOI 10.1128/JVI.74.6.2655-2662.2000; Scoggin KES, 2001, MOL CELL BIOL, V21, P5520, DOI 10.1128/MCB.21.16.5520-5530.2001; Semmes OJ, 1996, VIROLOGY, V217, P373, DOI 10.1006/viro.1996.0126; SHAH NP, 1986, MOL CELL BIOL, V6, P3626, DOI 10.1128/MCB.6.11.3626; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Sol-Foulon N, 2002, IMMUNITY, V16, P145, DOI 10.1016/S1074-7613(02)00260-1; SUGITO S, 1991, INT J CANCER, V49, P880, DOI 10.1002/ijc.2910490614; Suzuki T, 1999, ONCOGENE, V18, P4137, DOI 10.1038/sj.onc.1202766; Takemoto S, 2000, BLOOD, V95, P3939; Tie F, 1996, J VIROL, V70, P8368, DOI 10.1128/JVI.70.12.8368-8374.1996; UITTENBOGAARD MN, 1995, J BIOL CHEM, V270, P28503, DOI 10.1074/jbc.270.48.28503; Van Orden K, 1999, J BIOL CHEM, V274, P26321, DOI 10.1074/jbc.274.37.26321; Van PL, 2001, J VIROL, V75, P396, DOI 10.1128/JVI.75.1.396-407.2001; Wang TG, 2000, AIDS RES HUM RETROV, V16, P1661, DOI 10.1089/08892220050193119; YAMATO K, 1993, JPN J CANCER RES, V84, P4, DOI 10.1111/j.1349-7006.1993.tb02775.x; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; Yu Q, 2001, FEBS LETT, V505, P7, DOI 10.1016/S0014-5793(01)02756-9	57	20	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2004	23	32					5447	5458		10.1038/sj.onc.1207719	http://dx.doi.org/10.1038/sj.onc.1207719			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15156194				2022-12-28	WOS:000222588400004
J	Ohtsuka, T; Jensen, MR; Kim, HG; Kim, KT; Lee, SW				Ohtsuka, T; Jensen, MR; Kim, HG; Kim, KT; Lee, SW			The negative role of cyclin G in ATM-dependent p53 activation	ONCOGENE			English	Article						p53; cyclin G; ATM; cell cycle; DNA damage	DNA-DAMAGE; G2/M ARREST; PHOSPHORYLATION; GROWTH; CELLS; MODULATION; P53-MDM2; PROTEIN; TARGET; MDM2	Cyclin G is one of the earliest p53 target genes to be identified, but its function in the p53 pathway has been elusive. Although the precise mechanisms of cyclin G in this novel network have not been explored, recent studies have demonstrated that cyclin G is a key regulator of the p53-Mdm2 network. Here we present evidence that cyclin G-mediated p53 regulation is dependent upon the status of ataxia-telangiectasia mutated (ATM) protein, which activates p53 in response to DNA damage. Abrogation of cyclin G enhances p53 accumulation and phosphorylation of p53 at the Ser-15 residue, resulting in cell cycle arrest. Ectopically expressed cyclin G significantly reduces the steady-state levels of p53 as well as that of phosphorylated p53 at Ser-15 after DNA damage in normal human dermal fibroblasts containing normal ATM. However, cyclin G does not cause similar reductions in p53 levels in ATM-mutated cells. We also show that translocation of cyclin G to the nucleus requires functional ATM. Thus, our findings identify a new role of cyclin G in ATM-dependent p53 regulation and in cell cycle regulation during DNA damage.	Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Canc Biol Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; FIRC Inst Mol Oncol, Milan, Italy	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; IFOM - FIRC Institute of Molecular Oncology	Lee, SW (corresponding author), Harvard Inst Med, 4 Blackfan Circle,Room 921, Boston, MA 02115 USA.	slee2@caregroup.harvard.edu			NCI NIH HHS [CA78356, CA85681] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078356, R01CA085681] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alarcon-Vargas D, 2002, CARCINOGENESIS, V23, P541, DOI 10.1093/carcin/23.4.541; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chen XB, 2002, DEV CELL, V2, P518, DOI 10.1016/S1534-5807(02)00182-X; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Jensen MR, 2003, HEPATOLOGY, V37, P862, DOI 10.1053/jhep.2003.50137; Kimura SH, 2001, ONCOGENE, V20, P3290, DOI 10.1038/sj.onc.1204270; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Ohtsuka T, 2003, ONCOGENE, V22, P1678, DOI 10.1038/sj.onc.1206306; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Okamoto K, 1999, ONCOGENE, V18, P4606, DOI 10.1038/sj.onc.1202821; Okamoto K, 1996, MOL CELL BIOL, V16, P6593; Okamoto K, 2002, MOL CELL, V9, P761, DOI 10.1016/S1097-2765(02)00504-X; Reimers L, 1999, J BIOL CHEM, V274, P11022, DOI 10.1074/jbc.274.16.11022; Shimizu A, 1998, BIOCHEM BIOPH RES CO, V242, P529, DOI 10.1006/bbrc.1997.8004; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SKOTZKO M, 1995, CANCER RES, V55, P5493; Smith ML, 1997, EXP CELL RES, V230, P61, DOI 10.1006/excr.1996.3402; TAMURA K, 1993, ONCOGENE, V8, P2113; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; Zhao L, 2003, MOL CANCER RES, V1, P195	20	43	47	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2004	23	31					5405	5408		10.1038/sj.onc.1207693	http://dx.doi.org/10.1038/sj.onc.1207693			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15077171				2022-12-28	WOS:000222491600016
J	Manenti, G; Galbiati, F; Gianni-Barrera, R; Pettinicchio, A; Acevedo, A; Dragani, TA				Manenti, G; Galbiati, F; Gianni-Barrera, R; Pettinicchio, A; Acevedo, A; Dragani, TA			Haplotype sharing suggests that a genomic segment containing six genes accounts for the pulmonary adenoma susceptibility 1 (Pas1) locus activity in mice	ONCOGENE			English	Article						genetic susceptibility; inbred strains; lung tumors; Kras2	QUANTITATIVE TRAIT LOCUS; LUNG-TUMOR SUSCEPTIBILITY; BUTYLATED HYDROXYTOLUENE; CANCER; MOUSE; PROTEIN; RISK; CARCINOGENESIS; TUMORIGENESIS; POLYMORPHISM	The pulmonary adenoma susceptibility 1 (Pas1) locus affects inherited predisposition and resistance to chemically induced lung tumorigenesis in mice. The A/J and C57BL/6J mouse strains carry the susceptibility and resistance allele, respectively. We identified and geno-typed 65 polymorphisms in the Pas1 locus region in 29 mouse inbred strains, and delimited the Pas1 locus to a minimal region of 468 kb containing six genes. That region defined a core Pas1 haplotype with 42 tightly linked markers, including intragenic polymorphisms in five genes (Bcat1, Lrmp, Las1, Ghiso, and Kras2) and amino-acid changes in three genes ( Lrmp, Las1, Lmna-rs1). In (A/J x C57BL/6J) F1 mouse lung tumors, the Lmna-rs1 gene was completely downregulated, whereas allele-specific downregulation of the C57BL/6J-derived allele was observed at the Las1 gene, suggesting the potential role of these genes in tumor suppression. These results indicate a complex multigenic nature of the Pas1 locus, and point to a functional role for both intronic and exonic polymorphisms of the Pas1 haplotype in lung tumor susceptibility.	Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; Univ La Laguna, Fac Med, Tenerife, Spain	Fondazione IRCCS Istituto Nazionale Tumori Milan; Universidad de la Laguna	Dragani, TA (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Via G Venezian 1, I-20133 Milan, Italy.	dragani@istitutotumori.mi.it	Dragani, Tommaso A./K-4493-2016; Arozena, Abraham Acevedo/L-6584-2018; Gianni-Barrera, Roberto/ACU-4280-2022; Manenti, Giacomo/J-3339-2017	Dragani, Tommaso A./0000-0001-5915-4598; Arozena, Abraham Acevedo/0000-0001-6127-7116; Gianni-Barrera, Roberto/0000-0001-6303-4513; Manenti, Giacomo/0000-0002-4887-4482				AKAMATSU Y, 1975, J NATL CANCER I, V55, P893, DOI 10.1093/jnci/55.4.893; Askling J, 1999, AM J RESP CRIT CARE, V160, P1668, DOI 10.1164/ajrccm.160.5.9904045; Bauer AK, 2001, EXP LUNG RES, V27, P197, DOI 10.1080/019021401300053948; BEHRENS TW, 1994, J IMMUNOL, V153, P682; Brownson RC, 2000, CANCER CAUSE CONTROL, V11, P853, DOI 10.1023/A:1008999202040; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; Cormier RT, 2000, ONCOGENE, V19, P3182, DOI 10.1038/sj.onc.1203646; Darvasi A, 2002, TRENDS GENET, V18, P489, DOI 10.1016/S0168-9525(02)02767-1; De Luca M, 2003, NAT GENET, V34, P429, DOI 10.1038/ng1218; DEVEREUX TR, 1994, MAMM GENOME, V5, P749, DOI 10.1007/BF00292007; Dragani TA, 2003, CANCER RES, V63, P3011; Eden A, 1999, FEBS LETT, V457, P255, DOI 10.1016/S0014-5793(99)01054-6; FESTING MFW, 1994, GENET RES, V64, P99, DOI 10.1017/S0016672300032705; GARIBOLDI M, 1993, NAT GENET, V3, P132, DOI 10.1038/ng0293-132; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Kawakami K, 2001, CLIN CANCER RES, V7, P4096; Liang TB, 2003, P NATL ACAD SCI USA, V100, P4690, DOI 10.1073/pnas.0737182100; MALKINSON AM, 1989, TOXICOLOGY, V54, P241, DOI 10.1016/0300-483X(89)90062-0; MALKINSON AM, 1984, J NATL CANCER I, V73, P925; Manenti G, 1999, GENOME RES, V9, P639; Manenti G, 2002, INT J CANCER, V99, P555, DOI 10.1002/ijc.10386; Maria DA, 2003, ONCOGENE, V22, P426, DOI 10.1038/sj.onc.1206157; Mayne ST, 1999, AM J EPIDEMIOL, V149, P13; RE FC, 1992, MOL CARCINOGEN, V5, P155, DOI 10.1002/mc.2940050211; Shaughnessy JD, 1999, ONCOGENE, V18, P2069; Steinmetz LM, 2002, NATURE, V416, P326, DOI 10.1038/416326a; TRAININ N, 1967, INT J CANCER, V2, P326, DOI 10.1002/ijc.2910020407; Wade CM, 2002, NATURE, V420, P574, DOI 10.1038/nature01252; Wang M, 2003, CANCER RES, V63, P3317; Webb KE, 2003, EXP HEMATOL, V31, P488, DOI 10.1016/S0301-472X(03)00065-1; Wiltshire T, 2003, P NATL ACAD SCI USA, V100, P3380, DOI 10.1073/pnas.0130101100; Zhang ZQ, 2001, NAT GENET, V29, P25, DOI 10.1038/ng721; Zhang ZQ, 2003, P NATL ACAD SCI USA, V100, P12642, DOI 10.1073/pnas.2133947100	35	39	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2004	23	25					4495	4504		10.1038/sj.onc.1207584	http://dx.doi.org/10.1038/sj.onc.1207584			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	824CJ	15064703				2022-12-28	WOS:000221661300015
J	Kaeser, MD; Iggo, RD				Kaeser, MD; Iggo, RD			Promoter-specific p53-dependent histone acetylation following DNA damage	ONCOGENE			English	Article						chromatin immunoprecipitation; p53; p21; MDM2; PUMA; histone acetyltransferase	CELL-CYCLE ARREST; TRANSCRIPTIONAL ACTIVATION; IN-VIVO; CANCER CELLS; P53 PROTEIN; BINDING; EXPRESSION; COMPLEX; GENE; PHOSPHORYLATION	We have used chromatin immunoprecipitation (ChIP) to measure p53-dependent histone acetylation at the p21, MDM2, and PUMA promoters. The pattern of histone acetylation was different at each promoter. H3 and H4 acetylation increased at both the p21 and PUMA promoters in response to p53 activation, whereas there was only a minimal increase in H4 acetylation and no increase in H3 acetylation at the MDM2 promoter. The high p53 occupancy of the p21, MDM2 and PUMA promoters has been attributed to the presence of two p53 binding sites in these promoters, but mutation of the p53 binding sites in integrated p21 promoter constructs showed that the two sites in the p21 promoter do not cooperate to stabilize p53 binding. Despite 10-fold higher p53 binding to the proximal than the distal site in the p21 promoter, both sites showed similar patterns of H3 and H4 acetylation. Mutation of the binding sites showed that acetylation of the proximal, low-affinity site requires p53 binding to that site but not to the distal, high-affinity site. Since low-affinity p53 binding sites can confer strong acetylation, the DNA binding affinity in vitro is an unreliable guide to the likely importance of p53 in regulating candidate target genes in vivo.	Swiss Inst Expt Canc Res, Oncogene Grp, CH-1066 Epalinges, Switzerland	Swiss Institute Experimental Cancer Research	Iggo, RD (corresponding author), Swiss Inst Expt Canc Res, Oncogene Grp, Ch Boveresses 155, CH-1066 Epalinges, Switzerland.	richard.iggo@isrec.unil.ch	Iggo, Richard/G-3546-2014	Kaeser, Matthias/0000-0003-0050-9408				Agalioti T, 2002, CELL, V111, P381, DOI 10.1016/S0092-8674(02)01077-2; ANDERSON CW, 2003, HDB CELL SIGNALING, V3, P237; Ard PG, 2002, MOL CELL BIOL, V22, P5650, DOI 10.1128/MCB.22.16.5650-5661.2002; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Espinosa JM, 2003, MOL CELL, V12, P1015, DOI 10.1016/S1097-2765(03)00359-9; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; FREEMAN J, 1994, EMBO J, V13, P5393, DOI 10.1002/j.1460-2075.1994.tb06874.x; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Jackson P, 1998, ONCOGENE, V16, P283, DOI 10.1038/sj.onc.1201491; Kaeser MD, 2004, J BIOL CHEM, V279, P7598, DOI 10.1074/jbc.M311732200; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Klein C, 2001, J BIOL CHEM, V276, P49020, DOI 10.1074/jbc.M107516200; Lee D, 2002, J BIOL CHEM, V277, P22330, DOI 10.1074/jbc.M111987200; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Saller E, 1999, EMBO J, V18, P4424, DOI 10.1093/emboj/18.16.4424; STENGER JE, 1994, EMBO J, V13, P6011, DOI 10.1002/j.1460-2075.1994.tb06947.x; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Winkler GS, 2002, P NATL ACAD SCI USA, V99, P3517, DOI 10.1073/pnas.022042899; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; Zhao RB, 2000, GENE DEV, V14, P981; Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873-9880.1998	41	45	45	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					4007	4013		10.1038/sj.onc.1207536	http://dx.doi.org/10.1038/sj.onc.1207536			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15007388	Bronze			2022-12-28	WOS:000221382000013
J	Koziczak, M; Holbro, T; Hynes, NE				Koziczak, M; Holbro, T; Hynes, NE			Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins	ONCOGENE			English	Article						FGFR; cyclin D; breast cancer; tyrosine kinase inhibitor	FIBROBLAST-GROWTH-FACTOR; TRANSCRIPTIONAL REGULATION; PHOSPHOINOSITIDE 3-KINASE; RECEPTOR GENES; PROTEIN-KINASE; EXPRESSION; AMPLIFICATION; ERBB2; OVEREXPRESSION; ANGIOGENESIS	Overexpression of fibroblast growth factor receptor ( FGFR) tyrosine kinases has been found in many human breast cancers and has been associated with poor patient prognosis. In order to understand the mechanism by which FGFR mediates breast cancer cell proliferation, we used a low molecular weight compound, PD173074, that selectively inhibits FGFR tyrosine kinase activity and autophosphorylation. This potential anticancer agent caused a G1 growth arrest of MDA-MB-415, MDA-MB-453 and SUM 52 breast cancer cells. Our analyses revealed that FGFR signaling links to the cell cycle machinery via D-type cyclins. PD173074-mediated inhibition of FGFR activity caused downregulation of cyclin D1 and cyclin D2 expression, inhibition of cyclin D/cdk4 activity and, as a consequence, reduction of pRB phosphorylation. Retroviral-mediated ectopic expression of cyclin D1 prevented pRB hypophosphorylation and the cell cycle G1 block in PD173074-treated cells, suggesting a central role for D cyclins in proliferation of FGFR-driven breast cancer cells. The repression of FGFR activity caused downregulation of MAPK in MDA-MB-415 and MDA-MB453 cells. In SUM 52 cells, both MAPK and PI3K signaling pathways were suppressed. In conclusion, results shown here describe a mechanism by which FGFR promotes proliferation of breast cancer cells.	Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Hynes, NE (corresponding author), Friedrich Miescher Inst Biomed Res, Maulbeerstr 66, CH-4058 Basel, Switzerland.	nancy.hynes@fmi.ch						ADNANE J, 1991, ONCOGENE, V6, P659; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Boilly B, 2000, CYTOKINE GROWTH F R, V11, P295, DOI 10.1016/S1359-6101(00)00014-9; Chodosh LA, 2000, DEV BIOL, V219, P259, DOI 10.1006/dbio.2000.9614; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; Cross MJ, 2000, J CELL SCI, V113, P643; Cross MJ, 2001, TRENDS PHARMACOL SCI, V22, P201, DOI 10.1016/S0165-6147(00)01676-X; Cuny M, 2000, CANCER RES, V60, P1077; DAKSIS JI, 1994, ONCOGENE, V9, P3635; DICKSON C, 1995, CANCER LETT, V90, P43, DOI 10.1016/0304-3835(94)03676-A; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; ETHIER SP, 1993, CANCER RES, V53, P627; Gerwins P, 2000, CRIT REV ONCOL HEMAT, V34, P185, DOI 10.1016/S1040-8428(00)00062-7; Giri D, 1999, CLIN CANCER RES, V5, P1063; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Hosokawa Y, 1998, GENE CHROMOSOME CANC, V22, P66, DOI 10.1002/(SICI)1098-2264(199805)22:1<66::AID-GCC9>3.0.CO;2-5; JAAKKOLA S, 1993, INT J CANCER, V54, P378, DOI 10.1002/ijc.2910540305; Jang JH, 2001, CANCER RES, V61, P3541; Kim I, 2001, BBA-GENE STRUCT EXPR, V1518, P152, DOI 10.1016/S0167-4781(00)00282-7; KLINT P, 1999, FRONT BIOSCI, V4, P165; Kornmann M, 1997, ONCOGENE, V15, P1417, DOI 10.1038/sj.onc.1201307; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Koziczak M, 2000, MOL CELL BIOL, V20, P2014, DOI 10.1128/MCB.20.6.2014-2022.2000; Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000; Lavia P, 1999, BIOESSAYS, V21, P221; LEBWOHL DE, 1994, ONCOGENE, V9, P1925; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; Mohammadi M, 1998, EMBO J, V17, P5896, DOI 10.1093/emboj/17.20.5896; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nagata D, 2001, J BIOL CHEM, V276, P662, DOI 10.1074/jbc.M005522200; Neve RM, 2000, ONCOGENE, V19, P1647, DOI 10.1038/sj.onc.1203470; Neve RM, 2002, ONCOGENE, V21, P4567, DOI 10.1038/sj.onc.1205555; Ong SH, 2001, P NATL ACAD SCI USA, V98, P6074, DOI 10.1073/pnas.111114298; Ong SH, 2000, MOL CELL BIOL, V20, P979, DOI 10.1128/MCB.20.3.979-989.2000; Ornitz DM, 2001, GENOME BIOL, V2; PENAULTLLORCA F, 1995, INT J CANCER, V61, P170, DOI 10.1002/ijc.2910610205; Plotnikov AN, 2000, CELL, V101, P413, DOI 10.1016/S0092-8674(00)80851-X; RIMOKH R, 1994, BLOOD, V83, P3689; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Suyama K, 2002, CANCER CELL, V2, P301, DOI 10.1016/S1535-6108(02)00150-2; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; THEILLET C, 1993, GENE CHROMOSOME CANC, V7, P219, DOI 10.1002/gcc.2870070407; Valve E, 2000, INT J CANCER, V88, P718, DOI 10.1002/1097-0215(20001201)88:5<718::AID-IJC6>3.0.CO;2-F; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484; Yayon A, 1997, ONCOGENE, V14, P2999, DOI 10.1038/sj.onc.1201159	51	137	165	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3501	3508		10.1038/sj.onc.1207331	http://dx.doi.org/10.1038/sj.onc.1207331			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15116089				2022-12-28	WOS:000221101700001
J	Sasaki, H; Hirai, K; Yamamoto, H; Tanooka, H; Sakamoto, H; Iwamoto, T; Takahashi, T; Terada, M; Ochiya, T				Sasaki, H; Hirai, K; Yamamoto, H; Tanooka, H; Sakamoto, H; Iwamoto, T; Takahashi, T; Terada, M; Ochiya, T			HST-1/FGF-4 plays a critical role in crypt cell survival and facilitates epithelial cell restitution and proliferation	ONCOGENE			English	Article						HST-1/FGF-4; intestinal damage; crypt survival; apoptosis; radiation	ADENOVIRUS-MEDIATED TRANSFER; KERATINOCYTE GROWTH-FACTOR; INTESTINAL STEM-CELLS; IN-VIVO; RADIATION-DAMAGE; PROTECTS MICE; SMALL-BOWEL; FACTOR-BETA; IRRADIATION; MIGRATION	The fibroblast growth factor-4 (HST-1/FGF-4) is a heparin-binding growth factor that influences on epithelial and many other cells through interaction with FGF receptors. It has been demonstrated that the HST-1/FGF-4 gene protects mice from lethal irradiation by preventing bone marrow damage and intestinal tract damage. However, the radioprotective mechanism is unknown. In this study, we have investigated the expression of Hst-1/Fgf-4 in mouse small intestine after irradiation, and determined the role of HST-1/FGF-4 in mouse intestinal crypt cell survival and epithelial cell proliferation and restitution. We found the induction of endogenous Hst-1/Fgf-4 expression in intestine when mice are exposed to 9.0 Gy irradiation. Laser-captured microdissection (LCM) coupled with RT-PCR analysis revealed that expression of Hst-1/Fgf-4 was found in epithelial cell of the villi and crypt cells. Pretreatment of HST-1/FGF-4 caused an increase in the number of surviving crypt cells, and clearly suppresses the radiation-induced apoptosis of the crypt cells. Moreover, exogenous HST-1/FGF-4 enhances epithelial cell restitution and proliferation in an in vitro model. These data suggest that HST-1/FGF-4 is induced by irradiation injury, and that HST-1/FGF-4 will find a therapeutic role in the prevention of intestinal cell toxicity following intensive chemotherapy and radiation therapy protocols, and in allogenic cell transplantation.	Natl Canc Ctr, Res Inst, Sect Studies Metastasis, Chuo Ku, Tokyo 1040045, Japan; Natl Inst Radiol Sci, Inage Ku, Chiba 2638555, Japan; Natl Inst Canc Res, Div Genet, Chuo Ku, Tokyo 1040045, Japan; St Marianna Univ, Sch Med, Dept Urol, Miyamae Ku, Kanagawa 2168511, Japan	National Cancer Center - Japan; National Institutes for Quantum Science & Technology; National Cancer Center - Japan; Saint Marianna University	Ochiya, T (corresponding author), Natl Canc Ctr, Res Inst, Sect Studies Metastasis, Chuo Ku, 1-1 Tsukiji,5 Chome, Tokyo 1040045, Japan.	tochiya@ncc.go.jp	Ochiya, Takahiro/AAH-7585-2019					Arman E, 1998, P NATL ACAD SCI USA, V95, P5082, DOI 10.1073/pnas.95.9.5082; Aviezer D, 1999, BIOCHEM BIOPH RES CO, V263, P621, DOI 10.1006/bbrc.1999.1434; Bach SP, 2000, CARCINOGENESIS, V21, P469, DOI 10.1093/carcin/21.3.469; CIACCI C, 1993, GASTROENTEROLOGY, V105, P93, DOI 10.1016/0016-5085(93)90014-4; COHN SM, 1992, J CELL BIOL, V119, P27, DOI 10.1083/jcb.119.1.27; Cohn SM, 1997, J CLIN INVEST, V99, P1367, DOI 10.1172/JCI119296; Cutler NS, 2003, CANCER RES, V63, P1748; Deroanne CF, 1997, CANCER RES, V57, P5590; DIGNASS AU, 1993, GASTROENTEROLOGY, V105, P1323, DOI 10.1016/0016-5085(93)90136-Z; DIGNASS AU, 1994, GASTROENTEROLOGY, V106, P1254, DOI 10.1016/0016-5085(94)90017-5; Farrell CL, 1998, CANCER RES, V58, P933; FEIL W, 1987, GASTROENTEROLOGY, V92, P1973, DOI 10.1016/0016-5085(87)90632-9; FELDMAN B, 1995, SCIENCE, V267, P246, DOI 10.1126/science.7809630; Houchen CW, 1999, AM J PHYSIOL-GASTR L, V276, pG249, DOI 10.1152/ajpgi.1999.276.1.G249; HUGHES SE, 1993, LAB INVEST, V69, P173; Khan WB, 1997, RADIAT RES, V148, P248, DOI 10.2307/3579609; LACY ER, 1988, J CLIN GASTROENTEROL, V10, P72; LEIGH BR, 1995, RADIAT RES, V142, P12, DOI 10.2307/3578961; LI YQ, 1992, CARCINOGENESIS, V13, P361, DOI 10.1093/carcin/13.3.361; MCCORMACK SA, 1992, AM J PHYSIOL-GASTR L, V263, P426; NUSRAT A, 1992, J CLIN INVEST, V89, P1501, DOI 10.1172/JCI115741; OCHIYA T, 1997, J TOXICOL PATHOL, V10, P129; Okunieff P, 1998, RADIAT RES, V150, P204, DOI 10.2307/3579856; Paris F, 2001, SCIENCE, V293, P293, DOI 10.1126/science.1060191; POTTEN CS, 1990, INT J RADIAT BIOL, V58, P925, DOI 10.1080/09553009014552281; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; Potten CS, 1997, BRIT J CANCER, V75, P1454, DOI 10.1038/bjc.1997.249; POTTEN CS, 1981, INT J RADIAT BIOL, V40, P321, DOI 10.1080/09553008114551251; POTTEN CS, 1992, CARCINOGENESIS, V13, P2305, DOI 10.1093/carcin/13.12.2305; ROBERTS DB, 1993, RADIAT RES, V135, P56, DOI 10.2307/3578396; SAKAMOTO H, 1994, P NATL ACAD SCI USA, V91, P12368, DOI 10.1073/pnas.91.26.12368; Santos MF, 1997, J CLIN INVEST, V100, P216, DOI 10.1172/JCI119515; Takahama Y, 1999, ONCOGENE, V18, P5943, DOI 10.1038/sj.onc.1203171; Wambersie A, 1996, Rev Med Brux, V17, P75; WINTON DJ, 1990, P ROY SOC B-BIOL SCI, V241, P13, DOI 10.1098/rspb.1990.0059; WITHERS HR, 1970, INT J RADIAT BIOL RE, V17, P261, DOI 10.1080/09553007014550291; Wright JA, 1996, HISTOL HISTOPATHOL, V11, P521; YOSHIDA T, 1994, CANCER LETT, V83, P261, DOI 10.1016/0304-3835(94)90328-X	38	17	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3681	3688		10.1038/sj.onc.1207348	http://dx.doi.org/10.1038/sj.onc.1207348			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15116099				2022-12-28	WOS:000221101700020
J	Scheijen, B; Ngo, HT; Kang, H; Griffin, JD				Scheijen, B; Ngo, HT; Kang, H; Griffin, JD			FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins	ONCOGENE			English	Article						Akt; Bim; FLT3; forkhead transcription factors; p27(Kip1)	FORKHEAD TRANSCRIPTION FACTOR; ACUTE MYELOID-LEUKEMIA; TYROSINE KINASE INHIBITOR; BCL-2 FAMILY; FACTOR FKHR; GENE-EXPRESSION; FACTOR AFX; IN-VIVO; PHOSPHATIDYLINOSITOL 3-KINASE; CAENORHABDITIS-ELEGANS	In about 30% of the patients with acute myeloid leukemia, activating FLT3 receptor mutations have been identified, often as in-frame internal tandem duplications (ITD) at the juxtamembrane domain of the receptor. FLT3-ITD receptors exhibit constitutive tyrosine kinase activity in the absence of FLT3 ligand (FL) binding, and when expressed in cytokine-dependent cell lines and primary hematopoietic cells suppress programmed cell death and increase cell division. However, the signaling pathways important for transformation, in particular the nuclear targets, are unknown. Here we demonstrate that FLT3-ITD expression in Ba/F3 cells results in activation of Akt and concomitant phosphorylation of the Forkhead family member Foxo3a. Phosphorylation of Foxo proteins through FLT3-ITD signaling promotes their translocation from the nucleus into the cytoplasm, which requires the presence of conserved Akt phosphorylation sites in Forkhead transcription factors and PI3K activity. Induction of Foxo3a phosphorylation by FLT3-ITD receptors in Ba/F3 cells correlates with the suppression of Foxo-target genes p27(Kip1) and the proapoptotic Bcl-2 family member Bim. Specifically, FLT3-ITD expression prevents Foxo3a-mediated apoptosis and upregulation of p27(Kip1) and Bim gene expression. These data indicate that the oncogenic tyrosine kinase FLT3 can negatively regulate Foxo transcription factors, thereby promoting cell survival and proliferation.	Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Griffin, JD (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, Mayer 540,44 Binney St, Boston, MA 02115 USA.	James_Griffin@dfci.harvard.edu	Scheijen, Blanca/E-3523-2016	Scheijen, Blanca/0000-0001-8029-9230	NCI NIH HHS [R01 CA66996] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA066996] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abu-Duhier FM, 2001, BRIT J HAEMATOL, V113, P983, DOI 10.1046/j.1365-2141.2001.02850.x; Alvarez B, 2001, NATURE, V413, P744, DOI 10.1038/35099574; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Brownawell AM, 2001, MOL CELL BIOL, V21, P3534, DOI 10.1128/MCB.21.10.3534-3546.2001; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Carow CE, 1996, BLOOD, V87, P1089, DOI 10.1182/blood.V87.3.1089.bloodjournal8731089; Castrillon DH, 2003, SCIENCE, V301, P215, DOI 10.1126/science.1086336; DASILVA N, 1994, LEUKEMIA, V8, P885; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; De Ruiter ND, 2001, MOL CELL BIOL, V21, P8225, DOI 10.1128/MCB.21.23.8225-8235.2001; DEL PL, 1997, SCIENCE, V278, P687; Dierov J, 2002, BLOOD, V99, P1758, DOI 10.1182/blood.V99.5.1758; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Engstrom M, 2003, EXP HEMATOL, V31, P316, DOI 10.1016/S0301-472X(03)00002-X; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Gilliland DG, 2002, BLOOD, V100, P1532, DOI 10.1182/blood-2002-02-0492; Harris CA, 2001, J BIOL CHEM, V276, P37754; Hayakawa F, 2000, ONCOGENE, V19, P624, DOI 10.1038/sj.onc.1203354; Kaestner KH, 2000, GENE DEV, V14, P142; Kashii Y, 2000, BLOOD, V96, P941, DOI 10.1182/blood.V96.3.941.015k14_941_949; Kelly LM, 2002, BLOOD, V99, P310, DOI 10.1182/blood.V99.1.310; Klucher KM, 1998, BLOOD, V91, P3927, DOI 10.1182/blood.V91.10.3927.3927_3927_3934; Komatsu N, 2003, J BIOL CHEM, V278, P6411, DOI 10.1074/jbc.M211562200; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; Lawlor MA, 2001, J CELL SCI, V114, P2903; Levis M, 2002, BLOOD, V99, P3885, DOI 10.1182/blood.V99.11.3885; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu D, 2000, CURR BIOL, V10, P1233, DOI 10.1016/S0960-9822(00)00733-8; Lyman SD, 1998, BLOOD, V91, P1101, DOI 10.1182/blood.V91.4.1101; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; MEIERHOFF G, 1995, LEUKEMIA, V9, P1368; Minami Y, 2003, BLOOD, V102, P2969, DOI 10.1182/blood-2002-12-3813; Miyashita MUT, 2001, FEBS LETT, V509, P135, DOI 10.1016/S0014-5793(01)03145-3; Mizuki M, 2000, BLOOD, V96, P3907, DOI 10.1182/blood.V96.12.3907; Modur V, 2002, J BIOL CHEM, V277, P47928, DOI 10.1074/jbc.M207509200; Nakae J, 2001, BIOCHEMISTRY-US, V40, P11768, DOI 10.1021/bi015532m; Nakae J, 2000, EMBO J, V19, P989, DOI 10.1093/emboj/19.5.989; Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534-5807(02)00401-X; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; Nakao M, 1996, LEUKEMIA, V10, P1911; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Parada Y, 2001, J BIOL CHEM, V276, P23572, DOI 10.1074/jbc.M101885200; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Rena G, 2002, EMBO J, V21, P2263, DOI 10.1093/emboj/21.9.2263; Rena G, 2001, BIOCHEM J, V354, P605, DOI 10.1042/0264-6021:3540605; Rokudai S, 2002, MOL CELL BIOL, V22, P8695, DOI 10.1128/MCB.22.24.8695-8708.2002; ROSNET O, 1991, ONCOGENE, V6, P1641; ROSNET O, 1993, BLOOD, V82, P1110, DOI 10.1182/blood.V82.4.1110.bloodjournal8241110; Scheid MP, 2002, MOL CELL BIOL, V22, P6247, DOI 10.1128/MCB.22.17.6247-6260.2002; Scheijen B, 2002, ONCOGENE, V21, P3314, DOI 10.1038/sj.onc.1205317; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; Shinjyo T, 2001, MOL CELL BIOL, V21, P854, DOI 10.1128/MCB.21.3.854-864.2001; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Spiekermann K, 2003, CLIN CANCER RES, V9, P2140; Spiekermann K, 2002, BLOOD, V100, P3423, DOI 10.1182/blood-2002-03-0953; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Tanaka M, 2001, J BIOL CHEM, V276, P15082, DOI 10.1074/jbc.M007958200; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Thiede C, 2002, BLOOD, V99, P4326, DOI 10.1182/blood.V99.12.4326; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Uddin S, 2000, BIOCHEM BIOPH RES CO, V275, P16, DOI 10.1006/bbrc.2000.3266; Villunger A, 2003, BLOOD, V101, P2393, DOI 10.1182/blood-2002-07-2132; Weisberg E, 2002, CANCER CELL, V1, P433, DOI 10.1016/S1535-6108(02)00069-7; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Williamson EA, 2002, ONCOGENE, V21, P3199, DOI 10.1038/sj.onc.1205461; Woods YL, 2001, BIOCHEM J, V355, P597, DOI 10.1042/bj3550597; Yamamoto Y, 2001, BLOOD, V97, P2434, DOI 10.1182/blood.V97.8.2434; Yang W, 2001, ONCOGENE, V20, P1688, DOI 10.1038/sj.onc.1204245; Zhang SL, 2000, J EXP MED, V192, P719, DOI 10.1084/jem.192.5.719; Zhao M, 2000, LEUKEMIA, V14, P374, DOI 10.1038/sj.leu.2401680; Zheng R, 2002, BLOOD, V100, P4154, DOI 10.1182/blood-2002-03-0936	81	92	94	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3338	3349		10.1038/sj.onc.1207456	http://dx.doi.org/10.1038/sj.onc.1207456			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	14981546				2022-12-28	WOS:000220975000008
J	Bader, AG; Vogt, PK				Bader, AG; Vogt, PK			An essential role for protein synthesis in oncogenic cellular transformation	ONCOGENE			English	Review						P3k; Akt; translation; TOR; TSC; Rheb; Raptor; YB-1	NF-KAPPA-B; RNA-ASSOCIATED PROTEIN; CAP-BINDING PROTEIN; REPRESSOR PHAS-I; P70 S6 KINASE; MESSENGER-RNA; MAMMALIAN TARGET; TUBEROUS-SCLEROSIS; PHOSPHOINOSITIDE 3-KINASE; TRANSCRIPTION FACTOR	The induction and maintenance of oncogenic transformation requires interference with the controls that regulate translation and transcription. The PI 3-kinase pathway, which shows gain of function in numerous and diverse human cancers, generates signals that have a positive effect on the initiation of protein synthesis. Here we review the components of the PI 3-kinase signaling pathway and the mRNA-binding protein YB-1, exploring their roles in protein synthesis and oncogenic cell transformation.	Scripps Res Inst, Dept Mol & Expt Med, Div Oncovirol, La Jolla, CA 92037 USA	Scripps Research Institute	Bader, AG (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, Div Oncovirol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	andreas@scripps.edu	Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500				Abraham RT, 2003, CURR TOP MICROBIOL, V279, P299; Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; Altiok S, 1999, J BIOL CHEM, V274, P32274, DOI 10.1074/jbc.274.45.32274; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; Aoki M, 2000, J BIOL CHEM, V275, P6267, DOI 10.1074/jbc.275.9.6267; Bacus SS, 2002, ONCOGENE, V21, P3532, DOI 10.1038/sj.onc.1205438; Bader AG, 2003, P NATL ACAD SCI USA, V100, P12384, DOI 10.1073/pnas.2135336100; BARRIEUX A, 1976, BIOCHEMISTRY-US, V15, P3523, DOI 10.1021/bi00661a020; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; BLOBEL G, 1972, BIOCHEM BIOPH RES CO, V47, P88, DOI 10.1016/S0006-291X(72)80014-7; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Choi KM, 2003, J BIOL CHEM, V278, P19667, DOI 10.1074/jbc.M301142200; Clemens MJ, 1999, INT J BIOCHEM CELL B, V31, P1, DOI 10.1016/S1357-2725(98)00127-7; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; De Benedetti A, 1999, INT J BIOCHEM CELL B, V31, P59, DOI 10.1016/S1357-2725(98)00132-0; DEL PL, 1997, SCIENCE, V278, P687; Depowski PL, 2001, MODERN PATHOL, V14, P672, DOI 10.1038/modpathol.3880371; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; Dilling MB, 2002, J BIOL CHEM, V277, P13907, DOI 10.1074/jbc.M110782200; DILLING MB, 1994, CANCER RES, V54, P903; Dudkin L, 2001, CLIN CANCER RES, V7, P1758; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Elit Laurie, 2002, Curr Opin Investig Drugs, V3, P1249; Evdokimova V, 2001, EMBO J, V20, P5491, DOI 10.1093/emboj/20.19.5491; Evdokimova VM, 1999, INT J BIOCHEM CELL B, V31, P139, DOI 10.1016/S1357-2725(98)00137-X; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Geoerger B, 2001, CANCER RES, V61, P1527; Gingras AC, 2003, CURR TOP MICROBIOL, V279, P169; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Hamilton GS, 1998, J MED CHEM, V41, P5119, DOI 10.1021/jm980307x; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; HESKETH R, 1997, FACTSBOOK SER, P3; Houghton PJ, 2003, CURR TOP MICROBIOL, V279, P339; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Ito T, 2003, CURR TOP MICROBIOL, V274, P1; Izumi H, 2001, NUCLEIC ACIDS RES, V29, P1200, DOI 10.1093/nar/29.5.1200; Jaeschke A, 2003, CURR TOP MICROBIOL, V279, P283; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Katsani KR, 2003, CURR TOP MICROBIOL, V274, P113; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Koike K, 1997, FEBS LETT, V417, P390, DOI 10.1016/S0014-5793(97)01296-9; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kuppers R, 2001, ONCOGENE, V20, P5580, DOI 10.1038/sj.onc.1204640; Kwiatkowski DJ, 2003, ANN HUM GENET, V67, P87, DOI 10.1046/j.1469-1809.2003.00012.x; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liao YD, 2003, INT J CANCER, V107, P676, DOI 10.1002/ijc.11471; Liu ET, 2003, CURR OPIN GENET DEV, V13, P97, DOI 10.1016/S0959-437X(03)00008-X; Lu YL, 2003, J BIOL CHEM, V278, P40057, DOI 10.1074/jbc.M303621200; Ma YY, 2000, ONCOGENE, V19, P2739, DOI 10.1038/sj.onc.1203597; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Mertens PR, 1997, J BIOL CHEM, V272, P22905, DOI 10.1074/jbc.272.36.22905; Meyuhas O, 2000, EUR J BIOCHEM, V267, P6321, DOI 10.1046/j.1432-1327.2000.01719.x; MINICH WB, 1992, BIOCHIMIE, V74, P477, DOI 10.1016/0300-9084(92)90088-V; Miralem T, 2003, MOL CELL BIOL, V23, P579, DOI 10.1128/MCB.23.2.579-593.2003; Miwa W, 1996, BIOCHEM BIOPH RES CO, V225, P968, DOI 10.1006/bbrc.1996.1280; MONTAGNE J, 2001, SCI STKE, pPE36; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Nekrasov MP, 2003, J BIOL CHEM, V278, P13936, DOI 10.1074/jbc.M209145200; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Nojima H, 2003, J BIOL CHEM, V278, P15461, DOI 10.1074/jbc.C200665200; Ozes ON, 1999, NATURE, V401, P82; Penuel E, 1999, MOL BIOL CELL, V10, P1693, DOI 10.1091/mbc.10.6.1693; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Proud CG, 2003, CURR TOP MICROBIOL, V279, P215; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; Raught B, 1999, INT J BIOCHEM CELL B, V31, P43, DOI 10.1016/S1357-2725(98)00131-9; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Ruggeri BA, 1998, MOL CARCINOGEN, V21, P81, DOI 10.1002/(SICI)1098-2744(199802)21:2<81::AID-MC1>3.0.CO;2-R; Russo G, 2003, ONCOGENE, V22, P6497, DOI 10.1038/sj.onc.1206865; Samuels Y., 2004, SCIENCE; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Sekulic A, 2000, CANCER RES, V60, P3504; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Sommerville J, 1996, FASEB J, V10, P435, DOI 10.1096/fasebj.10.4.8647342; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; STAAL SP, 1977, P NATL ACAD SCI USA, V74, P3065, DOI 10.1073/pnas.74.7.3065; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Tee AR, 2002, MOL CELL BIOL, V22, P1674, DOI 10.1128/MCB.22.6.1674-1683.2002; TING JPY, 1994, J EXP MED, V179, P1605, DOI 10.1084/jem.179.5.1605; VEZINA C, 1975, J ANTIBIOT, V28, P721, DOI 10.7164/antibiotics.28.721; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999; Zhang YF, 2003, ONCOGENE, V22, P2782, DOI 10.1038/sj.onc.1206357; Zimmer SG, 2000, ANTICANCER RES, V20, P1343; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	110	38	45	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2004	23	18					3145	3150		10.1038/sj.onc.1207550	http://dx.doi.org/10.1038/sj.onc.1207550			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	813AJ	15094764				2022-12-28	WOS:000220879700003
J	Holland, EC; Sonenberg, N; Pandolfi, PP; Thomas, G				Holland, EC; Sonenberg, N; Pandolfi, PP; Thomas, G			Signaling control of mRNA translation in cancer pathogenesis	ONCOGENE			English	Review						mRNA translation; PTEN; TSC1/2; mTOR; Rheb; eIF4E; prostate cancer; glioblastoma	INITIATION-FACTOR 4E; CAP-BINDING PROTEIN; AMINO-ACID-TRANSPORT; CELL-GROWTH; MAMMALIAN TARGET; PROSTATE-CANCER; S6 KINASE; PHOSPHORYLATION SITES; TUMOR SUPPRESSION; RAPAMYCIN TOR	The regulation of translation and the control of ribosome biogenesis are essential cellular processes whose impact on cell growth and proliferation is manifested at a number of specific levels. Disruption in one or more of the steps that control protein biosynthesis has been associated with alterations in the regulation of cell growth and cell cycle progression. Consistent with this, tumor suppressors and proto-oncogenes have been found to act on these functions and may therefore regulate malignant progression by affecting the protein synthetic machinery. Although many studies have correlated deregulation of protein biosynthesis with cancer, it remains to be established whether this process is necessary and/or sufficient for neoplastic transformation and metastasis.	Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Cell Biol, New York, NY 10021 USA; McGill Univ, Dept Biochem, Montreal, PQ, Canada; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; McGill University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Friedrich Miescher Institute for Biomedical Research	Holland, EC (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Surg, 1275 York Ave, New York, NY 10021 USA.	hollande@mskcc.org; nahum.sonenberg@mcgill.ca; p-pandolfi@ski.mskcc.org; george.thomas@fmi.ch	Thomas, George/K-9235-2014	Thomas, George/0000-0003-3518-8149				ALTMANN M, 1987, MOL CELL BIOL, V7, P998, DOI 10.1128/MCB.7.3.998; Anand N, 2002, NAT GENET, V31, P301, DOI 10.1038/ng904; ANTONETTI DA, 1993, J BIOL CHEM, V268, P25277; Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200; Backman SA, 2001, NAT GENET, V29, P396, DOI 10.1038/ng782; Backman SA, 2002, CURR OPIN NEUROBIOL, V12, P516, DOI 10.1016/S0959-4388(02)00354-9; Biondi RM, 2001, EMBO J, V20, P4380, DOI 10.1093/emboj/20.16.4380; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; Blommaart EFC, 1997, HISTOCHEM J, V29, P365, DOI 10.1023/A:1026486801018; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Crackower MA, 2002, CELL, V110, P737, DOI 10.1016/S0092-8674(02)00969-8; De Benedetti A, 1999, INT J BIOCHEM CELL B, V31, P59, DOI 10.1016/S1357-2725(98)00132-0; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; DUNCAN R, 1987, J BIOL CHEM, V262, P380; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 2001, GENE DEV, V15, P2852; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; GOMEZ M, 1999, TUBEROUS SCLEROSIS, V340; Gray IC, 1998, BRIT J CANCER, V78, P1296, DOI 10.1038/bjc.1998.674; GRESSNER AM, 1974, J BIOL CHEM, V249, P6917; Grewe M, 1999, CANCER RES, V59, P3581; Grunwald V, 2002, CANCER RES, V62, P6141; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P637; Hidalgo M, 2000, ONCOGENE, V19, P6680, DOI 10.1038/sj.onc.1204091; Hosoi H, 1998, MOL PHARMACOL, V54, P815, DOI 10.1124/mol.54.5.815; Huang Shile, 2002, Curr Opin Investig Drugs, V3, P295; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jaeschke A, 2002, J CELL BIOL, V159, P217, DOI 10.1083/jcb.jcb.200206108; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; Jefferson LS, 2001, J NUTR, V131, p2460S, DOI 10.1093/jn/131.9.2460S; Kenerson HL, 2002, CANCER RES, V62, P5645; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kimball SR, 1999, J BIOL CHEM, V274, P11647, DOI 10.1074/jbc.274.17.11647; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; KOZMA SC, 1994, SEMIN CANCER BIOL, V5, P255; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Kwon CH, 2001, NAT GENET, V29, P404, DOI 10.1038/ng781; Lachance PED, 2002, MOL CELL BIOL, V22, P1656, DOI 10.1128/MCB.22.6.1656-1663.2002; LAZARISKARATZAS A, 1992, GENE DEV, V6, P1631, DOI 10.1101/gad.6.9.1631; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Li SN, 2002, MOL CELL BIOL, V22, P2853, DOI 10.1128/MCB.22.8.2853-2861.2002; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Luo Y, 1996, MOL CELL BIOL, V16, P6744; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Marcotrigiano J, 1999, MOL CELL, V3, P707, DOI 10.1016/S1097-2765(01)80003-4; McDowell HE, 1998, FEBS LETT, V441, P15, DOI 10.1016/S0014-5793(98)01508-7; Meric F, 2002, MOL CANCER THER, V1, P971; Meyuhas O, 2000, EUR J BIOCHEM, V267, P6321, DOI 10.1046/j.1432-1327.2000.01719.x; Miron M, 2001, NAT CELL BIOL, V3, P596, DOI 10.1038/35078571; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; MUNOZ M, 1995, EXP PHYSIOL, V80, P745, DOI 10.1113/expphysiol.1995.sp003883; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Pestova TV, 2001, P NATL ACAD SCI USA, V98, P7029, DOI 10.1073/pnas.111145798; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Radimerski T, 2002, NAT CELL BIOL, V4, P251, DOI 10.1038/ncb763; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; Raught B, 2000, COLD SPRING HARBOR M, V39, P245; Raught B, 2000, EMBO J, V19, P434, DOI 10.1093/emboj/19.3.434; RAUGHT B, 2004, IN PRESS EMBO J; Rousseau D, 1996, ONCOGENE, V13, P2415; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Saucedo LJ, 2003, NAT CELL BIOL, V5, P680, DOI 10.1038/ncb0703-680c; Scheper GC, 2002, EUR J BIOCHEM, V269, P5350, DOI 10.1046/j.1432-1033.2002.03291.x; Scheper GC, 2001, MOL CELL BIOL, V21, P743, DOI 10.1128/MCB.21.3.743-754.2001; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; Shigemitsu K, 1999, J BIOL CHEM, V274, P1058, DOI 10.1074/jbc.274.2.1058; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Suzuki A, 2001, IMMUNITY, V14, P523, DOI 10.1016/S1074-7613(01)00134-0; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; TERADA N, 1993, J CELL PHYSIOL, V154, P7, DOI 10.1002/jcp.1041540103; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; THOMAS G, 1979, P NATL ACAD SCI USA, V76, P3952, DOI 10.1073/pnas.76.8.3952; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; van der Velden AW, 1999, INT J BIOCHEM CELL B, V31, P87, DOI 10.1016/S1357-2725(98)00134-4; Volarevic S, 2001, PROG NUCLEIC ACID RE, V65, P101; Volarevic S, 2000, SCIENCE, V288, P2045, DOI 10.1126/science.288.5473.2045; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; WICKER LS, 1990, EUR J IMMUNOL, V20, P2277, DOI 10.1002/eji.1830201017; Wool I. G., 1996, TRANSLATIONAL CONTRO, P685; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999	104	130	135	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2004	23	18					3138	3144		10.1038/sj.onc.1207590	http://dx.doi.org/10.1038/sj.onc.1207590			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	813AJ	15094763	Green Published			2022-12-28	WOS:000220879700002
J	White, RJ				White, RJ			RNA polymerase III transcription and cancer	ONCOGENE			English	Review						cancer; c-Myc; p53; RB; RNA polymerase III transcription; TFIIIB	TATA-BINDING PROTEIN; CASEIN KINASE-II; VIRUS-X PROTEIN; TUMOR-SUPPRESSOR PROTEIN; RETINOBLASTOMA PROTEIN; CELL-CYCLE; RIBOSOMAL-RNA; FACTOR UBF; MALIGNANT-TRANSFORMATION; RDNA TRANSCRIPTION	RNA polymerase (pol) III synthesizes a range of essential products, including tRNA, 5S rRNA and 7SL RNA, which are required for protein synthesis and trafficking. High rates of pol III transcription are necessary for cells to sustain growth. A wide range of transformed and tumour cell types have been shown to express elevated levels of pol III products. This review will summarize what is known about the mechanisms responsible for this deregulation. Some transforming agents have been shown to stimulate expression of the pol III-specific transcription factors TFIIIB or TFIIIC2. In addition, TFIIIB is bound and activated by several oncogenic proteins, including c-Myc. Conversely, TFIIIB interacts in healthy cells with the tumour suppressors RB and p53. Indeed, the ability to limit pol III transcription through TFIIIB may contribute to their growth-suppression capacities. The function of p53 and/or RB is compromised in most if not all transformed cells; the resultant derepression of TFIIIB may provide an almost universal route to deregulate pol III transcription in cancers. In addition to effects on protein synthesis and growth, there is a precedent for a pol III product having oncogenic activity.	Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	White, RJ (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	rwhite@udcf.gla.ac.uk						AKUSJARVI G, 1987, MOL CELL BIOL, V7, P549, DOI 10.1128/MCB.7.1.549; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; ALTMANN GG, 1982, J CELL SCI, V56, P83; ARRAND JR, 1982, J VIROL, V41, P376, DOI 10.1128/JVI.41.2.376-389.1982; BATES S, 1995, SEMIN CANCER BIOL, V6, P73, DOI 10.1006/scbi.1995.0010; Beier R, 2000, EMBO J, V19, P5813, DOI 10.1093/emboj/19.21.5813; BELENGUER P, 1989, NUCLEIC ACIDS RES, V17, P6625; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Brandenburger Y, 2001, FASEB J, V15, P2051, DOI 10.1096/fj.00-0853fje; Brown TRP, 2000, GENE EXPRESSION, V9, P15; Bullock AN, 2000, ONCOGENE, V19, P1245, DOI 10.1038/sj.onc.1203434; Busch H, 1970, NUCLEOLUS, P448; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; Chen W, 1997, J PATHOL, V183, P345, DOI 10.1002/(SICI)1096-9896(199711)183:3<345::AID-PATH930>3.0.CO;2-8; Chen W, 1997, EUR J CANCER, V33, P288, DOI 10.1016/S0959-8049(96)00453-4; Chesnokov I, 1996, MOL CELL BIOL, V16, P7084; Chu WM, 1997, J BIOL CHEM, V272, P14755, DOI 10.1074/jbc.272.23.14755; Ciarmatori S, 2001, MOL CELL BIOL, V21, P5806, DOI 10.1128/MCB.21.17.5806-5814.2001; CLARKE PA, 1991, NUCLEIC ACIDS RES, V19, P243, DOI 10.1093/nar/19.2.243; CLEMENS M, 1992, NATURE, V360, P210, DOI 10.1038/360210a0; Crighton D, 2003, EMBO J, V22, P2810, DOI 10.1093/emboj/cdg265; DALY NL, UNPUB ONCOGENE; DAVIES MV, 1989, P NATL ACAD SCI USA, V86, P9163, DOI 10.1073/pnas.86.23.9163; Derenzini M., 1994, MOL BIOL HISTOPATHOL, P231; DiCiommo D, 2000, SEMIN CANCER BIOL, V10, P255, DOI 10.1006/scbi.2000.0326; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Elia A, 1996, NUCLEIC ACIDS RES, V24, P4471, DOI 10.1093/nar/24.22.4471; Faust RA, 1996, CANCER LETT, V101, P31, DOI 10.1016/0304-3835(96)04110-9; Felton-Edkins ZA, 2003, EMBO J, V22, P2422, DOI 10.1093/emboj/cdg240; Felton-Edkins ZA, 2002, J BIOL CHEM, V277, P48182, DOI 10.1074/jbc.M201333200; Felton-Edkins ZA, 2003, CELL CYCLE, V2, P181, DOI 10.4161/cc.2.3.375; FRANCIS MA, 1990, MOL CELL BIOL, V10, P4486, DOI 10.1128/MCB.10.9.4486; Geiduschek EP, 2001, J MOL BIOL, V310, P1, DOI 10.1006/jmbi.2001.4732; Ghavidel A, 2001, CELL, V106, P575, DOI 10.1016/S0092-8674(01)00473-1; Ghavidel A, 1997, GENE DEV, V11, P2780, DOI 10.1101/gad.11.21.2780; Gomez-Roman N, 2003, NATURE, V421, P290, DOI 10.1038/nature01327; Gottesfeld JM, 1996, MOL CELL BIOL, V16, P1777; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Hannan KM, 2000, ONCOGENE, V19, P3487, DOI 10.1038/sj.onc.1203690; Hannan KM, 2000, ONCOGENE, V19, P4988, DOI 10.1038/sj.onc.1203875; Hannan RD, 1998, J BIOL CHEM, V273, P1257, DOI 10.1074/jbc.273.2.1257; Harbour JW, 1998, OPHTHALMOLOGY, V105, P1442, DOI 10.1016/S0161-6420(98)98025-3; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HIRAMA T, 1995, BLOOD, V86, P841; Hirsch HA, 2000, MOL CELL BIOL, V20, P9182, DOI 10.1128/MCB.20.24.9182-9191.2000; Hockman DJ, 1996, MOL CELL BIOL, V16, P892; HOEFFLER WK, 1985, CELL, V41, P955, DOI 10.1016/S0092-8674(85)80076-3; HOEFFLER WK, 1988, CELL, V53, P907, DOI 10.1016/S0092-8674(88)90409-6; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Huang RM, 2002, FASEB J, V16, DOI 10.1096/fj.01-0687com; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JOHNSON LF, 1974, CELL, V1, P95, DOI 10.1016/0092-8674(74)90068-3; Johnson SAS, 2000, MOL CELL BIOL, V20, P5000, DOI 10.1128/MCB.20.14.5000-5009.2000; Johnson SAS, 2003, MOL CELL BIOL, V23, P3043, DOI 10.1128/MCB.23.9.3043-3051.2003; Johnston IM, 2002, MOL CELL BIOL, V22, P3757, DOI 10.1128/MCB.22.11.3757-3768.2002; KING RJB, 1996, CANC BIOL, P27; Kitagawa N, 2000, EMBO J, V19, P6742, DOI 10.1093/emboj/19.24.6742; Klein J, 1999, P NATL ACAD SCI USA, V96, P6096, DOI 10.1073/pnas.96.11.6096; Komano J, 1999, J VIROL, V73, P9827, DOI 10.1128/JVI.73.12.9827-9831.1999; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KRATZKE RA, 1994, ONCOGENE, V9, P1321; KURATA SI, 1978, CHROMOSOMA, V68, P313, DOI 10.1007/BF00327166; LAING KG, 1995, BIOCHEM SOC T, V23, pS311, DOI 10.1042/bst023311s; Larminie CGC, 1999, MOL CELL BIOL, V19, P4927; Larminie CGC, 1997, EMBO J, V16, P2061, DOI 10.1093/emboj/16.8.2061; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; LIEBHABER SA, 1978, CELL, V13, P121, DOI 10.1016/0092-8674(78)90143-5; LITCHFIELD DW, 1993, MOL CELL BIOCHEM, V128, P187, DOI 10.1007/BF01076770; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; MAUCK JC, 1974, CELL, V3, P171, DOI 10.1016/0092-8674(74)90122-6; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MOSS T, 1995, PROG NUCLEIC ACID RE, V50, P25, DOI 10.1016/S0079-6603(08)60810-7; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; Nanbo A, 2002, EMBO J, V21, P954, DOI 10.1093/emboj/21.5.954; Nasmyth K, 1996, NATURE, V382, P28, DOI 10.1038/382028a0; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Neufeld TP, 1998, CURR OPIN CELL BIOL, V10, P784, DOI 10.1016/S0955-0674(98)80122-1; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; Notterman DA, 2001, CANCER RES, V61, P3124; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Pelletier G, 2000, MOL CELL, V6, P1059, DOI 10.1016/S1097-2765(00)00104-0; Pianese G., 1896, BEITR PATHOL ANAT AL, V142, P1; Pombo A, 1999, EMBO J, V18, P2241, DOI 10.1093/emboj/18.8.2241; Rocco JW, 2001, EXP CELL RES, V264, P42, DOI 10.1006/excr.2000.5149; Ruf IK, 2000, J VIROL, V74, P10223, DOI 10.1128/JVI.74.21.10223-10228.2000; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Schramm L, 2002, GENE DEV, V16, P2593, DOI 10.1101/gad.1018902; SCHWARTZ LB, 1974, J BIOL CHEM, V249, P5889; SCOTT MRD, 1983, CELL, V34, P557, DOI 10.1016/0092-8674(83)90388-4; Scott PH, 2001, J BIOL CHEM, V276, P1005, DOI 10.1074/jbc.M005417200; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; SHARP TV, 1993, NUCLEIC ACIDS RES, V21, P4483, DOI 10.1093/nar/21.19.4483; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Stefanovsky VY, 2001, MOL CELL, V8, P1063, DOI 10.1016/S1097-2765(01)00384-7; Stein T, 2002, ONCOGENE, V21, P5540, DOI 10.1038/sj.onc.1205739; Stein T, 2002, ONCOGENE, V21, P2961, DOI 10.1038/sj.onc.1205372; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Sutcliffe JE, 1999, MOL CELL BIOL, V19, P4255; Sutcliffe JE, 2000, MOL CELL BIOL, V20, P9192, DOI 10.1128/MCB.20.24.9192-9202.2000; SUTCLIFFE JE, 2000, THESIS U GLASGOW; THIMMAPPAYA B, 1982, CELL, V31, P543, DOI 10.1016/0092-8674(82)90310-5; VOIT R, 1995, NUCLEIC ACIDS RES, V23, P2593, DOI 10.1093/nar/23.14.2593; Voit R, 1997, MOL CELL BIOL, V17, P4230, DOI 10.1128/MCB.17.8.4230; VOIT R, 1992, EMBO J, V11, P2211, DOI 10.1002/j.1460-2075.1992.tb05280.x; Voit R, 2001, P NATL ACAD SCI USA, V98, P13631, DOI 10.1073/pnas.231071698; VOUSDEN KH, 1995, SEMIN CANCER BIOL, V6, P109, DOI 10.1006/scbi.1995.0014; WANG HD, 1995, MOL CELL BIOL, V15, P6720; Wang HD, 1997, MOL CELL BIOL, V17, P6838, DOI 10.1128/MCB.17.12.6838; Wang HD, 1998, MOL CELL BIOL, V18, P7086, DOI 10.1128/MCB.18.12.7086; Warner JR, 1999, TRENDS BIOCHEM SCI, V24, P437, DOI 10.1016/S0968-0004(99)01460-7; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Whitaker LL, 1998, MOL CELL BIOL, V18, P4032, DOI 10.1128/MCB.18.7.4032; WHITE RJ, 1990, EMBO J, V9, P3713, DOI 10.1002/j.1460-2075.1990.tb07584.x; WHITE RJ, 1995, MOL CELL BIOL, V15, P6653; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0; White RJ, 1997, TRENDS BIOCHEM SCI, V22, P77, DOI 10.1016/S0968-0004(96)10067-0; WHITE RJ, 2002, LANDES BIOSCIENCE; WHTIE RJ, 2004, CELL GROWTH CONTROL; Winter AG, 2000, P NATL ACAD SCI USA, V97, P12619, DOI 10.1073/pnas.230224097; Yamamoto N, 2000, FEBS LETT, V484, P153, DOI 10.1016/S0014-5793(00)02145-1; Ying CW, 1996, MOL CELL ENDOCRINOL, V118, P207, DOI 10.1016/0303-7207(96)03786-0; YOSHINAGA S, 1986, EMBO J, V5, P343, DOI 10.1002/j.1460-2075.1986.tb04218.x; Zhai WG, 1999, MOL CELL BIOL, V19, P2791; Zhai WG, 2000, MOL CELL BIOL, V20, P5930, DOI 10.1128/MCB.20.16.5930-5938.2000; Zhao J, 2003, MOL CELL, V11, P405, DOI 10.1016/S1097-2765(03)00036-4; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690	130	146	148	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2004	23	18					3208	3216		10.1038/sj.onc.1207547	http://dx.doi.org/10.1038/sj.onc.1207547			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	813AJ	15094770				2022-12-28	WOS:000220879700009
J	Hui, LJ; Zhang, X; Wu, X; Lin, ZX; Wang, QK; Li, YX; Hu, GX				Hui, LJ; Zhang, X; Wu, X; Lin, ZX; Wang, QK; Li, YX; Hu, GX			Identification of alternatively spliced mRNA variants related to cancers by genome-wide ESTs alignment	ONCOGENE			English	Article						alternative splicing prediction; database; cancer; EST alignment	EXPRESSED SEQUENCE TAGS; COMPUTATIONAL ANALYSIS; GENE-EXPRESSION; DATABASE; PROTEIN; EXON	Several databases have been published to predict alternative splicing of mRNAs by analysing the exon linkage relationship by alignment of expressed sequence tags (ESTs) to the genome sequence; however, little effort has been made to investigate the relationship between cancers and alternative splicing. We developed a program, Alternative Splicing Assembler (ASA), to look for splicing variants of human gene transcripts by genome-wide ESTs alignment. Using ASA, we constructed the biosino alternative splicing database (BASD), which predicted splicing variants for reference sequences from the reference sequence database (RefSeq) and presented them in both graph and text formats. EST clusters that differ from the reference sequences in at least one splicing site were counted as splicing variants. Of 4322 genes screened, 3490 (81%) were observed with at least one alternative splicing variants. To discover the variants associated with cancers, tissue sources of EST sequences were extracted from the UniLib database and ESTs from the same tissue type were counted. These were regarded as the indicators for gene expression level. Using Fisher's exact test, alternative splicing variants, of which EST counts were significantly different between cancer tissues and their counterpart normal tissues, were identified. It was predicted that 2149 variants, or 383 variants after Bonferroni correction, of 26 812 variants were likely tumor-associated. By reverse transcription-PCR, 11 of 13 novel alternative splicing variants and eight of nine variants' tissue specificity were confirmed in hepatocelluar carcinoma and in lung cancer. The possible involvement of alternative splicing in cancer is discussed.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, State Key Lab Mol Biol, Shanghai 200031, Peoples R China; Shanghai Jiao Tong Univ, Inst Microelect, Shanghai 200030, Peoples R China; Zhongshan Hosp, Liver Canc Inst, Guangzhou, Peoples R China; Shanghai Jiao Tong Univ, Sch Life Sci, Shanghai 200030, Peoples R China; Chinese Acad Sci, Shanghai Inst Biol Sci, Bioinformat Ctr, Shanghai 200031, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Li, YX (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, State Key Lab Mol Biol, Room 400,Cell Bldg,Yueyang Rd 320, Shanghai 200031, Peoples R China.	yxli@sibs.ac.cn; xbshu@sunm.shcnc.ac.cn	Wu, Xin/B-2244-2010					Ars E, 2000, NUCLEIC ACIDS RES, V28, P1307, DOI 10.1093/nar/28.6.1307; Baranova AV, 2001, FEBS LETT, V508, P143, DOI 10.1016/S0014-5793(01)03028-9; Black DL, 2000, CELL, V103, P367, DOI 10.1016/S0092-8674(00)00128-8; Brett D, 2000, FEBS LETT, V474, P83, DOI 10.1016/S0014-5793(00)01581-7; Claverie JM, 2001, SCIENCE, V291, P1255, DOI 10.1126/science.1058969; Coward E, 2002, TRENDS GENET, V18, P53, DOI 10.1016/S0168-9525(01)02525-2; Dralyuk I, 2000, NUCLEIC ACIDS RES, V28, P296, DOI 10.1093/nar/28.1.296; Goodison S, 1999, J CLIN PATHOL-MOL PA, V52, P189; He JQ, 2001, J BIOL CHEM, V276, P26814, DOI 10.1074/jbc.M101820200; Hogenesch JB, 2001, CELL, V106, P413, DOI 10.1016/S0092-8674(01)00467-6; Huang RM, 2003, CANCER RES, V63, P3775; Huang YH, 2002, NUCLEIC ACIDS RES, V30, P186, DOI 10.1093/nar/30.1.186; Ji HK, 2001, NUCLEIC ACIDS RES, V29, P260, DOI 10.1093/nar/29.1.260; Kan ZY, 2002, GENOME RES, V12, P1837, DOI 10.1101/gr.764102; Kan ZY, 2001, GENOME RES, V11, P889, DOI 10.1101/gr.155001; Kaufmann D, 2002, CANCER RES, V62, P1503; Kawamoto S, 2000, GENOME RES, V10, P1817, DOI 10.1101/gr.151500; KRAWCZAK M, 1992, HUM GENET, V90, P41; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Matsui A, 2000, CANCER LETT, V150, P23, DOI 10.1016/S0304-3835(99)00368-7; McDoniels-Silvers AL, 2002, CLIN CANCER RES, V8, P1127; Mironov AA, 1999, GENOME RES, V9, P1288, DOI 10.1101/gr.9.12.1288; Modrek B, 2001, NUCLEIC ACIDS RES, V29, P2850, DOI 10.1093/nar/29.13.2850; Nash MA, 2002, CLIN CANCER RES, V8, P1754; Olopade OI, 1997, CANCER J SCI AM, V3, P230; Pruitt KD, 2001, NUCLEIC ACIDS RES, V29, P137, DOI 10.1093/nar/29.1.137; Reeve JG, 1996, BRIT J CANCER, V73, P1193, DOI 10.1038/bjc.1996.230; Scheurle D, 2000, CANCER RES, V60, P4037; Schuler GD, 1997, J MOL MED, V75, P694, DOI 10.1007/s001090050155; Stamm S, 2000, DNA CELL BIOL, V19, P739, DOI 10.1089/104454900750058107; Thompson TE, 2002, CANCER RES, V62, P3251; Valve EM, 2001, LAB INVEST, V81, P815, DOI 10.1038/labinvest.3780291; van der Spuy J, 2002, HUM MOL GENET, V11, P823, DOI 10.1093/hmg/11.7.823; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wang ZN, 2003, CANCER RES, V63, P655; Wolfsberg TG, 1997, NUCLEIC ACIDS RES, V25, P1626, DOI 10.1093/nar/25.8.1626; Xie HQ, 2002, GENOMICS, V80, P326, DOI 10.1006/geno.2002.6841; Xu L, 2001, CANCER RES, V61, P3176; Xu Q, 2002, NUCLEIC ACIDS RES, V30, P3754, DOI 10.1093/nar/gkf492	39	62	64	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2004	23	17					3013	3023		10.1038/sj.onc.1207362	http://dx.doi.org/10.1038/sj.onc.1207362			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	812NC	15048092				2022-12-28	WOS:000220845200005
J	Masucci, MG				Masucci, MG			Epstein-Barr virus oncogenesis and the ubiquitin-proteasome system	ONCOGENE			English	Review						EBV; LMP/EBNA; ubiquitin-proteasome system; Gly-Ala; isopeptidases; TPPII	TRIPEPTIDYL-PEPTIDASE-II; MEMBRANE-PROTEIN 2A; BURKITTS-LYMPHOMA CELLS; N-TERMINAL RESIDUE; MEMORY B-CELLS; GLY-ALA REPEAT; NUCLEAR ANTIGEN 1; GENE-PRODUCT 9.5; C-MYC; LATENT GENES	Epstein - Barr virus (EBV), a human herpesvirus associated with lymphoid and epithelial cell tumors, encodes several proteins that exploit the ubiquitin - proteasome system to regulate latency and allow the persistence of infected cells in immunocompetent hosts. Further modi. cations of ubiquitin-dependent proteolysis by activated cellular oncogenes contribute to malignant transformation. A detailed understanding of these processes may lead to the development of new therapeutic strategies for EBV-associated cancers.	Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden	Karolinska Institutet	Masucci, MG (corresponding author), Karolinska Inst, Ctr Microbiol & Tumor Biol, Box 280, S-17177 Stockholm, Sweden.	maria.masucci@mtc.ki.se	Masucci, Maria G/B-8588-2009; Masucci, Maria/AAC-6666-2019	Masucci, Maria/0000-0002-5541-2809				ANDERSSON ML, 1991, INT J CANCER, V47, P544, DOI 10.1002/ijc.2910470412; Aumuller G, 1999, PROSTATE, V38, P261; Aviel S, 2000, J BIOL CHEM, V275, P23491, DOI 10.1074/jbc.M002052200; AVILACARINO J, 1987, INT J CANCER, V40, P691, DOI 10.1002/ijc.2910400521; Babcock GJ, 2000, P NATL ACAD SCI USA, V97, P12250, DOI 10.1073/pnas.200366597; Babcock GJ, 2000, IMMUNITY, V13, P497, DOI 10.1016/S1074-7613(00)00049-2; Babcock GJ, 1999, J EXP MED, V190, P567, DOI 10.1084/jem.190.4.567; Babcock GJ, 1998, IMMUNITY, V9, P395, DOI 10.1016/S1074-7613(00)80622-6; Bahram F, 2000, BLOOD, V95, P2104, DOI 10.1182/blood.V95.6.2104; Balakirev MY, 2003, EMBO REP, V4, P517, DOI 10.1038/sj.embor.embor824; BALOW RM, 1983, J BIOL CHEM, V258, P1622; BALOW RM, 1987, BIOCHEM J, V241, P75, DOI 10.1042/bj2410075; BALOW RM, 1986, J BIOL CHEM, V261, P2409; Blake N, 1997, IMMUNITY, V7, P791, DOI 10.1016/S1074-7613(00)80397-0; Blake NW, 1999, J VIROL, V73, P7381, DOI 10.1128/JVI.73.9.7381-7389.1999; Bloom J, 2003, CELL, V115, P71, DOI 10.1016/S0092-8674(03)00755-4; Borodovsky A, 2002, CHEM BIOL, V9, P1149, DOI 10.1016/S1074-5521(02)00248-X; Boutell C, 2003, J BIOL CHEM, V278, P36596, DOI 10.1074/jbc.M300776200; Boutell C, 2002, J VIROL, V76, P841, DOI 10.1128/JVI.76.2.841-850.2002; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; Brichory F, 2001, CANCER RES, V61, P7908; Brown KD, 2001, J EXP MED, V193, P943, DOI 10.1084/jem.193.8.943; CHEN F, 1995, J VIROL, V69, P3752, DOI 10.1128/JVI.69.6.3752-3758.1995; Cope GA, 2002, SCIENCE, V298, P608, DOI 10.1126/science.1075901; Coscoy L, 2001, J CLIN INVEST, V107, P1599, DOI 10.1172/JCI12432; Curran JA, 2001, CANCER RES, V61, P6730; D'Andrea V, 1997, G Chir, V18, P521; Dantuma NP, 2000, NAT BIOTECHNOL, V18, P538, DOI 10.1038/75406; Dantuma NP, 2000, P NATL ACAD SCI USA, V97, P8381, DOI 10.1073/pnas.140217397; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Dolcetti R, 2003, J CELL PHYSIOL, V196, P207, DOI 10.1002/jcp.10263; Dukers DF, 2000, J IMMUNOL, V165, P663, DOI 10.4049/jimmunol.165.2.663; Engels N, 2001, J EXP MED, V194, P255, DOI 10.1084/jem.194.3.255; Everett RD, 1997, EMBO J, V16, P1519, DOI 10.1093/emboj/16.7.1519; FALK K, 1995, J GEN VIROL, V76, P779, DOI 10.1099/0022-1317-76-4-779; Fernandez-Funez P, 2000, NATURE, V408, P101, DOI 10.1038/35040584; Frisan T, 1996, INT J CANCER, V68, P251, DOI 10.1002/(SICI)1097-0215(19961009)68:2<251::AID-IJC19>3.0.CO;2-D; Frisan T, 1998, J IMMUNOL, V160, P3281; Fruh K, 2002, VIRUS RES, V88, P55, DOI 10.1016/S0168-1702(02)00120-X; Gavioli R, 2001, NAT CELL BIOL, V3, P283, DOI 10.1038/35060076; Geier E, 1999, SCIENCE, V283, P978, DOI 10.1126/science.283.5404.978; Glas R, 1998, NATURE, V392, P618, DOI 10.1038/33443; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Heessen S, 2003, FEBS LETT, V555, P397, DOI 10.1016/S0014-5793(03)01296-1; Heessen S, 2002, P NATL ACAD SCI USA, V99, P1532, DOI 10.1073/pnas.022306499; Hemelaar J, 2001, J VIROL, V75, P11106, DOI 10.1128/JVI.75.22.11106-11115.2001; Herbst H, 1996, SEMIN CANCER BIOL, V7, P183, DOI 10.1006/scbi.1996.0025; Hilbi H, 2000, INFECT IMMUN, V68, P5502, DOI 10.1128/IAI.68.10.5502-5508.2000; Holowaty MN, 2003, J BIOL CHEM, V278, P47753, DOI 10.1074/jbc.M307200200; Holowaty MN, 2003, J BIOL CHEM, V278, P29987, DOI 10.1074/jbc.M303977200; HU LF, 1993, ONCOGENE, V8, P1575; IEZZONI JC, 1995, AM J CLIN PATHOL, V103, P308, DOI 10.1093/ajcp/103.3.308; Ikeda A, 2003, J VIROL, V77, P5529, DOI 10.1128/JVI.77.9.5529-5534.2003; Ikeda M, 2000, VIROLOGY, V268, P178, DOI 10.1006/viro.1999.0166; Ikeda M, 2002, VIROLOGY, V300, P153, DOI 10.1006/viro.2002.1562; Kelly G, 2002, NAT MED, V8, P1098, DOI 10.1038/nm758; Kessler B, 2003, J BIOL CHEM, V278, P10013, DOI 10.1074/jbc.M211221200; KIEFF E, 1996, FIELDS VIROLOGY, V2, P2343; Kieser A, 1999, EMBO J, V18, P2511, DOI 10.1093/emboj/18.9.2511; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; KLEIN G, 1994, ANTIBIOT CHEMOTHER, V46, P110; Knecht H, 2001, ONCOLOGY-BASEL, V60, P289, DOI 10.1159/000058523; Kulwichit W, 1998, P NATL ACAD SCI USA, V95, P11963, DOI 10.1073/pnas.95.20.11963; Lansbury PT, 2002, CURR OPIN CELL BIOL, V14, P653, DOI 10.1016/S0955-0674(02)00377-0; Larsen CN, 1998, BIOCHEMISTRY-US, V37, P3358, DOI 10.1021/bi972274d; Leight ER, 2000, REV MED VIROL, V10, P83, DOI 10.1002/(SICI)1099-1654(200003/04)10:2&lt;83::AID-RMV262&gt;3.0.CO;2-T; Leonchiks A, 2002, FEBS LETT, V522, P93, DOI 10.1016/S0014-5793(02)02897-1; Levitskaya J, 1997, P NATL ACAD SCI USA, V94, P12616, DOI 10.1073/pnas.94.23.12616; LEVITSKAYA J, 1995, NATURE, V375, P685, DOI 10.1038/375685a0; Liu YC, 2002, CELL, V111, P209, DOI 10.1016/S0092-8674(02)01012-7; LONGNECKER R, 1993, J VIROL, V67, P2006, DOI 10.1128/JVI.67.4.2006-2013.1993; Longnecker R, 2000, EXP CELL RES, V257, P332, DOI 10.1006/excr.2000.4900; Lorenzo ME, 2002, J VIROL, V76, P5522, DOI 10.1128/JVI.76.11.5522-5531.2002; Masucci Maria G., 1994, Trends in Microbiology, V2, P125, DOI 10.1016/0966-842X(94)90599-1; MILLER CL, 1994, INFECT AGENT DIS, V3, P128; MILLER CL, 1994, P NATL ACAD SCI USA, V91, P772, DOI 10.1073/pnas.91.2.772; Miyashita EM, 1997, J VIROL, V71, P4882, DOI 10.1128/JVI.71.7.4882-4891.1997; MOORTHY R, 1990, J VIROL, V64, P829, DOI 10.1128/JVI.64.2.829-837.1990; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Mukherjee S, 1998, J EXP MED, V187, P445, DOI 10.1084/jem.187.3.445; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; Naze P, 2002, NEUROSCI LETT, V328, P1, DOI 10.1016/S0304-3940(02)00231-8; Niedobitek G, 2000, J PATHOL, V191, P394, DOI 10.1002/1096-9896(2000)9999:9999&lt;::AID-PATH651&gt;3.0.CO;2-0; Paludan C, 2003, CURR MOL MED, V3, P341, DOI 10.2174/1566524033479771; Reinstein E, 2000, ONCOGENE, V19, P5944, DOI 10.1038/sj.onc.1203989; RICKINSON AB, 1992, CANCER SURV, V13, P53; RICKINSON AB, 1996, FIELDS VIROLOGY, P2397; Rose C, 1996, NEUROPEPTIDES, V30, P231, DOI 10.1016/S0143-4179(96)90069-4; Rothenberger S, 2002, CELL MOL LIFE SCI, V59, P171, DOI 10.1007/s00018-002-8413-y; Rousset R, 1996, NATURE, V381, P328, DOI 10.1038/381328a0; ROWE DT, 1986, EMBO J, V5, P2599, DOI 10.1002/j.1460-2075.1986.tb04540.x; ROWE M, 1995, EUR J IMMUNOL, V25, P1374, DOI 10.1002/eji.1830250536; ROWE M, 1992, J VIROL, V66, P122, DOI 10.1128/JVI.66.1.122-131.1992; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Sasaki H, 2001, JPN J CLIN ONCOL, V31, P532, DOI 10.1093/jjco/hye113; SCHUMACHER U, 1994, DNA CELL BIOL, V13, P839, DOI 10.1089/dna.1994.13.839; Seifert U, 2003, NAT IMMUNOL, V4, P375, DOI 10.1038/ni905; Sharipo A, 2001, FEBS LETT, V499, P137, DOI 10.1016/S0014-5793(01)02542-X; Sharipo A, 1998, NAT MED, V4, P939, DOI 10.1038/nm0898-939; Sohn HW, 2003, J EXP MED, V197, P1511, DOI 10.1084/jem.20021686; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; Staege MS, 2002, P NATL ACAD SCI USA, V99, P4550, DOI 10.1073/pnas.072495599; Takanashi M, 1999, ARCH VIROL, V144, P241, DOI 10.1007/s007050050501; Tezel E, 2000, CLIN CANCER RES, V6, P4764; THOMAS JA, 1991, ADV CANCER RES, V57, P329; Thorley-Lawson DA, 2001, NAT REV IMMUNOL, V1, P75, DOI 10.1038/35095584; Tomkinson B, 1997, FEBS LETT, V405, P277, DOI 10.1016/S0014-5793(97)00173-7; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Wang EW, 2000, P NATL ACAD SCI USA, V97, P9990, DOI 10.1073/pnas.180328897; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; Winberg G, 2000, MOL CELL BIOL, V20, P8526, DOI 10.1128/MCB.20.22.8526-8535.2000; Yamazaki T, 2002, CLIN CANCER RES, V8, P192; Yanagisawa TY, 1998, TOHOKU J EXP MED, V184, P229; Yang XH, 2000, J VIROL, V74, P883, DOI 10.1128/JVI.74.2.883-891.2000; Yao TT, 2002, NATURE, V419, P403, DOI 10.1038/nature01071; Zhang ZS, 2000, J BIOL CHEM, V275, P15157, DOI 10.1074/jbc.M910378199	118	44	46	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2004	23	11					2107	2115		10.1038/sj.onc.1207372	http://dx.doi.org/10.1038/sj.onc.1207372			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	803EC	15021898				2022-12-28	WOS:000220213400015
J	Benoit, V; Relic, B; de Leval, X; Chariot, A; Merville, MP; Bours, V				Benoit, V; Relic, B; de Leval, X; Chariot, A; Merville, MP; Bours, V			Regulation of HER-2 oncogene expression by cyclooxygenase-2 and prostaglandin E2	ONCOGENE			English	Article						cyclooxygenase-2; HER-2; erbB-2; prostaglandin; PGE2; cancer	METASTATIC BREAST-CANCER; RECEPTOR-ENHANCED CHEMOSENSITIVITY; MAMMARY EPITHELIAL-CELLS; TUMOR NECROSIS FACTOR; TRASTUZUMAB HERCEPTIN; MONOCLONAL-ANTIBODY; NEU ONCOGENE; EGF RECEPTOR; PHASE-II; GROWTH	The oncoprotein HER-2/neu is a prosurvival factor and its overexpression has been correlated with adverse prognosis in breast cancers. High levels of the cyclooxygenase-2 (COX-2), a proinflammatory and antiapoptotic enzyme, were detected in HER-2-positive tumors and this observation was linked to an HER-2-mediated induction of COX-2 gene transcription. Here, we report that COX-2 expression, and synthesis of its major enzymatic product, PGE2, leads in turn to an enhanced HER-2 expression. Moreover, COX-2 enzymatic inhibition dramatically reduced HER-2 protein levels, efficiently increased the cancer cells sensitility to chemotherapeutic treatment and acted in synergy with HER-2 inhibitor, trastuzumab. Therefore, we propose an original model where HER-2 and COX-2 transcriptionally regulate each other in a positive loop.	Univ Liege, Ctr Mol & Cellular Therapy, Lab Rheumatol, B-4000 Liege, Belgium; Univ Liege, Nat & Synthet Drugs Res Ctr, B-4000 Liege, Belgium; Univ Liege, Ctr Mol & Cellular Therapy, Lab Med Chem & Human Genet, B-4000 Liege, Belgium	University of Liege; University of Liege; University of Liege	Bours, V (corresponding author), CHU, Lab Med Chem & Human Genet, B35, B-4000 Liege, Belgium.	vbours@ulg.ac.be		BENOIT, Valerie/0000-0002-1098-9452; Chariot, Alain/0000-0002-1691-4347				Baselga J, 1999, SEMIN ONCOL, V26, P78; Baselga J, 1998, CANCER RES, V58, P2825; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; GROOTECLAES M, 1994, CANCER RES, V54, P4193; Harris RE, 2000, CANCER RES, V60, P2101; Howe LR, 2002, CANCER RES, V62, P5405; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; HUDZIAK RM, 1988, P NATL ACAD SCI USA, V85, P5102, DOI 10.1073/pnas.85.14.5102; HUNG MC, 1992, CANCER LETT, V61, P95, DOI 10.1016/0304-3835(92)90166-S; Ignatoski KMW, 2000, BRIT J CANCER, V82, P666, DOI 10.1054/bjoc.1999.0979; Kawamori T, 1998, CANCER RES, V58, P409; Kiguchi K, 2001, CANCER RES, V61, P6971; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200; Mann M, 2001, GASTROENTEROLOGY, V120, P1713, DOI 10.1053/gast.2001.24844; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; Pegram MD, 1999, SEMIN ONCOL, V26, P89; Pegram MD, 1998, J CLIN ONCOL, V16, P2659, DOI 10.1200/JCO.1998.16.8.2659; PRESS MF, 1993, CANCER RES, V53, P4960; Ross JS, 1998, STEM CELLS, V16, P413, DOI 10.1002/stem.160413; Sawaoka H, 1998, AM J PHYSIOL-GASTR L, V274, pG1061, DOI 10.1152/ajpgi.1998.274.6.G1061; Sheng HM, 1998, CANCER RES, V58, P362; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; Sirica AE, 2002, SEMIN LIVER DIS, V22, P303, DOI 10.1055/s-2002-34507; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Subbaramaiah K, 2002, J BIOL CHEM, V277, P18649, DOI 10.1074/jbc.M111415200; Subbaramaiah K, 1996, CANCER RES, V56, P4424; Tiano HF, 2002, CANCER RES, V62, P3395; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Vadlamudi R, 1999, ONCOGENE, V18, P305, DOI 10.1038/sj.onc.1202307; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4	36	54	61	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2004	23	8					1631	1635		10.1038/sj.onc.1207295	http://dx.doi.org/10.1038/sj.onc.1207295			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778BP	14985703	Green Published			2022-12-28	WOS:000189219500018
J	Sin, WC; Zhang, YP; Zhong, W; Adhikarakunnathu, S; Powers, S; Hoey, T; An, SZ; Yang, JX				Sin, WC; Zhang, YP; Zhong, W; Adhikarakunnathu, S; Powers, S; Hoey, T; An, SZ; Yang, JX			G protein-coupled receptors GPR4 and TDAG8 are oncogenic and overexpressed in human cancers	ONCOGENE			English	Article						human cancers; G protein-coupled receptors; GPR4; TDAG8; overexpression; tumorigenesis	CELL-PROLIFERATION; IDENTIFICATION; CLONING; TARGET; TRANSFORMATION; EXPRESSION; ACTIVATION; MECHANISMS; PATHWAYS; LIGANDS	The GPR4 subfamily consists of four G protein-coupled receptors that share significant sequence homology. In addition to GPR4, this subfamily includes OGR1, TDAG8 and G2A. G2A has previously been shown to be a potent transforming oncogene for murine 3T3 cells. Here we show that GPR4 also malignantly transforms NIH3T3 cells and that TDAG8 malignantly transforms the normal mammary epithelial cell line NMuMG. Overexpression of GPR4 or TDAG8 in HEK293 cells led to transcriptional activation from SRE- and CRE-driven promoters, independent of exogenously added ligand. TDAG8 and GPR4 are also overexpressed in a range of human cancer tissues. Our results suggest that GPR4 and TDAG8 overexpression in human tumors plays a role in driving or maintaining tumor formation.	Tularik Inc, Genom Div, Greenlawn, NY 11740 USA; Tularik Inc, Dept Biol, San Francisco, CA 94080 USA		Yang, JX (corresponding author), Tularik Inc, Genom Div, 266 E Pulaski Rd, Greenlawn, NY 11740 USA.	jyang@tularik.com		Powers, Scott/0000-0003-2769-1932				ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; AN SZ, 1995, FEBS LETT, V375, P121, DOI 10.1016/0014-5793(95)01196-L; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Choi JW, 1996, CELL IMMUNOL, V168, P78, DOI 10.1006/cimm.1996.0051; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; GUPTA SK, 1992, MOL BIOL CELL, V3, P123, DOI 10.1091/mbc.3.1.123; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; HEIBER M, 1995, DNA CELL BIOL, V14, P25, DOI 10.1089/dna.1995.14.25; Im DS, 2001, J CELL BIOL, V153, P429, DOI 10.1083/jcb.153.2.429; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; Kyaw H, 1998, DNA CELL BIOL, V17, P493, DOI 10.1089/dna.1998.17.493; Ludwig MG, 2003, NATURE, V425, P93, DOI 10.1038/nature01905; MAHADEVAN MS, 1995, GENOMICS, V30, P84, DOI 10.1006/geno.1995.0013; Marchese A, 1999, TRENDS PHARMACOL SCI, V20, P370, DOI 10.1016/S0165-6147(99)01366-8; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Mayr BM, 2001, P NATL ACAD SCI USA, V98, P10936, DOI 10.1073/pnas.191152098; Nathanson NM, 2000, P NATL ACAD SCI USA, V97, P6245, DOI 10.1073/pnas.97.12.6245; Radhika V, 2001, ONCOGENE, V20, P1607, DOI 10.1038/sj.onc.1204274; Ridley AJ, 2004, BREAST CANCER RES TR, V84, P13, DOI 10.1023/B:BREA.0000018423.47497.c6; Rubin MA, 2000, CLIN CANCER RES, V6, P1038; RUSSO D, 1995, ONCOGENE, V11, P1907; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Subarsky P, 2003, CLIN EXP METASTAS, V20, P237, DOI 10.1023/A:1022939318102; Torigoe T, 2002, ANTI-CANCER DRUG, V13, P237, DOI 10.1097/00001813-200203000-00005; Weng ZG, 1998, P NATL ACAD SCI USA, V95, P12334, DOI 10.1073/pnas.95.21.12334; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; Xu Y, 1996, GENOMICS, V35, P397, DOI 10.1006/geno.1996.0377; Zhu K, 2001, J BIOL CHEM, V276, P41325, DOI 10.1074/jbc.M008057200; Zohn IE, 2000, ONCOGENE, V19, P3866, DOI 10.1038/sj.onc.1203731	32	74	82	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2004	23	37					6299	6303		10.1038/sj.onc.1207838	http://dx.doi.org/10.1038/sj.onc.1207838			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	847NC	15221007				2022-12-28	WOS:000223399000014
J	Luwor, RB; Zhu, HJ; Walker, F; Vitali, AA; Perera, RM; Burgess, AW; Scott, AM; Johns, TG				Luwor, RB; Zhu, HJ; Walker, F; Vitali, AA; Perera, RM; Burgess, AW; Scott, AM; Johns, TG			The tumor-specific de2-7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFR	ONCOGENE			English	Article						epidermal growth factor receptor; phosphatidylinositol-3 kinase; cell survial; dimerization	CONFERS ENHANCED TUMORIGENICITY; HUMAN GLIOBLASTOMA CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; MONOCLONAL-ANTIBODIES; SIGNAL-TRANSDUCTION; KINASE ACTIVATION; CELLULAR-RESPONSE; LUNG CARCINOMAS; CANCER-THERAPY	Mutations of the epidermal growth factor receptor (EGFR) gene are found at a relatively high frequency in glioma, with the most common being the de2-7 EGFR (or EGFRvIII). This mutation arises from an in-frame deletion of exons 2-7, which removes 267 amino acids from the extracellular domain of the receptor. Despite being unable to bind ligand, the de2-7 EGFR is constitutively active and imparts a significant in vivo growth advantage to glioma cells. In order to examine the signalling pathways activated by the de2-7 EGFR and its biological effects in an in vitro system, the de2-7 EGFR gene was transfected into the murine IL-3-dependent pro-B-cell line BaF/3. Expression of the de2-7 EGFR enhanced the survival of BaF/3 cells in the absence of IL-3 by reducing apoptosis in a phosphatidylinositol 3-kinase (PI3-K)-dependent manner. Interestingly, while de2-7 EGFR also enhanced proliferation of BaF/3 cells in low levels of IL-3, this effect was independent of PI3-K. Survival and proliferation were further enhanced when BaF/3 cells were cotransfected with the de2-7 and wt EGFR. This was due to heterodimerization between the de2-7 and wt EGFR leading to trans-phosphorylation of the wt EGFR. This observation is directly relevant to glioma where de2-7 and wt EGFR appear to be coexpressed. Thus, expression of de2-7 EGFR in BaF/3 cells provides an in vitro model for evaluating the signalling pathways activated by this receptor.	Austin Hosp, Ludwig Inst Canc Res, Oncogen Signalling Lab, Tumour Targeting Program,Melbourne Branch, Heidelberg, Vic 3084, Australia; Royal Melbourne Hosp, Epithelial Biochem Lab, Parkville, Vic 3050, Australia	Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Ludwig Institute for Cancer Research; Royal Melbourne Hospital	Johns, TG (corresponding author), Austin Hosp, Ludwig Inst Canc Res, Oncogen Signalling Lab, Tumour Targeting Program,Melbourne Branch, Heidelberg, Vic 3084, Australia.	Terry.Johns@ludwig.edu.au	Johns, Terrance/C-2441-2008	Johns, Terrance/0000-0002-8874-4543; Luwor, Rodney/0000-0002-3020-4245; Zhu, Hong-Jian/0000-0002-1478-995X; Scott, Andrew/0000-0002-6656-295X				BATRA SK, 1995, CELL GROWTH DIFFER, V6, P1251; Burri SH, 1999, INT J RADIAT ONCOL, V43, P423, DOI 10.1016/S0360-3016(98)00385-X; Chu CT, 1997, BIOCHEM J, V324, P855, DOI 10.1042/bj3240855; Coffer PJ, 1998, BIOCHEM J, V335, P1; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; David M, 1996, J BIOL CHEM, V271, P9185, DOI 10.1074/jbc.271.16.9185; DEPALAZZO IEG, 1993, CANCER RES, V53, P3217; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; Grandis JR, 1998, JNCI-J NATL CANCER I, V90, P824, DOI 10.1093/jnci/90.11.824; GULLICK WJ, 1991, BRIT MED BULL, V47, P87, DOI 10.1093/oxfordjournals.bmb.a072464; Hidalgo M, 2000, ONCOGENE, V19, P6680, DOI 10.1038/sj.onc.1204091; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Klingler-Hoffmann M, 2003, INT J CANCER, V105, P331, DOI 10.1002/ijc.11085; Korshunov A, 1999, J CLIN PATHOL, V52, P574, DOI 10.1136/jcp.52.8.574; Kuan CT, 2001, ENDOCR-RELAT CANCER, V8, P83, DOI 10.1677/erc.0.0080083; LEVITZKI A, 1991, METHOD ENZYMOL, V201, P347; Lorimer IAJ, 2001, BBA-MOL CELL RES, V1538, P1, DOI 10.1016/S0167-4889(00)00129-4; Luwor RB, 2001, CANCER RES, V61, P5355; MASUI H, 1984, CANCER RES, V44, P1002; Montgomery RB, 1995, J BIOL CHEM, V270, P30562, DOI 10.1074/jbc.270.51.30562; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Moscatello DK, 1996, ONCOGENE, V13, P85; Nagane M, 1996, CANCER RES, V56, P5079; Narita Y, 2002, CANCER RES, V62, P6764; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; O'Rourke DM, 1998, ONCOGENE, V16, P1197, DOI 10.1038/sj.onc.1201635; Olapade-Olaopa EO, 2000, BRIT J CANCER, V82, P186; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1996, ONCOGENE, V12, P345; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; Tang CK, 2000, CANCER RES, V60, P3081; Walker F, 1998, GROWTH FACTORS, V16, P53, DOI 10.3109/08977199809017491; Walker F, 1998, MOL CELL BIOL, V18, P7192, DOI 10.1128/MCB.18.12.7192; WATERFIELD MD, 1982, J CELL BIOCHEM, V20, P149, DOI 10.1002/jcb.240200207; Weinmann P, 1999, BLOOD, V93, P3106; WIKSTRAND CJ, 1995, CANCER RES, V55, P3140; Wikstrand CJ, 1998, J NEUROVIROL, V4, P148, DOI 10.3109/13550289809114515; Wright JH, 1999, P NATL ACAD SCI USA, V96, P11335, DOI 10.1073/pnas.96.20.11335; Wu CJ, 1999, DNA CELL BIOL, V18, P731, DOI 10.1089/104454999314872; Zhu HJ, 2003, GROWTH FACTORS, V21, P15, DOI 10.1080/0897719031000096424	45	63	68	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6095	6104		10.1038/sj.onc.1207870	http://dx.doi.org/10.1038/sj.onc.1207870			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15221011				2022-12-28	WOS:000223261000009
J	Yuan, JP; Yan, RL; Kramer, A; Eckerdt, F; Roller, M; Kaufmann, M; Strebhardt, K				Yuan, JP; Yan, RL; Kramer, A; Eckerdt, F; Roller, M; Kaufmann, M; Strebhardt, K			Cyclin B1 depletion inhibits proliferation and induces apoptosis in human tumor cells	ONCOGENE			English	Article						small interfering RNAs; cyclin B1; G2/M arrest; proliferation; apoptosis	B1 OVEREXPRESSION; CANCER-CELLS; CARCINOMA; LOCALIZATION; ACTIVATION; PLK1	Cyclin B1 is the regulatory subunit of M-phase promoting factor, and proper regulation of cyclin B1 is essential for the initiation of mitosis. Increasing evidence indicates that the deregulation of cyclin B1 is involved in neoplastic transformation, suggesting the suppression of cyclin B1 could be an attractive strategy for antiproliferative therapy. In the present work, we analysed the impact of small interfering RNAs (siRNAs) targeted to cyclin B1 on different human tumor cell lines. Cyclin B1 siRNAs reduced the protein level of cyclin B1 in HeLa, MCF-7, BT-474 and MDA-MB-435 tumor cells and efficiently reduced the kinase activity of Cdc2/cyclin B1 in HeLa cells. siRNA-treated cells were arrested in G2/M phase in all tumor cell lines tested. Proliferation of tumor cells from different origins was suppressed by 50-80% 48 h after transfection and apoptosis was increased from 5 to 40-50%. Furthermore, tumor cells showed less colony-forming ability after siRNA treatment. In contrast, primary human umbilical vein endothelial cells exhibited only a slight change in cell cycle, and neither apoptosis nor clear inhibition of proliferation was observed after cyclin B1 siRNA treatment for 48 h. These results indicate that siRNAs against cyclin B1 could become a powerful antiproliferative tool in future antitumor therapy.	Univ Frankfurt, Dept Obstet & Gynaecol, Sch Med, D-60590 Frankfurt, Germany	Goethe University Frankfurt	Strebhardt, K (corresponding author), Univ Frankfurt, Dept Obstet & Gynaecol, Sch Med, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	strebhardt@em.uni-frankfurt.de	Strebhardt, Klaus/E-8765-2011	Strebhardt, Klaus/0000-0003-2173-9763				Cogswell JP, 2000, CELL GROWTH DIFFER, V11, P615; Davies TG, 2002, NAT STRUCT BIOL, V9, P745, DOI 10.1038/nsb842; Dong YY, 2002, CANCER LETT, V177, P13, DOI 10.1016/S0304-3835(01)00770-4; Hassan KA, 2002, CANCER RES, V62, P6414; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; Knockaert M, 2002, ONCOGENE, V21, P6413, DOI 10.1038/sj.onc.1205908; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Li JQ, 2003, INT J ONCOL, V22, P1101; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; Park M, 2000, CANCER RES, V60, P542; Santana C, 2002, MUTAT RES-FUND MOL M, V508, P49, DOI 10.1016/S0027-5107(02)00172-0; Sarafan-Vasseur N, 2002, ONCOGENE, V21, P2051, DOI 10.1038/sj.onc.1205257; Spankuch-Schmitt B, 2002, JNCI-J NATL CANCER I, V94, P1863, DOI 10.1093/jnci/94.24.1863; Takeno S, 2002, CANCER, V94, P2874, DOI 10.1002/cncr.10542; Tuschl T, 2002, NAT BIOTECHNOL, V20, P446, DOI 10.1038/nbt0502-446; Yin XY, 2001, CANCER RES, V61, P6487; Yuan JP, 2002, CANCER RES, V62, P4186; Yuan JP, 2002, ONCOGENE, V21, P8282, DOI 10.1038/sj.onc.1206011	20	163	180	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2004	23	34					5843	5852		10.1038/sj.onc.1207757	http://dx.doi.org/10.1038/sj.onc.1207757			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KW	15208674				2022-12-28	WOS:000222629800014
J	Mao, XL; Seidlitz, E; Truant, R; Hitt, M; Ghosh, HP				Mao, XL; Seidlitz, E; Truant, R; Hitt, M; Ghosh, HP			Re-expression of TSLC1 in a non-small-cell lung cancer cell line induces apoptosis and inhibits tumor growth	ONCOGENE			English	Article						TSLC1; lung cancer; adenovirus vector; apoptosis; tumorigenesis	SUPPRESSOR ACTIVITY; BINDING INTERFACE; GLYCOPHORIN-C; PDZ DOMAINS; GENE; PROMOTER; PROTEIN; ADENOCARCINOMA; TUMORIGENICITY; ASSOCIATION	The TSLC1 tumor-suppressor gene is silenced in a number of human cancer tissues and cell lines, including lung, prostate, liver, stomach, pancreatic, and breast cancers. Expression of TSLC1 in a non-small-cell lung cancer (NSCLC) cell line A549 suppresses tumorigenicity in nude mice. However, the molecular mechanism of TSLC1 action is not yet elucidated. In the present study, we show that the expression of TSLC1 from a recombinant adenovirus vector (Ad-TSLC1) inhibited cell proliferation and induced apoptosis in the NSCLC cell line A549. We also demonstrated that subcutaneous tumor growth in nude mice induced by A549 cells was suppressed to the extent of 70-80% by intratumoral injection of Ad-TSLC1. Re-expression of TSLC1 also resulted in activation of the apoptotic protease caspase-3, accompanied by the cleavage of its substrate poly (ADP-ribose) polymerase (PARP). The antiproliferative and proapoptotic activity of TSLC1 required the presence of the FERM-binding and PDZ-interacting motifs located in the cytoplasmic domain. Our results demonstrate the proapoptotic and oncosuppressive activity of TSLC1 protein, and suggest the potential of TSLC1 for gene therapy.	McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada; Hamilton Reg Canc Ctr, Hamilton, ON L8V 5C2, Canada; McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8N 3Z5, Canada	McMaster University; McMaster University; McMaster University	Ghosh, HP (corresponding author), McMaster Univ, Dept Biochem, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	ghosh@mcmaster.ca	Seidlitz, Eric P/K-6765-2013; Singh, Gurmit/C-6744-2014	Seidlitz, Eric P/0000-0001-9760-1133; 				Allinen M, 2002, GENE CHROMOSOME CANC, V34, P384, DOI 10.1002/gcc.10079; ASHE PC, 2003, BIOL PSYCHIAT, V27, P199; Aznar S, 2001, CANCER LETT, V165, P1, DOI 10.1016/S0304-3835(01)00412-8; Fujita E, 2003, EXP CELL RES, V287, P57, DOI 10.1016/S0014-4827(03)00095-8; Fukami T, 2003, INT J CANCER, V107, P53, DOI 10.1002/ijc.11348; Fukuhara H, 2003, ONCOGENE, V22, P6160, DOI 10.1038/sj.onc.1206744; Fukuhara H, 2002, JPN J CANCER RES, V93, P605, DOI 10.1111/j.1349-7006.2002.tb01297.x; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Harris BZ, 2001, J CELL SCI, V114, P3219; Honda T, 2002, JPN J CANCER RES, V93, P857, DOI 10.1111/j.1349-7006.2002.tb01329.x; Hoover KB, 2000, CURR OPIN CELL BIOL, V12, P229, DOI 10.1016/S0955-0674(99)00080-0; Ito A, 2003, LAB INVEST, V83, P1175, DOI 10.1097/01.LAB.0000081391.28136.80; Jansen M, 2002, CANCER BIOL THER, V1, P293, DOI 10.4161/cbt.84; Ji L, 1999, CANCER RES, V59, P3333; Katsuda K, 2002, ONCOGENE, V21, P2108, DOI 10.1038/sj.onc.1205272; Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934; Mao XL, 2003, CANCER RES, V63, P7979; Marfatia SM, 1997, J BIOL CHEM, V272, P24191, DOI 10.1074/jbc.272.39.24191; MARFATIA SM, 1995, J BIOL CHEM, V270, P715, DOI 10.1074/jbc.270.2.715; Masuda M, 2002, J BIOL CHEM, V277, P31014, DOI 10.1074/jbc.M203620200; Murakami Y, 1998, P NATL ACAD SCI USA, V95, P8153, DOI 10.1073/pnas.95.14.8153; Ng Philip, 2002, Methods Mol Med, V69, P389; Roz L, 2002, P NATL ACAD SCI USA, V99, P3615, DOI 10.1073/pnas.062030799; Saeki T, 2002, ONCOGENE, V21, P4558, DOI 10.1038/sj.onc.1205553; Saeki T, 2000, GENE THER, V7, P2051, DOI 10.1038/sj.gt.3301330; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Smith SA, 1996, GENOMICS, V31, P145, DOI 10.1006/geno.1996.0025; Tran YK, 1999, CANCER RES, V59, P35; Uchino K, 2003, CANCER-AM CANCER SOC, V98, P1002, DOI 10.1002/cncr.11599; Yageta M, 2002, CANCER RES, V62, P5129	30	81	93	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5632	5642		10.1038/sj.onc.1207756	http://dx.doi.org/10.1038/sj.onc.1207756			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15184878				2022-12-28	WOS:000222629500008
J	Sumigama, S; Ito, T; Kajiyama, H; Shibata, K; Tamakoshi, K; Kikkawa, F; Williams, T; Tainsky, MA; Nomura, S; Mizutani, S				Sumigama, S; Ito, T; Kajiyama, H; Shibata, K; Tamakoshi, K; Kikkawa, F; Williams, T; Tainsky, MA; Nomura, S; Mizutani, S			Suppression of invasion and peritoneal carcinomatosis of ovarian cancer cells by overexpression of AP-2 alpha	ONCOGENE			English	Article						tumorigenicity; erbB2; Akt; ERK; E-cadherin; matrix metalloproteinase; peritoneal dissemination	TRANSCRIPTION FACTOR AP-2; HUMAN BREAST-CANCER; SIGNALING PATHWAYS; PROSTATE-CANCER; DOWN-REGULATION; UP-REGULATION; TUMOR-GROWTH; DNA-BINDING; EXPRESSION; GENE	A previous report demonstrated that AP-2alpha favors the survival of ovarian cancer patients by clinical findings. However, the functional roles of AP-2alpha in human ovarian cancers have not been determined. To clarify the roles, we overexpressed AP-2alpha in SKOV3 human ovarian cancer cells, which originally possess little AP-2alpha. AP-2alpha overexpression changed cell morphology from spindle to epithelioid type and suppressed cell proliferation and invasion, which would be partially correlated with decreased phosphorylation levels of the erbB2, Akt and ERK pathways, increased E-cadherin and reduced pro-matrix metalloproteinase-2 levels. Moreover, nude mice intraperitoneally injected with AP-2alpha-overexpressing cells survived longer than those with neotransfected cells. The present data represent the first direct evidence that AP-2alpha plays a tumor suppressive role in ovarian cancer.	Nagoya Grad Univ, Dept Obstet & Gynecol, Sch Med, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Grad Univ, Dept Publ Hlth, Sch Med, Showa Ku, Nagoya, Aichi 4668550, Japan; Univ Colorado, Hlth Sci Ctr, Dept Craniofacial Biol, Denver, CO 80262 USA; Wayne State Univ, Program Mol Biol & Genet, Karmanos Canc Inst, Detroit, MI 48201 USA	Nagoya University; Nagoya University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Barbara Ann Karmanos Cancer Institute; Wayne State University	Ito, T (corresponding author), Nagoya Grad Univ, Dept Obstet & Gynecol, Sch Med, Showa Ku, Tsurumai Cho 65, Nagoya, Aichi 4668550, Japan.	itoto@med.nagoya-u.ac.jp	KIKKAWA, Fumitaka/I-7341-2014; Kotani, Tomomi/I-7360-2014; Sumigama, Seiji/AAR-9926-2020	Sumigama, Seiji/0000-0001-6913-3731; Kotani, Tomomi/0000-0002-3082-6116; Tainsky, Michael/0000-0002-0261-831X				Agus DB, 2000, SEMIN ONCOL, V27, P53; Anttila MA, 2000, BRIT J CANCER, V82, P1974; Auman HJ, 2002, DEVELOPMENT, V129, P2733; BACUS SS, 1994, AM J CLIN PATHOL S1, V102, P13; Bar-Eli M, 2001, PIGM CELL RES, V14, P78, DOI 10.1034/j.1600-0749.2001.140202.x; BarEli M, 1997, J CELL PHYSIOL, V173, P275, DOI 10.1002/(SICI)1097-4652(199711)173:2<275::AID-JCP35>3.0.CO;2-C; Bosher JM, 1996, ONCOGENE, V13, P1701; BUETTNER R, 1993, MOL CELL BIOL, V13, P4174, DOI 10.1128/MCB.13.7.4174; CLIBY W, 1993, CANCER RES, V53, P2393; Daly RJ, 1999, GROWTH FACTORS, V16, P255, DOI 10.3109/08977199909069144; Davidson B, 2001, ANAL CELL PATHOL, V23, P107, DOI 10.1155/2001/418547; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; ENOMOTO T, 1990, CANCER RES, V50, P6139; FOULKES WD, 1993, BRIT J CANCER, V67, P551, DOI 10.1038/bjc.1993.101; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; GAYNOR RB, 1991, GENOMICS, V10, P1100, DOI 10.1016/0888-7543(91)90209-W; Gershenwald JE, 2001, ONCOGENE, V20, P3363, DOI 10.1038/sj.onc.1204450; Hayakawa A, 1999, CANCER LETT, V140, P113, DOI 10.1016/S0304-3835(99)00062-2; Ho AT, 2001, J BIOL CHEM, V276, P40215, DOI 10.1074/jbc.M101647200; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; Jean D, 1998, J BIOL CHEM, V273, P16501, DOI 10.1074/jbc.273.26.16501; Kajiyama H, 2002, CANCER RES, V62, P2753; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KIKKAWA F, 1993, ANTICANCER RES, V13, P891; Kikkawa F, 2000, GYNECOL OBSTET INVES, V50, P269, DOI 10.1159/000010330; Klapper LN, 2000, ADV CANCER RES, V77, P25; Levkowitz G, 1996, ONCOGENE, V12, P1117; Luo J, 1999, CANCER RES, V59, P3552; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; McPherson LA, 2002, J BIOL CHEM, V277, P45028, DOI 10.1074/jbc.M208924200; MIZUNO K, 1992, ANTICANCER RES, V12, P21; MIZUTANI S, 1985, Acta Obstetrica et Gynaecologica Japonica (Japanese Edition), V37, P769; Moser M, 1997, GENE DEV, V11, P1938, DOI 10.1101/gad.11.15.1938; Nawrocki-Raby B, 2003, AM J PATHOL, V163, P653, DOI 10.1016/S0002-9440(10)63692-9; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; Orsulic S, 2002, CANCER CELL, V1, P53, DOI 10.1016/S1535-6108(01)00002-2; Qvist H, 1998, BIOL CHEM, V379, P75; Schmalfeldt B, 2001, CLIN CANCER RES, V7, P2396; SLAMON DJ, 1987, NEW ENGL J MED, V317, P955, DOI 10.1056/NEJM198710083171509; Turner BC, 1998, CANCER RES, V58, P5466; Venkateswarlu S, 2002, ONCOGENE, V21, P78, DOI 10.1038/sj.onc.1205011; Vernimmen D, 2003, BRIT J CANCER, V89, P899, DOI 10.1038/sj.bjc.6601200; VIKHANSKAYA F, 1994, NUCLEIC ACIDS RES, V22, P1012, DOI 10.1093/nar/22.6.1012; West-Mays JA, 2003, DIFFERENTIATION, V71, P206, DOI 10.1046/j.1432-0436.2003.710302.x; Williams TM, 1999, J MOL DIAGN, V1, P5; Williamson JA, 1996, GENOMICS, V35, P262, DOI 10.1006/geno.1996.0351; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0; Zhao F, 2001, J BIOL CHEM, V276, P40755, DOI 10.1074/jbc.M106284200; Zhu CH, 2002, BREAST CANCER RES TR, V71, P47, DOI 10.1023/A:1013378113916	49	23	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2004	23	32					5496	5504		10.1038/sj.onc.1207723	http://dx.doi.org/10.1038/sj.onc.1207723			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15146170				2022-12-28	WOS:000222588400009
J	Edwards, KM; Munger, K				Edwards, KM; Munger, K			Make WARTS, not cancer!	ONCOGENE			English	Editorial Material							TUMOR-SUPPRESSOR; CELL-GROWTH; HOMOLOG	The WARTS gene encodes a kinase that localizes to the mitotic apparatus of a dividing cell. Named WARTS after the growths that develop in the eyes of Drosophila in which the gene is deleted. WARTS is also implicated as a tumor suppressor in mice and humans. In this issue of Oncogene, Iida et al. describe experiments suggesting that, in addition to a role in regulating mitosis, WARTS functions to prevent further rounds of DNA synthesis and mitosis in tetraploid cells. As well as opening up new possibilities of exploring the yet ill-defined mechanistic basis of the tetraploidy checkpoint, the involvement of a tumor-suppressor gene in this checkpoint supports its importance as a safeguard against the acquisition of genomic instability, a key event in the progression to cancer.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Munger, K (corresponding author), Harvard Univ, Sch Med, Dept Pathol, New Res Bldg 0958C,77 Ave Louis Pasteur, Boston, MA 02115 USA.	karl_munger@hms.harvard.edu		Munger, Karl/0000-0003-3288-9935				Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Duensing S, 2002, CANCER RES, V62, P7075; Duensing S, 2001, CANCER RES, V61, P2356; GATEFF E, 1994, ANN NY ACAD SCI, V712, P260, DOI 10.1111/j.1749-6632.1994.tb33578.x; Hay BA, 2003, DEV CELL, V5, P361, DOI 10.1016/S1534-5807(03)00270-3; Hisaoka M, 2002, LAB INVEST, V82, P1427, DOI 10.1097/01.LAB.0000032381.68634.CA; IIDA S, 2004, ONCOGENE A B, V10; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; Kamikubo Y, 2003, J BIOL CHEM, V278, P17609, DOI 10.1074/jbc.M211974200; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Storchova Z, 2004, NAT REV MOL CELL BIO, V5, P45, DOI 10.1038/nrm1276; Weinberg R A, 1998, ONE RENEGADE CELL CA	14	4	4	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2004	23	31					5263	5265		10.1038/sj.onc.1207686	http://dx.doi.org/10.1038/sj.onc.1207686			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15122320				2022-12-28	WOS:000222491600001
J	Huerta-Yepez, S; Vega, M; Jazirehi, A; Garban, H; Hongo, F; Cheng, GH; Bonavida, B				Huerta-Yepez, S; Vega, M; Jazirehi, A; Garban, H; Hongo, F; Cheng, GH; Bonavida, B			Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-(xL) expression	ONCOGENE			English	Article						NF-kappa B; prostate cancer; nitric oxide; TRAIL; apoptosis	CANCER-CELLS; UP-REGULATION; DNA-BINDING; BCL-X; CONSTITUTIVE ACTIVATION; TRANSCRIPTION FACTOR; PROTEIN-KINASE; ACTINOMYCIN-D; MITOCHONDRIA; OVEREXPRESSION	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been shown to be selective in the induction of apoptosis in cancer cells with minimal toxicity to normal tissues and this prompted its potential therapeutic application in cancer. However, not all cancers are sensitive to TRAIL-mediated apoptosis and, therefore, TRAIL-resistant cancer cells must be sensitized first to become sensitive to TRAIL. Treatment of prostate cancer (CaP) cell lines (DU145, PC-3, CL-1, and LNCaP) with nitric oxide donors (e.g. (Z)-1-[2-(2-aminoethyl)-N-(2-ammonio-ethyl)amino]diazen-1-ium-1, 2- diolate ( DETANONOate)) sensitized CaP cells to TRAIL-induced apoptosis and synergy was achieved. The mechanism by which DETANONOate mediated the sensitization was examined. DETANONOate inhibited the constitutive NF-kappaB activity as assessed by EMSA. Also, p50 was S-nitrosylated by DETANONOate resulting in inhibition of NF-kappaB. Inhibition of NF-kappaB activity by the chemical inhibitor Bay 11-7085, like DETANONOate, sensitized CaP to TRAIL apoptosis. In addition, DETANONOate downregulated the expression of Bcl-2 related gene (Bcl-(xL)) which is under the transcriptional regulation of NF-kappaB. The regulation of NF-kappaB and Bcl-(xL) by DETANONOate was corroborated by the use of Bcl-(xL) and Bcl-kappaB reporter systems. DETANONOate inhibited luciferase activity in the wild type and had no effect on the mutant cells. Inhibition of NF-kappaB resulted in downregulation of Bcl-(xL) expression and sensitized CaP to TRAIL-induced apoptosis. The role of Bcl-(xL) in the regulation of TRAIL apoptosis was corroborated by inhibiting Bcl-(xL) function by the chemical inhibitor 2-methoxyantimycin A(3) and this resulted in sensitization of the cells to TRAIL apoptosis. Signaling by DETANONOate and TRAIL for apoptosis was examined. DETANONOate altered the mitochondria by inducing membrane depolarization and releasing modest amounts of cytochrome c and Smac/DIABLO in the absence of downstream activation of caspases 9 and 3. However, the combination of DETANONOate and TRAIL resulted in activation of the mitochondrial pathway and activation of caspases 9 and 3, and induction of apoptosis. These findings demonstrate that DETANONOate-mediated sensitization of CaP to TRAIL-induced apoptosis is via inhibition of constitutive NF-kappaB activity and Bcl-(xL) expression.	Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA; Hosp Infectol, CMN La Raza, IMSS, Unidad Invest Med Inmunol & Infectol, Mexico City, DF, Mexico; Univ Calif Los Angeles, David Geffen Sch Med, Johnsson Comprehens Cacn Ctr, Dept Mol Pharmacol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; Instituto Mexicano del Seguro Social; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Bonavida, B (corresponding author), Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, 10833 Le Conte Ave,A2-060 CHS, Los Angeles, CA 90095 USA.	bbonavida@mednet.ucla.edu	Vega, Mario/AAZ-4315-2020	Vega, Mario I/0000-0002-3932-2483; Garban, Hermes/0000-0001-7754-5357	FIC NIH HHS [D43 TW00013-14] Funding Source: Medline; NCI NIH HHS [P50 CA92131-01A1] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [D43TW000013] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P50CA092131] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altuwaijri S, 2003, CANCER RES, V63, P7106; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; BERENBAUM MC, 1978, J INFECT DIS, V137, P122, DOI 10.1093/infdis/137.2.122; Bouralexis S, 2003, BRIT J CANCER, V89, P206, DOI 10.1038/sj.bjc.6601021; Chawla-Sarkar M, 2003, J BIOL CHEM, V278, P39461, DOI 10.1074/jbc.M306111200; Chinenov Y, 1998, J BIOL CHEM, V273, P6203, DOI 10.1074/jbc.273.11.6203; Connelly L, 2001, J IMMUNOL, V166, P3873, DOI 10.4049/jimmunol.166.6.3873; de Jong S, 2001, CANCER METAST REV, V20, P51, DOI 10.1023/A:1013112624971; DelaTorre A, 1997, BIOCHEM BIOPH RES CO, V238, P703, DOI 10.1006/bbrc.1997.7279; Di Nardo A, 2000, BRIT J DERMATOL, V143, P491, DOI 10.1111/j.1365-2133.2000.03700.x; Garban HJ, 2001, J IMMUNOL, V167, P75, DOI 10.4049/jimmunol.167.1.75; Garban HJ, 2001, J BIOL CHEM, V276, P8918, DOI 10.1074/jbc.M008471200; Gasparian AV, 2002, J CELL SCI, V115, P141; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; Hersey P, 2003, J CELL PHYSIOL, V196, P9, DOI 10.1002/jcp.10256; Huang SY, 2001, ONCOGENE, V20, P4188, DOI 10.1038/sj.onc.1204535; Huerta-Yepez S, 2003, 94 ANN M AM ASS CANC, V44, P918; Ichikawa K, 2001, NAT MED, V7, P954, DOI 10.1038/91000; Jazirehi AR, 2003, MOL CANCER THER, V2, P1183; Jazirehi AR, 2001, CLIN CANCER RES, V7, P3874; Jun CD, 1999, J IMMUNOL, V162, P3395; Katsuyama K, 1998, ARTERIOSCL THROM VAS, V18, P1796, DOI 10.1161/01.ATV.18.11.1796; Lebedeva IV, 2000, MOL BIOL+, V34, P875, DOI 10.1023/A:1026679826610; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Lee YJ, 2001, ONCOGENE, V20, P1476, DOI 10.1038/sj.onc.1204225; Li XY, 2001, CANCER RES, V61, P1699; LINDMARK R, 1983, J IMMUNOL METHODS, V62, P1, DOI 10.1016/0022-1759(83)90104-7; Marshall HE, 2001, BIOCHEMISTRY-US, V40, P1688, DOI 10.1021/bi002239y; MATTHEWS JR, 1993, NUCLEIC ACIDS RES, V21, P1727, DOI 10.1093/nar/21.8.1727; Matthews JR, 1996, NUCLEIC ACIDS RES, V24, P2236, DOI 10.1093/nar/24.12.2236; McKay LI, 2000, MOL ENDOCRINOL, V14, P1222, DOI 10.1210/me.14.8.1222; Messmer UK, 1996, BIOCHEM J, V319, P299, DOI 10.1042/bj3190299; Mori N, 2001, VIRUS GENES, V22, P279, DOI 10.1023/A:1011158021749; Munshi A, 2002, CANCER CHEMOTH PHARM, V50, P46, DOI 10.1007/s00280-002-0465-z; Ng CP, 2002, PROSTATE, V53, P286, DOI 10.1002/pros.10155; Ng CP, 2002, MOL CANCER THER, V1, P1051; Ng CP, 2002, ADV CANCER RES, V85, P145, DOI 10.1016/S0065-230X(02)85005-9; Nyormoi O, 2003, CELL DEATH DIFFER, V10, P558, DOI 10.1038/sj.cdd.4401209; Palayoor ST, 1999, ONCOGENE, V18, P7389, DOI 10.1038/sj.onc.1203160; Palvimo JJ, 1996, J BIOL CHEM, V271, P24151, DOI 10.1074/jbc.271.39.24151; Park SY, 2002, BIOCHEM BIOPH RES CO, V291, P233, DOI 10.1006/bbrc.2002.6452; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Poderoso JJ, 1996, ARCH BIOCHEM BIOPHYS, V328, P85, DOI 10.1006/abbi.1996.0146; RAFFO AJ, 1995, CANCER RES, V55, P4438; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Rokhlin OW, 2002, PROSTATE, V52, P1, DOI 10.1002/pros.10074; Rokhlin OW, 2001, ONCOGENE, V20, P2836, DOI 10.1038/sj.onc.1204410; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SCHMIDT HHHW, 1992, FEBS LETT, V307, P102, DOI 10.1016/0014-5793(92)80910-9; Secchiero P, 2001, BLOOD, V98, P2220, DOI 10.1182/blood.V98.7.2220; Sevilla L, 2001, HISTOL HISTOPATHOL, V16, P595, DOI 10.14670/HH-16.595; Shigeno M, 2003, ONCOGENE, V22, P1653, DOI 10.1038/sj.onc.1206139; So HS, 1998, BIOCHEM BIOPH RES CO, V247, P809, DOI 10.1006/bbrc.1998.8788; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Suh JH, 2002, PROSTATE, V52, P183, DOI 10.1002/pros.10082; Tell G, 1998, J BIOL CHEM, V273, P25062, DOI 10.1074/jbc.273.39.25062; Tillman DM, 2003, CANCER RES, V63, P5118; Tso CL, 2000, CANCER J, V6, P220; Tzung SP, 2001, NAT CELL BIOL, V3, P183, DOI 10.1038/35055095; VEGA M, 2004, IN PRESS ONCOGENE; Wajant H, 2002, APOPTOSIS, V7, P449, DOI 10.1023/A:1020039225764; Zisman A, 2001, J IMMUNOTHER, V24, P459, DOI 10.1097/00002371-200111000-00003	64	127	135	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					4993	5003		10.1038/sj.onc.1207655	http://dx.doi.org/10.1038/sj.onc.1207655			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15048072				2022-12-28	WOS:000222237300005
J	Zhu, HB; Zhang, LD; Wu, SH; Teraishi, F; Davis, JJ; Jacob, D; Fang, BL				Zhu, HB; Zhang, LD; Wu, SH; Teraishi, F; Davis, JJ; Jacob, D; Fang, BL			Induction of S-phase arrest and p21 overexpression by a small molecule 2[[3-(2,3-dichlorophenoxy)propyl] amino]ethanol in correlation with activation of ERK	ONCOGENE			English	Article						S-phase arrest; p21; ATM; p53; ERK; small molecule	CYCLIN-DEPENDENT KINASES; TAXOL-INDUCED APOPTOSIS; CELL-CYCLE; CANCER-CELLS; DNA-DAMAGE; PROTEIN-KINASES; INHIBITOR P21; GENE-THERAPY; ADENOVIRUS; P53	We recently found that a small molecule 2[[3-(2,3-dichlorophenoxy)propyl]amino]ethanol (2,3-DCPE) could induce apoptosis and downregulate Bcl-XL expression in various cancer cells. Here, we found that 2,3- DCPE suppressed the proliferation of Bcl-XL-overexpressing cancer cells without inducing apoptosis. Subsequently, we found that 2,3-DCPE could induce S-phase arrest and upregulate p21 but not p27 at a time- and dose-dependent but p53-dispensable manner in DLD-1 human colon cancer cells. Activation of ERK was also detected after treatment with 2,3-DCPE. Moreover, p21 induction was dramatically attenuated by ERK inhibitors PD98059 and U0126. Induction of p21 and S-phase arrest and corresponding activation of ERK were also observed in ATM-defective cells, suggesting that 2,3-DCPE-induced these events were ATM-dispensable. Furthermore, ERK inhibitors dramatically attenuated 2,3-DCPE-induced S-phase arrest. Together, our data indicate that ERK activation correlated with the 2,3-DCPE-mediated induction of p21 expression and S-phase arrest. This finding may have implication for cancer therapy.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Unit 445, Houston, TX 77030 USA; Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Surg Oncol, Hangzhou 310016, Peoples R China; Univ Texas, Grad Sch Biomed Sci, Program Gene Therapy & Virol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Zhejiang University; University of Texas System	Fang, BL (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Unit 445, 1515 Holcombe Blvd, Houston, TX 77030 USA.	Bfang@mdanderson.org			NATIONAL CANCER INSTITUTE [R01CA098582, R01CA092487, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, R01 CA 098582-01A1, R01 CA 092487-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bacus SS, 2001, ONCOGENE, V20, P147, DOI 10.1038/sj.onc.1204062; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Beier F, 1999, J BIOL CHEM, V274, P30273, DOI 10.1074/jbc.274.42.30273; Borel F, 2002, J CELL SCI, V115, P2829; Chen G, 1997, ONCOGENE, V15, P1643, DOI 10.1038/sj.onc.1201347; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EASTHAM JA, 1995, CANCER RES, V55, P5151; EL DW, 1993, CELL, V75, P817; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Gartel AL, 2002, MOL CANCER THER, V1, P639; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Hall MC, 2000, J UROLOGY, V163, P1033, DOI 10.1016/S0022-5347(05)67877-9; HARPER JW, 1993, CELL, V75, P805; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kagawa S, 2001, CANCER RES, V61, P3330; Katayose Y, 1997, CANCER RES, V57, P5441; Kim GY, 2002, J BIOL CHEM, V277, P29792, DOI 10.1074/jbc.M201299200; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; Kornmann M, 1998, J CLIN INVEST, V101, P344, DOI 10.1172/JCI1323; Lodygin D, 2002, J CLIN INVEST, V110, P1717, DOI 10.1172/JCI200216588; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Ogryzko VV, 1997, MOL CELL BIOL, V17, P4877, DOI 10.1128/MCB.17.8.4877; Park KS, 2002, BRIT J PHARMACOL, V137, P597, DOI 10.1038/sj.bjp.0704909; Pedeux R, 1998, J INVEST DERMATOL, V111, P472, DOI 10.1046/j.1523-1747.1998.00324.x; Schreiber M, 1999, ONCOGENE, V18, P1663, DOI 10.1038/sj.onc.1202466; Seidman R, 2001, EXP CELL RES, V268, P84, DOI 10.1006/excr.2001.5262; Senderowicz AM, 2000, ONCOGENE, V19, P6600, DOI 10.1038/sj.onc.1204085; Shapiro GI, 1999, J CLIN INVEST, V104, P1645, DOI 10.1172/JCI9054; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Toogood PL, 2002, CURR OPIN CHEM BIOL, V6, P472, DOI 10.1016/S1367-5931(02)00342-3; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wu SH, 2004, CANCER RES, V64, P1110, DOI 10.1158/0008-5472.CAN-03-2790; Zhang L, 2002, GENE THER, V9, P1262, DOI 10.1038/sj.gt.3301797; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	38	70	76	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					4984	4992		10.1038/sj.onc.1207645	http://dx.doi.org/10.1038/sj.onc.1207645			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15122344				2022-12-28	WOS:000222237300004
J	Pedraza, LG; Stewart, RA; Li, DM; Xu, T				Pedraza, LG; Stewart, RA; Li, DM; Xu, T			Drosophila Src-family kinases function with Csk to regulate cell proliferation and apoptosis	ONCOGENE			English	Article						Src; Csk; oncogene; proliferation; apoptosis	C-SRC; TYROSINE KINASES; TRANSGENIC MICE; DEATH; GENE; EYE; EXPRESSION; ACTIVATION; CANCER; MATTER	Elevated Src protein levels and activity are associated with the development and progression of a variety of cancers. The consequences of deregulated Src activity have been studied extensively in cell culture; however, the effects of this deregulation in vivo, as well as the mechanisms of Src-induced tumorigenesis, remain poorly understood. In this study, the effect of expressing wildtype and constitutively active Drosophila Src-family kinases (SFKs) in the developing eye was examined. Overexpression of either wild-type Drosophila SFK (Src64 and Src42) is sufficient to induce ectopic proliferation in G(1)/G(0)-arrested, uncommitted cells in eye imaginal discs. In addition, both kinases trigger apoptosis in vivo, in a dosage-dependent manner. Constitutively active mutants are hypermorphic as they trigger proliferation and death more potently than their wild-type counterparts. Moreover, SFK-induced proliferation and apoptosis are largely independent events, as blocking ectopic proliferation does not block cell death. Further, DCsk (the Drosophila homolog of the C-terminal Src kinase) phosphorylates and interacts genetically with the wild-type SFKs, but not with the constitutively active mutants in which a conserved C-terminal tyrosine was mutated to phenylalanine, providing the first in vivo evidence that Csk regulates SFKs during development through phosphorylation of their C-terminal tyrosine.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Howard Hughes Med Inst,Dept Genet, New Haven, CT 06536 USA	Howard Hughes Medical Institute; Yale University	Xu, T (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Howard Hughes Med Inst,Dept Genet, 295 Congress Ave,POB 9812, New Haven, CT 06536 USA.	tian.xu@yale.edu	Stewart, Rodney/ABA-6757-2020	Stewart, Rodney/0000-0003-1220-1830	NATIONAL CANCER INSTITUTE [R01CA069408] Funding Source: NIH RePORTER; NCI NIH HHS [CA69408] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aouacheria A, 2002, BIOCHEM PHARMACOL, V64, P1605, DOI 10.1016/S0006-2952(02)01385-0; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; Boudny V, 2002, BRIT J CANCER, V86, P463, DOI 10.1038/sj.bjc.6600080; BOUGERET C, 1993, ONCOGENE, V8, P1241; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; DENOOIJ JC, 1995, SCIENCE, V270, P983, DOI 10.1126/science.270.5238.983; Dodson GS, 1998, DEVELOPMENT, V125, P2883; Du W, 1996, EMBO J, V15, P3684, DOI 10.1002/j.1460-2075.1996.tb00738.x; Duffy JB, 2002, GENESIS, V34, P1, DOI 10.1002/gene.10150; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Evan G, 1997, INT J CANCER, V71, P709, DOI 10.1002/(SICI)1097-0215(19970529)71:5<709::AID-IJC2>3.0.CO;2-V; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Guo M, 1999, CURR OPIN CELL BIOL, V11, P745, DOI 10.1016/S0955-0674(99)00046-0; Igaki T, 2002, EMBO J, V21, P3009, DOI 10.1093/emboj/cdf306; Igaki T, 2000, P NATL ACAD SCI USA, V97, P662, DOI 10.1073/pnas.97.2.662; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; Johnson D, 2000, CELL DEATH DIFFER, V7, P685, DOI 10.1038/sj.cdd.4400700; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KUSSICK SJ, 1993, ONCOGENE, V8, P2791; KUSSICK SJ, 1992, ONCOGENE, V7, P2461; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; Ollmann M, 2000, CELL, V101, P91, DOI 10.1016/S0092-8674(00)80626-1; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; Stewart RA, 2003, ONCOGENE, V22, P6436, DOI 10.1038/sj.onc.1206820; Takahashi F, 1996, GENE DEV, V10, P1645, DOI 10.1101/gad.10.13.1645; Tateno M, 2000, SCIENCE, V287, P324, DOI 10.1126/science.287.5451.324; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Webb BL, 2000, MOL CELL BIOL, V20, P9271, DOI 10.1128/MCB.20.24.9271-9280.2000; WEBSTER MA, 1995, P NATL ACAD SCI USA, V92, P7849, DOI 10.1073/pnas.92.17.7849; Weissenberger J, 1997, ONCOGENE, V14, P2005, DOI 10.1038/sj.onc.1201168; WOLFF T, 1991, DEVELOPMENT, V113, P841	36	43	44	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2004	23	27					4754	4762		10.1038/sj.onc.1207635	http://dx.doi.org/10.1038/sj.onc.1207635			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZX	15107833				2022-12-28	WOS:000221799200010
J	Hanissian, SH; Akbar, U; Teng, B; Janjetovic, Z; Hoffmann, A; Hitzler, JK; Iscove, N; Hamre, K; Du, XP; Tong, Y; Mukatira, S; Robertson, JH; Morris, SW				Hanissian, SH; Akbar, U; Teng, B; Janjetovic, Z; Hoffmann, A; Hitzler, JK; Iscove, N; Hamre, K; Du, XP; Tong, Y; Mukatira, S; Robertson, JH; Morris, SW			CDNA cloning and characterization of a novel gene encoding the MLF1-interacting protein MLF1IP	ONCOGENE			English	Article						MLF1; NPM-MLF1; MLF1IP; acute myeloid leukemia	CHROMOSOMAL LOCALIZATION; MYELOID-LEUKEMIA; BINDING; PHOSPHORYLATION; NUCLEOPHOSMIN; TRANSPORT; RECEPTOR; ADAPTER; DOMAIN; SITE	Myelodysplasia/acute myeloid leukemia (MDS/AML) is characterized by a t(3;5)(q25.1;q34) chromosomal translocation that forms a fusion gene between nucleophosmin (NPM) and MDS/myeloid leukemia factor 1 (MLF1). We identified a novel protein, MLF1-interacting protein (MLF1IP), that specifically associates with MLF1 by yeast two-hybrid analysis and in pulldown assays, and colocalizes with it in both the nuclei and cytoplasm of cells. The MLF1IP gene locus is at chromosome 4q35.1 and is composed of 14 exons spanning 75.8 kb of genomic DNA. The MLF1IP cDNA encodes a 46-kDa protein that contains two bipartite and two classical nuclear localization signals, two nuclear receptor-binding motifs (LXXLL), two leucine zippers, two PEST residues and several potential phosphorylation sites. MLF1IP transcripts are expressed in a variety of tissues (e.g. fetal liver, bone marrow, thymus and testis). MLF1IP appears to be a lineage-specific gene whose expression is confined exclusively to the CFU-E erythroid precursor cells, but not in mature erythrocytes. These observations, together with previous data demonstrating a role for MLF1 in suppressing red cell maturation, suggest a possible role for MLF1IP and MLF1 deregulation in the genesis of erythroleukemias.	Univ Tennessee, Ctr Hlth Sci, Dept Neurosurg, Memphis, TN 38163 USA; Univ Kiel, Ctr Biochem & Mol Biol, D-24118 Kiel, Germany; Univ Toronto, Hosp Sick Children, Dept Pediat, Div Hematol Oncol Canc & Blood, Toronto, ON, Canada; Univ Toronto, Ontario Canc Inst, Toronto, ON, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; Univ Tennessee, Ctr Hlth Sci, Dept Anat & Neurobiol, Memphis, TN 38163 USA; St Jude Childrens Res Hosp, Hartwell Ctr Bioinformat & Biotechnol, Memphis, TN 38105 USA; Univ Tennessee, Ctr Hlth Sci, Dept Pediat, Memphis, TN 38163 USA; St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Kiel; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital	Hanissian, SH (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Neurosurg, 847 Monroe,Room 427, Memphis, TN 38163 USA.	shanissi@utmem.edu		Akbar, Umair/0000-0001-5423-0002	NATIONAL CANCER INSTITUTE [R01CA076301] Funding Source: NIH RePORTER; NCI NIH HHS [CA76301, CA27165] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUSUBEL FM, 1992, IN SITU HYBRIDIZATIO; Billia F, 2001, BLOOD, V97, P2257, DOI 10.1182/blood.V97.8.2257; Bornberg-Bauer E, 1998, NUCLEIC ACIDS RES, V26, P2740, DOI 10.1093/nar/26.11.2740; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; Cope MJTV, 1996, STRUCTURE, V4, P969, DOI 10.1016/S0969-2126(96)00103-7; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476; Gregson HC, 2002, CHROMOSOME RES, V10, P267, DOI 10.1023/A:1016563523208; Gregson HC, 2001, J BIOL CHEM, V276, P47575, DOI 10.1074/jbc.M103364200; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hitzler JK, 1999, AM J PATHOL, V155, P53, DOI 10.1016/S0002-9440(10)65098-5; ISCOVE NN, 1977, CELL TISSUE KINET, V10, P323, DOI 10.1111/j.1365-2184.1977.tb00300.x; Kawasaki-Nishi S, 2001, J BIOL CHEM, V276, P47411, DOI 10.1074/jbc.M108310200; Kozak M, 2000, GENOMICS, V70, P396, DOI 10.1006/geno.2000.6412; Kuefer MU, 1996, GENOMICS, V35, P392, DOI 10.1006/geno.1996.0376; Lim R, 2002, J BIOL CHEM, V277, P40997, DOI 10.1074/jbc.M206041200; Matsumoto N, 2000, LEUKEMIA, V14, P1757, DOI 10.1038/sj.leu.2401897; OLSON MOJ, 1986, BIOCHEMISTRY-US, V25, P484, DOI 10.1021/bi00350a031; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; RAIMONDI SC, 1989, LEUKEMIA, V3, P42; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; Schmiesing JA, 1998, P NATL ACAD SCI USA, V95, P12906, DOI 10.1073/pnas.95.22.12906; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Speck O, 2003, NATURE, V421, P83, DOI 10.1038/nature01295; Tokuyama Y, 2001, J BIOL CHEM, V276, P21529, DOI 10.1074/jbc.M100014200; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; Williams JH, 1999, EMBO J, V18, P5559, DOI 10.1093/emboj/18.20.5559; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0	30	55	59	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3700	3707		10.1038/sj.onc.1207448	http://dx.doi.org/10.1038/sj.onc.1207448			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15116101				2022-12-28	WOS:000221101700022
J	Gross, M; Yang, R; Top, I; Gasper, C; Shuai, K				Gross, M; Yang, R; Top, I; Gasper, C; Shuai, K			PIASy-mediated repression of the androgen receptor is independent of sumoylation	ONCOGENE			English	Article						protein inhibitor of activated STAT; androgen receptor; sumoylation	PROTEIN INHIBITOR; PROSTATE-CANCER; TRANSCRIPTIONAL ACTIVATION; GENE ACTIVATION; COREPRESSOR; SUMO; UBIQUITIN; LIGASES; MOTIF; COREGULATOR	PIASy, a member of the protein inhibitor of activated STAT (PIAS) family, represses the transcriptional activity of the androgen receptor (AR). In this report, we investigate the mechanism of PIASy-mediated repression of AR. We show that AR binds to the RING-finger like domain of PIASy. PIASy contains two transcriptional repression domains, RD1 and RD2. RD1, but not RD2, is required for PIASy-mediated repression of AR. We show that the RD1 domain binds HDAC1 and HDAC2 and that HDAC activity is required for PIASy-mediated AR repression. PIAS proteins possess small ubiquitin-related modifier (SUMO) E3 ligase activity. Conjugation of SUMO-1 to AR has been implicated in the regulation of AR activity. We examine if the SUMO ligase activity of PIASy is required for PIASy to repress AR. We show that a mutant PIASy, defective in promoting sumoylation, retains the ability to repress AR transcription. In addition, mutation of all the known sumoylation acceptor sites of AR does not affect the transrepression activity of PIASy on AR. Our results suggest that PIASy may repress AR by recruiting histone deacetylases, independent of its SUMO ligase activity.	Univ Calif Los Angeles, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA; Cedars Sinai Med Ctr, Louis Warschaw Prostate Canc Ctr, Los Angeles, CA 90048 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Cedars Sinai Medical Center	Shuai, K (corresponding author), Univ Calif Los Angeles, Dept Med, Div Hematol Oncol, 11-934 Factor Bldg,10833 Le Conte Ave, Los Angeles, CA 90095 USA.	kshuai@mednet.ucla.edu		Gross, Mitchell/0000-0002-1691-921X	NCI NIH HHS [CA32737] Funding Source: Medline; NIAID NIH HHS [AI39612] Funding Source: Medline; NIDDK NIH HHS [K08 DK064379, DK64379] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA032737] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039612] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK064379] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aravind L, 2000, TRENDS BIOCHEM SCI, V25, P112, DOI 10.1016/S0968-0004(99)01537-6; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; EMAMI KH, 1992, EMBO J, V11, P5005, DOI 10.1002/j.1460-2075.1992.tb05607.x; Gross M, 2001, ONCOGENE, V20, P3880, DOI 10.1038/sj.onc.1204489; Huang WB, 1999, J BIOL CHEM, V274, P25756, DOI 10.1074/jbc.274.36.25756; Iniguez-Lluhi JA, 2000, MOL CELL BIOL, V20, P6040, DOI 10.1128/MCB.20.16.6040-6050.2000; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kotaja N, 2000, MOL ENDOCRINOL, V14, P1986, DOI 10.1210/me.14.12.1986; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Liu B, 2001, P NATL ACAD SCI USA, V98, P3203, DOI 10.1073/pnas.051489598; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Moilanen AM, 1999, J BIOL CHEM, V274, P3700, DOI 10.1074/jbc.274.6.3700; Nelson V, 2001, APOPTOSIS, V6, P221, DOI 10.1023/A:1011392811628; Nishida T, 2002, J BIOL CHEM, V277, P41311, DOI 10.1074/jbc.M206741200; Ordentlich P, 1999, P NATL ACAD SCI USA, V96, P2639, DOI 10.1073/pnas.96.6.2639; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Shuai K, 2003, NAT REV IMMUNOL, V3, P900, DOI 10.1038/nri1226; Sternsdorf T, 1999, J BIOL CHEM, V274, P12555, DOI 10.1074/jbc.274.18.12555; Tan JA, 2000, MOL ENDOCRINOL, V14, P14, DOI 10.1210/me.14.1.14; Tan JA, 2002, J BIOL CHEM, V277, P16993, DOI 10.1074/jbc.M109217200; Wu L, 2001, GENE THER, V8, P1416, DOI 10.1038/sj.gt.3301549; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Zamir I, 1997, P NATL ACAD SCI USA, V94, P14400, DOI 10.1073/pnas.94.26.14400; Zhang LQ, 2002, MOL THER, V5, P223, DOI 10.1006/mthe.2002.0551	31	71	75	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2004	23	17					3059	3066		10.1038/sj.onc.1207443	http://dx.doi.org/10.1038/sj.onc.1207443			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	812NC	14981544				2022-12-28	WOS:000220845200010
J	Crockett, DK; Lin, ZD; Elenitoba-Johnson, KSJ; Lim, MS				Crockett, DK; Lin, ZD; Elenitoba-Johnson, KSJ; Lim, MS			Identification of NPM-ALK interacting proteins by tandem mass spectrometry	ONCOGENE			English	Article						NPM-ALK; anaplastic lymphoma kinase; functional proteomics; mass spectrometry	ANAPLASTIC LYMPHOMA KINASE; LARGE-CELL LYMPHOMA; NON-HODGKINS-LYMPHOMA; RECEPTOR TYROSINE KINASE; KI-1 LYMPHOMA; DOWN-REGULATION; EXPRESSION; ACTIVATION; GENE; TRANSLOCATION	Constitutive overexpression of nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) is a key oncogenic event in anaplastic large-cell lymphomas with the characteristic chromosomal aberration t(2;5)(p23;q35). Proteins that interact with ALK tyrosine kinase play important roles in mediating downstream cellular signals, and are potential targets for novel therapies. Using a functional proteomic approach, we determined the identity of proteins that interact with the ALK tyrosine kinase by co-immunoprecipitation with anti-ALK antibody, followed by electro-spray ionization and tandem mass spectrometry (MS/MS). A total of 46 proteins were identified as unique to the ALK immunocomplex using monoclonal and polyclonal antibodies, while 11 proteins were identified in the NPM immunocomplex. Previously reported proteins in the ALK signal pathway were identified including PI3-K, Jak2, Jak3, Stat3, Grb2, IRS, and PLC1gamma. More importantly, many proteins previously not recognized to be associated with NPM-ALK, but with potential NPM-ALK interacting protein domains, were identified. These include adaptor molecules (SOCS, Rho-GTPase activating protein, RAB35), kinases (MEK kinase 1 and 4, PKC, MLCK, cyclin G-associated kinase, EphA1, JNK kinase, MAP kinase 1), phosphatases (meprin, PTPK, protein phosphatase 2 subunit), and heat shock proteins (Hsp60 precursor). Proteins identified by MS were confirmed by Western blotting and reciprocal immunoprecipitation. This study demonstrates the utility of antibody immunoprecipitation and subsequent peptide identification by tandem mass spectrometry for the elucidation of ALK-binding proteins, and its potential signal transduction pathways.	Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT 84132 USA; ARUP Inst Clin & Expt Pathol, Salt Lake City, UT 84108 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; ARUP Laboratories	Elenitoba-Johnson, KSJ (corresponding author), Univ Utah, Sch Med, Dept Pathol, 50 N Med Dr,Room A565, Salt Lake City, UT 84132 USA.	kojo.elenitobaj@path.utah.edu; megan.lim@path.utah.edu		Elenitoba-Johnson, Kojo/0000-0002-1082-1545; Lim, Megan/0000-0002-0415-2867				Amin HM, 2003, ONCOGENE, V22, P5399, DOI 10.1038/sj.onc.1206849; Baba T, 2003, BIOCHEM BIOPH RES CO, V304, P67, DOI 10.1016/S0006-291X(03)00542-4; Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Bai RY, 2000, BLOOD, V96, P4319, DOI 10.1182/blood.V96.13.4319; Bernhard OK, 2003, PROTEOMICS, V3, P139, DOI 10.1002/pmic.200390022; Blagoev B, 2003, NAT BIOTECHNOL, V21, P315, DOI 10.1038/nbt790; Bonvini P, 2002, CANCER RES, V62, P1559; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; DAVIS TH, 1992, NEW ENGL J MED, V326, P1115, DOI 10.1056/NEJM199204233261704; Edmondson RD, 2002, MOL CELL PROTEOMICS, V1, P421, DOI 10.1074/mcp.M100036-MCP200; EPSTEIN AL, 1974, CANCER-AM CANCER SOC, V34, P1851, DOI 10.1002/1097-0142(197412)34:6<1851::AID-CNCR2820340602>3.0.CO;2-4; Figeys D, 2001, METHODS, V24, P230, DOI 10.1006/meth.2001.1184; FISCHER P, 1988, BLOOD, V72, P234; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; Griffis ER, 2003, MOL BIOL CELL, V14, P600, DOI 10.1091/mbc.E02-09-0582; Hubinger G, 2003, EXP HEMATOL, V31, P226, DOI 10.1016/S0301-472X(02)01084-6; Hubinger G, 1999, EXP HEMATOL, V27, P1796, DOI 10.1016/S0301-472X(99)00116-2; Kai M, 2001, MOL CELL BIOL, V21, P3289, DOI 10.1128/MCB.21.10.3289-3301.2001; Kaiser BK, 2002, MOL BIOL CELL, V13, P2289, DOI 10.1091/mbc.01-11-0535; Kelkar N, 2000, MOL CELL BIOL, V20, P1030, DOI 10.1128/MCB.20.3.1030-1043.2000; Khoury JD, 2003, CLIN CANCER RES, V9, P3692; Knaus PI, 1996, MOL CELL BIOL, V16, P3480; Kuefer MU, 1997, BLOOD, V90, P2901, DOI 10.1182/blood.V90.8.2901; LUDERUS MEE, 1992, CELL, V70, P949, DOI 10.1016/0092-8674(92)90245-8; Lux A, 1999, J BIOL CHEM, V274, P9984, DOI 10.1074/jbc.274.15.9984; MASON DY, 1990, BRIT J HAEMATOL, V74, P161; Miyake I, 2002, ONCOGENE, V21, P5823, DOI 10.1038/sj.onc.1205735; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; Nieborowska-Skorska M, 2001, CANCER RES, V61, P6517; Ohta S, 2002, J BIOL CHEM, V277, P40362, DOI 10.1074/jbc.M206194200; PANDEY A, 1994, J BIOL CHEM, V269, P30154; Payen E, 1998, J BIOL CHEM, V273, P9099, DOI 10.1074/jbc.273.15.9099; Peng JM, 2003, J PROTEOME RES, V2, P43, DOI 10.1021/pr025556v; Pratt RL, 2002, ONCOGENE, V21, P7690, DOI 10.1038/sj.onc.1205758; Raetz EA, 2002, AM J PATHOL, V161, P875, DOI 10.1016/S0002-9440(10)64248-4; Ranish JA, 2003, NAT GENET, V33, P349, DOI 10.1038/ng1101; Rashid KA, 2002, J BIOL CHEM, V277, P22010, DOI 10.1074/jbc.M112448200; Rey M, 2002, J IMMUNOL, V169, P5410, DOI 10.4049/jimmunol.169.10.5410; Rossi L, 2003, INT J DEV BIOL, V47, P293; Ruchatz H, 2003, EXP HEMATOL, V31, P309, DOI 10.1016/S0301-472X(03)00007-9; Sharfe N, 2003, J IMMUNOL, V170, P6024, DOI 10.4049/jimmunol.170.12.6024; Shiio Y, 2002, EMBO J, V21, P5088, DOI 10.1093/emboj/cdf525; SHIOTA M, 1994, ONCOGENE, V9, P1567; Shiota Mami, 1997, Leukemia (Basingstoke), V11, P538; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Slupianek A, 2001, CANCER RES, V61, P2194; Souttou B, 2001, J BIOL CHEM, V276, P9526, DOI 10.1074/jbc.M007333200; STEIN H, 1985, BLOOD, V66, P848; Taimen P, 2000, EXP CELL RES, V256, P140, DOI 10.1006/excr.2000.4799; TESSIERLAVIGNE M, 1995, CELL, V82, P345, DOI 10.1016/0092-8674(95)90421-2; Walker-Daniels J, 1999, PROSTATE, V41, P275, DOI 10.1002/(SICI)1097-0045(19991201)41:4<275::AID-PROS8>3.0.CO;2-T; Zamo A, 2002, ONCOGENE, V21, P1038, DOI 10.1038/sj.onc.1205152; Zelinski DP, 2001, CANCER RES, V61, P2301; Zhang Q, 2002, J IMMUNOL, V168, P466, DOI 10.4049/jimmunol.168.1.466	55	89	93	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2004	23	15					2617	2629		10.1038/sj.onc.1207398	http://dx.doi.org/10.1038/sj.onc.1207398			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	810OZ	14968112				2022-12-28	WOS:000220714900003
J	Yoshida, K; Inoue, I				Yoshida, K; Inoue, I			Expression of MCM10 and TopBP1 is regulated by cell proliferation and UV irradiation via the E2F transcription factor	ONCOGENE			English	Article						MCM10; TopBP1; DNA replication; UV irradiation; promoter; E2F	DNA-DAMAGE; S-PHASE; REPLICATION ORIGINS; CYCLE PROGRESSION; SACCHAROMYCES-CEREVISIAE; MICROARRAY ANALYSIS; IN-VIVO; PROTEIN; PRB; ACTIVATION	MCM10 and TopBP1 function in the initiation of DNA replication, by regulating the chromatin binding of the DNA polymerase a loading factor, CDC45. TopBP1 is also known as a DNA damage response protein. In this study, we showed that the transcription of human MCM10 and TopBP1 is activated by transcription factors E2F1-3, but not by factors E2F4-7. Analysis of various MCM10 and TopBP1 promoter constructs showed that an E2F-responsive sequence in the vicinity of the transcription initiation site is necessary for the E2F1-induced activation of MCM10 and TopBP1 gene transcription, which is further suppressed by pRb. The promoter activities of human MCM10 and TopBP1 were demonstrated to be growth dependent via the E2F-responsive sequence. Although E2F1 was stabilized by ultraviolet (UV) irradiation, the mRNA expression level of TopBP1 was suppressed in HCT116 human diploid colon cancer cells. We showed, by performing chromatin immunoprecipitation that, in response to UV irradiation but not doxorubicin treatment, E2F4 accumulated on the MCM10 and TopBP1 promoters. Our data suggest a model in which UV irradiation-induced DNA damage depends, at least in part, on the accumulation of the E2F4 transcription factor on the MCM10 and TopBP1 promoters, which results in suppression of DNA replication.	Univ Tokyo, Inst Med Sci, Div Genet Diag, Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Yoshida, K (corresponding author), Univ Tokyo, Inst Med Sci, Div Genet Diag, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	yoshidak@ims.u-tokyo.ac.jp						Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Blattner C, 1999, MOL CELL BIOL, V19, P3704; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Dhar SK, 2001, CELL, V106, P287, DOI 10.1016/S0092-8674(01)00458-5; Diffley JFX, 1998, CURR BIOL, V8, pR771, DOI 10.1016/S0960-9822(07)00483-6; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; DOBROWOLSKI SF, 1994, ONCOGENE, V9, P2605; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; Hofferer M, 1999, NUCLEIC ACIDS RES, V27, P491, DOI 10.1093/nar/27.2.491; Homesley L, 2000, GENE DEV, V14, P913; Huang E, 2003, NAT GENET, V34, P226, DOI 10.1038/ng1167; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Izumi M, 2000, NUCLEIC ACIDS RES, V28, P4769, DOI 10.1093/nar/28.23.4769; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kalma Y, 2001, ONCOGENE, V20, P1379, DOI 10.1038/sj.onc.1204230; Kawasaki Y, 2000, GENES CELLS, V5, P975, DOI 10.1046/j.1365-2443.2000.00387.x; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; Lei M, 2001, J CELL SCI, V114, P1447; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Lin WC, 2001, GENE DEV, V15, P1833; Ma YH, 2002, ARCH BIOCHEM BIOPHYS, V399, P212, DOI 10.1006/abbi.2002.2761; Makiniemi M, 2001, J BIOL CHEM, V276, P30399, DOI 10.1074/jbc.M102245200; Mimura S, 1998, EMBO J, V17, P5699, DOI 10.1093/emboj/17.19.5699; Moberg K, 1996, MOL CELL BIOL, V16, P1436; O'Connor DJ, 2000, ONCOGENE, V19, P2369, DOI 10.1038/sj.onc.1203540; Potter T, 2000, RADIAT RES, V154, P151, DOI 10.1667/0033-7587(2000)154[0151:KETURR]2.0.CO;2; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Stanelle J, 2002, NUCLEIC ACIDS RES, V30, P1859, DOI 10.1093/nar/30.8.1859; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Suzuki S, 1998, GENE, V216, P85, DOI 10.1016/S0378-1119(98)00323-0; Takahashi Y, 2000, GENE DEV, V14, P804; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Van Hatten RA, 2002, J CELL BIOL, V159, P541, DOI 10.1083/jcb.200207090; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Wells J, 2003, ONCOGENE, V22, P1445, DOI 10.1038/sj.onc.1206264; Wohlschlegel JA, 2002, MOL CELL, V9, P233, DOI 10.1016/S1097-2765(02)00456-2; Yamamoto RR, 2000, GENETICS, V156, P711; Yamane K, 2002, MOL CELL BIOL, V22, P555, DOI 10.1128/MCB.22.2.555-566.2002; Yoshida K, 2004, ONCOGENE, V23, P3802, DOI 10.1038/sj.onc.1207488; Young AP, 2003, ONCOGENE, V22, P7209, DOI 10.1038/sj.onc.1206804; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou L, 2000, MOL CELL BIOL, V20, P3086, DOI 10.1128/MCB.20.9.3086-3096.2000	50	40	41	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 19	2004	23	37					6250	6260		10.1038/sj.onc.1207829	http://dx.doi.org/10.1038/sj.onc.1207829			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	847NC	15195143				2022-12-28	WOS:000223399000009
J	Kawakami, T; Zhang, C; Taniguchi, T; Kim, CJ; Okada, Y; Sugihara, H; Hattori, T; Reeve, AE; Ogawa, O; Okamoto, K				Kawakami, T; Zhang, C; Taniguchi, T; Kim, CJ; Okada, Y; Sugihara, H; Hattori, T; Reeve, AE; Ogawa, O; Okamoto, K			Characterization of loss-of-inactive X in Klinefelter syndrome and female-derived cancer cells	ONCOGENE			English	Article						X inactivation; Klinefelter syndrome; female-derived cancer	SEX-CHROMOSOMES; XIST EXPRESSION; CHROMATIN; TUMORS; BREAST; GENE; STR; CARCINOMA; BRCA1; LINE	The increased risk of several types of cancer in Klinefelter syndrome (47XXY) suggests that the extra X chromosome may be involved in the tumorigenesis associated with this syndrome. Here, we show that cancer cells (PSK-1) derived from a patient with Klinefelter syndrome (47XXY) showing loss of an inactive X chromosome subsequently gained active X chromosomes. We found that this abnormal X chromosome composition in PSK-1 is caused by a loss of an inactive X chromosome followed by multiplication of identical active X chromosomes, not by reactivation of an inactive X chromosome. Furthermore, we extended the characterization of loss-of-inactive X in a series of 22 female-derived cancer cell lines (eight breast cancer cell lines, seven ovarian cancer cell lines, and seven cervical cancer cell lines). The data demonstrate that loss-of-inactive X in the female-derived cancer cells is mainly achieved by loss of an inactive X chromosomes followed by multiplication of an identical active X chromosomes. However, distinctive pathways, including reactivation of an inactive X chromosome, are also involved in the mechanisms for loss-of-inactive X and gain-of-active X in female-derived cancer cells. The biological significance of the loss-of-inactive X and gain-of-active X in the oncogenesis of Klinefelter syndrome and female-derived cancer cells are discussed.	Shiga Univ Med Sci, Dept Urol, Shiga 5202192, Japan; Asahikawa Med Coll, Dept Biochem, Asahikawa, Hokkaido 078, Japan; Shiga Univ Med Sci, Dept Pathol, Otsu, Shiga 52021, Japan; Univ Otago, Dept Biochem, Dunedin, New Zealand; Kyoto Univ, Grad Sch Med, Dept Urol, Kyoto, Japan	Shiga University of Medical Science; Asahikawa Medical College; Shiga University of Medical Science; University of Otago; Kyoto University	Okamoto, K (corresponding author), Shiga Univ Med Sci, Dept Urol, Shiga 5202192, Japan.	keisei@belle.shiga-med.ac.jp						Brown CJ, 1997, AM J HUM GENET, V60, P1333, DOI 10.1086/515488; DUTRILLAUX B, 1986, INT J CANCER, V38, P475, DOI 10.1002/ijc.2910380404; Edelmann J, 2002, FORENSIC SCI INT, V125, P217, DOI 10.1016/S0379-0738(02)00005-1; Edelmann J, 2001, INT J LEGAL MED, V114, P301, DOI 10.1007/s004140000188; Ganesan S, 2002, CELL, V111, P393, DOI 10.1016/S0092-8674(02)01052-8; Giordano SH, 2002, ANN INTERN MED, V137, P678, DOI 10.7326/0003-4819-137-8-200210150-00013; HASLE H, 1995, BRIT J CANCER, V71, P416, DOI 10.1038/bjc.1995.85; HOPMAN AHN, 1989, AM J PATHOL, V135, P1105; Huang DX, 2003, FORENSIC SCI INT, V133, P246, DOI 10.1016/S0379-0738(03)00077-X; Huang KC, 2002, MOL CANCER THER, V1, P769; JACOBS PA, 1959, NATURE, V183, P302, DOI 10.1038/183302a0; Jazaeri AA, 2002, JNCI-J NATL CANCER I, V94, P990, DOI 10.1093/jnci/94.13.990; Kawakami T, 2004, LANCET, V363, P40, DOI 10.1016/S0140-6736(03)15170-7; Kawakami T, 2003, GENE CHROMOSOME CANC, V38, P97, DOI 10.1002/gcc.10234; Kawakami T, 2003, J UROLOGY, V169, P1546, DOI 10.1097/01.ju.0000044927.23323.5a; Kim CJ, 2000, PROSTATE, V42, P287; KIRCHGESSNER CU, 1995, J MED GENET, V32, P925, DOI 10.1136/jmg.32.12.925; KOKALJVOKAC N, 1991, CYTOGENET CELL GENET, V57, P11, DOI 10.1159/000133103; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; McDonald HL, 2000, GENE CHROMOSOME CANC, V28, P246, DOI 10.1002/1098-2264(200007)28:3<246::AID-GCC2>3.3.CO;2-S; Melki JR, 1999, CANCER RES, V59, P3730; MULERIS M, 1990, GENE CHROMOSOME CANC, V1, P221, DOI 10.1002/gcc.2870010306; PERRY M, 1972, BRIT J SURG, V59, P731, DOI 10.1002/bjs.1800590912; SAVINO A, 1971, ACTA CYTOL, V15, P372; Smyth CM, 1998, ARCH INTERN MED, V158, P1309, DOI 10.1001/archinte.158.12.1309; Son JY, 2002, INT J LEGAL MED, V116, P317, DOI 10.1007/s00414-002-0307-x; Stone C, 2003, CURR BIOL, V13, pR63, DOI 10.1016/S0960-9822(02)01430-6; THERMAN E, 1985, CANCER GENET CYTOGEN, V16, P1, DOI 10.1016/0165-4608(85)90072-X	28	76	81	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6163	6169		10.1038/sj.onc.1207808	http://dx.doi.org/10.1038/sj.onc.1207808			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15195139				2022-12-28	WOS:000223261000016
J	Logan, N; Delavaine, L; Graham, A; Reilly, C; Wilson, J; Brummelkamp, TR; Hijmans, EM; Bernards, R; La Thangue, NB				Logan, N; Delavaine, L; Graham, A; Reilly, C; Wilson, J; Brummelkamp, TR; Hijmans, EM; Bernards, R; La Thangue, NB			E2F-7: a distinctive E2F family member with an unusual organization of DNA-binding domains	ONCOGENE			English	Article						E2F; repression; cancer; cell cycle; transcription factor	TRANSCRIPTION FACTOR E2F-1; PROTEIN; DAMAGE; INDUCTION; LEADS; MICE; ATM	The E2F family of transcription factors play an important role in regulating cell cycle progression. We report here the characterization and functional properties of a new member of the human E2F family, referred to as E2F-7. E2F-7 has two separate DNA-binding domains, a feature that distinguishes E2F-7 from other mammalian E2F proteins, but resembling the organization of recently isolated E2F-like proteins from Arabidopsis. E2F-7 binds to DNA independently of a DP partner and delays cell cycle progression. Interestingly, E2F-7 modulates the transcription properties of other E2F proteins. A mutational analysis indicates that the integrity of both DNA-binding domains is required for cell cycle delay and transcriptional modulation. Biochemical results and protein modelling studies suggest that in binding to DNA interactions occur between the two DNA-binding domains, most probably as a homodimer, thereby mimicking the organization of an E2F/DP heterodimer. These structural and functional properties of E2F-7 imply a unique role in regulating cellular proliferation.	Univ Glasgow, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland; Natl Inst Med Res, Div Prot Struct, London NW7 1AA, England; Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands	University of Glasgow; MRC National Institute for Medical Research; Netherlands Cancer Institute	La Thangue, NB (corresponding author), Univ Glasgow, Div Biochem & Mol Biol, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	n.lathangue@bio.gla.ac.uk	Wilson, Jon R/B-7362-2019	Wilson, Jon R/0000-0002-5157-5432; Bernards, Rene/0000-0001-8677-3423; Hijmans, Marielle/0000-0003-4847-9412	Cancer Research UK [13058] Funding Source: Medline; Medical Research Council [G9400953] Funding Source: Medline; MRC [G9400953] Funding Source: UKRI	Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Chan HM, 2001, ONCOGENE, V20, P6152, DOI 10.1038/sj.onc.1204793; de Bruin A, 2003, J BIOL CHEM, V278, P42041, DOI 10.1074/jbc.M308105200; delaLuna S, 1996, J CELL SCI, V109, P2443; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Gaubatz S, 2000, MOL CELL, V6, P729, DOI 10.1016/S1097-2765(00)00071-X; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Humbert PO, 2000, MOL CELL, V6, P281, DOI 10.1016/S1097-2765(00)00029-0; Klemm JD, 1996, GENE DEV, V10, P27, DOI 10.1101/gad.10.1.27; Komori H, 1999, EMBO J, V18, P4597, DOI 10.1093/emboj/18.17.4597; Kosugi S, 2002, J BIOL CHEM, V277, P16553, DOI 10.1074/jbc.M200913200; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LATHANGUE NB, 1987, CELL, V49, P507, DOI 10.1016/0092-8674(87)90453-3; Lee JK, 1997, P NATL ACAD SCI USA, V94, P8427, DOI 10.1073/pnas.94.16.8427; Lin WC, 2001, GENE DEV, V15, P1833; Lindeman GJ, 1998, GENE DEV, V12, P1092, DOI 10.1101/gad.12.8.1092; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Morris L, 2000, NAT CELL BIOL, V2, P232, DOI 10.1038/35008660; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Rempel RE, 2000, MOL CELL, V6, P293, DOI 10.1016/S1097-2765(00)00030-7; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Stevens C, 2003, ARCH BIOCHEM BIOPHYS, V412, P157, DOI 10.1016/S0003-9861(03)00054-7; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Zheng N, 1999, GENE DEV, V13, P666, DOI 10.1101/gad.13.6.666	33	76	79	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2004	23	30					5138	5150		10.1038/sj.onc.1207649	http://dx.doi.org/10.1038/sj.onc.1207649			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	834AE	15133492	Green Published			2022-12-28	WOS:000222382500004
J	Baldanzi, G; Mitola, S; Cutrupi, S; Filigheddu, N; van Blitterswijk, WJ; Sinigaglia, F; Bussolino, F; Graziani, A				Baldanzi, G; Mitola, S; Cutrupi, S; Filigheddu, N; van Blitterswijk, WJ; Sinigaglia, F; Bussolino, F; Graziani, A			Activation of diacylglycerol kinase alpha is required for VEGF-induced angiogenic signaling in vitro	ONCOGENE			English	Article						diacylglycerol kinase; VEGF; phosphatidic acid; Src; angiogenesis	ENDOTHELIAL GROWTH-FACTOR; FOCAL ADHESION KINASE; PHOSPHATIDIC-ACID; PROCESSIVE PHOSPHORYLATION; PHOSPHOLIPASE-D; CELL MIGRATION; C-ALPHA; PHOSPHATIDYLINOSITOL; EXPRESSION; INHIBITOR	Vascular endothelial growth factor-A (VEGF-A) promotes angiogenesis by stimulating migration, proliferation and organization of endothelium, through the activation of signaling pathways involving Src tyrosine kinase. As we had previously shown that Src-mediated activation of diacylglycerol kinase-alpha (Dgk-alpha) is required for hepatocytes growth factor-stimulated cell migration, we asked whether Dgk-alpha is involved in the transduction of angiogenic signaling. In PAE-KDR cells, an endothelial-derived cell line expressing VEGFR-2, VEGF-A(165), stimulates the enzymatic activity of Dgk-alpha: activation is inhibited by R59949, an isoform-specific Dgk inhibitor, and is dependent on Src tyrosine kinase, with which Dgk-alpha forms a complex. Conversely in HUVEC, VEGF-A(165)-induced activation of Dgk is only partially sensitive to R59949, suggesting that also other isoforms may be activated, albeit still dependent on Src tyrosine kinase. Specific inhibition of Dgk-alpha, obtained in both cells by R59949 and in PAE-KDR by expression of Dgk-alpha dominant-negative mutant, imp airs VEGF-A(165)-dependent chemotaxis, proliferation and in vitro angiogenesis. In addition, in HUVEC, specific downregulation of Dgk-alpha by siRNA impairs in vitro angiogenesis on matrigel, further suggesting the requirement for Dgk-alpha in angiogenic signaling in HUVEC. Thus, we propose that activation of Dgk-alpha generates a signal essential for both proliferative and migratory response to VEGF-A(165), suggesting that it may constitute a novel pharmacological target for angiogenesis control.	Univ Amedeo Avogadro Piemonte Orientale, Dept Med Sci, I-28100 Novara, Italy; Univ Turin, Dept Oncol Sci, I-10124 Turin, Italy; Univ Turin, Inst Canc Res & Treatment IRCC, I-10124 Turin, Italy; Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands	University of Eastern Piedmont Amedeo Avogadro; University of Turin; IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; Netherlands Cancer Institute	Graziani, A (corresponding author), Univ Amedeo Avogadro Piemonte Orientale, Dept Med Sci, V Solaroli 17, I-28100 Novara, Italy.	graziani@med.unipmn.it	Bussolino, Federico/AES-3951-2022; Filigheddu, Nicoletta/N-7219-2015; graziani, andrea/B-2554-2009; Baldanzi, Gianluca/AAO-7673-2021; Graziani, Andrea/AAB-6301-2022; cutrupi, santina/AAC-4479-2022; Bussolino, Federico/K-2500-2016	Filigheddu, Nicoletta/0000-0002-3848-611X; graziani, andrea/0000-0002-6302-2317; Baldanzi, Gianluca/0000-0002-1370-9903; Graziani, Andrea/0000-0002-6302-2317; Bussolino, Federico/0000-0002-5348-1341; MITOLA, Stefania/0000-0002-5557-738X; CUTRUPI, SANTINA/0000-0002-2358-5852				Abu-Ghazaleh R, 2001, BIOCHEM J, V360, P255, DOI 10.1042/0264-6021:3600255; Andresen BT, 2002, FEBS LETT, V531, P65, DOI 10.1016/S0014-5793(02)03483-X; Baldanzi G, 2002, J CELL BIOL, V159, P1029, DOI 10.1083/jcb.200207165; Benelli R, 1999, INT J BIOL MARKER, V14, P243, DOI 10.1177/172460089901400408; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Cipres A, 2003, J BIOL CHEM, V278, P35629, DOI 10.1074/jbc.M305635200; Cutrupi S, 2000, EMBO J, V19, P4614, DOI 10.1093/emboj/19.17.4614; DAVIDSON L, 2004, IN PRESS J BIOL CHEM; DECOURCELLES DD, 1989, J BIOL CHEM, V264, P3274; Del Pozo MA, 2002, NAT CELL BIOL, V4, P232, DOI 10.1038/ncb759; Di Paolo G, 2002, NATURE, V420, P85, DOI 10.1038/nature01147; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Eliceiri BP, 2002, J CELL BIOL, V157, P149, DOI 10.1083/jcb.200109079; English D, 1996, CELL SIGNAL, V8, P341, DOI 10.1016/0898-6568(95)00076-3; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Flores I, 1996, J BIOL CHEM, V271, P10334, DOI 10.1074/jbc.271.17.10334; FOLKMAN J, 1972, ANN SURG, V175, P409, DOI 10.1097/00000658-197203000-00014; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047; Gomez-Cambronero J, 1998, CELL SIGNAL, V10, P387, DOI 10.1016/S0898-6568(97)00197-6; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; Jiang Y, 2000, BIOCHEM PHARMACOL, V59, P763, DOI 10.1016/S0006-2952(99)00395-0; Jones DR, 2002, FASEB J, V16, P595, DOI 10.1096/fj.01-0762fje; KAI M, 1994, J BIOL CHEM, V269, P18492; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; Marconcini L, 1999, P NATL ACAD SCI USA, V96, P9671, DOI 10.1073/pnas.96.17.9671; Matsumoto T, 2001, Sci STKE, V2001, pre21, DOI 10.1126/stke.2001.112.re21; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; O'Luanaigh N, 2002, MOL BIOL CELL, V13, P3730, DOI 10.1091/mbc.E02-04-0213; PANETTI TS, 2002, BIOCHIM BIOPHYS ACTA, V23, P190; Pellicena P, 2001, J BIOL CHEM, V276, P28190, DOI 10.1074/jbc.M100055200; POOLE CA, 1993, J CELL SCI, V106, P685; SCHAAP D, 1993, BIOCHEM J, V289, P875, DOI 10.1042/bj2890875; SCHAAP D, 1990, FEBS LETT, V275, P151, DOI 10.1016/0014-5793(90)81461-V; Scott MP, 2000, BIOCHEMISTRY-US, V39, P14531, DOI 10.1021/bi001850u; Seibenhener M L, 1999, Mol Cell Biol Res Commun, V2, P28, DOI 10.1006/mcbr.1999.0140; SUGIMOTO Y, 1984, P NATL ACAD SCI-BIOL, V81, P2117, DOI 10.1073/pnas.81.7.2117; SWIFT S, 1999, CURR PROTOCOLS IMMUN, DOI DOI 10.17.14-10.17.29; Thomas JW, 1998, J BIOL CHEM, V273, P577, DOI 10.1074/jbc.273.1.577; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; van Blitterswijk WJ, 2000, CELL SIGNAL, V12, P595, DOI 10.1016/S0898-6568(00)00113-3; Waltenberger J, 1999, CIRC RES, V85, P12; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wang AH, 2002, CIRC RES, V90, P609, DOI 10.1161/01.RES.0000012503.30315.E8; Wellner M, 1999, ARTERIOSCL THROM VAS, V19, P178, DOI 10.1161/01.ATV.19.1.178; Xie YH, 2002, J BIOL CHEM, V277, P32516, DOI 10.1074/jbc.M203864200; Zeng HY, 2002, J BIOL CHEM, V277, P46791, DOI 10.1074/jbc.M206133200; Zhong XP, 2002, J BIOL CHEM, V277, P31089, DOI 10.1074/jbc.M203818200	50	62	62	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2004	23	28					4828	4838		10.1038/sj.onc.1207633	http://dx.doi.org/10.1038/sj.onc.1207633			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	830EK	15122338	Green Published			2022-12-28	WOS:000222104200003
J	Taniuchi, I; Littman, DR				Taniuchi, I; Littman, DR			Epigenetic gene silencing by Runx proteins	ONCOGENE			English	Article						Runx; CD4; silencing; epigenetics	T-LYMPHOCYTE DEVELOPMENT; ACUTE MYELOID-LEUKEMIA; CD4 SILENCER; CELL DEVELOPMENT; EXPRESSION; REPRESSION; DELETION; DOMAIN; AML1; DIFFERENTIATION	Runx family proteins have the potential for either activating or suppressing gene expression in a context-dependent manner. There are several mechanisms by which transcriptional repression can occur. A wide range of locus inactivation, that is often called gene silencing, is thought to be achieved by chromatin modi. cations. Recently, Runx family proteins were found to have an essential role in either temporal transcriptional repression or irreversible epigenetic silencing at the CD4 locus through binding to a CD4 silencer at different stages of development. These findings link Runx function to epigenetic gene regulation, and shed new light on the mechanisms by which Runx represses target gene expression.	RIKEN, Res Ctr Allergy & Immunol, Lab Transcript Regulat, Yokohama, Kanagawa 2300045, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Mol Genet, Fukuoka 812, Japan; PREST, JST, Kawaguchi, Japan; NYU, Sch Med, Howard Hughes Med Inst, Skirball Inst Biomol Med, New York, NY 10016 USA	RIKEN; Kyushu University; Howard Hughes Medical Institute; New York University	Taniuchi, I (corresponding author), RIKEN, Res Ctr Allergy & Immunol, Lab Transcript Regulat, Yokohama, Kanagawa 2300045, Japan.	taniuchi@rcai.riken.jp	Taniuchi, Ichiro/N-6399-2015	Taniuchi, Ichiro/0000-0002-9853-9068				Chakraborty S, 2003, ONCOGENE, V22, P5229, DOI 10.1038/sj.onc.1206600; Chi TH, 2002, NATURE, V418, P195, DOI 10.1038/nature00876; Donda A, 1996, EUR J IMMUNOL, V26, P493, DOI 10.1002/eji.1830260232; Ellmeier W, 1999, ANNU REV IMMUNOL, V17, P523, DOI 10.1146/annurev.immunol.17.1.523; Ellmeier W, 2002, IMMUNITY, V16, P623, DOI 10.1016/S1074-7613(02)00309-6; Festenstein R, 2000, CURR OPIN GENET DEV, V10, P199, DOI 10.1016/S0959-437X(00)00060-5; Festenstein R, 1999, NAT GENET, V23, P457, DOI 10.1038/70579; Garefalaki A, 2002, IMMUNITY, V16, P635, DOI 10.1016/S1074-7613(02)00308-4; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kioussis D, 2002, NAT REV IMMUNOL, V2, P909, DOI 10.1038/nri952; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Leung RKM, 2001, NAT IMMUNOL, V2, P1167, DOI 10.1038/ni733; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; SAWADA S, 1994, CELL, V77, P917, DOI 10.1016/0092-8674(94)90140-6; Sebzda E, 1999, ANNU REV IMMUNOL, V17, P829, DOI 10.1146/annurev.immunol.17.1.829; SIU G, 1994, EMBO J, V13, P3570, DOI 10.1002/j.1460-2075.1994.tb06664.x; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Taniuchi I, 2002, MOL CELL, V10, P1083, DOI 10.1016/S1097-2765(02)00735-9; TANIUCHI I, 2004, IN PRESS ADV IMMUNOL; VONBOEHMER H, 1993, IMMUNOL REV, V135, P67; Wakimoto BT, 1998, CELL, V93, P321, DOI 10.1016/S0092-8674(00)81159-9; Wheeler JC, 2000, SEMIN CELL DEV BIOL, V11, P369, DOI 10.1006/scdb.2000.0184; Woolf E, 2003, P NATL ACAD SCI USA, V100, P7731, DOI 10.1073/pnas.1232420100; Zou YR, 2001, NAT GENET, V29, P332, DOI 10.1038/ng750	31	51	51	3	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 24	2004	23	24					4341	4345		10.1038/sj.onc.1207671	http://dx.doi.org/10.1038/sj.onc.1207671			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823BZ	15156191				2022-12-28	WOS:000221586000020
J	Toussaint-Smith, E; Donner, DB; Roman, A				Toussaint-Smith, E; Donner, DB; Roman, A			Expression of human papillomavirus type 16 E6 and E7 oncoproteins in primary foreskin keratinocytes is sufficient to alter the expression of angiogenic factors	ONCOGENE			English	Article						angiogenesis; papillomavirus; oncogenes; tumor suppressors	ENDOTHELIAL GROWTH-FACTOR; CCAAT DISPLACEMENT PROTEIN; WILD-TYPE P53; TUMOR-SUPPRESSOR; CERVICAL-CANCER; GENE-EXPRESSION; TRANSGENIC MICE; MESSENGER-RNAS; FACTOR FAMILY; CELL-LINES	Human papillomavirus (HPV) 16 is involved in causing cervical cancer. The E6 and E7 proteins of HPV 16 immortalize human keratinocytes and this is due, at least in part, to inactivation of the tumor suppressor proteins p53 and pRB. The se tumor suppressor proteins also regulate the expression of pro- and antiangiogenic factors by cells. For this reason, experiments were conducted to determine whether the expression of E6 and E7 in primary keratinocytes alters the phenotype of these cells such that they express diminished levels of antiangiogenic factors and/or increased levels of proangiogenic factors. To avoid variances in experimental observations, pools of human foreskin keratinocytes from multiple sources were infected with recombinant retrovirus expressing HPV 16 E6 and E7 or control retrovirus. Gene array analysis, RT-PCR, ELISAs and Western blotting showed that in cells expressing HPV 16 E6 and E7, expression levels of two potent angiogenesis inhibitors, thrombospondin-1 and maspin, were lower compared to controls. Additionally, major angiogenesis inducers, interleukin-8 and vascular endothelial growth factor ( VEGF), were increased relative to controls. VEGF can be produced as multiple splice variants, all of which are required for the formation of patent blood vessels. The expression of HPV 16 E6 and E7 in keratinocytes augmented expression of VEGF 121, 145, 165 and 189. These observations show that HPV 16 E6 and E7 alter the phenotype of primary keratinocytes, diminishing expression of inhibitors and increasing expression of inducers of angiogenesis. This altered phenotype may permit keratinocytes infected by HPV 16 to play a role in the progression of cancer by permitting tumors to acquire a blood supply permissive of growth and spread.	Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Walther Cancer Institute	Roman, A (corresponding author), Indiana Univ, Sch Med, Dept Microbiol & Immunol, 635 Barnhill Dr, Indianapolis, IN 46202 USA.	aroman@iupui.edu			NATIONAL CANCER INSTITUTE [R55CA067891, R01CA067891, R01CA073023] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI031494, U19AI031494] Funding Source: NIH RePORTER; NCI NIH HHS [CA73023, CA67891] Funding Source: Medline; NIAID NIH HHS [AI31494] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ai WD, 1999, J VIROL, V73, P4220, DOI 10.1128/JVI.73.5.4220-4229.1999; Antinore MJ, 1996, EMBO J, V15, P1950, DOI 10.1002/j.1460-2075.1996.tb00546.x; ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; Bequet-Romero M, 2000, BIOCHEM BIOPH RES CO, V277, P55, DOI 10.1006/bbrc.2000.3628; Bouck N, 1996, BBA-REV CANCER, V1287, P63, DOI 10.1016/0304-419X(96)00005-4; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; Boyer SN, 1996, CANCER RES, V56, P4620; CHARNOCKJONES DS, 1993, BIOL REPROD, V48, P1120, DOI 10.1095/biolreprod48.5.1120; Cinatl J, 1999, AM J PATHOL, V155, P285, DOI 10.1016/S0002-9440(10)65122-X; Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; DESAINTES C, 1992, J VIROL, V66, P325, DOI 10.1128/JVI.66.1.325-333.1992; Dobbs SP, 1997, BRIT J CANCER, V76, P1410, DOI 10.1038/bjc.1997.571; FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Furumoto Hiroyuki, 2002, Journal of Medical Investigation, V49, P124; Gillitzer R, 2001, J LEUKOCYTE BIOL, V69, P513; Gomez-Manzano C, 2003, ANN NEUROL, V53, P109, DOI 10.1002/ana.10396; Gonzalez SL, 2001, J VIROL, V75, P7583, DOI 10.1128/JVI.75.16.7583-7591.2001; Grassmann K, 1996, J VIROL, V70, P2339, DOI 10.1128/JVI.70.4.2339-2349.1996; GUIDI AJ, 1995, J NATL CANCER I, V87, P1237, DOI 10.1093/jnci/87.16.1237; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harada H, 2003, CANCER LETT, V191, P109, DOI 10.1016/S0304-3835(02)00592-X; Hoffmann E, 2002, J LEUKOCYTE BIOL, V72, P847; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HU GY, 1995, CANCER GENE THER, V2, P19; Huang SM, 2002, J VIROL, V76, P8710, DOI 10.1128/JVI.76.17.8710-8721.2002; Igarashi H, 2002, CANCER-AM CANCER SOC, V95, P47, DOI 10.1002/cncr.10635; JEON S, 1995, P NATL ACAD SCI USA, V92, P1654, DOI 10.1073/pnas.92.5.1654; KIESER A, 1994, ONCOGENE, V9, P963; Kodama J, 1999, EUR J CANCER, V35, P485, DOI 10.1016/S0959-8049(98)00410-9; Kodama J, 2001, CLIN CANCER RES, V7, P2826; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Lingen MW, 1996, AM J PATHOL, V149, P247; Lopez-Ocejo O, 2000, ONCOGENE, V19, P4611, DOI 10.1038/sj.onc.1203817; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; Nees M, 2001, J VIROL, V75, P4283, DOI 10.1128/JVI.75.9.4283-4296.2001; Pattison S, 1997, J VIROL, V71, P2013, DOI 10.1128/JVI.71.3.2013-2022.1997; Ravi R, 2000, GENE DEV, V14, P34; Rheinwald J G, 1980, Methods Cell Biol, V21A, P229, DOI 10.1016/S0091-679X(08)60769-4; Rhim JS, 1998, CARCINOGENESIS, V19, P673, DOI 10.1093/carcin/19.4.673; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SmithMcCune K, 1997, CANCER RES, V57, P1294; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Tjiong MY, 1999, GYNECOL ONCOL, V73, P285, DOI 10.1006/gyno.1999.5358; Vikhanskaya F, 2001, ONCOGENE, V20, P7293, DOI 10.1038/sj.onc.1204896; Volpert OV, 1997, ONCOGENE, V14, P1495, DOI 10.1038/sj.onc.1200977; VONKNEBEL M, 1992, INT J CANCER, V51, P831, DOI 10.1002/ijc.2910510527; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051	53	109	115	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2004	23	17					2988	2995		10.1038/sj.onc.1207442	http://dx.doi.org/10.1038/sj.onc.1207442			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	812NC	14968115	Bronze			2022-12-28	WOS:000220845200002
J	Kao, CF; Chen, SY; Chen, JY; Lee, YHW				Kao, CF; Chen, SY; Chen, JY; Lee, YHW			Modulation of p53 transcription regulatory activity and post-translational modification by hepatitis C virus core protein	ONCOGENE			English	Article						HCV; core protein; p53; post-translational modification	PML NUCLEAR-BODIES; TUMOR-SUPPRESSOR; COMPLEX-FORMATION; DNA-BINDING; CELL-PROLIFERATION; GENE-EXPRESSION; IN-VITRO; ACTIVATION; RNA; INHIBITION	Oncogenic virus proteins often target to tumor suppressor p53 during virus life cycle. In the case of hepatitis C virus (HCV) core protein, it has been shown to affect p53-dependent transcription. Here, we further characterized the in vitro and in vivo interactions between HCV core protein and p53 and showed that these two proteins colocalized in subnuclear granular structures and the perinuclear area. By use of a reporter assay, we observed that while low level of HCV core protein enhanced the transactivational activity of p53, high level of HCV core protein inhibited this activity. In both cases, however, HCV core protein increased the p53 DNA-binding affinity in gel retardation analyses, likely due to the hyperacetylation of p53 Lys(373) and Lys(382) residues. Additionally, HCV core protein, depending on its expression level, had differential effects on the Ser(15) phosphorylation of p53. Moreover, HCV core protein could rescue p53-mediated suppressive effects on both RNA polymerase I and III transcriptions. Collectively, our results indicate that HCV core protein targets to p53 pathway via at least three means: physical interaction, modulation of p53 gene regulatory activity and post-translational modification. This feature of HCV core protein, may potentially contribute to the HCV-associated pathogenesis.	Natl Yang Ming Univ, Inst Biochem, Taipei 112, Taiwan; Acad Sinica, Inst Biomed Sci, Taipei, Taiwan	National Yang Ming Chiao Tung University; Academia Sinica - Taiwan	Lee, YHW (corresponding author), Natl Yang Ming Univ, Inst Biochem, Taipei 112, Taiwan.	yhwulee@ym.edu.tw	Chen, Joanne Jeou-Yuan/S-7022-2018	Lee Wu, Yan-Hwa/0000-0001-7299-7354				Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Aoki H, 2000, J VIROL, V74, P1736, DOI 10.1128/JVI.74.4.1736-1741.2000; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Appella E, 2000, PATHOL BIOL, V48, P227; Arima N, 2001, J BIOL CHEM, V276, P12675, DOI 10.1074/jbc.M008329200; Barba G, 1997, P NATL ACAD SCI USA, V94, P1200, DOI 10.1073/pnas.94.4.1200; BUKH J, 1993, P NATL ACAD SCI USA, V90, P1848, DOI 10.1073/pnas.90.5.1848; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; Chang J, 1998, J VIROL, V72, P3060, DOI 10.1128/JVI.72.4.3060-3065.1998; Chen CM, 1997, J VIROL, V71, P9417, DOI 10.1128/JVI.71.12.9417-9426.1997; CHEN JY, 1993, ONCOGENE, V8, P2159; Chen SY, 2003, J BIOL CHEM, V278, P591, DOI 10.1074/jbc.M204241200; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; Cho JW, 2001, LIVER, V21, P137, DOI 10.1034/j.1600-0676.2001.021002137.x; DINGERMANN T, 1983, J BIOL CHEM, V258, P395; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Erhardt A, 2002, VIROLOGY, V292, P272, DOI 10.1006/viro.2001.1227; FILHOL O, 1992, J BIOL CHEM, V267, P20577; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hirohashi S, 1991, Princess Takamatsu Symp, V22, P87; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hsieh TY, 1998, J BIOL CHEM, V273, P17651, DOI 10.1074/jbc.273.28.17651; HSU YS, 1995, J BIOL CHEM, V270, P6966, DOI 10.1074/jbc.270.12.6966; Ishido S, 1998, FEBS LETT, V438, P258, DOI 10.1016/S0014-5793(98)01312-X; JACKSON P, 1994, BIOCHEM BIOPH RES CO, V203, P133, DOI 10.1006/bbrc.1994.2159; JAMAL S, 1995, ONCOGENE, V10, P2095; Jayaraman L, 1997, METHOD ENZYMOL, V283, P245; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; Jin DY, 2000, EMBO J, V19, P729, DOI 10.1093/emboj/19.4.729; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kwun HJ, 2001, J GEN VIROL, V82, P2235, DOI 10.1099/0022-1317-82-9-2235; Lai MMC, 2000, CURR TOP MICROBIOL, V242, P117; Lain S, 1999, EXP CELL RES, V248, P457, DOI 10.1006/excr.1999.4433; Lan KH, 2002, ONCOGENE, V21, P4801, DOI 10.1038/sj.onc.1205589; Larminie CGC, 1998, J MOL MED, V76, P94, DOI 10.1007/s001090050196; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu L, 1999, MOL CELL BIOL, V19, P1202; Liu Y, 2000, MOL CELL BIOL, V20, P5540, DOI 10.1128/MCB.20.15.5540-5553.2000; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; Lu W, 1999, VIROLOGY, V264, P134, DOI 10.1006/viro.1999.9979; Majumder M, 2001, J VIROL, V75, P1401, DOI 10.1128/JVI.75.3.1401-1407.2001; MARTIN DW, 1993, BIOCHEM BIOPH RES CO, V195, P428, DOI 10.1006/bbrc.1993.2061; Martin MED, 1998, J VIROL, V72, P3146, DOI 10.1128/JVI.72.4.3146-3154.1998; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; Moriya K, 1998, NAT MED, V4, P1065, DOI 10.1038/2053; Otsuka M, 2000, J BIOL CHEM, V275, P34122, DOI 10.1074/jbc.M000578200; Paule MR, 2000, NUCLEIC ACIDS RES, V28, P1283, DOI 10.1093/nar/28.6.1283; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; Ray RB, 2001, FEMS MICROBIOL LETT, V202, P149, DOI 10.1111/j.1574-6968.2001.tb10796.x; Ray RB, 1998, GENE, V208, P331, DOI 10.1016/S0378-1119(98)00030-4; Ray RB, 2000, VIROLOGY, V271, P197, DOI 10.1006/viro.2000.0295; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; SANG BC, 1994, ONCOGENE, V9, P853; SANTOLINI E, 1994, J VIROL, V68, P3631, DOI 10.1128/JVI.68.6.3631-3641.1994; Seeler JS, 1999, CURR OPIN GENET DEV, V9, P362, DOI 10.1016/S0959-437X(99)80054-9; Sheppard HM, 1999, MOL CELL BIOL, V19, P2746; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SHIH CM, 1993, J VIROL, V67, P5823, DOI 10.1128/JVI.67.10.5823-5832.1993; SHIH CM, 1995, J VIROL, V69, P1160, DOI 10.1128/JVI.69.2.1160-1171.1995; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; Shrivastava A, 1998, J VIROL, V72, P9722, DOI 10.1128/JVI.72.12.9722-9728.1998; TERAMOTO T, 1992, CANER RES, V54, P231; TERRIS B, 1995, CANCER RES, V55, P1590; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang F, 2000, BIOCHEM BIOPH RES CO, V273, P479, DOI 10.1006/bbrc.2000.2970; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; Yasui K, 1998, J VIROL, V72, P6048, DOI 10.1128/JVI.72.7.6048-6055.1998; You LR, 1999, J VIROL, V73, P2841, DOI 10.1128/JVI.73.4.2841-2853.1999; Zhai WG, 1997, GENE DEV, V11, P1605, DOI 10.1101/gad.11.12.1605; Zhai WG, 2000, MOL CELL BIOL, V20, P5930, DOI 10.1128/MCB.20.16.5930-5938.2000; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583	80	91	96	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2004	23	14					2472	2483		10.1038/sj.onc.1207368	http://dx.doi.org/10.1038/sj.onc.1207368			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808GQ	14968111				2022-12-28	WOS:000220558000005
J	Ohta, T; Fukuda, M				Ohta, T; Fukuda, M			Ubiquitin and breast cancer	ONCOGENE			English	Review						breast cancer; ubiquitin; RING finger	ESTROGEN-RECEPTOR-ALPHA; GROWTH-FACTOR RECEPTOR; DNA-DAMAGE RESPONSE; CELL-CYCLE; C-CBL; TUMOR-SUPPRESSOR; LIGASE ACTIVITY; PROTEIN-LIGASE; RING FINGER; DEPENDENT UBIQUITINATION	The regulation of protein stability by the ubiquitin proteasome pathway is a critical issue central to the comprehension of the molecular basis of carcinogenesis. However, ubiquitin modi. cation of target substrates signals many cellular processes other than proteolysis that are also important for the development of cancer. It is noteworthy that many proteins studied by clinical breast cancer researchers are involved in these ubiquitin pathways. This review summarizes recent works on such proteins including cyclins, CDK inhibitors, and the SCF in cell cycle control; the breast and ovarian cancer suppressor BRCA1-BARD1; ErbB2/HER2/Neu and its ubiquitin ligase c-Cbl or CHIP; and the estrogen receptor and its downstream target Efp. Understanding these pathways may provide some hints toward developing diagnostic tools and treatments for breast cancer patients.	St Marianna Univ, Sch Med, Div Breast & Endocrine Surg, Kawasaki, Kanagawa 2168511, Japan	Saint Marianna University	Ohta, T (corresponding author), St Marianna Univ, Sch Med, Div Breast & Endocrine Surg, Kawasaki, Kanagawa 2168511, Japan.	to@marianna-u.ac.jp		Ohta, Tomohiko/0000-0002-9700-7342				Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Brzovic PS, 2003, P NATL ACAD SCI USA, V100, P5646, DOI 10.1073/pnas.0836054100; Brzovic PS, 2001, NAT STRUCT BIOL, V8, P833, DOI 10.1038/nsb1001-833; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chen A, 2002, J BIOL CHEM, V277, P22085, DOI 10.1074/jbc.M201252200; Chen LC, 1998, CANCER RES, V58, P3677; Chen XA, 2001, J BIOL CHEM, V276, P48175, DOI 10.1074/jbc.M106808200; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; de Melker AA, 2001, J CELL SCI, V114, P2167; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Hsu LC, 2001, CANCER RES, V61, P7713; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Joukov V, 2001, P NATL ACAD SCI USA, V98, P12078, DOI 10.1073/pnas.211427098; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Keyomarsi K, 2002, NEW ENGL J MED, V347, P1566, DOI 10.1056/NEJMoa021153; Klapper LN, 2000, CANCER RES, V60, P3384; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Lee KB, 2002, P NATL ACAD SCI USA, V99, P4239, DOI 10.1073/pnas.072068399; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Li BH, 2003, BLOOD, V101, P1769, DOI 10.1182/blood-2002-05-1517; Li BH, 2002, MOL CELL BIOL, V22, P4997, DOI 10.1128/MCB.22.14.4997-5005.2002; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Mallery DL, 2002, EMBO J, V21, P6755, DOI 10.1093/emboj/cdf691; McCarthy EE, 2003, MOL CELL BIOL, V23, P5056, DOI 10.1128/MCB.23.14.5056-5063.2003; MCINTOSH GG, 1995, ONCOGENE, V11, P885; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; Nag A, 2001, MOL CELL BIOL, V21, P6738, DOI 10.1128/MCB.21.20.6738-6747.2001; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nawaz Z, 1999, MOL CELL BIOL, V19, P1182; NIRMALA PB, 1995, BIOCHEM BIOPH RES CO, V213, P24, DOI 10.1006/bbrc.1995.2093; NISHIKAWA H, 2003, IN PRESS J BIOL CHEM; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Orimo A, 1999, P NATL ACAD SCI USA, V96, P12027, DOI 10.1073/pnas.96.21.12027; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Pearce ST, 2003, J BIOL CHEM, V278, P7630, DOI 10.1074/jbc.M211129200; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Preisler-Mashek MT, 2002, AM J PHYSIOL-ENDOC M, V282, pE891, DOI 10.1152/ajpendo.00353.2001; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Sabbah M, 1999, P NATL ACAD SCI USA, V96, P11217, DOI 10.1073/pnas.96.20.11217; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Signoretti S, 2002, J CLIN INVEST, V110, P633, DOI 10.1172/JCI200215795; Sivaraman L, 2000, BREAST CANCER RES TR, V62, P185, DOI 10.1023/A:1006410111706; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Subramaniam V, 2003, BRIT J CANCER, V89, P1538, DOI 10.1038/sj.bjc.6601301; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tan P, 1997, CANCER RES, V57, P1259; Tang BW, 2003, J CLIN INVEST, V112, P1116, DOI 10.1172/JCI200318899; Thai TH, 1998, HUM MOL GENET, V7, P195, DOI 10.1093/hmg/7.2.195; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Trujillo KM, 1998, J BIOL CHEM, V273, P21447, DOI 10.1074/jbc.273.34.21447; Urano T, 2002, NATURE, V417, P871, DOI 10.1038/nature00826; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vandenberg CJ, 2003, MOL CELL, V12, P247, DOI 10.1016/S1097-2765(03)00281-8; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Wang Y, 2000, GENE DEV, V14, P927; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Wu-Baer F, 2003, J BIOL CHEM, V278, P34743, DOI 10.1074/jbc.C300249200; Xia Y, 2003, J BIOL CHEM, V278, P5255, DOI 10.1074/jbc.M204591200; Xu WP, 2002, P NATL ACAD SCI USA, V99, P12847, DOI 10.1073/pnas.202365899; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Yun JH, 2003, MOL CELL BIOL, V23, P7305, DOI 10.1128/MCB.23.20.7305-7314.2003; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298; Zheng L, 2000, MOL CELL, V6, P757, DOI 10.1016/S1097-2765(00)00075-7; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747; Zhout PC, 2003, J BIOL CHEM, V278, P13829, DOI 10.1074/jbc.M209640200	99	97	105	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2004	23	11					2079	2088		10.1038/sj.onc.1207371	http://dx.doi.org/10.1038/sj.onc.1207371			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	803EC	15021895				2022-12-28	WOS:000220213400012
J	Bao, SL; Lu, T; Wang, X; Zheng, HY; Wang, LE; Wei, QY; Hittelman, WN; Li, L				Bao, SL; Lu, T; Wang, X; Zheng, HY; Wang, LE; Wei, QY; Hittelman, WN; Li, L			Disruption of the Rad9/Rad1/Hus1 (9-1-1) complex leads to checkpoint signaling and replication defects	ONCOGENE			English	Article						RAD1; DNA damage; checkpoint; replication	DNA-DAMAGE RESPONSE; CELL-CYCLE; SCHIZOSACCHAROMYCES-POMBE; MOUSE HUS1; PROTEIN; RAD17; ATR; CHK1; INTERACTS; HOMOLOG	The checkpoint sliding-clamp complex, Rad9/Rad1/Hus1, plays a critical role during initiation of checkpoint signals in response to DNA damage and replication disruption. We investigated the impact of loss of Rad1 on checkpoint function and on DNA replication in mammalian cells. We show that RAD1 is an essential gene for sustained cell proliferation and that loss of Rad1 causes destabilization of Rad9 and Hus1 and consequently disintegration of the sliding-clamp - complex. In Rad1-depleted cells, Atr-dependent Chk1 activation was impaired whereas Atm-mediated Chk2 activation was unaffected, suggesting that the sliding clamp is required primarily in Atr-dependent signal activation. Disruption of sliding-clamp function also caused a major defect in S-phase control. Rad1-depleted cells exhibited an RDS phenotype, indicating that damage-induced S-phase arrest was compromised by Rad1 loss. Furthermore, lack of Rad1 also affected the efficiency of replication recovery from DNA synthesis blockage, resulting in a prolonged S phase. These deficiencies may perpetually generate DNA strand breakage as we have found chromosomal abnormalities in Rad1-depleted cells. We conclude that the Rad9/Rad1/Hus1 complex is essential for Atr-dependent checkpoint signaling, which may play critical roles in the facilitation of DNA replication and in the maintenance of genomic integrity.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Unit 66, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Chinese Acad Sci, Inst Genet & Dev Biol, Beijing 100101, Peoples R China	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Chinese Academy of Sciences; Institute of Genetics & Developmental Biology, CAS	Li, L (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Unit 66, 1515 Holcombe Blvd, Houston, TX 77030 USA.	leili@mdanderson.org			NATIONAL CANCER INSTITUTE [R01CA076172, R29CA076172, R01CA091029] Funding Source: NIH RePORTER; NCI NIH HHS [CA76172, CA91029] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bermudez VP, 2003, P NATL ACAD SCI USA, V100, P1633, DOI 10.1073/pnas.0437927100; Boddy MN, 1998, SCIENCE, V280, P909, DOI 10.1126/science.280.5365.909; Brondello JM, 1999, MOL CELL BIOL, V19, P4262; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Caspari T, 2000, MOL CELL BIOL, V20, P1254, DOI 10.1128/MCB.20.4.1254-1262.2000; Caspari T, 1999, BIOCHIMIE, V81, P173, DOI 10.1016/S0300-9084(99)80050-9; Casper AM, 2002, CELL, V111, P779, DOI 10.1016/S0092-8674(02)01113-3; Chen FQ, 1996, MUTAT RES-DNA REPAIR, V362, P9, DOI 10.1016/0921-8777(95)00026-7; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Edwards RJ, 1999, NAT CELL BIOL, V1, P393, DOI 10.1038/15623; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; GRIFFITHS DJF, 1995, EMBO J, V14, P5812, DOI 10.1002/j.1460-2075.1995.tb00269.x; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Kaur R, 2001, MOL BIOL CELL, V12, P3744, DOI 10.1091/mbc.12.12.3744; Kolodner RD, 2002, SCIENCE, V297, P552, DOI 10.1126/science.1075277; Komatsu K, 2000, ONCOGENE, V19, P5291, DOI 10.1038/sj.onc.1203901; Komatsu K, 2000, NAT CELL BIOL, V2, P1, DOI 10.1038/71316; Kondo T, 2001, SCIENCE, V294, P867, DOI 10.1126/science.1063827; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; Lindsey-Boltz LA, 2001, P NATL ACAD SCI USA, V98, P11236, DOI 10.1073/pnas.201373498; Lopes M, 2001, NATURE, V412, P557, DOI 10.1038/35087613; Martinho RG, 1998, EMBO J, V17, P7239, DOI 10.1093/emboj/17.24.7239; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Melo JA, 2001, GENE DEV, V15, P2809; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502-505; Post SM, 2003, NUCLEIC ACIDS RES, V31, P5568, DOI 10.1093/nar/gkg765; Roos-Mattjus P, 2003, J BIOL CHEM, V278, P24428, DOI 10.1074/jbc.M301544200; ROWLEY R, 1992, EMBO J, V11, P1335, DOI 10.1002/j.1460-2075.1992.tb05178.x; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Sijbers AM, 1996, CELL, V86, P811, DOI 10.1016/S0092-8674(00)80155-5; Tercero JA, 2001, NATURE, V412, P553, DOI 10.1038/35087607; Venclovas C, 2000, NUCLEIC ACIDS RES, V28, P2481, DOI 10.1093/nar/28.13.2481; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; Wang X, 2003, GENE DEV, V17, P965, DOI 10.1101/gad.1065103; Wang X, 2001, CANCER RES, V61, P7417; Weiss RS, 1999, GENOMICS, V59, P32, DOI 10.1006/geno.1999.5865; Weiss RS, 2003, MOL CELL BIOL, V23, P791, DOI 10.1128/MCB.23.3.791-803.2003; Weiss RS, 2002, CURR BIOL, V12, P73, DOI 10.1016/S0960-9822(01)00626-1; Wolkow TD, 2002, MOL BIOL CELL, V13, P480, DOI 10.1091/mbc.01-03-0104; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302	46	57	59	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5586	5593		10.1038/sj.onc.1207753	http://dx.doi.org/10.1038/sj.onc.1207753			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15184880				2022-12-28	WOS:000222629500003
J	Guo, FK; Zheng, Y				Guo, FK; Zheng, Y			Rho family GTPases cooperate with p53 deletion to promote primary mouse embryonic fibroblast cell invasion	ONCOGENE			English	Article						Rho GTPases; p53; cell migration; invasion	TUMOR-SUPPRESSOR PROTEIN; GENE-EXPRESSION; BREAST-CANCER; RAS; TRANSFORMATION; MOTILITY; GROWTH; RAC1; OVEREXPRESSION; PROLIFERATION	The Rho family GTPases Rac1, RhoA and Cdc42 function as molecular switches that transduce intracellular signals regulating multiple cell functions including gene expression, adhesion, migration and invasion. p53 and its regulator p19(Arf) on the other hand, are tumor suppressors that are critical in regulating cell cycle progression and apoptosis. Previously, we have demonstrated that the Rho proteins contribute to the cell proliferation, gene transcription and migration phenotypes unleashed by p19Arf or p53 deletion in primary mouse embryo fibroblasts (MEFs). To further investigate their functional interaction in the present study, we have examined the involvement of Rho signaling pathways in p53-mediated cell invasion. We found that in primary MEFs (1) p53 or p19(Arf) deficiency led to a marked increase in the number of focal adhesion plaques and fibronectin production, and RhoA, Rac1 and Cdc42 contribute to the p53- and p19(Arf)-mediated focal adhesion regulation, but not fibronectin synthesis; (2) although endogenous Rac1 activity was required for the p19(Arf) or p53 deficiency-induced migration phenotype, hyperactive Rho GTPases could not further enhance cell migration, rather they suppressed cell-cell adhesion of p53(-/-) MEFs; (3) expression of the active mutant of RhoA, Rac1 or Cdc42, but not Ras, promoted an invasion phenotype of p53(-/-), not p19Arf(-/-), cells; (4) although ROCK activation can partially recapitulate Rho-induced invasion phenotype, multiple pathways regulated by RhoA, in addition to ROCK, are required to fully cooperate with p53 deficiency to promote cell invasion; and (5) extracellular proteases produced by the active RhoA-transduced cells are also required for the invasion phenotype of p53(-/-) cells. Combined with our previous observations, these results strongly suggest that mitogenic activation of Rho family GTPases can cooperate with p53 deficiency to promote primary cell invasion as well as transformation and that multiple signaling components regulated by the Rho proteins are involved in these processes.	Univ Cincinnati, Childrens Hosp Res Fdn, Div Expt Hematol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati	Zheng, Y (corresponding author), Univ Cincinnati, Childrens Hosp Res Fdn, Div Expt Hematol, Cincinnati, OH 45229 USA.	yi.zheng@chmcc.org	Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074	NCI NIH HHS [CA105117] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA105117] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexandrova A, 2000, ONCOGENE, V19, P5826, DOI 10.1038/sj.onc.1203944; Aznar S, 2001, CANCER LETT, V165, P1, DOI 10.1016/S0304-3835(01)00412-8; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Boettner B, 2002, GENE, V286, P155, DOI 10.1016/S0378-1119(02)00426-2; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Comer KA, 1998, ONCOGENE, V16, P1299, DOI 10.1038/sj.onc.1201645; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Fujisawa K, 1998, J BIOL CHEM, V273, P18943, DOI 10.1074/jbc.273.30.18943; Gadea G, 2002, EMBO J, V21, P2373, DOI 10.1093/emboj/21.10.2373; Gloushankova N, 1997, ONCOGENE, V15, P2985, DOI 10.1038/sj.onc.1201483; Guo FK, 2004, MOL CELL BIOL, V24, P1426, DOI 10.1128/MCB.24.3.1426-1438.2004; Guo FK, 2003, J BIOL CHEM, V278, P14414, DOI 10.1074/jbc.M300341200; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Iotsova V, 1996, CELL GROWTH DIFFER, V7, P629; Kaibuchi K, 1999, CURR OPIN CELL BIOL, V11, P591, DOI 10.1016/S0955-0674(99)00014-9; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; Mira JP, 2000, P NATL ACAD SCI USA, V97, P185, DOI 10.1073/pnas.97.1.185; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Preudhomme C, 2000, ONCOGENE, V19, P2023, DOI 10.1038/sj.onc.1203521; Ridley AJ, 2001, J CELL SCI, V114, P2713; Sablina AA, 2003, J BIOL CHEM, V278, P27362, DOI 10.1074/jbc.M300547200; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621; Schwartz MA, 2000, TRENDS BIOCHEM SCI, V25, P388, DOI 10.1016/S0968-0004(00)01605-4; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Sun YB, 1999, J BIOL CHEM, V274, P11535, DOI 10.1074/jbc.274.17.11535; Suwa H, 1998, BRIT J CANCER, V77, P147, DOI 10.1038/bjc.1998.23; VAN AL, 1997, GENE DEV, V11, P2295; Zhao RB, 2000, GENE DEV, V14, P981; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	43	69	70	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5577	5585		10.1038/sj.onc.1207752	http://dx.doi.org/10.1038/sj.onc.1207752			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15122327				2022-12-28	WOS:000222629500002
J	Knight-Krajewski, S; Welsh, CF; Liu, YQ; Lyons, LS; Faysal, JM; Yang, ES; Burnstein, KL				Knight-Krajewski, S; Welsh, CF; Liu, YQ; Lyons, LS; Faysal, JM; Yang, ES; Burnstein, KL			Deregulation of the Rho GTPase, Rac1, suppresses cyclin-dependent kinase inhibitor p21(CIP1) levels in androgen-independent human prostate cancer cells	ONCOGENE			English	Article						Rho GTPases; Rac1; Cdc42; cyclin-dependent kinase inhibitor; p21; cell cycle	INFLAMMATORY BREAST-CANCER; ACTIVATED PROTEIN-KINASE; GROWTH-INHIBITION; TUMOR-CELLS; DNA-REPLICATION; FAMILY GTPASES; IN-VIVO; EXPRESSION; PROLIFERATION; LNCAP	Abnormally suppressed levels of cyclin-dependent kinase inhibitors (CKIs) are associated with aggressive androgen-independent prostate cancer and contribute to uncontrolled proliferation. The androgen-independent human prostate cancer cell lines, LNCaP-104R1, ALVA31 and PC-3, express low levels of the CKI, p21(CIP1), compared to the less-malignant, androgen-dependent LNCaP cells. We investigated the mechanism underlying this suppression by examining the role of Rho GTPases, signaling proteins that play important roles in cell cycle progression, at least in part through regulation of CKIs. Inhibition of Rac1 induced p21 expression in androgen-independent lines but had no effect on the higher p21 levels characteristic of LNCaP cells. This induction of p21 was functionally significant as evidenced by inhibition of cyclin-dependent kinase 2 activity and decreased cell proliferation. Conversely, overexpression of constitutively active Rac1 suppressed the higher p21 levels seen in LNCaP cells. Thus, Rac1 activity is both necessary and sufficient for suppression of p21 in prostate cancer cells. Furthermore, Rac1 Activity was significantly higher in all three androgen-independent cell lines compared to LNCaP cells. Thus in three models of aggressive human prostate cancer, hyperactivity of Rac1 corresponds to suppressed levels of p21. These results are unique in describing a role for Rac1 in p21 regulation and may implicate the Rac1 signaling pathway as a potential therapeutic target for controlling prostate cancer cell growth following progression to androgen independence.	Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA; Univ Miami, Sch Med, Dept Med, Miami, FL 33136 USA; Univ Miami, Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA	University of Miami; University of Miami; University of Miami	Burnstein, KL (corresponding author), Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, R-189,1600 NW 10th Ave, Miami, FL 33136 USA.	kburnste@miami.edu			NCI NIH HHS [CA 87668] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA087668] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aaltomaa S, 1999, PROSTATE, V39, P8; Adnane J, 1998, MOL CELL BIOL, V18, P6962, DOI 10.1128/MCB.18.12.6962; Agus DB, 1999, J NATL CANCER I, V91, P1869, DOI 10.1093/jnci/91.21.1869; AKTORIES K, 1995, TRENDS CELL BIOL, V5, P441, DOI 10.1016/S0962-8924(00)89107-2; Auer KL, 1998, BIOCHEM J, V336, P551, DOI 10.1042/bj3360551; Bao WJ, 2002, MOL CELL BIOL, V22, P4587, DOI 10.1128/MCB.22.13.4587-4597.2002; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; Chen H, 2002, GENOMICS, V79, P573, DOI 10.1006/geno.2002.6739; Cheng L, 2000, CLIN CANCER RES, V6, P1896; Cipriano SC, 1998, ONCOGENE, V17, P1549, DOI 10.1038/sj.onc.1202069; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Fizazi K, 2002, CLIN CANCER RES, V8, P775; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Ghosh PM, 1999, ONCOGENE, V18, P4120, DOI 10.1038/sj.onc.1202792; Ghosh PM, 2002, CANCER RES, V62, P2630; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Gjoerup O, 1998, J BIOL CHEM, V273, P18812, DOI 10.1074/jbc.273.30.18812; Guo YP, 1997, CLIN CANCER RES, V3, P2269; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Ingram DA, 2001, J EXP MED, V194, P57, DOI 10.1084/jem.194.1.57; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; KOKONTIS J, 1994, CANCER RES, V54, P1566; Kokontis JM, 1998, MOL ENDOCRINOL, V12, P941, DOI 10.1210/me.12.7.941; Liberto M, 2002, ONCOGENE, V21, P1590, DOI 10.1038/sj.onc.1205242; LOOP SM, 1995, PROSTATE, V26, P179, DOI 10.1002/pros.2990260403; LOOP SM, 1993, PROSTATE, V22, P93, DOI 10.1002/pros.2990220202; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; Matsushima H, 1998, HUM PATHOL, V29, P778, DOI 10.1016/S0046-8177(98)90445-2; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Mira JP, 2000, P NATL ACAD SCI USA, V97, P185, DOI 10.1073/pnas.97.1.185; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; Navone NM, 1998, CANCER METAST REV, V17, P361, DOI 10.1023/A:1006165017279; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; ORDONEZ NG, 2002, CLIN CANCER RES, V8, P775; Page K, 1999, J BIOL CHEM, V274, P22065, DOI 10.1074/jbc.274.31.22065; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Reed N, 2001, TRENDS MOL MED, V7, P157, DOI 10.1016/S1471-4914(01)01955-4; RUBIN SJ, 1991, J SURG ONCOL, V46, P31, DOI 10.1002/jso.2930460108; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SEKINE A, 1989, J BIOL CHEM, V264, P8602; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; STAHLEBACKDHAL M, 1995, AM J PATHOL, V146, P1073; TILLEY WD, 1990, CANCER RES, V50, P5382; Tsihlias J, 1999, ANNU REV MED, V50, P401; Umekita Y, 1996, P NATL ACAD SCI USA, V93, P11802, DOI 10.1073/pnas.93.21.11802; VAN AL, 1997, GENE DEV, V11, P2295; van Bokhoven A, 2001, PROSTATE, V47, P36; van Golen KL, 1999, CLIN CANCER RES, V5, P2511; van Golen KL, 2000, CANCER RES, V60, P5832; Vogt A, 1997, J BIOL CHEM, V272, P27224, DOI 10.1074/jbc.272.43.27224; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Waltregny D, 2001, MOL ENDOCRINOL, V15, P765, DOI 10.1210/me.15.5.765; Welsh CF, 2001, NAT CELL BIOL, V3, P950, DOI 10.1038/ncb1101-950; Welsh CF, 2000, BBA-REV CANCER, V1471, pM21, DOI 10.1016/S0304-419X(00)00016-0; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Yang ES, 2002, MOL CELL ENDOCRINOL, V186, P69, DOI 10.1016/S0303-7207(01)00671-2; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhuang SH, 1998, ENDOCRINOLOGY, V139, P1197, DOI 10.1210/en.139.3.1197; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	66	37	38	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2004	23	32					5513	5522		10.1038/sj.onc.1207708	http://dx.doi.org/10.1038/sj.onc.1207708			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15077174				2022-12-28	WOS:000222588400011
J	Cabart, P; Chew, HK; Murphy, S				Cabart, P; Chew, HK; Murphy, S			BRCA1 cooperates with NUFIP and P-TEFb to activate transcription by RNA polymerase II	ONCOGENE			English	Article						BRCA1; P-TEFb; NUFIP; RNA polymerase II; transcriptional activator	CARBOXYL-TERMINAL DOMAIN; DOUBLE-STRAND BREAKS; DNA-DAMAGE RESPONSE; MAJOR LATE PROMOTER; ELONGATION COMPLEXES; TATA-BOX; DEPENDENT TRANSCRIPTION; FUNCTIONAL INTERACTIONS; BINDING PROTEIN; KINASE-ACTIVITY	The tumor suppressor gene product BRCA1 is a component of the RNA polymerase II (pol II) holoenzyme that is involved, through binding to various regulatory proteins, in either activation or repression of transcription. Using a yeast two-hybrid screen, we have identified a human zinc-finger-containing protein NUFIP that interacts with BRCA1. The ubiquitous, stably expressed, nuclear protein NUFIP specifically stimulates activator-independent pol II transcription in vitro and in vivo. Immunodepletion of the endogenous NUFIP causes a marked decrease of pol II transcription, which is then shown to be restored by stable complex of ectopically produced NUFIP and associated factors. NUFIP not only interacts with BRCA1 but also associates with the positive elongation factor P-TEFb through interaction with the regulatory Cyclin T1 subunit. Cyclin T1 is required for BRCA1- and NUFIP-dependent synergistic activation of pol II transcription in 293 cells. Mutation of the zinc-finger domain abolishes the NUFIP-mediated transcriptional activation. We show that NUFIP is associated with preinitiation complexes, open transcription complexes, and elongation complexes. In addition, NUFIP facilitates ATP-dependent dissociation of hyperphosphorylated pol II from open transcription complexes in vitro.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Univ Calif Davis, Ctr Canc, Div Hematol Oncol, Sacramento, CA 95817 USA	University of Oxford; University of California System; University of California Davis	Cabart, P (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Pathol, Jack & Pearl Resnick Campus,1300 Morris Pk Ave, Bronx, NY 10461 USA.	pcabart@aecom.yu.edu		Cabart, Pavel/0000-0003-0065-367X				Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; AKOULITCHEV S, 1995, NATURE, V377, P557, DOI 10.1038/377557a0; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; ARIAS JA, 1989, J BIOL CHEM, V264, P3223; AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; Bardoni B, 1999, HUM MOL GENET, V8, P2557, DOI 10.1093/hmg/8.13.2557; Bardoni B, 2003, EXP CELL RES, V289, P95, DOI 10.1016/S0014-4827(03)00222-2; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; Cabart P, 2001, J BIOL CHEM, V276, P43056, DOI 10.1074/jbc.M108515200; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CHAMBERS RS, 1995, J BIOL CHEM, V270, P14962, DOI 10.1074/jbc.270.25.14962; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YM, 1999, J CELL PHYSIOL, V181, P385, DOI 10.1002/(SICI)1097-4652(199912)181:3<385::AID-JCP2>3.0.CO;2-4; Chen YM, 1996, CANCER RES, V56, P3168; Chiba N, 2002, CANCER RES, V62, P4222; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; DAHMUS ME, 1994, PROG NUCLEIC ACID RE, V48, P143, DOI 10.1016/S0079-6603(08)60855-7; DAHMUS ME, 1981, J BIOL CHEM, V256, P3332; Deng CX, 2000, BIOESSAYS, V22, P728; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Dvir A, 1997, P NATL ACAD SCI USA, V94, P9006, DOI 10.1073/pnas.94.17.9006; Edwards MC, 1998, MOL CELL BIOL, V18, P4291, DOI 10.1128/MCB.18.7.4291; Fu TJ, 1999, J BIOL CHEM, V274, P34527, DOI 10.1074/jbc.274.49.34527; Fujinaga K, 1999, P NATL ACAD SCI USA, V96, P1285, DOI 10.1073/pnas.96.4.1285; Gatei M, 2001, J BIOL CHEM, V276, P17276, DOI 10.1074/jbc.M011681200; Haile DT, 1999, J BIOL CHEM, V274, P2113, DOI 10.1074/jbc.274.4.2113; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; HAWLEY DK, 1987, J BIOL CHEM, V262, P3452; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; Hu YF, 1999, GENE DEV, V13, P637, DOI 10.1101/gad.13.6.637; Ivanov D, 2000, MOL CELL BIOL, V20, P2970, DOI 10.1128/MCB.20.9.2970-2983.2000; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; Kim JB, 2001, J BIOL CHEM, V276, P12317, DOI 10.1074/jbc.M010908200; Kleiman FE, 2001, CELL, V104, P743, DOI 10.1016/S0092-8674(02)07059-9; Krum SA, 2003, J BIOL CHEM, V278, P52012, DOI 10.1074/jbc.M308418200; Kugel JF, 1998, P NATL ACAD SCI USA, V95, P9232, DOI 10.1073/pnas.95.16.9232; Kugel JF, 2002, MOL CELL BIOL, V22, P762, DOI 10.1128/MCB.22.3.762-773.2002; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; Monteiro ANA, 2000, TRENDS BIOCHEM SCI, V25, P469, DOI 10.1016/S0968-0004(00)01632-7; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Murphy S, 1997, NUCLEIC ACIDS RES, V25, P2068, DOI 10.1093/nar/25.11.2068; MURPHY S, 1992, MOL CELL BIOL, V12, P3247, DOI 10.1128/MCB.12.7.3247; Narita T, 2003, MOL CELL BIOL, V23, P1863, DOI 10.1128/MCB.23.6.1863-1873.2003; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; PARVIN JD, 1994, J BIOL CHEM, V269, P18414; Parvin JD, 2001, P NATL ACAD SCI USA, V98, P5952, DOI 10.1073/pnas.121184998; Paull TT, 2001, P NATL ACAD SCI USA, V98, P6086, DOI 10.1073/pnas.111125998; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Ping YH, 1999, J BIOL CHEM, V274, P7399, DOI 10.1074/jbc.274.11.7399; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; ROHAN RM, 1987, J BIOL CHEM, V262, P8500; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; Schlegel BP, 2000, P NATL ACAD SCI USA, V97, P3148, DOI 10.1073/pnas.070452397; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Shore SM, 2003, GENE, V307, P175, DOI 10.1016/S0378-1119(03)00466-9; Somasundaram K, 1999, ONCOGENE, V18, P6605, DOI 10.1038/sj.onc.1203284; Spangler L, 2001, P NATL ACAD SCI USA, V98, P5544, DOI 10.1073/pnas.101004498; Starita LM, 2003, CURR OPIN CELL BIOL, V15, P345, DOI 10.1016/S0955-0674(03)00042-5; SZENTIRMAY MN, 1994, NUCLEIC ACIDS RES, V22, P5341, DOI 10.1093/nar/22.24.5341; Taube R, 2002, MOL CELL BIOL, V22, P321, DOI 10.1128/MCB.22.1.321-331.2002; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Venkitaraman AR, 2001, J CELL SCI, V114, P3591; Wada T, 1998, EMBO J, V17, P7395, DOI 10.1093/emboj/17.24.7395; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; Yamaguchi Y, 1999, J BIOL CHEM, V274, P8085, DOI 10.1074/jbc.274.12.8085; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Ye QN, 2001, J CELL BIOL, V155, P911, DOI 10.1083/jcb.200108049; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479; Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298; Zhong Q, 2002, J BIOL CHEM, V277, P28641, DOI 10.1074/jbc.M200748200; Zhong Q, 2002, CANCER RES, V62, P3966; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	84	20	20	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 8	2004	23	31					5316	5329		10.1038/sj.onc.1207684	http://dx.doi.org/10.1038/sj.onc.1207684			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15107825				2022-12-28	WOS:000222491600007
J	Tomida, S; Koshikawa, K; Yatabe, Y; Harano, T; Ogura, N; Mitsudomi, T; Some, M; Yanagisawa, K; Takahashi, T; Osada, H; Takahashi, T				Tomida, S; Koshikawa, K; Yatabe, Y; Harano, T; Ogura, N; Mitsudomi, T; Some, M; Yanagisawa, K; Takahashi, T; Osada, H; Takahashi, T			Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients	ONCOGENE			English	Article						lung cancer; gene expression profile; microarray; prognosis	SQUAMOUS DIFFERENTIATION MARKER; PROGNOSTIC-SIGNIFICANCE; CELL-LINES; ADENOCARCINOMA; CLASSIFICATION; TUMORS; METASTASIS; TRANSFORMATION; PROGRESSION; CARCINOMAS	Individualized outcome prediction classifiers were successfully constructed through expression pro. ling of a total of 8644 genes in 50 non-small-cell lung cancer (NSCLC) cases, which had been consecutively operated on within a defined short period of time and followed up for more than 5 years. The resultant classifier of NSCLCs yielded 82% accuracy for forecasting survival or death 5 years after surgery of a given patient. In addition, since two major histologic classes may differ in terms of outcome-related expression signatures, histologic-type-specific outcome classifiers were also constructed. The resultant highly predictive classifiers, designed specifically for nonsquamous cell carcinomas, showed a prediction accuracy of more than 90% independent of disease stage. In addition to the presence of heterogeneities in adenocarcinomas, our unsupervised hierarchical clustering analysis revealed for the first time the existence of clinicopathologically relevant subclasses of squamous cell carcinomas with marked differences in their invasive growth and prognosis. This finding clearly suggests that NSCLCs comprise distinct subclasses with considerable heterogeneities even within one histologic type. Overall, these findings should advance not only our understanding of the biology of lung cancer but also our ability to individualize postoperative therapies based on the predicted outcome.	Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr Hosp, Dept Pathol & Mol Diagnost, Nagoya, Aichi 4648681, Japan; Fuji Photo Film Co Ltd, Miyanodai Technol Dev Ctr, Kanagawa 2588538, Japan; Aichi Canc Ctr Hosp, Dept Thorac Surg, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr, Res Inst, Div Immunol, Nagoya, Aichi 4648681, Japan	Aichi Cancer Center; Aichi Cancer Center; Fujifilm Corporation; Aichi Cancer Center; Aichi Cancer Center	Takahashi, T (corresponding author), Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	tak@aichi-cc.jp	YATABE, Yasushi/J-6461-2014; Takahashi, Takashi/I-7262-2014; Yanagisawa, Kiyoshi/I-7263-2014	YATABE, Yasushi/0000-0003-1788-559X; Takahashi, Takashi/0000-0003-0615-7001; tomida, shuta/0000-0003-3786-936X; Mitsudomi, Tetsuya/0000-0001-9860-8505				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Chu PG, 2002, HISTOPATHOLOGY, V40, P403, DOI 10.1046/j.1365-2559.2002.01387.x; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Craig SW, 2003, CURR BIOL, V13, pR236, DOI 10.1016/S0960-9822(03)00160-X; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; HORIO Y, 1993, CANCER RES, V53, P1; Hu R, 1998, LUNG CANCER, V20, P25, DOI 10.1016/S0169-5002(97)00097-4; JOHNSON BE, 1987, J CLIN INVEST, V79, P1629, DOI 10.1172/JCI112999; Khan J, 2001, NAT MED, V7, P673, DOI 10.1038/89044; Kikuchi T, 2003, ONCOGENE, V22, P2192, DOI 10.1038/sj.onc.1206288; Magnaldo T, 1998, DIFFERENTIATION, V63, P159, DOI 10.1046/j.1432-0436.1998.6330159.x; Martin-Benito J, 2002, EMBO J, V21, P6377, DOI 10.1093/emboj/cdf640; Masaki T, 2003, HEPATOLOGY, V37, P534, DOI 10.1053/jhep.2003.50112; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; MINNA JD, 1997, MOL BIOL LUNG CANC, P849; Mitsudomi T, 2000, CLIN CANCER RES, V6, P4055; Osada H, 2002, ONCOGENE, V21, P7421, DOI 10.1038/sj.onc.1205802; Patterson T, 2001, ONCOGENE, V20, P634, DOI 10.1038/sj.onc.1204134; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Robert C, 1999, CLIN CANCER RES, V5, P2094; Shelton JG, 2003, ONCOGENE, V22, P2478, DOI 10.1038/sj.onc.1206321; SLEBOS RJC, 1990, NEW ENGL J MED, V323, P561, DOI 10.1056/NEJM199008303230902; Tseng GC, 2001, NUCLEIC ACIDS RES, V29, P2549, DOI 10.1093/nar/29.12.2549; VENNSTROM B, 1982, J VIROL, V42, P773, DOI 10.1128/JVI.42.3.773-779.1982; Virtanen C, 2002, P NATL ACAD SCI USA, V99, P12357, DOI 10.1073/pnas.192240599; Vuong H, 2002, AM J PHYSIOL-LUNG C, V282, pL215, DOI 10.1152/ajplung.00125.2001; Walker-Daniels J, 2003, AM J PATHOL, V162, P1037, DOI 10.1016/S0002-9440(10)63899-0; Willett CG, 1998, AM J RESP CELL MOL, V18, P489, DOI 10.1165/ajrcmb.18.4.2978; Wu WJ, 2000, NATURE, V405, P800, DOI 10.1038/35015585; Yatabe Y, 2002, AM J SURG PATHOL, V26, P767, DOI 10.1097/00000478-200206000-00010; Ye QH, 2003, NAT MED, V9, P416, DOI 10.1038/nm843	37	110	116	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2004	23	31					5360	5370		10.1038/sj.onc.1207697	http://dx.doi.org/10.1038/sj.onc.1207697			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15064725				2022-12-28	WOS:000222491600011
J	Wang, LG; Ossowski, L; Ferrari, AC				Wang, LG; Ossowski, L; Ferrari, AC			Androgen receptor level controlled by a suppressor complex lost in an androgen-independent prostate cancer cell line	ONCOGENE			English	Article						androgen receptor; suppressor element; androgen-independent prostate cancer	GENE PROMOTER; HISTONE ACETYLATION; LNCAP CELLS; EXPRESSION; TRANSCRIPTION; BINDING; PROTEIN; INHIBITION; CARCINOMA; ANTIGEN	Androgen receptor (AR) overexpression is one of the characteristics of prostate cancer ( PC) that progresses to hormone independence. An androgen-independent ( AI) derivative, with much higher AR-mRNAand protein levels than the parental LNCaP cell line, whose proliferation was androgen dependent ( AD), was used to explore the mechanism of AR overexpression. We found that a suppressor element (ARS), previously identified in mouse AR and located in the 5'-untranslated region of human AR gene, malfunctions in AI cells. Transfection of constructs that included ARS element into AD cells reduced the transactivating activities of both AR promoter and a heterologous SV40 promoter. The deletion of ARS resulted in an eightfold increase in AR-promoter activity in AD cells, but had no effect in AI cells. Moreover, the nuclear extracts of AD cells contained proteins that produced a specific, ARS-binding complex, while this complex appeared to have been lost from AI cells. Most importantly, treatment of AI cells with a demethylating agent or histone deacetylase inhibitors restored the lost ARS-binding complex. The restoration of the complex coincided with a reduced expression of AR-mRNA and protein and a reduced rate of AR-gene transcription, determined by nuclear run-on experiment. Thus, epigenetic transcriptional silencing of the suppressor protein(s) may be responsible for AR overexpression in AI cells, and its reversal in hormone-independent PC may normalize AR levels and restore their hormone dependence.	Mt Sinai Sch Med, Dept Med, Div Hematol Oncol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Ferrari, AC (corresponding author), Mt Sinai Sch Med, Dept Med, Div Hematol Oncol, Box 1129,1 Gustave Levy Pl, New York, NY 10029 USA.	Anna.Ferrari@mssm.edu			NATIONAL CANCER INSTITUTE [R01CA098135, R01CA040758] Funding Source: NIH RePORTER; NCI NIH HHS [CA9813501, CA-40758] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Banerjee PP, 2001, ENDOCRINOLOGY, V142, P4066, DOI 10.1210/en.142.9.4066; Baxevanis AD, 2002, NUCLEIC ACIDS RES, V30, P1, DOI 10.1093/nar/30.1.1; BLOK LJ, 1992, MOL CELL ENDOCRINOL, V88, P153, DOI 10.1016/0303-7207(92)90020-7; Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; BRUCHOVSKY N, 1990, CANCER RES, V50, P2275; BUETTER R, 1994, GEN BANK; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chen S, 1997, MOL ENDOCRINOL, V11, P3, DOI 10.1210/me.11.1.3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Culig Z, 1999, BRIT J CANCER, V81, P242, DOI 10.1038/sj.bjc.6690684; Culig Z, 2002, ENDOCR-RELAT CANCER, V9, P155, DOI 10.1677/erc.0.0090155; Debes JD, 2002, CANCER LETT, V187, P1, DOI 10.1016/S0304-3835(02)00413-5; DEWINTER JAR, 1994, AM J PATHOL, V144, P735; DEWINTER JAR, 1994, J HISTOCHEM CYTOCHEM, V42, P125, DOI 10.1177/42.1.8263324; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Eder IE, 2000, CANCER GENE THER, V7, P997, DOI 10.1038/sj.cgt.7700202; FABER PW, 1991, J BIOL CHEM, V266, P10743; Ferrari AC, 2001, CANCER, V91, P2039, DOI 10.1002/1097-0142(20010601)91:11<2039::AID-CNCR1230>3.0.CO;2-R; Gao M, 1999, J CELL PHYSIOL, V179, P336, DOI 10.1002/(SICI)1097-4652(199906)179:3<336::AID-JCP11>3.0.CO;2-Q; Geck P, 2000, P NATL ACAD SCI USA, V97, P10185, DOI 10.1073/pnas.97.18.10185; Gregory CW, 1998, CANCER RES, V58, P5718; GROSSMANN ME, 1995, J BIOL CHEM, V270, P10968, DOI 10.1074/jbc.270.18.10968; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; HOBISCH A, 1995, CANCER RES, V55, P3068; ISAACS JT, 1981, CANCER RES, V41, P5070; KUMAR MV, 1994, NUCLEIC ACIDS RES, V22, P3693, DOI 10.1093/nar/22.18.3693; Kumar VL, 2002, ASIAN J ANDROL, V4, P229; Latil A, 2001, CANCER RES, V61, P1919; LEO ME, 1991, J UROLOGY, V145, P802, DOI 10.1016/S0022-5347(17)38456-2; Linja MJ, 2001, CANCER RES, V61, P3550; LOIDL P, 1994, CHROMOSOMA, V103, P441; McPhaul MJ, 2002, RECENT PROG HORM RES, V57, P181, DOI 10.1210/rp.57.1.181; MIZOKAMI A, 1994, J BIOL CHEM, V269, P25655; PARTIN AW, 1990, J UROLOGY, V143, P747, DOI 10.1016/S0022-5347(17)40079-6; PETROS JA, 1993, UROL CLIN N AM, V20, P749; REIGMAN PHJ, 1989, BIOCHEM BIOPH RES CO, V159, P95, DOI 10.1016/0006-291X(89)92409-1; Song CS, 1999, MOL ENDOCRINOL, V13, P1487, DOI 10.1210/me.13.9.1487; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; SUPAKAR PC, 1995, J BIOL CHEM, V270, P837, DOI 10.1074/jbc.270.2.837; SUPAKAR PC, 1993, J BIOL CHEM, V268, P26400; Takane KK, 1996, MOL CELL ENDOCRINOL, V119, P83, DOI 10.1016/0303-7207(96)03800-2; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; Turner BM, 1998, CELL MOL LIFE SCI, V54, P21, DOI 10.1007/s000180050122; Wang LG, 2001, CANCER RES, V61, P7544; Wang LG, 1997, CANCER RES, V57, P714; WANG LG, 1994, CELL GROWTH DIFFER, V5, P1243; White RD, 1997, EUR UROL, V31, P1; YANG TH, 1994, MOL CELL BIOL, V14, P6068, DOI 10.1128/MCB.14.9.6068; Zegarra-Moro OL, 2002, CANCER RES, V62, P1008; Zhou J, 2001, CANCER METAST REV, V20, P351, DOI 10.1023/A:1015504015302	50	49	50	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2004	23	30					5175	5184		10.1038/sj.onc.1207654	http://dx.doi.org/10.1038/sj.onc.1207654			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	834AE	15156193				2022-12-28	WOS:000222382500007
J	Suzuki, H; Yagi, K; Kondo, M; Kato, M; Miyazono, K; Miyazawa, K				Suzuki, H; Yagi, K; Kondo, M; Kato, M; Miyazono, K; Miyazawa, K			c-Ski inhibits the TGF-beta signaling pathway through stabilization of inactive Smad complexes on Smad-binding elements	ONCOGENE			English	Article						Ski; Smad; TGF-beta; Smad-binding element	TGF-BETA-1 INHIBITION; MEDIATED REPRESSION; ONCOPROTEIN SKI; CELL-MEMBRANE; GROWTH; MYC; PROTEINS; PROMOTER; SNON; TRANSCRIPTION	c-Ski inhibits transforming growth factor-beta (TGF-beta) signaling through interaction with Smad proteins. c-Ski represses Smad-mediated transcriptional activation, probably through its action as a transcriptional co-repressor. c-Ski also inhibits TGF-beta-induced downregulation of genes such as c-myc. How ever, mechanisms for transcriptional regulation of target genes by c-Ski have not been fully determined. In this study, we examined how c-Ski inhibits both TGF-beta-induced transcriptional activation and repression. DNA-affinity precipitation analysis revealed that c-Ski enhances the binding of Smad2 and 4, and to a lesser extent Smad3, to both CAGA and TGF-beta1 inhibitory element probes. A c-Ski mutant, which is unable to interact with Smad4, failed to enhance the binding of Smad complex on these probes and to inhibit the Smad-responsive promoter. These results suggest that stabilization of inactive Smad complexes on DNA is a critical event in c-Ski-mediated inhibition of TGF-beta signaling.	Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Tokyo 1130033, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Toshima Ku, Tokyo 1708455, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Miyazono, K (corresponding author), Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Tokyo 1130033, Japan.	miyazono-ind@umin.ac.jp	MIYAZAWA, KEIJI/I-9713-2014					Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Liu R, 2001, CELL, V106, P309, DOI 10.1016/S0092-8674(01)00446-9; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Miyazawa K, 2002, GENES CELLS, V7, P1191, DOI 10.1046/j.1365-2443.2002.00599.x; Mizuide M, 2003, J BIOL CHEM, V278, P531, DOI 10.1074/jbc.C200596200; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nishihara A, 1999, J BIOL CHEM, V274, P28716, DOI 10.1074/jbc.274.40.28716; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; PEPPER MS, 1990, J CELL BIOL, V111, P743, DOI 10.1083/jcb.111.2.743; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; Prunier C, 2003, J BIOL CHEM, V278, P26249, DOI 10.1074/jbc.M304459200; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Stroschein SL, 2001, GENE DEV, V15, P2822; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; Suzuki H, 2001, ONCOGENE, V20, P5779, DOI 10.1038/sj.onc.1204742; Takeda M, 2004, MOL BIOL CELL, V15, P963, DOI 10.1091/mbc.E03-07-0478; Ueki N, 2003, J BIOL CHEM, V278, P32489, DOI 10.1074/jbc.C300276200; Ueki N, 2003, J BIOL CHEM, V278, P24858, DOI 10.1074/jbc.M303447200; Wu JW, 2002, CELL, V111, P357, DOI 10.1016/S0092-8674(02)01006-1; Yagi K, 2002, J BIOL CHEM, V277, P854, DOI 10.1074/jbc.M104170200; Yagi K, 1999, J BIOL CHEM, V274, P703, DOI 10.1074/jbc.274.2.703	33	95	108	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					5068	5076		10.1038/sj.onc.1207690	http://dx.doi.org/10.1038/sj.onc.1207690			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15107821				2022-12-28	WOS:000222237300013
J	Lee, J; Ahnn, J; Bae, SC				Lee, J; Ahnn, J; Bae, SC			Homologs of RUNX and CBF beta/PEBP2 beta in C-elegans	ONCOGENE			English	Article						C. elegans; RUNX; BRO-1; evolution; TGF-beta	CORE-BINDING-FACTOR; CAENORHABDITIS-ELEGANS; EGF RECEPTOR; TGF-BETA; CBL PROTOONCOGENE; TRANSCRIPTION FACTORS; SIGNAL-TRANSDUCTION; NEGATIVE REGULATOR; VULVAR DEVELOPMENT; PROTEIN PRODUCT	RUNX proteins are evolutionarily well-conserved transcription factors that are involved in essential aspects of the development of metazoan animals ranging from nematodes to humans. Geneticor epigenetic defects in any one of the three RUNX proteins in humans cause severe diseases. Although much is known about the functions and signaling pathways of the RUNX proteins through the use of mammalian systems, there are still gaps in our knowledge with regard to the functions of the RUNX proteins in normal development and disease states. Recently, the nematode Caenorhabditis elegans was revealed to bear one RUNX homolog (RNT-1) and one homolog of the RUNX protein partner CBFbeta/PEBP2beta (BRO-1). The expression patterns and biological functions of RNT-1 and the manner in which it is regulated are all comparable to what has been observed for the mammalian RUNX proteins. Thus, the nematode system is a promising model system for elucidating the functions and regulation of Runt proteins. In addition, it has recently emerged that the RNT-1 protein is involved in a transforming growth factor beta signaling pathway. The bro-1 gene encoding the CBFbeta homolog is exclusively expressed in the hypodermis, not in the intestine, which indicates that additional tissue-specific cofactors in the intestine might exist. The possible autoregulation of RNT1 expression by RNT-1/BRO-1 in the hypodermal cells is also discussed.	Yonsei Univ, Dept Biol, Natl Res Lab, Seoul 120749, South Korea; Kwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea; Chungbuk Natl Univ, Coll Med, Dept Biochem, Tumor Res Ctr, Cheongju 361763, South Korea	Yonsei University; Gwangju Institute of Science & Technology (GIST); Chungbuk National University	Lee, J (corresponding author), Yonsei Univ, Dept Biol, Natl Res Lab, 134 Shinchon, Seoul 120749, South Korea.	leej@yonsei.ac.kr						AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1995, GENE, V159, P245, DOI 10.1016/0378-1119(95)00060-J; Bae SC, 2000, GENE, V241, P255, DOI 10.1016/S0378-1119(99)00488-6; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; BRENNER S, 1974, GENETICS, V77, P71; Broome MA, 1999, ONCOGENE, V18, P2908, DOI 10.1038/sj.onc.1202873; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Coffman JA, 2003, CELL BIOL INT, V27, P315, DOI 10.1016/S1065-6995(03)00018-0; Drissi H, 2000, J CELL PHYSIOL, V184, P341, DOI 10.1002/1097-4652(200009)184:3<341::AID-JCP8>3.0.CO;2-Z; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GERGEN JP, 1985, DEV BIOL, V109, P321, DOI 10.1016/0012-1606(85)90459-2; HAN M, 1990, GENETICS, V126, P899; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; Hime GR, 1997, ONCOGENE, V14, P2709, DOI 10.1038/sj.onc.1201223; Hopper NA, 2000, MOL CELL, V6, P65, DOI 10.1016/S1097-2765(00)00008-3; Hwang SB, 2003, J MOL BIOL, V333, P237, DOI 10.1016/j.jmb.2003.08.055; Imai Y, 1998, BIOCHEM BIOPH RES CO, V252, P582, DOI 10.1006/bbrc.1998.9705; JONGEWARD GD, 1995, GENETICS, V139, P1553; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; Kataoka H, 2000, MECH DEVELOP, V98, P139, DOI 10.1016/S0925-4773(00)00445-7; Krishna S, 1999, DEVELOPMENT, V126, P251; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; Li FQ, 2004, J BIOL CHEM, V279, P2873, DOI 10.1074/jbc.M310759200; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Lupher ML, 1998, INT J BIOCHEM CELL B, V30, P439, DOI 10.1016/S1357-2725(97)00075-7; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Mao SF, 1999, MOL CELL BIOL, V19, P3635; Martensson A, 2001, EUR J IMMUNOL, V31, P3165, DOI 10.1002/1521-4141(200111)31:11<3165::AID-IMMU3165>3.0.CO;2-N; McCarthy TL, 2000, J BIOL CHEM, V275, P21746, DOI 10.1074/jbc.M002291200; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Miyake S, 1997, CRIT REV ONCOGENESIS, V8, P189, DOI 10.1615/CritRevOncog.v8.i2-3.30; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Montgomery MK, 1998, P NATL ACAD SCI USA, V95, P15502, DOI 10.1073/pnas.95.26.15502; Morita K, 2002, EMBO J, V21, P1063, DOI 10.1093/emboj/21.5.1063; Morita K, 1999, DEVELOPMENT, V126, P1337; Nam S, 2002, MOL CELL BIOL, V22, P547, DOI 10.1128/MCB.22.2.547-554.2002; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Otto F, 2003, J CELL BIOCHEM, V89, P9, DOI 10.1002/jcb.10491; Patterson GI, 2000, TRENDS GENET, V16, P27, DOI 10.1016/S0168-9525(99)01916-2; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; Smit L, 1997, CRIT REV ONCOGENESIS, V8, P359, DOI 10.1615/CritRevOncog.v8.i4.50; Suzuki Y, 1999, DEVELOPMENT, V126, P241; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; Zhang DE, 1996, MOL CELL BIOL, V16, P1231	54	21	30	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2004	23	24					4346	4352		10.1038/sj.onc.1207669	http://dx.doi.org/10.1038/sj.onc.1207669			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823BZ	15156192				2022-12-28	WOS:000221586000021
J	van Wijnen, AJ; Stein, GS; Gergen, JP; Groner, Y; Hiebert, SW; Ito, Y; Liu, P; Neil, JC; Ohki, M; Speck, N				van Wijnen, AJ; Stein, GS; Gergen, JP; Groner, Y; Hiebert, SW; Ito, Y; Liu, P; Neil, JC; Ohki, M; Speck, N			Nomenclature for Runt-related (RUNX) proteins	ONCOGENE			English	Article									Inst Mol & Cell Biol, Mol & Cell Biol & Oncol Res Inst, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Ito, Y (corresponding author), Inst Mol & Cell Biol, Mol & Cell Biol & Oncol Res Inst, 30 Med Dr, Singapore 117609, Singapore.	itoy@imcb.nus.edu.sg	van Wijnen, Andre J./AAG-3578-2019	van Wijnen, Andre J./0000-0002-4458-0946	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000030] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049069] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR049069] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))			0	91	95	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2004	23	24					4209	4210		10.1038/sj.onc.1207758	http://dx.doi.org/10.1038/sj.onc.1207758			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823BZ	15156174				2022-12-28	WOS:000221586000003
J	Vanni, C; Parodi, A; Mancini, P; Visco, V; Ottaviano, C; Torrisi, MR; Eva, A				Vanni, C; Parodi, A; Mancini, P; Visco, V; Ottaviano, C; Torrisi, MR; Eva, A			Phosphorylation-independent membrane relocalization of ezrin following association with Dbl in vivo	ONCOGENE			English	Article						ERM; Dbl oncogene; PH domain	F-ACTIN BINDING; EZRIN/RADIXIN/MOESIN ERM PROTEINS; RHO-KINASE; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; THREONINE 558; PROTO-DBL; DOMAIN; SITE; MOESIN; ACTIVATION	Ezrin, a widespread protein involved in cell migration, morphogenesis and cell adhesion, belongs to a large family of proteins known as ERM ( ezrin, radixin, moesin). These three closely related proteins are thought to function as linkers between plasma membrane and actin cytoskeleton and their function is regulated by the small GTP-binding protein Rho. It has been previously shown that the active form of radixin can bind in vitro to Dbl, a Rho-specific guanine nucleotide exchange factor, although an in vivo interaction has not yet been demonstrated. In this paper, we attempted to investigate whether ezrin can also associate with Dbl. We show here that Dbl protein can effectively bind both in vitro and in vivo to the N-terminal region ( amino acids 1 - 531) of a constitutively active mutant of ezrin and with the full-length molecule. We found that this binding is mediated by the Dbl pleckstrin homology domain, responsible for the proper subcellular localization of the Dbl protein. Moreover, we show that Dbl induces localization to the plasma membrane of both the active deletion mutant and the full-length ezrin proteins. Finally, we show that the relocalization of ezrin is independent of Dbl GEF activity. These results indicate that Dbl could induce translocation of ezrin to the plasma membrane through a mechanism that does not require ezrin C-terminus phosphorylation by Rho-associated kinases.	Ist Giannina Gaslini, Mol Biol Lab, I-16147 Genoa, Italy; Univ Roma La Sapienza, Dipartimento Med Sperimentale & Patol, I-00161 Rome, Italy	University of Genoa; IRCCS Istituto Giannina Gaslini; Sapienza University Rome	Eva, A (corresponding author), Ist Giannina Gaslini, Mol Biol Lab, Largo G Gaslini 5, I-16147 Genoa, Italy.	alessandraeva@ospedale-gaslini.ge.it	Eva, Alessandra/J-8268-2016	Eva, Alessandra/0000-0003-2949-078X; mancini, patrizia/0000-0003-0556-2056				ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; Barret C, 2000, J CELL BIOL, V151, P1067, DOI 10.1083/jcb.151.5.1067; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hamada K, 2000, EMBO J, V19, P4449, DOI 10.1093/emboj/19.17.4449; HART MJ, 1994, J BIOL CHEM, V269, P62; Hayashi K, 1999, J CELL SCI, V112, P1149; Heiska L, 1998, J BIOL CHEM, V273, P21893, DOI 10.1074/jbc.273.34.21893; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Huang LQ, 1999, J BIOL CHEM, V274, P12803, DOI 10.1074/jbc.274.18.12803; Katan M, 1999, FEBS LETT, V452, P36, DOI 10.1016/S0014-5793(99)00531-1; Mangeat P, 1999, TRENDS CELL BIOL, V9, P187, DOI 10.1016/S0962-8924(99)01544-5; Matsui T, 1999, CURR BIOL, V9, P1259, DOI 10.1016/S0960-9822(99)80508-9; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Nakamura F, 1999, MOL BIOL CELL, V10, P2669, DOI 10.1091/mbc.10.8.2669; Nakamura F, 1996, BIOCHEM BIOPH RES CO, V226, P650, DOI 10.1006/bbrc.1996.1410; Niggli V, 2001, TRENDS BIOCHEM SCI, V26, P604, DOI 10.1016/S0968-0004(01)01927-2; NIGGLI V, 1995, FEBS LETT, V376, P172, DOI 10.1016/0014-5793(95)01270-1; Oshiro N, 1998, J BIOL CHEM, V273, P34663, DOI 10.1074/jbc.273.52.34663; Quang CT, 2000, EMBO J, V19, P4565, DOI 10.1093/emboj/19.17.4565; Razzini G, 2000, J BIOL CHEM, V275, P14873, DOI 10.1074/jbc.275.20.14873; RON D, 1991, NEW BIOL, V3, P372; Russo C, 2001, J BIOL CHEM, V276, P19524, DOI 10.1074/jbc.M009742200; Shaw RJ, 1998, MOL BIOL CELL, V9, P403, DOI 10.1091/mbc.9.2.403; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Takahashi K, 1998, ONCOGENE, V16, P3279, DOI 10.1038/sj.onc.1201874; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; VAN AL, 1997, GENE DEV, V11, P2295; Vanni C, 2002, J BIOL CHEM, V277, P19745, DOI 10.1074/jbc.M111025200; Weernink PAO, 2000, J BIOL CHEM, V275, P10168, DOI 10.1074/jbc.275.14.10168; Yonemura S, 2002, J CELL SCI, V115, P2569; ZANGRILLI D, 1995, CELL TRANSFORMATION, P347; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9	34	20	21	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4098	4106		10.1038/sj.onc.1207509	http://dx.doi.org/10.1038/sj.onc.1207509			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15064738				2022-12-28	WOS:000221520200008
J	Cheng, HYY; Li, P; David, M; Smithgall, TE; Feng, LL; Lieberman, MW				Cheng, HYY; Li, P; David, M; Smithgall, TE; Feng, LL; Lieberman, MW			Arsenic inhibition of the JAK-STAT pathway	ONCOGENE			English	Article						arsenite; JAK; STAT3; SOCS; IL-6	ACTIVATED T-CELLS; SERINE PHOSPHORYLATION; PROLIFERATION; EXPRESSION; STRESS; SECRETION; APOPTOSIS; SIGNALS; LINES; IL-6	The Janus kinase (JAK)-signal transducer and activator of transcription ( STAT) pathway is an essential cascade for mediating normal functions of different cytokines in the development of the hematopoietic and immune systems. Chronic exposure to arsenic has been found to cause immunotoxicity and has been associated with the suppression of hematopoiesis ( anemia and leukopenia). Here, we report the novel finding of arsenic-mediated inactivation of the JAK-STAT signaling pathway by its direct interaction with JAK tyrosine kinase. Pretreatment with sodium arsenite strongly inhibited IL-6-inducible STAT3 tyrosine phosphorylation in HepG2 cells and did not affect its serine phosphorylation. As a result, sodium arsenite completely abolished STAT activity-dependent expression of suppressors of cytokine signaling ( SOCS). Both cellular and subcelluar experiments showed that the inhibition of JAK-STAT signaling resulted from JAK tyrosine kinase's direct interaction with arsenite, and that arsenic's suppression of JAK tyrosine kinase activity also occurred in the interferon gamma (IFNgamma) pathway. The ligand-independent inhibition by arsenic indicates that JAK was the direct target of arsenic action. Other inflammatory stimulants, stress agents, and metal cadmium failed to induce similar effects on the tyrosine phosphorylation of STAT3 as arsenic does. Our experiments also revealed that arsenic inactivation of the JAK-STAT pathway occurred independent of arsenic activation of MAP kinases. Taken together, our findings indicate that arsenic directly inhibits JAK tyrosine kinase activity and suggest that this direct interference in the JAK-STAT pathway may play a role in arsenic-associated pathogenesis.	Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Univ Calif San Diego, UCSD Canc Ctr, La Jolla, CA 92093 USA; Univ Calif San Diego, Div Biol, La Jolla, CA 92093 USA; Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15261 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; University of California System; University of California San Diego; University of California System; University of California San Diego; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Baylor College of Medicine	Lieberman, MW (corresponding author), Baylor Coll Med, Dept Pathol, 1 Baylor Olazam, Houston, TX 77030 USA.	mikel@bcm.tmc.edu			NIEHS NIH HHS [ES 10389] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010389] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AHMAD S, 1995, ARCH INSECT BIOCHEM, V29, P135, DOI 10.1002/arch.940290205; Ahmed ST, 2000, J IMMUNOL, V165, P5227, DOI 10.4049/jimmunol.165.9.5227; Aringer M, 1999, LIFE SCI, V64, P2173, DOI 10.1016/S0024-3205(98)00538-4; Barchowsky A, 1999, TOXICOL APPL PHARM, V159, P65, DOI 10.1006/taap.1999.8723; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; BURNS LA, 1993, J PHARMACOL EXP THER, V265, P150; BURNS LA, 1993, J PHARMACOL EXP THER, V265, P178; Bustamante J, 1997, TOXICOLOGY, V118, P129, DOI 10.1016/S0300-483X(96)03607-4; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; FUJITANI Y, 1994, BIOCHEM BIOPH RES CO, V202, P1181, DOI 10.1006/bbrc.1994.2053; Galicia G, 2003, INT IMMUNOPHARMACOL, V3, P671, DOI 10.1016/S1567-5769(03)00049-3; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; Haq R, 2002, J BIOL CHEM, V277, P17359, DOI 10.1074/jbc.M201842200; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Ishitsuka K, 2002, LEUKEMIA LYMPHOMA, V43, P1107, DOI 10.1080/10428190290021461; Iwamoto T, 2000, ONCOGENE, V19, P4795, DOI 10.1038/sj.onc.1203829; Kunisada K, 1998, CIRCULATION, V98, P346, DOI 10.1161/01.CIR.98.4.346; Lacronique V, 2000, BLOOD, V95, P2076, DOI 10.1182/blood.V95.6.2076; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; LOH JE, 1994, MOL CELL BIOL, V14, P2170, DOI 10.1128/MCB.14.3.2170; *NAT RES COUNC SUB, 2001, ARS DRINK WAT, P82; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; Sengupta TK, 1998, P NATL ACAD SCI USA, V95, P11107, DOI 10.1073/pnas.95.19.11107; Sengupta TK, 1996, P NATL ACAD SCI USA, V93, P9499, DOI 10.1073/pnas.93.18.9499; Vega L, 1999, IMMUNOPHARM IMMUNOT, V21, P203, DOI 10.3109/08923979909052758; WOODS JS, 1996, TOXICOLOGY METALS, P939; Yoo JY, 2002, CELL, V108, P331, DOI 10.1016/S0092-8674(02)00636-0; Yu HS, 1998, ARCH DERMATOL RES, V290, P681, DOI 10.1007/s004030050373; Zhou YJ, 2001, MOL CELL, V8, P959, DOI 10.1016/S1097-2765(01)00398-7	33	52	58	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3603	3612		10.1038/sj.onc.1207466	http://dx.doi.org/10.1038/sj.onc.1207466			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15116095	Green Published			2022-12-28	WOS:000221101700012
J	Pradeep, A; Sharma, C; Sathyanarayana, P; Albanese, C; Fleming, JV; Wang, TC; Wolfe, MM; Baker, KM; Pestell, RG; Rana, B				Pradeep, A; Sharma, C; Sathyanarayana, P; Albanese, C; Fleming, JV; Wang, TC; Wolfe, MM; Baker, KM; Pestell, RG; Rana, B			Gastrin-mediated activation of cyclin D1 transcription involves beta-catenin and CREB pathways in gastric cancer cells	ONCOGENE			English	Article						cyclin D1; Wnt signaling; transcription; gastrin (G-17); CREB	ELEMENT-BINDING PROTEIN; C-MYC; COLORECTAL-CANCER; ACID-SECRETION; KINASE PATHWAY; MOUSE MODEL; AGS CELLS; EXPRESSION; HYPERGASTRINEMIA; PHOSPHORYLATION	Gastrin and its precursors promote proliferation in different gastrointestinal cells. Since mature, amidated gastrin (G-17) can induce cyclin D1, we determined whether G-17-mediated induction of cyclin D1 transcription involved Wnt signaling and CRE-binding protein (CREB) pathways. Our studies indicate that G-17 induces protein, mRNA expression and transcription of the G(1)-specific marker cyclin D1, in the gastric adenocarcinoma cell line AGSE (expressing the gastrin/cholecystokinin B receptor). This was associated with an increase in steady-state levels of total and nonphospho beta-catenin and its nuclear translocation, indicating the activation of the Wnt-signaling pathway. In addition, G-17-mediated increase in cyclin D1 transcription was significantly attenuated by axin or dominant-negative (dn) T-cell factor 4(TCF4), suggesting crosstalk of G-17 with the Wnt-signaling pathway. Mutational analysis indicated that this effect was mediated through the cyclic AMP response element (CRE) (predominantly) and the TCF sites in the cyclin D1 promoter, which was also inhibited by dnCREB. Furthermore, G-17 stimulation resulted in increased CRE-responsive reporter activity and CREB phosphorylation, indicating an activation of CREB. Chromatin immunoprecipitation studies revealed a G-17-mediated increase in the interaction of beta-catenin with cyclin D1 CRE, which was attenuated by dnTCF4 and dnCREB. These results indicate that G-17 induces cyclin D1 transcription, via the activation of beta-catenin and CREB pathways.	Texas A&M Univ Syst Hlth Sci Ctr, Coll Med, Div Mol Cardiol, Temple, TX 76504 USA; Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Washington, DC 20057 USA; Univ Massachusetts, Sch Med, Gastrointestinal Div, Worcester, MA 01605 USA; Boston Med Ctr, Gastroenterol Sect, Boston, MA 02118 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Georgetown University; University of Massachusetts System; University of Massachusetts Worcester; Boston Medical Center	Rana, B (corresponding author), Texas A&M Univ Syst Hlth Sci Ctr, Coll Med, Div Mol Cardiol, Temple, TX 76504 USA.	brana@medicine.tamu.edu		Wang, Timothy/0000-0001-5730-3019	NATIONAL CANCER INSTITUTE [R55CA075503, R01CA086072, R01CA075503, R29CA070896, R01CA070896] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044883] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053158] Funding Source: NIH RePORTER; NCI NIH HHS [CA75503, CA70896, CA86072] Funding Source: Medline; NHLBI NIH HHS [HL54583, HL44883] Funding Source: Medline; NIA NIH HHS [AG2033] Funding Source: Medline; NIDDK NIH HHS [DK53158] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arato-Ohshima T, 1999, INT J CANCER, V83, P387, DOI 10.1002/(SICI)1097-0215(19991029)83:3<387::AID-IJC15>3.0.CO;2-O; Barthwal MK, 2003, J BIOL CHEM, V278, P3897, DOI 10.1074/jbc.M211598200; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Bierkamp C, 2002, ONCOGENE, V21, P7656, DOI 10.1038/sj.onc.1205999; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Du KY, 2000, MOL CELL BIOL, V20, P4320, DOI 10.1128/MCB.20.12.4320-4327.2000; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Hirata Y, 2001, INFECT IMMUN, V69, P3965, DOI 10.1128/IAI.69.6.3965-3971.2001; Hollande F, 2001, J BIOL CHEM, V276, P40402, DOI 10.1074/jbc.M105090200; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; Jung A, 2001, AM J PATHOL, V159, P1613, DOI 10.1016/S0002-9440(10)63007-6; Kikuchi A, 1999, CYTOKINE GROWTH F R, V10, P255, DOI 10.1016/S1359-6101(99)00017-9; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; Konturek SJ, 2000, REGUL PEPTIDES, V93, P13, DOI 10.1016/S0167-0115(00)00173-7; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; LIND T, 1988, SCAND J GASTROENTERO, V23, P1259, DOI 10.3109/00365528809090202; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Miyaji M, 1997, TUMOR BIOL, V18, P311, DOI 10.1159/000218044; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; Noble PJM, 2003, AM J PHYSIOL-GASTR L, V284, pG75, DOI 10.1152/ajpgi.00300.2002; Oda K, 1999, RES COMMUN MOL PATH, V105, P237; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Parker D, 1996, MOL CELL BIOL, V16, P694; PENMAN ID, 1993, GUT, V34, P1559, DOI 10.1136/gut.34.11.1559; Pestell RG, 1999, ENDOCR REV, V20, P501, DOI 10.1210/er.20.4.501; PINSON DM, 1995, GASTROENTEROLOGY, V108, P1068, DOI 10.1016/0016-5085(95)90204-X; Pisani P, 1999, INT J CANCER, V83, P18, DOI 10.1002/(SICI)1097-0215(19990924)83:1&lt;18::AID-IJC5&gt;3.0.CO;2-M; Qvigstad G, 2002, APMIS, V110, P132, DOI 10.1034/j.1600-0463.2002.100302.x; RANA B, 1995, J BIOL CHEM, V270, P18123, DOI 10.1074/jbc.270.30.18123; Raychowdhury R, 2002, BIOCHEM BIOPH RES CO, V297, P1089, DOI 10.1016/S0006-291X(02)02345-8; ROSS SE, 2000, SCIENCE, V0289, P00950, DOI [DOI 10.1126/SCIENCE.289.5481.950, DOI 10.1126/science.289.5481.950, 10.1126/science.289.5481.950]; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Rozengurt E, 2001, ANNU REV PHYSIOL, V63, P49, DOI 10.1146/annurev.physiol.63.1.49; SEVA C, 1994, SCIENCE, V265, P410, DOI 10.1126/science.8023165; Singh P, 2000, GASTROENTEROLOGY, V119, P162, DOI 10.1053/gast.2000.8527; SINGH US, 1995, BIOCHEMISTRY-US, V34, P15863, DOI 10.1021/bi00048a032; SMITH JTL, 1990, GUT, V31, P522, DOI 10.1136/gut.31.5.522; Song DH, 2003, AM J PHYSIOL-GASTR L, V285, pG217, DOI 10.1152/ajpgi.00516.2002; Staal FJT, 2002, EMBO REP, V3, P63, DOI 10.1093/embo-reports/kvf002; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Thommesen L, 2001, AM J PHYSIOL-ENDOC M, V281, pE1316, DOI 10.1152/ajpendo.2001.281.6.E1316; Thorburn CM, 1998, GASTROENTEROLOGY, V115, P275, DOI 10.1016/S0016-5085(98)70193-3; Varro A, 2002, GUT, V50, P827, DOI 10.1136/gut.50.6.827; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Wang TC, 1996, J CLIN INVEST, V98, P1918, DOI 10.1172/JCI118993; Wang TC, 2000, GASTROENTEROLOGY, V118, P36, DOI 10.1016/S0016-5085(00)70412-4; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; Watson SA, 2000, CANCER RES, V60, P5902; Watson SA, 2001, CANCER RES, V61, P625; Watson SA, 2001, EXPERT OPIN BIOL TH, V1, P309, DOI 10.1517/14712598.1.2.309; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; Wu GY, 2001, P NATL ACAD SCI USA, V98, P2808, DOI 10.1073/pnas.051634198; Xu LF, 2000, GENE DEV, V14, P585; Zhukova E, 2001, J CELL PHYSIOL, V189, P291, DOI 10.1002/jcp.10018	62	87	91	1	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3689	3699		10.1038/sj.onc.1207454	http://dx.doi.org/10.1038/sj.onc.1207454			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15116100				2022-12-28	WOS:000221101700021
J	Bao, BY; Hu, YC; Ting, HJ; Lee, YF				Bao, BY; Hu, YC; Ting, HJ; Lee, YF			Androgen signaling is required for the vitamin D-mediated growth inhibition in human prostate cancer cells	ONCOGENE			English	Article						vitamin D; androgen; androgen receptor; prostate cancer	9-CIS RETINOIC ACID; D-RECEPTOR EXPRESSION; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; 1,25-DIHYDROXYVITAMIN D-3; GENE-EXPRESSION; CDK INHIBITOR; LINE LNCAP; D ANALOGS; P21 GENE; DIFFERENTIATION	Epidemiological data on prostate cancer incidence has suggested that vitamin D deficiency may be a risk factor for prostate cancer. The antiproliferative activity of 1alpha, 25-dihydroxyvitamin D-3 (1,25-VD) and its analogues has been demonstrated in many prostate cancer models, yet the detailed mechanisms underlying this protective effect of vitamin D remain to be determined. Here, we demonstrate that two androgen receptor (AR)-positive prostate cancer cell lines, LNCaP and CWR22R, are more sensitive to the growth inhibitory effects of 1,25-VD compared to the AR-negative prostate cancer cell lines, PC-3 and DU 145. 1,25-VD treatment inhibited cyclin-dependent kinase 2 (cdk2) activity and induced G0/G1 arrest. Interestingly, we also found that 1,25-VD treatment induced the expression of AR, and that the onset of the G0/G1 arrest in LNCaP and CWR22R cells is correlated with the onset of increasing expression of AR. This implies that the antiproliferative actions of 1,25-VD in AR-positive prostate cancer might be mediated through AR. Furthermore, a reduction in 1,25-VD-mediated growth inhibition was observed when AR signaling was blocked by antiandrogens, AR RNA interference, or targeted disruption of AR. Taken together, our data suggest that the androgen/AR signaling plays an important role in the antiproliferative effects of 1,25-VD and restoration of androgen responsiveness by 1,25-VD might be beneficial for the treatment of hormone-refractory prostate cancer patients.	Univ Rochester, Dept Urol, Rochester, NY 14642 USA; Univ Rochester, Dept Chem Engn, Rochester, NY 14642 USA; Univ Rochester, Dept Pathol, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester	Lee, YF (corresponding author), Univ Rochester, Dept Urol, Rochester, NY 14642 USA.	yifen_lee@urmc.rochester.edu	Bao, Bo-Ying/D-1789-2012; Hu, Yueh-Chiang/AAX-2370-2020; Bao, Bo-Ying/H-4589-2019	Bao, Bo-Ying/0000-0001-5510-6513; Bao, Bo-Ying/0000-0001-5510-6513; Hu, Yueh-Chiang/0000-0002-7992-0525; Ting, Huei-Ju/0000-0003-3709-5755				BIKLE DD, 1992, ENDOCR REV, V13, P765, DOI 10.1210/er.13.4.765; Blutt SE, 1997, ENDOCRINOLOGY, V138, P1491, DOI 10.1210/en.138.4.1491; Chlenski A, 2001, PROSTATE, V47, P66; Chu YW, 1999, CYTOMETRY, V36, P333, DOI 10.1002/(SICI)1097-0320(19990801)36:4<333::AID-CYTO8>3.0.CO;2-F; Darwish Hisham, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P89; Esquenet M, 1996, PROSTATE, V28, P182, DOI 10.1002/(SICI)1097-0045(199603)28:3<182::AID-PROS5>3.0.CO;2-H; HANCHETTE CL, 1992, CANCER, V70, P2861, DOI 10.1002/1097-0142(19921215)70:12<2861::AID-CNCR2820701224>3.0.CO;2-G; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; Hedlund TE, 1996, J STEROID BIOCHEM, V58, P277, DOI 10.1016/0960-0760(96)00030-1; HENTTU P, 1992, ENDOCRINOLOGY, V130, P766, DOI 10.1210/en.130.2.766; Hofman K, 2001, BIOCHEM BIOPH RES CO, V283, P97, DOI 10.1006/bbrc.2001.4738; Inoue T, 1999, J BIOL CHEM, V274, P32309, DOI 10.1074/jbc.274.45.32309; Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Knudsen KE, 1998, J BIOL CHEM, V273, P20213, DOI 10.1074/jbc.273.32.20213; Lee MS, 2003, ONCOGENE, V22, P781, DOI 10.1038/sj.onc.1206066; LIAO J, 1990, P NATL ACAD SCI USA, V87, P9751, DOI 10.1073/pnas.87.24.9751; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Lu S, 2000, MOL ENDOCRINOL, V14, P753, DOI 10.1210/me.14.5.753; Lu S, 1999, MOL ENDOCRINOL, V13, P376, DOI 10.1210/me.13.3.376; MACDONALD PN, 1994, SEMIN NEPHROL, V14, P101; MACDONALD PN, 1993, MOL CELL BIOL, V13, P5907, DOI 10.1128/MCB.13.9.5907; MILLER GJ, 1992, CANCER RES, V52, P515; Miller GJ, 1995, CLIN CANCER RES, V1, P997; Munker R, 1996, BLOOD, V88, P2201, DOI 10.1182/blood.V88.6.2201.bloodjournal8862201; Muto A, 1999, BLOOD, V93, P2225, DOI 10.1182/blood.V93.7.2225.407a05_2225_2233; Myers RB, 1999, INT J CANCER, V82, P424, DOI 10.1002/(SICI)1097-0215(19990730)82:3<424::AID-IJC16>3.0.CO;2-B; PEEHL DM, 1994, CANCER RES, V54, P805; POLS HAP, 1990, J STEROID BIOCHEM, V37, P873, DOI 10.1016/0960-0760(90)90435-N; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; SCHWARTZ GG, 1990, ANTICANCER RES, V10, P1307; SCHWARTZ GG, 1994, ANTICANCER RES, V14, P1077; SKOWRONSKI RJ, 1993, ENDOCRINOLOGY, V132, P1952, DOI 10.1210/en.132.5.1952; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Tsihlias J, 2000, ONCOGENE, V19, P670, DOI 10.1038/sj.onc.1203369; Yang ES, 2002, MOL CELL ENDOCRINOL, V186, P69, DOI 10.1016/S0303-7207(01)00671-2; Yeh SY, 2003, J EXP MED, V198, P1899, DOI 10.1084/jem.20031233; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; Zhao XY, 2000, ENDOCRINOLOGY, V141, P2548, DOI 10.1210/en.141.7.2548; Zhao XY, 1997, ENDOCRINOLOGY, V138, P3290, DOI 10.1210/en.138.8.3290; Zhao XY, 1999, ENDOCRINOLOGY, V140, P1205, DOI 10.1210/en.140.3.1205; Zhao XY, 2000, NAT MED, V6, P703, DOI 10.1038/76287; Zhuang SH, 1998, ENDOCRINOLOGY, V139, P1197, DOI 10.1210/en.139.3.1197; Zhuang SH, 1997, MOL CELL ENDOCRINOL, V126, P83, DOI 10.1016/S0303-7207(96)03974-3	44	52	59	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3350	3360		10.1038/sj.onc.1207461	http://dx.doi.org/10.1038/sj.onc.1207461			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15048085				2022-12-28	WOS:000220975000009
J	Doan, DN; Veal, TM; Yan, ZJ; Wang, WD; Jones, SN; Imbalzano, AN				Doan, DN; Veal, TM; Yan, ZJ; Wang, WD; Jones, SN; Imbalzano, AN			Loss of the INI1 tumor suppressor does not impair the expression of multiple BRG1-dependent genes or the assembly of SWI/SNF enzymes	ONCOGENE			English	Article						INI1; BRG1; SWI/SNF; tumor suppressor; gene regulation	CHROMATIN-REMODELING COMPLEX; CELL-CYCLE ARREST; TRANSCRIPTIONAL ACTIVATORS; SACCHAROMYCES-CEREVISIAE; GLUCOCORTICOID-RECEPTOR; MUSCLE DIFFERENTIATION; MULTISUBUNIT COMPLEX; ORDERED RECRUITMENT; INTERFERON-GAMMA; BINDING PROTEIN	The INI1/hSNF5 tumor suppressor is an integral component of mammalian SWI/SNF chromatin remodeling enzymes that contain SNF2 family ATPases BRM (Brahma) or BRG1 (Brahma Related Gene 1) and that contribute to the regulation of many genes. Genetic studies of yeast SWI/SNF enzyme revealed similar phenotypes when single or multiple components of the enzyme were deleted, indicating a requirement for each subunit. To address the contribution of INI1 in the regulation of SWI/SNF-dependent genes in mammalian cells, we examined the expression of multiple BRG1-dependent, constitutively expressed genes in INI1-deficient cancer cell lines. At least one INI1-deficient line expressed each gene, and reintroduction of INI1 had negligible effects on expression levels. Lack of INI1 also did not prevent interferon gamma (IFNc)-mediated induction of CIITA, which is BRG1 dependent, and GBP-1, which is BRG1 enhanced, and reintroduction of INI1 had minimal effects. Chromatin immunoprecipitation experiments revealed that BRG1 inducibly binds to the CIITA promoter despite the absence of INI1. Unlike yeast deleted for the INI1 homologue, SWI/SNF enzymes in INI1-deficient cells were largely intact. Thus in human cells, SWI/SNF enzyme complex formation and the expression of many BRG1-dependent genes are independent of INI1.	Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; NIA, Genet Lab, NIH, Baltimore, MD 21224 USA	University of Massachusetts System; University of Massachusetts Worcester; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Imbalzano, AN (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, 55 Lake Ave N, Worcester, MA 01655 USA.	anthony.imbalzano@umassmed.edu	Wang, Weidong/AAV-2446-2021	Wang, Weidong/0000-0002-0658-7928	NATIONAL INSTITUTE ON AGING [Z01AG000650, ZIAAG000650] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adler HT, 1999, MOL CELL BIOL, V19, P7050; Ae K, 2002, ONCOGENE, V21, P3112, DOI 10.1038/sj.onc.1205414; Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Armstrong JA, 1998, CELL, V95, P93, DOI 10.1016/S0092-8674(00)81785-7; Becker PB, 2002, ANNU REV BIOCHEM, V71, P247, DOI 10.1146/annurev.biochem.71.110601.135400; Betz BL, 2002, ONCOGENE, V21, P5193, DOI 10.1038/sj.onc.1205706; Biegel JA, 2000, CLIN CANCER RES, V6, P2759; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Cosma MP, 2002, MOL CELL, V10, P227, DOI 10.1016/S1097-2765(02)00604-4; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; De la Serna IL, 2000, MOL CELL BIOL, V20, P2839, DOI 10.1128/MCB.20.8.2839-2851.2000; de la Serna IL, 2001, J BIOL CHEM, V276, P41486, DOI 10.1074/jbc.M107281200; de la Serna IL, 2001, NAT GENET, V27, P187, DOI 10.1038/84826; DeCristofaro MF, 1999, ONCOGENE, V18, P7559, DOI 10.1038/sj.onc.1203168; DiRenzo J, 2000, MOL CELL BIOL, V20, P7541, DOI 10.1128/MCB.20.20.7541-7549.2000; Fletcher TM, 2002, MOL CELL BIOL, V22, P3255, DOI 10.1128/MCB.22.10.3255-3263.2002; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Green CM, 2002, EMBO REP, V3, P28, DOI 10.1093/embo-reports/kvf005; Guidi CJ, 2001, MOL CELL BIOL, V21, P3598, DOI 10.1128/MCB.21.10.3598-3603.2001; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Kim JK, 2001, MOL CELL BIOL, V21, P7787, DOI 10.1128/MCB.21.22.7787-7795.2001; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; KRUGER W, 1995, GENE DEV, V9, P2770, DOI 10.1101/gad.9.22.2770; KRUGER W, 1991, MOL CELL BIOL, V11, P4135, DOI 10.1128/MCB.11.8.4135; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Liu R, 2001, CELL, V106, P309, DOI 10.1016/S0092-8674(01)00446-9; MUCHARDT C, 1995, NUCLEIC ACIDS RES, V23, P1127, DOI 10.1093/nar/23.7.1127; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Mudhasani R, 2002, MOL CELL BIOL, V22, P5019, DOI 10.1128/MCB.22.14.5019-5026.2002; Murphy DJ, 1999, MOL CELL BIOL, V19, P2724; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Neely KE, 1999, MOL CELL, V4, P649, DOI 10.1016/S1097-2765(00)80216-6; NEIGEBORN L, 1984, GENETICS, V108, P845; Nie ZQ, 2000, MOL CELL BIOL, V20, P8879, DOI 10.1128/MCB.20.23.8879-8888.2000; O'Neill DW, 2000, MOL CELL BIOL, V20, P7572, DOI 10.1128/MCB.20.20.7572-7582.2000; Olave I, 2002, GENE DEV, V16, P2509, DOI 10.1101/gad.992102; Papoulas O, 1998, DEVELOPMENT, V125, P3955; Pattenden SG, 2002, EMBO J, V21, P1978, DOI 10.1093/emboj/21.8.1978; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Reincke BS, 2003, J CELL PHYSIOL, V194, P303, DOI 10.1002/jcp.10201; Reyes JC, 1998, EMBO J, V17, P6979, DOI 10.1093/emboj/17.23.6979; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; Roberts CWM, 2002, CANCER CELL, V2, P415, DOI 10.1016/S1535-6108(02)00185-X; Sevenet N, 1999, AM J HUM GENET, V65, P1342, DOI 10.1086/302639; Sevenet N, 1999, HUM MOL GENET, V8, P2359, DOI 10.1093/hmg/8.13.2359; Sif S, 1998, GENE DEV, V12, P2842, DOI 10.1101/gad.12.18.2842; Sif S, 2001, GENE DEV, V15, P603, DOI 10.1101/gad.872801; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Strobeck MW, 2001, J BIOL CHEM, V276, P9273, DOI 10.1074/jbc.M009747200; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Turelli P, 2001, MOL CELL, V7, P1245, DOI 10.1016/S1097-2765(01)00255-6; Versteege I, 2002, ONCOGENE, V21, P6403, DOI 10.1038/sj.onc.1205841; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Wang S, 2002, EMBO J, V21, P3019, DOI 10.1093/emboj/cdf302; Wang WD, 1998, P NATL ACAD SCI USA, V95, P492, DOI 10.1073/pnas.95.2.492; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; Wu DY, 2002, J BIOL CHEM, V277, P27706, DOI 10.1074/jbc.M200955200; Xue YT, 2000, P NATL ACAD SCI USA, V97, P13015, DOI 10.1073/pnas.240208597; Yudkovsky N, 1999, GENE DEV, V13, P2369, DOI 10.1101/gad.13.18.2369; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zhang ZK, 2002, MOL CELL BIOL, V22, P5975, DOI 10.1128/MCB.22.16.5975-5988.2002; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	73	60	60	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3462	3473		10.1038/sj.onc.1207472	http://dx.doi.org/10.1038/sj.onc.1207472			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	14990991				2022-12-28	WOS:000220975000021
J	Yokota, N; Mainprize, TG; Taylor, MD; Kohata, T; Loreto, M; Ueda, S; Dura, W; Grajkowska, W; Kuo, JS; Rutka, JT				Yokota, N; Mainprize, TG; Taylor, MD; Kohata, T; Loreto, M; Ueda, S; Dura, W; Grajkowska, W; Kuo, JS; Rutka, JT			Identification of differentially expressed and developmentally regulated genes in medulloblastoma using suppression subtraction hybridization	ONCOGENE			English	Article						medulloblastoma; developmentally regulated gene; differentially expressed gene; subtractive suppression hybridization; cerebellum; external granule cell	PRIMITIVE NEUROECTODERMAL TUMORS; POLYMERASE-CHAIN-REACTION; RNA-BINDING PROTEIN; NERVOUS-SYSTEM; HOMEOBOX GENES; AXONAL GUIDANCE; MESSENGER-RNA; CELL FATE; BRAIN; RECEPTORS	To increase our understanding of the molecular pathogenesis of medulloblastoma (MB), we utilized the technique of suppression subtractive hybridization (SSH) to identify genes that are dysregulated in MB when compared to cerebellum. SSH-enriched cDNA libraries from both human and Ptch(+/-) heterozygous murine MBs were generated by subtracting common cDNAs from corresponding non-neoplastic cerebellum. For the human classic MB library, total human cerebellar RNA was used as control tissue; for the Ptch(+/-) heterozygous MB, non-neoplastic cerebellum from an unaffected Ptch(+/-) littermate was used as the control. Through differential screening of these libraries, over 100 upregulated tumor cDNA fragments were isolated, sequenced and identified with the NCBI BLAST program. From these, we selected genes involved in cellular proliferation, antiapoptosis, and cerebellar differentiation for further analysis. Upregulated genes identified in the human MB library included Unc33-like protein (ULIP), SOX4, Neuronatin (NNAT), the mammalian homologue of Drosophila BarH-like 1(BARHL1), the nuclear matix protein NRP/B (ENC1), and the homeobox OTX2 gene. Genes found to be upregulated in the murine MB library included cyclin D2 (Ccnd2), thymopoietin (Tmpo), Musashi-1 (Msh1), protein phosphatase 2A inhibitor-2 (I-2pp2a), and Unc5h4(D). Using semiquantitative reverse transcription-polymerase chain reaction (RT-PCR), the mRNA expression levels for these genes were markedly higher in human MBs than in cerebellum. Western blot analysis was used to further confirm the overexpression of a subset of these genes at the protein level. Notch pathway overactivity was demonstrated in the TE671 MB cell line expressing high levels of MSH1 through HES1-Luciferase transfections. This study has revealed a panel of developmentally regulated genes that may be involved in the pathogenesis of MB.	Univ Toronto, Arthur Sonia Labatt Brain Tumor Res Ctr, Toronto, ON, Canada; Univ Toronto, Div Neurosurg, Toronto, ON, Canada; Hamamatsu Univ Sch Med, Dept Neurosurg, Hamamatsu, Shizuoka 43131, Japan; Univ Warsaw, Dept Pathol, Warsaw, Poland	University of Toronto; University of Toronto; Hamamatsu University School of Medicine; University of Warsaw	Rutka, JT (corresponding author), Hosp Sick Children, Div Neurosurg, Suite 1502,555 Univ Ave, Toronto, ON M5G 1X8, Canada.	james.rutka@sickkids.ca	Kuo, John S/D-3561-2013	Kuo, John S/0000-0001-6809-4806; Taylor, Michael/0000-0001-7009-3466; Grajkowska, Wieslawa/0000-0001-8318-5781				Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Bayani J, 2000, J NEUROSURG, V93, P437, DOI 10.3171/jns.2000.93.3.0437; BONCINELLI E, 1993, J NEUROBIOL, V24, P1356, DOI 10.1002/neu.480241008; Buhren J, 2000, J NEUROPATH EXP NEUR, V59, P229; Bulfone A, 2000, HUM MOL GENET, V9, P1443, DOI 10.1093/hmg/9.9.1443; Byk T, 1996, J NEUROSCI, V16, P688; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; Cheung M, 2000, MOL BRAIN RES, V79, P180, DOI 10.1016/S0169-328X(00)00109-1; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Duman-Scheel M, 2002, NATURE, V417, P299, DOI 10.1038/417299a; FRANTZ GD, 1994, J NEUROSCI, V14, P5725; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; Hong KS, 1999, CELL, V97, P927, DOI 10.1016/S0092-8674(00)80804-1; Huard JMT, 1999, DEVELOPMENT, V126, P1927; Imai T, 2001, MOL CELL BIOL, V21, P3888, DOI 10.1128/MCB.21.12.3888-3900.2001; Ji W, 2002, BMC GENOMICS, V3, DOI 10.1186/1471-2164-3-12; Kanemura Y, 2001, DIFFERENTIATION, V68, P141, DOI 10.1046/j.1432-0436.2001.680208.x; KOZMIK Z, 1995, P NATL ACAD SCI USA, V92, P5709, DOI 10.1073/pnas.92.12.5709; LAUDET V, 1993, NUCLEIC ACIDS RES, V21, P2493, DOI 10.1093/nar/21.10.2493; Lee CJ, 2002, J NEURO-ONCOL, V57, P201, DOI 10.1023/A:1015773818302; Leonardo ED, 1997, NATURE, V386, P833, DOI 10.1038/386833a0; LI W, 1992, GENETICS, V132, P675; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Llambi F, 2001, EMBO J, V20, P2715, DOI 10.1093/emboj/20.11.2715; McGill MA, 2003, J BIOL CHEM, V278, P23196, DOI 10.1074/jbc.M302827200; Michiels EMC, 1999, PHYSIOL GENOMICS, V1, P83, DOI 10.1152/physiolgenomics.1999.1.2.83; Okano H, 2002, J CELL SCI, V115, P1355; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Ross ME, 1996, J NEUROSCI, V16, P210; Rostomily RC, 1997, CANCER RES, V57, P3526; Rubin JB, 2002, CANCER CELL, V2, P7, DOI 10.1016/S1535-6108(02)00090-9; Saito T, 1998, DEV BIOL, V199, P216, DOI 10.1006/dbio.1998.8889; Sambrook J., 1989, MOL CLONING; SIMEONE A, 1992, NATURE, V358, P687, DOI 10.1038/358687a0; Solecki DJ, 2001, NEURON, V31, P557, DOI 10.1016/S0896-6273(01)00395-6; Taylor MD, 2000, NEUROSURGERY, V47, P888, DOI 10.1097/00006123-200010000-00020; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; Vincent S, 1996, INT J ONCOL, V8, P901; Wakamatsu Y, 1999, NEURON, V23, P71, DOI 10.1016/S0896-6273(00)80754-0; Wang LH, 1996, J NEUROSCI, V16, P6197; Wechsler-Reya R, 2001, ANNU REV NEUROSCI, V24, P385, DOI 10.1146/annurev.neuro.24.1.385; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wetmore C, 2001, CANCER RES, V61, P513; Yokota N, 1996, CANCER RES, V56, P377; Yokota N, 2002, INT J CANCER, V101, P198, DOI 10.1002/ijc.10559; Yokota N, 2001, STROKE, V32, P168, DOI 10.1161/01.STR.32.1.168; Yoon JW, 2002, J BIOL CHEM, V277, P5548, DOI 10.1074/jbc.M105708200	50	126	133	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 22	2004	23	19					3444	3453		10.1038/sj.onc.1207475	http://dx.doi.org/10.1038/sj.onc.1207475			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15064731				2022-12-28	WOS:000220975000019
J	Jaattela, M				Jaattela, M			Multiple cell death pathways as regulators of tumour initiation and progression	ONCOGENE			English	Review						cancer; caspase independent; cell death; lysosome; transformation	MITOCHONDRIAL PERMEABILITY TRANSITION; NECROSIS-FACTOR-ALPHA; BREAST-CANCER CELLS; VITAMIN-D COMPOUNDS; WILD-TYPE P53; CATHEPSIN-B; C-MYC; DEPENDENT APOPTOSIS; CYTOCHROME-C; DAP KINASE	Acquired defects in signalling pathways leading to programmed cell death (PCD) are among the major hallmarks of cancer. Although focus has been on caspase-dependent apoptotic death pathways, evidence is now accumulating that nonapoptotic PCD also can form an important barrier against tumour initiation and progression. Akin to the earlier landmark discoveries that lead to the identification of the major cancer-related proteins like p53, c-Myc and Bcl-2 as controllers of spontaneous and therapy-induced apoptosis, numerous proteins with properties of tumour suppressors and oncoproteins have recently been identified as key regulators of alternative death programmes. The emerging data on the molecular mechanisms regulating nonapoptotic PCD may have potent therapeutic consequences.	Danish Canc Soc, Inst Canc Biol, Apoptosis Lab, DK-2100 Copenhagen, Denmark	Danish Cancer Society	Jaattela, M (corresponding author), Danish Canc Soc, Inst Canc Biol, Apoptosis Lab, Strandblvd 49, DK-2100 Copenhagen, Denmark.	mhj@biobase.dk	Jäättelä, Marja/AAT-7932-2021	Jäättelä, Marja/0000-0001-5950-7111				Alexander CM, 1996, J CELL BIOL, V135, P1669, DOI 10.1083/jcb.135.6.1669; Alonso M, 2003, MOL CANCER THER, V2, P139; Altairac S, 2003, CELL DEATH DIFFER, V10, P548, DOI 10.1038/sj.cdd.4401195; Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Bao JJ, 2002, CANCER RES, V62, P7264; Bidere N, 2003, J BIOL CHEM, V278, P31401, DOI 10.1074/jbc.M301911200; Boya P, 2003, J EXP MED, V197, P1323, DOI 10.1084/jem.20021952; Brunk UT, 1999, REDOX REP, V4, P3, DOI 10.1179/135100099101534675; Brunk UT, 2001, REDOX REP, V6, P91, DOI 10.1179/135100001101536094; Bursch W, 1996, CARCINOGENESIS, V17, P1595, DOI 10.1093/carcin/17.8.1595; Chan HTC, 2003, CANCER RES, V63, P5480; Charette SJ, 2001, J BIOL CHEM, V276, P36071, DOI 10.1074/jbc.C100340200; Chen G, 1997, ONCOGENE, V15, P1643, DOI 10.1038/sj.onc.1201347; Chi SJ, 1999, ONCOGENE, V18, P2281, DOI 10.1038/sj.onc.1202538; Choi WS, 2001, J NEUROCHEM, V77, P1531, DOI 10.1046/j.1471-4159.2001.00368.x; CIRMAN T, 2003, J BIOL CHEM     1027; Coultas L, 2003, SEMIN CANCER BIOL, V13, P115, DOI 10.1016/S1044-579X(02)00129-3; Creagh EM, 2000, EXP CELL RES, V257, P58, DOI 10.1006/excr.2000.4856; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Duffy MJ, 1996, CLIN CANCER RES, V2, P613; Elliott K, 2000, ONCOGENE, V19, P4669, DOI 10.1038/sj.onc.1203681; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; Foghsgaard L, 2002, J BIOL CHEM, V277, P39499, DOI 10.1074/jbc.M206669200; Forcet C, 2001, P NATL ACAD SCI USA, V98, P3416, DOI 10.1073/pnas.051378298; Frese S, 2003, J THORAC CARDIOV SUR, V126, P748, DOI 10.1016/S0022-5223(03)00703-7; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gong JG, 1999, NATURE, V399, P806; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Inbal B, 2002, J CELL BIOL, V157, P455, DOI 10.1083/jcb.200109094; Jaattela M, 2003, NAT IMMUNOL, V4, P416, DOI 10.1038/ni0503-416; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; JIN Y, 2003, J BIOL CHEM     1006; Joseph B, 2002, ONCOGENE, V21, P65, DOI 10.1038/sj/onc/1205018; Kaufmann SH, 2001, TRENDS CELL BIOL, V11, P526, DOI 10.1016/S0962-8924(01)02173-0; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kennedy NJ, 2003, GENE DEV, V17, P629, DOI 10.1101/gad.1062903; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Khwaja A, 1999, J BIOL CHEM, V274, P36817, DOI 10.1074/jbc.274.51.36817; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; Komata T, 2003, BRIT J CANCER, V88, P1277, DOI 10.1038/sj.bjc.6600862; Kothari S, 2003, ONCOGENE, V22, P4734, DOI 10.1038/sj.onc.1206666; Kubasiak LA, 2002, P NATL ACAD SCI USA, V99, P12825, DOI 10.1073/pnas.202474099; Kuopio T, 1998, CANCER RES, V58, P432; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Lamy L, 2003, J BIOL CHEM, V278, P23915, DOI 10.1074/jbc.M301869200; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Liao DJ, 2003, LAB INVEST, V83, P1437, DOI 10.1097/01.LAB.0000090153.13977.AE; Liossis SNC, 1997, J IMMUNOL, V158, P5668; Liu N, 2003, EMBO J, V22, P5313, DOI 10.1093/emboj/cdg510; Lockshin RA, 2002, CURR OPIN CELL BIOL, V14, P727, DOI 10.1016/S0955-0674(02)00383-6; Lotem J, 1996, P NATL ACAD SCI USA, V93, P12507, DOI 10.1073/pnas.93.22.12507; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Luschen S, 2000, J BIOL CHEM, V275, P24670, DOI 10.1074/jbc.M003280200; Madge LA, 2003, J BIOL CHEM, V278, P21295, DOI 10.1074/jbc.M212837200; Mateo V, 1999, NAT MED, V5, P1277, DOI 10.1038/15233; Mateo W, 2002, BLOOD, V100, P2882, DOI 10.1182/blood-2001-12-0217; Mathiasen IS, 2002, TRENDS MOL MED, V8, P212, DOI 10.1016/S1471-4914(02)02328-6; Mathiasen IS, 1999, CANCER RES, V59, P4848; Mathiasen IS, 2002, J BIOL CHEM, V277, P30738, DOI 10.1074/jbc.M201558200; Mattson MP, 2000, TRENDS NEUROSCI, V23, P222, DOI 10.1016/S0166-2236(00)01548-4; Multhoff G, 1997, J IMMUNOL, V158, P4341; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Nylandsted J, 2002, CANCER RES, V62, P7139; Nylandsted J, 2000, P NATL ACAD SCI USA, V97, P7871, DOI 10.1073/pnas.97.14.7871; Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0; Pattingre S, 2003, J BIOL CHEM, V278, P16667, DOI 10.1074/jbc.M210998200; Pettersen RD, 2001, J IMMUNOL, V166, P4931, DOI 10.4049/jimmunol.166.8.4931; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Raveh T, 2001, EXP CELL RES, V264, P185, DOI 10.1006/excr.2000.5134; Raveh T, 2001, NAT CELL BIOL, V3, P1, DOI 10.1038/35050500; Reed JC, 2001, TRENDS MOL MED, V7, P314, DOI 10.1016/S1471-4914(01)02026-3; Reggiori F, 2002, EUKARYOT CELL, V1, P11, DOI 10.1128/EC.01.1.11-21.2002; Roberg K, 2002, AM J PATHOL, V161, P89, DOI 10.1016/S0002-9440(10)64160-0; Roshy S, 2003, CANCER METAST REV, V22, P271, DOI 10.1023/A:1023007717757; Saeki K, 2000, CELL DEATH DIFFER, V7, P1263, DOI 10.1038/sj.cdd.4400759; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Scorrano L, 2001, J BIOL CHEM, V276, P12035, DOI 10.1074/jbc.M010603200; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Sperandio S, 2000, P NATL ACAD SCI USA, V97, P14376, DOI 10.1073/pnas.97.26.14376; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Tal-Or P, 2003, PROSTATE, V55, P147, DOI 10.1002/pros.10200; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Thome M, 2001, NAT REV IMMUNOL, V1, P50, DOI 10.1038/35095508; Tolkovsky AM, 2002, BIOCHIMIE, V84, P233, DOI 10.1016/S0300-9084(02)01371-8; Torriglia A, 1998, MOL CELL BIOL, V18, P3612, DOI 10.1128/MCB.18.6.3612; Turk B, 2002, BIOL CHEM, V383, P1035, DOI 10.1515/BC.2002.112; van Eijk M, 1999, J IMMUNOL, V163, P2478; Vancompernolle K, 1998, FEBS LETT, V438, P150, DOI 10.1016/S0014-5793(98)01275-7; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Von Ahsen O, 2000, CELL DEATH DIFFER, V7, P1192, DOI 10.1038/sj.cdd.4400782; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wang XC, 2002, SCIENCE, V298, P1587, DOI 10.1126/science.1076194; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wilson CA, 2002, CELL DEATH DIFFER, V9, P1321, DOI 10.1038/sj.cdd.4401107; Wu GS, 1998, ONCOGENE, V16, P2177, DOI 10.1038/sj.onc.1201755; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yanagisawa H, 2003, CELL DEATH DIFFER, V10, P798, DOI 10.1038/sj.cdd.4401246; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869; YAO XR, 1993, P NATL ACAD SCI USA, V90, P7946, DOI 10.1073/pnas.90.17.7946; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Yuan XM, 2002, P NATL ACAD SCI USA, V99, P6286, DOI 10.1073/pnas.092135599; Zang Y, 2001, CELL DEATH DIFFER, V8, P477, DOI 10.1038/sj.cdd.4400843; Zanke BW, 1998, CANCER RES, V58, P2801; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681	131	242	264	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2004	23	16					2746	2756		10.1038/sj.onc.1207513	http://dx.doi.org/10.1038/sj.onc.1207513			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	811VO	15077138				2022-12-28	WOS:000220799600002
J	Neben, K; Tews, B; Wrobel, G; Hahn, M; Kokocinski, F; Giesecke, C; Krause, U; Ho, AD; Kramer, A; Lichter, P				Neben, K; Tews, B; Wrobel, G; Hahn, M; Kokocinski, F; Giesecke, C; Krause, U; Ho, AD; Kramer, A; Lichter, P			Gene expression patterns in acute myeloid leukemia correlate with centrosome aberrations and numerical chromosome changes	ONCOGENE			English	Article						centrosome aberrations; aneuploidy; numerical chromosome changes; acute myeloid leukemia	CHRONIC LYMPHOCYTIC-LEUKEMIA; CELL-CYCLE; INSTABILITY; CANCER; PATHWAYS; DISTINCT; REVEALS	Centrosomes, which mediate accurate chromosome segregation during mitosis, undergo duplication precisely once per cell division at the G(1)/S boundary. Recently, we described centrosome aberrations as a possible cause of aneuploidy in acute myeloid leukemia (AML) and found a correlation of the percentage of cells carrying abnormal centrosomes to their cytogenetic risk pro. le. To elucidate the molecular events responsible for the development of centrosome aberrations in AML, tumor RNA of 29 AML samples was hybridized to cDNA microarrays. The microarrays comprised some 2800 different genes with relevance to hematopoiesis, tumorigenesis and mitosis and included a set of 359 centrosome-associated genes. We identified two gene expression signatures, which allowed an accurate classification according to the extent of centrosome aberrations and the ploidy status in 28 of 29 patients each. Specifically, 18 genes were present in both signatures, including genes that code for cell cycle regulatory proteins (cyclin A2, cyclin D3, cyclin H, CDK6, p18(INK4c), p21(Cip1), PAK1) and centrosome-associated proteins ( pericentrin, alpha2-tubulin, NUMA1, TUBGCP2, PRKAR2A). In conclusion, the high expression of centrosome-associated genes matches the description of centrosome aberrations in several tumor types. Moreover, in AML the identification of G(1)/S-phase stimulatory genes suggests that one mechanism of aneuploidy induction might be the deregulation of centrosome replication at the G(1)/S boundary.	Deutsch Krebsforschungszentrum, Div Mol Genet B060, D-69120 Heidelberg, Germany; Heidelberg Univ, Med Klin & Poliklin 5, D-69115 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg	Lichter, P (corresponding author), Deutsch Krebsforschungszentrum, Div Mol Genet B060, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	m.macleod@dkfz.de		Kokocinski, Felix/0000-0002-8472-9207				Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Chen QH, 2003, ONCOGENE, V22, P992, DOI 10.1038/sj.onc.1206193; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Debernardi S, 2003, GENE CHROMOSOME CANC, V37, P149, DOI 10.1002/gcc.10198; Dictenberg JB, 1998, J CELL BIOL, V141, P163, DOI 10.1083/jcb.141.1.163; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Huber Wolfgang, 2002, Bioinformatics, V18 Suppl 1, pS96; Korshunov A, 2003, AM J PATHOL, V163, P1721, DOI 10.1016/S0002-9440(10)63530-4; Korz C, 2002, BLOOD, V99, P4554, DOI 10.1182/blood.V99.12.4554; Kramer A, 2002, LEUKEMIA, V16, P767, DOI 10.1038/sj.leu.2402454; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Marx J, 2001, SCIENCE, V292, P426, DOI 10.1126/science.292.5516.426; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Merdes A, 1997, J CELL BIOL, V138, P953, DOI 10.1083/jcb.138.5.953; Neben K, 2003, BLOOD, V101, P289, DOI 10.1182/blood-2002-04-1188; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pihan GA, 2001, CANCER RES, V61, P2212; Schoch C, 2002, P NATL ACAD SCI USA, V99, P10008, DOI 10.1073/pnas.142103599; Stratowa C, 2001, INT J CANCER, V91, P474, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1078>3.0.CO;2-C; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299; Virtaneva K, 2001, P NATL ACAD SCI USA, V98, P1124, DOI 10.1073/pnas.98.3.1124; Waters JC, 1997, CURR OPIN CELL BIOL, V9, P37, DOI 10.1016/S0955-0674(97)80149-4; Wrobel G, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng067; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	28	46	61	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2004	23	13					2379	2384		10.1038/sj.onc.1207401	http://dx.doi.org/10.1038/sj.onc.1207401			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806IN	14767474				2022-12-28	WOS:000220427700012
J	Ingham, RJ; Gish, G; Pawson, T				Ingham, RJ; Gish, G; Pawson, T			The Nedd4 family of E3 ubiquitin ligases: functional diversity within a common modular architecture	ONCOGENE			English	Review						ubiquitination; Nedd4; E3 ubiquitin ligase; HECT; WW; C2	EPITHELIAL NA+ CHANNEL; EPSTEIN-BARR-VIRUS; TRANSFORMING-GROWTH-FACTOR; VESICULAR STOMATITIS-VIRUS; CONSERVED DOMAIN ALIGNMENTS; EXCHANGE FACTOR CNRASGEF; YES-ASSOCIATED PROTEIN; PROLINE-RICH LIGANDS; AMINO-ACID PERMEASE; TGF-BETA RECEPTOR	Neuronal precursor cell-expressed developmentally downregulated 4 (Nedd4) is the prototypical protein in a family of E3 ubiquitin ligases that have a common domain architecture. They are comprised of a catalytic C-terminal HECT domain and N-terminal C2 domain and WW domains responsible for cellular localization and substrate recognition. These proteins are found throughout eukaryotes and regulate diverse biological processes through the targeted degradation of proteins that generally have a PPxY motif for WW domain recognition, and are found in the nucleus and at the plasma membrane. Whereas the yeast Saccharomyces cerevisiae uses a single protein, Rsp5p, to carry out these functions, evolution has provided higher eukaryotes with several related Nedd4 proteins that appear to have specialized roles. In this review we discuss how knowledge of individual domain function has provided insight into the physiological roles of the Nedd4 proteins and describe recent results that suggest discrete functions for individual family members.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Ingham, RJ (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.	ingham@mshri.on.ca	Pawson, Tony J/E-4578-2013; Gish, Gerald D/C-7228-2017					Abriel H, 1999, J CLIN INVEST, V103, P667, DOI 10.1172/JCI5713; Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Asher C, 2003, BBA-BIOMEMBRANES, V1612, P59, DOI 10.1016/S0005-2736(03)00083-X; Asher C, 2001, BIOCHEM BIOPH RES CO, V286, P1228, DOI 10.1006/bbrc.2001.5508; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Bedford MT, 2000, J BIOL CHEM, V275, P10359, DOI 10.1074/jbc.275.14.10359; Bedford MT, 1998, P NATL ACAD SCI USA, V95, P10602, DOI 10.1073/pnas.95.18.10602; Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; Boehmer C, 2003, BIOCHEM BIOPH RES CO, V306, P156, DOI 10.1016/S0006-291X(03)00921-5; Boname JM, 2001, IMMUNITY, V15, P627, DOI 10.1016/S1074-7613(01)00213-8; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; BOTEROVELEZ M, 1994, NEW ENGL J MED, V330, P178, DOI 10.1056/NEJM199401203300305; BURKHARDT AL, 1992, J VIROL, V66, P5161, DOI 10.1128/JVI.66.8.5161-5167.1992; Caldwell RG, 2000, J VIROL, V74, P1101, DOI 10.1128/JVI.74.3.1101-1113.2000; Caldwell RG, 1998, IMMUNITY, V9, P405, DOI 10.1016/S1074-7613(00)80623-8; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; Chan NL, 2001, NAT STRUCT BIOL, V8, P650, DOI 10.1038/90337; Chen HI, 1997, J BIOL CHEM, V272, P17070, DOI 10.1074/jbc.272.27.17070; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Chen HM, 2001, EUR J HUM GENET, V9, P922, DOI 10.1038/sj.ejhg.5200747; Chen SY, 1999, P NATL ACAD SCI USA, V96, P2514, DOI 10.1073/pnas.96.5.2514; Cornell M, 1999, GENETICS, V152, P567; Coscoy L, 2001, J CELL BIOL, V155, P1265, DOI 10.1083/jcb.200111010; Courbard JR, 2002, J BIOL CHEM, V277, P45267, DOI 10.1074/jbc.M206460200; Craven RC, 1999, J VIROL, V73, P3359, DOI 10.1128/JVI.73.4.3359-3365.1999; de la Rosa DA, 1999, J BIOL CHEM, V274, P37834, DOI 10.1074/jbc.274.53.37834; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; Di Fiore PP, 2003, NAT REV MOL CELL BIO, V4, P491, DOI 10.1038/nrm1124; Dunn DM, 2002, J HUM GENET, V47, P665, DOI 10.1007/s100380200102; Dunn R, 2001, J BIOL CHEM, V276, P25974, DOI 10.1074/jbc.M104113200; Dunn R, 2001, MOL BIOL CELL, V12, P421, DOI 10.1091/mbc.12.2.421; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Essen LO, 1997, BIOCHEMISTRY-US, V36, P2753, DOI 10.1021/bi962466t; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; FIEDLER K, 1995, J CELL BIOL, V128, P1043, DOI 10.1083/jcb.128.6.1043; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Fisk HA, 1999, J CELL BIOL, V145, P1199, DOI 10.1083/jcb.145.6.1199; Flasza M, 2002, BIOCHEM BIOPH RES CO, V290, P431, DOI 10.1006/bbrc.2001.6206; Fostier M, 1998, GENETICS, V150, P1477; Fotia AB, 2002, FASEB J, V16, P70, DOI 10.1096/fj.02-0497fje; Fruehling S, 1998, J VIROL, V72, P7796, DOI 10.1128/JVI.72.10.7796-7806.1998; Fruehling S, 1997, VIROLOGY, V235, P241, DOI 10.1006/viro.1997.8690; Gajewska B, 2001, GENETICS, V157, P91; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; Galan JM, 1996, J BIOL CHEM, V271, P10946, DOI 10.1074/jbc.271.18.10946; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Gold MR, 2002, TRENDS PHARMACOL SCI, V23, P316, DOI 10.1016/S0165-6147(02)02045-X; Goulet CC, 1998, J BIOL CHEM, V273, P30012, DOI 10.1074/jbc.273.45.30012; Grobler JA, 1996, NAT STRUCT BIOL, V3, P788, DOI 10.1038/nsb0996-788; Hamilton MH, 2001, J BIOL CHEM, V276, P26324, DOI 10.1074/jbc.M101205200; Harty RN, 2000, P NATL ACAD SCI USA, V97, P13871, DOI 10.1073/pnas.250277297; Harty RN, 1999, J VIROL, V73, P2921, DOI 10.1128/JVI.73.4.2921-2929.1999; Harty RN, 2001, J VIROL, V75, P10623, DOI 10.1128/JVI.75.22.10623-10629.2001; Harvey KF, 1999, TRENDS CELL BIOL, V9, P166, DOI 10.1016/S0962-8924(99)01541-X; Harvey KF, 2001, J BIOL CHEM, V276, P8597, DOI 10.1074/jbc.C000906200; Harvey KF, 1999, J BIOL CHEM, V274, P12525, DOI 10.1074/jbc.274.18.12525; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; HEIN C, 1995, MOL MICROBIOL, V18, P77, DOI 10.1111/j.1365-2958.1995.mmi_18010077.x; Helliwell SB, 2001, J CELL BIOL, V153, P649, DOI 10.1083/jcb.153.4.649; Henry PC, 2003, J BIOL CHEM, V278, P20019, DOI 10.1074/jbc.M211153200; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hicke L, 2001, CELL, V106, P527, DOI 10.1016/S0092-8674(01)00485-8; Hicke L, 1998, J CELL BIOL, V141, P349, DOI 10.1083/jcb.141.2.349; Huang K, 2000, GENE, V252, P137, DOI 10.1016/S0378-1119(00)00216-X; Huang L, 1999, SCIENCE, V286, P1321, DOI 10.1126/science.286.5443.1321; Huang X, 2000, NAT STRUCT BIOL, V7, P634, DOI 10.1038/77923; Huibregtse JM, 1997, P NATL ACAD SCI USA, V94, P3656, DOI 10.1073/pnas.94.8.3656; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; HUSTAD CM, 1995, GENETICS, V140, P255; Ikeda M, 2000, VIROLOGY, V268, P178, DOI 10.1006/viro.1999.0166; Ikeda M, 2002, VIROLOGY, V300, P153, DOI 10.1006/viro.2002.1562; Ikeda M, 2001, J VIROL, V75, P5711, DOI 10.1128/JVI.75.12.5711-5718.2001; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Itani OA, 2003, AM J PHYSIOL-RENAL, V285, pF916, DOI 10.1152/ajprenal.00203.2003; Jayakar HR, 2000, J VIROL, V74, P9818, DOI 10.1128/JVI.74.21.9818-9827.2000; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Jiang YH, 1999, AM J HUM GENET, V65, P1, DOI 10.1086/302473; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Jolliffe CN, 2000, BIOCHEM J, V351, P557, DOI 10.1042/0264-6021:3510557; Kamynina E, 2001, AM J PHYSIOL-RENAL, V281, pF469, DOI 10.1152/ajprenal.2001.281.3.F469; Kanelis V, 2001, NAT STRUCT BIOL, V8, P407, DOI 10.1038/87562; Kanelis V, 1998, BIOCHEM CELL BIOL, V76, P341, DOI 10.1139/bcb-76-2-3-341; Kasanov J, 2001, CHEM BIOL, V8, P231, DOI 10.1016/S1074-5521(01)00005-9; Katz M, 2002, TRAFFIC, V3, P740, DOI 10.1034/j.1600-0854.2002.31006.x; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kikonyogo A, 2001, P NATL ACAD SCI USA, V98, P11199, DOI 10.1073/pnas.201268998; Kishino T, 1997, NAT GENET, V15, P70, DOI 10.1038/ng0197-70; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; Kumar S, 1997, J BIOL CHEM, V272, P13548, DOI 10.1074/jbc.272.21.13548; Kurosaki T, 2002, CURR OPIN IMMUNOL, V14, P341, DOI 10.1016/S0952-7915(02)00344-8; Lafont F, 1998, J CELL BIOL, V142, P1413, DOI 10.1083/jcb.142.6.1413; Lecat S, 2000, J CELL SCI, V113, P2607; LIDDLE GW, 1963, T ASSOC AM PHYSICIAN, V76, P199; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Lott JS, 2002, BIOCHEM J, V361, P481, DOI 10.1042/0264-6021:3610481; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Lu ZM, 2002, MOL CELL, V9, P945, DOI 10.1016/S1097-2765(02)00519-1; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Macias MJ, 2002, FEBS LETT, V513, P30, DOI 10.1016/S0014-5793(01)03290-2; Magasanik B, 2002, GENE, V290, P1, DOI 10.1016/S0378-1119(02)00558-9; Marchler-Bauer A, 2003, NUCLEIC ACIDS RES, V31, P383, DOI 10.1093/nar/gkg087; Marchler-Bauer A, 2002, NUCLEIC ACIDS RES, V30, P281, DOI 10.1093/nar/30.1.281; Martin-Serrano J, 2001, NAT MED, V7, P1313, DOI 10.1038/nm1201-1313; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, GENE DEV, V14, P627; McDonald FJ, 2002, AM J PHYSIOL-RENAL, V283, pF431, DOI 10.1152/ajprenal.00080.2002; MILLER CL, 1995, IMMUNITY, V2, P155, DOI 10.1016/S1074-7613(95)80040-9; MILLER CL, 1994, P NATL ACAD SCI USA, V91, P772, DOI 10.1073/pnas.91.2.772; Miyazono K, 2000, CYTOKINE GROWTH F R, V11, P15, DOI 10.1016/S1359-6101(99)00025-8; Morrione A, 1999, J BIOL CHEM, V274, P24094, DOI 10.1074/jbc.274.34.24094; Murillas R, 2002, J BIOL CHEM, V277, P2897, DOI 10.1074/jbc.M110047200; Myat A, 2002, NEURON, V35, P447, DOI 10.1016/S0896-6273(02)00795-X; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Naray-Fejes-Toth A, 1999, J BIOL CHEM, V274, P16973, DOI 10.1074/jbc.274.24.16973; Nefsky B, 1996, EMBO J, V15, P1301, DOI 10.1002/j.1460-2075.1996.tb00472.x; Otte L, 2003, PROTEIN SCI, V12, P491, DOI 10.1110/ps.0233203; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; Perry WL, 1998, NAT GENET, V18, P143, DOI 10.1038/ng0298-143; Pham N, 2000, CURR BIOL, V10, P555, DOI 10.1016/S0960-9822(00)00473-5; Pham N, 2001, J BIOL CHEM, V276, P46995, DOI 10.1074/jbc.M108373200; Pires JR, 2001, J MOL BIOL, V314, P1147, DOI 10.1006/jmbi.2000.5199; Plant PJ, 1997, J BIOL CHEM, V272, P32329, DOI 10.1074/jbc.272.51.32329; Plant PJ, 2000, J CELL BIOL, V149, P1473, DOI 10.1083/jcb.149.7.1473; Podos SD, 2001, DEV CELL, V1, P567, DOI 10.1016/S1534-5807(01)00057-0; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Ponting CP, 1996, PROTEIN SCI, V5, P162; Pornillos O, 2002, EMBO J, V21, P2397, DOI 10.1093/emboj/21.10.2397; PUTTERMAN D, 1990, VIROLOGY, V176, P633, DOI 10.1016/0042-6822(90)90035-P; Qiu L, 2000, J BIOL CHEM, V275, P35734, DOI 10.1074/jbc.M007300200; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Robertson JW, 1997, ASTR SOC P, V137, P469; Rossier BC, 2002, ANNU REV PHYSIOL, V64, P877, DOI 10.1146/annurev.physiol.64.082101.143243; Rotin D, 2000, J MEMBRANE BIOL, V176, P1; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; Schwarz SE, 1998, J BIOL CHEM, V273, P12148, DOI 10.1074/jbc.273.20.12148; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; Shi HK, 2002, EUR J BIOCHEM, V269, P4551, DOI 10.1046/j.1432-1033.2002.03154.x; Shi HK, 2002, J BIOL CHEM, V277, P13539, DOI 10.1074/jbc.M111717200; Shih SC, 2000, EMBO J, V19, P187, DOI 10.1093/emboj/19.2.187; Snyder PM, 2002, J BIOL CHEM, V277, P5, DOI 10.1074/jbc.C100623200; Snyder PM, 2001, J BIOL CHEM, V276, P28321, DOI 10.1074/jbc.M011487200; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Soetens O, 2001, J BIOL CHEM, V276, P43949, DOI 10.1074/jbc.M102945200; Springael JY, 1999, BIOCHEM BIOPH RES CO, V257, P561, DOI 10.1006/bbrc.1999.0505; Springael JY, 1998, MOL BIOL CELL, V9, P1253, DOI 10.1091/mbc.9.6.1253; Springael JY, 1999, J CELL SCI, V112, P1375; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Strack B, 2000, P NATL ACAD SCI USA, V97, P13063, DOI 10.1073/pnas.97.24.13063; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; Suzuki C, 2002, J BIOL CHEM, V277, P39919, DOI 10.1074/jbc.M201901200; Tajima Y, 2003, J BIOL CHEM, V278, P10716, DOI 10.1074/jbc.M212663200; TAKADA K, 1984, INT J CANCER, V33, P27, DOI 10.1002/ijc.2910330106; Tamai KK, 2002, J CELL SCI, V115, P1847; Terrell J, 1998, MOL CELL, V1, P193, DOI 10.1016/S1097-2765(00)80020-9; Timmins J, 2003, J MOL BIOL, V326, P493, DOI 10.1016/S0022-2836(02)01406-7; Traweger A, 2002, J BIOL CHEM, V277, P10201, DOI 10.1074/jbc.M111384200; Van Sant C, 2001, P NATL ACAD SCI USA, V98, P8815, DOI 10.1073/pnas.161283098; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; Vecchione A, 2003, MOL CELL BIOL, V23, P3363, DOI 10.1128/MCB.23.9.3363-3372.2003; Verdecia MA, 2003, MOL CELL, V11, P249, DOI 10.1016/S1097-2765(02)00774-8; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P639, DOI 10.1038/77929; VerPlank L, 2001, P NATL ACAD SCI USA, V98, P7724, DOI 10.1073/pnas.131059198; Verrey F., 2000, KIDNEY PHYSL PATHOPH, P1441; Wang GL, 1999, MOL CELL BIOL, V19, P342; Wang GL, 2001, MOL CELL BIOL, V21, P3564, DOI 10.1128/MCB.21.10.3564-3575.2001; WEBSTER MK, 1993, MOL CELL BIOL, V13, P2031, DOI 10.1128/MCB.13.4.2031; Winberg G, 2000, MOL CELL BIOL, V20, P8526, DOI 10.1128/MCB.20.22.8526-8535.2000; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Yashiroda H, 1998, GENE, V225, P39, DOI 10.1016/S0378-1119(98)00535-6; Yashiroda H, 1996, MOL CELL BIOL, V16, P3255; Yasuda J, 1998, J VIROL, V72, P4095, DOI 10.1128/JVI.72.5.4095-4103.1998; Yasuda J, 2002, EMBO REP, V3, P636, DOI 10.1093/embo-reports/kvf132; You JX, 2001, J BIOL CHEM, V276, P19871, DOI 10.1074/jbc.M100034200; Yuan B, 1999, EMBO J, V18, P4700, DOI 10.1093/emboj/18.17.4700; Zarrinpar A, 2000, NAT STRUCT BIOL, V7, P611, DOI 10.1038/77891; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	197	377	390	2	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2004	23	11					1972	1984		10.1038/sj.onc.1207436	http://dx.doi.org/10.1038/sj.onc.1207436			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	803EC	15021885				2022-12-28	WOS:000220213400002
J	Lai, JP; Chien, J; Strome, SE; Staub, J; Montoya, DP; Greene, EL; Smith, DI; Roberts, LR; Shridhar, V				Lai, JP; Chien, J; Strome, SE; Staub, J; Montoya, DP; Greene, EL; Smith, DI; Roberts, LR; Shridhar, V			HSulf-1 modulates HGF-mediated tumor cell invasion and signaling in head and neck squamous carcinoma	ONCOGENE			English	Article						head and neck squamous carcinoma; heparin-binding; growth factors; heparan sulfate glycosaminoglycans; hepatocyte growth factor; apoptosis; tumor cell invasion	HEPATOCYTE GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; LYMPH-NODE METASTASES; HEPARAN-SULFATE; BINDING; EXPRESSION; RECEPTOR; PHOSPHORYLATION; PROLIFERATION; MIGRATION	Recently, we cloned a novel sulfatase domain-containing downregulated gene, HSulf-1, which modulates heparin-binding growth factor signaling in ovarian cancer. Based on the pilot data showing the loss of HSulf-1 in head and neck squamous cell carcinoma cell lines (SCCHN), we sought to employ SCCHN as a model to de. ne the role of HSulf-1 in the molecular regulation of tumorigenecity. Three SCCHN lines (012SCC, WMMSCC, and 015SCC) had no detectable HSulf-1 mRNA. Clonal lines of HSulf-1-expressing 012SCC attenuated the activation of ERK/mitogen-activated protein kinase ( MAPK) signaling mediated by fibroblast growth factor (FGF-2) and both ERK/MAPK and Akt signaling mediated by hepatocyte growth factor (HGF). Consistent with this downregulation, phosphorylation of HGF receptor, c-Met, which is frequently overexpressed in SCCHN, was also attenuated in HSulf-1 clonal 012SCC cell lines. HGF markedly enhanced the motility and migration of vector-transfected cells in a transwell invasion chamber. However, HGF-mediated motility and invasion was attenuated in HSulf-1 clonal 012SCC cell lines. In addition, transfected cells displayed significant growth inhibition concomitant with a decrease in mitogenecity, as measured by thymidine incorporation and increased sensitivity to staurosporine- and cisplatin-induced apoptosis. The se data suggest that HSulf-1 normally functions as a negative regulator in cell growth and loss of HSulf-1 in SCCHN potentiates growth factor signaling, enhances motility, invasiveness and inhibits stress-induced apoptosis, with a resulting increase in tumorigenecity.	Mayo Clin & Mayo Fdn, Mayo Clin Canc Ctr, Dept Expt Pathol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Clin Canc Ctr, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA; Cent S Univ, Xiang Ya Sch Med, Xiangya Hosp, Dept Otolaryngol, Changsha 410008, Hunan, Peoples R China; Mayo Clin & Mayo Fdn, Mayo Clin Canc Ctr, Dept Otorhinolaryngol Head & Neck Surg, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Clin Canc Ctr, Div Nephrol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Central South University; Mayo Clinic; Mayo Clinic	Shridhar, V (corresponding author), Mayo Clin & Mayo Fdn, Mayo Clin Canc Ctr, Dept Expt Pathol, 200 1st St SW, Rochester, MN 55905 USA.	roberts.lewis@mayo.edu; shridv@exrch.mayo.edu	Chien, Jeremy/AID-8939-2022	Roberts, Lewis/0000-0001-7885-8574; Chien, Jeremy/0000-0003-4744-8374	NATIONAL CANCER INSTITUTE [K08CA082862] Funding Source: NIH RePORTER; NCI NIH HHS [CA82862] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Betz CS, 2002, PHOTOCH PHOTOBIO SCI, V1, P315, DOI 10.1039/b109817a; Bhalla US, 2002, SCIENCE, V297, P1018, DOI 10.1126/science.1068873; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Chien J, 2001, INT J CANCER, V91, P46, DOI 10.1002/1097-0215(20010101)91:1<46::AID-IJC1008>3.0.CO;2-0; Chikamatsu K, 1999, INT J CANCER, V82, P532, DOI 10.1002/(SICI)1097-0215(19990812)82:4<532::AID-IJC11>3.0.CO;2-G; Cortesina G, 2000, INT J CANCER, V89, P286, DOI 10.1002/1097-0215(20000520)89:3<286::AID-IJC12>3.3.CO;2-L; Delehedde M, 2002, BIOCHEM J, V366, P235, DOI 10.1042/BJ20011718; Dent P, 2001, CLIN CANCER RES, V7, P775; Dong G, 2001, CANCER RES, V61, P5911; Fleigel J, 2002, OTOLARYNG HEAD NECK, V127, P271, DOI 10.1067/mhn.2002.127414; Galeazzi E, 1997, EUR ARCH OTO-RHINO-L, V254, pS138, DOI 10.1007/BF02439745; Gescher A, 2000, CRIT REV ONCOL HEMAT, V34, P127, DOI 10.1016/S1040-8428(00)00058-5; Gleich Lyon L, 2002, Cancer Control, V9, P369; HARDISSON D, 2003, EUR ARCH OTO-RHINO-L, V8, P8; Hughes RS, 1997, AM J CLIN ONCOL-CANC, V20, P449, DOI 10.1097/00000421-199710000-00004; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Katoh M, 2002, INT J ONCOL, V21, P1269; Khurana D, 2001, HEAD NECK-J SCI SPEC, V23, P899, DOI 10.1002/hed.1130; Lai JP, 2002, LARYNGOSCOPE, V112, P402, DOI 10.1097/00005537-200202000-00036; Lai JP, 2003, J BIOL CHEM, V278, P23107, DOI 10.1074/jbc.M302203200; Liu DF, 2002, SEMIN THROMB HEMOST, V28, P67, DOI 10.1055/s-2002-20565; Lundin L, 2000, J BIOL CHEM, V275, P24653, DOI 10.1074/jbc.M908930199; LYON M, 1994, J BIOL CHEM, V269, P11216; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; MODJTAHEDI H, 1995, BIOCHEM BIOPH RES CO, V207, P389, DOI 10.1006/bbrc.1995.1200; Morimoto-Tomita M, 2002, J BIOL CHEM, V277, P49175, DOI 10.1074/jbc.M205131200; Riedel F, 2000, HEAD NECK-J SCI SPEC, V22, P183, DOI 10.1002/(SICI)1097-0347(200003)22:2<183::AID-HED11>3.0.CO;2-R; Riedel F, 2002, INT J ONCOL, V21, P11; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; Rubin JS, 2001, J BIOL CHEM, V276, P32977, DOI 10.1074/jbc.M105486200; Sasisekharan R, 2002, NAT REV CANCER, V2, P521, DOI 10.1038/nrc842; Shridhar V, 2002, CANCER RES, V62, P262; Simon C, 1998, LARYNGOSCOPE, V108, P1686, DOI 10.1097/00005537-199811000-00018; Strome SE, 2002, CLIN CANCER RES, V8, P281; Vlachtsis K, 2002, ONCOL REP, V9, P1133; Wakulich C, 2002, ORAL SURG ORAL MED O, V93, P573, DOI 10.1067/moe.2002.124461; Zeng QH, 2002, J BIOL CHEM, V277, P25203, DOI 10.1074/jbc.M201598200	37	109	112	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2004	23	7					1439	1447		10.1038/sj.onc.1207258	http://dx.doi.org/10.1038/sj.onc.1207258			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	775HZ	14973553				2022-12-28	WOS:000189035800011
J	Asnaghi, L; Calastretti, A; Bevilacqua, A; D'Agnano, I; Gatti, G; Canti, G; Delia, D; Capaccioli, S; Nicolin, A				Asnaghi, L; Calastretti, A; Bevilacqua, A; D'Agnano, I; Gatti, G; Canti, G; Delia, D; Capaccioli, S; Nicolin, A			Bcl-2 phosphorylation and apoptosis activated by damaged microtubules require mTOR and are regulated by Akt	ONCOGENE			English	Article						mTOR; BCL-2; microtubules; Akt; p70S6K; apoptosis	P70 S6 KINASE; MAMMALIAN TARGET; CELL-SURVIVAL; RAPAMYCIN; PROTEIN; GROWTH; LIFE; DEATH; INHIBITION; PATHWAY	The serine/threonine kinase mTOR, the major sensor of cell growth along the PI3K/Akt pathway, can be activated by agents acting on microtubules. Damaged microtubules induce phosphorylation of the Bcl-2 protein and lower the threshold of programmed cell death, both of which are inhibited by rapamycin. In HEK293 cells expressing Akt mutants, the level of Bcl-2 phosphorylation and the threshold of apoptosis induced by taxol or by nocodazole are significantly modified. In cells expressing dominant-negative Akt (DN-Akt), Bcl-2 phosphorylation and p70S6K(Thr421/Ser424) phosphorylation induced by taxol or nocodazole were significantly enhanced as compared to cells expressing constitutively active Akt (CA-Akt) and inhibited by rapamycin. Moreover, DN-Akt cells were more sensitive to antitubule agents than CA-Akt cells. In nocodazole-treated HEK293 cells sorted according to cell cycle, the p70S6K(Thr421/Ser424) phosphorylation was associated to the G2/M fraction. More relevant, nocodazole inhibited, in a dose-response manner, mTOR phosphorylation at Ser2448. This activity, potentiated in DN-Akt cells, was not detectable in CA-Akt cells. Our results suggest that death signals originating from damaged microtubules in G2/M can compete with G1 survival pathways at the level of mTOR. These findings have implications for cancer therapy and drug resistance.	Univ Milan, Dept Pharmacol, I-20129 Milan, Italy; CNR, Inst Biochem Technol, I-20090 Milan, Italy; Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; Univ Florence, Inst Gen Pathol, I-50134 Florence, Italy	University of Milan; Consiglio Nazionale delle Ricerche (CNR); Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Florence	Nicolin, A (corresponding author), Univ Milan, Dept Pharmacol, Via Vanvitelli 32, I-20129 Milan, Italy.	angelo.nicolin@unimi.it	D'Agnano, Igea/AAR-7282-2020; Bevilacqua, Annamaria/C-6357-2008	Bevilacqua, Annamaria/0000-0002-3136-3424; D'Agnano, Igea/0000-0002-2646-9224; Gatti, Giuliana/0000-0001-8844-4543				Abraham RT, 1998, CURR OPIN IMMUNOL, V10, P330, DOI 10.1016/S0952-7915(98)80172-6; Agami R, 2002, CANCER LETT, V177, P111, DOI 10.1016/S0304-3835(01)00785-6; Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; Bevilacqua A, 2003, J CELL PHYSIOL, V195, P356, DOI 10.1002/jcp.10272; Bevilacqua A, 2003, J BIOL CHEM, V278, P23451, DOI 10.1074/jbc.M210620200; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; Borner C, 2003, MOL IMMUNOL, V39, P615, DOI 10.1016/S0161-5890(02)00252-3; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; Calastretti A, 2001, EUR J CANCER, V37, P2121, DOI 10.1016/S0959-8049(01)00256-8; Calastretti A, 2001, ONCOGENE, V20, P6172, DOI 10.1038/sj.onc.1204751; Chau BN, 2003, NAT REV CANCER, V3, P130, DOI 10.1038/nrc993; Chen J, 2002, BIOCHEM PHARMACOL, V64, P1071, DOI 10.1016/S0006-2952(02)01263-7; Church AC, 2003, QJM-INT J MED, V96, P91, DOI 10.1093/qjmed/hcg014; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Decary S, 2002, MOL CELL BIOL, V22, P7877, DOI 10.1128/MCB.22.22.7877-7888.2002; DU L, 2003, P 94 AACR ANN M TOR; Dudkin L, 2001, CLIN CANCER RES, V7, P1758; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Fisher DE, 2001, APOPTOSIS, V6, P7, DOI 10.1023/A:1009659708549; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Haldar S, 1998, CANCER RES, V58, P1609; Haldar S, 1997, CANCER RES, V57, P229; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Hill MM, 2002, PHARMACOL THERAPEUT, V93, P243, DOI 10.1016/S0163-7258(02)00193-6; Jacinto E, 2003, NAT REV MOL CELL BIO, V4, P117, DOI 10.1038/nrm1018; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Jordan MA, 1998, CURR OPIN CELL BIOL, V10, P123, DOI 10.1016/S0955-0674(98)80095-1; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kim JE, 2000, P NATL ACAD SCI USA, V97, P14340, DOI 10.1073/pnas.011511898; Koyasu S, 2003, NAT IMMUNOL, V4, P313, DOI 10.1038/ni0403-313; Kozma SC, 2002, BIOESSAYS, V24, P65, DOI 10.1002/bies.10031; Krystal GW, 2002, MOL CANCER THER, V1, P913; Kurzrock R, 2003, ANN INTERN MED, V138, P819, DOI 10.7326/0003-4819-138-10-200305200-00010; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Law BK, 2002, MOL CELL BIOL, V22, P8184, DOI 10.1128/MCB.22.23.8184-8198.2002; Le XF, 2003, ONCOGENE, V22, P484, DOI 10.1038/sj.onc.1206175; Ling YH, 2002, MOL CANCER THER, V1, P841; Ling YH, 1998, J BIOL CHEM, V273, P18984, DOI 10.1074/jbc.273.30.18984; Mayer TU, 2003, TRENDS CELL BIOL, V13, P270, DOI 10.1016/S0962-8924(03)00077-1; McMahon LP, 2002, MOL CELL BIOL, V22, P7428, DOI 10.1128/MCB.22.21.7428-7438.2002; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Ofir R, 2002, CELL DEATH DIFFER, V9, P636, DOI 10.1038/sj.cdd.4401012; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Pene F, 2002, ONCOGENE, V21, P6587, DOI 10.1038/sj.onc.1205923; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Ruvolo PP, 2001, LEUKEMIA, V15, P515, DOI 10.1038/sj.leu.2402090; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Sekulic A, 2000, CANCER RES, V60, P3504; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Vincent AM, 2002, GROWTH HORM IGF RES, V12, P193, DOI 10.1016/S1096-6374(02)00017-5; Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(05)00089-4; Werlen G, 2003, SCIENCE, V299, P1859, DOI 10.1126/science.1067833; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469	63	122	128	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2004	23	34					5781	5791		10.1038/sj.onc.1207698	http://dx.doi.org/10.1038/sj.onc.1207698			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KW	15208671				2022-12-28	WOS:000222629800007
J	Zugaza, JL; Caloca, MJ; Bustelo, XR				Zugaza, JL; Caloca, MJ; Bustelo, XR			Inverted signaling hierarchy between RAS and RAC in T-lymphocytes	ONCOGENE			English	Article						Vav; Rac1; RasGRP1; Ras; phospholipase C; T-lymphocytes	PROTEIN-KINASE-C; NUCLEOTIDE EXCHANGE FACTORS; CELL-RECEPTOR SIGNALS; PHOSPHOLIPASE-C; RHO-GTPASES; SELECTIVE INHIBITOR; PLASMA-MEMBRANE; VAV FAMILY; ACTIVATION; PATHWAY	In order to generate coherent biological responses to extracellular stimuli, cells have established synergistic and antagonistic crosstalk between pathways with similar or opposing functions, respectively. Two routes cooperating in the generation of mitogenic and cytoskeletal functions are those induced by Ras and Rho/Rac GTPases. In these signaling interactions, Rho/Rac proteins have been always placed in a downstream position respect to Ras in all cell systems analysed so far. In this report, we describe that such signaling hierarchy does not apply to T-lymphocytes. Thus, we show that both Racl GDP/GTP exchange factors such as Vav and constitutively active versions of Racl can promote the effective stimulation of the Ras pathway in T-lymphocytes. The molecular link for this new type of pathway interconnectivity is RasGRP1, a diacylglycerol-dependent GDP/GTP exchange factor for Ras that translocates to the plasma membrane in a Vav- and Racl-dependent manner. The effect of the Vav/Rac1 pathway on the Ras pathway is highly dependent on the activity of phospholipase C-gamma, the key cellular supplier of intracellular diacylglycerol. Signaling experiments suggest that this crosstalk represents a signaling strategy used by the T-cell receptor to promote robust biological responses of both the Rac/Rho and Ras pathways upon antigen engagement.	Univ Salamanca, CSIC, Ctr Invest Canc, E-37007 Salamanca, Spain; Univ Salamanca, CSIC, Inst Biol Mol & Celular Canc, E-37007 Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Bustelo, XR (corresponding author), Univ Salamanca, CSIC, Ctr Invest Canc, Campus Unamuno, E-37007 Salamanca, Spain.	xbustelo@usal.es	Bustelo, Xose R./AAD-2081-2022; Bustelo, Xose R./A-9526-2010; Caloca, María-José/K-9357-2014	Bustelo, Xose R./0000-0001-9398-6072; Bustelo, Xose R./0000-0001-9398-6072; ZUGAZA GURRUCHAGA, JOSE LUIS/0000-0003-2287-6671; Caloca, Maria-Jose/0000-0002-1003-2685	NCI NIH HHS [CA7373501] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073735] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bivona TG, 2003, NATURE, V424, P694, DOI 10.1038/nature01806; Boettner B, 2002, GENE, V286, P155, DOI 10.1016/S0378-1119(02)00426-2; Bustelo XR, 2002, BIOESSAYS, V24, P602, DOI 10.1002/bies.10107; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Bustelo XR, 2002, HISTOL HISTOPATHOL, V17, P871, DOI 10.14670/HH-17.871; Caloca MJ, 2003, J BIOL CHEM, V278, P33465, DOI 10.1074/jbc.M302807200; Caloca MJ, 2003, EMBO J, V22, P3326, DOI 10.1093/emboj/cdg316; Cantrell DA, 2003, IMMUNOL REV, V192, P122, DOI 10.1034/j.1600-065X.2003.00028.x; Costello PS, 1999, P NATL ACAD SCI USA, V96, P3035, DOI 10.1073/pnas.96.6.3035; Crespo P, 1996, ONCOGENE, V13, P455; Diaz-Flores E, 2003, J BIOL CHEM, V278, P29208, DOI 10.1074/jbc.M303165200; Dower NA, 2000, NAT IMMUNOL, V1, P317, DOI 10.1038/79766; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Ebinu JO, 2000, BLOOD, V95, P3199; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fujikawa K, 2003, J EXP MED, V198, P1595, DOI 10.1084/jem.20030874; Hogquist K, 2001, Trends Immunol, V22, P69, DOI 10.1016/S1471-4906(00)01845-7; Inabe K, 2002, J EXP MED, V195, P189, DOI 10.1084/jem.20011571; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; Kranewitter WJ, 1999, FEBS LETT, V455, P123, DOI 10.1016/S0014-5793(99)00857-1; Lambert JM, 2002, NAT CELL BIOL, V4, P621, DOI 10.1038/ncb833; Layer K, 2003, IMMUNITY, V19, P243, DOI 10.1016/S1074-7613(03)00209-7; Lopez-Lago M, 2000, MOL CELL BIOL, V20, P1678, DOI 10.1128/MCB.20.5.1678-1691.2000; Lorenzo PS, 2000, MOL PHARMACOL, V57, P840; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Matthews SA, 2000, J EXP MED, V191, P2075, DOI 10.1084/jem.191.12.2075; Ohtsuka T, 1996, BBA-MOL CELL RES, V1310, P223, DOI 10.1016/0167-4889(95)00172-7; OVERBECK AF, 1995, MOL REPROD DEV, V42, P468, DOI 10.1002/mrd.1080420415; POWIS G, 1994, CANCER RES, V54, P2419; Priatel JJ, 2002, IMMUNITY, V17, P617, DOI 10.1016/S1074-7613(02)00451-X; PRONK GJ, 1994, BBA-REV CANCER, V1198, P131, DOI 10.1016/0304-419X(94)90010-8; Reynolds LF, 2002, J EXP MED, V195, P1103, DOI 10.1084/jem.20011663; Shan XC, 2000, MOL CELL BIOL, V20, P6945, DOI 10.1128/MCB.20.18.6945-6957.2000; Teixeira C, 2003, BLOOD, V102, P1414, DOI 10.1182/blood-2002-11-3621; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Turner M, 2002, NAT REV IMMUNOL, V2, P476, DOI 10.1038/nri840; VASSILOPOULOS D, 1995, CLIN IMMUNOL IMMUNOP, V77, P59, DOI 10.1016/0090-1229(95)90137-X; Villalba M, 2000, EUR J IMMUNOL, V30, P1587, DOI 10.1002/1521-4141(200006)30:6<1587::AID-IMMU1587>3.0.CO;2-T; Villalba M, 2000, IMMUNITY, V12, P151, DOI 10.1016/S1074-7613(00)80168-5; Villalba M, 2002, J CELL BIOL, V157, P253, DOI 10.1083/jcb.200201097; Wang XJ, 2001, EXP CELL RES, V267, P28, DOI 10.1006/excr.2001.5241; WU J, 1995, MOL CELL BIOL, V15, P4337; Yu H, 2001, J EXP MED, V194, P915, DOI 10.1084/jem.194.7.915; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	48	34	35	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2004	23	34					5823	5833		10.1038/sj.onc.1207768	http://dx.doi.org/10.1038/sj.onc.1207768			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KW	15184873				2022-12-28	WOS:000222629800012
J	Koma, Y; Ito, A; Wakayama, T; Watabe, K; Okada, M; Tsubota, N; Iseki, S; Kitamura, Y				Koma, Y; Ito, A; Wakayama, T; Watabe, K; Okada, M; Tsubota, N; Iseki, S; Kitamura, Y			Cloning of a soluble isoform of the SgIGSF adhesion molecule that binds the extracellular domain of the membrane-bound isoform	ONCOGENE			English	Article						IGSF4; TSLC1; homophilic binding; splicing	IMMUNOGLOBULIN SUPERFAMILY; TSLC1 GENE; EXPRESSION; IDENTIFICATION; VCAM-1; LIGAND	SgIGSF (spermatogenic immunoglobulin superfamily) is a recently identified intercellular adhesion molecule of the immunoglobulin superfamily. In a mast-cell cDNA library, we found a clone that resulted from the retention of intron 7 within the mature SgIGSF message. This clone was predicted to encode a soluble isoform of SgIGSF (sSgIGSF) with 336 amino-acid residues because its open reading frame ended just before the transmembrane domain. We constructed a plasmid expressing sSgIGSF fused to the human IgG Fc fragment at its C-terminus (sSgIGSF-Fc), and transfected it into COS-7 cells. The fusion protein was readily detectable in the culture supernatant. Solid-phase binding assay showed that sSgIGSF interacted directly the extracellular domain of membrane-bound SgIGSF (mSgIGSF). We next examined whether this interaction inhibited homophilic binding of mSgIGSF by aggregation assays using L cells that did not express mSgIGSF. A stable L-cell clone that overexpressed mSgIGSF aggregated with each other but not with mock-transfected L cells, indicating that a homophilic interaction of mSgIGSF mediated the aggregation. Addition of sSgIGSF-Fc inhibited the aggregation of L cells overexpressing mSgIGSF in a dose-dependent manner. Moreover, FACScan analyses revealed the specific binding of sSgIGSF-Fc to mSgIGSF expressed in L cells. Binding of sSgIGSF-Fc to mSgIGSF appeared to inhibit homophilic interactions of mSgIGSF.	Osaka Univ, Sch Med, Dept Pathol, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan; Kanazawa Univ, Grad Sch Med Sci, Dept Histol & Embryol, Kanazawa, Ishikawa 9208640, Japan; Hyogo Med Ctr Adults, Dept Thorac Surg, Akashi, Hyogo 6738558, Japan	Osaka University; Kanazawa University	Ito, A (corresponding author), Kobe Univ, Grad Sch Med, Div Surg Pathol, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 650, Japan.	akito@med.kobe-u.ac.jp						Budt M, 2002, BIOCHEM BIOPH RES CO, V292, P749, DOI 10.1006/bbrc.2002.6704; Fukami T, 2003, INT J CANCER, V107, P53, DOI 10.1002/ijc.11348; Fukami T, 2002, GENE, V295, P7, DOI 10.1016/S0378-1119(02)00835-1; HAHNE M, 1994, EUR J IMMUNOL, V24, P421, DOI 10.1002/eji.1830240223; Ito A, 2003, LAB INVEST, V83, P1175, DOI 10.1097/01.LAB.0000081391.28136.80; Ito A, 2003, BLOOD, V101, P2601, DOI 10.1182/blood-2002-07-2265; Ito A, 1998, BLOOD, V91, P3210, DOI 10.1182/blood.V91.9.3210.3210_3210_3221; KAPLAN AJ, 1993, J IMMUNOL, V151, P4022; Kumanogoh A, 2000, IMMUNITY, V13, P621, DOI 10.1016/S1074-7613(00)00062-5; Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934; Lee G, 2003, BLOOD, V101, P1790, DOI 10.1182/blood-2002-08-2529; Masuda M, 2002, J BIOL CHEM, V277, P31014, DOI 10.1074/jbc.M203620200; MEYER DM, 1995, J IMMUNOL, V155, P3578; Mountain CF, 1997, CHEST, V111, P1710, DOI 10.1378/chest.111.6.1710; Nakamoto K, 2001, AM J PATHOL, V159, P1363, DOI 10.1016/S0002-9440(10)62523-0; PIGOTT R, 1992, BIOCHEM BIOPH RES CO, V187, P584, DOI 10.1016/0006-291X(92)91234-H; Pletcher MT, 2001, GENE, V273, P181, DOI 10.1016/S0378-1119(01)00592-3; SUDA T, 1994, J EXP MED, V179, P873, DOI 10.1084/jem.179.3.873; Wakayama T, 2003, BIOL REPROD, V68, P1755, DOI 10.1095/biolreprod.102.012344; Wakayama T, 2001, MOL REPROD DEV, V60, P158, DOI 10.1002/mrd.1072; Yageta M, 2002, CANCER RES, V62, P5129	21	29	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5687	5692		10.1038/sj.onc.1207761	http://dx.doi.org/10.1038/sj.onc.1207761			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15184876				2022-12-28	WOS:000222629500014
J	Broemer, M; Krappmann, D; Scheidereit, C				Broemer, M; Krappmann, D; Scheidereit, C			Requirement of Hsp90 activity for I kappa B kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF-kappa B activation	ONCOGENE			English	Article						ubiquitin; chaperones; proteasome; ribosome; Reed-Sternberg cells; tumor cell pharmacology	DEATH DOMAIN KINASE; RIP; INHIBITION; ALPHA; LYMPHOTOXIN; RECRUITMENT; RECEPTOR; EXPRESSION; ARSENITE; CELLS	The molecular chaperone Hsp90 affects the function and fate of a number of signaling molecules. We have investigated the Hsp90 requirement for constitutive and inducible activity of the IkappaB kinase (IKK) complex and of NF-kappaB. Inhibition by the Hsp90 ATPase inhibitors, geldanamycin (GA) and radicicol ( RC), revealed that Hsp90 controls IKKs at two levels, inducibility of enzymatic activity and biogenesis, which can be discriminated by short- and long-time GA incubation, respectively. Short-time inhibition of Hsp90 resulted in impaired IKK kinase activation by TNFalpha, IL-1beta or phorbolester PMA. Furthermore, GA inhibited constitutive activation of IKK and NF-kappaB in Hodgkin's lymphoma cells. Hsp90 function was also required for trans- and autophosphorylation of transfected IKKbeta. GA exposure for several hours resulted in a downmodulation of IKK complex alpha, beta and gamma subunits to various extent. Proteasome inhibition interfered with GA mediated IKK depletion and Hsp90 inhibition induced polyubiquitination of IKKalpha and beta during protein synthesis. In fact, GA blocked biogenesis of IKKalpha and IKKbeta but did not interfere with post-translational turnover. Together, these results define a dual requirement for Hsp90 as a regulator of NF-kappaB signaling by its general involvement in IKK activation and by its role in IKK homeostasis.	Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; Free Univ Berlin, Fac Biol Chem & Pharm, D-14195 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin	Scheidereit, C (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.	scheidereit@mdc-berlin.de	Krappmann, Daniel/AAT-4354-2021; Krappmann, Daniel/ABF-4038-2021	Krappmann, Daniel/0000-0001-7640-3234; Krappmann, Daniel/0000-0001-7640-3234				BASSO AD, 2002, J BIOL CHEM, V9, P9; Bijlmakers MJJE, 2000, MOL BIOL CELL, V11, P1585, DOI 10.1091/mbc.11.5.1585; Byrd CA, 1999, P NATL ACAD SCI USA, V96, P5645, DOI 10.1073/pnas.96.10.5645; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; Chakravortty D, 2001, J IMMUNOL, V166, P2011, DOI 10.4049/jimmunol.166.3.2011; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Emmerich F, 1999, BLOOD, V94, P3129, DOI 10.1182/blood.V94.9.3129.421k03_3129_3134; Fisher DL, 2000, EMBO J, V19, P1516, DOI 10.1093/emboj/19.7.1516; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Hatada EN, 2000, CURR OPIN IMMUNOL, V12, P52, DOI 10.1016/S0952-7915(99)00050-3; Hohfeld J, 2001, EMBO REP, V2, P885, DOI 10.1093/embo-reports/kve206; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; Kapahi P, 2000, J BIOL CHEM, V275, P36062, DOI 10.1074/jbc.M007204200; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Krappmann D, 1999, ONCOGENE, V18, P943, DOI 10.1038/sj.onc.1202351; Lewis J, 2000, J BIOL CHEM, V275, P10519, DOI 10.1074/jbc.275.14.10519; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Maloney A, 2002, EXPERT OPIN BIOL TH, V2, P3, DOI 10.1517/14712598.2.1.3; Mathas S, 2003, BLOOD, V102, P1028, DOI 10.1182/blood-2002-04-1154; Mathas S, 2002, EMBO J, V21, P4104, DOI 10.1093/emboj/cdf389; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Mordmuller B, 2003, EMBO REP, V4, P82, DOI 10.1038/embor710; Poyet JL, 2000, J BIOL CHEM, V275, P37966, DOI 10.1074/jbc.M006643200; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Shao J, 2001, J BIOL CHEM, V276, P206, DOI 10.1074/jbc.M007583200; Staudt LM, 2000, J EXP MED, V191, P207, DOI 10.1084/jem.191.2.207; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Sugita T, 1999, BIOCHEM MOL BIOL INT, V47, P587; Tegethoff S, 2003, MOL CELL BIOL, V23, P2029, DOI 10.1128/MCB.23.6.2029-2041.2003; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Yilmaz ZB, 2003, EMBO J, V22, P121, DOI 10.1093/emboj/cdg004; Yorgin PD, 2000, J IMMUNOL, V164, P2915, DOI 10.4049/jimmunol.164.6.2915; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	38	181	187	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2004	23	31					5378	5386		10.1038/sj.onc.1207705	http://dx.doi.org/10.1038/sj.onc.1207705			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15077173				2022-12-28	WOS:000222491600013
J	Matsuzaki, Y; Takaoka, Y; Hitomi, T; Nishino, H; Sakai, T				Matsuzaki, Y; Takaoka, Y; Hitomi, T; Nishino, H; Sakai, T			Activation of protein kinase C promotes human cancer cell growth through downregulation of p18(INK4c)	ONCOGENE			English	Article						p18(ink4c); TPA; PKC	CDK INHIBITORS; RETINOBLASTOMA PROTEIN; P18 GENES; P16(INK4A); EXPRESSION; P15(INK4B); MICE; PHOSPHORYLATION; PROLIFERATION; TRANSDUCTION	p18(INK4c), a member of INK4 family of cyclin-dependent kinase inhibitors, negatively regulates the cyclin D-cyclin-dependent kinase 4/6 complexes which promote G1/S transition by phosphorylating the retinoblastoma tumor-suppressor gene product. Several recent studies using p18(INK4c)-null mice revealed that the p18(INK4c) plays an important role in cell proliferation and tumor development. We report here that 12-O-tetradecanoylphorbol-13-acetate (TPA), widely used as a protein kinase C (PKC) activator, suppresses the expression of p18(INK4c) through its promoter, accompanied by the induction of human cancer cell growth. Reduction of p18(INK4c) using small interfering RNA (siRNA) also enhanced cell growth, suggesting that p18(INK4c) is a critical target of TPA. Ro 31-8425, a potent and highly specific PKC inhibitor abrogated the suppressive effect of TPA on p18(INK4c) gene expression. However, the expression of dominant-negative c-Jun (TAM-67) did not inhibit the action of TPA on p18(INK4c). These findings suggest that activation of PKC promotes human cancer cell growth through downregulation of p18(INK4c) in an AP-1 activation-independent manner. These results suggest that the accelerated cellular proliferation of some human tumors caused by enhanced PKC activity at least partially involves the suppression of p18(INK4c), which is a ubiquitously expressed cyclin-dependent kinase inhibitor.	Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Targeting Canc Prevent, Kamigyo Ku, Kyoto 6028566, Japan; Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Biochem & Mol Biol, Kamigyo Ku, Kyoto 6028566, Japan	Kyoto Prefectural University of Medicine; Kyoto Prefectural University of Medicine	Sakai, T (corresponding author), Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Targeting Canc Prevent, Kamigyo Ku, Kyoto 6028566, Japan.	tsakai@koto.kpu-m.ac.jp						ALVARO V, 1992, INT J CANCER, V50, P724, DOI 10.1002/ijc.2910500510; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Bai F, 2003, MOL CELL BIOL, V23, P1269, DOI 10.1128/MCB.23.4.1269-1277.2003; BIT RA, 1993, J MED CHEM, V36, P21, DOI 10.1021/jm00053a003; BROWN PH, 1994, ONCOGENE, V9, P791; da Rocha AB, 2002, ONCOLOGIST, V7, P17, DOI 10.1634/theoncologist.7-1-17; Franklin DS, 1998, GENE DEV, V12, P2899, DOI 10.1101/gad.12.18.2899; Goekjian PG, 2001, EXPERT OPIN INV DRUG, V10, P2117; Gordge PC, 1996, EUR J CANCER, V32A, P2120, DOI 10.1016/S0959-8049(96)00255-9; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; Hatta Y, 1997, BRIT J HAEMATOL, V99, P665; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Latres E, 2000, EMBO J, V19, P3496, DOI 10.1093/emboj/19.13.3496; Liebmann C, 2001, CELL SIGNAL, V13, P777, DOI 10.1016/S0898-6568(01)00192-9; Miller CW, 1996, CANCER GENET CYTOGEN, V86, P136, DOI 10.1016/0165-4608(95)00216-2; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OBRIAN CA, 1989, CANCER RES, V49, P3215; Otsuki T, 1996, LEUKEMIA, V10, P356; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Rusin MR, 1996, INT J CANCER, V65, P734, DOI 10.1002/(SICI)1097-0215(19960315)65:6<734::AID-IJC4>3.0.CO;2-#; Schenk PW, 1999, BBA-MOL CELL RES, V1449, P1, DOI 10.1016/S0167-4889(98)00178-5; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Swannie Helen C, 2002, Curr Oncol Rep, V4, P37, DOI 10.1007/s11912-002-0046-7; Virchis Andres, 2002, Hematol J, V3, P131, DOI 10.1038/sj.thj.6200165; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Yamamoto H, 1999, CLIN CANCER RES, V5, P1805; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; Zindy F, 2000, MOL CELL BIOL, V20, P372, DOI 10.1128/MCB.20.1.372-378.2000; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	36	20	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2004	23	31					5409	5414		10.1038/sj.onc.1207702	http://dx.doi.org/10.1038/sj.onc.1207702			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15107819				2022-12-28	WOS:000222491600017
J	Edel, MJ; Shvarts, A; Medema, JP; Bernards, R				Edel, MJ; Shvarts, A; Medema, JP; Bernards, R			An in vivo functional genetic screen reveals a role for the TRK-T3 oncogene in tumor progression	ONCOGENE			English	Article						functional screen; tumor progression; cancer; transformation	COILED-COIL DOMAIN; C-MYC; CANCER; CELLS; EXPRESSION; ACTIVATION; IMMUNITY; PRODUCT; RAS	Over the past decades, much has been learnt about the genes that contribute to oncogenic transformation of primary cells in vitro. However, much less is known about the genes that contribute to the later stages of tumor progression, in which cells of ever increasing malignancy arise through clonal selection in vivo. To search for genes that confer a tumor progression phenotype in vivo, we have used a functional genetic approach. We used adenovirus-transformed mouse embryo fibroblasts, which are tumorigenic in immunodeficient nude mice, but not in immunocompetent mice, due to strong cytotoxic T-cell-mediated immune rejection. We infected these cells in vitro with several high-complexity retroviral cDNA expression libraries and selected rare variants that formed tumors in immunocompetent mice. Using this approach, we identify here the TRK-T3 oncogene as a tumor progression gene. TRK-T3 does not inhibit T-cell reactivity towards the tumor cells. Instead, we find that cells expressing TRK-T3 enhances in vivo growth rate, most likely by stimulating anchorage-independent proliferation in growth factor-limiting conditions. Our data indicate that cDNA expression libraries can be used to identify tumor progression genes in vivo that cannot be readily identified using in vitro cell culture systems.	Netherlands Canc Inst, Ctr Biomed Genet, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands; Leiden Univ, Med Ctr, Dept Clin Oncol, NL-2333 ZA Leiden, Netherlands	Netherlands Cancer Institute; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Bernards, R (corresponding author), Netherlands Canc Inst, Ctr Biomed Genet, Div Mol Carcinogenesis, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	r.bernards@nki.nl	Edel, Michael J/L-1954-2014	Edel, Michael J/0000-0002-5619-8680; Bernards, Rene/0000-0001-8677-3423; Medema, Jan Paul/0000-0003-3045-2924				BERNARDS R, 1982, VIROLOGY, V120, P422, DOI 10.1016/0042-6822(82)90042-3; BERNARDS R, 1986, CELL, V47, P667, DOI 10.1016/0092-8674(86)90509-X; BERNARDS R, 1983, NATURE, V305, P776, DOI 10.1038/305776a0; Brummelkamp TR, 2003, NAT REV CANCER, V3, P781, DOI 10.1038/nrc1191; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Coulie PG, 2003, CURR OPIN IMMUNOL, V15, P131, DOI 10.1016/S0952-7915(03)00009-8; GRECO A, 1995, MOL CELL BIOL, V15, P6118; Greco A, 1998, ONCOGENE, V16, P809, DOI 10.1038/sj.onc.1201596; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; Jonkers J, 1997, EMBO J, V16, P441, DOI 10.1093/emboj/16.3.441; KAST WM, 1989, CELL, V59, P603, DOI 10.1016/0092-8674(89)90006-8; Lazarov M, 2002, NAT MED, V8, P1105, DOI 10.1038/nm779; Mencinger M, 1997, GENOMICS, V41, P327, DOI 10.1006/geno.1997.4625; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; Roccato E, 2003, ONCOGENE, V22, P807, DOI 10.1038/sj.onc.1206189; Roccato E, 2002, BRIT J CANCER, V87, P645, DOI 10.1038/sj.bjc.6600544; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; Shvarts A, 2002, GENE DEV, V16, P681, DOI 10.1101/gad.929302; Toes REM, 1996, CANCER RES, V56, P3782; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Xu XW, 2003, J CUTAN PATHOL, V30, P318, DOI 10.1034/j.1600-0560.2003.00068.x	24	8	8	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					4959	4965		10.1038/sj.onc.1207667	http://dx.doi.org/10.1038/sj.onc.1207667			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15077169	Green Published			2022-12-28	WOS:000222237300001
J	Guerrero, C; Martin-Encabo, S; Fernandez-Medarde, A; Santos, E				Guerrero, C; Martin-Encabo, S; Fernandez-Medarde, A; Santos, E			C3G-mediated suppression of oncogene-induced focus formation in fibroblasts involves inhibition of ERK activation, cyclin A expression and alterations of anchorage-independent growth	ONCOGENE			English	Article						C3G; Ras; focus formation; anchorage-independent growth; transformation suppression	EXCHANGE FACTOR C3G; HEMATOPOIETIC-CELL ADHESION; NUCLEOTIDE-RELEASING FACTOR; ADAPTER PROTEIN CRKL; SMALL GTPASE RAP1; R-RAS; FOCAL ADHESIONS; KINASE; PHOSPHORYLATION; RECEPTOR	We showed previously that exogenous overexpression of C3G, a guanine nucleotide releasing factor (GEF) for Rap1 and R-Ras proteins, blocks the focus-forming activity of cotransfected, activated, sis, ras and v-raf oncogenes in NIH 3T3 cells. In this report, we show that C3G also interferes with dbl and R-Ras focus-forming activity and demonstrate that the transformation suppressor ability of C3G maps to its Crk-binding region (SH3-b domain). Using full-length C3G and C3GDeltaCat mutant, lacking catalytic domain, we showed here that overexpression of cotransfected C3G or C3GDeltaCat inhibited oncogenic Hras(lys12)-mediated phosphorylation of ERK, without altering Ras and Raf-1 kinase activation. We also showed that, overexpressed C3G and C3GDeltaCat inhibited the viability of oncogenic Ras-induced colonies in soft agar, indicating that C3G interferes with the anchorage-independent growth of Ras-transformed cells in a Rap1-independent manner. Consistent with both observations, overexpression of exogenous C3G and C3GDeltaCat also caused downregulation of Ras-induced cyclin A expression. Altogether, our results indicate that C3G interferes with at least two separate aspects of oncogenic transformation-cell cycle progression and loss of contact inhibition-and that these inhibitory effects probably account for its transformation suppressor activity.	Univ Salamanca, CSIC, Ctr Invest Canc, IBMCC, Salamanca 37007, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Santos, E (corresponding author), Univ Salamanca, CSIC, Ctr Invest Canc, IBMCC, Campus Miguel de Unamuno, Salamanca 37007, Spain.	esantos@usal.es	Guerrero, Carmen/F-1776-2010; Fernández-Medarde, Alberto/B-3839-2017	Guerrero, Carmen/0000-0002-8747-6831; Fernández-Medarde, Alberto/0000-0002-1230-5501				Abassi YA, 2002, EMBO J, V21, P4571, DOI 10.1093/emboj/cdf446; Arai A, 1999, BLOOD, V93, P3713, DOI 10.1182/blood.V93.11.3713.411a36_3713_3722; Arai A, 2001, J BIOL CHEM, V276, P10453, DOI 10.1074/jbc.M004627200; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; de Jong R, 1998, ONCOGENE, V17, P2805, DOI 10.1038/sj.onc.1202207; Dhillon AS, 2002, MOL CELL BIOL, V22, P3237, DOI 10.1128/MCB.22.10.3237-3246.2002; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; Gotoh T, 1997, J BIOL CHEM, V272, P18602, DOI 10.1074/jbc.272.30.18602; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; Guerrero C, 1998, ONCOGENE, V16, P613, DOI 10.1038/sj.onc.1201569; Guerrero C, 2002, AM J PHYSIOL-LUNG C, V282, pL1099, DOI 10.1152/ajplung.00178.2001; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Ishimaru S, 1999, EMBO J, V18, P145, DOI 10.1093/emboj/18.1.145; Kang JS, 1996, MOL CELL BIOL, V16, P3370; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; LACAL JC, 1986, P NATL ACAD SCI USA, V83, P5400, DOI 10.1073/pnas.83.15.5400; Li LM, 2002, MOL CELL BIOL, V22, P1203, DOI 10.1128/MCB.22.4.1203-1217.2002; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MATTER ML, 1994, J CELL BIOL, V124, P1083, DOI 10.1083/jcb.124.6.1083; McLeod SJ, 1998, J BIOL CHEM, V273, P29218, DOI 10.1074/jbc.273.44.29218; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; Mochizuki N, 2000, J BIOL CHEM, V275, P12667, DOI 10.1074/jbc.275.17.12667; Ohba Y, 2000, J BIOL CHEM, V275, P20020, DOI 10.1074/jbc.M000981200; Ohba Y, 2001, EMBO J, V20, P3333, DOI 10.1093/emboj/20.13.3333; PaasinenSohns A, 1997, ONCOGENE, V15, P1953, DOI 10.1038/sj.onc.1201366; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Quilliam LA, 2002, PROG NUCLEIC ACID RE, V71, P391, DOI 10.1016/S0079-6603(02)71047-7; Reedquist KA, 1998, J BIOL CHEM, V273, P4944, DOI 10.1074/jbc.273.9.4944; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; SAEZ R, 1994, ONCOGENE, V9, P2977; Sakkab D, 2000, J BIOL CHEM, V275, P10772, DOI 10.1074/jbc.275.15.10772; SAKODA T, 1992, ONCOGENE, V7, P1705; Schulze A, 1996, MOL CELL BIOL, V16, P4632; SOZERI O, 1992, ONCOGENE, V7, P2259; Takuwa N, 2001, MOL CELL ENDOCRINOL, V177, P25, DOI 10.1016/S0303-7207(01)00439-7; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Uemura N, 1999, J BIOL CHEM, V274, P37525, DOI 10.1074/jbc.274.53.37525; Voss AK, 2003, DEVELOPMENT, V130, P355, DOI 10.1242/dev.00217; Yam CH, 2002, CELL MOL LIFE SCI, V59, P1317, DOI 10.1007/s00018-002-8510-y; Yang JJ, 1998, MOL CELL BIOL, V18, P2586, DOI 10.1128/MCB.18.5.2586; Yokote K, 1998, ONCOGENE, V16, P1229, DOI 10.1038/sj.onc.1201641; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zhu T, 1998, J BIOL CHEM, V273, P33864, DOI 10.1074/jbc.273.50.33864	48	31	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2004	23	28					4885	4893		10.1038/sj.onc.1207622	http://dx.doi.org/10.1038/sj.onc.1207622			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	830EK	15077165	Green Submitted			2022-12-28	WOS:000222104200009
J	Ding, Y; Wang, L; Su, LK; Frey, JA; Shao, RP; Hunt, KK; Yan, DH				Ding, Y; Wang, L; Su, LK; Frey, JA; Shao, RP; Hunt, KK; Yan, DH			Antitumor activity of IFIX, a novel interferon-inducible HIN-200 gene, in breast cancer	ONCOGENE			English	Article						IFIX; interferon; HIN-200; p21(CIP1); breast cancer	DEATH-DOMAIN-FOLD; CARCINOMA CELL-LINES; INDUCED APOPTOSIS; PYRIN DOMAIN; TUMOR SUPPRESSION; CDK INHIBITORS; CYCLE CONTROL; EXPRESSION; GROWTH; FAMILY	We identified IFIX as a new member of the hematopoietic interferon (IFN)-inducible nuclear protein with the 200-amino-acid repeat (HIN-200) family. Six different alternatively spliced forms of mRNA are transcribed from the IFIX gene, which are predicted to encode six different isoforms of IFIX proteins (IFIXalpha1, alpha2, beta1, beta2, gamma1, and gamma2). The IFIX proteins are primarily localized in the nucleus. They share a common N-terminal region that contains a predicted pyrin domain and a putative nuclear localization signal. Unlike IFIXalpha and IFIXbeta, IFIXgamma isoforms do not have the 200-amino-acid signature motif. Interestingly, the expression of IFIX was reduced in most human breast tumors and breast cancer cell lines. Expression of IFIXalpha1, the longest isoform of IFIX, in human breast cancer cell lines reduced their anchorage-dependent and -independent growth in vitro and tumor-igenicity in nude mice. Moreover, a liposome-mediated IFIXalpha1 gene transfer suppressed the growth of already-formed tumors in a breast cancer xenograft model. IFIXalpha1 appears to suppress the growth of breast cancer cells in a pRB- and p53-independent manner by increasing the expression of the cyclin-dependent kinase inhibitor p21(CIp1), which leads to the reduction of the kinase activity of both Cdk2 and p34(Cdc2). Together, our results show that IFIXalpha1 possesses a tumor-suppressor activity and suggest IFIXalpha1 may be used as a therapeutic agent in cancer treatment.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System	Yan, DH (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	dyan@mdanderson.org			NCI NIH HHS [CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Choubey D, 2000, FEBS LETT, V474, P38, DOI 10.1016/S0014-5793(00)01571-4; Choubey D, 2000, J BIOL REG HOMEOS AG, V14, P187; Coradini D, 1998, ANTICANCER RES, V18, P177; Cox LS, 1997, J PATHOL, V183, P134, DOI 10.1002/(SICI)1096-9896(199710)183:2<134::AID-PATH960>3.0.CO;2-D; Dawson MJ, 1996, J LEUKOCYTE BIOL, V60, P310, DOI 10.1002/jlb.60.3.310; DAWSON MJ, 1995, J CELL BIOCHEM, V57, P39, DOI 10.1002/jcb.240570106; DeYoung KL, 1997, ONCOGENE, V15, P453, DOI 10.1038/sj.onc.1201206; Ding Y, 2002, CLIN CANCER RES, V8, P3290; Doree M, 2002, J CELL SCI, V115, P2461; DOTTO GP, 2000, BIOCHIM BIOPHYS ACTA, V1471, P43; Fairbrother WJ, 2001, PROTEIN SCI, V10, P1911, DOI 10.1110/ps.13801; Fang M, 2000, ANTICANCER RES, V20, P103; Funk JO, 1998, TRENDS BIOCHEM SCI, V23, P337; Gariglio M, 2002, J INTERF CYTOK RES, V22, P815, DOI 10.1089/107999002320271413; Gooch JL, 2000, CELL GROWTH DIFFER, V11, P335; Gribaudo G, 1999, FEBS LETT, V456, P31, DOI 10.1016/S0014-5793(99)00916-3; Gutterman JU, 1999, CELL GROWTH DIFFER, V10, P93; Hingorani R, 2000, J IMMUNOL, V164, P4032, DOI 10.4049/jimmunol.164.8.4032; Johnstone RW, 1999, MOL CELL BIOL, V19, P5833; KIMCHI A, 1988, MOL CELL BIOL, V8, P2828, DOI 10.1128/MCB.8.7.2828; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; Liepinsh E, 2003, J MOL BIOL, V332, P1155, DOI 10.1016/j.jmb.2003.07.007; MACLACHLAN TK, 1995, CRIT REV EUKAR GENE, V5, P127, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.20; Martinon F, 2001, CURR BIOL, V11, pR118, DOI 10.1016/S0960-9822(01)00056-2; Nadal A, 1997, J PATHOL, V183, P156; Naldini A, 2002, J CELL PHYSIOL, V191, P290, DOI 10.1002/jcp.10101; PRICE JE, 1990, CANCER RES, V50, P717; Shao RP, 1997, J BIOL CHEM, V272, P32739, DOI 10.1074/jbc.272.52.32739; Staub E, 2001, TRENDS BIOCHEM SCI, V26, P83, DOI 10.1016/S0968-0004(00)01717-5; Wei W, 2003, HISTOCHEM CELL BIOL, V119, P45, DOI 10.1007/s00418-002-0485-0; Wen Y, 2000, CANCER RES, V60, P42; Wen Y, 2001, CANCER RES, V61, P7142; XIE YM, 1994, BIOCHEM BIOPH RES CO, V203, P1589, DOI 10.1006/bbrc.1994.2368; Yin F, 2001, ANTICANCER RES, V21, P413; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Zhang JF, 1996, P NATL ACAD SCI USA, V93, P4513, DOI 10.1073/pnas.93.9.4513; ZHANG RD, 1991, INVAS METAST, V11, P204; Zhou YH, 2002, CANCER INVEST, V20, P348, DOI 10.1081/CNV-120001180; Zou YY, 2002, CANCER RES, V62, P8	39	51	56	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2004	23	26					4556	4566		10.1038/sj.onc.1207592	http://dx.doi.org/10.1038/sj.onc.1207592			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZV	15122330				2022-12-28	WOS:000221799000005
J	Parghi, SS; Brandvold, KA; Bowers, SJ; Neiman, PE; Ruddell, A				Parghi, SS; Brandvold, KA; Bowers, SJ; Neiman, PE; Ruddell, A			Reduced Myc overexpression and normal B-cell differentiation mediate resistance to avian leukosis virus lymphomagenesis	ONCOGENE			English	Article						lymphoma resistance; c-Myc oncogene; avian leukosis virus	REPEAT-ENHANCED TRANSCRIPTION; PROVIRAL C-MYC; LYMPHOID LEUKOSIS; DNA INTEGRATION; EXPRESSION; CHICKENS; BURSA; FABRICIUS; INFECTION; ACTIVATION	Avian leukosis virus (ALV) induces bursal lymphoma in tumor-susceptible chicken strains after proviral integration within the c-myc gene, and subsequent expansion of Myc-overexpressing lymphocytes within transformed follicles. Line 63 strain chickens are resistant to ALV tumorigenesis, largely failing to develop Myc-transformed follicles, although they show similar levels of ALV infection and integration as lymphoma-susceptible strains. Immunohistochemical analysis determined that the transformed follicles that do arise in lymphoma-resistant birds show much lower and more variable Myc overexpression than those of susceptible birds. This reduced Myc overexpression fails to block B-cell differentiation in resistant birds, while high Myc consistently blocks development at a late embryo stage in susceptible birds. This failure of Myc to block differentiation results in a normal pattern of posthatching bursal emigration in resistant transformed follicles, while transformed follicles of susceptible birds grow rapidly due to blocked emigration. Forced Myc overexpression produces transformed follicles in resistant birds, indicating that resistant lymphocytes can tolerate high Myc expression. The coding sequence and expression of the endogenous c-myc gene is the same in resistant and susceptible birds, suggesting that genetic resistance is instead mediated by reduced ALV LTR enhancer-driven transcription in the target lymphocytes of resistant birds.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Ruddell, A (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N,POB 19024,MS C2-023, Seattle, WA 98109 USA.	aruddell@fhcrc.org		Ruddell, Alanna/0000-0002-0195-5576	NATIONAL CANCER INSTITUTE [R01CA068328, R01CA020068] Funding Source: NIH RePORTER; NCI NIH HHS [CA68328, CA20068] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BABA TW, 1984, J VIROL, V51, P123, DOI 10.1128/JVI.51.1.123-130.1984; BABA TW, 1985, P NATL ACAD SCI USA, V82, P213, DOI 10.1073/pnas.82.1.213; Bird KJ, 1999, ONCOGENE, V18, P201, DOI 10.1038/sj.onc.1202283; Bowers WJ, 1996, J VIROL, V70, P3051, DOI 10.1128/JVI.70.5.3051-3059.1996; Brandvold KA, 2000, ONCOGENE, V19, P2780, DOI 10.1038/sj.onc.1203589; Brandvold KA, 2001, ONCOGENE, V20, P3226, DOI 10.1038/sj.onc.1204431; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; COOPER MD, 1968, JNCI-J NATL CANCER I, V41, P373; Curristin SM, 1997, J VIROL, V71, P5972, DOI 10.1128/JVI.71.8.5972-5981.1997; ENRIETTO PJ, 1983, CELL, V35, P369, DOI 10.1016/0092-8674(83)90170-8; EWERT DL, 1988, ADV VET SCI COMP MED, V32, P37; FADLY AM, 1986, INT J CANCER, V38, P139, DOI 10.1002/ijc.2910380122; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; FUNG YKT, 1982, VIROLOGY, V119, P411; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gong M, 1998, J VIROL, V72, P5517, DOI 10.1128/JVI.72.7.5517-5525.1998; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HAYWARD WS, 1981, NATURE, V290, P475, DOI 10.1038/290475a0; HENRIKSSON M, 1996, ADV CANCER RES, V68, P110; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; LEE LF, 1981, J NATL CANCER I, V66, P789; MAAS HJL, 1982, AVIAN PATHOL, V11, P309, DOI 10.1080/03079458208436103; MASTELLER EL, 1995, J IMMUNOL, V155, P5550; NEIMAN PE, 1994, ADV IMMUNOL, V56, P467, DOI 10.1016/S0065-2776(08)60457-5; Neiman PE, 2001, P NATL ACAD SCI USA, V98, P6378, DOI 10.1073/pnas.111144898; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Ngo CV, 2000, CELL GROWTH DIFFER, V11, P201; OLSON WC, 1990, HYBRIDOMA, V9, P331, DOI 10.1089/hyb.1990.9.331; PARAMITHIOTIS E, 1994, EUR J IMMUNOL, V24, P458, DOI 10.1002/eji.1830240229; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; PURCHASE HG, 1977, NATURE, V270, P61, DOI 10.1038/270061a0; RUDDELL A, 1988, J VIROL, V62, P2728, DOI 10.1128/JVI.62.8.2728-2735.1988	33	3	4	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2004	23	25					4413	4421		10.1038/sj.onc.1207577	http://dx.doi.org/10.1038/sj.onc.1207577			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	824CJ	15064748				2022-12-28	WOS:000221661300007
J	Hubalek, MM; Widschwendter, A; Erdel, M; Gschwendtner, A; Fiegl, HM; Muller, HM; Goebel, G; Mueller-Holzner, E; Marth, C; Spruck, CH; Reed, SI; Widschwendter, M				Hubalek, MM; Widschwendter, A; Erdel, M; Gschwendtner, A; Fiegl, HM; Muller, HM; Goebel, G; Mueller-Holzner, E; Marth, C; Spruck, CH; Reed, SI; Widschwendter, M			Cyclin E dysregulation and chromosomal instability in endometrial cancer	ONCOGENE			English	Article						cyclin E; dysregulation; chromosomal instability; endometrial cancer	BREAST-CANCER; CELL-LINES; PHOSPHORYLATION; CARCINOMAS; ACTIVATION; TRANSITION; INDUCTION	Deregulation of cyclin E, an activator of cyclin-dependent kinase 2 (Cdk2), has been associated with a broad spectrum of human malignancies. Yet the mechanism linking abnormal cyclin E expression to carcinogenesis is largely unknown. The gene encoding the F-box protein hCdc4, a key component of the molecular machinery that targets cyclin E for degradation, is frequently mutated in endometrial cancer, leading to deregulation of cyclin E expression. Here we show that hCDC4 gene mutation and hyperphosphorylation of cyclin E, a parameter that usually correlates with hCDC4 mutation, have a strong statistically significant association with polypoidy and aneuploidy in endometrial cancer. On the contrary, elevated expression of cyclin E by itself was not significantly correlated with polyploidy or aneuploidy when tumors of similar grade are evaluated. These data suggest that impairment of cell cycle regulated proteolysis of cyclin E may be linked to carcinogenesis by promoting genomic instability.	Univ Innsbruck Hosp, Dept Obstet & Gynecol, A-6020 Innsbruck, Austria; Univ Innsbruck, Inst Med Biol & Human Genet, A-6020 Innsbruck, Austria; Univ Innsbruck, Dept Pathol, A-6020 Innsbruck, Austria; Univ Innsbruck, Dept Biostat & Documentat, A-6020 Innsbruck, Austria; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Medical University of Innsbruck; University of Innsbruck; University of Innsbruck; University of Innsbruck; Scripps Research Institute	Widschwendter, M (corresponding author), Univ Innsbruck Hosp, Dept Obstet & Gynecol, Anichstr 35, A-6020 Innsbruck, Austria.	martin.widschwendter@uibk.ac.at	Goebel, Georg/P-6909-2015; Hubalek, Michael/ABD-8041-2021; Fiegl, Heidi/K-4445-2017	Fiegl, Heidi/0000-0002-1236-6806; Widschwendter, Martin/0000-0002-7778-8380	NCI NIH HHS [CA78343] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078343, R56CA078343] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blegen H, 2003, ANAL CELL PATHOL, V25, P103, DOI 10.1155/2003/491362; BOCKING A, 1994, STATIC DNA CYTOMETRY, P107; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Coverley D, 2002, NAT CELL BIOL, V4, P523, DOI 10.1038/ncb813; Donnellan R, 1999, FASEB J, V13, P773, DOI 10.1096/fasebj.13.8.773; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; Erlanson M, 1998, CYTOMETRY, V32, P214, DOI 10.1002/(SICI)1097-0320(19980701)32:3<214::AID-CYTO8>3.3.CO;2-N; Haas K, 1997, ONCOGENE, V15, P2615, DOI 10.1038/sj.onc.1201434; Haroske G, 2001, ANAL CELL PATHOL, V23, P89, DOI 10.1155/2001/657642; Keyomarsi K, 2002, NEW ENGL J MED, V347, P1566, DOI 10.1056/NEJMoa021153; KEYOMARSI K, 1995, ONCOGENE, V11, P941; Knuutila S, 1999, AM J PATHOL, V155, P683, DOI 10.1016/S0002-9440(10)65166-8; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; MIKUZ G, 1985, ANAL QUANT CYTOL, V7, P343; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; Reed SI, 1996, BBA-REV CANCER, V1287, P151, DOI 10.1016/0304-419X(96)00006-6; Reed SI, 1997, CANCER SURV, V29, P7; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Spruck CH, 2002, CANCER RES, V62, P4535; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Suzuki A, 1997, HUM GENET, V100, P629, DOI 10.1007/s004390050565; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x	25	53	53	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 20	2004	23	23					4187	4192		10.1038/sj.onc.1207560	http://dx.doi.org/10.1038/sj.onc.1207560			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15048079				2022-12-28	WOS:000221520200019
J	Rajasekhar, VK; Holland, EC				Rajasekhar, VK; Holland, EC			Postgenomic global analysis of translational control induced by oncogenic signaling	ONCOGENE			English	Review						AKT; cancer; eiF-4E; oncogenic signal; Ras; translation	INITIATION-FACTOR 4E; MESSENGER-RNA TRANSLATION; CAP-BINDING PROTEIN; GENE-EXPRESSION PATTERNS; INTERNAL RIBOSOME ENTRY; 5' UNTRANSLATED REGION; GROWTH-FACTOR; MAMMALIAN TARGET; BREAST-CANCER; ORNITHINE-DECARBOXYLASE	It is commonly assumed that developmental and oncogenic signaling achieve their phenotypic effects primarily by directly regulating the transcriptional profile of cells. However, there is growing evidence that the direct effect on transcription may be overshadowed by differential effects on the translational efficiency of specific existing mRNA species. Global analysis of this effect using microarrays indicates that this mechanism of controlling protein production provides a highly specific, robust, and rapid response to oncogenic and developmental stimuli. The mRNAs so affected encode proteins involved in cell cell interaction, signal transduction, and growth control. Furthermore, a large number of transcription factors capable of secondarily rearranging the transcriptional pro. le of the cell are controlled at this level as well. To what degree this translational control is either necessary or sufficient for tumor formation or maintenance remains to be determined.	Mem Sloan Kettering Canc Ctr, Dept Surg Neurosurg, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Rajasekhar, VK (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Surg Neurosurg, 1275 York Ave, New York, NY 10021 USA.	vinagolr@mskcc.org; hollande@mskcc.org		Vinagolu, Rajasekhar/0000-0002-7364-2675	NCI NIH HHS [R01CA94842, U01CA894314, R01CA099489] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA099489, R01CA094842] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe A, 2002, TOHOKU J EXP MED, V198, P181, DOI 10.1620/tjem.198.181; Abrahante JE, 2003, DEV CELL, V4, P625, DOI 10.1016/S1534-5807(03)00127-8; Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Allan LA, 2003, NAT CELL BIOL, V5, P647, DOI 10.1038/ncb1005; Allenspach EJ, 2002, CANCER BIOL THER, V1, P466, DOI 10.4161/cbt.1.5.159; Amara FM, 1996, J BIOL CHEM, V271, P15279, DOI 10.1074/jbc.271.25.15279; Ambros V, 2003, CELL, V113, P673, DOI 10.1016/S0092-8674(03)00428-8; Anant S, 2002, BBA-GENE STRUCT EXPR, V1575, P54, DOI 10.1016/S0167-4781(02)00250-6; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; Aronov S, 1999, J MOL NEUROSCI, V12, P131, DOI 10.1007/BF02736927; ARRICK BA, 1991, MOL CELL BIOL, V11, P4306, DOI 10.1128/MCB.11.9.4306; Aster JC, 2001, CURR OPIN HEMATOL, V8, P237, DOI 10.1097/00062752-200107000-00010; Avni D, 1997, NUCLEIC ACIDS RES, V25, P995, DOI 10.1093/nar/25.5.995; Baehrecke EH, 2003, CURR BIOL, V13, pR473, DOI 10.1016/S0960-9822(03)00405-6; Balmer LA, 2001, MOL CELL BIOL, V21, P2070, DOI 10.1128/MCB.21.6.2070-2084.2001; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; BARNARD GF, 1993, CANCER RES, V53, P4048; Bauer C, 2002, INT J CANCER, V98, P181, DOI 10.1002/ijc.10180; Bauer C, 2001, CANCER, V92, P822, DOI 10.1002/1097-0142(20010815)92:4<822::AID-CNCR1388>3.0.CO;2-A; Begemann M, 2002, BRAIN PATHOL, V12, P117; Berkel HJ, 2001, CANCER EPIDEM BIOMAR, V10, P663; Beugnet A, 2003, J BIOL CHEM, V278, P40717, DOI 10.1074/jbc.M308573200; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Bhattacharya M, 2002, NAT CELL BIOL, V4, P547, DOI 10.1038/ncb821; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; BOHM H, 1991, BIOMED BIOCHIM ACTA, V50, P1193; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Brown CY, 1999, ONCOGENE, V18, P5631, DOI 10.1038/sj.onc.1202949; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calkhoven CF, 2002, TRENDS MOL MED, V8, P577, DOI 10.1016/S1471-4914(02)02424-3; Chappell SA, 2000, ONCOGENE, V19, P4437, DOI 10.1038/sj.onc.1203791; Chen X, 2003, MOL BIOL CELL, V14, P3208, DOI 10.1091/mbc.E02-12-0833; Cheok MH, 2003, NAT GENET, V34, P85, DOI 10.1038/ng1151; CHESTER KA, 1989, BIOCHIM BIOPHYS ACTA, V1009, P297, DOI 10.1016/0167-4781(89)90119-X; Child SJ, 1999, INT J BIOCHEM CELL B, V31, P201, DOI 10.1016/S1357-2725(98)00068-5; Choe G, 2003, CANCER RES, V63, P2742; Choi KM, 2003, J BIOL CHEM, V278, P19667, DOI 10.1074/jbc.M301142200; Choudhury A, 2000, J BIOL CHEM, V275, P33929, DOI 10.1074/jbc.M005115200; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Clemens MJ, 1999, INT J BIOCHEM CELL B, V31, P1, DOI 10.1016/S1357-2725(98)00127-7; COHEN RB, 1990, EMBO J, V9, P3831, DOI 10.1002/j.1460-2075.1990.tb07601.x; Coldwell MJ, 2000, ONCOGENE, V19, P899, DOI 10.1038/sj.onc.1203407; Conte N, 2002, ONCOGENE, V21, P5619, DOI 10.1038/sj.onc.1205658; Dahlman T, 2002, INT J CANCER, V98, P186, DOI 10.1002/ijc.10181; De Benedetti A, 1999, INT J BIOCHEM CELL B, V31, P59, DOI 10.1016/S1357-2725(98)00132-0; de la Vega CM, 2001, BIOCHEM J, V357, P819; De Vos J, 2002, ONCOGENE, V21, P6848, DOI 10.1038/sj.onc.1205868; DeFatta RJ, 2000, LARYNGOSCOPE, V110, P928, DOI 10.1097/00005537-200006000-00007; Del Valle L, 2000, ANN NEUROL, V48, P932, DOI 10.1002/1531-8249(200012)48:6<932::AID-ANA15>3.0.CO;2-E; Detich N, 2001, J BIOL CHEM, V276, P24881, DOI 10.1074/jbc.M103056200; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; Doench JG, 2003, GENE DEV, V17, P438, DOI 10.1101/gad.1064703; Doherty JK, 1999, GYNECOL ONCOL, V74, P408, DOI 10.1006/gyno.1999.5467; Doi N, 2003, CURR BIOL, V13, P41, DOI 10.1016/S0960-9822(02)01394-5; Dostie J, 2000, J CELL BIOL, V148, P239, DOI 10.1083/jcb.148.2.239; Dua K, 2001, PROTEOMICS, V1, P1191, DOI 10.1002/1615-9861(200110)1:10<1191::AID-PROT1191>3.0.CO;2-8; Dumont E, 2000, ONCOGENE, V19, P556, DOI 10.1038/sj.onc.1203352; Dyer JR, 2003, NAT NEUROSCI, V6, P219, DOI 10.1038/nn1018; Eberle J, 1997, INT J CANCER, V71, P396, DOI 10.1002/(SICI)1097-0215(19970502)71:3<396::AID-IJC16>3.0.CO;2-E; Edmonds BT, 1996, J CELL SCI, V109, P2705; ELBADRY OM, 1991, PROG CLIN BIOL RES, V366, P257; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; ENDER B, 1993, MOL CARCINOGEN, V7, P18, DOI 10.1002/mc.2940070104; Evers EE, 2000, EUR J CANCER, V36, P1269, DOI 10.1016/S0959-8049(00)00091-5; Ferrando AA, 2003, BLOOD, V102, P262, DOI 10.1182/blood-2002-10-3221; Flynn A, 1996, CANCER SURV, V27, P293; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Gingras AC, 2003, CURR TOP MICROBIOL, V279, P169; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Gopalkrishnan RV, 1999, INT J BIOCHEM CELL B, V31, P151, DOI 10.1016/S1357-2725(98)00138-1; Graff JR, 2003, CLIN EXP METASTAS, V20, P265, DOI 10.1023/A:1022943419011; GRENS A, 1990, J BIOL CHEM, V265, P11810; Groisman I, 2002, CELL, V109, P473, DOI 10.1016/S0092-8674(02)00733-X; Guan XY, 2001, CANCER RES, V61, P3806; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; Gygi SP, 1999, ELECTROPHORESIS, V20, P310, DOI 10.1002/(SICI)1522-2683(19990201)20:2<310::AID-ELPS310>3.0.CO;2-M; Ha PK, 2003, CLIN CANCER RES, V9, P3058; Hahn WC, 2002, NEW ENGL J MED, V347, P1593, DOI 10.1056/NEJMra021902; Han BG, 2003, ONCOGENE, V22, P5325, DOI 10.1038/sj.onc.1206783; Han XS, 2001, ONCOGENE, V20, P7976, DOI 10.1038/sj.onc.1204996; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Henics T, 2000, BIOCHEM BIOPH RES CO, V279, P40, DOI 10.1006/bbrc.2000.3900; Herbert TP, 2000, CURR BIOL, V10, P793, DOI 10.1016/S0960-9822(00)00567-4; Hernandez-Munoz I, 2000, ONCOGENE, V19, P2745, DOI 10.1038/sj.onc.1203586; Hernandez-Munoz I, 2003, CANCER RES, V63, P4188; Hofer F, 1998, CURR BIOL, V8, P839, DOI 10.1016/S0960-9822(98)70327-6; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Hoover DS, 1997, CELL GROWTH DIFFER, V8, P1371; Ikeda M, 1998, J BIOL CHEM, V273, P814, DOI 10.1074/jbc.273.2.814; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Johannes G, 1999, P NATL ACAD SCI USA, V96, P13118, DOI 10.1073/pnas.96.23.13118; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; Keene JD, 2002, MOL CELL, V9, P1161, DOI 10.1016/S1097-2765(02)00559-2; Keene JD, 2001, P NATL ACAD SCI USA, V98, P7018, DOI 10.1073/pnas.111145598; Kennedy NJ, 2003, GENE DEV, V17, P629, DOI 10.1101/gad.1062903; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kim SH, 2000, ONCOGENE, V19, P3086, DOI 10.1038/sj.onc.1203632; Kleijn M, 1998, EUR J BIOCHEM, V253, P531, DOI 10.1046/j.1432-1327.1998.2530531.x; Kolettas E, 1998, ANTICANCER RES, V18, P385; Krichevsky AM, 2003, RNA, V9, P1274, DOI 10.1261/rna.5980303; Kuhn KM, 2001, MOL CELL BIOL, V21, P916, DOI 10.1128/MCB.21.3.916-927.2001; Kumar V, 2000, J BIOL CHEM, V275, P10779, DOI 10.1074/jbc.275.15.10779; Kurz EU, 2001, BIOCHEM BIOPH RES CO, V285, P981, DOI 10.1006/bbrc.2001.5262; Lachance PED, 2002, MOL CELL BIOL, V22, P1656, DOI 10.1128/MCB.22.6.1656-1663.2002; Lai EC, 2003, CURR BIOL, V13, pR285, DOI 10.1016/S0960-9822(03)00203-3; Lasko P, 2003, DEV CELL, V5, P671, DOI 10.1016/S1534-5807(03)00333-2; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LECAM A, 1995, EUR J BIOCHEM, V231, P620; Leonardi P, 2002, ONCOGENE, V21, P5108, DOI 10.1038/sj.onc.1205694; Lin L, 2001, J CELL BIOCHEM, V80, P483, DOI 10.1002/1097-4644(20010315)80:4<483::AID-JCB1002>3.0.CO;2-B; Lin SY, 2003, DEV CELL, V4, P639, DOI 10.1016/S1534-5807(03)00124-2; Linnemann T, 2002, J BIOL CHEM, V277, P7831, DOI 10.1074/jbc.M110800200; Liu L, 1999, NAT GENET, V21, P128, DOI 10.1038/5082; Lobo MVT, 2000, HISTOCHEM J, V32, P139, DOI 10.1023/A:1004091122351; Loeb LA, 2003, P NATL ACAD SCI USA, V100, P776, DOI 10.1073/pnas.0334858100; Lowell S, 2000, CURR BIOL, V10, P491, DOI 10.1016/S0960-9822(00)00451-6; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Lyubimova A, 2000, J CELL BIOCHEM, V76, P1, DOI 10.1002/(SICI)1097-4644(20000101)76:1<1::AID-JCB1>3.0.CO;2-R; Manjeshwar S, 2003, CANCER RES, V63, P5251; Manning BD, 2003, BIOCHEM SOC T, V31, P573, DOI 10.1042/BST0310573; Marchetti A, 2001, INT J ONCOL, V18, P175; MARTH JD, 1988, NATURE, V332, P171, DOI 10.1038/332171a0; Martin G. Steven, 2003, Cancer Cell, V4, P167, DOI 10.1016/S1535-6108(03)00216-2; Martin ME, 2000, INT J BIOCHEM CELL B, V32, P633, DOI 10.1016/S1357-2725(00)00007-8; Mathur S, 1998, CANCER, V82, P816, DOI 10.1002/(SICI)1097-0142(19980301)82:5<816::AID-CNCR3>3.0.CO;2-H; McGonigle S, 2002, BIOCHEMISTRY-US, V41, P579, DOI 10.1021/bi011407z; McKendrick L, 2001, EUR J BIOCHEM, V268, P5375, DOI 10.1046/j.0014-2956.2001.02478.x; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Meric F, 2002, MOL CANCER THER, V1, P971; Meyuhas O, 2000, EUR J BIOCHEM, V267, P6321, DOI 10.1046/j.1432-1327.2000.01719.x; Miao WY, 1996, J BIOL CHEM, V271, P15322, DOI 10.1074/jbc.271.26.15322; Mikulits W, 2000, FASEB J, V14, P1641, DOI 10.1096/fj.14.11.1641; Miller SJ, 2000, MOL CELL BIOL, V20, P8420, DOI 10.1128/MCB.20.22.8420-8431.2000; MIMORI K, 1995, CANCER, V75, P1446, DOI 10.1002/1097-0142(19950315)75:6+<1446::AID-CNCR2820751509>3.0.CO;2-P; Mimori K, 1996, GUT, V38, P66, DOI 10.1136/gut.38.1.66; Miskimins WK, 2001, MOL CELL BIOL, V21, P4960, DOI 10.1128/MCB.21.15.4960-4967.2001; Modrek B, 2003, NAT GENET, V34, P177, DOI 10.1038/ng1159; Morrisey K, 2001, AM J PATHOL, V159, P1905, DOI 10.1016/S0002-9440(10)63037-4; Mousses S, 2002, CANCER RES, V62, P1256; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Nathan CAO, 2000, CANCER RES, V60, P3599; Nickoloff BJ, 2003, ONCOGENE, V22, P6598, DOI 10.1038/sj.onc.1206758; Nickoloff BJ, 2002, CELL DEATH DIFFER, V9, P842, DOI 10.1038/sj.cdd.4401036; NIELSEN FC, 1995, NATURE, V377, P358, DOI 10.1038/377358a0; Nojima H, 2003, J BIOL CHEM, V278, P15461, DOI 10.1074/jbc.C200665200; Nupponen NN, 1999, AM J PATHOL, V154, P1777, DOI 10.1016/S0002-9440(10)65433-8; O'Donnell WT, 2002, ANNU REV NEUROSCI, V25, P315, DOI 10.1146/annurev.neuro.25.112701.142909; Oliver TG, 2003, P NATL ACAD SCI USA, V100, P7331, DOI 10.1073/pnas.0832317100; Olsen PH, 1999, DEV BIOL, V216, P671, DOI 10.1006/dbio.1999.9523; Ostareck DH, 2001, CELL, V104, P281, DOI 10.1016/S0092-8674(01)00212-4; Ouwens DM, 2002, EMBO J, V21, P3782, DOI 10.1093/emboj/cdf361; Pedersen N, 2003, CANCER RES, V63, P1943; Pestova TV, 2001, P NATL ACAD SCI USA, V98, P7029, DOI 10.1073/pnas.111145798; Pincheira R, 2001, BRIT J CANCER, V84, P1520, DOI 10.1054/bjoc.2001.1828; Pollack JR, 2002, SEMIN ONCOL, V29, P280, DOI 10.1053/sonc.2002.32903; Polunovsky VA, 2000, J BIOL CHEM, V275, P24776, DOI 10.1074/jbc.M001938200; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Pozner A, 2000, MOL CELL BIOL, V20, P2297, DOI 10.1128/MCB.20.7.2297-2307.2000; Prendergast GC, 2003, CANCER CELL, V4, P244, DOI 10.1016/S1535-6108(03)00247-2; Proud CG, 1997, BIOCHEM J, V328, P329; Proud CG, 2001, BIOCHEM SOC T, V29, P541, DOI 10.1042/BST0290541; Pruitt K, 2002, J BIOL CHEM, V277, P31808, DOI 10.1074/jbc.M203964200; Ptashne M, 2003, SCIENCE, V299, P1025, DOI 10.1126/science.1081519; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Rajagopal S, 2001, CELL COMMUN ADHES, V8, P87, DOI 10.3109/15419060109080709; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Ramirez de Molina A, 2002, ONCOGENE, V21, P937, DOI 10.1038/sj.onc.1205144; RAO LVM, 1983, PLANT SCI LETT, V29, P207; RHOADS RE, 1993, PROG NUCLEIC ACID RE, V46, P183, DOI 10.1016/S0079-6603(08)61022-3; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; Rosenwald IB, 1996, CANCER LETT, V102, P113, DOI 10.1016/0304-3835(96)04171-7; Rosenwald IB, 2003, CANCER-AM CANCER SOC, V98, P1080, DOI 10.1002/cncr.11619; Ross ME, 2003, BLOOD, V102, P2951, DOI 10.1182/blood-2003-01-0338; Rothe M, 2000, AM J PATHOL, V157, P1597, DOI 10.1016/S0002-9440(10)64797-9; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Sachs AB, 2000, NAT STRUCT BIOL, V7, P356, DOI 10.1038/75120; Sager R, 1997, P NATL ACAD SCI USA, V94, P952, DOI 10.1073/pnas.94.3.952; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Savitsky K, 1997, NUCLEIC ACIDS RES, V25, P1678, DOI 10.1093/nar/25.9.1678; Sawaoka H, 2003, J BIOL CHEM, V278, P13928, DOI 10.1074/jbc.M300016200; Saxena A, 2002, CANCER LETT, V187, P199, DOI 10.1016/S0304-3835(02)00378-6; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; Schaner ME, 2003, MOL BIOL CELL, V14, P4376, DOI 10.1091/mbc.e03-05-0279; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Seggerson K, 2002, DEV BIOL, V243, P215, DOI 10.1006/dbio.2001.0563; Senga T, 2001, J BIOL CHEM, V276, P32678, DOI 10.1074/jbc.M105749200; Shai R, 2003, ONCOGENE, V22, P4918, DOI 10.1038/sj.onc.1206753; Shamji AF, 2003, MOL CELL, V12, P271, DOI 10.1016/j.molcel.2003.08.016; Shantz LM, 1996, CANCER RES, V56, P3265; Shibao K, 1999, INT J CANCER, V83, P732; Shuda M, 2000, ANTICANCER RES, V20, P2489; Signori E, 2001, ONCOGENE, V20, P4596, DOI 10.1038/sj.onc.1204620; Sonenberg N, 2003, CURR OPIN STRUC BIOL, V13, P56, DOI 10.1016/S0959-440X(03)00009-5; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; Sorrells DL, 1999, HEAD NECK-J SCI SPEC, V21, P60, DOI 10.1002/(SICI)1097-0347(199901)21:1<60::AID-HED8>3.3.CO;2-A; Sorrells DL, 1998, ANN SURG ONCOL, V5, P232, DOI 10.1007/BF02303778; Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100; Spurdle AB, 2003, GYNECOL ONCOL, V90, P145, DOI 10.1016/S0090-8258(03)00193-8; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Struyk L, 2000, MOL CARCINOGEN, V28, P42, DOI 10.1002/(SICI)1098-2744(200005)28:1<42::AID-MC6>3.0.CO;2-8; Tanaka M, 2001, MOL BRAIN RES, V91, P81, DOI 10.1016/S0169-328X(01)00125-5; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Tenenbaum SA, 2002, METHODS, V26, P191, DOI 10.1016/S1046-2023(02)00022-1; Tenenbaum SA, 2000, P NATL ACAD SCI USA, V97, P14085, DOI 10.1073/pnas.97.26.14085; Trotta R, 2003, CANCER CELL, V3, P145, DOI 10.1016/S1535-6108(03)00020-5; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van den Boom J, 2003, AM J PATHOL, V163, P1033, DOI 10.1016/S0002-9440(10)63463-3; van der Velden AW, 1999, INT J BIOCHEM CELL B, V31, P87, DOI 10.1016/S1357-2725(98)00134-4; Van der Velden AW, 2000, INT J DEV BIOL, V44, P843; VARESIO L, 1980, J IMMUNOL, V124, P2288; Verma A, 2003, CANCER METAST REV, V22, P423, DOI 10.1023/A:1023805715476; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; Vidal A, 2002, J BIOL CHEM, V277, P16433, DOI 10.1074/jbc.M112090200; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; vonManteuffel SR, 1997, MOL CELL BIOL, V17, P5426, DOI 10.1128/MCB.17.9.5426; WANG CY, 1993, CELL GROWTH DIFFER, V4, P871; Wang LJ, 2002, CIRC RES, V91, P821, DOI 10.1161/01.RES.0000041029.97988.E9; Wang ST, 1999, AM J PATHOL, V155, P247, DOI 10.1016/S0002-9440(10)65118-8; Ward Y, 2001, MOL CELL BIOL, V21, P5958, DOI 10.1128/MCB.21.17.5958-5969.2001; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Watkins SJ, 2002, BRIT J CANCER, V86, P1023, DOI 10.1038/sj/bjc/6600222; Welsh GI, 1996, J BIOL CHEM, V271, P11410, DOI 10.1074/jbc.271.19.11410; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; WIKSTRAND CJ, 1995, CANCER RES, V55, P3140; Wilkie GS, 2003, TRENDS BIOCHEM SCI, V28, P182, DOI 10.1016/S0968-0004(03)00051-3; Willert Jennifer, 2002, BMC Dev Biol, V2, P8, DOI 10.1186/1471-213X-2-8; Willis AE, 1999, INT J BIOCHEM CELL B, V31, P73, DOI 10.1016/S1357-2725(98)00133-2; Witteck A, 2003, EXP CELL RES, V287, P106, DOI 10.1016/S0014-4827(03)00129-0; Wolthuis RMF, 1998, CURR BIOL, V8, P471, DOI 10.1016/S0960-9822(98)70183-6; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1; WOLTHUIS RMF, 1993, BIOCHIM BIOPHYS ACTA, V1177, P160, DOI 10.1016/0167-4889(93)90035-N; Xu Q, 2003, NUCLEIC ACIDS RES, V31, P5635, DOI 10.1093/nar/gkg786; Yamaguchi A, 1997, J BIOL CHEM, V272, P31230, DOI 10.1074/jbc.272.50.31230; Yang DQ, 2000, NAT CELL BIOL, V2, P893, DOI 10.1038/35046542; Yee WM, 1997, MOL CELL BIOL, V17, P921, DOI 10.1128/MCB.17.2.921; Yu JJ, 2001, ONCOGENE, V20, P7694, DOI 10.1038/sj.onc.1204977; Zimmer SG, 2000, ANTICANCER RES, V20, P1343; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775	253	73	80	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2004	23	18					3248	3264		10.1038/sj.onc.1207546	http://dx.doi.org/10.1038/sj.onc.1207546			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	813AJ	15094774				2022-12-28	WOS:000220879700013
J	Debatin, KM; Krammer, PH				Debatin, KM; Krammer, PH			Death receptors in chemotherapy and cancer	ONCOGENE			English	Review						apoptosis; death receptors; CD95; drugs; resistance	ACUTE MYELOID-LEUKEMIA; APOPTOSIS-INDUCING LIGAND; DRUG-INDUCED APOPTOSIS; NF-KAPPA-B; BAX PROTEIN EXPRESSION; NON-HODGKINS-LYMPHOMA; BCL-2 ANTISENSE OLIGONUCLEOTIDE; FLICE-INHIBITORY PROTEIN; IRRADIATION-INDUCED APOPTOSIS; ACUTE LYMPHOBLASTIC-LEUKEMIA	Apoptosis, the cell's intrinsic death program, is a key regulator of tissue homeostasis. An imbalance between cell death and proliferation may result in tumor formation. Also, killing of cancer cells by cytotoxic therapies such as chemotherapy, gamma-irradiation or ligation of death receptors is predominantly mediated by triggering apoptosis in target cells. In addition to the intrinsic mitochondrial pathway, elements of death receptor signaling pathways have been implied to contribute to the efficacy of cancer therapy. Failure to undergo apoptosis in response to anticancer therapy may lead to resistance. Also, deregulated expression of death receptor pathway molecules may contribute to tumorigenesis and tumor escape from endogenous growth control. Understanding the molecular events that regulate apoptosis induced by anticancer therapy and how cancer cells evade apoptosis may provide new opportunities for pathway-based rational therapy and for drug development.	Univ Childrens Hosp, D-89075 Ulm, Germany; German Canc Res Ctr, D-69120 Heidelberg, Germany	Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf; Helmholtz Association; German Cancer Research Center (DKFZ)	Debatin, KM (corresponding author), Univ Childrens Hosp, Prittwitzstr 43, D-89075 Ulm, Germany.	klaus-michael.debatin@medizin.uni-ulm.de	Debatin, Klaus-Michael/J-9704-2014	Debatin, Klaus-Michael/0000-0002-8397-1886				Adida C, 2000, BRIT J HAEMATOL, V111, P196, DOI 10.1046/j.1365-2141.2000.02328.x; Adida C, 1998, LANCET, V351, P882, DOI 10.1016/S0140-6736(05)70294-4; Adrain C, 2001, TRENDS BIOCHEM SCI, V26, P390, DOI 10.1016/S0968-0004(01)01844-8; Algeciras-Schimnich A, 2003, P NATL ACAD SCI USA, V100, P11445, DOI 10.1073/pnas.2034995100; Allison J, 1997, P NATL ACAD SCI USA, V94, P3943, DOI 10.1073/pnas.94.8.3943; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Altieri DC, 2001, TRENDS MOL MED, V7, P542, DOI 10.1016/S1471-4914(01)02243-2; Altieri DC, 2003, ADV CANCER RES, V88, P31, DOI 10.1016/S0065-230X(03)88303-3; Apolinario RM, 1997, J CLIN ONCOL, V15, P2456, DOI 10.1200/JCO.1997.15.6.2456; Arai H, 1997, P NATL ACAD SCI USA, V94, P13862, DOI 10.1073/pnas.94.25.13862; Arnt CR, 2002, J BIOL CHEM, V277, P44236, DOI 10.1074/jbc.M207578200; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baghdassarian N, 2001, LEUKEMIA LYMPHOMA, V42, P1067, DOI 10.3109/10428190109097727; Banerjee D, 2001, Curr Opin Investig Drugs, V2, P574; BARGOU RC, 1995, INT J CANCER, V60, P854, DOI 10.1002/ijc.2910600622; Baylin S, 2002, CANCER CELL, V1, P299, DOI 10.1016/S1535-6108(02)00061-2; Behrens CK, 2001, J IMMUNOL, V166, P3240, DOI 10.4049/jimmunol.166.5.3240; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; Beltinger C, 1999, P NATL ACAD SCI USA, V96, P8699, DOI 10.1073/pnas.96.15.8699; Beltinger C, 1998, BLOOD, V91, P3943; Bennett MW, 1998, J IMMUNOL, V160, P5669; Borner C, 1999, CELL DEATH DIFFER, V6, P497, DOI 10.1038/sj.cdd.4400525; Boudard D, 2002, AM J HEMATOL, V70, P115, DOI 10.1002/ajh.10108; Bratton SB, 2000, EXP CELL RES, V256, P27, DOI 10.1006/excr.2000.4835; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; CAMPOS L, 1993, BLOOD, V81, P3091; Campos L, 1996, LEUKEMIA, V10, P434; Campos L, 1999, LEUKEMIA LYMPHOMA, V33, P499, DOI 10.3109/10428199909058454; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Chen Y, 1999, ANTICANCER RES, V19, P1351; Cheok MH, 2003, NAT GENET, V34, P85, DOI 10.1038/ng1151; Chi KN, 2001, CLIN CANCER RES, V7, P3920; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; Chuntharapai A, 2001, J IMMUNOL, V166, P4891, DOI 10.4049/jimmunol.166.8.4891; Colomo L, 2003, BLOOD, V101, P78, DOI 10.1182/blood-2002-04-1286; COTTER FE, 1994, ONCOGENE, V9, P3049; CoustanSmith E, 1996, BLOOD, V87, P1140, DOI 10.1182/blood.V87.3.1140.bloodjournal8731140; Cowling V, 2002, CELL DEATH DIFFER, V9, P1046, DOI 10.1038/sj.cdd.4401065; Datta R, 2000, J BIOL CHEM, V275, P31733, DOI 10.1074/jbc.M910231199; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; Debatin KM, 1997, J NATL CANCER I, V89, P750, DOI 10.1093/jnci/89.11.750; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Del Poeta G, 2003, BLOOD, V101, P2125, DOI 10.1182/blood-2002-06-1714; Droin N, 1998, ONCOGENE, V16, P2885, DOI 10.1038/sj.onc.1201821; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; EBATIN KM, 1999, ROLE CD95 SYSTEM CHE, P85; Ehrhardt H, 2003, ONCOGENE, V22, P3842, DOI 10.1038/sj.onc.1206520; Eichhorst ST, 2001, CANCER RES, V61, P243; Eichhorst ST, 2000, MOL CELL BIOL, V20, P7826, DOI 10.1128/MCB.20.20.7826-7837.2000; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; El-Deiry WS, 2001, CELL DEATH DIFFER, V8, P1066, DOI 10.1038/sj.cdd.4400943; Elnemr A, 2001, INT J ONCOL, V18, P311; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; Estrov Z, 1998, BLOOD, V92, P3090, DOI 10.1182/blood.V92.9.3090; Ferri KF, 2000, NAT CELL BIOL, V2, pE63, DOI 10.1038/35008692; Finkel E, 1999, SCIENCE, V286, P2256, DOI 10.1126/science.286.5448.2256; French LE, 2002, SEMIN CANCER BIOL, V12, P51, DOI 10.1006/scbi.2001.0405; French LE, 1999, J EXP MED, V190, P891, DOI 10.1084/jem.190.7.891; Friesen C, 1999, CELL DEATH DIFFER, V6, P471, DOI 10.1038/sj.cdd.4400512; Friesen C, 1997, LEUKEMIA, V11, P1833, DOI 10.1038/sj.leu.2400827; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fulda S, 1997, CANCER RES, V57, P4956; Fulda S, 1998, CANCER RES, V58, P4453; Fulda S, 2000, BLOOD, V95, P301, DOI 10.1182/blood.V95.1.301.001k24_301_308; Fulda S, 1998, CELL DEATH DIFFER, V5, P884, DOI 10.1038/sj.cdd.4400419; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Fulda S, 1997, CANCER RES, V57, P3823; Fulda S, 2002, ONCOGENE, V21, P2295, DOI 10.1038/sj.onc.1205255; Fulda S, 1998, INT J CANCER, V76, P105; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Fulda S, 2001, ONCOGENE, V20, P1063, DOI 10.1038/sj.onc.1204141; Fulda S, 2000, CANCER RES, V60, P3947; GALA JL, 1994, ANN HEMATOL, V69, P17, DOI 10.1007/BF01757343; Gascoyne RD, 1997, BLOOD, V90, P3173, DOI 10.1182/blood.V90.8.3173; Gascoyne RD, 1997, BLOOD, V90, P244; Gessner C, 2002, EUR RESPIR J, V19, P134, DOI 10.1183/09031936.02.00219402; Giatromanolaki A, 2001, ANTICANCER RES, V21, P253; Glaser T, 1999, ONCOGENE, V18, P5044, DOI 10.1038/sj.onc.1202882; Gliniak B, 1999, CANCER RES, V59, P6153; Golub TR, 2003, NAT MED, V9, P510, DOI 10.1038/nm0503-510; Green DR, 2001, NAT REV MOL CELL BIO, V2, P917, DOI 10.1038/35103104; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Gronbaek K, 1998, BLOOD, V92, P3018; Guo F, 2002, BLOOD, V99, P3419, DOI 10.1182/blood.V99.9.3419; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Harper N, 2001, J BIOL CHEM, V276, P34743, DOI 10.1074/jbc.M105693200; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hermine O, 1996, BLOOD, V87, P265, DOI 10.1182/blood.V87.1.265.bloodjournal871265; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; Hogarth LA, 1999, BLOOD, V93, P2671, DOI 10.1182/blood.V93.8.2671.408k26_2671_2678; Holcik M, 2001, NAT REV MOL CELL BIO, V2, P550, DOI 10.1038/35080103; Houghton JA, 1997, P NATL ACAD SCI USA, V94, P8144, DOI 10.1073/pnas.94.15.8144; Hu W, 2003, LANCET ONCOL, V4, P721, DOI 10.1016/S1470-2045(03)01277-4; Hyer ML, 2000, MOL THER, V2, P348, DOI 10.1006/mthe.2000.0139; Ichikawa K, 2001, NAT MED, V7, P954, DOI 10.1038/91000; Igney FH, 2002, J LEUKOCYTE BIOL, V71, P907; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Igney FH, 2000, EUR J IMMUNOL, V30, P725, DOI 10.1002/1521-4141(200003)30:3<725::AID-IMMU725>3.3.CO;2-4; Iijima N, 1997, BLOOD, V90, P4901, DOI 10.1182/blood.V90.12.4901.4901_4901_4909; Ionov Y, 2000, P NATL ACAD SCI USA, V97, P10872, DOI 10.1073/pnas.190210897; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Jeremias I, 1998, BLOOD, V91, P4624, DOI 10.1182/blood.V91.12.4624.412k19_4624_4631; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Johnson DE, 2000, LEUKEMIA, V14, P1695, DOI 10.1038/sj.leu.2401879; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kamihira S, 1999, BRIT J HAEMATOL, V107, P851, DOI 10.1046/j.1365-2141.1999.01792.x; Kang SM, 1997, NAT MED, V3, P738, DOI 10.1038/nm0797-738; Kang SM, 1997, SCIENCE, V278, P1322, DOI 10.1126/science.278.5341.1322; Kanwar JR, 2001, J NATL CANCER I, V93, P1541, DOI 10.1093/jnci/93.20.1541; Kapranos N, 1997, ANTICANCER RES, V17, P2499; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kataoka T, 1998, J IMMUNOL, V161, P3936; KAUFMANN SH, 1989, CANCER RES, V49, P5870; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; Kaufmann SH, 2003, ONCOGENE, V22, P7414, DOI 10.1038/sj.onc.1206945; Keane MM, 2000, BREAST CANCER RES TR, V64, P211, DOI 10.1023/A:1006458407515; Kinoshita H, 2000, INT J CANCER, V88, P986, DOI 10.1002/1097-0215(20001215)88:6<986::AID-IJC23>3.0.CO;2-B; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kohler T, 2002, LEUKEMIA, V16, P22, DOI 10.1038/sj.leu.2402340; KRAJEWSKI S, 1995, LAB INVEST, V72, P42; Krajewski S, 1999, ENDOCR-RELAT CANCER, V6, P29, DOI 10.1677/erc.0.0060029; Krajewski S, 1997, CLIN CANCER RES, V3, P199; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kymionis GD, 2001, J SURG RES, V99, P161, DOI 10.1006/jsre.2001.6084; Landowski TH, 1999, BLOOD, V94, P265, DOI 10.1182/blood.V94.1.265.413k37_265_274; Landowski TH, 2001, LEUKEMIA LYMPHOMA, V42, P835, DOI 10.3109/10428190109097702; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Lau HT, 1996, SCIENCE, V273, P109, DOI 10.1126/science.273.5271.109; Lauria F, 1997, LEUKEMIA, V11, P2075, DOI 10.1038/sj.leu.2400854; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Lee SH, 2000, J INVEST DERMATOL, V114, P122, DOI 10.1046/j.1523-1747.2000.00819.x; Lee SH, 2001, ONCOGENE, V20, P399, DOI 10.1038/sj.onc.1204103; LEE SH, 2001, NAT REV MOL CELL BIO, V2, P589; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Leverkus M, 1997, EXP CELL RES, V232, P255, DOI 10.1006/excr.1997.3514; Li JL, 2001, ENDOCRINOLOGY, V142, P370, DOI 10.1210/en.142.1.370; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Lopez-Guillermo A, 1999, BLOOD, V93, P3081, DOI 10.1182/blood.V93.9.3081; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Lowe Scott W., 1995, Current Opinion in Oncology, V7, P547, DOI 10.1097/00001622-199511000-00013; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Mandruzzato S, 1997, J EXP MED, V186, P785, DOI 10.1084/jem.186.5.785; Marcucci G, 2003, BLOOD, V101, P425, DOI 10.1182/blood-2002-06-1899; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; MAUNG ZT, 1994, BRIT J HAEMATOL, V88, P105, DOI 10.1111/j.1365-2141.1994.tb04984.x; Meng RD, 2000, MOL THER, V1, P130, DOI 10.1006/mthe.2000.0025; Meng RD, 2001, EXP CELL RES, V262, P154, DOI 10.1006/excr.2000.5073; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Micheau O, 1999, BIOCHEM BIOPH RES CO, V256, P603, DOI 10.1006/bbrc.1999.0391; Min YH, 1996, BRIT J HAEMATOL, V93, P928; MIYASHITA T, 1993, BLOOD, V81, P151; Mo YY, 1999, MOL PHARMACOL, V55, P216, DOI 10.1124/mol.55.2.216; Morris MJ, 2002, CLIN CANCER RES, V8, P679; Mrozek A, 2003, CELL DEATH DIFFER, V10, P461, DOI 10.1038/sj.cdd.4401193; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Muschen M, 2002, TRENDS IMMUNOL, V23, P75, DOI 10.1016/S1471-4906(01)02115-9; Nagane M, 2000, CANCER RES, V60, P847; Nakata B, 1998, ONCOLOGY-BASEL, V55, P543, DOI 10.1159/000011910; Nitsch R, 2000, LANCET, V356, P827, DOI 10.1016/S0140-6736(00)02659-3; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; Olie RA, 2002, J INVEST DERMATOL, V118, P505, DOI 10.1046/j.0022-202x.2001.01677.x; Olsson A, 2001, LEUKEMIA, V15, P1868, DOI 10.1038/sj.leu.2402287; Ong YL, 2000, BRIT J HAEMATOL, V111, P182, DOI 10.1046/j.1365-2141.2000.02315.x; Ozoren N, 2003, SEMIN CANCER BIOL, V13, P135, DOI 10.1016/S1044-579X(02)00131-1; Pai SI, 1998, CANCER RES, V58, P3513; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Park WS, 2002, ONCOGENE, V21, P2919, DOI 10.1038/sj.onc.1205394; Park WS, 2001, GASTROENTEROLOGY, V121, P1219, DOI 10.1053/gast.2001.28663; Park WS, 2001, J PATHOL, V193, P162; Parker JE, 2000, BLOOD, V96, P3932, DOI 10.1182/blood.V96.12.3932.h8003932_3932_3938; PEZZELLA F, 1992, BRIT J CANCER, V65, P87, DOI 10.1038/bjc.1992.16; PIRIS MA, 1994, BRIT J CANCER, V69, P337, DOI 10.1038/bjc.1994.61; Pitti RM, 1998, NATURE, V396, P699, DOI 10.1038/25387; Plumas J, 1998, BLOOD, V91, P2875, DOI 10.1182/blood.V91.8.2875.2875_2875_2885; Poulaki V, 2001, DRUG RESIST UPDATE, V4, P233, DOI 10.1054/drup.2001.0210; Prokop A, 2000, LEUKEMIA, V14, P1606, DOI 10.1038/sj.leu.2401866; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Rassidakis GZ, 2002, BLOOD, V100, P3935, DOI 10.1182/blood.V100.12.3935; Rau B, 2003, J CLIN ONCOL, V21, P3391, DOI 10.1200/JCO.2003.07.077; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Reap EA, 1997, P NATL ACAD SCI USA, V94, P5750, DOI 10.1073/pnas.94.11.5750; Reed J C, 1997, Adv Pharmacol, V41, P501, DOI 10.1016/S1054-3589(08)61070-4; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Reed JC, 1996, J CLIN INVEST, V97, P2403, DOI 10.1172/JCI118684; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Restifo NP, 2001, NAT MED, V7, P259, DOI 10.1038/85357; Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717; Robertson LE, 1996, LEUKEMIA, V10, P456; Rochaix P, 1999, J PATHOL, V187, P410, DOI 10.1002/(SICI)1096-9896(199903)187:4<410::AID-PATH266>3.0.CO;2-F; Rohn TA, 2001, ONCOGENE, V20, P4128, DOI 10.1038/sj.onc.1204534; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Roy S, 2000, J EXP MED, V192, pF21, DOI 10.1084/jem.192.8.F21; Rudin CM, 2002, ANN ONCOL, V13, P539, DOI 10.1093/annonc/mdf124; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; Samowitz WS, 2002, GENE CHROMOSOME CANC, V35, P368, DOI 10.1002/gcc.10125; Satomi D, 2002, INT J ONCOL, V20, P1167; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schelwies K, 2002, INT J CANCER, V99, P589, DOI 10.1002/ijc.10380; Schimmer Aaron D, 2003, Curr Treat Options Oncol, V4, P211, DOI 10.1007/s11864-003-0022-y; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; SCHREIVER F, 2001, LANCET, V2, P33; Shin MS, 2001, CANCER RES, V61, P4942; Shin MS, 2002, BLOOD, V99, P4094, DOI 10.1182/blood.V99.11.4094; Shin MS, 2002, ONCOGENE, V21, P4129, DOI 10.1038/sj.onc.1205527; Sjostrom J, 2002, CLIN CANCER RES, V8, P811; Sjostrom J, 1998, BRIT J CANCER, V78, P812, DOI 10.1038/bjc.1998.584; Slee EA, 1999, CELL DEATH DIFFER, V6, P1067, DOI 10.1038/sj.cdd.4400601; Solary E, 2000, LEUKEMIA, V14, P1833, DOI 10.1038/sj.leu.2401902; Sperandio S, 2000, P NATL ACAD SCI USA, V97, P14376, DOI 10.1073/pnas.97.26.14376; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Srinivasula SM, 1999, CANCER RES, V59, P999; Stahnke K, 2003, LEUKEMIA, V17, P2130, DOI 10.1038/sj.leu.2403144; Stahnke K, 2001, BLOOD, V98, P3066, DOI 10.1182/blood.V98.10.3066; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; Sturm I, 2001, J CLIN ONCOL, V19, P2272, DOI 10.1200/JCO.2001.19.8.2272; Sturm I, 1999, J CLIN ONCOL, V17, P1364, DOI 10.1200/JCO.1999.17.5.1364; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Svingen PA, 2000, BLOOD, V96, P3922, DOI 10.1182/blood.V96.12.3922.h8003922_3922_3931; TAKAKAWA T, 2001, CANCER RES, V15, P1382; Takayama H, 2002, AM J PATHOL, V161, P635, DOI 10.1016/S0002-9440(10)64219-8; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Tamm I, 2000, CLIN CANCER RES, V6, P1796; Tamm I, 2003, J BIOL CHEM, V278, P14401, DOI 10.1074/jbc.M210133200; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; ten Berge RL, 2002, BLOOD, V99, P4540, DOI 10.1182/blood.V99.12.4540; Tepper CG, 1999, BLOOD, V94, P1727, DOI 10.1182/blood.V94.5.1727.417k03_1727_1737; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; Tsurusawa M, 1998, PEDIATR HEMAT ONCOL, V15, P143, DOI 10.3109/08880019809167229; Utz PJ, 2000, CELL DEATH DIFFER, V7, P589, DOI 10.1038/sj.cdd.4400696; Vakkala M, 1999, CLIN CANCER RES, V5, P319; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; van Noesel MM, 2002, CANCER RES, V62, P2157; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vassallo J, 2003, LEUKEMIA LYMPHOMA, V44, P483, DOI 10.1080/1042819021000037958; Veronese S, 1998, INT J CANCER, V79, P13, DOI 10.1002/(SICI)1097-0215(19980220)79:1<13::AID-IJC3>3.0.CO;2-Z; Villunger A, 1999, NAT MED, V5, P874, DOI 10.1038/11311; Villunger A, 1997, CANCER RES, V57, P3331; Villunger A, 1997, BLOOD, V90, P12; Wajant H, 2002, APOPTOSIS, V7, P449, DOI 10.1023/A:1020039225764; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Waters JS, 2000, J CLIN ONCOL, V18, P1812, DOI 10.1200/JCO.2000.18.9.1812; Webb A, 1997, LANCET, V349, P1137, DOI 10.1016/S0140-6736(96)11103-X; Wendum D, 1997, J CLIN ONCOL, V15, P1654, DOI 10.1200/JCO.1997.15.4.1654; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; WHANGPENG J, 1995, BLOOD, V85, P203, DOI 10.1182/blood.V85.1.203.bloodjournal851203; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Wuchter C, 2000, BRIT J HAEMATOL, V110, P154, DOI 10.1046/j.1365-2141.2000.02147.x; Wuchter C, 1999, LEUKEMIA, V13, P1943, DOI 10.1038/sj.leu.2401605; WUCHTER C, 1999, BLOOD, V93, P2671; Xia CY, 2002, MOL CANCER THER, V1, P687; Yamamoto H, 1999, GASTROENTEROLOGY, V116, P1348, DOI 10.1016/S0016-5085(99)70499-3; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang LL, 2003, CANCER RES, V63, P831; Yang XH, 2001, CANCER RES, V61, P348; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Ziegler A, 1997, JNCI-J NATL CANCER I, V89, P1027, DOI 10.1093/jnci/89.14.1027	284	395	424	0	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2004	23	16					2950	2966		10.1038/sj.onc.1207558	http://dx.doi.org/10.1038/sj.onc.1207558			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	811VO	15077156				2022-12-28	WOS:000220799600020
J	Saelens, X; Festjens, N; Vande Walle, L; van Gurp, M; van Loo, G; Vandenabeele, P				Saelens, X; Festjens, N; Vande Walle, L; van Gurp, M; van Loo, G; Vandenabeele, P			Toxic proteins released from mitochondria in cell death	ONCOGENE			English	Review						mitochondria; cytochrome c; Smac/DIABLO; endonuclease G; AIF; HtrA2/OMI	APOPTOSIS-INDUCING FACTOR; SERINE-PROTEASE OMI/HTRA2; CYTOCHROME-C RELEASE; WD-40 REPEAT REGION; CASPASE ACTIVATION; DNA-DEGRADATION; STRUCTURAL BASIS; ENDONUCLEASE-G; PDZ DOMAINS; CAENORHABDITIS-ELEGANS	A plethora of apoptotic stimuli converge on the mitochondria and affect their membrane integrity. As a consequence, multiple death-promoting factors residing in the mitochondrial intermembrane space are liberated in the cytosol. Pro- and antiapoptotic Bcl-2 family proteins control the release of these mitochondrial proteins by inducing or preventing permeabilization of the outer mitochondrial membrane. Once released into the cytosol, these mitochondrial proteins activate both caspase-dependent and -independent cell death pathways. Cytochrome c was the first protein shown to be released from the mitochondria into the cytosol, where it induces apoptosome formation. Other released mitochondrial proteins include apoptosis-inducing factor (AIF) and endonuclease G, both of which contribute to apoptotic nuclear DNA damage in a caspase-independent way. Other examples are Smac/DIABLO(second mitochondria-derived activator of caspase/direct IAP-binding protein with low PI) and the serine protease HtrA2/OMI (high-temperature requirement protein A2), which both promote caspase activation and instigate caspase-independent cytotoxicity. The precise mode of action and importance of cytochrome c in apoptosis in mammalian cells has become clear through biochemical, structural and genetic studies. More recently identified factors, for example HtrA2/OMI and Smac/DIABLO, are still being studied intensively in order to delineate their functions in apoptosis. A better understanding of these functions may help to develop new strategies to treat cancer.	VIB, Dept Mol & Biomed Res, Mol Signalling & Cell Death Unit, B-9052 Ghent, Belgium; State Univ Ghent, B-9052 Ghent, Belgium; EMBL Monterotondo, Mouse Biol Program, I-00016 Monterotondo, Italy	Flanders Institute for Biotechnology (VIB); Ghent University; European Molecular Biology Laboratory (EMBL)	Vandenabeele, P (corresponding author), VIB, Dept Mol & Biomed Res, Mol Signalling & Cell Death Unit, Fiers Shell Van Montagu Bldg, B-9052 Ghent, Belgium.	peter.vandenabeele@dmbr.ugent.be	van Loo, Geert/C-1505-2009; , van Loo Geert/AAD-1220-2019; Vandenabeele, Peter/C-8597-2009; Vandenabeele, Peter/AAD-5793-2022; Festjens, Nele/C-2093-2009; Saelens, Xavier/N-5728-2015	, van Loo Geert/0000-0002-8427-4775; Vandenabeele, Peter/0000-0002-6669-8822; Festjens, Nele/0000-0002-3429-5463; , Xavier/0000-0002-3861-6965				Abdullaev ZK, 2002, BIOCHEM J, V362, P749, DOI 10.1042/0264-6021:3620749; Acehan D, 2002, MOL CELL, V9, P423, DOI 10.1016/S1097-2765(02)00442-2; Adrain C, 1999, J BIOL CHEM, V274, P20855, DOI 10.1074/jbc.274.30.20855; Arnoult D, 2003, EMBO J, V22, P4385, DOI 10.1093/emboj/cdg423; Arnoult D, 2001, MOL BIOL CELL, V12, P3016, DOI 10.1091/mbc.12.10.3016; Arnt CR, 2002, J BIOL CHEM, V277, P44236, DOI 10.1074/jbc.M207578200; ASHWELL G, 1952, P SOC EXP BIOL MED, V80, P407; BERNARDI P, 1981, J BIOL CHEM, V256, P7187; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Bratton SB, 2001, EMBO J, V20, P998, DOI 10.1093/emboj/20.5.998; Cain K, 2000, J BIOL CHEM, V275, P6067, DOI 10.1074/jbc.275.9.6067; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Chautan M, 1999, CURR BIOL, V9, P967, DOI 10.1016/S0960-9822(99)80425-4; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; CLARK CG, 1995, P NATL ACAD SCI USA, V92, P6518, DOI 10.1073/pnas.92.14.6518; Clausen T, 2002, MOL CELL, V10, P443, DOI 10.1016/S1097-2765(02)00658-5; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Denecker G, 2001, CELL MOL LIFE SCI, V58, P356, DOI 10.1007/PL00000863; Denecker G, 2001, CELL DEATH DIFFER, V8, P829, DOI 10.1038/sj.cdd.4400883; Deshmukh M, 2000, J CELL BIOL, V150, P131, DOI 10.1083/jcb.150.1.131; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Dorstyn L, 2002, J CELL BIOL, V156, P1089, DOI 10.1083/jcb.200111107; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Dumont C, 2000, BLOOD, V96, P1030, DOI 10.1182/blood.V96.3.1030.015k21_1030_1038; Esposti MD, 2001, MOL CELL BIOL, V21, P7268, DOI 10.1128/MCB.21.21.7268-7276.2001; Faccio L, 2000, J BIOL CHEM, V275, P2581, DOI 10.1074/jbc.275.4.2581; Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249; Forman HJ, 1997, FASEB J, V11, P374, DOI 10.1096/fasebj.11.5.9141504; Frade JM, 1997, BIOESSAYS, V19, P827, DOI 10.1002/bies.950190913; Frank J, 2002, J STRUCT BIOL, V138, P85, DOI 10.1016/S1047-8477(02)00019-9; FU J, 2003, J BIOL CHEM, V30, P30; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Glatz JFC, 2002, MOL CELL BIOCHEM, V239, P3, DOI 10.1023/A:1020529918782; Gray CW, 2000, EUR J BIOCHEM, V267, P5699, DOI 10.1046/j.1432-1327.2000.01589.x; Gurbuxani S, 2003, ONCOGENE, V22, P6669, DOI 10.1038/sj.onc.1206794; Hackstein JHP, 1999, TRENDS MICROBIOL, V7, P441, DOI 10.1016/S0966-842X(99)01613-3; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Harris BZ, 2001, J CELL SCI, V114, P3219; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Honarpour N, 2000, DEV BIOL, V218, P248, DOI 10.1006/dbio.1999.9585; Hu YM, 1998, J BIOL CHEM, V273, P33489, DOI 10.1074/jbc.273.50.33489; HUANG Y, 2003, J BIOL CHEM, V25, P25; Huang YH, 2001, CELL, V104, P781, DOI 10.1016/S0092-8674(01)00273-2; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Jia L, 2003, ONCOGENE, V22, P1589, DOI 10.1038/sj.onc.1206322; Jiang XJ, 2000, J BIOL CHEM, V275, P31199, DOI 10.1074/jbc.C000405200; Jones JM, 2003, NATURE, V425, P721, DOI 10.1038/nature02052; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kanuka H, 1999, MOL CELL, V4, P757, DOI 10.1016/S1097-2765(00)80386-X; Kawane K, 2003, NAT IMMUNOL, V4, P138, DOI 10.1038/ni881; Klein JA, 2002, NATURE, V419, P367, DOI 10.1038/nature01034; Kluck RM, 2000, J BIOL CHEM, V275, P16127, DOI 10.1074/jbc.275.21.16127; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kohler C, 1999, FEBS LETT, V447, P10, DOI 10.1016/S0014-5793(99)00251-3; Koonin EV, 2002, CELL DEATH DIFFER, V9, P394, DOI 10.1038/sj.cdd.4400991; Kovacsovics M, 2002, CURR BIOL, V12, P838, DOI 10.1016/S0960-9822(02)00842-4; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Krojer T, 2002, NATURE, V416, P455, DOI 10.1038/416455a; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Lang BF, 1999, ANNU REV GENET, V33, P351, DOI 10.1146/annurev.genet.33.1.351; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Li WY, 2002, NAT STRUCT BIOL, V9, P436, DOI 10.1038/nsb795; LIPINSKA B, 1990, J BACTERIOL, V172, P1791, DOI 10.1128/jb.172.4.1791-1797.1990; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; MacFarlane M, 2002, J BIOL CHEM, V277, P36611, DOI 10.1074/jbc.M200317200; Mancini M, 1998, J CELL BIOL, V140, P1485, DOI 10.1083/jcb.140.6.1485; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Martins LM, 2003, J BIOL CHEM, V278, P49417, DOI 10.1074/jbc.M308659200; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; McIlroy D, 2000, GENE DEV, V14, P549; Melloni E, 2000, J BIOL CHEM, V275, P82, DOI 10.1074/jbc.275.1.82; Miramar MD, 2001, J BIOL CHEM, V276, P16391, DOI 10.1074/jbc.M010498200; Mitchell SA, 2001, MOL CELL BIOL, V21, P3364, DOI 10.1128/MCB.21.10.3364-3374.2001; Mootha VK, 2001, EMBO J, V20, P661, DOI 10.1093/emboj/20.4.661; Ohiro Y, 2002, FEBS LETT, V524, P163, DOI 10.1016/S0014-5793(02)03049-1; Okada H, 2002, MOL CELL BIOL, V22, P3509, DOI 10.1128/MCB.22.10.3509-3517.2002; Parrish J, 2001, NATURE, V412, P90, DOI 10.1038/35083608; Parrish JZ, 2003, EMBO J, V22, P3451, DOI 10.1093/emboj/cdg320; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Qin ZH, 2001, J BIOL CHEM, V276, P8079, DOI 10.1074/jbc.M007028200; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Renatus M, 2001, P NATL ACAD SCI USA, V98, P14250, DOI 10.1073/pnas.231465798; Ricci JE, 2003, J CELL BIOL, V160, P65, DOI 10.1083/jcb.200208089; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(02)02036-6; Roberts DL, 2001, J CELL BIOL, V153, P221, DOI 10.1083/jcb.153.1.221; Rodriguez A, 1999, NAT CELL BIOL, V1, P272, DOI 10.1038/12984; Sahara S, 1999, NATURE, V401, P168, DOI 10.1038/43678; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Samali A, 1998, FEBS LETT, V431, P167, DOI 10.1016/S0014-5793(98)00740-6; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Shiozaki EN, 2003, MOL CELL, V11, P519, DOI 10.1016/S1097-2765(03)00054-6; Skorko-Glonek J, 1999, MOL GEN GENET, V262, P342, DOI 10.1007/s004380051092; Spiess C, 1999, CELL, V97, P339, DOI 10.1016/S0092-8674(00)80743-6; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 2003, J BIOL CHEM, V278, P31469, DOI 10.1074/jbc.C300240200; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; TYLER DD, 1992, MITOCHONDRION HLTH D, P1; van Loo G, 2001, CELL DEATH DIFFER, V8, P1136, DOI 10.1038/sj.cdd.4400944; van Loo G, 2002, CELL DEATH DIFFER, V9, P1207, DOI 10.1038/sj.cdd.4401101; Van Loo G, 2002, CELL DEATH DIFFER, V9, P301, DOI 10.1038/sj.cdd.4400966; van Loo G, 2002, CELL DEATH DIFFER, V9, P20, DOI 10.1038/sj.cdd.4400970; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Wang XC, 2002, SCIENCE, V298, P1587, DOI 10.1126/science.1076194; Waterhouse NJ, 2001, J CELL BIOL, V153, P319, DOI 10.1083/jcb.153.2.319; Widlak P, 2001, J BIOL CHEM, V276, P48404, DOI 10.1074/jbc.M108461200; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Wu M, 2002, J BIOL CHEM, V277, P25617, DOI 10.1074/jbc.M202285200; Xue LZ, 1999, MOL CELL NEUROSCI, V14, P180, DOI 10.1006/mcne.1999.0780; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang QH, 2003, GENE DEV, V17, P1487, DOI 10.1101/gad.1097903; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Ye H, 2002, NAT STRUCT BIOL, V9, P680, DOI 10.1038/nsb836; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zhang JH, 1998, P NATL ACAD SCI USA, V95, P12480, DOI 10.1073/pnas.95.21.12480; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 2003, J BIOL CHEM, V278, P8091, DOI 10.1074/jbc.M204783200	133	666	695	0	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2004	23	16					2861	2874		10.1038/sj.onc.1207523	http://dx.doi.org/10.1038/sj.onc.1207523			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	811VO	15077149				2022-12-28	WOS:000220799600013
J	Vultur, A; Cao, J; Arulanandam, R; Turkson, J; Jove, R; Greer, P; Craig, A; Elliott, B; Raptis, L				Vultur, A; Cao, J; Arulanandam, R; Turkson, J; Jove, R; Greer, P; Craig, A; Elliott, B; Raptis, L			Cell-to-cell adhesion modulates Stat3 activity in normal and breast carcinoma cells	ONCOGENE			English	Article						Stat3; cell confluence; cell-to-cell adhesion; breast cancer; breast carcinoma lines; rodent fibroblasts	GROWTH-FACTOR RECEPTOR; DNA-BINDING ACTIVITY; CONSTITUTIVE ACTIVATION; E-CADHERIN; PHOSPHATIDYLINOSITOL 3-KINASE; NEOPLASTIC TRANSFORMATION; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; SRC ONCOPROTEIN; KINASE-ACTIVITY	Stat3 (signal transducer and activator of transcription-3) activity is required for transformation by a number of oncogenes, while a constitutively active form of Stat3 alone is sufficient to induce neoplastic transformation. Although in most instances Stat3 is growth-promoting, the impact of cell density on Stat3 activation status and the biological importance of Stat3 during growth arrest have not been characterized. Previous results indicated that cell density alters tyrosine phosphorylation levels of cultured cells. Since signalling through Stat3 is determined by a key phosphorylation at tyr705, we examined the effects of cell density upon Stat3 activity in normal breast epithelial cells, breast carcinoma lines and normal mouse fibroblasts. Intriguingly, the results revealed a dramatic increase in Stat3, tyr705 phosphorylation and activity with cell density, which gradually declined at later stages. This activation was dependent upon cell-cell contact, since it was eliminated if cell adhesion was disrupted through calcium chelation, while it was reinstated through cell aggregation. Furthermore, this activation was suppressed following inhibition of JAKs (Janus kinases) but not inhibition of Fer, IGF1-R, or kinases of the c-Src family. On the other hand, constitutively active Stat3 in carcinoma lines, known to harbor activated Src, was blocked by pharmacological inhibitors of Src as well as JAKs. These results point to the existence of two distinct pathways of Stat3 activation in breast carcinomas, based on Src dependence. More importantly, our results suggest that Stat3 activity is upregulated during the confluence-mediated growth arrest by a signalling mechanism that requires JAKs.	Queens Univ, Dept Microbiol & Immunol, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Pathol, Kingston, ON K7L 3N6, Canada; Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33612 USA	Queens University - Canada; Queens University - Canada; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Raptis, L (corresponding author), Queens Univ, Dept Microbiol & Immunol, Botterell Hall,Rm 715, Kingston, ON K7L 3N6, Canada.	raptisl@post.queensu.ca	Craig, Andrew/AAC-6923-2019; Craig, Andrew/G-2312-2017	Craig, Andrew/0000-0002-2039-2393; Craig, Andrew/0000-0002-2039-2393; Vultur, Adina/0000-0003-0068-9496				Balhoff JP, 1998, BIOCHEM BIOPH RES CO, V247, P894, DOI 10.1006/bbrc.1998.8890; Batt DB, 1998, J BIOL CHEM, V273, P3408, DOI 10.1074/jbc.273.6.3408; Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Catlett-Falcone Robyn, 1999, Current Opinion in Oncology, V11, P490, DOI 10.1097/00001622-199911000-00010; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Cirri P, 1997, BIOCHEM BIOPH RES CO, V239, P493, DOI 10.1006/bbrc.1997.7493; Coffer PJ, 2000, ONCOGENE, V19, P2511, DOI 10.1038/sj.onc.1203479; Deng JB, 2000, ENDOCRINOLOGY, V141, P2370, DOI 10.1210/en.141.7.2370; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; Faruqi TR, 2001, P NATL ACAD SCI USA, V98, P9014, DOI 10.1073/pnas.161281298; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Goodwin M, 2003, J BIOL CHEM, V278, P20533, DOI 10.1074/jbc.M213171200; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Greer P, 2002, NAT REV MOL CELL BIO, V3, P278, DOI 10.1038/nrm783; Hauser PJ, 1998, CELL GROWTH DIFFER, V9, P847; Hung W, 2001, J BIOL CHEM, V276, P12395, DOI 10.1074/jbc.M010715200; Huttenlocher A, 1998, J CELL BIOL, V141, P515, DOI 10.1083/jcb.141.2.515; Juliano RL, 2002, ANNU REV PHARMACOL, V42, P283, DOI 10.1146/annurev.pharmtox.42.090401.151133; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Lin JY, 2002, CANCER RES, V62, P376; Mauro L, 2003, J CELL PHYSIOL, V194, P108, DOI 10.1002/jcp.10207; Mora LB, 2002, CANCER RES, V62, P6659; Narimatsu M, 2001, MOL CELL BIOL, V21, P6615, DOI 10.1128/MCB.21.19.6615-6625.2001; Nelson PJ, 2002, KIDNEY INT S1, V61, P99, DOI DOI 10.1046/J.1523-1755.2002.0610S1099.X; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Pece S, 1999, J BIOL CHEM, V274, P19347, DOI 10.1074/jbc.274.27.19347; Raptis L, 1997, EXP CELL RES, V235, P188, DOI 10.1006/excr.1997.3646; Raptis L, 1997, CELL GROWTH DIFFER, V8, P891; Raptis L, 2000, CELL GROWTH DIFFER, V11, P293; Rothen-Rutishauser B, 2002, J MEMBRANE BIOL, V188, P151, DOI 10.1007/s00232-001-0182-2; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; Simon AR, 2000, SCIENCE, V290, P144, DOI 10.1126/science.290.5489.144; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; Steinman RA, 2003, ONCOGENE, V22, P3608, DOI 10.1038/sj.onc.1206523; Stephens JM, 1996, J BIOL CHEM, V271, P10441, DOI 10.1074/jbc.271.18.10441; Turkson J, 2001, J BIOL CHEM, V276, P45443, DOI 10.1074/jbc.M107527200; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; Vignais ML, 1999, MOL CELL BIOL, V19, P3727; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Wang YZ, 2000, ONCOGENE, V19, P2075, DOI 10.1038/sj.onc.1203548; Whittard JD, 2002, MATRIX BIOL, V21, P525, DOI 10.1016/S0945-053X(02)00037-9; Xu FP, 2001, EXP CELL RES, V262, P49, DOI 10.1006/excr.2000.5075; Yamamoto T, 2002, BIOCHEM BIOPH RES CO, V297, P811, DOI 10.1016/S0006-291X(02)02291-X; Yap AS, 2003, J CELL BIOL, V160, P11, DOI 10.1083/jcb.200208156; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhang Y, 2000, J BIOL CHEM, V275, P24935, DOI 10.1074/jbc.M002383200	58	91	94	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2004	23	15					2600	2616		10.1038/sj.onc.1207378	http://dx.doi.org/10.1038/sj.onc.1207378			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	810OZ	15007380	Green Published			2022-12-28	WOS:000220714900002
J	Hurst, CD; Fiegler, H; Carr, P; Williams, S; Carter, NP; Knowles, MA				Hurst, CD; Fiegler, H; Carr, P; Williams, S; Carter, NP; Knowles, MA			High-resolution analysis of genomic copy number alterations in bladder cancer by microarray-based comparative genomic hybridization	ONCOGENE			English	Article						bladder cancer; comparative genomic hybridization; array	TRANSITIONAL-CELL-CARCINOMA; TUMOR-SUPPRESSOR GENE; CHROMOSOMAL IMBALANCES; IN-VITRO; DELETION; AMPLIFICATION; HETEROZYGOSITY; PROGRESSION; LOCI; REGIONS	We have screened 22 bladder tumour- derived cell lines and one normal urothelium- derived cell line for genome- wide copy number changes using array comparative genomic hybridization ( CGH). Comparison of array CGH with existing multiplex-fluorescence in situ hybridization ( M-FISH) results revealed excellent concordance. Regions of gain and loss were defined more accurately by array CGH, and several small regions of deletion were detected that were not identified by M- FISH. Numerous genetic changes were identified, many of which were compatible with previous results from conventional CGH and loss of heterozygosity analyses on bladder tumours. The most frequent changes involved complete or partial loss of 4q ( 83%) and gain of 20q ( 78%). Other frequent losses were of 18q ( 65%), 8p ( 65%), 2q ( 61%), 6q ( 61%), 3p ( 56%), 13q ( 56%), 4p ( 52%), 6p ( 52%), 10p ( 52%), 10q ( 52%) and 5p ( 43%). We have refined the localization of a region of deletion at 8p21.2- p21.3 to an interval of approximately 1 Mb. Five homozygous deletions of tumour suppressor genes were confirmed, and several potentially novel homozygous deletions were identified. In all, 15 high- level amplifications were detected, with a previously reported amplification at 6p22.3 being the most frequent. Real- time PCR analysis revealed a novel candidate gene with consistent overexpression in all cell lines with the 6p22.3 amplicon.	St James Univ Hosp, Canc Res UK Clin Ctr, Leeds LS9 7TF, W Yorkshire, England; Wellcome Trust Sanger Inst, Sanger Inst Canc Res UK Genom Microarray Grp, Cambridge CB10 1SA, England	Cancer Research UK; Saint James's University Hospital; University of Leeds; Wellcome Trust Sanger Institute	Knowles, MA (corresponding author), St James Univ Hosp, Canc Res UK Clin Ctr, Beckett St, Leeds LS9 7TF, W Yorkshire, England.	margaret.knowles@cancer.org.uk		Knowles, Margaret/0000-0002-9363-8657				Aboulkassim TO, 2003, ONCOGENE, V22, P2967, DOI 10.1038/sj.onc.1206513; Albertson DG, 2000, NAT GENET, V25, P144, DOI 10.1038/75985; Aveyard JS, 1999, BRIT J CANCER, V80, P904, DOI 10.1038/sj.bjc.6690439; Billerey C, 2001, AM J PATHOL, V158, P1955, DOI 10.1016/S0002-9440(10)64665-2; Bohm M, 1997, INT J CANCER, V74, P291; Bringuier PP, 1996, ONCOGENE, V12, P1747; Bruch J, 1998, GENE CHROMOSOME CANC, V23, P167, DOI 10.1002/(SICI)1098-2264(199810)23:2<167::AID-GCC10>3.0.CO;2-L; Bruch J, 2000, CANCER RES, V60, P4526; CAIRNS P, 1993, ONCOGENE, V8, P1083; Cappellen D, 1997, ONCOGENE, V14, P3059, DOI 10.1038/sj.onc.1201154; Choi C, 2000, INT J CANCER, V86, P501, DOI 10.1002/(SICI)1097-0215(20000515)86:4<501::AID-IJC9>3.0.CO;2-#; CHRISTIAN BJ, 1987, CANCER RES, V47, P6066; Collins C, 2001, GENOME RES, V11, P1034, DOI 10.1101/gr.GR1743R; COOMBS LM, 1991, BRIT J CANCER, V63, P601, DOI 10.1038/bjc.1991.139; Dai ZY, 2003, HUM MOL GENET, V12, P791, DOI 10.1093/hmg/ddg083; ELDER PA, 1994, ONCOGENE, V9, P3433; Fadl-Elmula I, 2000, GENE CHROMOSOME CANC, V29, P256, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1034>3.0.CO;2-O; Fiegler H, 2003, GENE CHROMOSOME CANC, V36, P361, DOI 10.1002/gcc.10155; Habuchi T, 1998, GENOMICS, V48, P277, DOI 10.1006/geno.1997.5165; Heselmeyer K, 1997, GENE CHROMOSOME CANC, V19, P233, DOI 10.1002/(SICI)1098-2264(199708)19:4<233::AID-GCC5>3.0.CO;2-Y; Hodgson G, 2001, NAT GENET, V29, P459, DOI 10.1038/ng771; Hodgson JG, 2003, BREAST CANCER RES TR, V78, P337, DOI 10.1023/A:1023085825042; Hoque MO, 2003, CANCER RES, V63, P2216; Hornigold N, 1999, ONCOGENE, V18, P2657, DOI 10.1038/sj.onc.1202854; Hovey RM, 1998, CANCER RES, V58, P3555; Imoto I, 2001, CANCER RES, V61, P6629; Jain AN, 2002, GENOME RES, V12, P325, DOI 10.1101/gr.210902; Kagan J, 1998, ONCOGENE, V16, P909, DOI 10.1038/sj.onc.1201606; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; KALLIONIEMI A, 1995, GENE CHROMOSOME CANC, V12, P213, DOI 10.1002/gcc.2870120309; Knowles MA, 1999, BJU INT, V84, P412; Koo SH, 1999, CANCER GENET CYTOGEN, V110, P87, DOI 10.1016/S0165-4608(98)00193-9; Lichter P, 2000, SEMIN HEMATOL, V37, P348, DOI 10.1053/shem.2000.16594; Miyamoto H, 1996, J UROLOGY, V155, P1444, DOI 10.1016/S0022-5347(01)66304-3; Muscheck M, 2000, LAB INVEST, V80, P1089, DOI 10.1038/labinvest.3780114; Ohgaki K, 1999, GENE CHROMOSOME CANC, V25, P1, DOI 10.1002/(SICI)1098-2264(199905)25:1<1::AID-GCC1>3.0.CO;2-3; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; POLASCIK TJ, 1995, CANCER RES, V55, P5396; PRATT CI, 1992, CANCER RES, V52, P688; Primdahl H, 2002, J NATL CANCER I, V94, P216; PROCTOR AJ, 1991, ONCOGENE, V6, P789; Randerson-Moor JA, 2001, HUM MOL GENET, V10, P55, DOI 10.1093/hmg/10.1.55; Richter J, 1999, CANCER RES, V59, P5687; Richter J, 1998, AM J PATHOL, V153, P1615, DOI 10.1016/S0002-9440(10)65750-1; Richter J, 1997, CANCER RES, V57, P2860; Sengelov L, 2000, CANCER GENET CYTOGEN, V123, P109, DOI 10.1016/S0165-4608(00)00308-3; Simon R, 2000, INT J ONCOL, V17, P1025; Simon R, 2002, ONCOGENE, V21, P2476, DOI 10.1038/sj.onc.1205304; Simon R, 1998, J PATHOL, V185, P345; SMEETS W, 1987, CANCER GENET CYTOGEN, V29, P29, DOI 10.1016/0165-4608(87)90028-8; Takle LA, 1996, ONCOGENE, V12, P1083; Veltman JA, 2002, AM J HUM GENET, V70, P1269, DOI 10.1086/340426; von Knobloch R, 2000, J PATHOL, V190, P163, DOI 10.1002/(SICI)1096-9896(200002)190:2<163::AID-PATH509>3.0.CO;2-0; VOORTER C, 1995, AM J PATHOL, V146, P1341; Wagner U, 1997, AM J PATHOL, V151, P753; WANG MR, 1994, CANCER GENET CYTOGEN, V73, P8, DOI 10.1016/0165-4608(94)90175-9; Williams SV, 2002, GENE CHROMOSOME CANC, V34, P86, DOI 10.1002/gcc.10050; WILLIAMSON MP, 1995, HUM MOL GENET, V4, P1569, DOI 10.1093/hmg/4.9.1569	58	117	122	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2004	23	12					2250	2263		10.1038/sj.onc.1207260	http://dx.doi.org/10.1038/sj.onc.1207260			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	804EB	14968109				2022-12-28	WOS:000220280900016
J	Janoueix-Lerosey, I; Novikov, E; Monteiro, M; Gruel, N; Schleiermacher, G; Loriod, B; Nguyen, C; Delattre, O				Janoueix-Lerosey, I; Novikov, E; Monteiro, M; Gruel, N; Schleiermacher, G; Loriod, B; Nguyen, C; Delattre, O			Gene expression profiling of 1p35-36 genes in neuroblastoma	ONCOGENE			English	Article						neuroblastoma; 1p deletion; gene expression profiling; hierarchical clustering	CHROMOSOME-I; SHORT ARM; DELETION; IDENTIFICATION; HYBRIDIZATION; PREDICTION; INSIGHTS; REGIONS; BINDING; PROTEIN	Deletion of the chromosome 1p36 region is a frequent abnormality in neuroblastoma. To gain further insights into the role of this alteration in oncogenesis, we have constructed a specific cDNA microarray representing most known genes and ESTs from the 1p35-36 region and analysed the expression profiles of 15 neuroblastoma cell lines and 28 neuroblastoma tumours. Hierarchical clustering using expression levels of 320 cDNAs from 1p35-36 separated localized or 4S cases without 1p deletion from advanced stages and cell tines. Supervised learning classification enabled to predict reliably the status of chromosome 1p according to its expression profile. Around 15% of the genes or ESTs presented a significantly decreased expression in samples with 1p deletion as compared to 1p-normal samples suggesting that 1p deletion results in a gene dosage effect on a subset of genes critical for the development of 1p-deleted neuroblastoma. Several genes presumed to have functions in neural differentiation (CDC42, VAMP3, CLSTN1), signal transduction in neural cells (GNB1) and cell cycle regulation (STMN1, RPA2, RBAF600, FBXO6, MAD2L2) exhibited a decreased expression in samples presenting 1p deletion. The identification of such genes provides baseline information for further studies to elucidate how these genes could individually or collectively play a critical role in neuroblastoma tumorigenesis.	Inst Curie, U509, INSERM, Sect Rech,Lab Pathol Mol Canc, F-75248 Paris 05, France; Ctr Immunol Marseille Luminy, Equipe TAGC, F-13288 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Delattre, O (corresponding author), Inst Curie, U509, INSERM, Sect Rech,Lab Pathol Mol Canc, Pavillon Trouillet Rossignol 26,Rue Ulm, F-75248 Paris 05, France.	delattre@curie.fr	Janoueix-Lerosey, Isabelle/G-1758-2018; Monteiro, Marta/B-2833-2011; loriod, beatrice bl/L-2948-2016; Nguyen, Catherine/M-4119-2016	Janoueix-Lerosey, Isabelle/0000-0003-0434-3003; loriod, beatrice bl/0000-0001-5801-2264; Nguyen, Catherine/0000-0001-9376-6360; Monteiro C. Antunes, Marta/0000-0002-0327-0917; delattre, olivier/0000-0002-8730-2276				Bauer A, 2001, GENE CHROMOSOME CANC, V31, P228, DOI 10.1002/gcc.1139; Bertucci F, 2000, HUM MOL GENET, V9, P2981, DOI 10.1093/hmg/9.20.2981; BIEGEL JA, 1993, AM J HUM GENET, V52, P176; Bo TH, 2002, GENOME BIOL, V3; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Cassimeris L, 2002, CURR OPIN CELL BIOL, V14, P18, DOI 10.1016/S0955-0674(01)00289-7; CHENG NC, 1995, ONCOGENE, V10, P291; COMBARET V, 1995, INT J CANCER, V61, P185, DOI 10.1002/ijc.2910610208; Dickson BJ, 2001, CURR OPIN NEUROBIOL, V11, P103, DOI 10.1016/S0959-4388(00)00180-X; Dudoit S. F. J. a. S. T. P, 2000, 576 U CAL DEP STAT; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fix A, 2004, GENE CHROMOSOME CANC, V40, P266, DOI 10.1002/gcc.20041; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Hepp R, 2001, CELL TISSUE RES, V305, P247, DOI 10.1007/s004410100359; Lastowska M, 2001, J CLIN ONCOL, V19, P3080; LAUREYS G, 1990, GENE CHROMOSOME CANC, V2, P252, DOI 10.1002/gcc.2870020315; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; Mukasa A, 2002, ONCOGENE, V21, P3961, DOI 10.1038/sj.onc.1205495; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Nadon R, 2002, TRENDS GENET, V18, P265, DOI 10.1016/S0168-9525(02)02665-3; Ohira M, 2003, ONCOGENE, V22, P5525, DOI 10.1038/sj.onc.1206853; Ohira M, 2000, ONCOGENE, V19, P4302, DOI 10.1038/sj.onc.1203786; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; Schleiermacher G, 2003, CANCER GENET CYTOGEN, V141, P32, DOI 10.1016/S0165-4608(02)00644-1; Van Roy N, 2001, GENE CHROMOSOME CANC, V32, P126, DOI 10.1002/gcc.1174; Vogt L, 2001, MOL CELL NEUROSCI, V17, P151, DOI 10.1006/mcne.2000.0937; WESS J, 1995, LIFE SCI, V56, P915, DOI 10.1016/0024-3205(95)00028-5; White PS, 2001, MED PEDIATR ONCOL, V36, P37, DOI 10.1002/1096-911X(20010101)36:1<37::AID-MPO1010>3.0.CO;2-L	30	48	51	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2004	23	35					5912	5922		10.1038/sj.onc.1207784	http://dx.doi.org/10.1038/sj.onc.1207784			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15195138				2022-12-28	WOS:000222941100005
J	Frontelo, P; Leader, JE; Yoo, N; Potocki, AC; Crawford, M; Kulik, M; Lechleider, RJ				Frontelo, P; Leader, JE; Yoo, N; Potocki, AC; Crawford, M; Kulik, M; Lechleider, RJ			Suv39h histone methyltransferases interact with Smads and cooperate in BMP-induced repression	ONCOGENE			English	Article						Smad; BMP; histone methyltransferase; transcription; repression	TRANSCRIPTIONAL ACTIVATION; BREAST-CANCER; I RECEPTORS; LYSINE 9; PROTEINS; METHYLATION; H3; HETEROCHROMATIN; SIGNALS; BINDING	Smad proteins transduce signals from transforming growth factor-beta (TGF-beta) superfamily ligands to regulate the expression of target genes. In order to identify novel partners of Smad proteins in transcriptional regulation, we performed a two-hybrid screen using Smad5, a protein that is activated predominantly by bone morphogenetic protein (BMP) signaling. We identified an interaction between Smad5 and suppressor of variegation 3-9 homolog 2 (Suv39h2), a chromatin modifier enzyme. Suv39h proteins are histone methyltransferases that methylate histone H3 on lysine 9, resulting in transcriptional repression or silencing of target genes. Biochemical studies in mammalian cells demonstrated that Smad5 binds to both known mammalian isoforms of Suv39h proteins, and that Smad proteins activated by the TGF-beta signaling pathway, Smad2 and Smad3, do not bind with significant affinity. Functional studies using the muscle creatine kinase (MCK) promoter, which is suppressed by BMP signaling, demonstrate that Suv39h proteins and Smads cooperate to repress promoter activity. These data suggest a model where association of Smad proteins with Suv39h methyltransferases can repress or silence genes involved in developmental processes, and argues that inefficient gene repression may result in the alteration of the differentiated phenotype. Thus, examination of the Smad - Suv interaction may provide insight into the mechanism of phenotypic determination mediated by BMP signaling.	Georgetown Univ, Sch Med, Dept Cell Biol, Washington, DC 20057 USA; Georgetown Univ, Sch Med, Tumor Biol Program, Washington, DC 20057 USA; Uniformed Serv Univ Hlth Sci, Mol & Cell Biol Program, Bethesda, MD 20814 USA	Georgetown University; Georgetown University; Uniformed Services University of the Health Sciences - USA	Lechleider, RJ (corresponding author), Georgetown Univ, Sch Med, Dept Cell Biol, Box 571436, Washington, DC 20057 USA.	rjl24@georgetown.edu	Yoo, Nam Jin/GNM-9060-2022		NATIONAL CANCER INSTITUTE [R21CA102660] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065681] Funding Source: NIH RePORTER; NCI NIH HHS [CA102660] Funding Source: Medline; NHLBI NIH HHS [HL65681] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aagaard L, 1999, EMBO J, V18, P1923, DOI 10.1093/emboj/18.7.1923; Akiyama S, 1997, EXP CELL RES, V235, P362, DOI 10.1006/excr.1997.3680; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Brubaker KD, 2004, J CELL BIOCHEM, V91, P151, DOI 10.1002/jcb.10679; CAESTECKER MD, 2001, RESP RES, V2, P193; Chakraborty S, 2003, ONCOGENE, V22, P5229, DOI 10.1038/sj.onc.1206600; Cong YS, 2000, J BIOL CHEM, V275, P35665, DOI 10.1074/jbc.C000637200; Davey C, 2003, J MOL BIOL, V325, P873, DOI 10.1016/S0022-2836(02)01340-2; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; deCaestecker MP, 1997, J BIOL CHEM, V272, P13690, DOI 10.1074/jbc.272.21.13690; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Firestein R, 2000, MOL CELL BIOL, V20, P4900, DOI 10.1128/MCB.20.13.4900-4909.2000; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Howe JR, 2001, NAT GENET, V28, P184, DOI 10.1038/88919; Itoh S, 2000, NUCLEIC ACIDS RES, V28, P4291, DOI 10.1093/nar/28.21.4291; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Keeton EK, 2002, J BIOL CHEM, V277, P28247, DOI 10.1074/jbc.M203898200; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Li JW, 2002, MOL CELL BIOL, V22, P5688, DOI 10.1128/MCB.22.16.5688-5697.2002; Liberati NT, 2001, J BIOL CHEM, V276, P22595, DOI 10.1074/jbc.M010778200; Liu D, 2001, GENE DEV, V15, P2950, DOI 10.1101/gad.925901; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Melcher M, 2000, MOL CELL BIOL, V20, P3728, DOI 10.1128/MCB.20.10.3728-3741.2000; Melhuish TA, 2000, J BIOL CHEM, V275, P39762, DOI 10.1074/jbc.C000416200; Moustakas A, 2001, J CELL SCI, V114, P4359; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Pouliot F, 2002, J ENDOCRINOL, V172, P187, DOI 10.1677/joe.0.1720187; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; REEVES R, 1985, NUCLEIC ACIDS RES, V13, P3599, DOI 10.1093/nar/13.10.3599; Remacle JE, 1999, EMBO J, V18, P5073, DOI 10.1093/emboj/18.18.5073; Snowden AW, 2002, CURR BIOL, V12, P2159, DOI 10.1016/S0960-9822(02)01391-X; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Vandel L, 2001, MOL CELL BIOL, V21, P6484, DOI 10.1128/MCB.21.19.6484-6494.2001; Vaute O, 2002, NUCLEIC ACIDS RES, V30, P475, DOI 10.1093/nar/30.2.475; von Bubnoff A, 2001, DEV BIOL, V239, P1, DOI 10.1006/dbio.2001.0388; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445	43	20	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2004	23	30					5242	5251		10.1038/sj.onc.1207660	http://dx.doi.org/10.1038/sj.onc.1207660			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	834AE	15107829				2022-12-28	WOS:000222382500013
J	Winteringham, LN; Kobelke, S; Williams, JH; Ingley, E; Klinken, SP				Winteringham, LN; Kobelke, S; Williams, JH; Ingley, E; Klinken, SP			Myeloid Leukemia Factor 1 inhibits erythropoietin-induced differentiation, cell cycle exit and p27(Kip1) accumulation	ONCOGENE			English	Article						Mlf1; erythroleukemia; p27(Kip1)	TERMINAL ERYTHROID-DIFFERENTIATION; MYELODYSPLASTIC SYNDROME; DEPENDENT KINASES; PROGENITOR CELLS; UP-REGULATION; IN-VITRO; LINE M1; EXPRESSION; GENE; PROTEIN	Myeloid leukemia factor 1 (MLF1) is a novel oncoprotein involved in translocations associated with acute myeloid leukemia (AML), especially erythroleukemias. In this study, we demonstrate that ectopic expression of Mlf1 prevented J2E erythroleukemic cells from undergoing biological and morphological maturation in response to erythropoietin (Epo). We show that Mlf1 inhibited Epo-induced cell cycle exit and suppressed a rise in the cell cycle inhibitor p27(Kip1). Unlike differentiating J2E cells, Mlf1-expressing cells did not downregulate Cul1 and Skp2, components of the ubiquitin E3 ligase complex SCFSkp2 involved in the proteasomal degradation of p27(Kip1). In contrast, Mlf1 did not interfere with increases in p27(Kip1) and terminal differentiation initiated by thyroid hormone withdrawal from erythroid cells, or cytokine-stimulated maturation of myeloid cells. These data demonstrate that Mlf1 interferes with an Epo-responsive pathway involving p27(Kip1) accumulation, which inhibits cell cycle arrest essential for erythroid terminal differentiation.	Western Australian Inst Med Res, Lab Canc Med, Perth, WA 6000, Australia; Univ Western Australia, Med Res Ctr, Perth, WA 6000, Australia	University of Western Australia; University of Western Australia	Klinken, SP (corresponding author), Western Australian Inst Med Res, Lab Canc Med, Level 6,MRF Bldg,50 Murray St, Perth, WA 6000, Australia.	pklinken@waimr.uwa.edu.au	Ingley, Evan/C-2401-2013; Winteringham, Louise/H-6105-2014	Ingley, Evan/0000-0002-8112-9134; Williams, James/0000-0002-0950-1958; Winteringham, Louise/0000-0002-8117-5069				Bouscary D, 2003, BLOOD, V101, P3436, DOI 10.1182/blood-2002-07-2332; BUSFIELD SJ, 1992, BLOOD, V80, P412; Caslini C, 2000, P NATL ACAD SCI USA, V97, P2797, DOI 10.1073/pnas.040574897; Dai MS, 2000, BLOOD, V96, P3985, DOI 10.1182/blood.V96.12.3985.h8003985_3985_3987; Dimberg A, 2002, BLOOD, V99, P2199, DOI 10.1182/blood.V99.6.2199; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Hitzler JK, 1999, AM J PATHOL, V155, P53, DOI 10.1016/S0002-9440(10)65098-5; Hochheimer A, 2002, NATURE, V420, P439, DOI 10.1038/nature01167; Hsieh FF, 2000, BLOOD, V96, P2746, DOI 10.1182/blood.V96.8.2746.h8002746_2746_2754; Ingley E, 2001, J BIOL CHEM, V276, P43428, DOI 10.1074/jbc.M106645200; Jacobs-Helber SM, 2002, J BIOL CHEM, V277, P4859, DOI 10.1074/jbc.M107243200; KLINKEN SP, 1988, P NATL ACAD SCI USA, V85, P8506, DOI 10.1073/pnas.85.22.8506; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; Lim R, 2002, J BIOL CHEM, V277, P40997, DOI 10.1074/jbc.M206041200; Matsumoto N, 2000, LEUKEMIA, V14, P1757, DOI 10.1038/sj.leu.2401897; Matushansky I, 2000, BLOOD, V96, P2755, DOI 10.1182/blood.V96.8.2755.h8002755_2755_2764; Matushansky I, 2000, P NATL ACAD SCI USA, V97, P14317, DOI 10.1073/pnas.250488697; O'Hagan RC, 2000, NAT GENET, V24, P113, DOI 10.1038/72761; Ohno K, 2000, GENE, V260, P133, DOI 10.1016/S0378-1119(00)00447-9; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Panzenbock B, 1998, BLOOD, V92, P3658, DOI 10.1182/blood.V92.10.3658.422k18_3658_3668; RAIMONDI SC, 1989, LEUKEMIA, V3, P42; Rylski M, 2003, MOL CELL BIOL, V23, P5031, DOI 10.1128/MCB.23.14.5031-5042.2003; Tamir A, 2000, CELL GROWTH DIFFER, V11, P269; Tanaka H, 2000, BLOOD, V95, P1264, DOI 10.1182/blood.V95.4.1264.004k09_1264_1273; Tilbrook PA, 1997, EMBO J, V16, P1610, DOI 10.1093/emboj/16.7.1610; Whyatt David J., 1997, Genes and Function, V1, P11; Williams JH, 1999, EMBO J, V18, P5559, DOI 10.1093/emboj/18.20.5559; Yamaguchi Y, 1998, BLOOD, V91, P450, DOI 10.1182/blood.V91.2.450.450_450_457; Yoneda-Kato N, 1999, BLOOD, V94, p484A; YonedaKato N, 1996, ONCOGENE, V12, P265	32	39	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					5105	5109		10.1038/sj.onc.1207661	http://dx.doi.org/10.1038/sj.onc.1207661			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15122318				2022-12-28	WOS:000222237300019
J	Tong, XJ; O'Kelly, J; Xie, D; Mori, A; Lemp, N; McKenna, R; Miller, CW; Koeffler, HP				Tong, XJ; O'Kelly, J; Xie, D; Mori, A; Lemp, N; McKenna, R; Miller, CW; Koeffler, HP			Cyr61 suppresses the growth of non-small-cell lung cancer cells via the beta-catenin-c-myc-p53 pathway	ONCOGENE			English	Article						Cyr61; beta-catenin; c-myc; p53; p21; p130	HUMAN-PAPILLOMAVIRUS TYPE-16; IMMEDIATE-EARLY GENE; GLYCOGEN-SYNTHASE KINASE; WILD-TYPE P53; BETA-CATENIN; C-MYC; TUMOR-SUPPRESSOR; BREAST-CANCER; P53-DEPENDENT APOPTOSIS; FUNCTIONAL INTERACTION	Cysteine-rich protein 61 (Cyr61) is a growth factor-inducible, immediate-early gene that has multifaceted activities in various cancers. In a previous study, we found that Cyr61 inhibited the growth of the H520 and H460 non-small-cell lung cancer (NSCLC) cell lines. In further studies, we now report that p53 plays a pivotal role in Cyr61-dependent cellular growth arrest. Blockin g Cyr61 with a Cyr61 antibody resulted in the downregulation of expression of p53 and p21, as well as partially reversing the growth suppression of H520-Cyr61 cells. Proliferation of NSCLC cell lines (NCI-H157, H125, H1299), having a mutant p53, were not suppressed by Cyr61. Inhibition of wild-type p53, by either human papilloma virus type 16 E6 or a dominant-negative p53, resulted in the rescue of the growth suppression mediated by Cyr61 in the H520-Cyr61 cells. The enhanced levels of p21(WAF1) and p130/RB2, in the Cyr61-expressing H520-Cyr61 cells, were also inhibited by blocking p53 showing that p21 and p130 were induced by p53 in these cells. In addition, levels of both c-myc and beta-catenin increased in Cyr61 stably transfected H520 cells. Moreover, beta-catenin was translocated into the nucleus in these cells. Inhibition of c-myc expression in the H520-Cyr61 cells with antisense c-myc resulted in their decreased levels of p53. Transfecting cells with a dominant-negative T-cell factor (TCF4), the specific inhibitor of the beta-catenin/TCF4 complex, downregulated the expression of c-myc. Taken together, the data suggest that Cyr61 suppressed the growth of NSCLC cells by triggering a signal transduction pathway through beta-catenin. In this pathway, Cyr61 activated the beta-catenin/TCF4 complex, which promoted the expression of c-myc and the latter induced expression of p53, and p53 upregulated p21(WAF1) and p130/RB2, resulting in growth arrest.	Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Div Hematol Oncol, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Div Surg, Los Angeles, CA 90048 USA; Peking Univ, Coll Life Sci, Beijing 100871, Peoples R China; Chinese Acad Sci, Inst Nutr Sci, Shanghai, Peoples R China	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Peking University; Chinese Academy of Sciences	O'Kelly, J (corresponding author), Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Div Hematol Oncol, Los Angeles, CA 90048 USA.	okellyj@cshs.org		Xie, Dong/0000-0002-1150-8657	NATIONAL CANCER INSTITUTE [P50CA090388] Funding Source: NIH RePORTER; NCI NIH HHS [CA90388] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allan LA, 1999, ONCOGENE, V18, P5403, DOI 10.1038/sj.onc.1202931; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; Bienz M, 1999, CURR OPIN GENET DEV, V9, P595, DOI 10.1016/S0959-437X(99)00016-7; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; Blagosklonny MV, 2000, FASEB J, V14, P1901, DOI 10.1096/fj.99-1078rev; BODNER SM, 1992, ONCOGENE, V7, P743; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Carroll JS, 2000, J BIOL CHEM, V275, P38221, DOI 10.1074/jbc.M004424200; Chen NY, 2000, J BIOL CHEM, V275, P24953, DOI 10.1074/jbc.M003040200; Clevers H, 2000, NAT CELL BIOL, V2, pE177, DOI 10.1038/35036424; Cox RT, 1998, CURR BIOL, V8, pR140, DOI 10.1016/S0960-9822(98)70081-8; Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912; Damalas A, 1999, EMBO J, V18, P3054, DOI 10.1093/emboj/18.11.3054; Dang CV, 1999, MOL CELL BIOL, V19, P1; Danilkovitch-Miagkova A, 2001, MOL CELL BIOL, V21, P5857, DOI 10.1128/MCB.21.17.5857-5868.2001; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Grzeszkiewicz TM, 2001, J BIOL CHEM, V276, P21943, DOI 10.1074/jbc.M100978200; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HARPER JW, 1993, CELL, V75, P805; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Huang SL, 2001, CANCER RES, V61, P3373; Jedsadayanmata A, 1999, J BIOL CHEM, V274, P24321, DOI 10.1074/jbc.274.34.24321; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Kireeva ML, 1998, J BIOL CHEM, V273, P3090, DOI 10.1074/jbc.273.5.3090; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEVINE AJ, 1992, NEW ENGL J MED, V326, P1350, DOI 10.1056/NEJM199205143262008; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Marutani M, 1999, CANCER RES, V59, P4765; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Pilarsky CP, 1998, PROSTATE, V36, P85; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; ROY B, 1994, MOL CELL BIOL, V14, P7805, DOI 10.1128/MCB.14.12.7805; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sadot E, 2000, ONCOGENE, V19, P1992, DOI 10.1038/sj.onc.1203519; Sampath D, 2001, J CLIN ENDOCR METAB, V86, P1707, DOI 10.1210/jc.86.4.1707; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Seewaldt VL, 2001, CANCER RES, V61, P616; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; Shih IM, 2000, CANCER RES, V60, P1671; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Stiegler P, 1999, ANAL QUANT CYTOL, V21, P363; Tan C, 2001, ONCOGENE, V20, P133, DOI 10.1038/sj.onc.1204052; TAVTIGIAN SV, 1994, MOL BIOL CELL, V5, P375, DOI 10.1091/mbc.5.3.375; Tong XJ, 2001, J BIOL CHEM, V276, P47709, DOI 10.1074/jbc.M107878200; Tsai MS, 2000, CANCER RES, V60, P5603; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Waikel RL, 2001, NAT GENET, V28, P165, DOI 10.1038/88889; Wang YC, 1998, ONCOGENE, V17, P1923, DOI 10.1038/sj.onc.1202113; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; Xie D, 2001, J BIOL CHEM, V276, P14187, DOI 10.1074/jbc.M009755200; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Yu K, 1997, CELL GROWTH DIFFER, V8, P731; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	81	77	96	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2004	23	28					4847	4855		10.1038/sj.onc.1207628	http://dx.doi.org/10.1038/sj.onc.1207628			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	830EK	15077166				2022-12-28	WOS:000222104200005
J	Martin, SS; Ridgeway, AG; Pinkas, J; Lu, Y; Reginato, MJ; Koh, EY; Michelman, M; Daley, GQ; Brugge, JS; Leder, P				Martin, SS; Ridgeway, AG; Pinkas, J; Lu, Y; Reginato, MJ; Koh, EY; Michelman, M; Daley, GQ; Brugge, JS; Leder, P			A cytoskeleton-based functional genetic screen identifies Bcl-xL as an enhancer of metastasis, but not primary tumor growth	ONCOGENE			English	Article						apoptosis.; cytoskeleton; metastasis; breast; cancer; Bcl	CELL-CYCLE ENTRY; TRANSGENIC MICE; BREAST-CANCER; MAMMARY TUMORIGENESIS; LATRUNCULIN-A; MOUSE MODEL; APOPTOSIS; PROGRESSION; BAX; EXPRESSION	Many mouse models of breast cancer form large primary tumors that rarely metastasize. Models with aggressive metastasis express oncoproteins that simultaneously affect growth and apoptosis pathways. To define the role of apoptotic resistance and to model a challenge faced by tumor cells during metastatic dissemination, we focused on apoptosis induced by cell shape change. Inhibiting actin polymerization with Latrunculin-A causes cell rounding and death within hours in nontumorigenic human 10A-Ras mammary epithelial cells. In contrast, MDA-MB-231 metastatic breast tumor cells resist LA-induced death, and survive for days despite cell rounding. Infecting 10A-Ras cells with a MDA-MB-231 retroviral expression library, and selecting with Latrunculin-A repeatedly identified Bcl-xL as a suppressor of cytoskeleton-dependent death. Although Bcl-xL enhances the spread of metastatic breast tumor cell lines, the distinct effects of apoptotic resistance on tumor growth in the mammary gland and during metastasis have not been compared directly. We find that Bcl-xL overexpression in mouse mammary epithelial cells does not induce primary tumor formation or enhance MEK-induced tumorigenesis within the mammary gland environment. However, it strongly enhances metastatic potential. These results with Bcl-xL provide novel evidence that isolated apoptotic resistance can increase metastatic potential, but remain overlooked by assays based on breast tumor growth.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA; Genzyme Corp, Framingham, MA 01701 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; MIT, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Sanofi-Aventis; Genzyme Corporation; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Whitehead Institute	Leder, P (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA.	leder@rascal.med.harvard.edu	Reginato, Mauricio/I-6155-2013	Reginato, Mauricio/0000-0002-7541-4094				Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; BenZeev A, 1997, CURR OPIN CELL BIOL, V9, P99, DOI 10.1016/S0955-0674(97)80158-5; Birchmeier C, 1996, ACTA ANAT, V156, P217; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Eischen CM, 2002, CANCER RES, V62, P2184; Fernandez Y, 2002, INT J CANCER, V101, P317, DOI 10.1002/ijc.10628; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Fujita M, 2003, ONCOGENE, V22, P627, DOI 10.1038/sj.onc.1206173; Furth PA, 1999, ONCOGENE, V18, P6589, DOI 10.1038/sj.onc.1203073; Greider C, 2002, ONCOGENE, V21, P7765, DOI 10.1038/sj.onc.1205928; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Jager R, 1997, ONCOGENE, V15, P1787, DOI 10.1038/sj.onc.1201353; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Martin S, 2001, MOL CELL BIOL, V21, P6529, DOI 10.1128/MCB.21.19.6529-6536.2001; MARTIN SS, 2004, IN PRESS BBA MOL CEL; Murphy KL, 1999, ONCOGENE, V18, P6597, DOI 10.1038/sj.onc.1203099; Nikiforov MA, 1997, ONCOGENE, V15, P3007, DOI 10.1038/sj.onc.1201723; Olopade OI, 1997, CANCER J SCI AM, V3, P230; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Pinkas J, 2002, CANCER RES, V62, P4781; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Rubio N, 2001, LAB INVEST, V81, P725, DOI 10.1038/labinvest.3780281; Schmidt-Kittler O, 2003, P NATL ACAD SCI USA, V100, P7737, DOI 10.1073/pnas.1331931100; Shi HY, 2003, HISTOL HISTOPATHOL, V18, P201, DOI 10.14670/HH-18.201; Shibata MA, 1999, EMBO J, V18, P2692, DOI 10.1093/emboj/18.10.2692; Siegel PM, 2003, P NATL ACAD SCI USA, V100, P8430, DOI 10.1073/pnas.0932636100; Streuli CH, 1999, J MAMMARY GLAND BIOL, V4, P183, DOI 10.1023/A:1018729308878; WEBSTER MA, 1994, SEMIN CANCER BIOL, V5, P69; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0	31	56	57	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2004	23	26					4641	4645		10.1038/sj.onc.1207595	http://dx.doi.org/10.1038/sj.onc.1207595			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZV	15064711				2022-12-28	WOS:000221799000014
J	Scian, MJ; Stagliano, KER; Deb, D; Ellis, MA; Carchman, EH; Das, A; Valerie, K; Deb, SP; Deb, S				Scian, MJ; Stagliano, KER; Deb, D; Ellis, MA; Carchman, EH; Das, A; Valerie, K; Deb, SP; Deb, S			Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes	ONCOGENE			English	Article						'gain of function'; mutations; p53; transactivation; microarray	WILD-TYPE P53; CREB-BINDING-PROTEIN; ASPARAGINE SYNTHETASE GENE; HUMAN LEUKEMIA-CELLS; GAIN-OF-FUNCTION; TRANSCRIPTIONAL ACTIVATION; DNA-BINDING; HETERO-OLIGOMERIZATION; VIRAL PROMOTERS; BREAST-CANCER	We have studied the mechanism of mutant p53-mediated oncogenesis using several tumor-derived mutants. Using a colony formation assay, we found that the majority of the mutants increased the number of colonies formed compared to the vector. Expression of tumor-derived p53 mutants increases the rate of cell growth, suggesting that the p53 mutants have 'gain of function' properties. We have studied the gene expression pro. le of cells expressing tumor-derived p53-D281G to identify genes transactivated by mutant p53. We report the transactivation of two genes, asparagine synthetase and human telomerase reverse transcriptase. Quantitative real-time PCR confirms this upregulation. Transient transfection promoter assays verify that tumor-derived p53 mutants trans-activate these promoters significantly. An electrophoretic mobility shift assay shows that tumor-derived p53-mutants cannot bind to the wild-type p53 consensus sequence. The results presented here provide some evidence of a possible mechanism for mutant p53-mediated transactivation.	Virginia Commonwealth Univ, Dept Biochem, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Radiat Oncol, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University	Deb, S (corresponding author), Virginia Commonwealth Univ, Dept Biochem, POB 980614, Richmond, VA 23298 USA.	sdeb@hsc.vcu.edu	Das, Anindita/K-8003-2013; Valerie, Kristoffer/AAL-8299-2021	Das, Anindita/0000-0003-4422-7277; Anderson, Michelle/0000-0003-1510-2942	NATIONAL CANCER INSTITUTE [F31CA097520, R01CA070712, R01CA074172] Funding Source: NIH RePORTER; NCI NIH HHS [1 F31 CA97520, CA74172, CA70712] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aslanian AM, 2001, BIOCHEM J, V357, P321, DOI 10.1042/0264-6021:3570321; Asschert JGW, 1999, INT J CANCER, V81, P236, DOI 10.1002/(SICI)1097-0215(19990412)81:2<236::AID-IJC12>3.0.CO;2-R; Barbosa-Tessmann IP, 2000, J BIOL CHEM, V275, P26976; Bargonetti J, 1997, CELL MOL BIOL, V43, P935; Benard J, 2003, HUM MUTAT, V21, P182, DOI 10.1002/humu.10172; Bensaad K, 2003, J BIOL CHEM, V278, P10546, DOI 10.1074/jbc.M208233200; Beroud C, 1998, NUCLEIC ACIDS RES, V26, P200, DOI 10.1093/nar/26.1.200; Bronder JL, 2003, J BIOL CHEM, V278, P48861, DOI 10.1074/jbc.M304844200; Cadwell C, 2001, GENE, V277, P15, DOI 10.1016/S0378-1119(01)00696-5; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; Davis BB, 2003, AM J PHYSIOL-CELL PH, V284, pC16, DOI 10.1152/ajpcell.00211.2002; Deb D, 2002, ONCOGENE, V21, P176, DOI 10.1038/sj/onc/1205035; Deb D, 2001, INT J ONCOL, V18, P401; Deb D, 1999, INT J ONCOL, V15, P413; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DEB SP, 1994, ONCOGENE, V9, P1341; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; Doyle L Austin, 2002, Expert Rev Anticancer Ther, V2, P217, DOI 10.1586/14737140.2.2.217; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ellis MJ, 1998, BREAST CANCER RES TR, V52, P175, DOI 10.1023/A:1006127621512; Fafournoux P, 2000, BIOCHEM J, V351, P1, DOI 10.1042/0264-6021:3510001; Giebler HA, 2000, MOL CELL BIOL, V20, P4849, DOI 10.1128/MCB.20.13.4849-4858.2000; GRECO A, 1989, MOL CELL BIOL, V9, P2350, DOI 10.1128/MCB.9.6.2350; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; Hassan S, 2003, J BIOL CHEM, V278, P38860, DOI 10.1074/jbc.M305040200; Herbert BS, 2001, BREAST CANCER RES, V3, P146, DOI 10.1186/bcr288; Hernandez-Boussard T, 1999, HUM MUTAT, V14, P1; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; Hussain SP, 1998, TOXICOL LETT, V103, P219, DOI 10.1016/S0378-4274(98)00310-5; Hutson RG, 1997, AM J PHYSIOL-CELL PH, V272, pC1691, DOI 10.1152/ajpcell.1997.272.5.C1691; JUVEN T, 1993, ONCOGENE, V8, P3411; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kannan K, 2001, ONCOGENE, V20, P3449, DOI 10.1038/sj.onc.1204446; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; KERN SE, 1991, ONCOGENE, V6, P131; Kerns RT, 2003, METHODS, V31, P274, DOI 10.1016/S1046-2023(03)00156-7; Kiyooka K, 1999, Ann Thorac Cardiovasc Surg, V5, P293; LANE DP, 1994, BRIT MED BULL, V50, P582, DOI 10.1093/oxfordjournals.bmb.a072911; Lanyi A, 1998, ONCOGENE, V16, P3169, DOI 10.1038/sj.onc.1201857; LENG P, 1995, ONCOGENE, V10, P1275; Leung-Pineda V, 2002, J BIOL CHEM, V277, P16585, DOI 10.1074/jbc.M110972200; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1995, ONCOGENE, V10, P2387; Madden SL, 1997, ONCOGENE, V15, P1079, DOI 10.1038/sj.onc.1201091; MARGULIES L, 1993, J BIOL CHEM, V268, P15096; MARTIN DW, 1993, BIOCHEM BIOPH RES CO, V195, P428, DOI 10.1006/bbrc.1993.2061; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; Matsui H, 1999, CARDIOVASC RES, V42, P104, DOI 10.1016/S0008-6363(98)00285-5; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Morali OG, 2000, DEV BIOL, V227, P133, DOI 10.1006/dbio.2000.9875; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; OConnor DJ, 1995, EMBO J, V14, P6184, DOI 10.1002/j.1460-2075.1995.tb00309.x; Ohlsson C, 1998, ENDOCRINOLOGY, V139, P1101, DOI 10.1210/en.139.3.1101; Polanowska J, 2000, GENE CHROMOSOME CANC, V28, P126, DOI 10.1002/(SICI)1098-2264(200005)28:1<126::AID-GCC15>3.0.CO;2-G; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Preuss U, 2000, INT J CANCER, V88, P162, DOI 10.1002/1097-0215(20001015)88:2<162::AID-IJC3>3.0.CO;2-M; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Prives C, 1999, J PATHOL, V187, P112; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; Rice JC, 2003, MOL CELL, V12, P1591, DOI 10.1016/S1097-2765(03)00479-9; Scheel C, 2002, VIRCHOWS ARCH, V440, P573, DOI 10.1007/s00428-002-0634-9; Scolnick DM, 1997, CANCER RES, V57, P3693; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; Sigal A, 2000, CANCER RES, V60, P6788; Smith ER, 2001, J BIOL CHEM, V276, P31483, DOI 10.1074/jbc.C100351200; Sorensen TS, 1996, MOL CELL BIOL, V16, P5888; Soussi T, 2000, HUM MUTAT, V15, P105, DOI 10.1002/(SICI)1098-1004(200001)15:1<105::AID-HUMU19>3.0.CO;2-G; SPERGEL JM, 1992, J VIROL, V66, P1021, DOI 10.1128/JVI.66.2.1021-1030.1992; STORY MD, 1993, CANCER CHEMOTH PHARM, V32, P129, DOI 10.1007/BF00685615; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUBLER MA, 1994, ONCOGENE, V9, P1351; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Valerie E, 1999, UROLOGY, V54, P1082, DOI 10.1016/S0090-4295(99)00311-8; Van Orden K, 1999, J BIOL CHEM, V274, P26321, DOI 10.1074/jbc.274.37.26321; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; Webb SJ, 2002, J DENT RES, V81, P17, DOI 10.1177/154405910208100105; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Xiang H, 2002, ONCOGENE, V21, P3784, DOI 10.1038/sj.onc.1205455; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang CR, 2000, FASEB J, V14, P379, DOI 10.1096/fasebj.14.2.379; Zhao RB, 2000, GENE DEV, V14, P981; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030; Zilfou JT, 2001, MOL CELL BIOL, V21, P3974, DOI 10.1128/MCB.21.12.3974-3985.2001	90	82	83	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2004	23	25					4430	4443		10.1038/sj.onc.1207553	http://dx.doi.org/10.1038/sj.onc.1207553			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	824CJ	15077194				2022-12-28	WOS:000221661300009
J	Osato, M				Osato, M			Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia	ONCOGENE			English	Article						RUNX; AML1; PEBP2; point mutation; familial leukemia	ACUTE MYELOID-LEUKEMIA; FAMILIAL PLATELET DISORDER; GENOTYPE-PHENOTYPE CORRELATIONS; ACUTE MYELOGENOUS LEUKEMIA; TUMOR-SUPPRESSOR GENE; AML1 GENE; CLEIDOCRANIAL DYSPLASIA; PLECKSTRIN PHOSPHORYLATION; MYELODYSPLASTIC SYNDROME; AML1/PEBP2-ALPHA-B GENE	The RUNX1/AML1 gene is the most frequent target for chromosomal translocation in leukemia. In addition, recent studies have demonstrated point mutations in the RUNX1 gene as another mode of genetic alteration in development of leukemia. Monoallelic germline mutations in RUNX1 result in familial platelet disorder predisposed to acute myelogenous leukemia (FPD/AML). Sporadic point mutations are frequently found in three leukemia entities: AML M0 subtype, MDS-AML, and secondary (therapy-related) MDS/AML. Therapy-related leukemias resulting from anticancer treatments are not uncommon, and the incidence of RUNX1 point mutations appears comparable to the incidence of the t(8; 21) AML M2 subtype and the inv(16) AML M4Eo subtype. Half of the point mutations in M0 cases are biallelic, although the frequencyvaries with ethnicity. Most of the RUNX1 mutations are clustered in the Runt domain and result in defective DNA binding but active beta-subunit binding, which is consistent with three-dimensional structural findings and may explain the dominant inhibitory effects. Unlike the classical tumor suppressor genes requiring biallelic inactivation, haploinsufficient RUNX1 is apparently leukemogenic. However, RUNX1 abnormalities per se are insufficient to cause full-blown leukemia. Intensive investigation of cooperating genetic alterations should elucidate leukemic mechanisms.	Natl Univ Singapore, Oncol Res Inst, Inst Mol & Cell Biol, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Osato, M (corresponding author), Natl Univ Singapore, Oncol Res Inst, Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.	motomi@imcb.a-star.edu.sg	Osato, Motomi/N-5056-2014	Osato, Motomi/0000-0003-3982-9054				Antonarakis SE, 1998, HUM MUTAT, V11, P1; Buijs A, 2001, BLOOD, V98, P2856, DOI 10.1182/blood.V98.9.2856; Carnicer MJ, 2002, LEUKEMIA, V16, P2329, DOI 10.1038/sj.leu.2402656; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; DOWTON SB, 1985, BLOOD, V65, P557; Ferrari T, 2001, ANN HEMATOL, V80, P72, DOI 10.1007/s002770000238; Gabbeta J, 1996, BLOOD, V87, P1368, DOI 10.1182/blood.V87.4.1368.bloodjournal8741368; GERRARD JM, 1991, BRIT J HAEMATOL, V79, P246, DOI 10.1111/j.1365-2141.1991.tb04529.x; Harada H, 2004, BLOOD, V103, P2316, DOI 10.1182/blood-2003-09-3074; Harada H, 2003, BLOOD, V101, P673, DOI 10.1182/blood-2002-04-1010; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; Huang G, 2001, EMBO J, V20, P723, DOI 10.1093/emboj/20.4.723; Ichikawa M, 2004, NAT MED, V10, P299, DOI 10.1038/nm997; Imai Y, 2000, BLOOD, V96, P3154, DOI 10.1182/blood.V96.9.3154.h8003154_3154_3160; Langabeer SE, 2002, GENE CHROMOSOME CANC, V34, P24, DOI 10.1002/gcc.10031; Li FQ, 2004, J BIOL CHEM, V279, P2873, DOI 10.1074/jbc.M310759200; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; Matsuno N, 2003, LEUKEMIA, V17, P2492, DOI 10.1038/sj.leu.2403160; Michaud J, 2002, BLOOD, V99, P1364, DOI 10.1182/blood.V99.4.1364; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Nagata T, 1999, NAT STRUCT BIOL, V6, P615; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Osato M, 2001, INT J HEMATOL, V74, P245, DOI 10.1007/BF02982056; Preudhomme C, 2000, BLOOD, V96, P2862, DOI 10.1182/blood.V96.8.2862.h8002862_2862_2869; Rodenhiser DI, 1997, MUTAT RES-FUND MOL M, V373, P185, DOI 10.1016/S0027-5107(96)00171-6; Roumier C, 2003, BLOOD, V101, P1277, DOI 10.1182/blood-2002-05-1474; Roumier C, 2003, LEUKEMIA, V17, P9, DOI 10.1038/sj.leu.2402766; Silva FPG, 2003, ONCOGENE, V22, P538, DOI 10.1038/sj.onc.1206141; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Sun LS, 2004, BLOOD, V103, P948, DOI 10.1182/blood-2003-07-2299; Tahirov TH, 2001, CELL, V104, P755, DOI 10.1016/S0092-8674(01)00271-9; Taketani T, 2003, GENE CHROMOSOME CANC, V38, P1, DOI 10.1002/gcc.10246; Taketani T, 2002, LEUKEMIA, V16, P1866, DOI 10.1038/sj.leu.2402612; Vegesna VA, 2002, LEUKEMIA RES, V26, P451, DOI 10.1016/S0145-2126(01)00150-3; Walker LC, 2002, BRIT J HAEMATOL, V117, P878, DOI 10.1046/j.1365-2141.2002.03512.x; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Yoshida T, 2003, BLOOD CELL MOL DIS, V30, P184, DOI 10.1016/S1079-9796(03)00020-2; Yoshida T, 2002, AM J HUM GENET, V71, P724, DOI 10.1086/342717; Zhou G, 1999, HUM MOL GENET, V8, P2311, DOI 10.1093/hmg/8.12.2311	41	204	208	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2004	23	24					4284	4296		10.1038/sj.onc.1207779	http://dx.doi.org/10.1038/sj.onc.1207779			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823BZ	15156185	Bronze			2022-12-28	WOS:000221586000014
J	Pavey, S; Johansson, P; Packer, L; Taylor, J; Stark, M; Pollock, PM; Walker, GJ; Boyle, GM; Harper, U; Cozzi, SJ; Hansen, K; Yudt, L; Schmidt, C; Hersey, P; Ellem, KAO; O'Rourke, MGE; Parsons, PG; Meltzer, P; Ringner, M; Hayward, NK				Pavey, S; Johansson, P; Packer, L; Taylor, J; Stark, M; Pollock, PM; Walker, GJ; Boyle, GM; Harper, U; Cozzi, SJ; Hansen, K; Yudt, L; Schmidt, C; Hersey, P; Ellem, KAO; O'Rourke, MGE; Parsons, PG; Meltzer, P; Ringner, M; Hayward, NK			Microarray expression profiling in melanoma reveals a BRAF mutation signature	ONCOGENE			English	Article						BRAF; melanoma; microarray; mitogenactivated protein kinase; mutation	PROTEIN-TYROSINE-PHOSPHATASE; N-RAS; DIFFERENTIAL DISPLAY; ONCOGENIC PATHWAYS; KINASE ACTIVATION; GENE; CANCER; CLASSIFICATION; PROGRESSION; ADHESION	We have used microarray gene expression pro. ling and machine learning to predict the presence of BRAF mutations in a panel of 61 melanoma cell lines. The BRAF gene was found to be mutated in 42 samples (69%) and intragenic mutations of the NRAS gene were detected in seven samples (11%). No cell line carried mutations of both genes. Using support vector machines, we have built a classifier that differentiates between melanoma cell lines based on BRAF mutation status. As few as 83 genes are able to discriminate between BRAF mutant and BRAF wild-type samples with clear separation observed using hierarchical clustering. Multidimensional scaling was used to visualize the relationship between a BRAF mutation signature and that of a generalized mitogen-activated protein kinase ( MAPK) activation ( either BRAF or NRAS mutation) in the context of the discriminating gene list. We observed that samples carrying NRAS mutations lie somewhere between those with or without BRAF mutations. These observations suggest that there are gene-specific mutation signals in addition to a common MAPK activation that result from the pleiotropic effects of either BRAF or NRAS on other signaling pathways, leading to measurably different transcriptional changes.	Queensland Inst Med Res, Herston, Qld 4006, Australia; Lund Univ, Dept Theoret Phys, Complex Syst Div, SE-22362 Lund, Sweden; Pk Ctr Mental Hlth, Queensland Ctr Schizophrenia Res, Wacol, Qld 4076, Australia; NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA; Univ Newcastle, Newcastle, NSW 2300, Australia; Mater Misericordiae Univ Hosp, Brisbane, Qld 4101, Australia	QIMR Berghofer Medical Research Institute; Lund University; Queensland Centre for Mental Health Research; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Newcastle; University College Dublin	Hayward, NK (corresponding author), Queensland Inst Med Res, 300 Herston Rd, Herston, Qld 4006, Australia.	nickH@qimr.edu.au	hayward, nick/AAV-8802-2020; Stark, Mitchell/K-3874-2019; Pavey, Sandra/B-3662-2011; Parsons, Peter G/H-8163-2015; Stark, Mitchell S/E-3542-2010; Stark, Mitchell/K-6794-2019; Taylor, Jennifer M/A-1686-2010; Boyle, Glen/G-1347-2013; hayward, nicholas k/C-1367-2015; Ringnér, Markus/G-3641-2011; Johansson, Peter A/K-1053-2014; Walker, Graeme J/C-2548-2012; Schmidt, Christopher W/A-4353-2009	Pavey, Sandra/0000-0003-4519-5932; Parsons, Peter G/0000-0002-0473-3346; Stark, Mitchell S/0000-0002-4510-2161; Stark, Mitchell/0000-0002-4510-2161; Taylor, Jennifer M/0000-0003-4231-0181; Boyle, Glen/0000-0002-1385-529X; hayward, nicholas k/0000-0003-4760-1033; Ringnér, Markus/0000-0001-5469-8940; Johansson, Peter A/0000-0001-7015-5452; Walker, Graeme J/0000-0002-9392-8769; Schmidt, Christopher W/0000-0002-3955-5076; Pollock, Pamela/0000-0001-8420-1026	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000186] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Bastian BC, 1997, CELL MOL LIFE SCI, V53, P554, DOI 10.1007/s000180050071; Brose MS, 2002, CANCER RES, V62, P6997; Castellano M, 1997, CANCER RES, V57, P4868; Chuaqui RF, 2002, NAT GENET, V32, P509, DOI 10.1038/ng1034; Cohen C, 2002, CLIN CANCER RES, V8, P3728; Cohen J, 2003, J NATL CANCER I, V95, P625, DOI 10.1093/jnci/95.8.625; Cristianini N, 2000, INTRO SUPPORT VECTOR; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dong JL, 2003, CANCER RES, V63, P3883; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Francia G, 1996, CANCER RES, V56, P3855; Fukushima T, 2003, ONCOGENE, V22, P6455, DOI 10.1038/sj.onc.1206739; Furey TS, 2000, BIOINFORMATICS, V16, P906, DOI 10.1093/bioinformatics/16.10.906; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Gorden A, 2003, CANCER RES, V63, P3955; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801; Huang E, 2003, NAT GENET, V34, P226, DOI 10.1038/ng1167; Jazaeri AA, 2002, JNCI-J NATL CANCER I, V94, P990, DOI 10.1093/jnci/94.13.990; Johnson JP, 1997, INT J CANCER, V73, P769; Khan J, 2001, NAT MED, V7, P673, DOI 10.1038/89044; Kimura ET, 2003, CANCER RES, V63, P1454; LUCA M, 1993, MELANOMA RES, V3, P35, DOI 10.1097/00008390-199304000-00006; Medrano EE, 2003, ONCOGENE, V22, P3123, DOI 10.1038/sj.onc.1206452; MUSTELIN T, 2002, SCI STKE, V115, pPE3; Naoki K, 2002, CANCER RES, V62, P7001; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Prathapam T, 2002, NUCLEIC ACIDS RES, V30, P5261, DOI 10.1093/nar/gkf658; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Rajeevan MS, 2001, METHODS, V25, P443, DOI 10.1006/meth.2001.1266; Satyamoorthy K, 2003, CANCER RES, V63, P756; Schleger C, 2000, MOL CARCINOGEN, V28, P31, DOI 10.1002/(SICI)1098-2744(200005)28:1<31::AID-MC5>3.0.CO;2-F; Schoch C, 2002, P NATL ACAD SCI USA, V99, P10008, DOI 10.1073/pnas.142103599; Shih IM, 1997, CANCER RES, V57, P3835; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Srivastava M, 2001, P NATL ACAD SCI USA, V98, P4575, DOI 10.1073/pnas.071055798; Troyanskaya OG, 2002, BIOINFORMATICS, V18, P1454, DOI 10.1093/bioinformatics/18.11.1454; vanElsas A, 1996, AM J PATHOL, V149, P883; Xie SH, 1997, CANCER RES, V57, P2295; Yuen ST, 2002, CANCER RES, V62, P6451; Zheng XM, 2001, EMBO J, V20, P6037, DOI 10.1093/emboj/20.21.6037; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	45	144	154	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4060	4067		10.1038/sj.onc.1207563	http://dx.doi.org/10.1038/sj.onc.1207563			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15048078				2022-12-28	WOS:000221520200003
J	Wu, LQ; Zhu, HY; Nie, LH; Maki, CG				Wu, LQ; Zhu, HY; Nie, LH; Maki, CG			A link between p73 transcriptional activity and p73 degradation	ONCOGENE			English	Article						p53; p73; degradation	RING-FINGER DOMAIN; P53-RELATED PROTEIN; ONCOPROTEIN MDM2; UBIQUITIN LIGASE; P53; P63; IDENTIFICATION; ACTIVATION; TRANSACTIVATION; APOPTOSIS	The p53 family of proteins includes three members, p53, p63, and p73. The levels and stability of p53 are controlled in large part by MDM2, which can bind the p53 N-terminus and promote its degradation. Because the MDM2 gene is transcriptionally activated by p53, it forms part of an autoregulatory feedback loop that directly links the transcriptional activity of p53 with its degradation. In contrast, little is known about the mechanisms that control p63 or p73 stability. In the current study, p73 deletion or point mutants that lacked transactivation activity were stable compared to wild-type p73. A naturally occurring p73 variant (DeltaNp73) was also stable compared to wild-type p73. Finally, fusion of the VP16-transactivation domain to an inactive, stable p73 mutant restored transactivation function and rendered the mutant protein unstable. These results demonstrate that p73 transactivation activity is necessary for rapid p73 turnover, and suggest that one or more transcriptional targets of p73 may promote its degradation.	Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA	University of Chicago	Maki, CG (corresponding author), Univ Chicago, Dept Radiat & Cellular Oncol, 5841 S Maryland Ave,MC1105,Room G-06, Chicago, IL 60637 USA.	cmaki@rover.uchicago.edu			NCI NIH HHS [1R01CA80918-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080918] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; Douc-Rasy S, 2002, AM J PATHOL, V160, P631, DOI 10.1016/S0002-9440(10)64883-3; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Gu JJ, 2000, MOL CELL BIOL, V20, P1243, DOI 10.1128/MCB.20.4.1243-1253.2000; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kadakia M, 2001, DNA CELL BIOL, V20, P321, DOI 10.1089/10445490152122433; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lee CW, 1999, ONCOGENE, V18, P4171, DOI 10.1038/sj.onc.1202793; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Little NA, 2001, ONCOGENE, V20, P4576, DOI 10.1038/sj.onc.1204615; MELIKHOV D, 2002, EUR PHYS J C, V2, P1; Miyazaki K, 2003, BIOCHEM BIOPH RES CO, V308, P106, DOI 10.1016/S0006-291X(03)01347-0; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Takada N, 1999, CANCER RES, V59, P2810; Ueda Y, 1999, ONCOGENE, V18, P4993, DOI 10.1038/sj.onc.1202817; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030	25	22	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					4032	4036		10.1038/sj.onc.1207538	http://dx.doi.org/10.1038/sj.onc.1207538			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15021899				2022-12-28	WOS:000221382000016
J	Makino, K; Day, CP; Wang, SC; Li, YM; Hung, MC				Makino, K; Day, CP; Wang, SC; Li, YM; Hung, MC			Upregulation of IKK alpha/IKK beta by integrin-linked kinase is required for HER2/neu-induced NF-kappa B antiapoptotic pathway	ONCOGENE			English	Article						HER2/neu; ILK; PI-3K; Akt; TNF-alpha; antiapoptotic pathway; IKK	ACTIVATED PROTEIN-KINASE; CELL-PROLIFERATION; INDUCED APOPTOSIS; MAP KINASE; AKT; PHOSPHORYLATION; HER-2/NEU; CANCER; OVEREXPRESSION; TRANSFORMATION	Constitutively active HER2/neu activates nuclear factor kappa-B (NF-kappaB) in cells and induces their resistance to apoptotic stimuli such as tumor necrosis factor-alpha (TNF-alpha). Here, we show that integrin-linked kinase (ILK), the crucial signal transducer in the integrin pathway, is involved in HER2/neu-mediated activation of NF-kappaB. Expression of HER2/neu increases ILK activity. Blocking ILK activity with a kinase-deficient mutant ILK (ILK-KD) inhibits NF-kappaB activation and sensitizes HER2/neu-transformed cells to TNF-alpha-induced apoptosis. Stable expression of ILK-KD in HER2/neu-transformed cells suppressed Akt phosphorylation and the expression of IkappaB kinase alpha and beta (IKKalpha and beta) at both the protein and mRNA levels, preventing IkappaB-alpha degradation and NF-kappaB activation. Furthermore, HER2/neu stimulated the transcriptional activity of the putative IKKbeta promoter through ILK and Akt. Our results demonstrate that upregulation of IKKalpha and IKKbeta by the ILK/Akt pathway is required for the HER2/neu-mediated NF-kappaB antiapoptotic pathway.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Kumamoto Univ, Sch Med, Dept Neurosurg, Kumamoto 860, Japan; Univ Texas, Hlth Sci Ctr, Grad Sch Biomed Sci, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Kumamoto University; University of Texas System; University of Texas Health Science Center Houston	Hung, MC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	mhung@mail.mdanderson.org	Wang, Shao-Chun/P-9904-2019; Hung, Mien-Chie/ABD-5911-2021	Wang, Shao-Chun/0000-0002-5477-1682; Hung, Mien-Chie/0000-0003-4317-4740	NCI NIH HHS [P01 CA 99031] Funding Source: Medline; PHS HHS [R01 58880] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA099031] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Cruet-Hennequart S, 2003, ONCOGENE, V22, P1688, DOI 10.1038/sj.onc.1206347; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; Gambaletta D, 2000, J BIOL CHEM, V275, P10604, DOI 10.1074/jbc.275.14.10604; Gary DS, 2003, J NEUROCHEM, V84, P878, DOI 10.1046/j.1471-4159.2003.01579.x; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hung MC, 1999, SEMIN ONCOL, V26, P51; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Ozes ON, 1999, NATURE, V401, P82; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Sundberg C, 1996, J CELL BIOL, V132, P741, DOI 10.1083/jcb.132.4.741; Tan C, 2002, J BIOL CHEM, V277, P3109, DOI 10.1074/jbc.M108673200; Tan M, 2002, MOL CELL, V9, P993, DOI 10.1016/S1097-2765(02)00510-5; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Yu DH, 2000, ONCOGENE, V19, P6115, DOI 10.1038/sj.onc.1203972; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	29	36	43	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2004	23	21					3883	3887		10.1038/sj.onc.1207485	http://dx.doi.org/10.1038/sj.onc.1207485			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	818JX	15021910				2022-12-28	WOS:000221242500015
J	Watson, JEV; Doggett, NA; Albertson, DG; Andaya, A; Chinnaiyan, A; van Dekken, H; Ginzinger, D; Haqq, C; James, K; Kamkar, S; Kowbel, D; Pinkel, D; Schmitt, L; Simko, JP; Volik, S; Weinberg, VK; Paris, PL; Collins, C				Watson, JEV; Doggett, NA; Albertson, DG; Andaya, A; Chinnaiyan, A; van Dekken, H; Ginzinger, D; Haqq, C; James, K; Kamkar, S; Kowbel, D; Pinkel, D; Schmitt, L; Simko, JP; Volik, S; Weinberg, VK; Paris, PL; Collins, C			Integration of high-resolution array comparative genomic hybridization analysis of chromosome 16q with expression array data refines common regions of loss at16q23-qter and identifies underlying candidate tumor suppressor genes in prostate cancer	ONCOGENE			English	Article						prostate cancer; chromosome 16q; array CGH; tumor suppressor genes	FRAGILE SITE FRA16D; ALLELIC IMBALANCE; GROWTH; CARCINOMAS; BREAST; TRANSLOCATION; DYSREGULATION; MICROARRAYS; DELETIONS; SEQUENCE	We have constructed a high-resolution genomic microarray of human chromosome 16q, and used it for comparative genomic hybridization analysis of 16 prostate tumors. We demarcated 10 regions of genomic loss between 16q23.1 and 16qter that occurred in five or more samples. Mining expression array data from four independent studies allowed us to identify 11 genes that were frequently underexpressed in prostate cancer and that co-localized with a region of genomic loss. Quantitative expression analyses of these genes in matched tumor and benign tissue from 13 patients showed that six of these 11 (WWOX, WFDC1, MAF, FOXF1, MVD and the predicted novel transcript Q9H0B8 (NM_031476)) had significant and consistent downregulation in the tumors relative to normal prostate tissue expression making them candidate tumor suppressor genes.	Univ Calif San Francisco, Ctr Comprehens Canc, Collins Lab, San Francisco, CA 94143 USA; Los Alamos Natl Lab, Biosci Div, Los Alamos, NM 87545 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Med Ctr, Erasmus Med Ctr, Rotterdam, Netherlands	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; United States Department of Energy (DOE); Los Alamos National Laboratory; University of Michigan System; University of Michigan; Erasmus University Rotterdam; Erasmus MC	Watson, JEV (corresponding author), Univ Calif San Francisco, Ctr Comprehens Canc, Collins Lab, 2340 Sutter St, San Francisco, CA 94143 USA.	vwatson@cc.ucsf.edu			NATIONAL CANCER INSTITUTE [P50CA089520] Funding Source: NIH RePORTER; NCI NIH HHS [CA89520] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bednarek AK, 2001, CANCER RES, V61, P8068; Buckley PG, 2002, HUM MOL GENET, V11, P3221, DOI 10.1093/hmg/11.25.3221; Chesi M, 1998, BLOOD, V91, P4457, DOI 10.1182/blood.V91.12.4457.412k48_4457_4463; Chu LW, 2003, GENE CHROMOSOME CANC, V36, P303, DOI 10.1002/gcc.10171; Collins C, 2001, GENOME RES, V11, P1034, DOI 10.1101/gr.GR1743R; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Elo JP, 1999, BRIT J CANCER, V79, P156, DOI 10.1038/sj.bjc.6690025; Giese A, 2002, GENE, V299, P101, DOI 10.1016/S0378-1119(02)01018-1; Hale TK, 2000, J BIOL CHEM, V275, P17991, DOI 10.1074/jbc.M000921200; Han CS, 2000, GENOME RES, V10, P714, DOI 10.1101/gr.10.5.714; Hodgson G, 2001, NAT GENET, V29, P459, DOI 10.1038/ng771; Jain AN, 2002, GENOME RES, V12, P325, DOI 10.1101/gr.210902; Kochetkova M, 2002, CANCER RES, V62, P4599; Larsen M, 1998, J BIOL CHEM, V273, P4574, DOI 10.1074/jbc.273.8.4574; Luo J, 2001, CANCER RES, V61, P4683; Magee JA, 2001, CANCER RES, V61, P5692; Mahlapuu M, 2001, DEVELOPMENT, V128, P2397; Matsuyama H, 2003, PROSTATE, V54, P103, DOI 10.1002/pros.10173; Paige AJW, 2001, P NATL ACAD SCI USA, V98, P11417, DOI 10.1073/pnas.191175898; Paige AJW, 2000, CANCER RES, V60, P1690; Paris PL, 2000, CANCER RES, V60, P3645; Paris PL, 2003, AM J PATHOL, V162, P763, DOI 10.1016/S0002-9440(10)63873-4; Rhodes DR, 2002, CANCER RES, V62, P4427; Ried K, 2000, HUM MOL GENET, V9, P1651, DOI 10.1093/hmg/9.11.1651; ROWLEY DR, 1995, J BIOL CHEM, V270, P22058, DOI 10.1074/jbc.270.37.22058; Ruijter ETG, 1999, J PATHOL, V188, P271, DOI 10.1002/(SICI)1096-9896(199907)188:3<271::AID-PATH359>3.0.CO;2-K; Smith DM, 2001, MECH DEVELOP, V102, P223, DOI 10.1016/S0925-4773(01)00293-3; Strup SE, 1999, J UROLOGY, V162, P590, DOI 10.1016/S0022-5347(05)68631-4; Toyooka KO, 2001, CANCER RES, V61, P4556; Van Dekken H, 2000, ACTA HISTOCHEM, V102, P85, DOI 10.1078/0065-1281-00540; Verhage BAJ, 2003, PROSTATE, V54, P50, DOI 10.1002/pros.10148; Wadhwa R, 2003, BIOCHEM BIOPH RES CO, V302, P735, DOI 10.1016/S0006-291X(03)00226-2; Welsh JB, 2001, CANCER RES, V61, P5974	33	77	84	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 22	2004	23	19					3487	3494		10.1038/sj.onc.1207474	http://dx.doi.org/10.1038/sj.onc.1207474			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15007382				2022-12-28	WOS:000220975000024
J	Brummer, T; Stehelin, D; Misawa, Y; Reth, M				Brummer, T; Stehelin, D; Misawa, Y; Reth, M			A revised and complete map of the chicken c-mil/raf-1 locus	ONCOGENE			English	Article						chicken; c-mil; DT40; genomics; protooncogene; Raf-1; serine/threonine kinase	ONCOGENE V-MIL; AVIAN CARCINOMA VIRUS-MH2; MURINE SARCOMA VIRUS-3611; C-MIL; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; RETROVIRUS MH2; GENE; RAF; PROTEIN	The chicken c-mil/raf-1 gene (formerly also known as c-mht) was originally identified in the search for the cellular counterpart to the v-mil oncogene of the Mill Hill 2 retrovirus and was among the first cellular proto-oncogenes discovered. Although the c-mil/raf-1 promotor, as well as the exons transduced into v-mil, were characterized in detail, an entire map of this locus has never been published. Here, we now report the location of five previously unmapped exons. In addition, we have noticed inconsistent numbering of the c-mil/raf-1 exons in the literature and the GenBank database. Thus, we provide here a complete map of the c-mil/raf-1 gene and a revision of the exon numbers. Comparison of the chicken c-mil/raf-1 gene with those of other vertebrates suggests that the numbers and lengths of the translated exons of the raf-1 locus were established early in the vertebrate lineage and have been conserved during the divergent evolution of teleosts and tetrapods.	Univ Freiburg, Inst Biol 3, Dept Mol Immunol, D-79108 Freiburg, Germany; Max Planck Inst Immunbiol, D-79108 Freiburg, Germany; Univ Lille 2, Inst Pasteur Lille, Inst Biol Lille, Dept 3,Lab Oncol Mol, F-59021 Lille, France	University of Freiburg; Max Planck Society; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille	Reth, M (corresponding author), Univ Freiburg, Inst Biol 3, Dept Mol Immunol, Stubeweg 51, D-79108 Freiburg, Germany.	reth@immunbio.mpg.de	Brummer, Tilman/AAA-9428-2020; Brummer, Tilman/B-6218-2016	Brummer, Tilman/0000-0003-4387-7905; Brummer, Tilman/0000-0003-4387-7905				ANSIEAU S, 1993, GENOMICS, V18, P537, DOI 10.1016/S0888-7543(11)80010-8; Aparicio S, 2002, SCIENCE, V297, P1301, DOI 10.1126/science.1072104; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Brummer T, 2002, EMBO J, V21, P5611, DOI 10.1093/emboj/cdf588; COLL J, 1983, EMBO J, V2, P2189, DOI 10.1002/j.1460-2075.1983.tb01722.x; DOZIER C, 1988, MOL CELL BIOL, V8, P1835, DOI 10.1128/MCB.8.4.1835; DOZIER C, 1991, ONCOGENE, V6, P1307; EYCHENE A, 1990, J VIROL, V64, P231; FLORDELLIS CS, 1985, VIROLOGY, V141, P267, DOI 10.1016/0042-6822(85)90257-0; JANSEN HW, 1983, J VIROL, V48, P61, DOI 10.1128/JVI.48.1.61-73.1983; JANSEN HW, 1985, VIROLOGY, V143, P359, DOI 10.1016/0042-6822(85)90376-9; JANSEN HW, 1984, VIROLOGY, V137, P217, DOI 10.1016/0042-6822(84)90028-X; JANSEN HW, 1983, EMBO J, V2, P1969, DOI 10.1002/j.1460-2075.1983.tb01686.x; KAN NC, 1983, P NATL ACAD SCI-BIOL, V80, P6566, DOI 10.1073/pnas.80.21.6566; KAN NC, 1984, SCIENCE, V223, P813, DOI 10.1126/science.6320371; KOENEN M, 1988, ONCOGENE, V2, P179; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; SUTRAVE P, 1984, NATURE, V309, P85, DOI 10.1038/309085a0; SYMONDS G, 1986, J VIROL, V59, P172, DOI 10.1128/JVI.59.1.172-175.1986; VOGT PK, 1979, ONCOGENIC VIRUSES HO	22	0	1	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2004	23	17					3128	3131		10.1038/sj.onc.1207434	http://dx.doi.org/10.1038/sj.onc.1207434			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	812NC	14968114				2022-12-28	WOS:000220845200018
J	Bahassi, ELM; Hennigan, RF; Myer, DL; Stambrook, PJ				Bahassi, ELM; Hennigan, RF; Myer, DL; Stambrook, PJ			Cdc25C phosphorylation on serine 191 by Plk3 promotes its nuclear translocation	ONCOGENE			English	Article						Cdc25C; Plk3; phosphorylation; nuclear exclusion	14-3-3 PROTEIN-BINDING; CELL-CYCLE REGULATION; G(2) CHECKPOINT; KINASE; PHOSPHATASE; LOCALIZATION; B1; AMPLIFICATION; ACTIVATION; INITIATION	Mitosis in human cells is initiated at the end of G2 by activation of the Cdc2/cyclin B complex. Activation occurs by dephosphorylation of the inhibitory residues, threonine 14 (T14) and tyrosine 15 (Y15), on Cdc2 by the Cdc25C phosphatase. Entry into mitosis is regulated by the subcellular relocalization of Cdc2/cyclin B, which is rapidly imported into the nucleus at the end of G2. Here, we show that polo-like kinase 3 (Plk3) is able to phosphorylate Cdc25C primarily on S191, and to a lesser extent on S198 in vitro, both of which are within a nuclear exclusion motif. Following transfection, the S191D Cdc25C mutant leads to an enhanced accumulation of Cdc25C in the nucleus, while the S191A mutant facilitated the Cdc25C nuclear exclusion. Furthermore, translocation of Cdc25C to the nucleus was accompanied by a decrease in Cdc2 phosphorylation on Y15. Plk3-WT overexpression led to a sharp increase in Cdc25C nuclear accumulation, while Plk3-KD overexpression failed to do so. The effect of Plk3 overexpression on Cdc25C was reversed by coexpression of a Plk3 siRNA. These results support a role for the polo kinases in coordinating the translocation and perhaps the timing of both Cdc25C and its target Cdc2/cyclin B to the nucleus upon entry into mitosis.	Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Stambrook, PJ (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol, 3125 Eden Ave, Cincinnati, OH 45267 USA.	peter.stambrook@uc.edu			NATIONAL CANCER INSTITUTE [R01CA090934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007250, U01ES011038] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA90934] Funding Source: Medline; NIEHS NIH HHS [UO1 ES011038, T32 ES07250] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abrieu A, 1998, J CELL SCI, V111, P1751; Bahassi EM, 2002, ONCOGENE, V21, P6633, DOI 10.1038/sj.onc.1205850; Bin OY, 1999, ONCOGENE, V18, P6029, DOI 10.1038/sj.onc.1202983; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Chen MS, 2001, MOL CELL BIOL, V21, P3853, DOI 10.1128/MCB.21.12.3853-3861.2001; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; Golsteyn R M, 1996, Prog Cell Cycle Res, V2, P107; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Graves PR, 2001, ONCOGENE, V20, P1839, DOI 10.1038/sj.onc.1204259; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Mailand N, 2002, EMBO J, V21, P5911, DOI 10.1093/emboj/cdf567; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAGATA A, 1991, NEW BIOL, V3, P959; Nilsson I, 2000, Prog Cell Cycle Res, V4, P107; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Pines J, 1999, NATURE, V397, P104, DOI 10.1038/16344; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Takizawa CG, 2000, CURR OPIN CELL BIOL, V12, P658, DOI 10.1016/S0955-0674(00)00149-6; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; Toyoshima-Morimoto F, 2002, EMBO REP, V3, P341, DOI 10.1093/embo-reports/kvf069; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; TSVETKOV L, 2002, J BIOL CHEM     1218; Yang J, 2001, J BIOL CHEM, V276, P3604, DOI 10.1074/jbc.M008151200	32	62	64	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2004	23	15					2658	2663		10.1038/sj.onc.1207425	http://dx.doi.org/10.1038/sj.onc.1207425			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	810OZ	14968113				2022-12-28	WOS:000220714900007
J	Duxbury, MS; Ito, H; Zinner, MJ; Ashley, SW; Whang, EE				Duxbury, MS; Ito, H; Zinner, MJ; Ashley, SW; Whang, EE			EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma	ONCOGENE			English	Article						EphA2; RNAi; siRNA; pancreatic adenocarcinoma; cancer; in vivo; anoikis; invasion; metastasis	FOCAL-ADHESION-KINASE; RECEPTOR TYROSINE KINASE; RNA INTERFERENCE; EPITHELIAL-CELLS; DIFFERENTIAL REGULATION; GROWTH-FACTOR; CANCER; OVEREXPRESSION; EXPRESSION; INVASION	The EphA2 receptor tyrosine kinase is overexpressed in a variety of human cancers. We sought to characterize the role of EphA2 in pancreatic adenocarcinoma and, using RNA interference (RNAi) mediated by small interfering RNA ( siRNA), we determined the effects of suppressing EphA2 expression in vitro and in vivo. EphA2 expression in PANC1, MIAPaCa2, BxPC3 and Capan2 cells was assessed by Northern and Western blot. We artificially overexpressed EphA2 by transient transfection and suppressed EphA2 expression using RNAi. Cellular invasiveness was quantified by modified Boyden chamber assay. Anoikis was induced by anchorage-independent polyHEMA culture and caspase 3 activity was quantified fluorometrically. Focal adhesion kinase (FAK) phosphorylation was assessed by immunoprecipitation. EphA2 siRNA treatment was assessed in a nude mouse xenograft model. Pancreatic adenocarcinoma cells differentially express EphA2. Inherent and induced EphA2 overexpression is associated with increased cellular invasiveness and anoikis resistance. EphA2 siRNA suppresses EphA2 expression, cellular invasiveness, anoikis resistance and FAK phosphorylation in vitro and retards tumor growth and inhibits metastasis in vivo. EphA2 is both a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma.	Harvard Univ, Brigham & Womens Hosp, Dept Surg, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Whang, EE (corresponding author), Harvard Univ, Brigham & Womens Hosp, Dept Surg, Sch Med, 75 Francis St, Boston, MA 02115 USA.	ewhang1@partners.org						Balis FM, 2002, J NATL CANCER I, V94, P78, DOI 10.1093/jnci/94.2.78; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; Bertrand JR, 2002, BIOCHEM BIOPH RES CO, V296, P1000, DOI 10.1016/S0006-291X(02)02013-2; Braasch DA, 2002, BIOCHEMISTRY-US, V41, P4503, DOI 10.1021/bi0122112; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Carles-Kinch K, 2002, CANCER RES, V62, P2840; Carter N, 2002, NAT CELL BIOL, V4, P565, DOI 10.1038/ncb823; Dohn M, 2001, ONCOGENE, V20, P6503, DOI 10.1038/sj.onc.1204816; DVORAK HF, 1990, PROG CLIN BIOL RES, V354, P317; EASTY DJ, 1995, CANCER RES, V55, P2528; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Farrell TJ, 1997, ANN SURG, V226, P66, DOI 10.1097/00000658-199707000-00009; Filleur S, 2003, CANCER RES, V63, P3919; Flenniken AM, 1996, DEV BIOL, V179, P382, DOI 10.1006/dbio.1996.0269; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Fujiwara H, 2002, J CLIN ENDOCR METAB, V87, P5801, DOI 10.1210/jc.2002-020508; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; GORELIK E, 1991, CANCER RES, V51, P5212; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Hauck CR, 2002, IUBMB LIFE, V53, P115, DOI 10.1080/15216540211470; Himanen JP, 2003, INT J BIOCHEM CELL B, V35, P130, DOI 10.1016/S1357-2725(02)00096-1; Holder N, 1999, DEVELOPMENT, V126, P2033; Hsia DA, 2003, J CELL BIOL, V160, P753, DOI 10.1083/jcb.200212114; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Kim HRC, 1999, CANCER RES, V59, P4148; Kinch MS, 2003, CLIN EXP METASTAS, V20, P59, DOI 10.1023/A:1022546620495; Kornberg LJ, 1998, HEAD NECK-J SCI SPEC, V20, P745, DOI 10.1002/(SICI)1097-0347(199812)20:8<745::AID-HED14>3.0.CO;2-Z; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; Lu M, 2003, CANCER RES, V63, P3425; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Miao H, 2001, NAT CELL BIOL, V3, P527, DOI 10.1038/35074604; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; Miknyoczki SJ, 1999, CLIN CANCER RES, V5, P2205; Miyazaki T, 2003, BRIT J CANCER, V89, P140, DOI 10.1038/sj.bjc.6601050; OWENS LV, 1995, CANCER RES, V55, P2752; RAZ A, 1983, SCIENCE, V221, P1307, DOI 10.1126/science.6612347; Rosenberg IM, 1997, AM J PHYSIOL-GASTR L, V273, pG824, DOI 10.1152/ajpgi.1997.273.4.G824; Schneider GB, 2002, CANCER, V95, P2508, DOI 10.1002/cncr.10992; Shanmugathasan M, 2000, PATHOL INT, V50, P273, DOI 10.1046/j.1440-1827.2000.01047.x; Streuli CH, 1999, J MAMMARY GLAND BIOL, V4, P183, DOI 10.1023/A:1018729308878; Sun FX, 2003, CANCER RES, V63, P80; Walker-Daniels J, 2003, AM J PATHOL, V162, P1037, DOI 10.1016/S0002-9440(10)63899-0; Walker-Daniels J, 2002, MOL CANCER RES, V1, P79; Walker-Daniels J, 1999, PROSTATE, V41, P275, DOI 10.1002/(SICI)1097-0045(19991201)41:4<275::AID-PROS8>3.0.CO;2-T; Weckbecker G, 1997, YALE J BIOL MED, V70, P549; Wilda M, 2002, ONCOGENE, V21, P5716, DOI 10.1038/sj.onc.1205653; Wilkinson DG, 2000, INT REV CYTOL, V196, P177; Yawata A, 1998, ONCOGENE, V16, P2681, DOI 10.1038/sj.onc.1201792; Zantek ND, 1999, CELL GROWTH DIFFER, V10, P629; Zelinski DP, 2001, CANCER RES, V61, P2301	53	184	202	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2004	23	7					1448	1456		10.1038/sj.onc.1207247	http://dx.doi.org/10.1038/sj.onc.1207247			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	775HZ	14973554				2022-12-28	WOS:000189035800012
J	Carlomagno, F; Guida, T; Anaganti, S; Vecchio, G; Fusco, A; Ryan, AJ; Billaud, M; Santoro, M				Carlomagno, F; Guida, T; Anaganti, S; Vecchio, G; Fusco, A; Ryan, AJ; Billaud, M; Santoro, M			Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors	ONCOGENE			English	Article						thyroid; tyrosine kinase inhibitors; RET; MEN2	MEDULLARY-THYROID CARCINOMA; NEOPLASIA TYPE 2B; IMATINIB MESYLATE; BLAST CRISIS; GROWTH; ABL; GERMLINE; ACTIVATION; DOMAIN; ZD6474	We have recently demonstrated that the pyrazolopyrimidines PP1 and PP2 and the 4-anilinoquinazoline ZD6474 display a strong inhibitory activity (IC(50)less than or equal to100 nM) towards constitutively active oncogenic RET kinases. Here, we show that most oncogenic MEN2-associated RET kinase mutants are highly susceptible to PP1, PP2 and ZD6474 inhibition. In contrast, MEN2-associated swap of bulky hydrophobic leucine or methionine residues for valine 804 in the RET kinase domain causes resistance to the three compounds. Substitution of valine 804 with the small amino-acid glycine renders the RET kinase even more susceptible to inhibition (ZD6474 IC50: 20 nM) than the wild-type kinase. Our data identify valine 804 of RET as a structural determinant mediating resistance to pyrazolopyrimidines and 4-anilinoquinazolines.	Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Ist Endocrinol & Oncol Sperimentale, CNR, I-80131 Naples, Italy; Astra Zeneca Mereside, Canc Discovery, Macclesfield, Cheshire, England; CNRS, Genet Lab, Lyon, France	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; AstraZeneca; Centre National de la Recherche Scientifique (CNRS)	Santoro, M (corresponding author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Ist Endocrinol & Oncol Sperimentale, CNR, Via S Pansini 5, I-80131 Naples, Italy.	masantor@unina.it	RYAN, Anderson/ACG-0319-2022; Billaud, Marc N/M-6954-2013; Ryan, Anderson J/O-7701-2015	RYAN, Anderson/0000-0001-6241-7969; Ryan, Anderson J/0000-0001-6241-7969; Fusco, Alfredo/0000-0003-3332-5197				Apperley JF, 2002, NEW ENGL J MED, V347, P481, DOI 10.1056/NEJMoa020150; ASAI N, 1995, MOL CELL BIOL, V15, P1613; Bartsch DK, 2000, EXP CLIN ENDOCR DIAB, V108, P128, DOI 10.1055/s-2000-5806; Bishop AC, 2000, NATURE, V407, P395, DOI 10.1038/35030148; Blencke S, 2003, J BIOL CHEM, V278, P15435, DOI 10.1074/jbc.M211158200; BOLINO A, 1995, ONCOGENE, V10, P2415; Brandi ML, 2001, J CLIN ENDOCR METAB, V86, P5658, DOI 10.1210/jc.86.12.5658; Carlomagno F, 2002, CANCER RES, V62, P7284; Carlomagno F, 1997, CANCER RES, V57, P391; Carlomagno F, 2003, J CLIN ENDOCR METAB, V88, P1897, DOI 10.1210/jc.2002-021278; Carlomagno F, 2002, CANCER RES, V62, P1077; Chappuis-Flament S, 1998, ONCOGENE, V17, P2851, DOI 10.1038/sj.onc.1202202; Ciardiello F, 2003, CLIN CANCER RES, V9, P1546; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Fagin JA, 2002, ENDOCRINOLOGY, V143, P2025, DOI 10.1210/en.143.6.2025; Frohnauer MK, 2000, SURGERY, V128, P1052, DOI 10.1067/msy.2000.11/6/111080; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Ito S, 1997, CANCER RES, V57, P2870; Iwashita T, 1999, ONCOGENE, V18, P3919, DOI 10.1038/sj.onc.1202742; Iwashita T, 2000, BIOCHEM BIOPH RES CO, V268, P804, DOI 10.1006/bbrc.2000.2227; Iwashita T, 1996, ONCOGENE, V12, P481; Joensuu H, 2002, LANCET ONCOL, V3, P655, DOI 10.1016/S1470-2045(02)00899-9; Kasprzak L, 2001, J MED GENET, V38, P784, DOI 10.1136/jmg.38.11.784; La Rosee P, 2002, CANCER RES, V62, P7149; Lombardo F, 2002, J CLIN ENDOCR METAB, V87, P1674, DOI 10.1210/jcem.87.4.8403; Machens A, 2003, NEW ENGL J MED, V349, P1517, DOI 10.1056/NEJMoa012915; Manie S, 2001, TRENDS GENET, V17, P580, DOI 10.1016/S0168-9525(01)02420-9; Menko FH, 2002, J CLIN ENDOCR METAB, V87, P393, DOI 10.1210/jc.87.1.393; Nagar B, 2002, CANCER RES, V62, P4236; Pasini A, 1997, ONCOGENE, V15, P393, DOI 10.1038/sj.onc.1201199; Ponder BAJ, 1999, CANCER RES, V59, p1736S; Salvatore D, 2000, J CLIN ENDOCR METAB, V85, P3898, DOI 10.1210/jc.85.10.3898; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Sawyers CL, 2002, BLOOD, V99, P3530, DOI 10.1182/blood.V99.10.3530; Sawyers CL, 2002, J CLIN ONCOL, V20, P3568, DOI 10.1200/JCO.2002.20.17.3568; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; Sherman SI, 2003, LANCET, V361, P501, DOI 10.1016/S0140-6736(03)12488-9; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Wedge SR, 2002, CANCER RES, V62, P4645; Zwick E, 2002, TRENDS MOL MED, V8, P17, DOI 10.1016/S1471-4914(01)02217-1	45	194	200	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6056	6063		10.1038/sj.onc.1207810	http://dx.doi.org/10.1038/sj.onc.1207810			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15184865				2022-12-28	WOS:000223261000005
J	Ramirez-Montagut, T; Blachere, NE; Sviderskaya, EV; Bennett, DC; Rettig, WJ; Garin-Chesa, P; Houghton, AN				Ramirez-Montagut, T; Blachere, NE; Sviderskaya, EV; Bennett, DC; Rettig, WJ; Garin-Chesa, P; Houghton, AN			FAP alpha, a surface peptidase expressed during wound healing, is a tumor suppressor	ONCOGENE			English	Article						peptidase; wound healing; fibroblast activation protein alpha; melanoma; tumor suppressor	FIBROBLAST ACTIVATION PROTEIN; REACTIVE STROMAL FIBROBLASTS; SERINE-PROTEASE; EPITHELIAL CANCERS; MOLECULAR-CLONING; HUMAN MELANOCYTES; MELANOMA; CELLS; DIFFERENTIATION; GROWTH	Fibroblast activation protein-alpha (FAP) is a cell surface serine protease expressed at sites of tissue remodeling in embryonic development. FAP is not expressed by mature somatic tissues except activated melanocytes and fibroblasts in wound healing or tumor stroma. FAP expression is specifically silenced in proliferating melanocytic cells during malignant transformation. To study the role of FAP as a tumor suppressor, the gene for mouse fap was cloned and mutated at the catalytic domain (FAP serine mutant, FSM). We found that expression of FAP or FSM at physiologic levels in mouse melanoma cells abrogated tumorigenicity. Remarkably, the mutant form FSM lacking specific serine protease activity was a more potent tumor suppressor. Tumor rejection was not due to adaptive immune responses because RAG1-/- mice challenged with melanoma cells expressing either FAP or FSM were not tumorigenic. In in vitro assays, FAP or FSM expression restored contact inhibition, led to cell cycle arrest at G0/G1 phase, and increased susceptibility to stress-induced apoptosis. Cell death in FAP + or FSM + melanoma cells was readily triggered by depletion of survival factors from the media, leading to subsequent activation of caspases via the intrinsic pathway. These results show that expression of FAP is a tumor suppressor that abrogates tumorigenicity through regulation of cell growth and survival.	Cornell Univ, Mem Sloan Kettering Canc Ctr, Swim Amer Lab, New York, NY 10021 USA; Cornell Univ, Weill Grad Sch Med Sci, New York, NY 10021 USA; Rockefeller Univ, Mol Neurooncol Lab, New York, NY 10021 USA; Howard Hughes Med Inst, New York, NY 10021 USA; St George Hosp, Sch Med, London SW17 0RE, England; Boehringer Ingelheim Austria GmbH, Div Res & Dev, Vienna, Austria; Univ Vienna, Dept Clin Pathol, Gen Hosp, Vienna, Austria	Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Rockefeller University; Howard Hughes Medical Institute; St Georges University London; Boehringer Ingelheim; University of Vienna	Houghton, AN (corresponding author), Cornell Univ, Mem Sloan Kettering Canc Ctr, Swim Amer Lab, 1275 York Ave, New York, NY 10021 USA.	a-houghton@ski.mskcc.org	Bennett, Dorothy C/C-2418-2008; Sviderskaya, Elena V/D-2419-2009	Bennett, Dorothy C/0000-0002-3639-7527; 				BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; BERKELHAMMER J, 1982, CANCER RES, V42, P3157; Brown DD, 1996, P NATL ACAD SCI USA, V93, P1924, DOI 10.1073/pnas.93.5.1924; Cheng JD, 2002, CANCER RES, V62, P4767; DESMOULIERE A, 1995, CELL BIOL INT, V19, P471, DOI 10.1006/cbir.1995.1090; GARINCHESA P, 1990, P NATL ACAD SCI USA, V87, P7235, DOI 10.1073/pnas.87.18.7235; HEARING VJ, 1985, INT J CANCER, V35, P403, DOI 10.1002/ijc.2910350317; HEARING VJ, 1988, INT J CANCER, V41, P275, DOI 10.1002/ijc.2910410219; Hofmann UB, 2000, J INVEST DERMATOL, V115, P337, DOI 10.1046/j.1523-1747.2000.00068.x; HOUGHTON AN, 1988, J EXP MED, V167, P197, DOI 10.1084/jem.167.1.197; HOUGHTON AN, 1987, J EXP MED, V165, P812, DOI 10.1084/jem.165.3.812; Huber MA, 2003, J INVEST DERMATOL, V120, P182, DOI 10.1046/j.1523-1747.2003.12035.x; MORRISON ME, 1993, J EXP MED, V177, P1135, DOI 10.1084/jem.177.4.1135; Niedermeyer J, 1997, INT J CANCER, V71, P383, DOI 10.1002/(SICI)1097-0215(19970502)71:3<383::AID-IJC14>3.0.CO;2-H; Niedermeyer J, 2001, INT J DEV BIOL, V45, P445; Park JE, 1999, J BIOL CHEM, V274, P36505, DOI 10.1074/jbc.274.51.36505; RETTIG WJ, 1993, CANCER RES, V53, P3327; RETTIG WJ, 1994, INT J CANCER, V58, P385, DOI 10.1002/ijc.2910580314; SCANLAN MJ, 1994, P NATL ACAD SCI USA, V91, P5657, DOI 10.1073/pnas.91.12.5657; SVIDERSKAYA EV, 1995, DEVELOPMENT, V121, P1547; Tsujimoto H, 1999, MOL CARCINOGEN, V26, P298, DOI 10.1002/(SICI)1098-2744(199912)26:4<298::AID-MC8>3.0.CO;2-M; Tuxhorn JA, 2001, J UROLOGY, V166, P2472, DOI 10.1016/S0022-5347(05)65620-0; Wesley UV, 1999, J EXP MED, V190, P311, DOI 10.1084/jem.190.3.311	23	88	101	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2004	23	32					5435	5446		10.1038/sj.onc.1207730	http://dx.doi.org/10.1038/sj.onc.1207730			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15133496				2022-12-28	WOS:000222588400003
J	Saran, A; Spinola, M; Pazzaglia, S; Peissel, B; Tiveron, C; Tatangelo, L; Mancuso, M; Covelli, V; Giovannelli, L; Pitozzi, V; Pignatiello, C; Milani, S; Dolara, P; Dragani, TA				Saran, A; Spinola, M; Pazzaglia, S; Peissel, B; Tiveron, C; Tatangelo, L; Mancuso, M; Covelli, V; Giovannelli, L; Pitozzi, V; Pignatiello, C; Milani, S; Dolara, P; Dragani, TA			Loss of tyrosinase activity confers increased skin tumor susceptibility in mice	ONCOGENE			English	Article						polymorphism; genetic predisposition; animal models	CANCER MODIFIER LOCI; OUTBRED MICE; COMET ASSAY; MOUSE; RESISTANCE; 12-O-TETRADECANOYLPHORBOL-13-ACETATE; CARCINOGENESIS; MUTATION; GENETICS; DAMAGE	The tyrosinase (Tyr) gene encodes the enzyme tyrosinase that catalyses the conversion of L-tyrosine into DOPA (3,4-dihydroxyphenylalanine)- quinone. The albino mutation abrogates functional activity of tyrosinase resulting in deficiency of melanin pigment production in skin and retina. Tyr maps to a region in the central position of Chromosome 7 that contains a skin tumor-modi. er locus. We rescued the albino mutation in transgenic mice to assess a possible role of Tyr gene in two-stage skin carcinogenesis. Transgenic expression of the functional Tyr(Cys) allele in albino mice (Tyr(Ser)) caused a reduction in skin papilloma multiplicity, in four independent experiments and at three dose levels of DMBA (9,10-dimethyl-1,2- benzanthracene). In vitro mechanistic studies demonstrated that transfection of the Tyr(Cys) allele in a human squamous cell carcinoma cell line (NCI-H520) increases tyrosinase enzyme activity and confers resistance to hydrogen peroxide-induced oxidative DNA damage. These results provide direct evidence that the Tyr gene can act as a skin cancer-modifier gene, whose mechanism of action may involve modulation of oxidative DNA damage.	Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; ENEA CR Casaccia, Biotechnol Unit, Rome, Italy; Ist Regina Elena, Transgen Mice Serv Ctr, I-00161 Rome, Italy; Univ Florence, Dept Pharmacol, Florence, Italy; Univ Milan, Inst Med Stat & Biometry, Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Italian National Agency New Technical Energy & Sustainable Economics Development; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Florence; University of Milan	Dragani, TA (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Via G Venezian 1, I-20133 Milan, Italy.	dragani@istitutotumori.mi.it	Dragani, Tommaso A./K-4493-2016; Peissel, Bernard/E-8187-2017; Giovannelli, Lisa/H-3766-2012; milani, silvano/I-7889-2012	Dragani, Tommaso A./0000-0001-5915-4598; Peissel, Bernard/0000-0001-9233-3571; milani, silvano/0000-0002-5677-1758; Saran, Anna/0000-0002-5587-064X; Giovannelli, Lisa/0000-0002-4027-4693	Telethon [B.55] Funding Source: Medline	Telethon(Fondazione Telethon)		Angel JM, 1997, MOL CARCINOGEN, V20, P162, DOI 10.1002/(SICI)1098-2744(199710)20:2<162::AID-MC2>3.0.CO;2-P; Collins AR, 1997, MUTAT RES-FUND MOL M, V375, P183, DOI 10.1016/S0027-5107(97)00013-4; Cormier RT, 2000, ONCOGENE, V19, P3182, DOI 10.1038/sj.onc.1203646; Darvasi A, 2002, TRENDS GENET, V18, P489, DOI 10.1016/S0168-9525(02)02767-1; delMarmol V, 1996, FEBS LETT, V381, P165, DOI 10.1016/0014-5793(96)00109-3; Dragani TA, 2003, CANCER RES, V63, P3011; Draper N.R., 1998, APPL REGRESSION ANAL, P79; FRENKEL K, 1995, FREE RADICAL BIO MED, V19, P373, DOI 10.1016/0891-5849(95)00046-Z; GANSS R, 1994, EMBO J, V13, P3083, DOI 10.1002/j.1460-2075.1994.tb06607.x; Giovannelli L, 2003, MUTAT RES-GEN TOX EN, V538, P71, DOI 10.1016/S1383-5718(03)00090-1; Hogan B, 1994, MANIPULATING MOUSE E; Lutsenko EA, 2002, J BIOL CHEM, V277, P16895, DOI 10.1074/jbc.M201151200; Manenti G, 1997, MAMM GENOME, V8, P801, DOI 10.1007/s003359900582; Maria DA, 2003, ONCOGENE, V22, P426, DOI 10.1038/sj.onc.1206157; Mock BA, 1998, CARCINOGENESIS, V19, P1109, DOI 10.1093/carcin/19.6.1109; NAGASE H, 1995, NAT GENET, V10, P424, DOI 10.1038/ng0895-424; Nagase H, 2001, CANCER RES, V61, P1305; Park KK, 2003, MUTAT RES-GEN TOX EN, V542, P89, DOI 10.1016/j.mrgentox.2003.09.001; Peissel B, 2000, MAMM GENOME, V11, P979, DOI 10.1007/s003350010184; Peissel B, 2001, MAMM GENOME, V12, P291, DOI 10.1007/s003350010274; PERIN F, 1994, CANCER RES, V54, P4635; Saran A, 2000, INT J CANCER, V88, P424, DOI 10.1002/1097-0215(20001101)88:3<424::AID-IJC15>3.0.CO;2-D; SEARLE AG, 1990, OPHTHALMIC PAED GEN, V11, P159, DOI 10.3109/13816819009020974; Shi YL, 2002, LIFE SCI, V70, P1595, DOI 10.1016/S0024-3205(01)01546-6; SLAGA TJ, 1995, ADV EXP MED BIOL, V369, P167; Steinmetz LM, 2002, NATURE, V416, P326, DOI 10.1038/416326a; WEI HC, 1993, CARCINOGENESIS, V14, P1195, DOI 10.1093/carcin/14.6.1195; WINDER AJ, 1994, J BIOCHEM BIOPH METH, V28, P173, DOI 10.1016/0165-022X(94)90014-0; YOKOYAMA T, 1990, NUCLEIC ACIDS RES, V18, P7293, DOI 10.1093/nar/18.24.7293	29	18	18	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4130	4135		10.1038/sj.onc.1207565	http://dx.doi.org/10.1038/sj.onc.1207565			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15007389				2022-12-28	WOS:000221520200011
J	Xie, SQ; Wang, Q; Ruan, Q; Liu, TY; Jhanwar-Uniyal, M; Guan, KL; Dai, W				Xie, SQ; Wang, Q; Ruan, Q; Liu, TY; Jhanwar-Uniyal, M; Guan, KL; Dai, W			MEK1-induced Golgi dynamics during cell cycle progression is partly mediated by Polo-like kinase-3	ONCOGENE			English	Article						Plk3; Golgi breakdown; polo-like kinases; MEK1; cell cycle	MATRIX PROTEIN GM130; MITOTIC PHOSPHORYLATION; CDC2 KINASE; FRAGMENTATION; MITOSIS; APOPTOSIS; COMPLEX; MEK1; IDENTIFICATION; ACTIVATION	MEK1, a gene product that regulates cell growth and differentiation, also plays an important role in Golgi breakdown during the cell cycle. We have recently shown that polo-like kinase (Plk3) is Golgi localized and involved in Golgi dynamics during the cell cycle. To study the mode of action of Plk3 in the Golgi fragmentation cascade, we examined functional as well as physical interactions between Plk3 and MEK1/ERKs. In HeLa cells, although a significant amount of Plk3 signals dispersed in a manner similar to those of Golgi during mitosis concentrated Plk3 was detected at spindle poles, which colocalized with phospho-MEKs and phospho-ERKs. Pull-down assays showed that Plk3 physically interacted with MEK1 and ERK2. Nocodazole activated Plk3 and its activation was blocked by MEK-specific inhibitors (PD98059 or U0126). Moreover, transfection of activated MEK1 resulted in an enhanced kinase activity of Plk3; Plk3-induced fragmentation of Golgi stacks was significantly reduced after treatment with MEK inhibitors. Consistently, ectopic expression of activated MEK1, but not kinase-dead MEK1(K97R), stimulated Plk3 to induce Golgi breakdown and the stimulation was not observed in cells expressing Plk3(K52R). Furthermore, PLK3(-/-) murine embryonic fibroblast cells exhibited a significantly less fragmentation of the Golgi complex than that in wild-type cells after exposed to nocodazole. Thus, our studies strongly suggest that Plk3 may be a key protein kinase mediating MEK1 function in the Golgi fragmentation pathway during cell division.	New York Med Coll, Dept Med, Valhalla, NY 10595 USA; Inst Canc Prevent, Valhalla, NY 10595 USA; Univ Michigan, Dept Biochem, Ann Arbor, MI 48109 USA	New York Medical College; University of Michigan System; University of Michigan	Dai, W (corresponding author), New York Med Coll, Dept Med, Valhalla, NY 10595 USA.	wei_dai@nymc.edu		Dai, Wei/0000-0003-0169-8327	NCI NIH HHS [R01-CA74229] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074229] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acharya U, 1998, CELL, V92, P183, DOI 10.1016/S0092-8674(00)80913-7; BEAUVAIS F, 1995, J LEUKOCYTE BIOL, V57, P851, DOI 10.1002/jlb.57.6.851; Bin OY, 1999, ONCOGENE, V18, P6029, DOI 10.1038/sj.onc.1202983; Bin OY, 1997, J BIOL CHEM, V272, P28646, DOI 10.1074/jbc.272.45.28646; Cha HJ, 2001, J CELL BIOL, V153, P1355, DOI 10.1083/jcb.153.7.1355; Colanzi A, 2000, J CELL BIOL, V149, P331, DOI 10.1083/jcb.149.2.331; Colanzi A, 2003, J CELL BIOL, V161, P27, DOI 10.1083/jcb.200208099; Jesch SA, 2001, MOL BIOL CELL, V12, P1811, DOI 10.1091/mbc.12.6.1811; Kano F, 2000, J CELL BIOL, V149, P357, DOI 10.1083/jcb.149.2.357; Kee HJ, 2003, YONSEI MED J, V44, P65, DOI 10.3349/ymj.2003.44.1.65; Lin CY, 2000, P NATL ACAD SCI USA, V97, P12589, DOI 10.1073/pnas.220423497; Lowe M, 2000, J CELL BIOL, V149, P341, DOI 10.1083/jcb.149.2.341; Lowe M, 1998, CELL, V94, P783, DOI 10.1016/S0092-8674(00)81737-7; LUCOCQ J, 1991, J CELL SCI, V100, P753; Mansour SJ, 1996, BIOCHEMISTRY-US, V35, P15529, DOI 10.1021/bi961854s; RUAN Q, 2004, IN PRESS EXP CELL RE; Sutterlin C, 2002, CELL, V109, P359, DOI 10.1016/S0092-8674(02)00720-1; Sutterlin C, 2001, P NATL ACAD SCI USA, V98, P9128, DOI 10.1073/pnas.161283998; Wang Q, 2002, MOL CELL BIOL, V22, P3450, DOI 10.1128/MCB.22.10.3450-3459.2002; Yu SP, 1997, SCIENCE, V278, P114, DOI 10.1126/science.278.5335.114; Zambrowicz BP, 1998, NATURE, V392, P608, DOI 10.1038/33423; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	22	40	41	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2004	23	21					3822	3829		10.1038/sj.onc.1207479	http://dx.doi.org/10.1038/sj.onc.1207479			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	818JX	15021912				2022-12-28	WOS:000221242500009
J	Blagosklonny, MV				Blagosklonny, MV			Prospective strategies to enforce selectively cell death in cancer cells	ONCOGENE			English	Review						apoptosis; cancer therapy; drug resistance	NF-KAPPA-B; PACLITAXEL-INDUCED APOPTOSIS; TYROSINE KINASE INHIBITOR; GROWTH-FACTOR RECEPTOR; S-PHASE CHECKPOINT; LEUKEMIA-CELLS; ACHILLES-HEEL; DEPENDENT POTENTIATION; CHEMOTHERAPEUTIC DRUGS; MOLECULAR DETERMINANTS	Although induction of apoptosis (cell death mediated by caspases) determines response to cancer therapy, this approach is limited by lack of selectivity in available apoptosis-inducing agents. Furthermore, most cancers, almost by definition, are resistant to apoptosis, growth arrest and cell senescence. Then, how can anticancer agents kill cancer cell without unacceptable toxicity to a patient? The potential therapeutic approaches range from selective inhibition of antiapoptotic pathways, antiangiogenic therapy, tissue-selective therapy (including immunotherapy) to exploitation of, for example, drug resistance, oncoprotein addiction, unrestricted cell cycles, hypermitogenic and hypoxic features of cancer cells. These overlapping and complementary approaches rely on rational drug combinations (at mechanism-based doses and sequences) aimed at matching targets. To ensure killing of cancer cells selectively, we may combine apoptosis- and senescence-inducing agents with inhibitors of apoptosis (to protect normal cells), inhibitors of signal transduction with cell cycle-dependent chemotherapy, antiangiogenic agents with hypoxia-inducible factor-1 inhibitors, tissue-selective therapy with differentiating agents and activators of death receptors with chemotherapy. In theory, consecutive use of these drug combinations may control cancer.	New York Med Coll, Brander Canc Res Inst, Valhalla, NY 10532 USA	New York Medical College	Blagosklonny, MV (corresponding author), New York Med Coll, Brander Canc Res Inst, 19 Bradhurst Ave, Valhalla, NY 10532 USA.	m_blagosklonny@nymc.edu						Abal M, 2003, CURR CANCER DRUG TAR, V3, P193, DOI 10.2174/1568009033481967; Akay C, 2003, CELL CYCLE, V2, P358, DOI 10.4161/cc.2.4.417; Amarante-Mendes GP, 1998, ONCOGENE, V16, P1383, DOI 10.1038/sj.onc.1201664; An WG, 1997, CANCER CHEMOTH PHARM, V40, P60, DOI 10.1007/s002800050626; An WG, 2000, LEUKEMIA, V14, P1276, DOI 10.1038/sj.leu.2401812; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Berg G, 2002, J ENDOCRINOL INVEST, V25, P44, DOI 10.1007/BF03343960; Bishop PC, 2002, ONCOGENE, V21, P119, DOI 10.1038/sj.onc.1205028; Blagosklonny MV, 2002, CELL CYCLE, V1, P375, DOI 10.4161/cc.1.6.259; Blagosklonny MV, 2003, DRUG DISCOV TODAY, V8, P1104, DOI 10.1016/S1359-6446(03)02806-X; Blagosklonny MV, 2003, BRIT J CANCER, V89, P1147, DOI 10.1038/sj.bjc.6601256; Blagosklonny MV, 2003, TRENDS MOL MED, V9, P307, DOI 10.1016/S1471-4914(03)00111-4; Blagosklonny MV, 2003, EMBO REP, V4, P358, DOI 10.1038/sj.embor.embor806; Blagosklonny MV, 2002, NAT REV CANCER, V2, P221, DOI 10.1038/nrc743; Blagosklonny MV, 2002, CANCER BIOL THER, V1, P113, DOI 10.4161/cbt.53; Blagosklonny MV, 1998, INT J CANCER, V78, P511, DOI 10.1002/(SICI)1097-0215(19981109)78:4<511::AID-IJC19>3.0.CO;2-8; Blagosklonny MV, 2001, LEUKEMIA, V15, P1537, DOI 10.1038/sj.leu.2402257; Blagosklonny MV, 2001, INT J ONCOL, V19, P257; Blalock WL, 2003, LEUKEMIA, V17, P1058, DOI 10.1038/sj.leu.2402925; Brenner C, 2003, J CLIN IMMUNOL, V23, P73, DOI 10.1023/A:1022541009662; Broker LE, 2002, CANCER RES, V62, P4081; Brown JM, 1998, CANCER RES, V58, P1408; Chang F, 2003, LEUKEMIA, V17, P590, DOI 10.1038/sj.leu.2402824; Cohn DE, 2000, CURR OPIN ONCOL, V12, P492, DOI 10.1097/00001622-200009000-00017; Daley GQ, 2003, CELL CYCLE, V2, P190, DOI 10.4161/cc.2.3.401; Dancey J, 2003, NAT REV DRUG DISCOV, V2, P296, DOI 10.1038/nrd1066; Dancey JE, 2003, LANCET, V362, P62, DOI 10.1016/S0140-6736(03)13810-X; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; Dixon H, 2002, CELL CYCLE, V1, P362, DOI 10.4161/cc.1.6.257; Druker BJ, 2002, CANCER CELL, V1, P31, DOI 10.1016/S1535-6108(02)00025-9; Ebnoether M, 2002, LANCET, V359, P1751, DOI 10.1016/S0140-6736(02)08616-6; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FREI E, 1985, CANCER RES, V45, P6523; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Fulda S, 2001, ONCOGENE, V20, P1063, DOI 10.1038/sj.onc.1204141; FUMO G, 2003, BLOOD; Garrido C, 2003, CELL CYCLE, V2, P579, DOI 10.4161/cc.2.6.521; George D, 2003, ADV EXP MED BIOL, V532, P141; Giaccia A, 2003, NAT REV DRUG DISCOV, V2, P803, DOI 10.1038/nrd1199; Giannakakou P, 2001, ONCOGENE, V20, P3806, DOI 10.1038/sj.onc.1204487; Goncalves A, 2000, BIOCHEM PHARMACOL, V60, P1579, DOI 10.1016/S0006-2952(00)00481-0; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Grant S, 2002, CELL CYCLE, V1, P383, DOI 10.4161/cc.1.6.260; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Houghton Janet A., 1999, Current Opinion in Oncology, V11, P475, DOI 10.1097/00001622-199911000-00008; Ibrado AM, 1997, CANCER RES, V57, P1109; Jia WT, 2003, BLOOD, V102, P1824, DOI 10.1182/blood-2002-12-3785; Jin ZY, 2002, CELL CYCLE, V1, P82, DOI 10.4161/cc.1.1.104; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Jones RH, 2003, EUR J CANCER, V39, P147, DOI 10.1016/S0959-8049(02)00612-3; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; Kerbel RS, 1997, NATURE, V390, P335, DOI 10.1038/36978; Kim CY, 1997, CANCER RES, V57, P4200; Klement G, 2002, CLIN CANCER RES, V8, P221; Krishnamachary B, 2003, CANCER RES, V63, P1138; Leverkus M, 2003, MOL CELL BIOL, V23, P777, DOI 10.1128/MCB.23.3.777-790.2003; Levis M, 2002, BLOOD, V99, P3885, DOI 10.1182/blood.V99.11.3885; Mack PC, 2003, CANCER CHEMOTH PHARM, V51, P337, DOI 10.1007/s00280-003-0571-6; MacKeigan JP, 2000, J BIOL CHEM, V275, P38953, DOI 10.1074/jbc.C000684200; Martin Seamus J., 1994, Current Opinion in Oncology, V6, P616, DOI 10.1097/00001622-199411000-00015; Mayer F, 2003, CLIN CANCER RES, V9, P767; McCarty MF, 2003, MED HYPOTHESES, V61, P509, DOI 10.1016/S0306-9877(03)00229-9; Merlin JL, 2000, ANTI-CANCER DRUG, V11, P295, DOI 10.1097/00001813-200004000-00011; Milner AE, 2002, CELL DEATH DIFFER, V9, P287, DOI 10.1038/sj/cdd/4400945; Mitsiades N, 2003, BLOOD, V101, P2377, DOI 10.1182/blood-2002-06-1768; Monks A, 2000, INVEST NEW DRUG, V18, P95, DOI 10.1023/A:1006313611677; Motwani M, 1999, CLIN CANCER RES, V5, P1876; Mueller T, 2003, CANCER RES, V63, P513; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Overwijk WW, 2000, CRIT REV IMMUNOL, V20, P433; Panvichian R, 1998, CANCER RES, V58, P4667; Pardee AB, 2002, CANCER BIOL THER, V1, P426, DOI 10.4161/cbt.1.4.22; Pelikan DMV, 1997, CLIN ENDOCRINOL, V47, P713, DOI 10.1046/j.1365-2265.1997.3281154.x; Pepper C, 2003, CELL CYCLE, V2, P53, DOI 10.4161/cc.2.1.249; Perkins CL, 2000, CANCER RES, V60, P1645; Prokop A, 2000, LEUKEMIA, V14, P1606, DOI 10.1038/sj.leu.2401866; Reed JC, 2003, CANCER CELL, V3, P17, DOI 10.1016/S1535-6108(02)00241-6; Reese DM, 2000, LANCET, V355, P1474, DOI 10.1016/S0140-6736(00)02155-3; Roninson IB, 2003, CANCER RES, V63, P2705; Sane AT, 1999, CANCER RES, V59, P3565; Sattler M, 2003, SEMIN HEMATOL, V40, P4, DOI 10.1053/shem.2003.50034; Sattler M, 2003, SEMIN HEMATOL, V40, pS4; Sawyers CL, 2002, CANCER CELL, V1, P413, DOI 10.1016/S1535-6108(02)00080-6; Sayers TJ, 2003, BLOOD, V102, P303, DOI 10.1182/blood-2002-09-2975; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Sellers WR, 1999, J CLIN INVEST, V104, P1655, DOI 10.1172/JCI9053; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shah MA, 2001, CLIN CANCER RES, V7, P2168; Shao RG, 1997, CANCER RES, V57, P4029; Simon D, 2002, EUR J NUCL MED MOL I, V29, P775, DOI 10.1007/s00259-001-0737-6; Skorski T, 2002, ONCOGENE, V21, P8591, DOI 10.1038/sj.onc.1206087; Sohal J, 2003, BLOOD, V101, P3188, DOI 10.1182/blood-2002-06-1800; Solary E, 2000, LEUKEMIA, V14, P1833, DOI 10.1038/sj.leu.2401902; Solit DB, 2003, CANCER RES, V63, P2139; Spierings DCJ, 2003, CELL DEATH DIFFER, V10, P808, DOI 10.1038/sj.cdd.4401248; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; Strair RK, 2002, CLIN CANCER RES, V8, P2512; Szlosarek PW, 2003, LANCET ONCOL, V4, P565, DOI 10.1016/S1470-2045(03)01196-3; Voelkel-Johnson C, 2003, CANCER BIOL THER, V2, P283, DOI 10.4161/cbt.2.3.398; von Mehren M, 2003, CANCER INVEST, V21, P553, DOI 10.1081/CNV-120022374; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang JL, 2002, CELL CYCLE, V1, P267, DOI 10.4161/cc.1.4.137; Wilkinson E, 2002, LANCET ONCOL, V3, P583, DOI 10.1016/S1470-2045(02)00883-5; Winegarden JD, 2003, LUNG CANCER-J IASLC, V39, P191, DOI 10.1016/S0169-5002(02)00447-6; Yao Q, 2003, CLIN CANCER RES, V9, P4483; Yu CR, 2001, MOL PHARMACOL, V60, P143, DOI 10.1124/mol.60.1.143; Yu JL, 2002, SCIENCE, V295, P1526, DOI 10.1126/science.1068327; Zhivotovsky B, 2003, SEMIN CANCER BIOL, V13, P125, DOI 10.1016/S1044-579X(02)00130-X	109	72	82	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2004	23	16					2967	2975		10.1038/sj.onc.1207520	http://dx.doi.org/10.1038/sj.onc.1207520			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	811VO	15077157				2022-12-28	WOS:000220799600021
J	Thangaraju, M; Sharan, S; Sterneck, E				Thangaraju, M; Sharan, S; Sterneck, E			Comparison of mammary gland involution between 129S1 and C57BL/6 inbred mouse strains: differential regulation of Bcl2a1, Trp53, Cebpb, and Cebpd expression	ONCOGENE			English	Article						C/EBP; mouse strain; mammary gland; Involution; Bfl1; p53	PLASMACYTOMA SUSCEPTIBILITY; CELL-PROLIFERATION; EPITHELIAL-CELLS; GENE-EXPRESSION; BCL-2 HOMOLOG; BREAST-CANCER; EGF RECEPTOR; C/EBP-BETA; APOPTOSIS; FAMILY	Genetic engineering has made the mouse an invaluable tool to address the function of individual genes in a targeted manner. Over the last decade it has become apparent that the genetic mouse strain background can significantly influence the phenotype of an engineered mouse. Therefore, it is essential to characterize the biology of the different wild-type background strains. In this study, we have compared mouse mammary gland involution in the 129S1 and C57BL/6 inbred strains and report significant differences at the molecular level with differential expression of Bcl2a1 (Bfl1), Trp53 (p53), Cebpb (C/EBPbeta), and Cebpd (C/EBPdelta). The C57BL/6 strain exhibits dynamic responses with induction of Trp53 and Cebpd and concomitant downregulation of Bcl2a1 during the first phase of involution. In contrast, expression of these genes does not change significantly in 129S1 mice. During the second phase, C57BL/6 glands contain more Cebpb than 129S1 glands. Nevertheless, involution proceeds morphologically with similar kinetics in both strains. The data demonstrate that the genetic response of mammary tissue varies significantly between 129S1 and C57BL/6. These results may provide a basis for the interpretation of strain-specific phenotypes in engineered mice and underline the importance of pure strains for large-scale expression studies with mutant mice.	NCI, Regulat Cell Growth Lab, Ctr Canc Res, NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Sterneck, E (corresponding author), NCI, Regulat Cell Growth Lab, Ctr Canc Res, NIH, POB B, Frederick, MD 21702 USA.	sterneck@ncifcrf.gov		Sterneck, Esta/0000-0001-7716-8766	NATIONAL CANCER INSTITUTE [Z01BC010307, ZIABC010307] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beck JA, 2000, NAT GENET, V24, P23, DOI 10.1038/71641; D'Sa-Eipper C, 1998, ONCOGENE, V16, P3105, DOI 10.1038/sj.onc.1201851; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; DSaEipper C, 1996, CANCER RES, V56, P3879; Furth PA, 1999, J MAMMARY GLAND BIOL, V4, P123, DOI 10.1023/A:1018764922082; Gigliotti AP, 2003, EXP BIOL MED, V228, P278, DOI 10.1177/153537020322800306; Gigliotti AP, 1998, J CELL PHYSIOL, V174, P232, DOI 10.1002/(SICI)1097-4652(199802)174:2<232::AID-JCP10>3.0.CO;2-E; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Heermeier K, 1996, MECH DEVELOP, V56, P197, DOI 10.1016/0925-4773(96)88032-4; Hennighausen L, 1998, GENE DEV, V12, P449, DOI 10.1101/gad.12.4.449; Hodge DL, 2002, MOL CELL BIOL, V22, P1742, DOI 10.1128/MCB.22.6.1742-1753.2002; HOWLETT AR, 1993, EPITHELIAL CELL BIOL, V2, P79; Jager R, 1997, ONCOGENE, V15, P1787, DOI 10.1038/sj.onc.1201353; Jerry DJ, 1998, ONCOGENE, V17, P2305, DOI 10.1038/sj.onc.1202157; Li ML, 1996, CELL GROWTH DIFFER, V7, P13; Lund LR, 1996, DEVELOPMENT, V122, P181; O'Reilly MA, 2000, LAB INVEST, V80, P1845, DOI 10.1038/labinvest.3780195; O'Rourke JP, 1999, J BIOL CHEM, V274, P16582, DOI 10.1074/jbc.274.23.16582; QUARRIE LH, 1995, CELL TISSUE RES, V281, P413, DOI 10.1007/BF00417859; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; Schorr K, 1999, CANCER RES, V59, P2541; Schorr K, 1999, J MAMMARY GLAND BIOL, V4, P153, DOI 10.1023/A:1018773123899; Seagroves TN, 1998, GENE DEV, V12, P1917, DOI 10.1101/gad.12.12.1917; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; STRANGE R, 1995, METHOD CELL BIOL, V46, P355; STRANGE R, 1992, DEVELOPMENT, V115, P49; Takiguchi M, 1998, INT J EXP PATHOL, V79, P369, DOI 10.1046/j.1365-2613.1998.00082.x; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Werner AB, 2002, J BIOL CHEM, V277, P22781, DOI 10.1074/jbc.M201469200; Wiseman BS, 2002, SCIENCE, V296, P1046, DOI 10.1126/science.1067431; Zhang SL, 1998, P NATL ACAD SCI USA, V95, P2429, DOI 10.1073/pnas.95.5.2429; Zhang SL, 2001, MOL CELL BIOL, V21, P310, DOI 10.1128/MCB.21.1.310-318.2001	32	8	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2004	23	14					2548	2553		10.1038/sj.onc.1207363	http://dx.doi.org/10.1038/sj.onc.1207363			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808GQ	14981542				2022-12-28	WOS:000220558000012
J	Gomez-Manzano, C; Balague, C; Alemany, R; Lemoine, MG; Mitlianga, P; Jiang, H; Khan, A; Alonso, M; Lang, FF; Conrad, CA; Liu, TJ; Bekele, BN; Yung, WKA; Fueyo, J				Gomez-Manzano, C; Balague, C; Alemany, R; Lemoine, MG; Mitlianga, P; Jiang, H; Khan, A; Alonso, M; Lang, FF; Conrad, CA; Liu, TJ; Bekele, BN; Yung, WKA; Fueyo, J			A novel E1A-E1B mutant adenovirus induces glioma regression in vivo	ONCOGENE			English	Article						glioma; therapy; E1A; E1B; adenovirus	CONDITIONALLY REPLICATIVE ADENOVIRUS; ONCOLYTIC ADENOVIRUS; CANCER-THERAPY; E1A PROTEINS; EFFICACY; TUMOR; CELLS; TRANSFORMATION; PATHWAY; POTENT	Malignant gliomas are the most frequently occurring primary brain tumors and are resistant to conventional therapy. Conditionally replicating adenoviruses are a novel strategy in glioma treatment. Clinical trials using E1B mutant adenoviruses have been reported recently and E1A mutant replication-competent adenoviruses are in advanced preclinical testing. Here we constructed a novel replication-selective adenovirus (CB1) incorporating a double deletion of a 24 bp Rb-binding region in the E1a gene, and a 903 bp deleted region in the E1b gene that abrogates the expression of a p53-binding E1B-55 kDa protein. CB1 exerted a potent anticancer effect in vitro in U-251 MG, U-373 MG, and D-54 MG human glioma cell lines, as assessed by qualitative and quantitative viability assays. Replication analyses demonstrated that CB1 replicates in vitro in human glioma cells. Importantly, CB1 acquired a highly attenuated replicative phenotype in both serum-starved and proliferating normal human astrocytes. In vivo experiments using intracranially implanted D-54 MG glioma xenografts in nude mice showed that a single dose of CB1 (1.5 x 10(8) PFU/tumor) significantly improved survival. Immunohistochemical analyses of expressed adenoviral proteins confirmed adenoviral replication within the tumors. The CB1 oncolytic adenovirus induces a potent antiglioma effect and could ultimately demonstrate clinical relevance and therapeutic utility.	Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA; Univ Alabama Birmingham, Gene Therapy Ctr, Birmingham, AL 35294 USA; Inst Catala Oncol, Barcelona 08907, Spain; Univ Texas, MD Anderson Canc Ctr, Dept Pediat, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Alabama System; University of Alabama Birmingham; Catalan Institute of Oncology; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Fueyo, J (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Box 316,1515 Holcombe Blvd, Houston, TX 77030 USA.	jfueyo@mdanderson.org	Alonso, Marta M/AAI-9457-2020; Mitlianga, Paraskevi/AAU-1541-2020	Alonso, Marta M/0000-0002-7520-7351; Mitlianga, Paraskevi/0000-0003-3145-5596; Gomez-Manzano, Candelaria/0000-0002-1259-2133; Fueyo, Juan/0000-0001-6941-2335	NCI NIH HHS [R01CA90879] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090879] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alemany R, 2000, NAT BIOTECHNOL, V18, P723, DOI 10.1038/77283; BABISS LE, 1985, MOL CELL BIOL, V5, P2552, DOI 10.1128/MCB.5.10.2552; Balague C, 2001, J VIROL, V75, P7602, DOI 10.1128/JVI.75.16.7602-7611.2001; Bauerschmitz GJ, 2002, CANCER RES, V62, P1266; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Cripe TP, 2001, CANCER RES, V61, P2953; Fueyo J, 2000, ONCOGENE, V19, P2, DOI 10.1038/sj.onc.1203251; Fueyo J, 2003, J NATL CANCER I, V95, P652, DOI 10.1093/jnci/95.9.652; Heise C, 2000, NAT MED, V6, P1134, DOI 10.1038/80474; Howe JA, 2000, MOL THER, V2, P485, DOI 10.1006/mthe.2000.0206; Jakubczak JL, 2003, CANCER RES, V63, P1490; Johnson L, 2002, CANCER CELL, V1, P325, DOI 10.1016/S1535-6108(02)00060-0; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; Lal S, 2000, J NEUROSURG, V92, P326, DOI 10.3171/jns.2000.92.2.0326; Lamfers MLM, 2002, CANCER RES, V62, P5736; LEVINE AJ, 1990, BIOESSAYS, V12, P60, DOI 10.1002/bies.950120203; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; PILDER S, 1986, MOL CELL BIOL, V6, P470, DOI 10.1128/MCB.6.2.470; Ramachandra M, 2001, NAT BIOTECHNOL, V19, P1035, DOI 10.1038/nbt1101-1035; SHENK T, 1991, ADV CANCER RES, V57, P47; Suzuki K, 2001, CLIN CANCER RES, V7, P120; Tsukuda K, 2002, CANCER RES, V62, P3438; van Beusechem VW, 2002, CANCER RES, V62, P6165; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; YOSHIDA K, 1995, CURR TOP MICROBIOL, V199, P113	27	48	50	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	2004	23	10					1821	1828		10.1038/sj.onc.1207321	http://dx.doi.org/10.1038/sj.onc.1207321			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	801XV	15014451				2022-12-28	WOS:000220129500003
J	Castellone, MD; Guarino, V; De Falco, V; Carlomagno, F; Basolo, F; Faviana, P; Kruhoffer, M; Orntoft, T; Russel, JP; Rothstein, JL; Fusco, A; Santoro, M; Melillo, RM				Castellone, MD; Guarino, V; De Falco, V; Carlomagno, F; Basolo, F; Faviana, P; Kruhoffer, M; Orntoft, T; Russel, JP; Rothstein, JL; Fusco, A; Santoro, M; Melillo, RM			Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas	ONCOGENE			English	Article						thyroid tumor; RET/PTC oncogenes; chemokine receptor	RET TYROSINE KINASE; LUNG-CANCER CELLS; BREAST-CANCER; SIGNALING PATHWAY; INVASIVE GROWTH; HIGH PREVALENCE; BRAF MUTATIONS; IN-VITRO; KAPPA-B; METASTASIS	To identify genes involved in the transformation of thyroid follicular cells, we explored, using DNA oligonucleotide microarrays, the transcriptional response of PC CI3 rat thyroid epithelial cells to the ectopic expression of the RET/PTC oncogenes. We found that RET/PTC was able to induce the expression of CXCR4, the receptor for the chemokine CXCL12/SDF-1alpha/beta. We observed that CXCR4 expression correlated with the transforming ability of the oncoprotein and depended on the integrity of the RET/PTC-RAS/ERK signaling pathway. We found that CXCR4 was expressed in RET/PTC-positive human thyroid cancer cell lines, but not in normal thyroid cells. Furthermore, we found CXCR4 expression in human thyroid carcinomas, but not in normal thyroid samples by immunohistochemistry. Since CXCR4 has been recently implicated in tumor proliferation, motility and invasiveness, we asked whether treatment with SDF-1alpha was able to induce a biological response in thyroid cells. We observed that SDF-1alpha induced S-phase entry and survival of thyroid cells. Invasion through a reconstituted extracellular matrix was also supported by SDF-1alpha and inhibited by a blocking antibody to CXCR4. Taken together, these results suggest that human thyroid cancers bearing RET/PTC rearrangements may use the CXCR4/SDF-1alpha: receptor-ligand pathway to proliferate, survive and migrate.	CNR G Salvatore, Ist Endocrinol & Oncol Sperimentale, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Dipartimento Oncol, Pisa, Italy; Aarhus Univ Hosp, Mol Diagnost Lab, Dept Clin Biochem, DK-8000 Aarhus, Denmark; Thomas Jefferson Univ, Dept Microbiol Immunol, Kimmel Canc Inst, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Otolaryngol Head & Neck Surg, Kimmel Canc Inst, Philadelphia, PA 19107 USA	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); Aarhus University; Jefferson University; Jefferson University	Melillo, RM (corresponding author), CNR G Salvatore, Ist Endocrinol & Oncol Sperimentale, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy.	rosmelil@unina.it	Faviana, Pinuccia/L-5620-2019; Faviana, Pinuccia/ABA-8436-2021; DE FALCO, VALENTINA/C-2061-2015; melillo, rosa marina/O-5255-2015; Basolo, Fulvio/AAC-2727-2019; FAVIANA, PINUCCIA/R-7928-2017	Faviana, Pinuccia/0000-0003-4283-1083; DE FALCO, VALENTINA/0000-0002-8972-7921; Basolo, Fulvio/0000-0003-1657-5020; FAVIANA, PINUCCIA/0000-0003-4283-1083; CASTELLONE, MARIADOMENICA/0000-0003-0507-8037; Fusco, Alfredo/0000-0003-3332-5197; MELILLO, Rosa Marina/0000-0002-9233-5275				Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; Aust G, 2001, J CLIN ENDOCR METAB, V86, P3368, DOI 10.1210/jc.86.7.3368; Bachelder RE, 2002, CANCER RES, V62, P7203; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Barbero S, 2003, CANCER RES, V63, P1969; Basolo F, 2002, INT J CANCER, V97, P608, DOI 10.1002/ijc.10116; Bernards R, 2003, NATURE, V425, P247, DOI 10.1038/425247a; Buckwalter TLF, 2002, ONCOGENE, V21, P8166, DOI 10.1038/sj.onc.1205938; Burger M, 2003, ONCOGENE, V22, P8093, DOI 10.1038/sj.onc.1207097; Carlomagno F, 2002, CANCER RES, V62, P7284; Carlomagno F, 2002, CANCER RES, V62, P1077; Castellone MD, 2003, ONCOGENE, V22, P246, DOI 10.1038/sj.onc.1206112; Cerutti J, 1996, CLIN CANCER RES, V2, P119; Chen YC, 2003, CANCER RES, V63, P4801; Comoglio PM, 2002, J CLIN INVEST, V109, P857, DOI 10.1172/JCI200215392; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; CURCIO F, 1994, P NATL ACAD SCI USA, V91, P9004, DOI 10.1073/pnas.91.19.9004; De Clercq E, 2003, NAT REV DRUG DISCOV, V2, P581, DOI 10.1038/nrd1134; De Vita G, 2000, CANCER RES, V60, P3727; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; Grimm J, 2001, J CELL BIOL, V154, P345, DOI 10.1083/jcb.200102032; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; Helbig G, 2003, J BIOL CHEM, V278, P21631, DOI 10.1074/jbc.M300609200; Jhiang SM, 1996, ENDOCRINOLOGY, V137, P375, DOI 10.1210/en.137.1.375; Kijima T, 2002, CANCER RES, V62, P6304; Kimura ET, 2003, CANCER RES, V63, P1454; Knauf JA, 2003, ONCOGENE, V22, P4406, DOI 10.1038/sj.onc.1206602; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Kroll TG, 2002, AM J PATHOL, V160, P1941, DOI 10.1016/S0002-9440(10)61142-X; Lorenz K, 2003, NATURE, V426, P574, DOI 10.1038/nature02158; Ludwig L, 2001, CANCER RES, V61, P4526; Medico E, 2001, CANCER RES, V61, P5861; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; Melillo RM, 2001, MOL CELL BIOL, V21, P4177, DOI 10.1128/MCB.21.13.4177-4187.2001; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murakami H, 2002, J BIOL CHEM, V277, P32781, DOI 10.1074/jbc.M202336200; Murakami T, 2002, CANCER RES, V62, P7328; Murphy PM, 2001, NEW ENGL J MED, V345, P833, DOI 10.1056/NEJM200109133451113; Namba H, 2003, J CLIN ENDOCR METAB, V88, P4393, DOI 10.1210/jc.2003-030305; Nikiforov YE, 2002, ENDOCR PATHOL, V13, P3, DOI 10.1385/EP:13:1:03; Nikiforova MN, 2003, J CLIN ENDOCR METAB, V88, P5399, DOI 10.1210/jc.2003-030838; Oh JW, 2001, J IMMUNOL, V166, P2695, DOI 10.4049/jimmunol.166.4.2695; Ohta K, 2001, J CLIN ENDOCR METAB, V86, P2170, DOI 10.1210/jc.86.5.2170; Pelicci G, 2002, MOL CELL BIOL, V22, P7351, DOI 10.1128/MCB.22.20.7351-7363.2002; Powell DJ, 1998, CANCER RES, V58, P5523; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Russell JP, 2003, ONCOGENE, V22, P4569, DOI 10.1038/sj.onc.1206759; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; Santoro M, 1996, ONCOGENE, V12, P1821; Schioppa T, 2003, J EXP MED, V198, P1391, DOI 10.1084/jem.20030267; Scotton CJ, 2002, CANCER RES, V62, P5930; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; Taichman RS, 2002, CANCER RES, V62, P1832; Tamamura H, 2003, FEBS LETT, V550, P79, DOI 10.1016/S0014-5793(03)00824-X; Wang JW, 2003, MOL ENDOCRINOL, V17, P1425, DOI 10.1210/me.2003-0041; Xu XL, 2003, CANCER RES, V63, P4561; Zeelenberg IS, 2003, CANCER RES, V63, P3833; Zhou Y, 2002, J BIOL CHEM, V277, P49481, DOI 10.1074/jbc.M206222200	58	107	116	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2004	23	35					5958	5967		10.1038/sj.onc.1207790	http://dx.doi.org/10.1038/sj.onc.1207790			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15184868				2022-12-28	WOS:000222941100010
J	Amin, HM; McDonnell, TJ; Ma, YP; Lin, Q; Fujio, Y; Kunisada, K; Leventaki, V; Das, P; Rassidakis, GZ; Cutler, C; Medeiros, LJ; Lai, R				Amin, HM; McDonnell, TJ; Ma, YP; Lin, Q; Fujio, Y; Kunisada, K; Leventaki, V; Das, P; Rassidakis, GZ; Cutler, C; Medeiros, LJ; Lai, R			Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma	ONCOGENE			English	Article						STAT3; anaplastic large cell lymphoma; NPM-ALK; adenoviral vectors; apoptosis; cell cycle	RECEPTOR TYROSINE KINASE; CONSTITUTIVE ACTIVATION; SIGNAL TRANSDUCER; NEGATIVE REGULATORS; EXPRESSION; GENE; PROTEINS; MEDIATE; T(2/5); LINES	Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) is an aberrant fusion gene product expressed in a subset of cases of anaplastic large cell lymphoma (ALCL). It has been shown that NPM-ALK binds to and activates signal transducer and activator of transcription 3 (STAT3) in vitro, and that STAT3 is constitutively active in ALK(+) ALCL cell lines and tumors. In view of the oncogenic potential of STAT3, we further examined its biological significance in ALCL using two ALK(+) ALCL cell lines (Karpas 299 and SU-DHL-1) and an adenoviral vector that carries dominant-negative STAT3 (AdSTAT3DN). Infection by AdSTAT3DN led to the expression of STAT3DN in both ALK(+) ALCL cell lines at a similar efficiency. Subcellular fractionation studies showed that a significant proportion of the expressed STAT3DN protein translocated to the nucleus, despite the fact that STAT3DN has a mutation at residue 705(tyrosine --> phenylalanine), a site that is believed to be crucial for STAT3 activation and nuclear translocation. Introduction of STAT3DN induced apoptosis and G, cell cycle arrest. Western blot studies showed that expression of STAT3DN resulted in caspase-3 cleavage, downregulation of Bcl-2, Bcl-xL, cyclin D3, survivin, Mcl-1, c-Myc and suppressor of cytokine signaling 3. These results support the concept that STAT3 activation is pathogenetically important in ALCL cells by deregulating the expression of multiple target proteins that are involved in the control of apoptosis and cell cycle progression.	Univ Texas, MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Grad Sch Med, Dept Mol Med, Osaka, Japan	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Amin, HM (corresponding author), Univ Alberta, Dept Lab Med & Pathol, Fac Med & Dent, Walter MacKenzie Hlth Sci Ctr 4B1, 8440 112 St, Edmonton, AB T6G 2B7, Canada.	raymondmail_65@yahoo.com	Fujio, Yasushi/H-3421-2017; Rassidakis, George/V-9553-2019; Leventaki, Vasiliki/N-8175-2018	Fujio, Yasushi/0000-0003-0828-2930; 				Alexander WS, 1999, J LEUKOCYTE BIOL, V66, P588, DOI 10.1002/jlb.66.4.588; Altieri DC, 2001, TRENDS MOL MED, V7, P542, DOI 10.1016/S1471-4914(01)02243-2; Aoki Y, 2003, BLOOD, V101, P1535, DOI 10.1182/blood-2002-07-2130; Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Brender C, 2001, BLOOD, V97, P1056, DOI 10.1182/blood.V97.4.1056; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Buettner R, 2002, CLIN CANCER RES, V8, P945; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chai SK, 1997, J IMMUNOL, V159, P4720; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Delsol G, 2001, WHO CLASSIFICATION T, P230; Duyster J, 2001, ONCOGENE, V20, P5623, DOI 10.1038/sj.onc.1204594; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; EPSTEIN AL, 1979, CANCER RES, V39, P1748; Fagerlund R, 2002, J BIOL CHEM, V277, P30072, DOI 10.1074/jbc.M202943200; Falini B, 1999, BLOOD, V93, P2697; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Gascoyne RD, 1999, BLOOD, V93, P3913, DOI 10.1182/blood.V93.11.3913.411k22_3913_3921; GouilleuxGruart V, 1996, BLOOD, V87, P1692; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Hilton DJ, 1999, CELL MOL LIFE SCI, V55, P1568, DOI 10.1007/s000180050396; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Kube D, 2001, BLOOD, V98, P762, DOI 10.1182/blood.V98.3.762; Kunisada K, 1998, CIRCULATION, V98, P346, DOI 10.1161/01.CIR.98.4.346; Mahboubi K, 2001, LAB INVEST, V81, P327, DOI 10.1038/labinvest.3780241; Matsui T, 2002, J BIOL CHEM, V277, P36167, DOI 10.1074/jbc.M203184200; Mora LB, 2002, CANCER RES, V62, P6659; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Negoro S, 2001, CIRCULATION, V104, P979, DOI 10.1161/hc3401.095947; Nielsen M, 1999, LEUKEMIA, V13, P735, DOI 10.1038/sj.leu.2401415; Niu G, 2002, ONCOGENE, V21, P7001, DOI 10.1038/sj.onc.1205859; Osugi T, 2002, J BIOL CHEM, V277, P6676, DOI 10.1074/jbc.M108246200; Rassidakis GZ, 2002, AM J PATHOL, V160, P2309, DOI 10.1016/S0002-9440(10)61178-9; Sasaki A, 1999, GENES CELLS, V4, P339, DOI 10.1046/j.1365-2443.1999.00263.x; SCHLETTE EJ, 2004, IN PRESS J CLIN ONCO; Slupianek A, 2001, CANCER RES, V61, P2194; STEIN H, 1985, BLOOD, V66, P848; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; Wood GS, 1996, BLOOD, V88, P1765, DOI 10.1182/blood.V88.5.1765.bloodjournal8851765; Zamo A, 2002, ONCOGENE, V21, P1038, DOI 10.1038/sj.onc.1205152; Zhang Q, 2002, J IMMUNOL, V168, P466, DOI 10.4049/jimmunol.168.1.466	47	135	154	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2004	23	32					5426	5434		10.1038/sj.onc.1207703	http://dx.doi.org/10.1038/sj.onc.1207703			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15184887				2022-12-28	WOS:000222588400002
J	Park, HU; Jeong, JH; Chung, JH; Brady, JN				Park, HU; Jeong, JH; Chung, JH; Brady, JN			Human T-cell leukemia virus type 1 Tax interacts with Chk1 and attenuates DNA-damage induced G(2) arrest mediated by Chk1	ONCOGENE			English	Article						HTLV-1 Tax; Chk1; interaction; attenuation; G(2) checkpoint	TELANGIECTASIA-MUTATED ATM; PRIMARY HUMAN-LYMPHOCYTES; S-PHASE CHECKPOINT; HTLV-I; IONIZING-RADIATION; TRANSACTIVATION FUNCTION; TUMOR-SUPPRESSOR; GENE-EXPRESSION; PROTEIN-KINASE; CANCER-CELLS	Checkpoint kinase 1 (Chk1) mediates diverse cellular responses to genotoxic stress, regulating the network of genome-surveillance pathways that coordinate cell cycle progression with DNA repair. Chk1 is essential for mammalian development and viability, and has been shown to be important for both S and G(2) checkpoints. We now present evidence that the HTLV-1 Tax protein interacts directly with Chk1 and impairs its kinase activities in vitro and in vivo. The direct and physical interaction of Chk1 and Tax was observed in HTLV-1-infected T cells (C81, HuT 102 and MT-2) and transfected fibroblasts (293 T) by coimmunoprecipitation and by in vitro GST pull-down assays. Interestingly, Tax inhibited the kinase activity of Chk1 protein in in vitro and in vivo kinase assays. Consistent with these results, Tax inhibited the phosphorylation-dependent degradation of Cdc25A and G(2) arrest in response to gamma-irradiation (IR) in a dose-dependent manner in vivo. The G(2) arrest did not require Chk2 or p53. These studies provide the first example of a viral transforming protein targeting Chk1 and provide important insights into checkpoint pathway regulation.	NCI, Virus Tumor Biol Sect, Cellular Oncol Lab, Ctr Canc Res,NIH, Bethesda, MD 20892 USA; NHLBI, Lab Biochem Genet, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Brady, JN (corresponding author), NCI, Virus Tumor Biol Sect, Cellular Oncol Lab, Ctr Canc Res,NIH, Bethesda, MD 20892 USA.	bradyj@exchange.nih.gov			NATIONAL CANCER INSTITUTE [ZIABC005691, Z01BC005691] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL002243, Z01HL002243] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Akagi T, 1997, FEBS LETT, V406, P263, DOI 10.1016/S0014-5793(97)00280-9; Anderson CW, 1998, J PROTEIN CHEM, V17, P527; Ariumi Y, 2000, ONCOGENE, V19, P1491, DOI 10.1038/sj.onc.1203450; Ariumi Y, 2003, ONCOGENE, V22, P1611, DOI 10.1038/sj.onc.1206244; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bex F, 1998, METHODS, V16, P83, DOI 10.1006/meth.1998.0646; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Burton M, 2000, J VIROL, V74, P2351, DOI 10.1128/JVI.74.5.2351-2364.2000; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; Chen ZH, 2003, MOL CANCER THER, V2, P543; Clifford B, 2003, CANCER RES, V63, P4074; Coscoy L, 1998, VIROLOGY, V248, P332, DOI 10.1006/viro.1998.9298; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; FRANCHINI G, 1995, BLOOD, V86, P3619, DOI 10.1182/blood.V86.10.3619.bloodjournal86103619; Gartenhaus RB, 1995, LEUKEMIA, V9, P2082; Gatei M, 2003, J BIOL CHEM, V278, P14806, DOI 10.1074/jbc.M210862200; Gatei M, 2001, J BIOL CHEM, V276, P17276, DOI 10.1074/jbc.M011681200; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Guerra B, 2003, ONCOGENE, V22, P4933, DOI 10.1038/sj.onc.1206721; Haoudi A, 2003, J BIOL CHEM, V278, P37736, DOI 10.1074/jbc.M301649200; Haoudi A, 2003, VIROLOGY, V305, P229, DOI 10.1006/viro.2002.1642; Heffernan TP, 2002, MOL CELL BIOL, V22, P8552, DOI 10.1128/MCB.22.24.8552-8561.2002; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hollsberg P, 1999, MICROBIOL MOL BIOL R, V63, P308; Jallepalli PV, 2003, J BIOL CHEM, V278, P20475, DOI 10.1074/jbc.M213159200; Jeang KT, 1997, J VIROL, V71, P6277, DOI 10.1128/JVI.71.9.6277-6278.1997; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Johnson JM, 2001, INT J EXP PATHOL, V82, P135, DOI 10.1046/j.1365-2613.2001.00191.x; Kaneko Y, 1999, ONCOGENE, V18, P3673, DOI 10.1038/sj.onc.1202706; Kao SY, 1999, J VIROL, V73, P4299, DOI 10.1128/JVI.73.5.4299-4304.1999; Kasai T, 2002, J BIOL CHEM, V277, P5187, DOI 10.1074/jbc.M110295200; Lemoine FJ, 2001, J BIOL CHEM, V276, P31851, DOI 10.1074/jbc.M105195200; Lemoine FJ, 2000, AIDS RES HUM RETROV, V16, P1623, DOI 10.1089/08892220050193056; Liu QH, 2000, GENE DEV, V14, P1448; Marriott SJ, 2002, J BIOMED SCI, V9, P292, DOI 10.1159/000064998; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; McGowan CH, 2002, BIOESSAYS, V24, P502, DOI 10.1002/bies.10101; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; MIWA M, 1984, GANN, V75, P752; Mulloy JC, 1998, J VIROL, V72, P8852, DOI 10.1128/JVI.72.11.8852-8860.1998; Philpott SM, 1999, J NATL CANCER I, V91, P933, DOI 10.1093/jnci/91.11.933; Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; Pise-Masison CA, 2001, J BIOL CHEM, V276, P200, DOI 10.1074/jbc.M005601200; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Robek MD, 1999, J VIROL, V73, P4856, DOI 10.1128/JVI.73.6.4856-4865.1999; Saka Y, 1997, GENE DEV, V11, P3387, DOI 10.1101/gad.11.24.3387; Semmes OJ, 1996, J VIROL, V70, P6347, DOI 10.1128/JVI.70.9.6347-6357.1996; Shieh SY, 2000, GENE DEV, V14, P289; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Sugiyama K, 2000, INT J CANCER, V85, P703, DOI 10.1002/(SICI)1097-0215(20000301)85:5<703::AID-IJC17>3.0.CO;2-7; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Taylor WR, 1999, MOL BIOL CELL, V10, P3607, DOI 10.1091/mbc.10.11.3607; Van Orden K, 1999, J BIOL CHEM, V274, P26321, DOI 10.1074/jbc.274.37.26321; Walworth NC, 2000, CURR OPIN CELL BIOL, V12, P697, DOI 10.1016/S0955-0674(00)00154-X; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; Xiao Z, 2003, J BIOL CHEM, V278, P21767, DOI 10.1074/jbc.M300229200; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Yu Q, 2002, CANCER RES, V62, P5743; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060; Zhao B, 2002, J BIOL CHEM, V277, P46609, DOI 10.1074/jbc.M201233200; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	73	46	48	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					4966	4974		10.1038/sj.onc.1207644	http://dx.doi.org/10.1038/sj.onc.1207644			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15107832				2022-12-28	WOS:000222237300002
J	Levina, E; Oren, M; Ben-Ze'ev, A				Levina, E; Oren, M; Ben-Ze'ev, A			Downregulation of beta-catenin by p53 involves changes in the rate of beta-catenin phosphorylation and Axin dynamics	ONCOGENE			English	Article						beta-catenin degradation by p53; Axin; beta-catenin-phosphorylation	TRANSCRIPTION FACTOR LEF-1; WNT SIGNALING PATHWAY; APC TUMOR-SUPPRESSOR; COLORECTAL-CANCER; COLON-CARCINOMA; CYCLIN D1; PROTEIN; ACTIVATION; COMPLEX; TARGET	beta-Catenin, a structural component of cell-cell adhesions, is also a potent signaling molecule in the Wnt pathway activating target genes together with Lef/Tcf transcription factors. In colorectal and many other types of cancer, beta-catenin is hyperactive owing to mutations in beta-catenin, or in components regulating beta-catenin degradation. Deregulated beta-catenin can cause the activation of p53, a key tumor suppressor mutated in most cancers. Activated p53 can feed back and downregulate beta-catenin. Here we investigated the mechanisms involved in downregulation of beta-catenin by p53. We found that the p53-mediated reduction in beta-catenin involves enhanced phosphorylation of beta-catenin on key NH2-terminal serines and requires CK1 and GSK-3beta activities, both being components of the beta-catenin degradation machinery. Mutations in these NH2-terminal beta-catenin serines blocked the ability of p53 to enhance the turnover of beta-catenin. p53 also induced a shift in the distribution of the scaffold molecule Axin to a Triton X-100-soluble fraction, and led to depletion of beta-catenin from this Triton-soluble fraction. The majority of Axin and phosphorylated beta-catenin, however, colocalized in Triton X-100-insoluble punctate aggregates near the plasma membrane, and kinetics studies indicated that in the presence of p53 the movement of Axin into and out of the Triton X-100-insoluble fraction is accelerated. These results suggest that p53 induces a faster mobilization of Axin into the degradation complex thereby enhancing beta-catenin turnover as part of a protective mechanism against the development of cancer.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Ben-Ze'ev, A (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	avri.ben-zeev@weizmann.ac.il		ben-ze'ev, avri/0000-0001-6113-3921				Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302; Amson RB, 1996, P NATL ACAD SCI USA, V93, P3953, DOI 10.1073/pnas.93.9.3953; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cliffe A, 2003, CURR BIOL, V13, P960, DOI 10.1016/S0960-9822(03)00370-1; Conacci-Sorrell ME, 2002, GENE DEV, V16, P2058, DOI 10.1101/gad.227502; Dajani R, 2003, EMBO J, V22, P494, DOI 10.1093/emboj/cdg068; Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912; Damalas A, 1999, EMBO J, V18, P3054, DOI 10.1093/emboj/18.11.3054; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Hu G, 1999, MOL CELL BIOL, V19, P724; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Matsuzawa S, 1998, EMBO J, V17, P2736, DOI 10.1093/emboj/17.10.2736; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Oren M, 2002, ANN NY ACAD SCI, V973, P374, DOI 10.1111/j.1749-6632.2002.tb04669.x; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Polakis P, 2000, GENE DEV, V14, P1837; Polakis P, 2002, CURR BIOL, V12, pR499, DOI 10.1016/S0960-9822(02)00969-7; Roperch JP, 1999, P NATL ACAD SCI USA, V96, P8070, DOI 10.1073/pnas.96.14.8070; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Sadot E, 2001, MOL CELL BIOL, V21, P6768, DOI 10.1128/MCB.21.20.6768-6781.2001; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Simcha I, 1998, J CELL BIOL, V141, P1433, DOI 10.1083/jcb.141.6.1433; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tolwinski NS, 2003, DEV CELL, V4, P407, DOI 10.1016/S1534-5807(03)00063-7; Watcharasit P, 2002, P NATL ACAD SCI USA, V99, P7951, DOI 10.1073/pnas.122062299; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Yanagawa S, 2002, EMBO J, V21, P1733, DOI 10.1093/emboj/21.7.1733; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	48	79	84	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2004	23	25					4444	4453		10.1038/sj.onc.1207587	http://dx.doi.org/10.1038/sj.onc.1207587			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	824CJ	15064706				2022-12-28	WOS:000221661300010
J	Li, HM; Zhuang, ZH; Wang, Q; Pang, JCS; Wang, XH; Wong, HL; Feng, HC; Jin, DY; Ling, MT; Wong, YC; Eliopoulos, AG; Young, LS; Huang, DP; Tsao, SW				Li, HM; Zhuang, ZH; Wang, Q; Pang, JCS; Wang, XH; Wong, HL; Feng, HC; Jin, DY; Ling, MT; Wong, YC; Eliopoulos, AG; Young, LS; Huang, DP; Tsao, SW			Epstein-Barr virus latent membrane protein 1 (LMP1) upregulates Id1 expression in nasopharyngeal epithelial cells	ONCOGENE			English	Article						Epstein-Barr virus; nasopharyngeal carcinoma; LMP1; Id1; nuclear factor kappa B	NF-KAPPA-B; CELLULAR SIGNALING PATHWAYS; MEMBRANE-PROTEIN; CARCINOMA-CELLS; SEQUENCE; GROWTH; ID-1; DIFFERENTIATION; PHOSPHORYLATION; TRANSFORMATION	Nasopharyngeal carcinoma is closely associated with Epstein-Barr virus (EBV) infection. The EBV-encoded LMP1 has cell transformation property. It suppresses cellular senescence and enhances cell survival in various cell types. Many of the downstream events of LMP1 expression are mediated through its ability to activate NF-kappaB. In this study, we report a novel function of LMP1 to induce Id1 expression in nasopharyngeal epithelial cells (NP69) and human embryonal kidney cells (HEK293). The Id1 is a basic helix-loop-helix (bHLH) protein and a negative transcriptional regulator of p16(INK4a). Expression of Id1 facilitates cellular immortalization and stimulates cell proliferation. With the combination of both specific chemical inhibitors and genetic inhibitors of cell signaling, we showed that induction of Id1 by LMP1 was dependent on its NF-kappaB activation domain at the carboxy-terminal region, CTAR1 and CTAR2. Induction of Id1 by LMP1 may facilitate clonal expansion of premalignant nasopharyngeal epithelial cells infected with EBV and may promote their malignant transformation.	Univ Hong Kong, Dept Anat, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Fac Med, Dept Biochem, Hong Kong, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Prince Wales Hosp, Hong Kong, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Inst Mol Oncol, Prince Wales Hosp, Hong Kong, Hong Kong, Peoples R China; Univ Birmingham, Inst Canc Studies, Birmingham B15 2TT, W Midlands, England	University of Hong Kong; University of Hong Kong; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; University of Birmingham	Tsao, SW (corresponding author), Univ Hong Kong, Dept Anat, Room L01-53,Lab Block,Fac Med Bldg,21 Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.	gswtsao@hkucc.hku.hk	ELIOPOULOS, ARISTIDES/R-9449-2018; Li, Hoi Ming/B-5828-2008; ELIOPOULOS, ARISTIDES/ABI-6632-2020; Tsao, George/C-4422-2009; Feng, Huichen/F-5502-2011; Young, Lawrence S/B-7213-2009	ELIOPOULOS, ARISTIDES/0000-0002-6403-6761; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761; Feng, Huichen/0000-0003-3069-8174; Young, Lawrence S/0000-0003-3919-4298				Alani RM, 1999, P NATL ACAD SCI USA, V96, P9637, DOI 10.1073/pnas.96.17.9637; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; Blake SMS, 2001, VIROLOGY, V282, P278, DOI 10.1006/viro.2001.0828; Cahir-McFarland ED, 2000, P NATL ACAD SCI USA, V97, P6055, DOI 10.1073/pnas.100119497; Cheung ST, 1998, INT J CANCER, V76, P399, DOI 10.1002/(SICI)1097-0215(19980504)76:3<399::AID-IJC18>3.0.CO;2-6; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Dawson CW, 2003, J BIOL CHEM, V278, P3694, DOI 10.1074/jbc.M209840200; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Eliopoulos AG, 1999, J VIROL, V73, P1023, DOI 10.1128/JVI.73.2.1023-1035.1999; Eliopoulos AG, 2001, SEMIN CANCER BIOL, V11, P435, DOI 10.1006/scbi.2001.0410; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; Fielding CA, 2001, J VIROL, V75, P9129, DOI 10.1128/JVI.75.19.9129-9141.2001; HAMMERSCHMIDT W, 1989, J VIROL, V63, P2469, DOI 10.1128/JVI.63.6.2469-2475.1989; Hatzivassiliou E, 2002, FRONT BIOSCI, V7, pD319, DOI 10.2741/hatziva; Jeannel D, 1999, CANCER SURV, V33, P125; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; Ling MT, 2002, ONCOGENE, V21, P8498, DOI 10.1038/sj.onc.1206007; LO AK, 2003, LAB INVEST, V83, P1; Nehlin JO, 1997, BIOCHEM BIOPH RES CO, V231, P628, DOI 10.1006/bbrc.1997.6152; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Ohtani N, 2003, J CELL BIOL, V162, P173, DOI 10.1083/jcb.200302085; PATHMANATHAN R, 1995, NEW ENGL J MED, V333, P693, DOI 10.1056/NEJM199509143331103; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Raab-Traub N, 2002, SEMIN CANCER BIOL, V12, P431, DOI 10.1016/S1044579X0200086X; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SHAM JST, 1990, INT J RADIAT ONCOL, V19, P929, DOI 10.1016/0360-3016(90)90014-B; Sikder HA, 2003, CANCER CELL, V3, P525, DOI 10.1016/S1535-6108(03)00141-7; Tsao SW, 2002, SEMIN CANCER BIOL, V12, P473, DOI 10.1016/S1044579X02000901; Tsao SW, 2002, BBA-MOL CELL RES, V1590, P150, DOI 10.1016/S0167-4889(02)00208-2; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; Wang XH, 2003, ONCOGENE, V22, P109, DOI 10.1038/sj.onc.1206069; Wang XH, 2002, MOL CARCINOGEN, V35, P42, DOI 10.1002/mc.10072; Yang XH, 2000, J VIROL, V74, P883, DOI 10.1128/JVI.74.2.883-891.2000; ZABEL U, 1991, J BIOL CHEM, V266, P252	36	40	42	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2004	23	25					4488	4494		10.1038/sj.onc.1207580	http://dx.doi.org/10.1038/sj.onc.1207580			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	824CJ	15064751				2022-12-28	WOS:000221661300014
J	Radhakrishnan, SK; Feliciano, CS; Najmabadi, F; Haegebarth, A; Kandel, ES; Tyner, AL; Gartel, AL				Radhakrishnan, SK; Feliciano, CS; Najmabadi, F; Haegebarth, A; Kandel, ES; Tyner, AL; Gartel, AL			Constitutive expression of E2F-1 leads to p21-dependent cell cycle arrest in S phase of the cell cycle	ONCOGENE			English	Article						p21; E2F-1; cell cycle; cdk2	TRANSCRIPTION FACTOR E2F1; DEPENDENT KINASES; P21; APOPTOSIS; PROGRESSION; BINDING; SUPPRESSION; REPRESSION; CHECKPOINT; ACTIVATION	p21 is a potent inhibitor of cyclin-dependent kinases capable of arresting cell cycle progression. p21 is primarily regulated at the transcriptional level by several transcription factors, including p53. Previously, we reported that certain members of the E2F family of transcription factors may activate p21 transcription via a p53-independent mechanism. To further elucidate the consequences of E2F-1-regulated induction of p21, we developed cell lines with a tamoxifen-dependent form of E2F-1. We confirmed direct interaction of E2F-1 with the proximal region of the p21 promoter. Interestingly, elevated E2F-1 activity was sufficient to arrest a substantial subset of cells in S phase and this effect was correlated to and dependent on the induction of p21 protein. Since E2F proteins control genes required for cell cycle progression and are activated by various oncogenic events, we believe that the p21-dependent arrest described in this report represents an additional mechanism that guards against unrestricted cell proliferation.	Univ Illinois, Coll Med, Dept Med, Chicago, IL 60612 USA; Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, Cleveland, OH 44195 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Cleveland Clinic Foundation	Gartel, AL (corresponding author), Univ Illinois, Coll Med, Dept Med, 840 S Wood ,Room 1041, Chicago, IL 60612 USA.	agartel@uic.edu		Radhakrishnan, Senthil/0000-0002-5211-9498; Tyner, Angela/0000-0001-7448-8625	NCI NIH HHS [CA91146-01A1] Funding Source: Medline; NIDDK NIH HHS [DK48836, R01 DK044525, R01 DK044525-10] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA091146] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044525, R01DK048836] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DOLBEARE F, 1983, P NATL ACAD SCI-BIOL, V80, P5573, DOI 10.1073/pnas.80.18.5573; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Farhana L, 2002, CANCER RES, V62, P3842; Gartel A L, 1998, Prog Mol Subcell Biol, V20, P43; Gartel AL, 1996, P SOC EXP BIOL MED, V213, P138; Gartel AL, 1998, ONCOGENE, V17, P3463, DOI 10.1038/sj.onc.1202240; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; HARPER JW, 1993, CELL, V75, P805; Hiyama H, 1998, ONCOGENE, V16, P1513, DOI 10.1038/sj.onc.1201667; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; LOGAN TJ, 1995, CANCER RES, V55, P2883; Ma YH, 2002, ARCH BIOCHEM BIOPHYS, V399, P212, DOI 10.1006/abbi.2002.2761; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Ogryzko VV, 1997, MOL CELL BIOL, V17, P4877, DOI 10.1128/MCB.17.8.4877; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Takahashi Y, 2000, GENE DEV, V14, P804; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Vigo E, 1999, MOL CELL BIOL, V19, P6379; WALDMAN T, 1995, CANCER RES, V55, P5187; Yamasaki L, 1998, NAT GENET, V18, P360, DOI 10.1038/ng0498-360; Zhang YX, 2000, CANCER RES, V60, P2025	28	84	97	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4173	4176		10.1038/sj.onc.1207571	http://dx.doi.org/10.1038/sj.onc.1207571			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15048076				2022-12-28	WOS:000221520200016
J	Yang, O; Zhang, R; Wang, XW; Linke, SP; Sengupta, S; Hickson, ID; Pedrazzi, G; Perrera, C; Stagljar, I; Littman, SJ; Modrich, P; Harris, CC				Yang, O; Zhang, R; Wang, XW; Linke, SP; Sengupta, S; Hickson, ID; Pedrazzi, G; Perrera, C; Stagljar, I; Littman, SJ; Modrich, P; Harris, CC			The mismatch DNA repair heterodimer, hMSH2/6, regulates BLM helicase	ONCOGENE			English	Article						p53; Rad51; homologous recombination; DNA repair	SYNDROME GENE-PRODUCT; MODULATES HOMOLOGOUS RECOMBINATION; DOUBLE-STRAND BREAKS; HOLLIDAY JUNCTIONS; MAMMALIAN-CELLS; REPLICATION FORKS; SYNDROME PROTEIN; BULGED BASES; TUMOR-CELLS; S-PHASE	The human MSH2/6 complex is essential for mismatch recognition during the repair of replication errors. Although mismatch repair components have been implicated in DNA homologous recombination repair, the exact function of hMSH2/6 in this pathway is unclear. Here, we show that the recombinant hMSH2/6 protein complex stimulated the ability of the Bloom's syndrome gene product, BLM, to process Holliday junctions in vitro, an activity that could also be regulated by p53. Consistent with these observations, hMSH6 colocalized with BLM and phospho-ser15-p53 in hydroxyurea-induced RAD51 nuclear foci that may correspond to the sites of presumed stalled DNA replication forks and more likely the resultant DNA double-stranded breaks. In addition, we show that hMSH2 and hMSH6 coimmunoprecipitated with BLM, p53, and RAD51. Bot h the number of RAD51 foci and the amount of the BLM-p53-RAD51 complex are increased in hMSH2- or hMSH6-deficient cells. These data suggest that hMSH2/6 formed a complex with BLM-p53-RAD51 in response to the damaged DNA forks during double-stranded break repair.	NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA; Univ Oxford, John Radcliffe Hosp, Canc Res UK, Weatherall Inst Mol Med, Oxford OX3 9DS, England; Univ Zurich Irchel, Inst Vet Biochem & Mol Biol, CH-8057 Zurich, Switzerland; Univ Zurich, Inst Mol Canc Res, CH-8006 Zurich, Switzerland; Duke Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Med Ctr, Howard Hughes Med Inst, Dept Biochem, Durham, NC 27710 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Cancer Research UK; University of Oxford; University of Zurich; University of Zurich; Duke University; Duke University; Howard Hughes Medical Institute	Harris, CC (corresponding author), NCI, Human Carcinogenesis Lab, NIH, Bldg 37,Rm 3068,37 Convent Dr, Bethesda, MD 20892 USA.	Curtis_Harris@nih.gov	Hickson, Ian/AAJ-7548-2020; Wang, Xin Wei/B-6162-2009; Sengupta, Sagar/AGR-1063-2022	Wang, Xin Wei/0000-0001-9735-606X; Sengupta, Sagar/0000-0002-6365-1770	NATIONAL CANCER INSTITUTE [ZIABC005795, Z01BC005795] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045190] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45190] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; Bean LJH, 2001, ONCOGENE, V20, P1076, DOI 10.1038/sj.onc.1204204; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; Blackwell LJ, 2001, J BIOL CHEM, V276, P33233, DOI 10.1074/jbc.M105076200; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; Chakraverty RK, 1999, BIOESSAYS, V21, P286; Chen SH, 2001, P NATL ACAD SCI USA, V98, P13802, DOI 10.1073/pnas.241508098; Davalos AR, 2003, J CELL BIOL, V162, P1197, DOI 10.1083/jcb.200304016; de Wind N, 1999, NAT GENET, V23, P359, DOI 10.1038/15544; Degtyareva N, 2001, J BIOL CHEM, V276, P8778, DOI 10.1074/jbc.M006795200; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Duckett DR, 1999, P NATL ACAD SCI USA, V96, P12384, DOI 10.1073/pnas.96.22.12384; Dudenhoffer C, 1999, ONCOGENE, V18, P5773, DOI 10.1038/sj.onc.1202964; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; Elliott B, 2001, MOL CELL BIOL, V21, P2671, DOI 10.1128/MCB.21.8.2671-2682.2001; Evans E, 2000, MOL CELL, V5, P789, DOI 10.1016/S1097-2765(00)80319-6; Franchitto A, 2003, ONCOGENE, V22, P2110, DOI 10.1038/sj.onc.1206254; Frei C, 2000, GENE DEV, V14, P81; Gebow D, 2000, MOL CELL BIOL, V20, P4028, DOI 10.1128/MCB.20.11.4028-4035.2000; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; Jiricny J, 1998, MUTAT RES-DNA REPAIR, V409, P107, DOI 10.1016/S0921-8777(98)00056-1; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Langland G, 2001, J BIOL CHEM, V276, P30031, DOI 10.1074/jbc.M009664200; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Linke SP, 2003, CANCER RES, V63, P2596; Marsischky GT, 1999, J BIOL CHEM, V274, P7200, DOI 10.1074/jbc.274.11.7200; McGlynn P, 1999, NUCLEIC ACIDS RES, V27, P3049, DOI 10.1093/nar/27.15.3049; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; Myung K, 2001, NAT GENET, V27, P113, DOI 10.1038/83673; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Pedrazzi G, 2003, BIOL CHEM, V384, P1155, DOI 10.1515/BC.2003.128; Pedrazzi G, 2001, NUCLEIC ACIDS RES, V29, P4378, DOI 10.1093/nar/29.21.4378; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; Sengupta S, 2003, EMBO J, V22, P1210, DOI 10.1093/emboj/cdg114; Spillare EA, 1999, GENE DEV, V13, P1355, DOI 10.1101/gad.13.11.1355; Subramanian D, 2002, NUCLEIC ACIDS RES, V30, P2427, DOI 10.1093/nar/30.11.2427; Thompson LH, 2001, MUTAT RES-FUND MOL M, V477, P131, DOI 10.1016/S0027-5107(01)00115-4; Umar A, 1997, CANCER RES, V57, P3949; van Brabant AJ, 2000, ANNU REV GENOM HUM G, V1, P409, DOI 10.1146/annurev.genom.1.1.409; Wang XW, 2001, J BIOL CHEM, V276, P32948, DOI 10.1074/jbc.M103298200; Wang Y, 2000, GENE DEV, V14, P927; Warnick CT, 2001, J BIOL CHEM, V276, P27363, DOI 10.1074/jbc.M103088200; Wu L, 2001, J BIOL CHEM, V276, P19375, DOI 10.1074/jbc.M009471200; Wu L, 2000, J BIOL CHEM, V275, P9636, DOI 10.1074/jbc.275.13.9636; Yang Q, 2002, J BIOL CHEM, V277, P31980, DOI 10.1074/jbc.M204111200; Zink D, 2002, ONCOGENE, V21, P4788, DOI 10.1038/sj.onc.1205614	58	53	56	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2004	23	21					3749	3756		10.1038/sj.onc.1207462	http://dx.doi.org/10.1038/sj.onc.1207462			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	818JX	15064730				2022-12-28	WOS:000221242500002
J	Halawani, D; Mondeh, R; Stanton, LA; Beier, F				Halawani, D; Mondeh, R; Stanton, LA; Beier, F			p38 MAP kinase signaling is necessary for rat chondrosarcoma cell proliferation	ONCOGENE			English	Article						chondrosarcoma; p38 MAPK; cell cycle; cyclins; p21(waf1/cip1)	ACTIVATED PROTEIN-KINASE; CYCLIN-A PROMOTER; TRANSCRIPTION FACTOR-2; RETINOBLASTOMA PROTEIN; MELANOMA-CELLS; D1; DIFFERENTIATION; INDUCTION; EXPRESSION; CHONDROCYTES	Chondrosarcomas represent the second most frequent class of primary skeletal malignancies. This tumor type is highly resistant to radiation therapy and currently available chemotherapies, thereby limiting treatment choice to surgical resection. Identifying the mechanisms responsible for chondrosarcoma cell proliferation is therefore crucial for the development of new treatment strategies. Here, we demonstrate a significant reduction in rat chondrosarcoma cell proliferation following treatment with pharmacological inhibitors (SB202190 and PD169316) of p38 mitogen-activated protein (MAP) kinases. In an attempt to dissect possible mechanisms, we investigated the effect of p38 inhibition on promoter activity of cell-cycle genes. Surprisingly, p38 inhibition resulted in upregulation of the activities of all three D-type cyclin promoters. In addition, p38 inhibitors induced increased transcription of the cell-cycle inhibitor p21(waf1/cip1). As expected, promoter activity of the cyclin A gene, which lies downstream of D-type cyclins and p21 in cell-cycle progression, was strongly reduced by p38 inhibitors. These effects were independent of a cyclic AMP response element and conferred by the proximal 150 nucleotides of the cyclin A promoter. Decreased transcription was accompanied by greatly reduced cyclin A protein levels upon p38 inhibition. These observations indicate complex regulation of chondrosarcoma cell-cycle progression by p38 signaling, and suggest that components of p38 MAP kinase pathways may be effective targets in the treatment of these tumors.	Univ Western Ontario, Dept Physiol & Pharmacol, Canadian Inst Hlth Res Grp Skeletal Dev & Remodel, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Beier, F (corresponding author), Univ Western Ontario, Dept Physiol & Pharmacol, Canadian Inst Hlth Res Grp Skeletal Dev & Remodel, London, ON N6A 5C1, Canada.	fbeier@uwo.ca	Beier, Frank/T-4734-2019; Beier, Frank/G-4595-2013; Halawani, Dalia/AAN-3261-2021	Beier, Frank/0000-0002-8505-7537; Beier, Frank/0000-0002-8505-7537; Halawani, Dalia/0000-0003-4738-0656				Aigner T, 2002, VIRCHOWS ARCH, V441, P219, DOI 10.1007/s00428-002-0641-X; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Alderton F, 2001, MOL PHARMACOL, V59, P1119, DOI 10.1124/mol.59.5.1119; Ambrosino C, 2001, BIOL CELL, V93, P47, DOI 10.1016/S0248-4900(01)01124-8; Beier F, 1999, J BIOL CHEM, V274, P30273, DOI 10.1074/jbc.274.42.30273; Beier F, 2000, J BIOL CHEM, V275, P12948, DOI 10.1074/jbc.275.17.12948; Beier F, 1999, P NATL ACAD SCI USA, V96, P1433, DOI 10.1073/pnas.96.4.1433; Beier F, 2002, MOL ENDOCRINOL, V16, P2163, DOI 10.1210/me.2001-0103; Beier F, 2001, MOL BIOL CELL, V12, P3852, DOI 10.1091/mbc.12.12.3852; Brooks AR, 1996, J BIOL CHEM, V271, P9090, DOI 10.1074/jbc.271.15.9090; Carnero A, 2002, BRIT J CANCER, V87, P129, DOI 10.1038/sj.bjc.6600458; Casanovas O, 2000, J BIOL CHEM, V275, P35091, DOI 10.1074/jbc.M006324200; Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023; Diehl NL, 2000, J EXP MED, V191, P321, DOI 10.1084/jem.191.2.321; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; Greenberg AK, 2002, AM J RESP CELL MOL, V26, P558, DOI 10.1165/ajrcmb.26.5.4689; Juretic N, 2001, J CELL BIOCHEM, V83, P92, DOI 10.1002/jcb.1211; Kakonen SM, 2002, J BIOL CHEM, V277, P24571, DOI 10.1074/jbc.M202561200; KIESS M, 1995, ONCOGENE, V10, P159; Maher P, 1999, J BIOL CHEM, V274, P17491, DOI 10.1074/jbc.274.25.17491; Meyyappan M, 1998, MOL CELL BIOL, V18, P3163, DOI 10.1128/MCB.18.6.3163; Mollano Anthony V, 2002, Iowa Orthop J, V22, P1; MUKHOPADHYAY K, 1995, J BIOL CHEM, V270, P27711, DOI 10.1074/jbc.270.46.27711; NAKAMURA T, 1995, EXP CELL RES, V216, P422, DOI 10.1006/excr.1995.1053; Neve RM, 2002, ONCOGENE, V21, P4567, DOI 10.1038/sj.onc.1205555; PETERS G, 1994, J CELL SCI, P89; Pring ME, 2001, J BONE JOINT SURG AM, V83A, P1630, DOI 10.2106/00004623-200111000-00003; Puri PL, 2000, GENE DEV, V14, P574; Recio JA, 2002, ONCOGENE, V21, P1000, DOI 10.1038/sj.onc.1205150; Royuela M, 2002, HUM PATHOL, V33, P299, DOI 10.1053/hupa.2002.32227; Shemirani B, 2002, ORAL ONCOL, V38, P251, DOI 10.1016/S1368-8375(01)00052-5; Shimizu M, 1998, EXP CELL RES, V239, P93, DOI 10.1006/excr.1997.3884; Smalley KSM, 2002, MELANOMA RES, V12, P187, DOI 10.1097/00008390-200206000-00001; Sylvester AM, 1998, J CLIN INVEST, V101, P940, DOI 10.1172/JCI1630; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; YAN GZ, 1995, J NEUROSCI, V15, P6200; Yosimichi G, 2001, EUR J BIOCHEM, V268, P6058, DOI 10.1046/j.0014-2956.2001.02553.x; Zhao M, 2002, ARCH BIOCHEM BIOPHYS, V400, P199, DOI 10.1016/S0003-9861(02)00028-0; Zhu T, 2000, J BIOL CHEM, V275, P2103, DOI 10.1074/jbc.275.3.2103	40	43	46	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3726	3731		10.1038/sj.onc.1207422	http://dx.doi.org/10.1038/sj.onc.1207422			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15116104				2022-12-28	WOS:000221101700026
J	Jefford, CE; Feki, A; Harb, J; Krause, KH; Irminger-Finger, I				Jefford, CE; Feki, A; Harb, J; Krause, KH; Irminger-Finger, I			Nuclear-cytoplasmic translocation of BARD1 is linked to its apoptotic activity	ONCOGENE			English	Article						BARD1; BRCA1; apoptosis; nuclear export; protein stability; RING	CANCER-PREDISPOSING MUTATIONS; MAMMARY EPITHELIAL-CELLS; BRCA1 TUMOR-SUPPRESSOR; RING DOMAIN; UBIQUITIN LIGASE; GENE-PRODUCT; DNA-DAMAGE; PROTEIN; IDENTIFICATION; BRCA1-BARD1	The tumor suppressor protein BARD1 plays a dual role in response to genotoxic stress: DNA repair as a BARD1 BRCA1 heterodimer and induction of apoptosis in a BRCA1-independent manner. We have constructed a series of BARD1 deletion mutants and analysed their cellular distribution and capacity to induce apoptosis. As opposed to previous studies suggesting an exclusively nuclear localization of BARD1, we found, both in tissues and cell cultures, nuclear and cytoplasmic localization of BARD1. Enhanced cytoplasmic localization of BARD1, as well as appearance of a 67 kDa C-terminal proteolytic cleavage product, coincided with apoptosis. BARD1 translocates to the nucleus independently of BRCA1. For recruitment to nuclear dots, however, the BRCA1-interacting RING finger domain is required but not sufficient. Protein levels of N-terminal RING finger deletion mutants were much higher than those of full-length BARD1, despite comparable mRNA levels, suggesting that the N-terminal region comprising the RING finger is important for BARD1 degradation. Sequences required for apoptosis induction were mapped between the ankyrin repeats and the BRCT domains coinciding with two known cancer-associated missense mutations. We suggest that nuclear and cytoplasmic localization of BARD1 reflect its dual function and that the increased cytoplasmic localization of BARD1 is associated with apoptosis.	Univ Geneva, Dept Geriatr, Biol Aging Lab, CH-1225 Geneva, Switzerland; INSERM, U419, Inst Biol, F-44035 Nantes 03, France	University of Geneva; Institut National de la Sante et de la Recherche Medicale (Inserm)	Irminger-Finger, I (corresponding author), Univ Geneva, Dept Geriatr, Biol Aging Lab, CH-1225 Geneva, Switzerland.	irmgard.irminger@medecine.unige.ch	Krause, Karl-Heinz/E-8030-2011; Harb, Jean/S-9610-2017	Krause, Karl-Heinz/0000-0002-9033-6768; Harb, Jean/0000-0002-1727-8610; Feki, Anis/0000-0002-9817-9445				Ayi TC, 1998, ONCOGENE, V17, P2143, DOI 10.1038/sj.onc.1202123; Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Baer R, 2001, NAT STRUCT BIOL, V8, P822, DOI 10.1038/nsb1001-822; Brzovic PS, 2001, J BIOL CHEM, V276, P41399, DOI 10.1074/jbc.M106551200; Brzovic PS, 2001, NAT STRUCT BIOL, V8, P833, DOI 10.1038/nsb1001-833; Chen A, 2002, J BIOL CHEM, V277, P22085, DOI 10.1074/jbc.M201252200; Chiba N, 2002, CANCER RES, V62, P4222; Conus S, 2000, CELL DEATH DIFFER, V7, P947, DOI 10.1038/sj.cdd.4400729; Dechend R, 1999, ONCOGENE, V18, P3316, DOI 10.1038/sj.onc.1202717; Deng CX, 2002, ONCOGENE, V21, P6222, DOI 10.1038/sj.onc.1205713; Fabbro M, 2003, EXP CELL RES, V282, P59, DOI 10.1016/S0014-4827(02)00019-8; Fabbro M, 2002, J BIOL CHEM, V277, P21315, DOI 10.1074/jbc.M200769200; Ferrer I, 2003, J NEUROPATH EXP NEUR, V62, P329, DOI 10.1093/jnen/62.4.329; Gautier F, 2000, CANCER RES, V60, P6895; Ghimenti C, 2002, GENE CHROMOSOME CANC, V33, P235, DOI 10.1002/gcc.1223; Gu JJ, 2001, MOL CELL BIOL, V21, P8533, DOI 10.1128/MCB.21.24.8533-8546.2001; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Irminger-Finger I, 2001, MOL CELL, V8, P1255, DOI 10.1016/S1097-2765(01)00406-3; Irminger-Finger I, 2002, INT J BIOCHEM CELL B, V34, P582, DOI 10.1016/S1357-2725(01)00161-3; Irminger-Finger I, 1998, J CELL BIOL, V143, P1329, DOI 10.1083/jcb.143.5.1329; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; Kleiman FE, 1999, SCIENCE, V285, P1576, DOI 10.1126/science.285.5433.1576; Kleiman FE, 2001, CELL, V104, P743, DOI 10.1016/S0092-8674(02)07059-9; Lohrum MAE, 2001, MOL CELL BIOL, V21, P8521, DOI 10.1128/MCB.21.24.8521-8532.2001; Lotti LV, 2002, GENE CHROMOSOME CANC, V35, P193, DOI 10.1002/gcc.10105; Mallery DL, 2002, EMBO J, V21, P6755, DOI 10.1093/emboj/cdf691; Meza JE, 1999, J BIOL CHEM, V274, P5659, DOI 10.1074/jbc.274.9.5659; Morris JR, 2002, J BIOL CHEM, V277, P9382, DOI 10.1074/jbc.M109249200; Parvin JD, 2001, P NATL ACAD SCI USA, V98, P5952, DOI 10.1073/pnas.121184998; RODRIGUEZ JA, 2003, ONCOGENE; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Soriano JV, 2000, ADV EXP MED BIOL, V480, P175; Spahn L, 2002, CANCER RES, V62, P4583; Thai TH, 1998, HUM MOL GENET, V7, P195, DOI 10.1093/hmg/7.2.195; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xia Y, 2003, J BIOL CHEM, V278, P5255, DOI 10.1074/jbc.M204591200; Yu X, 2000, J BIOL CHEM, V275, P18541, DOI 10.1074/jbc.M909494199	40	46	50	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3509	3520		10.1038/sj.onc.1207427	http://dx.doi.org/10.1038/sj.onc.1207427			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15077185	Bronze			2022-12-28	WOS:000221101700002
J	Hsu, JH; Shi, YJ; Frost, P; Yan, HJ; Hoang, B; Sharma, S; Gera, J; Lichtenstein, A				Hsu, JH; Shi, YJ; Frost, P; Yan, HJ; Hoang, B; Sharma, S; Gera, J; Lichtenstein, A			Interleukin-6 activates phosphoinositol-30 kinase in multiple myeloma tumor cells by signaling through RAS-dependent and, separately, through p85-dependent pathways	ONCOGENE			English	Article						multiple myeloma; interleukin-6; AKT; phosphatidylinositol-3 '-kinase	PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY; TYROSINE PHOSPHORYLATION; GROWTH-FACTORS; AKT KINASE; N-RAS; SURVIVAL; RECEPTOR; PROTOONCOGENE; APOPTOSIS; RESPONSES	The IL-6-induced activation of the phosphatidylinositol-3' kinase (PI3-K)/AKTcascade in multiple myeloma (MM) cells is critical for tumor cell proliferation and viability. Since the IL-6 receptor does not contain binding sites for the p85 regulatory portion of PI3-K, intermediate molecules must play a role. Coimmunoprecipitation studies in MM cell lines demonstrated the IL-6-induced formation of two independent PI3-K-containing complexes: one containing p21 RAS but not STAT-3 and a second containing STAT-3 but not RAS. Both complexes demonstrated IL-6-induced lipid kinase activity. IL-6 also generated kinase activity in a mutant p110 molecule that could not bind p85. Use of dominant-negative (DN) constructs confirmed the presence of two independent pathways of activation: a DN RAS prevented the IL-6-induced generation of lipid kinase activity in the mutant p110 molecule but had no effect on activity generated in the STAT-3-containing complex. In contrast, a DN p85 prevented the generation of kinase activity in the STAT-3-containing complex but had no effect on activity generated in the p110 molecule. Both DN constructs significantly prevented the IL-6-induced activation of AKT. MM cells expressing activating RAS mutations demonstrated enhanced IL-6-independent growth and constitutive PI3-K activity. These data indicate two potential independent pathways of PI3-K/AKT activation in MM cells: one mediated via signaling through RAS which is independent of p85 and a second mediated via p85 and due to a STAT-3-containing complex.	W LA VA UCLA Med Ctr, Dept Med, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90073 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	Lichtenstein, A (corresponding author), VA W LA Hosp, W111H,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.	alan.lichtenstein@med.va.gov		Gera, Joseph/0000-0002-2908-6894; Frost, Patrick/0000-0003-3348-5983				ANDERSON KC, 1989, BLOOD, V73, P1915; BILLADEAU D, 1995, CANCER RES, V55, P3640; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Hakak Y, 2000, ONCOGENE, V19, P3164, DOI 10.1038/sj.onc.1203655; Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833; Hsu JH, 2002, ONCOGENE, V21, P1391, DOI 10.1038/sj/onc/1205194; Hsu JH, 2001, BLOOD, V98, P2853, DOI 10.1182/blood.V98.9.2853; Hu LP, 2003, BLOOD, V101, P3126, DOI 10.1182/blood-2002-08-2640; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; Lee IS, 1997, FEBS LETT, V401, P133, DOI 10.1016/S0014-5793(96)01456-1; Liu PC, 1996, BLOOD, V88, P2699, DOI 10.1182/blood.V88.7.2699.bloodjournal8872699; Ogata A, 1997, J IMMUNOL, V159, P2212; Oh H, 1998, J BIOL CHEM, V273, P9703, DOI 10.1074/jbc.273.16.9703; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; Podar K, 2002, J BIOL CHEM, V277, P7875, DOI 10.1074/jbc.M109068200; PODAR K, 2003, HEMATOL J, V4, pS140; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Rowley M, 2000, BLOOD, V96, P3175, DOI 10.1182/blood.V96.9.3175.h8003175_3175_3180; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; Shigematsu H, 1997, J BIOL CHEM, V272, P14334, DOI 10.1074/jbc.272.22.14334; SJOLANDER A, 1991, P NATL ACAD SCI USA, V88, P7908, DOI 10.1073/pnas.88.18.7908; Tu YP, 2000, CANCER RES, V60, P6763; Ueno H, 1998, BLOOD, V91, P46, DOI 10.1182/blood.V91.1.46.46_46_53	30	43	43	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3368	3375		10.1038/sj.onc.1207459	http://dx.doi.org/10.1038/sj.onc.1207459			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15021914				2022-12-28	WOS:000220975000011
J	Yan, DH; Wen, Y; Su, LK; Xia, WY; Wang, SC; Zhang, S; Gan, L; Lee, DF; Spohn, B; Frey, JA; Hortobagyi, GN; Hung, MC				Yan, DH; Wen, Y; Su, LK; Xia, WY; Wang, SC; Zhang, S; Gan, L; Lee, DF; Spohn, B; Frey, JA; Hortobagyi, GN; Hung, MC			A delayed chemically induced tumorigenesis in Brca2 mutant mice	ONCOGENE			English	Article						Brca2; knockout; mammary tumors; DMBA; carcinogenesis	MOUSE MAMMARY-TUMORS; BREAST-CANCER; OVARIAN-CANCER; DNA-REPAIR; GENE; SUSCEPTIBILITY; EXPRESSION; MUTATION; PROLIFERATION; SENSITIVITY	BRCA2 is a breast cancer susceptibility gene. Germline mutations of BRCA2 account for about 10-30% of familial breast cancer cases. Consistent with its tumor-suppressor activity, BRCA2 plays an important role in DNA repair. To assess the susceptibility of carriers of mutant BRCA2 to tumorigenesis induced by DNA-damaging carcinogens, we generated a Brca2 knockout mouse strain and studied its susceptibility to chemically induced tumorigenesis. Similar to previously reported Brca2 knockout mice, our Brca2(-/-) embryos die at E8.5-9.5, while the Brca2(+/-) mice are tumor-free and fertile. Unexpectedly, Brca2(+/-) mice developed tumors slower than did their wild-type littermates when treated with a potent carcinogen 7,12-dimethylbenz[a]anthracene (DMBA). In vitro experiments showed that Brca2(+/-) mouse cells and Capan-1 cells, a human pancreatic cancer cell line deficient of BRCA2, were more sensitive to DMBA-induced apoptosis, than were Brca2(+/+) mouse cells and a derivative of Capan-1 cells that expressed exogenous wild-type BRCA2, respectively. Our results suggest that enhanced sensitivity of Brca2 mutant cells to DMBA-induced apoptosis at the dose of DMBA we used contributes to the delayed tumorigenesis of Brca2(+/-) animals. This suggestion may also provide a rational explanation for a previous unexpected finding that cigarette smoking appears to reduce the breast cancer risk of BRCA2 mutation carriers.	Univ Texas, Grad Sch Biomed Sci, Dept Mol & Cellular Oncol, Houston, TX 77025 USA; Univ Texas, Dept Surg Oncol, Houston, TX USA; Univ Rochester, Ctr Aging & Dev Biol, Rochester, NY USA; Univ Texas, MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA	University of Texas System; University of Texas System; University of Rochester; University of Texas System; UTMD Anderson Cancer Center	Hung, MC (corresponding author), Univ Texas, Grad Sch Biomed Sci, Dept Mol & Cellular Oncol, Houston, TX 77025 USA.	mhung@mdanderson.org	Wang, Shao-Chun/P-9904-2019; Hung, Mien-Chie/ABD-5911-2021	Wang, Shao-Chun/0000-0002-5477-1682; Hung, Mien-Chie/0000-0003-4317-4740; Lee, Dung-Fang/0000-0003-2387-597X	NCI NIH HHS [R01CA58880, R01CA 77858, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058880, P30CA016672, R01CA077858] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbott DW, 1998, J NATL CANCER I, V90, P978, DOI 10.1093/jnci/90.13.978; Aldaz CM, 1996, MOL CARCINOGEN, V17, P126, DOI 10.1002/(SICI)1098-2744(199611)17:3<126::AID-MC4>3.0.CO;2-D; Aldaz CM, 1996, CARCINOGENESIS, V17, P2069, DOI 10.1093/carcin/17.9.2069; Bennett LM, 2000, MOL CARCINOGEN, V28, P174, DOI 10.1002/1098-2744(200007)28:3<174::AID-MC6>3.0.CO;2-C; Boyd J, 2000, JAMA-J AM MED ASSOC, V283, P2260, DOI 10.1001/jama.283.17.2260; Brunet JS, 1998, J NATL CANCER I, V90, P761, DOI 10.1093/jnci/90.10.761; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Ding Y, 2002, CLIN CANCER RES, V8, P3290; Egawa C, 2001, INT J CANCER, V95, P255, DOI 10.1002/1097-0215(20010720)95:4<255::AID-IJC1043>3.0.CO;2-O; Friedman LS, 1998, CANCER RES, V58, P1338; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Goggins M, 1996, CANCER RES, V56, P5360; Hecht SS, 2002, ENVIRON MOL MUTAGEN, V39, P119, DOI 10.1002/em.10071; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Levine DA, 2002, GYNECOL ONCOL, V85, P431, DOI 10.1006/gyno.2002.6646; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Ludwig T, 2001, ONCOGENE, V20, P3937, DOI 10.1038/sj.onc.1204512; Maniatis T., 1982, MOL CLONING; McAllister KA, 2002, CANCER RES, V62, P990; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; Morimatsu M, 1998, CANCER RES, V58, P3441; Orelli BJ, 2001, BREAST CANCER RES, V3, P294, DOI 10.1186/bcr310; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Pena JC, 1998, CANCER RES, V58, P2111; Schwab M, 2002, CANCER LETT, V175, P1, DOI 10.1016/S0304-3835(01)00752-2; Scully R, 2002, BIOCHIMIE, V84, P95, DOI 10.1016/S0300-9084(01)01359-1; Sharan SK, 1997, GENOMICS, V40, P234, DOI 10.1006/geno.1996.4573; Su LK, 1998, ONCOGENE, V17, P2377, DOI 10.1038/sj.onc.1202162; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; Venkitaraman AR, 2001, J CELL SCI, V114, P3591; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Venkitaraman AR, 2001, CURR OPIN CELL BIOL, V13, P338; Wang SC, 2002, CANCER RES, V62, P1311; Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705; Zheng L, 2000, ONCOGENE, V19, P6159, DOI 10.1038/sj.onc.1203968	36	8	8	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	2004	23	10					1896	1901		10.1038/sj.onc.1207314	http://dx.doi.org/10.1038/sj.onc.1207314			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	801XV	14981540				2022-12-28	WOS:000220129500011
J	Li, XR; Cowell, JK; Sossey-Alaoui, K				Li, XR; Cowell, JK; Sossey-Alaoui, K			CLCA2 tumour suppressor gene in 1p31 is epigenetically regulated in breast cancer	ONCOGENE			English	Article						CLCA2; tumour suppressor gene; 1p31; breast cancer; epigenetics	ACTIVATED CHLORIDE CHANNEL; SPORADIC BREAST; 5-METHYLCYTOSINE RESIDUES; DNA HYPERMETHYLATION; ALLELIC IMBALANCE; OVARIAN-CANCER; CHROMOSOME 1P; HUMAN HOMOLOG; REGION; METHYLATION	The calcium-activated chloride channel gene family is clustered in the 1p31 region, which is frequently deleted in sporadic breast cancer. Recent studies have indicated the association of the second member of this gene family (CLCA2) with the development of breast cancer and metastasis. We have now shown the absence of expression of CLCA2 in several breast cancer tumours and cell lines, which confirms the results from other reports. When overexpressed in CLCA2-negative cell lines, their tumorigenicity and metastasis capability were significantly reduced, suggesting a tumour suppressor role for CLCA2 in breast cancer. The mechanisms behind the silencing of CLCA2 in breast cancer, however, have not been elucidated to date. Although we were able to identify CLCA2 mutations in breast cancers, somatic mutations are not the major cause of CLCA2 gene silencing. On the other hand, treatment of breast cancer CLCA2-negative cell lines with demethylating agents was able to restore CLCA2 expression, suggesting an epigenetic inactivation of this gene. Bisulphite-sequencing of the promoter-associated CpG island of the CLCA2 gene in breast tumours demonstrated that the absence of expression in these tumours was caused by hypermethylation of the promoter CpG island. In contrast, in breast cancer cell lines, tumours, and control cell lines that express CLCA2, a much lower level, and often absence, of methylation of the promoter were demonstrated. These findings demonstrate that CLCA2 is frequently inactivated in breast cancer by promoter region hypermethylation, which makes it an excellent candidate for the 1p31 breast cancer tumour suppressor gene.	Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Sossey-Alaoui, K (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, 110 C&V Bldg,Elm & Carlton St, Buffalo, NY 14263 USA.	khalid.sossey-alaoui@roswellpark.org		Cowell, John/0000-0002-2079-5950	NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER; NCI NIH HHS [CA16056] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdollahi A, 2003, J BIOL CHEM, V278, P6041, DOI 10.1074/jbc.M210361200; Agnel M, 1999, FEBS LETT, V455, P295, DOI 10.1016/S0014-5793(99)00891-1; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; Antoniou A, 2003, AM J HUM GENET, V72, P1117, DOI 10.1086/375033; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; BUBIEN JK, 1990, SCIENCE, V248, P1416, DOI 10.1126/science.2162561; Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3; Dallol A, 2002, CANCER RES, V62, P5874; Dammann R, 2003, HISTOL HISTOPATHOL, V18, P665, DOI 10.14670/HH-18.665; DEANE KHO, 1992, EUR J IMMUNOL, V22, P1165, DOI 10.1002/eji.1830220509; Elble RC, 2001, J BIOL CHEM, V276, P40510, DOI 10.1074/jbc.M104821200; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Garinis GA, 2002, HUM GENET, V111, P115, DOI 10.1007/s00439-002-0783-6; GRIGG G, 1994, BIOESSAYS, V16, P431, DOI 10.1002/bies.950160612; Gruber AD, 1999, AM J PHYSIOL-CELL PH, V276, pC1261; Gruber AD, 1999, CANCER RES, V59, P5488; Gruber AD, 1998, GENOMICS, V54, P200, DOI 10.1006/geno.1998.5562; Hoff C, 2001, CANCER GENET CYTOGEN, V129, P145, DOI 10.1016/S0165-4608(01)00450-2; HOGGARD N, 1995, GENOMICS, V30, P233, DOI 10.1006/geno.1995.9882; HOLLIDAY R, 1993, MUTAT RES, V285, P61, DOI 10.1016/0027-5107(93)90052-H; Lichy JH, 1998, AM J PATHOL, V153, P271, DOI 10.1016/S0002-9440(10)65568-X; NAGAI H, 1995, CANCER RES, V55, P1752; Pauli BU, 2000, CLIN EXP PHARMACOL P, V27, P901, DOI 10.1046/j.1440-1681.2000.03358.x; Roy D, 2003, INT J CANCER, V103, P730, DOI 10.1002/ijc.10895; Sossey-Alaoui K, 2002, ONCOGENE, V21, P5967, DOI 10.1038/sj.onc.1205734; Sossey-Alaoui K, 2002, GENOMICS, V80, P5, DOI 10.1006/geno.2002.6792; Sossey-Alaoui K, 2001, INT J MOL MED, V7, P543; SOULE HD, 1990, CANCER RES, V50, P6075; Su GF, 1999, GENOMICS, V55, P157, DOI 10.1006/geno.1998.5633; Tsukamoto K, 1998, CANCER-AM CANCER SOC, V82, P317, DOI 10.1002/(SICI)1097-0142(19980115)82:2<323::AID-CNCR11>3.3.CO;2-P; Ullrich N, 1997, AM J PHYSIOL-CELL PH, V273, pC1290, DOI 10.1152/ajpcell.1997.273.4.C1290; White GRM, 1998, ONCOGENE, V17, P3513, DOI 10.1038/sj.onc.1202487; Zochbauer-Muller S, 2001, CANCER RES, V61, P3581	38	46	48	5	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2004	23	7					1474	1480		10.1038/sj.onc.1207249	http://dx.doi.org/10.1038/sj.onc.1207249			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	775HZ	14973555				2022-12-28	WOS:000189035800015
J	Carnero, A; Beach, DH				Carnero, A; Beach, DH			Absence of p21(WAF1) cooperates with c-myc in bypassing Ras-induced senescence and enhances oncogenic cooperation	ONCOGENE			English	Article						oncogenic cooperation; c-myc; ras; waf1; PI3k	SKIN CARCINOGENESIS; EMBRYO FIBROBLASTS; TUMOR SUPPRESSION; TRANSGENIC MICE; ACTIVATED RAS; HA-RAS; P53; TRANSFORMATION; APOPTOSIS; CELLS	The absence of p21(waf1) combined with an ectopic expression of c-myc prevents ras-induced senescence in mouse embryo fibroblasts. Extension of lifespan after c-myc transduction into p21-null cells was followed at later passages by apoptosis of a large fraction of c-myc-overexpressing p21-null cells. This apoptotic effect could be overridden by inactivation of the p53 tumor suppressor or oncogenic Pas expression. Ras-induced inhibition of apoptosis is mediated by PI3K activation. These results suggest a functional relationship between Pas and myc that may explain their oncogenic cooperation. The number of foci formed by myc + Pas increased cooperatively in the absence of p21(waf1). Thus, the reciprocal cooperation between myc and ras in a p21-null background during cellular immortalization lead to increased oncogenic cooperation between Pas and myc.	CNIO, Expt Therapeut Programme, Madrid, Spain; UCL, Wolfson Inst Biomed Res, London WC1E 6BT, England	Centro Nacional de Investigaciones Oncologicas (CNIO); University of London; University College London	Carnero, A (corresponding author), CNIO, Expt Therapeut Programme, Madrid, Spain.	acarnero@cnio.es	IBIS, CANCER/P-3323-2015	Carnero, Amancio/0000-0003-4357-3979				Amati B, 1998, FRONT BIOSCI, V3, pd250, DOI [10.2741/a239, DOI 10.2741/A239]; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; Carnero A, 2000, NUCLEIC ACIDS RES, V28, P2234, DOI 10.1093/nar/28.11.2234; Ceballos E, 2000, ONCOGENE, V19, P2194, DOI 10.1038/sj.onc.1203541; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; HARVEY M, 1993, ONCOGENE, V8, P2457; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; Jones JM, 1999, CELL GROWTH DIFFER, V10, P213; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LANGDON WY, 1989, ONCOGENE RES, V4, P253; Latres E, 2000, EMBO J, V19, P3496, DOI 10.1093/emboj/19.13.3496; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Martin-Caballero J, 2001, CANCER RES, V61, P6234; Michieli P, 1996, ONCOGENE, V12, P775; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; Philipp J, 1999, ONCOGENE, V18, P4689, DOI 10.1038/sj.onc.1202840; Rudolph B, 1996, EMBO J, V15, P3065, DOI 10.1002/j.1460-2075.1996.tb00669.x; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; Tsuneoka M, 2000, ONCOGENE, V19, P115, DOI 10.1038/sj.onc.1203232; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WEINBERG RA, 1989, CANCER RES, V49, P3713; Weinberg WC, 1999, CANCER RES, V59, P2050; WEINBERG WC, 1995, ONCOGENE, V10, P2271; Wu SQ, 2003, ONCOGENE, V22, P351, DOI 10.1038/sj.onc.1206145; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	42	28	28	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2004	23	35					6006	6011		10.1038/sj.onc.1207839	http://dx.doi.org/10.1038/sj.onc.1207839			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15195145				2022-12-28	WOS:000222941100016
J	Narayan, S; Jaiswal, AS; Kang, D; Srivastava, P; Das, GM; Gairola, CG				Narayan, S; Jaiswal, AS; Kang, D; Srivastava, P; Das, GM; Gairola, CG			Cigarette smoke condensate-induced transformation of normal human breast epithelial cells in vitro	ONCOGENE			English	Article						cigarette smoke condensate; normal breast epithelial cells; anchorage-independent growth; transformation; Bcl-xL/Bax; neuropilin-1	PASSIVE SMOKING; ACTIVE SMOKING; GROWTH-FACTOR; TUMOR-CELLS; CANCER RISK; KAPPA-B; EXPRESSION; NEUROPILIN-1; GADD45; GENES	In the present study, we showed that a single-dose treatment of normal breast epithelial cell line, MCF10A, for 72h with cigarette smoke condensate (CSC) resulted in a transformed phenotype. The anchorage-dependent growth of these cells was decreased due to increased cell cycle arrest in S-G(2)/M phase; however, the surviving cells developed resistance due to an increased Bcl-xL to Bax ratio. Levels of PCNA and gadd45 proteins - involved in DNA repair in response to genomic damage - were increased, suggesting that the cells were responding to CSC-induced genomic damage. The transformation of MCF10A cells was determined by their colony-forming efficiency in soft-agar in an anchorage-independent manner. CSC-treated MCF10A cells efficiently formed colonies in soft-agar. We then re-established cell lines from the soft-agar colonies and further examined the persistence of their transforming characteristics. The re-established cell lines, when plated after 17 passages without CSC treatment, still formed colonies in the soft-agar. An increased staining of neuropilin-1 (NRP-1) further showed a transformation characteristic of MCF10A cells treated with CSC. In summary, our results suggest that CSC is capable of transforming the MCF10A cells in vitro, supporting the role cigarette smoking and increased risk for breast cancer.	Univ Florida, Dept Anat & Cell Biol, UF Shands Canc Ctr, Gainesville, FL 32610 USA; Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA; Univ Kentucky, Coll Pharm, Div Pharmaceut Sci, Lexington, KY 40536 USA	State University System of Florida; University of Florida; Roswell Park Cancer Institute; University of Kentucky	Narayan, S (corresponding author), Univ Florida, Dept Anat & Cell Biol, UF Shands Canc Ctr, Acad Res Bldg,Room R4-216,POB 100232, Gainesville, FL 32610 USA.	snarayan@ufscc.ufl.edu	Das, Gokul M/A-5772-2013	Das, Gokul M/0000-0003-2937-8093				Anto RJ, 2002, CARCINOGENESIS, V23, P1511, DOI 10.1093/carcin/23.9.1511; Bachelder RE, 2001, CANCER RES, V61, P5736; Band PR, 2003, BIOMED PHARMACOTHER, V57, P110; Band PR, 2002, LANCET, V360, P1044, DOI 10.1016/S0140-6736(02)11140-8; Beral V, 2002, BRIT J CANCER, V87, P1234, DOI 10.1038/sj.bjc.6600596; CALAF G, 1993, CARCINOGENESIS, V14, P483, DOI 10.1093/carcin/14.3.483; Cavalieri E, 2000, J Natl Cancer Inst Monogr, P75; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CIARDIELLO F, 1992, MOL CARCINOGEN, V6, P43, DOI 10.1002/mc.2940060108; DAS G, 1995, NATURE, V374, P657, DOI 10.1038/374657a0; Egan KM, 2002, EPIDEMIOLOGY, V13, P138, DOI 10.1097/00001648-200203000-00007; Fink AK, 2003, CANCER CAUSE CONTROL, V14, P497, DOI 10.1023/A:1024922824237; HALL PA, 1995, ONCOGENE, V10, P2427; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hecht SS, 2002, ENVIRON MOL MUTAGEN, V39, P119, DOI 10.1002/em.10071; Hoffmann D, 2001, CHEM RES TOXICOL, V14, P767, DOI 10.1021/tx000260u; HSU TC, 1991, MUTAT RES, V259, P67, DOI 10.1016/0165-1218(91)90110-8; Jaiswal AS, 2002, ONCOGENE, V21, P8414, DOI 10.1038/sj.onc.1205947; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; Johnson KC, 2000, CANCER CAUSE CONTROL, V11, P211, DOI 10.1023/A:1008906105790; Lantuejoul S, 2003, J PATHOL, V200, P336, DOI 10.1002/path.1367; Lash TL, 1999, AM J EPIDEMIOL, V149, P5; Liebermann DA, 2002, ONCOGENE, V21, P3391, DOI 10.1038/sj.onc.1205312; Mei JX, 2003, BREAST CANCER RES TR, V79, P95, DOI 10.1023/A:1023326121951; Miao HQ, 2000, FASEB J, V14, P2532, DOI 10.1096/fj.00-0250com; Millikan RC, 1998, CANCER EPIDEM BIOMAR, V7, P371; Morabia A, 1996, AM J EPIDEMIOL, V143, P918, DOI 10.1093/oxfordjournals.aje.a008835; Morabia A, 2002, EPIDEMIOLOGY, V13, P744, DOI 10.1097/00001648-200211000-00026; Narayan S, 1997, J BIOL CHEM, V272, P30619, DOI 10.1074/jbc.272.49.30619; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; PAINE TM, 1992, INT J CANCER, V50, P463, DOI 10.1002/ijc.2910500323; PERERA FP, 1995, CANCER EPIDEM BIOMAR, V4, P233; PILLSBURY HC, 1972, J ASSOC OFF ANA CHEM, V55, P636; Pluquet O, 2001, CANCER LETT, V174, P1, DOI 10.1016/S0304-3835(01)00698-X; Prosperi E, 1997, Prog Cell Cycle Res, V3, P193; Reynolds P, 2004, JNCI-J NATL CANCER I, V96, P29, DOI 10.1093/jnci/djh002; Rodgman A, 2000, HUM EXP TOXICOL, V19, P573, DOI 10.1191/096032700701546514; Rubin H, 2002, ONCOGENE, V21, P7392, DOI 10.1038/sj.onc.1205800; Russo I.H., 2001, J WOMENS CANC, V3, P29; Russo J, 2002, ENVIRON MOL MUTAGEN, V39, P254, DOI 10.1002/em.10052; Russo J, 1982, Breast Cancer Res Treat, V2, P5, DOI 10.1007/BF01805718; Sevilla L, 2001, HISTOL HISTOPATHOL, V16, P595, DOI 10.14670/HH-16.595; Sheikh MS, 2000, BIOCHEM PHARMACOL, V59, P43, DOI 10.1016/S0006-2952(99)00291-9; SMITH SJ, 1994, BRIT J CANCER, V70, P112, DOI 10.1038/bjc.1994.258; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; SOULE HD, 1990, CANCER RES, V50, P6075; Stampfer MR, 2000, J MAMMARY GLAND BIOL, V5, P365, DOI 10.1023/A:1009525827514; Stephenson JM, 2002, INT J CANCER, V101, P409, DOI 10.1002/ijc.10611; TAIT L, 1990, CANCER RES, V50, P6087; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Terry PD, 2002, CANCER EPIDEM BIOMAR, V11, P953; Tomlinson IPM, 2001, BREAST CANCER RES, V3, P299, DOI 10.1186/bcr311; Vanveldhuizen PJ, 2003, ONCOL REP, V10, P1067; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; [No title captured]	57	60	64	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2004	23	35					5880	5889		10.1038/sj.onc.1207792	http://dx.doi.org/10.1038/sj.onc.1207792			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15208684				2022-12-28	WOS:000222941100002
J	Xiao, D; Choi, S; Johnson, DE; Vogel, VG; Johnson, CS; Trump, DL; Lee, YJ; Singh, SV				Xiao, D; Choi, S; Johnson, DE; Vogel, VG; Johnson, CS; Trump, DL; Lee, YJ; Singh, SV			Diallyl trisulfide-induced apoptosis in human prostate cancer cells involves c-Jun N-terminal kinase and extracellular-signal regulated kinase-mediated phosphorylation of Bcl-2	ONCOGENE			English	Article						diallyl trisulfide; JNK; ERK; Bcl-2; apoptosis; prostate cancer	OCCURRING ORGANOSULFUR COMPOUNDS; METABOLIC OXIDATIVE STRESS; PROTEIN-KINASE; COLON-CANCER; S-ALLYLMERCAPTOCYSTEINE; MAMMARY CARCINOGENESIS; ALLIUM VEGETABLES; CYTOCHROME-C; P38 MAPK; DISULFIDE	Garlic-derived organosulfides (OSCs) including diallyl trisulfide (DATS) are highly effective in affording protection against chemically induced cancer in animals. Evidence is also mounting to indicate that some naturally occurring OSCs can suppress proliferation of cancer cells by causing apoptosis, but the sequence of events leading to proapoptotic effect of OSCs is poorly defined. Using PC-3 and DU145 human prostate cancer cells as a model, we now demonstrate that DATS is a significantly more potent apoptosis inducer than diallyl sulfide (DAS) or diallyl disulfide (DADS). DATS-induced apoptosis in PC-3 cells was associated with phosphorylation of Bcl-2, reduced Bcl-2: Bax interaction, and cleavage of procaspase-9 and -3. Bcl-2 overexpressing PC-3 cells were significantly more resistant to apoptosis induction by DATS compared with vector-transfected control cells. DATS treatment resulted in activation of extracellular-signal regulated kinase 1/2 (ERK1/2) and c-jun N-terminal kinase 1 (JNK1) and/or JNK2, but not p38 mitogen-activated protein kinase. Phosphorylation of Bcl-2 in DATS-treated PC-3 cells was fully blocked in the presence of JNK-specific inhibitor SP600125. Moreover, JNK inhibitor afforded significant protection against DATS-induced apoptosis in both cells. DATS-induced Bcl-2 phosphorylation and apoptosis were partially attenuated by pharmacological inhibition of ERK1/2 using PD98059 or U0126. Overexpression of catalase inhibited DATS-mediated activation of JNK1/2, but not ERK1\/2, and apoptosis induction in DU145 cells suggesting involvement of hydrogen peroxide as a second messenger in DATS-induced apoptosis. In conclusion, our data point towards important roles for Bcl-2, JNK and ERK in DATS-induced apoptosis in human prostate cancer cells.	Univ Pittsburgh, Pittsburgh Canc Inst, Hillman Canc Ctr, Sch Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pharmacol & Med, Pittsburgh, PA 15261 USA; Roswell Pk Canc Inst, Buffalo, NY 14263 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Roswell Park Cancer Institute	Singh, SV (corresponding author), Univ Pittsburgh, Pittsburgh Canc Inst, Hillman Canc Ctr, Sch Med, Res Pavil,Suite 2-32A,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	singhs@msx.upmc.edu			NATIONAL CANCER INSTITUTE [R01CA101753, R01CA095191, R01CA096989] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Agarwal KC, 1996, MED RES REV, V16, P111, DOI 10.1002/(SICI)1098-1128(199601)16:1&lt;111::AID-MED4&gt;3.0.CO;2-5; Blagosklonny MV, 2001, LEUKEMIA, V15, P869, DOI 10.1038/sj.leu.2402134; Blagosklonny MV, 1996, CANCER RES, V56, P1851; DAUSCH JG, 1990, PREV MED, V19, P346, DOI 10.1016/0091-7435(90)90034-H; Deng XM, 2001, J BIOL CHEM, V276, P23681, DOI 10.1074/jbc.M100279200; DORANT E, 1993, BRIT J CANCER, V67, P424, DOI 10.1038/bjc.1993.82; Fang GF, 1998, CANCER RES, V58, P3202; Ferreira CG, 2002, CLIN CANCER RES, V8, P2024; Filomeni G, 2003, CANCER RES, V63, P5940; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Haldar S, 1996, CANCER RES, V56, P1253; Halliwell B, 1996, BIOCHEM SOC T, V24, P1023, DOI 10.1042/bst0241023; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hsing AW, 2002, J NATL CANCER I, V94, P1648, DOI 10.1093/jnci/94.21.1648; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Knowles LM, 1998, NUTR CANCER, V30, P169, DOI 10.1080/01635589809514659; Knowles LM, 2001, J NUTR, V131, p1061S, DOI 10.1093/jn/131.3.1061S; Kwon KB, 2002, BIOCHEM PHARMACOL, V63, P41, DOI 10.1016/S0006-2952(01)00860-7; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; MAY WS, 1994, J BIOL CHEM, V269, P26865; NAGAE S, 1994, PLANTA MED, V60, P214, DOI 10.1055/s-2006-959461; Nakagawa H, 2001, CARCINOGENESIS, V22, P891, DOI 10.1093/carcin/22.6.891; REDDY BS, 1993, CANCER RES, V53, P3493; Robert V, 2001, CARCINOGENESIS, V22, P1155, DOI 10.1093/carcin/22.8.1155; Rosini P, 2000, BIOCHEM BIOPH RES CO, V278, P753, DOI 10.1006/bbrc.2000.3871; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Scatena CD, 1998, J BIOL CHEM, V273, P30777, DOI 10.1074/jbc.273.46.30777; Schaffer EM, 1996, CANCER LETT, V102, P199, DOI 10.1016/0304-3835(96)04160-2; Sheen LY, 1996, FOOD CHEM TOXICOL, V34, P971, DOI 10.1016/S0278-6915(96)00066-X; Shirin H, 2001, CANCER RES, V61, P725; Song JJ, 2003, BIOCHEM J, V373, P845, DOI 10.1042/BJ20030275; Song JJ, 2002, J BIOL CHEM, V277, P46566, DOI 10.1074/jbc.M206826200; SPARNINS VL, 1988, CARCINOGENESIS, V9, P131, DOI 10.1093/carcin/9.1.131; Srivastava RK, 1998, MOL CELL BIOL, V18, P3509, DOI 10.1128/MCB.18.6.3509; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; SUMIYOSHI H, 1990, CANCER RES, V50, P5084; Sundaram SG, 1996, CARCINOGENESIS, V17, P669, DOI 10.1093/carcin/17.4.669; Suzui N, 1997, JPN J CANCER RES, V88, P705, DOI 10.1111/j.1349-7006.1997.tb00440.x; TAKAHASHI S, 1992, CARCINOGENESIS, V13, P1513, DOI 10.1093/carcin/13.9.1513; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Torcia M, 2001, J BIOL CHEM, V276, P39027, DOI 10.1074/jbc.M102970200; Vantieghem A, 2002, J BIOL CHEM, V277, P37718, DOI 10.1074/jbc.M204348200; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; WARGOVICH MJ, 1987, CARCINOGENESIS, V8, P487, DOI 10.1093/carcin/8.3.487; WARGOVICH MJ, 1988, CANCER RES, V48, P6872; WATTENBERG LW, 1989, CANCER RES, V49, P2689; Xiao D, 2003, CARCINOGENESIS, V24, P891, DOI 10.1093/carcin/bgg023; Xiao D, 2002, CANCER RES, V62, P3615; Xiao DH, 2003, CANCER RES, V63, P6825; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; YOU WC, 1989, J NATL CANCER I, V81, P162, DOI 10.1093/jnci/81.2.162	53	224	235	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5594	5606		10.1038/sj.onc.1207747	http://dx.doi.org/10.1038/sj.onc.1207747			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15184882				2022-12-28	WOS:000222629500004
J	Salatino, M; Schillaci, R; Proietti, CJ; Carnevale, R; Frahm, I; Molinolo, AA; Iribarren, A; Charreau, EH; Elizalde, PV				Salatino, M; Schillaci, R; Proietti, CJ; Carnevale, R; Frahm, I; Molinolo, AA; Iribarren, A; Charreau, EH; Elizalde, PV			Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity	ONCOGENE			English	Article						breast cancer; IGF-IR; antisense strategies	ACTIVATED PROTEIN-KINASE; MOUSE MAMMARY ADENOCARCINOMAS; ESTROGEN-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; DEPENDENT PHOSPHORYLATION; GLIOBLASTOMA CELLS; DOWN-REGULATION; GENE-TRANSFER; TUMOR-GROWTH; MCF-7 CELLS	The present study addresses the effect of targeting type I insulin-like growth factor receptor (IGF-IR) with antisense strategies in in vivo growth of breast cancer cells. Our research was carried out on C4HD tumors from an experimental model of hormonal carcinogenesis in which the synthetic progestin medroxyprogesterone acetate (MPA) induced mammary adenocarcinomas in Balb/c mice. We employed two different experimental strategies. With the first one we demonstrated that direct intratumor injection of phosphorothioate antisense oligodeoxynucleotides (AS[S] ODNs) to IGF-IR mRNA resulted in a significant inhibition of C4HD tumor growth. In the second experimental strategy, we assessed the effect of intravenous ( i. v.) injection of AS [S] ODN on C4HD tumor growth. This systemic treatment also resulted in significant reduction in tumor growth. The antitumor effect of IGF-IR AS[S] ODNs in both experimental protocols was due to a specific antisense mechanism, since growth inhibition was dose-dependent and no abrogation of tumor proliferation was observed in mice treated with phosphorothioate sense ODNs ( S[ S] ODNs). In addition, IGF-IR expression was inhibited in tumors from mice receiving AS[ S] ODNs, as compared to tumors from control groups. We then investigated signal transduction pathways modulated in vivo by AS[ S] ODNs treatment. Tumors from AS[ S] ODN-treated mice of both intratumoral and intravenous protocols showed a significant decrease in the degree of insulin receptor substrate-1 (IRS-1) tyrosine phosphorylation. Activation of two of the main IGF-IR signaling pathways, phosphatidylinositol 3-kinase (PI-3K)/Akt and p42/p44 mitogen-activated protein kinases ( MAPK) was abolished in tumors growing in AS[ S] ODN-treated animals. Moreover, ErbB-2 tyrosine phosphorylation was blocked by in vivo administration of AS[ S] ODNs. On the other hand, we found no regulation of either progesterone receptor expression or activity by in vivo AS[S] ODNs administration. Our results for the first time demonstrated that breast cancer growth can be inhibited by direct in vivo administration of IGF-IR AS[S] ODNs.	Consejo Nacl Invest Cient & Tecn, IBYME, Lab Mol Mech Carcinogenesis, RA-1428 Buenos Aires, DF, Argentina; Sanatorio Mater Dei, Serv Pathol, Buenos Aires, DF, Argentina; Inst Invest Ingn Genet & Biol Mol, Buenos Aires, DF, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Institute of Biology & Experimental Medicine	Elizalde, PV (corresponding author), Consejo Nacl Invest Cient & Tecn, IBYME, Lab Mol Mech Carcinogenesis, Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.	elizalde@dna.uba.ar		Elizalde, Patricia V./0000-0002-5923-9898				Adeyinka A, 2002, CLIN CANCER RES, V8, P1747; ARTEAGA CL, 1989, CANCER RES, V49, P6237; BACKER JM, 1993, J BIOL CHEM, V268, P8204; Balana ME, 2001, ONCOGENE, V20, P34, DOI 10.1038/sj.onc.1204050; Balana ME, 1999, ONCOGENE, V18, P6370, DOI 10.1038/sj.onc.1203028; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Boonyaratanakornkit V, 2001, MOL CELL, V8, P269, DOI 10.1016/S1097-2765(01)00304-5; Burfeind P, 1996, P NATL ACAD SCI USA, V93, P7263, DOI 10.1073/pnas.93.14.7263; Chakravarti A, 2002, CANCER RES, V62, P200; Chernicky CL, 2000, CANCER GENE THER, V7, P384, DOI 10.1038/sj.cgt.7700126; Chernicky CL, 2002, J CLIN PATHOL-MOL PA, V55, P102, DOI 10.1136/mp.55.2.102; CHO HS, 1994, ENDOCRINOLOGY, V134, P658, DOI 10.1210/en.134.2.658; Clemm DL, 2000, MOL ENDOCRINOL, V14, P52, DOI 10.1210/me.14.1.52; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; Cui XJ, 2003, MOL ENDOCRINOL, V17, P575, DOI 10.1210/me.2002-0318; Dunn SE, 1998, CANCER RES, V58, P3353; Elizalde PV, 1998, J STEROID BIOCHEM, V67, P305, DOI 10.1016/S0960-0760(98)00123-X; IGNARTROWBRIDGE DM, 1992, P NATL ACAD SCI USA, V89, P4658, DOI 10.1073/pnas.89.10.4658; KATZENELLENBOGEN BS, 1990, ENDOCRINOLOGY, V126, P891, DOI 10.1210/endo-126-2-891; Labriola L, 2003, MOL CELL BIOL, V23, P1095, DOI 10.1128/MCB.23.3.1095-1111.2003; Lange CA, 2000, P NATL ACAD SCI USA, V97, P1032, DOI 10.1073/pnas.97.3.1032; Lange CA, 1998, J BIOL CHEM, V273, P31308, DOI 10.1074/jbc.273.47.31308; Lee AV, 1999, MOL ENDOCRINOL, V13, P787, DOI 10.1210/me.13.5.787; Lee CT, 1996, CANCER RES, V56, P3038; Lee CT, 2003, CANCER GENE THER, V10, P57, DOI 10.1038/sj.cgt.7700524; Li WQ, 2000, CANCER RES, V60, P3909; Liu XD, 1998, CANCER RES, V58, P5432; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; NABEL GJ, 1993, P NATL ACAD SCI USA, V90, P11307, DOI 10.1073/pnas.90.23.11307; Nakamura K, 2000, CANCER RES, V60, P760; Navarro M, 2001, ENDOCRINOLOGY, V142, P1073, DOI 10.1210/en.142.3.1073; NEUENSCHWANDER S, 1995, ENDOCRINOLOGY, V136, P4298, DOI 10.1210/en.136.10.4298; Oesterreich S, 2001, CANCER RES, V61, P5771; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; PLAUTZ GE, 1993, P NATL ACAD SCI USA, V90, P4645, DOI 10.1073/pnas.90.10.4645; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; Qiu M, 2003, MOL ENDOCRINOL, V17, P628, DOI 10.1210/me.2002-0378; Ram TG, 1996, MOL CARCINOGEN, V15, P227, DOI 10.1002/(SICI)1098-2744(199603)15:3<227::AID-MC8>3.0.CO;2-E; RESNICOFF M, 1994, CANCER RES, V54, P2218; RESNICOFF M, 1994, CANCER RES, V54, P4848; RESNICOFF M, 1995, CANCER RES, V55, P3739; RESNICOFF M, 1995, CANCER RES, V55, P2463; ROHLIK QT, 1987, BIOCHEM BIOPH RES CO, V149, P276, DOI 10.1016/0006-291X(87)91635-4; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; Scrimgeour AG, 1997, ENDOCRINOLOGY, V138, P2552, DOI 10.1210/en.138.6.2552; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; Shen TJ, 2001, MOL CELL BIOL, V21, P6122, DOI 10.1128/MCB.21.18.6122-6131.2001; STEWART AJ, 1990, J BIOL CHEM, V265, P21172; Surmacz E, 1998, BREAST CANCER RES TR, V47, P255, DOI 10.1023/A:1005907101686; Swantek JL, 1999, ENDOCRINOLOGY, V140, P3163, DOI 10.1210/en.140.7.3163; Tamm I, 2001, LANCET, V358, P489, DOI 10.1016/S0140-6736(01)05629-X; Werner H, 2000, CELL MOL LIFE SCI, V57, P932, DOI 10.1007/PL00000735; Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472	54	60	65	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2004	23	30					5161	5174		10.1038/sj.onc.1207659	http://dx.doi.org/10.1038/sj.onc.1207659			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	834AE	15122317	Green Published			2022-12-28	WOS:000222382500006
J	Feshchenko, EA; Smirnova, EV; Swaminathan, G; Teckchandani, AM; Agrawal, R; Band, H; Zhang, XL; Annan, RS; Carr, SA; Tsygankov, AY				Feshchenko, EA; Smirnova, EV; Swaminathan, G; Teckchandani, AM; Agrawal, R; Band, H; Zhang, XL; Annan, RS; Carr, SA; Tsygankov, AY			TULA: an SH3- and UBA-containing protein that binds to c-Cbl and ubiquitin	ONCOGENE			English	Article						TULA; c-Cbl; UBA; SH3; ubiquitin; protein tyrosine kinase	GROWTH-FACTOR RECEPTOR; T-CELL-RECEPTOR; DAMAGE-INDUCIBLE PROTEINS; TYROSINE KINASE; RING FINGER; EGF-RECEPTOR; NEGATIVE REGULATION; PHOSPHORYLATION SITES; HERPESVIRUS-SAIMIRI; MASS-SPECTROMETRY	Downregulation of protein tyrosine kinases is a major function of the multidomain protein c-Cbl. This effect of c-Cbl is critical for both negative regulation of normal physiological stimuli and suppression of cellular transformation. In spite of the apparent importance of these effects of c-Cbl, their own regulation is poorly understood. To search for possible novel regulators of c-Cbl, we purified a number of c-Cbl-associated proteins by affinity chromatography and identified them by mass spectrometry. Among them, we identified the UBA- and SH3-containing protein T-cell Ubiquitin LigAnd (TULA), which can also bind to ubiquitin. Functional studies in a model system based on co-expression of TULA, c-Cbl, and EGF receptor in 293T cells demonstrate that TULA is capable of inhibiting c-Cbl-mediated downregulation of EGF receptor. Furthermore, modulation of TULA concentration in Jurkat T-lymphoblastoid cells demonstrates that TULA upregulates the activity of both Zap kinase and NF-AT transcription factor. Therefore, our study indicates that TULA counters the inhibitory effect of c-Cbl on protein tyrosine kinases and, thus, may be involved in the regulation of biological effects of c-Cbl. Finally, our results suggest that TULA-mediated inhibition of the effects of c-Cbl on protein tyrosine kinases is caused by TULA-induced ubiquitylation and degradation of c-Cbl.	Temple Univ, Sch Med, Dept Microbiol & Immunol, Philadelphia, PA 19140 USA; GlaxoSmithKline, King Of Prussia, PA USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; GlaxoSmithKline; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Tsygankov, AY (corresponding author), Temple Univ, Sch Med, Dept Microbiol & Immunol, 3400 N Broad St, Philadelphia, PA 19140 USA.	alexander.tsygankov@temple.edu	Tsygankov, Alexander Y/K-6205-2017; Carr, Steven A./AAH-8366-2019		NCI NIH HHS [CA78499] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078499] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Alwan HAJ, 2003, J BIOL CHEM, V278, P35781, DOI 10.1074/jbc.M301326200; Andoniou CE, 2000, MOL CELL BIOL, V20, P851, DOI 10.1128/MCB.20.3.851-867.2000; Bao J, 2003, P NATL ACAD SCI USA, V100, P2438, DOI 10.1073/pnas.0437945100; Bartkiewicz M, 1999, J BIOL CHEM, V274, P30887, DOI 10.1074/jbc.274.43.30887; Bertolaet BL, 2001, NAT STRUCT BIOL, V8, P417, DOI 10.1038/87575; Bertolaet BL, 2001, J MOL BIOL, V313, P955, DOI 10.1006/jmbi.2001.5105; Broome MA, 1999, ONCOGENE, V18, P2908, DOI 10.1038/sj.onc.1202873; Courbard JR, 2002, J BIOL CHEM, V277, P45267, DOI 10.1074/jbc.M206460200; de Melker AA, 2001, J CELL SCI, V114, P2167; Duan L, 2003, J BIOL CHEM, V278, P28950, DOI 10.1074/jbc.M304474200; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Ettenberg SA, 1999, ONCOGENE, V18, P1855, DOI 10.1038/sj.onc.1202499; Ettenberg SA, 2001, J BIOL CHEM, V276, P27677, DOI 10.1074/jbc.M102641200; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; Gatlin CL, 1998, ANAL BIOCHEM, V263, P93, DOI 10.1006/abio.1998.2809; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Hartley D, 1996, J BIOL CHEM, V271, P21939, DOI 10.1074/jbc.271.36.21939; Hasham MG, 2004, VIROLOGY, V320, P313, DOI 10.1016/j.virol.2003.11.032; Jiang XJ, 2003, MOL BIOL CELL, V14, P858, DOI 10.1091/mbc.E02-08-0532; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Klapper LN, 2000, CANCER RES, V60, P3384; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 2000, J BIOL CHEM, V275, P35532, DOI 10.1074/jbc.M002661200; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lill NL, 2000, J BIOL CHEM, V275, P367, DOI 10.1074/jbc.275.1.367; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Magnifico A, 2003, J BIOL CHEM, V278, P43169, DOI 10.1074/jbc.M308009200; Mancini A, 2002, J BIOL CHEM, V277, P14635, DOI 10.1074/jbc.M109214200; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; Merlo JJ, 2001, VIROLOGY, V279, P325, DOI 10.1006/viro.2000.0714; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Naramura M, 1998, P NATL ACAD SCI USA, V95, P15547, DOI 10.1073/pnas.95.26.15547; Oksvold MP, 2001, EUR J CELL BIOL, V80, P285, DOI 10.1078/0171-9335-00160; Ota S, 2000, J BIOL CHEM, V275, P414, DOI 10.1074/jbc.275.1.414; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Rao N, 2002, J LEUKOCYTE BIOL, V71, P753; Rao N, 2001, EMBO J, V20, P7085, DOI 10.1093/emboj/20.24.7085; Rao N, 2000, J IMMUNOL, V164, P4616, DOI 10.4049/jimmunol.164.9.4616; Rao NV, 2002, P NATL ACAD SCI USA, V99, P3794, DOI 10.1073/pnas.062055999; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; SANJAY A, 2001, SCI STKE, pE40; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Teckchandani AM, 2001, ONCOGENE, V20, P1739, DOI 10.1038/sj.onc.1204246; Thien CBF, 2001, MOL CELL, V7, P355, DOI 10.1016/S1097-2765(01)00183-6; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; TSYGANKOV AY, 1994, J LEUKOCYTE BIOL, V55, P289, DOI 10.1002/jlb.55.3.289; TSYGANKOV AY, 1994, J BIOL CHEM, V269, P7792; Tsygankov AY, 2001, ONCOGENE, V20, P6382, DOI 10.1038/sj.onc.1204781; Wang HY, 2001, J BIOL CHEM, V276, P26004, DOI 10.1074/jbc.M010738200; Wang J, 2001, BIOTECHNIQUES, V31, P722, DOI 10.2144/01314bm01; Wang WX, 1999, CLIN CANCER RES, V5, P119; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Waterman H, 1998, J BIOL CHEM, V273, P13819, DOI 10.1074/jbc.273.22.13819; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; Wattenhofer M, 2001, HUM GENET, V108, P140, DOI 10.1007/s004390000453; Wilhelmsen K, 2002, ONCOGENE, V21, P1079, DOI 10.1038/sj.onc.1205166; Wilkinson CRM, 2001, NAT CELL BIOL, V3, P939, DOI 10.1038/ncb1001-939; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Yokouchi M, 2001, J BIOL CHEM, V276, P35185, DOI 10.1074/jbc.M102219200; Zhang XL, 1998, ANAL CHEM, V70, P2050, DOI 10.1021/ac971207m; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	72	64	65	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2004	23	27					4690	4706		10.1038/sj.onc.1207627	http://dx.doi.org/10.1038/sj.onc.1207627			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZX	15107835				2022-12-28	WOS:000221799200005
J	Rieger-Christ, KM; Lee, P; Zagha, R; Kosakowski, M; Moinzadeh, A; Stoffel, J; Ben-Ze'ev, A; Libertino, JA; Summerhayes, IC				Rieger-Christ, KM; Lee, P; Zagha, R; Kosakowski, M; Moinzadeh, A; Stoffel, J; Ben-Ze'ev, A; Libertino, JA; Summerhayes, IC			Novel expression of N-cadherin elicits in vitro bladder cell invasion via the Akt signaling pathway	ONCOGENE			English	Article						N-cadherin; bladder; invasion; Akt	CANCER CELLS; CARCINOMA-CELLS; PROTEIN-KINASE; HUMAN BREAST; PROGRESSION; PP60C-SRC; ADHESION; METASTASIS; ACTIVATION; MIGRATION	Novel N-cadherin expression has been linked to the invasive phenotype in bladder tumors yet a primary role for N-cadherin in invasion has not been defined in this model. To address this, N-cadherin was stably transfected into E-cadherin expressing bladder carcinoma cells. This resulted in an enhanced invasive capacity in in vitro assays that was blocked by incubation with an N-cadherin function-blocking antibody in a dose-dependent manner. Analysis of the signaling pathway(s) implicated in N-cadherin-mediated invasion in bladder carcinoma cell fines revealed no correlation between MAPK signaling and invasion, in the presence or absence of fibroblast growth factor 2. Also, while MAPK and p38 kinase inhibitors did not alter the invasive behavior of these cells, an increase in the phosphorylation of Akt at serine-473 was detected in N-cadherin transfectants, suggestive of N-cadherin-mediated Akt activation in bladder cell invasion. Incubation of N-cadherin transfectants with either PI3 kinase or Akt inhibitors resulted in a significant decrease in the invasive capacity of these cells. Exposure of cells to PP2, a src family kinase inhibitor, also decreased the invasive potential of N-cadherin transfectants and resulted in reduced phosphorylation of Akt. The involvement of Akt signaling in bladder cell invasion was also supported by the inhibition of bladder cell invasion by cells constitutively expressing an activated Akt kinase, using the PI3 kinase and Akt inhibitors and PP2. These results suggest that activation of PI3/AKT kinase following N-cadherin expression contributes to the increased invasive potential of bladder carcinoma cells.	RE Wise MD Res & Educ Inst, Cell & Mol Biol Lab, Burlington, MA 01805 USA; Lahey Clin Fdn, Dept Urol, Burlington, MA 01805 USA; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Lahey Hospital & Medical Center; Weizmann Institute of Science	Summerhayes, IC (corresponding author), Lahey Clin Fdn, Cell & Mol Biol Lab, 31 Mall Rdd, Burlington, MA 01805 USA.	ian.c.summerhayes@lahey.org	Stoffel, John T./X-1441-2019	Stoffel, John/0000-0002-5503-4940; ben-ze'ev, avri/0000-0001-6113-3921	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059400] Funding Source: NIH RePORTER; NIDDK NIH HHS [1DK59400] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arboleda MJ, 2003, CANCER RES, V63, P196; BRINGUIER PP, 1993, CANCER RES, V53, P3241; Bussemakers MJG, 2000, INT J CANCER, V85, P446, DOI 10.1002/(SICI)1097-0215(20000201)85:3<446::AID-IJC23>3.3.CO;2-2; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen RY, 2001, J BIOL CHEM, V276, P31858, DOI 10.1074/jbc.C100271200; FANNING P, 1992, CANCER RES, V52, P1457; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Gee J, 1998, MOL UROL, V2, P73; Giroldi LA, 1999, INT J CANCER, V82, P70, DOI 10.1002/(SICI)1097-0215(19990702)82:1<70::AID-IJC13>3.0.CO;2-#; Grille SJ, 2003, CANCER RES, V63, P2172; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Hazan RB, 1996, CELL ADHES COMMUN, V4, P399, DOI 10.3109/15419069709004457; HONG RL, 1995, J UROLOGY, V153, P2025, DOI 10.1016/S0022-5347(01)67395-6; Hsu MY, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P188; Islam S, 1996, J CELL BIOL, V135, P1643, DOI 10.1083/jcb.135.6.1643; Kawakita Mutsushi, 1994, Acta Urologica Japonica, V40, P1077; Kim D, 2001, FASEB J, V15, P1953, DOI 10.1096/fj.01-0198com; Levenberg S, 1998, J CELL SCI, V111, P347; Li G, 2001, CANCER RES, V61, P3819; LIPPONEN PK, 1995, J CANCER RES CLIN, V121, P303, DOI 10.1007/BF01209598; Lu YL, 2003, J BIOL CHEM, V278, P40057, DOI 10.1074/jbc.M303621200; Mialhe A, 1997, ANAL CELL PATHOL, V13, P125, DOI 10.1155/1997/246136; MIYAZAKI J, 1995, JPN J UROL, V86, P1208; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; Paez Juan, 2003, Cancer Treat Res, V115, P145; Rieger-Christ KM, 2001, HUM PATHOL, V32, P18, DOI 10.1053/hupa.2001.21140; Sanders DSA, 1999, J CLIN PATHOL-MOL PA, V52, P151, DOI 10.1136/mp.52.3.151; Sotsios Y, 2000, IMMUNOL REV, V177, P217, DOI 10.1034/j.1600-065X.2000.17712.x; Suyama K, 2002, CANCER CELL, V2, P301, DOI 10.1016/S1535-6108(02)00150-2; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Thant AA, 2001, CLIN EXP METASTAS, V18, P423, DOI 10.1023/A:1010921730952; Tomita K, 2000, CANCER RES, V60, P3650; Tran NL, 2002, J BIOL CHEM, V277, P32905, DOI 10.1074/jbc.M200300200; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wang DS, 2000, INT J CANCER, V88, P620, DOI 10.1002/1097-0215(20001115)88:4<620::AID-IJC16>3.0.CO;2-Z; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781	39	67	73	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2004	23	27					4745	4753		10.1038/sj.onc.1207629	http://dx.doi.org/10.1038/sj.onc.1207629			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZX	15122336				2022-12-28	WOS:000221799200009
J	Li, B; Yuan, M; Kim, IA; Chang, CM; Bernhard, EJ; Shu, HKG				Li, B; Yuan, M; Kim, IA; Chang, CM; Bernhard, EJ; Shu, HKG			Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin	ONCOGENE			English	Article						epidermal growth factor receptor; cell signaling; radioresistance; phosphatidylinositol-3 kinase; malignant glioma	HUMAN GLIOBLASTOMA CELLS; TUMOR-SUPPRESSOR; ANAPLASTIC ASTROCYTOMA; 3-KINASE/AKT PATHWAY; MALIGNANT GLIOMAS; CANCER-CELLS; GENE; PHOSPHATASE; RESISTANCE; ACTIVATION	Amplification and mutation of the epidermal growth factor receptor (EGFR) are common features of malignant gliomas. The most frequent mutation seen in these tumors involves deletion of exon 2-7 resulting in a constitutively active form of the receptor (EGFRvIII, or deltaEGFR). Since EGFRvIII is found primarily in gliomas and has not been reported in sarcomas, we compared the effects of this altered receptor in immortalized primary astrocytes and fibroblasts. While EGFRvIII displayed ligand-independent autophosphorylation in both cell types, downstream signaling differed. While EGFRvIII increased the proliferative capacity of both astrocytes and fibroblasts consistent with activation of ERK in these cells, EGFRvIII activated AKT only in the immortalized astrocytes. EGFRvIII expression in astrocytes also led to increased radioresistance in that cell type. Furthermore, specific inhibition of phosphotidylinositol-3 kinase (PI-3K) with LY294002 reverted the radioresistant phenotype in the immortalized astrocytes. Thus, selective activation of PI-3K/AKT in astrocytes expressing EGFRvIII appears to be responsible for the observed increase in radio resistance. EGFRvIII's differential ability to activate the PI-3K downstream signal may explain why this mutant receptor is such a prominent lesion in malignant gliomas but less often seen in other tumor types, even those where EGFR signaling has a prominent role.	Univ Penn, Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA	University of Pennsylvania	Shu, HKG (corresponding author), Univ Penn, Sch Med, Dept Radiat Oncol, John Morgan Bldg,Room 195,3620 Hamilton Walk, Philadelphia, PA 19104 USA.	shu@xrt.upenn.edu	BERNHARD, ERIC/HIU-0025-2022; Kim, In Ah/J-5426-2012	Shu, Hui-Kuo/0000-0002-4060-0874				Antonyak MA, 1998, J BIOL CHEM, V273, P2817, DOI 10.1074/jbc.273.5.2817; Brognard J, 2001, CANCER RES, V61, P3986; BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033; Chu CT, 1997, BIOCHEM J, V324, P855, DOI 10.1042/bj3240855; Davis FG, 1998, J NEUROSURG, V88, P1, DOI 10.3171/jns.1998.88.1.0001; Fernandes H, 2001, J BIOL CHEM, V276, P5375, DOI 10.1074/jbc.M005599200; FINE HA, 1993, CANCER, V71, P2585, DOI 10.1002/1097-0142(19930415)71:8<2585::AID-CNCR2820710825>3.0.CO;2-S; Gupta AK, 2001, CANCER RES, V61, P4278; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Holland EC, 1998, GENE DEV, V12, P3675, DOI 10.1101/gad.12.23.3675; HUMPHREY PA, 1990, P NATL ACAD SCI USA, V87, P4207, DOI 10.1073/pnas.87.11.4207; JUNGBLUTH AA, 2003, P NATL ACAD SCI USA, V6, P6; Klingler-Hoffmann M, 2003, INT J CANCER, V105, P331, DOI 10.1002/ijc.11085; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nagane M, 1996, CANCER RES, V56, P5079; Nagane M, 1998, P NATL ACAD SCI USA, V95, P5724, DOI 10.1073/pnas.95.10.5724; Narita Y, 2002, CANCER RES, V62, P6764; NELSON D F, 1988, NCI (National Cancer Institute) Monographs, P279; Rich JN, 2001, CANCER RES, V61, P3556; Sonoda Y, 2001, CANCER RES, V61, P4956; Sonoda Y, 2001, CANCER RES, V61, P6674; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tezuka M, 2001, CLIN CANCER RES, V7, P3206; Vermeulen K, 2003, CELL PROLIFERAT, V36, P165, DOI 10.1046/j.1365-2184.2003.00267.x; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587	33	129	138	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2004	23	26					4594	4602		10.1038/sj.onc.1207602	http://dx.doi.org/10.1038/sj.onc.1207602			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZV	15077177				2022-12-28	WOS:000221799000009
J	Hug, BA; Lazar, MA				Hug, BA; Lazar, MA			ETO interacting proteins	ONCOGENE			English	Article						ETO; MTG8; repression; corepressor; HDAC	ACUTE MYELOID-LEUKEMIA; HISTONE DEACETYLASE COMPLEX; N-COR; TRANSCRIPTIONAL REPRESSION; COREPRESSOR COMPLEX; FUSION TRANSCRIPT; RECEPTOR; SMRT; FAMILY; GENE	The 8; 21 translocation produces a fusion between the ETO gene and that encoding the myeloid transcription factor AML1. The AML1-ETO fusion substitutes the majority of the ETO protein for the coregulator recruitment domains of AML1. Biochemical analyses of ETO have led to the identification of numerous interacting proteins including many corepressors. Importantly, the proteins interacting with ETO are different from those of wild-type AML1, suggesting that altered coregulator recruitment underlies the oncogenic properties of AML1 - ETO. The list of corepressors capable of binding ETO includes histone deacetylases (HDACs) and components of distinct HDAC core complexes. These investigations have provided mechanistic insight into corepressor recruitment by ETO and clues to the leukemogenic activity of AML1 - ETO.	Univ Penn, Sch Med, Dept Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Penn Diabet Ctr, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Lazar, MA (corresponding author), Univ Penn, Sch Med, Dept Med, Div Endocrinol Diabet & Metab, 611 CRB,415 Curie Blvd, Philadelphia, PA 19104 USA.	brucehug@mail.med.upenn.edu; lazar@mail.med.upenn.edu	Lazar, Mitchell A/AAF-3738-2019		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL004339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK043806, R01DK045586, R01DK043806] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL004339] Funding Source: Medline; NIDDK NIH HHS [DK43806, DK45586] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Ansieau S, 2002, J BIOL CHEM, V277, P4906, DOI 10.1074/jbc.M110078200; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Davis JN, 2003, GENE, V303, P1, DOI 10.1016/S0378-1119(02)01172-1; Davis JN, 1999, ONCOGENE, V18, P1375, DOI 10.1038/sj.onc.1202412; Downing JR, 1999, BRIT J HAEMATOL, V106, P296, DOI 10.1046/j.1365-2141.1999.01377.x; ERICKSON PF, 1994, CANCER RES, V54, P1782; Espinas ML, 2000, EMBO REP, V1, P253, DOI 10.1093/embo-reports/kvd046; FEINSTEIN PG, 1995, GENETICS, V140, P573; Gamou T, 1998, BLOOD, V91, P4028, DOI 10.1182/blood.V91.11.4028.411a45_4028_4037; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Gottlieb PD, 2002, NAT GENET, V31, P25, DOI 10.1038/ng866; Gross CT, 1996, EMBO J, V15, P1961, DOI 10.1002/j.1460-2075.1996.tb00547.x; Guenther MG, 2000, GENE DEV, V14, P1048; Guenther MG, 2001, MOL CELL BIOL, V21, P6091, DOI 10.1128/MCB.21.18.6091-6101.2001; Hildebrand D, 2001, J BIOL CHEM, V276, P9889, DOI 10.1074/jbc.M010582200; Hug BA, 2002, CANCER RES, V62, P2906; Humphrey GW, 2001, J BIOL CHEM, V276, P6817, DOI 10.1074/jbc.M007372200; Hung HL, 1999, MOL CELL BIOL, V19, P3496; Hung HL, 2001, J BIOL CHEM, V276, P10715, DOI 10.1074/jbc.M007846200; Iizuka M, 2003, CURR OPIN GENET DEV, V13, P154, DOI 10.1016/S0959-437X(03)00020-0; Ishizuka T, 2003, MOL CELL BIOL, V23, P5122, DOI 10.1128/MCB.23.15.5122-5131.2003; Kitabayashi I, 1998, MOL CELL BIOL, V18, P846, DOI 10.1128/MCB.18.2.846; Kozu Tomoko, 1997, Leukemia (Basingstoke), V11, P297; Li H, 1997, MOL ENDOCRINOL, V11, P2025, DOI 10.1210/me.11.13.2025; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Li JW, 2002, GENE DEV, V16, P687, DOI 10.1101/gad.962502; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Lutterbach B, 1998, MOL CELL BIOL, V18, P3604, DOI 10.1128/MCB.18.6.3604; Melnick AM, 2000, MOL CELL BIOL, V20, P2075, DOI 10.1128/MCB.20.6.2075-2086.2000; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Morohoshi F, 2000, GENE, V241, P287, DOI 10.1016/S0378-1119(99)00481-3; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Odaka R, 2000, ONCOGENE, V19, P3584, DOI 10.1038/sj.onc.1203689; Parthun MR, 1996, CELL, V87, P85, DOI 10.1016/S0092-8674(00)81325-2; Soderstrom M, 1997, MOL ENDOCRINOL, V11, P682, DOI 10.1210/me.11.6.682; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wang L, 2002, GENE, V285, P119, DOI 10.1016/S0378-1119(02)00418-3; Wen YD, 2000, P NATL ACAD SCI USA, V97, P7202, DOI 10.1073/pnas.97.13.7202; Wolford JK, 1998, GENE, V212, P103, DOI 10.1016/S0378-1119(98)00141-3; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yoon HG, 2003, EMBO J, V22, P1336, DOI 10.1093/emboj/cdg120; You A, 2001, P NATL ACAD SCI USA, V98, P1454, DOI 10.1073/pnas.98.4.1454; Yu JJ, 2003, EMBO J, V22, P3403, DOI 10.1093/emboj/cdg326; Zhang JS, 2001, MOL CELL BIOL, V21, P156, DOI 10.1128/MCB.21.1.156-163.2001; Zhang JS, 2002, MOL CELL, V9, P611, DOI 10.1016/S1097-2765(02)00468-9; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; Zhang Y, 1998, MOL CELL, V1, P1021, DOI 10.1016/S1097-2765(00)80102-1	50	83	88	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 24	2004	23	24					4270	4274		10.1038/sj.onc.1207674	http://dx.doi.org/10.1038/sj.onc.1207674			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823BZ	15156183				2022-12-28	WOS:000221586000012
J	D'Assoro, AB; Busby, R; Suino, K; Delva, E; Almodovar-Mercado, GJ; Johnson, H; Folk, C; Farrugia, DJ; Vasile, V; Stivala, F; Salisbury, JL				D'Assoro, AB; Busby, R; Suino, K; Delva, E; Almodovar-Mercado, GJ; Johnson, H; Folk, C; Farrugia, DJ; Vasile, V; Stivala, F; Salisbury, JL			Genotoxic stress leads to centrosome amplification in breast cancer cell lines that have an inactive G1/S cell cycle checkpoint	ONCOGENE			English	Article						centrioles; cyclin; genomic instability; p53; retinoblastoma	GENOMIC INSTABILITY; S-PHASE; MUTANT P53; DNA-PLOIDY; EXPRESSION; KINASE; REPLICATION; DUPLICATION; INDUCTION; STABILITY	Centrosome amplification plays a key role in the origin of chromosomal instability during cancer development and progression. In this study, breast cancer cell lines with different p53 backgrounds were used to investigate the relationship between genotoxic stress, G(1)/S cell cycle checkpoint integrity, and the development of centrosome amplification. Introduction of DNA damage in the MCF-7 cell line by treatment with hydroxyurea (HU) or daunorubicin (DR) resulted in the arrest of both G(1)/S cell cycle progression and centriole duplication. In these cells, which carry functional p53, HU treatment also led to nuclear accumulation of p53 and p21(WAF1), retinoblastoma hypophosphorylation, and downregulation of cyclin A. MCF-7 cells carrying a recombinant dominant-negative p53 mutant (vMCF-7(DNp53)) exhibited a shortened G(1) phase of the cell cycle and retained a normal centrosome phenotype. However, these cells developed amplified centrosomes following HU treatment. The MDA-MB 231 cell line, which carries mutant p53 at both alleles, showed amplified centrosomes at the outset, and developed a hyperamplified centrosome phenotype following HU treatment. In cells carrying defective p53, the development of centrosome amplification also occurred following treatment with another DNA damaging agent, DR. Taken together, these findings demonstrate that loss of p53 function alone is not sufficient to drive centrosome amplification, but plays a critical role in this process following DNA damage through abrogation of the G(1)/S cell cycle checkpoint. Furthermore, these studies have important clinical implications because they suggest that breast cancers with compromised p53 function may develop centrosome amplification and consequent chromosomal instability following treatment with genotoxic anticancer drugs.	Mayo Clin Coll Med, Tumor Biol Program, Rochester, MN 55905 USA	Mayo Clinic	Salisbury, JL (corresponding author), Mayo Clin Coll Med, Tumor Biol Program, 200 1st St SW, Rochester, MN 55905 USA.	Salisbury@mayo.edu	Farrugia, Daniel/E-4752-2015	Salisbury, Jeffrey/0000-0001-9257-4578	NATIONAL CANCER INSTITUTE [R01CA072836] Funding Source: NIH RePORTER; NCI NIH HHS [CA72836] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANBAZHAGAN R, 1991, ANN ONCOL, V2, P47, DOI 10.1093/oxfordjournals.annonc.a057824; Angus SP, 2002, EXP CELL RES, V276, P201, DOI 10.1006/excr.2002.5510; BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Borel F, 2002, P NATL ACAD SCI USA, V99, P9819, DOI 10.1073/pnas.152205299; Brinkley BR, 2001, TRENDS CELL BIOL, V11, P18, DOI 10.1016/S0962-8924(00)01872-9; D'Assoro AB, 2002, ONCOGENE, V21, P6146, DOI 10.1038/sj.onc.1205772; D'Assoro AB, 2002, BREAST CANCER RES TR, V75, P25, DOI 10.1023/A:1016550619925; Duensing S, 2003, CRIT REV EUKAR GENE, V13, P9, DOI 10.1615/CritRevEukaryotGeneExpr.v13.i1.20; Duensing S, 2002, CANCER RES, V62, P7075; Faivre J, 2002, ONCOGENE, V21, P1493, DOI 10.1038/sj.onc.1205215; Fry AM, 1999, J BIOL CHEM, V274, P16304, DOI 10.1074/jbc.274.23.16304; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Gartel AL, 2003, ONCOL RES, V13, P405; Goepfert TM, 2002, CANCER RES, V62, P4115; Gunther T, 1997, J CANCER RES CLIN, V123, P388, DOI 10.1007/s004320050076; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Jin SK, 2001, J CELL SCI, V114, P4139; KELLOGG DR, 1989, NATURE, V340, P99, DOI 10.1038/340099a0; Khong HT, 2002, NAT IMMUNOL, V3, P999, DOI 10.1038/ni1102-999; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; Kramer A, 2002, LEUKEMIA, V16, P767, DOI 10.1038/sj.leu.2402454; Kronenwett U, 2003, BMC CELL BIOL, V4, DOI 10.1186/1471-2121-4-8; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Lingle WL, 1999, AM J PATHOL, V155, P1941, DOI 10.1016/S0002-9440(10)65513-7; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Loeb LA, 2001, CANCER RES, V61, P3230; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Mgbonyebi OP, 1999, CANCER RES, V59, P1903; Murphy KL, 2000, ONCOGENE, V19, P1045, DOI 10.1038/sj.onc.1203274; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; Okuda M, 2002, ONCOGENE, V21, P6170, DOI 10.1038/sj.onc.1205708; Palazzo RE, 2003, CELL MOTIL CYTOSKEL, V54, P148, DOI 10.1002/cm.10103; Pihan GA, 2001, CANCER RES, V61, P2212; Pihan GA, 2003, CANCER RES, V63, P1398; Pinto AE, 2003, INT J BIOL MARKER, V18, P7, DOI 10.1177/172460080301800102; Riley RR, 2003, CANCER RES, V63, P4862; RUBIN EH, 2003, CANC MED, V6, P781; Sakano K, 2001, JPN J CANCER RES, V92, P1166, DOI 10.1111/j.1349-7006.2001.tb02136.x; Senderowicz AM, 2003, ONCOGENE, V22, P6609, DOI 10.1038/sj.onc.1206954; Sluder G, 2000, CURR TOP DEV BIOL, V49, P267; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Tarapore P, 2001, ONCOGENE, V20, P3173, DOI 10.1038/sj.onc.1204424; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; WENGER CR, 1993, BREAST CANCER RES TR, V28, P9, DOI 10.1007/BF00666351	51	59	61	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4068	4075		10.1038/sj.onc.1207568	http://dx.doi.org/10.1038/sj.onc.1207568			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15064746				2022-12-28	WOS:000221520200004
J	Zhang, ZQ; Wang, Y; Yao, RS; Li, J; Yan, Y; La Regina, M; Lemon, WL; Grubbs, CL; Lubet, RA; You, M				Zhang, ZQ; Wang, Y; Yao, RS; Li, J; Yan, Y; La Regina, M; Lemon, WL; Grubbs, CL; Lubet, RA; You, M			Cancer chemopreventive activity of a mixture of Chinese herbs (antitumor B) in mouse lung tumor models	ONCOGENE			English	Article						antitumor B; lung cancer; chemoprevention; A/J mice; transgenic mice; p53; Ink4a/Arf	BREAST-CANCER CELLS; FEMALE A/J MICE; BETA-SITOSTEROL; ALPHA-SUBUNITS; G13 PROTEINS; GREEN TEA; TUMORIGENESIS; CARCINOGENESIS; PHYTOSTEROLS; INHIBITION	Antitumor B (ATB), also known as Zeng Sheng Ping, is a Chinese herbal mixture composed of six plants. Previously, clinical studies have shown a significant chemopreventive efficacy of ATB against human esophageal and lung cancers. In the present study, A/J mice harboring a dominant-negative p53 and/or heterozygous deletion of Ink4a/Arf and treated with benzo[a] pyrene were used to investigate the chemopreventive effects of ATB on chemically induced lung tumorigenesis. Mice with various genotypes treated with ATB displayed a significant reduction in lung tumor multiplicity and tumor load. Treatment with ATB resulted in an approximately 40% decrease in tumor multiplicity and a 70% decrease in tumor load in both wild-type mice and in mice with a loss of the Ink4a/Arf tumor suppressor genes. Interestingly, ATB decreased tumor multiplicity and volume by 50 and 90%, respectively, in mice with a dominant-negative p53 and in mice with both a p53 mutation and deletion of Ink4a/Arf. Kras2 mutation analysis of the lung tumors revealed that tumors harbored mutations in the 12th codon of Kras2. There were no differences in either the incidence or types of mutations between tumors treated with or without ATB. Oligonucleotide array analysis revealed 284 genes that were differentially expressed in mouse lung tumors as compared to the normal lung, and it was found that 114 out of these 284 genes changed their expression toward the normal levels in tumors treated with ATB. Most of the genes modulated by ATB belong to several cellular signaling pathways, including Notch (Notch homolog 2, manic fringe homolog), growth factor (FGF intracellular-binding protein, PDGFalpha), G protein-Ras-MAPK (MAPK3, MAP3K4, rab3A, Rap1, RSG5, PKCh), ubiquitin- proteasome (CDC34, Cullin1, 26S proteasome), and apoptosis (BAD promoter, caspase 3). These results suggest that ATB is an effective chemopreventive against mouse lung tumorigenesis. Furthermore, ATB exhibited an enhanced inhibitory effect in animals harboring genetic alterations (Kras2, p53, and Ink4a/Arf), which are often seen in human lung adenocarcinomas.	Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Alvin J Siteman Canc Ctr, St Louis, MO 63110 USA; Washington Univ, Sch Med, Div Comparat Med, St Louis, MO 63110 USA; Univ Alabama, Chemoprevent Ctr, Dept Surg, Birmingham, AL 35295 USA; NCI, Chemoprevent Branch, Bethesda, MD 20892 USA	Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL); Washington University (WUSTL); University of Alabama System; University of Alabama Birmingham; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	You, M (corresponding author), Washington Univ, Sch Med, Dept Surg, Campus Box 8109,660 S Euclid Ave, St Louis, MO 63110 USA.	youm@msnotes.wustl.edu						Awad AB, 2001, NUTR CANCER, V40, P157, DOI 10.1207/S15327914NC402_12; Awad AB, 2000, J NUTR, V130, P2127, DOI 10.1093/jn/130.9.2127; Awad AB, 2000, ANTICANCER RES, V20, P821; Awad AB, 2000, NUTR CANCER, V36, P74, DOI 10.1207/S15327914NC3601_11; Awad AB, 2000, INT J MOL MED, V5, P541; Berestetskaya YV, 1998, J BIOL CHEM, V273, P27816, DOI 10.1074/jbc.273.43.27816; Castonguay A, 1998, EXP LUNG RES, V24, P605, DOI 10.3109/01902149809087389; Dahlquist KD, 2002, NAT GENET, V31, P19, DOI 10.1038/ng0502-19; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fan X, 1993, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V15, P71; Hansen H H, 1999, Cancer Chemother Biol Response Modif, V18, P336; LIN P, 1990, Proceedings of the Chinese Academy of Medical Sciences and the Peking Union Medical College, V5, P121; Markel P, 1997, NAT GENET, V17, P280, DOI 10.1038/ng1197-280; Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2; Minna JD, 1989, CANCER PRINCIPLES PR, P591; MORSE MA, 1991, CANCER RES, V51, P1846; RAICHT RF, 1980, CANCER RES, V40, P403; RAO AV, 1992, NUTR CANCER, V18, P43, DOI 10.1080/01635589209514203; SHI ST, 1994, CANCER RES, V54, P4641; von Holtz RL, 1998, NUTR CANCER, V32, P8, DOI 10.1080/01635589809514709; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Wang Y, 2003, CANCER RES, V63, P4389; Wattenberg LW, 1996, CANCER RES, V56, P5132; Wattenberg LW, 1997, CARCINOGENESIS, V18, P2015, DOI 10.1093/carcin/18.10.2015; You M, 1998, HEMATOL ONCOL CLIN N, V12, P1037, DOI 10.1016/S0889-8588(05)70040-X; Zhang ZQ, 2003, ONCOGENE, V22, P6257, DOI 10.1038/sj.onc.1206630; Zhang ZQ, 2000, CANCER RES, V60, P901; Zhang ZQ, 2002, ONCOGENE, V21, P5960, DOI 10.1038/sj.onc.1205725	29	49	51	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2004	23	21					3841	3850		10.1038/sj.onc.1207496	http://dx.doi.org/10.1038/sj.onc.1207496			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	818JX	15021904				2022-12-28	WOS:000221242500011
J	Yan, J; Yu, YL; Wang, N; Chang, YC; Ying, H; Liu, WZ; He, J; Li, SQ; Jiang, WL; Li, YL; Liu, HM; Wang, HY; Xu, YH				Yan, J; Yu, YL; Wang, N; Chang, YC; Ying, H; Liu, WZ; He, J; Li, SQ; Jiang, WL; Li, YL; Liu, HM; Wang, HY; Xu, YH			LFIRE-1/HFREP-1, a liver-specific gene, is frequently downregulated and has growth suppressor activity in hepatocellular carcinoma	ONCOGENE			English	Article						hepatocellular carcinoma (HCC); 8p22; fibrinogen-related domain; liver-specific expression; differentiation	CANCER EPIGENETICS; CHROMOSOME 8P; CLONING; PROGRESSION; STAGE; ARM	We have previously identified several novel genes, which are differentially expressed among human normal liver and hepatocellular carcinomas (HCCs). The full-length liver fibrinogen-related gene-1 (LFIRE-1) cDNA was cloned from the human normal liver cDNA library. LFIRE-1 is highly homologous to HFREP-1 with discrepancy at 50 untranslated region (UTR) and encodes the same fibrinogen-related protein, which suggest that these two sequences might be alternative splicing forms of the same gene, LFIRE-1/HFREP-1, located at human chromosome 8p22. The LFIRE-1 and HFREP-1 are specifically expressed in normal human liver tissue, but reduced or undetectable in most of HCC specimens at both RNA and protein level. Furthermore, the reduction or nonexpression of LFIRE-1/HFREP-1 is significantly associated with the degree of tumor differentiation. Loss of heterozygosity (LOH) analysis revealed allelic loss of LFIRE-1/HFREP-1 on chromosome 8p22 in 57.1% (24/42) of HCC specimens. We detected three inactivation mutations among 45 cases of HCC specimens examined, two of which lost the remaining allele and the third had a replacement of conserved cysteine residue with glycine residue. Notably, the downregulation of LFIRE-1/HFREP-1 expression is frequently associated with allelic loss. The reduction of LFIRE-1/HFREP-1 expression by antisense approach enhances cancer cell proliferation and colony formation in soft agar. Moreover, restoration of exogenous wild-type LFIRE-1/HFREP-1 expression but not LFIRE-1/HFREP-1 missense mutations in human HCC cells inhibited their anchorage-dependent or independent growth in vitro, and suppressed their tumorigenicity in nude mice. In conclusion, our data demonstrated that liver-specific gene LFIRE-1/HFREP-1 was frequently downregulated and might possess growth suppressor activity in HCC.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Lab Mol & Cellular Oncol, Shanghai 200031, Peoples R China; Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Mol Cell Biol Lab, Shanghai 200031, Peoples R China; Second Mil Med Univ, Changzheng Hosp, Shanghai, Peoples R China; Eastern Hepatobiliary Surg Hosp, Int Cooperat Lab Signal Transduct, Shanghai, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Naval Medical University; Naval Medical University	Xu, YH (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Lab Mol & Cellular Oncol, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.	yhxu@sunm.shcnc.ac.cn	Yan, Jun/Q-3031-2017	Yan, Jun/0000-0002-1303-1952				ALTSCHUL SF, 1994, NAT GENET, V6, P119, DOI 10.1038/ng0294-119; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; Chan KL, 2002, CANCER, V94, P3179, DOI 10.1002/cncr.10612; Chang Y C, 2001, Shi Yan Sheng Wu Xue Bao, V34, P319; CHEN CJ, 1997, J GASTROEN HEPATOL, V12, P294; CHEN R, 1980, SCI SINICA, V23, P236; COLOMBO M, 1992, J HEPATOL, V15, P225, DOI 10.1016/0168-8278(92)90041-M; EMI M, 1993, GENE CHROMOSOME CANC, V7, P152, DOI 10.1002/gcc.2870070307; FARRELL DH, 1994, J BIOL CHEM, V269, P226; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Feinberg AP, 2001, P NATL ACAD SCI USA, V98, P392, DOI 10.1073/pnas.98.2.392; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HAYDON GH, 1995, BRIT J HOSP MED, V53, P74; Hermann S, 2001, INT J CANCER, V92, P805, DOI 10.1002/ijc.1284; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KUROKI T, 1995, GENE CHROMOSOME CANC, V13, P163, DOI 10.1002/gcc.2870130305; Mironov AA, 1999, GENOME RES, V9, P1288, DOI 10.1101/gr.9.12.1288; Modrek B, 2002, NAT GENET, V30, P13, DOI 10.1038/ng0102-13; Nagai H, 1998, HEPATITIS B VIRUS, P182; Pineau P, 1999, ONCOGENE, V18, P3127, DOI 10.1038/sj.onc.1202648; Procopio WN, 1999, J BIOL CHEM, V274, P30196, DOI 10.1074/jbc.274.42.30196; Qiang S, 1997, INT J ARTIF ORGANS, V20, P119, DOI 10.1177/039139889702000213; Qin LX, 1999, CANCER RES, V59, P5662; Sherman M, 1995, Gastroenterologist, V3, P55; YAMAMOTO T, 1993, BIOCHEM BIOPH RES CO, V193, P681, DOI 10.1006/bbrc.1993.1678; Yan J, 2002, CELL RES, V12, P353, DOI 10.1038/sj.cr.7290137; Ying H, 2001, ONCOL RES, V12, P485, DOI 10.3727/096504001108747495; Ying H, 2001, BIOCHEM BIOPH RES CO, V286, P394, DOI 10.1006/bbrc.2001.5390; ZHU H, 1981, ZHONGHUA ZHONGLIU ZA, V3, P241	32	45	49	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	2004	23	10					1939	1949		10.1038/sj.onc.1207306	http://dx.doi.org/10.1038/sj.onc.1207306			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	801XV	14981537				2022-12-28	WOS:000220129500016
J	Ramirez, CJ; Fleming, MA; Potter, JD; Ostrander, GK; Ostrander, EA				Ramirez, CJ; Fleming, MA; Potter, JD; Ostrander, GK; Ostrander, EA			Marsupial BRCA1: conserved regions in mammals and the potential effect of missense changes	ONCOGENE			English	Article						breast cancer; comparative analysis; exon 11; gene evolution; missense; phylogenetics	OVARIAN-CANCER FAMILIES; SPONTANEOUS PROLIFERATIONS; AUSTRALIAN MARSUPIALS; INFORMATION CORE; MUTATIONS; BREAST; GENE; SEQUENCES; FREQUENCY; EVOLUTION	More than half of the reported missense changes in the breast cancer susceptibility protein BRCA1 occur in exon 11, but none has been clearly identified as disease associated and only 28 are designated 'probable' neutral polymorphisms. Previously, in a comparison of sequences from 57 eutherian mammal species, we found seven 'highly conserved regions' between amino acids 282 and 1103, and identified 38 missense changes as likely to disrupt gene function. These conserved regions were also present in birds and amphibians and included only six of the mutations predicted to affect function. In this new analysis, we hypothesized that using 37 ancestral sequences derived from the 57 GenBank sequences and including eight marsupial sequences would allow us to identify regions unique to mammals and re. ne our predictions of disease-associated missense changes. We identified 13 conserved regions, three of which appear to be unique to mammals, and 21 likely disease-associated missense changes, 11 of which occur in conserved regions. Seven regions identified in this analysis, including the three found only in mammalian sequences, and nine missense changes predicted to affect function are in the putative STAT1-interaction domain, suggesting that the role of STAT1 in immune response is important to mammary function. The reduction in the number of missense changes predicted to be disease associated and the identification of conserved regions specific to mammals can facilitate the further study of the role of missense changes in BRCA1-associated breast cancers.	Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA; Univ Washington, Dept Mol & Cellular Biol, Seattle, WA 98195 USA; Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA; Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Johns Hopkins Univ, Dept Comparat Med, Baltimore, MD 21218 USA	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; Johns Hopkins University; Johns Hopkins University	Ostrander, EA (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave N,D4-100, Seattle, WA 98109 USA.	eostrand@fhcrc.org		Potter, John/0000-0001-5439-1500; Ostrander, Elaine/0000-0001-6075-9738	NATIONAL CANCER INSTITUTE [K05CA090754, U24CA078164] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [T32HG000035] Funding Source: NIH RePORTER; NCI NIH HHS [U24 CA-78164, K05 CA-90754-01] Funding Source: Medline; NHGRI NIH HHS [T32-HG00035] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759; Brown JR, 2001, NAT GENET, V28, P281, DOI 10.1038/90129; Brzovic PS, 2001, J BIOL CHEM, V276, P41399, DOI 10.1074/jbc.M106551200; CANFIELD PJ, 1990, J COMP PATHOL, V103, P147, DOI 10.1016/S0021-9975(08)80171-5; CANFIELD PJ, 1990, J COMP PATHOL, V103, P135, DOI 10.1016/S0021-9975(08)80170-3; Casey H W, 1979, Recent Results Cancer Res, V66, P129; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; Chapman MA, 2003, GENOMICS, V81, P249, DOI 10.1016/S0888-7543(03)00005-3; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; Durocher F, 1996, HUM MOL GENET, V5, P835, DOI 10.1093/hmg/5.6.835; Fabbro M, 2002, J BIOL CHEM, V277, P21315, DOI 10.1074/jbc.M200769200; Findlay L., 1984, Symposia of the Zoological Society of London, P403; Fleming MA, 2003, P NATL ACAD SCI USA, V100, P1151, DOI 10.1073/pnas.0237285100; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; Ganesh S, 2001, BIOCHEM BIOPH RES CO, V283, P1046, DOI 10.1006/bbrc.2001.4914; GONNET GH, 1992, SCIENCE, V256, P1443, DOI 10.1126/science.1604319; Hamilton J M, 1974, Adv Cancer Res, V19, P1, DOI 10.1016/S0065-230X(08)60051-2; Huber LJ, 2001, MOL CELL BIOL, V21, P4005, DOI 10.1128/MCB.21.12.4005-4015.2001; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Huttley GA, 2000, NAT GENET, V25, P410, DOI 10.1038/78092; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; KNIGHT CH, 1984, PHYSL STRATEGIES LAC, V51, P147; KOEBERL DD, 1990, AM J HUM GENET, V47, P202; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; Lee WH, 2001, LANCET, pS5, DOI 10.1016/S0140-6736(01)07018-0; MADDISON DR, 2001, MACCLADE 4 ANAL PHYL; Malone KE, 2000, CANCER, V88, P1393, DOI 10.1002/(SICI)1097-0142(20000315)88:6<1393::AID-CNCR17>3.0.CO;2-P; Misdorp W, 1996, VET QUART, V18, P32, DOI 10.1080/01652176.1996.9694610; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Newman B, 1998, JAMA-J AM MED ASSOC, V279, P915, DOI 10.1001/jama.279.12.915; Nielsen R, 1998, GENETICS, V148, P929; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817; Rose TM, 1998, NUCLEIC ACIDS RES, V26, P1628, DOI 10.1093/nar/26.7.1628; Shen DJ, 1999, ONCOL RES, V11, P63; SIEGEL S., 1956, NONPARAMETRIC STAT B; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; Sokal R.R., 2012, BIOMETRY; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; STRAUBE EF, 1980, J COMP PATHOL, V90, P495, DOI 10.1016/0021-9975(80)90020-1; SWOFFORD DL, 1998, PAUP ASTERISK PHYLOG; Szabo C, 2000, HUM MUTAT, V16, P123, DOI 10.1002/1098-1004(200008)16:2<123::AID-HUMU4>3.0.CO;2-Y; TYNDALEBISCOE CH, 1984, PHYSL STRATEGIES LAC, V51, P389; Vail DM, 2000, CANCER INVEST, V18, P781, DOI 10.3109/07357900009012210; Vallon-Christersson J, 2001, HUM MOL GENET, V10, P353, DOI 10.1093/hmg/10.4.353; Venkitaraman AR, 2001, J CELL SCI, V114, P3591; Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705	47	15	15	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2004	23	9					1780	1788		10.1038/sj.onc.1207292	http://dx.doi.org/10.1038/sj.onc.1207292			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	800LH	15001988				2022-12-28	WOS:000220029300013
J	Wang, D; Shen, Q; Chen, YQ; Wang, MH				Wang, D; Shen, Q; Chen, YQ; Wang, MH			Collaborative activities of macrophage-stimulating protein and transforming growth factor-beta 1 in induction of epithelial to mesenchymal transition: roles of the RON receptor tyrosine kinase	ONCOGENE			English	Article						receptor tyrosine kinases; transforming-growth factor; epithelial-mesenchymal transitions; signal transduction	GROWTH-FACTOR-BETA; TRANSCRIPTION FACTOR SNAIL; FACTOR SCATTER FACTOR; E-CADHERIN; SIGNAL-TRANSDUCTION; CELL PLASTICITY; GENE; METASTASIS; RAS; EXPRESSION	Epithelial to mesenchymal transition (EMT) is a process occurring during embryonic development and cancer progression. Using recepteur d'origine nantais (RON)expressing epithelial cells as a model, we showed that RON activation causes spindle-shaped morphology with increased cell motilities. These activities resemble those observed in EMT induced by transforming growth factor (TGF)-beta1 or by Ras-Raf signaling. By immunofluorescent and Western blot analyses, we found that constitutive RON expression results in diminished expression of E-cadherin, redistribution of beta-catenin, reorganization of actin cytoskeleton, and increased expression of vimentin, a mesenchymal. lament. RON expression is also essential for TGF-beta1-induced expression of alpha-smooth muscle actin (alpha-SMA), a specialized mesenchymal marker. In the study of signaling pathways responsible for RON-mediated EMT, it was found that PD98059, a MAP kinase inhibitor, blocks the collaborative activities of RON and TGF-beta1 in induction of alpha-SMA expression and restores epithelial cells to their original morphology. Moreover, we showed that RON expression increases Smad2 gene promoter activities and protein expression, which significantly lowers TGF-beta1 threshold for EMT induction. These results suggest that persistent RON expression and activation cause the loss of epithelial phenotypes. These changes, collaborating with TGF-beta1 signaling, could play a critical role in epithelial transdifferentiation towards invasiveness and metastasis of certain cancers.	UCHSC, Dept Med, Denver Hlth Med Ctr, Denver, CO 80204 USA; Zhejiang Univ, Lab Chang Jiang Scholar Endowment Biomed Sci, Inst Infect Dis, Sch Med, Hangzhou 310027, Zhejiang, Peoples R China; Zhejiang Univ, Affiliated Hosp 1, Sch Med, Hangzhou 310027, Zhejiang, Peoples R China; Univ Colorado, Sch Med, Dept Med, Ctr Canc, Denver, CO USA	Denver Health Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus; Zhejiang University; Zhejiang University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Wang, MH (corresponding author), UCHSC, Dept Med, Denver Hlth Med Ctr, 777 Bannock St,Mail 4000, Denver, CO 80204 USA.	ming-hai.wang@uchsc.edu			NCI NIH HHS [R01 CA91890] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Beavon IRG, 2000, EUR J CANCER, V36, P1607, DOI 10.1016/S0959-8049(00)00158-1; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Boyer B, 2000, BIOCHEM PHARMACOL, V60, P1091, DOI 10.1016/S0006-2952(00)00427-5; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Cavallaro U, 2001, BBA-REV CANCER, V1552, P39, DOI 10.1016/S0304-419X(01)00038-5; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Comoglio PM, 1999, EXP CELL RES, V253, P88, DOI 10.1006/excr.1999.4684; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; Ellenrieder V, 2001, CANCER RES, V61, P4222; Elliott BE, 2002, CAN J PHYSIOL PHARM, V80, P91, DOI 10.1139/y02-010; Fujimoto K, 2001, EXP CELL RES, V266, P239, DOI 10.1006/excr.2000.5229; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; Gherardi E, 1997, CIBA F SYMP, V212, P24; Gilles C, 2003, CANCER RES, V63, P2658; Grande M, 2002, J CELL SCI, V115, P4227, DOI 10.1242/jcs.00091; Grille SJ, 2003, CANCER RES, V63, P2172; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Lamorte L, 2002, MOL BIOL CELL, V13, P1449, DOI 10.1091/mbc.01-10-0477; Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700; LI BQ, 1995, BIOCHEM BIOPH RES CO, V216, P110, DOI 10.1006/bbrc.1995.2598; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; Masszi A, 2003, AM J PHYSIOL-RENAL, V284, pF911, DOI 10.1152/ajprenal.00183.2002; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; Muraoka RS, 2002, J CLIN INVEST, V109, P1551, DOI 10.1172/JCI200215234; Nicolas FJ, 2003, J BIOL CHEM, V278, P3251, DOI 10.1074/jbc.M209019200; Oft M, 2002, NAT CELL BIOL, V4, P487, DOI 10.1038/ncb807; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Piek E, 1999, J CELL SCI, V112, P4557; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; RONSIN C, 1993, ONCOGENE, V8, P1195; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; Ruiz P, 1996, WORLD J UROL, V14, P141; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; Santoro MM, 1998, ONCOGENE, V17, P741, DOI 10.1038/sj.onc.1201994; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Serini G, 1999, EXP CELL RES, V250, P273, DOI 10.1006/excr.1999.4543; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; Takenoshita S, 1998, GENOMICS, V48, P1, DOI 10.1006/geno.1997.5149; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thiery JP, 1999, CANCER METAST REV, V18, P31, DOI 10.1023/A:1006256219004; Vleminckx K, 1999, BIOESSAYS, V21, P211, DOI 10.1002/(SICI)1521-1878(199903)21:3<211::AID-BIES5>3.3.CO;2-G; Wang MH, 1996, ONCOGENE, V13, P2167; Wang MH, 2003, CARCINOGENESIS, V24, P1291, DOI 10.1093/carcin/bgg089; Wang MH, 1996, EXP CELL RES, V226, P39, DOI 10.1006/excr.1996.0200; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; Yang YA, 2002, J CLIN INVEST, V109, P1607, DOI 10.1172/JCI200215333; Yue JB, 2001, PHARMACOL THERAPEUT, V91, P1, DOI 10.1016/S0163-7258(01)00143-7; Zhou YQ, 2002, J BIOL CHEM, V277, P38104, DOI 10.1074/jbc.M206167200; Zhou YQ, 2003, ONCOGENE, V22, P186, DOI 10.1038/sj.onc.1206075	53	72	78	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2004	23	9					1668	1680		10.1038/sj.onc.1207282	http://dx.doi.org/10.1038/sj.onc.1207282			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	800LH	15001985				2022-12-28	WOS:000220029300003
J	Phelps, CB; Ghosh, G				Phelps, CB; Ghosh, G			Discreet mutations from c-Rel to v-Rel alter kappa B DNA recognition, I kappa B alpha binding, and dimerization: implications for v-Rel oncogenicity	ONCOGENE			English	Article						DNA binding; v-Rel; NF-kappa B; I kappa B alpha; fluorescence; anisotropy	VIRUS STRAIN-T; CHICKEN-EMBRYO FIBROBLASTS; RAY CRYSTAL-STRUCTURE; CASEIN KINASE-II; GENE-EXPRESSION; SPLEEN-CELLS; MALIGNANT-TRANSFORMATION; P50/P65 HETERODIMER; CELLULAR HOMOLOG; IMMUNE-SYSTEM	The avian Rev-T retrovirus encodes the oncoprotein v-Rel, a member of the Rel/nuclear factor (NF)-kappaB transcription factor family. The aggressive oncogenic potential of v-Rel has arisen from multiple mutations within the coding sequence of the avian cellular protein c-Rel. In this study, using quantitative biochemical experiments, we have tested the role of a limited set of alterations between v-Rel and c-Rel located within the Rel homology region (RHR) of the family that might confer functional differences. Our results show that only a set of six mutations within the RHR of v-Rel are responsible for its ability to bind to a broad spectrum of kappaB-DNA that are normally regulated by distinct NF-kappaB dimers. We also observe that both v-Rel homodimer and p50/v-Rel heterodimer bind IkappaBalpha weakly compared to other cellular Rel/NF-kappaB dimers with transcription activation potential. We suggest that the ability of v-Rel homodimer to deregulate subunit-specific gene expression and its ability to evade IkappaB inhibition are crucial to its strong oncogenic potential.	Univ Calif San Diego, Dept Chem & Biochem, San Diego, CA 92103 USA	University of California System; University of California San Diego	Ghosh, G (corresponding author), 9500 Gilman Dr,MC 0359, La Jolla, CA 92093 USA.	gghosh@ucsd.edu						Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; Berkowitz B, 2002, J BIOL CHEM, V277, P24694, DOI 10.1074/jbc.M200006200; Bharti AC, 2002, BIOCHEM PHARMACOL, V64, P883, DOI 10.1016/S0006-2952(02)01154-1; CAPOBIANCO AJ, 1992, J VIROL, V66, P3758, DOI 10.1128/JVI.66.6.3758-3767.1992; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Chen CL, 1999, MOL CELL BIOL, V19, P307; Chen FE, 1999, PROTEIN ENG, V12, P423, DOI 10.1093/protein/12.5.423; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen FE, 1999, ONCOGENE, V18, P6845, DOI 10.1038/sj.onc.1203224; Chen YQ, 1998, NAT STRUCT BIOL, V5, P67, DOI 10.1038/nsb0198-67; Chen YQ, 2000, STRUCT FOLD DES, V8, P419, DOI 10.1016/S0969-2126(00)00123-4; CHENG Q, 1994, J BIOL CHEM, V269, P13551; Cramer P, 1997, EMBO J, V16, P7078, DOI 10.1093/emboj/16.23.7078; DAVIS N, 1990, J VIROL, V64, P584, DOI 10.1128/JVI.64.2.584-591.1990; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; Epinat JC, 2000, ONCOGENE, V19, P599, DOI 10.1038/sj.onc.1203376; Epinat JC, 2000, ONCOGENE, V19, P3131, DOI 10.1038/sj.onc.1203651; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; Grumont RJ, 2000, J EXP MED, V191, P1281, DOI 10.1084/jem.191.8.1281; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HANNINK M, 1990, ONCOGENE, V5, P1843; Heckman CA, 2002, ONCOGENE, V21, P3898, DOI 10.1038/sj.onc.1205483; HRDLICKOVA R, 1995, J VIROL, V69, P403; Hrdlickova R, 2001, MOL CELL BIOL, V21, P6369; Huang DB, 2001, STRUCTURE, V9, P669, DOI 10.1016/S0969-2126(01)00635-9; Huxford T, 2000, J BIOL CHEM, V275, P32800, DOI 10.1074/jbc.M006037200; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Kralova J, 1998, MOL CELL BIOL, V18, P2997, DOI 10.1128/MCB.18.5.2997; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Liss AS, 2002, J VIROL, V76, P4928, DOI 10.1128/JVI.76.10.4928-4939.2002; Malek S, 1998, J BIOL CHEM, V273, P25427, DOI 10.1074/jbc.273.39.25427; Malek S, 2001, J BIOL CHEM, V276, P45225, DOI 10.1074/jbc.M105865200; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; MORRISON LE, 1992, ONCOGENE, V7, P1137; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; Nehyba J, 1997, ONCOGENE, V14, P2881, DOI 10.1038/sj.onc.1201150; Perkins ND, 1997, INT J BIOCHEM CELL B, V29, P1433, DOI 10.1016/S1357-2725(97)00088-5; Petrenko O, 1997, ONCOGENE, V15, P1671, DOI 10.1038/sj.onc.1201334; Phelps CB, 2000, J BIOL CHEM, V275, P29840, DOI 10.1074/jbc.M004899200; Phelps CB, 2000, J BIOL CHEM, V275, P24392, DOI 10.1074/jbc.M003784200; Rayet B, 2003, MOL CELL BIOL, V23, P1520, DOI 10.1128/MCB.23.5.1520-1533.2003; Sachdev S, 1997, ONCOGENE, V14, P2585, DOI 10.1038/sj.onc.1201108; Sachdev S, 1998, MOL CELL BIOL, V18, P5445, DOI 10.1128/MCB.18.9.5445; SCHATZLE JD, 1995, J VIROL, V69, P5383, DOI 10.1128/JVI.69.9.5383-5390.1995; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Tam WF, 2001, MOL CELL BIOL, V21, P4837, DOI 10.1128/MCB.21.14.4837-4846.2001; THEILEN GH, 1966, J NATL CANCER I, V37, P731; Tsukahara T, 1999, J VIROL, V73, P7981, DOI 10.1128/JVI.73.10.7981-7987.1999; Walker AK, 1996, ONCOGENE, V12, P2515; WHITE DW, 1993, J VIROL, V67, P6876, DOI 10.1128/JVI.67.11.6876-6881.1993; WILHELMSEN KC, 1984, J VIROL, V49, P521, DOI 10.1128/JVI.49.2.521-529.1984; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; You MJ, 1997, MOL CELL BIOL, V17, P7328, DOI 10.1128/MCB.17.12.7328	63	10	10	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1229	1238		10.1038/sj.onc.1207242	http://dx.doi.org/10.1038/sj.onc.1207242			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14961076				2022-12-28	WOS:000188892200007
J	Wang, YL; Zhu, SJ; Cloughesy, TF; Liau, LM; Mischel, PS				Wang, YL; Zhu, SJ; Cloughesy, TF; Liau, LM; Mischel, PS			P53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition	ONCOGENE			English	Article						glioblastoma; p53; p16; senescence; apoptosis	KINASE C-ABL; APOPTOTIC RESPONSE; MOLECULAR SUBTYPES; CANCER; CAMPTOTHECIN; SENESCENCE; RECEPTOR; PATHWAY; CPT-11; ACTIVATION	A critical challenge in cancer research is to identify genetic lesions that sensitize patients to chemotherapy. p53, which is mutated in nearly one-third to half of glioblastomas, may be such a lesion. In this paper, we demonstrate that p53 disruption dramatically sensitizes glioblastoma cells to DNA topoisomerase I inhibitor-mediated apoptosis. Using 19 glioblastoma cell lines, including 15 low-passage ex vivo cell lines derived from patients, as well as isogenic glioblastoma cells varying in p53 status, we show that clinically relevant levels of SN-38 potently induce cell cycle arrest and temporary senescence in glioblastoma cells with wild-type p53 while causing massive apoptosis in p53-deficient cells (P<0.0002). We demonstrate that glioblastoma cells with wild-type p53 proliferate when recultured in drug-free medium, whereas p53-deficient cells do not. We also show that p16 protein expression is neither necessary nor sufficient for initiation and/or maintenance of SN-38-induced arrest/senescence. These results indicate that p53 disruption has a dramatic effect on how glioblastoma cells process topoisomerase I inhibitor-mediated DNA damage.	Univ Calif Los Angeles, Sch Med, Ctr Hlth Sci 13 317, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Henry E Singleton Brain Canc Res Program, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Mischel, PS (corresponding author), Univ Calif Los Angeles, Sch Med, Ctr Hlth Sci 13 317, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA.	pmischel@mednet.ucla.edu	Cloughesy, Timothy Francis/AGV-1013-2022	Liau, Linda/0000-0002-4053-0052	NCI NIH HHS [U01 CA88127] Funding Source: Medline; NINDS NIH HHS [K08NS43147-01, T32-NS07449] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA088127] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007449, K08NS043147] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Agami R, 1999, NATURE, V399, P809; Ahrendt SA, 1999, P NATL ACAD SCI USA, V96, P7382, DOI 10.1073/pnas.96.13.7382; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Azzam EI, 1997, CELL GROWTH DIFFER, V8, P1161; Bachoo RM, 2002, CANCER CELL, V1, P269, DOI 10.1016/S1535-6108(02)00046-6; Brown JM, 1999, CANCER RES, V59, P1391; Chang BD, 1999, CANCER RES, V59, P3761; Choe G, 2003, CANCER RES, V63, P2742; Choe GY, 2002, CLIN CANCER RES, V8, P2894; Coggins CA, 1998, CANCER CHEMOTH PHARM, V41, P485, DOI 10.1007/s002800050771; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Druker BJ, 2002, CANCER CELL, V1, P31, DOI 10.1016/S1535-6108(02)00025-9; Flatt PM, 2000, MOL CELL BIOL, V20, P4210, DOI 10.1128/MCB.20.12.4210-4223.2000; Friedman HS, 1999, J CLIN ONCOL, V17, P1516, DOI 10.1200/JCO.1999.17.5.1516; GIANI C, 1994, CANCER RES, V54, P6338; Gong JG, 1999, NATURE, V399, P806; Han ZY, 2002, J BIOL CHEM, V277, P17154, DOI 10.1074/jbc.M112401200; Hare CB, 1997, CANCER CHEMOTH PHARM, V39, P187; Ino Y, 2001, CLIN CANCER RES, V7, P839; JEN J, 1994, CANCER RES, V54, P6353; Keshelava N, 2001, CANCER RES, V61, P6185; Kleihues P, 1999, Neuro Oncol, V1, P44, DOI 10.1093/neuonc/1.1.44; Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215, DOI 10.1093/jnen/61.3.215; LARSEN JK, 1994, METHOD CELL BIOL, V41, P377; Liu LF, 2000, ANN NY ACAD SCI, V922, P1; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Magrini R, 2002, INT J CANCER, V101, P23, DOI 10.1002/ijc.10565; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Mischel PS, 2003, BRAIN PATHOL, V13, P52; MISHCEL PS, 2003, ONCOGENE, V22, P2361; NEGORO S, 1991, J NATL CANCER I, V83, P1164, DOI 10.1093/jnci/83.16.1164; Nieves-Neira W, 1999, INT J CANCER, V82, P396, DOI 10.1002/(SICI)1097-0215(19990730)82:3<396::AID-IJC13>3.0.CO;2-Z; Roninson IB, 2003, CANCER RES, V63, P2705; Sawyers CL, 2002, CURR OPIN GENET DEV, V12, P111, DOI 10.1016/S0959-437X(01)00273-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Shai R, 2003, ONCOGENE, V22, P4918, DOI 10.1038/sj.onc.1206753; Shao RG, 2001, ONCOGENE, V20, P1852, DOI 10.1038/sj.onc.1204264; Shawver LK, 2002, CANCER CELL, V1, P117, DOI 10.1016/S1535-6108(02)00039-9; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; te Poele RH, 2002, CANCER RES, V62, P1876; Truong T, 2003, P NATL ACAD SCI USA, V100, P10281, DOI 10.1073/pnas.1635435100; Vivo C, 2003, J BIOL CHEM, V278, P25461, DOI 10.1074/jbc.M302161200; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Watanabe K, 1996, BRAIN PATHOL, V6, P217, DOI 10.1111/j.1750-3639.1996.tb00848.x; Weller M, 1998, INT J CANCER, V79, P640; Yang J, 2001, J BIOL CHEM, V276, P27129, DOI 10.1074/jbc.M100729200; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zeng MS, 2002, J BIOL CHEM, V277, P45611, DOI 10.1074/jbc.M208447200	48	60	62	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1283	1290		10.1038/sj.onc.1207244	http://dx.doi.org/10.1038/sj.onc.1207244			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14961077				2022-12-28	WOS:000188892200013
J	Kintscher, J; Yamkamon, V; Braas, D; Klempnauer, KH				Kintscher, J; Yamkamon, V; Braas, D; Klempnauer, KH			Identification of a Myb-responsive enhancer of the chicken C/EBP beta gene	ONCOGENE			English	Article						Myb; C/EBP beta; target gene; chromatin; enhancer	LEUCINE-ZIPPER PROTEINS; RECEPTOR FUSION PROTEIN; I-HYPERSENSITIVE SITES; V-MYB; C-MYB; TRANSCRIPTION FACTOR; MYELOMONOCYTIC CELLS; MYELOID CELLS; MIM-1 GENE; NF-M	The retroviral oncogene v-myb encodes a transcription factor (v-Myb) that disrupts myelomonocytic differentiation and transforms myelomonocytic cells. It is thought that the biological effects of v-Myb are caused by deregulation of specific target genes. The CCAAT box/enhancer binding protein beta (C/EBPbeta), a member of the basic region-leucine zipper (bzip) class of transcription factors, which itself plays an important role during myelomonocytic differentiation, has previously been shown to be regulated by Myb. Here we have addressed the mechanism by which v-Myb affects C/EBPbeta expression. We have employed the mapping of DNase I hypersensitive sites (DHSs) in chromatin as a tool to detect in vivo target sites of v-Myb. Our data identify a DHS downstream of the C/EBPbeta gene that appears to be specific for v-myb-transformed myeloblasts. We have confirmed by chromatin immunoprecipitation that v-Myb is bound to this region in vivo. Furthermore, we have found that ectopic expression of v-Myb in a myelomonocytic cell line is able to induce a DHS downstream of the C/EBPbeta gene, showing for the first time that v-Myb can affect chromatin structure. Reporter gene experiments demonstrate that the downstream DHS acts as a Myb-dependent enhancing element in transiently as well as in stably transfected myelomonocytic cells. Previous work has shown that v-Myb acts on the C/EBPbeta promoter; it now appears that Myb stimulates C/EBPbeta expression by acting on the promoter as well as on an enhancer of the C/EBPbeta gene. Interestingly, the mechanisms by which Myb acts on both elements differ; while Myb activation of the promoter requires the cooperation with C/EBPbeta, activation of the enhancer by Myb is independent of C/EBPbeta. Apart from the identification of a novel Myb-dependent enhancer, our work demonstrates the potential of chromatin structure analysis for the identification of Myb target sites.	Univ Munster, Inst Biochem, D-48149 Munster, Germany	University of Munster	Klempnauer, KH (corresponding author), Univ Munster, Inst Biochem, Wilhelm Klemm Str 2, D-48149 Munster, Germany.	klempna@uni-muenster.de						AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BritosBray M, 1997, MOL CELL BIOL, V17, P5127, DOI 10.1128/MCB.17.9.5127; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; Burk O, 1997, EMBO J, V16, P1371, DOI 10.1093/emboj/16.6.1371; Calkhoven CF, 2000, GENE DEV, V14, P1920; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHANG CJ, 1995, DNA CELL BIOL, V14, P529, DOI 10.1089/dna.1995.14.529; Chumakov AM, 1997, MOL CELL BIOL, V17, P1375, DOI 10.1128/MCB.17.3.1375; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; ESS KC, 1995, MOL CELL BIOL, V15, P5707; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; Himly M, 1998, VIROLOGY, V248, P295, DOI 10.1006/viro.1998.9290; Hogg A, 1997, ONCOGENE, V15, P2885, DOI 10.1038/sj.onc.1201472; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; KATZ S, 1993, EMBO J, V12, P1321, DOI 10.1002/j.1460-2075.1993.tb05777.x; Kintscher J, 2003, DNA CELL BIOL, V22, P201, DOI 10.1089/104454903321655828; KLEMPNAUER KH, 1986, EMBO J, V5, P1903, DOI 10.1002/j.1460-2075.1986.tb04443.x; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KowenzLeutz E, 1997, CELL, V91, P185, DOI 10.1016/S0092-8674(00)80401-8; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Lin WC, 2002, DNA CELL BIOL, V21, P551, DOI 10.1089/104454902320308924; Lipsick JS, 1999, ONCOGENE, V18, P3047, DOI 10.1038/sj.onc.1202745; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; Mink S, 1996, MOL CELL BIOL, V16, P1316; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Mink S, 1999, BBA-GENE STRUCT EXPR, V1447, P175, DOI 10.1016/S0167-4781(99)00168-2; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NATSUKA S, 1992, BLOOD, V79, P460; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NESS SA, 1996, BIOCHIM BIOPHYS ACTA, V1288, P123; Niehof M, 2001, J MOL BIOL, V309, P855, DOI 10.1006/jmbi.2001.4708; Niehof M, 2001, J BIOL CHEM, V276, P9016, DOI 10.1074/jbc.M009284200; Niehof M, 1997, MOL CELL BIOL, V17, P3600, DOI 10.1128/MCB.17.7.3600; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; Reizis B, 2001, J EXP MED, V194, P979, DOI 10.1084/jem.194.7.979; Rushton JJ, 2003, ONCOGENE, V22, P308, DOI 10.1038/sj.onc.1206131; Schlichter U, 2001, ONCOGENE, V20, P231, DOI 10.1038/sj.onc.1204071; SCOTT LM, 1992, BLOOD, V80, P1725; Sippel AE, 1996, METHOD ENZYMOL, V274, P233; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; STERNECK E, 1992, EMBO J, V11, P115, DOI 10.1002/j.1460-2075.1992.tb05034.x; Tahirov TH, 2002, CELL, V108, P57, DOI 10.1016/S0092-8674(01)00636-5; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; Worpenberg S, 1997, ONCOGENE, V15, P213, DOI 10.1038/sj.onc.1201179; Yamanaka R, 1998, INT J MOL MED, V1, P213; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168	58	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2004	23	34					5807	5814		10.1038/sj.onc.1207722	http://dx.doi.org/10.1038/sj.onc.1207722			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KW	15195136				2022-12-28	WOS:000222629800010
J	Tang, XH; Milyavsky, M; Shats, I; Erez, N; Goldfinger, N; Rotter, V				Tang, XH; Milyavsky, M; Shats, I; Erez, N; Goldfinger, N; Rotter, V			Activated p53 suppresses the histone methyltransferase EZH2 gene	ONCOGENE			English	Article						senescence; p53; EZH2; repression; HMTase; G2/M arrest	HUMAN-DIPLOID FIBROBLASTS; POLYCOMB-GROUP PROTEINS; LIFE-SPAN; CELL-DIFFERENTIATION; TELOMERASE ACTIVITY; SENESCENCE; MECHANISMS; EXPRESSION; PROLIFERATION; PATHWAY	Replicative senescence is an irreversible cell cycle arrest that limits the proliferation of damaged cells and may be an important tumor suppression mechanism in vivo. This process is regulated at critical steps by the tumor suppressor p53. To identify genes that may regulate the senescence process, we performed cDNA microarray analysis of gene expression in senescent, young proliferating, and hTERT-immortalized primary human fibroblasts. The histone methyltransferase (HMTase), EZH2, was specifically downregulated in senescent cells. Activated p53 suppressed EZH2 gene expression through repression of the EZH2 gene promoter. This activity of p53 requires intact p53 transactivation and DNA binding domains. Furthermore, the repression of EZH2 promoter by p53 is dependent on p53 transcriptional target p2l(waf1) inactivating RB/E2F pathways. In addition, the knockdown of EZH2 expression retards cell proliferation and induces G2/M arrest. We suggest that the p53-dependent suppression of EZH2 expression is a novel pathway that contributes to p53-mediated G2/M arrest. EZH2 associated complex possesses HMTase activity and is involved in epigenetic regulation. Activated p53 suppresses EZH2 expression, suggesting a further role for p53 in epigenetic regulation and in the maintenance of genetic stability. Suppression of EZH2 expression in tumors by p53 may lead to novel approaches to control cancer progression.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Rotter, V (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	varda.rotter@weizmann.ac.il	Tang, Xiaohu/AAX-4577-2021; Milyavsky, Michael/E-8306-2011; Shats, Igor/AAD-8775-2019	Shats, Igor/0000-0001-6449-5979; Erez, Neta/0000-0001-6506-9074				AFSHARI CA, 1993, EXP CELL RES, V209, P231, DOI 10.1006/excr.1993.1306; Almog N, 1997, BBA-REV CANCER, V1333, pF1, DOI 10.1016/S0304-419X(97)00012-7; ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BOND JA, 1994, ONCOGENE, V9, P1885; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Bringold F, 2000, EXP GERONTOL, V35, P317, DOI 10.1016/S0531-5565(00)00083-8; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Campisi J, 2003, NAT REV CANCER, V3, P339, DOI 10.1038/nrc1073; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Francis NJ, 2001, NAT REV MOL CELL BIO, V2, P409, DOI 10.1038/35073039; Fukuyama T, 2000, BRIT J HAEMATOL, V108, P842, DOI 10.1046/j.1365-2141.2000.01914.x; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; Hobert O, 1996, MOL CELL BIOL, V16, P3066; Itahana K, 2001, EUR J BIOCHEM, V268, P2784, DOI 10.1046/j.1432-1327.2001.02228.x; Itahana K, 2003, MOL CELL BIOL, V23, P389, DOI 10.1128/MCB.23.1.389-401.2003; Jacobs JJL, 2002, BBA-REV CANCER, V1602, P151, DOI 10.1016/S0304-419X(02)00052-5; Jones CA, 1998, MOL CELL BIOL, V18, P2825, DOI 10.1128/MCB.18.5.2825; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; MACLEAN K, 1994, ONCOGENE, V9, P719; Mahmoudi T, 2001, ONCOGENE, V20, P3055, DOI 10.1038/sj.onc.1204330; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Offer H, 2002, CARCINOGENESIS, V23, P1025, DOI 10.1093/carcin/23.6.1025; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Raaphorst FM, 2000, J IMMUNOL, V164, P1, DOI 10.4049/jimmunol.164.1.1; Raaphorst FM, 2000, AM J PATHOL, V157, P709, DOI 10.1016/S0002-9440(10)64583-X; Rhodes DR, 2003, J NATL CANCER I, V95, P661, DOI 10.1093/jnci/95.9.661; Schwartz D, 1998, SEMIN CANCER BIOL, V8, P325, DOI 10.1006/scbi.1998.0095; Seluanov A, 2001, MOL CELL BIOL, V21, P1552, DOI 10.1128/MCB.21.5.1552-1564.2001; Sewalt RGAB, 1998, MOL CELL BIOL, V18, P3586, DOI 10.1128/MCB.18.6.3586; Sharpless NE, 2002, CELL, V110, P9, DOI 10.1016/S0092-8674(02)00818-8; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAY JW, 1993, ONCOGENE, V8, P1407; Simon JA, 2002, CURR OPIN GENET DEV, V12, P210, DOI 10.1016/S0959-437X(02)00288-5; Stein GH, 1999, MOL CELL BIOL, V19, P2109; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; Taylor WR, 1999, MOL BIOL CELL, V10, P3607, DOI 10.1091/mbc.10.11.3607; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; van Kemenade FJ, 2001, BLOOD, V97, P3896, DOI 10.1182/blood.V97.12.3896; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang QJ, 1997, MOL CELL BIOL, V17, P389, DOI 10.1128/MCB.17.1.389; Yeager TR, 1998, GENE DEV, V12, P163, DOI 10.1101/gad.12.2.163; Zhang H, 2003, P NATL ACAD SCI USA, V100, P3251, DOI 10.1073/pnas.2627983100	66	160	186	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2004	23	34					5759	5769		10.1038/sj.onc.1207706	http://dx.doi.org/10.1038/sj.onc.1207706			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KW	15208672				2022-12-28	WOS:000222629800005
J	Oeggerli, M; Tomovska, S; Schraml, P; Calvano-Forte, D; Schafroth, S; Simon, R; Gasser, T; Mihatsch, MJ; Sauter, G				Oeggerli, M; Tomovska, S; Schraml, P; Calvano-Forte, D; Schafroth, S; Simon, R; Gasser, T; Mihatsch, MJ; Sauter, G			E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer	ONCOGENE			English	Article						bladder cancer; 6p22; E2F3; amplification; FISH; IHC	COMPARATIVE GENOMIC HYBRIDIZATION; TISSUE MICROARRAY ANALYSIS; CHROMOSOMAL IMBALANCES; TRANSCRIPTION FACTORS; GENE AMPLIFICATION; COPY NUMBER; S-PHASE; CARCINOMA; P53; EXPRESSION	E2F3 is located in the 6p22 bladder amplicon and encodes a transcription factor important for cell cycle regulation and DNA replication. To further investigate the role of E2F3 in bladder cancer, a tissue microarray containing samples from 2317 bladder tumors was used for gene copy number and expression analysis by means of fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC). E2F3 amplification was strongly associated with invasive tumor phenotype and high tumor grade (P<0.0001 each). None of 272 pTaG1/G2 tumors, but 35 of 311 pT1-4 carcinomas (11.3%), had E2F3 amplification. A high E2F3 expression level was associated with high grade, advanced stage, and E2F3 gene amplification (P<0.0001 each). To evaluate whether E2F3 expression correlates with tumor proliferation, the Ki67 labeling index (LI) was analysed for each tumor. There was a strong association between a high Ki67 LI and E2F3 expression (P < 0.0001), which was independent of grade and stage. We conclude that E2F3 is frequently amplified and overexpressed in invasively growing bladder cancer (stage pT1-4). E2F3 expression appears to provide a growth advantage to tumor cells by activating cell proliferation in a subset of bladder tumors.	Univ Basel, Inst Pathol, CH-4031 Basel, Switzerland; Inst Pathol, CH-4031 Basel, Switzerland; Urol Clin, CH-4410 Liestal, Switzerland	University of Basel	Sauter, G (corresponding author), Univ Basel, Inst Pathol, Schoenbeinstr 40, CH-4031 Basel, Switzerland.			Simon, Ronald/0000-0003-0158-4258				Anantharaman V, 2001, FEMS MICROBIOL LETT, V197, P215, DOI 10.1111/j.1574-6968.2001.tb10606.x; Bruch J, 2000, CANCER RES, V60, P4526; Bubendorf L, 2001, AM J CLIN PATHOL, V116, P79; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DIMATTIA GE, 1990, J BIOL CHEM, V265, P16412; FARR CJ, 1993, MAMM GENOME, V4, P577, DOI 10.1007/BF00361388; Halling KC, 2000, J UROLOGY, V164, P1768, DOI 10.1016/S0022-5347(05)67104-2; Hui R, 1997, ONCOGENE, V15, P1617, DOI 10.1038/sj.onc.1201311; Humbert PO, 2000, GENE DEV, V14, P690; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; KALLIONIEMI A, 1995, GENE CHROMOSOME CANC, V12, P213, DOI 10.1002/gcc.2870120309; KONDO I, 1983, CYTOGENET CELL GENET, V35, P9, DOI 10.1159/000131829; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Leone G, 2001, MOL CELL, V8, P105, DOI 10.1016/S1097-2765(01)00275-1; LIPPONEN PK, 1993, BRIT J UROL, V72, P451, DOI 10.1111/j.1464-410X.1993.tb16176.x; Liukkonen T, 1999, EUR UROL, V36, P393, DOI 10.1159/000020039; MITELMAN F, 1994, CATALOG CHROMOSOME A; Moch H, 1997, UROL RES, V25, pS25, DOI 10.1007/BF00942044; Mostofi FK, 1973, HISTOLOGICAL TYPING; Nakopoulou L, 1998, HUM PATHOL, V29, P146, DOI 10.1016/S0046-8177(98)90225-8; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Nocito A, 2001, J PATHOL, V194, P349, DOI 10.1002/1096-9896(200107)194:3<349::AID-PATH887>3.0.CO;2-D; Pfister C, 1998, EUR UROL, V33, P278, DOI 10.1159/000019580; Polanowska J, 2000, GENE CHROMOSOME CANC, V28, P126, DOI 10.1002/(SICI)1098-2264(200005)28:1<126::AID-GCC15>3.0.CO;2-G; POPESCU NC, 1989, GENOMICS, V4, P362, DOI 10.1016/0888-7543(89)90343-1; Rabbani F, 1999, J NATL CANCER I, V91, P874, DOI 10.1093/jnci/91.10.874; REIFENBERGER G, 1994, CANCER RES, V54, P4299; Richter J, 1999, CANCER RES, V59, P5687; Richter J, 2000, AM J PATHOL, V157, P787, DOI 10.1016/S0002-9440(10)64592-0; Richter J, 1998, AM J PATHOL, V153, P1615, DOI 10.1016/S0002-9440(10)65750-1; Richter J, 1997, CANCER RES, V57, P2860; SAITO M, 1995, GENOMICS, V25, P130, DOI 10.1016/0888-7543(95)80118-6; Sauter G., 1994, Pathology Research and Practice, V190, P281; Simon R, 2000, INT J ONCOL, V17, P1025; Simon R, 2003, INT J CANCER, V107, P764, DOI 10.1002/ijc.11477; Simon R, 2002, ONCOGENE, V21, P2476, DOI 10.1038/sj.onc.1205304; Simon R, 1998, J PATHOL, V185, P345; Simon R, 2001, CANCER RES, V61, P4514; Terracciano L, 1999, J PATHOL, V189, P230, DOI 10.1002/(SICI)1096-9896(199910)189:2<230::AID-PATH407>3.0.CO;2-8; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Union for International Cancer Control (UICC), 1992, TNM CLASS MAL TUM; Veltman JA, 2003, CANCER RES, V63, P2872; VOORTER C, 1995, AM J PATHOL, V146, P1341; Wagner U, 1997, AM J PATHOL, V151, P753; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; Zaharieva BM, 2003, J PATHOL, V201, P603, DOI 10.1002/path.1481; Zhao JM, 1999, CANCER RES, V59, P4658	50	127	138	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 22	2004	23	33					5616	5623		10.1038/sj.onc.1207749	http://dx.doi.org/10.1038/sj.onc.1207749			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15122326				2022-12-28	WOS:000222629500006
J	Shollar, D; Del Valle, L; Khalili, K; Otte, J; Gordon, J				Shollar, D; Del Valle, L; Khalili, K; Otte, J; Gordon, J			JCV T-antigen interacts with the neurofibromatosis type 2 gene product in a transgenic mouse model of malignant peripheral nerve sheath tumors	ONCOGENE			English	Article						mpnst; polyomavirus; NF2; p53; animal model; JC virus; T-antigen	HUMAN NEUROTROPIC POLYOMAVIRUS; BRAIN-TUMORS; VIRUS; EXPRESSION; PROTEIN; INVOLVEMENT; SUPPRESSOR; MERLIN	The human polyomavirus, JC virus, has recently been associated with several human CNS tumors, including medulloblastomas and a broad range of glial-origin tumors. This ubiquitous virus is the causative agent of the rare demyelinating disease, progressive multifocal leukoencephalopathy in immunocompromised individuals. Expression of the viral protein, T-antigen, which possesses the ability to transform cells of neural origin, has been detected in human CNS tumors. In an effort to further understand the transforming potential of JCV T-antigen, transgenic mice expressing JCV T-antigen under the control of the Mad-4 promoter were generated. As described previously, approximately 50% of the animals developed pituitary tumors by 1 year of age. However, a small subset of the animals developed solid masses arising from the soft tissues surrounding the salivary gland, the sciatic nerve, and along the extremities that histologically resemble malignant peripheral nerve sheath tumors, rare neoplasms that occur in individuals with neurofibromatosis type 1 (NF1). JCV T-antigen was detected in tumor tissue by immunohistochemistry and immunoprecipitation/Western blotting, but not in normal tissues and was colocalized with NF2, the putative tumor suppressor protein associated with neurofibromatosis type 2, in the nucleus of some cells. In addition, T-antigen was co-precipitated with NF2, but not with NF1 protein, although NF1 was detectable in tumor tissue. Furthermore, precipitated immunocomplexes contained T-antigen, NF2, and p53, suggesting that these three proteins may form a ternary complex. The importance of these findings on mechanisms of T-antigen-mediated tumorigenesis and the pathogenesis of neurofibromatosis are discussed.	Temple Univ, Ctr Neurovirol & Canc Biol, Coll Sci & Technol, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Gordon, J (corresponding author), Temple Univ, Ctr Neurovirol & Canc Biol, Coll Sci & Technol, 1900 N 12th St,015-96,Room 203, Philadelphia, PA 19122 USA.	jennifer.gordon@temple.edu	Del Valle, Luis/J-4085-2015	Del Valle, Luis/0000-0003-3894-9206				Baser ME, 2002, NEUROLOGY, V59, P290, DOI 10.1212/WNL.59.2.290; BERGER JR, 1995, J NEUROVIROL, V1, P5, DOI 10.3109/13550289509111006; BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; Carbone M, 1997, NAT MED, V3, P908, DOI 10.1038/nm0897-908; Chestukhin A, 2002, MOL CELL BIOL, V22, P453, DOI 10.1128/MCB.22.2.453-468.2002; Cichowski K, 1999, SCIENCE, V286, P2172, DOI 10.1126/science.286.5447.2172; Del Valle L, 2001, CANCER RES, V61, P4287; DELVALLE L, 2001, HUMAN POLYOMAVIRUSES, P409; Enam S, 2002, CANCER RES, V62, P7093; Frank D, 2003, CANCER GENET CYTOGEN, V144, P18, DOI 10.1016/S0165-4608(02)00870-1; Franks RR, 1996, ONCOGENE, V12, P2573; Gan DD, 2001, ONCOGENE, V20, P4864, DOI 10.1038/sj.onc.1204670; Gordon J, 2000, ONCOGENE, V19, P4840, DOI 10.1038/sj.onc.1203849; Kim H, 2004, J BIOL CHEM, V279, P7812, DOI 10.1074/jbc.M305526200; Kim H.S., 2001, HUMAN POLYOMAVIRUSES, P73; Kressel M, 2002, HUM MOL GENET, V11, P2269, DOI 10.1093/hmg/11.19.2269; Krynska B, 1999, ONCOGENE, V18, P39, DOI 10.1038/sj.onc.1202278; Krynska B, 2000, VIROLOGY, V274, P65, DOI 10.1006/viro.2000.0450; Krynska B, 1999, P NATL ACAD SCI USA, V96, P11519, DOI 10.1073/pnas.96.20.11519; LONDON WT, 1978, SCIENCE, V201, P1246, DOI 10.1126/science.211583; LOUIS DN, 2000, PATHOLOGY GENETICS T, P219; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; McClatchey AI, 2001, BBA-REV CANCER, V1471, pM73, DOI 10.1016/S0304-419X(00)00026-3; OHSUMI S, 1986, ACTA PATHOL JAPON, V36, P815; RESSETAR HG, 1990, LAB INVEST, V62, P287; REY JA, 1993, CANCER GENET CYTOGEN, V66, P28, DOI 10.1016/0165-4608(93)90144-B; Safak M, 1999, J VIROL, V73, P10146, DOI 10.1128/JVI.73.12.10146-10157.1999; Schmucker B, 1999, HUM MOL GENET, V8, P1561, DOI 10.1093/hmg/8.8.1561; Side L, 1997, NEW ENGL J MED, V336, P1713, DOI 10.1056/NEJM199706123362404; SMALL JA, 1986, CELL, V46, P13, DOI 10.1016/0092-8674(86)90855-X; SMALL JA, 1986, P NATL ACAD SCI USA, V83, P8288, DOI 10.1073/pnas.83.21.8288; Sun CX, 2002, J CELL SCI, V115, P3991, DOI 10.1242/jcs.00094; Testa JR, 1998, CANCER RES, V58, P4505; THEILE M, 1990, ARCH VIROL, V113, P221, DOI 10.1007/BF01316675; Vogel KS, 1999, SCIENCE, V286, P2176, DOI 10.1126/science.286.5447.2176; VONDEIMLING A, 2000, PATHOLOGY GENETICS T, P216; Woodruff J.M., 2000, PATHOLOGY GENETICS T, P172; ZURHEIN GM, 1983, POLYOMAVIRUSES HUMAN, P205	38	41	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2004	23	32					5459	5467		10.1038/sj.onc.1207728	http://dx.doi.org/10.1038/sj.onc.1207728			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15133494				2022-12-28	WOS:000222588400005
J	Fukamachi, H; Ito, K				Fukamachi, H; Ito, K			Growth regulation of gastric epithelial cells by Runx3	ONCOGENE			English	Article						Runx3; gastric cancer; growth; TGF-beta tumorigeneisis	METHYL-N-NITROSOUREA; TRANSFORMING GROWTH-FACTOR-BETA-1; CLEIDOCRANIAL DYSPLASIA; TUMOR-SUPPRESSOR; TRANSCRIPTION; CANCER; TGF-BETA-1; INDUCTION; MUTATIONS; PROLIFERATION	Runx3 is expressed by gastric epithelial cells throughout development. Mice whose Runx3 gene has been knocked out died soon after birth. In the knockout mouse, gastric epithelia exhibited hyperplasia and epithelial apoptosis was suppressed. Analysis using a primary culture system for the epithelial cells suggested that this is caused by the reduced sensitivity of Runx3 -/- gastric epithelial cells to the growth-inhibiting and apoptosis-inducing activities of TGF-beta. In human and mouse gastric cancer cell lines, RUNX3/Runx3 was silenced due to hypermethylation of CpG islands in the promoter region. Exogenous expression of RUNX3 in the cells that do not express the endogenous gene caused an inhibition of growth both in vivo and in vitro. These observations indicate that Runx3 is a major growth regulator of gastric epithelial cells, and that it is deeply involved in gastric tumorigenesis in both humans and mice.	Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Bunkyo Ku, Tokyo 1130033, Japan; Inst Mol & Cell Biol, Singapore 117609, Singapore	University of Tokyo; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Fukamachi, H (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Bunkyo Ku, Tokyo 1130033, Japan.	h_fukama@biol.s.u-tokyo.ac.jp						Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; Furihata C, 1997, JPN J CANCER RES, V88, P363, DOI 10.1111/j.1349-7006.1997.tb00390.x; Guo WH, 2002, ONCOGENE, V21, P8351, DOI 10.1038/sj.onc.1206037; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Ichinose M, 1998, JPN J CANCER RES, V89, P516, DOI 10.1111/j.1349-7006.1998.tb03292.x; Kallapur S, 1999, MOL REPROD DEV, V52, P341, DOI 10.1002/(SICI)1098-2795(199904)52:4&lt;341::AID-MRD2&gt;3.0.CO;2-N; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797-307; Levanon D, 2003, EMBO REP, V4, P560, DOI 10.1038/sj.embor.embor868; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; MARTIKAINEN P, 1990, ENDOCRINOLOGY, V127, P2963, DOI 10.1210/endo-127-6-2963; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; ROTELLO RJ, 1991, P NATL ACAD SCI USA, V88, P3412, DOI 10.1073/pnas.88.8.3412; Shi MJ, 1998, J IMMUNOL, V161, P6751; TATEMATSU M, 1993, JPN J CANCER RES, V84, P1258, DOI 10.1111/j.1349-7006.1993.tb02831.x; YANAGIHARA K, 1992, CANCER RES, V52, P4042	22	48	53	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2004	23	24					4330	4335		10.1038/sj.onc.1207121	http://dx.doi.org/10.1038/sj.onc.1207121			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823BZ	15156189				2022-12-28	WOS:000221586000018
J	Duensing, A; Medeiros, F; McConarty, B; Joseph, NE; Panigrahy, D; Singer, S; Fletcher, CDM; Demetri, GD; Fletcher, JA				Duensing, A; Medeiros, F; McConarty, B; Joseph, NE; Panigrahy, D; Singer, S; Fletcher, CDM; Demetri, GD; Fletcher, JA			Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs)	ONCOGENE			English	Article						KIT; imatinib; GIST; kinase; signal transduction	STEM-CELL FACTOR; RECEPTOR TYROSINE KINASE; HUMAN LEUKEMIA-CELLS; SRC FAMILY KINASES; C-KIT; INTERSTITIAL-CELLS; GERMLINE MUTATION; ACTIVATING MUTATIONS; JUXTAMEMBRANE DOMAIN; HEMATOPOIETIC-CELLS	Most gastrointestinal stromal tumors (GISTs) express constitutively activated forms of the KIT receptor tyrosine kinase protein, resulting from oncogenic mutations in the extracellular, juxtamembrane, or kinase domains. KIT oncoproteins are detected early in GIST tumorigenesis, and most GIST patients respond well to treatment with the KIT kinase inhibitor imatinib mesylate (STI571, Gleevec(R)). However, GISTs can develop resistance to imatinib, and additional therapeutic strategies are needed. Little is known about oncogenic KIT signal transduction in GISTs, and whether the type of KIT mutation accounts for selective activation of downstream signaling intermediates. We therefore evaluated KIT downstream signaling profiles in 15 primary GISTs with mutations in KIT exons 9, 11, 13, and 17, and in two human GIST cell lines. All GISTs showed constitutive phosphorylation at KIT tyrosine residues Y703 and Y721. Additionally, most GISTs showed activation of MAPK p42/44, AKT, S6K, STAT1, and STAT3. STAT5 and JNK were not demonstrably activated in any GIST. Using GIST in vitro models, we showed that activation of MAPK p42/44, AKT, and S6K was KIT dependent, whereas STAT1 and STAT3 phosphorylation was only partially dependent on KIT activation. Correlation of activated signaling pathways with the type of KIT mutation revealed low levels of AKT phosphorylation in exon 9 mutant GISTs in contrast to a subset of GISTs with exon 11 mutations. However, additional factors are likely to modify the engagement of signaling pathways in GISTs as suggested by the fact that four GISTs with identical KIT exon 9 mutations had differential activation of MAPK p42/44 and STAT proteins. In summary, in this first report on KIT signal transduction in primary GISTs and GIST cell lines, we identified pathways that are constitutively activated in a KIT-dependent manner and therefore warrant further study as molecular targets in GISTs.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp, Dept Surg, Boston, MA 02115 USA; Mem Sloan Kettering Canc Ctr, Dept Surg Oncol, New York, NY 10021 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Memorial Sloan Kettering Cancer Center; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Duensing, A (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.	aduensing@rics.bwh.harvard.edu; jfletcher@partners.org		Duensing, Anette/0000-0002-0168-4067; Singer, Samuel/0000-0001-9713-8230				Beghini A, 2001, CANCER, V92, P657, DOI 10.1002/1097-0142(20010801)92:3<657::AID-CNCR1367>3.0.CO;2-D; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Brizzi MF, 1999, J BIOL CHEM, V274, P16965, DOI 10.1074/jbc.274.24.16965; Caruana G, 1999, ONCOGENE, V18, P5573, DOI 10.1038/sj.onc.1202939; Casteran N, 2003, ONCOGENE, V22, P4710, DOI 10.1038/sj.onc.1206587; Chen H, 2003, INT J CANCER, V105, P130, DOI 10.1002/ijc.11025; Chian RJ, 2001, BLOOD, V98, P1365, DOI 10.1182/blood.V98.5.1365; Corless CL, 2002, AM J PATHOL, V160, P1567, DOI 10.1016/S0002-9440(10)61103-0; De Miguel MP, 2002, P NATL ACAD SCI USA, V99, P10458, DOI 10.1073/pnas.122249399; DeBerry C, 1997, BIOCHEM J, V327, P73, DOI 10.1042/bj3270073; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Dolci S, 2001, J BIOL CHEM, V276, P40225, DOI 10.1074/jbc.M105143200; Ernst SI, 1998, LAB INVEST, V78, P1633; Feng LX, 2000, J BIOL CHEM, V275, P25572, DOI 10.1074/jbc.M002218200; Fletcher CDM, 2002, HUM PATHOL, V33, P459, DOI 10.1053/hupa.2002.123545; Frost MJ, 2002, MOL CANCER THER, V1, P1115; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Heinrich MC, 2003, J CLIN ONCOL, V21, P4342, DOI 10.1200/JCO.2003.04.190; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Hirota S, 2000, AM J SURG PATHOL, V24, P326, DOI 10.1097/00000478-200002000-00045; Hornick JL, 2002, AM J CLIN PATHOL, V117, P188; HUIZINGA JD, 1995, NATURE, V373, P347, DOI 10.1038/373347a0; Isozaki K, 2000, AM J PATHOL, V157, P1581, DOI 10.1016/S0002-9440(10)64795-5; Joensuu H, 2001, NEW ENGL J MED, V344, P1052, DOI 10.1056/NEJM200104053441404; Kindblom LG, 1998, AM J PATHOL, V152, P1259; Klejman A, 2002, EMBO J, V21, P5766, DOI 10.1093/emboj/cdf562; LAI CF, 1995, J BIOL CHEM, V270, P23254, DOI 10.1074/jbc.270.40.23254; Lasota J, 1999, AM J PATHOL, V154, P53, DOI 10.1016/S0002-9440(10)65250-9; Lennartsson J, 1999, ONCOGENE, V18, P5546, DOI 10.1038/sj.onc.1202929; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; Linnekin D, 1999, INT J BIOCHEM CELL B, V31, P1053, DOI 10.1016/S1357-2725(99)00078-3; Linnekin D, 1996, ACTA HAEMATOL-BASEL, V95, P224; Lux ML, 2000, AM J PATHOL, V156, P791, DOI 10.1016/S0002-9440(10)64946-2; Maeyama H, 2001, GASTROENTEROLOGY, V120, P210; Nieborowska-Skorska M, 2002, BLOOD, V99, P4531, DOI 10.1182/blood.V99.12.4531; Ning ZQ, 2001, LEUKEMIA LYMPHOMA, V41, P513, DOI 10.3109/10428190109060342; Ning ZQ, 2001, BLOOD, V97, P3559, DOI 10.1182/blood.V97.11.3559; Nishida T, 1998, NAT GENET, V19, P323, DOI 10.1038/1209; Rubin BP, 2001, CANCER RES, V61, P8118; Sircar K, 1999, AM J SURG PATHOL, V23, P377, DOI 10.1097/00000478-199904000-00002; Sommer G, 2003, P NATL ACAD SCI USA, V100, P6706, DOI 10.1073/pnas.1037763100; Taniguchi M, 1999, CANCER RES, V59, P4297; Taylor ML, 2000, HEMATOL ONCOL CLIN N, V14, P517, DOI 10.1016/S0889-8588(05)70294-X; Thommes K, 1999, BIOCHEM J, V341, P211, DOI 10.1042/0264-6021:3410211; TSAI M, 1993, EUR J IMMUNOL, V23, P3286, DOI 10.1002/eji.1830231234; Tuveson DA, 2001, ONCOGENE, V20, P5054, DOI 10.1038/sj.onc.1204704; van Oosterom AT, 2001, LANCET, V358, P1421, DOI 10.1016/S0140-6736(01)06535-7; Voytyuk O, 2003, J BIOL CHEM, V278, P9159, DOI 10.1074/jbc.M211726200; Weiler SR, 1996, BLOOD, V87, P3688, DOI 10.1182/blood.V87.9.3688.bloodjournal8793688; Wu M, 2000, GENE DEV, V14, P301; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x	51	249	264	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					3999	4006		10.1038/sj.onc.1207525	http://dx.doi.org/10.1038/sj.onc.1207525			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15007386				2022-12-28	WOS:000221382000012
J	Perrotti, D; Calabretta, B				Perrotti, D; Calabretta, B			Translational regulation by the p210 BCR/ABL oncoprotein	ONCOGENE			English	Review						chronic myelogenous leukemia; BCR/ABL; translation	CHRONIC MYELOGENOUS LEUKEMIA; NUCLEAR RIBONUCLEOPROTEIN-K; BINDING PROTEIN ALPHA; C-MYC TRANSCRIPTION; MESSENGER-RNA SUBSETS; ABL TYROSINE KINASE; HUMAN LA ANTIGEN; HNRNP-K; BLAST CRISIS; ERYTHROID-DIFFERENTIATION	The ability of oncogenic proteins to regulate the rate of translation of specific mRNA subsets may be a rapid and efficient mechanism to modulate the levels and, in many cases, the activity of the corresponding proteins. In the past few years, we have identified several RNA binding proteins with translation regulatory activity whose expression is markedly activated in the blast crisis of chronic myelogenous leukemia, which represents the most malignant disease stage. Perturbation of the activity of some RNA binding proteins suppresses the leukemogenic potential of BCR/ABL-expressing cells. Most importantly, we have identified some of the targets of these RNA binding proteins. Two of these targets, c/ebpalpha and mdm2 mRNAs, are directly relevant for the altered differentiation and survival of leukemic cells. The identification of mRNA targets translationally regulated by RNA binding proteins overexpressed in tumor cells may lead to the development of therapeutic strategies aimed at modulating the translation rate of specific mRNAs.	Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Human Canc Genet Program, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Jefferson University	Perrotti, D (corresponding author), Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Human Canc Genet Program, Columbus, OH 43210 USA.	perrotti-1@medctr.osu.edu	Perrotti, Danilo/E-3852-2011		NCI NIH HHS [1R01 CA095512-01A2, P01 CA78890, P30 CA16058] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095512, P30CA016058, P01CA078890] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEDNAREK JM, 1988, J NATL CANCER I, V80, P251, DOI 10.1093/jnci/80.4.251; Blyn LB, 1997, J VIROL, V71, P6243, DOI 10.1128/JVI.71.8.6243-6246.1997; Bomsztyk K, 1997, FEBS LETT, V403, P113, DOI 10.1016/S0014-5793(97)00041-0; Brown V, 2001, CELL, V107, P477, DOI 10.1016/S0092-8674(01)00568-2; BUSTELO XR, 1995, MOL CELL BIOL, V15, P1324; Calkhoven CF, 2000, GENE DEV, V14, P1920; Cardinali B, 2003, J BIOL CHEM, V278, P35145, DOI 10.1074/jbc.M300722200; Carella A, 2001, CHRONIC MYELOID LEUK; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Cazzola M, 2000, BLOOD, V95, P3280, DOI 10.1182/blood.V95.11.3280.011k41_3280_3288; Clemens MJ, 1999, INT J BIOCHEM CELL B, V31, P1, DOI 10.1016/S1357-2725(98)00127-7; Collier B, 1998, J BIOL CHEM, V273, P22648, DOI 10.1074/jbc.273.35.22648; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; Cristofano A. D., 2001, J EXP MED, V194, P275; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; Derrigo M, 2000, INT J MOL MED, V5, P111; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Dua K, 2001, PROTEOMICS, V1, P1191, DOI 10.1002/1615-9861(200110)1:10<1191::AID-PROT1191>3.0.CO;2-8; Evans JR, 2003, ONCOGENE, V22, P8012, DOI 10.1038/sj.onc.1206645; Fan H, 1998, MOL CELL BIOL, V18, P3201, DOI 10.1128/MCB.18.6.3201; Fang GF, 2000, BLOOD, V96, P2246, DOI 10.1182/blood.V96.6.2246.h8002246_2246_2253; Feigenblum D, 1996, MOL CELL BIOL, V16, P5450; Fu LN, 1996, EMBO J, V15, P4392, DOI 10.1002/j.1460-2075.1996.tb00812.x; Fu LN, 1999, ONCOGENE, V18, P6419, DOI 10.1038/sj.onc.1203064; GAILLARD C, 1994, NUCLEIC ACIDS RES, V22, P4183, DOI 10.1093/nar/22.20.4183; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Gopalkrishnan RV, 1999, INT J BIOCHEM CELL B, V31, P151, DOI 10.1016/S1357-2725(98)00138-1; Graff J, 1998, J VIROL, V72, P9668, DOI 10.1128/JVI.72.12.9668-9675.1998; Gray NK, 1998, METH MOL B, V77, P379; GRIFFIN JD, 1983, BLOOD, V61, P85; Groysman M, 1998, ONCOGENE, V17, P1597, DOI 10.1038/sj.onc.1202074; Habelhah H, 2001, NAT CELL BIOL, V3, P325, DOI 10.1038/35060131; Han BG, 2003, ONCOGENE, V22, P5325, DOI 10.1038/sj.onc.1206783; Harford JB, 1997, MRNA METABOLISM POST; Holcik M, 2003, MOL CELL BIOL, V23, P280, DOI 10.1128/MCB.23.1.280-288.2003; Holcik M, 2000, MOL CELL BIOL, V20, P4648, DOI 10.1128/MCB.20.13.4648-4657.2000; Honda H, 2000, BLOOD, V95, P1144, DOI 10.1182/blood.V95.4.1144.004k04_1144_1150; Iervolino A, 2002, MOL CELL BIOL, V22, P2255, DOI 10.1128/MCB.22.7.2255-2266.2002; Intine RV, 2003, MOL CELL, V12, P1301, DOI 10.1016/S1097-2765(03)00429-5; Kahvejian A, 2001, COLD SPRING HARB SYM, V66, P293, DOI 10.1101/sqb.2001.66.293; Kantarjian HM, 2002, BLOOD, V99, P3547, DOI 10.1182/blood.V99.10.3547; KANTARJIAN HM, 1993, BLOOD, V82, P691; Keene JD, 2002, MOL CELL, V9, P1161, DOI 10.1016/S1097-2765(02)00559-2; Kim JH, 2003, MOL CELL BIOL, V23, P708, DOI 10.1128/MCB.23.2.708-720.2003; Kim YK, 2001, NUCLEIC ACIDS RES, V29, P5009, DOI 10.1093/nar/29.24.5009; KOZAK M, 2001, SCI STKE, V71, pPE1; Kuersten S, 2003, NAT REV GENET, V4, P626, DOI 10.1038/nrg1125; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Lee MH, 1996, J BIOL CHEM, V271, P3420; Lincoln AJ, 1998, J BIOL CHEM, V273, P9552, DOI 10.1074/jbc.273.16.9552; Makeyev AV, 2002, RNA, V8, P265, DOI 10.1017/S1355838202024627; Maraia RJ, 2001, MOL CELL BIOL, V21, P367, DOI 10.1128/MCB.21.2.367-379.2001; MATULONIS U, 1993, EXP HEMATOL, V21, P1460; Mazan-Mamczarz K, 2003, P NATL ACAD SCI USA, V100, P8354, DOI 10.1073/pnas.1432104100; Meijer HA, 2002, BIOCHEM J, V367, P1, DOI 10.1042/BJ20011706; Meric F, 2002, MOL CANCER THER, V1, P971; Miau LH, 1998, J BIOL CHEM, V273, P10784, DOI 10.1074/jbc.273.17.10784; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; Nowicki MO, 2003, ONCOGENE, V22, P3952, DOI 10.1038/sj.onc.1206620; Ostareck DH, 2001, CELL, V104, P281, DOI 10.1016/S0092-8674(01)00212-4; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; Ostareck-Lederer A, 2002, MOL CELL BIOL, V22, P4535, DOI 10.1128/MCB.22.13.4535-4543.2002; Ostareck-Lederer A, 1998, TRENDS BIOCHEM SCI, V23, P409, DOI 10.1016/S0968-0004(98)01301-2; Perrotti D, 2000, MOL CELL BIOL, V20, P6159, DOI 10.1128/MCB.20.16.6159-6169.2000; Perrotti D, 2002, ONCOGENE, V21, P8577, DOI 10.1038/sj.onc.1206085; Perrotti D, 2002, NAT GENET, V30, P48, DOI 10.1038/ng791; Perrotti D, 1998, EMBO J, V17, P4442, DOI 10.1093/emboj/17.15.4442; Pestova TV, 2001, P NATL ACAD SCI USA, V98, P7029, DOI 10.1073/pnas.111145798; Prats AC, 2002, PROG NUCLEIC ACID RE, V72, P367, DOI 10.1016/S0079-6603(02)72075-8; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; Raught B, 1996, CANCER RES, V56, P4382; Raught B, 2001, P NATL ACAD SCI USA, V98, P7037, DOI 10.1073/pnas.121145898; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; Rosenwald IB, 1996, BIOESSAYS, V18, P243, DOI 10.1002/bies.950180312; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Salesse S, 2002, ONCOGENE, V21, P8605, DOI 10.1038/sj.onc.1206088; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Sawyers CL, 2002, BLOOD, V99, P3530, DOI 10.1182/blood.V99.10.3530; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; Schullery DS, 1999, J BIOL CHEM, V274, P15101, DOI 10.1074/jbc.274.21.15101; Shyu AB, 2000, CELL, V102, P135, DOI 10.1016/S0092-8674(00)00018-0; Silvera D, 1999, J BIOL CHEM, V274, P38163, DOI 10.1074/jbc.274.53.38163; Skorski T, 1996, P NATL ACAD SCI USA, V93, P13137, DOI 10.1073/pnas.93.23.13137; Skorski T, 1998, BLOOD, V91, P406, DOI 10.1182/blood.V91.2.406.406_406_418; Skorski T, 2002, ONCOGENE, V21, P8591, DOI 10.1038/sj.onc.1206087; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Skorski T, 1996, BLOOD, V88, P1005, DOI 10.1182/blood.V88.3.1005.1005; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; Sonenberg N, 1993, CURR OPIN CELL BIOL, V5, P955, DOI 10.1016/0955-0674(93)90076-3; STEWART MJ, 1995, LEUKEMIA, V9, P1499; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; Tenenbaum SA, 2002, METHODS, V26, P191, DOI 10.1016/S1046-2023(02)00022-1; Tenenbaum SA, 2000, P NATL ACAD SCI USA, V97, P14085, DOI 10.1073/pnas.97.26.14085; Thisted T, 2001, J BIOL CHEM, V276, P17484, DOI 10.1074/jbc.M010594200; Timchenko NA, 1999, NUCLEIC ACIDS RES, V27, P4517, DOI 10.1093/nar/27.22.4517; Tomonaga T, 1996, P NATL ACAD SCI USA, V93, P5830, DOI 10.1073/pnas.93.12.5830; Trotta R, 2003, CANCER CELL, V3, P145, DOI 10.1016/S1535-6108(03)00020-5; van der Velden AW, 1999, INT J BIOCHEM CELL B, V31, P87, DOI 10.1016/S1357-2725(98)00134-4; Waggoner SA, 2003, MOL CELL BIOL, V23, P7055, DOI 10.1128/MCB.23.19.7055-7067.2003; Willis AE, 1999, INT J BIOCHEM CELL B, V31, P73, DOI 10.1016/S1357-2725(98)00133-2; Wolin SL, 2002, ANNU REV BIOCHEM, V71, P375, DOI 10.1146/annurev.biochem.71.090501.150003; WONG KK, 1995, MOL CELL BIOL, V15, P6535; Yin YL, 2002, NAT CELL BIOL, V4, P462, DOI 10.1038/ncb801; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zimmer SG, 2000, ANTICANCER RES, V20, P1343; Zou XM, 1999, J BIOL CHEM, V274, P18141, DOI 10.1074/jbc.274.26.18141; Zou XM, 1997, GENE DEV, V11, P654, DOI 10.1101/gad.11.5.654	109	26	28	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2004	23	18					3222	3229		10.1038/sj.onc.1207543	http://dx.doi.org/10.1038/sj.onc.1207543			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	813AJ	15094772				2022-12-28	WOS:000220879700011
J	Salvesen, GS; Abrams, JM				Salvesen, GS; Abrams, JM			Caspase activation - stepping on the gas or releasing the brakes? Lessons from humans and flies	ONCOGENE			English	Review						caspase; IAP; apoptosis; zymogen activation; drosophila	PROGRAMMED CELL-DEATH; STRESS-INDUCED APOPTOSIS; DROSOPHILA CASPASE; CYTOCHROME-C; STRUCTURAL BASIS; CYSTEINE PROTEASE; IMMUNE-RESPONSE; IAP PROTEINS; GRANZYME-B; REAPER	The central components of the execution phase of apoptosis in worms, flies, and humans are members of the caspase protease family. Work in Drosophila and mammalian systems has revealed a web of interactions that govern the activity of these proteases, and two fundamental control points have been identified. These are zymogen activation-the process that converts a latent caspase into its active form, and inhibition of the resulting active protease. In humans, the driving force for caspase activity is activation of the zymogens, but in Drosophila, a major thrust is derepression of caspase inhibitors. In this review, we consider evidence for these two distinct events in terms of the regulation of caspase activity. This sets the scene for therapy to reinstate the normal death mechanisms that have been overcome in a cancer cell's quest for immortality.	Burnham Inst, Program Apoptosis & Cell Death Res, La Jolla, CA 92122 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA	Sanford Burnham Prebys Medical Discovery Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Salvesen, GS (corresponding author), Burnham Inst, Program Apoptosis & Cell Death Res, 10901 N Torrey Pines Rd, La Jolla, CA 92122 USA.	gsalvesen@burnham.org; john.abrams@utsouthwestern.edu			NCI NIH HHS [CA69381] Funding Source: Medline; NIA NIH HHS [AG15402, AG12466] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA069381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012466, R01AG015402] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abrams JM, 2002, CELL, V110, P403, DOI 10.1016/S0092-8674(02)00904-2; Abrams JM, 1999, TRENDS CELL BIOL, V9, P435, DOI 10.1016/S0962-8924(99)01646-3; Arama E, 2003, DEV CELL, V4, P687, DOI 10.1016/S1534-5807(03)00120-5; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Bose K, 2001, BIOCHEMISTRY-US, V40, P14236, DOI 10.1021/bi0110387; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; Chai JJ, 2001, CELL, V107, P399, DOI 10.1016/S0092-8674(01)00544-X; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chai JJ, 2003, NAT STRUCT BIOL, V10, P892, DOI 10.1038/nsb989; Chang DW, 2002, EMBO J, V21, P3704, DOI 10.1093/emboj/cdf356; Chaudhary PM, 2000, ONCOGENE, V19, P4451, DOI 10.1038/sj.onc.1203812; Chen P, 1996, J BIOL CHEM, V271, P25735, DOI 10.1074/jbc.271.42.25735; Chen P, 1998, DEV BIOL, V201, P202, DOI 10.1006/dbio.1998.9000; Christich A, 2002, CURR BIOL, V12, P137, DOI 10.1016/S0960-9822(01)00658-3; Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063; Claveria C, 2002, EMBO J, V21, P3327, DOI 10.1093/emboj/cdf354; Denault JB, 2003, J BIOL CHEM, V278, P34042, DOI 10.1074/jbc.M305110200; Denault JB, 2002, CHEM REV, V102, P4489, DOI 10.1021/cr010183n; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Ditzel M, 2003, NAT CELL BIOL, V5, P467, DOI 10.1038/ncb984; Donepudi M, 2003, MOL CELL, V11, P543, DOI 10.1016/S1097-2765(03)00059-5; Dorstyn L, 2002, J CELL BIOL, V156, P1089, DOI 10.1083/jcb.200111107; Dorstyn L, 1999, P NATL ACAD SCI USA, V96, P4307, DOI 10.1073/pnas.96.8.4307; Dorstyn L, 1999, J BIOL CHEM, V274, P30778, DOI 10.1074/jbc.274.43.30778; Doumanis J, 2001, CELL DEATH DIFFER, V8, P387, DOI 10.1038/sj.cdd.4400864; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Fraser AG, 1997, EMBO J, V16, P6192, DOI 10.1093/emboj/16.20.6192; Fraser AG, 1997, EMBO J, V16, P2805, DOI 10.1093/emboj/16.10.2805; Friedlander RM, 1997, NATURE, V388, P31, DOI 10.1038/40299; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Georgel P, 2001, DEV CELL, V1, P503, DOI 10.1016/S1534-5807(01)00059-4; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Harvey NL, 2001, J BIOL CHEM, V276, P25342, DOI 10.1074/jbc.M009444200; Hawkins CJ, 2000, J BIOL CHEM, V275, P27084; Hay BA, 2000, CELL DEATH DIFFER, V7, P1045, DOI 10.1038/sj.cdd.4400765; HEGDE R, 2001, J BIOL CHEM; Hoffmann JA, 2002, NAT IMMUNOL, V3, P121, DOI 10.1038/ni0202-121; Hoffmann JA, 2003, NATURE, V426, P33, DOI 10.1038/nature02021; Holley CL, 2002, NAT CELL BIOL, V4, P439, DOI 10.1038/ncb798; Hu SM, 2000, J BIOL CHEM, V275, P30761, DOI 10.1074/jbc.C000341200; Huang HK, 2000, J BIOL CHEM, V275, P26661; Huang YH, 2001, CELL, V104, P781, DOI 10.1016/S0092-8674(01)00273-2; Igaki T, 2002, EMBO J, V21, P3009, DOI 10.1093/emboj/cdf306; Jiang XJ, 2003, SCIENCE, V299, P223, DOI 10.1126/science.1076807; Kaiser WJ, 1998, FEBS LETT, V440, P243, DOI 10.1016/S0014-5793(98)01465-3; Kanda H, 2002, J BIOL CHEM, V277, P28372, DOI 10.1074/jbc.C200324200; Kanuka H, 1999, MOL CELL, V4, P757, DOI 10.1016/S1097-2765(00)80386-X; Kaufmann SH, 2003, ONCOGENE, V22, P7414, DOI 10.1038/sj.onc.1206945; Kauppila S, 2003, ONCOGENE, V22, P4860, DOI 10.1038/sj.onc.1206715; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Krajewska M, 2003, CLIN CANCER RES, V9, P4914; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Kumar S, 2000, CELL DEATH DIFFER, V7, P1039, DOI 10.1038/sj.cdd.4400756; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Leulier F, 2000, EMBO REP, V1, P353, DOI 10.1093/embo-reports/kvd073; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lippens S, 2000, CELL DEATH DIFFER, V7, P1218, DOI 10.1038/sj.cdd.4400785; Lisi S, 2000, GENETICS, V154, P669; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Lu YR, 2001, GENE DEV, V15, P104, DOI 10.1101/gad.856901; Manderson AP, 2001, J EXP MED, V194, P747, DOI 10.1084/jem.194.6.747; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; MARTINS LM, 2001, J BIOL CHEM; MCCALL K, 2003, 44 ANN DROS RES C A, V946; Meier P, 2000, EMBO J, V19, P598, DOI 10.1093/emboj/19.4.598; Meier P, 1998, CELL, V95, P295, DOI 10.1016/S0092-8674(00)81760-2; Micheau O, 2002, J BIOL CHEM, V277, P45162, DOI 10.1074/jbc.M206882200; Moreno E, 2002, CURR BIOL, V12, P1263, DOI 10.1016/S0960-9822(02)00954-5; Muro I, 2002, J BIOL CHEM, V277, P49644, DOI 10.1074/jbc.M203464200; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Naitza S, 2002, IMMUNITY, V17, P575, DOI 10.1016/S1074-7613(02)00454-5; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; Pop C, 2001, BIOCHEMISTRY-US, V40, P14224, DOI 10.1021/bi011037e; Quinn LM, 2000, J BIOL CHEM, V275, P40416, DOI 10.1074/jbc.M002935200; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Read SH, 2002, J CELL BIOL, V159, P739, DOI 10.1083/jcb.200209004; Reed JC, 2003, GENOME RES, V13, P1376, DOI 10.1101/gr.1053803; Reed John C., 1999, Current Opinion in Oncology, V11, P68, DOI 10.1097/00001622-199901000-00014; Riedl SJ, 2001, P NATL ACAD SCI USA, V98, P14790, DOI 10.1073/pnas.221580098; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(02)02036-6; Roberts DL, 2001, J CELL BIOL, V153, P221, DOI 10.1083/jcb.153.1.221; Rodriguez A, 2002, EMBO J, V21, P2189, DOI 10.1093/emboj/21.9.2189; Rodriguez A, 1999, NAT CELL BIOL, V1, P272, DOI 10.1038/12984; Ryoo HD, 2002, NAT CELL BIOL, V4, P432, DOI 10.1038/ncb795; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Schimmer AD, 2004, CANCER CELL, V5, P25, DOI 10.1016/S1535-6108(03)00332-5; Shi YG, 2001, NAT STRUCT BIOL, V8, P394, DOI 10.1038/87548; Shiozaki EN, 2003, MOL CELL, V11, P519, DOI 10.1016/S1097-2765(03)00054-6; Silverman N, 2000, GENE DEV, V14, P2461, DOI 10.1101/gad.817800; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Song ZW, 2000, MOL CELL BIOL, V20, P2907, DOI 10.1128/MCB.20.8.2907-2914.2000; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Srinivasula SM, 2002, CURR BIOL, V12, P125, DOI 10.1016/S0960-9822(01)00657-1; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Stoven S, 2000, EMBO REP, V1, P347, DOI 10.1093/embo-reports/kvd072; Stoven S, 2003, P NATL ACAD SCI USA, V100, P5991, DOI 10.1073/pnas.1035902100; Tamm I, 2000, CLIN CANCER RES, V6, P1796; Tenev T, 2002, EMBO J, V21, P5118, DOI 10.1093/emboj/cdf530; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Thress K, 1999, EMBO J, V18, P5486, DOI 10.1093/emboj/18.20.5486; Thress K, 1998, EMBO J, V17, P6135, DOI 10.1093/emboj/17.21.6135; Troy CM, 2001, J NEUROSCI, V21, P5007, DOI 10.1523/JNEUROSCI.21-14-05007.2001; Turk B, 2002, CURR PHARM DESIGN, V8, P1623, DOI 10.2174/1381612023394124; Uren AG, 1998, TRENDS BIOCHEM SCI, V23, P159, DOI 10.1016/S0968-0004(98)01198-0; van Loo G, 2002, CELL DEATH DIFFER, V9, P20, DOI 10.1038/sj.cdd.4400970; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Varkey J, 1999, J CELL BIOL, V144, P701, DOI 10.1083/jcb.144.4.701; VERHAGEN AM, 2001, J BIOL CHEM; Verhagen AM, 2001, GENOME BIOL, V2; Vernooy SY, 2002, CURR BIOL, V12, P1164, DOI 10.1016/S0960-9822(02)00935-1; Vucic D, 1997, P NATL ACAD SCI USA, V94, P10183, DOI 10.1073/pnas.94.19.10183; Vucic D, 1998, MOL CELL BIOL, V18, P3300, DOI 10.1128/MCB.18.6.3300; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; Wang SY, 1998, CELL, V92, P501, DOI 10.1016/S0092-8674(00)80943-5; Wei YY, 2000, CHEM BIOL, V7, P423, DOI 10.1016/S1074-5521(00)00123-X; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; Wilson R, 2002, NAT CELL BIOL, V4, P445, DOI 10.1038/ncb799; Wing JP, 2001, MECH DEVELOP, V102, P193, DOI 10.1016/S0925-4773(01)00316-1; Wing JP, 1998, CELL DEATH DIFFER, V5, P930, DOI 10.1038/sj.cdd.4400423; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Wu JW, 2001, MOL CELL, V8, P95, DOI 10.1016/S1097-2765(01)00282-9; Wu TYH, 2003, CHEM BIOL, V10, P759, DOI 10.1016/S1074-5521(03)00157-1; Yang XH, 1998, J BIOL CHEM, V273, P34278, DOI 10.1074/jbc.273.51.34278; Yoo SJ, 2002, NAT CELL BIOL, V4, P416, DOI 10.1038/ncb793; Yu SY, 2002, DEVELOPMENT, V129, P3269; Zheng TS, 2000, NAT MED, V6, P1241, DOI 10.1038/81343; Zhou L, 1999, MOL CELL, V4, P745, DOI 10.1016/S1097-2765(00)80385-8; Zimmermann KC, 2002, J CELL BIOL, V156, P1077, DOI 10.1083/jcb.20112068	135	204	208	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2004	23	16					2774	2784		10.1038/sj.onc.1207522	http://dx.doi.org/10.1038/sj.onc.1207522			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	811VO	15077141				2022-12-28	WOS:000220799600005
J	Slee, EA; O'Connor, DJ; Lu, X				Slee, EA; O'Connor, DJ; Lu, X			To die or not to die: how does p53 decide?	ONCOGENE			English	Review						p53; apoptosis; transactivation; transrepression	WILD-TYPE P53; TUMOR-SUPPRESSOR P53; TATA-BINDING PROTEIN; CELL-CYCLE ARREST; DNA-DAMAGE; P53-DEPENDENT APOPTOSIS; MUTANT P53; IN-VIVO; TRANSCRIPTIONAL REPRESSION; P53-INDUCED APOPTOSIS	p53 is frequently mutated in cancer and as a result is one of the most intensely studied tumour suppressors. Analysis of the primitive forms of p53 found in Caenorhabditis elegans and Drosophila, alongside studies using transgenic mouse models, indicate that the induction of apoptosis is both the most conserved function of p53 and vital for tumour suppression. p53-mediated apoptosis occurs through a combination of mechanisms which include pathways that are both dependent and independent of alterations in gene expression. In response to genotoxic insult, these pathways probably act together, thereby amplifying the apoptotic signal. However, the picture is complicated because the p53 activity is determined by stress type and individual cellular characteristics. The numerous p53 responsive genes that have been identified also provide further means of controlling the actions of p53. The recent discoveries of proteins that interact with p53 and specifically regulate the ability of p53 to trigger apoptosis have provided further mechanistic insights into the role of p53 in inducing cell death. Understanding the molecular basis of the proapoptotic action of p53 can assist in our quest to reintroduce or reactivate p53 in human tumours.	Imperial Coll Sch Med St Marys, Ludwig Inst Canc Res, London W2 1PG, England	Imperial College London; Ludwig Institute for Cancer Research	Lu, X (corresponding author), Imperial Coll Sch Med St Marys, Ludwig Inst Canc Res, Norfolk Pl, London W2 1PG, England.	x.lu@imperial.ac.uk		Lu, Xin/0000-0002-6587-1152				Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Bergamaschi D, 2003, NAT GENET, V33, P162, DOI 10.1038/ng1070; Bernal JA, 2002, NAT GENET, V32, P306, DOI 10.1038/ng997; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Bourdon JC, 2002, J CELL BIOL, V158, P235, DOI 10.1083/jcb.200203006; Bouvard V, 2000, ONCOGENE, V19, P649, DOI 10.1038/sj.onc.1203366; Brodsky MH, 2000, CELL, V101, P103, DOI 10.1016/S0092-8674(00)80627-3; Bullock AN, 2001, NAT REV CANCER, V1, P68, DOI 10.1038/35094077; Burns TF, 2003, CANCER BIOL THER, V2, P431, DOI 10.4161/cbt.2.4.478; Burns TF, 2001, ONCOGENE, V20, P4601, DOI 10.1038/sj.onc.1204484; Bykov VJN, 2003, EUR J CANCER, V39, P1828, DOI 10.1016/S0959-8049(03)00454-4; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Contente A, 2002, NAT GENET, V30, P315, DOI 10.1038/ng836; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Derry WB, 2001, SCIENCE, V294, P591, DOI 10.1126/science.1065486; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; Dobbelstein M, 1998, J GEN VIROL, V79, P3079, DOI 10.1099/0022-1317-79-12-3079; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Farmer G, 1996, MOL CELL BIOL, V16, P4295; Fei PW, 2002, CANCER RES, V62, P7316; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Friedler A, 2002, P NATL ACAD SCI USA, V99, P937, DOI 10.1073/pnas.241629998; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HALDAR S, 1994, CANCER RES, V54, P2095; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Hsieh JK, 2002, MOL CELL BIOL, V22, P78, DOI 10.1128/MCB.22.1.78-93.2002; Hwang PM, 2001, NAT MED, V7, P1111, DOI 10.1038/nm1001-1111; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; Jin SK, 2000, P NATL ACAD SCI USA, V97, P7301, DOI 10.1073/pnas.97.13.7301; Jin SK, 2003, GENE DEV, V17, P359, DOI 10.1101/gad.1047003; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Knudson CM, 2001, CANCER RES, V61, P659; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Langheinrich U, 2002, CURR BIOL, V12, P2023, DOI 10.1016/S0960-9822(02)01319-2; Le Bras M, 2003, ONCOGENE, V22, P5082, DOI 10.1038/sj.onc.1206424; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Liu G, 2002, ONCOGENE, V21, P7195, DOI 10.1038/sj.onc.1205862; Lossos IS, 2002, LEUKEMIA LYMPHOMA, V43, P2309, DOI 10.1080/1042819021000040017; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; LUNA RMD, 1995, NATURE, V378, P203; MacCallum DE, 1996, ONCOGENE, V13, P2575; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Matsuda K, 2002, CANCER RES, V62, P2883; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Moll UM, 2001, FEBS LETT, V493, P65, DOI 10.1016/S0014-5793(01)02284-0; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Nagashima M, 2001, P NATL ACAD SCI USA, V98, P9671, DOI 10.1073/pnas.161151798; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; O'Connor DJ, 2000, ONCOGENE, V19, P2369, DOI 10.1038/sj.onc.1203540; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Ollmann M, 2000, CELL, V101, P91, DOI 10.1016/S0092-8674(00)80626-1; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Sansome C, 2001, FEBS LETT, V488, P110, DOI 10.1016/S0014-5793(00)02368-1; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Schumacher B, 2001, CURR BIOL, V11, P1722, DOI 10.1016/S0960-9822(01)00534-6; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Shibue T, 2003, GENE DEV, V17, P2233, DOI 10.1101/gad.1103603; Shikama N, 1999, MOL CELL, V4, P365, DOI 10.1016/S1097-2765(00)80338-X; Smith PD, 1999, ONCOGENE, V18, P2451, DOI 10.1038/sj.onc.1202565; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Sogame N, 2003, P NATL ACAD SCI USA, V100, P4696, DOI 10.1073/pnas.0736384100; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wu GS, 2000, ADV EXP MED BIOL, V465, P143; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zhou YL, 2003, J BIOL CHEM, V278, P462, DOI 10.1074/jbc.M203793200; Zilfou JT, 2001, MOL CELL BIOL, V21, P3974, DOI 10.1128/MCB.21.12.3974-3985.2001	110	218	235	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2004	23	16					2809	2818		10.1038/sj.onc.1207516	http://dx.doi.org/10.1038/sj.onc.1207516			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	811VO	15077144				2022-12-28	WOS:000220799600008
J	Hwang, YS; Jeong, M; Park, JS; Kim, MH; Lee, DB; Shin, BA; Mukaida, N; Ellis, LM; Kim, HR; Ahn, BW; Jung, YD				Hwang, YS; Jeong, M; Park, JS; Kim, MH; Lee, DB; Shin, BA; Mukaida, N; Ellis, LM; Kim, HR; Ahn, BW; Jung, YD			Interleukin-1 beta stimulates IL-8 expression through MAP kinase and ROS signaling in human gastric carcinoma cells	ONCOGENE			English	Article						IL-8; MAPK; ROS; gastric cancer; IL-1 beta	NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; HELICOBACTER-PYLORI; MESSENGER-RNA; TRANSCRIPTION FACTOR; ACTIVATION; ANGIOGENESIS; CANCER; LINE; GENE	Recent studies have suggested that the expression of interleukin-8 (IL-8) directly correlates with the vascularity of human gastric carcinomas. In this study, the effect of IL-1beta on IL-8 expression in human gastric cancer TMK-1 cells and the underlying signal transduction pathways were investigated. IL-1beta induced the IL-8 expression in a time- and concentration-dependent manner. IL-1beta induced the activation of extracellular signal-regulated kinases-1/2 and P38 mitogen-activated protein kinase ( MAPK), but not the activation of c-jun amino-terminal kinse and Akt. Specific inhibitors of MEK-1 (PD980590) and P38 MAPK (SB203580) were found to suppress the IL-8 expression and the IL-8 promoter activity. Expression of vectors encoding a mutated-type MEK-1 and P38 MAPK resulted in decrease in the IL-8 promoter activity. IL-1beta also induced the production of reactive oxygen species (ROS). N-acetyl cysteine (NAC) prevented the IL-1beta-induced ROS production and IL-8 expression. In addition, exogenous H2O2 could induce the IL-8 expression. Deletional and site-directed mutagenesis studies on the IL-8 promoter revealed that activator protein-1 (AP-1) and nuclear factor (NF)-kappaB sites were required for the IL-1beta-induced IL-8 transcription. Electrophoretic mobility shift assay confirmed that IL-1beta increased the DNA-binding activity of AP-1 and NF-kappaB. Inhibitor ( PD980590, SB203580) and ROS scavenger ( NAC) studies revealed that the upstream signalings for the transcription factors AP-1 and NF-kappaB were MAPK and ROS, respectively. Conditioned media from the TMK-1 cells pretreated with IL-1beta could remarkably stimulate the in vitro growth of HUVEC and this effect was partially abrogated by IL-8-neutralizing antibodies. The above results suggest that MAPK-AP-1 and ROS-NF-kappaB signaling pathways are involved in the IL-1beta-induced IL-8 expression and that these paracrine signaling pathways induce endothelial cell proliferation.	Chonnam Natl Univ, Sch Med, Chonnam Univ Res Inst Med Sci, Dept Biochem, Kwangju 501190, South Korea; Kanazawa Univ, Canc Res Inst, Div Mol Bioregulat, Kanazawa, Ishikawa 9200934, Japan; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	Chonnam National University; Kanazawa University; University of Texas System; UTMD Anderson Cancer Center	Jung, YD (corresponding author), Chonnam Natl Univ, Sch Med, Chonnam Univ Res Inst Med Sci, Dept Biochem, 5 Hakdong, Kwangju 501190, South Korea.	ydjung@chonnam.ac.kr	KIM, MI HA/E-9765-2013; Mukaida, Naofumi/D-7623-2011	Mukaida, Naofumi/0000-0002-4193-1851				Anthonsen MW, 2001, J BIOL CHEM, V276, P35344, DOI 10.1074/jbc.M105264200; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Duval C, 2003, FREE RADICAL BIO MED, V35, P1589, DOI 10.1016/j.freeradbiomed.2003.09.008; Emrick MA, 2001, J BIOL CHEM, V276, P46469, DOI 10.1074/jbc.M107708200; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Ganesh S, 1996, CANCER-AM CANCER SOC, V77, P1035, DOI 10.1002/(SICI)1097-0142(19960315)77:6<1035::AID-CNCR5>3.0.CO;2-G; Ge BX, 2002, SCIENCE, V295, P1291, DOI 10.1126/science.1067289; Goede V, 1998, LAB INVEST, V78, P1385; Guan ZH, 1997, J BIOL CHEM, V272, P8083, DOI 10.1074/jbc.272.12.8083; Guiraldes E, 2001, J PEDIATR GASTR NUTR, V33, P127, DOI 10.1097/00005176-200108000-00006; Harris GK, 2003, MUTAT RES-FUND MOL M, V533, P183, DOI 10.1016/j.mrfmmm.2003.08.025; Heidemann J, 2003, J BIOL CHEM, V278, P8508, DOI 10.1074/jbc.M208231200; Hirschi K K, 1997, EXS, V79, P419; Hofmeister R, 1997, J BIOL CHEM, V272, P27730, DOI 10.1074/jbc.272.44.27730; Jung YD, 2002, CYTOKINE, V18, P206, DOI 10.1006/cyto.2002.1034; KASAHARA T, 1991, IMMUNOLOGY, V74, P60; Katsuyama K, 2001, J BIOCHEM, V129, P585, DOI 10.1093/oxfordjournals.jbchem.a002894; Kitadai Y, 1999, BRIT J CANCER, V81, P647, DOI 10.1038/sj.bjc.6690742; Kitadai Y, 1998, AM J PATHOL, V152, P93; Klezovitch O, 2001, J BIOL CHEM, V276, P46864, DOI 10.1074/jbc.M107943200; KUNSCH C, 1994, J IMMUNOL, V153, P153; Lo YYC, 1998, J CELL BIOCHEM, V69, P19, DOI 10.1002/(SICI)1097-4644(19980401)69:1<19::AID-JCB3>3.0.CO;2-Y; Maeda S, 2001, J BIOL CHEM, V276, P44856, DOI 10.1074/jbc.M105381200; Mastronarde JG, 1998, J INFECT DIS, V177, P1275, DOI 10.1086/515279; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; OCHIAI A, 1985, JPN J CANCER RES, V76, P1064; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; Rennekampff HO, 2000, J SURG RES, V93, P41, DOI 10.1006/jsre.2000.5892; Schwarz M, 1997, KIDNEY INT, V52, P1521, DOI 10.1038/ki.1997.482; Shin EY, 2001, EXP MOL MED, V33, P276, DOI 10.1038/emm.2001.45; Singh RK, 2000, HISTOL HISTOPATHOL, V15, P843, DOI 10.14670/HH-15.843; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Straubinger RK, 2003, INFECT IMMUN, V71, P2693, DOI 10.1128/IAI.71.5.2693-2703.2003; Thannickal VJ, 1995, J BIOL CHEM, V270, P30334, DOI 10.1074/jbc.270.51.30334; Wang MC, 1999, J GASTROENTEROL, V34, P10; Welsh N, 1996, J BIOL CHEM, V271, P8307, DOI 10.1074/jbc.271.14.8307; Wolf JS, 2001, CLIN CANCER RES, V7, P1812; Wu LL, 2004, CLIN CHIM ACTA, V339, P1, DOI 10.1016/j.cccn.2003.09.010; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506	40	107	111	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6603	6611		10.1038/sj.onc.1207867	http://dx.doi.org/10.1038/sj.onc.1207867			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15208668				2022-12-28	WOS:000223530800007
J	Nakata, S; Yoshida, T; Horinaka, M; Shiraishi, T; Wakada, M; Sakai, T				Nakata, S; Yoshida, T; Horinaka, M; Shiraishi, T; Wakada, M; Sakai, T			Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells	ONCOGENE			English	Article						death receptor 5; histone deacetylase inhibitors; TRAIL; apoptosis; Bid; caspases	TRAIL-INDUCED APOPTOSIS; WAF1/CIP1 GENE PROMOTER; DECOY RECEPTORS; LEUKEMIA-CELLS; LIGAND TRAIL; HUMAN COLON; SP1 SITES; TUMORICIDAL ACTIVITY; KILLER/DR5 GENE; GROWTH ARREST	Death receptor 5 (DR5) is a receptor for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). TRAIL is a promising candidate for cancer therapeutics due to its ability to induce apoptosis selectively in cancer cells. Here, we report that histone deacetylase inhibitors (HDACIs) such as trichostatin A (TSA), sodium butyrate, and suberoylanilide hydroxamic acid (SAHA) upregulated DR5 expression in various human malignant tumor cells. An RNase protection assay demonstrated that HDACIs induced DR5 mRNA markedly but not that of other death receptor family members in Jurkat cells. HDACIs increased DR5 mRNA and protein in a dose- and time-dependent manner. We also show TSA increased DR5 promoter activity using a luciferase promoter assay. Furthermore, we demonstrated that HDACIs strongly sensitized exogenous soluble recombinant human TRAIL-induced apoptosis synergistically in Jurkat and HL-60 cells that were tolerant to TRAIL alone. The combined use of HDACIs and TRAIL in suboptimal concentrations induced Bid cleavage and activation of caspase-8, -10, -3, and -9. Human recombinant DR5/Fc chimera protein, zVAD-fmk pancaspase inhibitor, and caspase-8 and -10 inhibitors efficiently reduced apoptosis induced by cotreatment with HDACIs and TRAIL. Furthermore, TSA did not significantly induce DR5 protein and HDACIs did not enhance TRAIL-induced apoptosis in normal human peripheral blood mononuclear cells. These results suggest that this combined treatment with HDACIs and TRAIL is a promising strategy for new cancer therapeutics.	Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Targeting Canc Prevent, Kamigyo Ku, Kyoto 6028566, Japan; Kyoto Prefectural Univ, Dept Appl Biochem, Kyoto 6068522, Japan; Kyoto Prefectural Univ Med, Dept Urol, Kyoto 6028566, Japan	Kyoto Prefectural University of Medicine; Kyoto Prefectural University; Kyoto Prefectural University of Medicine	Sakai, T (corresponding author), Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Targeting Canc Prevent, Kamigyo Ku, Kyoto 6028566, Japan.	tsakai@koto.kpu-m.ac.jp						Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Davie JR, 1998, CURR OPIN GENET DEV, V8, P173, DOI 10.1016/S0959-437X(98)80138-X; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Gong BD, 2000, CANCER RES, V60, P5754; Griffith TS, 1999, J IMMUNOL, V162, P2597; He Q, 2002, ONCOGENE, V21, P6032, DOI 10.1038/sj.onc.1205897; He Q, 2002, ONCOGENE, V21, P2623, DOI 10.1038/sj.onc.1205345; Hirose T, 2003, ONCOGENE, V22, P7762, DOI 10.1038/sj.onc.1207091; Hitomi T, 2003, FEBS LETT, V554, P347, DOI 10.1016/S0014-5793(03)01186-4; Huang LL, 2000, ONCOGENE, V19, P5712, DOI 10.1038/sj.onc.1203963; Huang Y, 2001, CANCER RES, V61, P6918; Ichikawa K, 2001, NAT MED, V7, P954, DOI 10.1038/91000; Inoue H, 2002, INT J MOL MED, V9, P521; Jang YJ, 2003, CANCER LETT, V194, P107, DOI 10.1016/S0304-3835(02)00680-8; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Keane MM, 1999, CANCER RES, V59, P734; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Koornstra JJ, 2003, J PATHOL, V200, P327, DOI 10.1002/path.1364; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; Kramer OH, 2001, TRENDS ENDOCRIN MET, V12, P294, DOI 10.1016/S1043-2760(01)00438-6; Kuang AA, 2000, J BIOL CHEM, V275, P25065, DOI 10.1074/jbc.C000284200; LaVallee TM, 2003, CANCER RES, V63, P468; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Mariani SM, 1997, J CELL BIOL, V137, P221, DOI 10.1083/jcb.137.1.221; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Meng RD, 2001, EXP CELL RES, V262, P154, DOI 10.1006/excr.2000.5073; Mitsiades N, 2001, CANCER RES, V61, P2704; Muhlenbeck F, 1998, J BIOL CHEM, V273, P33091, DOI 10.1074/jbc.273.49.33091; Nagane M, 2000, CANCER RES, V60, P847; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Neuzil H, 2004, BIOCHEM BIOPH RES CO, V314, P186, DOI 10.1016/j.bbrc.2003.12.074; Oh SC, 2001, MOL CELLS, V11, P192; Ohtsuka T, 2003, ONCOGENE, V22, P2034, DOI 10.1038/sj.onc.1206290; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Rosato RR, 2003, MOL CANCER THER, V2, P1273; Screaton GR, 1997, CURR BIOL, V7, P693, DOI 10.1016/S0960-9822(06)00297-1; Sheikh MS, 1998, CANCER RES, V58, P1593; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shigeno M, 2003, ONCOGENE, V22, P1653, DOI 10.1038/sj.onc.1206139; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Sun SY, 1999, ONCOGENE, V18, P2357, DOI 10.1038/sj.onc.1202543; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Tang XM, 2002, CANCER RES, V62, P4903; Walczak H, 2000, CANCER RES, V60, P3051; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wen JH, 2000, BLOOD, V96, P3900, DOI 10.1182/blood.V96.12.3900.h8003900_3900_3906; Wu GS, 1999, ONCOGENE, V18, P6411, DOI 10.1038/sj.onc.1203025; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; YOSHIDA M, 1988, EXP CELL RES, V177, P122, DOI 10.1016/0014-4827(88)90030-4; Yoshida T, 2001, FEBS LETT, V507, P381, DOI 10.1016/S0014-5793(01)02947-7; Zhang XD, 2003, BIOCHEM PHARMACOL, V66, P1537, DOI 10.1016/S0006-2952(03)00509-4	59	240	251	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2004	23	37					6261	6271		10.1038/sj.onc.1207830	http://dx.doi.org/10.1038/sj.onc.1207830			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	847NC	15208660				2022-12-28	WOS:000223399000010
J	Rao, G; Pedone, CA; Del Valle, L; Reiss, K; Holland, EC; Fults, DW				Rao, G; Pedone, CA; Del Valle, L; Reiss, K; Holland, EC; Fults, DW			Sonic hedgehog and insulin-like growth factor signaling synergize to induce medulloblastoma formation from nestin-expressing neural progenitors in mice	ONCOGENE			English	Article						medulloblastoma; IGF2; sonic hedgehog; RCAS/tv-a; neural progenitors	HUMAN HOMOLOG; I RECEPTOR; N-MYC; GENE; PROTEIN; PROLIFERATION; MUTATIONS; SYSTEM; ACTIVATION; ALLELE	Medulloblastoma (MB) is a malignant brain tumor that arises in the cerebellum of children. Activation of the Sonic hedgehog/Patched (Shh/Ptc) signaling pathway in neural progenitor cells of the cerebellum induces MBs in mice. The incomplete penetrance of tumor formation in mice, coupled with the low frequency of mutations in Shh/Ptc pathway genes in human tumors, suggests that other signaling molecules cooperate with Shh to enhance MB formation. We modeled the ability of insulin-like growth factor (IGF) signaling to induce MB using the RCAS/tv-a system, which allows postnatal gene transfer and expression in a cell-type-specific manner. We used RCAS retroviral vectors to target expression of Shh, IGF2, and activated Akt to nestin-expressing neural progenitors in the cerebella of newborn mice. The incidence of Shh-induced tumor formation (15%) was enhanced by coexpression with IGF2 (39%) and Akt (48%). Neither IGF2 nor Akt caused tumors when expressed independently. The induced tumors showed upregulated expression of insulin receptor substrate 1 and phosphorylated forms of IGF1 receptor and Akt, mimicking activated IGF signaling found in human MBs. These results indicate that combined activation of the Shh/Ptc and IGF signaling pathways is an important mechanism in MB pathogenesis.	Univ Utah, Sch Med, Dept Neurosurg, Salt Lake City, UT 84132 USA; Temple Univ, Ctr Neurovirol & Canc Biol, Philadelphia, PA 19112 USA; Mem Sloan Kettering Canc Ctr, Dept Surg Neurosurg, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Neurol & Cell Biol, New York, NY 10021 USA	Utah System of Higher Education; University of Utah; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Fults, DW (corresponding author), Univ Utah, Sch Med, Dept Neurosurg, 30 North 1900 East, Salt Lake City, UT 84132 USA.	daniel.fults@hsc.utah.edu	Del Valle, Luis/J-4085-2015	Del Valle, Luis/0000-0003-3894-9206				Adini I, 2003, GENE DEV, V17, P2721, DOI 10.1101/gad.1134603; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Calzada-Wack J, 2002, CARCINOGENESIS, V23, P727, DOI 10.1093/carcin/23.5.727; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; COFFIN CM, 1990, MODERN PATHOL, V3, P164; Dahmane N, 2001, DEVELOPMENT, V128, P5201; Del Valle L, 2002, CLIN CANCER RES, V8, P1822; EASTER SS, 1993, J NEUROSCI, V13, P285; FEDERSPIEL MJ, 1994, P NATL ACAD SCI USA, V91, P11241, DOI 10.1073/pnas.91.23.11241; Fults D, 2000, NEURO-ONCOLOGY, V2, P71, DOI 10.1093/neuonc/2.2.71; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Hahn H, 2000, J BIOL CHEM, V275, P28341, DOI 10.1074/jbc.C000352200; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; Holland EC, 1998, P NATL ACAD SCI USA, V95, P1218, DOI 10.1073/pnas.95.3.1218; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kenney AM, 2004, DEVELOPMENT, V131, P217, DOI 10.1242/dev.00891; Kenney AM, 2003, DEVELOPMENT, V130, P15, DOI 10.1242/dev.00182; Khandwala HM, 2000, ENDOCR REV, V21, P215, DOI 10.1210/er.21.3.215; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Oliver TG, 2003, P NATL ACAD SCI USA, V100, P7331, DOI 10.1073/pnas.0832317100; Pietsch T, 1997, CANCER RES, V57, P2085; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Raffel C, 1997, CANCER RES, V57, P842; Rao G, 2003, NEOPLASIA, V5, P198, DOI 10.1016/S1476-5586(03)80052-0; Rubini M, 1999, EXP CELL RES, V251, P22, DOI 10.1006/excr.1999.4562; WAKAMATSU Y, 1993, NEURON, V10, P1, DOI 10.1016/0896-6273(93)90236-K; Wang JY, 2001, ONCOGENE, V20, P3857, DOI 10.1038/sj.onc.1204532; Wechsler-Reya R, 2001, ANNU REV NEUROSCI, V24, P385, DOI 10.1146/annurev.neuro.24.1.385; Weiner HL, 2002, CANCER RES, V62, P6385; Wetmore C, 2000, CANCER RES, V60, P2239; Wolter M, 1997, CANCER RES, V57, P2581; Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6; Zhao Q, 2002, P NATL ACAD SCI USA, V99, P5704, DOI 10.1073/pnas.082092399; Zurawel RH, 2000, GENE CHROMOSOME CANC, V27, P44, DOI 10.1002/(SICI)1098-2264(200001)27:1<44::AID-GCC6>3.0.CO;2-V	37	186	191	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6156	6162		10.1038/sj.onc.1207818	http://dx.doi.org/10.1038/sj.onc.1207818			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15195141				2022-12-28	WOS:000223261000015
J	Michels, J; O'Neill, JW; Dallman, CL; Mouzakiti, A; Habens, F; Brimmell, M; Zhang, KYJ; Craig, RW; Marcusson, EG; Johnson, PWM; Packham, G				Michels, J; O'Neill, JW; Dallman, CL; Mouzakiti, A; Habens, F; Brimmell, M; Zhang, KYJ; Craig, RW; Marcusson, EG; Johnson, PWM; Packham, G			Mcl-1 is required for Akata6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage	ONCOGENE			English	Article						apoptosis; Mcl-1; antisense; non-Hodgkin's lymphoma; Bcl-2; caspase	CHRONIC LYMPHOCYTIC-LEUKEMIA; APOPTOSIS-REGULATING PROTEINS; BCL-2 FAMILY; IN-VIVO; EXPRESSION; HOMOLOG; DIFFERENTIATION; ACTIVATION; PROTECTS; MYELOMA	Enforced expression of the antiapoptotic Bcl-2 family protein Mcl-1 promotes lymphomagenesis in the mouse; however, the functional role of Mcl-1 in human B-cell lymphoma remains unclear. We demonstrate that Mcl-1 is widely expressed in malignant B-cells, and high-level expression of Mcl-1 is required for B-lymphoma cell survival, since transfection of Mcl-1-specific antisense oligodeoxynucleotides was sufficient to promote apoptosis in Akata6 lymphoma cells. Mcl-1 was efficiently cleaved by caspases at evolutionarily conserved aspartic acid residues in vitro, and during cisplatin-induced apoptosis in B-lymphoma cell lines and spontaneous apoptosis of primary malignant B-cells. Overexpression of the Mcl-1 cleavage product that accumulated during apoptosis was sufficient to kill cells. Therefore, Mcl-1 is an essential survival molecule for B-lymphoma cells and is cleaved by caspases to a death-promoting molecule during apoptosis. In contrast to Mcl-1, Bcl-2 and Bcl-X-L were relatively resistant to caspase cleavage in vitro and in intact cells. Interfering with Mcl-1 function appears to be an effective means of inducing apoptosis in Mcl-1-positive B-cell lymphoma, and the unique sensitivity of Mcl-1 to caspase-mediated cleavage suggests an attractive strategy for converting it to a proapoptotic molecule.	Univ Southampton, Sch Med, Canc Sci Div, Canc Res UK Oncol Unit, Southampton, Hants, England; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98104 USA; Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, Hanover, NH USA; ISIS Pharmaceut, Dept Mol Pharmacol, Carlsbad, CA 92008 USA	University of Southampton; Fred Hutchinson Cancer Center; Dartmouth College; Isis Pharmaceuticals Inc	Packham, G (corresponding author), Southampton Gen Hosp, Canc Res UK Oncol Unit, Somers Canc Res Bldg MP824,Tremona Rd, Southampton SO16 6YD, Hants, England.	G.K.Packham@soton.ac.uk	Zhang, Kam Y. J./B-3552-2012; Johnson, Peter/O-3529-2019; Johnson, Peter/L-2403-2018	Zhang, Kam Y. J./0000-0002-9282-8045; Johnson, Peter/0000-0003-2306-4974; Johnson, Peter/0000-0003-2306-4974; Marcusson, Eric/0000-0002-0504-8674; Packham, Graham/0000-0002-9232-5691	NATIONAL CANCER INSTITUTE [R01CA057359] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA57359] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Agarwal B, 2002, AM J HEMATOL, V70, P278, DOI 10.1002/ajh.10139; Akgul C, 2000, FEBS LETT, V478, P72, DOI 10.1016/S0014-5793(00)01809-3; Altmeyer A, 1997, IMMUNITY, V7, P667, DOI 10.1016/S1074-7613(00)80387-8; Bannerman DD, 2001, J BIOL CHEM, V276, P14924, DOI 10.1074/jbc.M100819200; Bellosillo B, 1999, BLOOD, V94, P2836, DOI 10.1182/blood.V94.8.2836.420k35_2836_2843; Borner C, 2003, MOL IMMUNOL, V39, P615, DOI 10.1016/S0161-5890(02)00252-3; Byrd JC, 2002, BLOOD, V99, P1038, DOI 10.1182/blood.V99.3.1038; CAZALSHATEM DL, 1992, BIOCHIM BIOPHYS ACTA, V1132, P109, DOI 10.1016/0167-4781(92)90064-7; Chen MC, 2001, BBA-GENE STRUCT EXPR, V1519, P127, DOI 10.1016/S0167-4781(01)00209-3; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; CRAIG RW, 1984, CANCER RES, V44, P2421; Craig RW, 2002, LEUKEMIA, V16, P444, DOI 10.1038/sj.leu.2402416; Cuconati A, 2003, GENE DEV, V17, P2922, DOI 10.1101/gad.1156903; DALLMAN CL, 2004, IN PRESS MOL METHODS; Derenne S, 2002, BLOOD, V100, P194, DOI 10.1182/blood.V100.1.194; Drexler HG., 2001, LEUKEMIA LYMPHOMA CE, P2, DOI [10.1016/B978-012221970-2/50002-4, DOI 10.1016/B978-012221970-2/50002-4]; Ghia P, 1998, BLOOD, V91, P244, DOI 10.1182/blood.V91.1.244.244_244_251; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Herrant M, 2002, ONCOGENE, V21, P4957, DOI 10.1038/sj.onc.1205689; Iglesias-Serret D, 2003, ARCH BIOCHEM BIOPHYS, V417, P141, DOI 10.1016/S0003-9861(03)00345-X; Inman GJ, 2001, J VIROL, V75, P2400, DOI 10.1128/JVI.75.5.2400-2410.2001; Johnson DE, 2000, LEUKEMIA, V14, P1695, DOI 10.1038/sj.leu.2401879; Khoury JD, 2003, J PATHOL, V199, P90, DOI 10.1002/path.1254; Kitada S, 1998, BLOOD, V91, P3379, DOI 10.1182/blood.V91.9.3379; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Lenoir G M, 1985, IARC Sci Publ, P309; Lomo J, 1996, CANCER RES, V56, P40; Moulding DA, 2000, BLOOD, V96, P1756, DOI 10.1182/blood.V96.5.1756.h8001756_1756_1763; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; NIHAWAN D, 2003, GENE DEV, V17, P1475; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; OXFORD SME, 2004, IN PRESS CURRENT MED; Packham G, 1997, BIOCHEM J, V328, P807, DOI 10.1042/bj3280807; Packham G, 1998, APOPTOSIS, V3, P75, DOI 10.1023/A:1009688706783; Pagnano KBB, 2002, ACTA HAEMATOL-BASEL, V107, P29, DOI 10.1159/000046626; Pedersen IM, 2002, BLOOD, V100, P1795, DOI 10.1182/blood.V100.5.1795.h81702001795_1795_1801; Pepper C, 2002, EUR J HAEMATOL, V69, P227, DOI 10.1034/j.1600-0609.2002.02799.x; Samejima K, 1999, J BIOL CHEM, V274, P4335, DOI 10.1074/jbc.274.7.4335; Snowden RT, 2003, LEUKEMIA, V17, P1981, DOI 10.1038/sj.leu.2403088; Soini Y, 1998, TUMOR BIOL, V19, P176, DOI 10.1159/000030005; Spender LC, 1999, J VIROL, V73, P4678, DOI 10.1128/JVI.73.6.4678-4688.1999; Spets H, 2002, EUR J HAEMATOL, V69, P76, DOI 10.1034/j.1600-0609.2002.01549.x; TAKADA K, 1991, VIRUS GENES, V5, P147, DOI 10.1007/BF00571929; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Vrana JA, 2002, CANCER RES, V62, P892; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885; Zhou P, 2001, BLOOD, V97, P3902, DOI 10.1182/blood.V97.12.3902	51	121	130	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2004	23	28					4818	4827		10.1038/sj.onc.1207648	http://dx.doi.org/10.1038/sj.onc.1207648			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	830EK	15122313				2022-12-28	WOS:000222104200002
J	Tonini, T; Bagella, L; D'Andrilli, G; Claudio, PP; Giordano, A				Tonini, T; Bagella, L; D'Andrilli, G; Claudio, PP; Giordano, A			Ezh2 reduces the ability of HDAC1-dependent pRb2/p130 transcriptional repression of cyclin A	ONCOGENE			English	Article						polycomb; Ezh2; pRb2/p130	POLYCOMB-GROUP PROTEINS; RETINOBLASTOMA FAMILY PROTEINS; CDK2 KINASE; GROUP GENES; EXPRESSION; BMI-1; P107; PROLIFERATION; CLONING; DIFFERENTIATION	The polycomb group (PcG) proteins are known to be involved in maintaining the silenced state of several developmentally regulated genes. Enhancer of zeste homolog 2 (Ezh2), a member of this large protein family, has also been shown to be deregulated in different tumor types and its role, both as a potential primary effector and as a mediator of tumorigenesis, has become a subject of increased interest. We observed that Ezh2 binds to pRb2/p130, a member of the retinoblastoma family; as such, we were led to consider the possible ability of Ezh2 to modulate cell cycle progression. Both Ezh2 and pRb2/p130 repress gene expression by recruiting histone deacetylase (HDAC1), which decreases DNA accessibility for activating transcription factors. Additionally, we observed that Ezh2 interacts with the C-terminal region of pRb2/p130, essential for interaction with HDAC1. We show that Ezh2 is able to reverse pRb2/p130-HDAC1-mediated repression of the cyclin A promoter. This indicates a functional role of this complex in regulating cyclin A expression, known to be crucial in mediating cell cycle advancement. We also detected a significant decrease in the retention of HDAC1 activity associated with pRb2/p130 when Ezh2 was overexpressed. Finally, electromobility shift assays ( EMSA) demonstrated that overexpression of Ezh2 caused the abrogation of the pRb2/p130-HDAC1 complex on the cyclin A promoter. These data, taken together, suggest that Ezh2 competes with HDAC1 in binding to pRb2/p130, disrupting their occupancy on the cyclin A promoter. In this study, we propose a new mechanism for the functional inactivation of pRb2/p130 that ultimately contributes to cell cycle progression and malignant transformation.	Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Ctr Biotechnol, Philadelphia, PA 19122 USA; Univ Siena, Policlin La Scotte, Dept Human Pathol & Oncol, I-53100 Siena, Italy; Dept Sci Odontostomatol & Maxillo Facciali, Naples, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Siena	Giordano, A (corresponding author), Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Ctr Biotechnol, Bio Life Sci Bldg,Suite 333,1900 N 12th St, Philadelphia, PA 19122 USA.	giordano@temple.edu	Claudio, Pier Paolo/AAW-7282-2021; Giordano, Antonio/F-1927-2010	Claudio, Pier Paolo/0000-0001-7790-1622; Giordano, Antonio/0000-0002-5959-016X; BAGELLA, Luigi/0000-0003-2815-037X				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Bardos JI, 2000, J BIOL CHEM, V275, P28785, DOI 10.1074/jbc.M001835200; Bellan C, 2002, INVEST OPHTH VIS SCI, V43, P3602; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Carbone M, 1997, ONCOGENE, V15, P1877, DOI 10.1038/sj.onc.1201375; Claudio P, 2002, GENOME BIOL, V3; Claudio PP, 2002, CLIN CANCER RES, V8, P1808; Cohen KJ, 1996, MOL CELL BIOL, V16, P5527; DeLuca A, 1997, J BIOL CHEM, V272, P20971, DOI 10.1074/jbc.272.34.20971; DeLuca A, 1997, NAT MED, V3, P913, DOI 10.1038/nm0897-913; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Fukuyama T, 2000, BRIT J HAEMATOL, V108, P842, DOI 10.1046/j.1365-2141.2000.01914.x; Galderisi U, 2001, MOL CELL NEUROSCI, V17, P415, DOI 10.1006/mcne.2000.0949; Gould A, 1997, CURR OPIN GENET DEV, V7, P488, DOI 10.1016/S0959-437X(97)80075-5; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; Gunster MJ, 1997, MOL CELL BIOL, V17, P2326, DOI 10.1128/MCB.17.4.2326; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; Hobert O, 1996, MOL CELL BIOL, V16, P3066; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Kennison JA, 1995, ANNU REV GENET, V29, P289, DOI 10.1146/annurev.ge.29.120195.001445; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; LaThangue NB, 1996, BIOCHEM SOC T, V24, P54; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; Macaluso M, 2003, ONCOGENE, V22, P6472, DOI 10.1038/sj.onc.1206955; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MAYOL X, 1993, ONCOGENE, V8, P2561; MULLER J, 1995, EMBO J, V14, P1209, DOI 10.1002/j.1460-2075.1995.tb07104.x; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; PIPAS JM, 1992, J VIROL, V66, P3979, DOI 10.1128/JVI.66.7.3979-3985.1992; Pirrotta V, 1997, CURR OPIN GENET DEV, V7, P249, DOI 10.1016/S0959-437X(97)80135-9; Pirrotta V, 1998, CELL, V93, P333, DOI 10.1016/S0092-8674(00)81162-9; Pirrotta V, 1997, TRENDS GENET, V13, P314, DOI 10.1016/S0168-9525(97)01178-5; Pupa SM, 1999, ONCOGENE, V18, P651, DOI 10.1038/sj.onc.1202363; Raaphorst FM, 2000, AM J PATHOL, V157, P709, DOI 10.1016/S0002-9440(10)64583-X; Raschella G, 1998, CELL DEATH DIFFER, V5, P401, DOI 10.1038/sj.cdd.4400359; Raschella G, 2001, MED PEDIATR ONCOL, V36, P104, DOI 10.1002/1096-911X(20010101)36:1<104::AID-MPO1024>3.0.CO;2-9; Rhodes DR, 2003, J NATL CANCER I, V95, P661, DOI 10.1093/jnci/95.9.661; Sanseverino F, 2003, CANCER BIOL THER, V2, P636; Satijn DPE, 1999, BBA-GENE STRUCT EXPR, V1447, P1, DOI 10.1016/S0167-4781(99)00130-X; Satijn DPE, 1999, MOL CELL BIOL, V19, P57; Schumacher A, 1997, TRENDS GENET, V13, P167, DOI 10.1016/S0168-9525(97)01133-5; Sellers WR, 2002, CANCER CELL, V2, P349, DOI 10.1016/S1535-6108(02)00187-3; Sewalt RGAB, 1998, MOL CELL BIOL, V18, P3586, DOI 10.1128/MCB.18.6.3586; Sidle A, 1996, CRIT REV BIOCHEM MOL, V31, P237, DOI 10.3109/10409239609106585; SIMON J, 1995, CURR OPIN CELL BIOL, V7, P376, DOI 10.1016/0955-0674(95)80093-X; Stiegler P, 1998, CANCER RES, V58, P5049; Tonini T, 2003, ONCOGENE, V22, P6549, DOI 10.1038/sj.onc.1206816; Tonini T, 2002, J CELL PHYSIOL, V192, P138, DOI 10.1002/jcp.10117; TURNER BM, 1991, J CELL SCI, V99, P13; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; van Kemenade FJ, 2001, BLOOD, V97, P3896, DOI 10.1182/blood.V97.12.3896; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Visser HPJ, 2001, BRIT J HAEMATOL, V112, P950, DOI 10.1046/j.1365-2141.2001.02641.x	56	57	68	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2004	23	28					4930	4937		10.1038/sj.onc.1207608	http://dx.doi.org/10.1038/sj.onc.1207608			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	830EK	15077161				2022-12-28	WOS:000222104200014
J	Treuner, K; Helton, R; Barlow, C				Treuner, K; Helton, R; Barlow, C			Loss of Rad52 partially rescues tumorigenesis and T-cell maturation in Atm-deficient mice	ONCOGENE			English	Article						Rad52; Ataxia Telangiectasia; Atm-/-mice; DNA repair; tumorigenesis	DOUBLE-STRAND BREAKS; HOMOLOGOUS RECOMBINATION; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; INCREASED FREQUENCY; PROTEIN; NEUROGENESIS; DISRUPTION; RESISTANCE; DOMAIN	Ataxia Telangiectasia (A-T) is an autosomal recessive disease caused by loss of function of the protein kinase ATM. Atm-deficient mice display several phenotypes consistent with the human disease, including predisposition to cancer, growth retardation, cell-proliferation defects and infertility. A-T patients have a several hundred fold increased risk of developing lymphomas and leukemias, which are typically highly invasive. By reducing homologous recombination through genetic deletion of the Rad52 protein, we were able to decrease substantially the development of T-cell lymphomas in Atm-/- mice, resulting in an increased life span of the double mutant mice. Additionally, we were able to partially rescue the T-cell development of Atm-/- mice. Other phenotypes, including growth defects, genomic instability, infertility and radiosensitivity, were not rescued. Our results suggest that excessive recombination is an important contributor to tumorigenesis in A-T.	Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA	Salk Institute	Barlow, C (corresponding author), Salk Inst Biol Studies, Genet Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	carrolee_barlow@merck.com			NINDS NIH HHS [NS39601] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039601] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Baynton K, 2003, J BIOL CHEM, V278, P36476, DOI 10.1074/jbc.M303885200; Bishop AJR, 2003, CANCER RES, V63, P5335; Bishop AJR, 2000, CANCER RES, V60, P395; Chakraverty RK, 1999, BIOESSAYS, V21, P286; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; Germain RN, 2002, NAT REV IMMUNOL, V2, P309, DOI 10.1038/nri798; GERMAN J, 1995, DERMATOL CLIN, V13, P7, DOI 10.1016/S0733-8635(18)30101-3; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687; Kagawa W, 2002, MOL CELL, V10, P359, DOI 10.1016/S1097-2765(02)00587-7; Lee Y, 2000, GENE DEV, V14, P2576, DOI 10.1101/gad.837100; Lisby M, 2003, NAT CELL BIOL, V5, P572, DOI 10.1038/ncb997; Liyanage M, 2000, BLOOD, V96, P1940, DOI 10.1182/blood.V96.5.1940.h8001940_1940_1946; Luo LP, 1998, CANCER RES, V58, P2293; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; Mohaghegh P, 2001, HUM MOL GENET, V10, P741, DOI 10.1093/hmg/10.7.741; Petiniot LK, 2000, P NATL ACAD SCI USA, V97, P6664, DOI 10.1073/pnas.97.12.6664; Petiniot LK, 2002, MOL CELL BIOL, V22, P3174, DOI 10.1128/MCB.22.9.3174-3177.2002; Rijkers T, 1998, MOL CELL BIOL, V18, P6423, DOI 10.1128/MCB.18.11.6423; Sekiguchi J, 2001, P NATL ACAD SCI USA, V98, P3243, DOI 10.1073/pnas.051632098; Sigurdsson S, 2002, J BIOL CHEM, V277, P42790, DOI 10.1074/jbc.M208004200; Singleton MR, 2002, P NATL ACAD SCI USA, V99, P13492, DOI 10.1073/pnas.212449899; Solinger JA, 2002, MOL CELL, V10, P1175, DOI 10.1016/S1097-2765(02)00743-8; Symington LS, 2002, MICROBIOL MOL BIOL R, V66, P630, DOI 10.1128/MMBR.66.4.630-670.2002; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Wong KK, 2003, NATURE, V421, P643, DOI 10.1038/nature01385	29	26	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2004	23	27					4655	4661		10.1038/sj.onc.1207604	http://dx.doi.org/10.1038/sj.onc.1207604			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZX	15122331				2022-12-28	WOS:000221799200001
J	Hasenjager, A; Gillissen, B; Muller, A; Normand, G; Hemmati, PG; Schuler, M; Dorken, B; Daniel, PT				Hasenjager, A; Gillissen, B; Muller, A; Normand, G; Hemmati, PG; Schuler, M; Dorken, B; Daniel, PT			Smac induces cytochrome c release and apoptosis independently from Bax/Bcl-x(L) in a strictly caspase-3-dependent manner in human carcinoma cells	ONCOGENE			English	Article						Smac; apoptosis; Bax; Bcl-x(L); caspase-3; caspase-9	DRUG-INDUCED APOPTOSIS; IDENTIFIES PATIENTS; DNA FRAGMENTATION; SERINE-PROTEASE; BAX; CASPASE-3; OVEREXPRESSION; ACTIVATION; EXPRESSION; DEATH	The mitochondrial apoptosis pathway mediates cell death through the release of various pro-apoptotic factors including cytochrome c and Smac, the second mitochondrial activator of caspases, into the cytosol. Smac was shown previously to inhibit IAP proteins and to facilitate initiation of the caspase cascade upon cytochrome c release. To investigate Smac function during apoptosis and to explore Smac as an experimental cancer therapeutic, we constructed an expression system based on a single adenoviral vector containing Smac under control of the Tet-off system supplied in cis. Conditional expression of Smac induced apoptosis in human HCT116 and DU145 carcinoma cells regardless of the loss of Bax or overexpression of BCl-X-L. Nevertheless, apoptosis induced by Smac was associated with cytochrome c release and breakdown of the mitochondrial membrane potential. This indicates that Smac acts independently of Bax and BCl-X-L during initiation of apoptosis and triggers a positive feedback loop that results in Bax/BCl-X-L-independent activation of mitochondria. In caspase-proficient cells, Smac-induced apoptosis could be inhibited partially by cell-permeable LEHD (caspase-9 inhibitor) and DEVD (caspase-3 inhibitor) peptides. Furthermore, loss of caspase-3 expression in MCF-7 cells carrying a caspase-3 null mutation completely abrogated the sensitivity for Smac-induced apoptotic or nonapoptotic, necrosis-like cell death, while re-expression of caspase-3 conferred sensitivity. Altogether, caspase-3 but not caspase-9 activation was necessary for execution of Smac-induced cell death. Notably, Smac did not induce caspase-9 processing in the absence of caspase-3. Thus, caspase-9 processing occurs secondary to caspase-3 activation during Smac-induced apoptosis. Altogether, Smac is capable of circumventing defects in mitochondrial apoptosis signaling such as loss of Bax or overexpression of BCl-X-L that are frequently observed in tumor cells resistant to anticancer therapy. Consequently, Smac appears to be a promising therapeutic target in anticancer treatment.	Humboldt Univ, Univ Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany; Johannes Gutenberg Univ Mainz, Dept Med 3, Mainz, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Johannes Gutenberg University of Mainz	Daniel, PT (corresponding author), Humboldt Univ, Univ Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, Campus Berlin Buch,Lindenberger Weg 80, D-13125 Berlin, Germany.	pdaniel@mdc-berlin.de	Normand, Guillaume/A-1975-2010	Gillissen, Bernhard/0000-0002-1815-2091; Normand, Guillaume/0000-0003-1228-3813				Anderson RD, 2000, GENE THER, V7, P1034, DOI 10.1038/sj.gt.3301197; Bosanquet AG, 2002, LEUKEMIA, V16, P1035, DOI 10.1038/sj.leu.2402539; Brand K, 1997, CANCER GENE THER, V4, P9; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; COSSET FL, 1995, J VIROL, V69, P7430, DOI 10.1128/JVI.69.12.7430-7436.1995; Daniel PT, 1999, ANAL BIOCHEM, V266, P110, DOI 10.1006/abio.1998.2929; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Ekert PG, 2001, J CELL BIOL, V152, P483, DOI 10.1083/jcb.152.3.483; Friedrich K, 2001, ONCOGENE, V20, P2749, DOI 10.1038/sj.onc.1204342; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Guner D, 2003, INT J CANCER, V103, P445, DOI 10.1002/ijc.10850; Guo F, 2002, BLOOD, V99, P3419, DOI 10.1182/blood.V99.9.3419; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Lorenzo HK, 1999, CELL DEATH DIFFER, V6, P516, DOI 10.1038/sj.cdd.4400527; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; MROZEK A, 2003, IN PRESS CELL DEATH; Okada H, 2002, MOL CELL BIOL, V22, P3509, DOI 10.1128/MCB.22.10.3509-3517.2002; Prokop A, 2000, LEUKEMIA, V14, P1606, DOI 10.1038/sj.leu.2401866; Radetzki S, 2002, ONCOGENE, V21, P227, DOI 10.1038/sj/onc/1205010; Raisova M, 2001, J INVEST DERMATOL, V117, P333, DOI 10.1046/j.0022-202x.2001.01409.x; RAU B, 2003, IN PRESS J CLIN ONCO; Roberts DL, 2001, J CELL BIOL, V153, P221, DOI 10.1083/jcb.153.1.221; Schelwies K, 2002, INT J CANCER, V99, P589, DOI 10.1002/ijc.10380; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Sturm I, 2003, CELL DEATH DIFFER, V10, P477, DOI 10.1038/sj.cdd.4401194; Sturm I, 2001, J CLIN ONCOL, V19, P2272, DOI 10.1200/JCO.2001.19.8.2272; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	37	68	77	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2004	23	26					4523	4535		10.1038/sj.onc.1207594	http://dx.doi.org/10.1038/sj.onc.1207594			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZV	15064710	Bronze			2022-12-28	WOS:000221799000003
J	Kimura, A; Ohmichi, M; Kawagoe, J; Kyo, S; Mabuchi, S; Takahashi, T; Ohshima, C; Arimoto-Ishida, E; Nishio, Y; Inoue, M; Kurachi, H; Tasaka, K; Murata, Y				Kimura, A; Ohmichi, M; Kawagoe, J; Kyo, S; Mabuchi, S; Takahashi, T; Ohshima, C; Arimoto-Ishida, E; Nishio, Y; Inoue, M; Kurachi, H; Tasaka, K; Murata, Y			Induction of hTERT expression and phosphorylation by estrogen via Akt cascade in human ovarian cancer cell lines	ONCOGENE			English	Article						estrogen; telomerase; Akt; ovarian cancer	TELOMERASE REVERSE-TRANSCRIPTASE; NF-KAPPA-B; REGULATED PROTEIN-KINASE; CATALYTIC SUBUNIT GENE; NITRIC-OXIDE SYNTHASE; CRITICAL DETERMINANT; MESSENGER-RNA; ACTIVATION; INHIBITION; RECEPTOR	We examined the mechanism by which estrogen regulates telomerase activity in Caov-3 human ovarian cancer cell lines, which express ER, to determine whether the regulation affects the expression and/or phosphorylation of the telomerase catalytic subunit (hTERT). 17beta-Estradiol (E-2) induced telomerase activity and hTERT expression. Transient expression assays using luciferase reporter plasmids containing various fragments of hTERT promoter showed that the estrogen-responsive element appeared to be partially responsible for the E-2-induced activation of the hTERT promoter. Either pretreatment with a phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002, or transfection with a dominant-negative Akt attenuated the E-2-induced activation of the hTERT promoter. In addition, estrogen induced the phosphorylation Of IkappaB inhibitor protein via the Akt cascade, and cotransfection with a dominant-negative subunit of NFkappaB attenuated the response of the ERE-deleted hTERT promoter to E-2-Moreover, E2 induced the phosphorylation of hTERT, the association of 14-3-3 protein and NFkappaB with hTERT, and nuclear accumulation of hTERT in an Akt-dependent manner. These results indicate that E-2 induces telomerase activity not only by transcriptional regulation of hTERT via an ERE-dependent mechanism and a PI3K/Akt/NFkappaB cascade, but also by post-transcriptional regulation via Akt-dependent phosphorylation of hTERT. Thus, the phosphorylation of Akt is a key event in the induction of telomeras activity by E-2 in human ovarian cancer cells.	Osaka Univ, Sch Med, Dept Obstet & Gynecol, Suita, Osaka 5650871, Japan; Yamagata Univ, Sch Med, Dept Obstet & Gynecol, Yamagata 9909585, Japan; Kanazawa Univ, Sch Med, Dept Obstet & Gynecol, Kanazawa, Ishikawa 920, Japan; Yamagata Univ, Sch Med, Div Nursing, Yamagata 9909585, Japan	Osaka University; Yamagata University; Kanazawa University; Yamagata University	Ohmichi, M (corresponding author), Osaka Univ, Sch Med, Dept Obstet & Gynecol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	masa@gyne.med.osaka-u.ac.jp	Mabuchi, Seiji/AAX-1986-2020					Akalin A, 2001, CANCER RES, V61, P4791; Akiyama M, 2003, CANCER RES, V63, P18; Akiyama M, 2002, CANCER RES, V62, P3876; Alfonso-De Matte MY, 2002, CANCER RES, V62, P4575; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Boldrini L, 2002, INT J ONCOL, V21, P493; Bourgarel-Rey V, 2001, MOL PHARMACOL, V59, P1165, DOI 10.1124/mol.59.5.1165; Breitschopf K, 2001, FEBS LETT, V493, P21, DOI 10.1016/S0014-5793(01)02272-4; Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chow SN, 1996, INT SURG, V81, P152; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARLEY CB, 1995, CURR OPIN GENET DEV, V5, P249, DOI 10.1016/0959-437X(95)80016-6; Hayakawa J, 2000, CANCER RES, V60, P5988; Hisamoto K, 2001, J BIOL CHEM, V276, P47642, DOI 10.1074/jbc.M103853200; Hisamoto K, 2001, J BIOL CHEM, V276, P3459, DOI 10.1074/jbc.M005036200; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; Kanaya T, 1998, INT J CANCER, V78, P539, DOI 10.1002/(SICI)1097-0215(19981123)78:5<539::AID-IJC2>3.0.CO;2-I; Kang SS, 1999, J BIOL CHEM, V274, P13085, DOI 10.1074/jbc.274.19.13085; Kawagoe J, 2003, J BIOL CHEM, V278, P43363, DOI 10.1074/jbc.M304363200; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kraemer K, 2003, CLIN CANCER RES, V9, P3794; Kyo S, 1999, INT J CANCER, V80, P804; Kyo S, 1999, INT J CANCER, V80, P60, DOI 10.1002/(SICI)1097-0215(19990105)80:1<60::AID-IJC12>3.3.CO;2-5; Kyo S, 1999, CANCER RES, V59, P5917; Lacey JV, 2002, JAMA-J AM MED ASSOC, V288, P334, DOI 10.1001/jama.288.3.334; Li H, 1998, J BIOL CHEM, V273, P33436, DOI 10.1074/jbc.273.50.33436; Li H, 1997, J BIOL CHEM, V272, P16729, DOI 10.1074/jbc.272.27.16729; Liu JP, 1999, FASEB J, V13, P2091, DOI 10.1096/fasebj.13.15.2091; Liu KB, 2001, J IMMUNOL, V166, P4826, DOI 10.4049/jimmunol.166.8.4826; Mabuchi S, 2002, J BIOL CHEM, V277, P33490, DOI 10.1074/jbc.M204042200; Maida Y, 2002, ONCOGENE, V21, P4071, DOI 10.1038/sj.onc.1205509; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406; Misiti S, 2000, MOL CELL BIOL, V20, P3764, DOI 10.1128/MCB.20.11.3764-3771.2000; Moorhead G, 1996, CURR BIOL, V6, P1104, DOI 10.1016/S0960-9822(02)70677-5; Murakami J, 1997, CANCER, V80, P1085; Nakano K, 1998, AM J PATHOL, V153, P857, DOI 10.1016/S0002-9440(10)65627-1; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; Ozes ON, 1999, NATURE, V401, P82; Park TW, 1999, INT J CANCER, V84, P426, DOI 10.1002/(SICI)1097-0215(19990820)84:4<426::AID-IJC17>3.3.CO;2-T; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Seimiya H, 2000, EMBO J, V19, P2652, DOI 10.1093/emboj/19.11.2652; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Takakura M, 1998, CANCER RES, V58, P1558; Taniguchi T, 1999, BLOOD, V93, P4167, DOI 10.1182/blood.V93.12.4167.412k05_4167_4178; Teng LS, 2003, J CLIN ENDOCR METAB, V88, P1362, DOI 10.1210/jc.2002-021222; Wang Z, 2000, CANCER RES, V60, P5376; Wang ZO, 2002, ONCOGENE, V21, P3517, DOI 10.1038/sj.onc.1205463; Wick M, 1999, GENE, V232, P97, DOI 10.1016/S0378-1119(99)00108-0; Yang J, 1999, EMBO J, V18, P2174, DOI 10.1093/emboj/18.8.2174; Yeilding NM, 1996, MOL CELL BIOL, V16, P3511; Yin L, 2000, J BIOL CHEM, V275, P36671, DOI 10.1074/jbc.M007378200	61	114	123	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2004	23	26					4505	4515		10.1038/sj.onc.1207582	http://dx.doi.org/10.1038/sj.onc.1207582			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZV	15048073				2022-12-28	WOS:000221799000001
J	Peterson, LF; Zhang, DE				Peterson, LF; Zhang, DE			The 8; 21 translocation in leukemogenesis	ONCOGENE			English	Review						translocation; myeloid leukemia; RUNX; AML; ETO; MTG8	ACUTE MYELOID-LEUKEMIA; CORE-BINDING-FACTOR; ACUTE MYELOGENOUS LEUKEMIA; T(8/21) FUSION PROTEIN; ZINC-FINGER PROTEIN; DROSOPHILA SEGMENTATION GENE; STIMULATING FACTOR-RECEPTOR; T-CELL-RECEPTOR; DNA-BINDING; GRANULOCYTIC DIFFERENTIATION	A common chromosomal translocation in acute myeloid leukemia (AML) involves the AML1 ( acute myeloid leukemia 1, also called RUNX1, core binding factor protein (CBFalpha), and PEBP2alphaB) gene on chromosome 21 and the ETO (eight-twenty one, also called MTG8) gene on chromosome 8. This translocation generates an AML1-ETO fusion protein. t(8; 21) is associated with 12% of de novo AML cases and up to 40% in the AML subtype M2 of the French-American-British classification. Furthermore, it is also reported in a small portion of M0, M1, and M4 AML samples. Despite numerous studies on the function of AML1-ETO, the precise mechanism by which the fusion protein is involved in leukemia development is still not fully understood. In this review, we will discuss structural aspects of the fusion protein and the accumulated knowledge from in vitro analyses on AML1-ETO functions, and outline putative mechanisms of its leukemogenic potential.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Zhang, DE (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, Mail Drop MEM-L51, La Jolla, CA 92037 USA.	dzhang@scripps.edu	Molina, Maria del Carmen MC/H-9399-2015	Molina, Maria del Carmen MC/0000-0002-8397-5887	NATIONAL CANCER INSTITUTE [P01CA072009, R01CA096735] Funding Source: NIH RePORTER; NCI NIH HHS [CA096735, CA072009] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn MY, 1998, P NATL ACAD SCI USA, V95, P1812, DOI 10.1073/pnas.95.4.1812; Alcalay M, 2003, J CLIN INVEST, V112, P1751, DOI 10.1172/JCI17595; Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Aplan PD, 1997, EMBO J, V16, P2408, DOI 10.1093/emboj/16.9.2408; Barseguian K, 2002, P NATL ACAD SCI USA, V99, P15434, DOI 10.1073/pnas.242588499; Burel SA, 2001, MOL CELL BIOL, V21, P5577, DOI 10.1128/MCB.21.16.5577-5590.2001; Calabi F, 1998, GENOMICS, V52, P332, DOI 10.1006/geno.1998.5429; Chen JD, 1998, CRIT REV EUKAR GENE, V8, P169, DOI 10.1615/CritRevEukarGeneExpr.v8.i2.40; Chen XN, 1997, BLOOD, V90, P156; Chevallier N, 2004, BLOOD, V103, P1454, DOI 10.1182/blood-2003-06-2081; Davie JR, 1999, BIOCHEM CELL BIOL, V77, P265, DOI 10.1139/bcb-77-4-265; Davie JR, 1997, MOL BIOL REP, V24, P197, DOI 10.1023/A:1006811817247; Davis JN, 1999, ONCOGENE, V18, P1375, DOI 10.1038/sj.onc.1202412; de Guzman CG, 2002, MOL CELL BIOL, V22, P5506, DOI 10.1128/MCB.22.15.5506-5517.2002; DEGREEF GE, 1995, LEUKEMIA, V9, P282; DUFFY JB, 1991, GENE DEV, V5, P2176, DOI 10.1101/gad.5.12a.2176; Elagib KE, 2003, BLOOD, V101, P4333, DOI 10.1182/blood-2002-09-2708; Elsasser A, 2003, ONCOGENE, V22, P5646, DOI 10.1038/sj.onc.1206673; ERICKSON P, 1992, BLOOD, V80, P1825; ERICKSON PF, 1994, CANCER RES, V54, P1782; FEINSTEIN PG, 1995, GENETICS, V140, P573; Felix CA, 1998, BBA-GENE STRUCT EXPR, V1400, P233, DOI 10.1016/S0167-4781(98)00139-0; Frank R, 1995, ONCOGENE, V11, P2667; Fukuyama T, 2001, ONCOGENE, V20, P6225, DOI 10.1038/sj.onc.1204794; GAO JZ, 1991, P NATL ACAD SCI USA, V88, P4882, DOI 10.1073/pnas.88.11.4882; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Ghozi MC, 1996, P NATL ACAD SCI USA, V93, P1935, DOI 10.1073/pnas.93.5.1935; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GILKS CB, 1993, MOL CELL BIOL, V13, P1759, DOI 10.1128/MCB.13.3.1759; Goetz TL, 2000, MOL CELL BIOL, V20, P81, DOI 10.1128/MCB.20.1.81-90.2000; Grisolano JL, 2003, P NATL ACAD SCI USA, V100, P9506, DOI 10.1073/pnas.1531730100; Gross CT, 1996, EMBO J, V15, P1961, DOI 10.1002/j.1460-2075.1996.tb00547.x; Gu TL, 2000, MOL CELL BIOL, V20, P91, DOI 10.1128/MCB.20.1.91-103.2000; Harada Y, 2001, BIOCHEM BIOPH RES CO, V284, P714, DOI 10.1006/bbrc.2001.5005; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; Hildebrand D, 2001, J BIOL CHEM, V276, P9889, DOI 10.1074/jbc.M010582200; Hock H, 2003, IMMUNITY, V18, P109, DOI 10.1016/S1074-7613(02)00501-0; HSIANG YHH, 1993, J IMMUNOL, V150, P3905; Hug BA, 2002, CANCER RES, V62, P2906; Hwang ES, 1999, FEBS LETT, V446, P86, DOI 10.1016/S0014-5793(99)00190-8; Imai Y, 1998, BIOCHEM BIOPH RES CO, V252, P582, DOI 10.1006/bbrc.1998.9705; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; Kanno T, 1998, MOL CELL BIOL, V18, P2444, DOI 10.1128/MCB.18.5.2444; Karsunky H, 2002, ONCOGENE, V21, P1571, DOI 10.1038/sj/onc/1205216; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; Kitabayashi I, 1998, MOL CELL BIOL, V18, P846, DOI 10.1128/MCB.18.2.846; Klampfer L, 1996, P NATL ACAD SCI USA, V93, P14059, DOI 10.1073/pnas.93.24.14059; Kohzaki H, 1999, ONCOGENE, V18, P4055, DOI 10.1038/sj.onc.1202735; Komori A, 1999, JPN J CANCER RES, V90, P60, DOI 10.1111/j.1349-7006.1999.tb00666.x; KOZU T, 1993, BLOOD, V82, P1270; Kurokawa M, 1996, ONCOGENE, V12, P883; Le XF, 1998, EUR J HAEMATOL, V60, P217; Levanon D, 1996, DNA CELL BIOL, V15, P175, DOI 10.1089/dna.1996.15.175; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Levanon D, 2001, GENE, V262, P23, DOI 10.1016/S0378-1119(00)00532-1; Li FQ, 2004, J BIOL CHEM, V279, P2873, DOI 10.1074/jbc.M310759200; Libermann TA, 1999, J BIOL CHEM, V274, P24671, DOI 10.1074/jbc.274.35.24671; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; Liu PT, 2003, NAT IMMUNOL, V4, P525, DOI 10.1038/ni925; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Lutterbach B, 1998, MOL CELL BIOL, V18, P3604, DOI 10.1128/MCB.18.6.3604; Mao SF, 1999, MOL CELL BIOL, V19, P3635; Mayall TP, 1997, GENE DEV, V11, P887, DOI 10.1101/gad.11.7.887; McGhee L, 2003, J CELL BIOCHEM, V89, P1005, DOI 10.1002/jcb.10548; McNeil S, 1999, P NATL ACAD SCI USA, V96, P14882, DOI 10.1073/pnas.96.26.14882; Melnick A, 2000, BLOOD, V96, P3939, DOI 10.1182/blood.V96.12.3939.h8003939_3939_3947; Melnick AM, 2000, MOL CELL BIOL, V20, P2075, DOI 10.1128/MCB.20.6.2075-2086.2000; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Mulloy JC, 2003, BLOOD, V102, P4369, DOI 10.1182/blood-2003-05-1762; Mulloy JC, 2002, BLOOD, V99, P15, DOI 10.1182/blood.V99.1.15; NISSON PE, 1992, CANCER GENET CYTOGEN, V63, P81, DOI 10.1016/0165-4608(92)90384-K; Odaka R, 2000, ONCOGENE, V19, P3584, DOI 10.1038/sj.onc.1203689; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; Rhoades KL, 1996, P NATL ACAD SCI USA, V93, P11895, DOI 10.1073/pnas.93.21.11895; ROWLEY JD, 1973, ANN GENET-PARIS, V16, P109; Saleque S, 2002, GENE DEV, V16, P301, DOI 10.1101/gad.959102; Schwieger M, 2002, J EXP MED, V196, P1227, DOI 10.1084/jem.20020824; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; Shimada H, 2002, LEUKEMIA, V16, P874, DOI 10.1038/sj.leu.2402465; Shimada H, 2000, BLOOD, V96, P655; SHIMIZU K, 1992, CANCER RES, V52, P6945; Shimizu K, 2000, BLOOD, V96, P288, DOI 10.1182/blood.V96.1.288.013k05_288_296; SUN WW, 1995, J VIROL, V69, P4941, DOI 10.1128/JVI.69.8.4941-4949.1995; TIGHE JE, 1993, BLOOD, V81, P592; TIGHE JE, 1995, CLIN SCI, V89, P215, DOI 10.1042/cs0890215; Tong B, 1998, MOL CELL BIOL, V18, P2462, DOI 10.1128/MCB.18.5.2462; TONKS A, 2002, BLOOD, V101, P2002; VANGALA RK, 2002, BLOOD, V101, P2002; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Wolford JK, 1998, GENE, V212, P103, DOI 10.1016/S0378-1119(98)00141-3; Wood JD, 2000, J CELL BIOL, V150, P939, DOI 10.1083/jcb.150.5.939; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; Xiao Z, 2001, LEUKEMIA, V15, P1906, DOI 10.1038/sj.leu.2402318; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Yuan YZ, 2001, P NATL ACAD SCI USA, V98, P10398, DOI 10.1073/pnas.171321298; Zeng CM, 1998, P NATL ACAD SCI USA, V95, P1585, DOI 10.1073/pnas.95.4.1585; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085; Zhang JS, 2001, MOL CELL BIOL, V21, P156, DOI 10.1128/MCB.21.1.156-163.2001; Zhang YM, 2002, P NATL ACAD SCI USA, V99, P3070, DOI 10.1073/pnas.042702899	113	233	258	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2004	23	24					4255	4262		10.1038/sj.onc.1207727	http://dx.doi.org/10.1038/sj.onc.1207727			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823BZ	15156181				2022-12-28	WOS:000221586000010
J	Lanvin, O; Gouilleux, F; Mullie, C; Maziere, C; Fuentes, V; Bissac, E; Dantin, F; Maziere, JC; Regnier, A; Lassoued, K; Gouilleux-Gruart, V				Lanvin, O; Gouilleux, F; Mullie, C; Maziere, C; Fuentes, V; Bissac, E; Dantin, F; Maziere, JC; Regnier, A; Lassoued, K; Gouilleux-Gruart, V			Interleukin-7 induces apoptosis of 697 pre-B cells expressing dominant-negative forms of STAT5: evidence for caspase-dependent and -independent mechanisms	ONCOGENE			English	Article						transcription factors; apoptosis; cytokines; pre-B cells	RECEPTOR-GAMMA CHAIN; GENE-EXPRESSION; T-LYMPHOCYTES; TRANSACTIVATION DOMAIN; LYMPHOID DEVELOPMENT; HEMATOPOIETIC-CELLS; CYCLE PROGRESSION; DNA-BINDING; MICE; ACTIVATION	The transcription factors STAT5A and STAT5B (STAT: signal transducer and activator of transcription) play a major role in the signaling events elicited by a number of growth factor and cytokine receptors. In this work, we aimed to investigate the role of STAT5 in human precursor B cell survival by introducing dominant-negative (DN) forms of STAT5A or STAT5B in the 697 pre-B cell line. All clones expressing DN forms of either transcription factor exhibited a higher spontaneous apoptotic rate that was massively enhanced upon interleukin-7 (IL-7) stimulation. This was associated with caspase 8 cleavage, mitochondrial transmembrane potential disruption and caspase 3 activation. However, the DN forms of STAT5 did not alter the expression of Bcl-2, Bax, Bcl-x, Bim, Al and Mcl1 proteins in IL-7-stimulated cells. The pancaspase inhibitor Z-Val-Ala-Asp-fluoromylmethyl ketone partially suppressed IL-7-mediated mitochondrial transmembrane potential disruption and cell death, suggesting that IL-7 induced the death of DN STAT5 expressing 697 cells through caspase-dependent and -independent mechanisms that both require mitochondrial activation.	INSERM, Immunol Lab, F-80036 Amiens, France; CHU Amiens, Biochim Lab, F-80054 Amiens, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Picardie Universites; Universite de Picardie Jules Verne (UPJV); CHU Amiens	Gouilleux-Gruart, V (corresponding author), INSERM, Immunol Lab, EMI 0351,3 Rue Louvels, F-80036 Amiens, France.	valerie.gouilleux@sa.u-picardie.fr	Mullié, Catherine/AAW-2304-2020	Mullié, Catherine/0000-0001-8986-9666; Gouilleux, Fabrice/0000-0001-6047-1718; Regnier, Jean-Claude/0000-0001-6992-9027				Ahonen TJ, 2003, J BIOL CHEM, V278, P27287, DOI 10.1074/jbc.M304307200; Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456; Bidere N, 2001, APOPTOSIS, V6, P371, DOI 10.1023/A:1011390103783; BILLIPS LG, 1995, J EXP MED, V182, P973, DOI 10.1084/jem.182.4.973; CAO XQ, 1995, IMMUNITY, V2, P223, DOI 10.1016/1074-7613(95)90047-0; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Constantino S, 2001, ONCOGENE, V20, P2080, DOI 10.1038/sj.onc.1204308; Cuvillier O, 1998, J BIOL CHEM, V273, P2910, DOI 10.1074/jbc.273.5.2910; Deas O, 1998, J IMMUNOL, V161, P3375; DISANTO JP, 1995, P NATL ACAD SCI USA, V92, P377, DOI 10.1073/pnas.92.2.377; DITTEL BN, 1995, J IMMUNOL, V154, P58; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; Feldman GM, 1997, BLOOD, V90, P1768, DOI 10.1182/blood.V90.5.1768; FINDLEY HW, 1982, BLOOD, V60, P1305; Fry TJ, 2002, BLOOD, V99, P3892, DOI 10.1182/blood.V99.11.3892; GouilleuxGruart V, 1996, BLOOD, V87, P1692; Isaksen DE, 1999, J IMMUNOL, V163, P5971; Karras JG, 1996, J IMMUNOL, V157, P39; Kieslinger M, 2000, GENE DEV, V14, P232; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; Komoriya A, 2000, J EXP MED, V191, P1819, DOI 10.1084/jem.191.11.1819; LeBien TW, 2000, BLOOD, V96, P9, DOI 10.1182/blood.V96.1.9; Levy Y, 1997, CLIN EXP IMMUNOL, V110, P329; Lord JD, 2000, J IMMUNOL, V164, P2533, DOI 10.4049/jimmunol.164.5.2533; Mahajan S, 2001, J BIOL CHEM, V276, P31216, DOI 10.1074/jbc.M104874200; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; Puthier D, 1999, EUR J IMMUNOL, V29, P3945, DOI 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O; Qin JZ, 2001, J INVEST DERMATOL, V117, P583, DOI 10.1046/j.0022-202x.2001.01436.x; Sexl V, 2000, BLOOD, V96, P2277, DOI 10.1182/blood.V96.6.2277; Shelburne CP, 2002, MOL IMMUNOL, V38, P1187, DOI 10.1016/S0161-5890(02)00061-5; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; vanderPlas DC, 1996, LEUKEMIA, V10, P1317; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; Wang DM, 2000, EMBO J, V19, P392, DOI 10.1093/emboj/19.3.392; WOLF ML, 1993, J IMMUNOL, V151, P138; Zamorano J, 1998, J IMMUNOL, V160, P3502	44	19	19	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2004	23	17					3040	3047		10.1038/sj.onc.1207450	http://dx.doi.org/10.1038/sj.onc.1207450			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	812NC	15048088	Green Published			2022-12-28	WOS:000220845200008
J	Fuchs, SY; Spiegelman, VS; Kumar, KGS				Fuchs, SY; Spiegelman, VS; Kumar, KGS			The many faces of beta-TrCP E3 ubiquitin ligases: reflections in the magic mirror of cancer	ONCOGENE			English	Review						beta-TrCP; F-box; ubiquitin ligase; NF-kappa B; beta-catenin	NF-KAPPA-B; F-BOX PROTEIN; PHOSPHORYLATION-DEPENDENT INTERACTION; P105 REQUIRES PHOSPHORYLATION; SIGNAL-INDUCED UBIQUITINATION; PROTEASOME PATHWAY; CONSTITUTIVE ACTIVATION; ALPHA UBIQUITINATION; MEDIATED PROTEOLYSIS; DEGRADATION PATHWAY	Beta-transducin repeats-containing proteins (beta-TrCP) serve as the substrate recognition subunits for the SCFbeta-TrCP E3 ubiquitin ligases. These ligases ubiquitinate specifically phosphorylated substrates and play a pivotal role in the regulation of cell division and various signal transduction pathways, which, in turn, are essential for many aspects of tumorigenesis. We review the functions of the SCFbeta-TrCP ligases in the light of their relevance to cell growth, survival and transformation. Mechanisms underlying beta-TrCP regulation and their aberration in human and animal cancer as well as prospective of targeting beta-TrCP as a means of anticancer therapy are also discussed.	Univ Penn, Dept Anim Biol, Philadelphia, PA 19104 USA; AMC, Canc Res Ctr, Lakewood, CO 80214 USA	University of Pennsylvania; AMC Cancer Research Center	Fuchs, SY (corresponding author), Univ Penn, Dept Anim Biol, 3800 Spruce St,Rm 161E, Philadelphia, PA 19104 USA.	sfuks@vet.upenn.edu	高, 雨莉/HGU-8187-2022	Spiegelman, Vladimir S/0000-0003-4847-155X	NCI NIH HHS [CA 92900] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092900] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Akari H, 2001, J EXP MED, V194, P1299, DOI 10.1084/jem.194.9.1299; Albanese C, 2003, MOL BIOL CELL, V14, P585, DOI 10.1091/mbc.02-06-0101; ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; Bach SP, 2000, GASTROENTEROLOGY, V118, P81, DOI 10.1016/S0016-5085(00)70416-1; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Ballarino M, 2002, BBA-GENE STRUCT EXPR, V1577, P81, DOI 10.1016/S0167-4781(02)00416-5; BESNARDGUERIN C, 2003, IN PRESS J BIOL CHEM; Bharti AC, 2002, BIOCHEM PHARMACOL, V64, P883, DOI 10.1016/S0006-2952(02)01154-1; Bhatia N, 2002, ONCOGENE, V21, P1501, DOI 10.1038/sj.onc.1205311; Bian X, 2002, J BIOL CHEM, V277, P42144, DOI 10.1074/jbc.M203891200; Bour S, 2001, J BIOL CHEM, V276, P15920, DOI 10.1074/jbc.M010533200; Budunova IV, 1999, ONCOGENE, V18, P7423, DOI 10.1038/sj.onc.1203104; Cenciarelli C, 1999, CURR BIOL, V9, P1177, DOI 10.1016/S0960-9822(00)80020-2; Chiaur DS, 2000, CYTOGENET CELL GENET, V88, P255, DOI 10.1159/000015532; Chinery R, 1997, J BIOL CHEM, V272, P30356, DOI 10.1074/jbc.272.48.30356; Cong F, 2003, BMC MOL BIOL, V4, DOI 10.1186/1471-2199-4-10; Davis M, 2002, GENE DEV, V16, P439, DOI 10.1101/gad.218702; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; ELDARFINKELMAN H, 1995, J BIOL CHEM, V270, P987, DOI 10.1074/jbc.270.3.987; Fong A, 2002, J BIOL CHEM, V277, P22111, DOI 10.1074/jbc.C200151200; Fuchs SY, 2002, CANCER BIOL THER, V1, P337; Fuchs SY, 1999, ONCOGENE, V18, P2039, DOI 10.1038/sj.onc.1202760; Gao ZH, 2002, P NATL ACAD SCI USA, V99, P1182, DOI 10.1073/pnas.032468199; Gerstein AV, 2002, GENE CHROMOSOME CANC, V34, P9, DOI 10.1002/gcc.10037; Guardavaccaro D, 2003, DEV CELL, V4, P799, DOI 10.1016/S1534-5807(03)00154-0; Gunawardena K, 2002, CANCER DETECT PREV, V26, P229, DOI 10.1016/S0361-090X(02)00061-2; HADJIOLOV D, 1992, J CANCER RES CLIN, V118, P401, DOI 10.1007/BF01629420; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hatakeyama S, 1999, P NATL ACAD SCI USA, V96, P3859, DOI 10.1073/pnas.96.7.3859; Hattori K, 1999, J BIOL CHEM, V274, P29641, DOI 10.1074/jbc.274.42.29641; Hayakawa M, 2003, EMBO J, V22, P3356, DOI 10.1093/emboj/cdg332; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; Heissmeyer V, 2001, MOL CELL BIOL, V21, P1024, DOI 10.1128/MCB.21.4.1024-1035.2001; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Joyce D, 2001, CYTOKINE GROWTH F R, V12, P73, DOI 10.1016/S1359-6101(00)00018-6; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Katoh M, 2003, INT J ONCOL, V22, P209; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Koike J, 2000, BIOCHEM BIOPH RES CO, V269, P103, DOI 10.1006/bbrc.2000.2241; Kroll M, 1999, J BIOL CHEM, V274, P7941, DOI 10.1074/jbc.274.12.7941; Kumar KGS, 2003, EMBO J, V22, P5480; Lamberti C, 2001, J BIOL CHEM, V276, P42276, DOI 10.1074/jbc.M104227200; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Lang V, 2003, MOL CELL BIOL, V23, P402, DOI 10.1128/MCB.23.1.402-413.2003; Lassot I, 2001, MOL CELL BIOL, V21, P2192, DOI 10.1128/MCB.21.6.2192-2202.2001; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Mantovani F, 2003, J BIOL CHEM, V278, P42477, DOI 10.1074/jbc.M302799200; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Margottin-Goguet F, 2003, DEV CELL, V4, P813, DOI 10.1016/S1534-5807(03)00153-9; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; MAYO MW, 2000, BIOCHIM BIOPHYS ACTA, V1470, P55; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; Nakayama K, 2003, P NATL ACAD SCI USA, V100, P8752, DOI 10.1073/pnas.1133216100; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Orian A, 2000, EMBO J, V19, P2580, DOI 10.1093/emboj/19.11.2580; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; OSSWALD H, 1990, J CANCER RES CLIN, V116, P448, DOI 10.1007/BF01612992; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Polakis P, 2000, GENE DEV, V14, P1837; Reifenberger J, 2002, INT J CANCER, V100, P549, DOI 10.1002/ijc.10512; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Richmond A, 2002, NAT REV IMMUNOL, V2, P664, DOI 10.1038/nri887; Saitoh T, 2001, INT J ONCOL, V18, P959; Sakamoto KM, 2001, P NATL ACAD SCI USA, V98, P8554, DOI 10.1073/pnas.141230798; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; Shirane M, 1999, J BIOL CHEM, V274, P28169, DOI 10.1074/jbc.274.40.28169; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Smirnov AS, 2001, CELL DEATH DIFFER, V8, P621, DOI 10.1038/sj.cdd.4400853; Soldatenkov VA, 1999, CANCER RES, V59, P5085; Speigelman VS, 2001, J BIOL CHEM, V276, P27152, DOI 10.1074/jbc.M100031200; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; SPEVAK W, 1993, MOL CELL BIOL, V13, P4953, DOI 10.1128/MCB.13.8.4953; Spiegelman V, 2002, ONCOGENE, V21, P856, DOI 10.1038/sj.onc.1205132; Spiegelman VS, 2000, MOL CELL, V5, P877, DOI 10.1016/S1097-2765(00)80327-5; Spiegelman VS, 2002, J BIOL CHEM, V277, P36624, DOI 10.1074/jbc.M204524200; Suh JH, 2002, PROSTATE, V52, P183, DOI 10.1002/pros.10082; Suzuki H, 1999, BIOCHEM BIOPH RES CO, V256, P121, DOI 10.1006/bbrc.1999.0296; Suzuki H, 2000, J BIOL CHEM, V275, P2877, DOI 10.1074/jbc.275.4.2877; Suzuki H, 1999, BIOCHEM BIOPH RES CO, V256, P127, DOI 10.1006/bbrc.1999.0289; Tang WG, 2003, J BIOL CHEM, V278, P48942, DOI 10.1074/jbc.M307962200; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Winston JT, 1999, CURR BIOL, V9, P1180, DOI 10.1016/S0960-9822(00)80021-4; Wojcik EJ, 2000, CURR BIOL, V10, P1131, DOI 10.1016/S0960-9822(00)00703-X; Wu C, 1999, J BIOL CHEM, V274, P29591, DOI 10.1074/jbc.274.42.29591; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Yaron A, 1997, EMBO J, V16, P6486, DOI 10.1093/emboj/16.21.6486; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zhou PB, 2000, MOL CELL, V6, P751, DOI 10.1016/S1097-2765(00)00074-5	97	256	266	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2004	23	11					2028	2036		10.1038/sj.onc.1207389	http://dx.doi.org/10.1038/sj.onc.1207389			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	803EC	15021890				2022-12-28	WOS:000220213400007
J	Yang, YL; Li, CCH; Weissman, AM				Yang, YL; Li, CCH; Weissman, AM			Regulating the p53 system through ubiquitination	ONCOGENE			English	Review						p53; Mdm2; ubiquitination; molecular targeting; apoptosis	EARLY EMBRYONIC LETHALITY; PROLYL ISOMERASE PIN1; ARF TUMOR-SUPPRESSOR; STABILIZES P53; MUTANT P53; PROTEIN LIGASE; MDM2-DEFICIENT MICE; MDM2 DEGRADATION; DOWN-REGULATION; C-ABL	The tumor suppressor p53 is tightly controlled at low levels in cells by constant ubiquitination and proteasomal degradation. In response to stresses, ubiquitination of p53 is inhibited through diverse pathways, depending on the nature of the stimulus and cell type. This leads to the accumulation and activation of p53, which induces cell cycle arrest and/or apoptosis to prevent cells from transformation. Many studies have indicated that defects of the p53 system are present in most, if not all, human tumor cells. Meanwhile, significant progress has been made in understanding the molecular mechanisms of p53 ubiquitination and the regulation of the p53 system. Therefore, it is possible now to consider targeting ubiquitination as a means to regulate and reactivate p53 in tumors. Emerging evidence suggests that inhibiting the E3 activity of Mdm2, blocking the interaction of p53 and Mdm2, and restoring the function of mutated p53 are potential effective strategies to kill certain tumor cells selectively. It is conceivable that new chemotherapeutic agents based on these studies will be generated in the not-so-distant future.	NCI, Regulat Prot Funct Lab, Ctr Canc Res, Frederick, MD 21702 USA; NCI, Lab Canc Prevent, SAIC Frederick, NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Yang, YL (corresponding author), NCI, Regulat Prot Funct Lab, Ctr Canc Res, 1050 Boyles St,560-22-64, Frederick, MD 21702 USA.	yangyili@ncifcrf.gov			NCI NIH HHS [N01-CA-12400] Funding Source: Medline; DIVISION OF BASIC SCIENCES - NCI [Z01BC010029] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [Z01BC010292] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham J, 2000, J MOL BIOL, V295, P853, DOI 10.1006/jmbi.1999.3415; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Badciong JC, 2002, J BIOL CHEM, V277, P49668, DOI 10.1074/jbc.M208593200; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; Balint E, 2001, BRIT J CANCER, V85, P1813, DOI 10.1054/bjoc.2001.2128; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Casciano I, 2002, CELL DEATH DIFFER, V9, P246, DOI 10.1038/sj.cdd.4400993; Chene P, 2002, FEBS LETT, V529, P293, DOI 10.1016/S0014-5793(02)03362-8; Colman MS, 2000, MUTAT RES-REV MUTAT, V462, P179, DOI 10.1016/S1383-5742(00)00035-1; Derry WB, 2001, SCIENCE, V294, P591, DOI 10.1126/science.1065486; Douc-Rasy S, 2002, AM J PATHOL, V160, P631, DOI 10.1016/S0002-9440(10)64883-3; Duncan SJ, 2001, J AM CHEM SOC, V123, P554, DOI 10.1021/ja002940p; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Finch RA, 2002, CANCER RES, V62, P3221; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Friedler A, 2002, P NATL ACAD SCI USA, V99, P937, DOI 10.1073/pnas.241629998; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Garcia-Echeverria C, 2000, J MED CHEM, V43, P3205, DOI 10.1021/jm990966p; Goldberg Z, 2002, EMBO J, V21, P3715, DOI 10.1093/emboj/cdf384; Gong JG, 1999, NATURE, V399, P806; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Gu JJ, 2002, J BIOL CHEM, V277, P19251, DOI 10.1074/jbc.C200150200; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hideshima T, 2003, BLOOD, V101, P1530, DOI 10.1182/blood-2002-08-2543; Hietanen S, 2000, P NATL ACAD SCI USA, V97, P8501, DOI 10.1073/pnas.97.15.8501; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kanovsky M, 2001, P NATL ACAD SCI USA, V98, P12438, DOI 10.1073/pnas.211280698; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Krause K, 2000, NUCLEIC ACIDS RES, V28, P4410, DOI 10.1093/nar/28.22.4410; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kuo ML, 2003, CANCER RES, V63, P1046; Lai ZH, 2002, P NATL ACAD SCI USA, V99, P14734, DOI 10.1073/pnas.212428599; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Leung KM, 2002, CANCER RES, V62, P4890; Li LM, 2001, P NATL ACAD SCI USA, V98, P1619, DOI 10.1073/pnas.98.4.1619; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Li MY, 2002, J BIOL CHEM, V277, P50607, DOI 10.1074/jbc.C200578200; Liefer KM, 2000, CANCER RES, V60, P4016; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Liu G, 2003, J BIOL CHEM, V278, P17557, DOI 10.1074/jbc.M210696200; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Lohrum MAE, 2001, MOL CELL BIOL, V21, P8521, DOI 10.1128/MCB.21.24.8521-8532.2001; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; Louria-Hayon I, 2003, J BIOL CHEM, V278, P33134, DOI 10.1074/jbc.M301264200; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Lu Q, 2003, P NATL ACAD SCI USA, V100, P7626, DOI 10.1073/pnas.0932599100; LUNA RMD, 1995, NATURE, V378, P203; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Luu Y, 2002, EXP CELL RES, V276, P214, DOI 10.1006/excr.2002.5526; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Maki CG, 1996, CANCER RES, V56, P2649; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Meulmeester E, 2003, MOL CELL BIOL, V23, P4929, DOI 10.1128/MCB.23.14.4929-4938.2003; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; Migliorini D, 2002, MOL CELL BIOL, V22, P5527, DOI 10.1128/MCB.22.15.5527-5538.2002; Mirnezami AH, 2003, CURR BIOL, V13, P1234, DOI 10.1016/S0960-9822(03)00454-8; Mirza A, 2003, ONCOGENE, V22, P3645, DOI 10.1038/sj.onc.1206477; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Pan Y, 2003, MOL CELL BIOL, V23, P5113, DOI 10.1128/MCB.23.15.5113-5121.2003; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Peng YH, 2003, ONCOGENE, V22, P4478, DOI 10.1038/sj.onc.1206777; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Riemenschneider MJ, 1999, CANCER RES, V59, P6091; Rowland BD, 2002, CANCER CELL, V2, P55, DOI 10.1016/S1535-6108(02)00085-5; Ruland J, 2001, P NATL ACAD SCI USA, V98, P1859, DOI 10.1073/pnas.98.4.1859; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Sax JK, 2003, J BIOL CHEM, V278, P36435, DOI 10.1074/jbc.M303191200; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Selivanova G, 1999, MOL CELL BIOL, V19, P3395; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Sogame N, 2003, P NATL ACAD SCI USA, V100, P4696, DOI 10.1073/pnas.0736384100; Stad R, 2001, EMBO REP, V2, P1029, DOI 10.1093/embo-reports/kve227; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; Tanikawa C, 2003, NAT CELL BIOL, V5, P216, DOI 10.1038/ncb943; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Wang WG, 2003, MOL CELL BIOL, V23, P2171, DOI 10.1128/MCB.23.6.2171-2181.2003; Wang XJ, 2002, J BIOL CHEM, V277, P15697, DOI 10.1074/jbc.M112068200; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wing SS, 2003, INT J BIOCHEM CELL B, V35, P590, DOI 10.1016/S1357-2725(02)00392-8; Xirodimas DP, 2001, EXP CELL RES, V270, P66, DOI 10.1006/excr.2001.5314; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yarbrough WG, 2002, CANCER RES, V62, P1171; Yu XD, 2002, J NATL CANCER I, V94, P504; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zhao JH, 2002, CANCER LETT, V183, P69, DOI 10.1016/S0304-3835(02)00084-8; Zheng HW, 2002, NATURE, V419, P849, DOI 10.1038/nature01116; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	129	149	162	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2004	23	11					2096	2106		10.1038/sj.onc.1207411	http://dx.doi.org/10.1038/sj.onc.1207411			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	803EC	15021897				2022-12-28	WOS:000220213400014
J	Murray, PG; Qiu, GH; Fu, L; Waites, ER; Srivastava, G; Heys, D; Agathanggelou, A; Latif, F; Grundy, RG; Mann, JR; Starczynski, J; Crocker, J; Parkes, SE; Ambinder, RF; Young, LS; Tao, Q				Murray, PG; Qiu, GH; Fu, L; Waites, ER; Srivastava, G; Heys, D; Agathanggelou, A; Latif, F; Grundy, RG; Mann, JR; Starczynski, J; Crocker, J; Parkes, SE; Ambinder, RF; Young, LS; Tao, Q			Frequent epigenetic inactivation of the RASSF1A tumor suppressor gene in Hodgkin's lymphoma	ONCOGENE			English	Article						Hodgkin's lymphoma; RASSF1A; hypermethylation; tumor suppressor gene; Hodgkin/Reed-Sternberg cells	ABERRANT PROMOTER METHYLATION; BREAST CANCERS; CPG ISLAND; 3P21.3; HYPERMETHYLATION; CELL; PROTEIN; DISEASE; FAMILY; LUNG	Epigenetic inactivation of RASSF1A, a putative tumor suppressor with proapoptotic activity, is frequently observed in a number of solid tumors, including a variety of epithelial cancers, but has not been described in hematopoietic tumors. We have analysed the expression and methylation status of RASSF1A in Hodgkin's lymphoma (HL)-derived cell lines, primary HL tumors and serum samples from HL patients. RASSF1A transcription was detectable in only 2/6 HL cell lines. Methylation-specific PCR and bisulfite genomic sequencing revealed that the RASSF1A promoter was hypermethylated in all four RASSF1A-nonexpressing cell lines. 5-aza-2'-deoxycytidine treatment resulted in demethylation of the promoter and RASSF1A expression in these lines. Hypermethylation of RASSF1A was also detected in 34/52 (65%) primary HL tumors and in 2/22 serum samples from these patients. Microdissection of Hodgkin/ Reed - Sternberg (HRS) cells from several of these cases confirmed that the RASSF1A hypermethylation we detected in the analysis of whole tumor originated from the tumor cell population. Although hypermethylation of RASSF1A was detected in 5/6 non-Hodgkin's lymphoma (NHL)-derived cell lines, only rare primary NHL (1/10 of Burkitt's lymphoma, 1/12 of post-transplant lymphoma, 1/12 diffuse large B-cell lymphoma, 0/27 of nasal lymphoma, 0/8 follicular center cell lymphoma, 0/4 mantle cell lymphoma, 0/4 anaplastic large cell (Ki-1+) lymphoma, 0/2 MALT lymphoma) showed hypermethylation of the promoter. No methylation was detected in any of the 14 normal PBMC. These results point to an important role for epigenetic silencing of RASSF1A in the pathogenesis of HL. Inactivation of RASSF1A could be one mechanism by which HRS cells escape the apoptosis that should occur following nonproductive immunoglobulin gene rearrangements.	Johns Hopkins Singapore, Canc Epigenet Tumor Virol Lab, Singapore 117597, Singapore; Univ Birmingham, Dept Pathol, Birmingham B15 2TT, W Midlands, England; Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Univ Birmingham, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England; Childrens Hosp, Dept Oncol, Birmingham B4 6NH, W Midlands, England; Birmingham Heartlands Hosp, Dept Cellular Pathol, Birmingham B15 2TT, W Midlands, England; Johns Hopkins Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA; Univ Birmingham, Div Canc Studies, Canc Res UK Inst Canc Studies, Birmingham B15 2TT, W Midlands, England	Johns Hopkins University; Johns Hopkins Medicine; University of Birmingham; University of Hong Kong; University of Birmingham; Heart of England NHS Foundation Trust; University of Birmingham; Johns Hopkins University; Johns Hopkins Medicine; Cancer Research UK; University of Birmingham	Murray, PG (corresponding author), Johns Hopkins Singapore, Canc Epigenet Tumor Virol Lab, CRC MD11,Level 5,10 Med Dr, Singapore 117597, Singapore.	p.g.murray@bham.ac.uk; taoqia@jhs.com.sg	Young, Lawrence S/B-7213-2009; Tao, Qian/T-4743-2018; QIU, GUO-HUA/B-5806-2011; Ambinder, Richard/G-1607-2011; Fu, Li/F-7182-2010	Young, Lawrence S/0000-0003-3919-4298; Tao, Qian/0000-0001-5383-4808; QIU, GUO-HUA/0000-0001-6202-4284; Fu, Li/0000-0003-2643-6278				Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Astuti D, 2001, ONCOGENE, V20, P7573, DOI 10.1038/sj.onc.1204968; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Harada K, 2002, ONCOGENE, V21, P4345, DOI 10.1038/sj.onc.1205446; Kanzler H, 1996, J EXP MED, V184, P1495, DOI 10.1084/jem.184.4.1495; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Lee MG, 2001, CANCER RES, V61, P6688; Lee TL, 2002, CLIN CANCER RES, V8, P1761; Lo KW, 2001, CANCER RES, V61, P3877; Maruyama R, 2001, CANCER RES, V61, P8659; Morrissey C, 2001, CANCER RES, V61, P7277; MURRAY PG, 1992, J PATHOL, V166, P1, DOI 10.1002/path.1711660102; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Tao Q, 1999, AM J PATHOL, V155, P619, DOI 10.1016/S0002-9440(10)65157-7; Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091; Tsai CN, 2002, P NATL ACAD SCI USA, V99, P10084, DOI 10.1073/pnas.152059399; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Zou HZ, 2002, CLIN CANCER RES, V8, P188	23	52	58	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1326	1331		10.1038/sj.onc.1207313	http://dx.doi.org/10.1038/sj.onc.1207313			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14961078				2022-12-28	WOS:000188892200019
J	Sumimoto, H; Miyagishi, M; Miyoshi, H; Yamagata, S; Shimizu, A; Taira, K; Kawakami, Y				Sumimoto, H; Miyagishi, M; Miyoshi, H; Yamagata, S; Shimizu, A; Taira, K; Kawakami, Y			Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference	ONCOGENE			English	Article						gene therapy; melanoma; lentiviral vector; BRAF; RNAi; MAPK	GENE-EXPRESSION; HAIRPIN RNAS; BETA-CATENIN; T-CELLS; INTEGRIN; SUPPRESSION; MODULATION; ACTIVATION; MUTATIONS; DELIVERY	Oncogenic mutations of molecules involved in the mitogen-activated protein kinase (MAPK) pathways provide signals mediating both tumor growth and invasion in various cancers including melanomas. BRAF somatic mutations, found in 66% of melanomas, have NIH3T3 transforming ability with the elevated kinase activity in vitro. We attempted to mediate RNA interference (RNAi) with HIV lentiviral vectors specific for either wild type or the most frequently mutated form of BRAF (V599E) in 10 melanoma cell lines, and found that RNAi inhibited the growth of most melanoma cell lines in vitro as well as in vivo, which was accompanied by decrease of both BRAF protein and ERK phosphorylation. Interestingly, the mutated BRAF (V599E)-specific siRNA inhibited the growth and MAPK activity of only melanoma cell lines with this mutation. Furthermore, BRAF RNAi inhibited matrigel invasion of melanoma cells accompanied with a decrease of matrix metalloproteinase activity and beta(1) integrin expression. These results clarify that the mutated BRAF (V599E) is essentially involved in malignant phenotype of melanoma cells through the MAPK activation and is an attractive molecular target for melanoma treatment. The lentivirus-mediated RNAi specific for oncogenic mutations may be a powerful technique for gene therapy of cancer.	Keio Univ, Sch Med, Inst Adv Med Res, Div Cellular Signaling,Shinjuku Ku, Tokyo 1608582, Japan; Univ Tokyo, Sch Engn, Dept Chem & Biotechnol, Tokyo 1138656, Japan; RIKEN, Tsukuba Inst, BioResource Ctr, Subteam Manipulat Cell Fate, Tsukuba, Ibaraki 3050074, Japan	Keio University; University of Tokyo; RIKEN	Kawakami, Y (corresponding author), Keio Univ, Sch Med, Inst Adv Med Res, Div Cellular Signaling,Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	yutakawa@sc.itc.keio.ac.jp	Kawakami, Yutaka/E-7429-2013; Miyoshi, Hiroyuki/G-9808-2013; Miyagishi, Makoto/L-8174-2016; Sumimoto, Hidetoshi/AAE-6873-2020	Kawakami, Yutaka/0000-0003-4836-2855; Miyagishi, Makoto/0000-0001-7654-3616; 				Abbas-Terki T, 2002, HUM GENE THER, V13, P2197, DOI 10.1089/104303402320987888; Barton GM, 2002, P NATL ACAD SCI USA, V99, P14943, DOI 10.1073/pnas.242594499; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Devroe Eric, 2002, BMC Biotechnol, V2, P15, DOI 10.1186/1472-6750-2-15; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Genersch E, 2000, J CELL SCI, V113, P4319; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hingorani SR, 2003, CANCER RES, V63, P5198; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KAWAKAMI Y, 1994, P NATL ACAD SCI USA, V91, P3515, DOI 10.1073/pnas.91.9.3515; Kawasaki H, 2003, NUCLEIC ACIDS RES, V31, P700, DOI 10.1093/nar/gkg158; Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500; MELCHIORI A, 1995, EXP CELL RES, V219, P233, DOI 10.1006/excr.1995.1223; Miyagishi M, 2002, NAT BIOTECHNOL, V20, P497, DOI 10.1038/nbt0502-497; MIYAGISHI M, IN PRESS J GENE MED; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; NATALI PG, 1993, INT J CANCER, V54, P68, DOI 10.1002/ijc.2910540112; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502-505; Petitclerc E, 1999, CANCER RES, V59, P2724; Puyraimond A, 1999, J CELL SCI, V112, P1283; Qin XF, 2003, P NATL ACAD SCI USA, V100, P183, DOI 10.1073/pnas.232688199; Robbins PF, 1996, J EXP MED, V183, P1185, DOI 10.1084/jem.183.3.1185; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Santibanez JF, 2000, BIOCHEM BIOPH RES CO, V273, P521, DOI 10.1006/bbrc.2000.2946; Satyamoorthy K, 2003, CANCER RES, V63, P756; Smalley KSM, 2003, INT J CANCER, V104, P527, DOI 10.1002/ijc.10978; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Tiscornia G, 2003, P NATL ACAD SCI USA, V100, P1844, DOI 10.1073/pnas.0437912100; Tuschl T, 2002, NAT BIOTECHNOL, V20, P446, DOI 10.1038/nbt0502-446; Vaisanen A, 1999, J PATHOL, V188, P56; Woods D, 2001, MOL CELL BIOL, V21, P3192, DOI 10.1128/MCB.21.9.3192-3205.2001; Xia HB, 2002, NAT BIOTECHNOL, V20, P1006, DOI 10.1038/nbt739; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499	40	140	158	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6031	6039		10.1038/sj.onc.1207812	http://dx.doi.org/10.1038/sj.onc.1207812			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15208655				2022-12-28	WOS:000223261000002
J	Hou, YF; Yuan, ST; Li, HC; Wu, J; Lu, JS; Liu, G; Lu, LJ; Shen, ZZ; Ding, J; Shao, ZM				Hou, YF; Yuan, ST; Li, HC; Wu, J; Lu, JS; Liu, G; Lu, LJ; Shen, ZZ; Ding, J; Shao, ZM			ER beta exerts multiple stimulative effects on human breast carcinoma cells	ONCOGENE			English	Article						breast carcinoma; estrogen receptor; matrix metalloproteinases (MMPs)	ESTROGEN-RECEPTOR-BETA; MESSENGER-RNA EXPRESSION; MATRIX METALLOPROTEINASE-2; METASTATIC PHENOTYPE; ALPHA; GENE; PROLIFERATION; TRANSFECTION; PROTEINASE; INVASION	Recent studies of ERs in breast cancer have demonstrated the existence of ERbeta in addition to ERalpha. Some clinical data indicated that ERbeta had prognostic value for patient's survival, which suggested that ERbeta plays a key role in breast cancer development and,metastasis. To test this hypothesis, we generated an ERbeta high-expression cell line by reintroduced human ERbeta cDNA into MDA-MB-435 cells. We demonstrated that ERbeta exerted multiple tumor-stimulative effects on human breast carcinoma cells both in vivo and in vitro. In in vitro studies, ERbeta was able to increase the proliferation and invasion of MDA-MB-435 cells significantly, while these effects were totally estradiol independent. Also, this stimulation was characterized by downregulation of p2l and upregulation of MMP-9, as well as transcriptional factor Est-1. In in vivo studies, we also demonstrated that ERbeta-transfected MDA-MB-435 cells grew much faster and had more pulmonary metastasis than mock or wild-type cells in nude mice. In ERbeta-transfected MDA-MB-435 xenografts, ERbeta caused significant reduction in p2l protein levels. Similar effects of ERbeta on MMP-9 and Ets-1 expression noted in vitro studies were also observed in the in vivo studies. These in vitro and in vivo studies indicated that ERbeta exerted multiple stimulative effects on breast cancer development and metastasis.	Chinese Acad Sci, Shanghai Inst Mat Med, Div Antitumor Pharmacol, State Key Lab Drug Res, Shanghai 201203, Peoples R China; Fudan Univ, Dept Surg, Canc Hosp, Inst Canc, Shanghai 200032, Peoples R China	Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; Fudan University	Ding, J (corresponding author), Chinese Acad Sci, Shanghai Inst Mat Med, Div Antitumor Pharmacol, State Key Lab Drug Res, 555 Zu Chong Zhi Rd, Shanghai 201203, Peoples R China.	jding@mail.shcnc.ac.cn; zhimingshao@yahoo.com	LIU, GANG/AAR-4584-2021	LIU, GANG/0000-0001-6620-176X				Albini A, 1998, Pathol Oncol Res, V4, P230; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Bhat RA, 1998, J STEROID BIOCHEM, V67, P233, DOI 10.1016/S0960-0760(98)00115-0; DelSal G, 1996, CRIT REV ONCOGENESIS, V7, P127, DOI 10.1615/CritRevOncog.v7.i1-2.80; Dotzlaw H, 1999, CANCER RES, V59, P529; Dotzlaw H, 1997, J CLIN ENDOCR METAB, V82, P2371, DOI 10.1210/jc.82.7.2371; Enmark E, 1997, J CLIN ENDOCR METAB, V82, P4258, DOI 10.1210/jc.82.12.4258; FOLKMAN J, 1990, CANCER METAST REV, V9, P171, DOI 10.1007/BF00046358; HAGGITT RC, 1994, HUM PATHOL, V25, P982, DOI 10.1016/0046-8177(94)90057-4; HIGASHINO F, 1995, ONCOGENE, V10, P1461; Hu YF, 1998, INT J ONCOL, V12, P1225; Irwin JC, 1996, J CLIN INVEST, V97, P438, DOI 10.1172/JCI118433; Jarvinen TAH, 2000, AM J PATHOL, V156, P29, DOI 10.1016/S0002-9440(10)64702-5; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Lazennec G, 2001, ENDOCRINOLOGY, V142, P4120, DOI 10.1210/en.142.9.4120; Leygue E, 1998, CANCER RES, V58, P3197; Lurlaro M, 1999, EUR J CLIN INVEST, V29, P793; Mizumoto H, 2002, INT J CANCER, V100, P401, DOI 10.1002/ijc.10504; Moore JT, 1998, BIOCHEM BIOPH RES CO, V247, P75, DOI 10.1006/bbrc.1998.8738; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; Nakayama T, 2001, MODERN PATHOL, V14, P415, DOI 10.1038/modpathol.3880328; Ogawa S, 1998, BIOCHEM BIOPH RES CO, V243, P122, DOI 10.1006/bbrc.1997.7893; Palmieri C, 2002, ENDOCR-RELAT CANCER, V9, P1, DOI 10.1677/erc.0.0090001; Saeki H, 2000, CANCER, V89, P1670, DOI 10.1002/1097-0142(20001015)89:8<1670::AID-CNCR4>3.0.CO;2-J; Shao ZM, 1998, EXP CELL RES, V241, P394, DOI 10.1006/excr.1998.4066; Shao ZM, 2002, INT J CANCER, V98, P234, DOI 10.1002/ijc.10183; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sillem M, 1999, EUR J GYNAECOL ONCOL, V20, P367; Tonetti DA, 2003, J STEROID BIOCHEM, V87, P47, DOI 10.1016/j.jsbmb.2003.07.003; Urquidi V, 2002, CLIN CANCER RES, V8, P61; vanGolen KL, 1996, CLIN EXP METASTAS, V14, P95, DOI 10.1007/BF00121206; Wen XF, 2002, ONCOL REP, V9, P937	32	63	71	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2004	23	34					5799	5806		10.1038/sj.onc.1207765	http://dx.doi.org/10.1038/sj.onc.1207765			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KW	15208676				2022-12-28	WOS:000222629800009
J	Schroeder, JA; Al Masri, A; Adriance, MC; Tessier, JC; Kotlarczyk, KL; Thompson, MC; Gendler, SJ				Schroeder, JA; Al Masri, A; Adriance, MC; Tessier, JC; Kotlarczyk, KL; Thompson, MC; Gendler, SJ			MUC1 overexpression results in mammary gland tumorigenesis and prolonged alveolar differentiation	ONCOGENE			English	Article						mucin; involution; apoptosis; breast cancer; mammary gland	CARCINOMA-ASSOCIATED ANTIGEN; ACTIVATED PROTEIN-KINASE; BETA-CATENIN; C-SRC; BREAST; APOPTOSIS; EXPRESSION; CLONING; TRANSCRIPTION; ASSOCIATION	MUC1 is a transmembrane mucin that was initially cloned from malignant mammary epithelial cells as a tumor antigen. More than 90% of human breast carcinomas overexpress MUC1. Numerous studies have demonstrated an interaction between MUC1 and other oncogenic proteins such as beta-catenin, erbB receptors and c-Src, but a functional role for MUC1 in transformation has not been identified. We previously reported the development of transgenic mice that overexpress human MUC1 in the mouse mammary gland (MMTV-MUC1). Analysis of these transgenic mice at an early age demonstrated the ability of MUC1 to potentiate EGF-dependent activation of MAP kinase signaling pathways in the lactating mammary gland. We now report that multiparous MMTV-MUC1 transgenic mice stochastically develop unifocal mammary gland carcinomas late in life. Molecular analysis of these tumors shows a tumor-specific coimmunoprecipitation between MUC1 and beta-catenin. Examination of the contralateral glands in MMTV-MUC1 transgenics demonstrates that the development of frank carcinomas is accompanied by a failure of multiparous glands to undergo postlactational involution. Furthermore, uniparous MMTV-MUC1 transgenic mice display decreased postlactational apoptosis, elevated whey acidic protein expression and aberrant pErk2 activation. These findings are the first to determine that MUC1 overexpression promotes in vivo transformation of the mammary gland.	Mayo Clin Scottsdale, Dept Biochem & Mol Biol, Coll Med, Scottsdale, AZ 85259 USA; Mayo Clin Scottsdale, Coll Med, Tumor Biol Program, Scottsdale, AZ 85259 USA	Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic Phoenix	Gendler, SJ (corresponding author), Mayo Clin Scottsdale, Dept Biochem & Mol Biol, Coll Med, 13400 E Shea Blvd,SC Johnson Med Res Bldg, Scottsdale, AZ 85259 USA.	gendler.sandra@mayo.edu		schroeder, joyce/0000-0003-1277-5172	NATIONAL CANCER INSTITUTE [R01CA064389, F32CA081703] Funding Source: NIH RePORTER; NCI NIH HHS [F32CA81703, F32 CA081703, R01CA64389, F32 CA081703-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BURDON T, 1991, J BIOL CHEM, V266, P6909; Flury N, 1997, EUR J BIOCHEM, V249, P421, DOI 10.1111/j.1432-1033.1997.00421.x; Garrity MM, 2003, MODERN PATHOL, V16, P389, DOI 10.1097/01.MP.0000062657.30170.92; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GENDLER SJ, 1987, P NATL ACAD SCI USA, V84, P6060, DOI 10.1073/pnas.84.17.6060; GIRLING A, 1989, INT J CANCER, V43, P1072, DOI 10.1002/ijc.2910430620; Grant S, 2002, FRONT BIOSCI-LANDMRK, V7, pD376, DOI 10.2741/grant; Huang L, 2003, CANCER BIOL THER, V2, P702; LAN MS, 1990, J BIOL CHEM, V265, P15294; Li Y, 2003, CANCER BIOL THER, V2, P187, DOI 10.4161/cbt.2.2.282; Li YQ, 2003, ONCOGENE, V22, P6107, DOI 10.1038/sj.onc.1206732; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Li YQ, 2001, BIOCHEM BIOPH RES CO, V281, P440, DOI 10.1006/bbrc.2001.4383; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; LIGTENBERG MJL, 1990, J BIOL CHEM, V265, P5573; Mahler JF, 1996, TOXICOL PATHOL, V24, P710, DOI 10.1177/019262339602400606; Marti A, 1999, J MAMMARY GLAND BIOL, V4, P145, DOI 10.1023/A:1018721107061; Meerzaman D, 2001, AM J PHYSIOL-LUNG C, V281, pL86, DOI 10.1152/ajplung.2001.281.1.L86; Mueller H, 2000, INT J CANCER, V89, P384, DOI 10.1002/1097-0215(20000720)89:4<384::AID-IJC11>3.0.CO;2-R; PANDEY P, 1995, CANCER RES, V55, P4000; Ren J, 2002, J BIOL CHEM, V277, P17616, DOI 10.1074/jbc.M200436200; Schroeder JA, 2003, ONCOGENE, V22, P1324, DOI 10.1038/sj.onc.1206291; SCHROEDER JA, 2001, J BIOL CHEM, V22, P22; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; SPICER AP, 1995, J BIOL CHEM, V270, P30093; SPICER AP, 1995, MAMM GENOME, V6, P885, DOI 10.1007/BF00292441; Strange R, 2001, MICROSC RES TECHNIQ, V52, P171, DOI 10.1002/1097-0029(20010115)52:2<171::AID-JEMT1003>3.3.CO;2-K; WALKER NI, 1989, AM J ANAT, V185, P19, DOI 10.1002/aja.1001850104; Wen YF, 2003, J BIOL CHEM, V278, P38029, DOI 10.1074/jbc.M304333200; WRESCHNER DH, 1990, EUR J BIOCHEM, V189, P463, DOI 10.1111/j.1432-1033.1990.tb15511.x; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; Yan Y, 2002, J BIOL CHEM, V277, P33422, DOI 10.1074/jbc.M201147200; ZOTTER S, 1988, Cancer Reviews, V11-12, P55	35	124	139	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2004	23	34					5739	5747		10.1038/sj.onc.1207713	http://dx.doi.org/10.1038/sj.onc.1207713			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KW	15221004				2022-12-28	WOS:000222629800003
J	Grabmaier, K; de Weijert, MCA; Verhaegh, GW; Schalken, JA; Oosterwijk, E				Grabmaier, K; de Weijert, MCA; Verhaegh, GW; Schalken, JA; Oosterwijk, E			Strict regulation of CAIX(G250/MN) by HIF-1 alpha in clear cell renal cell carcinoma	ONCOGENE			English	Article						renal cell carcinoma; G250/CAIX; gene regulation; hypoxia; von Hippel-Lindau	HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; CARBONIC-ANHYDRASE-IX; TRANSCRIPTIONAL REGULATION; NORMAL KIDNEY; DNA-BINDING; EXPRESSION; GENE; PROTEIN; CANCER; IDENTIFICATION	Renal cell carcinoma of the clear cell type (ccRCC) is associated with loss of functional von Hippel-Lindau (VHL) protein and high, homogeneous expression of the G250(MN) protein, an isoenzyme of the carbonic anhydrase family. High expression of G250(MN) is found in all ccRCCs, but not in most normal tissues, including normal human kidney. We specifically studied the mechanism of transcriptional regulation of the CAIX(G250) gene in RCC. Previous studies identified Sp1 and hypoxia-inducible factor (HIF) as main regulatory transcription factors of G250(MN) in various non-RCC backgrounds. However, G250(MN) regulation in RCC has not been studied and may be differently regulated in view of the HIF accumulation under normoxic conditions due to VHL mutations. Transient transfection of different G250(MN) promoter constructs revealed strong promoter activity in G250(MN) -positive RCC cell lines, but no activity in G250(MN) -negative cell lines. DNase-I footprint and handshift analysis demonstrated that Sp1 and HIF-1alpha proteins in nuclear extracts of RCC cells bind to the CAIX promoter and mutations in the most proximal Sp1 binding element or HIF binding element completely abolished CAIX promoter activity, indicating their critical importance for the activation of G250 expression in RCC. A close correlation between HIF-1alpha expression and G250(MN) expression was observed. In contrast, no relationship between HIF-2alpha expression and G250(MN) was seen. The participation of cofactor CBP/p300 in the regulation of G250 transcription was shown. In conclusion, HIF-1alpha and Sp1, in combination with CBP/p300, are crucial elements for G250(MN) expression in ccRCC, and CAIX(G250) can be regarded as a unique HIF-1alpha: target gene in ccRCC.	Catholic Univ Nijmegen, Med Ctr, Lab Expt Urol, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	Oosterwijk, E (corresponding author), Catholic Univ Nijmegen, Med Ctr, Lab Expt Urol, 190-RT NCMLS,POB 9101, NL-6500 HB Nijmegen, Netherlands.	e.oosterwijk@uro.umcn.nl	Verhaegh, Gerald/L-4708-2015; de Weijert, Mirjam/F-3192-2016; Schalken, Jack A/B-1277-2014; Oosterwijk, Egbert/P-5466-2014	Verhaegh, Gerald/0000-0003-0227-2280; Schalken, Jack A/0000-0001-8274-7797; 				Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Beasley NJP, 2001, CANCER RES, V61, P5262; Bockamp EO, 1998, J BIOL CHEM, V273, P29032, DOI 10.1074/jbc.273.44.29032; Bui MHT, 2003, CLIN CANCER RES, V9, P802; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Clifford SC, 2001, ONCOGENE, V20, P5067, DOI 10.1038/sj.onc.1204602; EBERT T, 1990, CANCER RES, V50, P5531; Elvert G, 2003, J BIOL CHEM, V278, P7520, DOI 10.1074/jbc.M211298200; Gothie E, 2000, J BIOL CHEM, V275, P6922, DOI 10.1074/jbc.275.10.6922; Grabmaier K, 2000, INT J CANCER, V85, P865, DOI 10.1002/(SICI)1097-0215(20000315)85:6<865::AID-IJC21>3.0.CO;2-Q; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Ivanov S, 2001, AM J PATHOL, V158, P905, DOI 10.1016/S0002-9440(10)64038-2; Kaanders JHAM, 2002, CANCER RES, V62, P7066; Kaluz S, 1999, J BIOL CHEM, V274, P32588, DOI 10.1074/jbc.274.46.32588; Kaluz S, 2003, CANCER RES, V63, P917; Kaluzova M, 2001, BIOCHEM J, V359, P669, DOI 10.1042/0264-6021:3590669; Liu Z, 1999, MOL CELL ENDOCRINOL, V153, P183, DOI 10.1016/S0303-7207(99)00036-2; Loncaster JA, 2001, CANCER RES, V61, P6394; Mandriota SJ, 2002, CANCER CELL, V1, P459, DOI 10.1016/S1535-6108(02)00071-5; Martinez A, 2000, J CLIN PATHOL-MOL PA, V53, P137, DOI 10.1136/mp.53.3.137; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Michel G, 2002, BBA-GENE STRUCT EXPR, V1578, P73, DOI 10.1016/S0167-4781(02)00484-0; Motzer RJ, 1996, NEW ENGL J MED, V335, P865, DOI 10.1056/NEJM199609193351207; OOSTERWIJK E, 1986, INT J CANCER, V38, P489, DOI 10.1002/ijc.2910380406; Opavsky R, 1996, GENOMICS, V33, P480, DOI 10.1006/geno.1996.0223; Rosenberger C, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000017223.49823.2A; Sambrook J., 2001, MOL CLONING LAB MANU; Sang NL, 2002, MOL CELL BIOL, V22, P2984, DOI 10.1128/MCB.22.9.2984-2992.2002; Suzuki T, 2000, GENES CELLS, V5, P29, DOI 10.1046/j.1365-2443.2000.00302.x; Thrash-Bingham CA, 1999, JNCI-J NATL CANCER I, V91, P143, DOI 10.1093/jnci/91.2.143; Uemura H, 1999, BRIT J CANCER, V81, P741, DOI 10.1038/sj.bjc.6690757; Verhaegh GW, 2000, J BIOL CHEM, V275, P37496, DOI 10.1074/jbc.M006293200; Vet JAM, 1998, AM J CLIN PATHOL, V110, P647, DOI 10.1093/ajcp/110.5.647; Wiesener MS, 2001, CANCER RES, V61, P5215; Wykoff CC, 2000, CANCER RES, V60, P7075	36	143	150	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5624	5631		10.1038/sj.onc.1207764	http://dx.doi.org/10.1038/sj.onc.1207764			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15184875				2022-12-28	WOS:000222629500007
J	O'Hagan, HM; Ljungman, M				O'Hagan, HM; Ljungman, M			Nuclear accumulation of p53 following inhibition of transcription is not due to diminished levels of MDM2	ONCOGENE			English	Article						DRB; nuclear export; ubiquitylation; nucleolus	PROTEASOME-MEDIATED DEGRADATION; DAMAGE-INDUCED PHOSPHORYLATION; ATM-DEPENDENT PHOSPHORYLATION; AUTOREGULATORY FEEDBACK LOOP; RING-FINGER DOMAIN; RNA-POLYMERASE-II; DNA-DAMAGE; TUMOR-SUPPRESSOR; DOWN-REGULATION; UV-RADIATION	A common mechanism by which the tumor suppressor p53 accumulates in the nucleus following cellular stress is through the attenuation of its interaction with MDM2, a protein involved in the nuclear export and degradation of p53. This is accomplished by induced modifications of p53, MDM2 or both. We have previously found that the kinase and mRNA synthesis inhibitor DRB (5,6-dichloro-1-b-D-ribofuranosylbenzimidazole) induces the nuclear accumulation of p53 without concomitant phosphorylation of the ser15 site of p53, which is thought to be a modification important for the attenuation of p53-MDM2 interaction. It has been proposed that the mechanism by which p53 accumulates following blockage of transcription involves the downregulation of MDM2 expression. In this study, we tested this hypothesis and found that after DRB treatment, p53 accumulated despite the fact that MDM2 levels remained high in human cells. Furthermore, over expression of MDM2 did not prevent the accumulation of p53 following DRB treatment. In, addition, p53 accumulating in the nucleus after DRB treatment was able to interact with MDM2 and was ubiquitylated. These findings suggest that blockage of transcription induce the nuclear accumulation of p53 without breaking the p53-MDM2 regulation loop.	Univ Michigan, Sch Med,Div Radiat & Canc Biol, Dept Radiat Oncol, Program Mol & Cellular Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Environm Hlth Sci, Sch Publ Hlth, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Ljungman, M (corresponding author), Univ Michigan, Sch Med,Div Radiat & Canc Biol, Dept Radiat Oncol, Program Mol & Cellular Biol, Ann Arbor, MI 48109 USA.	ljungman@umich.edu		O'Hagan, Heather/0000-0001-9750-5088	NATIONAL CANCER INSTITUTE [R01CA082376] Funding Source: NIH RePORTER; NCI NIH HHS [CA 82376] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arriola EL, 1999, ONCOGENE, V18, P1081, DOI 10.1038/sj.onc.1202391; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bean LJH, 2001, ONCOGENE, V20, P1076, DOI 10.1038/sj.onc.1204204; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chen LH, 1999, MOL MED, V5, P21, DOI 10.1007/BF03402136; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; David-Pfeuty T, 2001, ONCOGENE, V20, P5951, DOI 10.1038/sj.onc.1204741; DUBOIS MF, 1994, J BIOL CHEM, V269, P13331; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Inoue T, 2001, FEBS LETT, V490, P196, DOI 10.1016/S0014-5793(01)02123-8; Joseph TW, 2003, FASEB J, V17, P1622, DOI 10.1096/fj.02-0931com; Kapoor M, 2000, ONCOGENE, V19, P358, DOI 10.1038/sj.onc.1203300; KASTAN MB, 1991, CANCER RES, V51, P6304; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Klibanov SA, 2001, J CELL SCI, V114, P1867; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Latonen L, 2003, CELL SIGNAL, V15, P95, DOI 10.1016/S0898-6568(02)00044-X; LEACH FS, 1993, CANCER RES, V53, P2231; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; Ljungman M, 2001, ONCOGENE, V20, P5964, DOI 10.1038/sj.onc.1204734; Ljungman M, 1996, ONCOGENE, V13, P823; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Maki CG, 1996, CANCER RES, V56, P2649; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Nakamura S, 2000, MOL CELL BIOL, V20, P9391, DOI 10.1128/MCB.20.24.9391-9398.2000; O'Hagan HM, 2004, MUTAT RES-FUND MOL M, V546, P7, DOI 10.1016/j.mrfmmm.2003.10.003; OHAGAN HM, IN PRESS EXP CELL RE; Rodriguez MS, 2000, MOL CELL BIOL, V20, P8458, DOI 10.1128/MCB.20.22.8458-8467.2000; ROTTER V, 1983, EMBO J, V2, P1041, DOI 10.1002/j.1460-2075.1983.tb01543.x; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; SCHEER U, 1984, J CELL BIOL, V99, P672, DOI 10.1083/jcb.99.2.672; SCHEER U, 1990, BIOESSAYS, V12, P14, DOI 10.1002/bies.950120104; Schneiderhan N, 2003, ONCOGENE, V22, P2857, DOI 10.1038/sj.onc.1206431; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Shinozaki T, 2003, ONCOGENE, V22, P8870, DOI 10.1038/sj.onc.1207176; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Wang WG, 2003, MOL CELL BIOL, V23, P2171, DOI 10.1128/MCB.23.6.2171-2181.2003; Wang XJ, 2002, J BIOL CHEM, V277, P15697, DOI 10.1074/jbc.M112068200; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Xirodimas DP, 2001, EXP CELL RES, V270, P66, DOI 10.1006/excr.2001.5314; Yu ZK, 2000, ONCOGENE, V19, P5892, DOI 10.1038/sj.onc.1203980; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	64	34	35	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2004	23	32					5505	5512		10.1038/sj.onc.1207709	http://dx.doi.org/10.1038/sj.onc.1207709			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15094782				2022-12-28	WOS:000222588400010
J	Pan, Y; Oprysko, PR; Asham, AM; Koch, CJ; Simon, MC				Pan, Y; Oprysko, PR; Asham, AM; Koch, CJ; Simon, MC			p53 cannot be induced by hypoxia alone but responds to the hypoxic microenvironment	ONCOGENE			English	Article						hypoxia; anoxia; p53; HIF; tumor cells	INDUCIBLE FACTOR 1-ALPHA; LOW-OXYGEN CONDITIONS; TRANSCRIPTION FACTOR; TUMOR ANGIOGENESIS; PROTEIN; CELLS; MDM2; GENE; DEGRADATION; ACTIVATION	Solid tumors frequently contain hypoxic subregions due to insufficient blood supply. In these domains, cells can undergo p53-dependent apoptosis. Therefore, hypoxia has been implicated as a physiological stimulus for p53 accumulation and activation. In such an environment, p53 mutant cells exhibit a selective growth advantage. Hypoxic regulation of p53 has been proposed to be hypoxia inducible factor (HIF) dependent; however, controversy remains over whether and to what extent low oxygen (O-2) tension by itself enhances p53 protein stability. Here, we examined the p53 response to hypoxia and hypoxia mimetics in several cell lines expressing different HIF-alpha proteins. Most cells exhibited elevated levels of p53 in response to hypoxia mimetics such as deferoxamine mesylate and CoCl2, regardless of their HIF-alpha protein expression profile. However, over a range of O-2 levels, from 1.5% to less than 0.02%, we failed to observe p53 accumulation or p53 nuclear translocation in any cell lines tested. Only after treatment with a combination of hypoxia and acidosis/nutrient deprivation did some cells exhibit p53 induction. Our results suggest that, although hypoxia induces p53 accumulation in vivo, secondary effects such as acidosis caused by a hypoxic Pasteur effect ( instead of low O-2 by itself) are necessary for p53 accumulation. Therefore, the expression of HIF-1alpha and p53 proteins is not coupled during the cellular hypoxia response.	Univ Penn, Howard Hughes Med Inst, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Simon, MC (corresponding author), Univ Penn, Howard Hughes Med Inst, Abramson Family Canc Res Inst, BRB 2-3 Rm 456,421 Curie Blvd, Philadelphia, PA 19104 USA.	celeste2@mail.med.upenn.edu	Simon, Celeste/AAG-3941-2021		NATIONAL CANCER INSTITUTE [P01CA079862] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA79862] Funding Source: Medline; PHS HHS [66310] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Achison M, 2003, ONCOGENE, V22, P3431, DOI 10.1038/sj.onc.1206434; Alarcon R, 1999, CANCER RES, V59, P6046; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Denko NC, 2000, EXP CELL RES, V258, P82, DOI 10.1006/excr.2000.4928; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Gardner LB, 2001, J BIOL CHEM, V276, P7919, DOI 10.1074/jbc.M010189200; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Goda N, 2003, MOL CELL BIOL, V23, P359, DOI 10.1128/MCB.23.1.359-369.2003; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Gu YZ, 1998, GENE EXPRESSION, V7, P205; Hammond EM, 2002, MOL CELL BIOL, V22, P1834, DOI 10.1128/MCB.22.6.1834-1843.2002; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hon WC, 2002, NATURE, V417, P975, DOI 10.1038/nature00767; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jain S, 1998, MECH DEVELOP, V73, P117, DOI 10.1016/S0925-4773(98)00038-0; Kallio PJ, 1997, P NATL ACAD SCI USA, V94, P5667, DOI 10.1073/pnas.94.11.5667; Keith B, 2001, P NATL ACAD SCI USA, V98, P6692, DOI 10.1073/pnas.121494298; Kim CY, 1997, CANCER RES, V57, P4200; Koch CJ, 2002, METHOD ENZYMOL, V352, P3; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Makino Y, 2002, J BIOL CHEM, V277, P32405, DOI 10.1074/jbc.C200328200; Maltepe E, 2000, BIOCHEM BIOPH RES CO, V273, P231, DOI 10.1006/bbrc.2000.2928; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Maya R, 2000, ONCOGENE, V19, P3213, DOI 10.1038/sj.onc.1203658; Ohtsubo T, 1997, CANCER RES, V57, P3910; Pluquet O, 2001, CANCER LETT, V174, P1, DOI 10.1016/S0304-3835(01)00698-X; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Ravi R, 2000, GENE DEV, V14, P34; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Salceda S, 1996, ARCH BIOCHEM BIOPHYS, V334, P389, DOI 10.1006/abbi.1996.0469; Sax JK, 2002, CELL CYCLE, V1, P90, DOI 10.4161/cc.1.1.105; Schmaltz C, 1998, MOL CELL BIOL, V18, P2845, DOI 10.1128/MCB.18.5.2845; Seagroves TN, 2001, MOL CELL BIOL, V21, P3436, DOI 10.1128/MCB.21.10.3436-3444.2001; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; Semenza GL, 2002, INTERNAL MED, V41, P79, DOI 10.2169/internalmedicine.41.79; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; Sharpless NE, 2002, CELL, V110, P9, DOI 10.1016/S0092-8674(02)00818-8; Stempien-Otero A, 1999, J BIOL CHEM, V274, P8039, DOI 10.1074/jbc.274.12.8039; Tian H, 1998, GENE DEV, V12, P3320, DOI 10.1101/gad.12.21.3320; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Wenger RH, 1998, CANCER RES, V58, P5678; Wenger RH, 1996, NATURE, V380, P100, DOI 10.1038/380100d0; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; Zhong H, 1999, CANCER RES, V59, P5830; Zhu YH, 2002, J BIOL CHEM, V277, P22909, DOI 10.1074/jbc.M200042200	58	76	86	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					4975	4983		10.1038/sj.onc.1207657	http://dx.doi.org/10.1038/sj.onc.1207657			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15107830				2022-12-28	WOS:000222237300003
J	Finzer, P; Krueger, A; Stohr, M; Brenner, D; Soto, U; Kuntzen, C; Krammer, PH; Rosl, F				Finzer, P; Krueger, A; Stohr, M; Brenner, D; Soto, U; Kuntzen, C; Krammer, PH; Rosl, F			HDAC inhibitors trigger apoptosis in HPV-positive cells by inducing the E2F-p73 pathway	ONCOGENE			English	Article						human papillomavirus; cervical carcinoma cells; HDAC inhibitors	CERVICAL-CARCINOMA CELLS; RETINOBLASTOMA PROTEIN; HISTONE DEACETYLASE; CD95 APO-1/FAS; GENE-EXPRESSION; E2F; INDUCTION; P53; DEGRADATION; CANCER	Histone deacetylase (HDAC) inhibitors induce an intrinsic type of apoptosis in human papillomavirus (HPV)-positive cells by disrupting the mitochondrial transmembrane potential (DeltaPsi(m)). Loss of DeltaPsi(m) was only detected in E7, but not in E6 oncogene-expressing cells. HDAC inhibition led to a time-dependent degradation of the pocket proteins pRb, p107 and p130, releasing 'free' E2F-1 following initial G1 arrest. Inhibition of proteasomal proteolysis, but not of caspase activity rescued pRb from degradation and functionally restored its inhibitory effect on the cyclin E gene, known to be suppressedby pRb-E2F-1 in conjunction with HDAC1. Using siRNA targeted against p53, E2F-1 still triggered apoptosis by inducing the E2F-responsive proapoptotic alpha- and beta-isoforms of p73. These data may determine future therapeutic strategies in which HDAC inhibitors can effectively eliminate HPV-positive cells by an apoptotic route that does not rely on the reactivation of the 'classical' p53 pathway through a preceding shut-off of viral gene expression.	Deutsch Krebsforschungszentrum, Forschungsschewerpunkt Angew Tumorvirol, Abt Virale Transformat Mech, D-69120 Heidelberg, Germany; Abt Immungenet, D-69120 Heidelberg, Germany; Forschungsschwerpunkt Zytometrie, D-69120 Heidelberg, Germany; Univ Munich, Klinikum Grosshadern, D-8000 Munich, Germany; Dana Farber Canc Inst, Boston, MA 02115 USA	Helmholtz Association; German Cancer Research Center (DKFZ); University of Munich; Harvard University; Dana-Farber Cancer Institute	Finzer, P (corresponding author), Deutsch Krebsforschungszentrum, Forschungsschewerpunkt Angew Tumorvirol, Abt Virale Transformat Mech, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.	p.finzer@dkfz.de	Krueger, Andreas/B-9427-2009	Krueger, Andreas/0000-0001-7873-7334; Brenner, Dirk/0000-0001-8979-1045				Aguilar-Lemarroy A, 2001, INT J CANCER, V93, P823, DOI 10.1002/ijc.1405; ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bernard HU, 2002, ANTIVIR THER, V7, P219; Boutillier AL, 2000, ONCOGENE, V19, P2171, DOI 10.1038/sj.onc.1203532; Boyer SN, 1996, CANCER RES, V56, P4620; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; DEAN PN, 1974, J CELL BIOL, V60, P523, DOI 10.1083/jcb.60.2.523; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Eichhorst ST, 2000, MOL CELL BIOL, V20, P7826, DOI 10.1128/MCB.20.20.7826-7837.2000; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Finzer P, 2003, J CANCER RES CLIN, V129, P107, DOI 10.1007/s00432-003-0416-z; Finzer P, 2002, VIROLOGY, V304, P265, DOI 10.1006/viro.2002.1667; Finzer P, 2001, ONCOGENE, V20, P4768, DOI 10.1038/sj.onc.1204652; Fulda S, 1998, CELL DEATH DIFFER, V5, P884, DOI 10.1038/sj.cdd.4400419; Gomez-Manzano C, 2001, CANCER RES, V61, P6693; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Griffiths DJ, 1997, J VIROL, V71, P2866, DOI 10.1128/JVI.71.4.2866-2872.1997; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hwang SG, 2002, J BIOL CHEM, V277, P2923, DOI 10.1074/jbc.M109113200; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Lin KI, 1998, CELL DEATH DIFFER, V5, P577, DOI 10.1038/sj.cdd.4400384; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Meriin AB, 1998, J BIOL CHEM, V273, P6373, DOI 10.1074/jbc.273.11.6373; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Nees M, 2001, J VIROL, V75, P4283, DOI 10.1128/JVI.75.9.4283-4296.2001; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Phillips AC, 2001, APOPTOSIS, V6, P173, DOI 10.1023/A:1011332625740; Pisani P, 2002, INT J CANCER, V97, P72, DOI 10.1002/ijc.1571; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Re D, 2000, EXP HEMATOL, V28, P31, DOI 10.1016/S0301-472X(99)00125-3; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rogoff HA, 2002, MOL CELL BIOL, V22, P5308, DOI 10.1128/MCB.22.15.5308-5318.2002; Rosato RR, 2003, CANCER RES, V63, P3637; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Soto U, 1999, ONCOGENE, V18, P3187, DOI 10.1038/sj.onc.1202765; Stanelle J, 2002, NUCLEIC ACIDS RES, V30, P1859, DOI 10.1093/nar/30.8.1859; STOHR M, 1978, STAIN TECHNOL, V53, P205; Tan XQ, 1997, J BIOL CHEM, V272, P9613; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; Vander Heiden MG, 2000, P NATL ACAD SCI USA, V97, P4666, DOI 10.1073/pnas.090082297; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Wang QM, 2000, CLIN CANCER RES, V6, P2951; Wharton W, 2000, J BIOL CHEM, V275, P33981, DOI 10.1074/jbc.M005600200; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	73	38	38	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2004	23	28					4807	4817		10.1038/sj.onc.1207620	http://dx.doi.org/10.1038/sj.onc.1207620			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	830EK	15077164				2022-12-28	WOS:000222104200001
J	Cazillis, M; Bringuier, AF; Delautier, D; Buisine, M; Bernuau, D; Gespach, C; Groyer, A				Cazillis, M; Bringuier, AF; Delautier, D; Buisine, M; Bernuau, D; Gespach, C; Groyer, A			Disruption of MKK4 signaling reveals its tumor-suppressor role in embryonic stem cells	ONCOGENE			English	Article						SEK1/MKK4/JNKK; SAPK/JNK; p38; Erk-1/-2.; morphological transformation; cell proliferation and survival; apoptosis; growth in soft agar; tumor growth	GROWTH-FACTOR-BETA; PROTEIN-KINASE KINASE-4; N-TERMINAL KINASE; HUMAN T-CELLS; MAP KINASE; C-JUN; INDUCED APOPTOSIS; TRANSDUCTION PATHWAYS; MOUSE EMBRYOS; COLON-CANCER	The dual Ser/Thr kinase MKK4 and its downstream targets JNK and p38 regulate critical cellular functions during embryogenesis and development. MKK4 has been identified as a putative tumor-suppressor gene in human solid tumors of breast, prostate and pancreas. To clarify the mechanisms underlying the transforming potential of molecular defects targeting MKK4, we have generated totipotent embryonic stem (ES) cells expressing the dominant-negative mutant DN-MKK4(Ala), S257A/T261A. Stably transfected DN-MKK4-ES cells exhibit a transformed fibroblast-like morphology, reduced proliferation rate, were no more submitted to cell contact inhibition, were growing in soft agar, and were much more tumorigenic than parental ES cells in athymic nude mice. These phenotypic changes: (i) are consistent with the protection of DN-MKK4-transfected ES cells from spontaneous, cell density-dependent, and stress-induced apoptosis (DAPI staining and poly (ADP-ribose) polymerase (PARP) cleavage) and (ii) correlated with alterations in JNK, p38, and Erk-1/-2 MAPK/SAPK signaling. Taken together, our data provide a new mechanism linking the MKK4 signaling pathways to cancer progression and identify MKK4 as a tumor-suppressor gene implicated in several transforming functions.	Univ Paris 07, INSERM, U481, F-75870 Paris 18, France; Hop St Antoine, INSERM, U482, F-75571 Paris 12, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Groyer, A (corresponding author), Univ Paris 07, INSERM, U481, 16 Rue Henri Huchard,BP 416, F-75870 Paris 18, France.	groyer@bichat.inserm.fr						Allen M, 2000, J EXP MED, V191, P859, DOI 10.1084/jem.191.5.859; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; BEDDINGTON RSP, 1989, DEVELOPMENT, V105, P733; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; BRUNET A, 1994, ONCOGENE, V9, P3379; Burdon T, 1999, DEV BIOL, V210, P30, DOI 10.1006/dbio.1999.9265; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Day ML, 1997, J BIOL CHEM, V272, P8125, DOI 10.1074/jbc.272.13.8125; Draper JS, 2004, NAT BIOTECHNOL, V22, P53, DOI 10.1038/nbt922; Duriez PJ, 1997, BIOCHEM CELL BIOL, V75, P337, DOI 10.1139/bcb-75-4-337; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Ferrigno O, 2002, ONCOGENE, V21, P4879, DOI 10.1038/sj.onc.1205623; Ganiatsas S, 1998, P NATL ACAD SCI USA, V95, P6881, DOI 10.1073/pnas.95.12.6881; GLISE B, 1995, CELL, V83, P451, DOI 10.1016/0092-8674(95)90123-X; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; Ho DT, 2003, J BIOL CHEM, V278, P32662, DOI 10.1074/jbc.M304229200; Jirmanova L, 2002, ONCOGENE, V21, P5515, DOI 10.1038/sj.onc.1205728; Kieran MW, 1999, ONCOGENE, V18, P6647, DOI 10.1038/sj.onc.1203057; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Lee JK, 1999, MOL BRAIN RES, V66, P133, DOI 10.1016/S0169-328X(99)00035-2; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Manning AM, 2003, NAT REV DRUG DISCOV, V2, P554, DOI 10.1038/nrd1132; Markowitz SD, 2002, CANCER CELL, V1, P233, DOI 10.1016/S1535-6108(02)00053-3; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; McPherson JP, 1998, CANCER RES, V58, P4519; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; Moelling K, 2002, J BIOL CHEM, V277, P31099, DOI 10.1074/jbc.M111974200; Nakano T, 1995, Semin Immunol, V7, P197, DOI 10.1016/1044-5323(95)90047-0; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Nishina H, 1999, DEVELOPMENT, V126, P505; Okabe S, 1996, MECH DEVELOP, V59, P89, DOI 10.1016/0925-4773(96)00572-2; Prunier C, 2003, J BIOL CHEM, V278, P26249, DOI 10.1074/jbc.M304459200; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; Rao CV, 1997, CANCER RES, V57, P3717; Rivat C, 2003, FASEB J, V17, P1721, DOI 10.1096/fj.03-0132fje; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schultz RM, 2003, PROG DRUG RES, V60, P59; Shen YH, 2003, J BIOL CHEM, V278, P26715, DOI 10.1074/jbc.M303264200; Skov S, 1997, J CELL BIOL, V139, P1523, DOI 10.1083/jcb.139.6.1523; SPORN MB, 1986, SCIENCE, V233, P532, DOI 10.1126/science.3487831; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Teng DHF, 1997, CANCER RES, V57, P4177; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; WARE LM, 1972, VIROLOGY, V50, P339, DOI 10.1016/0042-6822(72)90385-6; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Wilson DJ, 1996, EUR J IMMUNOL, V26, P989, DOI 10.1002/eji.1830260505; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Wobus AM, 1997, J MOL CELL CARDIOL, V29, P1525, DOI 10.1006/jmcc.1997.0433; Yamada SD, 2002, CANCER RES, V62, P6717; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yoshida BA, 1999, CANCER RES, V59, P5483; Young MR, 2003, TRENDS MOL MED, V9, P36, DOI 10.1016/S1471-4914(02)00009-6	60	30	31	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2004	23	27					4735	4744		10.1038/sj.onc.1207619	http://dx.doi.org/10.1038/sj.onc.1207619			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZX	15122334				2022-12-28	WOS:000221799200008
J	Pakakasama, S; Chen, TTL; Frawley, W; Muller, CY; Douglass, EC; Lee, R; Pollock, BH; Tomlinson, GE				Pakakasama, S; Chen, TTL; Frawley, W; Muller, CY; Douglass, EC; Lee, R; Pollock, BH; Tomlinson, GE			CCND1 polymorphism and age of onset of hepatoblastoma	ONCOGENE			English	Article						hepatoblastoma; cyclin D1; CCND1 childhood cancer	CYCLIN D1 POLYMORPHISM; BETA-CATENIN GENE; COLORECTAL-CANCER; SOMATIC MUTATIONS; APC GENE; RISK	Cyclin D1, encoded by the gene CCND1, is a major regulator of the cell cycle transition from G1 phase to S phase. A CCND1 polymorphism (G to A) at codon 242, the boundary of exon 4 and intron 4, affects splicing such that exon 5 is not expressed in the A allele. Since exon 5 is involved in rapid turnover, the variant cyclin D1 corresponding to the A allele may have a longer half-life. A previous study demonstrated that in families with hereditary nonpolyposis colorectal cancer, the age of onset of colorectal cancer varied according to variation at this polymorphic site. We examined this CCND1 polymorphism in a series hepatoblastoma, a childhood liver cancer that shares other molecular features with colon cancer. We determined in an analysis of 84 children with hepatoblastoma that the G/A exon 4 polymorphism in CCND1 is correlated with the age of onset of hepatoblastomas. The A/A genotype is associated with an earlier age of onset compared to the G/A or G/G genotype. The median age of patients with the G/G genotype was 22 months, compared to 17 months in patients with the G/A genotype and 11 months for the A/A genotype. These findings suggest that the CCND1 A polymorphism may contribute to tumor development in children with hepatoblastoma.	Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX USA; Univ Texas, SW Med Ctr, Acad Comp Serv, Dallas, TX USA; Temple Univ, St Christophers Hosp, Dept Pediat, Philadelphia, PA 19122 USA; Univ Texas, Hlth Sci Ctr, Ctr Biostat & Epidemiol, San Antonio, TX USA; Univ Texas, SW Med Ctr, Dept Obstet Gynecol, Dallas, TX USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Tomlinson, GE (corresponding author), Univ Texas, SW Med Ctr, Dept Pediat, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	gail.tomlinson@utsouthwestern.edu	Tomlinson, Gail/AAR-9776-2020		NHLBI NIH HHS [HL-53917] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053917] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BETTICHER DC, 1995, ONCOGENE, V11, P1005; BULTERYS M, 1999, HEPATIC TUMORS CANC; DeBaun MR, 1998, J PEDIATR-US, V132, P398, DOI 10.1016/S0022-3476(98)70008-3; Donnellan R, 1998, J CLIN PATHOL-MOL PA, V51, P1; Hollander M., 2014, NONPARAMETRIC STAT M, V3rd ed.; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jeng YM, 2000, CANCER LETT, V152, P45, DOI 10.1016/S0304-3835(99)00433-4; Koch A, 1999, CANCER RES, V59, P269; Kong SM, 2001, JNCI-J NATL CANCER I, V93, P1106, DOI 10.1093/jnci/93.14.1106; Kong SM, 2000, CANCER RES, V60, P249; KURAHASHI H, 1995, CANCER RES, V55, P5007; Matthias C, 1998, CLIN CANCER RES, V4, P2411; McKay JA, 2000, INT J CANCER, V88, P77, DOI 10.1002/1097-0215(20001001)88:1<77::AID-IJC12>3.0.CO;2-O; Oda H, 1996, CANCER RES, V56, P3320; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; Sawa H, 1998, ONCOGENE, V16, P1701, DOI 10.1038/sj.onc.1201691; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Takayasu H, 2001, CLIN CANCER RES, V7, P901	19	33	35	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2004	23	27					4789	4792		10.1038/sj.onc.1207499	http://dx.doi.org/10.1038/sj.onc.1207499			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZX	15133490				2022-12-28	WOS:000221799200014
J	Dhar, A; Hu, J; Reeves, R; Resar, LMS; Colburn, NH				Dhar, A; Hu, J; Reeves, R; Resar, LMS; Colburn, NH			Dominant-negative c-Jun (TAM67) target genes: HMGA1 is required for tumor promoter-induced transformation	ONCOGENE			English	Article						TAM67 target; AP-1; HMGA1; tumor promoter; transformation; JB6	NF-KAPPA-B; INHIBITS AP-1 TRANSACTIVATION; ACTIVATED PROTEIN-KINASE; MAMMARY EPITHELIAL-CELLS; MOUSE EPIDERMAL-CELLS; JB6 CELLS; NEOPLASTIC TRANSFORMATION; TRANSCRIPTION FACTOR; INCREASED EXPRESSION; SKIN CARCINOGENESIS	Activation of the transcription factor AP-1 (activator protein-1) is required for tumor promotion and maintenance of malignant phenotype. A number of AP-1-regulated genes that play a role in tumor progression have been identified. However, AP-1-regulated genes driving tumor induction are yet to be defined. Previous studies have established that expression of a dominant-negative c-Jun (TAM67) inhibits phorbol 12-tetradecanoyl-13-acetate (TPA)-induced AP-1 transactivation as well as transformation in mouse epidermal JB6/P+ cells and tumor promotion in mouse skin carcinogenesis. In this study, we utilized the tumor promotion-sensitive JB6/P+ cells to identify AP-1-regulated TAM67 target genes and to establish causal significance in transformation for one target gene. A 2700 cDNA microarray was queried with RNA from TPA-treated P+ cells with or without TAM67 expression. Under conditions in which TAM expression inhibited TPA-induced transformation, microarray analysis identified a subset of six genes induced by TPA and suppressed by TAM67. One of the identified genes, the high-mobility group protein A1 (Hmga1) is induced by TPA in P+, but not in transformation-resistant P cells. We show that TPA induction of the architectural transcription factor HMGA1 is inhibited by TAM67, is extracellular-signal-regulated kinase (ERK)-activation dependent, and is mediated by AP-1. HMGA1 antisense construct transfected into P+ cells blocked HMGA1 protein expression and inhibited TPA-induced transformation indicating that HMGA1 is required for transformation. HMGA1 is not however sufficient as HMGA1a or HMGA1b overexpression did not confer transformation sensitivity on P- cells. Although HMGA1 expression is ERK dependent, it is not the only ERK-dependent event required for transformation because it does not suffice to rescue ERK-deficient P- cells. Our study shows (a) TAM 67 when it inhibits AP-1 and transformation, targets a relatively small number of genes; (b) HMGA1, a TAM67 target gene, is causally related to transformation and therefore a potentially important target for cancer prevention.	NCI, Gene Regulat Sect, Lab Canc Prevent, CCR, Ft Detrick, MD 21702 USA; Washington State Univ, Sch Mol Biosci, Dept Biochem, Pullman, WA 99164 USA; Johns Hopkins Univ, Sch Med, Div Pediat Hematol, Baltimore, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Washington State University; Johns Hopkins University	Dhar, A (corresponding author), NCI, Gene Regulat Sect, Lab Canc Prevent, CCR, Bldg 567,Rm 180,Chandler St, Ft Detrick, MD 21702 USA.	adhar@ncifcrf.gov	Hu, Jing/M-3130-2014					Abe N, 1999, CANCER RES, V59, P1169; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Angel P, 2001, ONCOGENE, V20, P2413, DOI 10.1038/sj.onc.1204380; Balmain A, 2001, NAT REV CANCER, V1, P77, DOI 10.1038/35094086; Berlingieri MT, 2002, ONCOGENE, V21, P2971, DOI 10.1038/sj.onc.1205368; BERNSTEIN LR, 1994, J BIOL CHEM, V269, P9401; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; BERNSTEIN LR, 1992, MOL CARCINOGEN, V6, P221, DOI 10.1002/mc.2940060308; Bouallaga I, 2003, MOL CELL BIOL, V23, P2329, DOI 10.1128/MCB.23.7.2329-2340.2003; BROWN PH, 1993, ONCOGENE, V8, P877; Budunova IV, 1999, ONCOGENE, V18, P7423, DOI 10.1038/sj.onc.1203104; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; Chang PL, 2003, CARCINOGENESIS, V24, P1749, DOI 10.1093/carcin/bgg138; CHIAPPETTA G, 1995, ONCOGENE, V10, P1307; Chin MT, 1998, J BIOL CHEM, V273, P9755, DOI 10.1074/jbc.273.16.9755; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Cmarik JL, 1998, ONCOGENE, V16, P3387, DOI 10.1038/sj.onc.1201888; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; COLBURN NH, 1981, P NATL ACAD SCI-BIOL, V78, P6912, DOI 10.1073/pnas.78.11.6912; COLBURN NH, 1982, CANCER RES, V42, P3093; COLBURN NH, 1979, NATURE, V281, P589, DOI 10.1038/281589a0; Cooper SJ, 2003, MOL CANCER RES, V1, P848; CRAIG AM, 1989, J BIOL CHEM, V264, P9682; Dhar A, 2002, MOL CELL BIOCHEM, V234, P185, DOI 10.1023/A:1015948505117; DONG ZG, 1995, CARCINOGENESIS, V16, P749, DOI 10.1093/carcin/16.4.749; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; Eto I, 1998, CELL PROLIFERAT, V31, P71, DOI 10.1046/j.1365-2184.1998.00112.x; FRIEDMANN M, 1993, NUCLEIC ACIDS RES, V21, P4259, DOI 10.1093/nar/21.18.4259; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Himes SR, 1996, IMMUNITY, V5, P479, DOI 10.1016/S1074-7613(00)80503-8; Himes SR, 2000, J IMMUNOL, V164, P3157, DOI 10.4049/jimmunol.164.6.3157; Hsu TC, 2001, CANCER RES, V61, P4160; Huang CS, 1998, P NATL ACAD SCI USA, V95, P156, DOI 10.1073/pnas.95.1.156; Huang CS, 1999, ONCOGENE, V18, P2828, DOI 10.1038/sj.onc.1202639; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Johnston IMP, 2000, ONCOGENE, V19, P5348, DOI 10.1038/sj.onc.1203927; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kovacic P, 2001, CURR MED CHEM, V8, P773, DOI 10.2174/0929867013373084; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; Li JJ, 1997, CANCER RES, V57, P3569; Li JJ, 2000, MOL CARCINOGEN, V29, P159, DOI 10.1002/1098-2744(200011)29:3<159::AID-MC5>3.0.CO;2-W; OGRAM SA, 1995, J BIOL CHEM, V270, P14235, DOI 10.1074/jbc.270.23.14235; Ozanne BW, 2000, EUR J CANCER, V36, P1640, DOI 10.1016/S0959-8049(00)00175-1; Pedulla ML, 2001, GENE, V271, P51, DOI 10.1016/S0378-1119(01)00500-5; RAM TG, 1993, CANCER RES, V53, P2655; Reeves R, 1999, METHOD ENZYMOL, V304, P155; Reeves R, 2001, MOL CELL BIOL, V21, P575, DOI 10.1128/MCB.21.2.575-594.2001; ROBELS AI, 1995, CARCINOGENESIS, V16, P781, DOI 10.1093/carcin/16.4.781; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Suzukawa K, 2002, ENVIRON HEALTH PERSP, V110, P865, DOI 10.1289/ehp.02110865; TAMIMI Y, 1993, CANCER RES, V53, P5512; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Watts RG, 1998, ONCOGENE, V17, P3493, DOI 10.1038/sj.onc.1202259; WATTS RG, 1995, MOL CARCINOGEN, V13, P27, DOI 10.1002/mc.2940130106; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058; Wood LJ, 2000, MOL CELL BIOL, V20, P5490, DOI 10.1128/MCB.20.15.5490-5502.2000; Wood LJ, 2000, CANCER RES, V60, P4256; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yang HS, 2001, ONCOGENE, V20, P669, DOI 10.1038/sj.onc.1204137; Yang TY, 2002, IEEE T ADV PACKAGING, V25, P54, DOI 10.1109/TADVP.2002.1017686; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; Young MR, 2003, TRENDS MOL MED, V9, P36, DOI 10.1016/S1471-4914(02)00009-6; Young MR, 2002, MOL CARCINOGEN, V34, P72, DOI 10.1002/mc.10050; Young MR, 2002, MOL CELL BIOL, V22, P587, DOI 10.1128/MCB.22.2.587-598.2002	68	43	49	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2004	23	25					4466	4476		10.1038/sj.onc.1207581	http://dx.doi.org/10.1038/sj.onc.1207581			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	824CJ	15064752				2022-12-28	WOS:000221661300012
J	Kang, AD; Park, G; Kim, YH; Oh, IH				Kang, AD; Park, G; Kim, YH; Oh, IH			Differential modulation of Myb family genes by Ets-2	ONCOGENE			English	Article						myb family gene; ets-2; transcriptional cooperation	MURINE A-MYB; C-MYB; B-MYB; TRANSCRIPTIONAL ACTIVATION; FUNCTIONAL DOMAINS; EXPRESSION; ONCOGENE; PHOSPHORYLATION; PROTEINS; DISTINCT	The myb family of genes encodes highly homologous nuclear transcription factors that play distinct roles in the development of breast, germ cells and hematoid organs. While the mechanisms associated with the regulation of these genes remain unknown, the transactivation of c-Myb was previously shown to be upregulated by transcriptional cooperation with Ets-2. The present study examines the transactivation potential of the myb gene family in cooperation with Ets-2. A-Myb and c-Myb showed similar transcriptional cooperation with Ets-2, but not with Ets-1. Interestingly, B-Myb showed no cooperative activity with Ets-2 or Ets-1. Additionally, deletion mutants of A-Myb or c-Myb, where the C-terminal negative regulatory domain was deleted, did not abrogate their ability to cooperate with Ets-2. However, the deletion mutant of B-Myb, where the C-terminal positive regulatory domain was deleted, restored its ability to cooperate with Ets-2. Furthermore, studies using a series of 'domain-swapped' mutants between c-Myb and B-Myb revealed that the C-terminus of B-Myb, which is responsible for the protein's transactivation potential, blocks transcriptional cooperation with Ets-2. These results suggest that the myb gene family can be differentially modulated by Ets-2, and that the C-terminus is the domain that regulates this activity.	Catholic Univ Korea, Cell & Gene Therapy Inst, Dept Cellular Med & Biol, Seoul 137701, South Korea; Catholic Univ Korea, Dept Clin Pathol, Seoul 137701, South Korea; Korea Univ, Seoul 136701, South Korea	Catholic University of Korea; Catholic University of Korea; Korea University	Oh, IH (corresponding author), Catholic Univ Korea, Cell & Gene Therapy Inst, Dept Cellular Med & Biol, 505 Banpo Dong, Seoul 137701, South Korea.	iho@catholic.ac.kr		Kim, Yeul Hong/0000-0002-2555-2333				BALUDA MA, 1994, ONCOGENE, V9, P2761; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BIES J, 1995, CELL GROWTH DIFFER, V6, P59; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; FUJIWARA S, 1990, MOL CELL BIOL, V10, P1249, DOI 10.1128/MCB.10.3.1249; KALKBRENNER F, 1990, ONCOGENE, V5, P657; METTUS RV, 1994, ONCOGENE, V9, P3077; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Oh IH, 1998, MOL CELL BIOL, V18, P499, DOI 10.1128/MCB.18.1.499; Oh IH, 1997, J BIOL CHEM, V272, P21432, DOI 10.1074/jbc.272.34.21432; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Patel G, 1996, ONCOGENE, V13, P1197; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; Rushton JJ, 2003, ONCOGENE, V22, P308, DOI 10.1038/sj.onc.1206131; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Tanaka Y, 1999, J BIOL CHEM, V274, P28067, DOI 10.1074/jbc.274.40.28067; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	25	1	1	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4177	4181		10.1038/sj.onc.1207537	http://dx.doi.org/10.1038/sj.onc.1207537			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15064740				2022-12-28	WOS:000221520200017
J	Li, JX; Tang, MS; Liu, BC; Shi, XL; Huang, C				Li, JX; Tang, MS; Liu, BC; Shi, XL; Huang, C			A critical role of PI-3K/Akt/JNKs pathway in benzo[a]pyrene diol-epoxide (B[a]PDE)-induced AP-1 transactivation in mouse epidermal Cl41 cells	ONCOGENE			English	Article						PI-3K; Akt; MAP kinase; PAH; AP-1	POLYCYCLIC AROMATIC-HYDROCARBONS; P70 S6 KINASE; PHOSPHOINOSITIDE 3-KINASE; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; ACTIVATED PROTEIN-1; OPTICAL ENANTIOMERS; CATALYTIC SUBUNIT; TRANSFORMATION; GENE	Mouse skin tumorigenicity studies indicate that benzo[a]-pyrene-7,8-diol-9,10-epoxide (B[a]PDE) contributes to carcinogenesis as both a tumor initiator and promoter. However, the mechanisms that mediate B[a] PDE tumor promotion effects remain unclear. Our results demonstrated that in mouse epidermal Cl41 cells, B[a] PDE treatment resulted in marked activation of AP-1 and its upstream MAPKs, including ERKs, JNKs and p38K. B[a] PDE exposure also led to activation of phosphotidy-linositol 3-kinase (PI-3K), Akt and p70 S6 kinase (p70(S6k)). B[a]PDE-induced AP-1 transactivation was inhibited by pretreatment of cells with PI-3K inhibitors, wortmannin or Ly294002. In contrast, inhibition of p70(S6k) with rapamycin did not show any inhibitory effects. An overexpression of dominant-negative mutant of PI-3K, Deltap85, impaired B[a]PDE-induced activation of PI-3K, Akt and AP-1 transactivation. Furthermore, an overexpression of dominant-negative Akt mutant, Akt-T308A/S473A, blocked B[a]PDE-induced activation of Akt, AP-1 and JNKs, while it did not affect the activation of p70S6k, ERKs and p38 kinase. These results demonstrated that B[a] PDE was able to induce AP-1 transactivation and this AP-1 induction was specific through PI-3K/Akt/JNKs-dependent and p70(S6k)-independent pathways. This study also indicated that Akt-T308A/S473A blocks B[a]PDE-induced AP-1 activation specific through impairing JNK pathway. These findings will help us to understand the signal transduction pathways involved in the carcinogenic effects of B[a] PDE.	NYU, Sch Med, Nelson Inst Environm Med, Tuxedo Pk, NY 10987 USA; Chinese Ctr Dis Control & Prevent, Natl Inst Occupat Hlth & Poisons Control, Beijing 100050, Peoples R China; Chinese Acad Sci, Inst Nutr Sci, Shanghai 200031, Peoples R China	New York University; Chinese Center for Disease Control & Prevention; Chinese Academy of Sciences	Huang, C (corresponding author), NYU, Sch Med, Nelson Inst Environm Med, 57 Old Forge Rd, Tuxedo Pk, NY 10987 USA.	chuanshu@env.med.nyu.edu	Shi, Xianglin/B-8588-2012	Huang, Chuanshu/0000-0003-4133-5096	NATIONAL CANCER INSTITUTE [R01CA103180, R01CA112557, R01CA094964] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES012451] Funding Source: NIH RePORTER; NCI NIH HHS [CA112557, CA094964, CA103180] Funding Source: Medline; NIEHS NIH HHS [ES012451] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALBERT RE, 1991, CARCINOGENESIS, V12, P1273, DOI 10.1093/carcin/12.7.1273; Alessi DR, 1998, BBA-MOL CELL BIOL L, V1436, P151, DOI 10.1016/S0005-2760(98)00133-7; Aoki M, 2000, J BIOL CHEM, V275, P6267, DOI 10.1074/jbc.275.9.6267; BERNELOTMOENS C, 1990, CARCINOGENESIS, V11, P781, DOI 10.1093/carcin/11.5.781; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; Bostrom CE, 2002, ENVIRON HEALTH PERSP, V110, P451, DOI 10.1289/ehp.02110s3451; Bral CM, 1997, MOL PHARMACOL, V52, P974, DOI 10.1124/mol.52.6.974; BRESNICK E, 1977, CANCER RES, V37, P984; BUENING MK, 1978, P NATL ACAD SCI USA, V75, P5358, DOI 10.1073/pnas.75.11.5358; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; CONNEY AH, 1994, DRUG METAB REV, V26, P125, DOI 10.3109/03602539409029788; CONNEY AH, 1982, CANCER RES, V42, P4875; Cooper SJ, 2003, MOL CANCER RES, V1, P848; COSMAN M, 1992, P NATL ACAD SCI USA, V89, P1914, DOI 10.1073/pnas.89.5.1914; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; DONG ZG, 1995, INT J ONCOL, V7, P359; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; EISENSTADT E, 1982, P NATL ACAD SCI-BIOL, V79, P1945, DOI 10.1073/pnas.79.6.1945; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; FUKUI Y, 1991, ONCOGENE, V6, P407; Funakoshi-Tago M, 2003, EUR J BIOCHEM, V270, P1257, DOI 10.1046/j.1432-1033.2003.03487.x; Gonzales M, 2002, ONCOGENE, V21, P2721, DOI 10.1038/sj.onc.1205366; HALL M, 1989, CARCINOGENESIS, V10, P1815, DOI 10.1093/carcin/10.10.1815; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; HECHT SS, 1974, JNCI-J NATL CANCER I, V53, P1121, DOI 10.1093/jnci/53.4.1121; Heidelberger C, 1973, Adv Cancer Res, V18, P317, DOI 10.1016/S0065-230X(08)60756-3; Hoffmann D, 1997, PREV MED, V26, P427, DOI 10.1006/pmed.1997.0183; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Huang CS, 1997, P NATL ACAD SCI USA, V94, P5826, DOI 10.1073/pnas.94.11.5826; Huang CS, 1999, J BIOL CHEM, V274, P29672, DOI 10.1074/jbc.274.42.29672; Huang CS, 1997, J BIOL CHEM, V272, P4187, DOI 10.1074/jbc.272.7.4187; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Huang CS, 2002, CANCER RES, V62, P6857; Huang CS, 2002, CANCER RES, V62, P5689; Huang CS, 1998, P NATL ACAD SCI USA, V95, P156, DOI 10.1073/pnas.95.1.156; Huang CS, 2001, J BIOL CHEM, V276, P40234, DOI 10.1074/jbc.M103684200; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kim AH, 2002, NEURON, V35, P697, DOI 10.1016/S0896-6273(02)00821-8; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; Lee YH, 2003, J BIOL CHEM, V278, P2896, DOI 10.1074/jbc.M208359200; Lei W, 1998, CANCER RES, V58, P2102; LEVIN W, 1977, CANCER RES, V37, P3356; Li JJ, 1997, CANCER RES, V57, P3569; Merimsky O, 1998, CLIN DERMATOL, V16, P585, DOI 10.1016/S0738-081X(98)00043-1; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; NEBERT DW, 1993, ANN NY ACAD SCI, V685, P624, DOI 10.1111/j.1749-6632.1993.tb35928.x; Parrish AR, 1998, TOXICOL APPL PHARM, V152, P302, DOI 10.1006/taap.1998.8525; Parrish AR, 2002, BIOCHEM PHARMACOL, V64, P31, DOI 10.1016/S0006-2952(02)01054-7; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; PHILLIPS DH, 1983, NATURE, V303, P468, DOI 10.1038/303468a0; Pitot HC, 1996, CASARETT DOULLS TOXI, P201; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; REINHARD C, 1992, P NATL ACAD SCI USA, V89, P4052, DOI 10.1073/pnas.89.9.4052; RODRIGUEZ H, 1993, CARCINOGENESIS, V14, P373, DOI 10.1093/carcin/14.3.373; SEILKIRK JK, 1982, MECH CHEM CARCINOGEN, P331; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Shimada T, 1999, CHEM RES TOXICOL, V12, P623, DOI 10.1021/tx990028s; Sims P, 1974, Adv Cancer Res, V20, P165, DOI 10.1016/S0065-230X(08)60111-6; SLAGA TJ, 1979, CANCER RES, V39, P67; Smith LE, 2000, JNCI-J NATL CANCER I, V92, P803, DOI 10.1093/jnci/92.10.803; SMITH MJ, 1992, BLOOD, V79, P2107; SUSA M, 1989, CELL, V57, P817, DOI 10.1016/0092-8674(89)90796-4; Tannheimer SL, 1998, CARCINOGENESIS, V19, P1291, DOI 10.1093/carcin/19.7.1291; Thompson EJ, 2002, CANCER RES, V62, P3044; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; Watts RG, 1998, ONCOGENE, V17, P3493, DOI 10.1038/sj.onc.1202259; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YANG JL, 1991, CARCINOGENESIS, V12, P71, DOI 10.1093/carcin/12.1.71; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827	79	46	47	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					3932	3944		10.1038/sj.onc.1207501	http://dx.doi.org/10.1038/sj.onc.1207501			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15021902				2022-12-28	WOS:000221382000005
J	Miyaoka, Y; Kadowaki, Y; Ishihara, S; Ose, T; Fukuhara, H; Kazumori, H; Takasawa, S; Okamoto, H; Chiba, T; Kinoshita, Y				Miyaoka, Y; Kadowaki, Y; Ishihara, S; Ose, T; Fukuhara, H; Kazumori, H; Takasawa, S; Okamoto, H; Chiba, T; Kinoshita, Y			Transgenic overexpression of Reg protein caused gastric cell proliferation and differentiation along parietal cell and chief cell lineages	ONCOGENE			English	Article						Reg; gastric cells; transgenic mice; growth factor	GROWTH-FACTOR-ALPHA; REGENERATING GENE PROTEIN; PANCREATIC THREAD PROTEIN; MUCOUS EPITHELIAL-CELLS; MENETRIERS DISEASE; PRIMARY CULTURES; MOUSE STOMACH; EXPRESSION; INSULIN; MICE	Reg (regenerating gene product) was originally identified as a growth factor involved in pancreatic regeneration. During the healing course of gastric erosion, Reg expression is highly increased in the enterochromaffin-like (ECL) cells surrounding the ulcer crater, suggesting its role as a regulator of gastric mucosal regeneration. However, there has been no direct in vivo evidence of a growth-promoting role of Reg for the gastric mucosal cells. In the current study, Reg-transgenic mice were created and gastric mucosa were analysed for histological changes. Transgenic mice showed a marked increase in the thickness of the fundic mucosa. Anti-proliferating cell nuclear antigen ( PCNA) staining of the fundic mucosa demonstrated the enlargement of the proliferating neck zone and the lower PCNA-negative zone. Histological analysis employing antibodies against cell-type markers revealed expansion of the chief cell and parietal cell populations and no change in the number of surface mucus-producing cells, ECL cells, or G cells. In conclusion, Reg has a growth-promoting effect on gastric progenitor cells and an activity to direct the differentiation of the cells into chief cell and parietal cell lineages. This was in contrast to other factors, all of which had been shown to drive differentiation towards mucus producing cells in vivo. In the injured gastric mucosa, Reg may play a unique and important part in the reconstruction of the properly organized mucosal architecture.	Tohoku Univ, Grad Sch Med, Dept Biochem, Sendai, Miyagi 980, Japan; Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Kyoto, Japan	Tohoku University; Kyoto University	Kadowaki, Y (corresponding author), Shimane Med Univ, Dept Internal Med 2, Izumo, Shimane 6938501, Japan.	y-kado@momo.so-net.ne.jp						Asahara M, 1996, GASTROENTEROLOGY, V111, P45, DOI 10.1053/gast.1996.v111.pm8698224; BEAUCHAMP RD, 1989, J CLIN INVEST, V84, P1017, DOI 10.1172/JCI114223; BORDI C, 1995, ENDOCR PATHOL, V6, P103, DOI 10.1007/BF02739873; CHEN MC, 1991, J CLIN INVEST, V87, P1716, DOI 10.1172/JCI115189; DEMPSEY PJ, 1992, GASTROENTEROLOGY, V103, P1950, DOI 10.1016/0016-5085(92)91455-D; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; Fukui H, 1998, GASTROENTEROLOGY, V115, P1483, DOI 10.1016/S0016-5085(98)70027-7; HATTORI T, 1976, CELL TISSUE RES, V172, P171; Higham AD, 1999, GASTROENTEROLOGY, V116, P1310, DOI 10.1016/S0016-5085(99)70495-6; Kadowaki Y, 2002, FEBS LETT, V530, P59, DOI 10.1016/S0014-5793(02)03398-7; KARAM SM, 1993, ANAT REC, V236, P333, DOI 10.1002/ar.1092360206; KARAM SM, 1992, ANAT RECORD, V232, P231, DOI 10.1002/ar.1092320208; Kazumori H, 2000, GASTROENTEROLOGY, V119, P1610, DOI 10.1053/gast.2000.20262; Kobayashi S, 2000, J BIOL CHEM, V275, P10723, DOI 10.1074/jbc.275.15.10723; POLK WH, 1992, GASTROENTEROLOGY, V102, P1467, DOI 10.1016/0016-5085(92)91703-7; RUTTEN MJ, 1993, AM J PHYSIOL, V265, pG361, DOI 10.1152/ajpgi.1993.265.2.G361; RUTTEN MJ, 1991, SCAND J GASTROENTERO, V26, P965, DOI 10.3109/00365529108996250; SHARP R, 1995, DEVELOPMENT, V121, P149; TAKAGI H, 1992, J CLIN INVEST, V90, P1161, DOI 10.1172/JCI115936; TAKAHASHI M, 1995, J CLIN INVEST, V95, P1994, DOI 10.1172/JCI117884; TERAZONO K, 1988, J BIOL CHEM, V263, P2111; TERAZONO K, 1990, DIABETOLOGIA, V33, P250, DOI 10.1007/BF00404804; UNNO M, 1993, J BIOL CHEM, V268, P15974; WATANABE T, 1990, J BIOL CHEM, V265, P7432; WATANABE T, 1994, P NATL ACAD SCI USA, V91, P3589, DOI 10.1073/pnas.91.9.3589; YOSHIURA K, 1994, DIGEST DIS SCI, V39, P1454, DOI 10.1007/BF02088048; Zenilman ME, 1996, GASTROENTEROLOGY, V110, P1208, DOI 10.1053/gast.1996.v110.pm8613011	27	55	59	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3572	3579		10.1038/sj.onc.1207333	http://dx.doi.org/10.1038/sj.onc.1207333			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15116092				2022-12-28	WOS:000221101700008
J	Chumakov, AM; Kubota, T; Walter, S; Koeffler, HP				Chumakov, AM; Kubota, T; Walter, S; Koeffler, HP			Identification of murine and human XCP1 genes as C/EBP-epsilon-dependent members of FIZZ/Resistin gene family	ONCOGENE			English	Article						C/EBP; resistin; transcriptional regulation; myeloid; chemotaxis; defensin; innate immunity	BINDING-PROTEIN-EPSILON; MYELOID TRANSCRIPTION FACTOR; CELL-LINE; EXPRESSION; DEFENSINS; LEUKEMIA; RESISTIN; DIFFERENTIATION; MYB; CHEMOKINES	The CCAAT enhancer binding protein epsilon (C/EBP-epsilon) transcription factor is expressed predominantly in granulocytes. Mice with a disruption of the C/EBP-epsilon gene fail to produce mature granulocytes and eosinophils. Cells derived from the peritoneal exudates of C/EBP-epsilon -/- mice lack the expression of a number of chemokines and chemokine receptor genes. We have found a novel C/EBP-epsilon dependent promyelocyte-specific gene, mXCP1. mXCP1 belongs to a family of XCP/FIZZ/Resistin genes, which includes four murine genes and two human genes, hXCP1 and hXCP2. These genes have four exons and encode short secreted proteins sharing a ten-cysteine motif. Murine mXCP1, mXCP2 and mXCP3 genes map to murine chromosome 16 and mXCP4 is positioned on chromosome 8; the hXCP1 and hXCP2 genes are located at homologous regions of chromosomes 3 and 19. Introduction of an inducible C/EBP-epsilon gene into the NIH3T3 and myeloid cells from C/EBP-epsilon-null mice line revealed that the conditional expression of C/EBP-epsilon induced mXCP1. The HXCP1 gene was identified as a C/EBP-epsilon-dependent regulatory homologue of mXCP1. The expression data for other members of XCP/FIZZ gene family are presented. Further studies indicate that XCP1 is a secreted protein that is chemotactic to myeloid cells from C/EBP-epsilon-null mice and is able to interact directly with alpha-defensin.	Univ Calif Los Angeles, Sch Med,Burns & Allen Res Inst, Cedars Sinai Med Ctr, Div Hematol Oncol, Los Angeles, CA 90048 USA; Kochi Med Sch, Dept Med, Kochi 783, Japan	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Kochi University	Chumakov, AM (corresponding author), Univ Calif Los Angeles, Sch Med,Burns & Allen Res Inst, Cedars Sinai Med Ctr, Div Hematol Oncol, Davis Bldg 5022,8700 Beverly Blvd, Los Angeles, CA 90048 USA.	achumakov@hotmail.com	Chumakov, Alexey/N-1541-2014	Chumakov, Alexey/0000-0003-2733-3166				ALTSCHUL SF, 1994, NAT GENET, V6, P119, DOI 10.1038/ng0294-119; Altschul SF, 1996, METHOD ENZYMOL, V266, P460; Antonson P, 1996, GENOMICS, V35, P30, DOI 10.1006/geno.1996.0319; BACON KB, 1988, BRIT J PHARMACOL, V95, P966, DOI 10.1111/j.1476-5381.1988.tb11727.x; Banerjee RR, 2001, J BIOL CHEM, V276, P25970, DOI 10.1074/jbc.M103109200; Broxmeyer HE, 1999, ANN NY ACAD SCI, V872, P142, DOI 10.1111/j.1749-6632.1999.tb08460.x; CHUMAKOV A, 1993, GENE, V131, P231, DOI 10.1016/0378-1119(93)90298-H; Chumakov AM, 1997, MOL CELL BIOL, V17, P1375, DOI 10.1128/MCB.17.3.1375; Dieu MC, 1998, J EXP MED, V188, P373, DOI 10.1084/jem.188.2.373; Ganz T, 1999, SCIENCE, V286, P420, DOI 10.1126/science.286.5439.420; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Gropp R, 1999, HUM GENE THER, V10, P957, DOI 10.1089/10430349950018355; Hartman HB, 2002, J BIOL CHEM, V277, P19754, DOI 10.1074/jbc.M201451200; Haugen F, 2001, FEBS LETT, V507, P105, DOI 10.1016/S0014-5793(01)02968-4; Herwig S, 1996, BLOOD, V87, P350, DOI 10.1182/blood.V87.1.350.bloodjournal871350; Holcomb IN, 2000, EMBO J, V19, P4046, DOI 10.1093/emboj/19.15.4046; HUTTNER KM, 1994, GENOMICS, V19, P448, DOI 10.1006/geno.1994.1093; Ichinose M, 1996, IMMUNOPHARMACOLOGY, V35, P103, DOI 10.1016/S0162-3109(96)00118-X; Kinoshita K, 2000, MOL CELL BIOL, V20, P4680, DOI 10.1128/MCB.20.13.4680-4690.2000; KOEFFLER HP, 1978, SCIENCE, V200, P1153, DOI 10.1126/science.306682; Kubota T, 2000, BLOOD, V96, P3953, DOI 10.1182/blood.V96.12.3953.h8003953_3953_3957; LANOTTE M, 1991, BLOOD, V77, P1080; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Lekstrom-Himes J, 1999, BLOOD, V93, P3096; Lekstrom-Himes JA, 1999, J EXP MED, V189, P1847, DOI 10.1084/jem.189.11.1847; Masera RG, 1996, REGUL PEPTIDES, V62, P13, DOI 10.1016/0167-0115(95)00150-6; Mink S, 1996, MOL CELL BIOL, V16, P1316; Morosetti R, 1997, BLOOD, V90, P2591, DOI 10.1182/blood.V90.7.2591.2591_2591_2600; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; Park DJ, 1999, J CLIN INVEST, V103, P1399, DOI 10.1172/JCI2887; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; Savage DB, 2001, DIABETES, V50, P2199, DOI 10.2337/diabetes.50.10.2199; SCOTT LM, 1992, BLOOD, V80, P1725; SELSTED ME, 1992, J CELL BIOL, V118, P929, DOI 10.1083/jcb.118.4.929; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Steppan CM, 2001, P NATL ACAD SCI USA, V98, P502, DOI 10.1073/pnas.98.2.502; Taupin DR, 2000, P NATL ACAD SCI USA, V97, P799, DOI 10.1073/pnas.97.2.799; Verbeek W, 1999, BLOOD, V93, P3327, DOI 10.1182/blood.V93.10.3327; Verbeek W, 1999, BLOOD, V94, P3141, DOI 10.1182/blood.V94.9.3141.421k41_3141_3150; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P6462, DOI 10.1073/pnas.94.12.6462; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P13187, DOI 10.1073/pnas.94.24.13187; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525; YOUNT NY, 1995, J IMMUNOL, V155, P4476; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569	46	31	36	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3414	3425		10.1038/sj.onc.1207126	http://dx.doi.org/10.1038/sj.onc.1207126			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15064728				2022-12-28	WOS:000220975000016
J	Weissenberger, J; Loeffler, S; Kappeler, A; Kopf, M; Lukes, A; Afanasieva, TA; Aguzzi, A; Weis, J				Weissenberger, J; Loeffler, S; Kappeler, A; Kopf, M; Lukes, A; Afanasieva, TA; Aguzzi, A; Weis, J			IL-6 is required for glioma development in a mouse model	ONCOGENE			English	Article						gliomas; mouse model; IL-6 knockout; STAT3 signalling	GROWTH-FACTOR; CELL-GROWTH; STAT3; ACTIVATION; GLIOBLASTOMA; ASTROCYTES; EXPRESSION; DIFFERENTIATION; OVEREXPRESSION; PROLIFERATION	The pleiotropic cytokine interleukin- 6 (IL-6) contributes to malignant progression and apoptosis resistance of various cancer types. Although IL-6 is elevated in malignant gliomas, and glioma cells respond to IL-6, its functional role in gliomagenesis is unclear. We have investigated this role of IL-6 in a mouse model of spontaneous astrocytoma by crossbreeding glial fibrillary acidic protein (GFAP)-viral src oncogene transgenic mice with IL-6-deficient mice. We show here that ablation of IL-6 prevents tumour formation in these predisposed animals, but did not affect preneoplastic astrogliosis. Moreover, we demonstrate phosphorylation and nuclear translocation of the transcription factor signal transducer and activator of transcription (STAT) 3, a prerequisite for IL-6 signalling, in 51 human gliomas WHO grade II-IV and all experimental mouse tumours investigated. Together with the observation that STAT3 activation increases with malignancy, these findings indicate an important role for IL-6 in the development and malignant progression of astrocytomas.	Univ Bern, Inst Pathol, Div Neuropathol, CH-3010 Bern, Switzerland; Swiss Fed Inst Technol, Dept Environm Sci, CH-8952 Zurich, Switzerland; Univ Bern, Inselspital, Dept Neurosurg, CH-3010 Bern, Switzerland; Univ Zurich, Inst Neuropathol, CH-8091 Zurich, Switzerland; Rhein Westfal TH Aachen, Univ Hosp, Inst Neuropathol, D-52074 Aachen, Germany	University of Bern; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Bern; University Hospital of Bern; University of Zurich; RWTH Aachen University; RWTH Aachen University Hospital	Weissenberger, J (corresponding author), Univ Bern, Inst Pathol, Div Neuropathol, Murtenstr 31, CH-3010 Bern, Switzerland.	weissenb@patho.unibe.ch	Weis, Joachim/G-1984-2014; Kopf, Manfred/B-6907-2009; Aguzzi, Adriano/A-3351-2008	Weis, Joachim/0000-0003-3280-6773; Kopf, Manfred/0000-0002-0628-7140; Adams, Tatiana/0000-0002-8656-7096; Aguzzi, Adriano/0000-0002-0344-6708				Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Brunello AG, 2000, AM J PATHOL, V157, P1485, DOI 10.1016/S0002-9440(10)64787-6; Buettner R, 2002, CLIN CANCER RES, V8, P945; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Candi E, 1997, J NEURO-ONCOL, V31, P115, DOI 10.1023/A:1005706019048; Cardenas H, 2003, BRAIN RES, V985, P89, DOI 10.1016/S0006-8993(03)03172-X; Faruqi TR, 2001, P NATL ACAD SCI USA, V98, P9014, DOI 10.1073/pnas.161281298; Fischer P, 2004, BIOCHEM J, V378, P449, DOI 10.1042/BJ20030893; Goswami S, 1998, J NEUROCHEM, V71, P1837; He B, 2003, P NATL ACAD SCI USA, V100, P14133, DOI 10.1073/pnas.2232790100; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Hirota K, 2001, J BIOL CHEM, V276, P21166, DOI 10.1074/jbc.M100677200; Holland EC, 2001, NAT REV GENET, V2, P120, DOI 10.1038/35052535; Justicia C, 2000, GLIA, V30, P253, DOI 10.1002/(SICI)1098-1136(200005)30:3<253::AID-GLIA5>3.0.CO;2-O; Kaptein A, 1996, J BIOL CHEM, V271, P5961, DOI 10.1074/jbc.271.11.5961; Kleihues P, 2000, PATHOLOGY GENETICS T; Klein MA, 1997, GLIA, V19, P227, DOI 10.1002/(SICI)1098-1136(199703)19:3<227::AID-GLIA5>3.0.CO;2-W; Konnikova L, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-23; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; Kossakowska AE, 1999, BLOOD, V94, P2080, DOI 10.1182/blood.V94.6.2080.418k30_2080_2089; Kretzschmar AK, 2004, BIOCHEM J, V377, P289, DOI 10.1042/BJ20030708; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Leu CM, 2003, ONCOGENE, V22, P7809, DOI 10.1038/sj.onc.1207084; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Nagai S, 2002, J NEUROSURG, V96, P909, DOI 10.3171/jns.2002.96.5.0909; Nagashima G, 2002, CLIN NEUROL NEUROSUR, V104, P125, DOI 10.1016/S0303-8467(01)00197-4; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Rahaman SO, 2002, ONCOGENE, V21, P8404, DOI 10.1038/sj.onc.1206047; Rolhion C, 2001, J NEUROSURG, V94, P97, DOI 10.3171/jns.2001.94.1.0097; Schaefer LK, 2002, ONCOGENE, V21, P2058, DOI 10.1038/sj.onc.1205263; SEHGAL PB, 2002, J BIOL CHEM, V28, P28; SELMAJ KW, 1990, J IMMUNOL, V144, P129; Senger DL, 2002, CANCER RES, V62, P2131; Shirogane T, 1999, IMMUNITY, V11, P709, DOI 10.1016/S1074-7613(00)80145-4; Takizawa T, 2001, CYTOKINE, V13, P272, DOI 10.1006/cyto.2000.0831; Tchirkov A, 2001, BRIT J CANCER, V85, P518, DOI 10.1054/bjoc.2001.1942; Theurillat JP, 1999, AM J PATHOL, V154, P581, DOI 10.1016/S0002-9440(10)65303-5; VAN MEIR E, 1990, CANCER RES, V50, P6683; Van Wagoner NJ, 1999, J NEUROSCI, V19, P5236; Wei LH, 2003, ONCOGENE, V22, P1517, DOI 10.1038/sj.onc.1206226; Weissenberger J, 1997, ONCOGENE, V14, P2005, DOI 10.1038/sj.onc.1201168; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	43	144	159	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3308	3316		10.1038/sj.onc.1207455	http://dx.doi.org/10.1038/sj.onc.1207455			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15064729				2022-12-28	WOS:000220975000005
J	Lee, MS; Igawa, T; Lin, MF				Lee, MS; Igawa, T; Lin, MF			Tyrosine-317 of p52(Shc) mediates androgen-stimulated proliferation signals in human prostate cancer cells	ONCOGENE			English	Article						PAcP; ErbB-2; p52(Shc); androgen sensitivity; human prostate cancer	EPIDERMAL-GROWTH-FACTOR; STEROID-HORMONE RECEPTORS; ACID-PHOSPHATASE-ACTIVITY; ADVANCED BREAST-CANCER; CARCINOMA-CELLS; PROTEIN-PHOSPHORYLATION; ENDOCRINE-THERAPY; INDUCED APOPTOSIS; SHC; EXPRESSION	The involvement of tyrosine phosphorylation signaling pathways in steroid-induced cell proliferation has received much attention. However, the adaptor molecule that mediates this interaction remains to be identified. In this communication, we identify p52(Shc) as the mediator between tyrosine phosphorylation signaling and steroid signaling in steroid-responsive cell proliferation. Although the different LNCaP prostate cancer cells, C-33, C-51 and C-81, express similar levels of functional androgen receptor (AR), they exhibit different levels of androgen sensitivity. C-33 cell proliferation is highly responsive to the presence of androgens, whereas C-51 cell proliferation is comparatively less responsive to androgens. In contrast, C-81 cell proliferation is independent of androgens. In these cells, tyrosine phosphorylation levels of both p52(Shc) and ErbB-2 were greatest in C-81 cells, comparatively less in C-51 cells and weaker in C-33 cells. The levels and activity of protein tyrosine phosphatase, cellular prostatic acid phosphatase, decreased correspondingly in those cells. In both androgen-independent, rapidly growing C-81 and ErbB-2 cDNA-transfected C-33 cells, p52(Shc) was hyperphosphorylated at Tyr317 (Y317). Conversely, p52(Shc) tyrophosphorylation was decreased in prostatic acid phosphatase cDNA-transfected stable subclones of C-81 cells, which restore androgen-sensitive proliferation and leads to slow growth rates. In C-33 cells, androgen-stimulated cell proliferation correlated with tyrophosphorylation of ErbB-2 and increased phosphorylation of p52(Shc) at Y317, but not at Y239, differing from phosphorylation patterns associated with epidermal growth factor (EGF) stimulation. Furthermore, over-expression of a mutant of p52(Shc), that is Y317F, blocks Y317 phosphorylation of endogenous p52(Shc) and abolishes androgen-stimulated proliferation, but not EGF-stimulated proliferation. Thus, Y317 of p52(Shc) serves as an important regulatory site that allows tyrosine phosphorylation pathways to moderate androgen sensitivity in human prostate cancer cells.	Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Sect Urol Surg, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Eppley Inst Res Canc, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Lin, MF (corresponding author), Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, 984525 Nebraska Med Ctr, Omaha, NE 68198 USA.	mlin@unmc.edu		LEE, MING-SHYUE/0000-0002-8673-5088; LEE, MING-SHYUE/0000-0002-5884-4535	NATIONAL CANCER INSTITUTE [R01CA088184] Funding Source: NIH RePORTER; NCI NIH HHS [CA88184] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chu TM, 1998, J CLIN LIGAND ASSAY, V21, P24; CHU TM, 1982, BIOCH MARKERS CANC, V117; CULIG Z, 1994, CANCER RES, V54, P5474; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Gao M, 1999, J CELL PHYSIOL, V179, P336, DOI 10.1002/(SICI)1097-4652(199906)179:3<336::AID-JCP11>3.0.CO;2-Q; Gioeli D, 1999, CANCER RES, V59, P279; GLAUBER JG, 1992, SEMIN ONCOL, V19, P308; Grasso AW, 1997, ONCOGENE, V15, P2705, DOI 10.1038/sj.onc.1201447; Gresham J, 1998, INT J CANCER, V77, P923, DOI 10.1002/(SICI)1097-0215(19980911)77:6<923::AID-IJC21>3.0.CO;2-0; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Houston SJ, 1999, BRIT J CANCER, V79, P1220, DOI 10.1038/sj.bjc.6690196; Hua WH, 1995, J STEROID BIOCHEM, V55, P279, DOI 10.1016/0960-0760(95)00187-5; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Igawa T, 2003, PROSTATE, V55, P247, DOI 10.1002/pros.10240; Igawa T, 2002, PROSTATE, V50, P222, DOI 10.1002/pros.10054; KAIGHN ME, 1979, INVEST UROL, V17, P16; Karan D, 2003, INT J CANCER, V103, P285, DOI 10.1002/ijc.10813; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Koivisto P, 1997, CANCER RES, V57, P314; Kokontis JM, 1999, VITAM HORM, V55, P219; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; LAI KMV, 1995, MOL CELL BIOL, V15, P4810; Landry F, 1996, J UROLOGY, V155, P386, DOI 10.1016/S0022-5347(01)66665-5; Lee MS, 2003, ONCOGENE, V22, P781, DOI 10.1038/sj.onc.1206066; Lennartsson J, 1999, ONCOGENE, V18, P5546, DOI 10.1038/sj.onc.1202929; Lin MF, 1996, BIOCHEM BIOPH RES CO, V226, P206, DOI 10.1006/bbrc.1996.1334; LIN MF, 1988, MOL CELL BIOL, V8, P5477, DOI 10.1128/MCB.8.12.5477; LIN MF, 1986, MOL CELL BIOL, V6, P4753, DOI 10.1128/MCB.6.12.4753; LIN MF, 1993, ARCH BIOCHEM BIOPHYS, V300, P384, DOI 10.1006/abbi.1993.1052; LIN MF, 1986, BIOCHEM J, V235, P351, DOI 10.1042/bj2350351; Lin MF, 1998, J BIOL CHEM, V273, P5939, DOI 10.1074/jbc.273.10.5939; LIN MF, 1992, CANCER RES, V52, P4600; LIN MF, 1994, DIFFERENTIATION, V57, P143, DOI 10.1046/j.1432-0436.1994.5720143.x; Lin MF, 2001, J UROLOGY, V166, P1943, DOI 10.1016/S0022-5347(05)65725-4; LIN MF, 1983, BIOCHEMISTRY-US, V22, P1055, DOI 10.1021/bi00274a009; LIN MF, 1987, ADV PROT PHOSPHATASE, V4, P199; LOOR R, 1981, CANCER LETT, V14, P63, DOI 10.1016/0304-3835(81)90010-0; Luzi L, 2000, CURR OPIN GENET DEV, V10, P668, DOI 10.1016/S0959-437X(00)00146-5; Meng TC, 2000, ONCOGENE, V19, P2664, DOI 10.1038/sj.onc.1203576; Meng TC, 1998, J BIOL CHEM, V273, P22096, DOI 10.1074/jbc.273.34.22096; Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; Osman I, 2001, CLIN CANCER RES, V7, P2643; Patarca R, 1996, CRIT REV ONCOGENESIS, V7, P343, DOI 10.1615/CritRevOncog.v7.i5-6.20; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Price DT, 1999, J UROLOGY, V162, P1537, DOI 10.1016/S0022-5347(05)68354-1; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; Ravichandran KS, 2001, ONCOGENE, V20, P6322, DOI 10.1038/sj.onc.1204776; RICCI A, 1995, ONCOGENE, V11, P1519; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sadar MD, 1999, ENDOCR-RELAT CANCER, V6, P487, DOI 10.1677/erc.0.0060487; Signoretti S, 2000, JNCI-J NATL CANCER I, V92, P1918, DOI 10.1093/jnci/92.23.1918; SOLIN T, 1990, BIOCHIM BIOPHYS ACTA, V1048, P72, DOI 10.1016/0167-4781(90)90024-V; Stevenson LE, 1998, BREAST CANCER RES TR, V49, P119, DOI 10.1023/A:1006007227747; Stevenson LE, 1999, CELL GROWTH DIFFER, V10, P61; STROHMEYER TG, 1994, J UROLOGY, V151, P1479, DOI 10.1016/S0022-5347(17)35284-9; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VANDERKWAST TH, 1991, INT J CANCER, V48, P189, DOI 10.1002/ijc.2910480206; VIHKO P, 1988, FEBS LETT, V236, P275, DOI 10.1016/0014-5793(88)80037-1; VIHKO P, 1993, P NATL ACAD SCI USA, V90, P799, DOI 10.1073/pnas.90.3.799; Walk SF, 1998, EUR J IMMUNOL, V28, P2265, DOI 10.1002/(SICI)1521-4141(199808)28:08<2265::AID-IMMU2265>3.0.CO;2-P; Weigel NL, 1998, J MOL MED, V76, P469, DOI 10.1007/s001090050241; Weigel NL, 1996, BIOCHEM J, V319, P657, DOI 10.1042/bj3190657; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; WEISS C, 1990, LEUKEMIA RES, V14, P327, DOI 10.1016/0145-2126(90)90159-7; Zelivianski S, 2003, INT J CANCER, V107, P478, DOI 10.1002/ijc.11413; Zhang XQ, 2001, J BIOL CHEM, V276, P2544, DOI 10.1074/jbc.M006661200	68	24	24	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2004	23	17					3048	3058		10.1038/sj.onc.1207451	http://dx.doi.org/10.1038/sj.onc.1207451			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	812NC	14990987				2022-12-28	WOS:000220845200009
J	Castedo, M; Perfettini, JL; Roumie, T; Andreau, K; Medema, R; Kroemer, G				Castedo, M; Perfettini, JL; Roumie, T; Andreau, K; Medema, R; Kroemer, G			Cell death by mitotic catastrophe: a molecular definition	ONCOGENE			English	Review						apoptosis; Cdk1; Chk2; caspases; Bcl-2	PREMATURE CHROMOSOME CONDENSATION; ANAPHASE-PROMOTING COMPLEX; APOPTOSIS-INDUCING FACTOR; DNA-DAMAGE CHECKPOINT; CYTOCHROME-C RELEASE; CENTROSOME AMPLIFICATION; MITOCHONDRIAL APOPTOSIS; SPINDLE CHECKPOINT; P53 PROTEIN; GLYCOPROTEIN COMPLEX	The current literature is devoid of a clearcut definition of mitotic catastrophe, a type of cell death that occurs during mitosis. Here, we propose that mitotic catastrophe results from a combination of deficient cell-cycle checkpoints (in particular the DNA structure checkpoints and the spindle assembly checkpoint) and cellular damage. Failure to arrest the cell cycle before or at mitosis triggers an attempt of aberrant chromosome segregation, which culminates in the activation of the apoptotic default pathway and cellular demise. Cell death occurring during the metaphase/anaphase transition is characterized by the activation of caspase-2 (which can be activated in response to DNA damage) and/or mitochondrial membrane permeabilization with the release of cell death effectors such as apoptosis-inducing factor and the caspase-9 and -3 activator cytochrome c. Although the morphological aspect of apoptosis may be incomplete, these alterations constitute the biochemical hallmarks of apoptosis. Cells that fail to execute an apoptotic program in response to mitotic failure are likely to divide asymmetrically in the next round of cell division, with the consequent generation of aneuploid cells. This implies that disabling of the apoptotic program may actually favor chromosomal instability, through the suppression of mitotic catastrophe. Mitotic catastrophe thus may be conceived as a molecular device that prevents aneuploidization, which may participate in oncogenesis. Mitotic catastrophe is controlled by numerous molecular players, in particular, cell-cycle specific kinases (such as the cyclin B1-dependent kinase Cdk1, polo-like kinases and Aurora kinases), cell-cycle checkpoint proteins, survivin, p53, caspases and members of the Bcl-2 family.	Inst Gustave Roussy, CNRS, UMR 8125, F-94805 Villejuif, France; Netherlands Canc Inst, Div Mol Biol H8, NL-1066 CX Amsterdam, Netherlands	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Netherlands Cancer Institute	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, UMR 8125, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	PERFETTINI, Jean-Luc/N-4699-2017; Medema, Rene H/E-2981-2013; Medema, Rene H/G-5415-2011; Kroemer, Guido/AAY-9859-2020; KROEMER, Guido/B-4263-2013	PERFETTINI, Jean-Luc/0000-0002-2427-2604; KROEMER, Guido/0000-0002-9334-4405; Medema, Rene/0000-0002-6754-0381; Andreau, Karine/0000-0002-9773-0733				ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; Altieri DC, 2003, ADV CANCER RES, V88, P31, DOI 10.1016/S0065-230X(03)88303-3; Andreassen PR, 2001, CANCER RES, V61, P7660; Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; AYSCOUGH K, 1992, MOL GEN GENET, V232, P344, DOI 10.1007/BF00266236; Baek KH, 2003, J LEUKOCYTE BIOL, V73, P850, DOI 10.1189/jlb.1202607; Behrend L, 2000, ONCOGENE, V19, P5303, DOI 10.1038/sj.onc.1203939; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; BLOUNT PL, 1994, CANCER RES, V54, P2292; Brinkley BR, 2001, TRENDS CELL BIOL, V11, P18, DOI 10.1016/S0962-8924(00)01872-9; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Burke DJ, 2000, CURR OPIN GENET DEV, V10, P26, DOI 10.1016/S0959-437X(99)00040-4; Burns TF, 2003, MOL CELL BIOL, V23, P5556, DOI 10.1128/MCB.23.16.5556-5571.2003; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Cande C, 2002, J CELL SCI, V115, P4727, DOI 10.1242/jcs.00210; Carter BZ, 2003, CELL CYCLE, V2, P488, DOI 10.4161/cc.2.5.500; Carvalho A, 2003, J CELL SCI, V116, P2987, DOI 10.1242/jcs.00612; Castedo M, 2002, CELL DEATH DIFFER, V9, P1287, DOI 10.1038/sj.cdd.4401130; Castedo M, 2001, J EXP MED, V194, P1097, DOI 10.1084/jem.194.8.1097; Castedo M, 2002, EMBO J, V21, P4070, DOI 10.1093/emboj/cdf391; CASTEDO M, 2004, IN PRESS ONCOGENE; CHAKRABARTI A, 1987, NEOPLASMA, V34, P557; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chehab NH, 2000, GENE DEV, V14, P278; Chen ZH, 2003, MOL CANCER THER, V2, P543; Choma D, 2001, BRIT J CANCER, V85, P14, DOI 10.1054/bjoc.2001.1892; Clarke DJ, 2003, NAT CELL BIOL, V5, P928, DOI 10.1038/ncb1046; Clarke DJ, 2001, NAT CELL BIOL, V3, P619, DOI 10.1038/35083009; Cogswell JP, 2000, CELL GROWTH DIFFER, V11, P615; COLOMBEL M, 1995, ONCOGENE, V10, P1269; Cutts SM, 1999, HUM MOL GENET, V8, P1145, DOI 10.1093/hmg/8.7.1145; D'Assoro AB, 2002, ONCOGENE, V21, P6146, DOI 10.1038/sj.onc.1205772; Datta NS, 2002, EXP HEMATOL, V30, P158, DOI 10.1016/S0301-472X(01)00780-9; Deacon K, 2003, MOL BIOL CELL, V14, P2071, DOI 10.1091/mbc.e02-10-0653; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; DeLuca JG, 2002, J CELL BIOL, V159, P549, DOI 10.1083/jcb.200208159; DeWitt N, 2002, NATURE, V416, P354, DOI 10.1038/416354a; Di Leonardo A, 1997, CANCER RES, V57, P1013; Driessens G, 2003, BRIT J CANCER, V89, P727, DOI 10.1038/sj.bjc.6601163; Elez R, 2003, ONCOGENE, V22, P69, DOI 10.1038/sj.onc.1206038; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Ferri KF, 2000, CELL DEATH DIFFER, V7, P1137, DOI 10.1038/sj.cdd.4400748; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Ferri KF, 2000, NAT CELL BIOL, V2, pE63, DOI 10.1038/35008692; Ferri KF, 2000, J EXP MED, V192, P1081, DOI 10.1084/jem.192.8.1081; FOTEDAR R, 1995, MOL CELL BIOL, V15, P932; Geley S, 2001, J CELL BIOL, V153, P137, DOI 10.1083/jcb.153.1.137; Gillet R, 2000, ONCOGENE, V19, P3498, DOI 10.1038/sj.onc.1203671; Gisselsson D, 2003, ADV CANCER RES, V87, P1; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Grossman D, 2001, J CLIN INVEST, V108, P991, DOI 10.1172/JCI200113345; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Habu T, 2002, EMBO J, V21, P6419, DOI 10.1093/emboj/cdf659; Hawkins DS, 1996, CANCER RES, V56, P892; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Hofmann WK, 2001, LEUKEMIA RES, V25, P333, DOI 10.1016/S0145-2126(00)00130-2; Ianzini F, 1997, INT J RADIAT BIOL, V72, P409, DOI 10.1080/095530097143185; Ibrado AM, 1998, LEUKEMIA, V12, P1930, DOI 10.1038/sj.leu.2401218; IOTSOVA V, 1995, EUR J CELL BIOL, V68, P122; Ivanov A, 2003, J CELL SCI, V116, P4095, DOI 10.1242/jcs.00740; Jallepalli PV, 2001, NAT REV CANCER, V1, P109, DOI 10.1038/35101065; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Konishi Y, 2002, MOL CELL, V9, P1005, DOI 10.1016/S1097-2765(02)00524-5; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; Lock RB, 1996, CANCER RES, V56, P4006; Mantel C, 1999, BLOOD, V93, P1390, DOI 10.1182/blood.V93.4.1390.404k25_1390_1398; Margottin-Goguet F, 2003, DEV CELL, V4, P813, DOI 10.1016/S1534-5807(03)00153-9; Masuda A, 2002, ONCOGENE, V21, P6884, DOI 10.1038/sj.onc.1205566; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Miller CW, 2002, GENE CHROMOSOME CANC, V33, P17, DOI 10.1002/gcc.1207; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; MOLZ L, 1989, GENETICS, V122, P773; Nabha SM, 2002, CLIN CANCER RES, V8, P2735; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Nitta M, 2002, GENES CELLS, V7, P151, DOI 10.1046/j.1356-9597.2001.00509.x; Notterman D, 1998, ONCOGENE, V17, P2743, DOI 10.1038/sj.onc.1202210; O'Connor DS, 2002, CANCER CELL, V2, P43, DOI 10.1016/S1535-6108(02)00084-3; Oberringer M, 1999, Mol Cell Biol Res Commun, V2, P190, DOI 10.1006/mcbr.1999.0172; Paroni G, 2002, J BIOL CHEM, V277, P15147, DOI 10.1074/jbc.M112338200; Peart MJ, 2003, CANCER RES, V63, P4460; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Penninger JM, 2003, NAT CELL BIOL, V5, P97, DOI 10.1038/ncb0203-97; Perfettini JL, 2004, J EXP MED, V199, P629, DOI 10.1084/jem.20031216; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Porter LA, 2003, BLOOD, V101, P1928, DOI 10.1182/blood-2002-04-1103; RAMEL S, 1995, PANCREAS, V11, P213, DOI 10.1097/00006676-199510000-00001; Raslova H, 2003, BLOOD, V101, P541, DOI 10.1182/blood-2002-05-1553; Read SH, 2002, J CELL BIOL, V159, P739, DOI 10.1083/jcb.200209004; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; ROTTER V, 1993, P NATL ACAD SCI USA, V90, P9075, DOI 10.1073/pnas.90.19.9075; ROUMIER T, 2003, BIOCH PHARM, V66; Ruth AC, 2000, CANCER RES, V60, P2576; Sato N, 2000, EXP CELL RES, V255, P321, DOI 10.1006/excr.1999.4797; Sen S, 2002, JNCI-J NATL CANCER I, V94, P1320; Senderowicz AM, 2003, CANCER CHEMOTH PHARM, V52, pS61, DOI 10.1007/s00280-003-0624-x; Seo GJ, 2003, BIOCHEM BIOPH RES CO, V304, P339, DOI 10.1016/S0006-291X(03)00589-8; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Shankar SL, 2001, J NEUROCHEM, V79, P426, DOI 10.1046/j.1471-4159.2001.00596.x; Shieh SY, 2000, GENE DEV, V14, P289; Shih IM, 2001, CANCER RES, V61, P818; Shin DM, 2001, CANCER EPIDEM BIOMAR, V10, P603; Slovak ML, 2000, BLOOD, V96, P4075, DOI 10.1182/blood.V96.13.4075; Smits VAJ, 2001, BBA-GENE STRUCT EXPR, V1519, P1, DOI 10.1016/S0167-4781(01)00204-4; Song ZY, 2003, J BIOL CHEM, V278, P23130, DOI 10.1074/jbc.M300957200; Spankuch-Schmitt B, 2002, ONCOGENE, V21, P3162, DOI 10.1038/sj.onc.1205412; SPERLING K, 1974, CHROMOSOMA, V45, P121, DOI 10.1007/BF00362306; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Strathdee G, 2001, ONCOGENE, V20, P1923, DOI 10.1038/sj.onc.1204276; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; SWANSON PE, 1995, AM J PATHOL, V146, P963; Takada S, 2003, CELL, V113, P87, DOI 10.1016/S0092-8674(03)00202-2; Taylor WR, 1999, MOL BIOL CELL, V10, P3607, DOI 10.1091/mbc.10.11.3607; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; TORT F, 2003, BLOOD, V100; Tsuiki H, 2001, ONCOGENE, V20, P420, DOI 10.1038/sj.onc.1204126; Tsvetkov L, 2003, J BIOL CHEM, V278, P8468, DOI 10.1074/jbc.M211202200; Uren AG, 2000, CURR BIOL, V10, P1319, DOI 10.1016/S0960-9822(00)00769-7; Vahteristo P, 2002, AM J HUM GENET, V71, P432, DOI 10.1086/341943; Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P602; Verdoodt B, 1999, MUTAGENESIS, V14, P513, DOI 10.1093/mutage/14.5.513; Verschuren EW, 2002, CANCER CELL, V2, P229, DOI 10.1016/S1535-6108(02)00123-X; Vikhanskaya F, 1998, EXP CELL RES, V241, P96, DOI 10.1006/excr.1998.4018; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Wall NR, 2003, CANCER RES, V63, P230; Wang Q, 2002, MOL CELL BIOL, V22, P3450, DOI 10.1128/MCB.22.10.3450-3459.2002; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; WU GW, 2001, CANCER RES, V61, P4155; Wu XL, 2001, J BIOL CHEM, V276, P2971, DOI 10.1074/jbc.M009727200; Wurmser AE, 2002, NATURE, V416, P485, DOI 10.1038/416485a; Xu JH, 2003, FEBS LETT, V545, P209, DOI 10.1016/S0014-5793(03)00536-2; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869; Yin XY, 1999, ONCOGENE, V18, P1177, DOI 10.1038/sj.onc.1202410; Yoshikawa R, 2001, CANCER RES, V61, P1029; Yu HT, 2002, CURR OPIN CELL BIOL, V14, P706, DOI 10.1016/S0955-0674(02)00382-4; Yu Q, 2002, CANCER RES, V62, P5743; Yuan JP, 2002, CANCER RES, V62, P4186; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677; Zamzami N, 2003, CURR BIOL, V13, pR71, DOI 10.1016/S0960-9822(02)01433-1; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989	156	943	998	1	85	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2004	23	16					2825	2837		10.1038/sj.onc.1207528	http://dx.doi.org/10.1038/sj.onc.1207528			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	811VO	15077146				2022-12-28	WOS:000220799600010
J	Morimoto, AM; Tan, N; West, K; McArthur, G; Toner, GC; Manning, WC; Smolich, BD; Cherrington, JM				Morimoto, AM; Tan, N; West, K; McArthur, G; Toner, GC; Manning, WC; Smolich, BD; Cherrington, JM			Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor	ONCOGENE			English	Article						SU11248; biomarker; in vivo; microarray; immunohistochemistry	GROWTH-FACTOR RECEPTOR; BREAST-CANCER; MOLECULAR CLASSIFICATION; IN-VIVO; IDENTIFICATION; CADHERIN-11; MICROARRAY; CARCINOMA; APOPTOSIS; PROTEIN	Biomarkers that indicate biological activity and/or efficacy are a potentially useful tool in the development of molecularly targeted therapeutics. It is useful, though challenging, to identify biomarkers during preclinical development in order to impact decision-making during early clinical development. SU11248 is an oral, selective multitargeted tyrosine kinase inhibitor currently in Phase II oncology clinical trials. It exhibits direct antitumor and antiangiogenic activity via inhibition of the receptor tyrosine kinases PDGFR, VEGFR, KIT and FLT3. To identify clinically translatable biomarkers of SU11248 activity, expression pro. ling was performed on Colo205 human xenograft tumors following treatment with SU11248. Over 100 transcripts changed in abundance in SU11248 as compared to vehicle-treated tumors. Nine candidate transcripts, chosen based on putative function, were also analysed and validated by TaqMan. One such potential biomarker, cadherin-11, was further evaluated at the protein level and was found to have increased expression in xenograft tumors after SU11248 treatment. Interestingly, cadherin-11 expression was also detected via immunohistochemical analysis of archived solid tumors, indicating the technical feasibility of translating this putative biomarker to clinical studies. Importantly, SU11248 treatment also resulted in increased expression of cadherin-11 protein in human tumor biopsies in three out of seven patients examined and confirms the feasibility of using transcriptional pro. ling of preclinical models to identify clinically translatable biomarkers.	SUGEN Inc, Dept Preclin Res & Exploratory Dev, San Francisco, CA 94080 USA; Peter MacCallum Canc Inst, Melbourne, Vic 3002, Australia	Pfizer; Peter Maccallum Cancer Center	Morimoto, AM (corresponding author), Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA.	morimoto@gene.com	Toner, Guy C/G-1738-2011	Toner, Guy/0000-0001-9873-3592				Adjei AA, 2000, CANCER RES, V60, P1871; Albanell J, 2002, J CLIN ONCOL, V20, P110, DOI 10.1200/JCO.20.1.110; Bae SK, 1998, CANCER LETT, V126, P97, DOI 10.1016/S0304-3835(97)00538-7; Bertucci F, 2002, ANN NY ACAD SCI, V975, P217, DOI 10.1111/j.1749-6632.2002.tb05954.x; Brockstedt E, 1999, J PROTEIN CHEM, V18, P225, DOI 10.1023/A:1020636308270; Cheadle C, 2003, J MOL DIAGN, V5, P73, DOI 10.1016/S1525-1578(10)60455-2; Clarke PA, 2000, ONCOGENE, V19, P4125, DOI 10.1038/sj.onc.1203753; DePrimo SE, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-3; DeRisi J, 1996, NAT GENET, V14, P457; Devilard E, 2002, ONCOGENE, V21, P3095, DOI 10.1038/sj.onc.1205418; Druker BJ, 2002, TRENDS MOL MED, V8, pS14, DOI 10.1016/S1471-4914(02)02305-5; Duggan DJ, 1999, NAT GENET, V21, P10, DOI 10.1038/4434; Feltes CM, 2002, CANCER RES, V62, P6688; Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; Fleming JA, 2002, P NATL ACAD SCI USA, V99, P1461, DOI 10.1073/pnas.032516399; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; Glaser KB, 2003, MOL CANCER THER, V2, P151; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Gupta S, 2002, FEBS LETT, V532, P61, DOI 10.1016/S0014-5793(02)03628-1; He LZ, 2001, J CLIN INVEST, V108, P1321, DOI 10.1172/JCI200111537; Hedenfalk I, 2003, P NATL ACAD SCI USA, V100, P2532, DOI 10.1073/pnas.0533805100; Herbst RS, 2002, EXPERT OPIN INV DRUG, V11, P837, DOI 10.1517/13543784.11.6.837; Kashima T, 2003, INT J CANCER, V104, P147, DOI 10.1002/ijc.10931; Kawaguchi J, 1999, J BONE MINER RES, V14, P764, DOI 10.1359/jbmr.1999.14.5.764; Koong AC, 2000, CANCER RES, V60, P883; Laird AD, 2002, FASEB J, V16, DOI 10.1096/fj.01-0700com; Lecanda F, 2000, J CELL BIOCHEM, V77, P499, DOI 10.1002/(SICI)1097-4644(20000601)77:3<499::AID-JCB14>3.0.CO;2-0; Marton MJ, 1998, NAT MED, V4, P1293, DOI 10.1038/3282; Mendel DB, 2003, CLIN CANCER RES, V9, P327; Nutt CL, 2003, CANCER RES, V63, P1602; OFARRELL AM, 2003, IN PRESS CLIN CAN RE; OKAZAKI M, 1994, J BIOL CHEM, V269, P12092; Potapova O, 2002, EUR J CANCER, V38, pS61; RAGIONE FD, 2001, FEBS LETT, V499, P199; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Schueneman AJ, 2003, CANCER RES, V63, P4009; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; Shibata T, 1996, CANCER LETT, V99, P147, DOI 10.1016/0304-3835(95)04047-1; Shimono R, 2000, ANTICANCER RES, V20, P917; Slamon D, 2001, SEMIN ONCOL, V28, P13, DOI 10.1053/sonc.2001.22812; Sonna LA, 2003, PHYSIOL GENOMICS, V12, P195, DOI 10.1152/physiolgenomics.00104.2002; SUNDBERG C, 1993, AM J PATHOL, V143, P1377; Tomita K, 2000, CANCER RES, V60, P3650; TONER GC, 2003, P AN M AM SOC CLIN, V22, P234; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; VanLint C, 1996, GENE EXPRESSION, V5, P245; Zembutsu H, 2003, INT J ONCOL, V23, P29; Zhou RX, 2000, DIFFERENTIATION, V66, P165, DOI 10.1046/j.1432-0436.2000.660402.x	50	37	46	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2004	23	8					1618	1626		10.1038/sj.onc.1207268	http://dx.doi.org/10.1038/sj.onc.1207268			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778BP	14985702				2022-12-28	WOS:000189219500016
J	Khan, S; Guevara, C; Fujii, G; Parry, D				Khan, S; Guevara, C; Fujii, G; Parry, D			P14ARF is a component of the p53 response following ionizing irradiation of normal human fibroblasts	ONCOGENE			English	Article						ARF; DNA damage; ionizing radiation; MDM2; p53	ARF TUMOR-SUPPRESSOR; DNA-DAMAGE; NUCLEOLAR-LOCALIZATION; RIBONUCLEOTIDE DEPLETION; CELLULAR-RESPONSE; DEFICIENT MICE; FEEDBACK LOOP; MDM2; P19(ARF); P14(ARF)	Ionizing radiation leads to rapid stabilization and activation of the p53 tumor suppressor. Previous reports demonstrate that murine p19ARF cooperates with p53 in the cellular response to gamma irradiation. Here, we show that endogenous ARF sequentially interacts with p53 and MDM2 following irradiation of primary human and mouse embryonic fibroblasts. Shortly after irradiation, p14ARF binds p53 independently of MDM2. As nuclear pools of p53 decline, endogenous p14ARF co-immunoprecipitates with MDM2 and is localized within the nucleolus. Interestingly, p14ARF nucleolar localization during this response is abrogated in cells lacking functional p53. Taken together, our data suggest that human and murine ARF contribute to the mammalian DNA damage response.	DNAX Res Inst Mol & Cellular Biol Inc, Dept Discovery Res, Palo Alto, CA 94304 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Parry, D (corresponding author), DNAX Res Inst Mol & Cellular Biol Inc, Dept Discovery Res, 901 Calif Ave, Palo Alto, CA 94304 USA.	david.parry@dnax.org						Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DEOCALUNA R, 1995, NATURE, V0378; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Groth A, 2000, J BIOL CHEM, V275, P27473; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kamijo T, 1999, CANCER RES, V59, P2217; Kamijo T, 1999, CANCER RES, V59, P2464; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KASTAN MB, 1991, CANCER RES, V51, P6304; Khan SH, 2000, P NATL ACAD SCI USA, V97, P3266, DOI 10.1073/pnas.050560997; KHANNA KK, 1993, ONCOGENE, V8, P3307; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lohrum MAE, 2000, CURR BIOL, V10, P539, DOI 10.1016/S0960-9822(00)00472-3; Lohrum MAE, 2000, NAT CELL BIOL, V2, P179, DOI 10.1038/35004057; Lyakhovich A, 2003, MOL CELL BIOL, V23, P2463, DOI 10.1128/MCB.23.7.2463-2475.2003; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Rubbi CP, 2000, ONCOGENE, V19, P85, DOI 10.1038/sj.onc.1203378; Smogorzewska A, 2002, EMBO J, V21, P4338, DOI 10.1093/emboj/cdf433; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Xu Y, 1998, MOL CELL BIOL, V18, P4385, DOI 10.1128/MCB.18.7.4385; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	41	37	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6040	6046		10.1038/sj.onc.1207824	http://dx.doi.org/10.1038/sj.onc.1207824			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15195142				2022-12-28	WOS:000223261000003
J	Jonckheere, N; Perrais, M; Mariette, C; Batra, SK; Aubert, JP; Pigny, P; Van Seuningen, I				Jonckheere, N; Perrais, M; Mariette, C; Batra, SK; Aubert, JP; Pigny, P; Van Seuningen, I			A role for human MUC4 mucin gene, the ErbB2 ligand, as a target of TGF-beta in pancreatic carcinogenesis	ONCOGENE			English	Article						MUC4; pancreatic cancer; TGF-beta; transcription; mucin; Smad4; acetylation	GROWTH-FACTOR-BETA; DPC4 INACTIVATION; CANCER; EXPRESSION; PROMOTER; INDUCTION; SEQUENCE; CELLS	MUC4 encodes a large transmembrane mucin that is overexpressed in pancreatic adenocarcinomas. The molecular mechanisms responsible for that altered pattern of expression are unknown. TGF-beta, a pleiotropic cytokine, regulates numerous genes involved in pancreatic carcinogenesis via activation of the Smads proteins and MUC4 promoter is rich in Smad-binding elements. Our aim was to study whether the regulation of MUC4 expression by TGF-beta in pancreatic cancer cells was strictly dependent on Smad4 activity. Three pancreatic cancer cell lines, CAPAN-1 (MUC4 + /Smad4-), CAPAN-2 (MUC4 + /Smad4+) and PANC-1 (MUC4-/Smad4 +), were used. By RT-PCR, transfection assays and immunohistochemistry, we show that (i) both MUC4 mRNA and apomucin expression are upregulated by TGF-beta, (ii) Smad2 positively cooperates with Smad4 to activate the promoter, (iii) activation of Smad4 by exogenous TGF-beta induces Smad4 binding to the promoter, (iv) Smad7 and c-ski both inhibit activation by Smad4. When Smad4 is mutated and inactive, TGF-beta activates MUC4 expression via MAPK, PI3K and PKA signaling pathways. Absence of expression in PANC-1 cells is due to historic deacetylation. Altogether, these results indicate that upregulation of MUC4 by TGF-beta is restricted to well-differentiated pancreatic cancer cells, and point out a novel mechanism for TGF-beta as a key molecule in targeting MUC4 overexpression in pancreatic adenocarcinomas.	INSERM, U560, F-59045 Lille, France; Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Eppley Canc Ctr, Omaha, NE USA	Institut National de la Sante et de la Recherche Medicale (Inserm); University of Nebraska System; University of Nebraska Medical Center	Van Seuningen, I (corresponding author), INSERM, U560, Place Verdun, F-59045 Lille, France.	isabelvs@lille.inserm.fr	VAN SEUNINGEN, Isabelle/N-6176-2016; Jonckheere, Nicolas/J-6028-2013	VAN SEUNINGEN, Isabelle/0000-0002-3131-2694; Jonckheere, Nicolas/0000-0002-0496-0661	NCI NIH HHS [R01 CA78590] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078590] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; AUDIE JP, 1993, J HISTOCHEM CYTOCHEM, V41, P1479, DOI 10.1177/41.10.8245407; BALAGUE C, 1995, GASTROENTEROLOGY, V109, P953, DOI 10.1016/0016-5085(95)90406-9; Baldwin RL, 1996, INT J CANCER, V67, P283, DOI 10.1002/(SICI)1097-0215(19960717)67:2<283::AID-IJC21>3.0.CO;2-B; Carraway KL, 2000, FRONT BIOSCI, V5, pD95, DOI 10.2741/Carraway; Choudhury A, 2000, J BIOL CHEM, V275, P33929, DOI 10.1074/jbc.M005115200; Choudhury A, 2000, J BIOCHEM-TOKYO, V128, P233, DOI 10.1093/oxfordjournals.jbchem.a022746; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Gendler SJ, 2001, J MAMMARY GLAND BIOL, V6, P339, DOI 10.1023/A:1011379725811; HOLLINGSWORTH MA, 1994, INT J CANCER, V57, P198, DOI 10.1002/ijc.2910570212; Hollingsworth MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251; Hruban RH, 2001, J GASTROINTEST SURG, V5, P583, DOI 10.1016/S1091-255X(01)80099-8; Huguier M, 1999, AM J SURG, V177, P257, DOI 10.1016/S0002-9610(99)00003-3; Kim YS, 1999, ANN ONCOL, V10, P51, DOI 10.1023/A:1008332602541; Lichtenstein D R, 1995, Gastrointest Endosc Clin N Am, V5, P237; Mariette C, 2004, BIOCHEM J, V377, P701, DOI 10.1042/BJ20031132; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Mesquita P, 2003, J BIOL CHEM, V278, P51549, DOI 10.1074/jbc.M309019200; Miyaki M, 2003, BIOCHEM BIOPH RES CO, V306, P799, DOI 10.1016/S0006-291X(03)01066-0; Miyazono K, 2003, CANCER SCI, V94, P230, DOI 10.1111/j.1349-7006.2003.tb01425.x; Moniaux N, 2001, FRONT BIOSCI-LANDMRK, V6, pD1192, DOI 10.2741/Moniaux; Park Hee-Ug, 2003, Pancreas, V26, pe48, DOI 10.1097/00006676-200304000-00022; Perrais M, 2002, J BIOL CHEM, V277, P32258, DOI 10.1074/jbc.M204862200; Perrais M, 2001, J BIOL CHEM, V276, P30923, DOI 10.1074/jbc.M104204200; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Roberts AB, 2002, CYTOKINE GROWTH F R, V13, P3, DOI 10.1016/S1359-6101(01)00027-2; Sakorafas GH, 2000, CANCER TREAT REV, V26, P29, DOI 10.1053/ctrv.1999.0144; Schutte M, 1999, ANN ONCOL, V10, P56, DOI 10.1023/A:1008336703450; Schutte M, 1996, CANCER RES, V56, P2527; Singh AP, 2004, CANCER RES, V64, P622, DOI 10.1158/0008-5472.CAN-03-2636; Sipos B, 2003, VIRCHOWS ARCH, V442, P444, DOI 10.1007/s00428-003-0784-4; Soto P, 2003, J BIOL CHEM, V278, P20338, DOI 10.1074/jbc.M301886200; Swartz MJ, 2002, AM J CLIN PATHOL, V117, P791; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Van Seuningen I, 2000, BIOCHEM J, V348, P675; VANSEUNINGEN I, 1995, J BIOL CHEM, V270, P26976, DOI 10.1074/jbc.270.45.26976; Wilentz RE, 2000, CANCER RES, V60, P2002	38	49	54	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2004	23	34					5729	5738		10.1038/sj.onc.1207769	http://dx.doi.org/10.1038/sj.onc.1207769			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KW	15184872	Green Published			2022-12-28	WOS:000222629800002
J	Tsuei, DJ; Hsu, HC; Lee, PH; Jeng, YM; Pu, YS; Chen, CN; Lee, YC; Chou, WC; Chang, CJ; Ni, YH; Chang, MH				Tsuei, DJ; Hsu, HC; Lee, PH; Jeng, YM; Pu, YS; Chen, CN; Lee, YC; Chou, WC; Chang, CJ; Ni, YH; Chang, MH			RBMY, a male germ cell-specific RNA-binding protein, activated in human liver cancers and transforms rodent fibroblasts	ONCOGENE			English	Article						RBMY; hepatocellular carcinoma; hepatoblastoma; RNA-binding motif; SRGY box	HEPATITIS-B-VIRUS; HUMAN Y-CHROMOSOME; HEPATOCELLULAR-CARCINOMA; GENE FAMILY; SPERMATOGENESIS; AZOOSPERMIA; TUMORS; OVEREXPRESSION; AMPLIFICATION; ORGANIZATION	The RNA-binding motif (RRM) gene on Y chromosome (RBMY), encoding a male germ cell-specific RNA-binding protein associated with spermatogenesis, was found inserted by hepatitis B virus (HBV) DNA in one childhood hepatocellular carcinoma (HCC). This study is aimed to explore the oncogenic potential of the RBMY protein. The RBMY transcripts, expressed exclusively in the testis of normal people, were detected by reverse transcription-polymerase chain reaction in 36% of HCCs from 90 males and in 67% of hepatoblastoma from six boys. The nontumor liver counter parts, cirrhotic liver tissues from children with biliary atresia, and other types of cancers, such as bile duct, colon, stomach, lung, prostate, and kidney, were all negative for RBMY expression. One to four types of RBMY transcripts, including wild type and variants with N-terminal RRM deletion, C-terminal SRGY (serine-arginine-glycine-tyrosine) boxes deletion, or deletion of both domains, were found in the testis and liver cancer tissues. The wild-type RBMY protein was expressed in the nucleus and demonstrated its tumorigenicity by transformation of mouse fibroblast NIH3T3 cells and in vivo tumor formation. The RBMY variant protein with deletion of C-terminal exons 9-12 was trapped in the cytoplasm and showed decreased tumorigenicity. Our results suggest that RBMY is a new candidate oncogene specific for male liver cancer.	Natl Taiwan Univ, Dept Pediat, Coll Med, Natl Taiwan Univ Hosp, Taipei 10016, Taiwan; Natl Taiwan Univ, Coll Med, Natl Taiwan Univ Hosp, Dept Pathol, Taipei 10018, Taiwan; Natl Taiwan Univ, Coll Med, Natl Taiwan Univ Hosp, Dept Surg, Taipei 10018, Taiwan; Natl Taiwan Univ, Coll Med, Natl Taiwan Univ Hosp, Dept Urol, Taipei 10018, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital	Chang, MH (corresponding author), Natl Taiwan Univ, Dept Pediat, Coll Med, Natl Taiwan Univ Hosp, 7 Chung Shan S Rd, Taipei 10016, Taiwan.	mhchang@ha.mc.ntu.edu.tw		PU, YEONG-SHIAU/0000-0002-2859-3966; Chang, Mei Hwei/0000-0002-3648-9261; Ni, Yen-Hsuan/0000-0002-1158-5249; CHEN, CHIUNG-NIEN/0000-0003-1192-5220; LEE, PO-HUANG/0000-0001-5831-035X; JENG, YUNG-MING/0000-0002-3878-4491				Brechot C, 2000, SEMIN CANCER BIOL, V10, P211, DOI 10.1006/scbi.2000.0321; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; BYRNE JA, 1993, GENE CHROMOSOME CANC, V8, P104, DOI 10.1002/gcc.2870080207; Chai NN, 1997, GENOMICS, V45, P355, DOI 10.1006/geno.1997.4944; Chai NN, 1998, GENOMICS, V49, P283, DOI 10.1006/geno.1998.5255; CHANG MH, 1989, CANCER-AM CANCER SOC, V64, P2377, DOI 10.1002/1097-0142(19891201)64:11<2377::AID-CNCR2820641130>3.0.CO;2-8; CHEN JY, 1986, BRIT J EXP PATHOL, V67, P279; CHEN WJ, 1988, J PEDIATR SURG, V23, P457, DOI 10.1016/S0022-3468(88)80448-2; DING SF, 1994, J HEPATOL, V20, P672, DOI 10.1016/S0168-8278(05)80359-9; Elliott DJ, 2000, P NATL ACAD SCI USA, V97, P5717, DOI 10.1073/pnas.97.11.5717; Elliott DJ, 1998, J CELL SCI, V111, P1255; Elliott DJ, 1997, P NATL ACAD SCI USA, V94, P3848, DOI 10.1073/pnas.94.8.3848; EXELBY PR, 1975, J PEDIATR SURG, V10, P329; Flickinger JC, 1997, CANC PRINCIPLES PRAC, P1087; GERAN RI, 1972, CANC CHEMOTHER REP, V3, P1; Idilman R, 1998, J VIRAL HEPATITIS, V5, P285, DOI 10.1046/j.1365-2893.1998.00116.x; IWAMA T, 1994, CANCER, V73, P2065, DOI 10.1002/1097-0142(19940415)73:8<2065::AID-CNCR2820730809>3.0.CO;2-O; Jiang ZH, 1999, P SOC EXP BIOL MED, V220, P64, DOI 10.1046/j.1525-1373.1999.d01-11.x; Kume T, 1999, HISTOPATHOLOGY, V34, P502, DOI 10.1111/j.1365-2559.1999.00686.x; Lee CL, 1998, EUR J CANCER, V34, P2064, DOI 10.1016/S0959-8049(98)00281-0; Lin T M, 1977, Taiwan Yi Xue Hui Za Zhi, V76, P656; Lin Y., 1996, Annals Academy of Medicine Singapore, V25, P22; Lingenfelter PA, 2001, MAMM GENOME, V12, P538, DOI 10.1007/s00335001-0003-z; MA K, 1993, CELL, V75, P1287, DOI 10.1016/0092-8674(93)90616-X; Mercatante D, 2000, PHARMACOL THERAPEUT, V85, P237, DOI 10.1016/S0163-7258(99)00067-4; Miyoshi Y, 1998, CANCER RES, V58, P2524; Montesano R, 1997, JNCI-J NATL CANCER I, V89, P1844, DOI 10.1093/jnci/89.24.1844; NAGAI K, 1995, TRENDS BIOCHEM SCI, V20, P235, DOI 10.1016/S0968-0004(00)89024-6; Najmabadi H, 1996, J CLIN ENDOCR METAB, V81, P1347, DOI 10.1210/jc.81.4.1347; Nakahori Y, 1996, HORM RES, V46, P20, DOI 10.1159/000185175; NI YH, 1991, CANCER, V8, P1731; NISHIDA N, 1994, CANCER RES, V54, P3107; Peng Shian-Yang, 1993, Journal of the Formosan Medical Association, V92, P866; Tsuei DJ, 2002, J MED VIROL, V68, P513, DOI 10.1002/jmv.10240; Valcarcel J, 1996, TRENDS BIOCHEM SCI, V21, P296, DOI 10.1016/0968-0004(96)10039-6; Venables JP, 2000, HUM MOL GENET, V9, P685, DOI 10.1093/hmg/9.5.685; Venables JP, 1999, HUM MOL GENET, V8, P959, DOI 10.1093/hmg/8.6.959; Venables JP, 1999, CURR OPIN GENET DEV, V9, P346, DOI 10.1016/S0959-437X(99)80052-5; Vernet C, 1997, TRENDS GENET, V13, P479, DOI 10.1016/S0168-9525(97)01269-9; Vogt PH, 1996, HUM MOL GENET, V5, P933, DOI 10.1093/hmg/5.7.933	40	29	31	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2004	23	34					5815	5822		10.1038/sj.onc.1207773	http://dx.doi.org/10.1038/sj.onc.1207773			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KW	15184870				2022-12-28	WOS:000222629800011
J	Stove, C; Vanrobaeys, F; Devreese, B; Van Beeumen, J; Mareel, M; Bracke, M				Stove, C; Vanrobaeys, F; Devreese, B; Van Beeumen, J; Mareel, M; Bracke, M			Melanoma cells secrete follistatin, an antagonist of activin-mediated growth inhibition	ONCOGENE			English	Article						follistatin; activin; Smad; melanoma; growth; apoptosis	MESSENGER-RIBONUCLEIC-ACID; FOLLICULAR-FLUID; BINDING PROTEIN; FACTOR SYSTEM; FACTOR-BETA; EXPRESSION; MORPHOGENESIS; LINE; FSH; PROLIFERATION	Using a proteomic approach to screen for new growth factors released by melanoma cells, we identified follistatin as a major heparin-binding factor in medium conditioned by the Bowes melanoma cell line. Since follistatin is primarily studied in relation to its neutralization of activin, a member of the transforming growth factor-beta family of ligands, the expression and function of this receptor system was investigated in a panel of melanoma cell lines and melanocytes. All cell lines expressed activin receptors and showed phosphorylation of Smad signal transduction molecules upon treatment with activin. Secretion of follistatin, either native or after retroviral transduction, efficiently prevented Smad activation or activation of an activin-responsive luciferase reporter construct. In melanocytes, activin treatment led to growth inhibition and induction of apoptosis. These effects were counteracted by cotreatment with follistatin. In summary, we characterized the activin-activin receptor system in melanocytes and melanoma cell lines and found that secretion of follistatin by melanoma cells may represent an effective way to circumvent activin's negative regulatory effects.	Ghent Univ Hosp, Dept Radiotherapy & Nucl Med, Expt Cancerol Lab, B-9000 Ghent, Belgium; Univ Ghent, Lab Prot Biochem & Prot Engn, B-9000 Ghent, Belgium	Ghent University; Ghent University Hospital; Ghent University	Bracke, M (corresponding author), Ghent Univ Hosp, Dept Radiotherapy & Nucl Med, Expt Cancerol Lab, De Pintelaan 185, B-9000 Ghent, Belgium.	brackemarc@hotmail.com	Devreese, Bart/B-2011-2009; Stove, Christophe/B-6057-2008; Devreese, Bart/K-2841-2019	Devreese, Bart/0000-0002-9764-2581; Stove, Christophe/0000-0001-7126-348X; Devreese, Bart/0000-0002-9764-2581				Alanko T, 2000, J INVEST DERMATOL, V115, P286, DOI 10.1046/j.1523-1747.2000.00045.x; Ball EMA, 2001, DEV BIOL, V238, P1, DOI 10.1006/dbio.2001.0399; Bartkova J, 1996, CANCER RES, V56, P5475; Beer HD, 2000, J INVEST DERM SYMP P, V5, P34, DOI 10.1046/j.1087-0024.2000.00009.x; Berking C, 2001, CANCER RES, V61, P8306; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Chen YG, 2002, EXP BIOL MED, V227, P75, DOI 10.1177/153537020222700201; Cho SH, 2003, J IMMUNOL, V170, P4045, DOI 10.4049/jimmunol.170.8.4045; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Delbaere A, 1999, ENDOCRINOLOGY, V140, P2463, DOI 10.1210/en.140.6.2463; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Devreese B, 2002, J CHROMATOGR A, V976, P113, DOI 10.1016/S0021-9673(02)01153-6; deWinter JP, 1996, MOL CELL ENDOCRINOL, V116, P105, DOI 10.1016/0303-7207(95)03705-5; ESCH FS, 1987, MOL ENDOCRINOL, V1, P849, DOI 10.1210/mend-1-11-849; Gray PC, 2003, P NATL ACAD SCI USA, V100, P5193, DOI 10.1073/pnas.0531290100; Gullick WJ, 2001, BREAST CANCER RES, V3, P390, DOI 10.1186/bcr328; Gumienny TL, 2002, TRENDS ENDOCRIN MET, V13, P295, DOI 10.1016/S1043-2760(02)00615-X; Hager JW, 2002, RAPID COMMUN MASS SP, V16, P512, DOI 10.1002/rcm.607; Hashimoto O, 1997, J BIOL CHEM, V272, P13835, DOI 10.1074/jbc.272.21.13835; Hempen PM, 2003, CANCER RES, V63, P994; Innis CA, 2003, J BIOL CHEM, V278, P39969, DOI 10.1074/jbc.M211284200; INOUYE S, 1991, ENDOCRINOLOGY, V129, P815, DOI 10.1210/endo-129-2-815; Knight PG, 1996, FRONT NEUROENDOCRIN, V17, P476, DOI 10.1006/frne.1996.0013; Lazar-Molnar E, 2000, CYTOKINE, V12, P547, DOI 10.1006/cyto.1999.0614; LING N, 1986, NATURE, V321, P779, DOI 10.1038/321779a0; Liu QY, 1996, CANCER RES, V56, P1155; Luisi S, 2001, EUR J ENDOCRINOL, V145, P225, DOI 10.1530/eje.0.1450225; Massague J, 2000, GENE DEV, V14, P627; Meier F., 1998, FRONT BIOSCI J VIS L, V3, P1005, DOI [10.2741/a341, DOI 10.2741/A341]; MICHEL U, 1992, ENDOCRINOLOGY, V130, P3684, DOI 10.1210/en.130.6.3684; Munz B, 1999, EMBO J, V18, P5205, DOI 10.1093/emboj/18.19.5205; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; Risbridger GP, 2001, ENDOCR REV, V22, P836, DOI 10.1210/er.22.6.836; ROBERTSON DM, 1987, BIOCHEM BIOPH RES CO, V149, P744, DOI 10.1016/0006-291X(87)90430-X; Rodeck U, 1999, CANCER RES, V59, P547; RODECK U, 1994, CANCER RES, V54, P575; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sandra K, 2004, J AM SOC MASS SPECTR, V15, P413, DOI 10.1016/j.jasms.2003.11.003; Schneyer AL, 1996, ENDOCRINOLOGY, V137, P240, DOI 10.1210/en.137.1.240; SCHNEYER AL, 1994, ENDOCRINOLOGY, V135, P667, DOI 10.1210/en.135.2.667; Shellman YG, 2000, J INVEST DERMATOL, V114, P1200, DOI 10.1046/j.1523-1747.2000.00988.x; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; SHIMASAKI S, 1988, P NATL ACAD SCI USA, V85, P4218, DOI 10.1073/pnas.85.12.4218; Sidis Y, 2002, ENDOCRINOLOGY, V143, P1613, DOI 10.1210/en.143.5.1613; Sidis Y, 2001, J BIOL CHEM, V276, P17718, DOI 10.1074/jbc.M100736200; Stove C, 2003, J INVEST DERMATOL, V121, P802, DOI 10.1046/j.1523-1747.2003.12522.x; Stove V, 2003, BLOOD, V102, P2925, DOI 10.1182/blood-2003-03-0833; TANO M, 1995, MOL CELL ENDOCRINOL, V109, P167, DOI 10.1016/0303-7207(95)03499-W; Tuveson DA, 2003, CANCER CELL, V4, P95, DOI 10.1016/S1535-6108(03)00189-2; UENO N, 1987, P NATL ACAD SCI USA, V84, P8282, DOI 10.1073/pnas.84.23.8282; VALE W, 1986, NATURE, V321, P776, DOI 10.1038/321776a0; Wang QF, 2000, ENDOCRINOLOGY, V141, P3183, DOI 10.1210/en.141.9.3183; Wankell M, 2001, J ENDOCRINOL, V171, P385, DOI 10.1677/joe.0.1710385; Wankell M, 2001, EMBO J, V20, P5361, DOI 10.1093/emboj/20.19.5361; Welt C, 2002, EXP BIOL MED, V227, P724, DOI 10.1177/153537020222700905; Willert Jennifer, 2002, BMC Dev Biol, V2, P8, DOI 10.1186/1471-213X-2-8	56	31	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2004	23	31					5330	5339		10.1038/sj.onc.1207699	http://dx.doi.org/10.1038/sj.onc.1207699			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15064726	Green Published			2022-12-28	WOS:000222491600008
J	Lee, CC; Putnam, AJ; Miranti, CK; Gustafson, M; Wang, LM; Woude, GFV; Gao, CF				Lee, CC; Putnam, AJ; Miranti, CK; Gustafson, M; Wang, LM; Woude, GFV; Gao, CF			Overexpression of sprouty 2 inhibits HGF/SF-mediated cell growth, invasion, migration, and cytokinesis	ONCOGENE			English	Article						sprouty; hepatocyte growth factor/scatter factor; met; signaling; invasion; migration	DROSOPHILA-SPROUTY; DOWN-REGULATION; MET; RECEPTOR; EXPRESSION; PATHWAY; FGF; METASTASIS; ANTAGONIST; ACTIVATION	A strict regulation of hepatocyte growth factor/scatter factor (HGF/SF)-Met signaling is essential for its appropriate function. Several negative regulators of Met signaling have been identified. Here we report that human Spry2 is induced by HGF/SF and negatively regulates HGF/SF-Met signaling. We show that overexpression of Spry2 inhibits cell proliferation, anchorage-independent cell growth, and migration in wound-healing and in vitro invasion assays. Measured in an electric cell-substrate impedance sensing biosensor, cell movement is restricted, because Spry2 dramatically facilitates cell attachment and spreading by enhancing focal adhesions and increasing stress fibers. An analysis of cell cycle distribution shows, unexpectedly, that Spry2-GFP cells are polyploid. Thus, as with FGF and EGF receptors, Spry2-GFP tempers downstream Met signaling in addition to its pronounced effect on cell adhesion, and it has properties suitable to be considered a tumor-suppressor protein.	Van Andel Res Inst, Grand Rapids, MI 49503 USA	Van Andel Institute	Woude, GFV (corresponding author), Van Andel Res Inst, 333 Bostwick Ave NE, Grand Rapids, MI 49503 USA.	george.vandewoude@vai.org	Miranti, Cindy/AAJ-3783-2020; Putnam, Andrew J./E-8643-2010	Putnam, Andrew J./0000-0002-1262-4377				Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; de Maximy AA, 1999, MECH DEVELOP, V81, P213, DOI 10.1016/S0925-4773(98)00241-X; Egan JE, 2002, P NATL ACAD SCI USA, V99, P6041, DOI 10.1073/pnas.052090899; Fong CW, 2003, J BIOL CHEM, V278, P33456, DOI 10.1074/jbc.M301317200; GIAEVER I, 1991, P NATL ACAD SCI USA, V88, P7896, DOI 10.1073/pnas.88.17.7896; Gross I, 2001, J BIOL CHEM, V276, P46460, DOI 10.1074/jbc.M108234200; Guy GR, 2003, J CELL SCI, V116, P3061, DOI 10.1242/jcs.00652; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Hall AB, 2003, CURR BIOL, V13, P308, DOI 10.1016/S0960-9822(03)00086-1; Hammond DE, 2003, MOL BIOL CELL, V14, P1346, DOI 10.1091/mbc.E02-09-0578; Hammond DE, 2001, ONCOGENE, V20, P2761, DOI 10.1038/sj.onc.1204475; Hanafusa H, 2002, NAT CELL BIOL, V4, P850, DOI 10.1038/ncb867; Impagnatiello MA, 2001, J CELL BIOL, V152, P1087, DOI 10.1083/jcb.152.5.1087; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; Keese CR, 2004, P NATL ACAD SCI USA, V101, P1554, DOI 10.1073/pnas.0307588100; Koochekpour S, 1999, MOL CELL BIOL, V19, P5902; Kramer S, 1999, DEVELOPMENT, V126, P2515; Lee SH, 2001, J BIOL CHEM, V276, P4128, DOI 10.1074/jbc.M006922200; Mailleux AA, 2001, MECH DEVELOP, V102, P81, DOI 10.1016/S0925-4773(01)00286-6; Minowada G, 1999, DEVELOPMENT, V126, P4465; Miranti CK, 2002, METHOD CELL BIOL, V69, P359, DOI 10.1016/S0091-679X(02)69023-5; Ozaki K, 2001, BIOCHEM BIOPH RES CO, V285, P1084, DOI 10.1006/bbrc.2001.5295; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; Reich A, 1999, DEVELOPMENT, V126, P4139; Rubin C, 2003, CURR BIOL, V13, P297, DOI 10.1016/S0960-9822(03)00053-8; Sasaki A, 2003, NAT CELL BIOL, V5, P427, DOI 10.1038/ncb978; Tefft JD, 1999, CURR BIOL, V9, P219, DOI 10.1016/S0960-9822(99)80094-3; TIRUPPATHI C, 1992, P NATL ACAD SCI USA, V89, P7919, DOI 10.1073/pnas.89.17.7919; Wong ESM, 2002, EMBO J, V21, P4796, DOI 10.1093/emboj/cdf493; Yigzaw Y, 2003, J BIOL CHEM, V278, P284, DOI 10.1074/jbc.M210359200; Yusoff P, 2002, J BIOL CHEM, V277, P3195, DOI 10.1074/jbc.M108368200; Zhang SB, 2001, MECH DEVELOP, V109, P367, DOI 10.1016/S0925-4773(01)00526-3	35	111	117	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2004	23	30					5193	5202		10.1038/sj.onc.1207646	http://dx.doi.org/10.1038/sj.onc.1207646			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	834AE	15122328				2022-12-28	WOS:000222382500009
J	Worm, J; Christensen, C; Gronbaek, K; Tulchinsky, E; Guldberg, P				Worm, J; Christensen, C; Gronbaek, K; Tulchinsky, E; Guldberg, P			Genetic and epigenetic alterations of the APC gene in malignant melanoma	ONCOGENE			English	Article						melanoma; APC; Wnt signalling; DNA methylation; beta-catenin; RNAi	ADENOMATOUS-POLYPOSIS-COLI; CELL-CYCLE PROGRESSION; BETA-CATENIN GENE; SOMATIC MUTATIONS; EXON 3; SIGNALING PATHWAY; COLORECTAL-CANCER; DNA METHYLATION; S-PHASE; PROMOTER	High levels of beta-catenin and activating mutations in the beta-catenin gene (CTNNB1) have been demonstrated in malignant melanomas, implicating dysregulated Wnt signalling in the pathogenesis of this malignancy. We systematically examined melanoma cell lines for activating CTNNB1 mutations as well as genetic and epigenetic alterations of the adenomatous polyposis coli gene (APC), another key component of the Wnt signalling transduction pathway. Of 40 cell lines tested, one carried a truncating APC mutation and loss of the corresponding wild-type allele, and one carried a CTNNB1 missense mutation. Hypermethylation of APC promoter 1A was present in five of the cell lines (13%) and in nine of 54 melanoma biopsies (17%). Cells with truncating APC or activating CTNNB1 mutations showed increased transcription from endogenous and ectopic beta-catenin/T-cell factor (Tcf)responsive target genes, consistent with the known effects of these alterations on beta-catenin stability and Tcf transactivation. In contrast, cell lines with APC promoter 1A hypermethylation did not show increased Wnt signalling, probably due to residual APC activity expressed from promoter 1B. Suppression of APC transcripts in melanoma cells by stable expression of short hairpin RNAs led to a Wnt signalling-independent increase in cell proliferation, but also reduced the invasive growth in collagen type I. Collectively, our data suggest that the tumour-suppressive function of APC in melanocytic cells is dose dependent. We propose that epigenetic silencing of promoter 1A may contribute to the development of malignant melanoma by reducing the expression of APC to a level that promotes cell proliferation without compromising the invasive capacity.	Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen, Denmark; Univ Leicester, Dept Canc Studies & Mol Med, Leicester LE1 7RH, Leics, England	Danish Cancer Society; University of Leicester	Guldberg, P (corresponding author), Danish Canc Soc, Inst Canc Biol, Strandblvd 49, DK-2100 Copenhagen, Denmark.	perg@cancer.dk	Tulchinsky, Eugene/ABD-7070-2021	Gronbaek, Kirsten/0000-0002-1535-9601				BAEG GH, 1995, EMBO J, V14, P5618, DOI 10.1002/j.1460-2075.1995.tb00249.x; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Carmen AA, 1999, P NATL ACAD SCI USA, V96, P12356, DOI 10.1073/pnas.96.22.12356; Chen C, 2001, J BIOL CHEM, V276, P320, DOI 10.1074/jbc.M007096200; Coffee B, 1999, NAT GENET, V22, P98, DOI 10.1038/8807; Cremonesi L, 1997, BIOTECHNIQUES, V22, P326, DOI 10.2144/97222rr01; Demunter A, 2002, MODERN PATHOL, V15, P454, DOI 10.1038/modpathol.3880546; Esteller M, 2000, CANCER RES, V60, P4366; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Fodde R, 2003, NAT CELL BIOL, V5, P190, DOI 10.1038/ncb0303-190; Fodde R, 2002, EUR J CANCER, V38, P867, DOI 10.1016/S0959-8049(02)00040-0; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Furuuchi K, 2000, AM J PATHOL, V156, P1997, DOI 10.1016/S0002-9440(10)65072-9; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Guldberg P, 1997, CANCER RES, V57, P3660; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hiltunen MO, 1997, INT J CANCER, V70, P644, DOI 10.1002/(SICI)1097-0215(19970317)70:6<644::AID-IJC3>3.3.CO;2-2; HORII A, 1992, CANCER RES, V52, P3231; HORII A, 1992, CANCER RES, V52, P6696; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Kawakami K, 2000, J NATL CANCER I, V92, P1805, DOI 10.1093/jnci/92.22.1805; Kielman MF, 2002, NAT GENET, V32, P594, DOI 10.1038/ng1045; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LERMAN LS, 1987, METHOD ENZYMOL, V155, P482; Leung JY, 2002, J BIOL CHEM, V277, P21657, DOI 10.1074/jbc.M200139200; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Miyoshi Y, 1998, CANCER RES, V58, P2524; Mogensen MM, 2002, J CELL BIOL, V157, P1041, DOI 10.1083/jcb.200203001; Moreno-Bueno G, 2002, ONCOGENE, V21, P7981, DOI 10.1038/sj.onc.1205924; Oda H, 1996, CANCER RES, V56, P3320; Omholt K, 2001, INT J CANCER, V92, P839, DOI 10.1002/ijc.1270; Pollock PM, 2002, MELANOMA RES, V12, P183, DOI 10.1097/00008390-200204000-00013; Reifenberger J, 2002, INT J CANCER, V100, P549, DOI 10.1002/ijc.10512; Rimm DL, 1999, AM J PATHOL, V154, P325, DOI 10.1016/S0002-9440(10)65278-9; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tsuchiya T, 2000, ONCOGENE, V19, P3642, DOI 10.1038/sj.onc.1203704; Usadel H, 2002, CANCER RES, V62, P371; Virmani AK, 2001, CLIN CANCER RES, V7, P1998; Worm J, 2001, J BIOL CHEM, V276, P39990, DOI 10.1074/jbc.M103181200; Worm J, 2001, CLIN CHEM, V47, P1183; Wu R, 2001, CANCER RES, V61, P8247; Xiao HY, 1999, J CELL BIOCHEM, V73, P291, DOI 10.1002/(SICI)1097-4644(19990601)73:3<291::AID-JCB1>3.0.CO;2-5; Yan D, 2001, P NATL ACAD SCI USA, V98, P14973, DOI 10.1073/pnas.261574498; ZEKI K, 1994, J CLIN ENDOCR METAB, V79, P1317, DOI 10.1210/jc.79.5.1317; Zumbrunn J, 2001, CURR BIOL, V11, P44, DOI 10.1016/S0960-9822(01)00002-1	48	81	83	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2004	23	30					5215	5226		10.1038/sj.onc.1207647	http://dx.doi.org/10.1038/sj.onc.1207647			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	834AE	15133491				2022-12-28	WOS:000222382500011
J	Tchernitsa, OI; Sers, C; Zuber, J; Hinzmann, B; Grips, M; Schramme, A; Lund, P; Schwendel, A; Rosenthal, A; Schafer, R				Tchernitsa, OI; Sers, C; Zuber, J; Hinzmann, B; Grips, M; Schramme, A; Lund, P; Schwendel, A; Rosenthal, A; Schafer, R			Transcriptional basis of KRAS oncogene-mediated cellular transformation in ovarian epithelial cells	ONCOGENE			English	Article						suppressive subtraction hybridization; signal transduction; ovarian cancer; gene regulation; mitogen-activated; protein kinase	JUNCTIONAL INTERCELLULAR COMMUNICATION; GENE-EXPRESSION PROFILES; K-RAS PROTOONCOGENE; GENOMIC INSTABILITY; DNA METHYLATION; PROTEIN-KINASES; DOWN-REGULATION; LUNG-CANCER; TUMOR-CELLS; E-CADHERIN	To understand the relationship between oncogenic signaling and the reprogramming of gene expression, we performed transcriptional profiling in rat ovarian surface epithelial cells (ROSE), in which neoplastic transformation is driven by a mutated KRAS oncogene. We identified >200 genes whose expression was elevated or reduced following permanent KRAS expression. Deregulated KRAS-responsive genes encode transcriptional regulators, signaling effectors, proteases, extracellular matrix and adhesion proteins, transformation-suppressing proteins and negative growth regulators. Many of them have not been previously identified in cells expressing oncogenic RAS genes or in other well-studied models of oncogenic signaling. The number of critical genes related to the execution of anchorage-independent proliferation and epithelial-mesenchymal transition was narrowed down to 79 by selectively inhibiting the mitogen-activated protein kinase (MAPK/ERK) and phosphatidylinositol 3-kinase (PI3K) pathways. Blocking MAPK/ERK-signaling caused reversion to the normal epithelial phenotype in conjunction with the reversal of deregulated target transcription to pretransformation levels. In addition, silencing of the overexpressed transcriptional regulator Fra-1 by RNA interference resulted in growth reduction, suggesting that this factor partially contributes to, but is not sufficient for the proliferative capacity of KRAS-transformed epithelial cells.	Humboldt Univ, Charite, Inst Pathol, Lab Mol Tumor Pathol, D-10117 Berlin, Germany; MetaGen Pharmaceut GmbH, D-13347 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Schafer, R (corresponding author), Humboldt Univ, Charite, Inst Pathol, Lab Mol Tumor Pathol, Schumannstr 20-21, D-10117 Berlin, Germany.	reinhold.schaefer@charite.de	Sers, Christine/B-5438-2010; Lund, Per G/M-9019-2017; Schäfer, Reinhold/AAB-5110-2021; Zuber, Johannes/E-7517-2011; Lund, Per/Q-6737-2017	Zuber, Johannes/0000-0001-8810-6835; Lund, Per/0000-0002-7457-4360; Schafer, Reinhold/0000-0001-7952-2124; Sers, christine/0000-0002-6219-1514				Abdollahi A, 1999, ONCOGENE, V18, P6477, DOI 10.1038/sj.onc.1203067; ADAMS AT, 1985, EXP CELL BIOL, V53, P181; Alaiya AA, 1997, INT J CANCER, V73, P678, DOI 10.1002/(SICI)1097-0215(19971127)73:5<678::AID-IJC11>3.0.CO;2-2; Alvarez AA, 2001, GYNECOL ONCOL, V82, P273, DOI 10.1006/gyno.2001.6287; Auersperg N, 1999, P NATL ACAD SCI USA, V96, P6249, DOI 10.1073/pnas.96.11.6249; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Baruch RR, 2001, CELL BIOL INT, V25, P411, DOI 10.1006/cbir.2000.0647; Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; BISHOP JM, 1985, TRENDS GENET, V1, P245, DOI 10.1016/0168-9525(85)90094-0; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; BOS JL, 1989, CANCER RES, V49, P4682; Bourguignon LYW, 2001, J BIOL CHEM, V276, P7327, DOI 10.1074/jbc.M006498200; Boyer B, 2000, BIOCHEM PHARMACOL, V60, P1091, DOI 10.1016/S0006-2952(00)00427-5; Brem R, 2001, ONCOGENE, V20, P2854, DOI 10.1038/sj.onc.1204403; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Cuatrecasas M, 1997, CANCER, V79, P1581, DOI 10.1002/(SICI)1097-0142(19970415)79:8<1581::AID-CNCR21>3.0.CO;2-T; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; DEVOUGE MW, 1992, ONCOGENE, V7, P109; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Downward J, 2001, NATURE, V411, P759, DOI 10.1038/35081138; DOWNWARD J, 1998, MOL B INT U, V3, P171; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; ENOMOTO T, 1991, AM J PATHOL, V139, P777; Evangelou A, 2000, CANCER RES, V60, P929; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Furuya M, 2000, GYNECOL ONCOL, V78, P106, DOI 10.1006/gyno.2000.5856; Giampuzzi M, 2001, J BIOL CHEM, V276, P29226, DOI 10.1074/jbc.M101695200; Gimona M, 1996, P NATL ACAD SCI USA, V93, P9618, DOI 10.1073/pnas.93.18.9618; Giunciuglio D, 1995, INT J CANCER, V63, P815, DOI 10.1002/ijc.2910630612; GLUCK U, 1993, P NATL ACAD SCI USA, V90, P383, DOI 10.1073/pnas.90.2.383; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Hanna EA, 1999, CARCINOGENESIS, V20, P1369, DOI 10.1093/carcin/20.7.1369; HOFMANN M, 1993, CANCER RES, V53, P1516; Hosono S, 2000, J BIOL CHEM, V275, P10943, DOI 10.1074/jbc.275.15.10943; ICHIKAWA Y, 1994, CANCER RES, V54, P33; Imren S, 1996, CANCER RES, V56, P2891; IVER VR, 1999, SCIENCE, V283, P83; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Johnston IMP, 2000, ONCOGENE, V19, P5348, DOI 10.1038/sj.onc.1203927; Kessler R, 1999, ONCOGENE, V18, P1733, DOI 10.1038/sj.onc.1202484; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; LEWIS JE, 1994, J INVEST DERMATOL, V102, P870, DOI 10.1111/1523-1747.ep12382690; LUO XN, 1995, ONCOGENE, V11, P743; MACLEOD AR, 1995, J BIOL CHEM, V270, P11327, DOI 10.1074/jbc.270.19.11327; Majidi M, 2000, J BIOL CHEM, V275, P6560, DOI 10.1074/jbc.275.9.6560; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Mok SC, 1996, ONCOGENE, V12, P1895; MOK SCH, 1993, CANCER RES, V53, P1489; Morrison BH, 2001, J BIOL CHEM, V276, P24965, DOI 10.1074/jbc.M101161200; Olski TM, 2001, J CELL SCI, V114, P525; OZAKI T, 1994, CANCER RES, V54, P646; Paterson IC, 2001, J PATHOL, V193, P458, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH822>3.0.CO;2-V; Patton SE, 1998, CANCER RES, V58, P2253; Risse-Hackl G, 1998, ONCOGENE, V16, P3057, DOI 10.1038/sj.onc.1201845; Rivedal E, 2001, CARCINOGENESIS, V22, P1543, DOI 10.1093/carcin/22.9.1543; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; Saavedra HI, 2000, ONCOGENE, V19, P3948, DOI 10.1038/sj.onc.1203723; Saha D, 2001, J BIOL CHEM, V276, P29531, DOI 10.1074/jbc.M100069200; Schorge JO, 2000, GYNECOL ONCOL, V76, P369, DOI 10.1006/gyno.1999.5711; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sehgal A, 1997, J SURG ONCOL, V65, P249, DOI 10.1002/(SICI)1096-9098(199708)65:4<249::AID-JSO5>3.0.CO;2-5; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; SLACK JL, 1992, MOL CELL BIOL, V12, P4714, DOI 10.1128/MCB.12.10.4714; Sumitomo K, 2000, CANCER LETT, V155, P37, DOI 10.1016/S0304-3835(00)00407-9; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; Travers H, 1996, CELL GROWTH DIFFER, V7, P1353; Umhauer S, 2000, AM J OBSTET GYNECOL, V182, P999, DOI 10.1016/S0002-9378(00)70135-9; van Engeland M, 2002, ONCOGENE, V21, P3792, DOI 10.1038/sj.onc.1205466; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; vonStein OD, 1997, NUCLEIC ACIDS RES, V25, P2598, DOI 10.1093/nar/25.13.2598; Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; ZABRENETZKY V, 1994, INT J CANCER, V59, P191, DOI 10.1002/ijc.2910590209; Zajchowski DA, 2001, CANCER RES, V61, P5168; Zavadil J, 2001, P NATL ACAD SCI USA, V98, P6686, DOI 10.1073/pnas.111614398; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	90	60	64	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2004	23	26					4536	4555		10.1038/sj.onc.1207585	http://dx.doi.org/10.1038/sj.onc.1207585			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZV	15064704				2022-12-28	WOS:000221799000004
J	Bae, SC; Choi, JK				Bae, SC; Choi, JK			Tumor suppressor activity of RUNX3	ONCOGENE			English	Article						RUNX3; cancer; TGF-beta; methylation	GROWTH-FACTOR-BETA; EPSTEIN-BARR-VIRUS; TRANSCRIPTION FACTOR; FREQUENT LOSS; C-MYC; FUNCTIONAL COOPERATION; CANCER CELLS; GENE; EXPRESSION; MUTATIONS	Recent analyses have revealed that RUNX family members play important roles in both normal developmental processes and carcinogenesis. Of the three known RUNX family members, RUNX3 has been shown to be involved in neurogenesis of the dorsal root ganglia, T-cell differentiation and tumorigenesis of gastric epithelium. Deletion of the Runx3 locus in mice resulted in hyperplasia of the gastric epithelium due to the stimulation of proliferation and suppression of apoptosis that was accompanied by a reduced sensitivity to TGF-beta1. In primary human gastric cancer specimens, RUNX3 is frequently inactivated by allele loss or gene silencing due to promoter hypermethylation. The tumorigenicity of human gastric cancer cell lines in nude mice decreased as the level of RUNX3 expression increased, which indicates that RUNX3 is a bona. de tumor suppressor of gastric cancers.	Chungbuk Natl Univ, Inst Tumor Res, Sch Med, Dept Biochem, Cheongju 361763, South Korea	Chungbuk National University	Bae, SC (corresponding author), Chungbuk Natl Univ, Inst Tumor Res, Sch Med, Dept Biochem, Cheongju 361763, South Korea.	scbae@med.chungbuk.ac.kr						ALEXANDROW MG, 1995, CANCER RES, V55, P1452; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; BAE SC, 1995, GENE, V159, P245, DOI 10.1016/0378-1119(95)00060-J; Bae SC, 2000, GENE, V241, P255, DOI 10.1016/S0378-1119(99)00488-6; Bangsow C, 2001, GENE, V279, P221, DOI 10.1016/S0378-1119(01)00760-0; Brownhill R, 2002, SCI ENG ETHICS, V8, P43, DOI 10.1007/s11948-002-0032-3; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cameron ER, 2003, BLOOD CELL MOL DIS, V30, P194, DOI 10.1016/S1079-9796(03)00031-7; Chalaux E, 1999, FEBS LETT, V457, P478, DOI 10.1016/S0014-5793(99)01051-0; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Chipuk JE, 2001, J BIOL CHEM, V276, P26614, DOI 10.1074/jbc.M100913200; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; Cohen MM, 2003, AM J MED GENET A, V116A, P1, DOI 10.1002/ajmg.a.10750; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Furihata C, 1997, JPN J CANCER RES, V88, P363, DOI 10.1111/j.1349-7006.1997.tb00390.x; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Guo WH, 2002, ONCOGENE, V21, P8351, DOI 10.1038/sj.onc.1206037; HAMMERSCHMIDT W, 1989, NATURE, V340, P393, DOI 10.1038/340393a0; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; HERZOG CR, 1995, ONCOGENE, V11, P1811; Hess J, 2001, J BIOL CHEM, V276, P20029, DOI 10.1074/jbc.M010601200; IMAI S, 1994, P NATL ACAD SCI USA, V91, P9131, DOI 10.1073/pnas.91.19.9131; Inoue K, 2002, NAT NEUROSCI, V5, P946, DOI 10.1038/nn925; Ito Y, 2003, CURR OPIN GENET DEV, V13, P43, DOI 10.1016/S0959-437X(03)00007-8; JOHANNSEN E, 1995, J VIROL, V69, P253, DOI 10.1128/JVI.69.1.253-262.1995; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kaiser C, 1999, J VIROL, V73, P4481, DOI 10.1128/JVI.73.5.4481-4484.1999; Kato N, 2003, AM J PATHOL, V163, P387, DOI 10.1016/S0002-9440(10)63668-1; Kim R, 2003, J VIROL, V77, P2056, DOI 10.1128/JVI.77.3.2056-2062.2003; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; KUNIYASU H, 1994, INT J CANCER, V59, P597, DOI 10.1002/ijc.2910590504; Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797-307; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Lund AH, 2002, CANCER CELL, V1, P213, DOI 10.1016/S1535-6108(02)00049-1; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Nam S, 2002, MOL CELL BIOL, V22, P547, DOI 10.1128/MCB.22.2.547-554.2002; North T, 1999, DEVELOPMENT, V126, P2563; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Parkin DM, 1999, INT J CANCER, V80, P827, DOI 10.1002/(SICI)1097-0215(19990315)80:6&lt;827::AID-IJC6&gt;3.0.CO;2-P; Robertson AJ, 2002, MECH DEVELOP, V117, P327, DOI 10.1016/S0925-4773(02)00201-0; SANO T, 1991, CANCER RES, V51, P2926; Schuster N, 2002, CELL TISSUE RES, V307, P1, DOI 10.1007/s00441-001-0479-6; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Spender LC, 2002, J VIROL, V76, P4919, DOI 10.1128/JVI.76.10.4919-4927.2002; Spieker N, 2001, GENE CHROMOSOME CANC, V31, P172, DOI 10.1002/gcc.1130.abs; Stewart M, 2002, J VIROL, V76, P4364, DOI 10.1128/JVI.76.9.4364-4369.2002; Stewart M, 1997, P NATL ACAD SCI USA, V94, P8646, DOI 10.1073/pnas.94.16.8646; TANAKA K, 1993, ONCOGENE, V8, P2253; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Teramoto T, 1998, BIOCHEM BIOPH RES CO, V251, P56, DOI 10.1006/bbrc.1998.9411; UCHINO S, 1992, CANCER RES, V52, P3099; Waki T, 2003, CANCER SCI, V94, P360, DOI 10.1111/j.1349-7006.2003.tb01447.x; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Warner BJ, 1999, MOL CELL BIOL, V19, P5913; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Weith A, 1996, CYTOGENET CELL GENET, V72, P114; Woolf E, 2003, P NATL ACAD SCI USA, V100, P7731, DOI 10.1073/pnas.1232420100; Wotton S, 2002, CANCER RES, V62, P7181; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200; Yokomizo T, 2001, GENES CELLS, V6, P13, DOI 10.1046/j.1365-2443.2001.00393.x; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang YW, 2000, P NATL ACAD SCI USA, V97, P10549, DOI 10.1073/pnas.180309597	70	106	122	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2004	23	24					4336	4340		10.1038/sj.onc.1207286	http://dx.doi.org/10.1038/sj.onc.1207286			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823BZ	15156190				2022-12-28	WOS:000221586000019
J	Guda, K; Upender, MB; Belinsky, G; Flynn, C; Nakanishi, M; Marino, JN; Ried, T; Rosenberg, DW				Guda, K; Upender, MB; Belinsky, G; Flynn, C; Nakanishi, M; Marino, JN; Ried, T; Rosenberg, DW			Carcinogen-induced colon tumors in mice are chromosomally stable and are characterized by low-level microsatellite instability	ONCOGENE			English	Article						azoxymethane; mice; colon tumorigenesis; chromosomal instability; spectral karyotyping; microsatellite instability	COLORECTAL-CANCER; GENOMIC INSTABILITY; BETA-CATENIN; ALTERED EXPRESSION; HIGH-FREQUENCY; AZOXYMETHANE; MUTATIONS; PATHWAYS; DNA; TUMORIGENESIS	The azoxymethane (AOM)-induced mouse colon tumor model recapitulates many of the histopathological features associated with the multistage progression of human sporadic colorectal cancers (CRCs). To better de. ne the genetic events associated with tumorigenesis in this murine model, we analysed tumors from A/J mice for chromosomal (CIN) and microsatellite (MSI) instabilities, two fundamental pathways of genomic instability that play a critical role in the pathogenesis of human CRCs. Male A/J mice, 6-week old, were injected with either AOM (n=5) (10 mg/kg b.w., i.p.) or vehicle (n=5) (0.9% NaCl solution) once a week for 6 weeks. At 32 weeks after the last dose, comparative genomic hybridization (CGH) was performed on 16 tumors harvested from five animals. Although 25% of the tumors displayed either a gain of chromosome 2 or loss of Y, the majority (75%) showed no genomic imbalances. Further analysis of chromosomal aberrations, using CGH and spectral karyotyping (SKY) was performed in our recently established A/J colon tumor-derived cell line, AJ02-NM0. Results showed a pseudotetraploid karyotype with loss of only the Y chromosome in these cultured cells, thereby providing additional evidence for the minimal role of CIN in the primary AOM-induced tumors. Interestingly, the majority (81%) of A/J tumors displayed low-level microsatellite instability (MSI-L) when analysed using mono- and dinucleotide repeat markers, and showed a significant expansion to high-level instability (MSI-H) in the AJ02-NM0 cells. This finding in cultured cells additionally provides evidence that a mild mutator pathway may contribute to the development of behaviorally benign carcinomas in situ in A/J mice. To better understand the tumorigenic process in the A/J colons, we screened for mutational alterations in key regions of the K-ras and Apc genes. Results showed a very low frequency (6%) of K-ras activating mutations, together with the absence of Apc truncation mutations in primary tumors and AJ02-NM0 cells. However, these tumors displayed intense nuclear accumulation of beta-catenin protein, indicating activation of the Wnt signaling pathway. Based on our molecular and cytogenetic findings, we propose that carcinogen-induced tumors may develop via mechanisms independent of the 'classical' CIN or MSI pathways.	NCI, Genet Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; Univ Connecticut, Ctr Hlth, Ctr Mol Med, Farmington, CT 06030 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Connecticut	Ried, T (corresponding author), NCI, Genet Branch, Ctr Canc Res, NIH, 50 South Dr,Room 1306, Bethesda, MD 20892 USA.	riedt@mail.nih.gov	guda, kishore/E-3389-2010		DIVISION OF CLINICAL SCIENCES - NCI [Z01SC010299] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA081428] Funding Source: NIH RePORTER; NCI NIH HHS [CA81428] Funding Source: Medline	DIVISION OF CLINICAL SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brink M, 2003, CARCINOGENESIS, V24, P703, DOI 10.1093/carcin/bgg009; Calvert PM, 2002, ANN INTERN MED, V137, P603, DOI 10.7326/0003-4819-137-7-200210010-00012; Chan TL, 2001, ONCOGENE, V20, P4871, DOI 10.1038/sj.onc.1204653; Corpet DE, 2003, CANCER EPIDEM BIOMAR, V12, P391; De Filippo C, 1998, BRIT J CANCER, V77, P2148, DOI 10.1038/bjc.1998.359; Doug M, 2003, CARCINOGENESIS, V24, P307, DOI 10.1093/carcin/24.2.307; Eshleman JR, 1998, ONCOGENE, V17, P719, DOI 10.1038/sj.onc.1201986; Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Georgiades IB, 1999, ONCOGENE, V18, P7933, DOI 10.1038/sj.onc.1203368; Goel A, 2003, CANCER RES, V63, P1608; Guda K, 2001, MOL CARCINOGEN, V31, P204, DOI 10.1002/mc.1055; Haag JD, 1999, MOL CARCINOGEN, V24, P47, DOI 10.1002/(SICI)1098-2744(199901)24:1<47::AID-MC7>3.0.CO;2-B; Hermsen M, 2002, GASTROENTEROLOGY, V123, P1109, DOI 10.1053/gast.2002.36051; Hoglund M, 2002, CANCER RES, V62, P5939; Iino H, 1999, J CLIN PATHOL, V52, P5, DOI 10.1136/jcp.52.1.5; Jass JR, 2002, EUR J CANCER, V38, P858, DOI 10.1016/S0959-8049(02)00041-2; Jass JR, 1999, J CLIN PATHOL, V52, P455, DOI 10.1136/jcp.52.6.455; Jass JR, 2003, J PATHOL, V199, P267, DOI 10.1002/path.1266; Kambara T, 2001, CANCER RES, V61, P7743; Kislitsin D, 2002, DIGEST DIS SCI, V47, P1073, DOI 10.1023/A:1015090124153; Kohonen-Corish MRJ, 2002, CANCER RES, V62, P2092; Kolligs FT, 2002, DIGESTION, V66, P131, DOI 10.1159/000066755; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lindblom A, 2001, CURR OPIN ONCOL, V13, P63, DOI 10.1097/00001622-200101000-00013; Liyanage M, 1996, NAT GENET, V14, P312, DOI 10.1038/ng1196-312; LOTHE RA, 1993, CANCER RES, V53, P5849; Luceri C, 2000, CARCINOGENESIS, V21, P1753, DOI 10.1093/carcin/21.9.1753; Nambiar PR, 2003, INT J ONCOL, V22, P145; Nambiar PR, 2002, CANCER RES, V62, P3667; Neufeld KL, 1997, P NATL ACAD SCI USA, V94, P3034, DOI 10.1073/pnas.94.7.3034; Olschwang S, 1997, P NATL ACAD SCI USA, V94, P12122, DOI 10.1073/pnas.94.22.12122; Rajagopalan H, 2003, NAT REV CANCER, V3, P695, DOI 10.1038/nrc1165; Ried T, 1996, GENE CHROMOSOME CANC, V15, P234, DOI 10.1002/(SICI)1098-2264(199604)15:4<234::AID-GCC5>3.0.CO;2-2; Ried T, 1999, GENE CHROMOSOME CANC, V25, P195, DOI 10.1002/(SICI)1098-2264(199907)25:3<195::AID-GCC1>3.0.CO;2-8; Sheng HM, 1998, CARCINOGENESIS, V19, P543, DOI 10.1093/carcin/19.4.543; Sohn KJ, 2003, CARCINOGENESIS, V24, P217, DOI 10.1093/carcin/24.2.217; Takahashi M, 2000, CARCINOGENESIS, V21, P1117, DOI 10.1093/carcin/21.6.1117; Takahashi M, 2000, CARCINOGENESIS, V21, P1319, DOI 10.1093/carcin/21.7.1319; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Tomlinson I, 2002, J PATHOL, V197, P6, DOI 10.1002/path.1071; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Walchle C, 1999, TOXICOL APPL PHARM, V157, P9, DOI 10.1006/taap.1999.8662; Wang QS, 1998, CARCINOGENESIS, V19, P2001, DOI 10.1093/carcin/19.11.2001; Weaver Z, 2002, ONCOGENE, V21, P5097, DOI 10.1038/sj.onc.1205636; Whitehall VLJ, 2001, CANCER RES, V61, P827; Wong MH, 1996, P NATL ACAD SCI USA, V93, P9588, DOI 10.1073/pnas.93.18.9588; Young J, 2001, AM J PATHOL, V159, P2107, DOI 10.1016/S0002-9440(10)63062-3	48	41	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2004	23	21					3813	3821		10.1038/sj.onc.1207489	http://dx.doi.org/10.1038/sj.onc.1207489			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	818JX	15021908				2022-12-28	WOS:000221242500008
J	Liu, H; Chen, B; Xiong, H; Huang, QH; Zhang, QH; Wang, ZG; Li, BL; Chen, Z; Chen, SJ				Liu, H; Chen, B; Xiong, H; Huang, QH; Zhang, QH; Wang, ZG; Li, BL; Chen, Z; Chen, SJ			Functional contribution of EEN to leukemogenic transformation by MLL-EEN fusion protein	ONCOGENE			English	Article						MLL-EEN; transcriptional factor; HoxA7; leukemogenesis	LEUKEMIA-CELL LINE; SYNAPTIC VESICLE ENDOCYTOSIS; CENTRAL-NERVOUS-SYSTEM; HOMOLOGY 3 DOMAIN; MYELOID PROGENITORS; DOWN-REGULATION; ANTISENSE OLIGODEOXYRIBONUCLEOTIDE; CHROMOSOMAL TRANSLOCATION; ONCOGENIC ACTIVATION; BINDING PARTNERS	The EEN (extra eleven nineteen) gene was originally cloned from a case of acute myeloid leukemia M5 subtype with translocation t (11;19)(q23; p13), in which EEN was fused with MLL. To explore the involvement of EEN in leukemogenesis caused by MLL-EEN, we studied the transformation potential of the MLL-EEN fusion protein. MLL-EEN had oncogenic features, while, as a control, MLLDelta, the truncated form of MLL lacking the EEN moiety, did not show any oncogenic potential. MLL-EEN exerted a dominant-negative effect over wild-type EEN in terms of subcellular localization. Normally, EEN was found in the cytoplasm, but the MLL-EEN fusion protein was located in the nucleus, and EEN could be delocalized by MLL-EEN. This interaction is via a coiled-coil dimerization domain of EEN, which is reserved in the fusion protein. In addition, MLL-EEN might act as a potential transcriptional factor with the MLL part providing the DNA-binding domain and the EEN part providing the transcription activation domain, though EEN seems to have no direct role in transcriptional regulation. As an aberrant transcriptional factor, MLL-EEN could transactivate the promoter of HoxA7, a potential target gene of MLL.	Shanghai Med Univ 2, Ruijin Hosp, Shanghai Inst Hematol, State Key Lab Med Gen, Shanghai 200025, Peoples R China; Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China; Chinese Natl Human Genome Ctr Shanghai, Shanghai 201203, Peoples R China	Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Chen, SJ (corresponding author), Shanghai Med Univ 2, Ruijin Hosp, Shanghai Inst Hematol, State Key Lab Med Gen, 197 Ruijin Rd 2, Shanghai 200025, Peoples R China.	sjchen@stn.sh.cn		Liu, Han/0000-0002-0022-1861				Akao Y, 1998, CANCER RES, V58, P3773; Ayton PM, 2003, GENE DEV, V17, P2298, DOI 10.1101/gad.1111603; Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; Birke M, 2002, NUCLEIC ACIDS RES, V30, P958, DOI 10.1093/nar/30.4.958; Butler LH, 1997, BLOOD, V89, P3361, DOI 10.1182/blood.V89.9.3361; Chan LC, 2002, BLOOD, V100, p199B; Chen Y, 2003, CELL, V115, P37, DOI 10.1016/S0092-8674(03)00726-8; Collins EC, 2002, TRENDS MOL MED, V8, P436, DOI 10.1016/S1471-4914(02)02397-3; COLLINS SJ, 1987, BLOOD, V70, P1233; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DiMartino JF, 2002, BLOOD, V99, P3780, DOI 10.1182/blood.V99.10.3780; DiMartino JF, 2000, BLOOD, V96, P3887, DOI 10.1182/blood.V96.12.3887.h8003887_3887_3893; Dobson CL, 2000, EMBO J, V19, P843, DOI 10.1093/emboj/19.5.843; Dorrie J, 1999, LEUKEMIA, V13, P1539, DOI 10.1038/sj.leu.2401479; Ernst P, 2002, CURR OPIN HEMATOL, V9, P282, DOI 10.1097/00062752-200207000-00004; Floyd S, 1998, TRENDS CELL BIOL, V8, P299, DOI 10.1016/S0962-8924(98)01316-6; Frank RC, 1999, ONCOGENE, V18, P1701, DOI 10.1038/sj.onc.1202459; Giachino C, 1997, GENOMICS, V41, P427, DOI 10.1006/geno.1997.4645; HAJRA A, 1995, P NATL ACAD SCI USA, V92, P1926, DOI 10.1073/pnas.92.6.1926; Hayashi Y, 2000, CANCER RES, V60, P1139; Hsu K, 2003, CANCER CELL, V4, P81, DOI 10.1016/S1535-6108(03)00192-2; Huret JL, 2001, LEUKEMIA, V15, P987, DOI 10.1038/sj.leu.2402135; Joh T, 1996, ONCOGENE, V13, P1945; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; Kawagoe H, 2001, LEUKEMIA, V15, P1743, DOI 10.1038/sj.leu.2402262; Kersey JH, 1998, LEUKEMIA, V12, P1561, DOI 10.1038/sj.leu.2401148; Kitada S, 2002, ONCOGENE, V21, P3459, DOI 10.1038/sj.onc.1205327; Kwon KB, 2002, EXP MOL MED, V34, P32, DOI 10.1038/emm.2002.5; Lanza C, 1996, GENE CHROMOSOME CANC, V15, P48, DOI 10.1002/(SICI)1098-2264(199601)15:1<48::AID-GCC7>3.0.CO;2-4; Lavau C, 2000, EMBO J, V19, P4655, DOI 10.1093/emboj/19.17.4655; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; Mahgoub N, 1998, GENE CHROMOSOME CANC, V21, P270, DOI 10.1002/(SICI)1098-2264(199803)21:3<270::AID-GCC14>3.0.CO;2-T; Martin ME, 2003, CANCER CELL, V4, P197, DOI 10.1016/S1535-6108(03)00214-9; Mayer BJ, 2001, J CELL SCI, V114, P1253; McPherson PS, 1999, CELL SIGNAL, V11, P229, DOI 10.1016/S0898-6568(98)00059-X; Mollinedo F, 1998, ANIMAL CELL CULTURE TECHNIQUES, P264; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; NAOE T, 1993, BLOOD, V82, P2260, DOI 10.1182/blood.V82.7.2260.bloodjournal8272260; Niitsu N, 2001, ONCOGENE, V20, P375, DOI 10.1038/sj.onc.1204081; Ormerod MG, 1998, LEUKEMIA, V12, P1013, DOI 10.1038/sj.leu.2401061; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; POCOCK CFE, 1995, BRIT J HAEMATOL, V90, P855, DOI 10.1111/j.1365-2141.1995.tb05207.x; Polak PE, 2003, MOL BIOL CELL, V14, P1517, DOI 10.1091/mbc.E02-07-0394; Reutens AT, 2002, INT J BIOCHEM CELL B, V34, P1173, DOI 10.1016/S1357-2725(02)00063-8; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; Ringstad N, 2001, J BIOL CHEM, V276, P40424, DOI 10.1074/jbc.M106338200; Rogaia D, 1997, CANCER RES, V57, P799; Rowley JD, 1998, ANNU REV GENET, V32, P495, DOI 10.1146/annurev.genet.32.1.495; Rubnitz JE, 1996, LEUKEMIA, V10, P74; SCHICHMAN SA, 1994, P NATL ACAD SCI USA, V91, P6236, DOI 10.1073/pnas.91.13.6236; Schreiner SA, 1999, LEUKEMIA, V13, P1525, DOI 10.1038/sj.leu.2401534; Simone F, 2001, BLOOD, V98, P201, DOI 10.1182/blood.V98.1.201; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; So CW, 1997, P NATL ACAD SCI USA, V94, P2563, DOI 10.1073/pnas.94.6.2563; So CW, 2003, CANCER CELL, V4, P99, DOI 10.1016/S1535-6108(03)00188-0; So CW, 2003, BLOOD, V101, P633, DOI 10.1182/blood-2002-06-1785; So CW, 2002, MOL CELL BIOL, V22, P6542, DOI 10.1128/MCB.22.18.6542-6552.2002; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; Trayner ID, 1998, LEUKEMIA RES, V22, P537, DOI 10.1016/S0145-2126(98)00041-1; YAM JW, 2003, BLOOD; Yano T, 1997, P NATL ACAD SCI USA, V94, P7286, DOI 10.1073/pnas.94.14.7286; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; Zeisig BB, 2003, LEUKEMIA, V17, P359, DOI 10.1038/sj.leu.2402804; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610	65	25	26	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3385	3394		10.1038/sj.onc.1207402	http://dx.doi.org/10.1038/sj.onc.1207402			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15077184				2022-12-28	WOS:000220975000013
J	Pickett, HA; Baird, DM; Hoff-Olsen, P; Meling, GI; Rognum, TO; Shaw, J; West, KP; Royle, NJ				Pickett, HA; Baird, DM; Hoff-Olsen, P; Meling, GI; Rognum, TO; Shaw, J; West, KP; Royle, NJ			Telomere instability detected in sporadic colon cancers, some showing mutations in a mismatch repair gene	ONCOGENE			English	Article						telomere; mutation; microsatellite instability; mismatch repair; colon cancer	HUMAN XP/YP TELOMERE; SMALL POOL PCR; COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; REPEAT INSTABILITY; SOMATIC MOSAICISM; HUMAN-CELLS; DNA; MAINTENANCE; CARCINOMAS	Human telomeres are essential for genome stability and are composed of long simple tandem repeat arrays (STRs), comprising the consensus TTAGGG repeat interspersed, at the proximal end, with sequence-variant repeats. While the dynamics of telomere attrition through incomplete replication has been studied extensively, the effects on telomeres of error-prone DNA repair processes, known to affect other STRs, are poorly understood. We have compared the TTAGGG and sequence-variant interspersion patterns in the proximal 720 bp of telomeres in colon cancer and normal DNA samples. The frequency of telomere mutations was 5.8% per allele in a randomly collected panel of sporadic colon cancers, showing that telomere mutations occur in vivo. The mutation frequency rose to 18.6% per allele in sporadic tumours that exhibit instability at the polyA tract in the TGFbetaRII gene and to 35% per allele in tumours with somatic mutations in the hMSH2 gene. The majority of the characterized mutations resulted in the loss of one or a few repeats. If the mutation spectrum and frequency described here is reiterated in the rest of the array, there is the potential for extensive telomere destabilization especially in mismatch repair-defective cells. This may in turn lead to a greater requirement for telomere length maintenance earlier in tumourigenesis.	Univ Leicester, Dept Genet, Leicester LE1 7RH, Leics, England; Univ Oslo, Rikshosp, Univ Hosp, Inst Forens Med, N-0027 Oslo, Norway; Univ Leicester, Dept Pathol, Leicester LE2 7LX, Leics, England	University of Leicester; University of Oslo; National Hospital Norway; University of Leicester	Royle, NJ (corresponding author), Univ Leicester, Dept Genet, Univ Rd, Leicester LE1 7RH, Leics, England.	njr@le.ac.uk	Baird, Duncan M/C-9671-2011	Baird, Duncan M/0000-0001-8408-5467; Royle, Nicola/0000-0003-1174-6329; Shaw, Jacqui/0000-0003-4227-503X				AALTONEN LA, 1994, CANCER RES, V54, P1645; AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ALLSHIRE RC, 1989, NUCLEIC ACIDS RES, V17, P4611, DOI 10.1093/nar/17.12.4611; BAIRD DM, 1995, EMBO J, V14, P5433, DOI 10.1002/j.1460-2075.1995.tb00227.x; Baird DM, 1997, HUM MOL GENET, V6, P2291, DOI 10.1093/hmg/6.13.2291; Baird DM, 2000, AM J HUM GENET, V66, P235, DOI 10.1086/302721; BORRESEN AL, 1995, HUM MOL GENET, V4, P2065, DOI 10.1093/hmg/4.11.2065; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Cheng AJ, 1998, J NATL CANCER I, V90, P316, DOI 10.1093/jnci/90.4.316; Coleman J, 1999, HUM MOL GENET, V8, P1637, DOI 10.1093/hmg/8.9.1637; Coleman MG, 2001, BRIT J CANCER, V85, P1486, DOI 10.1054/bjoc.2001.2058; Crawford DC, 2000, HUM MOL GENET, V9, P2909, DOI 10.1093/hmg/9.19.2909; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Ellegren H, 2000, NAT GENET, V24, P400, DOI 10.1038/74249; Eshleman JR, 1998, ONCOGENE, V17, P719, DOI 10.1038/sj.onc.1201986; Fortune MT, 2000, HUM MOL GENET, V9, P439, DOI 10.1093/hmg/9.3.439; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HOFFOLSEN P, 1995, HUM MUTAT, V5, P329, DOI 10.1002/humu.1380050410; JEFFREYS AJ, 1991, NATURE, V354, P204, DOI 10.1038/354204a0; Jiricny J, 2003, CURR OPIN GENET DEV, V13, P61, DOI 10.1016/S0959-437X(03)00004-2; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LOTHE RA, 1993, CANCER RES, V53, P5849; Lundblad V, 2002, ONCOGENE, V21, P522, DOI 10.1038/sj.onc.1205079; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Martorell L, 1998, HUM MOL GENET, V7, P307, DOI 10.1093/hmg/7.2.307; MONCKTON DG, 1995, HUM MOL GENET, V4, P1; PARSONS R, 1995, CANCER RES, V55, P5548; Rizki A, 2001, NATURE, V411, P713, DOI 10.1038/35079641; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Savouret C, 2003, EMBO J, V22, P2264, DOI 10.1093/emboj/cdg202; Sharma R, 2002, HUM MOL GENET, V11, P2175, DOI 10.1093/hmg/11.18.2175; Sinden RR, 2001, NATURE, V411, P757, DOI 10.1038/35081234; Takayanagi H, 2000, NTT REVIEW, V12, P17; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; van den Broek WJAA, 2002, HUM MOL GENET, V11, P191, DOI 10.1093/hmg/11.2.191; Varley H, 2002, NAT GENET, V30, P301, DOI 10.1038/ng834; Xu X, 2000, NAT GENET, V24, P396, DOI 10.1038/74238; Yamamoto H, 1999, GASTROENTEROLOGY, V116, P1348, DOI 10.1016/S0016-5085(99)70499-3	42	19	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3434	3443		10.1038/sj.onc.1207477	http://dx.doi.org/10.1038/sj.onc.1207477			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15048084				2022-12-28	WOS:000220975000018
J	Horejsi, Z; Falck, J; Bakkenist, CJ; Kastan, MB; Lukas, J; Bartek, J				Horejsi, Z; Falck, J; Bakkenist, CJ; Kastan, MB; Lukas, J; Bartek, J			Distinct functional domains of Nbs1 modulate the timing and magnitude of ATM activation after low doses of ionizing radiation	ONCOGENE			English	Article						Nbs1; ATM; DNA damage; ionizing radiation; cell cycle checkpoints	NIJMEGEN-BREAKAGE-SYNDROME; S-PHASE CHECKPOINT; TELANGIECTASIA-MUTATED ATM; DOUBLE-STRAND BREAKS; ATAXIA-TELANGIECTASIA; DNA-DAMAGE; DEPENDENT PHOSPHORYLATION; FOCUS FORMATION; MRE11 COMPLEX; IN-VIVO	The ATM kinase is a tumour suppressor and a key activator of genome integrity checkpoints in mammalian cells exposed to ionizing radiation (IR) and other insults that elicit DNA double-strand breaks (DSBs). In response to IR, autophosphorylation on serine 1981 causes dissociation of ATM dimers and initiates cellular ATM kinase activity. Here, we show that the kinetics and magnitude of ATM Ser1981 phosphorylation after exposure of human fibroblasts to low doses (2 Gy) of IR are altered in cells deficient in Nbs1, a substrate of ATM and a component of the MRN (Mre11-Rad50-Nbs1) complex involved in processing/repair of DSBs and ATM-dependent cell cycle checkpoints. Timely phosphorylation of both ATM Ser1981 and the ATM substrate Smc1 after IR were rescued via retrovirally mediated reconstitution of Nbs1-deficient cells by wild-type Nbs1 or mutants of Nbs1 defective in the FHA domain or nonphosphorylatable by ATM, but not by Nbs1 lacking the Mre11-interaction domain. Our data indicate that apart from its role downstream of ATM in the DNA damage checkpoint network, the MRN complex serves also as a modulator/amplifier of ATM activity. Although not absolutely required for ATM activation, the MRN nuclease complex may help reach the threshold activity of ATM necessary for optimal genome maintenance and prevention of cancer.	Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen, Denmark; St Jude Childrens Res Hosp, Memphis, TN 38105 USA	Danish Cancer Society; St Jude Children's Research Hospital	Bartek, J (corresponding author), Danish Canc Soc, Inst Canc Biol, Strandblvd 49, DK-2100 Copenhagen, Denmark.	bartek@biobase.dk	Bartek, Jiri/G-5870-2014	Licenikova Horejsi, Zuzana/0000-0002-9943-1649; Lukas, Jiri/0000-0001-9087-506X	NCI NIH HHS [CA 71387, CA 21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071387, P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn JY, 2000, CANCER RES, V60, P5934; Anderson L, 2001, MOL CELL BIOL, V21, P1719, DOI 10.1128/MCB.21.5.1719-1729.2001; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Buscemi G, 2001, MOL CELL BIOL, V21, P5214, DOI 10.1128/MCB.21.15.5214-5222.2001; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Cerosaletti KM, 2003, J BIOL CHEM, V278, P21944, DOI 10.1074/jbc.M211689200; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; Desai-Mehta A, 2001, MOL CELL BIOL, V21, P2184, DOI 10.1128/MCB.21.6.2184-2191.2001; Dong ZW, 1999, J BIOL CHEM, V274, P19513, DOI 10.1074/jbc.274.28.19513; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Gatei M, 2003, J BIOL CHEM, V278, P14806, DOI 10.1074/jbc.M210862200; Gatei M, 2001, J BIOL CHEM, V276, P17276, DOI 10.1074/jbc.M011681200; Girard PM, 2002, ONCOGENE, V21, P4191, DOI 10.1038/sj.onc.1205596; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Lee JH, 2003, MOL CANCER RES, V1, P674; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lou ZK, 2003, NATURE, V421, P957, DOI 10.1038/nature01447; Lukas C, 2003, NAT CELL BIOL, V5, P255, DOI 10.1038/ncb945; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Okada S, 2003, J BIOL CHEM, V278, P2015, DOI 10.1074/jbc.M208685200; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Petrini JHJ, 2000, CURR OPIN CELL BIOL, V12, P293, DOI 10.1016/S0955-0674(00)00091-0; Petrini JHJ, 2003, TRENDS CELL BIOL, V13, P458, DOI 10.1016/S0962-8924(03)00170-3; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Sorensen CS, 2000, MOL CELL BIOL, V20, P7613, DOI 10.1128/MCB.20.20.7613-7623.2000; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Thompson LH, 2002, MUTAT RES-FUND MOL M, V509, P49, DOI 10.1016/S0027-5107(02)00224-5; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; Zhao S, 2002, NUCLEIC ACIDS RES, V30, P4815, DOI 10.1093/nar/gkf612	41	99	107	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2004	23	17					3122	3127		10.1038/sj.onc.1207447	http://dx.doi.org/10.1038/sj.onc.1207447			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	812NC	15048089				2022-12-28	WOS:000220845200017
J	Gozuacik, D; Kimchi, A				Gozuacik, D; Kimchi, A			Autophagy as a cell death and tumor suppressor mechanism	ONCOGENE			English	Review						autophagy; autophagic type II cell death; apoptosis; programmed cell death; cancer; protein degradation	MITOCHONDRIAL PERMEABILITY TRANSITION; PROTEIN-ACTIVATING ENZYME; VACUOLE TARGETING PATHWAY; DAP-KINASE; SACCHAROMYCES-CEREVISIAE; CANCER-CELLS; ASCITES HEPATOMA; HT-29 CELLS; PROMOTER HYPERMETHYLATION; CONJUGATION SYSTEM	Autophagy is characterized by sequestration of bulk cytoplasm and organelles in double or multimembrane autophagic vesicles, and their delivery to and subsequent degradation by the cell's own lysosomal system. Autophagy has multiple physiological functions in multicellular organisms, including protein degradation and organelle turnover. Genes and proteins that constitute the basic machinery of the autophagic process were first identified in the yeast system and some of their mammalian orthologues have been characterized as well. Increasing lines of evidence indicate that these molecular mechanisms may be recruited by an alternative, caspase-independent form of programmed cell death, named autophagic type II cell death. In some settings, autophagy and apoptosis seem to be interconnected positively or negatively, introducing the concept of 'molecular switches' between them. Additionally, mitochondria may be central organelles integrating the two types of cell death. Malignant transformation is frequently associated with suppression of autophagy. The recent implication of tumor suppressors like Beclin 1, DAP-kinase and PTEN in autophagic pathways indicates a causative role for autophagy deficiencies in cancer formation. Autophagic cell death induction by some anticancer agents underlines the potential utility of its induction as a new cancer treatment modality.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Kimchi, A (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.	adi.kimchi@weizmann.ac.il	Devrim, Gozuacik/C-3330-2008	Devrim, Gozuacik/0000-0001-7739-2346				Abeliovich H, 2003, MOL BIOL CELL, V14, P477, DOI 10.1091/mbc.E02-07-0413; AHLBERG J, 1987, VIRCHOWS ARCH B, V53, P79, DOI 10.1007/BF02890228; Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851; Alonso ME, 2003, CANCER GENET CYTOGEN, V144, P134, DOI 10.1016/S0165-4608(02)00928-7; Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200; Bauvy C, 2001, EXP CELL RES, V268, P139, DOI 10.1006/excr.2001.5285; Blommaart EFC, 1997, HISTOCHEM J, V29, P365, DOI 10.1023/A:1026486801018; Bursch W, 2001, CELL DEATH DIFFER, V8, P569, DOI 10.1038/sj.cdd.4400852; Bursch W, 1996, CARCINOGENESIS, V17, P1595, DOI 10.1093/carcin/17.8.1595; Butler R, 2000, CELL GROWTH DIFFER, V11, P49; CANUTO RA, 1993, CARCINOGENESIS, V14, P2581, DOI 10.1093/carcin/14.12.2581; Chau YP, 2003, HISTOL HISTOPATHOL, V18, P715, DOI 10.14670/HH-18.715; Chen L, 2000, P NATL ACAD SCI USA, V97, P11557, DOI 10.1073/pnas.190133497; Chi SJ, 1999, ONCOGENE, V18, P2281, DOI 10.1038/sj.onc.1202538; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; COCKLE SM, 1984, BIOCHEM J, V221, P53, DOI 10.1042/bj2210053; Cohen O, 2001, CELL DEATH DIFFER, V8, P6, DOI 10.1038/sj.cdd.4400794; DAVID H, 1992, EXP TOXICOL PATHOL, V44, P74, DOI 10.1016/S0940-2993(11)80191-0; Desai BN, 2002, P NATL ACAD SCI USA, V99, P4319, DOI 10.1073/pnas.261702698; Elmore SP, 2001, FASEB J, V15, P2286, DOI 10.1096/fj.01-0206fje; Fernandez J, 2002, J BIOL CHEM, V277, P2050, DOI 10.1074/jbc.M109199200; Gillooly DJ, 2001, BIOCHEM J, V355, P249, DOI 10.1042/0264-6021:3550249; Gorski SM, 2003, CURR BIOL, V13, P358, DOI 10.1016/S0960-9822(03)00082-4; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; GRONOSTAJSKI RM, 1984, J CELL PHYSIOL, V119, P127, DOI 10.1002/jcp.1041190120; GUNN JM, 1977, NATURE, V266, P58, DOI 10.1038/266058a0; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARDING TM, 1995, J CELL BIOL, V131, P591, DOI 10.1083/jcb.131.3.591; HENDIL KB, 1977, J CELL PHYSIOL, V92, P353, DOI 10.1002/jcp.1040920304; HOURI JJ, 1993, BIOCHEM BIOPH RES CO, V197, P805, DOI 10.1006/bbrc.1993.2550; Huang WP, 2002, CELL STRUCT FUNCT, V27, P409, DOI 10.1247/csf.27.409; Huang WP, 2000, J BIOL CHEM, V275, P5845, DOI 10.1074/jbc.275.8.5845; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Inbal B, 2002, J CELL BIOL, V157, P455, DOI 10.1083/jcb.200109094; Inbal B, 1997, NATURE, V390, P180, DOI 10.1038/36599; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jang CW, 2002, NAT CELL BIOL, V4, P51, DOI 10.1038/ncb731; Jia L, 1997, BRIT J HAEMATOL, V98, P673, DOI 10.1046/j.1365-2141.1997.2623081.x; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kamada Y, 2000, J CELL BIOL, V150, P1507, DOI 10.1083/jcb.150.6.1507; Kanzawa T, 2003, CANCER RES, V63, P2103; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061; Kihara A, 2001, J CELL BIOL, V152, P519, DOI 10.1083/jcb.152.3.519; Kim DH, 2001, ONCOGENE, V20, P1765, DOI 10.1038/sj.onc.1204302; Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303; Kim J, 2002, J BIOL CHEM, V277, P763, DOI 10.1074/jbc.M109134200; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; KISEN GO, 1993, CARCINOGENESIS, V14, P2501, DOI 10.1093/carcin/14.12.2501; Kissil JL, 1997, ONCOGENE, V15, P403, DOI 10.1038/sj.onc.1201172; Kitanaka C, 2002, J NATL CANCER I, V94, P358; Kitanaka C, 1999, CELL DEATH DIFFER, V6, P508, DOI 10.1038/sj.cdd.4400526; Klionsky DJ, 2003, DEV CELL, V5, P539, DOI 10.1016/S1534-5807(03)00296-X; KNECHT E, 1984, EXP CELL RES, V154, P224, DOI 10.1016/0014-4827(84)90682-7; Kogel D, 2001, BIOESSAYS, V23, P352, DOI 10.1002/bies.1050; Kuma A, 2002, J BIOL CHEM, V277, P18619, DOI 10.1074/jbc.M111889200; Lee CY, 2003, CURR BIOL, V13, P350, DOI 10.1016/S0960-9822(03)00085-X; LEE HK, 1992, ARCH BIOCHEM BIOPHYS, V296, P271, DOI 10.1016/0003-9861(92)90572-E; Lehmann U, 2002, CANCER RES, V62, P6634; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Liang XH, 2001, CANCER RES, V61, P3443; LOCKWOOD TD, 1982, BIOCHEM J, V206, P251, DOI 10.1042/bj2060251; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; MANN SS, 1994, J BIOL CHEM, V269, P11492; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Mizushima N, 2003, INT J BIOCHEM CELL B, V35, P553, DOI 10.1016/S1357-2725(02)00343-6; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Mizushima N, 2003, J CELL SCI, V116, P1679, DOI 10.1242/jcs.00381; Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421; Mizushima N, 1999, EMBO J, V18, P3888, DOI 10.1093/emboj/18.14.3888; MIZUSHIMA N, 2003, MOL BIOL CELL   1229; Natarajan K, 2001, MOL CELL BIOL, V21, P4347, DOI 10.1128/MCB.21.13.4347-4368.2001; Noda T, 2002, TRENDS CELL BIOL, V12, P231, DOI 10.1016/S0962-8924(02)02278-X; Ogier-Denis E, 2000, J BIOL CHEM, V275, P39090, DOI 10.1074/jbc.M006198200; OgierDenis E, 1997, J BIOL CHEM, V272, P24599, DOI 10.1074/jbc.272.39.24599; OGIERDENIS E, 1995, J BIOL CHEM, V270, P13, DOI 10.1074/jbc.270.1.13; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; OTSUKA H, 1978, EXP CELL RES, V112, P127, DOI 10.1016/0014-4827(78)90533-5; Paglin S, 2001, CANCER RES, V61, P439; Panaretou C, 1997, J BIOL CHEM, V272, P2477; PAPADOPOULOS T, 1987, EXP CELL RES, V171, P110, DOI 10.1016/0014-4827(87)90255-2; Pattingre S, 2003, J BIOL CHEM, V278, P16667, DOI 10.1074/jbc.M210998200; Pattingre S, 2003, J BIOL CHEM, V278, P20995, DOI 10.1074/jbc.M300917200; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; PFEIFER U, 1988, VIRCHOWS ARCH B, V55, P363; Pfeifer U, 1985, Prog Clin Biol Res, V180, P659; Piacentini M, 2003, CELL DEATH DIFFER, V10, P937, DOI 10.1038/sj.cdd.4401282; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Raveh T, 2001, EXP CELL RES, V264, P185, DOI 10.1006/excr.2000.5134; Raveh T, 2001, NAT CELL BIOL, V3, P1, DOI 10.1038/35050500; Reed JC, 2002, NAT REV DRUG DISCOV, V1, P111, DOI 10.1038/nrd726; Rez G, 1999, CARCINOGENESIS, V20, P1893, DOI 10.1093/carcin/20.10.1893; Sagiv Y, 2000, EMBO J, V19, P1494, DOI 10.1093/emboj/19.7.1494; Sanchez-Cespedes M, 2000, CANCER RES, V60, P892; SCHWARZE PE, 1985, EXP CELL RES, V157, P15, DOI 10.1016/0014-4827(85)90148-X; SCHWEICHEL JU, 1973, TERATOLOGY, V7, P253, DOI 10.1002/tera.1420070306; Scott SV, 2000, J BIOL CHEM, V275, P25840, DOI 10.1074/jbc.M002813200; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; Shintani T, 1999, EMBO J, V18, P5234, DOI 10.1093/emboj/18.19.5234; Simpson DJ, 2002, ONCOGENE, V21, P1217, DOI 10.1038/sj.onc.1205195; STACK JH, 1995, J CELL BIOL, V129, P321, DOI 10.1083/jcb.129.2.321; Suzuki K, 2001, EMBO J, V20, P5971, DOI 10.1093/emboj/20.21.5971; Tada Y, 2002, CANCER RES, V62, P4048; Talloczy Z, 2002, P NATL ACAD SCI USA, V99, P190, DOI 10.1073/pnas.012485299; Tang XM, 2000, JNCI-J NATL CANCER I, V92, P1511, DOI 10.1093/jnci/92.18.1511; Tanida I, 1999, MOL BIOL CELL, V10, P1367, DOI 10.1091/mbc.10.5.1367; Tanida I, 2002, J BIOL CHEM, V277, P13739, DOI 10.1074/jbc.M200385200; Tanida I, 2001, J BIOL CHEM, V276, P1701, DOI 10.1074/jbc.C000752200; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; TESSITORE L, 1988, BIOCHEM J, V251, P483, DOI 10.1042/bj2510483; THUMM M, 1994, FEBS LETT, V349, P275, DOI 10.1016/0014-5793(94)00672-5; Toth S, 2002, CELL TISSUE RES, V309, P409, DOI 10.1007/s00441-001-0506-7; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; Tsuneoka M, 2003, CELL STRUCT FUNCT, V28, P195; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Wang WJ, 2002, J CELL BIOL, V159, P169, DOI 10.1083/jcb.200204050; Wen SH, 2001, P NATL ACAD SCI USA, V98, P4622, DOI 10.1073/pnas.081063798; Wishart MJ, 2001, CELL, V105, P817, DOI 10.1016/S0092-8674(01)00414-7; Xue L, 2001, CURR BIOL, V11, P361, DOI 10.1016/S0960-9822(01)00100-2; Xue LZ, 1999, MOL CELL NEUROSCI, V14, P180, DOI 10.1006/mcne.1999.0780; Yanagisawa H, 2003, CELL DEATH DIFFER, V10, P798, DOI 10.1038/sj.cdd.4401246; Yao KC, 2003, J NEUROSURG, V98, P378, DOI 10.3171/jns.2003.98.2.0378; YUCEL T, 1989, EXP MOL PATHOL, V50, P38, DOI 10.1016/0014-4800(89)90055-5; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100	129	1167	1273	4	157	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2004	23	16					2891	2906		10.1038/sj.onc.1207521	http://dx.doi.org/10.1038/sj.onc.1207521			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	811VO	15077152				2022-12-28	WOS:000220799600016
J	Jinnin, M; Ihn, H; Asano, Y; Yamane, K; Trojanowska, M; Tamaki, K				Jinnin, M; Ihn, H; Asano, Y; Yamane, K; Trojanowska, M; Tamaki, K			Tenascin-C upregulation by transforming growth factor-beta in human dermal broblasts involves Smad3, Sp1, and Ets1	ONCOGENE			English	Article						CREB-binding protein; P300; extracellular matrix	EXTRACELLULAR-MATRIX PROTEIN; HUMAN SKIN FIBROBLASTS; BREAST-CANCER CELLS; 2(I) COLLAGEN GENE; TGF-BETA; TRANSCRIPTIONAL ACTIVATION; INCREASED EXPRESSION; FUNCTIONAL-CHARACTERIZATION; SCLERODERMA FIBROBLASTS; IN-VITRO	In cultured human dermal fibroblasts, transforming growth factor ( TGF)-beta induced the mRNA expression of tenascin-C (TN-C). The molecular mechanism(s) underlying this process is not presently understood. In this study, we performed serial 50 deletion and a transient transfection analysis to de. ne a region in the TN-C promoter mediating the inducible responsiveness to TGF-beta. This region contains an atypical nucleotide recognition element for the Smad family of transcriptional regulators. A DNA affinity precipitation assay revealed that Smad2/ Smad3 bound to this site in a transient and specific manner. Overexpression of Smad3 or Smad4 activated the TN-C promoter activity and superinduced the TN-C promoter activity stimulated by TGF-beta. Moreover, simultaneous cotransfection of Smad3 and Smad4 activated the TN-C promoter activity in a synergistic manner. Mutation of the Smad-binding sites, the Ets-binding sites, or Sp1/3-binding sites in the TN-C promoter abrogated the TGF-beta/Smad-inducible promoter activity. Immunoprecipitation analysis revealed that Smad3, Sp1, and Ets1 form a transcriptionally active complex. Furthermore, the interaction between Smads and CBP/p300 in TGF-beta signaling was confirmed. These findings demonstrate the existence of a novel, functional binding element in the proximal region of the TN-C promoter mediating responsiveness to TGF-beta involving Smad3/4, Sp1, Ets1, and CBP/p300.	Univ Tokyo, Fac Med, Dept Dermatol, Bunkyo Ku, Tokyo 1138655, Japan; Med Univ S Carolina, Div Rheumatol & Immunol, Charleston, SC 29425 USA	University of Tokyo; Medical University of South Carolina	Ihn, H (corresponding author), Univ Tokyo, Fac Med, Dept Dermatol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	IN-DER@h.u-tokyo.ac.jp		Trojanowska, Maria/0000-0001-9550-7178				Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; BLUME SW, 1991, J CLIN INVEST, V88, P1613, DOI 10.1172/JCI115474; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; BORSI L, 1994, CELL ADHES COMMUN, V1, P307, DOI 10.3109/15419069409097262; Boyes WK, 1997, FUND APPL TOXICOL, V40, P175, DOI 10.1006/faat.1997.2388; Candia AF, 1997, DEVELOPMENT, V124, P4467; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; Chin GS, 2001, PLAST RECONSTR SURG, V108, P423, DOI 10.1097/00006534-200108000-00022; CHIQUET M, 1994, PERSPECT DEV NEUROBI, V2, P67; CHIQUETEHRISMANN R, 1995, EXPERIENTIA, V51, P853, DOI 10.1007/BF01921736; CHIQUETEHRISMANN R, 1989, CANCER RES, V49, P4322; Crossin KL, 1996, J CELL BIOCHEM, V61, P592; Czuwara-Ladykowska J, 2002, J BIOL CHEM, V277, P20399, DOI 10.1074/jbc.M200206200; Dandachi N, 2001, J PATHOL, V193, P181, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH752>3.0.CO;2-V; de Caestecker MP, 2000, J BIOL CHEM, V275, P2115, DOI 10.1074/jbc.275.3.2115; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dittmer J, 1997, J BIOL CHEM, V272, P4953, DOI 10.1074/jbc.272.8.4953; EKBLOM P, 1989, International Journal of Developmental Biology, V33, P71; Erickson HP, 1993, CURR OPIN CELL BIOL, V5, P869, DOI 10.1016/0955-0674(93)90037-Q; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; GHERZI R, 1995, J BIOL CHEM, V270, P3429, DOI 10.1074/jbc.270.7.3429; Ghosh AK, 2000, ONCOGENE, V19, P3546, DOI 10.1038/sj.onc.1203693; Gore-Hyer E, 2002, AM J PHYSIOL-RENAL, V283, pF707, DOI 10.1152/ajprenal.00007.2002; GULCHER JR, 1989, P NATL ACAD SCI USA, V86, P1588, DOI 10.1073/pnas.86.5.1588; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Holmes A, 2001, J BIOL CHEM, V276, P10594, DOI 10.1074/jbc.M010149200; Ihn H, 1996, J BIOL CHEM, V271, P26717, DOI 10.1074/jbc.271.43.26717; Ihn H, 1997, J BIOL CHEM, V272, P24666, DOI 10.1074/jbc.272.39.24666; Ihn H, 2002, J IMMUNOL, V168, P1895, DOI 10.4049/jimmunol.168.4.1895; Ihn H, 2001, ARTHRITIS RHEUM, V44, P474, DOI 10.1002/1529-0131(200102)44:2<474::AID-ANR67>3.3.CO;2-R; Ihn H, 2002, CURR OPIN RHEUMATOL, V14, P681, DOI 10.1097/00002281-200211000-00009; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Jang CW, 2002, NAT CELL BIOL, V4, P51, DOI 10.1038/ncb731; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kawakami T, 1998, J INVEST DERMATOL, V110, P47, DOI 10.1046/j.1523-1747.1998.00073.x; Kucich U, 2002, AM J RESP CELL MOL, V26, P183, DOI 10.1165/ajrcmb.26.2.4666; LACOUR JP, 1992, BRIT J DERMATOL, V127, P328, DOI 10.1111/j.1365-2133.1992.tb00450.x; Lai CF, 2000, J BIOL CHEM, V275, P36400, DOI 10.1074/jbc.M002131200; LEROY EC, 1992, ANN RHEUM DIS, V51, P286, DOI 10.1136/ard.51.2.286; Lindemann RK, 2001, J BIOL CHEM, V276, P46661, DOI 10.1074/jbc.M105816200; Lopez-Rovira T, 2000, J BIOL CHEM, V275, P28937, DOI 10.1074/jbc.M909923199; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Mackie EJ, 1997, INT J BIOCHEM CELL B, V29, P1133, DOI 10.1016/S1357-2725(97)00031-9; Makhluf HA, 1996, J INVEST DERMATOL, V107, P856, DOI 10.1111/1523-1747.ep12331160; MCCACHREN SS, 1992, ARTHRITIS RHEUM, V35, P1185, DOI 10.1002/art.1780351011; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; NATALI PG, 1991, INT J CANCER, V47, P811, DOI 10.1002/ijc.2910470603; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; Poncelet AC, 2001, J BIOL CHEM, V276, P6983, DOI 10.1074/jbc.M006442200; RETTIG WJ, 1989, J HISTOCHEM CYTOCHEM, V37, P1777, DOI 10.1177/37.12.2685108; RETTIG WJ, 1994, J CELL SCI, V107, P487; RODNAN GP, 1979, ARTHRITIS RHEUM, V22, P130, DOI 10.1002/art.1780220205; SHARIFI BG, 1992, J BIOL CHEM, V267, P23910; Shirasaki F, 1999, ONCOGENE, V18, P7755, DOI 10.1038/sj.onc.1203360; Stroschein SL, 1999, J BIOL CHEM, V274, P9431, DOI 10.1074/jbc.274.14.9431; Taylor LM, 2000, J BIOL CHEM, V275, P16709, DOI 10.1074/jbc.275.22.16709; TUCKER RP, 1993, J CELL SCI, V104, P69; Varga J, 2002, ARTHRITIS RHEUM-US, V46, P1703, DOI 10.1002/art.10413; Verrecchia F, 2001, J BIOL CHEM, V276, P17058, DOI 10.1074/jbc.M100754200; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; von Gersdorff G, 2000, J BIOL CHEM, V275, P11320, DOI 10.1074/jbc.275.15.11320; Wong C, 1999, MOL CELL BIOL, V19, P1821; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Xiao Z, 2000, P NATL ACAD SCI USA, V97, P7853, DOI 10.1073/pnas.97.14.7853; Yagi K, 2002, J BIOL CHEM, V277, P854, DOI 10.1074/jbc.M104170200; You LT, 2002, INVEST OPHTH VIS SCI, V43, P72; Yuan WH, 2001, J BIOL CHEM, V276, P38502, DOI 10.1074/jbc.M107081200	71	99	102	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2004	23	9					1656	1667		10.1038/sj.onc.1207064	http://dx.doi.org/10.1038/sj.onc.1207064			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	800LH	15001984				2022-12-28	WOS:000220029300002
J	Park, SS; Eom, YW; Kim, EH; Lee, JH; Min, DS; Kim, S; Kim, SJ; Choi, KS				Park, SS; Eom, YW; Kim, EH; Lee, JH; Min, DS; Kim, S; Kim, SJ; Choi, KS			Involvement of c-Src kinase in the regulation of TGF-beta 1-induced apoptosis	ONCOGENE			English	Article						TGF-beta 1; apoptosis; c-Src; hepatocellular carcinoma; caspases	FOCAL ADHESION KINASE; GROWTH-FACTOR-BETA; HUMAN HEPATOCELLULAR-CARCINOMA; FAO HEPATOMA-CELLS; TGF-BETA; TYROSINE KINASES; BINDING-SITE; II RECEPTOR; ACTIVATION; SMAD2	Transforming growth factor-beta1 (TGF-beta1) is a potent inducer of apoptosis in normal hepatocytes, and acquiring resistance to TGF-beta1 may be a critical step in the development of hepatocellular carcinoma (HCC). In this study, we investigated the possible involvement of c-Src in the regulation of TGF-beta1-induced apoptosis. TGF-beta1 induced transient activation of c-Src and its subsequent caspase-mediated degradation concomitant with cell death in FaO hepatoma cells, which are sensitive to TGF-beta1. In response to TGF-beta1, activated c-Src was translocated into the cytoplasmic membrane, then relocated to the nuclei of apoptotic cells during its cleavage. In TGF-beta1-induced apoptotic cells, c-Src maintained its tight association with p85 FAK fragment cleaved by caspases, possibly contributing to focal adhesion disassembly. TGF-beta1-induced apoptosis was enhanced by either inhibition of c-Src activity using PP1 or PP2, or by overexpression of dominant-negative c-Src. In contrast, overexpression of constitutively active c-Src inhibited apoptosis suppressing TGF-beta1-induced activation of p38, JNK and caspases. In many HCC cell lines resistant to TGF-beta1, enhanced c-Src activity was detected. We hypothesize that activated c-Src in HCC may contribute to resistance against the apoptotic and/or antiproliferative properties of TGF-beta1.	Ajou Univ, Sch Med, Inst Med Sci, Suwon 442749, South Korea; Catholic Univ Korea, Coll Med, Dept Physiol, Seoul, South Korea; LG Life Sci, Taejon, South Korea; NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA	Ajou University; Catholic University of Korea; LG Life Sciences Ltd; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Choi, KS (corresponding author), Ajou Univ, Sch Med, Inst Med Sci, 5 Wonchon Dong, Suwon 442749, South Korea.	kschoi@ajou.ac.kr	Eom, Young/AAW-4659-2021; Kim, Eunhee/AAK-3650-2020; Kim, Eunhee/Q-9162-2016	Kim, Eunhee/0000-0001-7143-7769; Eom, Young Woo/0000-0002-5985-6490; Choi, Kyeong Sook/0000-0003-2331-0856	NATIONAL CANCER INSTITUTE [Z01BC005617] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abou-Shady M, 1999, AM J SURG, V177, P209, DOI 10.1016/S0002-9610(99)00012-4; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Choi KS, 1998, HEPATOLOGY, V27, P415, DOI 10.1002/hep.510270215; Choi KS, 1999, J BIOL CHEM, V274, P31775, DOI 10.1074/jbc.274.45.31775; Crouch DH, 1996, ONCOGENE, V12, P2689; DECAESTECKER MP, 2000, J NATL CANCER I, V92, P555; Furuta K, 1999, INT J CANCER, V81, P851, DOI 10.1002/(SICI)1097-0215(19990611)81:6<851::AID-IJC2>3.0.CO;2-D; Gervais FG, 1998, J BIOL CHEM, V273, P17102, DOI 10.1074/jbc.273.27.17102; Ijichi H, 2001, BIOCHEM BIOPH RES CO, V289, P350, DOI 10.1006/bbrc.2001.5988; ITO N, 1991, CANCER RES, V51, P4080; Ito Y, 2001, J HEPATOL, V35, P68, DOI 10.1016/S0168-8278(01)00077-0; Jones RJ, 2000, EUR J CANCER, V36, P1595, DOI 10.1016/S0959-8049(00)00153-2; Jong HS, 2002, BIOCHEM BIOPH RES CO, V292, P383, DOI 10.1006/bbrc.2002.6666; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; Kanamaru C, 2002, HEPATOL RES, V23, P211, DOI 10.1016/S1386-6346(01)00175-9; Kawate S, 1999, INT J ONCOL, V14, P127; Kim BC, 2002, MOL CELL BIOL, V22, P1369, DOI 10.1128/MCB.22.5.1369-1378.2002; Kim SG, 2004, MOL BIOL CELL, V15, P420, DOI 10.1091/mbc.E03-04-0201; Lee JH, 1999, WORLD J GASTROENTERO, V5, P289; Lobo M, 2000, BIOCHEM BIOPH RES CO, V276, P1068, DOI 10.1006/bbrc.2000.3547; Masaki T, 1999, HEPATOLOGY, V29, P379, DOI 10.1002/hep.510290239; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Park HJ, 2002, HEPATOLOGY, V35, P1360, DOI 10.1053/jhep.2002.33205; PARK JG, 1995, INT J CANCER, V62, P276, DOI 10.1002/ijc.2910620308; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schaller MD, 2001, ONCOGENE, V20, P6459, DOI 10.1038/sj.onc.1204786; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; Song K, 2003, J BIOL CHEM, V278, P38342, DOI 10.1074/jbc.M304583200; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; Wildey GM, 2003, J BIOL CHEM, V278, P18069, DOI 10.1074/jbc.M211958200; Wilkes MC, 2003, MOL CELL BIOL, V23, P8878, DOI 10.1128/MCB.23.23.8878-8889.2003; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Yakicier MC, 1999, ONCOGENE, V18, P4879, DOI 10.1038/sj.onc.1202866	36	57	60	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2004	23	37					6272	6281		10.1038/sj.onc.1207856	http://dx.doi.org/10.1038/sj.onc.1207856			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	847NC	15208664				2022-12-28	WOS:000223399000011
J	Maillart, E; Brengel-Pesce, K; Capela, D; Roget, A; Livache, T; Canva, M; Levy, Y; Soussi, T				Maillart, E; Brengel-Pesce, K; Capela, D; Roget, A; Livache, T; Canva, M; Levy, Y; Soussi, T			Versatile analysis of multiple macromolecular interactions by SPR imaging: application to p53 and DNA interaction	ONCOGENE			English	Article						p53 tumor suppressor gene; DNA binding; SPR imaging; EMSA; polypyrrole	TRANSCRIPTION FACTOR; MUTANT P53; LABEL-FREE; BINDING; PROTEIN; CANCER; GENES; APOPTOSIS; MUTATIONS; SEQUENCE	The greatest challenge in the postgenomic era is the description of proteome interactions, such as protein-protein or protein-DNA interactions. Surface plasmon resonance (SPR) is an optical technique in which binding of an analyte to the surface changes the refractive index at the surface/solution interface. Molecular interactions are analysed in real time without a labeling step. Currently, the limit to SPR imaging is the small number of reactions that can be simultaneously analysed. Using a novel grafting technology and a new imaging system, we increased the throughput of SPR imaging. The interaction between p53 and DNA was chosen as a paradigm for validation of this assay. Using a tagged DNA methodology, we simultaneously targeted multiple DNA sequences on a single chip. The interaction between p53 and these DNA sequences was monitored by SPR imaging. Qualitative and quantitative analysis provides results similar to those obtained with conventional technologies.	UPMC IC, Hop Tenon, Lab Genotoxicol Tumeurs, EA 3493, F-75019 Paris, France; Univ Paris 11, Lab Charles Fabry, Inst Opt, CNRS,UMR 8501, F-91403 Orsay, France; Dept Rech Fondamentale Mat Condensee, CREAB, UMR 5819, CEA,CNRS,UJF, F-38054 Grenoble, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA	Soussi, T (corresponding author), UPMC IC, Hop Tenon, Lab Genotoxicol Tumeurs, EA 3493, 4 Rue Chine, F-75019 Paris, France.	thierry.soussi@tnn.ap-hop-paris.fr	Canva, Michael TG/D-4014-2009	Canva, Michael TG/0000-0001-5286-2380; soussi, thierry/0000-0001-8184-3293				BALAGURUMOORTHY P, 1995, P NATL ACAD SCI USA, V92, P8591, DOI 10.1073/pnas.92.19.8591; Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; Deppert W, 2000, J CELL BIOCHEM, P115; Dong SM, 2001, J NATL CANCER I, V93, P858, DOI 10.1093/jnci/93.11.858; Drewes G, 2003, CURR OPIN CELL BIOL, V15, P199, DOI 10.1016/S0955-0674(03)00005-X; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Favis R, 2000, NAT BIOTECHNOL, V18, P561, DOI 10.1038/75452; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; Gerry NP, 1999, J MOL BIOL, V292, P251, DOI 10.1006/jmbi.1999.3063; Guedon P, 2000, ANAL CHEM, V72, P6003, DOI 10.1021/ac000122+; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Hansen S, 1996, J BIOL CHEM, V271, P3917; Inga A, 2002, MOL CELL BIOL, V22, P8612, DOI 10.1128/MCB.22.24.8612-8625.2002; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Kato S, 2003, P NATL ACAD SCI USA, V100, P8424, DOI 10.1073/pnas.1431692100; Kim E, 2003, BIOCHEM CELL BIOL, V81, P141, DOI 10.1139/o03-046; Livache T, 2003, J PHARMACEUT BIOMED, V32, P687, DOI 10.1016/S0731-7085(03)00176-6; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Muller BF, 1996, ONCOGENE, V12, P1941; Qian H, 2002, ONCOGENE, V21, P7901, DOI 10.1038/sj.onc.1205974; Resnick MA, 2003, P NATL ACAD SCI USA, V100, P9934, DOI 10.1073/pnas.1633803100; Rich RL, 2000, CURR OPIN BIOTECH, V11, P54, DOI 10.1016/S0958-1669(99)00054-3; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Soussi T, 2003, HUM MUTAT, V21, P192, DOI 10.1002/humu.10189; Soussi T, 2001, NAT REV CANCER, V1, P233, DOI 10.1038/35106009; TOKINO T, 1994, HUM MOL GENET, V3, P1357; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Walhout AJM, 2001, NAT REV MOL CELL BIO, V2, P55, DOI 10.1038/35048107	32	41	42	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2004	23	32					5543	5550		10.1038/sj.onc.1207639	http://dx.doi.org/10.1038/sj.onc.1207639			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15184889				2022-12-28	WOS:000222588400014
J	Spierings, DCJ; de Vries, EGE; Stel, AJ; Rietstap, NT; Vellenga, E; de Jong, S				Spierings, DCJ; de Vries, EGE; Stel, AJ; Rietstap, NT; Vellenga, E; de Jong, S			Low p21(Waf1/Cip1) protein level sensitizes testicular germ cell tumor cells to Fas-mediated apoptosis	ONCOGENE			English	Article						TGCT; p21; Fas; cisplatin; irradiation	BCL-X-L; CISPLATIN-INDUCED APOPTOSIS; 3/P21 COMPLEX-FORMATION; WILD-TYPE P53; GAMMA-IRRADIATION; DNA-DAMAGE; C-ABL; TRANSCRIPTION FACTOR; RNA INTERFERENCE; SUPPRESSOR GENE	In the present study, we investigated the relation between p21 expression and the sensitivity of testicular germ cell tumor (TGCT) cells to apoptotic stimuli. Despite similar cisplatin-induced wild-type p53 accumulation, the TGCT cell lines Tera and Scha expressed low p21 protein and mRNA levels in comparison to A2780 ovarian cancer cells. Inhibition of the proteasome complex with MG-132 increased p21 protein levels in TGCT cells but much more in A2780 cells, whereas cisplatin had no additional effect on p21 protein levels. Inhibition of caspase-3 activity in TGCT cells with the broad-spectrum caspase inhibitor zVAD-fmk had no effect on p21 levels and also not upon cisplatin treatment. A similar induction of p53 irradiation, in contrast to cisplatin, substantially increased both p21 mRNA and protein expression in Tera cells. Cisplatin-treated Tera cells expressing low p21 protein levels were Fas-sensitive, while irradiation-induced p21, which was mainly localized in the cytosol, rendered irradiated Tera cells resistant to Fas-induced apoptosis. Sensitivity of irradiated Tera cells to Fas-induced apoptosis was restored by short interfering RNA-specific suppression of p21 expression. These results strongly indicate that the low p21 protein levels are caused by reduced p21 gene transcription and sensitize cisplatin-treated TGCT cells to the Fas death pathway.	Univ Groningen Hosp, Dept Med Oncol, NL-9713 GZ Groningen, Netherlands; Univ Groningen Hosp, Dept Hematol, NL-9713 GZ Groningen, Netherlands	University of Groningen; University of Groningen	de Jong, S (corresponding author), Univ Groningen Hosp, Dept Med Oncol, NL-9713 GZ Groningen, Netherlands.	s.de.jong@int.azg.nl		Spierings, Diana/0000-0001-8403-474X; de Vries, Elisabeth/0000-0002-8949-7425				Agami R, 1999, NATURE, V399, P809; Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Arriola EL, 1999, ONCOGENE, V18, P1457, DOI 10.1038/sj.onc.1202420; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Bartkova J, 2000, INT J CANCER, V85, P370, DOI 10.1002/(SICI)1097-0215(20000201)85:3<370::AID-IJC13>3.0.CO;2-A; Burger H, 1999, INT J CANCER, V81, P620, DOI 10.1002/(SICI)1097-0215(19990517)81:4<620::AID-IJC19>3.3.CO;2-J; Burger H, 1997, INT J CANCER, V73, P592, DOI 10.1002/(SICI)1097-0215(19971114)73:4<592::AID-IJC22>3.0.CO;2-A; Burger H, 1998, BRIT J CANCER, V77, P1562, DOI 10.1038/bjc.1998.257; Burger H, 1998, INT J RADIAT ONCOL, V41, P415, DOI 10.1016/S0360-3016(98)00065-0; Butz K, 1998, ONCOGENE, V17, P781, DOI 10.1038/sj.onc.1201995; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Charette SJ, 2000, MOL CELL BIOL, V20, P7602, DOI 10.1128/MCB.20.20.7602-7612.2000; Chresta CM, 1996, CANCER RES, V56, P1834; Cram EJ, 1998, J BIOL CHEM, V273, P2008, DOI 10.1074/jbc.273.4.2008; Datta MW, 2001, MODERN PATHOL, V14, P437, DOI 10.1038/modpathol.3880331; DEJONG S, 1993, INT J CANCER, V53, P110, DOI 10.1002/ijc.2910530121; DEJONG S, 1999, P AM ASSOC CANC RES, V40, P4588; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Deverman BE, 2002, CELL, V111, P51, DOI 10.1016/S0092-8674(02)00972-8; Dijkhuizen T, 1996, INT J CANCER, V68, P47, DOI 10.1002/(SICI)1097-0215(19960927)68:1<47::AID-IJC9>3.0.CO;2-X; Einhorn LH, 2002, P NATL ACAD SCI USA, V99, P4592, DOI 10.1073/pnas.072067999; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fillippovich I, 2001, ONCOGENE, V20, P514, DOI 10.1038/sj.onc.1204118; Fulda S, 1998, CELL DEATH DIFFER, V5, P884, DOI 10.1038/sj.cdd.4400419; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; Glaser T, 2001, ONCOGENE, V20, P4757, DOI 10.1038/sj.onc.1204498; Gong JG, 1999, NATURE, V399, P806; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Guillou L, 1996, AM J PATHOL, V149, P1221; Hara S, 2001, UROLOGY, V58, P471, DOI 10.1016/S0090-4295(01)01172-4; Hiyama H, 1998, ONCOGENE, V16, P1513, DOI 10.1038/sj.onc.1201667; Houldsworth J, 1998, ONCOGENE, V16, P2345, DOI 10.1038/sj.onc.1201770; HUDDART RA, 1995, EUR J CANCER, V31A, P739, DOI 10.1016/0959-8049(95)00047-M; Johnstone RW, 2002, MOL CELL, V10, P695, DOI 10.1016/S1097-2765(02)00693-7; Kersemaekers AMF, 2002, J PATHOL, V196, P423, DOI 10.1002/path.1058; Kersemaekers AMF, 2002, J CLIN ONCOL, V20, P1551, DOI 10.1200/JCO.20.6.1551; Kimura K, 2000, J BIOL CHEM, V275, P8610, DOI 10.1074/jbc.275.12.8610; Ko YG, 2001, J BIOL CHEM, V276, P39103, DOI 10.1074/jbc.M105928200; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Levrero M, 2000, J CELL SCI, V113, P1661; Lundberg AS, 1999, EUR J CANCER, V35, P1886, DOI 10.1016/S0959-8049(99)00292-0; Lutzker SG, 1998, APMIS, V106, P85, DOI 10.1111/j.1699-0463.1998.tb01323.x; Lutzker SG, 2001, ONCOGENE, V20, P2982, DOI 10.1038/sj.onc.1204394; Malashicheva AB, 2000, ONCOGENE, V19, P3858, DOI 10.1038/sj.onc.1203736; MASTERS JRW, 1993, INT J CANCER, V53, P340, DOI 10.1002/ijc.2910530228; MICHIELI P, 1994, CANCER RES, V54, P3391; Naujokat C, 2002, LAB INVEST, V82, P965, DOI 10.1097/01.LAB.0000022226.23741.37; Ogawa Y, 1998, INT J MOL MED, V2, P435; Prives C, 1999, J PATHOL, V187, P112; RIOU G, 1995, MOL CARCINOGEN, V12, P124, DOI 10.1002/mc.2940120303; SARK MWJ, 1995, BRIT J CANCER, V71, P684, DOI 10.1038/bjc.1995.135; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Schepers H, 2003, LEUKEMIA, V17, P2113, DOI 10.1038/sj.leu.2403106; Sheard MA, 1999, BRIT J CANCER, V80, P1689, DOI 10.1038/sj.bjc.6690585; Shen Y, 2001, ADV CANCER RES, V82, P55, DOI 10.1016/S0065-230X(01)82002-9; Skilling JS, 1996, GYNECOL ONCOL, V60, P72, DOI 10.1006/gyno.1996.0014; Snowden AW, 2000, MOL CELL BIOL, V20, P2676, DOI 10.1128/MCB.20.8.2676-2686.2000; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Spierings DCJ, 2003, CELL DEATH DIFFER, V10, P808, DOI 10.1038/sj.cdd.4401248; Spierings DCJ, 2003, J PATHOL, V200, P137, DOI 10.1002/path.1373; Stiewe T, 2002, J BIOL CHEM, V277, P14177, DOI 10.1074/jbc.M200480200; Sugihara A, 1997, ANTICANCER RES, V17, P3861; Suzuki A, 2000, CELL DEATH DIFFER, V7, P721, DOI 10.1038/sj.cdd.4400706; Suzuki A, 1999, MOL CELL BIOL, V19, P3842; Suzuki A, 2000, ONCOGENE, V19, P1346, DOI 10.1038/sj.onc.1203429; Tsai KKC, 2003, CANCER RES, V63, P3418; Vikhanskaya F, 2000, NUCLEIC ACIDS RES, V28, P513, DOI 10.1093/nar/28.2.513; Xiang H, 2002, ONCOGENE, V21, P3611, DOI 10.1038/sj.onc.1205449; Xu SQ, 2000, BIOCHEM BIOPH RES CO, V269, P179, DOI 10.1006/bbrc.2000.2247; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhang YK, 1999, ONCOGENE, V18, P1131, DOI 10.1038/sj.onc.1202426	78	35	37	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2004	23	28					4862	4872		10.1038/sj.onc.1207617	http://dx.doi.org/10.1038/sj.onc.1207617			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	830EK	15122333				2022-12-28	WOS:000222104200007
J	Lee, JH; Park, SJ; Abraham, SC; Seo, JS; Nam, JH; Choi, C; Juhng, SW; Rashid, A; Hamilton, SR; Wu, TT				Lee, JH; Park, SJ; Abraham, SC; Seo, JS; Nam, JH; Choi, C; Juhng, SW; Rashid, A; Hamilton, SR; Wu, TT			Frequent CpG island methylation in precursor lesions and early gastric adenocarcinomas	ONCOGENE			English	Article						gastric neoplasms; precursor lesions; CpG island methylation	HMLH1 GENE PROMOTER; DNA HYPERMETHYLATION; APC GENE; CLINICOPATHOLOGICAL FEATURES; MICROSATELLITE INSTABILITY; MALIGNANT TRANSFORMATION; ABERRANT METHYLATION; SOMATIC MUTATIONS; MULTIPLE GENES; E-CADHERIN	Gastric carcinogenesis involves multiple genetic and epigenetic alterations. Epigenetic silencing of tumor-related genes due to CpG island methylation (CIM) has been recently reported in gastric cancer, but the role in precursor lesions is not well understood. We analysed the methylation status of the tumor suppressor gene p16, the DNA mismatch repair gene hMLH1, and four CpG islands (MINT1, MINT2, MINT25, and MINT31) using methylation-specific polymerase chain reaction in 35 polypoid adenomas and 46 flat dysplasias unassociated with carcinoma, 34 early adenocarcinomas (T1N0M0) and associated adenomas/dysplasias, and corresponding adjacent non-neoplastic mucosa. The extent of CIM was defined by the fraction of methylated loci (methylation index), and compared with previously characterized genetic alterations (microsatellite instability (MSI) and APC gene mutation). We found that methylation of p16 was more frequent in adenocarcinoma-associated dysplasias/adenomas (29%) and adenocarcinomas (44%) as compared to flat dysplasias (4%) and adenomas (18%) unassociated with adenocarcinorna (P = 0.001). The mean methylation index increased from normal/chronic gastritis (CG) mucosa (0.09) to intestinal metaplasia (IM) (0.16), flat dysplasias (0.40) or polypoid adenomas (0.41) unassociated with carcinoma, dysplasias/adenomas associated with carcinoma (0.44), and adenocarcinomas (0.44). There was no difference in frequencies of high-level CpG island methylation (CIM-H, methylation index greater than or equal to0.5) among flat dysplasias (50%) and polypoid adenomas (51%) unassociated with carcinoma, dysplasias/adenomas associated with adenocarcinoma (47%), and adenocarcinoma (47%). CIM-H was present in 15% of IM, but not in normal/CG mucosa. There was a significant correlation between methylation of hMLH1 and high-level of microsatellite instability (MSI-H): methylation of hMLH1 was present in 71% of MSI-H tumors, but only 8% of MSI-low tumors and 13% of microsatellite-stable tumors (P=0.0001). There was no statistical difference between methylation index and APC mutation. Our results indicate that concurrent promoter methylation is an early and frequent event in gastric tumorigenesis, including both MSI-H and microsatellite-stable neoplasms. Methylation of the p16 gene may contribute to the malignant transformation of gastric precursor lesions.	Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA; Chonnam Natl Univ, Sch Med, Kwangju 501190, South Korea	University of Texas System; UTMD Anderson Cancer Center; Mayo Clinic; Chonnam National University	Wu, TT (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Pathol, G1-3595C,Box 85,1515 Holcombe Blvd, Houston, TX 77030 USA.	twu@mdanderson.org	Seo, Jeong-Sun/J-2763-2012					Akiyama Y, 1996, JPN J CANCER RES, V87, P595, DOI 10.1111/j.1349-7006.1996.tb00265.x; BANKFALVI A, 1994, J PATHOL, V174, P223, DOI 10.1002/path.1711740312; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; BECKER KF, 1994, CANCER RES, V54, P3845; CORREA P, 1994, CANCER RES, V54, pS1941; CORREA P, 1992, CANCER RES, V52, P6735; Eads CA, 2001, CANCER RES, V61, P3410; Eads CA, 2000, CANCER RES, V60, P5021; Endoh Y, 2000, AM J PATHOL, V157, P717, DOI 10.1016/S0002-9440(10)64584-1; Fleisher AS, 1999, CANCER RES, V59, P1090; Fleisher AS, 2001, ONCOGENE, V20, P329, DOI 10.1038/sj.onc.1204104; Fujimoto J, 2000, CANCER LETT, V149, P125, DOI 10.1016/S0304-3835(99)00349-3; Gunther T, 1998, PATHOL RES PRACT, V194, P809, DOI 10.1016/S0344-0338(98)80082-4; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; IIDA S, 2002, INT J CANCER, V87, P654; Jang TJ, 2001, INT J CANCER, V93, P629, DOI 10.1002/ijc.1394; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; KAMIYA T, 1982, CANCER, V50, P2496, DOI 10.1002/1097-0142(19821201)50:11<2496::AID-CNCR2820501140>3.0.CO;2-1; Kanai Y, 1998, CANCER LETT, V122, P135, DOI 10.1016/S0304-3835(97)00380-7; Kang GH, 2003, LAB INVEST, V83, P519, DOI 10.1097/01.LAB.0000064704.53132.65; Kang GH, 2001, CANCER RES, V61, P2847; Kang YH, 2002, LAB INVEST, V82, P285, DOI 10.1038/labinvest.3780422; KIHANA T, 1991, JPN J CANCER RES, V82, P308, DOI 10.1111/j.1349-7006.1991.tb01847.x; KOLODZIEJCZYK P, 1994, CANCER-AM CANCER SOC, V74, P2896, DOI 10.1002/1097-0142(19941201)74:11<2896::AID-CNCR2820741103>3.0.CO;2-P; Kwong J, 2002, CLIN CANCER RES, V8, P131; Lee JH, 2002, AM J PATHOL, V161, P611, DOI 10.1016/S0002-9440(10)64216-2; Lee S, 2002, AM J PATHOL, V161, P1015, DOI 10.1016/S0002-9440(10)64262-9; Leung WK, 2001, CANCER-AM CANCER SOC, V91, P2294; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; MAESAWA C, 1995, J PATHOL, V176, P249, DOI 10.1002/path.1711760307; Maruyama R, 2001, CANCER RES, V61, P8659; Maruyama R, 2002, CLIN CANCER RES, V8, P514; Momparler RL, 2000, J CELL PHYSIOL, V183, P145, DOI 10.1002/(SICI)1097-4652(200005)183:2<145::AID-JCP1>3.0.CO;2-V; Moskaluk CA, 1997, AM J PATHOL, V150, P1547; NAKATSURU S, 1993, HUM MOL GENET, V2, P1463, DOI 10.1093/hmg/2.9.1463; ORLOWSKA J, 1995, AM J GASTROENTEROL, V90, P2152; Panning B, 1998, CELL, V93, P305, DOI 10.1016/S0092-8674(00)81155-1; Park WS, 1999, CANCER RES, V59, P4257; RHYU MG, 1994, GASTROENTEROLOGY, V106, P1584, DOI 10.1016/0016-5085(94)90414-6; Stadtlander CTKH, 1999, CARCINOGENESIS, V20, P2195, DOI 10.1093/carcin/20.12.2195; TAMURA G, 1994, CANCER RES, V54, P1149; Toyota M, 2000, ELECTROPHORESIS, V21, P329, DOI 10.1002/(SICI)1522-2683(20000101)21:2<329::AID-ELPS329>3.0.CO;2-9; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Toyota M, 1999, CANCER RES, V59, P5438; Tsuchiya T, 2000, ONCOGENE, V19, P3642, DOI 10.1038/sj.onc.1203704; Ueki T, 2001, CANCER RES, V61, P8540; Virmani AK, 2001, CLIN CANCER RES, V7, P584; Wajed SA, 2001, ANN SURG, V234, P10, DOI 10.1097/00000658-200107000-00003; Waki T, 2002, AM J PATHOL, V161, P399, DOI 10.1016/S0002-9440(10)64195-8	49	96	105	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2004	23	26					4646	4654		10.1038/sj.onc.1207588	http://dx.doi.org/10.1038/sj.onc.1207588			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZV	15064707				2022-12-28	WOS:000221799000015
J	Soejima, H; Nakagawachi, T; Zhao, W; Higashimoto, K; Urano, T; Matsukura, S; Kitajima, Y; Takeuchi, M; Nakayama, M; Oshimura, M; Miyazaki, K; Joh, K; Mukai, T				Soejima, H; Nakagawachi, T; Zhao, W; Higashimoto, K; Urano, T; Matsukura, S; Kitajima, Y; Takeuchi, M; Nakayama, M; Oshimura, M; Miyazaki, K; Joh, K; Mukai, T			Silencing of imprinted CDKN1C gene expression is associated with loss of CpG and histone H3 lysine 9 methylation at DMR-LIT1 in esophageal cancer	ONCOGENE			English	Article						imprinting control region; differentially methylated region; CDKN1C; CpG methylation; histone H3 lysine 9 methylation	BECKWITH-WIEDEMANN-SYNDROME; DEPENDENT KINASE INHIBITOR; SQUAMOUS-CELL CARCINOMA; DNA METHYLATION; CHROMOSOME 11P15.5; REDUCED EXPRESSION; HUMAN P57(KIP2); GASTRIC-CANCER; CONTROL REGION; WILMS-TUMORS	The putative tumor suppressor CDKN1C is an imprinted gene at 11p15.5, a well-known imprinted region often deleted in tumors. The absence of somatic mutations and the frequent diminished expression in tumors would suggest that CDKN1C expression is regulated epigenetically. It has been, however, controversial whether the diminution is caused by imprinting disruption of the CDKN1C/LIT1 domain or by promoter hypermethylation of CDKN1C itself. To clarify this, we investigated the CpG methylation index of the CDKN1C promoter and the differentially methylated region of the LIT1 CpG island (differentially methylated region (DMR)-LIT1), an imprinting control region of the domain, and CDKN1C expression in esophageal cancer cell lines. CDKN1C expression was diminished in 10 of 17 lines and statistically correlated with the loss of methylation at DMR-LIT1 in all but three. However, there was no statistical correlation between CDKN1C promoter MI and CDKN1C expression. Furthermore, loss of CpG methylation was associated with loss of histone H3 lysine 9 (H3K9) methylation at DMR-LIT1. Histone modi. cations at CDKN1C promoter were not correlated with CDKN1C expression. The data suggested that the diminished CDKN1C expression is associated with the loss of methylation of CpG and H3K9 at DMR-LIT1, not by its own promoter CpG methylation, and is involved in esophageal cancer, implying that DMR-LIT1 epigenetically regulates CDKN1C expression not through histone modifications at CDKN1C promoter, but through that of DMR-LIT1.	Saga Med Sch, Dept Biomol Sci, Div Mol Biol & Genet, Saga 8498501, Japan; Nagoya Univ, Grad Sch Med, Dept Biochem 2, Showa Ku, Nagoya, Aichi 4668550, Japan; Saga Med Sch, Dept Surg, Div Gen Surg, Saga 8498501, Japan; Osaka Med Ctr, Osaka 5941101, Japan; Res Inst Maternal & Child Hlth, Osaka 5941101, Japan; Tottori Univ, Grad Sch Med Sci, Dept Biomed Sci, Yonago, Tottori 6838503, Japan	Saga University; Nagoya University; Saga University; Osaka Medical Center for Cancer & Cardiovascular Diseases; Tottori University	Soejima, H (corresponding author), Saga Med Sch, Dept Biomol Sci, Div Mol Biol & Genet, 5-1-1 Nabeshima, Saga 8498501, Japan.	soejimah@post.saga-med.ac.jp		Soejima, Hidenobu/0000-0001-5076-6563; Urano, Takeshi/0000-0003-3383-3554				Baffa R, 1996, CANCER RES, V56, P268; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; BEPLER G, 1994, P NATL ACAD SCI USA, V91, P5513, DOI 10.1073/pnas.91.12.5513; Bliek J, 2001, HUM MOL GENET, V10, P467, DOI 10.1093/hmg/10.5.467; Diaz-Meyer N, 2003, J MED GENET, V40, P797, DOI 10.1136/jmg.40.11.797; Du MJ, 2003, HUM MOL GENET, V12, P1927, DOI 10.1093/hmg/ddg194; Feinberg AD, 2000, J CLIN INVEST, V106, P739, DOI 10.1172/JCI10911; Fitzpatrick GV, 2002, NAT GENET, V32, P426, DOI 10.1038/ng988; Hatada I, 1996, NAT GENET, V14, P171, DOI 10.1038/ng1096-171; Hatada I, 1996, HUM MOL GENET, V5, P783, DOI 10.1093/hmg/5.6.783; HATADA I, 1995, NAT GENET, V11, P204, DOI 10.1038/ng1095-204; HENRY I, 1989, P NATL ACAD SCI USA, V86, P3247, DOI 10.1073/pnas.86.9.3247; Higashimoto K, 2003, AM J HUM GENET, V73, P948, DOI 10.1086/378595; Horike S, 2000, HUM MOL GENET, V9, P2075, DOI 10.1093/hmg/9.14.2075; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kikuchi T, 2002, ONCOGENE, V21, P2741, DOI 10.1038/sj.onc.1205376; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lam WWK, 1999, J MED GENET, V36, P518; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Lee MP, 1999, P NATL ACAD SCI USA, V96, P5203, DOI 10.1073/pnas.96.9.5203; Li YH, 2002, BLOOD, V100, P2572, DOI 10.1182/blood-2001-11-0026; Mancini-DiNardo D, 2003, HUM MOL GENET, V12, P283, DOI 10.1093/hmg/ddg024; Matsumoto M, 2000, ANTICANCER RES, V20, P1947; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Mitsuya K, 1999, HUM MOL GENET, V8, P1209, DOI 10.1093/hmg/8.7.1209; Nakagawachi T, 2003, ONCOGENE, V22, P8835, DOI 10.1038/sj.onc.1207183; OKeefe D, 1997, AM J HUM GENET, V61, P295, DOI 10.1086/514854; Oya M, 2000, BRIT J CANCER, V83, P626, DOI 10.1054/bjoc.2000.1298; Scelfo RAM, 2002, ONCOGENE, V21, P2564, DOI 10.1038/sj.onc.1205336; Schwienbacher C, 2000, P NATL ACAD SCI USA, V97, P5445, DOI 10.1073/pnas.090087497; SHIBAGAKI I, 1994, CANCER RES, V54, P2996; SHIMADA Y, 1992, CANCER, V69, P277, DOI 10.1002/1097-0142(19920115)69:2<277::AID-CNCR2820690202>3.0.CO;2-C; Shin JY, 2000, CANCER RES, V60, P262; Shin JY, 2000, EXP MOL MED, V32, P79, DOI 10.1038/emm.2000.14; Sleutels F, 2002, NATURE, V415, P810, DOI 10.1038/415810a; Smilinich NJ, 1999, P NATL ACAD SCI USA, V96, P8064, DOI 10.1073/pnas.96.14.8064; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strahl BD, 1999, P NATL ACAD SCI USA, V96, P14967, DOI 10.1073/pnas.96.26.14967; Thakur N, 2003, J BIOL CHEM, V278, P9514, DOI 10.1074/jbc.M212203200; Thompson JS, 1996, CANCER RES, V56, P5723; Tokino T, 1996, HUM GENET, V97, P625, DOI 10.1007/s004390050106; Ueijma H, 2000, NAT GENET, V25, P375, DOI 10.1038/78040; Watanabe H, 1998, P NATL ACAD SCI USA, V95, P1392, DOI 10.1073/pnas.95.4.1392; Weksberg R, 2001, HUM MOL GENET, V10, P2989, DOI 10.1093/hmg/10.26.2989; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Yatsuki H, 2002, GENOME RES, V12, P1860, DOI 10.1101/gr.110702	47	53	57	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2004	23	25					4380	4388		10.1038/sj.onc.1207576	http://dx.doi.org/10.1038/sj.onc.1207576			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	824CJ	15007390				2022-12-28	WOS:000221661300004
J	Squatrito, M; Mancino, M; Donzelli, M; Areces, LB; Draetta, GF				Squatrito, M; Mancino, M; Donzelli, M; Areces, LB; Draetta, GF			EBP1 is a nucleolar growth-regulating protein that is part of pre-ribosomal ribonucleoprotein complexes	ONCOGENE			English	Article						rRNA; nucleolus; growth control; localization signal; proteohics; ribosome assembly	ERBB-3 BINDING-PROTEIN; CELL-CYCLE; PROTEOMIC ANALYSIS; BIOGENESIS; INTERACTS; DOMAIN; PROLIFERATION; TRANSCRIPTION; REPRESSION; EXPRESSION	EBP1 was identified as a protein that interacts with the ErbB-3 receptor and possibly contributes to transducing growth regulatory signals. The existence of EBP1 homologs across species from simple eukaryotes to humans and its wide tissue expression pattern suggest that EBP1 acts as a general signaling molecule. We provide evidence that EBP1 is localized to the cytoplasm and to the nucleolus, and that its nucleolar localization requires amino-acid sequences present at both the amino- and carboxy-terminus of the molecule. We also show that EBP1 overexpression inhibits proliferation of human fibroblasts, and that this effect is linked to its nucleolar localization. Using mass spectrometry we demonstrate that EBP1 is part of ribonucleoprotein complexes and associates with different rRNA species. It is becoming clear that cell growth and proliferation are actively coordinated with rRNA processing and ribosome assembly. Our findings indicate that EBP1 is a nucleolar growth-regulating protein, and we propose that it could represent a new link between ribosome biosynthesis and cell proliferation.	European Inst Oncol, I-20141 Milan, Italy	IRCCS European Institute of Oncology (IEO)	Draetta, GF (corresponding author), European Inst Oncol, 435 Via Ripamonti, I-20141 Milan, Italy.	giulio.draetta@ieo-research.it	Squatrito, Massimo/F-4149-2016; Donzelli, Maddalena/ABD-3774-2020	Squatrito, Massimo/0000-0002-4593-3790; DONZELLI, MADDALENA/0000-0002-4045-0802	Telethon [E.0865] Funding Source: Medline	Telethon(Fondazione Telethon)		Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BOURBON HM, 1983, MOL BIOL REP, V9, P39, DOI 10.1007/BF00777472; Bouvet P, 1998, J BIOL CHEM, V273, P19025, DOI 10.1074/jbc.273.30.19025; Catez F, 2002, MOL CELL BIOL, V22, P1126, DOI 10.1128/MCB.22.4.1126-1139.2002; Dragon F, 2002, NATURE, V417, P967, DOI 10.1038/nature00769; Eisenhaber F, 2001, TRENDS BIOCHEM SCI, V26, P345, DOI 10.1016/S0968-0004(01)01851-5; Fatica A, 2002, CURR OPIN CELL BIOL, V14, P313, DOI 10.1016/S0955-0674(02)00336-8; Filipowicz W, 2002, CURR OPIN CELL BIOL, V14, P319, DOI 10.1016/S0955-0674(02)00334-4; Granneman S, 2003, NUCLEIC ACIDS RES, V31, P1877, DOI 10.1093/nar/gkg300; Guarente L, 1997, GENE DEV, V11, P2449, DOI 10.1101/gad.11.19.2449; Hayano T, 2003, J BIOL CHEM, V278, P34309, DOI 10.1074/jbc.M304304200; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Hernandez-Verdun D, 2002, J CELL SCI, V115, P2265; Kiss T, 2002, CELL, V109, P145, DOI 10.1016/S0092-8674(02)00718-3; Kressler D, 1999, MOL CELL BIOL, V19, P7897; Lamartine J, 1997, CYTOGENET CELL GENET, V78, P31, DOI 10.1159/000134621; Lessor TJ, 2000, J CELL PHYSIOL, V183, P321, DOI 10.1002/(SICI)1097-4652(200006)183:3<321::AID-JCP4>3.0.CO;2-O; Lixin R, 2001, BIOCHEM BIOPH RES CO, V284, P185, DOI 10.1006/bbrc.2001.4953; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Mann M, 1996, CURR OPIN BIOTECH, V7, P11, DOI 10.1016/S0958-1669(96)80089-9; Mitchell SA, 2003, MOL CELL, V11, P757, DOI 10.1016/S1097-2765(03)00093-5; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nissan TA, 2002, EMBO J, V21, P5539, DOI 10.1093/emboj/cdf547; Pederson T, 1998, J CELL BIOL, V143, P279, DOI 10.1083/jcb.143.2.279; Pestov DG, 2001, MOL CELL BIOL, V21, P4246, DOI 10.1128/MCB.21.13.4246-4255.2001; Pilipenko EV, 2000, GENE DEV, V14, P2028; Pinol-Roma S, 1999, MOL BIOL CELL, V10, P77, DOI 10.1091/mbc.10.1.77; Rizos H, 2000, ONCOGENE, V19, P2978, DOI 10.1038/sj.onc.1203629; Schafer T, 2003, EMBO J, V22, P1370, DOI 10.1093/emboj/cdg121; Scheer U, 1999, CURR OPIN CELL BIOL, V11, P385, DOI 10.1016/S0955-0674(99)80054-4; Scherl A, 2002, MOL BIOL CELL, V13, P4100, DOI 10.1091/mbc.E02-05-0271; SCHNEITER R, 1995, MOL BIOL CELL, V6, P357, DOI 10.1091/mbc.6.4.357; Shaw PJ, 1995, ANNU REV CELL DEV BI, V11, P93, DOI 10.1146/annurev.cb.11.110195.000521; Srivastava M, 1999, FASEB J, V13, P1911, DOI 10.1096/fasebj.13.14.1911; Strezoska Z, 2002, J BIOL CHEM, V277, P29617, DOI 10.1074/jbc.M204381200; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Warner JR, 1999, TRENDS BIOCHEM SCI, V24, P437, DOI 10.1016/S0968-0004(99)01460-7; Warner JR, 2001, CELL, V107, P133, DOI 10.1016/S0092-8674(01)00531-1; Wehner KA, 2002, MOL CELL, V9, P329, DOI 10.1016/S1097-2765(02)00438-0; Xia XM, 2001, BIOCHEM BIOPH RES CO, V289, P240, DOI 10.1006/bbrc.2001.5942; Xia XM, 2001, J CELL PHYSIOL, V187, P209, DOI 10.1002/jcp.1075; Yanagida M, 2001, PROTEOMICS, V1, P1390, DOI 10.1002/1615-9861(200111)1:11<1390::AID-PROT1390>3.0.CO;2-Z; Yoo JY, 2000, BRIT J CANCER, V82, P683; Zhang YX, 2003, NUCLEIC ACIDS RES, V31, P2168, DOI 10.1093/nar/gkg318; Zhang YX, 2002, ONCOGENE, V21, P5609, DOI 10.1038/sj.onc.1205638	46	104	115	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2004	23	25					4454	4465		10.1038/sj.onc.1207579	http://dx.doi.org/10.1038/sj.onc.1207579			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	824CJ	15064750				2022-12-28	WOS:000221661300011
J	Mitani, K				Mitani, K			Molecular mechanisms of leukemogenesis by AML1/EVI-1	ONCOGENE			English	Article						AML1/EVI-1; apoptosis; dominant-negative effects; JNK; TGF beta; transcription factor	CHRONIC MYELOCYTIC-LEUKEMIA; FETAL LIVER HEMATOPOIESIS; T(3/21) FUSION PRODUCT; ACUTE MYELOID-LEUKEMIA; FACTOR-BETA; GROWTH-INHIBITION; BLASTIC CRISIS; EVI-1; GENE; AML1	The AML1/EVI-1 chimeric gene is generated by the t(3; 21)(q26; q22) translocation and plays a pivotal role in progression of hematopoietic stem cell malignancies such as chronic myelocytic leukemia and myelodysplastic syndrome. In AML1/EVI-1, an N-terminal half of AML1 including a runt homology domain is fused to the entire zinc-finger EVI-1 protein. AML1 is essential for hematopoietic cell development in fetal liver and its lineage-specific differentiation in adult. In contrast, EVI-1 is barely expressed in normal hematopoietic cells, but it is overexpressed in chronic myelocytic leukemia in blastic crisis and myelodysplastic syndrome-derived leukemia. There are at least four mechanisms identified in AML1/EVI-1 fusion protein that possibly lead into malignant transformation of hematopoietic stem cells. Firstly, AML1/EVI-1 exerts dominant-negative effects over AML1-induced transcriptional activation. Although target genes repressed by AML1/EVI-1 are still not known, binding competition to a specific DNA sequence and histone deacetylase recruitment through a co-repressor CtBP in EVI-1 part are conceivable underlying mechanisms for the dominant-negative effects. Secondly, AML1/EVI-1 interferes with TGFbeta signaling and antagonizes the growth-inhibitory effects of TGFbeta. The first zinc-finger domain of EVI-1 associates with Smad3, a TGFb signal transducer, and represses its transcriptional activity by recruiting histone deacetylase through CtBP that interacts with EVI-1. Thirdly, AML1/EVI-1 blocks JNK activity and prevents stress-induced apoptosis. AML1/EVI-1 associates with JNK through the first zinc-finger domain of EVI-1 and disturbs the association between JNK and its substrates. Lastly, AML1/EVI-1 enhances AP-1 activity by activating the c-Fos promoter depending on the second zinc-finger domain of EVI-1, and promotes cell proliferation. All these functions cooperatively contribute to the malignant transformation of the hematopoietic stem cells by AML1/EVI-1.	Dokkyo Univ, Sch Med, Dept Hematol, Mibu, Tochigi 3210293, Japan	Dokkyo Medical University	Mitani, K (corresponding author), Dokkyo Univ, Sch Med, Dept Hematol, 880 Kitakobayashi, Mibu, Tochigi 3210293, Japan.	kinukom-tky@umin.ac.jp						BAE SC, 1993, ONCOGENE, V8, P809; DAGA A, 1992, NATURE, V356, P484, DOI 10.1038/356484b0; Huang G, 2001, EMBO J, V20, P723, DOI 10.1093/emboj/20.4.723; Izutsu K, 2002, ONCOGENE, V21, P2695, DOI 10.1038/sj.onc.1205356; Izutsu K, 2001, BLOOD, V97, P2815, DOI 10.1182/blood.V97.9.2815; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Kurokawa M, 2000, EMBO J, V19, P2958, DOI 10.1093/emboj/19.12.2958; Kurokawa M, 1998, BLOOD, V92, P4003, DOI 10.1182/blood.V92.11.4003.423a56_4003_4012; KUROKAWA M, 1995, ONCOGENE, V11, P833; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MITANI K, 1995, BRIT J HAEMATOL, V90, P711, DOI 10.1111/j.1365-2141.1995.tb05606.x; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MORISHITA K, 1990, ONCOGENE, V5, P963; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Ogawa S, 1996, LEUKEMIA, V10, P788; Ogawa S, 1996, ONCOGENE, V13, P183; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; Tanaka K, 1998, BLOOD, V91, P1688, DOI 10.1182/blood.V91.5.1688.1688_1688_1699; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; TANAKA T, 1994, J BIOL CHEM, V269, P24020; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444	28	63	70	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2004	23	24					4263	4269		10.1038/sj.onc.1207777	http://dx.doi.org/10.1038/sj.onc.1207777			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823BZ	15156182				2022-12-28	WOS:000221586000011
J	Miyazono, K; Maeda, S; Imamura, T				Miyazono, K; Maeda, S; Imamura, T			Coordinate regulation of cell growth and differentiation by TGF-beta superfamily and Runx proteins	ONCOGENE			English	Article						TGF-beta; BMP; Smad; Runx; leukemia; gastric cancer	E3 UBIQUITIN LIGASE; BONE MORPHOGENETIC PROTEIN-2; CONSTANT-REGION GENE; CORE-BINDING FACTOR; OSTEOBLAST DIFFERENTIATION; CLEIDOCRANIAL DYSPLASIA; FUNCTIONAL COOPERATION; IGA PRODUCTION; SMAD; EXPRESSION	Runx proteins regulate various biological processes, including growth and differentiation of hematopoietic cells, lymphocytes, osteoblasts, and gastric epithelial cells. Some of the biological activities of Runx proteins are reminiscent of those of transforming growth factor (TGF)-beta superfamily cytokines. Consistent with this notion, receptor-regulated Smads (R-Smads), signal mediators of the TGF-beta superfamily cytokines, and Runx proteins have been shown to physically interact with each other. R-Smads activated by TGF-beta and Runx proteins cooperatively induce synthesis of IgA in B lymphocytes, and those activated by bone morphogenetic proteins and Runx2 induce osteoblastic differentiation. Moreover, the R-Smad-Runx signaling pathways are regulated by an E3 ubiquitin ligase Smurf1, as well as a signal transducer of interferons, STAT1. Since Runxl and Runx3 are involved in the development of some cancers including acute leukemia and gastric cancer, it will be of interest to examine in detail whether TGF-beta-specific R-Smads and Runx proteins coordinately regulate growth and differentiation of hematopoietic cells and gastric epithelial cells.	Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Bunkyo Ku, Tokyo 1130033, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Toshima Ku, Tokyo 1708455, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Miyazono, K (corresponding author), Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	miyazono-ind@umin.ac.jp						Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; COFFMAN RL, 1989, J EXP MED, V170, P1039, DOI 10.1084/jem.170.3.1039; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Fukuchi M, 2002, CANCER RES, V62, P7162; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Huang G, 2001, EMBO J, V20, P723, DOI 10.1093/emboj/20.4.723; Inoue K, 2002, NAT NEUROSCI, V5, P946, DOI 10.1038/nn925; Ishida W, 2000, J BIOL CHEM, V275, P6075, DOI 10.1074/jbc.275.9.6075; Ito Y, 1999, GENES CELLS, V4, P685, DOI 10.1046/j.1365-2443.1999.00298.x; Ito Y, 2003, CURR OPIN GENET DEV, V13, P43, DOI 10.1016/S0959-437X(03)00007-8; Jang CW, 2002, NAT CELL BIOL, V4, P51, DOI 10.1038/ncb731; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kim S, 2003, GENE DEV, V17, P1979, DOI 10.1101/gad.1119303; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Lee MH, 1999, J CELL BIOCHEM, V73, P114, DOI 10.1002/(SICI)1097-4644(19990401)73:1<114::AID-JCB13>3.3.CO;2-D; Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; LIN YCA, 1992, J IMMUNOL, V149, P2914; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MELNIKOVA IN, 1993, J VIROL, V67, P2408, DOI 10.1128/JVI.67.4.2408-2411.1993; Miyama K, 1999, DEV BIOL, V208, P123, DOI 10.1006/dbio.1998.9197; Miyazawa K, 2002, GENES CELLS, V7, P1191, DOI 10.1046/j.1365-2443.2002.00599.x; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Murakami G, 2003, MOL BIOL CELL, V14, P2809, DOI 10.1091/mbc.E02-07-0441; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; NILSSON L, 1993, INT IMMUNOL, V5, P271; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Pardali E, 2000, J BIOL CHEM, V275, P3552, DOI 10.1074/jbc.275.5.3552; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Qin BY, 2002, GENE DEV, V16, P1950, DOI 10.1101/gad.1002002; Shi MJ, 1998, J IMMUNOL, V161, P6751; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; SONODA E, 1989, J EXP MED, V170, P1415, DOI 10.1084/jem.170.4.1415; Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102; Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Valderrama-Carvajal H, 2002, NAT CELL BIOL, V4, P963, DOI 10.1038/ncb885; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Woolf E, 2003, P NATL ACAD SCI USA, V100, P7731, DOI 10.1073/pnas.1232420100; Xie XQ, 1999, EUR J IMMUNOL, V29, P488, DOI 10.1002/(SICI)1521-4141(199902)29:02<488::AID-IMMU488>3.0.CO;2-N; Zaidi SK, 2002, P NATL ACAD SCI USA, V99, P8048, DOI 10.1073/pnas.112664499; Zhang Y, 2000, J BIOL CHEM, V275, P16979, DOI 10.1074/jbc.M001526200; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhang YW, 2000, P NATL ACAD SCI USA, V97, P10549, DOI 10.1073/pnas.180309597; Zhao M, 2003, J BIOL CHEM, V278, P27939, DOI 10.1074/jbc.M304132200; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	56	136	154	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 24	2004	23	24					4232	4237		10.1038/sj.onc.1207131	http://dx.doi.org/10.1038/sj.onc.1207131			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823BZ	15156178				2022-12-28	WOS:000221586000007
J	Schmitt, E; Paquet, C; Beauchemin, M; Bertrand, R				Schmitt, E; Paquet, C; Beauchemin, M; Bertrand, R			Bcl-xES, a BH4-and BH2-containing antiapoptotic protein, delays Bax oligomer formation and binds Apaf-1, blocking procaspase-9 activation	ONCOGENE			English	Review						Bcl-x; Bax; Apaf-1; caspase; apoptosis	INNER MITOCHONDRIAL-MEMBRANE; DEPENDENT ANION CHANNEL; PROGRAMMED CELL-DEATH; CYTOCHROME-C RELEASE; FAMILY-MEMBERS; X-L; PROMOTES APOPTOSIS; BH4 DOMAIN; CASPASE ACTIVATION; CONSERVED DOMAINS	Bcl-2 family members either negatively or positively regulate the apoptotic threshold of cells. Bcl-xES ( extra short), a novel Bcl-x member, possesses a unique combination of BH4 and BH2 domains as well as a COOH-terminal hydrophobic transmembrane anchor domain. Bcl-xES contains sequences of hydrophobic alpha-6 helices but lacks sequences of alpha-5 helices, suggesting that it does not have pore channel-forming activity but functions uniquely as a trapping protein. mRNA expression analysis by reverse transcriptase-polymerase chain reaction and RNase protection assay reveal that Bcl-xES is expressed in a variety of human cancer cell lines and human tumors, including bone marrow from patients with acute lymphoblastic leukemia. Bcl-xES expression is much less pronounced in some specimens of normal human tissues, including the breast, ovary, testis and lung. Stable, transfected human B lymphoma Namalwa variant cells expressing Bcl-xES were derived to investigate its role in apoptosis. Bcl-xES had a preventive effect on cell death induced by tumor necrosis factor-alpha and various concentrations of anticancer drugs, including camptothecin, etoposide and cisplatin. Its protective action on cell death was correlated with the inhibition of mitochondrial cytochrome c release and caspase activation. In a yeast two-hybrid system, Bcl-xES interacted with most Bcl-2 family members, including those containing only a BH3 domain, and with the Ced-4 homolog Apaf-1. Co-immunoprecipitation and gel filtration chromatography experiments suggest that Bcl-xES delays drug-induced apoptosis by disturbing the formation of Bax oligomers and preventing cytochrome c release, but also by interacting with Apaf-1 and inhibiting procaspase-9 activation, thus averting the apoptogenic proteolytic caspase cascade and cell death.	Univ Montreal, Notre Dame Hosp, Ctr Hosp, Ctr Rech, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Inst Canc Montreal, Montreal, PQ H2L 4M1, Canada	Universite de Montreal; Universite de Montreal	Bertrand, R (corresponding author), Univ Montreal, Notre Dame Hosp, Ctr Hosp, Ctr Rech, 1560 Sherbrooke St E,Room Y-5634, Montreal, PQ H2L 4M1, Canada.	richard.bertrand@umontreal.ca						Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; APTE SS, 1995, GENOMICS, V26, P592, DOI 10.1016/0888-7543(95)80180-T; Ban J, 1998, BIOCHEM BIOPH RES CO, V248, P147, DOI 10.1006/bbrc.1998.8907; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; BERTRAND R, 1991, CANCER RES, V51, P6280; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; Bottero V, 2001, J BIOL CHEM, V276, P21317, DOI 10.1074/jbc.M005850200; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Cain K, 1999, J BIOL CHEM, V274, P22686, DOI 10.1074/jbc.274.32.22686; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chaudhary D, 1998, J BIOL CHEM, V273, P17708, DOI 10.1074/jbc.273.28.17708; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Conus S, 2000, CELL DEATH DIFFER, V7, P947, DOI 10.1038/sj.cdd.4400729; de Moissac D, 1999, J BIOL CHEM, V274, P29505, DOI 10.1074/jbc.274.41.29505; Droin N, 2000, CANCER RES, V60, P7039; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Franke TF, 1997, NATURE, V390, P116, DOI 10.1038/36442; Garrido C, 1999, FASEB J, V13, P2061, DOI 10.1096/fasebj.13.14.2061; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Guo B, 2001, J BIOL CHEM, V276, P2780, DOI 10.1074/jbc.M005889200; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; Haraguchi M, 2000, J EXP MED, V191, P1709, DOI 10.1084/jem.191.10.1709; Hausmann G, 2000, J CELL BIOL, V149, P623, DOI 10.1083/jcb.149.3.623; He HL, 1998, J IMMUNOL, V161, P1169; Hsu SY, 1998, J BIOL CHEM, V273, P30139, DOI 10.1074/jbc.273.46.30139; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Huang DCS, 1998, EMBO J, V17, P1029, DOI 10.1093/emboj/17.4.1029; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; Inohara N, 1998, J BIOL CHEM, V273, P32479, DOI 10.1074/jbc.273.49.32479; Jia L, 2001, ONCOGENE, V20, P4817, DOI 10.1038/sj.onc.1204628; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Makin GWJ, 2001, EMBO J, V20, P6306, DOI 10.1093/emboj/20.22.6306; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Miyashita MUT, 2001, FEBS LETT, V509, P135, DOI 10.1016/S0014-5793(01)03145-3; Moriishi K, 1999, P NATL ACAD SCI USA, V96, P9683, DOI 10.1073/pnas.96.17.9683; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; Newmeyer DD, 2000, CELL DEATH DIFFER, V7, P402, DOI 10.1038/sj.cdd.4400665; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Parrish J, 2001, NATURE, V412, P90, DOI 10.1038/35083608; Pavlov EV, 2001, J CELL BIOL, V155, P725, DOI 10.1083/jcb.200107057; Qin HX, 1999, NATURE, V399, P549, DOI 10.1038/21124; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schmitt E, 1998, CELL DEATH DIFFER, V5, P506, DOI 10.1038/sj.cdd.4400376; Schmitt E, 1998, EXP CELL RES, V240, P107, DOI 10.1006/excr.1998.4003; Schmitt E, 2000, BIOCHEM BIOPH RES CO, V270, P868, DOI 10.1006/bbrc.2000.2537; Seshagiri S, 1997, CURR BIOL, V7, P455, DOI 10.1016/S0960-9822(06)00216-8; Shi B, 1999, BIOCHEM BIOPH RES CO, V254, P779, DOI 10.1006/bbrc.1998.0130; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Song QZ, 1999, EMBO J, V18, P167, DOI 10.1093/emboj/18.1.167; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Wu DY, 1997, J BIOL CHEM, V272, P21449, DOI 10.1074/jbc.272.34.21449; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang XF, 1997, IMMUNITY, V7, P629, DOI 10.1016/S1074-7613(00)80384-2; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zhang H, 1999, FEBS LETT, V448, P23, DOI 10.1016/S0014-5793(99)00335-X; Zhao YG, 2001, J BIOL CHEM, V276, P27432, DOI 10.1074/jbc.M102465200; Zhou M, 1998, J BIOL CHEM, V273, P11930, DOI 10.1074/jbc.273.19.11930; Zhou P, 1999, P NATL ACAD SCI USA, V96, P11265, DOI 10.1073/pnas.96.20.11265; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601; ZORATTI M, 1994, J BIOENERG BIOMEMBR, V26, P543, DOI 10.1007/BF00762739; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	103	25	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					3915	3931		10.1038/sj.onc.1207554	http://dx.doi.org/10.1038/sj.onc.1207554			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15048082				2022-12-28	WOS:000221382000004
J	de Fraipont, F; Keramidas, M; El Atifi, M; Chambaz, EM; Berger, F; Feige, JJ				de Fraipont, F; Keramidas, M; El Atifi, M; Chambaz, EM; Berger, F; Feige, JJ			Expression of the thrombospondin 1 fragment 167-569 in C6 glioma cells stimulates tumorigenicity despite reduced neovascularization	ONCOGENE			English	Article						tumor angiogenesis; thrombospondin; glioma	INTEGRIN-ASSOCIATED PROTEIN; ENDOTHELIAL GROWTH-FACTOR; TUMOR ANGIOGENESIS; BRAIN-TUMORS; FACTOR-BETA; TGF-BETA; INHIBITION; PROGRESSION; MECHANISMS; CARCINOMA	Gliomas are among the most malignant and most highly vascularized human tumors. We studied the therapeutic action of an angiostatic fragment of human thrombospondin 1 (named TSP1ang) on experimental glioma tumor growth. TSP1ang (enclosing amino acids 167-569) comprised the procollagen-homology domain and the three type I repeats of the original molecule. C6 glioma cells that stably express TSP1ang were generated, and their rate of in vitro growth did not appear to differ from that of C6 cells transfected with an empty plasmid. TSP1ang expressing C6 cells were then injected either subcutaneously or intracerebrally into nude mice. The resulting tumors appeared to be less vascularized, but unexpectedly started to grow earlier and had a much more invasive phenotype than tumors derived from control C6 cells. They were also much more aggressive, since the mice bearing intracerebral TSP1ang-expressing tumor cells died before day 19 post-implantation, whereas all mice bearing control C6 tumors were alive at this time point. These results indicate that careful attention should be paid at designing smaller fragments from the multimodular angiostatic molecule TSP1 since, as observed in this study, it may unmask protumorigenic properties that counteract its antiangiogenic activity.	CEA G, ANGIO, DRDC, Dept Cellular Response & Dynam,INSERM EMI 01 05, F-38054 Grenoble 09, France; Univ Hosp Grenoble, Dept Integrat Biol, F-38043 Grenoble, France; Univ Hosp Grenoble, INSERM, U318, F-38043 Grenoble, France	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm)	Feige, JJ (corresponding author), CEA G, ANGIO, DRDC, Dept Cellular Response & Dynam,INSERM EMI 01 05, 17 Rue Martyrs, F-38054 Grenoble 09, France.	jjfeige@cea.fr	Feige, Jean-Jacques/M-8905-2017; de Fraipont, Florence/P-4936-2014	Feige, Jean-Jacques/0000-0002-1354-7692; de Fraipont, Florence/0000-0001-9594-6584				ASCH AS, 1992, BIOCHEM BIOPH RES CO, V182, P1208, DOI 10.1016/0006-291X(92)91860-S; Bailly S, 1997, J BIOL CHEM, V272, P16329, DOI 10.1074/jbc.272.26.16329; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; BLACK PM, 1991, NEW ENGL J MED, V324, P1555, DOI 10.1056/NEJM199105303242205; BLACK PM, 1991, NEW ENGL J MED, V324, P1471, DOI 10.1056/NEJM199105233242105; Bleuel K, 1999, P NATL ACAD SCI USA, V96, P2065, DOI 10.1073/pnas.96.5.2065; BORNSTEIN P, 1994, METHOD ENZYMOL, V245, P62; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; Bunone G, 1999, AM J PATHOL, V155, P1967, DOI 10.1016/S0002-9440(10)65515-0; CASTLE V, 1991, J CLIN INVEST, V87, P1883, DOI 10.1172/JCI115212; Chandrasekaran L, 2000, MOL BIOL CELL, V11, P2885, DOI 10.1091/mbc.11.9.2885; Claffey KP, 1996, CANCER RES, V56, P172; de Fraipont F, 2000, J CLIN ENDOCR METAB, V85, P4734, DOI 10.1210/jc.85.12.4734; de Fraipont F, 2001, TRENDS MOL MED, V7, P401, DOI 10.1016/S1471-4914(01)02102-5; FEIGE JJ, 2000, ENCY REFERENCE VASCU, P285; Filleur S, 2001, GENE DEV, V15, P1373, DOI 10.1101/gad.193501; Folkman J, 1998, P NATL ACAD SCI USA, V95, P9064, DOI 10.1073/pnas.95.16.9064; Freyberg MA, 2000, BIOCHEM BIOPH RES CO, V271, P584, DOI 10.1006/bbrc.2000.2678; Gao AG, 1996, J BIOL CHEM, V271, P21, DOI 10.1074/jbc.271.1.21; Goldbrunner RH, 2000, J NEURO-ONCOL, V50, P53, DOI 10.1023/A:1006462504447; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; Grainger DJ, 2000, BIOCHEM J, V350, P291, DOI 10.1042/0264-6021:3500291; Grossfeld GD, 1997, J NATL CANCER I, V89, P219, DOI 10.1093/jnci/89.3.219; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Harpel JG, 2001, BIOCHEM BIOPH RES CO, V284, P11, DOI 10.1006/bbrc.2001.4922; Hsu SC, 1996, CANCER RES, V56, P5684; Iruela-Arispe ML, 1999, CIRCULATION, V100, P1423, DOI 10.1161/01.CIR.100.13.1423; IruelaArispe ML, 1997, THROMB HAEMOSTASIS, V78, P672; Jennings MT, 1998, J NEURO-ONCOL, V36, P123, DOI 10.1023/A:1005863419880; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Kalluri R, 2003, NAT REV CANCER, V3, P422, DOI 10.1038/nrc1094; Kerbel RS, 2000, CARCINOGENESIS, V21, P505, DOI 10.1093/carcin/21.3.505; Lawler J, 2000, CURR OPIN CELL BIOL, V12, P634, DOI 10.1016/S0955-0674(00)00143-5; Murphy-Ullrich JE, 2000, CYTOKINE GROWTH F R, V11, P59, DOI 10.1016/S1359-6101(99)00029-5; Ohta Y, 1999, CANCER, V85, P2570, DOI 10.1002/(SICI)1097-0142(19990615)85:12<2570::AID-CNCR12>3.3.CO;2-6; Piek E, 1999, INT J CANCER, V80, P756, DOI 10.1002/(SICI)1097-0215(19990301)80:5<756::AID-IJC21>3.0.CO;2-N; PLATE KH, 1995, GLIA, V15, P339, DOI 10.1002/glia.440150313; SAGE EH, 1991, J BIOL CHEM, V266, P14831; Siemeister G, 1998, CANCER METAST REV, V17, P241, DOI 10.1023/A:1006027124696; Stratmann A, 1997, ADV STER F, V12, P105; Streit M, 1999, AM J PATHOL, V155, P441, DOI 10.1016/S0002-9440(10)65140-1; Taraboletti G, 2000, FASEB J, V14, P1674; Tenan M, 2000, J EXP MED, V191, P1789, DOI 10.1084/jem.191.10.1789; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; TUSZYNSKI GP, 1993, J CELL BIOL, V120, P513, DOI 10.1083/jcb.120.2.513; Vailhe B, 2003, CURR PHARM DESIGN, V9, P583, DOI 10.2174/1381612033391342; VOLPERT OV, 1995, BIOCHEM BIOPH RES CO, V217, P326, DOI 10.1006/bbrc.1995.2780; Wang TN, 1996, SURGERY, V120, P449, DOI 10.1016/S0039-6060(96)80322-9; WEINSTATSASLOW DL, 1994, CANCER RES, V54, P6504; Yoshida Y, 1999, INT J ONCOL, V15, P1221; Zetter BR, 1998, ANNU REV MED, V49, P407, DOI 10.1146/annurev.med.49.1.407	51	15	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3642	3649		10.1038/sj.onc.1207438	http://dx.doi.org/10.1038/sj.onc.1207438			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15077189				2022-12-28	WOS:000221101700016
J	Aoyama, Y; Avruch, J; Zhang, XF				Aoyama, Y; Avruch, J; Zhang, XF			Norel inhibits tumor cell growth independent of Ras or the MST1/2 kinases	ONCOGENE			English	Article						Nore1; RASSF1A; growth suppression; Ras; MST	EPIGENETIC INACTIVATION; SUPPRESSOR GENE; FAMILY PROTEIN; RASSF1A; IDENTIFICATION; BINDING; LUNG; PROLIFERATION; HIPPO	Nore1, a noncatalytic protein identified by its ability to bind selectively to active Ras, is most closely related in amino-acid sequence to the tumor suppressor RASSF1. Both are expressed predominantly as a longer (Nore1A/RASSF1A) and/or shorter (Nore1B/RASSF1C) polypeptide; all four polypeptides contain a Ras-association domain and bind, through their conserved carboxytermini, the proapoptotic protein kinases MST1 and MST2. Moreover, the expression of the longer polypeptide is downregulated in human tumor cell lines through promoter methylation (frequently for RASSF1A, less regularly for Nore1A). Forced expression of RASSF1A in several such lines (including the NSCLC line A549) has been shown to suppress tumorigenicity; herein we inquire whether Nore has growth inhibitory activity. Four tumor cell lines were tested, selected for their low expression of both Nore1A and Nore1B; the two NSCLC lines, A549 and NCI-H460, each have a mutant active Ras oncogene, whereas the two melanoma lines G361 and M14 each contain the constitutively active BRaf(V599E) oncogene and wild-type Ras. The expression of Nore1A or Nore1B suppresses colony formation by the A549 and G361 lines, as effectively in A549 as does RASSF1A; colony formation in the NCI-H460 and M14 lines is unaffected. Nore1A inhibits anchorage-independent growth by A549 cells and delays A549 progression through G1 without evidence of increased apoptosis. The growth suppressive action of Nore1A is largely unaffected by deletion of both the MST- and Ras-binding domains, as well as by mutation of the Nore1A zinc finger. Thus, Nore1 suppresses the growth of some tumor cell lines through as yet unidentified effectors, independent of Ras-like proteins or MST1/2.	Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Med Serv, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Mol Biol, Diabet Res Lab, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Avruch, J (corresponding author), Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA.	avruch@helix.mgh.harvard.edu; zhang@mmolbio.mgh.harvard.edu			NCI NIH HHS [CA073818] Funding Source: Medline; NIDDK NIH HHS [DK17776] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017776, R37DK017776] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Belham C, 2003, J BIOL CHEM, V278, P34897, DOI 10.1074/jbc.M303663200; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Cifone M A, 1982, Cancer Metastasis Rev, V1, P335, DOI 10.1007/BF00124216; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2003, HISTOL HISTOPATHOL, V18, P665, DOI 10.14670/HH-18.665; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Harvey KF, 2003, CELL, V114, P457, DOI 10.1016/S0092-8674(03)00557-9; Hesson L, 2003, ONCOGENE, V22, P947, DOI 10.1038/sj.onc.1206191; Katagiri K, 2003, NAT IMMUNOL, V4, P741, DOI 10.1038/ni950; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Liu XD, 2000, ANAL BIOCHEM, V280, P20, DOI 10.1006/abio.2000.4478; Luo ZJ, 1997, MOL CELL BIOL, V17, P46, DOI 10.1128/MCB.17.1.46; Morris MR, 2003, ONCOGENE, V22, P6794, DOI 10.1038/sj.onc.1206914; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Scherf U, 2000, NAT GENET, V24, P236, DOI 10.1038/73439; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Steiner G, 1996, CANCER RES, V56, P5044; Tommasi S, 2002, ONCOGENE, V21, P2713, DOI 10.1038/sj.onc.1205365; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Vos MD, 2003, J BIOL CHEM, V278, P21938, DOI 10.1074/jbc.M211019200; Wu S, 2003, CELL, V114, P445, DOI 10.1016/S0092-8674(03)00549-X; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835	27	73	83	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3426	3433		10.1038/sj.onc.1207486	http://dx.doi.org/10.1038/sj.onc.1207486			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15007383				2022-12-28	WOS:000220975000017
J	Clemens, MJ				Clemens, MJ			Targets and mechanisms for the regulation of translation in malignant transformation	ONCOGENE			English	Review						eIF2; eIF4E-binding proteins; oncogenic viruses; p53; PKR; TNF family	EPSTEIN-BARR-VIRUS; PROTEIN-KINASE PKR; INITIATION-FACTORS 4E; TUMOR-NECROSIS-FACTOR; CAP-BINDING PROTEIN; MYC-DEPENDENT APOPTOSIS; HEPATITIS-C VIRUS; MESSENGER-RNA; TRANSCRIPTIONAL ACTIVATION; DIFFERENTIAL REQUIREMENTS	There is increasing evidence that deregulation of gene expression at the level of mRNA translation can contribute to cell transformation and the malignant phenotype. Two steps in the pathway of polypeptide chain initiation, viz. the assembly of the 43S initiation complex catalysed by polypeptide chain initiation factor eIF2 and the binding of eIF4E to eIF4G during the recruitment of mRNA to the ribosome, have been shown to be likely targets for changes associated with tumorigenesis. The activity of eIF2 is controlled by changes in phosphorylation of the a subunit of this factor. The availability of eIF4E for binding to eIF4G is regulated by the phosphorylation of a small family of eIF4E-binding proteins (the 4E-BPs). The activities of the protein kinases and/or phosphatases responsible for the (de)phosphorylation of these substrates may in turn be controlled by cellular and viral oncogenes and tumour-suppressor genes. This review will describe recent aspects of the mechanisms involved, with particular emphasis on the regulation of the eIF2alpha kinase PKR and the control of 4E-BP phosphorylation by viral gene products, growth-inhibitory cytokines and the tumour-suppressor protein p53.	St George Hosp, Sch Med, Dept Basic Med Sci, Translat Control Grp, London SW17 0RE, England	St Georges University London	Clemens, MJ (corresponding author), St George Hosp, Sch Med, Dept Basic Med Sci, Translat Control Grp, Cranmer Terrace, London SW17 0RE, England.	m.clemens@sghms.ac.uk						Abraham N, 1998, EXP CELL RES, V244, P394, DOI 10.1006/excr.1998.4201; Appella E, 2001, EUR J BIOCHEM, V268, P2763, DOI 10.1046/j.1432-1327.2001.02224.x; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Balachandran S, 2000, J VIROL, V74, P1513, DOI 10.1128/JVI.74.3.1513-1523.2000; Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; BARBER GN, 1995, J BIOL CHEM, V270, P17423, DOI 10.1074/jbc.270.29.17423; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Bauer C, 2001, CANCER, V92, P822, DOI 10.1002/1097-0142(20010815)92:4<822::AID-CNCR1388>3.0.CO;2-A; Brass N, 1997, HUM MOL GENET, V6, P33, DOI 10.1093/hmg/6.1.33; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Carter PS, 1999, ONCOGENE, V18, P4326, DOI 10.1038/sj.onc.1202890; Chacko MS, 2002, ENDOCRINOLOGY, V143, P525, DOI 10.1210/en.143.2.525; Chung J, 2002, J CELL BIOL, V158, P165, DOI 10.1083/jcb.200112015; CLEMENS M, 1992, NATURE, V360, P210, DOI 10.1038/360210a0; Clemens MJ, 2000, CELL DEATH DIFFER, V7, P603, DOI 10.1038/sj.cdd.4400695; Clemens MJ, 1999, INT J BIOCHEM CELL B, V31, P1, DOI 10.1016/S1357-2725(98)00127-7; Clemens MJ, 2001, PROG MOLEC, V27, P57; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; Constantinou C, 2003, EUR J BIOCHEM, V270, P3122, DOI 10.1046/j.1432-1033.2003.03687.x; Deb A, 2001, EMBO J, V20, P2487, DOI 10.1093/emboj/20.10.2487; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; Dilling MB, 2002, J BIOL CHEM, V277, P13907, DOI 10.1074/jbc.M110782200; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Ewen ME, 1996, BBA-REV CANCER, V1242, P181, DOI 10.1016/0304-419X(95)00010-D; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; Fox CJ, 2003, GENE DEV, V17, P1841, DOI 10.1101/gad.1105003; FukuchiShimogori T, 1997, CANCER RES, V57, P5041; Galy B, 2001, ONCOGENE, V20, P4613, DOI 10.1038/sj.onc.1204630; Galy B, 2001, ONCOGENE, V20, P1669, DOI 10.1038/sj.onc.1204271; Gao CF, 1999, JPN J CANCER RES, V90, P180, DOI 10.1111/j.1349-7006.1999.tb00731.x; Garcia MA, 2002, ONCOGENE, V21, P8379, DOI 10.1038/sj.onc.1206036; Gil J, 2000, ONCOGENE, V19, P3665, DOI 10.1038/sj.onc.1203710; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 2001, GENE DEV, V15, P2852; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Graff JR, 1997, BIOCHEM BIOPH RES CO, V240, P15, DOI 10.1006/bbrc.1997.7592; Graff JR, 2003, CLIN EXP METASTAS, V20, P265, DOI 10.1023/A:1022943419011; Haines GK, 1996, TUMOR BIOL, V17, P5, DOI 10.1159/000217961; Hidalgo M, 2000, ONCOGENE, V19, P6680, DOI 10.1038/sj.onc.1204091; Horton LE, 2002, ONCOGENE, V21, P5325, DOI 10.1038/sj.onc.1205662; Jagus R, 1999, INT J BIOCHEM CELL B, V31, P123, DOI 10.1016/S1357-2725(98)00136-8; Jeffrey IW, 2002, CANCER RES, V62, P2272; Jiang H, 2003, CANCER CELL INT, V3, DOI 10.1186/1475-2867-3-2; Kim SH, 2002, ONCOGENE, V21, P8741, DOI 10.1038/sj.onc.1205987; Kim SH, 2000, ONCOGENE, V19, P3086, DOI 10.1038/sj.onc.1203632; Kiyosawa K, 1998, CURR STUD HEMATOL BL, P161; Kokontis JM, 2001, ONCOGENE, V20, P659, DOI 10.1038/sj.onc.1204139; Komano J, 1999, J VIROL, V73, P9827, DOI 10.1128/JVI.73.12.9827-9831.1999; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Laing KG, 2002, VIROLOGY, V297, P253, DOI 10.1006/viro.2002.1354; Li S, 2003, J BIOL CHEM, V278, P3015, DOI 10.1074/jbc.M208821200; Li SN, 2002, MOL CELL BIOL, V22, P2853, DOI 10.1128/MCB.22.8.2853-2861.2002; Lobo MVT, 2000, HISTOCHEM J, V32, P139, DOI 10.1023/A:1004091122351; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; MARTH JD, 1988, NATURE, V332, P171, DOI 10.1038/332171a0; Meijer HA, 2002, BIOCHEM J, V367, P1, DOI 10.1042/BJ20011706; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Miller SJ, 2000, MOL CELL BIOL, V20, P8420, DOI 10.1128/MCB.20.22.8420-8431.2000; Morley SJ, 1998, FEBS LETT, V438, P41, DOI 10.1016/S0014-5793(98)01269-1; Morley SJ, 2000, FEBS LETT, V477, P229, DOI 10.1016/S0014-5793(00)01805-6; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Nanbo A, 2002, EMBO J, V21, P954, DOI 10.1093/emboj/21.5.954; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Nomura M, 2003, MOL CARCINOGEN, V38, P25, DOI 10.1002/mc.10140; Nussbaum JM, 2003, CANCER LETT, V196, P207, DOI 10.1016/S0304-3835(03)00276-3; Packham G, 1996, ONCOGENE, V13, P461; Parker LM, 2001, J BIOL CHEM, V276, P32522, DOI 10.1074/jbc.M104408200; Patel RC, 1998, EMBO J, V17, P4379, DOI 10.1093/emboj/17.15.4379; Polunovsky VA, 1996, MOL CELL BIOL, V16, P6573; Polunovsky VA, 2000, J BIOL CHEM, V275, P24776, DOI 10.1074/jbc.M001938200; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Rau M, 1996, J BIOL CHEM, V271, P8983, DOI 10.1074/jbc.271.15.8983; Raught B, 2001, P NATL ACAD SCI USA, V98, P7037, DOI 10.1073/pnas.121145898; Raveh T, 1996, J BIOL CHEM, V271, P25479, DOI 10.1074/jbc.271.41.25479; Rosenwald IB, 1996, CANCER LETT, V102, P113, DOI 10.1016/0304-3835(96)04171-7; Rosenwald IB, 1996, BIOESSAYS, V18, P243, DOI 10.1002/bies.950180312; Rosenwald IB, 2001, CANCER-AM CANCER SOC, V92, P2164, DOI 10.1002/1097-0142(20011015)92:8<2164::AID-CNCR1559>3.0.CO;2-A; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Ruf IK, 2000, J VIROL, V74, P10223, DOI 10.1128/JVI.74.21.10223-10228.2000; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Saelens X, 2001, J BIOL CHEM, V276, P41620, DOI 10.1074/jbc.M103674200; Salaun P, 2003, DEV BIOL, V255, P428, DOI 10.1016/S0012-1606(02)00099-4; Savinova O, 1999, INT J BIOCHEM CELL B, V31, P175, DOI 10.1016/S1357-2725(98)00140-X; SHARP TV, 1993, NUCLEIC ACIDS RES, V21, P4483, DOI 10.1093/nar/21.19.4483; SONENBERG N, 1994, BIOCHIMIE, V76, P839, DOI 10.1016/0300-9084(94)90185-6; Srivastava SP, 1998, J BIOL CHEM, V273, P2416, DOI 10.1074/jbc.273.4.2416; Tan A, 2000, ONCOGENE, V19, P1437, DOI 10.1038/sj.onc.1203446; Taylor DR, 2000, MICROBES INFECT, V2, P1743, DOI 10.1016/S1286-4579(00)01329-0; Tee AR, 2000, ONCOGENE, V19, P3021, DOI 10.1038/sj.onc.1203622; Tokino T, 2000, CRIT REV ONCOL HEMAT, V33, P1, DOI 10.1016/S1040-8428(99)00051-7; von der Haar T, 2002, MOL MICROBIOL, V46, P531, DOI 10.1046/j.1365-2958.2002.03172.x; Vorburger SA, 2002, ONCOGENE, V21, P6278, DOI 10.1038/sj.onc.1205761; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Vyas J, 2003, RNA, V9, P858, DOI 10.1261/rna.5330503; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang ST, 1999, AM J PATHOL, V155, P247, DOI 10.1016/S0002-9440(10)65118-8; Wang ST, 2001, THYROID, V11, P1101, DOI 10.1089/10507250152740939; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Yamamoto N, 2000, FEBS LETT, V484, P153, DOI 10.1016/S0014-5793(00)02145-1; Young LS, 2003, ONCOGENE, V22, P5108, DOI 10.1038/sj.onc.1206556; Zamanian-Daryoush M, 1999, ONCOGENE, V18, P315, DOI 10.1038/sj.onc.1202293; Zimmer SG, 2000, ANTICANCER RES, V20, P1343	107	171	196	0	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2004	23	18					3180	3188		10.1038/sj.onc.1207544	http://dx.doi.org/10.1038/sj.onc.1207544			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	813AJ	15094767				2022-12-28	WOS:000220879700006
J	Andre, F; Janssens, B; Bruyneel, E; van Roy, F; Gespach, C; Mareel, M; Bracke, M				Andre, F; Janssens, B; Bruyneel, E; van Roy, F; Gespach, C; Mareel, M; Bracke, M			Alpha-catenin is required for IGF-I-induced cellular migration but not invasion in human colonic cancer cells	ONCOGENE			English	Article						colorectal cancer; E-cadherin/catenin complex; IGF-IR; type-I collagen; woundhealing	COLLAGEN TYPE-I; E-CADHERIN; EPITHELIAL-CELLS; CARCINOMA-CELLS; GROWTH-FACTORS; INSULIN; EXPRESSION; ADHESION; RECEPTOR; BREAST	The mechanisms by which growth factors cooperate with cell adhesion molecules to modulate epithelial cell motility remain poorly understood. Here, we investigated the role of the E-cadherin/catenin complex in insulin-like growth factor (IGF-I)-dependent cell migration and invasion. We used variants of the HCT-8 colon cancer family that differ in their expression of alphaE-catenin, an intracellular molecule that links the E-cadherin/catenin complex to the actin cytoskeleton. Migration was determined using a monolayer wound model and cell invasion by the penetration of the cells into type-I collagen gels. We showed that alpha-catenin-deficient cells were not able to migrate in cohort upon IGF-I stimulation. Transfection of these cells with alpha-catenin isoforms (alphaN- or alphaT-catenin) restored migratory response IGF-I. These results suggest that alpha-catenins are involved in the signal issued from the E-cadherin/catenin complex to regulate IGF-I-stimulated migration. In contrast, IGF-I promoted invasion of both alpha-catenin-deficient and alpha-catenin-expressing cells, indicating that alpha-catenin did not participate in the regulation of IGF-I-induced invasion. Inhibition of E-cadherin function by treatment with MB-2 monoclonal antibodies inhibited both IGF-I-dependent cell migration and invasion. Taken together, our results indicate that functional alpha-catenin is essential for migration but not for invasion, while E-cadherin is involved in both phenomena.	Ghent Univ Hosp, Expt Cancerol Lab, B-9000 Ghent, Belgium; State Univ Ghent VIB, Dept Mol Biol, Mol Cell Biol Unit, Ghent, Belgium; Hop St Antoine, INSERM, U482, F-75571 Paris, France	Ghent University; Ghent University Hospital; Flanders Institute for Biotechnology (VIB); Ghent University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Bracke, M (corresponding author), Ghent Univ Hosp, Expt Cancerol Lab, De Pintelaan 185, B-9000 Ghent, Belgium.	brackemarc@hotmail.com	van Roy, Frans M/C-6123-2009	van Roy, Frans M/0000-0003-4358-1039				Andre F, 1999, INT J CANCER, V83, P497, DOI 10.1002/(SICI)1097-0215(19991112)83:4<497::AID-IJC11>3.3.CO;2-4; Andre F, 1999, GASTROENTEROLOGY, V116, P64, DOI 10.1016/S0016-5085(99)70230-1; Angst BD, 2001, J CELL SCI, V114, P629; Barbier M, 2001, NATURE, V413, P796, DOI 10.1038/35101660; Baserga R, 2000, ONCOGENE, V19, P5574, DOI 10.1038/sj.onc.1203854; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BRACKE ME, 1993, BRIT J CANCER, V68, P282, DOI 10.1038/bjc.1993.329; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; Debruyne PR, 2002, ONCOGENE, V21, P6740, DOI 10.1038/sj.onc.1205729; Furstenberger G, 2002, LANCET ONCOL, V3, P298, DOI 10.1016/S1470-2045(02)00731-3; GLUKHOVA M, 1995, AM J PATHOL, V146, P706; Guvakova MA, 1999, EXP CELL RES, V251, P244, DOI 10.1006/excr.1999.4566; Hiscox S, 1999, BIOCHEM BIOPH RES CO, V261, P406, DOI 10.1006/bbrc.1999.1002; Janssens B, 2001, J CELL SCI, V114, P3177; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Kotelevets L, 1998, J BIOL CHEM, V273, P14138, DOI 10.1074/jbc.273.23.14138; Leventhal PS, 1997, TRENDS ENDOCRIN MET, V8, P1, DOI 10.1016/S1043-2760(96)00202-0; Mareel M, 2003, PHYSIOL REV, V83, P337, DOI 10.1152/physrev.00024.2002; Matsubara S, 2001, J CELL BIOL, V154, P573, DOI 10.1083/jcb.200103097; Mauro L, 2001, J BIOL CHEM, V276, P39892, DOI 10.1074/jbc.M106673200; Menke A, 2001, CANCER RES, V61, P3508; Morali OG, 2001, ONCOGENE, V20, P4942, DOI 10.1038/sj.onc.1204660; Nabeshima K, 1999, HISTOL HISTOPATHOL, V14, P1183, DOI 10.14670/HH-14.1183; Sandhu MS, 2002, J NATL CANCER I, V94, P972; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; Steelant WFA, 2001, INT J CANCER, V92, P527, DOI 10.1002/ijc.1216; Van Hoorde L, 2000, Prog Mol Subcell Biol, V25, P105; vanHengel J, 1997, J CELL BIOL, V137, P1103, DOI 10.1083/jcb.137.5.1103; Vasioukhin V, 2001, CELL, V104, P605, DOI 10.1016/S0092-8674(01)00246-X; VERMEULEN SJ, 1995, CANCER RES, V55, P4722; Vermeulen SJ, 1999, ONCOGENE, V18, P905, DOI 10.1038/sj.onc.1202348; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M	32	29	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1177	1186		10.1038/sj.onc.1207238	http://dx.doi.org/10.1038/sj.onc.1207238			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14961074				2022-12-28	WOS:000188892200001
J	Komuro, A; Imamura, T; Saitoh, M; Yoshida, Y; Yamori, T; Miyazono, K; Miyazawa, K				Komuro, A; Imamura, T; Saitoh, M; Yoshida, Y; Yamori, T; Miyazono, K; Miyazawa, K			Negative regulation of transforming growth factor-beta (TGF-beta) signaling by WW domain-containing protein 1 (WWP1)	ONCOGENE			English	Article						WWP1; Smurfs; ubiquitin-proteasome pathway; Smad7; TGF-beta	UBIQUITIN LIGASE; SMAD7; RECEPTOR; TARGETS; SMURF1; INHIBITION; EXPRESSION; CANCER; DEGRADATION; ACTIVATION	Smad7 negatively regulates transforming growth factor (TGF)-beta superfamily signaling by binding to activated type I receptors, thereby preventing the phosphorylation of receptor-regulated Smads (R-Smads), as well as by recruiting HECT-type E3 ubiquitin ligases to degrade type I receptors through a ubiquitin-dependent mechanism. To elucidate the regulatory mechanisms of TGF-beta signaling, we searched for novel members of proteins that interact with Smad7 using a yeast two-hybrid system. One of the proteins identified was the WW domain-containing protein 1 (WWP1) that is structurally related to Smad ubiquitin regulatory factors (Smurfs), E3 ubiquitin ligases for Smads and TGF-beta superfamily receptors. Using a TGF-beta-responsive reporter in mammalian cells, we found that WWP1 inhibited transcriptional activities induced by TGF-beta. Similar to Smurfs, WWP1 associated with Smad7 and induced its nuclear export, and enhanced binding of Smad7 to TGF-beta type I receptor to cause ubiquitination and degradation of the receptor. Consistent with these results, WWP1 inhibited phosphorylation of Smad2 induced by TGF-beta. WWP1 thus negatively regulates TGF-beta signaling in cooperation with Smad7. However, unlike Smurfs, WWP1 failed to ubiquitinate R-Smads and SnoN. Importantly, WWP1 and Smurfs were expressed in distinct patterns in human tissues and carcinoma cell lines, suggesting unique pathophysiological roles of WWP1 and Smurfs.	Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Bunkyo Ku, Tokyo 1130033, Japan; Tokyo Inst Technol, Grad Sch Biosci Biotechnol, Dept Biol Sci, Yokohama, Kanagawa 2268501, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Toshima Ku, Tokyo 1708455, Japan; Japanese Fdn Canc Res, Inst Canc, Ctr Canc Chemotherapy, Toshima Ku, Tokyo 1708455, Japan	University of Tokyo; Tokyo Institute of Technology; Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research	Miyazawa, K (corresponding author), Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	keiji-miyazawa@umin.ac.jp	MIYAZAWA, KEIJI/I-9713-2014; 高, 雨莉/HGU-8187-2022					ARTEAGA CL, 1988, CANCER RES, V48, P3898; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Conkright MD, 2001, J BIOL CHEM, V276, P29299, DOI 10.1074/jbc.M103670200; Dan S, 2002, CANCER RES, V62, P1139; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Ebisawa T, 1999, J CELL SCI, V112, P3519; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Flasza M, 2002, BIOCHEM BIOPH RES CO, V290, P431, DOI 10.1006/bbrc.2001.6206; FROLIK CA, 1984, J BIOL CHEM, V259, P995; Fukuchi M, 2002, CANCER RES, V62, P7162; FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493; Hanyu A, 2001, J CELL BIOL, V155, P1017, DOI 10.1083/jcb.200106023; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Huang K, 2000, GENE, V252, P137, DOI 10.1016/S0378-1119(00)00216-X; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kleeff J, 1999, ONCOGENE, V18, P5363, DOI 10.1038/sj.onc.1202909; Koinuma D, 2003, EMBO J, V22, P6458, DOI 10.1093/emboj/cdg632; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Maeda S, 2004, EMBO J, V23, P552, DOI 10.1038/sj.emboj.7600067; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Miyazawa K, 2002, GENES CELLS, V7, P1191, DOI 10.1046/j.1365-2443.2002.00599.x; Murakami G, 2003, MOL BIOL CELL, V14, P2809, DOI 10.1091/mbc.E02-07-0441; Ota T, 2002, J CELL PHYSIOL, V193, P299, DOI 10.1002/jcp.10170; Pirozzi G, 1997, J BIOL CHEM, V272, P14611, DOI 10.1074/jbc.272.23.14611; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Schwarz SE, 1998, J BIOL CHEM, V273, P12148, DOI 10.1074/jbc.273.20.12148; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Suzuki C, 2002, J BIOL CHEM, V277, P39919, DOI 10.1074/jbc.M201901200; Tajima Y, 2003, J BIOL CHEM, V278, P10716, DOI 10.1074/jbc.M212663200; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	36	150	170	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2004	23	41					6914	6923		10.1038/sj.onc.1207885	http://dx.doi.org/10.1038/sj.onc.1207885			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	852JD	15221015	Bronze			2022-12-28	WOS:000223750700008
J	de Souza-Pinto, NC; Harris, CC; Bohr, VA				de Souza-Pinto, NC; Harris, CC; Bohr, VA			p53 functions in the incorporation step in DNA base excision repair in mouse liver mitochondria	ONCOGENE			English	Article						p53; mitochondrial DNA; DNA repair; BER; uracil	MICROSATELLITE INSTABILITY; POLYMERASE-GAMMA; LYASE ACTIVITY; NUCLEAR-DNA; URACIL; IDENTIFICATION; INVOLVEMENT; INCISION; BINDING; PROTEIN	The tumor suppressor p53 protein stimulates nuclear base excision repair (BER) in vitro. In response to certain cellular stresses, p53 translocates to mitochondria, where it can trigger an apoptotic response. However, a potential role for p53 in modulating mitochondrial DNA repair has not yet been examined. In this study, we show that p53 also modulates mitochondrial BER. Uracil-initiated BER incorporation, which measures flux through the entire BER pathway, was lower in mitochondrial extracts from nonstressed p53 knockout mice than in wild type. The addition of recombinant p53 complemented the BER incorporation in p53 knockout extracts and stimulated BER in wt extracts. The activities of three major mitochondrial DNA glycosylases were similar in extracts from wild-type and knockout animals. Likewise, AP endonuclease activity was unaffected by the absence of p53. Gel shift experiments with recombinant p53 demonstrated that p53 did not bind to the uracil-containing substrate used in the repair assay. Polymerase gamma gap-filing activity was less efficient in p53 knockout extracts, but it was complemented with the addition of recombinant p53. Thus, we conclude that p53 may participate in mtBER by stimulating the repair synthesis incorporation step.	NIA, Lab Mol Gerontol, GRC,IRP, NIH, Baltimore, MD 21224 USA; NCI, Human Carcinogenesis Lab, CTR, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Bohr, VA (corresponding author), NIA, Lab Mol Gerontol, GRC,IRP, NIH, 5600 Nathon Shock Dr,Box 1, Baltimore, MD 21224 USA.	vbohr@nih.gov	Bohr, Vilhelm/AAP-5931-2020; Souza-Pinto, Nadja C./C-3462-2013; Souza-Pinto, Nadja/T-3050-2019	Souza-Pinto, Nadja C./0000-0003-4206-964X; Souza-Pinto, Nadja/0000-0003-4206-964X	NATIONAL CANCER INSTITUTE [ZIABC005795, Z01BC005795] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [ZIAAG000733, Z01AG000733] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Allinson SL, 2001, EMBO J, V20, P6919, DOI 10.1093/emboj/20.23.6919; Bohr VA, 2002, GENE, V286, P127, DOI 10.1016/S0378-1119(01)00813-7; de Souza-Pinto NC, 2001, CANCER RES, V61, P5378; Degtyareva N, 2001, J BIOL CHEM, V276, P8778, DOI 10.1074/jbc.M006795200; DOMENA JD, 1985, BIOCHEMISTRY-US, V24, P7320, DOI 10.1021/bi00346a045; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Evans AR, 2000, MUTAT RES-DNA REPAIR, V461, P83, DOI 10.1016/S0921-8777(00)00046-X; EVANS MK, 1993, CANCER RES, V53, P5377; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; Gaiddon C, 1999, EMBO J, V18, P5609, DOI 10.1093/emboj/18.20.5609; Habano W, 2000, GASTROENTEROLOGY, V118, P835, DOI 10.1016/S0016-5085(00)70169-7; Hanawalt PC, 2002, ONCOGENE, V21, P8949, DOI 10.1038/sj.onc.1206096; Hofseth LJ, 2003, J CLIN INVEST, V112, P1887, DOI 10.1172/JCI200319757; Karahalil B, 2003, J BIOL CHEM, V278, P33701, DOI 10.1074/jbc.M301617200; Krokan HE, 2002, ONCOGENE, V21, P8935, DOI 10.1038/sj.onc.1205996; Krokan HE, 1997, BIOCHEM J, V325, P1; Lakshmipathy U, 1999, MOL CELL BIOL, V19, P3869; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Longley MJ, 1998, P NATL ACAD SCI USA, V95, P12244, DOI 10.1073/pnas.95.21.12244; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Meira LB, 1997, NAT GENET, V17, P145, DOI 10.1038/ng1097-145; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Moll UM, 2001, FEBS LETT, V493, P65, DOI 10.1016/S0014-5793(01)02284-0; NILSEN H, 1997, NUCLEIC ACIDS RES, V21, P2579; Offer H, 1999, FEBS LETT, V450, P197, DOI 10.1016/S0014-5793(99)00505-0; Offer H, 2001, ONCOGENE, V20, P581, DOI 10.1038/sj.onc.1204120; Seo YR, 2002, ONCOGENE, V21, P731, DOI 10.1038/sj.onc.1205129; Sobol RW, 2003, J BIOL CHEM, V278, P39951, DOI 10.1074/jbc.M306592200; Souza-Pinto NC, 1999, NUCLEIC ACIDS RES, V27, P1935, DOI 10.1093/nar/27.8.1935; Stierum RH, 1999, NUCLEIC ACIDS RES, V27, P3712, DOI 10.1093/nar/27.18.3712; Stuart JA, 2004, FASEB J, V18, P595, DOI 10.1096/fj.03-0890fje; TAGUCHI T, 1995, BIOCHEM BIOPH RES CO, V216, P715, DOI 10.1006/bbrc.1995.2680; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WILSON DM, 1995, J BIOL CHEM, V270, P16002, DOI 10.1074/jbc.270.27.16002; Yamada NA, 2002, CANCER RES, V62, P6061; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914; Zurer I, 2004, CARCINOGENESIS, V25, P11, DOI 10.1093/carcin/bgg186	38	77	78	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6559	6568		10.1038/sj.onc.1207874	http://dx.doi.org/10.1038/sj.onc.1207874			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15208669				2022-12-28	WOS:000223530800003
J	Lee, AY; He, B; You, L; Dadfarmay, S; Xu, ZD; Mazieres, J; Mikami, I; McCormick, F; Jablons, DM				Lee, AY; He, B; You, L; Dadfarmay, S; Xu, ZD; Mazieres, J; Mikami, I; McCormick, F; Jablons, DM			Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma	ONCOGENE			English	Article						SFRP; Wnt signaling; methylation; malignant pleural mesothelioma	DIFFERENTIAL EXPRESSION; BREAST-TUMORS; CANCER; INHIBITION; MECHANISMS; APOPTOSIS; PATTERNS; PATHWAY; BINDS; CELLS	Secreted frizzled-related proteins (sFRPs) comprise a family of five secreted glycoproteins that antagonize Wnt signaling. Aberrant activation and upregulation of the Wnt pathway is a key feature of many cancers. Thus, role of sFRP as a negative regulator of Wnt signaling may have important implications in tumorigenesis, and its downregulation has been correlated with human cancers. Recently, we reported Wnt signaling and dishevelled (Dvl) overexpression in malignant pleural mesothelioma (MM). Here, we report significant transcriptional downregulation of the SFRP gene family in MM primary tissues and cell lines as well as several other cancer cell lines ( breast, lung, glioma, and cervical) compared to normal cells. One or more SFRPs were downregulated in approximately 85% ( 18 of 21) of primary MM tumor specimens compared to normal pleural tissue. Eight of the nine cancer cell lines we examined showed silencing of the SFRP family. Methylation-specific PCR (MSP) analysis showed that SFRP1, SFRP4, and SFRP5 gene promoters are frequently methylated in MM primary tissue (>80%). Furthermore, transfection of the SFRP gene construct into MM cell lines lacking SFRP expression resulted in apoptosis and growth suppression. Our results suggest that methylation silencing of SFRPs may be one of the important mechanisms of aberrant Wnt signaling activation in MM.	Univ Calif San Francisco, Ctr Comprehens Canc, Dept Surg, Thorac Oncol Lab, San Francisco, CA 94115 USA	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Jablons, DM (corresponding author), Ctr Canc, Dept Surg, 1600 Divisadero St,C322C,Box 1674, San Francisco, CA 94115 USA.	jablonsd@surgery.ucsf.edu	MAZIERES, JULIEN/M-3986-2014	MAZIERES, JULIEN/0000-0002-5921-7613	NATIONAL CANCER INSTITUTE [R01CA093708] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA093708-01A3, R01 CA093708] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abu-Jawdeh G, 1999, LAB INVEST, V79, P439; Abutaily AS, 2003, J PATHOL, V201, P355, DOI 10.1002/path.1458; Bafico A, 1999, J BIOL CHEM, V274, P16180, DOI 10.1074/jbc.274.23.16180; Baylin SB, 2002, SEMIN CANCER BIOL, V12, P331, DOI 10.1016/S1044-579X(02)00053-6; Butchart E G, 1999, Oncologist, V4, P488; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; Fukuhara K, 2002, J CLIN ENDOCR METAB, V87, P1729, DOI 10.1210/jc.87.4.1729; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hu ED, 1998, BIOCHEM BIOPH RES CO, V247, P287, DOI 10.1006/bbrc.1998.8784; Ijiri K, 2002, J RHEUMATOL, V29, P2266; Jones SE, 2002, BIOESSAYS, V24, P811, DOI 10.1002/bies.10136; Ko JS, 2002, EXP CELL RES, V280, P280, DOI 10.1006/excr.2002.5649; Lee Y C, 2000, Curr Opin Pulm Med, V6, P267, DOI 10.1097/00063198-200007000-00003; Lustig B, 2003, J CANCER RES CLIN, V129, P199, DOI 10.1007/s00432-003-0431-0; Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859; Roth W, 2000, ONCOGENE, V19, P4210, DOI 10.1038/sj.onc.1203783; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Uematsu K, 2003, CANCER RES, V63, P4547; Uren A, 2000, J BIOL CHEM, V275, P4374, DOI 10.1074/jbc.275.6.4374; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4; Wong SCC, 2002, J PATHOL, V196, P145, DOI 10.1002/path.1035; Zhou ZJ, 1998, INT J CANCER, V78, P95, DOI 10.1002/(SICI)1097-0215(19980925)78:1<95::AID-IJC15>3.0.CO;2-4	23	172	192	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6672	6676		10.1038/sj.onc.1207881	http://dx.doi.org/10.1038/sj.onc.1207881			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15221014				2022-12-28	WOS:000223530800015
J	Robanus-Maandag, E; Giovannini, M; van der Valk, M; Niwa-Kawakita, M; Abramowski, V; Antonescu, C; Thomas, G; Berns, A				Robanus-Maandag, E; Giovannini, M; van der Valk, M; Niwa-Kawakita, M; Abramowski, V; Antonescu, C; Thomas, G; Berns, A			Synergy of Nf2 and p53 mutations in development of malignant tumours of neural crest origin	ONCOGENE			English	Article						MPNST; neural crest; P0 promoter; conditional knockout mice; compensatory signalling	SUPPRESSOR GENE-PRODUCT; NEUROFIBROMATOSIS TYPE-2; P53-DEFICIENT MICE; MOUSE; SPECTRUM; PROTEIN; CD44; ORGANIZATION; MERLIN; CELLS	Previously, we have mimicked human neuro. bromatosis type 2 (NF2) in conditional Nf2 mutant (P0Cre; Nf2(flox2/flox2)) mice. Schwannomas, characteristic for NF2, were found at low frequency in older mice. Here, we report that these mice, upon additional hemizygosity for p53, rapidly develop multiple tumours showing features consistent with malignant peripheral nerve sheath tumours. Thus, p53 hemizygosity promotes tumorigenesis of mutant Nf2 peripheral nerve cells. In contrast, young P0Cre; Nf2(flox2/+); p53(+/-) cis mice mainly succumb to Nf2/p53-related osteogenic tumours. Therefore, Cre-mediated early biallelic loss of Nf2 function in neural crest-derived cells hemizygous for p53 results in resistance to osteogenic tumours and increased susceptibility to peripheral nerve sheath tumours.	Netherlands Canc Inst, Div Mol Genet, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands; INSERM, Fdn Jean Dausset, CEPH, F-75010 Paris, France; Netherlands Canc Inst, Dept Anim Pathol, NL-1066 CX Amsterdam, Netherlands; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA	Netherlands Cancer Institute; Foundation Jean Dausset-CEPH; Institut National de la Sante et de la Recherche Medicale (Inserm); Netherlands Cancer Institute; Memorial Sloan Kettering Cancer Center	Berns, A (corresponding author), Netherlands Canc Inst, Div Mol Genet, Ctr Biomed Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	a.berns@nki.nl		Kawakita, Michiko/0000-0002-9450-583X				BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; Bretscher A, 2000, ANNU REV CELL DEV BI, V16, P113, DOI 10.1146/annurev.cellbio.16.1.113; Cichowski K, 1999, SCIENCE, V286, P2172, DOI 10.1126/science.286.5447.2172; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, MOL CARCINOGEN, V14, P16, DOI 10.1002/mc.2940140105; ERLANDSON RA, 1982, CANCER, V49, P273, DOI 10.1002/1097-0142(19820115)49:2<273::AID-CNCR2820490213>3.0.CO;2-R; Giovannini M, 2000, GENE DEV, V14, P1617; Giovannini M, 1999, GENE DEV, V13, P978, DOI 10.1101/gad.13.8.978; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JIN JJ, 1993, CELL GROWTH DIFFER, V4, P227; Kalamarides M, 2002, GENE DEV, V16, P1060, DOI 10.1101/gad.226302; Kaya G, 1997, GENE DEV, V11, P996, DOI 10.1101/gad.11.8.996; Kleihues P, 2000, CANCER, V88, P2887, DOI 10.1002/1097-0142(20000615)88:12<2887::AID-CNCR32>3.0.CO;2-F; McClatchey AI, 1997, GENE DEV, V11, P1253, DOI 10.1101/gad.11.10.1253; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; Mckusick V.A., 1994, MENDELIAN INHERITANC; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; MESSING A, 1994, J NEUROSCI, V14, P3533; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; PURDIE CA, 1994, ONCOGENE, V9, P603; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Sherman L, 1998, GENE DEV, V12, P1058, DOI 10.1101/gad.12.7.1058; Sherman L, 1999, ONCOGENE, V18, P6692, DOI 10.1038/sj.onc.1203055; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; Vogel KS, 1999, SCIENCE, V286, P2176, DOI 10.1126/science.286.5447.2176; Zorick TS, 1996, CURR OPIN CELL BIOL, V8, P870, DOI 10.1016/S0955-0674(96)80090-1	27	19	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6541	6547		10.1038/sj.onc.1207858	http://dx.doi.org/10.1038/sj.onc.1207858			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15221010				2022-12-28	WOS:000223530800001
J	Bursen, A; Moritz, S; Gaussmann, A; Moritz, S; Dingermann, T; Marschalek, R				Bursen, A; Moritz, S; Gaussmann, A; Moritz, S; Dingermann, T; Marschalek, R			Interaction of AF4 wild-type and AF4. MLL fusion protein with SIAH proteins: indication for t(4;11) pathobiology?	ONCOGENE			English	Article						AF4; chromosomal MLL translocation t(4;11); SIAH1	ACUTE LYMPHOBLASTIC-LEUKEMIA; MYELOID PROGENITORS; PROTEASOME PATHWAY; AF4-RELATED GENE; UBIQUITIN LIGASE; NUCLEAR-PROTEIN; AF-4 GENE; CELL-LINE; HRX-ENL; EXPRESSION	The human AF4 (ALL-1 fused gene on chromosome 4) gene (4q11) is recurrently involved in reciprocal translocations to the MLL (mixed lineage leukemia) gene (11q23), correlated with high-risk acute lymphoblastic leukemia (ALL) in infants and early childhood. The t(4; 11) translocation is one of the most frequent MLL translocations known today. In general, MLL translocations are the result of an illegitimate recombination process leading to reciprocal fusions of unrelated translocation partner (TP) genes with the MLL gene. Owing to the constant presence of the derivative (11) product, it was hypothesised that only MLL. TP fusion genes are responsible for the leukemogenic process. This concept has been successfully tested for some known MLL fusions, while other MLL fusions failed. Here, we demonstrate growth-transforming potential of AF4 wild-type and the AF4. MLL fusion protein. The underlying oncogenic mechanism involves the two E3 ubiquitin ligases SIAH1 and SIAH2, the N-terminal portion of AF4 and the protection of the AF4. MLL fusion protein against proteosomal degradation.	Univ Frankfurt, Bioctr N230, Inst Pharmaceut Biol, D-60439 Frankfurt, Germany; Ruhr Univ Bochum, Dept Cell Morphol & Mol Neurobiol, D-44801 Bochum, Germany	Goethe University Frankfurt; Ruhr University Bochum	Marschalek, R (corresponding author), Univ Frankfurt, Bioctr N230, Inst Pharmaceut Biol, Marie Curie Str 9, D-60439 Frankfurt, Germany.	Rolf.Marschalek@em.uni-frankfurt.de	Marschalek, Rolf/D-3404-2011; Dingermann, Theodor/M-6970-2014	Marschalek, Rolf/0000-0003-4870-3445; Dingermann, Theodor/0000-0002-2788-1085				Ayton PM, 2003, GENE DEV, V17, P2298, DOI 10.1101/gad.1111603; Boehm J, 2001, EMBO J, V20, P4153, DOI 10.1093/emboj/20.15.4153; Bruzzoni-Giovanelli H, 1999, ONCOGENE, V18, P7101, DOI 10.1038/sj.onc.1203187; Chakrabarti L, 1996, HUM MOL GENET, V5, P275, DOI 10.1093/hmg/5.2.275; CHEN CS, 1993, BLOOD, V82, P1080; COHEN A, 1991, BLOOD, V78, P94; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DiMartino JF, 2000, BLOOD, V96, P3887, DOI 10.1182/blood.V96.12.3887.h8003887_3887_3893; DOMER PH, 1993, P NATL ACAD SCI USA, V90, P7884, DOI 10.1073/pnas.90.16.7884; DOWNING JR, 1994, BLOOD, V83, P330, DOI 10.1182/blood.V83.2.330.bloodjournal832330; Frestedt JL, 1996, GENET ANAL-BIOMOL E, V12, P147, DOI 10.1016/1050-3862(95)00127-1; Frew IJ, 2003, MOL CELL BIOL, V23, P9150, DOI 10.1128/MCB.23.24.9150-9161.2003; Garcia-Cuellar MP, 2000, ONCOGENE, V19, P1744, DOI 10.1038/sj.onc.1203506; Garcia-Cuellar MP, 2001, ONCOGENE, V20, P411, DOI 10.1038/sj.onc.1204108; Gecz J, 1996, NAT GENET, V13, P105, DOI 10.1038/ng0596-105; Germani A, 2000, ONCOGENE, V19, P5997, DOI 10.1038/sj.onc.1204002; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GREIL J, 1994, BRIT J HAEMATOL, V86, P275, DOI 10.1111/j.1365-2141.1994.tb04726.x; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Gu YH, 1996, NAT GENET, V13, P109, DOI 10.1038/ng0596-109; Hemenway CS, 2001, ONCOGENE, V20, P3798, DOI 10.1038/sj.onc.1204478; House CM, 2003, P NATL ACAD SCI USA, V100, P3101, DOI 10.1073/pnas.0534783100; Hsieh JJD, 2003, CELL, V115, P293, DOI 10.1016/S0092-8674(03)00816-X; Hsieh JJD, 2003, MOL CELL BIOL, V23, P186, DOI 10.1128/MCB.23.1.186-194.2003; Hu G, 1999, MOL CELL BIOL, V19, P724; Hu G, 1997, GENOMICS, V46, P103, DOI 10.1006/geno.1997.4997; Hu G, 1997, GENE DEV, V11, P2701, DOI 10.1101/gad.11.20.2701; Isaacs AM, 2003, J NEUROSCI, V23, P1631; Isnard P, 2000, BLOOD, V96, P705; Johnsen SA, 2002, J BIOL CHEM, V277, P30754, DOI 10.1074/jbc.M204812200; Lavau C, 2000, P NATL ACAD SCI USA, V97, P10984, DOI 10.1073/pnas.190167297; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Ma C, 1996, BLOOD, V87, P734, DOI 10.1182/blood.V87.2.734.bloodjournal872734; Martin ME, 2003, CANCER CELL, V4, P197, DOI 10.1016/S1535-6108(03)00214-9; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Nilson I, 1997, BRIT J HAEMATOL, V98, P157, DOI 10.1046/j.1365-2141.1997.1522966.x; Passer BJ, 1999, J BIOL CHEM, V274, P24007, DOI 10.1074/jbc.274.34.24007; Polekhina G, 2002, NAT STRUCT BIOL, V9, P68, DOI 10.1038/nsb743; Prasad R, 1995, P NATL ACAD SCI USA, V92, P12160, DOI 10.1073/pnas.92.26.12160; Rasio D, 1996, CANCER RES, V56, P1766; Reichel M, 2001, ONCOGENE, V20, P2900, DOI 10.1038/sj.onc.1204401; Roperch JP, 1999, P NATL ACAD SCI USA, V96, P8070, DOI 10.1073/pnas.96.14.8070; ROWLEY JD, 1992, GENE CHROMOSOME CANC, V5, P264, DOI 10.1002/gcc.2870050316; Shinobu N, 1999, J BIOL CHEM, V274, P17003, DOI 10.1074/jbc.274.24.17003; Simone F, 2001, BLOOD, V98, P201, DOI 10.1182/blood.V98.1.201; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; So CW, 2003, CANCER CELL, V4, P99, DOI 10.1016/S1535-6108(03)00188-0; So CW, 2003, CANCER CELL, V3, P161, DOI 10.1016/S1535-6108(03)00019-9; Strehl S, 2003, ONCOGENE, V22, P157, DOI 10.1038/sj.onc.1206042; Susini L, 2001, P NATL ACAD SCI USA, V98, P15067, DOI 10.1073/pnas.261571998; Taki T, 1999, P NATL ACAD SCI USA, V96, P14535, DOI 10.1073/pnas.96.25.14535; Tanikawa J, 2000, J BIOL CHEM, V275, P15578, DOI 10.1074/jbc.M000372200; Tiedt R, 2001, EMBO J, V20, P4143, DOI 10.1093/emboj/20.15.4143; Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2; van Lohuizen M, 1999, CURR OPIN GENET DEV, V9, P355, DOI 10.1016/S0959-437X(99)80053-7; von Bergh ARM, 2002, GENE CHROMOSOME CANC, V35, P92, DOI 10.1002/gcc.10091; Yano T, 1997, P NATL ACAD SCI USA, V94, P7286, DOI 10.1073/pnas.94.14.7286; Yokoyama A, 2002, BLOOD, V100, P3710, DOI 10.1182/blood-2002-04-1015; Zeisig BB, 2004, MOL CELL BIOL, V24, P617, DOI 10.1128/MCB.24.2.617-628.2004; Zhang JS, 1998, GENE DEV, V12, P1775, DOI 10.1101/gad.12.12.1775	61	60	63	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2004	23	37					6237	6249		10.1038/sj.onc.1207837	http://dx.doi.org/10.1038/sj.onc.1207837			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	847NC	15221006				2022-12-28	WOS:000223399000008
J	Dong, G; Lee, TL; Yeh, NT; Geoghegan, J; Van Waes, C; Chen, Z				Dong, G; Lee, TL; Yeh, NT; Geoghegan, J; Van Waes, C; Chen, Z			Metastatic squamous cell carcinoma cells that overexpress c-Met exhibit enhanced angiogenesis factor expression, scattering and metastasis in response to hepatocyte growth factor	ONCOGENE			English	Article						HGF/c-Met; angiogenesis; squamous cell carcinoma; metastasis; Gro-1/KC; VEGF	PROINFLAMMATORY CYTOKINE EXPRESSION; PAPILLARY RENAL-CARCINOMAS; HOST ENVIRONMENT PROMOTES; FACTOR-KAPPA-B; TUMOR PROGRESSION; IN-VIVO; PROANGIOGENIC CYTOKINES; CANCER PATIENTS; CDNA ARRAYS; ONCOGENE	We previously performed gene expression pro. ling in a multistep squamous cell carcinoma (SCC) progression model, and identified growth-regulated oncogene-1 (Gro1/KC) as a factor that contributes to enhanced angiogenesis, tumorigenesis and metastasis. In the present study, we explored molecular pathways coactivated with Gro-1/KC, and identified a transcript that encodes c-Met, the receptor for hepatocyte growth factor/scatter factor (HGF). Northern, Western blot, and immunohistochemical analyses confirm that expression of c-Met mRNA and protein is increased with SCC progression. In vitro, HGF preferentially promoted scattering in the metastatic LY-1 and LY-2 lines, and enhanced angiogenesis factors Gro-1/KC and vascular endothelial growth factor (VEGF) production by all tumor cell lines. In vivo, tumor growth and lung metastasis were promoted by transfection and overexpression of HGF cDNA in metastatic LY-1 cells. Our data indicate that metastatic SCC cells that overexpress c-Met exhibit angiogenesis factor expression and enhanced scattering in response to HGF in vitro, and tumorigenesis and metastasis in response to HGF in the tumor microenvironment in vivo.	Natl Inst Deafness & Other Commun Disorders, Head & Neck Surg Branch, Tumor Biol Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD)	Chen, Z (corresponding author), Natl Inst Deafness & Other Commun Disorders, Head & Neck Surg Branch, Tumor Biol Sect, NIH, 10-5D55,MSC-1419, Bethesda, MD 20892 USA.	chenz@nided.nih.gov	Lee, Tin-Lap/A-7853-2009; Lee, Tin-Lap/W-6595-2019	Lee, Tin-Lap/0000-0002-6654-0988; Lee, Tin-Lap/0000-0002-6654-0988	NIDCD NIH HHS [Z01-DC-00016] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [ZIADC000016, Z01DC000016] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Aebersold DM, 2001, INT J CANCER, V96, P41, DOI 10.1002/1097-0215(20010220)96:1<41::AID-IJC5>3.0.CO;2-F; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Cao B, 2001, P NATL ACAD SCI USA, V98, P7443, DOI 10.1073/pnas.131200498; CHAN AML, 1988, ONCOGENE, V2, P593; Chen Z, 1998, CANCER RES, V58, P3668; Chen Z, 1999, CLIN CANCER RES, V5, P1369; Chen Z, 1997, CLIN EXP METASTAS, V15, P527, DOI 10.1023/A:1018474910432; Cortesina G, 2000, INT J CANCER, V89, P286, DOI 10.1002/1097-0215(20000520)89:3<286::AID-IJC12>3.3.CO;2-L; CROWLBANCROFT C, 2001, CLIN CANCER RES, V7, P435; Dong G, 1999, CANCER RES, V59, P3495; Dong G, 2001, CANCER RES, V61, P4797; Dong G, 2001, CANCER RES, V61, P5911; Duffey DC, 1999, CANCER RES, V59, P3468; Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264; Fukuura T, 1998, BRIT J CANCER, V78, P454, DOI 10.1038/bjc.1998.514; Gohji K, 2000, J CLIN ONCOL, V18, P2963, DOI 10.1200/JCO.2000.18.16.2963; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hu YC, 2001, CLIN CANCER RES, V7, P3519; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; Junbo Hu, 1999, In Vivo (Attiki), V13, P177; Kitadai Y, 1999, BRIT J CANCER, V81, P647, DOI 10.1038/sj.bjc.6690742; Leethanakul C, 2000, ONCOGENE, V19, P3220, DOI 10.1038/sj.onc.1203703; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Loukinova E, 2000, ONCOGENE, V19, P3477, DOI 10.1038/sj.onc.1203687; Luan J, 1997, J LEUKOCYTE BIOL, V62, P588, DOI 10.1002/jlb.62.5.588; Marshall DD, 1998, LARYNGOSCOPE, V108, P1413, DOI 10.1097/00005537-199809000-00031; Naughton M, 2001, J UROLOGY, V165, P1325, DOI 10.1016/S0022-5347(01)69893-8; Porte H, 1998, CLIN CANCER RES, V4, P1375; Qian CN, 2002, CANCER RES, V62, P589; RONG S, 1993, CELL GROWTH DIFFER, V4, P563; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Smith CW, 1998, CLIN EXP METASTAS, V16, P655, DOI 10.1023/A:1006559811429; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Takeo S, 2001, CANCER GENET CYTOGEN, V130, P127, DOI 10.1016/S0165-4608(01)00479-4; Takigawa N, 1997, LUNG CANCER-J IASLC, V17, P211, DOI 10.1016/S0169-5002(97)00651-X; Taniguchi T, 1997, BRIT J CANCER, V75, P673, DOI 10.1038/bjc.1997.120; Thomas GR, 1999, INT J CANCER, V82, P377, DOI 10.1002/(SICI)1097-0215(19990730)82:3<377::AID-IJC11>3.3.CO;2-0; Toi M, 1998, CLIN CANCER RES, V4, P659; Uchida D, 2001, INT J CANCER, V93, P489, DOI 10.1002/ijc.1368; Vande Woude GF, 1997, CIBA F SYMP, V212, P119; Wojta J, 1999, LAB INVEST, V79, P427; Yu YL, 2002, CANCER RES, V62, P2951; YUSPA SH, 1994, J INVEST DERMATOL, V103, pS90, DOI 10.1111/1523-1747.ep12399255; YUSPA SH, 1980, CANCER RES, V40, P4694; Zhang YW, 2003, P NATL ACAD SCI USA, V100, P12718, DOI 10.1073/pnas.2135113100; Zhuang ZP, 1998, NAT GENET, V20, P66, DOI 10.1038/1727	50	44	48	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2004	23	37					6199	6208		10.1038/sj.onc.1207851	http://dx.doi.org/10.1038/sj.onc.1207851			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	847NC	15221009				2022-12-28	WOS:000223399000004
J	Sandercock, LE; Kwok, MCH; Luchman, HA; Mark, SC; Giesbrecht, JL; Samson, LD; Jirik, FR				Sandercock, LE; Kwok, MCH; Luchman, HA; Mark, SC; Giesbrecht, JL; Samson, LD; Jirik, FR			Mutational-reporter transgenes rescued from mice lacking either Mgmt, or both Mgmt and Msh6 suggest that O(6-)alkylguanine-induced miscoding does not contribute to the spontaneous mutational spectrum	ONCOGENE			English	Article						Mgmt; Msh6; lacI; DNA mismatch repair; transgenic shuttle-phage; O-6 -alkylguanine; liver; small intestine; Big Blue (TM)	DNA-REPAIR METHYLTRANSFERASE; ELEVATED MUTANT FREQUENCIES; ESCHERICHIA-COLI; MISMATCH-REPAIR; LIPID-PEROXIDATION; O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; NITRIC-OXIDE; ALKYLATION SENSITIVITY; INDUCED TUMORIGENESIS; METHYLATING AGENT	O-6-methylguanine methyltransferase, Mgmt, constitutes the first line of defense against O-6-alkylguanine, which can result in G: C to A: T transitions upon DNA replication. Mgmt has been found in organisms as diverse as archaebacteria and mammals. This evolutionary conservation suggests that all organisms may be exposed to either endogenous or environmental alkylating agents. We thus hypothesized that tissues of Mgmt(-/-) mice would exhibit elevated mutant frequencies. Employing the Big Blue(TM) transgenic system, we evaluated lacI mutants rescued from liver and small intestinal DNA of young Mgmt(-/-) mice. Interestingly, while there was a small difference between Mgmt(-/-) mice and controls with respect to lacI mutant frequency, no differences attributable to Mgmt deficiency were apparent in the mutational spectra. Although mutations stemming from O-6-guanine alkylations would be predicted to be cumulative, we found no evidence of an Mgmt-dependent alteration in mutation spectrum in DNA samples from 12 month-old mice. To optimize our ability to detect mutations resulting from O-6-alkylguanine-induced G: T mismatches, mice with combined deficiencies of Mgmt and the DNA mismatch repair molecule, Msh6, were analysed. In spite of this strategy, we observed no significant differences between Mgmt(-/-) Msh6(-/-) and Msh6(-/-) mouse lacI mutations, except for a trend towards a greater percentage (of total transitions) of G: C to A: T changes in Mgmt(-/-) Msh6(-/-) livers. Therefore, despite the striking evolutionary conservation of Mgmt, deficiency of this gene did not significantly impact the spontaneous laeI mutational spectrum in vivo.	Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; MIT, Biol Engn Div, Cambridge, MA 02139 USA; MIT, Ctr Environm Hlth Sci, Cambridge, MA 02139 USA	University of Calgary; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Jirik, FR (corresponding author), Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada.	jirik@ucalgary.ca			NATIONAL CANCER INSTITUTE [R01CA149261, R01CA075576, R01CA055042] Funding Source: NIH RePORTER; NCI NIH HHS [CA55042, R01 CA149261, CA75576] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS WT, 1987, J MOL BIOL, V194, P391, DOI 10.1016/0022-2836(87)90669-3; Allay E, 1999, ONCOGENE, V18, P3783, DOI 10.1038/sj.onc.1202697; Allay E, 1997, ONCOGENE, V15, P2127, DOI 10.1038/sj.onc.1201384; Andrew SE, 1996, MUTAT RES-FUND MOL M, V357, P57, DOI 10.1016/0027-5107(96)00080-2; Andrew SE, 2000, CARCINOGENESIS, V21, P1291, DOI 10.1093/carcin/21.7.1291; Andrew SE, 1997, ONCOGENE, V15, P123, DOI 10.1038/sj.onc.1201180; Andrew SE, 1998, P NATL ACAD SCI USA, V95, P1126, DOI 10.1073/pnas.95.3.1126; Arrault X, 2002, MUTAGENESIS, V17, P353, DOI 10.1093/mutage/17.4.353; Baross-Francis A, 2001, ONCOGENE, V20, P619, DOI 10.1038/sj.onc.1204138; Bawa S, 1999, MUTAT RES-FUND MOL M, V430, P99, DOI 10.1016/S0027-5107(99)00163-3; Benjamin N, 2000, ANN ZOOTECH, V49, P207, DOI 10.1051/animres:2000118; Bignami M, 2000, MUTAT RES-REV MUTAT, V462, P71, DOI 10.1016/S1383-5742(00)00016-8; Cariello NF, 1996, ENVIRON MOL MUTAGEN, V28, P397, DOI 10.1002/(SICI)1098-2280(1996)28:4<397::AID-EM14>3.0.CO;2-A; Cariello NF, 1997, NUCLEIC ACIDS RES, V25, P136, DOI 10.1093/nar/25.1.136; Chung FL, 1996, CARCINOGENESIS, V17, P2105, DOI 10.1093/carcin/17.10.2105; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; de Boer JG, 1998, MUTAGENESIS, V13, P109; DYCAICO MJ, 1994, MUTAT RES, V307, P461, DOI 10.1016/0027-5107(94)90257-7; Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X; Espey MG, 2002, ANN NY ACAD SCI, V962, P195, DOI 10.1111/j.1749-6632.2002.tb04068.x; Georgiadis P, 2000, CANCER EPIDEM BIOMAR, V9, P299; Gerson SL, 2002, J CLIN ONCOL, V20, P2388, DOI 10.1200/JCO.2002.06.110; GERSON SL, 1986, CARCINOGENESIS, V7, P745, DOI 10.1093/carcin/7.5.745; Glassner BJ, 1999, MUTAGENESIS, V14, P339, DOI 10.1093/mutage/14.3.339; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; Hill KA, 2004, ENVIRON MOL MUTAGEN, V43, P110, DOI 10.1002/em.20004; HOGG N, 1993, FEBS LETT, V326, P199, DOI 10.1016/0014-5793(93)81790-7; Ishikawa T, 2001, MUTAT RES-FUND MOL M, V477, P41, DOI 10.1016/S0027-5107(01)00094-X; Iwakuma T, 1997, CARCINOGENESIS, V18, P1631, DOI 10.1093/carcin/18.8.1631; Jansen M, 2001, EUR J HAEMATOL, V67, P2, DOI 10.1034/j.1600-0609.2001.067001002.x; Janssen K, 2001, ARCH TOXICOL, V75, P306, DOI 10.1007/s002040100226; Jiricny J, 2000, CURR OPIN GENET DEV, V10, P157, DOI 10.1016/S0959-437X(00)00066-6; Kaina B, 2001, PROG NUCLEIC ACID RE, V68, P41; Kawate H, 2000, CARCINOGENESIS, V21, P301, DOI 10.1093/carcin/21.2.301; Kawate H, 1998, P NATL ACAD SCI USA, V95, P5116, DOI 10.1073/pnas.95.9.5116; KLEIN JC, 1990, NUCLEIC ACIDS RES, V18, P4131, DOI 10.1093/nar/18.14.4131; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MACKAY WJ, 1994, J BACTERIOL, V176, P3224, DOI 10.1128/jb.176.11.3224-3230.1994; Major G N, 1998, J Hepatobiliary Pancreat Surg, V5, P355, DOI 10.1007/s005340050059; Mark SC, 2002, ONCOGENE, V21, P7126, DOI 10.1038/sj.onc.1205861; Marnett LJ, 2000, CARCINOGENESIS, V21, P361, DOI 10.1093/carcin/21.3.361; MINNICK DT, 1993, CANCER RES, V53, P997; MIRSALIS JC, 1993, MUTAGENESIS, V8, P265, DOI 10.1093/mutage/8.3.265; Mostafa MH, 1999, CLIN MICROBIOL REV, V12, P97, DOI 10.1128/CMR.12.1.97; Mukai T, 2002, ONCOGENE, V21, P9033, DOI 10.1038/sj.onc.1206095; Nair J, 1999, MUTAT RES-FUND MOL M, V424, P59, DOI 10.1016/S0027-5107(99)00008-1; Nair J, 1998, CANCER EPIDEM BIOMAR, V7, P435; Nair J, 1998, CARCINOGENESIS, V19, P2081, DOI 10.1093/carcin/19.12.2081; NAKATSURU Y, 1993, P NATL ACAD SCI USA, V90, P6468, DOI 10.1073/pnas.90.14.6468; Narayanan L, 1997, P NATL ACAD SCI USA, V94, P3122, DOI 10.1073/pnas.94.7.3122; Pauly GT, 2001, CHEM RES TOXICOL, V14, P894, DOI 10.1021/tx010032f; Pegg AE, 2000, MUTAT RES-REV MUTAT, V462, P83, DOI 10.1016/S1383-5742(00)00017-X; Posnick LM, 1999, J BACTERIOL, V181, P6756, DOI 10.1128/JB.181.21.6756-6762.1999; PROVOST GS, 1993, MUTAT RES, V288, P133; Quillardet P, 2000, MUTAT RES-GEN TOX EN, V470, P177, DOI 10.1016/S1383-5718(00)00103-0; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; REBECK GW, 1991, J BACTERIOL, V173, P2068, DOI 10.1128/jb.173.6.2068-2076.1991; Reese JS, 2001, ONCOGENE, V20, P5258, DOI 10.1038/sj.onc.1204700; Rogozin IB, 2001, HUM MUTAT, V17, P83, DOI 10.1002/1098-1004(200102)17:2<83::AID-HUMU1>3.0.CO;2-E; Roth RB, 2000, MUTAT RES-REV MUTAT, V462, P107, DOI 10.1016/S1383-5742(00)00021-1; Sakumi K, 1997, CANCER RES, V57, P2415; Sedgwick B, 1997, CARCINOGENESIS, V18, P1561, DOI 10.1093/carcin/18.8.1561; Singer B, 1997, CHEM RES TOXICOL, V10, P713, DOI 10.1021/tx970011e; Stuart GR, 2000, GENETICS, V154, P1291; Taverna P, 1996, J BACTERIOL, V178, P5105, DOI 10.1128/jb.178.17.5105-5111.1996; Tsuzuki T, 1996, CARCINOGENESIS, V17, P1215, DOI 10.1093/carcin/17.6.1215; VACA CE, 1988, MUTAT RES, V195, P137, DOI 10.1016/0165-1110(88)90022-X; Vidal A, 1998, MUTAGENESIS, V13, P367, DOI 10.1093/mutage/13.4.367; Virag L, 2003, TOXICOL LETT, V140, P113, DOI 10.1016/S0378-4274(02)00508-8; Walter CA, 2001, ANN NY ACAD SCI, V928, P132; Wei K, 2002, TRENDS MOL MED, V8, P346, DOI 10.1016/S1471-4914(02)02359-6; WEI X, 1993, P NATL ACAD SCI USA, V90, P2117, DOI 10.1073/pnas.90.6.2117; Zhou ZQ, 2001, P NATL ACAD SCI USA, V98, P12566, DOI 10.1073/pnas.221232998	73	5	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2004	23	35					5931	5940		10.1038/sj.onc.1207791	http://dx.doi.org/10.1038/sj.onc.1207791			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15208683				2022-12-28	WOS:000222941100007
J	Skinner, J; Bounacer, A; Bond, JA; Haughton, MF; DeMicco, C; Wynford-Thomas, D				Skinner, J; Bounacer, A; Bond, JA; Haughton, MF; DeMicco, C; Wynford-Thomas, D			Opposing effects of mutant ras oncoprotein on human fibroblast and epithelial cell proliferation: implications for models of human tumorigenesis	ONCOGENE			English	Article						ras oncogene; cell cycle; human tumours; epithelial; fibroblast; senescence	HUMAN BREAST-CANCER; INDUCED SENESCENCE; ACTIVATION; P16(INK4A); MUTATIONS; P21(CIP1); TUMORS; GROWTH; KINASE; GENES	Using microinjection of recombinant protein to directly control 'expression' levels, we have compared the proliferative response to ras oncogene activation in two normal cell types - fibroblast and thyroid epithelial cell which give rise to human tumours with very low and high frequencies of ras mutation respectively. A concentration-dependent stimulation of DNA synthesis was observed in thyrocytes, matched by an almost perfectly reciprocal inhibition in fibroblasts. A concentration-dependent induction of the cyclin-dependent kinase (CDK) inhibitor p21(WAF1) was observed in both cell types, but p16(Ink4a) was induced by ras only in fibroblasts. This difference could not account for the fibroblast specificity of the growth-inhibitory response, however, since proliferation of p16-deficient fibroblasts was also inhibited by mutant ras. We conclude that the striking contrast in proliferative response to ras between fibroblasts and thyroid epithelial cells cannot readily be explained by differential induction of either of the two key CDK inhibitors, p16(Ink4a) and p21(WAF1), but is consistent with a differential ability of p21(WAF1) to antagonize ras-induced mitogenic signals in the two cell types. Such tissue-specific differences provide an attractive explanation for the observed specificity of ras mutation for particular human tumour types, and emphasize the inappropriateness of fibroblasts as a model for ras-induced tumorigenesis.	Cardiff Univ, Canc Res UK Labs, Dept Pathol, Cardiff CF14 4XN, S Glam, Wales; Fac Med Nord, F-13916 Marseille, France	Cardiff University; UDICE-French Research Universities; Aix-Marseille Universite	Wynford-Thomas, D (corresponding author), Cardiff Univ, Canc Res UK Labs, Dept Pathol, Cardiff CF14 4XN, S Glam, Wales.	kingtd@cardiff.ac.uk						ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BOND JA, 1994, ONCOGENE, V9, P281; BOS JL, 1989, CANCER RES, V49, P4682; Bredel M, 1999, BRAIN RES REV, V29, P232, DOI 10.1016/S0165-0173(98)00057-5; Brookes S, 2002, EMBO J, V21, P2936, DOI 10.1093/emboj/cdf289; CAMPBELL C, 1993, BRIT J DERMATOL, V128, P111, DOI 10.1111/j.1365-2133.1993.tb15137.x; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Gire V, 1999, ONCOGENE, V18, P4819, DOI 10.1038/sj.onc.1202857; Gire V, 1998, MOL CELL BIOL, V18, P1611, DOI 10.1128/MCB.18.3.1611; GRUIS NA, 1995, NAT GENET, V10, P351, DOI 10.1038/ng0795-351; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Jones CJ, 2000, MOL CELL BIOL, V20, P5690, DOI 10.1128/MCB.20.15.5690-5699.2000; Lazarov M, 2002, NAT MED, V8, P1105, DOI 10.1038/nm779; LEMOINE NR, 1989, ONCOGENE, V4, P159; Rich JN, 2001, CANCER RES, V61, P3556; Rossig L, 2001, MOL CELL BIOL, V21, P5644, DOI 10.1128/MCB.21.16.5644-5657.2001; Schmitt CA, 2003, NAT REV CANCER, V3, P286, DOI 10.1038/nrc1044; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SUAREZ HG, 1990, ONCOGENE, V5, P565; von Lintig FC, 2000, BREAST CANCER RES TR, V62, P51, DOI 10.1023/A:1006491619920; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; Wei WY, 2003, MOL CELL BIOL, V23, P2859, DOI 10.1128/MCB.23.8.2859-2870.2003; WILLIAMS DW, 1988, BRIT J CANCER, V57, P535, DOI 10.1038/bjc.1988.124; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Zhu YA, 2002, NAT REV CANCER, V2, P616, DOI 10.1038/nrc866	26	14	14	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2004	23	35					5994	5999		10.1038/sj.onc.1207798	http://dx.doi.org/10.1038/sj.onc.1207798			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15208687				2022-12-28	WOS:000222941100014
J	Wang, L; Pan, Y; Dai, JL				Wang, L; Pan, Y; Dai, JL			Evidence of MKK4 pro-oncogenic activity in breast and pancreatic tumors	ONCOGENE			English	Article						MKK4; MAP kinase; oncogenes; apoptosis	METASTASIS SUPPRESSOR GENE; JUN NH2-TERMINAL KINASE; LUNG-CARCINOMA CELLS; N-TERMINAL KINASE; SIGNAL-TRANSDUCTION; PROTEIN-KINASES; CANCER; GROWTH; JNK; TRANSFORMATION	MKK4, located in close proximity to p53 gene, is thought to be a tumor suppressor and a metastasis suppressor gene. A low-rate MKK4 gene alteration has been found in a few tumor types, including breast and pancreatic. A suppressor activity for prostate and ovarian tumor metastasis has also been suggested. To understand the pathobiologic roles of MKK4 in tumorigenesis, we examined the phenotypic changes in response to perturbation of the MKK4 expression in breast and pancreatic cancer cell lines. Ectopic expression of MKK4 by adenoviral delivery in MKK4-negative cancer lines stimulated the cell proliferation and invasion, whereas knockdown of MKK4 expression by small interference RNA in an MKK4-positive breast cancer cell line, MDA-MB-231, resulted in decreased anchorage-independent growth, suppressed tumor growth in mouse xenograft model, and increased cell susceptibility to apoptosis brought by stress signals such as serum deprivation. These results argue that MKK4 functions as a pro-oncogenic molecule instead of a suppressor in breast and pancreatic tumors.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Dai, JL (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Unit 089,1515 Holcombe Blvd, Houston, TX 77030 USA.	jldai@mdanderson.org						Behrens A, 2000, ONCOGENE, V19, P2657, DOI 10.1038/sj.onc.1203603; Bost F, 1997, J BIOL CHEM, V272, P33422, DOI 10.1074/jbc.272.52.33422; Chae KS, 2002, EUR J CANCER, V38, P2048, DOI 10.1016/S0959-8049(02)00147-8; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Cuenda A, 2000, INT J BIOCHEM CELL B, V32, P581, DOI 10.1016/S1357-2725(00)00003-0; Dai JL, 1999, MOL CARCINOGEN, V26, P37, DOI 10.1002/(SICI)1098-2744(199909)26:1<37::AID-MC5>3.0.CO;2-6; Dai JL, 1999, P NATL ACAD SCI USA, V96, P1427, DOI 10.1073/pnas.96.4.1427; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Ganiatsas S, 1998, P NATL ACAD SCI USA, V95, P6881, DOI 10.1073/pnas.95.12.6881; Hess P, 2002, NAT GENET, V32, P201, DOI 10.1038/ng946; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kennedy NJ, 2003, GENE DEV, V17, P629, DOI 10.1101/gad.1062903; Kim HL, 2001, CANCER RES, V61, P2833; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lee HY, 2003, J BIOL CHEM, V278, P23630, DOI 10.1074/jbc.M300997200; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Potapova O, 1997, J BIOL CHEM, V272, P14041, DOI 10.1074/jbc.272.22.14041; Potapova O, 2000, J BIOL CHEM, V275, P24767, DOI 10.1074/jbc.M904591199; ROCKWELL SC, 1972, J NATL CANCER I, V49, P735; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Su Gloria H, 2002, Hum Mutat, V19, P81, DOI 10.1002/humu.9002; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Teng DHF, 1997, CANCER RES, V57, P4177; Wang L, 2003, CANCER RES, V63, P4724; Wu CW, 2000, AM J PATHOL, V156, P2007, DOI 10.1016/S0002-9440(10)65073-0; Xiao L, 2000, CANCER RES, V60, P400; Yamada SD, 2002, CANCER RES, V62, P6717; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Yang YM, 2003, CLIN CANCER RES, V9, P391; Yoshida BA, 1999, CANCER RES, V59, P5483	35	85	93	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 5	2004	23	35					5978	5985		10.1038/sj.onc.1207802	http://dx.doi.org/10.1038/sj.onc.1207802			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15184866				2022-12-28	WOS:000222941100012
J	Vaidyanathan, G; Cismowski, MJ; Wang, GS; Vincent, TS; Brown, KD; Lanier, SM				Vaidyanathan, G; Cismowski, MJ; Wang, GS; Vincent, TS; Brown, KD; Lanier, SM			The Ras-related protein AGS1/RASD1 suppresses cell growth	ONCOGENE			English	Article						AGS1; RASD1; Dexras1; G-protein; apoptosis; cancer	SIGNAL-TRANSDUCTION; COUPLED RECEPTORS; BINDING PROTEIN; GENE; IDENTIFICATION; DEXRAS1; INTEGRATION; ACTIVATION; HORMONE	AGS1/RASD1 is a Ras-related protein identified as a dexamethasone-inducible cDNA and as a signal regulator in various functional and protein-interaction screens. As an initial approach to define the role of AGS1/RASD1 as a Ras-family member, we determined its influence on cell growth/survival. In clonogenic assays with NIH-3T3 murine fibroblast cells, the MCF-7 human breast cancer cell line and the human lung adenocarcinoma cell line A549, AGS1/RASD1 markedly diminished the number of G418-resistant colonies, whereas the Ras subgroup member K-Ras was without effect. A549 cell infection with adenovirus engineered to express AGS1/RASD1 (Ad.AGS1) inhibited log phase growth in vitro and increased the percentage of cells undergoing apoptosis. The anti-growth action was also observed in vivo as the expression of AGS1/RASD1 inhibited the subcutaneous tumor growth of A549 cells in athymic nude mice. These data indicate that AGS1/RASD1, a member of the Ras superfamily of small G-proteins that often promotes cell growth and tumor expansion, plays an active role in preventing aberrant cell growth.	Louisiana State Univ, Ctr Hlth Sci, Dept Pharmacol & Expt Therapeut, New Orleans, LA 70112 USA; NE Ohio Univ, Coll Med, Dept Physiol & Pharmacol, Rootstown, OH 44272 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Med & Genet, Baton Rouge, LA 70803 USA; W Virginia Univ, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA; Louisiana State Univ, Ctr Hlth Sci, Stanley S Scott Canc Ctr, Baton Rouge, LA 70803 USA	Louisiana State University System; Northeast Ohio Medical University (NEOMED); Louisiana State University System; Louisiana State University; Louisiana State University Health Sciences Center at Shreveport; West Virginia University; Louisiana State University System; Louisiana State University	Lanier, SM (corresponding author), Louisiana State Univ, Ctr Hlth Sci, Dept Pharmacol & Expt Therapeut, 1901 Perdido St, New Orleans, LA 70112 USA.	slanie@lsuhsc.edu	Cismowski, Mary/E-2897-2011	Lanier, Stephen/0000-0002-2740-7607	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024821, R29NS024821] Funding Source: NIH RePORTER; NIMH NIH HHS [MH90531] Funding Source: Medline; NINDS NIH HHS [NS24821] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Cismowski MJ, 2000, J BIOL CHEM, V275, P23421, DOI 10.1074/jbc.C000322200; Cismowski MJ, 1999, NAT BIOTECHNOL, V17, P878, DOI 10.1038/12867; Der C J, 1989, Cancer Treat Res, V47, P73; Ellis CA, 2002, P NATL ACAD SCI USA, V99, P9876, DOI 10.1073/pnas.142193799; Fang M, 2000, NEURON, V28, P183, DOI 10.1016/S0896-6273(00)00095-7; Finlin BS, 2001, J BIOL CHEM, V276, P42259, DOI 10.1074/jbc.M105888200; Foster R, 1996, MOL CELL BIOL, V16, P2689; Graham TE, 2001, ENDOCRINOLOGY, V142, P2631, DOI 10.1210/en.142.6.2631; Graham TE, 2002, J BIOL CHEM, V277, P10876, DOI 10.1074/jbc.M110397200; Gudermann T, 2000, N-S ARCH PHARMACOL, V361, P345, DOI 10.1007/s002109900208; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; Jaffrey SR, 2002, CHEM BIOL, V9, P1329, DOI 10.1016/S1074-5521(02)00293-4; Kemppainen RJ, 2003, BBA-GENE STRUCT EXPR, V1627, P85, DOI 10.1016/S0167-4781(03)00079-4; Kemppainen RJ, 1998, J BIOL CHEM, V273, P3129, DOI 10.1074/jbc.273.6.3129; Koga T, 2002, CANCER GENET CYTOGEN, V136, P113, DOI 10.1016/S0165-4608(02)00527-7; LANIER SM, 1991, J BIOL CHEM, V266, P10470; Lanson NA, 2003, CANCER RES, V63, P7936; Luo RZ, 2003, ONCOGENE, V22, P2897, DOI 10.1038/sj.onc.1206380; Soenen V, 1998, BLOOD, V91, P1008, DOI 10.1182/blood.V91.3.1008.1008_1008_1015; Stacey MW, 1999, GENE CHROMOSOME CANC, V25, P191, DOI 10.1002/(SICI)1098-2264(199906)25:2<191::AID-GCC16>3.0.CO;2-8; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Takesono A, 1999, J BIOL CHEM, V274, P33202, DOI 10.1074/jbc.274.47.33202; Takesono A, 2002, J BIOL CHEM, V277, P13827, DOI 10.1074/jbc.M201064200; Tu YZ, 1999, BBA-GENE STRUCT EXPR, V1489, P452, DOI 10.1016/S0167-4781(99)00197-9; Vargiu P, 2004, ONCOGENE, V23, P559, DOI 10.1038/sj.onc.1207161	25	86	91	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2004	23	34					5858	5863		10.1038/sj.onc.1207774	http://dx.doi.org/10.1038/sj.onc.1207774			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KW	15184869				2022-12-28	WOS:000222629800016
J	Chen, CF; Goyette, P; Lohnes, D				Chen, CF; Goyette, P; Lohnes, D			RAR gamma acts as a tumor suppressor in mouse keratinocytes	ONCOGENE			English	Article						retinoic acid receptors; Ras; skin tumorigenesis; keratinocytes; squamous cell carcinoma; tumor suppressor	RETINOIC ACID RECEPTOR; TARGETED DISRUPTION; NUCLEAR RECEPTORS; DOWN-REGULATION; CYCLIN D1; BETA 2; SKIN; CELLS; ACTIVATION; EXPRESSION	All-trans retinoic acid (RA), the principal biologically active form of vitamin A, is essential for many developmental process as well as homeostasis in the adult. Many lines of evidence also suggest that RA, acting through the RA receptors (RARs), can also suppress growth of tumors of diverse origin. To assess directly the role of the RARs in a model of epidermal tumorigenesis, we investigated the incidence of tumor formation using keratinocytes lacking specific RAR types. Our data suggest that loss of RARgamma, but not RARalpha, predisposed keratinocytes to v-Ha-Ras-induced squamous cell carcinoma. We also found that ablation of RARgamma, but not RARalpha, abolished RA-induced cell cycle arrest and apoptosis in these keratinocytes. Reconstitution of receptor expression into RAR-null cells restored sensitivity to RA, and reversed the tumorigenic potential of receptor-deficient keratinocytes. These data strongly support a tumor suppressor effect for the RARs, in particular endogenous RARgamma, in murine keratinocytes.	Clin Res Inst Montreal, Montreal, PQ H2W 1R7, Canada; McGill Univ, Div Expt Med, Montreal, PQ H3A 2T5, Canada; Univ Montreal, Dept Mol Biol, Montreal, PQ H3C 3J7, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; McGill University; Universite de Montreal	Lohnes, D (corresponding author), Clin Res Inst Montreal, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.	lohnesd@ircm.qc.ca						Adnane J, 2000, ONCOGENE, V19, P5338, DOI 10.1038/sj.onc.1203956; Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Angel P, 1992, Matrix Suppl, V1, P156; Berard J, 1996, FASEB J, V10, P1091, DOI 10.1096/fasebj.10.9.8801172; Borriello A, 2000, ONCOGENE, V19, P51, DOI 10.1038/sj.onc.1203231; Bost F, 2002, BIOCHEM J, V361, P621, DOI 10.1042/0264-6021:3610621; Boudjelal M, 2000, CANCER RES, V60, P2247; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; Boyle JO, 1999, J NATL CANCER I, V91, P373, DOI 10.1093/jnci/91.4.373; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chapellier B, 2002, EMBO J, V21, P3402, DOI 10.1093/emboj/cdf331; CHEN LC, 1995, CANCER LETT, V95, P113, DOI 10.1016/0304-3835(95)03868-W; Chiba H, 1997, MOL CELL BIOL, V17, P3013, DOI 10.1128/MCB.17.6.3013; Chiba H, 1997, J CELL BIOL, V139, P735, DOI 10.1083/jcb.139.3.735; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Darwiche N, 1996, CANCER RES, V56, P4942; DARWICHE N, 1995, CANCER RES, V55, P2774; De Luca LM, 1996, NUTR CANCER, V25, P249, DOI 10.1080/01635589609514449; Dimberg A, 2002, BLOOD, V99, P2199, DOI 10.1182/blood.V99.6.2199; Faria TN, 1999, J BIOL CHEM, V274, P26783, DOI 10.1074/jbc.274.38.26783; Fisher GJ, 1996, FASEB J, V10, P1002, DOI 10.1096/fasebj.10.9.8801161; Fontana JA, 2002, LEUKEMIA, V16, P463, DOI 10.1038/sj.leu.2402414; Ghyselinck NB, 1997, INT J DEV BIOL, V41, P425; Gianni M, 2002, J BIOL CHEM, V277, P24859, DOI 10.1074/jbc.C200230200; GIMENEZCONTI I, 1990, CARCINOGENESIS, V11, P1995, DOI 10.1093/carcin/11.11.1995; Goyette P, 2000, J BIOL CHEM, V275, P16497, DOI 10.1074/jbc.M909382199; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hansen LA, 2003, CANCER RES, V63, P5257; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; Houle M, 2000, MOL CELL BIOL, V20, P6579, DOI 10.1128/MCB.20.17.6579-6586.2000; Huang CS, 1997, P NATL ACAD SCI USA, V94, P5826, DOI 10.1073/pnas.94.11.5826; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Klaassen I, 2001, INT J CANCER, V92, P661, DOI 10.1002/1097-0215(20010601)92:5<661::AID-IJC1251>3.0.CO;2-O; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; KUMAR R, 1994, CARCINOGENESIS, V15, P701, DOI 10.1093/carcin/15.4.701; Langenfeld J, 1997, P NATL ACAD SCI USA, V94, P12070, DOI 10.1073/pnas.94.22.12070; LARCHER F, 1992, MOL CARCINOGEN, V6, P112, DOI 10.1002/mc.2940060206; Le Q, 2000, ONCOGENE, V19, P1457, DOI 10.1038/sj.onc.1203436; Lee HY, 1999, MOL CELL BIOL, V19, P1973; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; LOHNES D, 1994, DEVELOPMENT, V120, P2723; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; LUFKIN T, 1993, P NATL ACAD SCI USA, V90, P7225, DOI 10.1073/pnas.90.15.7225; MARKS R, 1995, CANCER-AM CANCER SOC, V75, P607, DOI 10.1002/1097-0142(19950115)75:2+<607::AID-CNCR2820751402>3.0.CO;2-8; Mehta K, 2003, J BIOL REG HOMEOS AG, V17, P1; MENDELSOHN C, 1994, DEVELOPMENT, V120, P2749; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Moller MB, 2000, LEUKEMIA LYMPHOMA, V39, P19, DOI 10.3109/10428190009053535; Naderi S, 1999, BLOOD, V94, P1348, DOI 10.1182/blood.V94.4.1348.416k29_1348_1358; NELSON KG, 1982, CANCER RES, V42, P4176; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Oridate N, 1996, ONCOGENE, V12, P2019; Pepper C, 2002, EUR J HAEMATOL, V69, P227, DOI 10.1034/j.1600-0609.2002.02799.x; Philipp J, 1999, ONCOGENE, V18, P4689, DOI 10.1038/sj.onc.1202840; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Rommel C, 1998, CURR OPIN GENET DEV, V8, P412, DOI 10.1016/S0959-437X(98)80111-1; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; Ross SA, 2000, PHYSIOL REV, V80, P1021, DOI 10.1152/physrev.2000.80.3.1021; Sebolt-Leopold JS, 2000, ONCOGENE, V19, P6594, DOI 10.1038/sj.onc.1204083; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; SHEIKH MS, 1994, J BIOL CHEM, V269, P21440; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; Sun SY, 2002, CRIT REV ONCOL HEMAT, V41, P41, DOI 10.1016/S1040-8428(01)00144-5; TANEJA R, 1995, P NATL ACAD SCI USA, V92, P7854, DOI 10.1073/pnas.92.17.7854; Taneja R, 1996, P NATL ACAD SCI USA, V93, P6197, DOI 10.1073/pnas.93.12.6197; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; Wang ZQ, 1999, NAT MED, V5, P418, DOI 10.1038/7417; Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773; Wei LN, 2003, ANNU REV PHARMACOL, V43, P47, DOI 10.1146/annurev.pharmtox.43.100901.140301; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wu JM, 2001, APOPTOSIS, V6, P377, DOI 10.1023/A:1011342220621; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Xu XC, 2001, CANCER RES, V61, P4306; Yen A, 1999, IN VITRO CELL DEV-AN, V35, P527; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; Yuspa SH, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P147; Zhang DM, 2001, ONCOGENE, V20, P7935, DOI 10.1038/sj.onc.1204971; ZHANG LX, 1995, J BIOL CHEM, V270, P6022, DOI 10.1074/jbc.270.11.6022	86	32	37	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2004	23	31					5350	5359		10.1038/sj.onc.1207682	http://dx.doi.org/10.1038/sj.onc.1207682			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15094780				2022-12-28	WOS:000222491600010
J	McGarry, LC; Winnie, JN; Ozanne, BW				McGarry, LC; Winnie, JN; Ozanne, BW			Invasion of v-Fos(FBR)-transformed cells is dependent upon histone deacetylase activity and suppression of histone deacetylase regulated genes	ONCOGENE			English	Article						Fos; invasion; deacetylase; STAT6; protocadherin; RYBP	TRANSCRIPTION FACTOR; TRANSFORMED FIBROBLASTS; MULTIGENIC INVASION; POLYCOMB COMPLEX; FLAT PHENOTYPE; UP-REGULATION; RAS-ONCOGENE; AP-1; DIFFERENTIATION; ACETYLATION	Transformation of fibroblasts with the v-fos oncogene produces a highly invasive phenotype that is mediated by changes in gene expression. Inhibition of histone deacetylase (HDAC) activity with trichostatin A (TSA) or valproic acid (VPA) at concentrations that do not affect morphology, motility, chemotaxis or proliferation, strongly inhibits invasion and results in the re-expression of a significant proportion of those genes that are downregulated in the v-Fos-transformed cells. Independent expression of three of these re-expressed genes, (Ring1 and YY1 binding protein (RYBP); protocadherin gamma subfamily C, 3 (PCDHGC3); and signal transducer and activator of transcription 6 (STAT6)) in Fos-transformed cells, has no effect on morphology, motility, chemotaxis or proliferation, but strongly inhibits invasion. Therefore, we conclude that the ability of v-Fos-transformed cells to invade is dependent upon repression of gene expression through either direct or indirect HDAC activity.	Beatson Inst Canc Res, Canc Res UK, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute; Cancer Research UK	Ozanne, BW (corresponding author), Beatson Inst Canc Res, Canc Res UK, Beatson Labs, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	b.ozanne@beatson.gla.ac.uk						Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Buttner C, 2004, J CELL PHYSIOL, V198, P248, DOI 10.1002/jcp.10395; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Garcia E, 1999, EMBO J, V18, P3404, DOI 10.1093/emboj/18.12.3404; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; HENNIGAN RF, 1994, ONCOGENE, V9, P3591; Imai T, 2003, ONCOGENE, V22, P9231, DOI 10.1038/sj.onc.1207184; Johnston IMP, 2000, ONCOGENE, V19, P5348, DOI 10.1038/sj.onc.1203927; Kelly WK, 2002, EXPERT OPIN INV DRUG, V11, P1695, DOI 10.1517/13543784.11.12.1695; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Kwon HJ, 1998, P NATL ACAD SCI USA, V95, P3356, DOI 10.1073/pnas.95.7.3356; Lamb RF, 1997, CURR BIOL, V7, P682, DOI 10.1016/S0960-9822(06)00295-8; Lamb RF, 1997, MOL CELL BIOL, V17, P963, DOI 10.1128/MCB.17.2.963; Lehrmann H, 2002, ADV CANCER RES, V86, P41, DOI 10.1016/S0065-230X(02)86002-X; Liu LT, 2003, CANCER RES, V63, P3069; Marks PA, 2003, CURR OPIN PHARMACOL, V3, P344, DOI 10.1016/S1471-4892(03)00084-5; Masui T, 2003, CLIN CANCER RES, V9, P1779; MATSUMOTO M, 1992, J ANTIBIOT, V45, P879, DOI 10.7164/antibiotics.45.879; McGaha TL, 2003, ARTHRITIS RHEUM-US, V48, P2275, DOI 10.1002/art.11089; Ozanne BW, 2000, EUR J CANCER, V36, P1640, DOI 10.1016/S0959-8049(00)00175-1; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; Rosato RR, 2003, CANCER RES, V63, P3637; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANO K, 1993, EMBO J, V12, P2249, DOI 10.1002/j.1460-2075.1993.tb05878.x; Schlisio S, 2002, EMBO J, V21, P5775, DOI 10.1093/emboj/cdf577; Scott LA, 2004, MOL CELL BIOL, V24, P1540, DOI 10.1128/MCB.24.4.1540-1559.2004; Spence HJ, 2000, ONCOGENE, V19, P1266, DOI 10.1038/sj.onc.1203433; Stapleton G, 2002, J CELL SCI, V115, P2713; SUGITA K, 1992, BIOCHEM BIOPH RES CO, V182, P379, DOI 10.1016/S0006-291X(05)80156-1; Suzuki ST, 2000, EXP CELL RES, V261, P13, DOI 10.1006/excr.2000.5039; Timmermann S, 2001, CELL MOL LIFE SCI, V58, P728, DOI 10.1007/PL00000896; Trimarchi JM, 2001, P NATL ACAD SCI USA, V98, P1519, DOI 10.1073/pnas.041597698; Yamashita Y, 2003, INT J CANCER, V103, P572, DOI 10.1002/ijc.10699; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	38	36	39	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2004	23	31					5284	5292		10.1038/sj.onc.1207687	http://dx.doi.org/10.1038/sj.onc.1207687			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15107823				2022-12-28	WOS:000222491600004
J	Apostolou, S; Klein, JO; Mitsuuchi, Y; Shetler, JN; Poulikakos, PI; Jhanwar, SC; Kruger, WD; Testa, JR				Apostolou, S; Klein, JO; Mitsuuchi, Y; Shetler, JN; Poulikakos, PI; Jhanwar, SC; Kruger, WD; Testa, JR			Growth inhibition and induction of apoptosis in mesothelioma cells by selenium and dependence on selenoprotein SEP15 genotype	ONCOGENE			English	Article						mesothelioma; selenium; chemoprevention; apoptosis; SEP15 genotype	SUPPRESSION SUBTRACTIVE HYBRIDIZATION; HUMAN-MALIGNANT MESOTHELIOMA; CANCER PREVENTION; EXPRESSION; GENE; SELENOCYSTEINE; PROTEIN; REGION; RISK	Malignant mesotheliomas (MMs) are aggressive tumors derived from mesothelial cells lining the lungs, pericardium and peritoneum, and are often associated with occupational asbestos exposure. Suppression subtractive hybridization was used to identify genes differentially expressed in MM cells compared to normal mesothelial cells. A gene, SEP15, encoding a 15-kDa selenium-containing protein was isolated using this approach and was subsequently shown to be downregulated in similar to60% of MM cell lines and tumor specimens. A SEP15 polymorphic variant, 1125A, resides in the SECIS recognition element in the 3'-UTR and may influence the efficiency of Sec incorporation into the protein during translation. Since previous studies have implicated a potential role of the trace element selenium as a chemopreventive agent in animal models and in several types of human cancer, we investigated the effect of selenium on MM cells and its dependence on SEP15 genotype. Selenium was shown to inhibit cell growth and induce apoptosis in a dose-dependent manner in MM cells but had minimal effect on normal mesothelial cells. However, MM cells with downregulated SEP15 or the 1125A variant were somewhat less responsive to the growth inhibitory and apoptotic effects of selenium than MM cells expressing wild-type protein. RNAi-based knockdown studies demonstrated that SEP15 inhibition makes sensitive MM cells more resistant to selenium. These data imply that selenium may be useful as a chemopreventive agent in individuals at high risk of MM due to asbestos exposure, although those with the 1125A polymorphism may be less responsive to the protective benefits of dietary selenium supplementation.	Fox Chase Canc Ctr, Human Genet Program, Philadelphia, PA 19111 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA	Fox Chase Cancer Center; Memorial Sloan Kettering Cancer Center	Testa, JR (corresponding author), Fox Chase Canc Ctr, Human Genet Program, 333 Cottman Ave, Philadelphia, PA 19111 USA.	JR_Testa@fccc.edu	Kruger, Warren/Y-2541-2018; kruger, warren/A-6407-2008	kruger, warren/0000-0002-4990-3695	NATIONAL CANCER INSTITUTE [R01CA045745, P30CA006927] Funding Source: NIH RePORTER; NCI NIH HHS [CA-06927, CA-45745] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Apostolou S, 1999, CELL, V97, P684, DOI 10.1016/S0092-8674(02)09765-9; BERRY MJ, 1993, EMBO J, V12, P3315, DOI 10.1002/j.1460-2075.1993.tb06001.x; Clark LC, 1996, JAMA-J AM MED ASSOC, V276, P1957, DOI 10.1001/jama.276.24.1957; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; DIPLOCK AT, 1993, AM J CLIN NUTR, V57, P256, DOI 10.1093/ajcn/57.2.256S; ELBAYOUMY K, 1991, CANCER PRINCIPLES PR, P1; Gladyshev VN, 1998, J BIOL CHEM, V273, P8910, DOI 10.1074/jbc.273.15.8910; Gray JW, 2000, CARCINOGENESIS, V21, P443, DOI 10.1093/carcin/21.3.443; Hu YJ, 2001, CANCER RES, V61, P2307; Hufton SE, 1999, FEBS LETT, V463, P77, DOI 10.1016/S0014-5793(99)01578-1; HUNTER DJ, 1990, JAMA-J AM MED ASSOC, V264, P1128, DOI 10.1001/jama.264.9.1128; Ip C, 1998, J NUTR, V128, P1845, DOI 10.1093/jn/128.11.1845; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kumaraswamy E, 2000, J BIOL CHEM, V275, P35540, DOI 10.1074/jbc.M004014200; Lee WC, 1996, CANCER RES, V56, P4297; Menter DG, 2000, CANCER EPIDEM BIOMAR, V9, P1171; Roberts D, 2002, DNA CELL BIOL, V21, P11, DOI 10.1089/10445490252810276; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Van Lieshout EMM, 1998, ONCOL REP, V5, P959; VANDENBRANDT PA, 1993, CANCER RES, V53, P4860; Zhang ZH, 1997, BIOL TRACE ELEM RES, V57, P147, DOI 10.1007/BF02778198	21	71	72	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					5032	5040		10.1038/sj.onc.1207683	http://dx.doi.org/10.1038/sj.onc.1207683			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15107826				2022-12-28	WOS:000222237300009
J	Kimmelman, AC; Qiao, RF; Narla, G; Banno, A; Lau, N; Bos, PD; Rodriguez, NN; Liang, BC; Guha, A; Martignetti, JA; Friedman, SL; Chan, AM				Kimmelman, AC; Qiao, RF; Narla, G; Banno, A; Lau, N; Bos, PD; Rodriguez, NN; Liang, BC; Guha, A; Martignetti, JA; Friedman, SL; Chan, AM			Suppression of glioblastoma tumorigenicity by the Kruppel-like transcription factor KLF6	ONCOGENE			English	Article						glioblastoma; tumor suppressor; KLF6; Kruppel; transcription factor	EPIDERMAL-GROWTH-FACTOR; HUMAN GLIOMAS; GENE; EXPRESSION; P53; OVEREXPRESSION; HETEROZYGOSITY; ACTIVATION; ONCOGENE; REGION	The Kruppel-like transcription factor KLF6 is a novel tumor-suppressor gene mutated in a significant fraction of human prostate cancer. It is localized to human chromosome 10p14-15, a region that displays frequent loss of heterozygosity in glioblastoma multiforme (GBM). Indeed, mutations of the KLF6 gene have recently been reported in this tumor type. In this study, we report that the expression of KLF6 is attenuated in human GBM when compared with primary astrocytes. Expression of KLF6 in GBM cells reverts their tumorigenicity both in vitro and in vivo, which is correlated with its transactivation of the p21/CIP1/WAF1 promoter. Additionally, KLF6 inhibits cellular transformation induced by several oncogenes (c-sis/PDGF-B, nu-src, H-Ras, and EGFR) that are components of signaling cascades implicated in GBM. Our results provide the first evidence of functional tumor suppression by KFL6, and its loss may contribute to glial tumor progression.	Mt Sinai Sch Med, Derald H Ruttenberg Ctr Canc, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Med, Div Liver Dis, New York, NY 10029 USA; Toronto Western Hosp, Div Neurosurg, Toronto, ON M5T 2S8, Canada; Biogen Idec, San Diego, CA 92121 USA; Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Biogen; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Chan, AM (corresponding author), Mt Sinai Sch Med, Derald H Ruttenberg Ctr Canc, 1 Gustave Levy Pl,Box 1130, New York, NY 10029 USA.	Andrew.Chan@mssm.edu	Chan, Andrew/AAC-1145-2020; Narla, Goutham/AAZ-5710-2020; Chan, Andrew Man-Lok/J-9497-2013	Chan, Andrew/0000-0001-9923-5464; Narla, Goutham/0000-0003-4098-4203; Chan, Andrew Man-Lok/0000-0001-9923-5464	NATIONAL CANCER INSTITUTE [R29CA078509, T32CA078207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037340] Funding Source: NIH RePORTER; NCI NIH HHS [CA78509, CA78207] Funding Source: Medline; NIDDK NIH HHS [DK37340] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANKER G, 1998, CULTURING NERVE CELL; Botella LM, 2002, BLOOD, V100, P4001, DOI 10.1182/blood.V100.12.4001; Broome MA, 1996, J BIOL CHEM, V271, P16798, DOI 10.1074/jbc.271.28.16798; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; Ding H, 2001, CANCER RES, V61, P3826; Givol I, 1995, ONCOGENE, V11, P2609; Harada K, 2000, GENOMICS, V67, P268, DOI 10.1006/geno.2000.6257; Holland EC, 2000, P NATL ACAD SCI USA, V97, P6242, DOI 10.1073/pnas.97.12.6242; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Jeng YM, 2003, INT J CANCER, V105, P625, DOI 10.1002/ijc.11123; Kato H, 2000, CLIN CANCER RES, V6, P3937; Kimmelman AC, 1996, GENOMICS, V34, P250, DOI 10.1006/geno.1996.0277; KLEIHUES P, 2000, WHO; Kojima S, 2000, BLOOD, V95, P1309; Kon H, 1998, ONCOGENE, V16, P257, DOI 10.1038/sj.onc.1201488; KRUSE CA, 1992, IN VITRO CELL DEV-AN, V28A, P609; LAROCHELLE WJ, 1990, SCIENCE, V248, P1541, DOI 10.1126/science.2163109; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; Osada M, 1999, MOL CELL BIOL, V19, P6333; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; RADANY EH, 1992, P NATL ACAD SCI USA, V89, P6467, DOI 10.1073/pnas.89.14.6467; Ratziu V, 1998, P NATL ACAD SCI USA, V95, P9500, DOI 10.1073/pnas.95.16.9500; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Theurillat JP, 1999, AM J PATHOL, V154, P581, DOI 10.1016/S0002-9440(10)65303-5; Turner J, 1999, TRENDS BIOCHEM SCI, V24, P236, DOI 10.1016/S0968-0004(99)01406-1; Voesten AMJ, 1997, GENE CHROMOSOME CANC, V20, P167, DOI 10.1002/(SICI)1098-2264(199710)20:2<167::AID-GCC7>3.0.CO;2-1; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200	30	69	71	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					5077	5083		10.1038/sj.onc.1207662	http://dx.doi.org/10.1038/sj.onc.1207662			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15064720				2022-12-28	WOS:000222237300014
J	Brennan, K; Gonzalez-Sancho, JM; Castelo-Soccio, LA; Howe, LR; Brown, AMC				Brennan, K; Gonzalez-Sancho, JM; Castelo-Soccio, LA; Howe, LR; Brown, AMC			Truncated mutants of the putative Wnt receptor LRP6/Arrow can stabilize beta-catenin independently of Frizzled proteins	ONCOGENE			English	Article						wnt signaling; beta-catenin; receptors; Frizzled; LRP6; Arrow	SIGNALING PATHWAY; SPEMANN ORGANIZER; ILLEGITIMATE TRANSCRIPTION; DROSOPHILA; WINGLESS; GENE; FAMILY; DENSITY; MECHANISM; MEMBER	Secreted signaling proteins of the Wnt family are known to regulate a diverse range of developmental processes, and their signaling pathway through beta-catenin is frequently activated in cancer. The identification of both Frizzled and LRP5/6 (LRP: low-density lipoprotein receptor-related protein) proteins as components of cell-surface receptors for Wnt proteins has raised questions about their individual functions. We have investigated this issue through a structure-function analysis of Frizzled and LRP proteins that have been implicated in Wnt1 signaling. Consistent with other reports, we find that LRP6/Arrow proteins deleted for their extracellular domain are able to activate the Wnt/beta-catenin signaling pathway. Importantly, our results demonstrate that this signaling from LRP6/Arrow derivatives can occur in a Frizzled- and ligand-independent manner. Furthermore, we show that the PPSP motifs within the intracellular domain of LRP6 are required for signaling. In contrast to results with LRP6, overexpression of Frizzled proteins did not activate the pathway. Based on evidence of ligand binding to both Frizzled and LRP6, current models suggest that both proteins are components of a Wnt receptor complex that signals to beta-catenin. In light of these models, our data imply that LRP5/6/Arrow proteins constitute the distal signal-initiating component of these receptors. The results also support the notion that LRP5/6 are candidate oncogenes.	Cornell Univ, Weill Med Coll, Dept Cell & Dev Biol, New York, NY 10021 USA; Rockefeller Univ, Strang Canc Res Lab, New York, NY 10021 USA	Cornell University; Rockefeller University	Brown, AMC (corresponding author), Cornell Univ, Weill Med Coll, Dept Cell & Dev Biol, 1300 York Ave, New York, NY 10021 USA.	amcbrown@med.cornell.edu	Gonzalez-Sancho, Jose/AAA-6010-2019	Gonzalez-Sancho, Jose/0000-0001-5875-1964; Howe, Louise/0000-0002-1468-7136; Brennan, Keith/0000-0002-9384-125X	NCI NIH HHS [CA47207, R01 CA047207] Funding Source: Medline; NIGMS NIH HHS [R01 GM067739, GM67739] Funding Source: Medline; Wellcome Trust [065994] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047207, R29CA047207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067739] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Bhanot P, 1999, DEVELOPMENT, V126, P4175; Binari RC, 1997, DEVELOPMENT, V124, P2623; Boutros M, 2000, SCIENCE, V288, P1825, DOI 10.1126/science.288.5472.1825; Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444; BRADLEY RS, 1995, MOL CELL BIOL, V15, P4616; Brown SD, 1998, BIOCHEM BIOPH RES CO, V248, P879, DOI 10.1006/bbrc.1998.9061; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CHAN SDH, 1992, J BIOL CHEM, V267, P25202; CHELLY J, 1989, P NATL ACAD SCI USA, V86, P2617, DOI 10.1073/pnas.86.8.2617; Chen CM, 1999, DEVELOPMENT, V126, P5441; Deardorff' MA, 1998, DEVELOPMENT, V125, P2687; Deardorff MA, 2001, DEVELOPMENT, V128, P3655; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Gazit A, 1999, ONCOGENE, V18, P5959, DOI 10.1038/sj.onc.1202985; Giarre M, 1998, ANN NY ACAD SCI, V857, P43, DOI 10.1111/j.1749-6632.1998.tb10106.x; He X, 1997, SCIENCE, V275, P1652, DOI 10.1126/science.275.5306.1652; Hecht A, 2000, EMBO REP, V1, P24, DOI 10.1093/embo-reports/kvd012; Holmen SL, 2002, J BIOL CHEM, V277, P34727, DOI 10.1074/jbc.M204989200; Howe LR, 2001, J BIOL CHEM, V276, P20108, DOI 10.1074/jbc.M010692200; Hsieh JC, 1999, P NATL ACAD SCI USA, V96, P3546, DOI 10.1073/pnas.96.7.3546; Huelsken J, 2001, CURR OPIN GENET DEV, V11, P547, DOI 10.1016/S0959-437X(00)00231-8; Huelsken J, 2002, J CELL SCI, V115, P3977, DOI 10.1242/jcs.00089; Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141; Kaplan Jean-Claude, 1992, Human Mutation, V1, P357, DOI 10.1002/humu.1380010502; Karasawa T, 2002, J BIOL CHEM, V277, P37479, DOI 10.1074/jbc.M205658200; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450; Liu GZ, 2003, MOL CELL BIOL, V23, P5825, DOI 10.1128/MCB.23.16.5825-5835.2003; Longo KA, 2002, J BIOL CHEM, V277, P38239, DOI 10.1074/jbc.M206402200; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; Nusse R, 1997, COLD SPRING HARB SYM, V62, P185; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Polakis P, 2000, GENE DEV, V14, P1837; Sato A, 1999, DEVELOPMENT, V126, P4421; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schweizer L, 2003, BMC CELL BIOL, V4, DOI 10.1186/1471-2121-4-4; Semenov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Tamai K, 2004, MOL CELL, V13, P149, DOI 10.1016/S1097-2765(03)00484-2; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Tolwinski NS, 2003, DEV CELL, V4, P407, DOI 10.1016/S1534-5807(03)00063-7; Toyofuku T, 2000, J CELL BIOL, V150, P225, DOI 10.1083/jcb.150.1.225; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; Umbhauer M, 2000, EMBO J, V19, P4944, DOI 10.1093/emboj/19.18.4944; Uren A, 2000, J BIOL CHEM, V275, P4374, DOI 10.1074/jbc.275.6.4374; Uusitalo M, 1999, EXP CELL RES, V253, P336, DOI 10.1006/excr.1999.4710; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4; Wang YS, 1996, J BIOL CHEM, V271, P4468; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960-9822(02)70716-1; You ZB, 2002, J CELL BIOL, V157, P429, DOI 10.1083/jcb.200201110	60	83	87	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2004	23	28					4873	4884		10.1038/sj.onc.1207642	http://dx.doi.org/10.1038/sj.onc.1207642			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	830EK	15064719	Green Accepted			2022-12-28	WOS:000222104200008
J	Cuadrado, A; Gonzalez, L; Suarez, Y; Martinez, T; Munoz, A				Cuadrado, A; Gonzalez, L; Suarez, Y; Martinez, T; Munoz, A			JNK activation is critical for Aplidin (TM)-induced apoptosis	ONCOGENE			English	Article						Aplidin (TM); apoptosis; JNK; c-Jun; AP-1 NF-kappa B	NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; OXIDATIVE STRESS; TYROSINE PHOSPHORYLATION; DEHYDRODIDEMNIN B; CANCER-CELLS; C-MYC; DEGRADATION; REQUIREMENT; APLIDINE	Aplidin(TM) is an antitumor drug that induces apoptosis and activates EGFR, Src, JNK and p38MAPK. Here, we show that Aplidin(TM) induces c-JUN, JUN B, JUN D, c-FOS, FRA-1 and FOS B genes of the activator-protein (AP)-1 family, and also p65/RELA, a major component of nuclear factor-kappaB (NF-kappaB). Concordantly, Aplidin(TM) increases AP-1 and NF-kappaB activity. c-FOS induction depends on EGFR, Src and JNK/p38MAPK. In contrast, induction of c-JUN does not require EGFR activity and p65/RELA induction is only partially dependent on these kinases. We used several genetically deficient cells to identify the critical target of Aplidin(TM). Mouse embryo fibroblasts (MEFs) deficient for src, yes and fyn, and those lacking all p38MAPK isoforms displayed normal Aplidin(TM) sensitivity (IC50 = 12 nM). In contrast, MEFs lacking jnk1 and jnk2, which do not express any JNK isoform, were much less sensitive (IC50 > 500 nM). Furthermore, cells lacking c-jun or expressing a c-Jun protein in which JNK targets Ser(63/73) were mutated (c-JunAA) showed intermediate sensitivity (IC50 = 60 nM). Additionally, Aplidin(T) has higher cytotoxic activity against proliferating than quiescent cells, which is reflected in higher JNK activation. We conclude that phosphorylation by JNK of c-Jun and additional substrate(s) is crucial for Aplidin(TM) activity.	Univ Autonoma Madrid, Inst Invest Biomed Alberto Sols, CSIC, E-28029 Madrid, Spain; Pharma Mar SA, E-28770 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); PharmaMar	Munoz, A (corresponding author), Univ Autonoma Madrid, Inst Invest Biomed Alberto Sols, CSIC, E-28029 Madrid, Spain.	amunoz@iib.uam.es	Cuadrado, Ana/HGU-4777-2022; Munoz, Alberto/O-6393-2014; Cuadrado, Ana/AAA-9277-2019	Munoz, Alberto/0000-0003-3890-4251; Cuadrado, Ana/0000-0002-9752-5932; Suarez, Yajaira/0000-0003-4549-2953				Biswas G, 2003, J CELL BIOL, V161, P507, DOI 10.1083/jcb.200211104; Bowie A, 2000, BIOCHEM PHARMACOL, V59, P13, DOI 10.1016/S0006-2952(99)00296-8; Broggini M, 2003, LEUKEMIA, V17, P52, DOI 10.1038/sj.leu.2402788; Canty TG, 1999, CIRCULATION, V100, P361; Cuadrado A, 2003, J BIOL CHEM, V278, P241, DOI 10.1074/jbc.M201010200; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Depenbrock H, 1998, BRIT J CANCER, V78, P739, DOI 10.1038/bjc.1998.570; Erba E, 2002, BRIT J CANCER, V86, P1510, DOI 10.1038/sj.bjc.6600265; Erba E., 1999, P AM ASSOC CANC RES, V40, P3; Faircloth G., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P103; Garcia-Fernandez LF, 2002, ONCOGENE, V21, P7533, DOI 10.1038/sj.onc.1205972; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; GomezFabre PM, 1997, CANCER LETT, V113, P141, DOI 10.1016/S0304-3835(96)04591-0; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Janssen-Heininger YMW, 1999, AM J RESP CELL MOL, V20, P942, DOI 10.1165/ajrcmb.20.5.3452; Janssen-Heininger YMW, 2000, FREE RADICAL BIO MED, V28, P1317, DOI 10.1016/S0891-5849(00)00218-5; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kaltschmidt B, 2000, EUR J BIOCHEM, V267, P3828, DOI 10.1046/j.1432-1327.2000.01421.x; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Liedtke C, 2002, HEPATOLOGY, V36, P315, DOI 10.1053/jhep.2002.34615; Lobo C, 1997, ANTICANCER RES, V17, P333; Morton S, 2003, EMBO J, V22, P3876, DOI 10.1093/emboj/cdg388; Newton TR, 1999, J BIOL CHEM, V274, P18827, DOI 10.1074/jbc.274.26.18827; Noguchi K, 1999, J BIOL CHEM, V274, P32580, DOI 10.1074/jbc.274.46.32580; ONGIL SL, 1998, BRIT J PHARMACOL, V124, P447; Raymond E., 2001, European Journal of Cancer, V37, pS32, DOI 10.1016/S0959-8049(01)80599-2; Sakai R, 1996, J MED CHEM, V39, P2819, DOI 10.1021/jm960048g; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Singh S, 1996, J BIOL CHEM, V271, P31049, DOI 10.1074/jbc.271.49.31049; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Urdiales JL, 1996, CANCER LETT, V102, P31, DOI 10.1016/0304-3835(96)04151-1; Wang XN, 2000, EXP CELL RES, V258, P425, DOI 10.1006/excr.2000.4939; Weiss C, 2003, EMBO J, V22, P3686, DOI 10.1093/emboj/cdg364; Yao L, 2003, IDRUGS, V6, P246	37	61	64	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2004	23	27					4673	4680		10.1038/sj.onc.1207636	http://dx.doi.org/10.1038/sj.onc.1207636			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZX	15122339				2022-12-28	WOS:000221799200003
J	Jackson, MW; Agarwal, MK; Agarwal, ML; Agarwal, A; Stanhope-Baker, P; Williams, BRG; Stark, GR				Jackson, MW; Agarwal, MK; Agarwal, ML; Agarwal, A; Stanhope-Baker, P; Williams, BRG; Stark, GR			Limited role of N-terminal phosphoserine residues in the activation of transcription by p53	ONCOGENE			English	Article						p14ARF; adriamycin; p21; MDM2	ARF TUMOR-SUPPRESSOR; CELL-CYCLE ARREST; PROLYL ISOMERASE PIN1; ACID-BINDING PROTEIN; RING-FINGER DOMAIN; DNA-DAMAGE; ONCOPROTEIN MDM2; STABILIZES P53; GROWTH ARREST; MAMMARY-GLAND	The p53 tumor suppressor is phosphorylated in response to various cellular stress signals, such as DNA damage, leading to its release from MDM2 and consequent stabilization and activation as a transcription factor. In human U2OS cells, treatment with adriamycin causes p53 to be phosphorylated on all six serine residues tested, leading to the dissociation of p53 from MDM2 and transcription of the p21 and mdm2 genes. In contrast, in these cells, IPTG-dependent induction of p14ARF, which sequesters MDM2 away from p53, does not lead to detectable phosphorylation of any of the five N-terminal serine residues tested (6, 9, 15, 20, 37). Only C-terminal serine 392 is phosphorylated. However, the increase of p21 and mdm2 mRNAs was indistinguishable following treatment with adriamycin or induction of p14ARF. By using cDNA arrays to examine global p53-dependent gene expression in response to adriamycin or p14ARF, we found that most genes were regulated similarly by the two treatments. However, a subset of p53-regulated genes whose products have proliferative roles or regulate VEGF activity, newly described here, are repressed by p14ARF much more than by adriamycin. We conclude that the phosphorylation of p53 on N-terminal serine residues is not required for increased transcription of the great majority of p53-responsive genes and that the induction of p53 by p14ARF, with little phosphorylation, leads to substantial repression of genes whose products have roles in proliferation.	Cleveland Clin Fdn, Dept Mol Biol, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Canc Biol, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Stark, GR (corresponding author), Cleveland Clin Fdn, Dept Mol Biol, Lerner Res Inst, NC20,9500 Euclid Ave, Cleveland, OH 44195 USA.	starkg@ccf.org	Williams, Bryan R. G./A-5021-2009	Williams, Bryan R. G./0000-0002-4969-1151	NATIONAL CANCER INSTITUTE [R01CA089279] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049345] Funding Source: NIH RePORTER; NCI NIH HHS [CA 89279] Funding Source: Medline; NIGMS NIH HHS [GM 049345] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Agarwal ML, 1998, P NATL ACAD SCI USA, V95, P14775, DOI 10.1073/pnas.95.25.14775; Agarwal ML, 2001, ONCOGENE, V20, P2527, DOI 10.1038/sj.onc.1204353; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Alarcon R, 1999, CANCER RES, V59, P6046; Alarcon-Vargas D, 2002, CARCINOGENESIS, V23, P541, DOI 10.1093/carcin/23.4.541; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bean LJH, 2001, ONCOGENE, V20, P1076, DOI 10.1038/sj.onc.1204204; Bean LJH, 2002, J BIOL CHEM, V277, P1864, DOI 10.1074/jbc.M108881200; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Chehab NH, 2000, GENE DEV, V14, P278; Chernov MV, 2001, J BIOL CHEM, V276, P31819, DOI 10.1074/jbc.M103170200; Chernova OB, 1998, MOL CELL BIOL, V18, P536, DOI 10.1128/MCB.18.1.536; Cong F, 1999, ONCOGENE, V18, P7731, DOI 10.1038/sj.onc.1203290; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Foster CJ, 2002, ONCOGENE, V21, P3525, DOI 10.1038/sj.onc.1205441; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Inoki I, 2001, FASEB J, V15, P219, DOI 10.1096/fj.01-0332fje; Jing C, 2000, CANCER RES, V60, P2390; Jing C, 2001, CANCER RES, V61, P4357; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kar S, 2002, J BIOL CHEM, V277, P15579, DOI 10.1074/jbc.M106915200; Kobuke K, 2001, J BIOL CHEM, V276, P34105, DOI 10.1074/jbc.M105293200; Komarova EA, 1998, ONCOGENE, V17, P1089, DOI 10.1038/sj.onc.1202303; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; Lowe SW, 1999, ENDOCR-RELAT CANCER, V6, P45, DOI 10.1677/erc.0.0060045; LUNA RMD, 1995, NATURE, V378, P203; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Mayo LD, 1997, CANCER RES, V57, P5013; McKeller RN, 2002, P NATL ACAD SCI USA, V99, P3848, DOI 10.1073/pnas.052484199; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Reinke V, 1997, RADIAT RES, V148, P115, DOI 10.2307/3579567; Rizos H, 2003, J BIOL CHEM, V278, P4981, DOI 10.1074/jbc.M210978200; Rocha S, 2003, MOL CELL, V12, P15, DOI 10.1016/S1097-2765(03)00223-5; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Saucedo LJ, 1998, CELL GROWTH DIFFER, V9, P119; Schlaak JF, 2002, J BIOL CHEM, V277, P49428, DOI 10.1074/jbc.M205571200; Sherr CJ, 2000, CANCER RES, V60, P3689; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Shieh SY, 2000, GENE DEV, V14, P289; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Taylor WR, 1999, MOL BIOL CELL, V10, P3607, DOI 10.1091/mbc.10.11.3607; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Weber HO, 2002, ONCOGENE, V21, P3207, DOI 10.1038/sj.onc.1205429; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Wulf GM, 2002, J BIOL CHEM, V277, P47976, DOI 10.1074/jbc.C200538200; Xiao G, 2000, CANCER RES, V60, P1711; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhao RB, 2000, GENE DEV, V14, P981; Zheng HW, 2002, NATURE, V419, P849, DOI 10.1038/nature01116; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	87	30	31	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2004	23	25					4477	4487		10.1038/sj.onc.1207575	http://dx.doi.org/10.1038/sj.onc.1207575			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	824CJ	15064747				2022-12-28	WOS:000221661300013
J	Obad, S; Brunnstrom, H; Vallon-Christersson, J; Borg, A; Drott, K; Gullberg, U				Obad, S; Brunnstrom, H; Vallon-Christersson, J; Borg, A; Drott, K; Gullberg, U			Staf50 is a novel p53 target gene conferring reduced clonogenic growth of leukemic U-937 cells	ONCOGENE			English	Article						p53; Staf50; transcriptional target	WILD-TYPE P53; INTERFERON-ALPHA/BETA; TUMOR SUPPRESSION; DIFFERENTIATION; EXPRESSION; INDUCTION; FAMILY; P73; APOPTOSIS; RECEPTOR	The tumor suppressor gene p53 is a transcription factor that mediates both cell cycle arrest and apoptosis. Interestingly, p53 also induces differentiation of a number of tissues, including leukemic cells. However, although p53-mediated differentiation of leukemic U-937 cells depends on the transcriptional activity of p53, a p53 target gene mediating differentiation has hitherto not been identified. To screen for novel p53 target genes in leukemic cells, a cDNA microarray analysis was performed with U-937-4/ptsp53 cells, expressing a temperature-sensitive p53 mutant. We report that transcription of the Staf50 ( stimulated transacting factor of 50 kDa) gene is upregulated in response to wild-type p53 in U-937-4, K562 and MCF-7 cells. Staf50 was directly activated by p53, as determined by the independence of de novo protein synthesis. Moreover, while the proximal promoter of Staf50 was found not to be p53 responsive, a functional enhancer-like p53-response element in intron 1 of the Staf50 gene was identified that was also transactivated by the p53-family member p73. Direct binding of p53 to the response element was shown by electrophoretic mobility shift analysis. Ectopic expression of Staf50 in U-937 cells resulted in reduced clonogenic growth. Moreover, levels of endogenous Staf50 mRNA correlated to all-trans retinoic acid-induced differentiation of promyelocytic NB-4 and HL60 cells, suggesting that Staf50 could be involved in proliferation and/or differentiation of leukemic cells.	Lund Univ, BMC, Dept Hematol, S-22184 Lund, Sweden; Lund Univ, Dept Oncol, S-22184 Lund, Sweden	Lund University; Lund University	Gullberg, U (corresponding author), Lund Univ, BMC, Dept Hematol, C14, S-22184 Lund, Sweden.	urban.gullberg@hematologi.lu.se	Brunnström, Hans/AAZ-6803-2020	Brunnström, Hans/0000-0001-7402-138X; Vallon-Christersson, Johan/0000-0002-2195-0385				ALMOG N, 1997, BIOCHIM BIOPHYS ACTA, V1333, P1; Asada M, 1998, LEUKEMIA, V12, P1944, DOI 10.1038/sj.leu.2401228; BANERJEE D, 1995, CELL GROWTH DIFFER, V6, P1405; Casini T, 1999, ONCOGENE, V18, P3235, DOI 10.1038/sj.onc.1202630; Chylicki K, 2000, CELL GROWTH DIFFER, V11, P315; Chylicki K, 2000, CELL GROWTH DIFFER, V11, P561; EHINGER M, 1995, CELL GROWTH DIFFER, V6, P9; Ehinger M, 1996, BLOOD, V87, P1064, DOI 10.1182/blood.V87.3.1064.bloodjournal8731064; Ehinger M, 1997, CELL GROWTH DIFFER, V8, P1127; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ellisen LW, 2001, EMBO J, V20, P1897, DOI 10.1093/emboj/20.8.1897; Fei PW, 2002, CANCER RES, V62, P7316; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; Gongora C, 2000, J INTERF CYTOK RES, V20, P955, DOI 10.1089/10799900050198390; GULLBERG U, 1992, EUR J CELL BIOL, V58, P307; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; JACKSON P, 1993, ONCOGENE, V8, P589; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lang D, 1998, ONCOGENE, V16, P1593, DOI 10.1038/sj.onc.1201665; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; Liu TX, 2000, BLOOD, V96, P1496, DOI 10.1182/blood.V96.4.1496.h8001496_1496_1504; Lohrum MAE, 2000, TRENDS CELL BIOL, V10, P197, DOI 10.1016/S0962-8924(00)01736-0; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Moll UM, 2001, BBA-REV CANCER, V1552, P47, DOI 10.1016/S0304-419X(01)00036-1; Momand J, 1997, J CELL BIOCHEM, V64, P343; Munsch D, 2000, J BIOL CHEM, V275, P3867, DOI 10.1074/jbc.275.6.3867; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; OLSSON I, 1983, CANCER RES, V43, P5862; PATARCA R, 1988, P NATL ACAD SCI USA, V85, P2733, DOI 10.1073/pnas.85.8.2733; Pestka S, 2003, CANCER CELL, V4, P85, DOI 10.1016/S1535-6108(03)00193-4; Peters UR, 1999, CANCER RES, V59, P4233; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Rizzo MG, 1998, BRIT J CANCER, V77, P1429, DOI 10.1038/bjc.1998.236; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Sharma K, 1998, INT J CANCER, V76, P259, DOI 10.1002/(SICI)1097-0215(19980413)76:2<259::AID-IJC14>3.0.CO;2-7; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; Soddu S, 1996, J CELL BIOL, V134, P193, DOI 10.1083/jcb.134.1.193; Song XD, 1999, J BIOL CHEM, V274, P1677, DOI 10.1074/jbc.274.3.1677; SUGIMOTO K, 1992, BLOOD, V79, P2378, DOI 10.1182/blood.V79.9.2378.2378; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; Swiatecka J, 2000, NEOPLASMA, V47, P15; Takaoka A, 2003, NATURE, V424, P516, DOI 10.1038/nature01850; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Tissot C, 1996, GENOMICS, V34, P151, DOI 10.1006/geno.1996.0258; TISSOT C, 1995, J BIOL CHEM, V270, P14891, DOI 10.1074/jbc.270.25.14891; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; Tschan MP, 2000, BIOCHEM BIOPH RES CO, V277, P62, DOI 10.1006/bbrc.2000.3627; Wang JA, 1999, INT J RADIAT BIOL, V75, P301, DOI 10.1080/095530099140483; Wang ZG, 1998, SCIENCE, V279, P1547; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; Wu GS, 1999, ONCOGENE, V18, P6411, DOI 10.1038/sj.onc.1203025; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; Zhang PM, 1999, GENE DEV, V13, P213, DOI 10.1101/gad.13.2.213	61	57	64	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4050	4059		10.1038/sj.onc.1207524	http://dx.doi.org/10.1038/sj.onc.1207524			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15064739				2022-12-28	WOS:000221520200002
J	Komarova, EA; Kondratov, RV; Wang, KH; Christov, K; Golovkina, TV; Goldblum, JR; Gudkov, AV				Komarova, EA; Kondratov, RV; Wang, KH; Christov, K; Golovkina, TV; Goldblum, JR; Gudkov, AV			Dual effect of p53 on radiation sensitivity in vivo: p53 promotes hematopoietic injury, but protects from gastro-intestinal syndrome in mice	ONCOGENE			English	Article						p53; radiation; hematopoietic syndrome; gastro-intestinal syndrome; apoptosis; growth arrest	SMALL-INTESTINE; INDUCED APOPTOSIS; P53-DEFICIENT MICE; IONIZING-RADIATION; CANCER-THERAPY; SUPPRESSION; IRRADIATION; INHIBITOR; NEURONS; CELLS	Ionizing radiation (IR) induces p53-dependent apoptosis in radiosensitive tissues, suggesting that p53 is a determinant of radiation syndromes. In fact, p53-deficient mice survive doses of IR that cause lethal hematopoietic syndrome in wild-type animals. Surprisingly, p53 deficiency results in sensitization of mice to higher doses of IR, causing lethal gastro-intestinal (GI) syndrome. While cells in the crypts of p53-wild-type epithelium undergo prolonged growth arrest after irradiation, continuous cell proliferation ongoing in p53-deficient epithelium correlates with accelerated death of damaged cells followed by rapid destruction of villi and accelerated lethality. p21-deficient mice are also characterized by increased sensitivity to GI syndrome-inducing doses of IR. We conclude that p53/p21-mediated growth arrest plays a protective role in the epithelium of small intestine after severe doses of IR. Pharmacological inhibition of p53 by a small molecule that can rescue from lethal hematopoietic syndrome has no effect on the lethality from gastro-intestinal syndrome, presumably because of a temporary and reversible nature of its action.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, Cleveland, OH 44195 USA; Quark Biotech Inc, Cleveland, OH 44195 USA; Univ Illinois, Dept Surg Oncol, Chicago, IL 60612 USA; Jackson Lab, Bar Harbor, ME 04609 USA; Cleveland Clin Fdn, Dept Anat Pathol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Jackson Laboratory; Cleveland Clinic Foundation	Gudkov, AV (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	gudkov@uic.edu		Kondratov, Roman/0000-0003-3449-745X; Gudkov, Andrei/0000-0003-2548-0154	NCI NIH HHS [CA75179] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075179] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Booth C, 2002, NAT MED, V8, P1360, DOI 10.1038/nm1202-1360; Botchkarev VA, 2000, CANCER RES, V60, P5002; Cai WB, 1997, INT J RADIAT BIOL, V71, P145, DOI 10.1080/095530097144265; Cui Y. F., 1995, Journal of Environmental Pathology Toxicology and Oncology, V14, P159; Culmsee C, 2001, J NEUROCHEM, V77, P220, DOI 10.1046/j.1471-4159.2001.00220.x; Duan WZ, 2002, ANN NEUROL, V52, P597, DOI 10.1002/ana.10350; Gudkov AV, 2003, NAT REV CANCER, V3, P117, DOI 10.1038/nrc992; Hendry JH, 1997, RADIAT RES, V148, P254, DOI 10.2307/3579610; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Komarova EA, 1998, SEMIN CANCER BIOL, V8, P389, DOI 10.1006/scbi.1998.0101; Komarova EA, 2000, ONCOGENE, V19, P3791, DOI 10.1038/sj.onc.1203717; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Merritt AJ, 1997, ONCOGENE, V14, P2759, DOI 10.1038/sj.onc.1201126; MERRITT AJ, 1994, CANCER RES, V54, P614; Ohkusu-Tsukada K, 1999, J IMMUNOL, V163, P1966; Ookawa K, 2002, J BIOL CHEM, V277, P48270, DOI 10.1074/jbc.M207986200; Paris F, 2001, SCIENCE, V293, P293, DOI 10.1126/science.1060191; POTTEN CS, 1990, INT J RADIAT BIOL, V58, P925, DOI 10.1080/09553009014552281; POTTEN CS, 1994, INT J RADIAT BIOL, V65, P71, DOI 10.1080/09553009414550101; Potten CS, 1997, INT J EXP PATHOL, V78, P219, DOI 10.1046/j.1365-2613.1997.280362.x; POTTEN CS, 1992, CANCER METAST REV, V11, P179, DOI 10.1007/BF00048063; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Somosy Z, 2002, MICRON, V33, P167, DOI 10.1016/S0968-4328(01)00013-0; Watson AJM, 2000, AM J PHYSIOL-GASTR L, V278, pG1, DOI 10.1152/ajpgi.2000.278.1.G1; Westphal CH, 1997, NAT GENET, V16, P397, DOI 10.1038/ng0897-397; Yamanishi Y, 2002, AM J PATHOL, V160, P123, DOI 10.1016/S0002-9440(10)64356-8; Zhu XX, 2002, J MED CHEM, V45, P5090, DOI 10.1021/jm020044d	27	181	197	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3265	3271		10.1038/sj.onc.1207494	http://dx.doi.org/10.1038/sj.onc.1207494			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15064735				2022-12-28	WOS:000220975000001
J	Rosenwald, IB				Rosenwald, IB			The role of translation in neoplastic transformation from a pathologist's point of view	ONCOGENE			English	Review						translation; translation factors; protein synthesis; ribosomes; cancer; neoplastic transformation	INITIATION-FACTOR 4E; CAP-BINDING-PROTEIN; CYCLIN D1 EXPRESSION; GROWTH-FACTOR-BETA; POLYMERASE-I TRANSCRIPTION; NF-KAPPA-B; SQUAMOUS-CELL CARCINOMAS; CHRONIC MYELOID-LEUKEMIA; C-MYC TRANSCRIPTION; MESSENGER-RNA	Increased cell proliferation, which is a hallmark of aggressive malignant neoplasms, requires a general increase in protein synthesis and a specific increase in the synthesis of replication-promoting proteins. Transient increase in the general protein synthesis rate, as well as preferential translation of specific mRNAs coding for growth promoting proteins (e.g. cyclin D1), takes place during normal mitogenic response. A number of extensively studied growth signal transduction pathways (Ras, PI3K, MAPK, mTOR-dependent pathways) activate the function and expression of various components of the translational machinery. In abnormal situations, constitutive activation of signal transduction pathways (e.g. oncogenic activation of Ras or Myc) leads to continuous upregulation of key elements of translational machinery. On the other hand, tumor suppressor genes (p53, pRb) downregulate ribosomal and tRNA synthesis, and their inactivation results in uncontrolled production of these translational components. During recent years, a significant effort has been dedicated to determining whether expression of translation factors is increased in human tumors using clinical biopsy specimens. The results of these studies indicate that expression of particular translation initiation factors is not always increased in human neoplasms. The pattern of expression is characteristic for a particular tumor type. For example, eIF-4E is usually increased in bronchioloalveolar carcinomas but not in squamous cell carcinomas of the lung. Interestingly, in certain highly proliferative and aggressive neoplasms (e.g. squamous cell carcinoma of the lung, melanoma), the expression of eIF-4E is barely detectable. These findings suggest that mechanisms for increasing general protein synthesis in various neoplasms differ significantly. Finally, the possibility of qualitative alterations in the translational machinery, rather than a simple increase in the activity of its components, is discussed along with the possibility of targeting those qualitative differences for tumor therapy.	Univ New Mexico, Dept Pathol, Div Hematopathol, Albuquerque, NM 87131 USA	University of New Mexico	Rosenwald, IB (corresponding author), Univ New Mexico, Dept Pathol, Div Hematopathol, BRF Bldg,Room 323 B,MSC08 4640, Albuquerque, NM 87131 USA.	irozenvald@salud.unm.edu						Abid MR, 1999, J BIOL CHEM, V274, P35991, DOI 10.1074/jbc.274.50.35991; Abou-Jawde R, 2003, CLIN THER, V25, P2121, DOI 10.1016/S0149-2918(03)80209-6; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ALEXANDROW MG, 1995, CANCER RES, V55, P1452; Ali IK, 2001, EMBO J, V20, P4233, DOI 10.1093/emboj/20.15.4233; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Bauer C, 2002, INT J CANCER, V98, P181, DOI 10.1002/ijc.10180; Berkel HJ, 2001, CANCER EPIDEM BIOMAR, V10, P663; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Brewer JW, 1999, P NATL ACAD SCI USA, V96, P8505, DOI 10.1073/pnas.96.15.8505; Budde A, 1999, ONCOGENE, V18, P1119, DOI 10.1038/sj.onc.1202402; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Cai DX, 2001, AM J CLIN PATHOL, V115, P213; Caraglia M, 2000, EUR J BIOCHEM, V267, P3919, DOI 10.1046/j.1432-1327.2000.01465.x; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; Ciarmatori S, 2001, MOL CELL BIOL, V21, P5806, DOI 10.1128/MCB.21.17.5806-5814.2001; Clemens MJ, 2001, PROG MOLEC, V27, P57; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; Cohen N, 2001, EMBO J, V20, P4547, DOI 10.1093/emboj/20.16.4547; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Crew JP, 2000, BRIT J CANCER, V82, P161; Crighton D, 2003, EMBO J, V22, P2810, DOI 10.1093/emboj/cdg265; DAKSIS JI, 1994, ONCOGENE, V9, P3635; Dang CV, 1999, MOL CELL BIOL, V19, P1; De Benedetti Arrigo, 1994, Molecular and Cellular Differentiation, V2, P347; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; DeFatta RJ, 2000, LARYNGOSCOPE, V110, P928, DOI 10.1097/00005537-200006000-00007; Donato NJ, 2003, BLOOD, V101, P690, DOI 10.1182/blood.V101.2.690; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; Epifanova O I, 1977, Int Rev Cytol Suppl, P303; Erickson FL, 2001, GENETICS, V158, P123; Felton-Edkins ZA, 2003, EMBO J, V22, P2422, DOI 10.1093/emboj/cdg240; Felton-Edkins ZA, 2003, CELL CYCLE, V2, P181, DOI 10.4161/cc.2.3.375; Frater JL, 2003, AM J CLIN PATHOL, V119, P833, DOI 10.1309/A4RGP4LF12GGH8MW; FREDERICKSON RM, 1991, MOL CELL BIOL, V11, P2896, DOI 10.1128/MCB.11.5.2896; FukuchiShimogori T, 1997, CANCER RES, V57, P5041; Gao MX, 1998, J BIOL CHEM, V273, P4622, DOI 10.1074/jbc.273.8.4622; Grady WM, 1998, CANCER RES, V58, P3101; GRAFF JR, 1995, INT J CANCER, V60, P255; Graff JR, 2003, CLIN EXP METASTAS, V20, P265, DOI 10.1023/A:1022943419011; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harrison CJ, 2001, BLOOD REV, V15, P49, DOI 10.1054/blre.2001.0150; Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424; HAUMEDER E, 1933, L KREBSFORSCH, V40, P105; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HEIM S, 1995, CANC CYTOGENETICS, P180; HERSHKO A, 1971, NATURE-NEW BIOL, V232, P206, DOI 10.1038/newbio232206a0; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Hochhaus A, 2003, SEMIN HEMATOL, V40, P69, DOI 10.1053/shem.2003.50045; Horton LE, 2002, ONCOGENE, V21, P5325, DOI 10.1038/sj.onc.1205662; Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/88264; Hughes TP, 2003, NEW ENGL J MED, V349, P1423, DOI 10.1056/NEJMoa030513; Iborra FJ, 2002, CURR OPIN CELL BIOL, V14, P780, DOI 10.1016/S0955-0674(02)00386-1; Iborra FJ, 2001, SCIENCE, V293, P1139, DOI 10.1126/science.1061216; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Jones RM, 1996, MOL CELL BIOL, V16, P4754; Kelly LM, 2002, ANNU REV GENOM HUM G, V3, P179, DOI 10.1146/annurev.genom.3.032802.115046; KEREKATTE V, 1995, INT J CANCER, V64, P27, DOI 10.1002/ijc.2910640107; Kerkhoff E, 1998, ONCOGENE, V16, P211, DOI 10.1038/sj.onc.1201520; KESSLER DJ, 1992, J EXP MED, V176, P787, DOI 10.1084/jem.176.3.787; Kevil C, 1995, ONCOGENE, V11, P2339; Kevil CG, 1996, INT J CANCER, V65, P785, DOI 10.1002/(SICI)1097-0215(19960315)65:6<785::AID-IJC14>3.0.CO;2-3; Kim S, 2000, P NATL ACAD SCI USA, V97, P11198, DOI 10.1073/pnas.200372597; Kim SH, 2002, ONCOGENE, V21, P8741, DOI 10.1038/sj.onc.1205987; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KOSS LG, 1982, ANAL QUANT CYTOL, V4, P251; Lamlum H, 2000, P NATL ACAD SCI USA, V97, P2225, DOI 10.1073/pnas.040564697; Larminie CGC, 1998, J MOL MED, V76, P94, DOI 10.1007/s001090050196; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LAZARISKARATZAS A, 1992, MOL CELL BIOL, V12, P1234, DOI 10.1128/MCB.12.3.1234; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LEJBKOWICZ F, 1992, P NATL ACAD SCI USA, V89, P9612, DOI 10.1073/pnas.89.20.9612; Li BDL, 2002, ANN SURG, V235, P732, DOI 10.1097/00000658-200205000-00016; Li BDL, 1997, CANCER-AM CANCER SOC, V79, P2385; LI C, 2003, CANCER RES, V63, P5716; Lobo MVT, 2000, HISTOCHEM J, V32, P139, DOI 10.1023/A:1004091122351; Marin D, 2003, LANCET, V362, P617, DOI 10.1016/S0140-6736(03)14182-7; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Markowitz S, 2000, BBA-REV CANCER, V1470, pM13, DOI 10.1016/S0304-419X(99)00031-1; Martin ME, 2000, INT J BIOCHEM CELL B, V32, P633, DOI 10.1016/S1357-2725(00)00007-8; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Mathews MB, 2000, COLD SPRING HARBOR M, V39, P1; Mayeur GL, 2002, FEBS LETT, V514, P49, DOI 10.1016/S0014-5793(02)02307-4; MELHEM MF, 1992, CANCER RES, V52, P5853; Menssen A, 2002, P NATL ACAD SCI USA, V99, P6274, DOI 10.1073/pnas.082005599; Meric F, 2002, MOL CANCER THER, V1, P971; Morley SJ, 2001, PROG MOLEC, V27, P1; MORRIS DR, 1995, PROG NUCLEIC ACID RE, V51, P339, DOI 10.1016/S0079-6603(08)60883-1; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; MULDER KM, 1988, INT J CANCER, V42, P64, DOI 10.1002/ijc.2910420113; MULDER KM, 1990, CANCER RES, V50, P7581; MUNGER K, 1992, CANCER SURV, V12, P197; Nathan CAO, 1997, ONCOGENE, V15, P579, DOI 10.1038/sj.onc.1201216; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Nika J, 2001, J BIOL CHEM, V276, P1051, DOI 10.1074/jbc.M007398200; Nupponen NN, 1999, AM J PATHOL, V154, P1777, DOI 10.1016/S0002-9440(10)65433-8; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; PARDEE AB, 1978, ANNU REV BIOCHEM, V47, P715, DOI 10.1146/annurev.bi.47.070178.003435; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Polakis P, 2001, CELL, V105, P563, DOI 10.1016/S0092-8674(01)00379-8; Polunovsky VA, 1996, MOL CELL BIOL, V16, P6573; Polunovsky VA, 2000, J BIOL CHEM, V275, P24776, DOI 10.1074/jbc.M001938200; Polyak K, 1996, BBA-REV CANCER, V1242, P185, DOI 10.1016/0304-419X(95)00009-5; Preiss T, 1998, NATURE, V392, P516, DOI 10.1038/33192; Raught B, 2000, COLD SPRING HARBOR M, V39, P245; Raught B, 2001, P NATL ACAD SCI USA, V98, P7037, DOI 10.1073/pnas.121145898; Rhoads RE, 1991, CURR OPIN CELL BIOL, V3, P1019, DOI 10.1016/0955-0674(91)90123-G; RINKERSCHAEFFER CW, 1992, J BIOL CHEM, V267, P10659; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; Rosenwald IB, 1996, CANCER LETT, V102, P113, DOI 10.1016/0304-3835(96)04171-7; Rosenwald IB, 1996, BIOESSAYS, V18, P243, DOI 10.1002/bies.950180312; Rosenwald IB, 1999, ONCOGENE, V18, P2507, DOI 10.1038/sj.onc.1202563; Rosenwald IB, 2003, CANCER-AM CANCER SOC, V98, P1080, DOI 10.1002/cncr.11619; Rosenwald IB, 2001, CANCER-AM CANCER SOC, V92, P2164, DOI 10.1002/1097-0142(20011015)92:8<2164::AID-CNCR1559>3.0.CO;2-A; Rosenwald IB, 2001, THROMB HAEMOSTASIS, V85, P142; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Rousseau D, 1996, ONCOGENE, V13, P2415; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; RUECKERT RR, 1960, CANCER RES, V20, P1584; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Sanchez-Beato M, 2003, BLOOD, V101, P1220, DOI 10.1182/blood-2002-07-2009; Saramaki O, 2001, AM J PATHOL, V159, P2089, DOI 10.1016/S0002-9440(10)63060-X; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397; Seki N, 2002, CLIN CANCER RES, V8, P3046; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Shantz LM, 1996, CANCER RES, V56, P3265; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SINGH C, 1995, TUMOR BIOL, V16, P281, DOI 10.1159/000217945; Sirri V, 2002, J CELL BIOL, V156, P969, DOI 10.1083/jcb.200201024; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; Sorrells DL, 1999, J ORAL MAXIL SURG, V57, P294, DOI 10.1016/S0278-2391(99)90676-6; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; STANNERS CP, 1979, J CELL PHYSIOL, V100, P127, DOI 10.1002/jcp.1041000113; Strudwick S, 2002, DIFFERENTIATION, V70, P10, DOI 10.1046/j.1432-0436.2002.700102.x; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Sun YL, 1997, CANCER RES, V57, P18; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Takuwa N, 1999, MOL CELL BIOL, V19, P1346; Tan A, 2000, ONCOGENE, V19, P1437, DOI 10.1038/sj.onc.1203446; TATSUKA M, 1992, NATURE, V359, P333, DOI 10.1038/359333a0; Thomas G, 2002, BIOL RES, V35, P305, DOI 10.4067/S0716-97602002000200022; Thornton S, 2003, J MOL MED, V81, P536, DOI 10.1007/s00109-003-0461-8; Topisirovic I, 2003, EMBO J, V22, P689, DOI 10.1093/emboj/cdg069; TUAZON PT, 1990, J BIOL CHEM, V265, P10617; Tuhackova Z, 1999, ONCOL REP, V6, P827; Voit R, 1999, EMBO J, V18, P1891, DOI 10.1093/emboj/18.7.1891; Voit R, 1997, MOL CELL BIOL, V17, P4230, DOI 10.1128/MCB.17.8.4230; VOLM M, 1992, ANTICANCER RES, V12, P11; Wang J, 1996, J BIOL CHEM, V271, P17366, DOI 10.1074/jbc.271.29.17366; Wang Q, 2001, GENE, V263, P205, DOI 10.1016/S0378-1119(00)00570-9; Wang ST, 1999, AM J PATHOL, V155, P247, DOI 10.1016/S0002-9440(10)65118-8; Wang ST, 2001, THYROID, V11, P1101, DOI 10.1089/10507250152740939; Warner BJ, 1999, MOL CELL BIOL, V19, P5913; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEK RC, 1994, TRENDS BIOCHEM SCI, V19, P491, DOI 10.1016/0968-0004(94)90136-8; Welsh GI, 1998, FEBS LETT, V421, P125, DOI 10.1016/S0014-5793(97)01548-2; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0; Yang Yu-Jie, 2003, Ai Zheng, V22, P1023; ZETTERBERG A, 1991, COLD SH Q B, V56, P137; ZETTERBERG A, 1995, CURR OPIN CELL BIOL, V7, P835, DOI 10.1016/0955-0674(95)80067-0; Zhao J, 2003, MOL CELL, V11, P405, DOI 10.1016/S1097-2765(03)00036-4	177	96	109	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2004	23	18					3230	3247		10.1038/sj.onc.1207552	http://dx.doi.org/10.1038/sj.onc.1207552			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	813AJ	15094773				2022-12-28	WOS:000220879700012
J	Yanamandra, N; Kondraganti, S; Srinivasula, SM; Gujrati, M; Olivero, WC; Dinh, DH; Rao, JS				Yanamandra, N; Kondraganti, S; Srinivasula, SM; Gujrati, M; Olivero, WC; Dinh, DH; Rao, JS			Activation of caspase-9 with irradiation inhibits invasion and angiogenesis in SNB19 human glioma cells	ONCOGENE			English	Article						caspase 9; radiation; in version angiogenesis; glioma	BROMODEOXYURIDINE LABELING INDEX; CYTOCHROME-C; IN-VIVO; GLIOBLASTOMA-MULTIFORME; BASEMENT-MEMBRANE; INDUCED APOPTOSIS; MALIGNANT GLIOMA; DEATH; RADIATION; MIGRATION	Glioblastoma multiforme, the most common brain tumor, typically exhibits markedly increased angiogenesis, which is crucial for tumor growth and invasion. Antiangiogenic strategies based on disruption of the tumor microvasculature have proven effective for the treatment of experimental brain tumors. Here, we have overexpressed human caspase-9 by stable transfection in the SNB19 glioblastoma cell line, which normally expresses low levels of caspase-9. Our studies revealed that overexpression of caspase-9 coupled with radiation has a synergistic effect on the inhibition of glioma invasion as demonstrated by Matrigel assay (465%). Furthermore, sense caspase stable clones cocultured with fetal rat brain aggregates along with radiation showed complete inhibition as compared to the parental and vector controls. During in vitro angiogenesis, SNB19 cells cocultured with human microvascular endothelial cells (HMEC) showed vascular network formation after 48-72 h. In contrast, these capillary-like structures were inhibited when HMEC cells were cocultured with sense caspase stable SNB19 cells. This effect was further enhanced by radiation (5 Gy). Signaling mechanisms revealed that apoptosis is induced by cleavage of caspase-9 by radiation, loss of mitochondrial membrane potential and activation of caspase-3. These results demonstrate that activation of caspase-9 disrupts glioma cell invasion and angiogenesis in vitro. Hence, overexpression of proapoptotic molecules such as caspase-9 may be an important determinant of the therapeutic effect of radiation in cancer therapy.	Univ Illinois, Coll Med, Program Canc Biol, Dept Biomed & Therapeut Sci, Peoria, IL 61656 USA; NCI, Lab Immune Cell Biol, NIH, Bethesda, MD USA; Univ Illinois, Coll Med, Dept Pathol, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Neurosurg, Peoria, IL 61656 USA	University of Illinois System; University of Illinois Peoria; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria	Rao, JS (corresponding author), Univ Illinois, Coll Med, Program Canc Biol, Dept Biomed & Therapeut Sci, Box 1649, Peoria, IL 61656 USA.	jsrao@uic.edu			NATIONAL CANCER INSTITUTE [R01CA095058, R01CA092393, R01CA075557, ZIABC010629, Z01BC010629, R01CA085216] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047699] Funding Source: NIH RePORTER; NCI NIH HHS [CA 95058, CA 75557, CA 92393, CA 85216] Funding Source: Medline; NINDS NIH HHS [NS 47699] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAE SN, 1993, BREAST CANCER RES TR, V24, P241, DOI 10.1007/BF01833264; Belka C, 1999, INT J RADIAT BIOL, V75, P1257, DOI 10.1080/095530099139412; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Bergmann A, 1998, ONCOGENE, V17, P3215, DOI 10.1038/sj.onc.1202586; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; DURAND RE, 1972, EXP CELL RES, V71, P75, DOI 10.1016/0014-4827(72)90265-0; Eshleman JS, 2002, CANCER RES, V62, P7291; Giese A, 2001, J CANCER RES CLIN, V127, P217, DOI 10.1007/s004320000188; Go Y, 1997, CLIN EXP METASTAS, V15, P440, DOI 10.1023/A:1018410523635; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; LABROUSSE F, 1991, J NEUROSURG, V75, P202, DOI 10.3171/jns.1991.75.2.0202; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; MAJACK RA, 1984, J CELL PHYSIOL, V118, P253, DOI 10.1002/jcp.1041180306; MELCHIORI A, 1987, ANTICANCER RES, V7, P475; MOHANAM S, 1993, CANCER RES, V53, P4143; Motyl T, 1999, REPROD NUTR DEV, V39, P49, DOI 10.1051/rnd:19990103; MURUGESAN G, 1993, J CELL BIOL, V120, P1011, DOI 10.1083/jcb.120.4.1011; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nor JE, 2002, GENE THER, V9, P444, DOI 10.1038/sj.gt.3301671; ONDA K, 1994, CANCER, V74, P1921, DOI 10.1002/1097-0142(19941001)74:7<1921::AID-CNCR2820740716>3.0.CO;2-9; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; PEDERSEN PH, 1993, CANCER RES, V53, P5158; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; RAMPLING R, 1994, INT J RADIAT ONCOL, V29, P427, DOI 10.1016/0360-3016(94)90432-4; Sarkar R, 1996, CIRC RES, V78, P225, DOI 10.1161/01.RES.78.2.225; Shinoura N, 2002, BRIT J CANCER, V86, P587, DOI 10.1038/sj.bjc.6600061; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; SUIT HD, 1990, INT J RADIAT ONCOL, V18, P365, DOI 10.1016/0360-3016(90)90102-P; TAGHIAN A, 1995, INT J RADIAT ONCOL, V32, P99, DOI 10.1016/0360-3016(94)00494-6; Uchida H, 2002, BIOCHEM BIOPH RES CO, V292, P347, DOI 10.1006/bbrc.2002.6643; Vajkoczy P, 1999, INT J DEV NEUROSCI, V17, P557, DOI 10.1016/S0736-5748(99)00021-0; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	42	18	18	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2004	23	13					2339	2346		10.1038/sj.onc.1207406	http://dx.doi.org/10.1038/sj.onc.1207406			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806IN	14767475				2022-12-28	WOS:000220427700008
